PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ping, YH; Rana, TM				Ping, YH; Rana, TM			DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; VIRUS TYPE-1 TAT; CELLULAR PROTEIN-KINASE; IN-VITRO; HIGH-AFFINITY; SUBUNIT-IIA; HELA-CELLS; PROMOTER; ACTIVATION; SPT5	Control of transcription elongation requires a complex interplay between the recently discovered positive transcription elongation factor b (P-TEFb) and negative transcription elongation factors, 5,6-dichloro-1-beta -D-ribofuranosylbenzimidazole (DRB) sensitivity inducing factors (DSIF) and the negative elongation factor (NELF), Activation of HIV-1 gene expression is regulated by a nascent RNA structure, termed TAR RNA, in concert with HIV-1 Tat protein and these positive and negative elongation factors. We have used a stepwise RNA pol II walking approach and Western blotting to determine the dynamics of interactions between HIV-1. Tat, DSIF/ NELF, and the transcription complexes actively engaged in elongation. In addition, we developed an in vitro kinase assay to determine the phosphorylation status of proteins during elongation stages. Our results demonstrate that DSIF/NELF associates with RNA pol 11 complexes during early transcription elongation and travels with elongation complexes as the nascent RNA is synthesized. Our results also show that HIV-1 Tat protein stimulated DSIF and RNA pol II phosphorylation by P-TEFb during elongation. These findings reveal a molecular mechanism for the negative and positive regulation of transcriptional elongation at the HIV-1 promoter.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Mol Biosci Grad Program, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Rana, TM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA.			Ping, Yueh-Hsin/0000-0003-2604-9913	NIAID NIH HHS [AI 43198] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043198] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Garber ME, 2000, MOL CELL BIOL, V20, P6958, DOI 10.1128/MCB.20.18.6958-6969.2000; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Kim JB, 1999, MOL CELL BIOL, V19, P5960; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Li XY, 1998, GENE DEV, V12, P2992, DOI 10.1101/gad.12.19.2992; Li XY, 1996, CURR BIOL, V6, P943, DOI 10.1016/S0960-9822(02)00633-4; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Minvielle-Sebastia L, 1999, CURR OPIN CELL BIOL, V11, P352, DOI 10.1016/S0955-0674(99)80049-0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Price D., COMMUNICATION; Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206; RHIM H, 1994, J ACQ IMMUN DEF SYND, V7, P1116; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; Stachora AA, 1997, FEBS LETT, V409, P74, DOI 10.1016/S0014-5793(97)00486-9; TAMM I, 1980, BIOCHEMISTRY-US, V19, P2743, DOI 10.1021/bi00553a032; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wang ZY, 1997, P NATL ACAD SCI USA, V94, P6688, DOI 10.1073/pnas.94.13.6688; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Wu-Baer F, 1998, J MOL BIOL, V277, P179, DOI 10.1006/jmbi.1997.1601; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZHOU CS, UNPUB; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	63	155	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12951	12958		10.1074/jbc.M006130200	http://dx.doi.org/10.1074/jbc.M006130200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11112772	hybrid			2022-12-25	WOS:000168198600071
J	Yu, TN; Wang, XD; Purring-Koch, C; Wei, Y; McLendon, GL				Yu, TN; Wang, XD; Purring-Koch, C; Wei, Y; McLendon, GL			A mutational epitope for cytochrome c binding to the apoptosis protease activation factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WD-40 REPEAT REGION; YEAST ISO-1-CYTOCHROME-C; CASPASE ACTIVATION; APAF-1; PROCASPASE-9; COMPLEX; OLIGOMERIZATION; TRIMETHYLATION; PROGRAM; CASCADE	Cytochrome c (Cc) binding to apoptosis protease activation factor-1 (Apaf-1) is a critical activation step in the execution phase of apoptosis. Here we report studies that help define the Cc:Apaf-1 binding surface. It is shown that a large number of Cc residues, including residues 7, 25, 39, 62-65, and 72, are involved in the Cc:Apaf-1 interaction. Mutation of residue 72 eliminated Cc activity whereas mutations of residues 7, 25, 39, and 62-65 showed reduced activity in an additive fashion. The implications of this binding model for both recognition and modulation of protein-protein interactions are briefly discussed.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Drexel Univ, Dept Chem, Philadelphia, PA 19104 USA	Princeton University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Drexel University	Wang, XD (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	xwang@biochem.swmed.edu	Wei, Yen/H-5329-2012	Wang, Xiaodong/0000-0001-9885-356X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059348] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59348, GM57158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; ANNI H, 1995, BIOCHEMISTRY-US, V34, P5744, DOI 10.1021/bi00017a006; Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; CUTLER RL, 1987, PROTEIN ENG, V1, P95, DOI 10.1093/protein/1.2.95; HAMPSEY DM, 1986, J BIOL CHEM, V261, P3259; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; KANG CH, 1977, J BIOL CHEM, V252, P919; Kluck RM, 2000, J BIOL CHEM, V275, P16127, DOI 10.1074/jbc.275.21.16127; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; MOERSCHELL RP, 1991, METHOD ENZYMOL, V194, P362; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Pollock WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/bi972188d; Purring C, 1999, J AM CHEM SOC, V121, P7435, DOI 10.1021/ja991235h; Purring-Koch C, 2000, P NATL ACAD SCI USA, V97, P11928, DOI 10.1073/pnas.220416197; RIEDER R, 1980, J BIOL CHEM, V255, P4732; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; VOET D, 1995, BIOCHEMISTRY-US, P126; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	28	112	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13034	13038		10.1074/jbc.M009773200	http://dx.doi.org/10.1074/jbc.M009773200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11112785	hybrid			2022-12-25	WOS:000168198600081
J	Fawcett, J; Hamel, FG; Bennett, RG; Vajo, Z; Duckworth, WC				Fawcett, J; Hamel, FG; Bennett, RG; Vajo, Z; Duckworth, WC			Insulin and analogue effects on protein degradation in different cell types - Dissociation between binding and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONAL-REGULATION; DEGRADING ENZYME; RECEPTOR-BINDING; RAT HEPATOCYTES; CLINICAL USE; PROTEASOME; INHIBITION; PROTEOLYSIS; MUSCLE; CATABOLISM	In adult animals, the major effect of insulin on protein turnover is inhibition of protein degradation. Cellular protein degradation is under the control of multiple systems, including lysosomes, proteasomes, calpains, and giant protease, Insulin has been shown to alter proteasome activity in vitro and in vivo, We examined the inhibition of protein degradation by insulin and insulin analogues (Lys(B28), Pro(B29)-insulin (LysPro), Asp(B10)-insulin (B10), and Glu(B4), Gln(B16), Phe(B17)-insulin (EQF)) in H4, HepG2, and L6 cells. These effects were compared with receptor binding. Protein degradation was examined by release of trichloroacetic acid-soluble radioactivity from cells previously labeled with [H-3]eucine. Short- and intermediate-lived proteins were examined. H4 cells bound insulin with an EC50 of 4.6 x 10(-9) M. LysPro was similar. The affinity of B10 was increased 2-fold; that of EQF decreased 15-fold. Protein degradation inhibition in H4 cells was highly sensitive to insulin (EC50 = 4.2 x 10(-11) and 1.6 x 10(-10) M, short- and intermediate-lived protein degradation, respectively) and analogues, Despite similar binding, LysPro was 11- to 18-fold more potent than insulin at inhibiting protein degradation, Conversely, although EQF showed lower binding to H4 cells than insulin, its action was similar. The relative binding potencies of analogues in HepG2 cells were similar to those in H4 cells. Examination of protein degradation showed insulin, LysPro, and B10 mere equivalent while EQF was less potent. L6 cells showed no difference in the binding of the analogues compared with insulin, but their effect on protein degradation was similar to that seen in HepG2 cells except BIO inhibited intermediate-lived protein degradation better than insulin. These studies illustrate the complexities of cellular protein degradation and the effects of insulin. The effect of insulin and analogues on protein degradation vary significantly in different cell types and with different experimental conditions. The differences seen in the action of the analogues cannot be attributed to binding differences. Post-receptor mechanisms, including intracellular processing and degradation, must be considered.	Carl T Hayden Vet Adm Med Ctr, Endocrinol Sect, Phoenix, AZ 85012 USA; Vet Adm Med Ctr, Res Serv, Omaha, NE 68105 USA; Univ Nebraska, Med Ctr, Div Endocrinol Diabet & Metab, Omaha, NE 68198 USA; Arizona State Univ, Mol & Cellular Biol Program, Tempe, AZ 85287 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Nebraska System; University of Nebraska Medical Center; Arizona State University; Arizona State University-Tempe	Fawcett, J (corresponding author), Carl T Hayden Vet Adm Med Ctr, Endocrinol Sect, CS-111E,650 E Indian Sch Rd, Phoenix, AZ 85012 USA.		Vajo, Zoltan/J-9016-2019	Vajo, Zoltan/0000-0003-1049-1694				BALLARD FJ, 1980, J CELL PHYSIOL, V105, P335, DOI 10.1002/jcp.1041050216; Bennett RG, 1997, DIABETES, V46, P197, DOI 10.2337/diabetes.46.2.197; Bennett RG, 2000, ENDOCRINOLOGY, V141, P2508, DOI 10.1210/en.141.7.2508; BEYNON RJ, 1986, AM J PHYSIOL, V251, pC141, DOI 10.1152/ajpcell.1986.251.2.C141; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BURKE GT, 1990, BIOCHEM BIOPH RES CO, V173, P982, DOI 10.1016/S0006-291X(05)80882-4; CHU YC, 1992, J PROTEIN CHEM, V11, P571, DOI 10.1007/BF01025035; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DRAZNIN B, 1982, J BIOL CHEM, V257, P1988; DREJER K, 1992, DIABETES METAB REV, V8, P259, DOI 10.1002/dmr.5610080305; DUCKWORTH WC, 1994, J BIOL CHEM, V269, P24575; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; FULKS RM, 1975, J BIOL CHEM, V250, P290; Garlick PJ, 1998, J NUTR, V128, p356S, DOI 10.1093/jn/128.2.356S; GUNN JM, 1977, NATURE, V266, P58, DOI 10.1038/266058a0; Hamel FG, 1999, METABOLISM, V48, P611, DOI 10.1016/S0026-0495(99)90059-8; Hamel FG, 2000, DIABETES, V49, pA26; Hamel FG, 1997, BIOCHEM BIOPH RES CO, V234, P671, DOI 10.1006/bbrc.1997.6693; Hansen BF, 1996, BIOCHEM J, V315, P271; Holleman F, 1997, NEW ENGL J MED, V337, P176, DOI 10.1056/NEJM199707173370307; HOWEY DC, 1994, DIABETES, V43, P396, DOI 10.2337/diabetes.43.3.396; KELLEY DS, 1978, CANCER RES, V38, P4591; KETTELHUT IC, 1988, DIABETES METAB REV, V4, P751, DOI 10.1002/dmr.5610040805; Kurtzhals P, 2000, DIABETES, V49, P999, DOI 10.2337/diabetes.49.6.999; Li BG, 2000, INT J BIOCHEM CELL B, V32, P677, DOI 10.1016/S1357-2725(00)00010-8; MANDEL JL, 1974, NATURE, V251, P618, DOI 10.1038/251618a0; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; MORTIMORE GE, 1989, DIABETES METAB REV, V5, P49, DOI 10.1002/dmr.5610050105; MORTIMORE GE, 1982, NUTR REV, V40, P1, DOI 10.1111/j.1753-4887.1982.tb06817.x; PEAVY DE, 1984, ENDOCRINOLOGY, V114, P753, DOI 10.1210/endo-114-3-753; Rooyackers OE, 1997, ANNU REV NUTR, V17, P457, DOI 10.1146/annurev.nutr.17.1.457; Slieker LJ, 1997, DIABETOLOGIA, V40, pS54, DOI 10.1007/s001250051402; SLIEKER LJ, 1994, CURRENT DIRECTIONS I, V343, P25; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; SVOBODA I, 1994, BIOL CHEM H-S, V375, P373, DOI 10.1515/bchm3.1994.375.6.373; Thompson MG, 1998, CELL SIGNAL, V10, P1, DOI 10.1016/S0898-6568(97)00076-4; VOLUND A, 1991, DIABETIC MED, V8, P839, DOI 10.1111/j.1464-5491.1991.tb02122.x; Yao TT, 1999, CURR BIOL, V9, pR551, DOI 10.1016/S0960-9822(99)80352-2	38	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11552	11558		10.1074/jbc.M007988200	http://dx.doi.org/10.1074/jbc.M007988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11116143	hybrid			2022-12-25	WOS:000168081800020
J	Loh, T; Murphy, KC; Marinus, MG				Loh, T; Murphy, KC; Marinus, MG			Mutational. analysis of the MutH protein from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE MUTATOR MUTATIONS; DIRECTED MISMATCH REPAIR; RESTRICTION ENDONUCLEASES; GENE REPLACEMENT; DNA; RECOMBINATION; RECOGNITION; SEQUENCES; BINDING; INVITRO	Site-directed mutagenesis was performed on several areas of MutH based on the similarity of MutH and PvuII structural models. The aims were to identify DNA-binding residues; to determine whether MutH has the same mechanism for DNA binding and catalysis as PvuII; and to localize the residues responsible for MutH stimulation by MutL. No DNA-binding residues were identified in the two flexible loop regions of MutH, although similar loops in PvuII are involved in DNA binding. Two histidines in MutH are in a similar position as two histidines (His-84 and His-85) in PvuII that signal for DNA binding and catalysis. These MutH histidines (His-112 and His-115) were changed to alanines, but the mutant proteins had wild-type activity both in vivo and in vitro, The results indicate that the MutH signal for DNA binding and catalysis remains unknown. Instead, a lysine residue (Lys-48) was found in the first flexible loop that functions in catalysis together with the three presumed catalytic amino acids (Asp-70, Glu-77, and Lys-79). Two deletion mutations (MutH Delta 224 and MutH Delta 214) in the C-terminal end of the protein, localized the MutL stimulation region to five amino acids (Ala-220, Leu-221, Leu-222, Ala-223, and Arg-224).	Univ Massachusetts, Sch Med, Dept Pharmacol & Mol Toxicol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Marinus, MG (corresponding author), Univ Massachusetts, Sch Med, Dept Pharmacol & Mol Toxicol, 55 Lake Ave N, Worcester, MA 01655 USA.		Murphy, Kenan/AHB-4771-2022	Murphy, Kenan/0000-0002-3677-2876				AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; AU KG, 1992, J BIOL CHEM, V267, P12142; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; FENG G, 1995, BIOTECHNIQUES, V19, P956; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Harris RS, 1997, GENE DEV, V11, P2426, DOI 10.1101/gad.11.18.2426; Horst JP, 1999, TRENDS MICROBIOL, V7, P29, DOI 10.1016/S0966-842X(98)01424-3; Horton JR, 1998, J MOL BIOL, V284, P1491, DOI 10.1006/jmbi.1998.2269; Horton JR, 1998, BIOL CHEM, V379, P451, DOI 10.1515/bchm.1998.379.4-5.451; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Murphy KC, 2000, GENE, V246, P321, DOI 10.1016/S0378-1119(00)00071-8; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Nastri HG, 1997, J BIOL CHEM, V272, P25761, DOI 10.1074/jbc.272.41.25761; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; PUKKILA PJ, 1983, GENETICS, V104, P571; Sambrook J., 2002, MOL CLONING LAB MANU; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994	26	24	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12113	12119		10.1074/jbc.M007935200	http://dx.doi.org/10.1074/jbc.M007935200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11124943	hybrid			2022-12-25	WOS:000168081800091
J	Asano, T; Ashida, M				Asano, T; Ashida, M			Transepithelially transported pro-phenoloxidase in the cuticle of the silkworm, Bombyx mori - Identification of its methionyl residues oxidized to methionine sulfoxides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL OXIDASE; DROSOPHILA-MELANOGASTER; ARTHROPOD HEMOCYANIN; MOLECULAR-CLONING; II HEMOCYANIN; PROTEIN; BINDING; SEQUENCE; PEPTIDES; SUBUNIT	Pro-phenoloxidase (proPO) in insects is activated through the action of a protease cascade triggered by minute amounts of microbial cell wall components. It is an important molecule for the defense against invading microorganisms and for the repair of wounds. In the accompanying paper (Asano, T,, and Ashida, M, (2001) J, Biol, Chem, 276, 11100-11112), a proPO isoform, proPO-HS, in the hemolymph of the silkworm, Bombyx mori, is reported to be transported to the cuticle. The transported proPO isoform was recovered from the cuticle and named proPO CS. The elution profiles of proPO-CS and proPO HS in reversed-phase high performance liquid chromatography (HPLC) were found to be different, giving a basis to the inference that proPO CS is a modified form of proPO-HS. In the present study, we investigated the nature of the modifications occurring in proPO-CS, in which proteolytically and chemically cleaved fragments originating from the subunits of proPO-CS and proPO-HS were analyzed by reversed-phase HPLC, amino acid sequencing, and mass spectrometry. A subunit of the heterodimeric proPO-CS was found to contain five or six methionine sulfoxides, and another subunit was found to contain one methionine residue oxidized to the sulfoxide, All of the oxidized methionyl residues were identified. Other than oxidation of the methionyl residues, no additional modification of proPO-CS was found. In the model structure of each subunit of proPO-CS constructed by protein modeling with the known structures of the horseshoe crab, Limulus polyphemus, hemocyanin type II subunit as templates, the methionine residues identified as methionine sulfoxide had high degrees of accessibility to the solvent. The implication of the oxidation at the methionine residues is discussed in relation to the mechanism of transepithelial transport of proPO from the hemolymph to the cuticle.	Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600819, Japan	Hokkaido University	Ashida, M (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600819, Japan.							ANDERSEN SO, 1995, INSECT BIOCHEM MOLEC, V25, P153, DOI 10.1016/0965-1748(94)00052-J; Asano T, 2001, J BIOL CHEM, V276, P11100, DOI 10.1074/jbc.M008426200; ASHIDA M, 1995, P NATL ACAD SCI USA, V92, P10698, DOI 10.1073/pnas.92.23.10698; Ashida M., 1997, MOL MECH IMMUNE RESP, P135; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROT N, 1991, BIOFACTORS, V3, P91; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; COLIGAN JE, 1997, CURRENT PROTOCOLS PR, V2; Csikos G, 1999, J CELL SCI, V112, P2113; Dow LK, 1997, FEBS LETT, V414, P514, DOI 10.1016/S0014-5793(97)01059-4; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; FUJIMOTO K, 1995, P NATL ACAD SCI USA, V92, P7769, DOI 10.1073/pnas.92.17.7769; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; Gros E., 1967, METHOD ENZYMOL, V11, P238; HALL M, 1995, P NATL ACAD SCI USA, V92, P7764, DOI 10.1073/pnas.92.17.7764; HAZES B, 1993, PROTEIN SCI, V2, P597; Hazes B, 1996, J MOL BIOL, V262, P532, DOI 10.1006/jmbi.1996.0533; Hughes AL, 1999, IMMUNOGENETICS, V49, P106, DOI 10.1007/s002510050469; JIANG X, 1999, J MASS SPECTROM, V31, P1309; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; Liang MN, 1996, BIOCHEMISTRY-US, V35, P14734, DOI 10.1021/bi961725b; LOCKE M, 1988, MOLTING METAMORPHOSI, P173; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; MARKI W, 1981, J AM CHEM SOC, V103, P3178; Michel CC, 1996, CARDIOVASC RES, V32, P644, DOI 10.1016/0008-6363(96)00064-8; MILES AM, 1993, BIOCHEMISTRY-US, V32, P8168, DOI 10.1021/bi00083a017; MOSTOV KE, 1995, HISTOL HISTOPATHOL, V10, P423; Okamoto CT, 1998, ADV DRUG DELIVER REV, V29, P215, DOI 10.1016/S0169-409X(97)00080-X; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; *PEIFER M, 1993, DEVELOPMENT S, P163; PEITSCH MC, 1995, MOL IMMUNOL, V32, P761, DOI 10.1016/0161-5890(95)00016-8; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SASS M, 1994, J INSECT PHYSIOL, V40, P407, DOI 10.1016/0022-1910(94)90159-7; SHARKE A, 1973, J MOL BIOL, V79, P351; Swaan PW, 1998, PHARM RES-DORDR, V15, P826, DOI 10.1023/A:1011908128045; TEH LC, 1987, J BIOL CHEM, V262, P6472; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TURECEK F, 1989, J AM CHEM SOC, V111, P7696, DOI 10.1021/ja00202a005; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; WIGGLESWORTH VB, 1972, PRINCIPLES INSECT PH, P25; Woods D F, 1993, J Cell Sci Suppl, V17, P171; YASUHARA Y, 1995, ARCH BIOCHEM BIOPHYS, V320, P14, DOI 10.1006/abbi.1995.1337	48	35	37	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11113	11125		10.1074/jbc.M008425200	http://dx.doi.org/10.1074/jbc.M008425200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11116145	hybrid			2022-12-25	WOS:000167980900073
J	Abel, ES; Davids, BJ; Robles, LD; Loflin, CE; Gillin, FD; Chakrabarti, R				Abel, ES; Davids, BJ; Robles, LD; Loflin, CE; Gillin, FD; Chakrabarti, R			Possible roles of protein kinase A in cell motility and excystation of the early diverging eukaryote Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; SWISS-MODEL; DETERMINANTS; ORGANIZATION; MECHANISM; SEQUENCE; INVITRO; CLONING; GENES; RNA	Since little is known of how the primitive protozoan parasite, Giardia lamblia, senses and responds to its changing environment, we characterized a giardial protein kinase A (gPKA) catalytic subunit with unusual subcellular localization. Sequence analysis of the 1080-base pair open reading frame shows 48% amino acid identity with the cyclic AMP-dependent kinase from Euglena gracilis, Northern analysis indicated a 1.28-kilobase pair transcript at relatively constant concentrations during growth and encystation, gPKA is autophosphorylated, although amino acid residues corresponding to Thr-197 and Ser-338 of human protein kinase A (PKA) that are important for autophosphorylation are absent, Kinetic analysis of the recombinant PKA showed that ATP and magnesium are preferred over GTP and manganese, Kinase activity of the native PKA has also been detected in crude extracts using kemptide as a substrate. A myristoylated PKA inhibitor, amide 14-22, inhibited excystation with an IC50 of 3 muM, suggesting an important role of gPKA during differentiation from the dormant cyst form into the active trophozoite, gPKA localizes independently of cell density to the eight flagellar basal bodies between the two nuclei together with centrin, a basal body/centrosome-specific protein. However, localization of gPKA to marginal plates along the intracellular portions of the anterior and caudal pairs of flagella was evident only at low cell density and higher endogenous cAMP concentrations or after refeeding with fresh medium. These data suggest an important role of PKA in trophozoite motility during vegetative growth and the cellular activation of excystation.	Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA; Univ Calif San Diego, Sch Med, Dept Pathol, Div Infect Dis, San Diego, CA 92103 USA	State University System of Florida; University of Central Florida; University of California System; University of California San Diego	Chakrabarti, R (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, 12722 Res Pkwy,Biomol Res Annex, Orlando, FL 32826 USA.	rchak@pegasus.cc.ucf.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035108] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42488] Funding Source: Medline; NIDDK NIH HHS [DK35108] Funding Source: Medline; NIGMS NIH HHS [GM53835] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam RD, 2000, INT J PARASITOL, V30, P475, DOI 10.1016/S0020-7519(99)00191-5; ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; ADAVANI SR, 1987, EUR J BIOCHEM, V167, P221, DOI 10.1111/j.1432-1033.1987.tb13326.x; BINGHAM AK, 1979, EXP PARASITOL, V47, P284, DOI 10.1016/0014-4894(79)90080-8; BURKI E, 1991, GENE, V102, P57, DOI 10.1016/0378-1119(91)90538-M; CHAKRABARTI R, 1995, GENE, V153, P163, DOI 10.1016/0378-1119(94)00751-D; COBB CE, 1988, METHOD ENZYMOL, V159, P202; DAVENPORT HW, 1977, PHYSL DIGESTIVE TRAC; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Erlandsen S.L., 1984, P33; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HABENER JF, 1995, ENDOCRINOLOGY, P77; HOLBERTON DV, 1973, J CELL SCI, V13, P11; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; LASKO P, 1995, BIOESSAYS, V17, P105, DOI 10.1002/bies.950170205; Li QD, 1998, ONCOL REP, V5, P227; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Marshall MM, 1997, CLIN MICROBIOL REV, V10, P67, DOI 10.1128/CMR.10.1.67; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; Meng TC, 1996, INFECT IMMUN, V64, P2151, DOI 10.1128/IAI.64.6.2151-2157.1996; Meng TC, 1996, MOL BIOCHEM PARASIT, V79, P103, DOI 10.1016/0166-6851(96)02636-9; Moss SB, 1999, BIOL REPROD, V61, P335, DOI 10.1095/biolreprod61.2.335; MOUJOU M, 1991, J CELL BIOL, V115, P129; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; RICE EW, 1981, J CLIN MICROBIOL, V14, P709, DOI 10.1128/JCM.14.6.709-710.1981; RUBIN CS, 1979, J BIOL CHEM, V254, P2439; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SimanTov MM, 1996, MOL BIOCHEM PARASIT, V77, P201, DOI 10.1016/0166-6851(96)02601-1; Skalhegg Bjorn S., 1997, Frontiers in Bioscience (online), V2, pD331; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; Smith MW, 1998, MOL BIOCHEM PARASIT, V95, P267, DOI 10.1016/S0166-6851(98)00113-3; SMITH PD, 1982, GASTROENTEROLOGY, V83, P797; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; UHLER MD, 1986, J BIOL CHEM, V261, P5360; Vassella E, 1997, J CELL SCI, V110, P2661; WALSH DA, 1968, J BIOL CHEM, V243, P3763; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Yang PF, 2000, J BIOL CHEM, V275, P18905, DOI 10.1074/jbc.M002134200	53	66	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10320	10329		10.1074/jbc.M006589200	http://dx.doi.org/10.1074/jbc.M006589200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11104758	Green Published, hybrid			2022-12-25	WOS:000167996400098
J	Salmon, AL; Cross, LJM; Irvine, AE; Lappin, TRJ; Dathe, M; Krause, G; Canning, P; Thim, L; Beyermann, M; Rothemund, S; Bienert, M; Shaw, C				Salmon, AL; Cross, LJM; Irvine, AE; Lappin, TRJ; Dathe, M; Krause, G; Canning, P; Thim, L; Beyermann, M; Rothemund, S; Bienert, M; Shaw, C			Peptide leucine arginine, a potent immunomodulatory peptide isolated and structurally characterized from the skin of the Northern Leopard frog, Rana pipiens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; CELL DEGRANULATING PEPTIDES; RAT MAST-CELLS; SUBSTANCE-P; ACTIVE PEPTIDES; ANTIMICROBIAL PEPTIDES; HISTAMINE-RELEASE; NEUROPEPTIDE-Y; SMOOTH-MUSCLE; VENOM	On the basis of histamine release from rat peritoneal mast cells, an octadecapeptide was isolated from the skin extract of the Northern Leopard frog (Rana pipiens), This peptide was purified to homogeneity using reversed-phase high performance liquid chromatography and found to have the following primary structure by Edman degradation and pyridylethylation: LVRGCWTKSYPPKPCFVR, in which Cys(5) and Cys(15) are disulfide bridged. The peptide was named peptide leucine-arginine (pLR), reflecting the N- and C-terminal residues. Molecular modeling predicted that pLR possessed a rigid tertiary loop structure with flexible end regions, pLR was synthesized and elicited rapid, noncytolytic histamine release that had a a-fold greater potency when compared with one of the most active histamine-liberating peptides, namely melittin, pLR was able to permeabilize negatively charged unilamellar lipid vesicles but not neutral vesicles, a finding that was consistent with its nonhemolytic action, pLR inhibited the early development of granulocyte macrophage colonies from bone marrow stem cells but did not induce apoptosis of the end stage granulocytes, i,e. mature neutrophils, pLR therefore displays biological activity with both granulopoietic progenitor cells and mast cells and thus represents a novel bioactive peptide from frog skin.	Queens Univ Belfast, Dept Med, Belfast BT12 6BJ, Antrim, North Ireland; Queens Univ Belfast, Dept Haematol, Belfast BT12 6BJ, Antrim, North Ireland; Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Univ Ulster, Dept Biotechnol, Coleraine BT52 1SA, Londonderry, North Ireland	Queens University Belfast; Queens University Belfast; Novo Nordisk; Ulster University	Salmon, AL (corresponding author), Queens Univ Belfast, Dept Med, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.		IRVINE, ALEXANDRA E/B-3497-2009	Canning, Paul/0000-0002-0888-0124				ALIAKBARI J, 1987, BIOCHEM BIOPH RES CO, V148, P1440, DOI 10.1016/S0006-291X(87)80293-0; ANASTASI A, 1965, COMP BIOCHEM PHYSIOL, V14, P43; ARGIOLAS A, 1985, PEPTIDES, V6, P431, DOI 10.1016/0196-9781(85)90410-3; ARGIOLAS A, 1984, J BIOL CHEM, V259, P106; ARGIOLAS A, 1985, J BIOL CHEM, V260, P1437; Boyer M, 1998, BRIT J CANCER, V78, P13; CARRAWAY R, 1982, J PHYSIOL-LONDON, V323, P403, DOI 10.1113/jphysiol.1982.sp014080; Cocchiara R, 1997, J NEUROIMMUNOL, V75, P9, DOI 10.1016/S0165-5728(96)00229-9; Conlon JM, 1997, PEPTIDES, V18, P361, DOI 10.1016/S0196-9781(96)00339-7; Cross LJM, 1996, BRIT J PHARMACOL, V117, P325, DOI 10.1111/j.1476-5381.1996.tb15194.x; Cross LJM, 1995, EUR J PHARM-MOLEC PH, V291, P291, DOI 10.1016/0922-4106(95)90069-1; Cross LJM, 1997, INFLAMM RES, V46, P306, DOI 10.1007/s000110050192; Dathe M, 1996, BIOCHEMISTRY-US, V35, P12612, DOI 10.1021/bi960835f; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; ERSPAMER V, 1984, COMP BIOCHEM PHYS C, V79, P1, DOI 10.1016/0742-8413(84)90153-1; ERSPAMER V, 1986, COMP BIOCHEM PHYS C, V85, P125, DOI 10.1016/0742-8413(86)90063-0; Forsythe P, 1998, CLIN EXP ALLERGY, V28, P1171; GMACHL M, 1995, J BIOL CHEM, V270, P12704, DOI 10.1074/jbc.270.21.12704; GOETZL EJ, 1995, INT ARCH ALLERGY IMM, V107, P202, DOI 10.1159/000236977; Graham GJ, 1997, BAILLIERE CLIN HAEM, V10, P539, DOI 10.1016/S0950-3536(97)80025-X; GRUNDEMAR L, 1991, BRIT J PHARMACOL, V104, P776, DOI 10.1111/j.1476-5381.1991.tb12505.x; HEANEY LG, 1995, CLIN EXP ALLERGY, V25, P179, DOI 10.1111/j.1365-2222.1995.tb01024.x; HORIKAWA R, 1985, FED PROC, V44, P695; Irvine AE, 1998, EXP HEMATOL, V26, P435; IRVINE AE, 1991, EXP HEMATOL, V19, P106; JACKSON IMD, 1977, SCIENCE, V198, P414, DOI 10.1126/science.410104; KALTREIDER HB, 1994, CLIN RES, V42, pA188; LU YA, 1990, SCI CHINA SER B, V33, P170; MIROSHNIKOV AI, 1981, BIOORG KHIM+, V7, P1467; MORIKAWA N, 1992, BIOCHEM BIOPH RES CO, V189, P184, DOI 10.1016/0006-291X(92)91542-X; NAKAJIMA T, 1970, FED PROC, V29, pA282; NAKAJIMA T, 1981, TRENDS PHARMACOL SCI, V2, P202, DOI 10.1016/0165-6147(81)90313-8; NAKAJIMA T, 1968, CHEM PHARM BULL, V16, P769; PEARCE FL, 1982, PROGR MED CHEM, V19, P59, DOI 10.1016/S0079-6468(08)70328-X; RAVAZZOLA M, 1979, LIFE SCI, V25, P1331, DOI 10.1016/0024-3205(79)90399-0; REPKE H, 1988, AGENTS ACTIONS, V23, P207, DOI 10.1007/BF02142542; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIMMACO M, 1990, BIOCHIM BIOPHYS ACTA, V1033, P318, DOI 10.1016/0304-4165(90)90140-R; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; Sterner-Kock A, 1999, J LEUKOCYTE BIOL, V65, P834, DOI 10.1002/jlb.65.6.834; TANG YQ, 1990, SCI CHINA SER B, V33, P828; Thennarasu S, 1999, BIOCHEM BIOPH RES CO, V254, P281, DOI 10.1006/bbrc.1998.9933; VLASAK R, 1983, EUR J BIOCHEM, V135, P123, DOI 10.1111/j.1432-1033.1983.tb07626.x; YASUHARA T, 1979, CHEM PHARM BULL, V27, P492; YASUHARA T, 1979, CHEM PHARM BULL, V27, P486; YASUHARA T, 1984, PEPTIDE CHEM 1983; YASUHARA T, 1985, PEPTIDE CHEM 1984; YASUHARA T, 1986, PEPTIDE CHEM 1985, P363; Yasuhara T., 1987, PEPTIDE CHEM, P69; YASUHARA T, 1983, PEPTIDE CHEM 1982	53	41	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10145	10152		10.1074/jbc.M009680200	http://dx.doi.org/10.1074/jbc.M009680200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11099505	hybrid			2022-12-25	WOS:000167996400075
J	Till, JH; Ablooglu, AJ; Frankel, M; Bishop, SM; Kohanski, RA; Hubbard, SR				Till, JH; Ablooglu, AJ; Frankel, M; Bishop, SM; Kohanski, RA; Hubbard, SR			Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase - Insights into kinase mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; DOMAIN; AUTOPHOSPHORYLATION; SRC; PHOSPHORYLATION; INHIBITOR; COMPLEX; FAMILY	The tyrosine kinase domain of the insulin receptor is subject to autoinhibition in the unphosphorylated basal state via steric interactions involving the activation loop. A mutation in the activation loop designed to relieve autoinhibition, Asp-1161 --> Ala, substantially increases the ability of the unphosphorylated kinase to bind ATP. The crystal structure of this mutant in complex with an ATP analog has been determined at 2.4-Angstrom resolution. The structure shows that the active site is unobstructed, but the end of the activation loop is disordered and therefore the binding site for peptide substrates is not fully formed. In addition, Phe-1151 of the protein kinase-conserved DFG motif, at the beginning of the activation loop, hinders closure of the catalytic cleft and proper positioning of alpha -helix C for catalysis, These results, together with viscometric kinetic measurements, suggest that peptide substrate binding induces a reconfiguration of the unphosphorylated activation loop prior to the catalytic step. The crystallographic and solution studies provide new insights into the mechanism by which the activation loop controls phosphoryl transfer as catalyzed by the insulin receptor.	CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York University; New York University	Kohanski, RA (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA.			Hubbard, Stevan/0000-0002-2707-9383	NIDDK NIH HHS [DK52916, DK50074] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050074, R01DK052916] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Bishop SM, 1999, BIOCHEMISTRY-US, V38, P3079, DOI 10.1021/bi982546s; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cann AD, 1997, BIOCHEMISTRY-US, V36, P7681, DOI 10.1021/bi970170x; CHLEBOWSKI JF, 1974, J BIOL CHEM, V249, P7192; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Frankel M, 1999, PROTEIN SCI, V8, P2158, DOI 10.1110/ps.8.10.2158; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P1533, DOI 10.1021/bi952435i; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; White MF, 1998, CURR TOP MICROBIOL, V228, P179; WHITE MF, 1988, J BIOL CHEM, V263, P2969; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423	40	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10049	10055		10.1074/jbc.M010161200	http://dx.doi.org/10.1074/jbc.M010161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124964	hybrid			2022-12-25	WOS:000167996400064
J	Wang, J; Dreyfuss, G				Wang, J; Dreyfuss, G			A cell system with targeted disruption of the SMN gene - Functional conservation of the SMN protein and dependence of gemin2 on SMN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; SURVIVAL MOTOR-NEURON; TRANSCRIPTION IN-VIVO; MOLECULAR ANALYSIS; BINDING-PROTEIN; MOUSE MODEL; PRODUCT; COMPLEX; DISEASE; ORTHOLOGUE	The motor neuron degenerative disease spinal muscular atrophy is caused by reduced expression of the survival motor neuron (SMN) protein. Here we report a genetic system developed in the chicken pre-B cell line DT40, in which the endogenous SMN gene is disrupted by homologous recombination, and SMN protein is expressed from a chicken SMN cDNA under control of a tetracycline (tet)-repressible promoter. Addition of tet results in depletion of SMN protein and consequent cell death, which directly demonstrates that SMN is required for cell viability. The tet-induced lethality can be rescued by expression of human SMN, indicating that the function of SMN is highly conserved between the two species. Cells expressing low levels of SMN display slow growth proportional to the amount of SMN they contain. Interestingly, the level of the SMN-interacting protein Gemin2 decreases significantly following depletion of SMN, supporting the conclusion that SMN and Gemin2 form a stable complex in vivo, This system provides a powerful setting for studying the function of SMN in vivo and for screening for potential therapeutics for spinal muscular atrophy.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Bechade C, 1999, EUR J NEUROSCI, V11, P293, DOI 10.1046/j.1460-9568.1999.00428.x; Bertrandy S, 1999, HUM MOL GENET, V8, P775, DOI 10.1093/hmg/8.5.775; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; CHANG JG, 1995, AM J HUM GENET, V57, P1503; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; COBBEN JM, 1995, AM J HUM GENET, V57, P805; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Frugier T, 2000, HUM MOL GENET, V9, P849, DOI 10.1093/hmg/9.5.849; GALL JG, 1995, DEV GENET, V16, P25, DOI 10.1002/dvg.1020160107; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen E, 1996, AM J HUM GENET, V59, P1057; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; Hsieh-Li HM, 2000, NAT GENET, V24, P66, DOI 10.1038/71709; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lorson CL, 1998, HUM MOL GENET, V7, P1269, DOI 10.1093/hmg/7.8.1269; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; Monani UR, 2000, HUM MOL GENET, V9, P333, DOI 10.1093/hmg/9.3.333; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Owen N, 2000, HUM MOL GENET, V9, P675, DOI 10.1093/hmg/9.5.675; Pagliardini S, 2000, HUM MOL GENET, V9, P47, DOI 10.1093/hmg/9.1.47; Paushkin S, 2000, J BIOL CHEM, V275, P23841, DOI 10.1074/jbc.M001441200; PEARN J, 1980, LANCET, V1, P919; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Williams BY, 2000, FEBS LETT, V470, P207, DOI 10.1016/S0014-5793(00)01320-X	45	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9599	9605		10.1074/jbc.M009162200	http://dx.doi.org/10.1074/jbc.M009162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11121410	hybrid, Green Submitted			2022-12-25	WOS:000167996400004
J	Lewis, RT; Andreucci, A; Nikolajczyk, BS				Lewis, RT; Andreucci, A; Nikolajczyk, BS			PU.1-mediated transcription is enhanced by HMG-I(Y)-dependent structural mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN GENE ENHANCER; IFN-BETA GENE; GROUP PROTEIN I/Y; DNA-BINDING; HMG I(Y); IN-VITRO; DEPENDENT TRANSCRIPTION; IMMUNOGLOBULIN ENHANCER; VIRUS INDUCTION; FACTOR PU.1	The ets transcription factor PU.1 is an important regulator of the immunoglobulin heavy chain gene intronic enhancer, or mu enhancer. However, PU.1 is only one component of the large multiprotein complex required for B cell-specific enhancer activation. The transcriptional coactivator HMG-I(Y), a protein demonstrated to physically interact with PU.1, increases PU.1 affinity for the mu enhancer muB element, indicating that HMG-I(Y) may play a role in the transcriptionally active mu enhanceosome. Increased PU.1 affinity is not mediated by HMG-I(Y)-induced changes in DNA structure. Investigation of alternative mechanisms to explain the HMG-I(Y)-mediated increase in PU.1/mu enhancer binding demonstrated, by trypsin and chymotrypsin mapping, that interaction between PU.1 and HMG-I(Y) in solution induces a structural change in PU.1. In the presence of HMG-I(Y) and wild-type mu enhancer DNA, PU.1 becomes more chymotrypsin resistant, suggesting an additional change in PU.1 structure upon HMG-I(Y)-induced PU.1/DNA binding, From these results, we suggest that increased DNA affinity under limiting PU.1 concentrations is mediated by an HMG-I(Y)-induced structural change in PU.1. In functional assays, HMG-I(Y) further augments transcriptional synergy between PU.1 and another member of the ets family; Ets-1, indicating that HMG-I(Y) is a functional component of the active enhancer complex. These studies suggest a new mechanism for HMG-I(Y)-mediated coactivation; HMG-I(Y) forms protein-protein interactions with a transcription factor, which alters the three-dimensional structure of the factor, resulting in enhanced DNA binding and transcriptional activation. This mechanism may be important for transcriptional activation under conditions of limiting transcription factor concentration such as at the low levels of PU.1 expressed in B cells.	Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA	Boston University; Boston University	Nikolajczyk, BS (corresponding author), Boston Univ, Sch Med, Dept Med, 650 Albany St X-438, Boston, MA 02118 USA.							ABDULKADIR SA, 1995, J EXP MED, V182, P487, DOI 10.1084/jem.182.2.487; Akbarali Y, 1996, J BIOL CHEM, V271, P26007, DOI 10.1074/jbc.271.42.26007; Bagga R, 1997, GENE DEV, V11, P629, DOI 10.1101/gad.11.5.629; Bagga R, 1998, COLD SPRING HARB SYM, V63, P569, DOI 10.1101/sqb.1998.63.569; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; Dang W, 1998, MOL CELL BIOL, V18, P6870, DOI 10.1128/MCB.18.11.6870; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Erman B, 1996, EMBO J, V15, P4665, DOI 10.1002/j.1460-2075.1996.tb00843.x; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 2000, J IMMUNOL, V164, P3157, DOI 10.4049/jimmunol.164.6.3157; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Nikolajczyk BS, 1997, MOL CELL BIOL, V17, P3527, DOI 10.1128/MCB.17.7.3527; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; Nikolajczyk BS, 1999, COLD SPRING HARB SYM, V64, P99, DOI 10.1101/sqb.1999.64.99; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Reeves R, 2000, MOL CELL BIOL, V20, P4666, DOI 10.1128/MCB.20.13.4666-4679.2000; Sakai E, 1999, P NATL ACAD SCI USA, V96, P1526, DOI 10.1073/pnas.96.4.1526; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Stevens S, 1996, J IMMUNOL, V157, P3491; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; Tian G, 1999, MOL CELL BIOL, V19, P2946; Wang DZ, 1997, J BIOL CHEM, V272, P25083, DOI 10.1074/jbc.272.40.25083; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649	49	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9550	9557		10.1074/jbc.M008726200	http://dx.doi.org/10.1074/jbc.M008726200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124259	hybrid			2022-12-25	WOS:000167607700123
J	Kristof, AS; Marks-Konczalik, J; Moss, J				Kristof, AS; Marks-Konczalik, J; Moss, J			Mitogen-activated protein kinases mediate activator protein-1-dependent human inducible nitric-oxide synthase promoter activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR AP-1; INDUCED LETHAL TOXICITY; TATA-BINDING PROTEIN; TOLL-LIKE RECEPTOR-2; ERK MAP KINASE; TYROSINE KINASE; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; GENE-EXPRESSION	Inducible nitric-oxide synthase (iNOS) is an important signaling protein involved in the regulation of biological processes (e.g. vasodilation, inflammation) and is subject to transcriptional regulation by cytokines and lipopolysaccharide (LPS). Full activation of the human iNOS (hiNOS) promoter by cytokines (i.e., tumor necrosis factor-alpha, interleukin-1 alpha, interferon-gamma (IFN-gamma)) required downstream and upstream nuclear factor-KB (-115, -8283) and activator protein-1 (AP-1) (-5115, -5301) transcription factor binding sites. Human lung epithelial (A549) cells were transiently transfected with luciferase reporter plasmids containing an 8.3-kilobase human iNOS promoter to examine the molecular signaling events necessary for hiNOS transcriptional activation. The combination of LPS and IFN-gamma, but neither alone, increased hiNOS promoter activity 28-fold, in a reaction requiring two critical AP-1 (JunD.Fra-2) promoter binding sites. Mitogen-activated protein kinases (MAPKs) were assessed as potential activators of AP-1 and the hiNOS promoter. Both pharmacological and molecular inhibitors of the extracellular signal-related kinase (ERK) and p38 pathways reduced cytokine mixture (CM)- and LPS/IFN-gamma -induced promoter activation. By gel retardation analysis, the addition of MAP/ERK kinase-1 and p38 inhibitors significantly diminished AP-1 binding in both CM- and LPS/IFN-gamma -stimulated cells. Thus, p38- and ERK dependent pathways, through effects on the AP-1 complex, activate the hiNOS promoter in cells stimulated with CM or LPS/IFN-gamma.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kristof, AS (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 5N307,MSC 1434,9000 Rockville Pike, Bethesda, MD 20892 USA.	kristofa@nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Biggs JR, 1998, CELL GROWTH DIFFER, V9, P667; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; CARMICHAEL J, 1988, BRIT J CANCER, V57, P540, DOI 10.1038/bjc.1988.125; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Cruz MT, 1999, AM J PHYSIOL-CELL PH, V277, pC1050, DOI 10.1152/ajpcell.1999.277.6.C1050; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Dlaska M, 1999, J IMMUNOL, V162, P6171; DONG Z, 1998, J EXP MED, V177, P1071; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Feng GJ, 1999, J IMMUNOL, V163, P6403; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kim YM, 1999, MOL CELLS, V9, P99; Kleinert H, 1998, BRIT J PHARMACOL, V123, P1716, DOI 10.1038/sj.bjp.0701782; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Martel-Pelletier J, 1999, ARTHRITIS RHEUM-US, V42, P2399, DOI 10.1002/1529-0131(199911)42:11<2399::AID-ANR19>3.0.CO;2-Y; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Ruetten H, 1997, BRIT J PHARMACOL, V122, P59, DOI 10.1038/sj.bjp.0701345; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sevransky JE, 1997, J CLIN INVEST, V99, P1966, DOI 10.1172/JCI119364; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Thiemermann C, 1997, GEN PHARMACOL-VASC S, V29, P159, DOI 10.1016/S0306-3623(96)00410-7; Thomas JE, 1997, J CELL BIOCHEM, V64, P182, DOI 10.1002/(SICI)1097-4644(199702)64:2<182::AID-JCB2>3.0.CO;2-T; Treinies I, 1999, MOL CELL BIOL, V19, P321; Vanichkin A, 1996, J INFECT DIS, V173, P927, DOI 10.1093/infdis/173.4.927; Wang LH, 1999, J IMMUNOL, V162, P3897; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yang RB, 1999, J IMMUNOL, V163, P639; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; Zachos G, 1999, J BIOL CHEM, V274, P5097, DOI 10.1074/jbc.274.8.5097; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	61	147	149	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8445	8452		10.1074/jbc.M009563200	http://dx.doi.org/10.1074/jbc.M009563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11112784	hybrid			2022-12-25	WOS:000167474900104
J	Ogawa, M; Herai, Y; Koizumi, N; Kusano, T; Sano, H				Ogawa, M; Herai, Y; Koizumi, N; Kusano, T; Sano, H			7-Methylxanthine methyltransferase of coffee plants - Gene isolation and enzymatic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEA-LEAF EXTRACTS; CAFFEINE BIOSYNTHESIS; PURINE ALKALOIDS; LEAVES; METABOLISM; XANTHOSINE; SYNTHASE; ARABICA	Caffeine is synthesized through sequential three-step methylation of xanthine derivatives at positions 7-N, 3-N, and 1-N, However, controversy exists as to the number and properties of the methyltransferases involved. Using primers designed on the basis of conserved amino acid regions of tea caffeine synthase and Arabidopsis hypothetical proteins, a particular DNA fragment was amplified from an mRNA population of coffee plants. Subsequently, this fragment was used as a probe, and four independent clones were isolated from a cDNA Library derived from coffee young leaves. Upon expression in Escherichia coli, one of them was found to encode a protein possessing 7-methylxanthine methyltransferase activity and was designated as C alpha MXMT. It consists of 378 amino acids with a relative molecular mass of 42.7 kDa and shows similarity to tea caffeine synthase (35.8%) and salicylic acid methyltransferase (34.1%). The bacterially expressed protein exhibited an optimal pH for activity ranging between 7 and 9 and methylated almost exclusively 7-methylxanthine with low activity toward paraxanthine, indicating a strict substrate specificity regarding the 3-N position of the purine ring, K-m values were estimated to be 50 and 12 muM for 7-methylxanthine and S-adenosyl-L-methionine, respectively. Transcripts of CaMXMT could be shown to accumulate in young leaves and stems containing buds and green fluorescent protein fusion protein assays indicated localization in cytoplasmic fractions. The results suggest that, in coffee plants, caffeine is synthesized through three independent methylation steps from xanthosine, in which CaMXMT catalyzes the second step to produce theobromine.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan	Nara Institute of Science & Technology	Sano, H (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan.							Ashihara H, 1999, ADV BOT RES, V30, P117; Ashihara H, 1996, PLANT PHYSIOL, V111, P747, DOI 10.1104/pp.111.3.747; Ashihara H, 1998, J PLANT RES, V111, P599, DOI 10.1007/BF02507798; BAUMANN T W, 1983, Plant Cell Reports, V2, P33, DOI 10.1007/BF00269231; CHENG X, 1999, S ADENOSYLMETHIONINE, P3; Croteau R., 2000, BIOCH MOL BIOL PLANT, P1250, DOI DOI 10.1201/B11003-3; Dudareva N, 2000, PLANT CELL, V12, P949, DOI 10.1105/tpc.12.6.949; Hara K, 2000, MOL GEN GENET, V263, P30, DOI 10.1007/PL00008673; Hatanaka T, 1999, PLANT CELL REP, V19, P106, DOI 10.1007/s002990050719; Hernandez A, 1998, BIOINFORMATICS, V14, P227, DOI 10.1093/bioinformatics/14.2.227; Ikeda Y, 1999, PLANT PHYSIOL, V121, P813, DOI 10.1104/pp.121.3.813; Kato M, 2000, NATURE, V406, P956, DOI 10.1038/35023072; Kato M, 1996, PHYSIOL PLANTARUM, V98, P629, DOI [10.1111/j.1399-3054.1996.tb05720.x, 10.1034/j.1399-3054.1996.980325.x]; Kato M, 1999, PLANT PHYSIOL, V120, P579, DOI 10.1104/pp.120.2.579; MOZZAFERA P, 1994, PHYTOCHEMISTRY, V37, P1577; NEGISHI O, 1985, AGR BIOL CHEM TOKYO, V49, P887, DOI 10.1080/00021369.1985.10866823; ROBERTS MF, 1979, PHYTOCHEMISTRY, V18, P451, DOI 10.1016/S0031-9422(00)81886-5; ROBERTS MF, 1998, ALKALOIDS BIOCH ECOL, P11; Ross JR, 1999, ARCH BIOCHEM BIOPHYS, V367, P9, DOI 10.1006/abbi.1999.1255; STILES JI, 1997, Patent No. 9735960; SUZUKI T, 1975, BIOCHEM J, V146, P87, DOI 10.1042/bj1460087; Waldhauser SSM, 1997, PHYTOCHEMISTRY, V44, P853, DOI 10.1016/S0031-9422(96)00662-0; Waldhauser SSM, 1997, PHYTOCHEMISTRY, V45, P1407, DOI 10.1016/S0031-9422(97)00187-8	23	95	120	3	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8213	8218		10.1074/jbc.M009480200	http://dx.doi.org/10.1074/jbc.M009480200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11108716	hybrid			2022-12-25	WOS:000167474900075
J	Yang, ZT; Strickland, DK; Bornstein, P				Yang, ZT; Strickland, DK; Bornstein, P			Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; CELLULAR INTERNALIZATION; MATRICELLULAR PROTEIN; HIGH-AFFINITY; DEGRADATION; LRP; ANGIOGENESIS; INHIBITOR; BINDING	We have recently shown that the adhesive defect observed in dermal fibroblasts derived from thrombospondin 2 (TSP2)-null mice results from an increase in matrix metalloproteinase 2 (MMP2) levels (Yang, Z., Kyriakides, T. R., and Bornstein, P. (2000) Mol. Biol. Cell 11, 3353-3364). Adhesion was restored by replacement of TSP2 and by inhibitors of MMP2 activity. In pursuing the observation that TSP2 and MMP2 interact, we now demonstrate that this interaction is required for optimal clearance of extracellular MMP2 by fibroblasts. Since TSP2 is known to be endocytosed by the scavenger receptor, low density lipoprotein receptor-related protein (LRP), we determined whether interference with LRP function affected fibroblast adhesion and/or extracellular MMP2 levels. Addition of heparin, which competes for the binding of TSP2 to LRP coreceptor proteoglycans, inhibited adhesion of control but not TSP2-null cells, and a blocking antibody to LRP as well as the LRP inhibitor, receptor-associated protein, also inhibited adhesion and increased MMP2 levels only in control fibroblasts. TSP2 did not inhibit active MMP2 directly and did not inhibit the activation of pro-MMP2. Finally, the internalization of I-125-MMP2 was reduced in TSP2-null compared with control fibroblasts. We propose that clearance of MMP2-TSP2 complexes by LRP is an important mechanism for the regulation of extracellular MMP2 levels in fibroblasts, and perhaps in other cells. Thus, some features of the phenotype of TSP2-null mice, such as abnormal collagen fibrillogenesis, accelerated wound healing, and increased angiogenesis, could result in part from increased MMP2 activity.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Amer Red Cross, Dept Vasc Biol, Rockville, MD 20855 USA	University of Washington; University of Washington Seattle; American Red Cross	Bornstein, P (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	bornsten@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045418] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 50784] Funding Source: Medline; NIAMS NIH HHS [AR 45418] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Barmina OY, 1999, J BIOL CHEM, V274, P30087, DOI 10.1074/jbc.274.42.30087; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Birkenmeier G, 1998, ARCH DERMATOL RES, V290, P561, DOI 10.1007/s004030050352; Bornstein P, 2000, MATRIX BIOL, V19, P557, DOI 10.1016/S0945-053X(00)00104-9; Bornstein P, 2000, J INVEST DERM SYMP P, V5, P61, DOI 10.1046/j.1087-0024.2000.00005.x; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; Chen H, 1996, BIOCHEM J, V318, P959, DOI 10.1042/bj3180959; Chen H, 1996, J BIOL CHEM, V271, P15993, DOI 10.1074/jbc.271.27.15993; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Hamik A, 1999, J BIOL CHEM, V274, P4962, DOI 10.1074/jbc.274.8.4962; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOGG PJ, 1994, THROMB HAEMOSTASIS, V72, P787; Itoh T, 1998, CANCER RES, V58, P1048; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; Kyriakides TR, 1999, J INVEST DERMATOL, V113, P782, DOI 10.1046/j.1523-1747.1999.00755.x; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Kyriakides TR, 1998, J HISTOCHEM CYTOCHEM, V46, P1007, DOI 10.1177/002215549804600904; Kyriakides TR, 1999, P NATL ACAD SCI USA, V96, P4449, DOI 10.1073/pnas.96.8.4449; LAFUMA C, 1994, J INVEST DERMATOL, V102, P945, DOI 10.1111/1523-1747.ep12384118; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; SAGE H, 1986, J BIOL CHEM, V261, P7082; Silletti S, 1999, FIBRINOLYSIS PROTEOL, V13, P226, DOI 10.1054/fipr.2000.0042; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, J CELL SCI, V107, P719; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353	42	225	235	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8403	8408		10.1074/jbc.M008925200	http://dx.doi.org/10.1074/jbc.M008925200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113133	hybrid			2022-12-25	WOS:000167474900099
J	Nguyen, R; Reczek, D; Bretscher, A				Nguyen, R; Reczek, D; Bretscher, A			Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN BINDING; NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; ERM PROTEINS; GENE-PRODUCT; EZRIN/RADIXIN/MOESIN PROTEINS; IN-VITRO; NHE-RF; MOESIN; PHOSPHORYLATION; FAMILY	The neurofibromatosis 2 tumor suppressor gene product merlin has strong sequence identity to the ezrin-radixin-moesin (ERM) family over its similar to 300-residue N-terminal domain, ERM proteins are membrane cytoskeletal linkers that are negatively regulated by an intramolecular association between domains known as NH2- and COOH-ERM association domains (N and C-ERMADs) that mask sites for binding membrane-associated proteins, such as EBP50 and E3KARP, and F-actin. Here we show that merlin has self-association regions analogous to the N- and C-ERMADs. Moreover, the N-/C-ERMAD interaction in merlin is relatively weak and dynamic, and this property is reflected by the ability of full-length recombinant merlin to form homooligomers, Remarkably, the merlin C-ERMAD has a higher affinity for the N-ERMAD of ezrin than the N-ERMAD of merlin, Both the ezrin and merlin N-ERMAD) bind EBP50, This interaction with the ezrin N-ERMAD can be inhibited by the presence of the ezrin C-ERMAD, whereas interaction with the merlin N-ERMAD is not inhibited by either C-ERMAD, E3KARP binds tightly to the ezrin N-ERMAD but has little affinity for the merlin N-ERMAD, The implications of these associations and the hierarchies of binding for the function and regulation of merlin and ERM proteins are discussed.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Bretscher, A (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Biotechnol Bldg, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM36652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akisawa N, 1999, BIOCHEM BIOPH RES CO, V258, P395, DOI 10.1006/bbrc.1999.0653; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; den Bakker MA, 1999, J HISTOCHEM CYTOCHEM, V47, P1471; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Gronholm M, 1999, J CELL SCI, V112, P895; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Huang LQ, 1998, BIOCHEM BIOPH RES CO, V248, P548, DOI 10.1006/bbrc.1998.9009; Huynh DP, 1996, CELL GROWTH DIFFER, V7, P1551; Kaul SC, 1999, EXP CELL RES, V250, P51, DOI 10.1006/excr.1999.4491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Maeda M, 1999, ONCOGENE, V18, P4788, DOI 10.1038/sj.onc.1202871; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; PYKETT MJ, 1994, HUM MOL GENET, V3, P559, DOI 10.1093/hmg/3.4.559; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Simons PC, 1998, BIOCHEM BIOPH RES CO, V253, P561, DOI 10.1006/bbrc.1998.9823; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Weinman EJ, 1997, EXP NEPHROL, V5, P449; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	49	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7621	7629		10.1074/jbc.M006708200	http://dx.doi.org/10.1074/jbc.M006708200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11106646	hybrid			2022-12-25	WOS:000167442900103
J	Sun, AQ; Arrese, MA; Zeng, L; Swaby, I; Zhou, MM; Suchy, FJ				Sun, AQ; Arrese, MA; Zeng, L; Swaby, I; Zhou, MM; Suchy, FJ			The rat liver Na+/bile acid cotransporter - Importance of the cytoplasmic tail to function and plasma membrane targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL SORTING SIGNAL; DARBY CANINE KIDNEY; INTERNALIZATION SIGNAL; TRANSFERRIN RECEPTOR; EPITHELIAL-CELLS; TYROSINE; LOCALIZATION; DOMAIN; DISTINCT; ENDOCYTOSIS	To understand the potential functions of the cytoplasmic tail of Na+/taurocholate cotransporter (Ntcp) and to determine the basolateral sorting mechanisms for this transporter, green fluorescent protein-fused wild type and mutant rat Ntcps were constructed and the transport properties and cellular localization were assessed in transfected COS 7 and Madin-Darby canine kidney (MDCK) cells. Truncation of the 56-amino acid cytoplasmic tail demonstrates that the cytoplasmic tail of rat Ntcp is involved membrane delivery of this protein in nonpolarized and polarized cells and removal of the tail does not affect the bile acid transport function of Ntcp, Using site-directed mutagenesis, two tyrosine residues, Tyr-321 and Tyr-307, in the cytoplasmic tail of Ntcp have been identified as important for the basolateral sorting of rat Ntcp in transfected MDCK cells. Tyr-321 appears to be the major basolateral-sorting determinant, and Tyr-307 acts as a supporting determinant to ensure delivery of the transporter to the basolateral surface, especially at high levels of protein expression, When the two Tyr-based basolateral sorting motifs have been removed, the N-linked carbohydrate groups direct the tyrosine to alanine mutants to the apical surface of transfected MDCK cells. The major basolateral sorting determinant Tyr-321 is within a novel beta -turn unfavorable tetrapeptide Y(321)KAA, which has not been found in any naturally occurring basolateral sorting motifs, Two-dimensional NMR spectroscopy of a 24-mer peptide corresponding to the sequence from Tyr-307 to Thr-330 on the cytoplasmic tail of Ntcp confirms that both the Tyr-321 and Tyr-307 regions do not adopt any turn structure. Since the major motif YKAA contains a beta -turn unfavorable structure, the Ntcp basolateral sorting may not be related to the clathrin-adaptor complex pathway, as is the case for many basolateral proteins.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Mt Sinai Sch Med, Struct Biol Program, Dept Physiol & Biophys, New York, NY 10029 USA; Catholic Univ Chile, Sch Med, Dept Gastroenterol, Santiago 6510260, Chile	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Pontificia Universidad Catolica de Chile	Sun, AQ (corresponding author), Mt Sinai Sch Med, Dept Pediat, Box 1664,1 Gustav L Levy Pl, New York, NY 10029 USA.		ARRESE, MARCO/ABB-9061-2021		NCRR NIH HHS [1 S10 RR0 9145-01] Funding Source: Medline; NICHD NIH HHS [HD20632] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020632, R37HD020632] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Aroeti B, 1998, BBA-REV BIOMEMBRANES, V1376, P57, DOI 10.1016/S0304-4157(98)00005-7; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Beau I, 1998, J BIOL CHEM, V273, P18610, DOI 10.1074/jbc.273.29.18610; BOYER JL, 1993, P NATL ACAD SCI USA, V90, P435, DOI 10.1073/pnas.90.2.435; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CourtoisCoutry N, 1997, CELL, V90, P501, DOI 10.1016/S0092-8674(00)80510-3; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FINDLAY J, 1990, TRENDS PHARMACOL SCI, V11, P492, DOI 10.1016/0165-6147(90)90050-I; Hagenbuch B., 1996, Hepatology, V24, p368A; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KHORANA HG, 1992, J BIOL CHEM, V267, P1; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; Matter K, 2000, CURR BIOL, V10, pR39, DOI 10.1016/S0960-9822(99)00256-0; Meier PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG801, DOI 10.1152/ajpgi.1995.269.6.G801; Mukhopadhayay S, 1997, AM J PHYSIOL-GASTR L, V273, pG842, DOI 10.1152/ajpgi.1997.273.4.G842; Mukhopadhyay S, 1998, J BIOL CHEM, V273, P30039, DOI 10.1074/jbc.273.45.30039; Mukhopadhyay S, 1998, HEPATOLOGY, V28, P1629, DOI 10.1002/hep.510280624; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4; SUCHY FJ, 1993, SEMIN LIVER DIS, V13, P235, DOI 10.1055/s-2007-1007352; Sun AQ, 1998, AM J PHYSIOL-GASTR L, V275, pG1045, DOI 10.1152/ajpgi.1998.275.5.G1045; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Yeaman C, 1996, AM J PHYSIOL-CELL PH, V270, pC753, DOI 10.1152/ajpcell.1996.270.3.C753	44	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6825	6833		10.1074/jbc.M008797200	http://dx.doi.org/10.1074/jbc.M008797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11112779	hybrid			2022-12-25	WOS:000167261000096
J	Brosh, RM; Majumdar, A; Desai, S; Hickson, ID; Bohr, VA; Seidman, MM				Brosh, RM; Majumdar, A; Desai, S; Hickson, ID; Bohr, VA; Seidman, MM			Unwinding of a DNA triple helix by the Werner and Bloom syndrome helicases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; SINGLE-STRANDED-DNA; REPLICATION PROTEIN-A; BINDING-PROTEIN; HUMAN-CELLS; FORMING-OLIGONUCLEOTIDES; QUARTET STRUCTURES; MUTATOR PHENOTYPE; TELOMERIC DNA; 3RD STRAND	Bloom syndrome and Werner syndrome are genome instability disorders, which result from mutations in two different genes encoding helicases, Both enzymes are members of the RecQ family of helicases, have a 3' --> 5' polarity, and require a 3' single strand tail. In addition to their activity in unwinding duplex substrates, recent studies show that the two enzymes are able to unwind G2 and G4 tetraplexes, prompting speculation that failure to resolve these structures in Bloom syndrome and Werner syndrome cells may contribute to genome instability. The triple helix is another alternate DNA structure that can be formed by sequences that are widely distributed throughout the human genome. Here we show that purified Bloom and Werner helicases can unwind a DNA triple helix. The reactions are dependent on nucleoside triphosphate hydrolysis and require a free 3' tail attached to the third strand. The two enzymes unwound triplexes without requirement for a duplex extension that would form a fork at the junction of the tail and the tripler. In contrast, a duplex formed by the third strand and a complement to the tripler region was a poor substrate for both enzymes. However, the same duplex was readily unwound when a noncomplementary 5' tail was added to form a forked structure. It seems likely that structural features of the tripler mimic those of a fork and thus support efficient unwinding by the two helicases.	NIA, Mol Genet Lab, NIH, Baltimore, MD 21224 USA; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cancer Research UK; University of Oxford	Seidman, MM (corresponding author), NIA, Mol Genet Lab, NIH, Box 1,GRC,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020	Hickson, Ian/0000-0002-0583-566X	NATIONAL INSTITUTE ON AGING [ZIAAG000726, Z01AG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agazie YM, 1996, BIOCHEM J, V316, P461, DOI 10.1042/bj3160461; Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; BASSETS I, 1999, NUCLEIC ACIDS RES, V27, P3267; Benet A, 1999, J MOL BIOL, V294, P851, DOI 10.1006/jmbi.1999.3295; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; BRERETON HM, 1993, NUCLEIC ACIDS RES, V21, P2563, DOI 10.1093/nar/21.11.2563; Brosh RM, 2000, NUCLEIC ACIDS RES, V28, P2420, DOI 10.1093/nar/28.12.2420; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chan PP, 1997, J MOL MED, V75, P267, DOI 10.1007/s001090050112; COLLICK A, 1991, NUCLEIC ACIDS RES, V19, P6399, DOI 10.1093/nar/19.23.6399; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gacy AM, 1998, BIOCHEMISTRY-US, V37, P9426, DOI 10.1021/bi980157s; Gacy AM, 1998, MOL CELL, V1, P583, DOI 10.1016/S1097-2765(00)80058-1; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Giovannangeli C, 1997, ANTISENSE NUCLEIC A, V7, P413, DOI 10.1089/oli.1.1997.7.413; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Guieysse AL, 1997, J MOL BIOL, V267, P289, DOI 10.1006/jmbi.1997.0884; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hisama FM, 2000, CANCER RES, V60, P2372; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 1999, J BIOL CHEM, V274, P6889, DOI 10.1074/jbc.274.11.6889; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KOHWI Y, 1993, GENE DEV, V7, P1766, DOI 10.1101/gad.7.9.1766; Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330; KUSUNOKI Y, 1994, JPN J CANCER RES, V85, P610, DOI 10.1111/j.1349-7006.1994.tb02403.x; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LIU QR, 1990, J MOL BIOL, V212, P453, DOI 10.1016/0022-2836(90)90324-F; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MAINE IP, 1994, BIOCHEM BIOPH RES CO, V204, P1119, DOI 10.1006/bbrc.1994.2578; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; Martin GM, 1997, MOL MED, V3, P356, DOI 10.1007/BF03401682; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1983, J BIOL CHEM, V258, P4017; Matson SW, 1995, METHOD ENZYMOL, V262, P389; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; Miyagawa K, 1998, INT J HEMATOL, V67, P3; Musso M, 1998, BIOCHEMISTRY-US, V37, P3086, DOI 10.1021/bi9717486; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Pearson CE, 1998, CURR OPIN STRUC BIOL, V8, P321, DOI 10.1016/S0959-440X(98)80065-1; Picha KM, 1998, J BIOL CHEM, V273, P27315, DOI 10.1074/jbc.273.42.27315; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; ROONEY SM, 1995, P NATL ACAD SCI USA, V92, P2141, DOI 10.1073/pnas.92.6.2141; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Salk D, 1985, Basic Life Sci, V35, P419; SEN D, 1992, METHOD ENZYMOL, V211, P191; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SEO YS, 1993, J BIOL CHEM, V268, P10282; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; SHIRAISHI Y, 1990, CANCER GENET CYTOGEN, V50, P175, DOI 10.1016/0165-4608(90)90178-D; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; SINDEN RR, 1984, J BIOL CHEM, V259, P6593; SULLIVAN NF, 1992, BIOESSAYS, V14, P333, DOI 10.1002/bies.950140508; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tachibana A, 1996, MOL CARCINOGEN, V17, P41, DOI 10.1002/(SICI)1098-2744(199609)17:1<41::AID-MC6>3.3.CO;2-Z; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; TUTEJA N, 1995, NUCLEIC ACIDS RES, V23, P2457, DOI 10.1093/nar/23.13.2457; Tuteja N, 1998, PLANT PHYSIOL, V118, P1029, DOI 10.1104/pp.118.3.1029; Van Raay T J, 1996, Microb Comp Genomics, V1, P317; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Wang Y, 2000, GENE DEV, V14, P927; WARREN ST, 1981, P NATL ACAD SCI-BIOL, V78, P3133, DOI 10.1073/pnas.78.5.3133; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; YU A, 1995, NUCLEIC ACIDS RES, V23, P4055, DOI 10.1093/nar/23.20.4055; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	95	97	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3024	3030		10.1074/jbc.M006784200	http://dx.doi.org/10.1074/jbc.M006784200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11110789	hybrid			2022-12-25	WOS:000166784900009
J	Manenti, G; Peissel, B; Gariboldi, M; Falvella, FS; Zaffaroni, D; Allaria, B; Pazzaglia, S; Rebessi, S; Covelli, V; Saran, A; Dragani, TA				Manenti, G; Peissel, B; Gariboldi, M; Falvella, FS; Zaffaroni, D; Allaria, B; Pazzaglia, S; Rebessi, S; Covelli, V; Saran, A; Dragani, TA			A cancer modifier role for parathyroid hormone-related protein	ONCOGENE			English	Article						linkage disequilibrium; skin cancer	CHEMICAL CARCINOGENESIS; SKIN CARCINOGENESIS; MICE; GROWTH; PEPTIDE; HYPERCALCEMIA; RESISTANCE; CARCINOMA; GENETICS; LINES	The parathyroid hormone-related protein (PTHrP) gene (Pthlh) maps in the distal region of mouse chromosome 6 that contains a quantitative trait locus associated with genetic predisposition to skin tumorigenesis. Here, we report a genetic polymorphism located in the osteostatin encoding region of the Pthlh gene and that produces Thr/ Pro PTHrP variants. Pthlh(Thr) and Pthlh(Pro) alleles were significantly linked with resistance and susceptibility to skin carcinogenesis in phenotypically selected Car-R and Car-S outbred mice. Transfection of human NCI-H520 squamous cell carcinoma cells with the Pthlh(Pro) allele resulted in cells growing in clusters, tending to pile up, and growing at a significantly faster rate in nude mice than non-transfected and Pthlh(Thr)-transfected cells. These results point to the role of the Pthlh gene as a cancer modifier gene in skin tumorigenesis.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, ICU, I-20133 Milan, Italy; ENEA CR Casaccia, Rome, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.		Dragani, Tommaso A./K-4493-2016; Manenti, Giacomo/J-3339-2017; Zaffaroni, Daniela/I-8731-2017; Peissel, Bernard/E-8187-2017; Gariboldi, Manuela/K-4744-2016	Dragani, Tommaso A./0000-0001-5915-4598; Manenti, Giacomo/0000-0002-4887-4482; Zaffaroni, Daniela/0000-0002-6995-2216; Peissel, Bernard/0000-0001-9233-3571; Gariboldi, Manuela/0000-0001-8406-165X; Saran, Anna/0000-0002-5587-064X				BANGRAZI C, 1990, CARCINOGENESIS, V11, P1711, DOI 10.1093/carcin/11.10.1711; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Dragani TA, 1997, NAT GENET, V17, P7, DOI 10.1038/ng0997-7; Hastings RH, 1999, CHEST, V116, p68S, DOI 10.1378/chest.116.suppl_1.68S; Hastings RH, 1997, AM J PHYSIOL-LUNG C, V272, pL394, DOI 10.1152/ajplung.1997.272.3.L394; Hastings RH, 1996, AM J PHYSIOL-LUNG C, V270, pL353, DOI 10.1152/ajplung.1996.270.3.L353; HEATH DA, 1990, LANCET, V335, P66, DOI 10.1016/0140-6736(90)90537-F; Henderson JE, 1996, J CELL PHYSIOL, V169, P33, DOI 10.1002/(SICI)1097-4652(199610)169:1<33::AID-JCP4>3.0.CO;2-F; HOLICK MF, 1994, P NATL ACAD SCI USA, V91, P8014, DOI 10.1073/pnas.91.17.8014; Iwamura M, 1999, CANCER, V86, P1028, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1028::AID-CNCR19>3.0.CO;2-G; Kremer R, 1996, AM J PHYSIOL-CELL PH, V271, pC164, DOI 10.1152/ajpcell.1996.271.1.C164; LI X, 1993, CANCER RES, V53, P2980; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Manenti G, 1999, GENOME RES, V9, P639; Manenti G, 1997, CARCINOGENESIS, V18, P1917, DOI 10.1093/carcin/18.10.1917; MANGIN M, 1990, GENE, V95, P195, DOI 10.1016/0378-1119(90)90362-U; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; PEISSEL B, 2000, IN PRESS MAMM GENOME; Saran A, 1996, CARCINOGENESIS, V17, P2463, DOI 10.1093/carcin/17.11.2463; *SAS I, 1988, SAS; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; Takai E, 1996, CANCER-AM CANCER SOC, V78, P1384, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1384::AID-CNCR3>3.0.CO;2-L; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133	24	28	30	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5324	5328		10.1038/sj.onc.1203916	http://dx.doi.org/10.1038/sj.onc.1203916			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103933	Bronze			2022-12-25	WOS:000165302300003
J	Anastasiadis, PZ; Jiang, H; Bezin, L; Kuhn, DM; Levine, RA				Anastasiadis, PZ; Jiang, H; Bezin, L; Kuhn, DM; Levine, RA			Tetrahydrobiopterin enhances apoptotic PC12 cell death following withdrawal of trophic support	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; DNA-DAMAGING AGENTS; SYMPATHETIC NEURONS; PARKINSONS-DISEASE; RAT-BRAIN; IN-VIVO; CATECHOLAMINE SYNTHESIS; ENDOTHELIAL-CELLS; CYCLE BLOCKERS	(6R)-Tetrahydro-L-biopterin (BH4) is the rate-limiting cofactor in the production of catecholamine and indoleamine neurotransmitters and is also essential for the synthesis of nitric oxide by nitric-oxide synthase. We have previously reported that BH4 administration induces PC12 cell proliferation and that nerve growth factor- or epidermal growth factor-induced PC12 cell proliferation requires the elevation of intracellular BH4 levels. We show here that BH, accelerates apoptosis in undifferentiated PC12 cells deprived of serum and in differentiated neuron-like PC12 cells after nerve growth factor withdrawal. Increased production of catecholamines or nitric oxide cannot account for the enhancement of apoptosis by BH4. Furthermore, increased calcium influx by exogenous BH4 administration is not involved in the BH4 proapoptotic effect. Our data also argue against the possibility that increased oxidative stress, due to BH4 autoxidation, is responsible for the observed BH4 effects. Instead, they are consistent with the hypothesis that BH4 induces apoptosis by increasing cell cycle progression. Elevation of intracellular BH4 during serum withdrawal increased c-Myc (and especially Myc S) expression earlier than serum withdrawal alone. Furthermore, N-acetylcysteine and the cyclin-dependent kinase inhibitor olomoucine ameliorated the BH4 proapoptotic effect. These data suggest that BH4 affects c-Myc:expression and cell cycle-dependent events, possibly accounting for its effects on promoting cell cycle progression or apoptosis.	Henry Ford Hosp, William T Gossett Neurol Labs, Detroit, MI 48202 USA; Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; John D Dingle Vet Adm Med Ctr, Detroit, MI 48201 USA	Henry Ford Health System; Henry Ford Hospital; Wayne State University	Anastasiadis, PZ (corresponding author), Vanderbilt Univ, Dept Cell Biol, 1161 21st Ave S,MCN C-2310, Nashville, TN 37232 USA.				NINDS NIH HHS [NS39132] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039132] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anastasiadis PZ, 1996, MOL PHARMACOL, V49, P149; Anastasiadis PZ, 1997, EUR J NEUROSCI, V9, P1831, DOI 10.1111/j.1460-9568.1997.tb00749.x; ANASTASIADIS PZ, 1995, PTERIDINES, V6, P132; ANASTASIADIS PZ, 1994, BRAIN RES, V665, P77, DOI 10.1016/0006-8993(94)91154-1; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Ayata C, 1997, J NEUROSCI, V17, P6908; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BRAUTIGAM M, 1984, J NEUROCHEM, V42, P390, DOI 10.1111/j.1471-4159.1984.tb02690.x; BRENNEMAN AR, 1964, BIOCHEM BIOPH RES CO, V17, P177, DOI 10.1016/0006-291X(64)90141-X; ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838; DAVIS MD, 1993, ARCH BIOCHEM BIOPHYS, V304, P9, DOI 10.1006/abbi.1993.1315; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; Desbarats L, 1996, EXPERIENTIA, V52, P1123, DOI 10.1007/BF01952111; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; Estevez AG, 1998, J NEUROSCI, V18, P923; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Farinelli SE, 1996, J NEUROSCI, V16, P2325; FERRARI G, 1995, J NEUROSCI, V15, P2857; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GAL EM, 1978, NEUROCHEM RES, V3, P69, DOI 10.1007/BF00964361; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JOSEPH R, 1993, MOL BRAIN RES, V17, P70, DOI 10.1016/0169-328X(93)90074-Y; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Koshimura K, 1999, NEUROSCIENCE, V88, P561, DOI 10.1016/S0306-4522(98)00199-7; LEVINE RA, 1981, SCIENCE, V214, P919, DOI 10.1126/science.6117945; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; LOVENBERG W, 1979, SCIENCE, V204, P624, DOI 10.1126/science.432666; Maas JW, 1998, J NEUROCHEM, V70, P1401; MARUYAMA K, 1987, ONCOGENE, V1, P361; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MICHEL PP, 1994, EUR J NEUROSCI, V6, P577, DOI 10.1111/j.1460-9568.1994.tb00302.x; MILSTIEN S, 1983, BIOCHEM BIOPH RES CO, V115, P888, DOI 10.1016/S0006-291X(83)80018-7; Mochizuki H, 1996, J NEUROL SCI, V137, P120, DOI 10.1016/0022-510X(95)00336-Z; NICHOL CA, 1983, P NATL ACAD SCI-BIOL, V80, P1546, DOI 10.1073/pnas.80.6.1546; NIEDERWIESER A, 1987, ENZYME, V38, P302, DOI 10.1159/000469220; Nijhawan D, 2000, ANNU REV NEUROSCI, V23, P73, DOI 10.1146/annurev.neuro.23.1.73; Park DS, 1998, J NEUROSCI, V18, P830; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Prasad VS, 1997, MOL CARCINOGEN, V18, P66, DOI 10.1002/(SICI)1098-2744(199702)18:2<66::AID-MC2>3.0.CO;2-O; Rong P, 1999, J NEUROCHEM, V72, P2294, DOI 10.1046/j.1471-4159.1999.0722294.x; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rubin Lee L., 1994, Current Opinion in Neurobiology, V4, P696, DOI 10.1016/0959-4388(94)90012-4; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Rush RA, 1997, CLIN EXP PHARMACOL P, V24, P549, DOI 10.1111/j.1440-1681.1997.tb02089.x; Shiraki T, 1996, BIOCHEM BIOPH RES CO, V221, P181, DOI 10.1006/bbrc.1996.0566; SPANDIDOS DA, 1989, INT J DEV NEUROSCI, V7, P1, DOI 10.1016/0736-5748(89)90039-7; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Stefanis L, 1998, J NEUROSCI, V18, P9204; SUZUKI S, 1988, BRAIN RES, V446, P1, DOI 10.1016/0006-8993(88)91290-5; Tanabe K, 1999, J BIOL CHEM, V274, P15725, DOI 10.1074/jbc.274.22.15725; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Teng KK, 1999, J BIOL CHEM, V274, P37315, DOI 10.1074/jbc.274.52.37315; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Troy CM, 1997, J NEUROSCI, V17, P1911; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WALKINSHAW G, 1995, J CLIN INVEST, V95, P2458, DOI 10.1172/JCI117946; WOLL E, 1993, FEBS LETT, V318, P249, DOI 10.1016/0014-5793(93)80522-V; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; Yan CYI, 1998, J NEUROSCI, V18, P4042; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	72	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9050	9058		10.1074/jbc.M006570200	http://dx.doi.org/10.1074/jbc.M006570200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124941	hybrid			2022-12-25	WOS:000167607700059
J	Imhof, M; Trueb, B				Imhof, M; Trueb, B			Alternative splicing of the first F3 domain from chicken collagen XIV affects cell adhesion and heparin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; NC1 DOMAIN; UNDULIN; FIBRONECTIN; SITE; PROTEINS; FIBRILS; IDENTIFICATION; LOCALIZATION; DECORIN	The N terminus of chicken collagen XIV is subject to alternative splicing. The longer isoform contains a fibronectin type III (F3) domain at its N terminus, whereas the shorter isoform is lacking this domain. Alternative splicing of the F3 domain is developmentally regulated. At early embryonic stages, both isoforms are expressed, whereas after hatching only the longer isoform is expressed. When immobilized on plastic dishes, the recombinant F3 domain promotes the adhesion of mesenchymal cells. Attachment to this domain is specifically inhibited by heparin but not by other glycosaminoglycans, Molecular modeling studies illustrate that the first F3 domain harbors a positively charged groove, which may accommodate the negatively charged heparin chain. Site-directed mutagenesis of a single lysine residue within this groove abolishes the cell binding activity but does not affect the heparin binding activity. Cell binding and heparin binding are therefore two functionally distinct properties shared by the N-terminal F3 domain. When full-length collagen XIV polypeptides that either contain or lack the first F3 domain are tested on heparin-Sepharose, a pronounced difference in their relative affinity is observed. Thus, alternative splicing of the N-terminal F3 domain influences the interaction of this FACIT (fibril-associated collagens with interrupted triple helices) collagen with cells and with glycosaminoglycans.	Univ Bern, ME Muller Inst, CH-3010 Bern, Switzerland	University of Bern	Trueb, B (corresponding author), Univ Bern, ME Muller Inst, POB 30, CH-3010 Bern, Switzerland.		Trueb, Beat/AAL-9621-2020	Trueb, Beat/0000-0001-8684-6856				Akutsu N, 1999, EXP DERMATOL, V8, P17, DOI 10.1111/j.1600-0625.1999.tb00343.x; Bauer M, 1997, BBA-GENE STRUCT EXPR, V1354, P183, DOI 10.1016/S0167-4781(97)00131-0; BROWM JC, 1995, INT ARCH ALLERGY IMM, V107, P484, DOI 10.1159/000237090; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CASTAGNOLA P, 1992, EUR J CELL BIOL, V59, P340; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Ehnis T, 1997, J BIOL CHEM, V272, P20414, DOI 10.1074/jbc.272.33.20414; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; Ehnis T, 1998, EXP CELL RES, V239, P477, DOI 10.1006/excr.1997.3895; FONT B, 1993, J BIOL CHEM, V268, P25015; GERECKE DR, 1993, J BIOL CHEM, V268, P12177; Giry-Lozinguez C, 1998, MATRIX BIOL, V17, P145, DOI 10.1016/S0945-053X(98)90027-0; Imhof M, 1999, CYTOGENET CELL GENET, V84, P217, DOI 10.1159/000015262; Imhof M, 1998, FEBS LETT, V438, P325, DOI 10.1016/S0014-5793(98)01329-5; JUST M, 1991, J BIOL CHEM, V266, P17326; Kania AM, 1999, J BIOL CHEM, V274, P22053, DOI 10.1074/jbc.274.31.22053; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; Klein G, 1998, MATRIX BIOL, V16, P307, DOI 10.1016/S0945-053X(98)90002-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Montserret R, 1999, BIOCHEMISTRY-US, V38, P6479, DOI 10.1021/bi9900222; Nakagawa H, 1999, BIOCHEM BIOPH RES CO, V256, P642, DOI 10.1006/bbrc.1999.0393; NISHIYAMA T, 1994, J BIOL CHEM, V269, P28193; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Ricard-Blum S, 2000, UNCONVENTIONAL COLLA; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; TRUEB J, 1992, BIOCHIM BIOPHYS ACTA, V1171, P97, DOI 10.1016/0167-4781(92)90145-P; TRUEB J, 1992, EUR J BIOCHEM, V207, P549, DOI 10.1111/j.1432-1033.1992.tb17081.x; WALCHLI C, 1994, J CELL SCI, V107, P669; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; WILLIMANN TE, 1994, J BIOL CHEM, V269, P332; Young BB, 2000, DEV DYNAM, V217, P430, DOI 10.1002/(SICI)1097-0177(200004)217:4<430::AID-DVDY10>3.0.CO;2-5	34	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9141	9148		10.1074/jbc.M009148200	http://dx.doi.org/10.1074/jbc.M009148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11098058	hybrid			2022-12-25	WOS:000167607700071
J	Lortat-Jacob, H; Chouin, E; Cusack, S; van Raaij, MJ				Lortat-Jacob, H; Chouin, E; Cusack, S; van Raaij, MJ			Kinetic analysis of adenovirus fiber binding to its receptor reveals an avidity mechanism for trimeric receptor-ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CELLULAR RECEPTOR; FACTORS TRAFS; DOMAIN; COXSACKIEVIRUS; AFFINITY; COMPLEX; PROTEIN; TYPE-2; SITE	Most adenoviruses bind to the N-terminal immunoglobulin domain D1 of the coxsackievirus and adenovirus receptor via the head part of their fiber proteins. Three receptor molecules can bind per fiber head. We expressed the D1 domain and the adenovirus type 2 fiber head in bacteria and studied binding interactions by surface plasmon resonance measurements. When receptor domains bind adenovirus fiber independently of each other, the dissociation constant is 20-25 nM. However, when adenovirus fiber binds to receptors immobilized on the sensor chip, a situation better mimicking adenovirus binding to receptors on the cell surface, the dissociation constant was around 1 nM. Kinetic analysis shows that this happens via an avidity mechanism; three identical interactions with high on and off rate constants lead to tight binding of one fiber head to three receptor molecules with a very low overall off rate. The avidity mechanism could be used by other viruses that have multimeric adhesion proteins to attach to target cells. It could also be more general to trimeric receptor-ligand interactions, including those involved in intracellular signaling.	CNRS, CEA, Inst Biol Struct, F-38027 Grenoble 1, France; Inst Max Von Laue Paul Langevin, Grenoble Outstn, European Mol Biol Lab, F-38042 Grenoble 9, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL)	van Raaij, MJ (corresponding author), Leiden Univ, Gorlaeus Labs, POB 9502,Einsteinweg 55, NL-2300 RA Leiden, Netherlands.	m.vanraaij@chem.leidenuniv.nl	van Raaij, Mark J/B-3678-2009	van Raaij, Mark J/0000-0002-4781-1375; Cusack, Stephen/0000-0002-9324-0796				Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Carson SD, 1997, BIOCHEM BIOPH RES CO, V233, P325, DOI 10.1006/bbrc.1997.6449; CASASNOVAS JM, 1995, J BIOL CHEM, V270, P13216, DOI 10.1074/jbc.270.22.13216; Chiu CY, 1999, J VIROL, V73, P6759, DOI 10.1128/JVI.73.8.6759-6768.1999; Einfeld DA, 1999, J VIROL, V73, P9130, DOI 10.1128/JVI.73.11.9130-9136.1999; Fields BN, 1996, VIROLOGY; Freimuth P, 1999, J VIROL, V73, P1392, DOI 10.1128/JVI.73.2.1392-1398.1999; Gilson MK, 1997, BIOPHYS J, V72, P1047, DOI 10.1016/S0006-3495(97)78756-3; GURNEY RW, 1953, IONIC PROCESSES SOLU, P80; HANSON JE, 1992, VIROLOGY, V189, P525, DOI 10.1016/0042-6822(92)90576-B; HOLTZER A, 1995, BIOPOLYMERS, V35, P595, DOI 10.1002/bip.360350605; Honda T, 2000, MOL BRAIN RES, V77, P19, DOI 10.1016/S0169-328X(00)00036-X; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; Mann DA, 1998, J AM CHEM SOC, V120, P10575, DOI 10.1021/ja9818506; MATROSOVICH MN, 1990, FEBS LETT, V272, P209, DOI 10.1016/0014-5793(90)80486-3; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Mitraki A, 1999, EUR J BIOCHEM, V264, P599, DOI 10.1046/j.1432-1327.1999.00683.x; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Tamura A, 1997, J MOL BIOL, V273, P1048, DOI 10.1006/jmbi.1997.1368; Tarbouriech N, 2000, VIROLOGY, V266, P99, DOI 10.1006/viro.1999.0066; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; van Raaij MJ, 1999, VIROLOGY, V262, P333, DOI 10.1006/viro.1999.9849; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; Wang XH, 1999, J VIROL, V73, P2559, DOI 10.1128/JVI.73.3.2559-2562.1999; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X	43	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9009	9015		10.1074/jbc.M009304200	http://dx.doi.org/10.1074/jbc.M009304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124261	hybrid			2022-12-25	WOS:000167607700054
J	Smith, EJ; Marie, I; Prakash, A; Garcia-Sastre, A; Levy, DE				Smith, EJ; Marie, I; Prakash, A; Garcia-Sastre, A; Levy, DE			IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or I kappa B kinase but is blocked by vaccinia virus E3L protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-3; STIMULATED RESPONSE ELEMENT; FACTOR 2-ALPHA KINASE; IFN-BETA GENE; BINDING-PROTEIN; TRANSCRIPTION FACTORS; MAMMALIAN HOMOLOG; POSITIVE FEEDBACK; NS1 PROTEIN; ALPHA GENES	Induction of interferon-alpha (IFN alpha) gene expression in virus-infected cells requires phosphorylation-induced activation of the transcription factors IRF3 and IRF7. However, the kinase(s) that targets these proteins has not been identified. Using a combined pharmacological and genetic approach, we found that none of the kinases tested was responsible for IRF phosphorylation in cells infected with Newcastle disease virus (NDV). Although the broad spectrum kinase inhibitor staurosporine potently blocked IRF3 and -7 phosphorylation, inhibitors for protein kinase C, protein kinase A, MEK, SAPK, IKK, and protein kinase R (PKR) were without effect. Both I kappaB kinase and PKR have been implicated in IFN induction, but cells genetically deficient in I kappaB kinase, PKR, or the PKR-related genes PERK; IRE1, or GCN2 retained the ability to phosphorylate IRF7 and induce IFN alpha. Interestingly, PKR mutant cells were defective for response to double-stranded (ds) RNA but not to virus infection, suggesting that dsRNA is not the only activating viral component. Consistent with this notion, protein synthesis was required for IRF7 phosphorylation in virus-infected cells, and the kinetics of phosphorylation and viral protein production were similar. Despite evidence for a lack of involvement of dsRNA and PKR, vaccinia virus E3L protein, a dsRNA-binding protein capable of inhibiting PKR, was an effective IRF3 and -7 phosphorylation inhibitor. These results suggest that a novel cellular protein that is activated by viral products in addition to dsRNA and is sensitive to E3L inhibition is responsible for IRF activation and reveal a novel mechanism for the anti-IFN effect of E3L distinct from its inhibition of PKR.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Mol Oncol & Immunol Program, New York, NY 10016 USA; NYU, Mt Sinai Sch Med, New York, NY 10029 USA	New York University; New York University; Icahn School of Medicine at Mount Sinai; New York University	Levy, DE (corresponding author), NYU, Sch Med, Dept Pathol, MSB 556,550 1st Ave, New York, NY 10016 USA.		Levy, David/AAG-6202-2019; Longo, Kenneth A/A-5631-2010; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; Marie, Isabelle/0000-0002-3091-7624; Garcia-Sastre, Adolfo/0000-0002-6551-1827	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046954, R01AI028900, R01AI046503] Funding Source: NIH RePORTER; NIAID NIH HHS [AI46503, AI28900, AI46954] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Alcami A, 2000, IMMUNOL TODAY, V21, P447, DOI 10.1016/S0167-5699(00)01699-6; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Berlanga JJ, 1998, J BIOL CHEM, V273, P32340, DOI 10.1074/jbc.273.48.32340; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Boyle KA, 1999, MOL CELL BIOL, V19, P3607; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHANG HW, 1995, J VIROL, V69, P6605, DOI 10.1128/JVI.69.10.6605-6608.1995; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; de Leeuw O, 1999, J GEN VIROL, V80, P131, DOI 10.1099/0022-1317-80-1-131; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doly J, 1998, CELL MOL LIFE SCI, V54, P1109, DOI 10.1007/s000180050240; Erlandsson L, 1998, CURR BIOL, V8, P223, DOI 10.1016/S0960-9822(98)70086-7; Falcon AM, 1999, NUCLEIC ACIDS RES, V27, P2241, DOI 10.1093/nar/27.11.2241; Feigenblum D, 1998, J VIROL, V72, P9257, DOI 10.1128/JVI.72.11.9257-9266.1998; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harlow E., 1988, ANTIBODIES LAB MANUA; Ho CK, 1996, VIROLOGY, V217, P272, DOI 10.1006/viro.1996.0114; Ho CK, 1996, J VIROL, V70, P2611, DOI 10.1128/JVI.70.4.2611-2614.1996; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; JAGUS R, 1994, BIOCHIMIE, V76, P779, DOI 10.1016/0300-9084(94)90082-5; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; Levy DE, 1998, METHODS, V15, P167, DOI 10.1006/meth.1998.0621; LEVY DE, 2000, IN PRESS CYTOKINE GR; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Marion RM, 1999, MOL CELL BIOL, V19, P2212; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Romano PR, 1998, MOL CELL BIOL, V18, P7304, DOI 10.1128/MCB.18.12.7304; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Shors ST, 1998, J INTERF CYTOK RES, V18, P721, DOI 10.1089/jir.1998.18.721; Shors T, 1997, VIROLOGY, V239, P269, DOI 10.1006/viro.1997.8881; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sood R, 2000, GENETICS, V154, P787; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; YUWEN H, 1993, VIROLOGY, V195, P732, DOI 10.1006/viro.1993.1424; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985	70	194	206	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8951	8957		10.1074/jbc.M008717200	http://dx.doi.org/10.1074/jbc.M008717200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124948	hybrid			2022-12-25	WOS:000167607700047
J	Martin, KA; Schalm, SS; Romanelli, A; Keon, KL; Blenis, J				Martin, KA; Schalm, SS; Romanelli, A; Keon, KL; Blenis, J			Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein-extracellular signal-regulated kinase kinase-regulated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70(S6K); INSULIN; TRANSLATION; CLONING; PATHWAY; SITES	Ribosomal S6 kinase 2 (S6K2) is a recently identified serine/threonine protein kinase that phosphorylates the 40 S ribosomal protein S6 in vitro. S6K2 is highly homologous to S6K1 in the core kinase and Linker regulatory domains but differs from S6K1 in the N- and C-terminal regions and is differently localized primarily to the nucleus because of a C-terminal nuclear localization signal unique to S6K2. We have recently demonstrated that S6K2 is regulated similarly to S6K1 by the mammalian target of rapamycin pathway and by multiple PI3-K pathway effecters in vivo. However, deletion of the C-terminal domain of S6K2 enhances kinase activity, whereas analogous deletion of S6K1 is inhibitory, Here, we characterize the S6K2 C-terminal motifs that confer this differential regulation. We demonstrate that the inhibitory effects of the S6K2 C-terminal domain are only partly attributable to the nuclear localization signal but that three C-terminal proline-directed potential mitogen-activated protein kinase phosphorylation sites are critical mediators of this inhibitory effect. Site-specific mutation of these sites to alanine completely desensitizes S6K2 to activating inputs, whereas mutation to aspartic acid to mimic phosphorylation results in an activated enzyme which is hypersensitive to activating inputs. Pretreatment of cells with the mitogen-activated protein-extracellular signal-regulated kinase kinase (MEK) inhibitor U0126 inhibited S6K2 activation to a greater extent than S6K1. Furthermore, S6K2 mutants with C-terminal deletion or acidic phosphorylation site mutations displayed greatly reduced U0126 sensitivity. Thus, MEK-dependent inputs to C-terminal phosphorylation sites appear to be essential for relief of S6K2 inhibition but less critical for activation of S6K1. These data suggest a mechanism by which weak PI3-K agonists can regulate S6 phosphorylation and selective translation in the presence of mitogen-activated protein kinase signaling.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	Harvard University; Harvard Medical School; Free University of Berlin	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.			Martin, Kathleen/0000-0002-1748-0034	NIGMS NIH HHS [GM51405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; Scott PH, 1997, FEBS LETT, V409, P171, DOI 10.1016/S0014-5793(97)00500-0; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; WENG QP, 1995, MOL CELL BIOL, V15, P2333	22	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7892	7898		10.1074/jbc.M009972200	http://dx.doi.org/10.1074/jbc.M009972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11108720	hybrid			2022-12-25	WOS:000167474900031
J	Shikano, S; Bonkobara, M; Zukas, PK; Ariizumi, K				Shikano, S; Bonkobara, M; Zukas, PK; Ariizumi, K			Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE GLYCOPROTEIN; EPIDERMAL LANGERHANS CELLS; SUBTRACTIVE CDNA CLONING; MELANOCYTE-SPECIFIC GENE; LYMPH-NODES; MIGRATION; IDENTIFICATION; MACROPHAGE; MATURATION; SURFACE	We isolated a novel molecule (DC-HIL) expressed abundantly by the XS52 dendritic cell (DC) line and epidermal Langerhans cells, but minimally by other cell lines. DC-HIL is a type I transmembrane protein that contains a heparin-binding motif and an integrin-recognition motif, RGD, in its extracellular domain (ECD), A soluble fusion protein (DC-HIL-Fc) of the ECD and an immunoglobulin Fc bound to the surface of an endothelial cell line (SVEC). This binding induced adhesion of SVEC to its immobilized form. Sulfated polysaccharides (e.g. heparin and fucoidan) inhibited binding of soluble DC-HIL-Fc and adhesion of SVEC. By contrast, an integrin inhibitor (RGDS tetramer) had no effect on binding to SVEC, but prevented adhesion of SVEC, This differential RGD requirement was confirmed by the finding that DC-HIL-Fc mutant lacking the RGD motif can bind to SVEC but is unable to induce adhesion of SVEC. Furthermore, DC-HIL appears to recognize directly these sulfated polysaccharides. These results suggest that DC-HIL binds to SVEC by recognizing heparan sulfate proteoglycans on endothelial cells, thereby inducing adhesion of SVEC in an RGD-dependent manner. We propose that DC-HIL serves as a DC-associated, heparan sulfate proteoglycan-dependent integrin ligand, which may be involved in transendothelial migration of DC.	Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ariizumi, K (corresponding author), Univ Texas, SW Med Ctr, Dept Dermatol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	kariiz@mednet.swmed.edu			NIAMS NIH HHS [R01-AR44189] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044189] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; ARIIZUMI K, 1995, J IMMUNOL, V154, P6031; ARIIZUMI K, 1995, EUR J IMMUNOL, V25, P2137, DOI 10.1002/eji.1830250803; Ariizumi K, 1997, ADV EXP MED BIOL, V417, P449; Brown ML, 2000, P NATL ACAD SCI USA, V97, P7488, DOI 10.1073/pnas.120184097; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CAVARI S, 1993, FEBS LETT, V323, P155, DOI 10.1016/0014-5793(93)81469-G; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; Chiba R, 1999, BLOOD, V94, P1319, DOI 10.1182/blood.V94.4.1319.416k28_1319_1329; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9; DENIS C, 1993, BLOOD, V82, P3622; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; HEUFLER C, 1992, J EXP MED, V176, P1221, DOI 10.1084/jem.176.4.1221; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; HUEBER AO, 1992, J IMMUNOL, V148, P3692; Ihrcke NS, 1996, J CELL PHYSIOL, V168, P625, DOI 10.1002/(SICI)1097-4652(199609)168:3<625::AID-JCP15>3.3.CO;2-A; Jonuleit H, 1996, ARCH DERMATOL RES, V289, P1, DOI 10.1007/s004030050144; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; Kodaira Y, 2000, J IMMUNOL, V165, P1599, DOI 10.4049/jimmunol.165.3.1599; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; Liang OD, 1997, FEBS LETT, V407, P169, DOI 10.1016/S0014-5793(97)00330-X; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; MA J, 1994, CELL IMMUNOL, V158, P389, DOI 10.1006/cimm.1994.1285; Matsue H, 1999, J IMMUNOL, V162, P5287; MATSUE H, 1992, J INVEST DERMATOL, V99, P537, DOI 10.1111/1523-1747.ep12667296; PARISH CR, 1988, IMMUNOL CELL BIOL, V66, P221, DOI 10.1038/icb.1988.28; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; Price AA, 1997, J EXP MED, V186, P1725, DOI 10.1084/jem.186.10.1725; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; Smith LL, 1998, EXP CELL RES, V242, P351, DOI 10.1006/excr.1998.4108; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Strunk D, 1997, J EXP MED, V185, P1131, DOI 10.1084/jem.185.6.1131; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; Udey MC, 1997, CLIN EXP IMMUNOL, V107, P6; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; VANWILSEM EJG, 1994, J INVEST DERMATOL, V103, P217, DOI 10.1111/1523-1747.ep12393088; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; Wang BH, 1999, J LEUKOCYTE BIOL, V66, P33, DOI 10.1002/jlb.66.1.33; Weiss JM, 1997, J CELL BIOL, V137, P1137, DOI 10.1083/jcb.137.5.1137; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; Wrenshall LE, 1999, J LEUKOCYTE BIOL, V66, P391, DOI 10.1002/jlb.66.3.391; WRENSHALL LE, 1995, J IMMUNOL, V154, P871; XU S, 1995, EUR J IMMUNOL, V25, P1018, DOI 10.1002/eji.1830250424; XU S, 1995, J IMMUNOL, V154, P2697	57	138	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8125	8134		10.1074/jbc.M008539200	http://dx.doi.org/10.1074/jbc.M008539200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11114299	hybrid			2022-12-25	WOS:000167474900064
J	Hosfield, CM; Moldoveanu, T; Davies, PL; Elce, JS; Jia, ZC				Hosfield, CM; Moldoveanu, T; Davies, PL; Elce, JS; Jia, ZC			Calpain mutants with increased Ca2+ sensitivity and implications for the role of the C-2-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-DEPENDENT PROTEASE; SEX DETERMINATION; CRYSTAL-STRUCTURE; ACTIVATION; GENE; CRYSTALLOGRAPHY; CLEAVAGE; CALCIUM; TRA-3; MODE	The ubiquitous calpain isoforms (mu- and m-calpain) are Ca2+-dependent cysteine proteases that require surprisingly high Ca2+ concentrations for activation in vitro (similar to 50 and similar to 300 muM, respectively), The molecular basis of such a high requirement for Ca2+ in vitro is not known. Tn this study, we substantially reduced the concentration of: Ca2+ required for the activation of m-calpain in vitro through the specific disruption of interdomain-interactions by structure-guided site-directed mutagenesis, Several interdomain electrostatic interactions involving lysine residues in domain II and acidic residues in the C-2-like domain III were disrupted, and the effects of these mutations on activity and Ca2+ sensitivity were analyzed. The mutation to serine of Glu-504, a residue: that is conserved in both mu- and m-calpain and interacts most notably with Lys-234, reduced the in vitro Ca2+ requirement for activity by almost 50%, The mutation of Lys-234 to serine or glutamic acid resulted in-a similar reduction. These are the first reported cases in which-point mutations have been able to reduce the Ca2+ requirement of calpain, The structures of the mutants in the absence of Ca2+ were shown by x-ray crystallography to be unchanged from the wild type, demonstrating that the increase in Ca2+ sensitivity was not attributable to-conformational change prior to activation. The conservation of sequence between EL-calpain, m-calpain, and calpain 3 in this region suggests that the results can be extended to all of these isoforms, Whereas the primary Ca2+ binding is assumed to occur at EF-hands in domains TV and VI, these results show that domain II-domain III salt bridges are important in the process Of the Ca2+-induced activation of calpain and that they influence the overall Ca2+ requirement of the enzyme.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Prot Engn Network Ctr Excellence, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Jia, ZC (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	jia@post.queensu.ca	Moldoveanu, Tudor/N-8173-2018	Moldoveanu, Tudor/0000-0003-0791-318X				Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; DUTT P, 2000, BIOCHEM J, V15, P37; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, ACTA CRYSTALLOGR D, V55, P1484, DOI 10.1107/S0907444999007386; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Sokol SB, 2000, GENE DEV, V14, P901; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; Wang K K, 1997, Adv Pharmacol, V37, P117	24	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7404	7407		10.1074/jbc.M007352200	http://dx.doi.org/10.1074/jbc.M007352200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11102442	hybrid			2022-12-25	WOS:000167442900075
J	Wang, Q; Lu, JH; Yong, EL				Wang, Q; Lu, JH; Yong, EL			Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; HUMAN PROGESTERONE-RECEPTOR; PROTEIN-PROTEIN-INTERACTION; AMINO-TERMINAL DOMAIN; NUCLEAR RECEPTOR; GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; C-JUN; INTERMEDIARY FACTOR-2	Transactivation functions (AF2) in the ligand-binding domains (LBD) of many steroid receptors are well characterized, but there is little evidence to support such a function for the LED of the androgen receptor (AR). We report a mutant AR, with residues 628-646 in the hinge region deleted, which exhibited transactivation activity that was more than double that of the wild type (WT) AR. Although no androgen-dependent AF2 activity could be observed for the WT ARLSD fused to a heterologous DNA-binding domain, the mutant ARLBD(Delta 628-646) was 30-40 times more active than the WT ARLBD. In the presence of the p160 coactivator TIF2, AR(Delta 628-646) was significantly more active than similarly treated WT AR. Deletion of residues 628-646 also enhanced TIF2-ARLBD activity 8-fold, an effect not present when the LED-interacting LXXLL motifs of TIF2 were mutated, suggesting that the negative modulatory activity of residues 628-646 were exerted via coactivator pathways. Although the AP-1 (c-Jun/c-Fos) system and NcoR have been reported to interact with and repress the activity of some steroid receptors, c-jun, c-Fos, c-Jun/c-Fos, nor NcoR function was consistently affected by the absence or presence of residues 628-646, implying that the AR hinge region exerts its silencing effects in a manner independent of these corepressors, Our data provide evidence for the novel finding that strong androgen-dependent AF2 exists in the ARLBD and is the first report of a negative regulatory domain in the AR. Because mutations in this region are commonly associated with prostate cancer, it is important to characterize the mechanisms by which the hinge region exerts its repressor effect on ligand-activated and coactivator-mediated AF2 activity of the ARLBD.	Natl Univ Singapore, Dept Obstet & Gynecol, Singapore 119074, Singapore; Natl Univ Singapore, Natl Univ Med Inst, Singapore 119074, Singapore	National University of Singapore; National University of Singapore	Yong, EL (corresponding author), Natl Univ Hosp, Dept Obstet & Gynecol, Level 2,Lower Kent Ridge Rd, Singapore 119074, Singapore.			Yong, Eu-Leong/0000-0001-6511-770X; Lu, Jinhua/0000-0002-3699-9894				Alen P, 1999, MOL CELL BIOL, V19, P6085; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Chien PY, 1999, MOL ENDOCRINOL, V13, P2122, DOI 10.1210/me.13.12.2122; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Ghadessy FJ, 1999, J CLIN INVEST, V103, P1517, DOI 10.1172/JCI4289; Gottlieb B, 1998, NUCLEIC ACIDS RES, V26, P234, DOI 10.1093/nar/26.1.234; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huse B, 1998, MOL ENDOCRINOL, V12, P1334, DOI 10.1210/me.12.9.1334; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Jimenez-Lara AM, 1999, J BIOL CHEM, V274, P13503, DOI 10.1074/jbc.274.19.13503; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee YF, 1999, P NATL ACAD SCI USA, V96, P14724, DOI 10.1073/pnas.96.26.14724; Lim J, 2000, MOL ENDOCRINOL, V14, P1187, DOI 10.1210/me.14.8.1187; Lobaccaro JM, 1999, ENDOCRINOLOGY, V140, P350, DOI 10.1210/en.140.1.350; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moilanen A, 1997, FEBS LETT, V412, P355, DOI 10.1016/S0014-5793(97)00791-6; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Schneikert J, 1999, J CELL BIOL, V146, P929, DOI 10.1083/jcb.146.5.929; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Sheldon LA, 1999, MOL CELL BIOL, V19, P8146; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wang Q, 1998, J CLIN ENDOCR METAB, V83, P4303, DOI 10.1210/jc.83.12.4303; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	54	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7493	7499		10.1074/jbc.M009916200	http://dx.doi.org/10.1074/jbc.M009916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11102454	hybrid			2022-12-25	WOS:000167442900087
J	Arana, ME; Haq, B; Le Gac, NT; Boehmer, PE				Arana, ME; Haq, B; Le Gac, NT; Boehmer, PE			Modulation of the herpes simplex virus type-1 UL9 DNA helicase by its cognate single-strand DNA-binding protein, ICP8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSICAL INTERACTION; I ORIGIN; REPLICATION; COMPLEX	The mechanism of stimulation of a DNA helicase by its cognate single-strand DNA binding protein was examined using herpes simplex virus type-1 UL9 DNA helicase and ICP8. UL9 and ICP8 are two essential components of the viral replisome that associate into a complex to unwind the origins of replication. The helicase and DNA stimulated ATPase activities of UL9 are greatly elevated as a consequence of this association. Given that ICPS acts as a single strand DNA;binding protein, the simplest model that can account for its stimulatory effect predicts that it tethers UL9 to the DNA template, thereby increasing its processivity. In contrast to the prediction, data presented here show that the stimulatory activity of ICP8 does not depend on its single-strand DNA binding activity. Our data support an alternative hypothesis in which ICPS modulates the activity of UL9. Accordingly, the data show that the ICP8 binding site of UL9 constitutes an inhibitory region that maintains the helicase in an inefficient ground state. ICP8 acts as a positive regulator by neutralizing this region. ICP8 does not affect substrate binding, ATP hydrolysis, or the efficiency of translocation/DNA unwinding. Rather, we propose that ICP8 increases the efficiency with which substrate binding and ATP hydrolysis are coupled to translocation/DNA unwinding.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Boehmer, PE (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.	pboehmer@molbio.med.miami.edu		Boehmer, Paul/0000-0003-4479-0529	NIGMS NIH HHS [GM62643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boehmer PE, 1998, J BIOL CHEM, V273, P2676, DOI 10.1074/jbc.273.5.2676; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; DODSON MS, 1993, J BIOL CHEM, V268, P1213; EARNSHAW DL, 1994, BIOCHEM BIOPH RES CO, V199, P1333, DOI 10.1006/bbrc.1994.1377; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; GEORGAKI A, 1994, NUCLEIC ACIDS RES, V22, P1128, DOI 10.1093/nar/22.7.1128; Gourves AS, 2000, J BIOL CHEM, V275, P10864, DOI 10.1074/jbc.275.15.10864; He XD, 2000, J VIROL, V74, P5726, DOI 10.1128/JVI.74.12.5726-5728.2000; Hughes P, 1997, NUCLEIC ACIDS RES, V25, P3881, DOI 10.1093/nar/25.19.3881; LEATHERBARROW RJ, 1987, ENZFITTER SOFTWARE B; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; Park JS, 1997, J BIOL CHEM, V272, P18910, DOI 10.1074/jbc.272.30.18910; Sampson DA, 2000, J BIOL CHEM, V275, P2931, DOI 10.1074/jbc.275.4.2931; Soultanas P, 1998, NUCLEIC ACIDS RES, V26, P2374, DOI 10.1093/nar/26.10.2374; THOMMES P, 1992, J BIOL CHEM, V267, P6063; White EJ, 1999, BIOCHEM BIOPH RES CO, V264, P493, DOI 10.1006/bbrc.1999.1566	27	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6840	6845		10.1074/jbc.M007219200	http://dx.doi.org/10.1074/jbc.M007219200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11112774	hybrid			2022-12-25	WOS:000167261000098
J	Brouwer, R; Allmang, C; Raijmakers, R; van Aarssen, Y; Egberts, WV; Petfalski, E; van Venrooij, WJ; Tollervey, D; Pruijn, GJM				Brouwer, R; Allmang, C; Raijmakers, R; van Aarssen, Y; Egberts, WV; Petfalski, E; van Venrooij, WJ; Tollervey, D; Pruijn, GJM			Three novel components of the human exosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 5.8S RIBOSOMAL-RNA; HUMAN PM-SCL; YEAST EXOSOME; PROTEIN; AUTOANTIGEN; END; IDENTIFICATION; PRECURSORS; INTERACTS	The yeast exosome is a complex of 3' --> 5' exoribonucleases. Sequence analysis identified putative human homologues for exosome components, although several were found only as expressed sequence tags. Here we report the cloning of full-length cDNAs, which encode putative human homologues of the Rrp40p, Rrp4lp, and Rrp46p components of the exosome. Recombinant proteins were expressed and used to raise rabbit antisera. In Western blotting experiments, these decorated HeLa cell proteins of the predicted sizes. All three human proteins were enriched in the HeLa cells nucleus and nucleolus, but were also clearly detected in the cytoplasm. Size exclusion chromatography revealed that hRrp40p, hRrp41p, and hRrp46p were present in a large complex. This cofractionated with the human homologues of other exosome components, hRrp4p and PM/ Scl-100. Anti-PM/Scl-positive patient sera coimmunoprecipitated hRrp40p, hRrp41p, and hRrp46p demonstrating their physical association. The immunoprecipitated complex exhibited 3' --> 5' exoribonuclease activity in vitro. hRrp41p was expressed in yeast and shown to suppress the lethality of genetic depletion of yeast Rrp4lp. We conclude that hRrp40p, hRrp41p, and hRrp46p represent novel components of the human exosome complex.	Catholic Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Radboud University Nijmegen; University of Edinburgh	Pruijn, GJM (corresponding author), Catholic Univ Nijmegen, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.	g.pruijn@bioch.kun.nl	Tollervey, David/AAR-6662-2020; Raijmakers, Reinout/A-3045-2010; Pruijn, Ger/D-6664-2012	Tollervey, David/0000-0003-2894-2772; Raijmakers, Reinout/0000-0001-6316-6663; Allmang, Christine/0000-0001-8883-0874				ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Baker RE, 1998, GENETICS, V149, P73; Benard L, 1998, MOL CELL BIOL, V18, P2688, DOI 10.1128/MCB.18.5.2688; Blum E, 1997, MOL MICROBIOL, V26, P387, DOI 10.1046/j.1365-2958.1997.5901947.x; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Briggs MW, 1998, J BIOL CHEM, V273, P13255, DOI 10.1074/jbc.273.21.13255; Brouwer R, 1998, ARTHRITIS RHEUM, V41, P1428, DOI 10.1002/1529-0131(199808)41:8<1428::AID-ART12>3.0.CO;2-J; Burkard KTD, 2000, MOL CELL BIOL, V20, P604, DOI 10.1128/MCB.20.2.604-616.2000; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GE Q, 1992, J CLIN INVEST, V90, P559, DOI 10.1172/JCI115895; GELPI C, 1990, CLIN EXP IMMUNOL, V81, P59; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayes R, 1999, TRENDS BIOCHEM SCI, V24, P199, DOI 10.1016/S0968-0004(99)01388-2; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; Kufel J, 2000, MOL CELL BIOL, V20, P5415, DOI 10.1128/MCB.20.15.5415-5424.2000; Lafontaine D, 1996, NUCLEIC ACIDS RES, V24, P3469, DOI 10.1093/nar/24.17.3469; Margossian SP, 1996, TRENDS BIOCHEM SCI, V21, P392, DOI 10.1016/S0968-0004(96)90129-2; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MIN JJ, 1993, J BACTERIOL, V175, P6245, DOI 10.1128/JB.175.19.6245-6253.1993; MIN JJ, 1993, J BIOL CHEM, V268, P7350; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; REICHLIN M, 1984, J CLIN IMMUNOL, V4, P40, DOI 10.1007/BF00915286; REIMER G, 1986, J IMMUNOL, V137, P3802; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shiomi T, 1998, J BIOCHEM-TOKYO, V123, P883; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Wahle E., 1994, RNA PROCESSING PRACT, VII, P1; Williams JM, 1998, MOL MICROBIOL, V27, P171, DOI 10.1046/j.1365-2958.1998.00670.x; Zanchin NIT, 1999, NUCLEIC ACIDS RES, V27, P1283, DOI 10.1093/nar/27.5.1283; Zanchin NIT, 1999, MOL CELL BIOL, V19, P1518	40	94	98	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6177	6184		10.1074/jbc.M007603200	http://dx.doi.org/10.1074/jbc.M007603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11110791	Green Published, hybrid			2022-12-25	WOS:000167261000018
J	Murai, T; Nakagawa, Y; Maeda, H; Terada, K				Murai, T; Nakagawa, Y; Maeda, H; Terada, K			Altered regulation of cell cycle machinery involved in interleukin-1-induced G(1) and G(2) phase growth arrest of A375S2 human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; GENE-EXPRESSION; CDK INHIBITORS; CYTO-TOXICITY; DNA-DAMAGE; HUMAN MYT1; I TRIAL; P21	Interleukin-1 (IL-1) inhibits the growth of A375S2 human melanoma cells by arresting them at G(1) and G(2) phases of the cell cycle. The arrests are preceded by a rapid decrease in kinase activities of cyclin E-Cdk2 and cyclin B1-Cdc2, which are critical for G(1)-S and G(2)-M progression, respectively. IL-1 quickly enhances the protein expression of the CDK inhibitor p21(cip1). The induced p21 binds preferentially to cyclin E-Cdk2, and the increase in pal binding parallels the decrease in cyclin E-Cdk2 activity. Thus, p21 is likely to be responsible for the inhibition of cyclin E-Cdk2 activity and G(1) arrest. Coinciding with the decrease in cyclin B1-Cdc2 activity, there is an increase in tyrosine phosphorylation of Cdc2, suggesting that an increase in the inactive Tyr-15-phosphorylated form of Cdc2 is involved in the decrease in cyclin B1-Cdc2 activity and G(2) arrest. Furthermore, we found that IL-1 causes rapid dephosphorylation of p107, but not of pRb or p130, while the total protein levels of p130 are increased. Thus, IL-1 may exert its growth arresting effects via p107 and p130 pathways rather than through pRb.	Natl Inst Hlth Sci, Dept Bbiol Evaluat, Osaka Branch, Div Biol Evaluat,Chuo Ku, Osaka 5400006, Japan	National Institute of Health Sciences - Japan	Murai, T (corresponding author), Natl Inst Hlth Sci, Dept Bbiol Evaluat, Osaka Branch, Div Biol Evaluat,Chuo Ku, Hoenzaka 1-1-43, Osaka 5400006, Japan.	murai@nihs.go.jp						Baldi A, 1997, CLIN CANCER RES, V3, P1691; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; CORBEIL HB, 1995, ONCOGENE, V11, P909; Corroyer S, 1996, J BIOL CHEM, V271, P25117, DOI 10.1074/jbc.271.41.25117; DANFORTH DN, 1991, CANCER RES, V51, P1488; Datta NS, 1998, CELL GROWTH DIFFER, V9, P639; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ENDO Y, 1986, IMMUNOBIOLOGY, V172, P316, DOI 10.1016/S0171-2985(86)80113-9; ENDO Y, 1988, J IMMUNOL, V141, P2342; Florenes VA, 1996, ONCOGENE, V13, P2447; FRYLING C, 1989, CANCER RES, V49, P3333; Furman WL, 1997, MED PEDIATR ONCOL, V28, P444, DOI 10.1002/(SICI)1096-911X(199706)28:6<444::AID-MPO10>3.0.CO;2-9; GAFFNEY EV, 1986, CANCER RES, V46, P3834; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HERZINGER T, 1995, ONCOGENE, V10, P2079; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ICHINOSE Y, 1988, CANCER IMMUNOL IMMUN, V27, P7; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Janik JE, 1996, JNCI-J NATL CANCER I, V88, P44, DOI 10.1093/jnci/88.1.44; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; KILIAN PL, 1991, CANCER RES, V51, P1823; Koudssi F, 1998, J BIOL CHEM, V273, P25796, DOI 10.1074/jbc.273.40.25796; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LOVETT D, 1986, J IMMUNOL, V136, P340; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORINAGA Y, 1990, BIOCHEM BIOPH RES CO, V173, P186, DOI 10.1016/S0006-291X(05)81039-3; Muthukkumar S, 1996, J BIOL CHEM, V271, P5733, DOI 10.1074/jbc.271.10.5733; NAKAI S, 1988, BIOCHEM BIOPH RES CO, V154, P1189, DOI 10.1016/0006-291X(88)90266-5; NAKAMURA S, 1986, JPN J CANCER RES, V77, P767; Nalca A, 1998, J BIOL CHEM, V273, P30517, DOI 10.1074/jbc.273.46.30517; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; ONOZAKI K, 1985, J IMMUNOL, V135, P314; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; ONOZAKI K, 1988, J IMMUNOL, V140, P112; Parry D, 1999, MOL CELL BIOL, V19, P1775; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; Rinehart J, 1997, CANCER INVEST, V15, P403, DOI 10.3109/07357909709047578; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Tanikawa M, 1998, J BIOL CHEM, V273, P18522, DOI 10.1074/jbc.273.29.18522; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TRIOZZI PL, 1995, J CLIN ONCOL, V13, P482, DOI 10.1200/JCO.1995.13.2.482; VARIO G, 1995, GENE DEV, V9, P869; Verschraegen CF, 1996, EUR J CANCER, V32A, P1609, DOI 10.1016/0959-8049(96)00108-6; YANG D, 1995, J BIOCHEM, V118, P802, DOI 10.1093/oxfordjournals.jbchem.a124983; Yoo YD, 1999, INT J CANCER, V83, P512, DOI 10.1002/(SICI)1097-0215(19991112)83:4<512::AID-IJC13>3.0.CO;2-Z; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	79	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6797	6806		10.1074/jbc.M009355200	http://dx.doi.org/10.1074/jbc.M009355200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11098059	hybrid			2022-12-25	WOS:000167261000093
J	Qian, YM; Song, WC; Cui, H; Cole, SPC; Deeley, RG				Qian, YM; Song, WC; Cui, H; Cole, SPC; Deeley, RG			Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; CANCER CELL-LINE; MRP GENE; MONOCLONAL-ANTIBODIES; VINCRISTINE TRANSPORT; TARGETED DISRUPTION; DEPENDENT TRANSPORT; MOLECULAR-CLONING; MEMBRANE-VESICLES; EPITHELIAL-CELLS	Multidrug resistance protein 1 (MRP1) is an ATP-binding cassette (ABC) transporter that transports a range of hydrophobic xenobiotics, as well as relatively hydrophilic organic anion conjugates. The protein is present at high levels in testicular Leydig and Sertoli cells. Studies with knockout mice suggest that MRP1 may protect germ cells from exposure to some cytotoxic xenobiotics, but potential endobiotic substrates in this organ have not been identified. Previously, we have shown certain D-ring, but not A-ring, estrogen glucuronides can act as competitive inhibitors of MRP1 mediated transport, suggesting that they are potential substrates for the protein. In the case of 17 beta -estradiol-17 beta -D-glucuronide, this has been confirmed by direct transport studies. The Leydig cell is the major site of estrogen conjugation in the testis. However, the principal products of conjugation are A-ring estrogen sulfates, which are then effluxed from the cell by an unknown transporter. To determine whether MRP1/mrp1 could fulfill this function, we used membrane vesicles from MRP1-transfected HeLa cells to assess this possibility. We found that estradiol and estrone 3-sulfate alone were poor competitors of MRP1-mediated transport of the cysteinyl leukotriene, leukotriene C-4. However, in the presence of reduced glutathione (GSH), their inhibitory potency was markedly increased. Direct transport studies using [H-3]estrone 3-sulfate confirmed that the conjugated estrogen could be efficiently transported (K-m = 0.73 muM, V-max = 440 pmol mg(-1) protein min(-1)), but only in the presence of either GSH or the nonreducing alkyl derivative, S-methyl GSH. In contrast to previous studies using vincristine as a substrate, we detected no reciprocal increase in MRP1-mediated GSH transport. These results provide the first example of GSH-stimulated, MRP1-mediated transport of a potential endogenous substrate and expand the range of MRP1 substrates whose transport is stimulated by GSH to include certain hydrophilic conjugated endobiotics, in addition to previously identified hydrophobic xenobiotics.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	Queens University - Canada; University of Pennsylvania; University of Pennsylvania	Deeley, RG (corresponding author), Queens Univ, Canc Res Labs, Botterell Hall, Kingston, ON K7L 3N6, Canada.		Cole, Susan/I-6389-2017	Cole, Susan/0000-0001-6571-6884; Qian, Yueming/0000-0001-7340-6421				BAUCHE F, 1994, FEBS LETT, V349, P392, DOI 10.1016/0014-5793(94)00709-8; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1990, MOL PHARMACOL, V37, P192; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Ding GY, 1999, ANTICANCER RES, V19, P3243; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; Flens MJ, 1996, AM J PATHOL, V148, P1237; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; GRANT CE, 1994, CANCER RES, V54, P357; Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Jedlitschky G, 1996, CANCER RES, V56, P988; Keppler D, 1999, ADV ENZYME REGUL, V39, P237, DOI 10.1016/S0065-2571(98)00015-6; Klein M, 2000, PLANT J, V21, P289, DOI 10.1046/j.1365-313x.2000.00684.x; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Lautier D, 1996, BIOCHEM PHARMACOL, V52, P967, DOI 10.1016/0006-2952(96)00450-9; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Qian YM, 1998, J PHARMACOL EXP THER, V286, P555; Qian YM, 1999, ENDOCRINOLOGY, V140, P1048, DOI 10.1210/en.140.3.1048; Rappa G, 1997, CANCER RES, V57, P5232; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; Sakamoto H, 1999, CANCER LETT, V135, P113; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Song WC, 1997, ENDOCRINOLOGY, V138, P5006, DOI 10.1210/en.138.11.5006; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Suiko M, 2000, BIOCHEM BIOPH RES CO, V267, P80, DOI 10.1006/bbrc.1999.1935; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; VERI JP, 1993, J ANDROL, V14, P23; Wijnholds J, 1998, J EXP MED, V188, P797, DOI 10.1084/jem.188.5.797; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690	42	157	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6404	6411		10.1074/jbc.M008251200	http://dx.doi.org/10.1074/jbc.M008251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11102445	hybrid			2022-12-25	WOS:000167261000046
J	Hinz, S; Trauzold, A; Boenicke, L; Sandberg, C; Beckmann, S; Bayer, E; Walczak, H; Kalthoff, H; Ungefroren, H				Hinz, S; Trauzold, A; Boenicke, L; Sandberg, C; Beckmann, S; Bayer, E; Walczak, H; Kalthoff, H; Ungefroren, H			Bcl-X-L protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis	ONCOGENE			English	Article						TRAIL; Bcl-X-L; Bax; apoptosis; pancreatic carcinoma; human	MYELOMA CELLS; CYTOCHROME-C; DEATH DOMAIN; LIGAND TRAIL; B-CELLS; FAS; EXPRESSION; BCL-X(L); FAMILY; GENE	In this study we sought to clarify the role of the proapoptotic potential of mitochondria in the death pathway emanating from the TRAIL (APO-2L) and CD95 receptors in pancreatic carcinoma cells. We focused on the role of the Bcl-2 family member Bcl-X-L, using three pancreatic carcinoma cell lines as a model system, two of which have high (Panc-1, PancTuI) and one has low (Colo357) Bcl-X-L expression. In these cell lines, the expression of Bcl-X-L correlated with sensitivity to apoptosis induced by TRAIL or anti-CD95. Flow cytometric analysis revealed cell surface expression of TRAIL-Ri and TRAIL-R2 on PancTuI and Colo357, and TRAIL-R2 on Panc-1 cells. In Colo357 cells retrovirally transduced with Bcl-X-L, caspase-8 activation in response to treatment with TRAIL or anti-CD95 antibody was not different from parental cells and EGFP-transfected controls, however, apoptosis was completely suppressed as measured by the mitochondrial transmembrane potential Delta Psim, caspase-3 activity (PARP cleavage) and DNA-fragmentation, Inhibition of Bcl-X-L function by overexpression of Bax or administration of antisense oligonucleotides against Bcl-X-L mRNA resulted in sensitization of Panc-1 cells to TRAIL and PancTuI cells to anti-CD95 antibody-induced cell death. The results show that Bcl-X-L can protect pancreatic cancer cells from CD95- and TRAIL-mediated apoptosis, Thus, in these epithelial tumour cells the mitochondrially mediated 'type II' pathway of apoptosis induction is not only operative regarding the CD95 system but also regarding the TRAIL system.	Univ Kiel, Res Unit Mol Oncol, Clin Gen Surg & Thorac Surg, D-24105 Kiel, Germany; Deutsch Krebsforschungszentrum, Tumor Immunol Program, Apoptosis Res Grp G0310, D-69120 Heidelberg, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany	University of Kiel; Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen	Ungefroren, H (corresponding author), Univ Kiel, Res Unit Mol Oncol, Clin Gen Surg & Thorac Surg, Arnold Heller Str 7, D-24105 Kiel, Germany.		Trauzold, Anna/P-4398-2014; Kalthoff, Holger/B-1618-2010; Walczak, Henning/AAV-2214-2020	Walczak, Henning/0000-0002-6312-4591				Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Alam MK, 1997, EUR J IMMUNOL, V27, P3485, DOI 10.1002/eji.1830271249; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BRAMHALL SR, 1997, INT J PANCREATOL, V21, P58; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Friess H, 1998, ANN SURG, V228, P780, DOI 10.1097/00000658-199812000-00009; Gauthier ER, 1996, CANCER RES, V56, P1451; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Howard BD, 2000, CANCER GENE THER, V7, P927, DOI 10.1038/sj.cgt.7700180; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kawahara A, 1998, ONCOGENE, V17, P2549, DOI 10.1038/sj.onc.1202192; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo S, 1998, ONCOGENE, V17, P2585, DOI 10.1038/sj.onc.1202194; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Krammer P H, 1999, Adv Immunol, V71, P163; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee SH, 1999, CANCER RES, V59, P5683; Leverkus M, 2000, CANCER RES, V60, P553; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MEMON SA, 1995, J IMMUNOL, V155, P4644; Miyamoto Y, 1999, ONCOLOGY-BASEL, V56, P73, DOI 10.1159/000011933; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Perkins CL, 2000, CANCER RES, V60, P1645; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider TJ, 1997, J IMMUNOL, V159, P4834; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shinoura N, 1999, CANCER RES, V59, P4119; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Ungefroren H, 1998, CANCER RES, V58, P1741; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WALCZAK H, 2000, CANCER RES, V60, P351; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Zhang XD, 1999, CANCER RES, V59, P2747	57	226	243	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5477	5486		10.1038/sj.onc.1203936	http://dx.doi.org/10.1038/sj.onc.1203936			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114725				2022-12-25	WOS:000165396100008
J	Perander, M; Bjorkoy, G; Johansen, T				Perander, M; Bjorkoy, G; Johansen, T			Nuclear import and export signals enable rapid nucleocytoplasmic shuttling of the atypical protein kinase C lambda	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-INDUCED DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; PKC-LAMBDA; INSULIN STIMULATION; LOCALIZATION SIGNAL; RAT ADIPOCYTES; ZETA ISOFORM; RICH DOMAINS; PI 3-KINASE; PC12 CELLS	The atypical protein kinase C (PKC) isoenzymes, lambda /L-and zeta PKC, play important roles in cellular signaling pathways regulating proliferation, differentiation, and cell survival. By using green fluorescent protein (G;FP) fusion proteins, we found that wild-type lambda PKC localized predominantly to the cytoplasm, whereas both a kinase-defective mutant and an activation loop mutant accumulated in the nucleus. We have mapped a functional nuclear localization signal (NLS) to the N-terminal part of the zinc finger domain of lambda PKC. Leptomycin B treatment induced rapid nuclear accumulation of GFP-lambda as well as endogenous lambda PKC suggesting the existence of a CRM1-dependent nuclear export signal (NES), Consequently, we identified a functional leucine-rich NES in the linker region between the zinc finger and the catalytic domain of lambda PKC. The presence of both the MLS and NES enables a continuous shuttling of lambda PKC between the cytoplasm and nucleus. Our results suggest that the exposure of the NLS in both lambda- and zeta PKC is regulated by intramolecular interactions between the N-terminal part, including the pseudosubstrate sequence, and the catalytic domain. Thus, either deletion of the N-terminal region, including the pseudosubstrate sequence, or a point mutation in this sequence leads to nuclear accumulation of lambda PKC. The ability of the two atypical PKC isoforms to enter the nucleus in HeLa cells upon leptomycin B treatment differs substantially. Although lambda PKC is able to enter the nucleus very rapidly, zeta PKC is much less efficiently imported into the nucleus. This difference can be explained by the different relative strengths of the NLS and NES in zeta PKC compared with zeta PKC.	Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Johansen, T (corresponding author), Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway.	terjej@fagmed.uit.no	Johansen, Terje/AAY-1753-2021; Johansen, Terje/N-2971-2015	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Perander, Maria/0000-0002-1177-2407				Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Bastiaens PIH, 1996, P NATL ACAD SCI USA, V93, P8407, DOI 10.1073/pnas.93.16.8407; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Brazil DP, 2000, CURR BIOL, V10, pR592, DOI 10.1016/S0960-9822(00)00635-7; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COLEMAN ES, 1994, J MOL NEUROSCI, V5, P39, DOI 10.1007/BF02736693; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEACH KL, 1992, J BIOL CHEM, V267, P21816; Liu Q, 1998, J IMMUNOL, V160, P1393; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; NERI LM, 1994, CELL MOL BIOL, V40, P619; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1994, J BIOL CHEM, V269, P8383; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Parissenti AM, 1998, J BIOL CHEM, V273, P8940, DOI 10.1074/jbc.273.15.8940; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; ROSENBERGER U, 1995, BIOCHEM J, V305, P269, DOI 10.1042/bj3050269; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schmalz D, 1998, J CELL SCI, V111, P1823; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Standaert ML, 1999, J BIOL CHEM, V274, P14074, DOI 10.1074/jbc.274.20.14074; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Truant R, 1999, MOL CELL BIOL, V19, P1210; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; Xu JH, 1996, J CELL BIOL, V134, P1301, DOI 10.1083/jcb.134.5.1301; Yamaga M, 1999, J BIOL CHEM, V274, P28537, DOI 10.1074/jbc.274.40.28537; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	77	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13015	13024		10.1074/jbc.M010356200	http://dx.doi.org/10.1074/jbc.M010356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11115515	hybrid			2022-12-25	WOS:000168198600079
J	Pio, R; Martinez, A; Unsworth, EJ; Kowalak, JA; Bengoechea, JA; Zipfel, PF; Elsasser, TH; Cuttitta, F				Pio, R; Martinez, A; Unsworth, EJ; Kowalak, JA; Bengoechea, JA; Zipfel, PF; Elsasser, TH; Cuttitta, F			Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; IMMUNOREACTIVE ADRENOMEDULLIN; NEISSERIA-GONORRHOEAE; RHEUMATOID-ARTHRITIS; PLASMA-CONCENTRATION; HYPOTENSIVE PEPTIDE; FACTOR-I; IDENTIFICATION; EXPRESSION; RESISTANCE	Adrenomedullin (AM) is an important regulatory peptide involved in both physiological and pathological states. We have previously demonstrated the existence of a specific AM-binding protein (AMBP-1) in human plasma. In the present study, we developed a nonradioactive ligand blotting assay, which, together with high pressure liquid chromatography/SDS-polyacrylamide gel electrophoresis purification techniques, allowed us to isolate AMBP-1 to homogeneity. The purified protein was identified as human complement factor H. We show that AM/factor H interaction interferes with the established methodology for quantification of circulating AM. Our data suggest that this routine procedure does not take into account the AM bound to its binding protein. In addition, we show that factor H affects AM in vitro functions. It enhances AM-mediated induction of cAMP in fibroblasts, augments the AM-mediated growth of a cancer cell line, and suppresses the bactericidal capability of AM on Escherichia coli. Reciprocally, AM influences the complement regulatory function of factor H by enhancing the cleavage of C3b via factor I. In summary, we report on a potentially new regulatory mechanism of AM biology, the influence of factor H on radioimmunoassay quantification of AM, and the possible involvement of AM as a regulator of the complement cascade.	NCI, Dept Cell & Canc Biol, NIH, Bethesda, MD 20892 USA; NIMH, Lab Neurotoxicol, Bethesda, MD 20892 USA; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Hans Knoell Inst Nat Prod Res, Dept Infect Biol, D-07745 Jena, Germany; ARS, Growth Biol Lab, USDA, Beltsville, MD 20705 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Turku; Hans Knoll Institute (HKI); United States Department of Agriculture (USDA)	Pio, R (corresponding author), NCI, Dept Cell & Canc Biol, NIH, Bldg 10 Rm 13N262, Bethesda, MD 20892 USA.		Martinez, Alfredo/GQH-5998-2022; Pio, Ruben/F-5353-2017	Martinez, Alfredo/0000-0003-4882-4044; Pio, Ruben/0000-0002-6831-6111; Bengoechea, Jose/0000-0002-9677-8751	NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH000274, Z01MH000274] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allaker RP, 1999, FEMS IMMUNOL MED MIC, V23, P289, DOI 10.1016/S0928-8244(98)00148-5; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Coppock HA, 1999, BIOCHEM J, V338, P15, DOI 10.1042/0264-6021:3380015; DECEULAER C, 1980, IMMUNOLOGY, V41, P37; Diaz A, 1997, J IMMUNOL, V158, P3779; DiScipio RG, 1998, J IMMUNOL, V160, P4057; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Elsasser TH, 1999, ENDOCRINOLOGY, V140, P4908, DOI 10.1210/en.140.10.4908; Elsasser TH, 1999, ENDOCRINOLOGY, V140, P5402, DOI 10.1210/en.140.11.5402; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; Friese MA, 2000, CLIN EXP IMMUNOL, V121, P406, DOI 10.1046/j.1365-2249.2000.01285.x; GHARAHDAGHI F, 1992, TECHNIQUES PROTEIN C, V3, P249; Grulich-Henn J, 1998, HORM RES, V49, P1, DOI 10.1159/000023118; GUC D, 1993, RHEUMATOL INT, V13, P139, DOI 10.1007/BF00301260; HARRISON RA, 1980, MOL IMMUNOL, V17, P9, DOI 10.1016/0161-5890(80)90119-4; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hirata Y, 1996, J CLIN ENDOCR METAB, V81, P1449, DOI 10.1210/jc.81.4.1449; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; ICHIKI Y, 1994, FEBS LETT, V338, P6, DOI 10.1016/0014-5793(94)80106-1; IFERROUDJENE D, 1991, EUR J IMMUNOL, V21, P967, DOI 10.1002/eji.1830210416; Iwai N, 1999, LUNG CANCER, V23, P209, DOI 10.1016/S0169-5002(99)00015-X; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Lewis LK, 1998, CLIN CHEM, V44, P571; Macri CJ, 1996, AM J OBSTET GYNECOL, V175, P906, DOI 10.1016/S0002-9378(96)80023-8; Malhotra R, 1999, BIOCHEM J, V341, P61, DOI 10.1042/0264-6021:3410061; Martinez A, 1997, ENDOCRINOLOGY, V138, P5597, DOI 10.1210/en.138.12.5597; Martinez A, 1999, PEPTIDES, V20, P1471, DOI 10.1016/S0196-9781(99)00158-8; Martinez A, 1996, ENDOCRINOLOGY, V137, P2626, DOI 10.1210/en.137.6.2626; MARTINEZ A, 1998, ADRENOMEDULLIN; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Nabil K, 1997, BIOCHEM J, V326, P377, DOI 10.1042/bj3260377; Neeleman C, 1999, INFECT IMMUN, V67, P4517, DOI 10.1128/IAI.67.9.4517-4524.1999; Nishio K, 1997, CRIT CARE MED, V25, P953, DOI 10.1097/00003246-199706000-00010; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; Pio R, 2000, PEPTIDES, V21, P1859, DOI 10.1016/S0196-9781(00)00341-7; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SATO K, 1995, LIFE SCI, V57, P189, DOI 10.1016/0024-3205(95)00259-9; SHOJI H, 1995, BIOCHEM BIOPH RES CO, V215, P531, DOI 10.1006/bbrc.1995.2497; SIM E, 1981, FEBS LETT, V132, P55, DOI 10.1016/0014-5793(81)80426-7; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; Takahashi K, 1997, PEPTIDES, V18, P459, DOI 10.1016/S0196-9781(96)00328-2; Ueda S, 1999, AM J RESP CRIT CARE, V160, P132, DOI 10.1164/ajrccm.160.1.9810006; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147	56	202	224	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12292	12300		10.1074/jbc.M007822200	http://dx.doi.org/10.1074/jbc.M007822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11116141	hybrid			2022-12-25	WOS:000168081800114
J	Olah, Z; Szabo, T; Karai, L; Hough, C; Fields, RD; Caudle, RM; Blumberg, PM; Iadarola, MJ				Olah, Z; Szabo, T; Karai, L; Hough, C; Fields, RD; Caudle, RM; Blumberg, PM; Iadarola, MJ			Ligand-induced dynamic membrane changes and cell deletion conferred by vanilloid receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-ROOT GANGLION; ACTIVATED ION-CHANNEL; CAPSAICIN RECEPTOR; SUBSTANCE-P; SENSORY NEURONS; SPINAL-CORD; RAT; CALCIUM; DESENSITIZATION; RESINIFERATOXIN	The real time dynamics of vanilloid-induced cytotoxicity and the specific deletion of nociceptive neurons expressing the wild-type vanilloid receptor (VR1) were investigated. VR1 was C-terminally tagged with either the 27-kDa enhanced green fluorescent protein (eGFP) or a 12-amino acid epsilon -epitope. Upon exposure to resiniferatoxin, VR1eGFP- or VR1 epsilon -expressing cells exhibited pharmacological responses similar to those of cells expressing the untagged VR1. Within seconds of vanilloid exposure, the intracellular free calcium ([Ca2+](i)) was elevated in cells expressing VR1, A functional pool of VR1 also was localized to the endoplasmic reticulum that, in the absence of extracellular calcium, also was capable of releasing calcium upon agonist treatment. Confocal imaging disclosed that resiniferatoxin treatment: induced vesiculation of the mitochondria and the endoplasmic reticulum (similar to1 min), nuclear membrane disruption (5-10 min), and cell lysis (1-2 h), Nociceptive primary sensory neurons endogenously express VR1, and resiniferatoxin treatment induced a sudden increase in [Ca2+](i) and mitochondrial disruption which was cell-selective, as glia and non-VR1-expressing neurons were unaffected. Early hallmarks of cytotoxicity were followed by specific deletion of VR1-expressing cells. These data demonstrate that vanilloids disrupt vital organelles within the cell body and, if administered to sensory ganglia, may be employed to rapidly and selectively delete nociceptive neurons.	NIDCR, Neuronal Gene Express Unit, Pain & Neurosensory Mechanisms Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Cellular Carcinogenesis & Tumor Promot, Bethesda, MD 20892 USA; NINDS, Neuroanl Excitabil Sect, Epilepsy Branch, Bethesda, MD 20892 USA; NICHD, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Olah, Z (corresponding author), NIDCR, Neuronal Gene Express Unit, Pain & Neurosensory Mechanisms Branch, NIH, Bldg 49,Rm 1A19,49 Convent Dr,MSC-4410, Bethesda, MD 20892 USA.			Caudle, Robert/0000-0002-2394-4114	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000688] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Acs G, 1996, MOL BRAIN RES, V35, P173, DOI 10.1016/0169-328X(95)00204-6; Acs G, 1997, J NEUROSCI, V17, P5622; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Biro T, 1998, MOL BRAIN RES, V56, P89, DOI 10.1016/S0169-328X(98)00033-3; Biro T, 1998, BLOOD, V91, P1332, DOI 10.1182/blood.V91.4.1332; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHIBA T, 1986, NEUROSCI LETT, V64, P311, DOI 10.1016/0304-3940(86)90347-2; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; DICKENSON A, 1990, PAIN, V43, P353, DOI 10.1016/0304-3959(90)90032-9; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EIMERL D, 1987, EXP NEUROL, V97, P169, DOI 10.1016/0014-4886(87)90291-3; ENDRENYI L, 1975, EUR J BIOCHEM, V51, P317, DOI 10.1111/j.1432-1033.1975.tb03931.x; FarkasSzallasi T, 1996, BRAIN RES, V719, P213, DOI 10.1016/0006-8993(96)00065-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guo A, 1999, EUR J NEUROSCI, V11, P946, DOI 10.1046/j.1460-9568.1999.00503.x; Hough CJ, 1996, J PHARMACOL EXP THER, V276, P143; HYLDEN JLK, 1992, J NEUROSCI, V12, P1716; JANCSO G, 1984, BRAIN RES, V295, P211, DOI 10.1016/0006-8993(84)90969-7; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; JANCSO G, 1990, NEUROSCIENCE, V39, P501, DOI 10.1016/0306-4522(90)90286-D; Jung J, 1999, J NEUROSCI, V19, P529; KIRALY E, 1991, BRAIN RES, V540, P279, DOI 10.1016/0006-8993(91)90518-Z; Liu L, 1998, BRAIN RES, V809, P246, DOI 10.1016/S0006-8993(98)00853-1; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; Purkiss J, 2000, BIOCHEM PHARMACOL, V59, P1403, DOI 10.1016/S0006-2952(00)00260-4; SANTICIOLI P, 1987, NEUROSCI LETT, V80, P167, DOI 10.1016/0304-3940(87)90648-3; Simpson PB, 1998, BRAIN RES REV, V26, P72, DOI 10.1016/S0165-0173(97)00056-8; Subramanian K, 1997, CELL, V89, P963, DOI 10.1016/S0092-8674(00)80281-0; Sugimoto T, 1999, BRAIN RES, V818, P147, DOI 10.1016/S0006-8993(98)01227-X; Szabo T, 1999, BRAIN RES, V840, P92, DOI 10.1016/S0006-8993(99)01763-1; Szallasi A, 1995, BRAIN RES, V703, P175, DOI 10.1016/0006-8993(95)01094-7; Szallasi A, 1999, MOL PHARMACOL, V56, P581, DOI 10.1124/mol.56.3.581; Szallasi A, 1996, BRIT J PHARMACOL, V119, P283, DOI 10.1111/j.1476-5381.1996.tb15983.x; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Usachev YM, 1999, BIOESSAYS, V21, P743, DOI 10.1002/(SICI)1521-1878(199909)21:9<743::AID-BIES5>3.0.CO;2-M; WINTER J, 1990, BRAIN RES, V520, P131, DOI 10.1016/0006-8993(90)91698-G; YAKSH TL, 1979, SCIENCE, V206, P481, DOI 10.1126/science.228392; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336	40	176	185	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11021	11030		10.1074/jbc.M008392200	http://dx.doi.org/10.1074/jbc.M008392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11124944	hybrid			2022-12-25	WOS:000167980900062
J	Lohi, J; Wilson, CL; Roby, JD; Parks, WC				Lohi, J; Wilson, CL; Roby, JD; Parks, WC			Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; 92-KDA GELATINASE EXPRESSION; GROWTH-FACTOR; INTERSTITIAL COLLAGENASE; EXTRACELLULAR-MATRIX; CHROMOSOMAL LOCATION; MATRILYSIN; IDENTIFICATION; CELLS; ACTIVATION	We have cloned a new human matrix metalloproteinase (MMP-28, epilysin) from human keratinocyte and testis cDNA libraries. Like most MMPs, epilysin contains a signal sequence, a prodomain with a PRCGVTD sequence, a zinc-binding catalytic domain with an HEIGHTLGLTH sequence, and a hemopexin-like domain. In addition, epilysin has a furin activation sequence (RRKKR) but has no transmembrane sequence. The exon-intron organization and splicing pattern of epilysin differ from that of other MMP genes. It has only 8 exons, and 5 exons are spliced at sites not used by other MMPs. Another novel feature of epilysin is that exon 4 is alternatively spliced to a transcript that does not encode the N-terminal half of the catalytic domain. Northern hybridization of tissue RNA indicated that epilysin is expressed at high levels in testis and at lower levels in lungs, heart, colon, intestine, and brain, RNase protection assay with various cell lines indicated that epilysin was selectively expressed in keratinocytes. Recombinant epilysin degraded casein in a zymography assay, and its proteolytic activity was inhibited by EDTA and by batimastat, a selective MMP inhibitor. Immunohistochemical staining showed expression of epilysin protein in the basal and suprabasal epidermis of intact skin. In injured skin, prominent staining for epilysin was seen in basal keratinocytes both at and some distance from the wound edge, a pattern that is quite distinct from that of other MMPs expressed during tissue repair. These findings suggest that this new MMP functions in several tissues both in tissue homeostasis and in repair.	Univ Helsinki, Haartman Inst, Dept Virol, FIN-00290 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00290 Helsinki, Finland; Washington Univ, Sch Med, Dept Pediat Allergy & Pulm Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	University of Helsinki; University of Helsinki; Washington University (WUSTL); Washington University (WUSTL)	Lohi, J (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, POB 21 Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	jouko.lohi@helsinki.fi	Parks, William C./AAH-6786-2021		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR045254] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45254] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Caterina J, 1999, GENOMICS, V62, P308, DOI 10.1006/geno.1999.5990; CLARK SD, 1985, ARCH BIOCHEM BIOPHYS, V241, P36, DOI 10.1016/0003-9861(85)90358-3; Cossins J, 1996, BIOCHEM BIOPH RES CO, V228, P494, DOI 10.1006/bbrc.1996.1688; de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; FRAGIONI JV, 1993, ANAL BIOCHEM, V210, P179; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Jeffrey JJ, 1998, BIOL EXTRAC, P15; Knauper V, 1998, BIOL EXTRAC, P199; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; LOHI J, 1995, J BIOL CHEM, V270, P17602, DOI 10.1074/jbc.270.29.17602; Lopez-Boado YS, 2000, J CELL BIOL, V148, P1305, DOI 10.1083/jcb.148.6.1305; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; Madlener M, 1996, BIOCHEM J, V320, P659, DOI 10.1042/bj3200659; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; Mueller MS, 2000, GENE, V252, P27, DOI 10.1016/S0378-1119(00)00236-5; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; Parks WC, 1998, BIOL EXTRAC, P263; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Pei DQ, 1999, FEBS LETT, V457, P262, DOI 10.1016/S0014-5793(99)01046-7; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; Puente XS, 1996, CANCER RES, V56, P944; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V105, P190, DOI 10.1111/1523-1747.ep12317104; SaarialhoKere UK, 1996, AM J PATHOL, V148, P519; SALO T, 1994, LAB INVEST, V70, P176; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SIRES UI, 1994, BIOCHEM BIOPH RES CO, V204, P613, DOI 10.1006/bbrc.1994.2503; Sudbeck BD, 1997, MOL BIOL CELL, V8, P811, DOI 10.1091/mbc.8.5.811; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Velasco G, 2000, CANCER RES, V60, P877; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Woessner JF, 1998, BIOL EXTRAC, P1	65	196	210	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10134	10144		10.1074/jbc.M001599200	http://dx.doi.org/10.1074/jbc.M001599200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11121398	hybrid			2022-12-25	WOS:000167996400074
J	Ang, D; Richardson, A; Mayer, MP; Keppel, F; Krisch, H; Georgopoulos, C				Ang, D; Richardson, A; Mayer, MP; Keppel, F; Krisch, H; Georgopoulos, C			Pseudo-T-even bacteriophage RB49 encodes CocO, a cochaperonin for GroEL, which can substitute for Escherichia coli's GroES and bacteriophage T4's Gp31	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BYPASS 31 MUTATIONS; CRYSTAL-STRUCTURE; CHAPERONIN GROEL; MOLECULAR CHAPERONES; CITRATE SYNTHASE; PROTEIN; BACTERIAL; GENE-31; EXPRESSION; SEQUENCE	Bacteriophage T4-encoded Gp31 is a functional ortholog of the Escherichia coli GroES cochaperonin protein. Both of these proteins form transient, productive complexes with the GroEL chaperonin, required for protein folding and other related functions in the cell, However, Gp31 is specifically required, in conjunction with GroEL, for the correct folding of Gp23, the major capsid protein of T4, To better understand the interaction between GroEL and its cochaperonin cognates, we determined whether the so-called "pseudo-T-even bacteriophages" are dependent on host GroEL function and whether they also encode their own cochaperonin, Here, we report the isolation of an allele-specific mutation of bacteriophage RB49, called epsilon 22, which permits growth on the E, coli groEL44 mutant hut not on the isogenic wild type host. RB49 epsilon 22 was used in marker rescue experiments to identify the corresponding wild type gene, which me have named cocO (cochaperonin cognate). CocO has extremely limited identity to GroES but is 34% identical and 55% similar at the protein sequence level to T4 Gp31, sharing all of the structural features of Gp31 that distinguish it from GroES. CocO can substitute for Gp31 in T4 growth and also suppresses the temperature-sensitive phenotype of the E. coli groES42 mutant. CocO's predicted mobile loop is one residue longer than that of Gp31, with the epsilon 22 mutation resulting in a Q36R substitution in this extra residue, Both the CocO wild type and epsilon 22 proteins have been purified and shown in vitro to assist GroEL in the refolding of denatured citrate synthase.	Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva 4, Switzerland; Lab Microbiol & Genet Mol, CNRS, UMR 5100, F-31062 Toulouse, France	University of Geneva; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Ang, D (corresponding author), Ctr Med Univ Geneva, Dept Biochim Med, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	deborah.ang@medecine.unige.ch	Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112				Andreadis JD, 1998, J BIOL CHEM, V273, P34075, DOI 10.1074/jbc.273.51.34075; BASCHONG W, 1991, J STRUCT BIOL, V106, P93, DOI 10.1016/1047-8477(91)90078-B; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CASTILLO CJ, 1978, J BIOL CHEM, V253, P2132; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; DOERMANN AH, 1984, J VIROL, V51, P315, DOI 10.1128/JVI.51.2.315-320.1984; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hunt JF, 1997, CELL, V90, P361, DOI 10.1016/S0092-8674(00)80343-8; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P14, DOI 10.1016/S0968-0004(00)88941-0; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; MANIATIS T, 1982, MOL CLONING LABORATO, P85; MAYER MP, 1995, GENE, V163, P41, DOI 10.1016/0378-1119(95)00389-N; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; Monod C, 1997, J MOL BIOL, V267, P237, DOI 10.1006/jmbi.1996.0867; NIVINSKAS R, 1988, GENE, V73, P251, DOI 10.1016/0378-1119(88)90332-0; REPOILA F, 1994, EMBO J, V13, P4181, DOI 10.1002/j.1460-2075.1994.tb06736.x; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Richardson A, 1999, GENETICS, V152, P1449; Richardson A, 1999, J BIOL CHEM, V274, P52, DOI 10.1074/jbc.274.1.52; RICHARDSON A, 2000, THESIS U GENEVA; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; SIMON LD, 1984, J VIROL, V51, P321, DOI 10.1128/JVI.51.2.321-328.1984; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; WANG Z, 1992, PROTEIN SCI, V1, P522; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; ZHI W, 1991, BIOCHEMISTRY-US, V30, P9281, DOI 10.1021/bi00102a021	46	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8720	8726		10.1074/jbc.M008477200	http://dx.doi.org/10.1074/jbc.M008477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11104767	hybrid			2022-12-25	WOS:000167607700015
J	Chu, ZL; Pio, F; Xie, ZH; Welsh, K; Krajewska, M; Krajewski, S; Godzik, A; Reed, JC				Chu, ZL; Pio, F; Xie, ZH; Welsh, K; Krajewska, M; Krajewski, S; Godzik, A; Reed, JC			A novel enhancer of the Apaf1 apoptosome involved in cytochrome c-dependent caspase activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DROSOPHILA HOMOLOG; FAMILY MEMBER; ELEGANS CED-4; KAPPA-B; OLIGOMERIZATION; PROCASPASE-9; COMPLEX; MITOCHONDRIA; PROTEIN	Apaf1/CED4 family members play central roles in apoptosis regulation as activators of caspase family cell death proteases, These proteins contain a nucleotide-binding (NB) self-oligomerization domain and a caspase recruitment domain (CARD). A novel human protein was identified, NAG, that contains an NE domain and CARD. The CARD of NAC interacts selectively with the CARD domain of Apaf1, a caspase-activating protein that couples mitochondria-released cytochrome c (cyt-c) to activation of cytosolic caspases. Cyt-c-mediated activation of caspases in cytosolic extracts and in cells is enhanced by overexpressing NAC and inhibited by reducing NAC using antisense/DNAzymes. Furthermore, association of NAC with Apaf1 is cyt c inducible, resulting in a mega-complex (>1 MDa) containing both NAC and Apaf1 and correlating with enhanced recruitment and proteolytic processing of pro-caspase-9. NAC also collaborates with Apaf1 in inducing caspase activation and apoptosis in intact cells, whereas fragments of NAC representing only the CARD or NE domain suppress Apaf1-dependent apoptosis induction. NAC expression in vivo is associated with terminal differentiation of short Lived cells in epithelia and some other tissues. The ability of NAC to enhance Apaf1-apoptosome function reveals a novel paradigm for apoptosis regulation.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Godzik, Adam/AAW-1467-2020; Godzik, Adam/A-7279-2009	Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X; pio, frederic/0000-0003-2050-847X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036821] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61694] Funding Source: Medline; NINDS NIH HHS [NS36821] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Burgess DH, 1999, CELL DEATH DIFFER, V6, P256, DOI 10.1038/sj.cdd.4400489; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Jaroszewski L, 2000, PROTEINS, V39, P197, DOI 10.1002/(SICI)1097-0134(20000515)39:3<197::AID-PROT10>3.0.CO;2-V; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	35	144	153	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9239	9245		10.1074/jbc.M006309200	http://dx.doi.org/10.1074/jbc.M006309200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11113115	hybrid			2022-12-25	WOS:000167607700083
J	Gautam, A; Bastia, D				Gautam, A; Bastia, D			A replication terminus located at or near a replication checkpoint of Bacillus subtilis functions independently of stringent control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; ESCHERICHIA-COLI; RNA-POLYMERASE; PROTEIN; FORK; TERMINATION; IDENTIFICATION; CONTRAHELICASE; MODULATION; MECHANISM	We have examined a replication terminus (omega L1) located on the left arm of the chromosome of Bacillus subtilis and within the yxcC gene and at or near the left replication checkpoint that is activated under stringent conditions. The psi L1 sequence appears to bind to two dimers of the replication terminator protein (RTP) rather weakly and seems to possess overlapping core and auxiliary sites that have some sequence similarities with normal Ter sites. Surprisingly, the asymmetrical, isolated psi L1 site arrested replication forks in vivo in both orientations and independent of stringent control. In vitro, the sequence arrested DnaB helicase in both orientations, albeit more weakly than the normal Ter1 terminus, The key points of mechanistic interest that emerge from the present work are: (i) strong binding of a Ter (psi L1) sequence to RTP did not appear to be essential for fork arrest and (ii) polarity of fork arrest could not be correlated in this case with just symmetrical protein-DNA interaction at the core and auxiliary sites of psi L1. On the basis of the result it would appear that the weak RTP-L1Ter interaction cannot by itself account for fork arrest, thus suggesting a role for DnaB-RTP interaction.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA	Duke University	Bastia, D (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.							Autret S, 1999, MOL MICROBIOL, V31, P1665, DOI 10.1046/j.1365-2958.1999.01299.x; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BUSSIERE DE, 1995, CELL, V80, P651; Bussiere DE, 1999, MOL MICROBIOL, V31, P1611, DOI 10.1046/j.1365-2958.1999.01287.x; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; CASHEL M, 1997, ESCHERICHIA COLI SAL, V2, P1410; Chatterji D, 1998, GENES CELLS, V3, P279, DOI 10.1046/j.1365-2443.1998.00190.x; Gentry DR, 1996, MOL MICROBIOL, V19, P1373, DOI 10.1111/j.1365-2958.1996.tb02480.x; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; LEVINE A, 1995, MOL MICROBIOL, V15, P287, DOI 10.1111/j.1365-2958.1995.tb02243.x; LEVINE A, 1991, J MOL BIOL, V219, P605, DOI 10.1016/0022-2836(91)90657-R; Manna AC, 1996, P NATL ACAD SCI USA, V93, P3253, DOI 10.1073/pnas.93.8.3253; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; Meijer WJJ, 1996, MOL MICROBIOL, V19, P1295, DOI 10.1111/j.1365-2958.1996.tb02474.x; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; SAHOO T, 1995, EMBO J, V14, P619, DOI 10.1002/j.1460-2075.1995.tb07038.x; SEROR SJ, 1986, NATURE, V321, P709, DOI 10.1038/321709a0; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; SZALEWSKAPALASZ A, 1994, EMBO J, V13, P5779, DOI 10.1002/j.1460-2075.1994.tb06916.x; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445	20	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8771	8777		10.1074/jbc.M009538200	http://dx.doi.org/10.1074/jbc.M009538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124956	hybrid			2022-12-25	WOS:000167607700022
J	Karihaloo, A; O'Rourke, DA; Nickel, C; Spokes, K; Cantley, LG				Karihaloo, A; O'Rourke, DA; Nickel, C; Spokes, K; Cantley, LG			Differential MAPK pathways utilized for HGF- and EGF- dependent renal epithelial morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; PHOSPHOLIPASE-C-GAMMA; CELL MOTILITY; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; FOCAL ADHESIONS; CARCINOMA CELLS; DOCKING PROTEIN	Cells derived from the inner medullary collecting duct undergo in vitro branching tubulogenesis to both the c-met receptor ligand hepatocyte growth factor (HGF) as well as epidermal growth factor (EGF) receptor ligands. In contrast, many other cultured renal epithelial cells respond in this manner only to HGF, suggesting that these two receptors may use independent signaling pathways during morphogenesis. We have therefore compared the signaling pathways for mIMCD-3 cell morphogenesis in response to EGF and HGF, Inhibition of the p42/44 mitogen-activated protein kinase (MAPK) pathway with the mitogen-activated protein kinase kinase (MKK1) inhibitor PD98059 (50 muM) markedly inhibits HGF-induced cell migration with only partial inhibition of EGF-induced cell motility. Similarly, HGF-dependent, but not EGF-dependent, branching morphogenesis was more greatly inhibited by the MKK1 inhibitor. Examination of EGF-stimulated cells demonstrated that extracellular-regulated kinase 5 (ERK5) was activated in response to EGF but not HGF, and that activation of ERK5 was only 60% inhibited by 50 muM PD98059. In contrast, the MKK inhibitor U0126 markedly inhibited both ERK1/2 and ERK5 activation and completely prevented HGF- and EGF-dependent migration and branching process formation. Expression of dominant negative ERK5 (dn-BMK1) likewise inhibited EGF-dependent-branching process formation, but did not affect HGF-dependent branching process formation. Our results indicate that activation of the ERK1/ERK2 signaling pathway is critical for HGF-induced cell motility/morphogenesis in mIMCD-3 cells, whereas ERK5 appears to be required for EGF-dependent morphogenesis.	Yale Univ, Sch Med, New Haven, CT 06520 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; ACLARA Biosci, Mt View, CA 94043 USA	Yale University; Harvard University; Beth Israel Deaconess Medical Center	Karihaloo, A (corresponding author), Yale Univ, Sch Med, 333 Cedar St,LMP 2093, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054911] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54911] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; BARROS EJG, 1995, P NATL ACAD SCI USA, V92, P4412, DOI 10.1073/pnas.92.10.4412; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Cantley LG, 1996, AM J PHYSIOL-RENAL, V271, pF1103, DOI 10.1152/ajprenal.1996.271.6.F1103; CANTLEY LG, 1994, AM J PHYSIOL, V267, P271; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Derman MP, 1996, J BIOL CHEM, V271, P4251; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Herrera R, 1998, J CELL SCI, V111, P1039; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kjelsberg C, 1997, AM J PHYSIOL-RENAL, V272, pF222, DOI 10.1152/ajprenal.1997.272.2.F222; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Nagamine K, 1996, EUR J BIOCHEM, V236, P476, DOI 10.1111/j.1432-1033.1996.t01-1-00476.x; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; Polk DB, 1999, AM J PHYSIOL-CELL PH, V277, pC1149, DOI 10.1152/ajpcell.1999.277.6.C1149; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; Slack JK, 1999, J BIOL CHEM, V274, P27177, DOI 10.1074/jbc.274.38.27177; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Xie H, 1998, J CELL SCI, V111, P615	39	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9166	9173		10.1074/jbc.M009963200	http://dx.doi.org/10.1074/jbc.M009963200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11118451	hybrid			2022-12-25	WOS:000167607700074
J	Shirakabe, K; Wakatsuki, S; Kurisaki, T; Fujisawa-Sehara, A				Shirakabe, K; Wakatsuki, S; Kurisaki, T; Fujisawa-Sehara, A			Roles of meltrin beta/ADAM19 in the processing of neuregulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; NECROSIS-FACTOR-ALPHA; AMYLOID PRECURSOR PROTEIN; METALLOPROTEASE-DISINTEGRIN; INTRACELLULAR MATURATION; REGULATED CLEAVAGE; SECRETASE CLEAVAGE; CELLS; DOMAIN; LIGAND	Meltrin beta /ADAM19 is a member of ADAMs (a disintegrin and metalloproteases), which are a family of membrane-anchored glycoproteins that play important roles in fertilization, myoblast fusion, neurogenesis, and proteolytic processing of several membrane-anchored proteins. The expression pattern of meltrin beta during mouse development coincided well with that of neuregulin-1 (NRG), a member of the epidermal growth factor family. Then we examined whether meltrin beta participates in the proteolytic processing of membrane-anchored NRGs. When NRG-beta1 was expressed in mouse L929 cells, its extracellular domain was constitutively processed and released into the culture medium. This basal processing activity was remarkably potentiated by overexpression of wild-type meltrin beta, which lead to the significant decrease in the cell surface exposure of extracellular domains of NRG-beta1. Furthermore, expression of protease-deficient mutants of meltrin beta exerted dominant negative effects on the basal processing of NRG-beta1. These results indicate that meltrin beta participates in the processing of NRG-beta1. Since meltrin beta affected the processing of NRG-beta4 but not that of NRG-alpha2, meltrin beta was considered to have a preference for beta -type NRGs as substrate. Furthermore, the effects of the secretory pathway inhibitors suggested that meltrin beta participates in the intracellular processing of NRGs rather than the cleavage on the cell surface.	Kyoto Univ, Inst Frontier Med Sci, Dept Growth Regulat, Kyoto 6068507, Japan; Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan	Kyoto University; Tokyo Metropolitan Institute of Medical Science	Fujisawa-Sehara, A (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Growth Regulat, Kawahara Cho 53,Shogo In, Kyoto 6068507, Japan.							Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Liu XF, 1998, P NATL ACAD SCI USA, V95, P13024, DOI 10.1073/pnas.95.22.13024; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	37	165	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9352	9358		10.1074/jbc.M007913200	http://dx.doi.org/10.1074/jbc.M007913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11116142	hybrid			2022-12-25	WOS:000167607700098
J	Shin, SY; Kim, SY; Kim, JH; Min, DS; Ko, J; Kang, UG; Kim, YS; Kwon, TK; Han, MY; Kim, YH; Lee, YH				Shin, SY; Kim, SY; Kim, JH; Min, DS; Ko, J; Kang, UG; Kim, YS; Kwon, TK; Han, MY; Kim, YH; Lee, YH			Induction of early growth response-1 gene expression by calmodulin antagonist trifluoperazine through the activation of Elk-1 in human fibrosarcoma HT1080 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR EGR-1; TERNARY COMPLEX FACTORS; C-FOS; PROTEIN PHOSPHATASE; SIGNAL-TRANSDUCTION; CALCIUM; RAS; TRANSFORMATION; CALCINEURIN; RECEPTOR	The early growth response gene-1 (Egr-1) is a transcription factor that plays an important role in cell growth and differentiation. It has been known that Egr-1 expression is down-regulated in many types of tumor tissues, including human fibrosarcoma HT1080 cells, and introduction of the Egr-1 gene into HT1080 cells inhibits cell growth and tumorigenic potential. Trifluoperazine (TFP), a phenothiazine class calmodulin antagonist, is known to inhibit DNA synthesis and cell proliferation and potentially important in antitumor activities. To understand the regulatory mechanism of Egr-1, we investigated the effect of TFP on expression of Egr-1 in HT1080 cells. Herein, we report that Egr-1 expression was increased by TFP in synergy with serum at the transcriptional level. Both the Ca2+/calmodulin-dependent protein kinase II inhibitor KN62 and the calcineurin inhibitor cyclosporin A enhanced TFP-dependent increase of Egr-1, suggesting that the Ca2+/calmodulindependent pathway plays a role in regulation of Egr-1 expression in HT1080 cells. The TFP-stimulated increase of the Egr-1 protein was preferentially inhibited by the MEK-specific inhibitor PD98059. In addition, activation of human Egr-1 promoter and the transcriptional activation of the ternary complex factor Elk-l induced by TFP were inhibited both by pretreatment of PD98059 and by expression of the dominant-negative RasN17. These results indicate that the Ras/MEK/Erk/Elk-1 pathway is necessary for TFP-induced Egr-1 expression. We propose that the calmodulin antagonist TFP stimulates Egr-1 gene expression by modulating Ras/MEK/Erk and activation of the Elk-1 pathway in human fibrosarcoma HT1080 cells.	Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Daegu 705717, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea; Univ Ulsan, Immunomodulat Res Ctr, Ulsan 138736, South Korea; Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 151742, South Korea; Keimyung Univ, Sch Med, Dept Immunol, Daegu 700712, South Korea; Korea Res Inst Biosci & Biotechnol, Cell Biol Lab, Taejon 305600, South Korea; Kyungpook Natl Univ, Dept Microbiol, Daegu 702701, South Korea	Yeungnam University; Catholic University of Korea; University of Ulsan; Seoul National University (SNU); Keimyung University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Kyungpook National University	Lee, YH (corresponding author), Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Daegu 705717, South Korea.	younglee@med.yu.ac.kr	Kang, Ung Gu/J-2729-2012					BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; Chen CY, 1996, MOL CELL BIOL, V16, P6582; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DURHAM ACH, 1982, BIOSCIENCE REP, V2, P15, DOI 10.1007/BF01142195; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; HAIT WN, 1986, J CLIN ONCOL, V4, P994, DOI 10.1200/JCO.1986.4.6.994; HICKIE RA, 1983, CAN J BIOCHEM CELL B, V61, P934, DOI 10.1139/o83-119; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kumar R, 1997, NEUROCHEM RES, V22, P1, DOI 10.1023/A:1027332000569; LEE YH, 1994, J BIOL CHEM, V269, P26842; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVIN WJ, 1995, ONCOGENE, V11, P1261; LIM RW, 1987, ONCOGENE, V1, P263; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; MACNEIL S, 1988, BIOCHEM PHARMACOL, V37, P1717, DOI 10.1016/0006-2952(88)90434-0; MEANS AR, 1980, NATURE, V285, P73, DOI 10.1038/285073a0; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NAFTALOVICH S, 1991, CANCER CHEMOTH PHARM, V28, P384, DOI 10.1007/BF00685694; OSBORN M, 1980, EXP CELL RES, V130, P484, DOI 10.1016/0014-4827(80)90033-6; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RIM M, 1992, ONCOGENE, V7, P2065; RUPPRECHT HD, 1993, AM J PHYSIOL, V265, pF351, DOI 10.1152/ajprenal.1993.265.3.F351; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; Schaefer A, 1998, BIOCHEM J, V335, P505, DOI 10.1042/bj3350505; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Tian JM, 1999, J BIOL CHEM, V274, P15173, DOI 10.1074/jbc.274.21.15173; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREISMAN R, 1990, CANCER BIOL, V1, P47; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WEI JW, 1981, BIOCHEM BIOPH RES CO, V100, P1562, DOI 10.1016/0006-291X(81)90697-5; Weiss B, 1978, Adv Cyclic Nucleotide Res, V9, P285; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zubiaur M, 1996, ONCOGENE, V12, P1213	56	36	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7797	7805		10.1074/jbc.M009465200	http://dx.doi.org/10.1074/jbc.M009465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11121417	hybrid, Green Published			2022-12-25	WOS:000167474900019
J	Price, SJ; Greaves, DR; Watkins, H				Price, SJ; Greaves, DR; Watkins, H			Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene - Role of Sp1 in allele-specific transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; IV COLLAGENASE; GELATINASE-A; CYP17 GENE; B PROMOTER; ACTIVATION; EXPRESSION; BINDING; MEMBRANE; CLEAVAGE	Matrix metalloproteinase-2 (MMP-8) is an enzyme with proteolytic activity against matrix and nonmatrix proteins, particularly basement membrane constituents. Thus, any naturally occurring genetic variants that directly affect gene expression and/or protein function would be expected to impact on progression of pathological processes involving tissue remodeling. We scanned a a-kilobase pair promoter region and all 13 exons of the human MMP-2 gene, from a panel of 32 individuals, and we identified the position, nature, and relative allele frequencies of 15 variant loci as follows: 6 in the promoter, 1 in the 5'-untranslated region, 6 in the coding region, 1 in intronic sequence, and 1 in the 3'-untranslated region. The majority of coding region polymorphisms resulted in synonymous substitutions, whereas three promoter variants (at -1306, -790, and +220) mapped onto cis-acting elements, We functionally characterized all promoter variants by transient transfection experiments with 293, RAW264.7, and A10 cells. The common C --> T transition at -1306 (allele frequency 0.26), which disrupts an Spl-type promoter site (CCACC box), displayed a strikingly lower promoter activity with the T allele, Electrophoretic mobility shift assays confirmed that these differences in allelic expression were attributable to abolition of Spl binding. These data suggest that this common functional genetic variant influences MMP-2 gene transcription in an allele-specific manner and is therefore an important candidate to test for association in a wide spectrum of pathologies for which a role for MMP-8 is implicated, including atherogenesis and tumor invasion and metastasis.	Univ Oxford, Dept Cardiovasc Med, Oxford OX1 2JD, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 2JD, England	University of Oxford; University of Oxford	Watkins, H (corresponding author), John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England.	hugh.watkins@cardiov.ox.ac.uk		Watkins, Hugh/0000-0002-5287-9016; Greaves, David/0000-0003-2856-9410				Alroy I, 1999, MOL CELL BIOL, V19, P1961; Altshuler D, 1998, NEW ENGL J MED, V338, P1626, DOI 10.1056/NEJM199805283382214; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; Bergman-Jungestrom M, 1999, INT J CANCER, V84, P350, DOI 10.1002/(SICI)1097-0215(19990820)84:4<350::AID-IJC3>3.0.CO;2-L; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOAG AH, 1994, AM J PATHOL, V144, P585; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CAREY AH, 1994, HUM MOL GENET, V3, P1873, DOI 10.1093/hmg/3.10.1873; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Feigelson HS, 1997, CANCER RES, V57, P1063; Fini ME, 1998, BIOL EXTRAC, P299; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gsur A, 2000, INT J CANCER, V87, P434, DOI 10.1002/1097-0215(20000801)87:3<434::AID-IJC19>3.0.CO;2-G; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Housman D, 1998, NAT BIOTECHNOL, V16, P492, DOI 10.1038/nbt0698-492; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; Imper V, 1998, BIOL EXTRAC, P219; Itoh T, 1998, CANCER RES, V58, P1048; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kang SH, 1996, J BIOL CHEM, V271, P7330, DOI 10.1074/jbc.271.13.7330; Konttinen YT, 1999, ANN RHEUM DIS, V58, P691, DOI 10.1136/ard.58.11.691; Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MAOUCHE L, 1995, EUR J BIOCHEM, V233, P793, DOI 10.1111/j.1432-1033.1995.793_3.x; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; Martin ER, 2000, AM J HUM GENET, V67, P383, DOI 10.1086/303003; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POULSOM R, 1992, AM J PATHOL, V141, P389; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Quinn CM, 1999, GENOMICS, V62, P468, DOI 10.1006/geno.1999.6031; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Sang QXA, 2000, BIOCHEM BIOPH RES CO, V274, P780, DOI 10.1006/bbrc.2000.3212; Shen LX, 1999, P NATL ACAD SCI USA, V96, P7871, DOI 10.1073/pnas.96.14.7871; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; van 't Hooft FM, 1999, J LIPID RES, V40, P1686; Watanabe K, 2000, BIOCHEMISTRY-US, V39, P7138, DOI 10.1021/bi992670r; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Woessner JF, 1998, BIOL EXTRAC, P1; Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788; Zuo J, 1998, J NEUROSCI, V18, P5203, DOI 10.1523/JNEUROSCI.18-14-05203.1998	57	337	363	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7549	7558		10.1074/jbc.M010242200	http://dx.doi.org/10.1074/jbc.M010242200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11114309	hybrid			2022-12-25	WOS:000167442900094
J	Braunstein, GM; Roman, RM; Clancy, JP; Kudlow, BA; Taylor, AL; Shylonsky, VG; Jovov, B; Peter, K; Jilling, T; Ismailov, II; Benos, DJ; Schwiebert, LM; Fitz, JG; Schwiebert, EM				Braunstein, GM; Roman, RM; Clancy, JP; Kudlow, BA; Taylor, AL; Shylonsky, VG; Jovov, B; Peter, K; Jilling, T; Ismailov, II; Benos, DJ; Schwiebert, LM; Fitz, JG; Schwiebert, EM			Cystic fibrosis transmembrane conductance regulator facilitates ATP release by stimulating a separate ATP release channel for autocrine control of cell volume regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE P-GLYCOPROTEIN; AIRWAY SURFACE FLUID; CHLORIDE CHANNEL; ADENOSINE-TRIPHOSPHATE; EPITHELIAL-CELLS; EXTRACELLULAR ATP; CFTR; RECEPTORS; EXPRESSION; NUCLEOTIDES	These studies provide evidence that cystic fibrosis transmembrane conductance regulator (CFTR) potentiates and accelerates regulatory volume decrease (RVD) following hypotonic challenge by an autocrine mechanism involving ATP release and signaling. In wild-type CFTR-expressing cells, CFTR augments constitutive ATP release and enhances ATP release stimulated by hypotonic challenge. CFTR itself does not appear to conduct ATP. Instead, ATP is released by a separate channel, whose activity is potentiated by CFTR. Blockade of ATP release by ion channel blocking drugs, gadolinium chloride (Gd3+) and 4,4'-diisothiocyanatostilbene-2,2'disulfonic acid (DIDS), attenuated the effects of CFTR on acceleration and potentiation of RVD. These results support a key role for extracellular ATP and autocrine and paracrine purinergic signaling in the regulation of membrane ion permeability and suggest that CFTR potentiates ATP release by stimulating a separate ATP channel to strengthen autocrine control of cell volume regulation.	Univ Alabama Birmingham, Gregory Fleming James CF Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA; Univ Colorado, Hlth Sci Ctr, Div Hepatol, Denver, CO 80262 USA; Evanston Hosp Corp, Dept Pediat, Evanston, IL 60201 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; NorthShore University Health System	Schwiebert, EM (corresponding author), Univ Alabama Birmingham, Gregory Fleming James CF Res Ctr, BHSB 740,1918 Univ Blvd, Birmingham, AL 35294 USA.	eschwiebert@physiology.uab.edu		Jilling, Tamas/0000-0002-6200-3851	NIDDK NIH HHS [DK-48764, R01 DK/HL 54367] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048764, R01DK054367] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; Abraham EH, 1997, SCIENCE, V275, P1324, DOI 10.1126/science.275.5304.1324; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; Buell G, 1996, EUR J NEUROSCI, V8, P2221, DOI 10.1111/j.1460-9568.1996.tb00745.x; CANTIELLO HF, 1994, J BIOL CHEM, V269, P11224; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Clancy JP, 1999, AM J PHYSIOL-CELL PH, V276, pC361, DOI 10.1152/ajpcell.1999.276.2.C361; COZENS AL, 1992, IN VITRO CELL DEV-AN, V28A, P735; COZENS AL, 1991, ADV EXP MED BIOL, V290, P187; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Frame MK, 1997, EXP CELL RES, V230, P197, DOI 10.1006/excr.1996.3409; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Grygorczyk R, 1997, SCIENCE, V275, P1325; Guggino WB, 1999, CELL, V96, P607, DOI 10.1016/S0092-8674(00)80570-X; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Hollins B, 1997, J NEUROPHYSIOL, V78, P3069, DOI 10.1152/jn.1997.78.6.3069; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; Inoue CN, 1997, AM J PHYSIOL-CELL PH, V272, pC1862, DOI 10.1152/ajpcell.1997.272.6.C1862; JACKSON PS, 1995, J GEN PHYSIOL, V105, P661, DOI 10.1085/jgp.105.5.661; JIANG Q, 1996, J CELL BIOL, V143, P645; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KNOWLES MR, 1992, CHEST, V101, pS60, DOI 10.1378/chest.101.3_Supplement.60S; KUNZELMANN K, 1993, AM J RESP CELL MOL, V8, P522, DOI 10.1165/ajrcmb/8.5.522; LAZAROWSKI ER, 1992, BRIT J PHARMACOL, V106, P774, DOI 10.1111/j.1476-5381.1992.tb14412.x; Li CH, 1996, J BIOL CHEM, V271, P11623, DOI 10.1074/jbc.271.20.11623; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Musante L, 1999, J BIOL CHEM, V274, P11701, DOI 10.1074/jbc.274.17.11701; Pasyk EA, 1997, J BIOL CHEM, V272, P7746, DOI 10.1074/jbc.272.12.7746; Reddy MM, 1997, SCIENCE, V275, P1325; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; REISIN IL, 1994, J BIOL CHEM, V269, P20584; REYMANN S, 1995, BIOCHEM MOL MED, V54, P75, DOI 10.1006/bmme.1995.1011; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Roman RM, 1996, AM J PHYSIOL-GASTR L, V271, pG239, DOI 10.1152/ajpgi.1996.271.2.G239; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Schwiebert LM, 1999, AM J PHYSIOL-CELL PH, V276, pC700, DOI 10.1152/ajpcell.1999.276.3.C700; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; Sprague RS, 1998, AM J PHYSIOL-HEART C, V275, pH1726, DOI 10.1152/ajpheart.1998.275.5.H1726; STUTTS MJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1442, DOI 10.1152/ajpcell.1994.267.5.C1442; Sugita M, 1998, EMBO J, V17, P898, DOI 10.1093/emboj/17.4.898; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Urbach V, 1999, J MEMBRANE BIOL, V171, P255, DOI 10.1007/s002329900576; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VALVERDE MA, 1995, P NATL ACAD SCI USA, V92, P9038, DOI 10.1073/pnas.92.20.9038; Valverde MA, 1996, EMBO J, V15, P4460, DOI 10.1002/j.1460-2075.1996.tb00823.x; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Zhang YL, 1999, AM J PHYSIOL-CELL PH, V276, pC469, DOI 10.1152/ajpcell.1999.276.2.C469	57	159	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6621	6630		10.1074/jbc.M005893200	http://dx.doi.org/10.1074/jbc.M005893200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11110786	hybrid			2022-12-25	WOS:000167261000073
J	Strawn, LA; Shen, TX; Wente, SR				Strawn, LA; Shen, TX; Wente, SR			The GLFG regions of Nup116p and Nup100p serve as binding sites for both Kap95p and Mex67p at the nuclear pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; TRANSPORT FACTOR; NUCLEOCYTOPLASMIC TRANSPORT; IMPORTIN-BETA; YEAST; ARCHITECTURE; INTERACTS; PATHWAYS; NUCLEOPORINS; SUBSTRATE	Our previous studies have focused on a family of Saccharomyces cerevisiae nuclear pore complex (NPC) proteins that contain domains composed of repetitive tetrapeptide glycine-leucine-phenylalanine-glycine (GLFG) motifs. We have previously shown that the GLFG regions of Nup116p and Nup100p directly bind the karyopherin transport factor Kap95p during nuclear protein import. In this report, we have further investigated potential roles for the GLFG region in mRNA export. The subcellular localizations of green fluorescent protein (GFP)-tagged mRNA transport factors were individually examined in yeast cells overexpressing the Nup116-GLFG region. The essential mRNA export factors Mex67-GFP, Mtr2-GFP, and Dbp5-GFP accumulated in the nucleus. In contrast, the localizations of Gle1-GFP and Gle2-GFP remained predominantly associated with the NPC, as in wild type cells. The localization of Kap95p was also not perturbed with GLFG overexpression. Coimmunoprecipitation experiments from yeast cell lysates resulted in the isolation of a Mex67p-Nup116p complex. Soluble binding assays with bacterially expressed recombinant proteins confirmed a direct interaction between Mex67p and the Nup116-GLFG or Nup100-GLFG regions. Mtr2p was not required for in vitro binding of Mex67p to the GLFG region. To map the Nup116-GLFG subregion(s) required for Kap95p and/or Mex67p association, yeast two-hybrid analysis was used. Of the 33 Nup116-GLFG repeats that compose the domain, a central subregion of nine GLFG repeats was sufficient for binding either Kap95p or Mex67p. Interestingly, the first 12 repeats from the full-length region only had a positive interaction with Mex67p, whereas the last 12 were only positive with Kap95p. Thus, the GLFG domain may have the capacity to bind both karyopherins and an mRNA export factor simultaneously. Taken together, our in vivo and in vitro results define an essential role for a direct Mex67p-GLFG interaction during mRNA export.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Wente, SR (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	swente@cellbio.wustl.edu			NIGMS NIH HHS [GM51219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051219, R37GM051219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bailer SM, 2000, J BIOL CHEM, V275, P23540, DOI 10.1074/jbc.M001963200; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bucci M, 1997, J CELL BIOL, V136, P1185, DOI 10.1083/jcb.136.6.1185; Bucci M, 1998, MOL BIOL CELL, V9, P2439, DOI 10.1091/mbc.9.9.2439; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Ho AK, 1998, MOL BIOL CELL, V9, P355, DOI 10.1091/mbc.9.2.355; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Hood JK, 2000, J CELL SCI, V113, P1471; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; James P, 1996, GENETICS, V144, P1425; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Marelli M, 1998, J CELL BIOL, V143, P1813, DOI 10.1083/jcb.143.7.1813; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382	52	95	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6445	6452		10.1074/jbc.M008311200	http://dx.doi.org/10.1074/jbc.M008311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11104765	hybrid			2022-12-25	WOS:000167261000051
J	Haugabook, SJ; Le, T; Yager, D; Zenk, B; Healy, BM; Eckman, EA; Prada, C; Younkin, L; Murphy, P; Pinnix, I; Onstead, L; Sambamurti, K; Golde, TE; Dickson, D; Younkin, SG; Eckman, CB				Haugabook, SJ; Le, T; Yager, D; Zenk, B; Healy, BM; Eckman, EA; Prada, C; Younkin, L; Murphy, P; Pinnix, I; Onstead, L; Sambamurti, K; Golde, TE; Dickson, D; Younkin, SG; Eckman, CB			Reduction of A beta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin	FASEB JOURNAL			English	Article									Mayo Clin, Jacksonville, FL 32224 USA	Mayo Clinic	Eckman, CB (corresponding author), Mayo Clin, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Eckman, Elizabeth/AAL-7316-2021; Sambamurti, Kumar/J-6102-2013	Sambamurti, Kumar/0000-0001-9507-9214; Eckman, Elizabeth/0000-0002-5391-4960; Dickson, Dennis W/0000-0001-7189-7917					0	43	48	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					16	18						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099491				2022-12-25	WOS:000166312400006
J	Berrie, CP; Falasca, M				Berrie, CP; Falasca, M			Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic intervention	FASEB JOURNAL			English	Article						phosphoinositide 3-kinase; polyphosphoinositides; inositol polyphosphates; PH/FYVE/HIKE domains; cancer therapy	PLECKSTRIN HOMOLOGY DOMAINS; INOSITOL HEXAKISPHOSPHATE; PHOSPHOINOSITIDE 3-KINASES; SIGNAL-TRANSDUCTION; MEMBRANE TRAFFICKING; PH DOMAIN; BINDING; NEURONS; PENTAKISPHOSPHATE; METABOLISM	Signaling pathways involving the inositol polyphosphates and the polyphosphoinositides have become intricately linked with a number of disease states. More recently, this has principally involved the 3-phosphorylated products of phosphoinositide S-kinase, an enzyme that itself shows oncogenic activity and has hence become of interest in the design of antitumorigenic drugs. The downstream effecters of phosphoinositide 3-kinase are involved in different aspects of cellular signaling and cytoskeleton and trafficking events that are linked to specific polyphosphoinositide binding properties of specific protein domains, which themselves have emerging roles in specific disease states. Our recent findings have demonstrated that there is a selectivity of the intracellular effects of extracellularly applied inositol polyphosphates in their abilities to inhibit a range of growth-related in vivo assay conditions, and that these can themselves be linked to the inhibition of the membrane localization of a green fluorescent protein (GFP) -tagged PH domain. We propose that GFP fusions of the polyphosphoinositides binding domains of specific proteins of interest can be used in high-throughput investigations of the therapeutic value of specific inositol polyphosphates analogs. Inhibition of in vivo membrane targeting of these domains from proteins involved in cell growth and tumorigenesis can thus be used in the search for new anticancer drugs.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy; Univ G DAnnunzio, Sch Med, Dept Oncol & Neurosci, Sect Med Oncol, I-66100 Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; G d'Annunzio University of Chieti-Pescara	Berrie, CP (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Via Nazl, I-66030 Santa Maria Imbaro, Chieti, Italy.		Falasca, Marco/S-4020-2016	Falasca, Marco/0000-0002-9801-7235	Telethon [E.0841] Funding Source: Medline	Telethon(Fondazione Telethon)		Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; [Anonymous], OMIM ONLINE MENDELIA; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Ciccarelli FD, 2000, HUM MOL GENET, V9, P1001, DOI 10.1093/hmg/9.6.1001; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Dong ZG, 1999, ANTICANCER RES, V19, P3743; Eckmann L, 1997, P NATL ACAD SCI USA, V94, P14456, DOI 10.1073/pnas.94.26.14456; EGGLETON P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P309, DOI 10.1016/0167-4889(91)90091-B; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; NICOLETTI F, 1989, J NEUROCHEM, V53, P1026, DOI 10.1111/j.1471-4159.1989.tb07390.x; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shamsuddin AM, 1999, ANTICANCER RES, V19, P3733; SORTINO MA, 1990, EUR J PHARM-MOLEC PH, V189, P115, DOI 10.1016/0922-4106(90)90238-S; Stenmark H, 1999, J CELL SCI, V112, P4175; SUN MK, 1992, EUR J PHARMACOL, V215, P9, DOI 10.1016/0014-2999(92)90601-Y; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang JF, 1999, MOL BRAIN RES, V70, P66, DOI 10.1016/S0169-328X(99)00128-X; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092; Yang XN, 1999, J BIOL CHEM, V274, P18973, DOI 10.1074/jbc.274.27.18973; Yenush L, 2000, FEBS LETT, V467, P321, DOI 10.1016/S0014-5793(00)01183-2; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; SMART SIMPLE MODULAR; EXPASY EXPERT PROTEI	42	21	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2618	2622		10.1096/fj.00-0096hyp	http://dx.doi.org/10.1096/fj.00-0096hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099481				2022-12-25	WOS:000165723400033
J	Krauss, S; Brand, MD				Krauss, S; Brand, MD			Quantitation of signal transduction	FASEB JOURNAL			English	Article						energy metabolism; lymphocytes; metabolic control analysis; mitogenic activation	METABOLIC CONTROL ANALYSIS; PROTEIN-KINASE CASCADE; ENERGY-METABOLISM; ELASTICITY ANALYSIS; CYCLOSPORINE-A; CALCINEURIN; PATHWAYS; CELLS; QUANTIFICATION; MITOCHONDRIA	Conventional qualitative approaches to signal transduction provide powerful ways to explore the architecture and function of signaling pathways, However, at the level of the complete system, they do not fully depict the interactions between signaling and metabolic pathways and fail to give a manageable overview of the complexity that is often a feature of cellular signal transduction, Here, we introduce a quantitative experimental approach to signal transduction that helps to overcome these difficulties. We present a quantitative analysis of signal transduction during early mitogen stimulation of lymphocytes, with steady-state respiration rate as a convenient marker of metabolic stimulation. First, by inhibiting various key signaling pathways, we measure their relative importance in regulating respiration. About 80% of the input signal is conveyed via identifiable routes: 50% through pathways sensitive to inhibitors of protein kinase C and MAP kinase and 30% through pathways sensitive to an inhibitor of calcineurin, Second, we quantify how each of these pathways differentially stimulates functional units of reactions that produce and consume a key intermediate in respiration: the mitochondrial membrane potential. Both the PKC and calcineurin routes stimulate consumption more strongly than production, whereas the unidentified signaling routes stimulate production more than consumption, leading to no change in membrane potential despite increased respiration rate. The approach allows a quantitative description of the relative importance of signal transduction pathways and the routes by which they activate a specific cellular process. It should be widely applicable.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; MRC, Dunn Human Nutr Unit, Cambridge, England	University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Krauss, S (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol, 99 Brookline Ave, Boston, MA 02215 USA.		Brand, Martin D/A-9423-2012	Brand, Martin D/0000-0003-4418-6153				Ainscow EK, 1999, BIOSYSTEMS, V49, P151, DOI 10.1016/S0303-2647(98)00040-9; Ainscow EK, 1998, J THEOR BIOL, V194, P223, DOI 10.1006/jtbi.1998.0760; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brand MD, 1996, J THEOR BIOL, V182, P351, DOI 10.1006/jtbi.1996.0174; Brand MD, 1998, MOL CELL BIOCHEM, V184, P13, DOI 10.1023/A:1006893619101; BROWN GC, 1990, EUR J BIOCHEM, V188, P321, DOI 10.1111/j.1432-1033.1990.tb15406.x; BUTTGEREIT F, 1992, BIOSCIENCE REP, V12, P381, DOI 10.1007/BF01121501; BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; Fell D., 1997, UNDERSTANDING CONTRO; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Horseman ND, 1997, TRENDS ENDOCRIN MET, V8, P123, DOI 10.1016/S1043-2760(97)00001-5; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Karlsson H, 1997, BBA-BIOENERGETICS, V1319, P301, DOI 10.1016/S0005-2728(96)00173-9; Kaufman M, 1999, P NATL ACAD SCI USA, V96, P3894, DOI 10.1073/pnas.96.7.3894; KHOLODENKO BN, 1988, FEBS LETT, V232, P383, DOI 10.1016/0014-5793(88)80775-0; Kholodenko BN, 1997, FEBS LETT, V414, P430, DOI 10.1016/S0014-5793(97)01018-1; Korzeniewski B, 1998, BIOPHYS CHEM, V75, P73, DOI 10.1016/S0301-4622(98)00193-8; Krauss S, 1999, BBA-BIOENERGETICS, V1412, P129, DOI 10.1016/S0005-2728(99)00058-4; KRAUSS S, 1999, THESIS U CAMBRIDGE U; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; PUSZTAI A, 1991, PLANT LECTINS, P78; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; SALISBURY JG, 1979, J BIOCHEM BIOPH METH, V1, P341, DOI 10.1016/0165-022X(79)90025-3; Scott JE, 1997, BIOCHEM J, V324, P597, DOI 10.1042/bj3240597; TOULLEC D, 1991, J BIOL CHEM, V266, P15771	30	19	20	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2581	2588		10.1096/fj.00-0064com	http://dx.doi.org/10.1096/fj.00-0064com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099477				2022-12-25	WOS:000165723400029
J	Schmid, M; Sen, M; Rosenbach, MD; Carrera, CJ; Friedman, H; Carson, DA				Schmid, M; Sen, M; Rosenbach, MD; Carrera, CJ; Friedman, H; Carson, DA			A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer	ONCOGENE			English	Article						glioma; lung cancer; MTAP; tumor suppressor gene	SQUAMOUS-CELL CARCINOMA; IN-SITU HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; CUTANEOUS MALIGNANT-MELANOMA; HOMOZYGOUS DELETIONS; BLADDER-CANCER; LUNG-CANCER; CDKN2 GENE; SHORT ARM; P15 MTS2	Homozygous deletions of human chromosome 9p21 occur frequently in malignant cell lines, and are also common in primary gliomas, lung cancers, and leukemias. Moving from the centromere to the telomere, this complex region encodes the tumor suppressor genes p15(INK4B) (CDKN2B), p14(ARF), P16(INK4A) (CDKN2A), and the housekeeping gene methylthioadenosine phosphorylase (MTAP). However, not all chromosome 9p21 deletions in tumors include these tumor suppressor genes. Here we describe the partial sequence and the exact localization of a nerv gene on chromosome 9p21 centromeric of p15(INK4B) that formed an in frame fusion transcript with MTAP in a glioma xenograft, and that is homozygously deleted in various malignant cell lines, Northern blot revealed corresponding 1.5 kb transcript in non-deleted cell lines as well as in normal lymphocytes, Using a RNA master blot membrane including 50 different tissues, we could show that this new transcript is expressed in all tissues of the adult but not or only at very low levels in most of the fetal tissues tested. The expression pattern is similar to that of p16(INK4A). The localization as well as the deletion pattern makes this transcript a candidate for a new tumor suppressor gene.	Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Duke Univ, Dept Pediat, Durham, NC 27710 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Duke University	Friedman, H (corresponding author), Univ Ulm, Room 4608,Robert Koch Str 8, D-89070 Ulm, Germany.				NCI NIH HHS [CA6976] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An HX, 1996, GENE CHROMOSOME CANC, V17, P14, DOI 10.1002/(SICI)1098-2264(199609)17:1<14::AID-GCC3>3.3.CO;2-Y; Balazs M, 1997, GENE CHROMOSOME CANC, V19, P84, DOI 10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.3.CO;2-U; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Chen ZH, 1997, MOL PHARMACOL, V52, P903, DOI 10.1124/mol.52.5.903; Dreyling MH, 1998, GENE CHROMOSOME CANC, V22, P72, DOI 10.1002/(SICI)1098-2264(199805)22:1<72::AID-GCC10>3.3.CO;2-G; Farrell WE, 1997, CANCER RES, V57, P2703; Flores JF, 1996, CANCER RES, V56, P5023; Gonzalez MV, 1997, J CLIN PATHOL, V50, P509, DOI 10.1136/jcp.50.6.509; HABUCHI T, 1995, ONCOGENE, V11, P1671; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Hori Y, 1998, INT J CANCER, V75, P51, DOI 10.1002/(SICI)1097-0215(19980105)75:1<51::AID-IJC9>3.0.CO;2-0; KEEN AJ, 1994, ONCOGENE, V9, P2083; Kim SK, 1997, CANCER RES, V57, P400; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; LI YJ, 1995, ONCOGENE, V11, P597; Marshall B, 1997, CANCER GENET CYTOGEN, V96, P134, DOI 10.1016/S0165-4608(96)00300-7; Matsuura K, 1998, ANTICANCER RES, V18, P453; MOULTON T, 1995, AM J PATHOL, V146, P613; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Okami K, 1997, INT J CANCER, V74, P588, DOI 10.1002/(SICI)1097-0215(19971219)74:6<588::AID-IJC5>3.3.CO;2-4; OLOPADE OI, 1992, CANCER RES, V52, P2523; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Perry A, 1997, J NEUROPATH EXP NEUR, V56, P999, DOI 10.1097/00005072-199709000-00005; PUIG S, 1995, AM J HUM GENET, V57, P395; Ruiz A, 1998, INT J CANCER, V76, P312, DOI 10.1002/(SICI)1097-0215(19980504)76:3<312::AID-IJC4>3.3.CO;2-B; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; Stadler WM, 1996, UROL RES, V24, P239, DOI 10.1007/BF00295899; Tran PT, 1997, GENE, V186, P263, DOI 10.1016/S0378-1119(96)00718-4; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; Wiest JS, 1997, CANCER RES, V57, P1; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778	33	44	47	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5747	5754		10.1038/sj.onc.1203942	http://dx.doi.org/10.1038/sj.onc.1203942			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126361				2022-12-25	WOS:000165477700006
J	Qiu, Y; Kung, HJ				Qiu, Y; Kung, HJ			Signaling network of the Btk family kinases	ONCOGENE			English	Review						PH domain; Btk; tyrosine kinase; apoptosis; motility	BRUTONS-TYROSINE-KINASE; PLECKSTRIN HOMOLOGY DOMAINS; X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; BETA-GAMMA-SUBUNITS; PROSTATE-CANCER CELLS; SERUM RESPONSE FACTOR; RI CROSS-LINKING; FACTOR-KAPPA-B; SRC-FAMILY	The Btk family kinases represent new members of nonreceptor tyrosine kinases,which include Btk/Atk, Itk/Emt/Tsk, Bmx/Etk, and Tee. They are characterized by having four structural modules: PH (pleckstrin homology) domain, SH3 (Src homology 3) domain, SH2 (Src homology 2) domain and kinase (Src homology 1) domain. Increasing evidence suggests that, like Src-family kinases, Btk family kinases play central but diverse modulatory roles in various cellular processes, They participate in signal transduction in response to virtually all types of extracellular stimuli which are transmitted by growth factor receptors, cytokine receptors, G-protein coupled receptors, antigen-receptors and integrins, They are regulated by many non-receptor tyrosine kinases such as Src, Jak, Syk and FAK family kinases, In turn, they regulate many of major signaling pathways including those of PI3K, PLC gamma and PKC, Both genetic and biochemical approaches have been used to dissect the signaling pathways and elucidate their roles in growth, differentiation and apoptosis, An emerging new role of this family of kinases is cytoskeletal reorganization and cell motility, The physiological importance of these kinases was amply demonstrated hy their link to the development of immunodeficiency diseases, due to germ-line mutations. The present article attempts to review the structure and functions of Btk family kinases by summarizing our current knowledge on the interacting partners associated with the different modules of the kinases and the diverse signaling pathways in which they are involved.	Univ Calif Davis, Sch Med, Dept Biol Chem, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Ctr Canc, Sacramento, CA 95817 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Kung, HJ (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, 4645 2nd Ave, Sacramento, CA 95817 USA.		Kung, Hsing-Jien/C-7651-2013; Roszak, Joanna/F-4003-2010					Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Cory GOC, 1996, J IMMUNOL, V157, P3791; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; Ekman N, 2000, ONCOGENE, V19, P4151, DOI 10.1038/sj.onc.1203763; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Gibson S, 1996, J IMMUNOL, V156, P2716; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Heyeck SD, 1997, J BIOL CHEM, V272, P25401, DOI 10.1074/jbc.272.40.25401; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Islam TC, 2000, J GENE MED, V2, P204; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; JUI HY, 2001, IN PRESS J BIOL CHEM; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kawakami Y, 2000, P NATL ACAD SCI USA, V97, P7423, DOI 10.1073/pnas.120175097; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kawakami Y, 1998, J IMMUNOL, V161, P1795; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Li TJ, 1997, ONCOGENE, V15, P1375, DOI 10.1038/sj.onc.1201308; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; MACHIDE M, 1995, ONCOGENE, V11, P619; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MANO H, 1995, BLOOD, V85, P343; Mano H, 1999, INT J HEMATOL, V69, P6; MANO H, 1993, ONCOGENE, V8, P417; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; Morrogh LM, 1999, EUR J IMMUNOL, V29, P2269; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Saharinen P, 1997, BLOOD, V90, P4341; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SATO K, 1994, LEUKEMIA, V8, P1663; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; Satterthwaite AB, 2000, P NATL ACAD SCI USA, V97, P6687, DOI 10.1073/pnas.110146697; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Uckun FM, 1998, BIOCHEM PHARMACOL, V56, P683, DOI 10.1016/S0006-2952(98)00122-1; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; Vihinen M, 1997, NUCLEIC ACIDS RES, V25, P166, DOI 10.1093/nar/25.1.166; Vihinen M, 1999, HUM MUTAT, V13, P280, DOI 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L; Vihinen Mauno, 1997, Frontiers in Bioscience (online), V2, pD27; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yamadori T, 1999, P NATL ACAD SCI USA, V96, P6341, DOI 10.1073/pnas.96.11.6341; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; Yang WC, 1999, EUR J IMMUNOL, V29, P1842, DOI 10.1002/(SICI)1521-4141(199906)29:06<1842::AID-IMMU1842>3.0.CO;2-D; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199	112	175	210	4	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2000	19	49					5651	5661		10.1038/sj.onc.1203958	http://dx.doi.org/10.1038/sj.onc.1203958			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114746				2022-12-25	WOS:000165659300013
J	Kawabe, S; Roth, JA; Wilson, DR; Meyn, RE				Kawabe, S; Roth, JA; Wilson, DR; Meyn, RE			Adenovirus-mediated p16(INK4a) gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner	ONCOGENE			English	Article						apoptosis; adenovirus, p16(INK4a); p53; radiation; lung cancer	RETINOBLASTOMA-PROTEIN; P53; INHIBITION; RB; APOPTOSIS	We examined the influence of adenovirus-mediated wildtype p16(INK4n) (Ad/p16) expression on the radiation sensitivity of NSCLC cell lines, all of which lacked constitutive p16(INK4n) but each of which varied in p53 status: A549 (- p16(INK4n)/+pRb/wt-p53), H322 (- p16(INK4n)/ + pRb/mt-p53), and H1299 (- p16(INK4a)/ +pRb/deleted-p53). The in vitro clonogenic survival results indicate that Ad/p16 enhanced the radiosensitivity of A549 but not H322 or H1299. Further analysis indicated that the apoptosis induced by combination therapy using Ad/p16 plus irradiation was dependent on the endogenous p53 status of the cancer cells. We performed Western blotting to analyst the p53 protein expression of A549 cells treated with either Ad/p16 or Ad/Luc. Endogenous p53 protein levels were higher in A549 cells transfected with Ad/p16 than in those transfected with Ad/Luc. Furthermore, when wt-p53 protein expression was restored in H1299 using Ad/ p53, Ad/p16 stabilized p53 protein expression and radiosensitized the cells. These results suggest that Ad/ p16-induccd stabilization of p53 protein may play an important role in Ad/p16 mediated radiosensitization by enhancing or restoring apoptosis properties. Thus, Ad/p16 plus radiation in combination may be a useful gene therapy strategy for tumors that have wt-p53 but nonfunctional p16(INK4n).	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Introgen Therapeut Inc, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Box 066,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, P01CA006294, P01CA078778] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA06294, CA16672, P01 CA78778] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG X, 1998, INT J ONCOL, V12, P665; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Gallardo D, 1996, CANCER RES, V56, P4891; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; JIN X, 1996, ONCOGENE, V12, P103; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Kratzke RA, 1996, CANCER RES, V56, P3415; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; McPake CR, 1999, CANCER RES, V59, P4247; Miyakoshi J, 1997, JPN J CANCER RES, V88, P34, DOI 10.1111/j.1349-7006.1997.tb00298.x; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; NEVINS JR, 1992, SCIENCE, V258, P424; Nishio M, 1996, J CLIN ONCOL, V14, P497, DOI 10.1200/JCO.1996.14.2.497; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; Spitz FR, 1996, CLIN CANCER RES, V2, P1665; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954	27	38	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5359	5366		10.1038/sj.onc.1203935	http://dx.doi.org/10.1038/sj.onc.1203935			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103937				2022-12-25	WOS:000165302300007
J	Hofr, C; Brabec, V				Hofr, C; Brabec, V			Thermal and thermodynamic properties of duplex DNA containing site-specific interstrand cross-link of antitumor cisplatin or its clinically ineffective trans isomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADDUCTS; CIS-DIAMMINEDICHLOROPLATINUM(II); REPAIR; TRANS-DIAMMINEDICHLOROPLATINUM(II); RECOGNITION; DISTORTIONS; GUANINE	The effect of the single, site-specific interstrand crosslink formed by cisplatin or transplatin on the thermal stability and energetics of a 20-base pair DNA duplex is reported. The cross-linked or unplatinated 20-base pair duplexes were investigated with the aid of differential scanning calorimetry, temperature-dependent W absorption, and circular dichroism, The cross-link of both platinum isomers increases the thermal stability of the modified duplexes by changing the molecularity of denaturation. The structural perturbation resulting from the interstrand cross-link of cisplatin increases entropy of the duplex and in this way entropically stabilizes the duplex. This entropic cross-link-induced stabilization of the duplex is partially but not completely compensated by the enthalpic destabilization of the duplex. The net result of these enthalpic and entropic effects is that the structural perturbation resulting from the formation of the interstrand cross-link by cisplatin induces a decrease in duplex thermodynamic stability, with this destabilization being enthalpic in origin. By contrast, the interstrand cross-link of transplatin is enthalpically almost neutral with the cross-link-induced destabilization entirely entropic in origin. These differences are consistent with distinct conformational distortions induced by the interstrand cross-links of the two isomers, Importantly, for the duplex cross-linked by cisplatin relative to that cross-linked by transplatin, the compensating enthalpic and entropic effects almost completely offset the difference in cross-link-induced energetic destabilization, It has been proposed that the results of the present work further support the view that the impact of the interstrand cross-links of cisplatin and transplatin on DNA is different for each and might also be associated with the distinctly different antitumor effects of these platinum compounds.	Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Brabec, V (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kralovospolska 135, CZ-61265 Brno, Czech Republic.	brabec@ibp.cz	Hofr, Ctirad/E-3322-2012; Brabec, Viktor/H-1946-2014	Brabec, Viktor/0000-0002-8233-1393				BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BRABEC V, 1993, P NATL ACAD SCI USA, V90, P5345, DOI 10.1073/pnas.90.11.5345; BRABEC V, 1993, BIOCHEMISTRY-US, V32, P11676, DOI 10.1021/bi00094a025; Brabec V, 2000, CANC DRUG DISC DEV, V7, P37; Brabec V, 2000, J BIOL INORG CHEM, V5, P364, DOI 10.1007/PL00010665; Brabec V, 1999, BIOCHEMISTRY-US, V38, P6781, DOI 10.1021/bi990124s; BRABEC V, 1992, BIOCHEMISTRY-US, V31, P12397, DOI 10.1021/bi00164a014; Breslauer KJ, 1995, METHOD ENZYMOL, V259, P221; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; Coste F, 1999, NUCLEIC ACIDS RES, V27, P1837, DOI 10.1093/nar/27.8.1837; EASTMAN A, 1988, CHEM-BIOL INTERACT, V67, P71, DOI 10.1016/0009-2797(88)90087-7; EASTMAN A, 1987, BIOCHEMISTRY-US, V26, P3303, DOI 10.1021/bi00386a009; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; Eastman A., 1999, CISPLATIN CHEM BIOCH, P111, DOI [DOI 10.1002/9783906390420.CH4, 10.1002/9783906390420.ch4]; FARRELL N, 1999, CISPLATIN CHEM BIOCH, P479; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; HUANG HF, 1995, SCIENCE, V270, P1842, DOI 10.1126/science.270.5243.1842; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; Malina J, 2000, BIOPHYS J, V78, P2008, DOI 10.1016/S0006-3495(00)76748-8; Malinge JM, 1999, J INORG BIOCHEM, V77, P23, DOI 10.1016/S0162-0134(99)00148-8; MALINGE JM, 1994, NUCLEIC ACIDS RES, V22, P3834, DOI 10.1093/nar/22.19.3834; MARKY LA, 1987, BIOPOLYMERS, V26, P1621, DOI 10.1002/bip.360260912; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; McANulty MM, 1996, MUTAT RES-DNA REPAIR, V362, P75, DOI 10.1016/0921-8777(95)00037-2; O'Dwyer P. J., 1999, CISPLATIN CHEM BIOCH, P31; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Osborne SE, 1996, J AM CHEM SOC, V118, P11993, DOI 10.1021/ja962386c; Paquet F, 1999, NUCLEIC ACIDS RES, V27, P4261, DOI 10.1093/nar/27.21.4261; PILCH DS, 1995, CURR OPIN STRUC BIOL, V5, P334, DOI 10.1016/0959-440X(95)80095-6; Pilch DS, 2000, J MOL BIOL, V296, P803, DOI 10.1006/jmbi.2000.3496; Poklar N, 1996, P NATL ACAD SCI USA, V93, P7606, DOI 10.1073/pnas.93.15.7606; Rosenberg B., 1999, CISPLATIN CHEM BIOCH, P1, DOI DOI 10.1002/9783906390420; SCHWARTZ A, 1994, J MOL BIOL, V236, P969, DOI 10.1016/0022-2836(94)90002-7; SIGMAN DS, 1990, ANNU REV BIOCHEM, V59, P207, DOI 10.1146/annurev.biochem.59.1.207; Vrana O, 1996, NUCLEIC ACIDS RES, V24, P3918, DOI 10.1093/nar/24.20.3918; Zakovska A, 1998, EUR J BIOCHEM, V254, P547, DOI 10.1046/j.1432-1327.1998.2540547.x; Zaludova R, 1997, MOL PHARMACOL, V52, P354, DOI 10.1124/mol.52.3.354; Zaludova R, 1997, EUR J BIOCHEM, V246, P508, DOI 10.1111/j.1432-1033.1997.00508.x; Zaludova R, 1996, BIOPHYS CHEM, V60, P135; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	43	54	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9655	9661		10.1074/jbc.M010205200	http://dx.doi.org/10.1074/jbc.M010205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11104778	hybrid			2022-12-25	WOS:000167996400012
J	Mitsuda, N; Ohkubo, N; Tamatani, M; Lee, YD; Taniguchi, M; Namikawa, K; Kiyama, H; Yamaguchi, A; Sato, N; Sakata, K; Ogihara, T; Vitek, MP; Tohyama, M				Mitsuda, N; Ohkubo, N; Tamatani, M; Lee, YD; Taniguchi, M; Namikawa, K; Kiyama, H; Yamaguchi, A; Sato, N; Sakata, K; Ogihara, T; Vitek, MP; Tohyama, M			Activated cAMP-response element-binding protein regulates neuronal expression of presenilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PRIMARY HIPPOCAMPAL-NEURONS; MAP KINASE KINASE; APOLIPOPROTEIN-E; MAMMALIAN-CELLS; RAT-BRAIN; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; MISSENSE MUTATION; GENE-EXPRESSION	Upon binding to the cAMP-response element of a gene's promoter, the transcription factor known as cAMP-response element-binding protein (CREB) facilitates transcription of many different neuronal genes including those involved with synaptic function. Based on our previous reports of gene structure (GenBank (TM) accession number AF029701), we now demonstrate that activated CREB binds to the proximal promoter of the human presenilin-1 (PS-1) gene to activate PS-l transcription in rat and in human neuronal cells. Specific stimulation of the N-methyl-D-aspartate subtype of neuronal glutamate receptors activates CREB and results in increased PS-l expression. Similarly, treatment with brain-derived neurotrophic factor activates CREB and increases PS-l expression in a dose-dependent fashion. By using adenovirus vectors expressing dominant negative forms of CREB, we were able to show that induction of PS-l expression requires the activation of CREB, Conversely, constitutive expression of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) results in activation of CREB and increased PS-1 expression that can be blocked by the addition of selective MEK inhibitors. Our findings suggest a hypothesis where stimulation of N-methyl-D-aspartate receptors signals CREB activation to enhance PS-l gene product expression that contributes to normal neuronal functions.	Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; Asahikawa Med Coll, Dept Anat, Japan Sci & Technol, CREST, Asakhikawa, Hokkaido 0788510, Japan; Osaka Univ, Grad Sch Med, Dept Geriatr Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan	Duke University; Asahikawa Medical College; Japan Science & Technology Agency (JST); Osaka University; Osaka University	Mitsuda, N (corresponding author), Ehime Univ, Sch Med, Dept Physiol, Shigenobu, Ehime 7910295, Japan.		Kiyama, Hiroshi/M-8867-2014; Sakata, Kazuko/I-2351-2017	Kiyama, Hiroshi/0000-0001-5963-046X; Vitek, Michael/0000-0001-8140-8048				BENKE D, 1995, J RECEPT SIGNAL TR R, V15, P393, DOI 10.3109/10799899509045229; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Boteva K, 1996, LANCET, V347, P130, DOI 10.1016/S0140-6736(96)90261-5; Bouras C, 1996, LANCET, V347, P1185; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Choi S, 2000, NAT NEUROSCI, V3, P330, DOI 10.1038/73895; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cribbs DH, 1996, AM J PATHOL, V148, P1797; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Higuchi S, 1996, LANCET, V347, P1186; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kehoe P, 1996, LANCET, V347, P1185, DOI 10.1016/S0140-6736(96)90643-1; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; Korovaitseva GI, 1997, LANCET, V350, P959, DOI 10.1016/S0140-6736(05)63300-4; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Mainen ZF, 1999, NATURE, V399, P151, DOI 10.1038/20187; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Mitsuda N, 1997, J BIOL CHEM, V272, P23489, DOI 10.1074/jbc.272.38.23489; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Moreno-Flores MT, 1999, J COMP NEUROL, V410, P556, DOI 10.1002/(SICI)1096-9861(19990809)410:4<556::AID-CNE4>3.0.CO;2-Q; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pastorcic M, 1999, J BIOL CHEM, V274, P24297, DOI 10.1074/jbc.274.34.24297; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; Quarteronet D, 1996, NEUROREPORT, V7, P2587, DOI 10.1097/00001756-199611040-00036; Rajadhyaksha A, 1999, J NEUROSCI, V19, P6348; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Rogaev EI, 1997, GENOMICS, V40, P415, DOI 10.1006/geno.1996.4523; Rossor MN, 1996, LANCET, V347, P1560, DOI 10.1016/S0140-6736(96)90715-1; Scott WK, 1996, LANCET, V347, P1186; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; SORBI S, 1995, LANCET, V346, P439, DOI 10.1016/S0140-6736(95)92809-X; Stopa EG, 1997, BRAIN PATHOL, V7, P1204; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Suzuki T, 1996, BIOCHEM BIOPH RES CO, V219, P708, DOI 10.1006/bbrc.1996.0299; Takami K, 1997, BRAIN RES, V748, P122, DOI 10.1016/S0006-8993(96)01274-7; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; TANAHASHI H, 1995, LANCET, V346, P440, DOI 10.1016/S0140-6736(95)92810-3; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; Wenzel A, 1997, J NEUROCHEM, V68, P469; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yoshioka A, 1996, J NEUROSCI RES, V46, P164; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	69	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9688	9698		10.1074/jbc.M006153200	http://dx.doi.org/10.1074/jbc.M006153200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11116137	Green Published, hybrid			2022-12-25	WOS:000167996400016
J	Schuck, P; Taraporewala, Z; McPhie, P; Patton, JT				Schuck, P; Taraporewala, Z; McPhie, P; Patton, JT			Rotavirus nonstructural protein NSP2 self-assembles into octamers that undergo ligand-induced conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BINDING-PROTEIN; ESCHERICHIA-COLI; ANALYTICAL ULTRACENTRIFUGATION; IN-VIVO; SEDIMENTATION ANALYSIS; CRYSTAL-STRUCTURE; RNA; REPLICATION; PHOSPHORYLATION	The nonstructural protein NSP2 is a component of the rotavirus replication machinery and binds single-stranded RNA cooperatively, with high affinity, and independent of sequence, Recently, NSP2 has been shown to form multimers and to possess an NTPase activity, but its precise function remains unclear. In the present study, we have characterized the solution structure of recombinant NSPS by velocity and equilibrium ultracentrifugation, dynamic light scattering, and circular dichroism spectroscopy. We found that NSP2 exists as an octamer, which is functional in the binding of RNA and ADP, In the presence of magnesium, a partial dissociation of the octamer into smaller oligomers was observed, This was reversed by binding of ADP and RNA. We observed an increased sedimentation rate in the presence of ADP and a nonhydrolyzable ATP analogue, which suggests a change toward a significantly more compact octameric conformation, The secondary structure of NSP2 showed a high fraction of P-sheet, with small changes induced by magnesium that were reversed in the presence of RNA. That NSP2 can exist in different conformations lends support to the previously proposed hypothesis (Taraporewala, Z,, Chen, D,, and Patton, J, T, (1999) J, Virol, 73, 9934-9943) of its function as a molecular motor involved in the packaging of viral mRNA.	NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; NIH, OD, ORS, Div Bioengn & Phys Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA	Patton, JT (corresponding author), NIAID, Infect Dis Lab, NIH, 7 Ctr Dr,MSC 0720,Rm 117, Bethesda, MD 20892 USA.	jpatton@niaid.nih.gov	Schuck, Peter/AAA-6888-2020; Patton, John/V-7651-2018	Schuck, Peter/0000-0002-8859-6966; Patton, John/0000-0003-1572-0732	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000754, ZIAAI000754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK024942] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Afrikanova I, 1998, J GEN VIROL, V79, P2679, DOI 10.1099/0022-1317-79-11-2679; Chen DY, 1999, VIROLOGY, V265, P120, DOI 10.1006/viro.1999.0029; CHEN DY, 1990, VIROLOGY, V178, P143, DOI 10.1016/0042-6822(90)90387-7; CHEN DY, 1994, J VIROL, V68, P7030, DOI 10.1128/JVI.68.11.7030-7039.1994; CLAVERIE JM, 1975, BIOPOLYMERS, V14, P1685, DOI 10.1002/bip.1975.360140811; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; DARAWSHE S, 1993, ANAL BIOCHEM, V209, P130, DOI 10.1006/abio.1993.1092; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Estes Mary K., 1996, P731; Fabbretti E, 1999, J GEN VIROL, V80, P333, DOI 10.1099/0022-1317-80-2-333; Ferrari ME, 1997, BIOPHYS CHEM, V64, P235, DOI 10.1016/S0301-4622(96)02223-5; FOLMER RHA, 1995, EMBO J, V14, P4132, DOI 10.1002/j.1460-2075.1995.tb00087.x; GALLEGOS CO, 1989, VIROLOGY, V172, P616, DOI 10.1016/0042-6822(89)90204-3; Genschel J, 1996, GENE, V182, P137, DOI 10.1016/S0378-1119(96)00535-5; Gonzalez RA, 1998, ARCH VIROL, V143, P981, DOI 10.1007/s007050050347; Johnson M.L., 1994, MODERN ANAL ULTRACEN, P37; KATTOURA MD, 1994, VIROLOGY, V202, P803, DOI 10.1006/viro.1994.1402; KUNTZ ID, 1971, J AM CHEM SOC, V93, P516, DOI 10.1021/ja00731a037; Lamm O., 1929, ARK MAT ASTR FYS, V21B, P1; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; Li K, 1997, J BIOL CHEM, V272, P8686, DOI 10.1074/jbc.272.13.8686; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MISSELWITZ R, 1995, J BIOMOL STRUCT DYN, V12, P1041, DOI 10.1080/07391102.1995.10508796; Murphy RM, 1997, CURR OPIN BIOTECH, V8, P25, DOI 10.1016/S0958-1669(97)80153-X; Passy SI, 1999, P NATL ACAD SCI USA, V96, P10684, DOI 10.1073/pnas.96.19.10684; Patton JT, 2001, NOVART FDN SYMP, V238, P64; Patton JT, 2000, VIROLOGY, V277, P217, DOI 10.1006/viro.2000.0645; Perugini MA, 2000, J BIOL CHEM, V275, P36758, DOI 10.1074/jbc.M005565200; Poncet D, 1997, J VIROL, V71, P34, DOI 10.1128/JVI.71.1.34-41.1997; Prasad B V, 1994, Curr Top Microbiol Immunol, V185, P9; PRASAD BVV, 1990, NATURE, V343, P476, DOI 10.1038/343476a0; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; Schuck P, 1998, BIOPHYS J, V74, P466, DOI 10.1016/S0006-3495(98)77804-X; SCHUCK P, 2000, CURRENT PROTOCOLS IM; Soengas MS, 1997, J BIOL CHEM, V272, P303; Svedberg T, 1940, THE ULTRACENTRIFUGE; Taraporewala Z, 1999, J VIROL, V73, P9934, DOI 10.1128/JVI.73.12.9934-9943.1999; Tian P, 1996, J VIROL, V70, P6973, DOI 10.1128/JVI.70.10.6973-6981.1996; Tian P, 1996, ARCH VIROL, P69; Torres-Vega MA, 2000, J GEN VIROL, V81, P821, DOI 10.1099/0022-1317-81-3-821; Tseng M, 1999, J BIOL CHEM, V274, P21637, DOI 10.1074/jbc.274.31.21637; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; Vende P, 2000, J VIROL, V74, P7064, DOI 10.1128/JVI.74.15.7064-7071.2000; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153	49	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9679	9687		10.1074/jbc.M009398200	http://dx.doi.org/10.1074/jbc.M009398200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11121414	hybrid			2022-12-25	WOS:000167996400015
J	Honsho, M; Fujiki, Y				Honsho, M; Fujiki, Y			Topogenesis of peroxisomal membrane protein requires a short, positively charged intervening-loop sequence and flanking hydrophobic segments - Study using human membrane protein PMP34	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; OVARY CELL MUTANTS; DEFICIENT ZELLWEGER-SYNDROME; FUNCTIONAL COMPLEMENTATION; TARGETING SIGNAL; CDNA CLONING; ENDOPLASMIC-RETICULUM; MUTATION ANALYSIS; IN-VITRO; BIOGENESIS	Human 34-kDa peroxisomal membrane protein (PMP34) consisting of 307 amino acids was previously identified as an ortholog of, or a similar protein (with 27% identity) to the, 423-amino acid-long PMP47 of the yeast Candida boidinii. We investigated membrane topogenesis of PMP34 with six putative transmembrane segments, as a model peroxisomal membrane protein. PMP34 was characterized as an integral membrane protein of peroxisomes. Transmembrane topology of PMP34 was determined by differential permeabilization and immunofluorescent staining of HeLa cells ectopically expressing PMP34 as well as of Chinese hamster ovary-K1 expressing epitope-tagged PMP34. As opposed to PMP47, PMP34 was found to expose its N- and C-terminal parts to the cytosol. Various deletion variants of PMP34 and their fusion proteins with green fluorescent protein were expressed in Chinese hamster ovary-KI and were verified with respect to intracellular localization, The loop region between transmembrane segments 4 and 5 was required for the peroxisome-targeting activity, in which Ala substitution for basic residues abrogated the activity. Three hydrophobic transmembrane segments linked in a flanking region of the basic loop were essential for integration of PMP34 to peroxisome membranes. Therefore, it is evident that the intervening basic loop plus three transmembrane segments of PMP34 function as a peroxisomal targeting and topogenic signal.	Kyushu Univ, Grad Sch, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci Technol, Tokyo 1070013, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch, Fac Sci, Dept Biol, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.			Honsho, Masanori/0000-0001-6165-4516				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baerends RJS, 2000, J BIOL CHEM, V275, P9986, DOI 10.1074/jbc.275.14.9986; DIESTELKOTTER P, 1993, J CELL BIOL, V123, P1717, DOI 10.1083/jcb.123.6.1717; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Ghaedi K, 1999, EXP CELL RES, V248, P489, DOI 10.1006/excr.1999.4413; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Imanaka T, 1996, J BIOL CHEM, V271, P3706; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; Nakagawa T, 2000, J BIOL CHEM, V275, P3455, DOI 10.1074/jbc.275.5.3455; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; Okumoto K, 1997, NAT GENET, V17, P265, DOI 10.1038/ng1197-265; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; SUZUKI Y, 1987, J BIOCHEM-TOKYO, V101, P491, DOI 10.1093/oxfordjournals.jbchem.a121935; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; Toyama R, 1999, HUM MOL GENET, V8, P1673, DOI 10.1093/hmg/8.9.1673; TSUKAMOTO T, 1994, MOL CELL BIOL, V14, P5458, DOI 10.1128/MCB.14.8.5458; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; Weber FE, 1997, P NATL ACAD SCI USA, V94, P8509, DOI 10.1073/pnas.94.16.8509; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Wylin T, 1998, EUR J BIOCHEM, V258, P332, DOI 10.1046/j.1432-1327.1998.2580332.x	39	51	52	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9375	9382		10.1074/jbc.M003304200	http://dx.doi.org/10.1074/jbc.M003304200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121399	hybrid			2022-12-25	WOS:000167607700101
J	Lindahl, M; Poteryaev, D; Yu, LY; Arumae, U; Timmusk, T; Bongarzone, I; Aiello, A; Pierotti, MA; Airaksinen, MS; Saarma, M				Lindahl, M; Poteryaev, D; Yu, LY; Arumae, U; Timmusk, T; Bongarzone, I; Aiello, A; Pierotti, MA; Airaksinen, MS; Saarma, M			Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET PROTOONCOGENE PRODUCT; NEOPLASIA TYPE 2B; TYROSINE KINASE; TRANSGENIC MICE; NEURTURIN RECEPTOR; NERVOUS-SYSTEM; 2A MUTATION; ADULT-RAT; GDNF; ACTIVATION	Glial cell line-derived neurotrophic factor (GDNF) family ligands signal through receptor complex consisting of a glycosylphosphatidylinositol-linked GDNF family receptor (GFR) ru subunit and the transmembrane receptor tyrosine kinase RET. The inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN2), associated with different mutations in RET, is characterized by medullary thyroid carcinoma. GDNF signals via GFR alpha1, neurturin via GFR alpha2, artemin via GFR alpha3, whereas the mammalian GFR alpha: receptor for persephin (PSPN) is unknown. Here we characterize the human GFR alpha4 as the ligand-binding subunit required together with BET for PSPN signaling. Human and mouse GFR alpha4 lack the first Cys-rich domain characteristic of other GFRa: receptors. Unlabeled PSPN displaces I-125-PSPN from GFRA4-transfected cells, which express endogenous Ret. PSPN can be specifically cross-linked to mammalian GFR alpha4 and Ret, and is able to promote autophosphorylation of Ret in GFRA4-transfected cells. PSPN, but not other GDNF family ligands, promotes the survival of cultured sympathetic neurons microinjected with GFRA4. We identified different splice forms of human GFRA4 mRNA encoding for two glycosylphosphatidylinositol-linked and one putative soluble isoform that were predominantly expressed in the thyroid gland, Overlapping expression of RET and GFRA4 but not other GFRA mRNAs in normal and malignant thyroid medullary cells suggests that GFR alpha4 may restrict the MEN2 syndrome to these cells.	Univ Helsinki, Vikki Bioctr, Inst Biotechnol, Program Mol Neurobiol, FIN-00014 Helsinki, Finland; Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Nazl Tumori, Div Expt Oncol, I-20133 Milan, Italy	University of Helsinki; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Saarma, M (corresponding author), Univ Helsinki, Vikki Bioctr, Inst Biotechnol, Program Mol Neurobiol, FIN-00014 Helsinki, Finland.		Aiello, Antonella/C-3290-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Lindahl, Maria/AHE-1252-2022; Arumäe, Urmas/E-8290-2016; Bongarzone, Italia/B-9544-2017; Timmusk, Tonis/H-4889-2015	Aiello, Antonella/0000-0002-1932-7113; Pierotti, Marco Alessandro/0000-0002-7431-8332; Arumäe, Urmas/0000-0003-3658-6464; Bongarzone, Italia/0000-0003-2530-9170; Airaksinen, Matti/0000-0002-7199-4984; Lindahl, Maria/0000-0002-5674-8830; Timmusk, Tonis/0000-0002-1015-3348; Poteryaev, Dmitry/0000-0003-2695-8869				Acton DS, 2000, ONCOGENE, V19, P3121, DOI 10.1038/sj.onc.1203648; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Frisk T, 2000, EUR J ENDOCRINOL, V142, P643, DOI 10.1530/eje.0.1420643; Ho TW, 2000, EXP NEUROL, V161, P664, DOI 10.1006/exnr.1999.7290; Iwashita T, 1996, ONCOGENE, V12, P481; Jaszai J, 1998, J NEUROSCI RES, V53, P494, DOI 10.1002/(SICI)1097-4547(19980815)53:4<494::AID-JNR12>3.0.CO;2-2; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kawai K, 2000, CANCER RES, V60, P5254; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Laurikainen A, 2000, J NEUROBIOL, V43, P198, DOI 10.1002/(SICI)1097-4695(200005)43:2<198::AID-NEU9>3.0.CO;2-D; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Lou H, 1998, J ENDOCRINOL, V156, P401, DOI 10.1677/joe.0.1560401; Masure S, 2000, J BIOL CHEM, V275, P39427, DOI 10.1074/jbc.M003867200; McGonigle Paul, 1994, P209; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PONDER BA, 1999, CANCER RES, V59, P1736; Rossi J, 1999, NEURON, V22, P243, DOI 10.1016/S0896-6273(00)81086-7; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; Thompson J, 1998, MOL CELL NEUROSCI, V11, P117, DOI 10.1006/mcne.1998.0682; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; TSUZUKI T, 1995, ONCOGENE, V10, P191; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023	36	72	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9344	9351		10.1074/jbc.M008279200	http://dx.doi.org/10.1074/jbc.M008279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11116144	hybrid			2022-12-25	WOS:000167607700097
J	Liu, GS; Sanchez-Fernandez, R; Li, ZS; Rea, PA				Liu, GS; Sanchez-Fernandez, R; Li, ZS; Rea, PA			Enhanced multispecificity of Arabidopsis vacuolar multidrug resistance-associated protein-type ATP-binding cassette transporter, AtMRP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ESTRADIOL 17-(BETA-D-GLUCURONIDE); DIRECTLY ENERGIZED UPTAKE; CHLOROPHYLL CATABOLITES; H+-PYROPHOSPHATASE; ABC TRANSPORTERS; P-GLYCOPROTEIN; GLUTATHIONE; CONJUGATE; MEMBRANE; INHIBITION	Recent investigations have established that Arabidopsis thaliana contains a family of genes encoding ATP-binding cassette transporters belonging to the multidrug resistance-associated protein (MRP) family, So named because of the phenotypes conferred by their animal prototypes, many MRPs are MgATP-energized pumps active in the transport of glutathione (GS) conjugates and other bulky amphipathic anions across membranes. Here we show that Arabidopsis MRPB (At-MRP2) localizes to the vacuolar membrane fraction from seedlings and is not only competent in the transport of GS conjugates but also glucuronate conjugates after heterologous expression in yeast. Based on the stimulatory action of the model GS conjugate 2,4-dinitrophenyl-GS (DNP-GS) on uptake of the model glucuronide 17 beta -estradiol 17-(beta -D-glucuronide) (E(2)17 betaG) and vice versa, double-label experiments demonstrating that the two substrates are subject to simultaneous transport by AtMRP2 and preloading experiments suggesting that the effects seen result from cis, not trans, interactions, it is inferred that some GS conjugates and some glucuronides reciprocally activate each other's transport via distinct but coupled binding sites. The results of parallel experiments on AtMRP1 and representative yeast and mammalian MRPs indicate that these properties are specific to AtMRP2, The effects exerted by DNP-GS on AtMRP2 are not, however, common to all GS conjugates and not simulated by oxidized glutathione or reduced glutathione, Decyl-GS, metolachlor-GS, and oxidized glutathione, although competitive with DNP-GS, do not promote E(2)17 betaG uptake by AtMRP2. Reduced glutathione, although subject to transport by AtMRP2 and able to markedly promote E(2)17PG uptake, neither competes with DNP-GS for uptake nor is subject to E(2)17 betaG-promoted uptake, A multisite model comprising three or four semi-autonomous transport; pathways plus distinct but tightly coupled binding sites is invoked for AtMRP2.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Rea, PA (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	parea@sas.upenn.edu						Coleman JOD, 1997, PLANT CELL ENVIRON, V20, P449, DOI 10.1046/j.1365-3040.1997.d01-93.x; Davies TGE, 1997, GENE, V199, P195, DOI 10.1016/S0378-1119(97)00367-3; DUDLER R, 1992, J BIOL CHEM, V267, P5882; Dudler R, 1998, METHOD ENZYMOL, V292, P162; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HARLOWE E, 1988, ANTIBODIES LAB MANUA; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hinder B, 1996, J BIOL CHEM, V271, P27233, DOI 10.1074/jbc.271.44.27233; KIM EJ, 1995, J BIOL CHEM, V270, P2630, DOI 10.1074/jbc.270.6.2630; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; Klein M, 2000, PLANT J, V21, P289, DOI 10.1046/j.1365-313x.2000.00684.x; Klein M, 1998, J BIOL CHEM, V273, P262, DOI 10.1074/jbc.273.1.262; LEIER I, 1994, J BIOL CHEM, V269, P27807; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; LI ZS, 1995, PLANT PHYSIOL, V107, P1257, DOI 10.1104/pp.107.4.1257; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Lu YP, 1998, PLANT CELL, V10, P267, DOI 10.1105/tpc.10.2.267; Lu YP, 1997, P NATL ACAD SCI USA, V94, P8243, DOI 10.1073/pnas.94.15.8243; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; Martinoia E., 2000, VACUOLAR COMPARTMENT, P221; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rappa G, 1997, CANCER RES, V57, P5232; REA PA, 1992, PLANT PHYSIOL, V100, P723, DOI 10.1104/pp.100.2.723; Rea PA, 1999, J EXP BOT, V50, P895, DOI 10.1093/jexbot/50.suppl_1.895; Rea PA, 1998, ANNU REV PLANT PHYS, V49, P727, DOI 10.1146/annurev.arplant.49.1.727; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Sidler M, 1998, PLANT CELL, V10, P1623, DOI 10.1105/tpc.10.10.1623; Smart CC, 1996, J BIOL CHEM, V271, P19351, DOI 10.1074/jbc.271.32.19351; Swanson SJ, 1998, PLANT CELL, V10, P685, DOI 10.1105/tpc.10.5.685; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; THEODOULOU F, 1998, 11 INT WORKSH PLANT; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; Tommasini R, 1998, PLANT J, V13, P773, DOI 10.1046/j.1365-313X.1998.00076.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Aubel RAMH, 1999, MOL PHARMACOL, V56, P714; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Wang W, 1996, PLANT MOL BIOL, V31, P683, DOI 10.1007/BF00042240; Wolf AE, 1996, FEBS LETT, V384, P31, DOI 10.1016/0014-5793(96)00272-4; Zeng H, 2000, CANCER RES, V60, P4779; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340	44	107	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8648	8656		10.1074/jbc.M009690200	http://dx.doi.org/10.1074/jbc.M009690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11115509	hybrid			2022-12-25	WOS:000167607700007
J	Matsushita, O; Koide, T; Kobayashi, R; Nagata, K; Okabe, A				Matsushita, O; Koide, T; Kobayashi, R; Nagata, K; Okabe, A			Substrate recognition by the collagen-binding domain of Clostridium histolyticum class I collagenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL PEPTIDES; STRESS PROTEIN HSP47; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; GENE DUPLICATION; PROCOLLAGEN; CALMODULIN; STABILITY	Clostridium histolyticum type I collagenase (ColG) has a segmental structure, S1+S2+S3a+S3b. S3a and S3b bound to insoluble collagen, but S2 did not, thus indicating that S3 forms a collagen-binding domain (CBD). Because S3a+S3b showed the most efficient binding to substrate, cooperative binding by both domains was suggested for the enzyme. Monomeric (S3b) and tandem (S3a+S3b) CBDs bound to atelocollagen, which contains only the collagenous region. However, they did not bind to telopeptides immobilized on Sepharose beads. These results suggested that the binding site(s) for the CBD is(are) present in the collagenous region. The CBD bound to immobilized collagenous peptides, (Pro-Hyp-Gly)(n) and (Pro-Pro-Gly)(n), only when n is large enough to allow the peptides to have a triple-helical conformation. They did not bind to various peptides with similar amino acid sequences or to gelatin, which lacks a triple-helical conformation, The CBD did not bind to immobilized Glc-Gal disaccharide, which is attached to the side chains of hydroxylysine residues in the collagenous region. These observations suggested that the CBD specifically recognizes the triple helical conformation made by three polypeptide chains in the collagenous region.	Kagawa Med Univ, Fac Med, Dept Microbiol, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Fac Med, Dept Chem, Miki, Kagawa 7610793, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Kyoto 6068397, Japan	Kagawa University; Kagawa University; Japan Science & Technology Agency (JST); Kyoto University	Matsushita, O (corresponding author), Kagawa Med Univ, Fac Med, Dept Microbiol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	microbio@kms.ac.jp						ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3092, DOI 10.1021/bi00308a037; BURJANADZE TV, 1979, BIOPOLYMERS, V18, P931, DOI 10.1002/bip.1979.360180413; BYERS DM, 1982, BIOCHEMISTRY-US, V21, P229, DOI 10.1021/bi00531a005; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Jung CM, 1999, J BACTERIOL, V181, P2816, DOI 10.1128/JB.181.9.2816-2822.1999; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; MATSUSHITA O, 1994, J BACTERIOL, V176, P149, DOI 10.1128/JB.176.1.149-156.1994; Matsushita O, 1999, J BACTERIOL, V181, P923, DOI 10.1128/JB.181.3.923-933.1999; Matsushita O, 1998, J BIOL CHEM, V273, P3643, DOI 10.1074/jbc.273.6.3643; MCDONALD JR, 1985, BIOCHEM J, V232, P569, DOI 10.1042/bj2320569; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; Nishi N, 1998, P NATL ACAD SCI USA, V95, P7018, DOI 10.1073/pnas.95.12.7018; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; Rost B, 1996, METHOD ENZYMOL, V266, P525; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SAKAKIBARA S, 1968, B CHEM SOC JPN, V41, P1273, DOI 10.1246/bcsj.41.1273; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; TANAKA T, 1980, J BIOL CHEM, V255, P1078; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WORTHINGTON CC, 1988, WORTHINTON ENZYME MA; YOSHIHARA K, 1994, J BACTERIOL, V176, P6489, DOI 10.1128/JB.176.21.6489-6496.1994	31	98	110	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8761	8770		10.1074/jbc.M003450200	http://dx.doi.org/10.1074/jbc.M003450200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121400	hybrid			2022-12-25	WOS:000167607700021
J	McCarthy, JB; Lim, ST; Elkind, NB; Trimmer, JS; Duvoisin, RM; Rodriquez-Boulan, E; Caplan, MJ				McCarthy, JB; Lim, ST; Elkind, NB; Trimmer, JS; Duvoisin, RM; Rodriquez-Boulan, E; Caplan, MJ			The C-terminal tail of the metabotropic glutamate receptor subtype 7 is necessary but not sufficient for cell surface delivery and polarized targeting in neurons and epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KV2.1 K+ CHANNEL; HIPPOCAMPAL-NEURONS; LOCALIZATION; GOLGI; RAT; TRANSPORT; IDENTIFICATION; MECHANISMS; EXPRESSION; PROTEINS	Complex neuronal functions rely upon the precise sorting, targeting, and restriction of receptors to specific synaptic microdomains, Little is known, however, of the molecular signals responsible for mediating these selective distributions. Here we report that metabotropic glutamate receptor subtype 7a (mGluR7a) is polarized at the basolateral surface when expressed in Madin-Darby canine kidney (MDCK) epithelial cells but is not polarized when expressed in cultured hippocampal neurons. Truncation of the mGluR7 cytoplasmic tail produces a protein that is restricted to a perinuclear intracellular compartment in both neurons and MDCK cells, where this protein colocalizes with a trans-Golgi network antigen. The mGluR7 cytoplasmic domain appended to the transmembrane portion of the vesicular stomatitis virus G protein and the ectodomain of human placental alkaline phosphatase is distributed over the entire cell surface in cultured neurons. When expressed in MDCK cells, this construct remains in an intracellular compartment distinct from endosomes or lysosomes. Thus, the cytoplasmic tail domain of mGluR7 is necessary but not sufficient for polarized targeting in MDCK monolayers, whereas in neurons the cytoplasmic tail is sufficient for cell surface expression but not polarization. Additional mechanisms are likely required to mediate mGluR7 neuronal polarization and synaptic clustering.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Cornell Univ, Weill Med Coll, Dept Ophthalmol, Dyson Vis Res Inst, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol, Dyson Vis Res Inst, New York, NY 10021 USA	Yale University; Yale University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cornell University; Dyson; Cornell University; Dyson	McCarthy, JB (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.			Caplan, Michael/0000-0001-5768-4405	NEI NIH HHS [EY09534] Funding Source: Medline; NIGMS NIH HHS [GM42136, R01 GM034107] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136, R01GM034107] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1996, J BIOL CHEM, V271, P6917, DOI 10.1074/jbc.271.12.6917; Bradley SR, 1996, J NEUROSCI, V16, P2044; Bradley SR, 1998, J NEUROCHEM, V71, P636; Brandstatter JH, 1996, J NEUROSCI, V16, P4749; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; Colman DR, 1999, NEURON, V23, P649, DOI 10.1016/S0896-6273(01)80024-6; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Foletti DL, 1999, NEURON, V23, P641, DOI 10.1016/S0896-6273(01)80022-2; Ghavami A, 1999, J CELL SCI, V112, P967; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Gu HH, 1996, J BIOL CHEM, V271, P18100, DOI 10.1074/jbc.271.30.18100; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kinoshita A, 1998, J COMP NEUROL, V393, P332; Kinzie JM, 1997, J COMP NEUROL, V385, P372; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Lim ST, 2000, NEURON, V25, P385, DOI 10.1016/S0896-6273(00)80902-2; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Riedel G, 1996, TRENDS NEUROSCI, V19, P219; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Scannevin RH, 1996, J CELL BIOL, V135, P1619, DOI 10.1083/jcb.135.6.1619; SHIEL MJ, 1995, AM J PHYSIOL-CELL PH, V269, pC207, DOI 10.1152/ajpcell.1995.269.1.C207; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; Trimmer JS, 1999, NEURON, V22, P411, DOI 10.1016/S0896-6273(00)80692-3; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	38	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9133	9140		10.1074/jbc.M008290200	http://dx.doi.org/10.1074/jbc.M008290200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11106656	hybrid			2022-12-25	WOS:000167607700070
J	Liaw, PCY; Mather, T; Oganesyan, N; Ferrell, GL; Esmon, CT				Liaw, PCY; Mather, T; Oganesyan, N; Ferrell, GL; Esmon, CT			Identification of the protein C/activated protein C binding sites on the endothelial cell protein C receptor - Implications for a novel mode of ligand recognition by a major histocompatibility complex class 1-type receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; FACTOR-V-LEIDEN; MYOCARDIAL-INFARCTION; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; PURPURA FULMINANS; SERINE PROTEASES; INCREASED RISK; ACTIVATION	The endothelial cell protein C receptor (EPCR) is an endothelial cell-specific transmembrane protein that binds both protein C and activated protein C (APC), EPCR regulates the protein C anticoagulant pathway by binding protein C and augmenting protein C activation by the thrombin-thrombomodulin complex. EPCR is homologous to the MHC class 1/CD1 family, members of which contain two alpha -helices that sit upon an 8-stranded beta- sheet platform. In this study, we identified 10 residues that, when mutated to alanine, result in the loss of protein C/APC binding (Arg-81, Leu-82, Val-83, Glu-86, Arg-87, Phe-146, Tyr-154, Thr-157, Arg-158, and Glu-160). Glutamine substitutions at the four N-linked carbohydrate attachment sites of EPCR have little affect on APC binding, suggesting that the carbohydrate moieties of EPCR are not critical for ligand recognition. We then mapped the epitopes for four anti-human EPCR monoclonal antibodies (mAbs), two of which block EPCR/Fl-APC (APC labeled at the active site with fluorescein) interactions, whereas two do not. These epitopes were localized by generating human-mouse EPCR chimeric proteins, since the mAbs under investigation do not recognize mouse EPCR. We found that 5 of the 10 candidate residues for protein C/APC binding (Arg-81, Leu-82, Val-83, Glu-86, Arg-87) colocalize with the epitope for one of the blocking mAbs, Three-dimensional molecular modeling of EPCR indicates that the 10 protein C/APC binding candidate residues are clustered at the distal end of the two alpha -helical segments. Protein C activation studies on 293 cells that coexpress EPCR variants and thrombomodulin demonstrate that protein C binding to EPCR is necessary for the EPCR-dependent enhancement in protein activation by the thrombin-thrombomodulin complex. These studies indicate that EPCR has exploited the MHC class 1 fold for an alternative and possibly novel mode of ligand recognition. These studies are also the first to identify the protein C/APC binding region of EPCR and may provide useful information about molecular defects in EPCR that could contribute to cardiovascular disease susceptibility.	Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Esmon, CT (corresponding author), Oklahoma Med Res Fdn, Howard Hughes Med Inst, 825 NE 13th St, Oklahoma City, OK 73104 USA.	Charles-Esmon@omrf.ouhsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNARD GR, 1998, CRIT CARE MED, V27, pS4; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; Clark P, 1999, BLOOD REV, V13, P127, DOI 10.1054/blre.1999.0114; Doggen CJM, 1998, CIRCULATION, V97, P1037, DOI 10.1161/01.CIR.97.11.1037; ESMON CT, 1983, BLOOD, V62, P1155; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Fukudome K, 1998, J EXP MED, V187, P1029, DOI 10.1084/jem.187.7.1029; Fukudome K, 1996, J BIOL CHEM, V271, P17491, DOI 10.1074/jbc.271.29.17491; FUKUDOME K, 1995, J BIOL CHEM, V270, P5571, DOI 10.1074/jbc.270.10.5571; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GODING JW, 1976, J IMMUNOL METHODS, V13, P215, DOI 10.1016/0022-1759(76)90068-5; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; Kurosawa S, 1997, J CLIN INVEST, V100, P411, DOI 10.1172/JCI119548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P824; Li PW, 1999, IMMUNITY, V10, P577, DOI 10.1016/S1074-7613(00)80057-6; Liaw PCY, 2000, J BIOL CHEM, V275, P5447, DOI 10.1074/jbc.275.8.5447; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; Mateo J, 1998, BLOOD COAGUL FIBRIN, V9, P71, DOI 10.1097/00001721-199801000-00009; Merati G, 1999, THROMB HAEMOSTASIS, P507; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; Nizzi FA, 1999, SEMIN THROMB HEMOST, V25, P265, DOI 10.1055/s-2007-994930; Norlund L, 1997, THROMB HAEMOSTASIS, V78, P1164; Norlund L, 1997, THROMB HAEMOSTASIS, V77, P248; Ohlin AK, 1997, THROMB HAEMOSTASIS, V78, P396; Porcelli SA, 1997, CURR BIOL, V7, pR508, DOI 10.1016/S0960-9822(06)00250-8; Regan LM, 1997, J BIOL CHEM, V272, P26279, DOI 10.1074/jbc.272.42.26279; Regan LM, 1996, J BIOL CHEM, V271, P17499, DOI 10.1074/jbc.271.29.17499; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rosendaal FR, 1997, BLOOD, V89, P2817, DOI 10.1182/blood.V89.8.2817; Smith OP, 1999, BRIT J HAEMATOL, V104, P202, DOI 10.1046/j.1365-2141.1999.01186.x; Smith OP, 1997, LANCET, V350, P1590, DOI 10.1016/S0140-6736(97)06356-3; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; Taylor FB, 2000, BLOOD, V95, P1680, DOI 10.1182/blood.V95.5.1680.005k33_1680_1686; Turk D., 1992, THESIS TU MUNCHEN GE; Villoutreix BO, 1999, PROTEIN ENG, V12, P833, DOI 10.1093/protein/12.10.833; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	44	65	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8364	8370		10.1074/jbc.M010572200	http://dx.doi.org/10.1074/jbc.M010572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11099506	hybrid			2022-12-25	WOS:000167474900094
J	Bixel, MG; Weise, C; Bolognesi, ML; Rosini, M; Brierly, MJ; Mellor, IR; Usherwood, PNR; Melchiorre, C; Hucho, F				Bixel, MG; Weise, C; Bolognesi, ML; Rosini, M; Brierly, MJ; Mellor, IR; Usherwood, PNR; Melchiorre, C; Hucho, F			Location of the polyamine binding site in the vestibule of the nicotinic acetylcholine receptor ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; AMINO-ACIDS; SUBUNIT INTERFACES; ALPHA-SUBUNIT; NONCOMPETITIVE INHIBITORS; MOLECULAR DISSECTION; GEL-ELECTROPHORESIS; GLUTAMATE RECEPTORS; DELTA-SUBUNIT; IDENTIFICATION	To map the structure of a ligand-gated ion channel, we used the photolabile polyamine-containing toxin MR44 as photoaffinity label. MR44 binds with high affinity to the nicotinic acetylcholine receptor in its closed channel conformation. The binding stoichiometry was two molecules of MR44 per receptor monomer. Upon UV irradiation of the receptor-ligand complex, I-125-MR44 was incorporated into the receptor alpha -subunit. From proteolytic mapping studies, we conclude that the site of I-125-MR44 cross-linking is contained in the sequence alpha His-186 to alpha Leu-199, which is part of the extracellular domain of the receptor. This sequence partially overlaps in its C-terminal region with one of the three leaps that form the agonist-binding site. The agonist carbachol and the competitive antagonist alpha -bungarotoxin had only minor influence on the photocross-linking of I-125-MR44. The site where the hydrophobic head group of I-125-MR44 binds must therefore be located outside the zone that is sterically influenced by agonist bound at the nicotinic acetylcholine receptor. In binding and photocross-linking experiments, the luminal noncompetitive inhibitors ethidium and triphenylmethylphosphonium were found to compete with I-125-MR44. We conclude that the polyamine moiety of I-125-MR44 interacts with the high affinity noncompetitive inhibitor site deep in the channel of the nicotinic acetylcholine receptor, while the aromatic ring of this compound binds in the upper part of the ion channel (i.e. in the vestibule) to a hydrophobic region on the alpha -subunit that is located in close proximity to the agonist binding site. The region of the alpha -subunit labeled by I-125-MR44 should therefore be accessible from the luminal side of the vestibule.	Free Univ Berlin, Inst Chem Biochem, Fachbereich Biol, D-14195 Berlin, Germany; Univ Bologna, Dipartimento Sci Farmaceut, I-40125 Bologna, Italy; Univ Nottingham, Sch Biol, Div Mol Toxicol, Nottingham NG7 2RD, England	Free University of Berlin; University of Bologna; University of Nottingham	Hucho, F (corresponding author), Free Univ Berlin, Inst Chem Biochem, Fachbereich Biol, Thielallee 63, D-14195 Berlin, Germany.		Bolognesi, Maria Laura/AAL-8062-2021	Mellor, Ian/0000-0002-8332-5155; Bolognesi, Maria Laura/0000-0002-1289-5361				ANIS N, 1990, J PHARMACOL EXP THER, V254, P764; BERTRAND D, 1995, NEUROSCIENCES, V7, P75; Bixel MG, 2000, EUR J BIOCHEM, V267, P110, DOI 10.1046/j.1432-1327.2000.00971.x; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Changeux JP, 1998, BRAIN RES REV, V26, P198, DOI 10.1016/S0165-0173(97)00040-4; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN JB, 1991, J BIOL CHEM, V266, P23354; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; CZAIJKOWSKI C, 1995, J BIOL CHEM, V270, P3160; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; ELDEFRAWI AT, 1988, P NATL ACAD SCI USA, V85, P4910, DOI 10.1073/pnas.85.13.4910; Galzi JL, 1996, EMBO J, V15, P5824, DOI 10.1002/j.1460-2075.1996.tb00969.x; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HARTIG PR, 1979, BIOCHEMISTRY-US, V18, P1146, DOI 10.1021/bi00574a004; HERZ JM, 1991, J BIOL CHEM, V266, P16691; HERZ JM, 1987, J BIOL CHEM, V262, P7238; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Jayaraman V, 1999, BIOCHEMISTRY-US, V38, P11406, DOI 10.1021/bi991219x; JEKEL PA, 1983, ANAL BIOCHEM, V134, P347, DOI 10.1016/0003-2697(83)90308-1; KAO PN, 1986, J BIOL CHEM, V261, P8085; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KONNO T, 1991, P ROY SOC B-BIOL SCI, V244, P69, DOI 10.1098/rspb.1991.0053; Krauss M, 2000, J BIOL CHEM, V275, P30196, DOI 10.1074/jbc.M001782200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUFFER L, 1982, P NATL ACAD SCI-BIOL, V79, P2406, DOI 10.1073/pnas.79.7.2406; MACHOLD J, 1995, P NATL ACAD SCI USA, V92, P7282, DOI 10.1073/pnas.92.16.7282; Martin MD, 1997, BIOCHEMISTRY-US, V36, P10742, DOI 10.1021/bi970896t; MITCHELL WM, 1968, J BIOL CHEM, V243, P4683; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Nakanishi K, 1997, BIOORGAN MED CHEM, V5, P1969, DOI 10.1016/S0968-0896(97)00137-5; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P532; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Pratt MB, 2000, BIOCHEMISTRY-US, V39, P11452, DOI 10.1021/bi0011680; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; RAGSDALE D, 1989, J PHARMACOL EXP THER, V251, P156; Rosini M, 1999, J MED CHEM, V42, P5212, DOI 10.1021/jm991110n; ROZENTAL R, 1989, J PHARMACOL EXP THER, V249, P123; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIEBLER W, 1977, FEBS LETT, V81, P39, DOI 10.1016/0014-5793(77)80923-X; Shao ZY, 1998, J PHARMACOL EXP THER, V286, P1269; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; STERZ R, 1982, EUR J PHARMACOL, V80, P393, DOI 10.1016/0014-2999(82)90085-1; Sugiyama S, 1996, PROTEIN SCI, V5, P1984, DOI 10.1002/pro.5560051004; TETAZ T, 1990, BIOCHEM INT, V22, P561; ULLMANN D, 1994, EUR J BIOCHEM, V223, P865, DOI 10.1111/j.1432-1033.1994.tb19063.x; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; USHERWOOD PNR, 1991, PHARMACOL THERAPEUT, V52, P245, DOI 10.1016/0163-7258(91)90012-B; VARKI A, 1983, J BIOL CHEM, V258, P2808; VILLARROEL A, 1992, P ROY SOC B-BIOL SCI, V249, P317, DOI 10.1098/rspb.1992.0121; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; [No title captured]	60	24	26	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6151	6160		10.1074/jbc.M008467200	http://dx.doi.org/10.1074/jbc.M008467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11104766	hybrid			2022-12-25	WOS:000167261000015
J	Lesourne, R; Bruhns, P; Fridman, WH; Daeron, M				Lesourne, R; Bruhns, P; Fridman, WH; Daeron, M			Insufficient phosphorylation prevents Fc gamma RIIB from recruiting the SH2 domain-containing protein-tyrosine phosphatase SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL ACTIVATION; NEGATIVE REGULATION; INHIBITORY RECEPTORS; IN-VIVO; CYTOPLASMIC DOMAIN; DEFICIENT MICE; B-CELLS; SHIP; MOTIFS; IGG	Fc gamma RIIB are IgG receptors that inhibit immunoreceptor tyrosine-based activation motif (ITAM)-dependent cell activation. Inhibition depends on an immunoreceptor tyrosine-based inhibition motif (ITIM) that is phosphorylated upon Fc gamma RIIB coaggregation with ITAM-bearing receptors and recruits SH2 domain-containing phosphatases. Agarose bead coated phosphorylated ITIM peptides (pITIMs) bind in vitro the single-SH2 inositol 5-phosphatases (SHIP1 and SHIP2) and the two-SH2 protein tyrosine phosphatases (SHP-1 and SHP-2). Phosphorylated Fc gamma RIIB, however, recruit selectively SHIP1/2 in vivo. We aimed here at explaining this discordance. We found that beads coated with low amounts of pITIM bound in vitro SHIP1, but not SHP-1, i.e. behaved as phosphorylated Fc gamma RIIB in vivo. The reason is that SHP-1 requires its two SH2 domains to bind on adjacent pITIMs. Consequently, the binding of SHP-1, but not of SHIP1, increased with pITIM density on beads. When trying to increase Fc gamma RIIB phosphorylation in B cells and mast cells, we found that concentrations of ligands optimal for Fc gamma RIIB phosphorylation failed to induce SHP-1 recruitment. SHP-1 was, however, recruited by Fc gamma RIIB when hyperphosphorylated following cell treatment with pervanadate. Our data suggest that Fc gamma RIIB phosphorylation may not be sufficient in vivo to enable the recruitment of SHP-1 but that (pathological?) conditions that would hyperphosphorylate Fc gamma RIIB might enable SHP-1 recruitment.	Inst Curie, INSERM, U255, Lab Immunol Cellulaire & Clin, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Daeron, M (corresponding author), Inst Curie, INSERM, U255, Lab Immunol Cellulaire & Clin, 26 Rue Ulm, F-75005 Paris, France.		Bruhns, Pierre/F-5567-2013; Lesourne, Renaud/M-1855-2014	Bruhns, Pierre/0000-0002-4709-8936; fridman, wolf herman/0000-0002-1332-0973; Lesourne, Renaud/0000-0003-3816-7087				Adachi T, 1998, J IMMUNOL, V160, P4662; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BENHAMOU M, 1990, J IMMUNOL, V144, P3071; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Binstadt BA, 1998, J BIOL CHEM, V273, P27518, DOI 10.1074/jbc.273.42.27518; Blery M, 1997, J BIOL CHEM, V272, P8989; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Bruhns P, 2000, J BIOL CHEM, V275, P37357, DOI 10.1074/jbc.M003518200; Bruhns P, 1999, J IMMUNOL, V162, P3168; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; DAERON M, 1992, J IMMUNOL, V149, P1365; Daeron M, 1999, CURR TOP MICROBIOL, V244, P1; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Famiglietti SJ, 1999, IMMUNOL LETT, V68, P35, DOI 10.1016/S0165-2478(99)00027-9; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; JONES B, 1986, J IMMUNOL, V136, P348; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Latour S, 1996, J IMMUNOL, V157, P189; LIU FT, 1980, J IMMUNOL, V124, P2728; Malbec O, 1998, J IMMUNOL, V160, P1647; Malbec O, 1999, J IMMUNOL, V162, P4424; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Nakamura A, 2000, J EXP MED, V191, P899, DOI 10.1084/jem.191.5.899; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; Rohrschneider LR, 2000, GENE DEV, V14, P505; Sato K, 1998, J IMMUNOL, V161, P2716; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SINCLAIR NRS, 1971, ADV EXP MED BIOL, V12, P609; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; Yuasa T, 1999, J EXP MED, V189, P187, DOI 10.1084/jem.189.1.187; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453	47	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6327	6336		10.1074/jbc.M006537200	http://dx.doi.org/10.1074/jbc.M006537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11099496	hybrid			2022-12-25	WOS:000167261000037
J	Obergfell, A; Judd, BA; del Pozo, MA; Schwartz, MA; Koretzky, GA; Shattil, SJ				Obergfell, A; Judd, BA; del Pozo, MA; Schwartz, MA; Koretzky, GA; Shattil, SJ			The molecular adapter SLP-76 relays signals from platelet integrin alpha(IIb)beta(3) to the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; PROTEIN-TYROSINE KINASE; INTERLEUKIN-2 PRODUCTION; PROMOTER ACTIVITY; FOCAL ADHESION; CELL-ADHESION; PHOSPHORYLATION; RECEPTOR; ACTIVATION; VAV	Platelet adhesion to fibrinogen through integrin alpha (IIb)beta (3) triggers actin rearrangements and cell spreading. Mice deficient in the SLP-76 adapter molecule bleed excessively, and their platelets spread poorly on fibrinogen. Here me used human platelets and a Chinese hamster ovary (CHO) cell expression system to better define the role of SLP-76 in alpha (IIb)beta (3) signaling. CHO cell adhesion to fibrinogen required cu,,P, and stimulated tyrosine phosphorylation of SLP-76, SLP-76 phosphorylation required coexpression of Syk tyrosine kinase and stimulated association of SLP-76 with the adapter, Nck, and with the Rac exchange factor, Vav1. SLP-76 expression increased lamellipodia formation induced by Syk and Vav1 in adherent CHO cells (p < 0.001). Although lamellipodia formation requires Rac, SLP-76 functioned downstream of Rac by potentiating adhesion-dependent activation of PAK kinase (p < 0.001), a Rac effector that associates with Nck, In platelets, adhesion to fibrinogen stimulated the association of SLP-76 with the SLAP-130 adapter and with VASP, a SLAP-130 binding partner implicated in actin reorganization. Furthermore, SLAP-130 colocalized with VASP at the periphery of spread platelets. Thus, SLP-76 functions to relay signals from cr,P, to effecters of cytoskeletal reorganization. Therefore, deficient recruitment of specific adapters and effecters to sites of adhesion may explain the integrin phenotype of SLP-76(-/-) platelets.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Leonard & Madlyn Abramson Family Canc Res Inst, Grad Program Immunol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Leonard & Madlyn Abramson Family Canc Res Inst, Signal Transduct Program, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Scripps Research Institute; Scripps Research Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Shattil, SJ (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd,VB-5, La Jolla, CA 92037 USA.		Koretzky, Gary/AAU-5381-2021; del Pozo, Miguel Angel/L-2861-2014	del Pozo, Miguel Angel/0000-0001-9077-391X; schwartz, martin/0000-0002-2071-1243				Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Fang N, 1999, J BIOL CHEM, V274, P16206, DOI 10.1074/jbc.274.23.16206; Fang N, 1996, J IMMUNOL, V157, P3769; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; Hagmann J, 1998, J CELL SCI, V111, P2181; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; Hunter AJ, 2000, J IMMUNOL, V164, P1143, DOI 10.4049/jimmunol.164.3.1143; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Judd BA, 2000, P NATL ACAD SCI USA, V97, P12056, DOI 10.1073/pnas.97.22.12056; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; LEONG L, 1995, J CELL SCI, V108, P3817; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Musci MA, 1997, J IMMUNOL, V159, P1639; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; NACHMIAS VT, 1991, CELL MOTIL CYTOSKEL, V20, P190, DOI 10.1002/cm.970200303; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Raab M, 1999, J BIOL CHEM, V274, P21170, DOI 10.1074/jbc.274.30.21170; RIDLEY AJ, 1992, COLD SPRING HARB SYM, V57, P661, DOI 10.1101/SQB.1992.057.01.072; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	55	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5916	5923		10.1074/jbc.M010639200	http://dx.doi.org/10.1074/jbc.M010639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11113155	hybrid			2022-12-25	WOS:000167115100069
J	Imam, A; Hoyos, B; Swenson, C; Levi, E; Chua, R; Viriya, E; Hammerling, U				Imam, A; Hoyos, B; Swenson, C; Levi, E; Chua, R; Viriya, E; Hammerling, U			Retinoids as ligands and coactivators of protein kinase C alpha	FASEB JOURNAL			English	Article									Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Hammerling, U (corresponding author), Mem Sloan Kettering Canc Ctr, Program Immunol, 1275 York Ave, New York, NY 10021 USA.								0	59	60	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					28	30						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099483				2022-12-25	WOS:000166312400010
J	Klockow, B; Ahmadian, MR; Block, C; Wittinghofer, A				Klockow, B; Ahmadian, MR; Block, C; Wittinghofer, A			Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling	ONCOGENE			English	Article						Ras; GTPase; oncogene; MAP kinase pathway	GTPASE-ACTIVATING PROTEINS; H-RAS; BINDING-PROTEINS; TRIPHOSPHATE CONFORMATION; STRUCTURAL DIFFERENCES; ESCHERICHIA-COLI; PC12 CELLS; IN-VITRO; P21; DOMAIN	Mutations of Ras with three extra amino acids inserted into the phosphate-binding (P) loop have been investigated both in vitro and in vivo. Such mutants have originally been detected as oncogenes both in the ras and the TC21 genes. Biochemical experiments reveal the molecular basis of their oncogenic potential: the mutants show a strongly attenuated binding affinity for nucleotides, most notably for GDP, leading to a preference for GTP binding. Furthermore, both the intrinsic as web as the GAP-stimulated GTP hydrolysis are drastically diminished. The binding interaction with GAP is reduced, whereas binding to the Ras-binding domain of the downstream effector c-Raf1 is not altered appreciably. Microinjection into PC12 cells shows the mutants to be as potent to induce neurite outgrowth as conventional oncogenic Ras mutants. Unexpectedly, their ability to stimulate the MAP kinase pathway as measured by a reporter gene assay in RK13 cells is much higher than that of the normal oncogenic mutant G12V. This characteristic was attributed to an increased stimulation of c-Raf1 kinase activity by the insertional Ras mutants.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.							Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Bollag G, 1996, J BIOL CHEM, V271, P32491, DOI 10.1074/jbc.271.51.32491; BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; ENOMOTO T, 1990, CANCER RES, V50, P6139; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; HUANG Y, 1995, ONCOGENE, V11, P1255; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; RENSLAND H, 1995, BIOCHEMISTRY-US, V34, P593, DOI 10.1021/bi00002a026; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schmidt G, 1996, ONCOGENE, V12, P87; SCHMIDT G, 1996, THESIS RUHR U BOCHUM; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; WIEST JS, 1994, ONCOGENE, V9, P2449; Zhang J, 1998, BIOCHEMISTRY-US, V37, P14881, DOI 10.1021/bi9811157; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	64	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5367	5376		10.1038/sj.onc.1203909	http://dx.doi.org/10.1038/sj.onc.1203909			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103938				2022-12-25	WOS:000165302300008
J	Brieba, LG; Gopal, V; Sousa, R				Brieba, LG; Gopal, V; Sousa, R			Scanning mutagenesis reveals roles for helix N of the bacteriophage T7 RNA polymerase thumb subdomain in transcription complex stability, pausing, and termination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; KINETIC MECHANISM; CRYSTAL-STRUCTURE; ELONGATION; INITIATION; LYSOZYME; BINDING; MUTANT; SITE; CONFORMATIONS	Deletions within the thumb subdomain (residues 335-408) of T7 RNA polymerase decrease elongation complex stability and processivity, but the structure of a T7RNAP initial transcription complex containing a 3-nucleotide RNA reveals no interactions between the thumb and the RNA or DNA. Modeling of a longer RNA in this structure, using a T7DNAP-primer-template structure as a guide, suggests that the phosphate ribose backbone of the RNA contacts a stretch of mostly positively charged side chains between residues 385 and 395 of helix N of the thumb. Scanning mutagenesis of this region reveals that alanine substitutions of Arg(391), Ser(393), and Arg(394) destabilize elongation complexes and that substitutions at 393 and 394 increase termination of transcripts 5 or more bases in length. The alpha -carbons of all 3 of these residues lie on the side of helix N, which faces into the template-binding cleft of the RNA polymerase, and modeling suggests that they can contact the RNA 4-5 bases away from the 3 ' -end. Alanine substitutions of other residues within 385-395 do not have marked effects on transcription complex stability, but alanine substitutions of Asp(388) and Tyr(385) reduce pausing and termination at the T7 concatemer junction , Both of these side chains lie on the outer side of helix N, pointing away from the template binding cleft. The thumb subdomain of T7RNAP therefore has roles both in transcription complex stabilization and in pausing and termination at the T7 concatemer junction.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Sousa, R (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Brieba, Luis/I-8447-2016	Brieba, Luis/0000-0002-6073-5207; Sousa, Rui/0000-0003-4314-121X	NIGMS NIH HHS [GM 52522, R01 GM052522] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; BONNER G, 1994, J BIOL CHEM, V269, P25129; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DZANTIEV L, 2000, BIOCHEMISTRY-US, V39, P536; Gopal V, 1999, J MOL BIOL, V290, P411, DOI 10.1006/jmbi.1999.2836; He B, 1998, J BIOL CHEM, V273, P18802, DOI 10.1074/jbc.273.30.18802; Huang JB, 1999, J MOL BIOL, V293, P457, DOI 10.1006/jmbi.1999.3135; Huang JB, 2000, BIOCHEMISTRY-US, V39, P11571, DOI 10.1021/bi000579d; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; JENG ST, 1990, J BIOL CHEM, V265, P3823; JENG ST, 1992, J BIOL CHEM, V267, P19306; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1997, J BIOL CHEM, V272, P30147, DOI 10.1074/jbc.272.48.30147; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Lyakhov DL, 1998, J MOL BIOL, V280, P201, DOI 10.1006/jmbi.1998.1854; Lyakhov DL, 1997, J MOL BIOL, V269, P28, DOI 10.1006/jmbi.1997.1015; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; MCALLISTER WT, 1993, MOL MICROBIOL, V10, P1, DOI 10.1111/j.1365-2958.1993.tb00897.x; MCALLISTER WT, 1997, MECH TRANSCRIPTION N, V11, P16; MENTESANAS PE, 2000, J MOL BIOL, V302; Mote J, 1998, J BIOL CHEM, V273, P16843, DOI 10.1074/jbc.273.27.16843; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; MUNOZ V, 1995, CURR OPIN BIOTECH, V6, P382, DOI 10.1016/0958-1669(95)80066-2; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; SOUSA R, 1994, J MOL BIOL, V244, P6, DOI 10.1006/jmbi.1994.1699; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TEMIAKOV D, 2000, IN PRESS P NATL ACAD; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Villemain J, 1998, J MOL BIOL, V281, P793, DOI 10.1006/jmbi.1998.1989; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358	43	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10306	10313		10.1074/jbc.M009866200	http://dx.doi.org/10.1074/jbc.M009866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124963	hybrid			2022-12-25	WOS:000167996400096
J	Cheng, H; Sukal, S; Callender, R; Leyh, TS				Cheng, H; Sukal, S; Callender, R; Leyh, TS			gamma-phosphate protonation and pH-dependent unfolding of the Ras center dot GTP center dot Mg2+ complex - A vibrational spectroscopy study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; FOURIER SELF-DECONVOLUTION; FREE-ENERGY RELATIONSHIPS; GTP HYDROLYSIS; SECONDARY STRUCTURES; P21(H-RAS) PROTEIN; ALPHA-LACTALBUMIN; DENATURED STATE; LIGAND-BINDING; AMIDE-I	The interdependence of GTP hydrolysis and the second messenger functions of virtually all GTPases has stimulated intensive study of the chemical mechanism of the hydrolysis, Despite numerous mutagenesis studies, the presumed general base, whose role is to activate hydrolysis by abstracting a proton from the nucleophilic water, has not been identified. Recent theoretical and experimental work suggest that the gamma -phosphate of GTP could be the general base. The current study investigates this possibility by studying the pH dependence of the vibrational spectrum of the Ras . GTP . Mg2+ and Ras . GDP . Mg2+ complexes. Isotope-edited IR studies of the Ras . GTP . Mg2+ complex show that GTP remains bound to Ras at pH as low as 2.0 and that the gamma -phosphate is not protonated at pH greater than or equal to 3.3, indicating that the active site decreases the gamma -phosphate pK(a) by at least 1.1 pK(a) units compared with solution. Amide I studies show that the Ras . GTP . Mg2+ and Ras . GDP . Mg2+ complexes partially unfold in what appear to be two transitions, The first occurs in the pH range 5.4-2.6 and is readily reversible, Differences in the pa-unfolding midpoints for the Ras . GTP . Mg2+ and Ras . GDP . Mg2+ complexes (3.7 and 4.8, respectively) reveal that the enzyme-gamma -phosphoryl interactions stabilize the structure, The second transition, pH 2.6-1.7, is not readily reversed, The pH-dependent unfolding of the Ras . GTP . Mg2+ complex provides an alternative interpretation of the data that had been used to support the gamma -phosphate mechanism, thereby raising the issue of whether this mechanism is operative in GTPase-catalyzed GTP hydrolysis reactions.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Leyh, TS (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054469, R01GM035183] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54469, GM35183] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDEKAR J, 1992, BIOCHIM BIOPHYS ACTA, V1120, P123, DOI 10.1016/0167-4838(92)90261-B; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bourne HR, 1997, SCIENCE, V278, P1898, DOI 10.1126/science.278.5345.1898; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cepus V, 1998, BIOCHEMISTRY-US, V37, P10263, DOI 10.1021/bi973183j; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; COHN M, 1960, J BIOL CHEM, V235, P3250; Deng H, 1998, J PHYS CHEM B, V102, P3617, DOI 10.1021/jp973314q; Du XL, 2000, J BIOL CHEM, V275, P8492, DOI 10.1074/jbc.275.12.8492; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; JOHN J, 1993, J BIOL CHEM, V268, P923; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KENNEDY DF, 1990, BIOCHIM BIOPHYS ACTA, V1040, P317, DOI 10.1016/0167-4838(90)90129-4; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; NEAL SE, 1988, J BIOL CHEM, V263, P19718; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PRESTRELSKI SJ, 1991, INT J PEPT PROT RES, V37, P508; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P133, DOI 10.1021/bi00215a020; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14232, DOI 10.1021/bi961119g; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14225, DOI 10.1021/bi961118o; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SHORTLE D, 1993, STRUCTURE, V1, P121, DOI 10.1016/0969-2126(93)90027-E; Shortle D, 1996, FASEB J, V10, P27, DOI 10.1096/fasebj.10.1.8566543; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; TREWHELLA J, 1989, BIOCHEMISTRY-US, V28, P1294, DOI 10.1021/bi00429a052; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Wang JH, 1998, BIOCHEMISTRY-US, V37, P11106, DOI 10.1021/bi980471m; Wi S, 1998, BIOSPECTROSCOPY, V4, P93, DOI 10.1002/(SICI)1520-6343(1998)4:2<93::AID-BSPY2>3.0.CO;2-T; YUTANI K, 1992, J MOL BIOL, V228, P347, DOI 10.1016/0022-2836(92)90824-4; Zhang J, 1998, BIOCHEMISTRY-US, V37, P14891, DOI 10.1021/bi981116z; Zhang J, 1998, BIOCHEMISTRY-US, V37, P14881, DOI 10.1021/bi9811157; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	43	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9931	9935		10.1074/jbc.M009295200	http://dx.doi.org/10.1074/jbc.M009295200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124953	hybrid			2022-12-25	WOS:000167996400049
J	Hitomi, K; Nakamura, H; Kim, ST; Mizukoshi, T; Ishikawa, T; Iwai, S; Todo, T				Hitomi, K; Nakamura, H; Kim, ST; Mizukoshi, T; Ishikawa, T; Iwai, S; Todo, T			Role of two histidines in the (6-4) photolyase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT PHOTORECEPTOR FAMILY; DNA PHOTOLYASE; ELECTRON-TRANSFER; PHOTOREACTIVATING ENZYME; ANACYSTIS-NIDULANS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; NUCLEIC-ACIDS; PHOTOPRODUCT; REPAIR	The reaction mechanism of Xenopus (6-4) photolyase was investigated using several mutant enzymes. In the active site, which is homologous between the cis,syncyclobutane pyrimidine dimer and (6-4) photolyases, four amino acid residues that are specific to (6-4) photolyase, Gln(288), His(354), Leu(355), and His(358), and two conserved tryptophans, Trp(291) and Trp(398), were substituted with alanine, Only the L355A mutant had a lower affinity for the substrate, which suggested a hydrophobic interaction with the (6-4) photoproduct. Both the H354A and H358A mutations resulted in an almost complete loss of the repair activity, although the Trp291 and Trp398 mutants retained some activity. Taking the pH profile of the (6-4) photolyase reaction into consideration with this observation, we propose a mechanism in which these histidines catalyze the formation of the four-membered ring intermediate in the repair process of this enzyme. When deuterium oxide was used as a solvent, the repair activity was decreased. The proton transfer shown by this isotope effect supports the proposed mechanism. The substrate binding and the reaction mechanism are discussed in detail using a molecular model.	Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan; Inst Prot Res, Res Ctr Struct Biol, Lab Prot Informat, Suita, Osaka 5650871, Japan	Kyoto University	Todo, T (corresponding author), Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Yoshidakonoe Cho, Kyoto 6068501, Japan.							Antony J, 2000, J AM CHEM SOC, V122, P1057, DOI 10.1021/ja993784t; CLIVIO P, 1991, J AM CHEM SOC, V113, P5481, DOI 10.1021/ja00014a065; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; EKER APM, 1990, J BIOL CHEM, V265, P8009; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hahn J, 1999, J PHYS CHEM B, V103, P2001, DOI 10.1021/jp984197h; Heelis PF, 1997, J AM CHEM SOC, V119, P2936, DOI 10.1021/ja9639877; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; Joseph A, 2000, J AM CHEM SOC, V122, P11219, DOI 10.1021/ja002541u; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; KATO T, 1994, NUCLEIC ACIDS RES, V22, P4119, DOI 10.1093/nar/22.20.4119; KIM JK, 1995, EUR J BIOCHEM, V228, P849, DOI 10.1111/j.1432-1033.1995.0849m.x; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; KIM ST, 1994, J BIOL CHEM, V269, P8535; Kobayashi Y, 2000, GENES CELLS, V5, P725, DOI 10.1046/j.1365-2443.2000.00364.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Mizukoshi T, 1998, J AM CHEM SOC, V120, P10634, DOI 10.1021/ja982004y; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; Nakajima S, 1998, NUCLEIC ACIDS RES, V26, P638, DOI 10.1093/nar/26.2.638; Nakamura H, 1996, Q REV BIOPHYS, V29, P1, DOI 10.1017/S0033583500005746; NAKAMURA H, 1991, NUCLEIC ACIDS RES, V19, P1817, DOI 10.1093/nar/19.8.1817; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; RAHN RO, 1969, PHOTOCHEM PHOTOBIOL, V10, P131, DOI 10.1111/j.1751-1097.1969.tb07230.x; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; Sanders DB, 1999, J AM CHEM SOC, V121, P5127, DOI 10.1021/ja982660y; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; TANIMURA R, 1994, PROTEIN SCI, V3, P2358, DOI 10.1002/pro.5560031220; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Todo T, 1997, NUCLEIC ACIDS RES, V25, P764, DOI 10.1093/nar/25.4.764; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; van Noort J, 1999, NUCLEIC ACIDS RES, V27, P3875, DOI 10.1093/nar/27.19.3875; Vande Berg BJ, 1998, J BIOL CHEM, V273, P20276, DOI 10.1074/jbc.273.32.20276; Wang YS, 2000, J AM CHEM SOC, V122, P5510, DOI 10.1021/ja992244t; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580	40	104	106	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10103	10109		10.1074/jbc.M008828200	http://dx.doi.org/10.1074/jbc.M008828200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124949	hybrid, Green Submitted			2022-12-25	WOS:000167996400070
J	Lins, L; Couvineau, A; Rouyer-Fessard, C; Nicole, P; Maoret, JJ; Benhamed, M; Brasseur, R; Thomas, A; Laburthe, M				Lins, L; Couvineau, A; Rouyer-Fessard, C; Nicole, P; Maoret, JJ; Benhamed, M; Brasseur, R; Thomas, A; Laburthe, M			The human VPAC(1) receptor - Three-dimensional model and mutagenesis of the N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CONSTITUTIVE ACTIVATION; ADENYLATE-CYCLASE; VIP; RESIDUES; SECRETIN; FAMILY; GLUCAGON; HORMONE; BINDING	The human VPAC(1), receptor for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide belongs to the class II family of G-protein-coupled receptors with seven transmembrane segments. Like for all class II receptors, the extracellular N-terminal domain of the human VPAC(1), receptor plays a predominant role in peptide ligand recognition. To determine the three-dimensional structure of this N-terninal domain (residues 1-144), the Protein Data Bank (PDB) was screened for a homologous protein. A subdomain of yeast lipase B was found to have 27% sequence identity and 50% sequence homology with the N-terminal domain (8-117) of the VPAC(1), receptor together with a good alignment of the hydrophobic clusters. A model of the N-terminal domain of VPAC(1), receptor was thus constructed by homology, It indicated the presence of a putative signal sequence in the N-terminal extremity. Moreover, residues (Glu(36) Trp(67) Asp(68), Trp(73), and Gly(109)) which were shown tb be crucial for VIP binding are gathered around a groove that is essentially negatively charged. New putatively important residues for VIP binding were suggested from the model analysis. Site-directed mutagenesis and stable transfection of mutants in CHO cells indicated that Pro(74), Pro(87), Phe(90), and Trp(110) are indeed important for VIP binding and activation of adenylyl cyclase activation, Combination of molecular modeling and directed mutagenesis provided the first partial three-dimensional structure of a VIP-binding domain, constituted of an electronegative groove with an outspanning tryptophan shell at one end, in the N-terminal extracellular region of the human VPAC(1), receptor.	Univ Paris 07, INSERM, U410, F-75018 Paris, France; Fac Univ Gembloux, Ctr Biophys Mol Numer, B-5030 Gembloux, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Liege	Laburthe, M (corresponding author), Univ Paris 07, INSERM, U410, F-75018 Paris, France.	laburthe@bichat.inserm.fr	couvineau, alain/T-3466-2019; LINS, LAURENCE/Y-1661-2019; couvineau, alain/G-3641-2013; LABURTHE, Marc/C-1875-2012	couvineau, alain/0000-0003-2912-5168; LINS, LAURENCE/0000-0001-7772-6748; couvineau, alain/0000-0003-2912-5168; 				BRADFORD M, 1979, ANAL BIOCHEM, V78, P248; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; Couvineau A, 1996, BIOCHEMISTRY-US, V35, P1745, DOI 10.1021/bi952022h; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; Du K, 1997, BIOCHEM BIOPH RES CO, V230, P289, DOI 10.1006/bbrc.1996.5949; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; Gaudin P, 1999, BIOCHEM BIOPH RES CO, V254, P15, DOI 10.1006/bbrc.1998.9883; Gozes I, 1999, CURR MED CHEM, V6, P1019; Jin L, 2000, J BIOL CHEM, V275, P27238; KUDSEN SM, 1997, FEBS LETT, V412, P141; LABURTHE M, 1987, J BIOL CHEM, V262, P10180; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; Laburthe M, 1999, CONT ENDOCRINOL, V8, P125; LABURTHE M, 1986, MOL PHARMACOL, V29, P23; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nicole P, 2000, BIOCHEM BIOPH RES CO, V276, P654, DOI 10.1006/bbrc.2000.3375; Nicole P, 1998, J PHARMACOL EXP THER, V284, P744; Nicole P, 2000, J BIOL CHEM, V275, P24003, DOI 10.1074/jbc.M002325200; NISHIO M, 1998, CH PI INTERACTION EV, P175; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAHMAN M, 1994, J MOL GRAPHICS, V12, P212, DOI 10.1016/0263-7855(94)80090-1; SAID SI, 1991, TRENDS ENDOCRIN MET, V2, P107, DOI 10.1016/S1043-2760(05)80006-2; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; Solano RM, 2001, J BIOL CHEM, V276, P1084, DOI 10.1074/jbc.M007686200; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3	33	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10153	10160		10.1074/jbc.M009730200	http://dx.doi.org/10.1074/jbc.M009730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124960	hybrid			2022-12-25	WOS:000167996400076
J	Petersen, G; Hahn, C; Gehring, U				Petersen, G; Hahn, C; Gehring, U			Dissection of the ATP-binding domain of the chaperone hsc70 for interaction with the cofactor Hap46	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC PROTEIN BAG-1; SHOCK COGNATE PROTEIN; MOLECULAR CHAPERONES; NEGATIVE REGULATOR; CANCER-CELLS; HUMAN HSP70; HSP70-BINDING PROTEIN; NUCLEOTIDE EXCHANGE; PHAGE DISPLAY; RECEPTOR	Several unrelated proteins are known that specifically interact with members of the mammalian hsp70 chaperone protein family independent of the hsp70 substrate-binding site. One of these is Hap46, also called BAG-1, which binds to the ATP-binding domain of hsp70 and its constitutively expressed, highly homologous counterpart hsc70, thereby affecting nucleotide binding, as well as protein folding properties, of these molecular chaperones. In an attempt to delineate the potential contact sites on hsp70/hsc70 involved in this interaction we made use of the following two independent approaches: (i) screening of membrane-bound peptide libraries based on the sequence of the ATP-binding domain and (ii) the phage-display technique with random dodecapeptides. These approaches yielded partially overlapping results and identified several possible contact regions. On the space-filling model of hsc70, the two major contact areas for Hap46 delineated in the present study are located on the same side of the molecule on either subdomain that border the central cleft harboring the nucleotide-binding site. We suggest that this bridging affects the conformation of the ATP-binding domain in a way similar to the opening of the nucleotide-binding cleft produced in the bacterial hsp70 homologue DnaK upon binding its regulatory protein GrpE.	Inst Mol Genet, D-69120 Heidelberg, Germany; Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Petersen, G (corresponding author), Inst Mol Genet, Neuenheimer Feld 230, D-69120 Heidelberg, Germany.							ADEY NB, 1995, GENE, V156, P27, DOI 10.1016/0378-1119(95)00058-E; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FRANK R, 1992, TETRAHEDRON, V48, P1588; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Gebauer M, 1997, FEBS LETT, V417, P109, DOI 10.1016/S0014-5793(97)01267-2; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Levitan B, 1998, J MOL BIOL, V277, P893, DOI 10.1006/jmbi.1997.1555; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Moore DD, 1995, GLOB MOB SURV; Naishiro Y, 1999, ONCOGENE, V18, P3244, DOI 10.1038/sj.onc.1202661; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Osipiuk J, 1999, ACTA CRYSTALLOGR D, V55, P1105, DOI 10.1107/S0907444999002103; Otvos L, 2000, BIOCHEMISTRY-US, V39, P14150, DOI 10.1021/bi0012843; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Petersen G, 1995, MOL GEN GENET, V249, P425, DOI 10.1007/BF00287104; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Raynes DA, 1998, J BIOL CHEM, V273, P32883, DOI 10.1074/jbc.273.49.32883; Raynes DA, 2000, BBA-GENE STRUCT EXPR, V1490, P203, DOI 10.1016/S0167-4781(99)00238-9; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schneikert J, 1999, J CELL BIOL, V146, P929, DOI 10.1083/jcb.146.5.929; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; Sousa MC, 1998, BIOCHEMISTRY-US, V37, P15392, DOI 10.1021/bi981510x; Sriram M, 1997, STRUCTURE, V5, P403, DOI 10.1016/S0969-2126(97)00197-4; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	53	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10178	10184		10.1074/jbc.M006967200	http://dx.doi.org/10.1074/jbc.M006967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11121403	hybrid			2022-12-25	WOS:000167996400079
J	Beterams, G; Nassal, M				Beterams, G; Nassal, M			Significant interference with hepatitis B virus replication by a core-nuclease fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE MUTANTS; STRAND DNA-SYNTHESIS; STEM-LOOP STRUCTURE; WILD-TYPE VIRUS; REVERSE TRANSCRIPTION; ENCAPSIDATION SIGNAL; STAPHYLOCOCCAL NUCLEASE; RNA ENCAPSIDATION; VIRAL REPLICATION; PACKAGING SIGNAL	Hepatitis B virus (HBV), a small DNA containing virus that replicates via reverse transcription, causes acute and chronic B-type hepatitis in humans. The limited success of current therapies for chronic infection has prompted exploration of alternative strategies. Capsid-targeted viral inactivation is a conceptually powerful approach that exploits virion structural proteins to target a degradative enzyme specifically into viral particles. Its principal feasibility has been demonstrated in retroviral model systems but not yet for a medically relevant virus outside the retrovirus family. Recently, we found that C proximal fusion to the HBV capsid protein of the Ca2+-dependent nuclease (SN) from Staphylococcus aureus yields a chimeric protein, coreSN, that in Escherichia coli coassembles with the wild-type capsid protein into particles with internal SN domains. Here we show that, in HBV co-transfected human hepatoma cells, less than 1 coreSN protein per 10 wild-type core protein subunits reduced titers of enveloped DNA containing virions by more than 95%. The antiviral effect depends on both an enzymatically active SN and on the core domain. CoreSN does not block assembly of RNA containing nucleocapsids but interferes with proper synthesis of viral DNA inside the capsid, or leads to rapid DNA degradation. Our data suggest an intracellular nuclease activation that, owing to the characteristics of HBV morphogenesis, is nonetheless highly virus specific. HBV may therefore be particularly vulnerable to the capsid-targeted viral inactivation approach.	Univ Hosp Freiburg, Dept Internal Med Mol Biol 2, D-79106 Freiburg, Germany	University of Freiburg	Nassal, M (corresponding author), Univ Hosp Freiburg, Dept Internal Med Mol Biol 2, Hugstetter Str 55, D-79106 Freiburg, Germany.		Nassal, Michael/U-4529-2019	Nassal, Michael/0000-0003-2204-9158				BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; Beck J, 1995, NUCLEIC ACIDS RES, V23, P4954, DOI 10.1093/nar/23.24.4954; Beck J, 1998, MOL CELL BIOL, V18, P6265, DOI 10.1128/MCB.18.11.6265; Beterams G, 2000, FEBS LETT, V481, P169, DOI 10.1016/S0014-5793(00)01927-X; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; Blumberg BS, 1997, P NATL ACAD SCI USA, V94, P7121, DOI 10.1073/pnas.94.14.7121; Boeke JD, 1996, TRENDS MICROBIOL, V4, P421, DOI 10.1016/0966-842X(96)10065-2; Conway JF, 1998, J MOL BIOL, V279, P1111, DOI 10.1006/jmbi.1998.1845; Gerelsaikhan T, 1996, J VIROL, V70, P4269, DOI 10.1128/JVI.70.7.4269-4274.1996; Giordano V, 2000, VIROLOGY, V267, P174, DOI 10.1006/viro.1999.0112; Hoofnagle JH, 1998, DIGESTION, V59, P563, DOI 10.1159/000007532; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Kann M, 1999, J CELL BIOL, V145, P45, DOI 10.1083/jcb.145.1.45; KNAUS T, 1993, NUCLEIC ACIDS RES, V21, P3967, DOI 10.1093/nar/21.17.3967; Kratz PA, 1999, P NATL ACAD SCI USA, V96, P1915, DOI 10.1073/pnas.96.5.1915; Locarnini S, 1999, J HEPATOL, V30, P536, DOI 10.1016/S0168-8278(99)80118-4; Lok ASF, 2000, J HEPATOL, V32, P89, DOI 10.1016/S0168-8278(00)80418-3; Nassal M, 1997, ARCH VIROL, V142, P611, DOI 10.1007/s007050050107; NASSAL M, 1992, J VIROL, V66, P4107, DOI 10.1128/JVI.66.7.4107-4116.1992; Nassal M, 1996, J VIROL, V70, P2764, DOI 10.1128/JVI.70.5.2764-2773.1996; Nassal M, 1999, INTERVIROLOGY, V42, P100, DOI 10.1159/000024970; NASSAL M, 2000, FRONTIERS MOL BIOL D, V26, P1; NATSOULIS G, 1991, NATURE, V352, P632, DOI 10.1038/352632a0; NATSOULIS G, 1995, P NATL ACAD SCI USA, V92, P364, DOI 10.1073/pnas.92.2.364; Okui N, 2000, HUM GENE THER, V11, P537, DOI 10.1089/10430340050015725; Paulij WP, 1999, J GEN VIROL, V80, P2121, DOI 10.1099/0022-1317-80-8-2121; POLLACK JR, 1993, J VIROL, V67, P3254, DOI 10.1128/JVI.67.6.3254-3263.1993; Protzer U, 1999, P NATL ACAD SCI USA, V96, P10818, DOI 10.1073/pnas.96.19.10818; PUSHKO P, 1994, VIROLOGY, V202, P912, DOI 10.1006/viro.1994.1413; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; Scaglioni P, 1996, HEPATOLOGY, V24, P1010; SCAGLIONI PP, 1994, VIROLOGY, V205, P112, DOI 10.1006/viro.1994.1625; Schumann G, 1996, J VIROL, V70, P4329, DOI 10.1128/JVI.70.7.4329-4337.1996; Schumann G, 1997, GENE THER, V4, P593, DOI 10.1038/sj.gt.3300421; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TAVIS JE, 1994, J VIROL, V68, P3536, DOI 10.1128/JVI.68.6.3536-3543.1994; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; TUCKER PW, 1979, MOL CELL BIOCHEM, V23, P67; VanBrocklin M, 1997, J VIROL, V71, P3312, DOI 10.1128/JVI.71.4.3312-3318.1997; VanBrocklin M, 2000, VIROLOGY, V267, P111, DOI 10.1006/viro.1999.0113; von Weizsacker F, 1999, HEPATOLOGY, V30, P308, DOI 10.1002/hep.510300139; vonWeizsacker F, 1996, HEPATOLOGY, V24, P294; Wands JR, 1997, J GASTROEN HEPATOL, V12, pS354, DOI 10.1111/j.1440-1746.1997.tb00521.x; WANG GH, 1993, J VIROL, V67, P6507, DOI 10.1128/JVI.67.11.6507-6512.1993; WEBER DJ, 1991, BIOCHEMISTRY-US, V30, P6103, DOI 10.1021/bi00239a004; WU XY, 1995, J VIROL, V69, P3389, DOI 10.1128/JVI.69.6.3389-3398.1995; Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	49	27	40	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8875	8883		10.1074/jbc.M006335200	http://dx.doi.org/10.1074/jbc.M006335200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124940	hybrid			2022-12-25	WOS:000167607700037
J	Hamilton, E; Miller, KM; Helm, KM; Langdon, WY; Anderson, SM				Hamilton, E; Miller, KM; Helm, KM; Langdon, WY; Anderson, SM			Suppression of apoptosis induced by growth factor withdrawal by an oncogenic form of c-Cbl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; TYROSINE-PHOSPHORYLATED CBL; PHOSPHATIDYLINOSITOL 3-KINASE; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; PROTEIN-KINASE; P85 SUBUNIT; IN-VIVO; T-CELLS; MALIGNANT TRANSFORMATION	The v-Cbl oncogene induces myeloid and B-cell leukemia; however, the mechanism by which transformation occurs is not understood. An oncogenic form of c-Cbl (Cbl-Delta Y371) was expressed in the interleukin-3 (IL-3) dependent cell line 32Dc13 to determine whether it was able to induce growth factor-independent proliferation. We mere unable to isolate clones of transfected 32Dc13 cells expressing Cbl-Delta Y371 that proliferated in the absence of IL-3. in contrast, 32Dcl3/Cbl-Delta Y371 cells did not undergo apoptosis like parental 32Dc13 cells when cultured in the absence of IL-3. Both 32Dc13 and 32D/Cbl Delta Y371 cells arrested in G(1) when cultured in the absence of IL-3, Approximately 18% of the 32Dcl3 cells cultured in the absence of IL-3 for 24 h were present in a sub-G(1) fraction, while only 4% of the 32D/Cbl-Delta Y371 and 2% of the 32D/Bcl-2 cells were found in a sub-G(1) fraction. There was no difference in the pattern of tyrosine-phosphorylated proteins observed following stimulation of either cell type with IL-3. The phosphorylation of JAK2, STAT5, and endogenous c-Cbl was identical in both cell types. No differences were detected in the activation of Akt, ERK1, or ERK2 in unstimulated or IL-3-stimulated 32D/Cbl-Delta Y371 cells compared with parental 32Dc13 cells. Likewise, there was no difference in the pattern of phosphorylation of JAK2, STATE, ERK1, ERK2, or Akt when 32Dcl3 and 32D/CblDY371 cells were withdrawn from medium containing IL-3. The protein levels of various Bcl-2 family members were examined in cells grown in the absence or presence of IL-3. We observed a consistent increased amount of Bcl-2 protein in five different clones of 32D/Cbl-Delta Y317 cells. These data suggest that the Cbl-Delta Y371 mutant may suppress apoptosis by a mechanism that involves the overexpression of Bcl-2. Consistent with this result, activation of caspase-3 was suppressed in 32D/Cbl-Delta Y371 cells cultured in the absence of IL-3 compared with 32Dcl3 cells cultured under the same conditions.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Ctr Canc, Denver, CO 80262 USA; Univ Western Australia, Dept Pathol, Nedlands, WA 6009, Australia	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Western Australia	Anderson, SM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, Ctr Canc, Box B216,4200 E 9th Ave, Denver, CO 80262 USA.	steve.anderson@uchsc.edu		Miller, Kyle/0000-0002-4544-0013	NATIONAL CANCER INSTITUTE [R29CA045241, R01CA045241, P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055754] Funding Source: NIH RePORTER; NCI NIH HHS [CA45241, CA46934] Funding Source: Medline; NIGMS NIH HHS [GM55754] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Anderson SM, 1996, BLOOD, V87, P238; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDERSON SM, 1990, ONCOGENE, V5, P317; ANDONIOU CE, 1995, J BIOL CHEM, V270, P4515; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BROOME HE, 1995, J IMMUNOL, V155, P2311; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DAMELL JE, 1994, SCIENCE, V264, P1415; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Hunter S, 1997, MOL ENDOCRINOL, V11, P1213, DOI 10.1210/me.11.9.1213; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KRUGER A, 1991, ONCOGENE, V6, P245; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; LIMPENS J, 1991, ONCOGENE, V6, P2271; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Oda A, 1996, BLOOD, V88, P1330, DOI 10.1182/blood.V88.4.1330.bloodjournal8841330; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; ROVERA G, 1987, ONCOGENE, V1, P29; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Smit L, 1996, ONCOGENE, V13, P381; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TORIGOE T, 1992, BLOOD, V80, P617; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; VAUX DL, 1993, MOL CELL BIOL, V13, P7000, DOI 10.1128/MCB.13.11.7000; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WHITE MF, 1994, J BIOL CHEM, V269, P1; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	80	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9028	9037		10.1074/jbc.M009386200	http://dx.doi.org/10.1074/jbc.M009386200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11113140	hybrid			2022-12-25	WOS:000167607700056
J	Le Du, MH; Stigbrand, T; Taussig, MJ; Menez, A; Stura, EA				Le Du, MH; Stigbrand, T; Taussig, MJ; Menez, A; Stura, EA			Crystal structure of alkaline phosphatase from human placenta at 1.8 A resolution - Implication for a substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; UNCOMPETITIVE INHIBITION; PROTEIN; BINDING; MECHANISM; INTERNALIZATION; EXPRESSION; SITE	Human placental alkaline phosphatase (PLAP) is one of three tissue-specific human APs extensively studied because of its ectopic expression in tumors. The crystal structure, determined at 1.8-Angstrom resolution, reveals that during evolution, only the overall features of the enzyme have been conserved with respect to Escherichia coli. The surface is deeply mutated with 8% residues in common, and in the active site, only residues strictly necessary to perform the catalysis have been preserved. Additional structural elements aid an understanding of the allosteric property that is specific for the mammalian enzyme (Hoylaerts, M. F., Manes, T., and Millan, J. L. (1997) J. Biol. Chem. 272, 22781-22787). Allostery is probably favored by the quality of the dimer interface, by a long N-terminal alpha -helix from one monomer that embraces the other one, and similarly by the exchange of a residue from one monomer in the active site of the other. In the neighborhood of the catalytic serine, the orientation of Glu-429, a residue unique to PLAP, and the presence of a hydrophobic pocket close to the phosphate product, account for the specific uncompetitive inhibition of PLAP by L-amino acids, consistent with the acquisition of substrate specificity. The location of the active site at the bottom of a large valley flanked by an interfacial crown-shaped domain and a domain containing an extra metal ion on the other side suggest that the substrate of PLAP could be a specific phosphorylated protein.	Ctr Etud Saclay, CEA, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Umea Univ, Dept Immunol, S-90187 Umea, Sweden; Babraham Inst, Lab Mol Recognit, Cambridge CB2 4AT, England	CEA; UDICE-French Research Universities; Universite Paris Saclay; Umea University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Le Du, MH (corresponding author), Ctr Etud Saclay, CEA, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.	mhledu@cea.fr; estura@cea.fr	Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118				BOSSI M, 1993, J BIOL CHEM, V268, P25409; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Butikofer P, 1999, J CELL SCI, V112, P1785; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CHAN JRA, 1986, J BIOL CHEM, V261, P7635; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; Dabare AANPM, 1999, UROL INT, V63, P168, DOI 10.1159/000030441; Fishman W. H., 1968, CANCER RES, V36, P935; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOLMGREN PA, 1979, OBSTET GYNECOL, V54, P631; HOYLAERTS MF, 1992, BIOCHEM J, V286, P23, DOI 10.1042/bj2860023; Hoylaerts MF, 1997, J BIOL CHEM, V272, P22781, DOI 10.1074/jbc.272.36.22781; HOYLAERTS MF, 1991, EUR J BIOCHEM, V202, P605, DOI 10.1111/j.1432-1033.1991.tb16414.x; HUMMER C, 1991, BIOCHEM J, V274, P91, DOI 10.1042/bj2740091; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MAKIYA R, 1992, BIOCHEM BIOPH RES CO, V182, P624, DOI 10.1016/0006-291X(92)91778-O; MAKIYA R, 1992, EUR J BIOCHEM, V205, P341, DOI 10.1111/j.1432-1033.1992.tb16785.x; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MILLAN JL, 1995, CRIT REV CL LAB SCI, V32, P1, DOI 10.3109/10408369509084680; MILLAN JL, 1992, CLIN CHIM ACTA, V209, P123, DOI 10.1016/0009-8981(92)90343-O; MILLAN JL, 1988, ANTICANCER RES, V8, P995; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; She QB, 2000, FEBS LETT, V469, P163, DOI 10.1016/S0014-5793(00)01273-4; Stefaner I, 1997, BIOCHEM J, V327, P585, DOI 10.1042/bj3270585; STURA EA, 1999, SEEDING TECHNIQUES C, P177; TELFER JF, 1993, FEBS LETT, V329, P238, DOI 10.1016/0014-5793(93)80229-N; WATANABE T, 1991, J BIOL CHEM, V266, P21174; WU LNY, 1991, J BIOL CHEM, V266, P1195	36	216	234	2	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9158	9165		10.1074/jbc.M009250200	http://dx.doi.org/10.1074/jbc.M009250200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124260	hybrid			2022-12-25	WOS:000167607700073
J	Sinha, D; Wyatt, MK; Sarra, R; Jaworski, C; Slingsby, C; Thaung, C; Pannell, L; Robison, WG; Favor, J; Lyon, M; Wistow, G				Sinha, D; Wyatt, MK; Sarra, R; Jaworski, C; Slingsby, C; Thaung, C; Pannell, L; Robison, WG; Favor, J; Lyon, M; Wistow, G			A temperature-sensitive mutation of Crygs in the murine Opj cataract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CRYSTALLIN SUPERFAMILY; EYE LENS; DOMINANT CATARACT; S-CRYSTALLIN; DELETION MUTATION; ALPHA-CRYSTALLIN; JUVENILE-ONSET; BETA-S; GENE; MOUSE	In Opj, an inherited cataract in mice, opacity is associated with a mutation in Crygs, the gene for gammaS-crystallin, the first mutation to be associated with this gene. A single base change causes replacement of Phe-9, a key hydrophobic residue in the core of the N-terminal domain, by serine. Despite this highly non-conservative change, mutant protein folds normally at low temperature. However, it exhibits a marked, concentration-dependent decrease in solubility, associated with loss of secondary structure, at close to physiological temperatures. This is reminiscent of processes thought to occur in human senile cataracts in which normal proteins become altered and aggregate. The Opj cataract is progressive and more severe in Opj/Opj than in Opj/+. Lens histology shows that whereas fiber cell morphology in Opj/+ mice is essentially normal, in Opj/Opj, cortical fiber cell morphology and the loss of maturing fiber cell nuclei are both severely disrupted from early stages. This may indicate a loss of function of gammaS-crystallin which would be consistent with ideas that members of the beta gamma -crystallin superfamily may have roles associated with maintenance of cytoarchitecture.	NEI, Sect Mol Struct & Funct, NIH, Bethesda, MD 20892 USA; NIDDK, NIH, Bethesda, MD 20892 USA; Birkbeck Coll, Dept Crystallog, London, England; MRC, Didcot OX11 0RD, Oxon, England; MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; GSF, Natl Res Ctr Environm & Hlth, Inst Mammalian Genet, D-85764 Neuherberg, Germany	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of London; Birkbeck University London; MRC Harwell; University of Edinburgh; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Wistow, G (corresponding author), NEI, Sect Mol Struct & Funct, NIH, Bldg 6,Rm 331, Bethesda, MD 20892 USA.		Thaung, Caroline/C-2180-2008	Thaung, Caroline/0000-0002-8318-046X	NATIONAL EYE INSTITUTE [ZIAEY000255, Z01EY000149, Z01EY000255] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Benedek GB, 1997, INVEST OPHTH VIS SCI, V38, P1911; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; Berry V, 2000, NAT GENET, V25, P15, DOI 10.1038/75538; BLOEMENDAL H, 1991, INVEST OPHTH VIS SCI, V32, P445; Bron AJ, 2000, OPHTHALMOLOGICA, V214, P86, DOI 10.1159/000027475; CARTIER M, 1992, NAT GENET, V2, P42, DOI 10.1038/ng0992-42; CHAMBERS C, 1991, J BIOL CHEM, V266, P6742; Chang B, 1999, Mol Vis, V5, P21; Clout NJ, 1997, NAT STRUCT BIOL, V4, P685, DOI 10.1038/nsb0997-685; Conley YP, 2000, AM J HUM GENET, V66, P1426, DOI 10.1086/302871; Counis MF, 1998, CELL DEATH DIFFER, V5, P251, DOI 10.1038/sj.cdd.4400351; Das KP, 1999, J BIOL CHEM, V274, P33209, DOI 10.1074/jbc.274.47.33209; DEJONG WW, 1981, CELLULAR BIOL EYE LE, P221; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; ESHAGIAN J, 1982, T OPHTHAL SOC UK, V102, P364; EVERETT CA, 1994, GENOMICS, V20, P429, DOI 10.1006/geno.1994.1197; FAVOR J, 1983, MUTAT RES, V110, P367, DOI 10.1016/0027-5107(83)90153-7; FAVOR J, 1984, GENET RES, V44, P183, DOI 10.1017/S0016672300026380; GAO CY, 1995, DEV BIOL, V169, P185, DOI 10.1006/dbio.1995.1136; Graw J, 1999, GENOMICS, V62, P67, DOI 10.1006/geno.1999.5974; Harding J J, 1998, Curr Opin Ophthalmol, V9, P10, DOI 10.1097/00055735-199802000-00003; Harding JJ, 1984, EYE B, V1b, P207; Hejtmancik JF, 1998, AM J HUM GENET, V62, P520, DOI 10.1086/301774; Heon E, 1999, AM J HUM GENET, V65, P1261, DOI 10.1086/302619; HOGAN B, 1986, MANIPULATING MOUSE E; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Jakobs PM, 2000, AM J HUM GENET, V66, P1432, DOI 10.1086/302872; Jaworski C, 1996, BIOCHEM J, V320, P49, DOI 10.1042/bj3200049; Kannabiran C, 1998, Mol Vis, V4, P21; Kerscher S, 1996, GENOMICS, V36, P17, DOI 10.1006/geno.1996.0420; Klopp N, 1998, GENOMICS, V52, P152, DOI 10.1006/geno.1998.5417; Kmoch S, 2000, HUM MOL GENET, V9, P1779, DOI 10.1093/hmg/9.12.1779; QUAXJEUKEN Y, 1985, EMBO J, V4, P2597, DOI 10.1002/j.1460-2075.1985.tb03976.x; Ray ME, 1997, P NATL ACAD SCI USA, V94, P3229, DOI 10.1073/pnas.94.7.3229; Ren ZX, 2000, HUM GENET, V106, P531, DOI 10.1007/s004390050021; ROBISON WG, 1986, DIABETES, V35, P295, DOI 10.2337/diabetes.35.3.295; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; Sinha D, 1998, Mol Vis, V4, P8; Slingsby C, 1999, EYE, V13, P395, DOI 10.1038/eye.1999.113; Smith RS, 2000, GENOMICS, V63, P314, DOI 10.1006/geno.1999.6054; Stephan DA, 1999, P NATL ACAD SCI USA, V96, P1008, DOI 10.1073/pnas.96.3.1008; Takemoto L, 2000, MOL VIS, V6, P164; Teichmann U, 1998, MAMM GENOME, V9, P715, DOI 10.1007/s003359900852; VANRENS GLM, 1989, GENE, V78, P225, DOI 10.1016/0378-1119(89)90225-4; VRENSEN GFJM, 1995, COMP BIOCHEM PHYS A, V111, P519, DOI 10.1016/0300-9629(95)00053-A; WALLACE BA, 1987, BIOCHEMISTRY-US, V26, P65, DOI 10.1021/bi00375a010; Wetzel R, 1996, CELL, V86, P699, DOI 10.1016/S0092-8674(00)80143-9; Wistow G, 2000, MOL VIS, V6, P79; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0; WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; Wistow G, 1995, MOL BIOL EVOLUTION C; YOSHIKI A, 1991, DEVELOPMENT, V113, P1293	53	48	50	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9308	9315		10.1074/jbc.M010583200	http://dx.doi.org/10.1074/jbc.M010583200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121426	hybrid			2022-12-25	WOS:000167607700092
J	Skowyra, D; Zeremski, M; Neznanov, N; Li, MY; Choi, YM; Uesugi, M; Hauser, CA; Gu, W; Gudkov, AV; Qin, J				Skowyra, D; Zeremski, M; Neznanov, N; Li, MY; Choi, YM; Uesugi, M; Hauser, CA; Gu, W; Gudkov, AV; Qin, J			Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDAC1 transcriptional corepressor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMAS; HISTONE DEACETYLASE; RETINOBLASTOMA PROTEIN; REPRESSOR SIN3; PHD FINGER; YEAST; GENE; TRANSFORMATION; COMPONENTS; CHROMATIN	The candidate tumor suppressor ING1 was identified in a genetic screen aimed at isolation of human genes whose expression is suppressed in cancer cells. It may function as a negative growth regulator in the p53 signal transduction pathway. However, its molecular mechanism is not clear. The ING1 locus encodes alternative transcripts of p47(ING1a), P33(ING1b) and p24(ING1c). Here we report differential association of protein products of ING1 with the mSin3 transcriptional corepressor complex. p33(ING1b) associates with Sin3, SAP30, HDAC1, RbAp48, and other proteins, to form large protein complexes, whereas p24(ING1c) does not. The ING1 immune complexes are active in deacetylating core histones in vitro, and p33(ING1b) is functionally associated with HDAC-1-mediated transcriptional repression in transfected cells, Our data provide basis for a p33(ING1b)-specific molecular mechanism for the function of the ING1 locus.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Burnham Inst, La Jolla, CA 92037 USA	Baylor College of Medicine; Baylor College of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Columbia University; Columbia University; Sanford Burnham Prebys Medical Discovery Institute	Qin, J (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.			Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R01CA085533, R01CA075179, R01CA060730] Funding Source: NIH RePORTER; NCI NIH HHS [CA85533, CA75179, CA60730] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GALANG CK, 1994, ONCOGENE, V9, P2913; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Garkavtsev I, 1999, NAT GENET, V23, P373, DOI 10.1038/15566; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Gunduz M, 2000, CANCER RES, V60, P3143; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Maestro R, 1996, CANCER RES, V56, P1146; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Saito A, 2000, J HUM GENET, V45, P177, DOI 10.1007/s100380050206; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	30	121	126	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8734	8739		10.1074/jbc.M007664200	http://dx.doi.org/10.1074/jbc.M007664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11118440	hybrid			2022-12-25	WOS:000167607700017
J	Strobeck, MW; DeCristofaro, MF; Banine, F; Weissman, BE; Sherman, LS; Knudsen, ES				Strobeck, MW; DeCristofaro, MF; Banine, F; Weissman, BE; Sherman, LS; Knudsen, ES			The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; SWI-SNF COMPLEX; METASTATIC BEHAVIOR; CARCINOMA-CELLS; PROSTATE-CANCER; BREAST-CANCER; S-PHASE; PROTEIN; REQUIRES; VARIANT	Aberrant regulation of CD44, a transmembrane glycoprotein, has been implicated in the growth and metastasis of numerous tumors. Although both CD44 overexpression and loss have been implicated in tumor progression, the mechanism of CD44 down-regulation in these tumor types is not known. By immunoblot and reverse transcription-polymerase chain reaction analysis we determined that a cervical carcinoma cell line, C33A, lacks CD44 expression. To determine how CD44 is down-regulated in C33A cells, we utilized cell fusions of C33A cells with a CD44-expressing cell line (SAOS-2). We found that SAOS-2 fusion restored CD44 expression in C33A cells, suggesting that a trans-acting factor present in SAOS-2 cells promotes CD44 production. C33A cells are BRG-1-deficient, and we found that CD44 was absent in another BRG-1-deficient tumor cell line, indicating that loss of BRG-1 may be a general mechanism by which cells lose CD44, Reintroduction of BRG-1 into these cells restored CD44 expression. Furthermore, disruption of BRG-1 function through the use of dominant negative BRG-1 demonstrated the requirement of BRG-1 in CD44 regulation. Finally, we show that Cyclin E overexpression resulted in the attenuation of CD44 stimulation, which is consistent with previous observations that Cyclin E can abrogate BRG-1 action. Taken together, these results suggest that BRG-1 is a critical regulator of CD44 expression, thus implicating SWI/SNF components in the regulation of cellular adhesion and metastasis.	Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University System of Ohio; University of Cincinnati; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Strobeck, MW (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.				NATIONAL CANCER INSTITUTE [R01CA082525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039550] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82525] Funding Source: Medline; NIDCR NIH HHS [DE 12355] Funding Source: Medline; NINDS NIH HHS [NS 39550] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; Goodison Steve, 1998, Frontiers in Bioscience, V3, pE89; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Herrlich P, 2000, ANN NY ACAD SCI, V910, P106; Herrlich P, 2000, ANN NY ACAD SCI, V910, P118; HOFMANN M, 1993, CANCER RES, V53, P1516; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; JAMAL HH, 1994, ONCOGENE, V9, P417; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Kallakury BVS, 1996, CANCER, V78, P1461, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1461::AID-CNCR13>3.0.CO;2-Y; Karjalainen JM, 2000, AM J PATHOL, V157, P957, DOI 10.1016/S0002-9440(10)64608-1; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Kohlberger PD, 1997, GYNECOL ONCOL, V66, P227, DOI 10.1006/gyno.1997.4748; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Ladeda V, 1998, EXP CELL RES, V242, P515, DOI 10.1006/excr.1998.4094; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LI H, 1995, BRIT J CANCER, V72, P160, DOI 10.1038/bjc.1995.294; Lou W, 1999, CANCER RES, V59, P2329; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; NAOT D, 1997, ADV CANCER RES, V71, P241; Nupponen NN, 1998, CANCER GENET CYTOGEN, V101, P53, DOI 10.1016/S0165-4608(97)00060-5; RUDY W, 1993, CANCER RES, V53, P1262; Saegusa M, 1999, J PATHOL, V187, P173; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Sherman L, 1996, CURR TOP MICROBIOL, V213, P249; Sherr CJ, 2000, CANCER RES, V60, P3689; Sleeman JP, 1996, CANCER RES, V56, P3134; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	47	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9273	9278		10.1074/jbc.M009747200	http://dx.doi.org/10.1074/jbc.M009747200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11108719	hybrid, Green Published			2022-12-25	WOS:000167607700087
J	VanderVeen, LA; Hashim, MF; Nechev, LV; Harris, TM; Harris, CM; Marnett, LJ				VanderVeen, LA; Hashim, MF; Nechev, LV; Harris, TM; Harris, CM; Marnett, LJ			Evaluation of the mutagenic potential of the principal DNA adduct of acrolein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; 1,N-2-PROPANODEOXYGUANOSINE ADDUCTS; FRAMESHIFT MUTAGENESIS; DEOXYGUANOSINE ADDUCTS; IN-VITRO; PROPANODEOXYGUANOSINE; REPLICATION; INDUCTION; CARCINOGENESIS	Acrolein is produced extensively in the environment by incomplete combustion of organic materials, and it arises endogenously in humans as a metabolic by-product. Acrolein reacts with DNA at guanine residues to form the exocyclic adduct, 8-hydroxypropanodeoxyguanosine (HOPdG). Acrolein is mutagenic,and a correlation exists between HOPdG levels in Salmonella typhimurium treated with acrolein and a resultant increase in mutation frequency. Site-specifically modified oligonucleotides were used to explore the mutagenic potential of HOPdG in Escherichia coli strains that mere either wild-type for repair or deficient in nucleotide excision repair or base excision repair. Oligonucleotides modified with HOPdG were inserted into double-stranded bacteriophage vectors using the gapped-duplex method or into single-stranded bacteriophage vectors and transformed into SOS-induced E. coli strains. Progeny phage were analyzed by oligonucleotide hybridization to establish the mutation frequency and the spectrum of mutations produced by HOPdG. The correct base, dCMP, was incorporated opposite HOPdG in all circumstances tested. In contrast, in vitro lesion bypass studies showed that HOPdG causes misincorporation opposite the modified base and is a block to replication. The combination of these studies showed that HOPdG is not miscoding in vivo at the level of sensitivity of these site-specific mutagenesis assays.	Vanderbilt Univ, Sch Med,Vanderbilt Ingram Canc Ctr, Dept Biochem,Ctr Mol Toxicol, AB Hancock Jr Mem Lab Canc Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med,Vanderbilt Ingram Canc Ctr, Dept Chem,Ctr Mol Toxicol, AB Hancock Jr Mem Lab Canc Res, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med,Vanderbilt Ingram Canc Ctr, Dept Biochem,Ctr Mol Toxicol, AB Hancock Jr Mem Lab Canc Res, 23rd Ave & Pierce, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R37CA087819, R35CA047479, R01CA087819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007781] Funding Source: NIH RePORTER; NCI NIH HHS [CA87819, CA47479] Funding Source: Medline; NIEHS NIH HHS [ES07781] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BEAUCHAMP RO, 1985, CRC CR REV TOXICOL, V14, P309, DOI 10.3109/10408448509037461; BENAMIRA M, 1993, CHEM RES TOXICOL, V6, P317, DOI 10.1021/tx00033a011; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BROCK N, 1979, ARZNEIMITTEL-FORSCH, V29-1, P659; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; CARSON BL, 1981, GOV REP ANNOUNCE, V12; CHUNG FL, 1988, J ORG CHEM, V53, P14, DOI 10.1021/jo00236a004; Chung FL, 1999, MUTAT RES-FUND MOL M, V424, P71, DOI 10.1016/S0027-5107(99)00009-3; CHUNG FL, 1984, CANCER RES, V44, P990; COHEN SM, 1992, CANCER RES, V52, P3577; de los Santos C, 2001, J BIOL CHEM, V276, P9077, DOI 10.1074/jbc.M009028200; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; Fink SP, 1996, CHEM RES TOXICOL, V9, P277, DOI 10.1021/tx950060w; FOILES PG, 1989, CARCINOGENESIS, V10, P87, DOI 10.1093/carcin/10.1.87; Hashim MF, 1996, J BIOL CHEM, V271, P9160, DOI 10.1074/jbc.271.15.9160; Khullar S, 1999, J MED CHEM, V42, P947, DOI 10.1021/jm980605u; Langouet S, 1998, BIOCHEMISTRY-US, V37, P5184, DOI 10.1021/bi972327r; MARNETT LJ, 1985, MUTAT RES, V148, P25; Marnett LJ, 1988, AIR POLLUTION AUTOMO, P579; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nechev LV, 2000, CHEM RES TOXICOL, V13, P421, DOI 10.1021/tx990167+; Sambrook J, 1989, MOL CLONING LABORATO; Singer B., 1999, EXOCYCLIC DNA ADDUCT; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Wang MY, 2000, CHEM RES TOXICOL, V13, P1065, DOI 10.1021/tx000095i; Yang IY, 2001, J BIOL CHEM, V276, P9071, DOI 10.1074/jbc.M008918200	28	88	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9066	9070		10.1074/jbc.M008900200	http://dx.doi.org/10.1074/jbc.M008900200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11106660	hybrid			2022-12-25	WOS:000167607700061
J	Li, SH; Liu, XB; Min, L; Ascoli, M				Li, SH; Liu, XB; Min, L; Ascoli, M			Mutations of the second extracellular loop of the human lutropin receptor emphasize the importance of receptor activation and die-emphasize the importance of receptor phosphorylation in agonist-induced internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; HUMAN CHORIONIC-GONADOTROPIN; LEYDIG TUMOR-CELLS; IMPAIR SIGNAL-TRANSDUCTION; C-TERMINAL TAIL; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; LUTEINIZING-HORMONE; BETA-ARRESTIN	Alanine scanning mutagenesis of the second extracellular loop of the human lutropin receptor (hLHR) showed that mutation of most of the residues present in this region either enhance or impair the internalization of agonist, A more complete analysis of four mutants, two that enhanced internalization (F515A and T521A) and two that impaired internalization (S512A and V519A), showed that the two mutants that impaired internalization also show a decrease in the sensitivity for agonist-induced cAMP accumulation, whereas the two mutants that enhanced internalization show an increase in the sensitivity for agonist-induced cAMP accumulation. None of these mutants had an effect on the agonist-induced phosphorylation of the hLHR, however. We conclude that, in contrast to the prevailing view of the relative importance of receptor phosphorylation in the internalization of G protein-coupled receptors, the phosphorylation of the hLHR is less important than the agonist-induced activation of the hLHR in the process of internalization.	Univ Iowa, Dept Pharmacol, Coll Med, Iowa City, IA 52242 USA	University of Iowa	Ascoli, M (corresponding author), Univ Iowa, Dept Pharmacol, Coll Med, 2-319B BSB,51 Newton Rd, Iowa City, IA 52242 USA.	mario-ascoli@uiowa.edu			NCI NIH HHS [CA-40629] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1987, ENDOCRINOLOGY, V120, P1161, DOI 10.1210/endo-120-3-1161; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bradbury FA, 1999, BIOCHEMISTRY-US, V38, P8703, DOI 10.1021/bi990169t; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Dhanwada KR, 1996, MOL ENDOCRINOL, V10, P544, DOI 10.1210/me.10.5.544; Fabritz J, 1998, BIOCHEMISTRY-US, V37, P664, DOI 10.1021/bi972355+; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HOELSCHER SR, 1991, ENDOCRINOLOGY, V128, P2837, DOI 10.1210/endo-128-6-2837; Hsu SY, 2000, MOL ENDOCRINOL, V14, P594, DOI 10.1210/me.14.5.594; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kishi M, 2000, MOL ENDOCRINOL, V14, P926, DOI 10.1210/me.14.6.926; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LLOYD CE, 1983, J CELL BIOL, V96, P521, DOI 10.1083/jcb.96.2.521; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Martens JWM, 1998, MOL ENDOCRINOL, V12, P775, DOI 10.1210/me.12.6.775; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Min KS, 1998, J BIOL CHEM, V273, P34911, DOI 10.1074/jbc.273.52.34911; Min L, 2000, MOL ENDOCRINOL, V14, P1797, DOI 10.1210/me.14.11.1797; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; Nakamura K, 1999, J BIOL CHEM, V274, P25426, DOI 10.1074/jbc.274.36.25426; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nakamura K, 1999, MOL ENDOCRINOL, V13, P1295, DOI 10.1210/me.13.8.1295; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	50	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7968	7973		10.1074/jbc.M010482200	http://dx.doi.org/10.1074/jbc.M010482200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11118455	hybrid			2022-12-25	WOS:000167474900043
J	Mishra, A; Weaver, TE; Beck, DC; Rothenberg, ME				Mishra, A; Weaver, TE; Beck, DC; Rothenberg, ME			Interleukin-5-mediated allergic airway inflammation inhibits the human surfactant protein C promoter in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; ASPERGILLUS-FUMIGATUS; MURINE MODEL; EOSINOPHIL; EOTAXIN; DYSFUNCTION; EXPRESSION; BINDING; CELLS; PHAGOCYTOSIS	Allergen challenge in the lung of humans and animals is associated with surfactant dysfunction, but the mechanism of this effect has not been established. By using a murine model of asthma we now report the effect of allergen-induced airway inflammation on the expression of transgenes regulated by the human surfactant protein (hSP)-C promoter. The hSP-C 3.7-kilobase pair promoter was used to direct the expression of eotaxin, an eosinophil-selective chemokine, into the lungs of several transgenic lines. As expected, the transgenic mice expressed increased amounts of eotaxin mRNA and protein compared with wild-type mice. Surprisingly, following allergen challenge, there was a marked down-regulation of transgene mRNA in three independent transgenic lines. The down-regulation was in contrast to other related proteins such as endogenous eotaxin and surfactant protein D levels, which were both increased following allergen challenge. Consistent with specific down-regulation of the eotaxin transgene, there was no increase in pulmonary eosinophil levels in the transgenic mice above that found in wild-type mice. Analysis of hSP-C transgenic mice with distinct reporter genes and S'-untranslated regions revealed that allergen challenge was directly affecting the hSP-C promoter. We hypothesized that allergen induced down-regulation of the hSP-C promoter was related to the eosinophilic inflammation. To test this, we blocked eosinophilic inflammation in the lungs by treating mice with neutralizing antiserum against interleukin-5, interestingly, this treatment also blocked allergen-induced inhibition of the hSP-C promoter. These results establish that allergic airway inflammation is associated with up-regulation of the surfactant proteins primarily involved in immunity, whereas down-regulation of the surfactant protein primarily involved in maintaining airway patency. Furthermore, the marked down-regulation of the hSP-C promoter is interleukin-5-dependent, implying a critical role for eosinophilic inflammation. These results suggest that alterations in surfactant protein levels may contribute to immune and airway dysfunction in asthma.	Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Rothenberg, ME (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA.	Rothenberg@chmcc.org	MISHRA, ANIL/S-7983-2017	MISHRA, ANIL/0000-0003-4266-4684	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042242] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI42242] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen MJ, 1999, INFECT IMMUN, V67, P4563, DOI 10.1128/IAI.67.9.4563-4569.1999; BACHURSKI CJ, 1995, J BIOL CHEM, V270, P19402, DOI 10.1074/jbc.270.33.19402; Beck DC, 2000, J BIOL CHEM, V275, P3371, DOI 10.1074/jbc.275.5.3371; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Elhalwagi BM, 1999, AM J RESP CELL MOL, V21, P380, DOI 10.1165/ajrcmb.21.3.3676; GLASSER SW, 1994, AM J PHYSIOL-LUNG C, V267, pL489, DOI 10.1152/ajplung.1994.267.5.L489; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Heeley EL, 2000, AM J PHYSIOL-LUNG C, V278, pL305, DOI 10.1152/ajplung.2000.278.2.L305; Hohlfeld JM, 1999, AM J RESP CRIT CARE, V159, P1803, DOI 10.1164/ajrccm.159.6.9806145; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Jarjour NN, 1999, AM J RESP CRIT CARE, V160, P336, DOI 10.1164/ajrccm.160.1.9806155; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kita H, 1996, J ALLERGY CLIN IMMUN, V97, P889, DOI 10.1016/S0091-6749(96)80061-3; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KURUP VP, 1994, J LEUKOCYTE BIOL, V56, P593, DOI 10.1002/jlb.56.5.593; KURUP VP, 1992, J IMMUNOL, V148, P3783; KURUP VP, 1994, J ALLERGY CLIN IMMUN, V93, P1013, DOI 10.1016/S0091-6749(94)70050-8; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279, DOI 10.1165/ajrcmb.20.2.3303; Lin S, 1999, J BIOL CHEM, V274, P19168, DOI 10.1074/jbc.274.27.19168; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; Liu M, 1996, CLIN EXP ALLERGY, V26, P270; Liu M, 1997, CLIN EXP ALLERGY, V27, P802, DOI 10.1111/j.1365-2222.1997.tb01215.x; Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620, DOI 10.1002/jlb.62.5.620; Madan T, 1997, CLIN EXP IMMUNOL, V110, P241; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; Mason RJ, 1998, AM J PHYSIOL-LUNG C, V275, pL1, DOI 10.1152/ajplung.1998.275.1.L1; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Ross GF, 1999, AM J PHYSIOL-LUNG C, V277, pL1104, DOI 10.1152/ajplung.1999.277.6.L1104; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; RUTLEDGE BJ, 1995, J IMMUNOL, V155, P4838; Weaver TE, 1999, BIOL NEONATE, V76, P15, DOI 10.1159/000047041; WHITSETT JA, 1992, NAT GENET, V2, P13, DOI 10.1038/ng0992-13; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255	44	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8453	8459		10.1074/jbc.M009481200	http://dx.doi.org/10.1074/jbc.M009481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113143	hybrid			2022-12-25	WOS:000167474900105
J	Denson, DD; Wang, XP; Worrell, RT; AlKhalili, O; Eaton, DC				Denson, DD; Wang, XP; Worrell, RT; AlKhalili, O; Eaton, DC			Cytosolic phospholipase A(2) is required for optimal ATP activation of BK channels in GH(3) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; DEPENDENT POTASSIUM CHANNEL; PROTEIN-KINASE; ION CHANNELS; RAT-BRAIN; CALCIUM; PHOSPHORYLATION; MACROPHAGES; MODULATION; DEPHOSPHORYLATION	To test the hypothesis that ATP activation of BK channels in GH(3) cells involves cytosolic phospholipase A(2) (cPLA(2)) as a potential protein target for phosphorylation, we first inhibited the activity of cPLA(2) by both pharmacologic and molecular biologic approaches. Both approaches resulted in a decrease rather than an increase in BK channel activity by ATP, suggesting that in the absence of cPLA(2), phosphorylation of other regulatory, elements, possibly the BK channel protein itself, results in inactivation rather than activation of the channel. The absence of changes in activity in the presence of the non-substrate ATP analog 5'-adenylyl-beta,gamma -imidodiphosphate verified that ATP hydrolysis was required for channel activation by ATP, Experiments with an activator and inhibitor of protein kinase C (PKC) support the hypothesis that PKC can be involved in the activation of BK channels by ATP; and in the absence of PKC, other kinases appear to phosphorylate additional elements in the regulatory pathway that reduce channel activity, Our data point to cPLA(2)-alpha (but not cPLA(2)-gamma) as one target protein for phosphorylation that is intimately associated with the BK channel protein.	Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Cellular & Mol Signaling, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Denson, DD (corresponding author), 3B S Emory Univ Hosp, Sch Med, Dept Anesthesiol, 1364 Clifton Rd, Atlanta, GA 30322 USA.			Eaton, Douglas/0000-0002-2686-6692	NIDDK NIH HHS [DK37963] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037963, R37DK037963] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Armstrong D L, 1999, Adv Second Messenger Phosphoprotein Res, V33, pix; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; DEKIN MS, 1987, J NEUROPHYSIOL, V58, P215, DOI 10.1152/jn.1987.58.1.215; DENSEN DD, 1994, BRAIN RES, V638, P61, DOI 10.1016/0006-8993(94)90633-5; Denson DD, 1996, AM J PHYSIOL-CELL PH, V270, pC636, DOI 10.1152/ajpcell.1996.270.2.C636; Denson DD, 1999, AM J PHYSIOL-CELL PH, V276, pC201, DOI 10.1152/ajpcell.1999.276.1.C201; ESGUERRA M, 1994, NATURE, V369, P563, DOI 10.1038/369563a0; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 2000, ADV ENZYME REGUL, V40, P255, DOI 10.1016/S0065-2571(99)00031-X; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GOLOMB D, 1994, J NEUROPHYSIOL, V72, P1109, DOI 10.1152/jn.1994.72.3.1109; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Osterhout JL, 2000, J BIOL CHEM, V275, P8248, DOI 10.1074/jbc.275.11.8248; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Ramanadham S, 1996, BIOCHEMISTRY-US, V35, P5464, DOI 10.1021/bi952652j; Ramanadham S, 1997, BBA-LIPID LIPID MET, V1344, P153, DOI 10.1016/S0005-2760(96)00139-7; REINHART PH, 1991, J NEUROSCI, V11, P1627; REINHART PH, 1995, J NEUROSCI, V15, P4572; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Shipston MJ, 1996, J PHYSIOL-LONDON, V493, P665, DOI 10.1113/jphysiol.1996.sp021413; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; WANG J, 1999, J NEUROSCI, V19, P1; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0	33	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7136	7142		10.1074/jbc.M009566200	http://dx.doi.org/10.1074/jbc.M009566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113145	hybrid			2022-12-25	WOS:000167442900040
J	Lupu-Meiri, M; Silver, RB; Simons, AH; Gershengorn, MC; Oron, Y				Lupu-Meiri, M; Silver, RB; Simons, AH; Gershengorn, MC; Oron, Y			Constitutive signaling by Kaposi's sarcoma-associated herpesvirus G-protein-couple receptor desensitizes calcium mobilization by other receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; XENOPUS-OOCYTES; RESPONSES; ONCOGENE; EFFLUX; CELLS	We coexpressed Kaposi's sarcoma-associated herpesvirus G protein-coupled receptors (KSHV-GPCRs) with thyrotropin-releasing hormone (TRH) receptors or mlmuscarinic-cholinergic receptors in Xenopus oocytes and in mammalian cells. In oocytes, KSHV-GPCR expression resulted in pronounced (81%) inhibition (heterologous desensitization) of Ca2+-activated chloride current responses to TRH and acetylcholine, Similar inhibitions of cytoplasmic free Ca2+ responses to TRH were observed in human embryonic kidney HEK 293 EM cells and in mouse pituitary AtT20 cells. Further study of oocytes showed that this inhibition was partially reversed by interferon-gamma -inducible protein 10 (IP-10), an inverse agonist of KSHV-GPCR, The basal rate of Ca-45(2+) efflux; in oocytes expressing KSHV-GPCRs was 4.4 times greater than in control oocytes, and IP-10 rapidly inhibited increased Ca-45(2+) efflux, In the absence of IP-10, growth-related oncogene alpha caused a further 2-fold increase in Ca-45(2+) efflux, In KSHV-GPCR-expressing oocytes,: responses to microinjected inositol 1,4,5-trisphosphate were inhibited by 74%, and this effect was partially reversed by interferon-gamma -inducible protein 10, Treatment with thapsigargin suggested that the pool of calcium available for mobilization by TRH was decreased in oocytes coexpressing KSHV-GPCRs, These results suggest that constitutive signaling by KSHV-GPCR causes heterologous desensitization of responses mediated by other receptors, which signal via the phosphoinositide/calcium pathway, which is caused by depletion of intracellular calcium pools.	Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel; Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Div Mol Med, New York, NY 10021 USA	Tel Aviv University; Sackler Faculty of Medicine; Cornell University; Cornell University	Oron, Y (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel.							ARVANITAKIS L, 1997, NATURE, V385, P37; Asher O, 1998, FEBS LETT, V431, P411, DOI 10.1016/S0014-5793(98)00805-9; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Cardone MH, 1996, J CELL BIOL, V133, P997, DOI 10.1083/jcb.133.5.997; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, J EXP MED, V187, P801, DOI 10.1084/jem.187.5.801; Grimberg H, 1999, BRIT J PHARMACOL, V126, P1097, DOI 10.1038/sj.bjp.0702415; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIRFLINK M, 1995, MOL ENDOCRINOL, V9, P1455; LUPUMEIRI M, 1990, PFLUG ARCH EUR J PHY, V417, P391, DOI 10.1007/BF00370658; LUPUMEIRI M, 1993, CELL CALCIUM, V14, P101, DOI 10.1016/0143-4160(93)90080-P; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; O'Dowd BF, 2000, MOL ENDOCRINOL, V14, P183, DOI 10.1210/me.14.1.183; ORON Y, 1987, MOL ENDOCRINOL, V1, P918, DOI 10.1210/mend-1-12-918; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; SHAPIRA H, 1990, BIOPHYS J, V57, P1281, DOI 10.1016/S0006-3495(90)82646-1; Shapira H, 1996, CELL CALCIUM, V19, P201, DOI 10.1016/S0143-4160(96)90021-4; Silver RB, 1998, METHOD CELL BIOL, V56, P237, DOI 10.1016/S0091-679X(08)60429-X; SIMONS AH, 2001, IN PRESS GENOME RES, V11; Wang W, 1999, ENDOCRINOLOGY, V140, P4916, DOI 10.1210/en.140.10.4916; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yu R, 1997, J BIOL CHEM, V272, P28301, DOI 10.1074/jbc.272.45.28301	23	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7122	7128		10.1074/jbc.M006359200	http://dx.doi.org/10.1074/jbc.M006359200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11116138	hybrid			2022-12-25	WOS:000167442900038
J	Poncelet, AC; Schnaper, HW				Poncelet, AC; Schnaper, HW			Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-INDUCED TRANSCRIPTION; TGF-BETA; DNA-BINDING; SIGNALING PATHWAY; HUMAN FIBROBLAST; GENE-EXPRESSION; PROMOTER; ACTIVATION; KINASE; RICH	The mechanism(s) by which Smads mediate and modulate the transforming growth factor (TGF)-beta signal transduction pathway in fibrogenesis are not well characterized. We previously showed that Smads promotes alpha2(I) collagen gene (COL1A2) activation in human glomerular mesangial cells, potentially contributing to glomerulosclerosis. Here, we report that Sp1 binding is necessary for TGF-beta1-induced type I collagen mRNA expression. Deletion of three Spl sites (GC box) between -376 and -268 or mutation of a CAGA box at -268/-260 inhibited TGF-beta1-induced alpha2(I) collagen promoter activity. TGF-beta1 inducibility was also blocked by a SmadS dominant negative mutant, Chemical inhibition of Spl binding with mithramycin A, or deletion of the GC boxes, inhibited COLIA2 activation by SmadS, suggesting cooperation between SmadS and Spl in the TGF-beta1 response. Electrophoretic mobility shift assay showed that Spl and Smads form complexes with -283/-250 promoter sequences. Coimmunoprecipitation experiments demonstrate that endogenous Spl, Smad3, and Smad4 form complexes in mesangial cells. In a Gal4-LUC reporter assay system, Spl stimulated the TGF-beta1-induced transcriptional activity of Gal4-Smads, Gal4-Smad4 (266-552), or both. Using the transactivation domain B of Spl fused to the Gal4 DNA binding domain, we show that, in our system, the transcriptional activity of this Spl domain is not regulated by TGF-beta1, but it becomes responsive to this factor when Smad8 is coexpressed. Finally, combined Spl and Smads overexpression induces marked ligand-independent and ligand-dependent promoter activity of COLIA2, Thus, Spl and Smad proteins form complexes and their synergy plays an important role in mediating TGF-beta1-induced alpha2(I) collagen expression in human mesangial cells.	Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60611 USA; Childrens Mem Inst Educ & Res, Chicago, IL 60611 USA	Northwestern University	Poncelet, AC (corresponding author), Northwestern Univ, Sch Med, Dept Pediat, Pediat W-140,303 E Chicago Ave, Chicago, IL 60611 USA.	anne-c@northwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049362] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK049362, R0I DK49362] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BOAST S, 1990, J BIOL CHEM, V265, P13351; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 2000, J INVEST DERMATOL, V114, P1011, DOI 10.1046/j.1523-1747.2000.00956.x; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Parks CL, 1996, J BIOL CHEM, V271, P4417; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Schnaper H. William, 1997, P1003; Schnaper HW, 1996, J CELL SCI, V109, P2521; SCHRODER FH, 1989, PROSTATE, P17; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wang LW, 1998, J BIOL CHEM, V273, P8522, DOI 10.1074/jbc.273.14.8522; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	65	203	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6983	6992		10.1074/jbc.M006442200	http://dx.doi.org/10.1074/jbc.M006442200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11114293	hybrid			2022-12-25	WOS:000167442900018
J	Swarthout, JT; Doggett, TA; Lemker, JL; Partridge, NC				Swarthout, JT; Doggett, TA; Lemker, JL; Partridge, NC			Stimulation of extracellular signal-regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; OSTEOSARCOMA CELLS; COUPLED RECEPTORS; CYCLIC-AMP; TYROSINE KINASE; GROWTH-FACTORS; GENE-PRODUCT; BONE-CELLS; ACTIVATION; PATHWAYS	Parathyroid hormone (PTH) is known to have both catabolic and-anabolic effects on bone. The dual functionality of PTH may stem from its ability to activate two signal transduction mechanisms: adenylate cyclase and phospholipase C. Here, we demonstrate that continuous treatment of UMR 106-01 and primary osteoblasts with PTH peptides, which selectively activate protein kinase C, results in significant increases in DNA synthesis. Given that ERKs are involved in cellular proliferation, we examined the regulation of ERKs in UMR 106-01 and primary rat osteoblasts following PTH treatment. We demonstrate that treatment of osteoblastic cells with very low concentrations of PTH (10(-12) to 10(-11) at) is sufficient for, substantial increases in ERK activity. Treatment with PTH-(1-34) (10(-8) M), PTH-(1-31), or 8-bromo-cAMP failed to stimulate ERKs, whereas treatment;with phorbol 12-myristate 18-acetate, serum, or PTH peptides lacking the N-terminal amino acids stimulated activity. Furthermore, the activation of ERKs was prevented by pretreatment of osteoblastic cells with inhibitors of protein kinase C (GF 109203X) and MEK (PD 98059). Treatment of UMR cells with epidermal growth factor (EGF), but not PTH, promoted tyrosine phosphorylation of the EGF receptor. Transient transfection of UMR cells with p21(N17Ras) did not block activation of ERKs following treatment with low concentrations of PTH, Thus, activation of ERKs and proliferation by PTH is protein kinase C-dependent, but stimulation occurs :independently of the EGF receptor and Ras activation.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; St Louis Univ, Sch Med, Cell & Mol Biol Program, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63104 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Saint Louis University; Saint Louis University; Saint Louis University	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu		Partridge, Nicola/0000-0002-5406-4814; Swarthout, John/0000-0002-3043-9386	NIDDK NIH HHS [R01 DK047420] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047420] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CANALIS E, 1989, J ENDOCRINOL INVEST, V12, P577, DOI 10.1007/BF03350764; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; Cole JA, 1999, ENDOCRINOLOGY, V140, P5771, DOI 10.1210/en.140.12.5771; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; FAURE M, 1994, J BIOL CHEM, V269, P7851; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUJIMORI A, 1991, ENDOCRINOLOGY, V128, P3032, DOI 10.1210/endo-128-6-3032; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; Garcia-Ocana A, 1998, LIFE SCI, V62, P2267, DOI 10.1016/S0024-3205(98)00207-0; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HABENER JF, 1984, PHYSIOL REV, V64, P985, DOI 10.1152/physrev.1984.64.3.985; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; IIDAKLEIN A, 1989, J BONE MINER RES, V4, P767; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; PARTRIDGE NC, 1985, CALCIFIED TISSUE INT, V37, P519, DOI 10.1007/BF02557835; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; PARTRIDGE NC, 1982, ENDOCRINOLOGY, V111, P178, DOI 10.1210/endo-111-1-178; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PFEILSCHIFTER J, 1993, J BONE MINER RES, V8, P707; PUCCINELLI JM, 1991, J CELL PHYSIOL, V147, P505, DOI 10.1002/jcp.1041470317; REID IR, 1988, AM J PHYSIOL, V255, pE9, DOI 10.1152/ajpendo.1988.255.1.E9; REID IR, 1987, AM J PHYSIOL, V252, pE45; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHALHOUB V, 1989, BIOCHEMISTRY-US, V28, P5318, DOI 10.1021/bi00439a002; SIDDHANTI SR, 1995, ENDOCRINOLOGY, V136, P4834, DOI 10.1210/en.136.11.4834; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; YAMAGUCHI DT, 1987, J BIOL CHEM, V262, P7711; YAMAGUCHI DT, 1987, J BIOL CHEM, V262, P14967; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	66	125	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7586	7592		10.1074/jbc.M007400200	http://dx.doi.org/10.1074/jbc.M007400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11108712	hybrid			2022-12-25	WOS:000167442900098
J	David, M; Borza, DB; Leinonen, A; Belmont, JM; Hudson, BC				David, M; Borza, DB; Leinonen, A; Belmont, JM; Hudson, BC			Hydrophobic amino acid residues are critical for the immunodominant epitope of the goodpasture autoantigen - A molecular basis for the cryptic nature of the epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ANTIGENIC DETERMINANTS; GLOMERULAR-BASEMENT-MEMBRANE; IV COLLAGEN; ALPHA-3(IV) CHAIN; NC1 DOMAIN; IDENTIFICATION; PREDICTION; LOCALIZATION; PATHOGENESIS; EXPRESSION	Goodpasture (GP) autoimmune disease is caused by autoantibodies to type IV collagen that bind to the glomerular basement membrane, causing rapidly progressing glomerulonephritis. The immunodominant GP(A) autoepitope is encompassed by residues 17-31 (the E-A region) within the noncollagenous (NC1) domain of the alpha3(IV) chain. The GP epitope is cryptic in the NC1 hexamer complex that occurs in the type IV collagen network found in tissues and inaccessible to autoantibodies unless the hexamer dissociates. In contrast, the epitope for the Mab3 monoclonal antibody is also located within the E-A region, but is fully accessible in the hexamer complex. In this study, the identity of residues that compose the GP(A) autoepitope was determined, and the molecular basis of its cryptic nature was explored. This was achieved using site-directed mutagenesis to exchange the alpha3(IV) residues in the E-A region with the corresponding residues of the homologous but non-immunoreactive alpha1(IV) NC1 domain and then comparing the reactivity of the mutated chimeras with GP(A) and Mab3 antibodies. It was shown that three hydrophobic residues (Ala(18), Ile(19), and Val(27)) and Pro(28) are critical for the GP(A) autoepitope, whereas two hydrophilic residues (Ser(21) and Ser(31)) along with pro(28) are critical for the Mab3 epitope. These results suggest that the cryptic nature of the GP(A) autoepitope is the result of quaternary interactions of the alpha3, alpha4, and alpha5 NC1 domains of the hexamer complex that bury the one or more hydrophobic residues. These findings provide critical information for understanding the etiology and pathogenesis of the disease as well as for designing drugs that would mimic the epitope and thus block the binding of GP autoantibodies to autoantigen.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pediat, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Hudson, BC (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.		Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Hudson, Billy/0000-0002-5420-4100	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018381, R37DK018381] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18381] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARLOW DJ, 1986, NATURE, V322, P747, DOI 10.1038/322747a0; Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; Gunnarsson A, 2000, J BIOL CHEM, V275, P30844, DOI 10.1074/jbc.M004717200; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; Hellmark T, 1999, J BIOL CHEM, V274, P25862, DOI 10.1074/jbc.274.36.25862; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; HOPP TP, 1993, PEPTIDE RES, V6, P183; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 2000, J BIOL CHEM, V275, P20027, DOI 10.1074/jbc.M904549199; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leinonen A, 1999, KIDNEY INT, V55, P926, DOI 10.1046/j.1523-1755.1999.055003926.x; LESSER GJ, 1990, PROTEINS, V8, P6, DOI 10.1002/prot.340080104; MENENDEZARIAS L, 1990, COMPUT APPL BIOSCI, V6, P101; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Netzer KO, 1998, PROTEIN SCI, V7, P1340, DOI 10.1002/pro.5560070610; PENADES JR, 1995, EUR J BIOCHEM, V229, P754, DOI 10.1111/j.1432-1033.1995.tb20524.x; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; Ryan JJ, 1998, CLIN EXP IMMUNOL, V113, P17, DOI 10.1046/j.1365-2249.1998.00623.x; SAUS J, 1988, J BIOL CHEM, V263, P13374; STERN PS, 1991, TRENDS BIOTECHNOL, V9, P163, DOI 10.1016/0167-7799(91)90054-L; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; WILSON CB, 2000, MOL PATHOLOGY AUTOIM, P981	27	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6370	6377		10.1074/jbc.M008956200	http://dx.doi.org/10.1074/jbc.M008956200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11098057	hybrid			2022-12-25	WOS:000167261000042
J	Haracska, L; Washington, MT; Prakash, S; Prakash, L				Haracska, L; Washington, MT; Prakash, S; Prakash, L			Inefficient bypass of an abasic site by DNA polymerase eta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; PIGMENTOSUM VARIANT CELLS; SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; POSTREPLICATION REPAIR; REPLICATION FIDELITY; YEAST; NMR; OPPOSITE; DUPLEX	DNA polymerase eta (Pol eta) bypasses a cis-syn thymine-thymine dimer efficiently and accurately, and inactivation of Pol eta in humans results in the cancer-prone syndrome, the variant form of xeroderma pigmentosum. Also, Pol eta bypasses the 8-oxoguanine lesion efficiently by predominantly inserting a C opposite this lesion, and it bypasses the O-6-methylguanine lesion by inserting a C or a T. To further assess the range of DNA lesions tolerated by Pol eta, here we examine the bypass of an abasic site, a prototypical noninstructional lesion. Steady state kinetic analyses show that both yeast and human Pol eta are very inefficient in both inserting a nucleotide opposite an abasic site and in extending from the nucleotide inserted. Hence, Pol eta bypasses this lesion extremely poorly. These results suggest that Pol eta requires the presence of template bases opposite both the incoming nucleotide and the primer terminus to catalyze efficient nucleotide incorporation.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Washington, Todd/0000-0001-8680-2992; Prakash, Satya/0000-0001-7228-1444	NIGMS NIH HHS [GM19261] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; Creighton S, 1995, METHOD ENZYMOL, V262, P232; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; HUSAIN I, 1988, P NATL ACAD SCI USA, V85, P2558, DOI 10.1073/pnas.85.8.2558; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Lawrence CW, 1996, CANCER SURV, V28, P21; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; McDonald JP, 1997, GENETICS, V147, P1557; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Torres-Ramos CA, 2000, MOL CELL BIOL, V20, P3522, DOI 10.1128/MCB.20.10.3522-3528.2000; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686	37	91	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6861	6866		10.1074/jbc.M008021200	http://dx.doi.org/10.1074/jbc.M008021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11106652	hybrid			2022-12-25	WOS:000167261000101
J	Ichai, C; El-Mir, MY; Nogueira, V; Piquet, MA; Chauvin, C; Fontaine, E; Leverve, XM				Ichai, C; El-Mir, MY; Nogueira, V; Piquet, MA; Chauvin, C; Fontaine, E; Leverve, XM			Exogenous Mg-ATP induces a large inhibition of pyruvate kinase in intact rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-CELLS; EXTRACELLULAR ATP; FRUCTOSE 2,6-BISPHOSPHATE; GLYCEROL METABOLISM; TRAUMA-HEMORRHAGE; GLUCONEOGENESIS; GLUCAGON; STIMULATION; ATP-MGCL2; RESUSCITATION	Mg-ATP infusion in vivo has been reported to be beneficial both to organ function and survival rate in various models of shock. Moreover, a large variety of metabolic effects has been shown to occur in several tissues due to purinergic receptor activation. In the present work we studied the effects of exogenous Mg-ATP in rat liver cells perifused with dihydroxyacetone to investigate simultaneously gluconeogenetic and glycolytic pathways. We found a significant effect on oxidative phosphorylation as characterized by a decrease in oxygen consumption rate and in the cellular ATP-to-ADP ratio associated with an increase in lactate-to pyruvate ratio. In addition, exogenous Mg-ATP induced rapid and reversible inhibition of both gluconeogenesis and glycolysis. The main effect on gluconeogenesis was located at the level of the fructose cycle, whereas the decrease in glycolysis was due to a strong inhibition of pyruvate kinase. Although pyruvate kinase inhibition induced by exogenous Mg-ATP was allosteric when assessed in vitro after enzyme extraction, we found a large decrease in the apparent maximal velocity when kinetics were assessed in vivo in intact perifused hepatocytes. This newly described short-term regulation of pyruvate kinase occurs only in the intact cell and may open new potentials for the pharmacological regulation of pyruvate kinase in vivo.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Leverve, XM (corresponding author), Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, BP 53X, F-38041 Grenoble, France.		Fontaine, Eric/ABA-8853-2020	Fontaine, Eric/0000-0002-5204-9477				ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; ASENSI M, 1991, AM J PHYSIOL, V261, pR1522, DOI 10.1152/ajpregu.1991.261.6.R1522; Ayala A, 1996, SHOCK, V6, pS27, DOI 10.1097/00024382-199610001-00007; BARTRONS R, 1984, BIOCHEM J, V218, P157, DOI 10.1042/bj2180157; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V4, P1127; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BUXTON DB, 1986, BIOCHEM J, V237, P773, DOI 10.1042/bj2370773; CASTANO JG, 1979, J BIOL CHEM, V254, P5576; CHAREST R, 1985, J BIOL CHEM, V260, P5789; CHAUDRY IH, 1975, CAN J PHYSIOL PHARM, V53, P859, DOI 10.1139/y75-118; CHAUDRY IH, 1990, ANN NY ACAD SCI, V603, P130; CHAUDRY IH, 1983, AM J PHYSIOL, V245, P117; CLAUS TH, 1981, BIOCHEM BIOPH RES CO, V100, P716, DOI 10.1016/S0006-291X(81)80234-3; CLAUS TH, 1979, J BIOL CHEM, V254, P7855; CRABTREE B, 1978, EUR J BIOCHEM, V89, P19, DOI 10.1111/j.1432-1033.1978.tb20891.x; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; FELL DA, 1985, EUR J BIOCHEM, V148, P555, DOI 10.1111/j.1432-1033.1985.tb08876.x; GROEN AK, 1983, J BIOL CHEM, V258, P4346; GROEN AK, 1986, BIOCHEM J, V237, P379, DOI 10.1042/bj2370379; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; HAUSSINGER D, 1987, EUR J BIOCHEM, V167, P65; HAYASHI H, 1986, AM J PHYSIOL, V250, pR573, DOI 10.1152/ajpregu.1986.250.4.R573; HERS HG, 1982, BIOCHEM J, V206, P1; IBARRONDO J, 1991, CELL SIGNAL, V3, P577, DOI 10.1016/0898-6568(91)90034-R; KEPPENS S, 1993, GEN PHARMACOL, V24, P283, DOI 10.1016/0306-3623(93)90304-G; KOIKE M, 1992, BIOCHEM J, V283, P265, DOI 10.1042/bj2830265; LAVOINNE A, 1990, EUR J BIOCHEM, V187, P403, DOI 10.1111/j.1432-1033.1990.tb15318.x; Leclercq P, 1997, BIOCHEM J, V325, P519, DOI 10.1042/bj3250519; LEE JW, 1987, CIRC SHOCK, V22, P205; LEVERVE XM, 1986, EUR J BIOCHEM, V155, P551, DOI 10.1111/j.1432-1033.1986.tb09523.x; LEVERVE XM, 1994, EUR J BIOCHEM, V224, P967, DOI 10.1111/j.1432-1033.1994.00967.x; LLORENTE P, 1970, EUR J BIOCHEM, V13, P45, DOI 10.1111/j.1432-1033.1970.tb00897.x; LUND P, 1975, BIOCHEM J, V152, P593, DOI 10.1042/bj1520593; Mahmoud MSW, 1997, BBA-GEN SUBJECTS, V1336, P549, DOI 10.1016/S0304-4165(97)00069-X; MAHMOUD MSW, 1994, AM J PHYSIOL, V266, pR1804, DOI 10.1152/ajpregu.1994.266.6.R1804; OETJEN E, 1990, BIOCHEM J, V271, P337, DOI 10.1042/bj2710337; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Piquet MA, 1996, BIOCHEM J, V317, P667, DOI 10.1042/bj3170667; RIOU JP, 1978, J BIOL CHEM, V253, P656; Robinson DA, 1997, J SURG RES, V69, P159, DOI 10.1006/jsre.1997.5065; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SIESS EA, 1977, BIOCHEM J, V166, P225, DOI 10.1042/bj1660225; SU C, 1983, ANNU REV PHARMACOL, V23, P397, DOI 10.1146/annurev.pa.23.040183.002145; SUMPIO BE, 1987, AM J PHYSIOL, V252, pR388, DOI 10.1152/ajpregu.1987.252.2.R388; VANDERMEER R, 1976, FEBS LETT, V67, P36, DOI 10.1016/0014-5793(76)80865-4; WANG P, 1992, CAN J PHYSIOL PHARM, V70, P349, DOI 10.1139/y92-044; WANG P, 1992, AM J PHYSIOL, V263, pG895, DOI 10.1152/ajpgi.1992.263.6.G895; WANG P, 1995, AM J PHYSIOL-HEART C, V268, pH1390, DOI 10.1152/ajpheart.1995.268.4.H1390; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	51	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6398	6403		10.1074/jbc.M004169200	http://dx.doi.org/10.1074/jbc.M004169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11104754	hybrid			2022-12-25	WOS:000167261000045
J	Quitterer, U; Hoffmann, M; Freichel, M; Lohse, MJ				Quitterer, U; Hoffmann, M; Freichel, M; Lohse, MJ			Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; INTRACELLULAR FREE MAGNESIUM; BOVINE PARATHYROID CELLS; G-PROTEIN; CA2+-SENSING RECEPTOR; GUANINE-NUCLEOTIDES; STRUCTURAL-ANALYSIS; ACTIVATION	The paradox of blunted parathormone (PTH) secretion in patients with severe hypomagnesemia has been known for more than 20 years, but the underlying mechanism is not deciphered, We determined the effect of low magnesium on in vitro PTH release and on the signals triggered by activation of the calcium sensing receptor (CaSR), Analogous to the in vivo situation, PTH release from dispersed parathyroid cells was suppressed under low magnesium, In parallel, the two major signaling pathways responsible for CaSR triggered block of PTH secretion, the generation of inositol phosphates, and the inhibition of cAMP were enhanced, Desensitization or pertussis toxin-mediated inhibition of CaSR-stimulated signaling suppressed the effect of low magnesium, further confirming that magnesium acts within the axis CaSR-G-protein, However, the magnesium binding site responsible for inhibition of PTH secretion is not identical with the extracellular ion binding site of the CaSR, because the magnesium deficiency-dependent signal enhancement was not altered on CaSR receptor mutants with increased or decreased affinity for calcium and magnesium, By contrast, when the magnesium affinity of the G alpha subunit was decreased, CaSR activation was no longer affected by magnesium, Thus, the paradoxical block of PTH release under magnesium deficiency seems to be mediated through a novel mechanism involving an increase in the activity of G alpha subunits of heterotrimeric G-proteins.	Univ Wurzburg, Inst Pharmakol & Toxikol, D-97078 Wurzburg, Germany; Univ Saarlandes, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany	University of Wurzburg; Saarland University	Quitterer, U (corresponding author), Univ Wurzburg, Inst Pharmakol & Toxikol, Versbacher Str 9, D-97078 Wurzburg, Germany.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; ALTURA BM, 1983, SCIENCE, V221, P376, DOI 10.1126/science.6867714; ANAST CS, 1972, SCIENCE, V177, P606, DOI 10.1126/science.177.4049.606; ANAST CS, 1983, ENDOCRINOLOGY, V113, P184, DOI 10.1210/endo-113-1-184; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Boehm S, 1997, BRIT J PHARMACOL, V122, P455, DOI 10.1038/sj.bjp.0701404; BROWN EM, 1976, ENDOCRINOLOGY, V99, P1582, DOI 10.1210/endo-99-6-1582; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1981, AM J MED, V71, P565, DOI 10.1016/0002-9343(81)90207-2; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Cheng DY, 1996, AM J PHYSIOL-HEART C, V270, pH200, DOI 10.1152/ajpheart.1996.270.1.H200; COHAN BW, 1982, J CLIN ENDOCR METAB, V54, P975, DOI 10.1210/jcem-54-5-975; Coleman DE, 1998, BIOCHEMISTRY-US, V37, P14376, DOI 10.1021/bi9810306; DURAN MJ, 1984, AM J MED, V76, P151, DOI 10.1016/0002-9343(84)90764-2; Freichel M, 1996, ENDOCRINOLOGY, V137, P3842, DOI 10.1210/en.137.9.3842; HAMILTON JW, 1971, J BIOL CHEM, V246, P3224; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; Inaba M, 1992, J Endocrinol Invest, V15, P135; JOHN J, 1993, J BIOL CHEM, V268, P923; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; MENNES P, 1978, ANN INTERN MED, V88, P206, DOI 10.7326/0003-4819-88-2-206; NAKAYAMA S, 1991, J PHYSIOL-LONDON, V435, P559, DOI 10.1113/jphysiol.1991.sp018525; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Quitterer U, 1999, P NATL ACAD SCI USA, V96, P10626, DOI 10.1073/pnas.96.19.10626; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; RUDE RK, 1978, J CLIN ENDOCR METAB, V47, P800, DOI 10.1210/jcem-47-4-800; Seyedi N, 1997, CIRC RES, V81, P774; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Touyz RM, 1996, J BIOL CHEM, V271, P24353, DOI 10.1074/jbc.271.40.24353; WALLFELT C, 1988, J ENDOCRINOL, V116, P457, DOI 10.1677/joe.0.1160457	39	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6763	6769		10.1074/jbc.M007727200	http://dx.doi.org/10.1074/jbc.M007727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11102444	hybrid			2022-12-25	WOS:000167261000089
J	Bergo, MO; Leung, GK; Ambroziak, P; Otto, JC; Casey, PJ; Gomes, AQ; Seabra, MC; Young, SG				Bergo, MO; Leung, GK; Ambroziak, P; Otto, JC; Casey, PJ; Gomes, AQ; Seabra, MC; Young, SG			Isoprenylcysteine carboxyl methyltransferase deficiency in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; A-FACTOR; ENDOPLASMIC-RETICULUM; MEMBRANE ASSOCIATION; CYSTEINE RESIDUES; C-TERMINUS; IN-VITRO; RAS; GENE; METHYLATION	undergo endoproteolytic processing by Reel and methylation of the isoprenylcysteine by Icmt (isoprenylcysteine carboxyl methyltransferase). We reported previously that Rce1-deficient mice died during late gestation or soon after birth. We hypothesized that Icmt deficiency might cause a milder phenotype, in part because of reports suggesting the existence of more than one activity for methylating isoprenylated proteins. To address this hypothesis and also to address the issue of other methyltransferase activities, we generated Icmt-deficient mice. Contrary to our expectation, Icmt deficiency caused a more severe phenotype than Reel deficiency, with virtually all of the knockout embryos (Icmt-/-) dying by mid-gestation. An analysis of chimeric mice produced from Icmt-/- embryonic stem cells showed that the Icmt-/- cells retained the capacity to contribute to some tissues (e.g. skeletal muscle) but not to others (e.g. brain). Lysates from Icmt-/- embryos lacked the ability to methylate either recombinant K-Ras or small molecule substrates (e.g, N-acetyl-S-geranylgeranyl-L-cysteine). In addition, Icmt -/- cells lacked the ability to methylate Rab proteins. Thus, Icmt appears to be the only enzyme participating in the carboxyl methylation of isoprenylated proteins.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ London Imperial Coll Sci Technol & Med, Sch Med, Mol Genet Sect, Div Biomed Sci, London SW7 2AZ, England	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University; Imperial College London	Bergo, MO (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.		Gomes, Anita Q./C-3580-2014; Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Gomes, Anita Q./0000-0002-3348-0448; Seabra, Miguel C/0000-0002-6404-4892; Casey, Patrick/0000-0002-7366-9309; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline; NIA NIH HHS [AG15451] Funding Source: Medline; NIGMS NIH HHS [GM46372] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; GIANNAKOUROS T, 1993, J BIOL CHEM, V268, P24467; GINER JL, 1994, BIOCHEMISTRY-US, V33, P15116, DOI 10.1021/bi00254a022; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; LI GP, 1993, ARCH BIOCHEM BIOPHYS, V304, P471, DOI 10.1006/abbi.1993.1377; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Parish CA, 1996, BIOCHEMISTRY-US, V35, P8473, DOI 10.1021/bi960603g; PEREIRALEAL JB, 2001, IN PRESS METHODS MOL; PHILIPS MR, 1995, P NATL ACAD SCI USA, V92, P2283, DOI 10.1073/pnas.92.6.2283; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Seabra MC, 1998, METH MOL B, V84, P251; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; SMELAND TE, 1994, P NATL ACAD SCI USA, V91, P10712, DOI 10.1073/pnas.91.22.10712; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; WEI C, 1992, ONCOGENE, V7, P467; Young S. G., 2001, ENZYMES, V21, P156	28	130	137	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5841	5845		10.1074/jbc.C000831200	http://dx.doi.org/10.1074/jbc.C000831200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11121396	hybrid			2022-12-25	WOS:000167115100060
J	Caiveau, O; Fortune, D; Cantrel, C; Zachowski, A; Moreau, F				Caiveau, O; Fortune, D; Cantrel, C; Zachowski, A; Moreau, F			Consequences of omega-6-oleate desaturase deficiency on lipid dynamics and functional properties of mitochondrial membranes of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID COMPOSITION; CELL-SUSPENSION CULTURES; TOP-DOWN APPROACH; LATERAL DIFFUSION; LOW-TEMPERATURE; PROTON PERMEABILITY; ELECTRON-TRANSPORT; STEADY-STATE; PHOSPHORYLATION; PHOSPHOLIPIDS	We probed the role of the polyunsaturated fatty acids on the dynamic and functional properties of mitochondrial membranes using the fad2 mutant of Arabidopsis thaliana, deficient in omega -6-oleate desaturase, In mitochondria of this mutant, the oleic acid content exceeded 70% of the total fatty acids, and the lipid/protein ratio was greatly enhanced. As a consequence, local microviscosity, probed by anthroyloxy fatty acid derivatives, was increased by 30%, whereas the lipid lateral diffusion, assayed using 1-pyrenedodecanoic acid, was approximately 4 times increased. Functional parameters such as oxygen consumption rate under phosphorylating and nonphosphorylating conditions and proton permeability of the inner mitochondrial membrane were significantly reduced in fad2 mitochondrial membranes, while the thermal dependence of the respiration was enhanced. Moreover, metabolic control analysis of the respiration clearly showed an enhancement of the control exerted by the membrane proton leaks. Our data suggest that the loss of omega -6-oleate desaturase activity in Arabidopsis cells induced an enhancement of both microviscosity and lipid/protein ratio of mitochondrial membranes, which in turn were responsible for the change in lateral mobility of lipids and for bioenergetic parameter modifications.	Univ Paris 06, CNRS, Lab Physiol Cellulaire & Mol Plantes, UMR 7632, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Moreau, F (corresponding author), Univ Paris 06, CNRS, Lab Physiol Cellulaire & Mol Plantes, UMR 7632, Case 154,4 Pl Jussieu, F-75252 Paris 05, France.		ZACHOWSKI, Alain/A-9029-2011					Alonso A, 1997, BBA-BIOMEMBRANES, V1323, P75, DOI 10.1016/S0005-2736(96)00177-0; BLIGNY R, 1985, J BIOL CHEM, V260, P9166; BRAND MD, 1994, BIOCHEM J, V297, P27, DOI 10.1042/bj2970027; Brookes PS, 1997, J MEMBRANE BIOL, V155, P167, DOI 10.1007/s002329900168; Brookes PS, 1997, BBA-BIOMEMBRANES, V1330, P157, DOI 10.1016/S0005-2736(97)00160-0; CAVAZZONI M, 1993, ARCH BIOCHEM BIOPHYS, V303, P246, DOI 10.1006/abbi.1993.1279; CHAZOTTE B, 1989, J BIOL CHEM, V264, P4978; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; De Santis A, 1999, PLANT PHYSIOL, V119, P743, DOI 10.1104/pp.119.2.743; de Virville JD, 1998, PLANT PHYSIOL BIOCH, V36, P347, DOI 10.1016/S0981-9428(98)80076-4; DEVIRVILLE JD, 1994, PLANT PHYSIOL BIOCH, V32, P159; DIOLEZ P, 1985, BIOCHIM BIOPHYS ACTA, V806, P56, DOI 10.1016/0005-2728(85)90081-7; EISINGER J, 1986, BIOPHYS J, V49, P987, DOI 10.1016/S0006-3495(86)83727-4; Fontaine EM, 1996, BBA-BIOENERGETICS, V1276, P181, DOI 10.1016/0005-2728(96)00075-8; GALLA HJ, 1980, BIOCHIM BIOPHYS ACTA, V596, P108, DOI 10.1016/0005-2736(80)90174-1; GOUBERN M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P334, DOI 10.1016/0005-2728(90)90038-6; GUILLOTSALOMON T, 1988, PHYSL PLANTA, V69, P113; HAFNER RP, 1990, EUR J BIOCHEM, V188, P313, DOI 10.1111/j.1432-1033.1990.tb15405.x; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KESSELER A, 1992, EUR J BIOCHEM, V210, P775, DOI 10.1111/j.1432-1033.1992.tb17480.x; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; LENAZ G, 1988, J MEMBRANE BIOL, V104, P193, DOI 10.1007/BF01872322; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIQUEL M, 1993, P NATL ACAD SCI USA, V90, P6208, DOI 10.1073/pnas.90.13.6208; MIQUEL M, 1992, J BIOL CHEM, V267, P1; MIQUEL MF, 1994, PLANT PHYSIOL, V106, P421, DOI 10.1104/pp.106.2.421; Murata N, 1997, PLANT PHYSIOL, V115, P875, DOI 10.1104/pp.115.3.875; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; OLEARY TJ, 1987, P NATL ACAD SCI USA, V84, P429, DOI 10.1073/pnas.84.2.429; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2; SOMMERVILLE C, 1991, SCIENCE, V252, P80; TRICERRI MA, 1994, CHEM PHYS LIPIDS, V71, P61, DOI 10.1016/0009-3084(94)02303-4	33	32	34	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5788	5794		10.1074/jbc.M006231200	http://dx.doi.org/10.1074/jbc.M006231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11104757	hybrid			2022-12-25	WOS:000167115100053
J	Tsutsui, K; Tsutsui, K; Sano, K; Kikuchi, A; Tokunaga, A				Tsutsui, K; Tsutsui, K; Sano, K; Kikuchi, A; Tokunaga, A			Involvement of DNA topoisomerase II beta in neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR SCAFFOLD; GRANULE NEURONS; GENE-EXPRESSION; PROTEIN CLAMP; HUMAN TISSUES; M-PHASE; CELLS; ALPHA; INHIBITION; FORMS	Two isoforms of DNA topoisomerase II (topo II) have been identified in mammalian cells. While topo II alpha is essential for chromosome segregation in mitotic cells, in vivo function of topo II beta remains to be clarified. Here we demonstrate that the nucleoplasmic topo II beta, highly expressed in differentiating cerebellar neurons, is the catalytically competent entity operating directly on chromatin DNA in vivo. When the cells reached terminal differentiation, this in vivo activity decreased to a negligible level with concomitant loss of the nucleoplasmic enzyme. Effects of topo II-specific inhibitors were analyzed in a primary culture of cerebellar granule neurons that can mimic the in vivo situation. Only the beta isoform was expressed in granule cells differentiating in vitro. ICRF-193, a catalytic topo II inhibitor, suppressed the transcriptional induction of amphiphysin I which is essential for mature neuronal activity. The effect decreased significantly as the cells differentiate. Expression profiling with a cDNA macroarray showed that 18% of detectable transcripts were up-regulated during the differentiation and one-third of them were susceptible to ICRF-193. The results suggest that topo II beta is involved in an early stage of granule cell differentiation by potentiating inducible neuronal genes to become transcribable probably through alterations in higher order chromatin structure.	Okayama Univ, Sch Med, Dept Mol Biol, Inst Mol & Cellular Biol, Okayama 7008558, Japan; Okayama Univ, Sch Med, Dept Anat 3, Okayama 7008558, Japan; Nagoya Univ, Sch Med, Med Mycol Lab, Dis Mechanism & Control Res Inst, Nagoya, Aichi 4668550, Japan	Okayama University; Okayama University; Nagoya University	Tsutsui, K (corresponding author), Okayama Univ, Sch Med, Dept Mol Biol, Inst Mol & Cellular Biol, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	tsukken@cc.okayama-u.ac.jp	Tsutsui, Ken/B-1863-2011					Altman J, 1997, DEV CEREBELLAR SYSTE; Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Bauman ME, 1997, MODERN PATHOL, V10, P168; BEATTIE CE, 1993, J NEUROSCI, V13, P1784; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A; CHEN M, 1995, ONCOL RES, V7, P103; Condorelli DF, 1998, NEUROCHEM INT, V32, P87, DOI 10.1016/S0197-0186(97)00038-7; DEISHER TA, 1993, CELL ADHES COMMUN, V1, P133, DOI 10.3109/15419069309095689; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; Floyd S, 1998, MOL MED, V4, P29, DOI 10.1007/BF03401727; FRANCIS GE, 1987, LEUKEMIA, V1, P653; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; Grue P, 1998, J BIOL CHEM, V273, P33660, DOI 10.1074/jbc.273.50.33660; Hatten ME, 1997, CURR OPIN NEUROBIOL, V7, P40, DOI 10.1016/S0959-4388(97)80118-3; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; Kimura K, 1996, J BIOL CHEM, V271, P21439, DOI 10.1074/jbc.271.35.21439; KIMURA K, 1994, J BIOL CHEM, V269, P24523; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; MULLER MT, 1988, MOL CELL BIOL, V8, P3661, DOI 10.1128/MCB.8.9.3661; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; Perez C, 1997, J CELL SCI, V110, P337; PETROV P, 1993, EXP CELL RES, V204, P73, DOI 10.1006/excr.1993.1010; Raetzman LT, 1999, J NEUROBIOL, V38, P559; Rashid Z, 1996, BIOCHEM BIOPH RES CO, V219, P82, DOI 10.1006/bbrc.1996.0185; RIUS C, 1991, MOL PHARMACOL, V39, P442; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; SAKURAI H, 1992, J NEUROCHEM, V59, P2067; TAKASUGA Y, 1995, EXP CELL RES, V217, P378, DOI 10.1006/excr.1995.1100; TAN KB, 1992, CANCER RES, V52, P231; TANABE K, 1991, CANCER RES, V51, P4903; Tohda H, 1997, BIOCHEM BIOPH RES CO, V232, P398, DOI 10.1006/bbrc.1997.6293; TSUTSUI K, 1989, J BIOL CHEM, V264, P7644; TSUTSUI K, 1993, J BIOL CHEM, V268, P19076; TSUTSUI K, 1988, J BIOL CHEM, V263, P7235; TSUTSUI K, 1986, BIOCHEM BIOPH RES CO, V138, P1116, DOI 10.1016/S0006-291X(86)80398-9; Turley H, 1997, BRIT J CANCER, V75, P1340, DOI 10.1038/bjc.1997.227; UDVARDY A, 1991, MOL CELL BIOL, V11, P4973, DOI 10.1128/MCB.11.10.4973; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WATANABE M, 1994, NEUROSCI RES, V19, P519; Wessel I, 1999, CANCER RES, V59, P3442; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Zuckerkandl E, 1997, GENE, V205, P323, DOI 10.1016/S0378-1119(97)00543-X	55	98	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5769	5778		10.1074/jbc.M008517200	http://dx.doi.org/10.1074/jbc.M008517200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11106659	hybrid			2022-12-25	WOS:000167115100051
J	Ding, K; Jonsson, M; Mani, K; Sandgren, S; Belting, M; Fransson, LA				Ding, K; Jonsson, M; Mani, K; Sandgren, S; Belting, M; Fransson, LA			N-unsubstituted glucosamine in heparan sulfate of recycling glypican-1 from suramin-treated and nitrite-deprived endothelial cells - Mapping of nitric oxide/nitrite-susceptible glucosamine residues to clustered sites near the: Core protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MAMMALIAN HEPARANASE; SKIN FIBROBLASTS; BREFELDIN-A; PROTEOGLYCAN; CLONING; 2,5-ANHYDRO-D-MANNITOL; INHIBITION; EXPRESSION; OLIGOSACCHARIDES	We have analyzed the content of N-unsubstituted glucosamine in heparan sulfate from glypican-1 synthesized by endothelial cells during inhibition of (a) intracellular progression by brefeldin A, (b) heparan sulfate degradation by suramin, and/or (c) endogenous nitrite formation. Glypican-1 from brefeldin A-treated cells carried heparan sulfate chains that were extensively degraded by nitrous acid at pH 3.9, indicating the presence of glucosamines with free amino groups. Chains with such residues were rare in glypican-1 isolated from unperturbed cells and from cells treated with suramin and, surprisingly, when nitrite-deprived, However, when nitrite-deprived cells were simultaneously treated with suramin, such glucosamine residues were more prevalent. To locate these residues, chains were first cleaved at linkages to sulfated L-iduronic acid by heparin lyase and released fragments were separated from core protein carrying heparan sulfate stubs. These stubs were then cleaved off at sites linking N-substituted glucosamines to D-glucuronic acid. These fragments were extensively degraded by nitrous acid at pH 3.9. When purified proteoglycan isolated from brefeldin A-treated cells was incubated with intact cells, endoheparanese-catalyzed degradation generated a core protein with heparan sulfate stubs that were similarly sensitive to nitrous acid. We conclude that there is a concentration of N-unsubstituted glucosamines to the reducing side of the endoheparanase cleavage site in the transition region between unmodified and modified chain segments near the linkage region to the protein. Both sites as well as the heparin lyase-sensitive sites seem to be in close proximity to one another.	Univ Lund, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, S-22100 Lund, Sweden	Lund University	Fransson, LA (corresponding author), Univ Lund, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, POB 94, S-22100 Lund, Sweden.			Belting, Mattias/0000-0003-1585-5434; Mani, Katrin/0000-0002-1821-0634				Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bame KJ, 1997, J BIOL CHEM, V272, P2245; Bame KJ, 1998, BIOCHEM J, V336, P191, DOI 10.1042/bj3360191; Belting M, 1999, BIOCHEM J, V338, P317, DOI 10.1042/0264-6021:3380317; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; CIFONELLI JA, 1977, BIOCHEMISTRY-US, V16, P2137, DOI 10.1021/bi00629a014; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Edgren G, 1997, GLYCOBIOLOGY, V7, P103, DOI 10.1093/glycob/7.1.103; FRANSSON L, 1995, GLYCOBIOLOGY, V5, P407, DOI 10.1093/glycob/5.4.407; FRANSSON LA, 1980, EUR J BIOCHEM, V106, P59; Gagliardi ART, 1998, CANCER LETT, V125, P97, DOI 10.1016/S0304-3835(97)00496-5; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; HANSON RL, 1984, J BIOL CHEM, V259, P218; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDBLOM A, 1990, GLYCOCONJUGATE J, V7, P545, DOI 10.1007/BF01189076; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LINKER A, 1975, BIOCHIM BIOPHYS ACTA, V385, P324, DOI 10.1016/0304-4165(75)90360-8; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; NAKAJIMA M, 1991, J BIOL CHEM, V266, P9661; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RIQUELME PT, 1984, J BIOL CHEM, V259, P5115; Sandback-Pikas D., 1998, J BIOL CHEM, V273, P18770; SCHMIDTCHEN A, 1994, EUR J BIOCHEM, V223, P211, DOI 10.1111/j.1432-1033.1994.tb18985.x; STEVENS HC, 1984, FEBS LETT, V165, P247, DOI 10.1016/0014-5793(84)80178-7; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Vilar RE, 1997, BIOCHEM J, V324, P473, DOI 10.1042/bj3240473; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518	37	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3885	3894		10.1074/jbc.M005238200	http://dx.doi.org/10.1074/jbc.M005238200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11110783	hybrid			2022-12-25	WOS:000166921200024
J	Loetscher, P; Pellegrino, A; Gong, JH; Mattioli, I; Loetscher, M; Bardi, G; Baggiolini, M; Clark-Lewis, I				Loetscher, P; Pellegrino, A; Gong, JH; Mattioli, I; Loetscher, M; Bardi, G; Baggiolini, M; Clark-Lewis, I			The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ACTIVATED T-CELLS; FUNCTIONAL EXPRESSION; INTERLEUKIN-8 RECEPTORS; ALLERGIC INFLAMMATION; EOSINOPHIL RECRUITMENT; NH2-TERMINAL RESIDUES; MOLECULAR-CLONING; HUMAN-NEUTROPHILS; HIV-1 CORECEPTOR	Th1 and Th2 lymphocytes express a different repertoire of chemokine receptors (CCRs), CXCR3, the receptor for I-TAG (interferon-inducible T cell alpha -chemoattractant), Mig (monokine induced by gamma -interferon), and IP10 (interferon-inducible protein 10), is expressed preferentially on Th1 cells, whereas CCR3, the receptor for eotaxin and several other CC chemokines, is characteristic of Th2 cells. While studying responses that are mediated by these two receptors, we found that the agonists for CXCR3 act as antagonists for CCR3. I-TAG, Mig, and IP10 compete for the binding of eotaxin to CCR3-bearing cells and inhibit migration and Ca2+ changes induced in such cells by stimulation with eotaxin, eotanin-2, MCP-S (monocyte chemottractant protein-2), MCP-S, MCP-4, and RANTES (regulated on activation normal T cell expressed and secreted). A hybrid chemokine generated by substituting the first eight NH2-terminal residues of eotaxin with those of I-TAG bound CCR3 with higher affinity than eotaxin or I-TAG (3- and 10-fold, respectively). The hybrid was 5-fold more potent than I-TAG as an inhibitor of eotaxin activity and was effective at concentrations as low as 5 nM. None of the antagonists described induced the internalization of CCR3, indicating that they lack agonistic effects and thus qualify as pure antagonists. These results suggest that chemokines that attract Th1 cells via CXCR3 can concomitantly block the migration of Th2 cells in response to CCR3 ligands, thus enhancing the polarization of T cell recruitment.	Univ Bern, Theodor Kocher Inst, CH-3000 Bern 9, Switzerland; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of Bern; University of British Columbia; University of British Columbia	Loetscher, P (corresponding author), Univ Bern, Theodor Kocher Inst, POB 99, CH-3000 Bern 9, Switzerland.		Bardi, Giuseppe/K-7057-2019; Bardi, Giuseppe/B-6452-2013	Bardi, Giuseppe/0000-0001-9662-3007; Bardi, Giuseppe/0000-0001-9662-3007				Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ARENZANASEISDED.F, 1998, SCIENCE, V281, pA487; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 1997, J EXP MED, V186, P1189, DOI 10.1084/jem.186.8.1189; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Blanpain C, 1999, BLOOD, V94, P1899; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Elsner J, 2000, J BIOL CHEM, V275, P7787, DOI 10.1074/jbc.275.11.7787; Forster R, 1998, J IMMUNOL, V160, P1522; Franci C, 1996, J IMMUNOL, V157, P5606; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Gerber BO, 1997, CURR BIOL, V7, P836, DOI 10.1016/S0960-9822(06)00371-X; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Gutierrez-Ramos JC, 1999, IMMUNOL TODAY, V20, P500, DOI 10.1016/S0167-5699(99)01522-4; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Jenh CH, 1999, J IMMUNOL, V162, P3765; Jones SA, 1997, J BIOL CHEM, V272, P16166, DOI 10.1074/jbc.272.26.16166; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; LOETSCHER P, 1994, FASEB J, V8, P1055, DOI 10.1096/fasebj.8.13.7926371; Loetscher P, 2000, Adv Immunol, V74, P127; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Mochizuki M, 1998, J IMMUNOL, V160, P60; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; MOSER B, 1993, J BIOL CHEM, V268, P7125; Murphy PM, 2000, PHARMACOL REV, V52, P145; Power CA, 1997, J EXP MED, V186, P825, DOI 10.1084/jem.186.6.825; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Rothenberg ME, 1999, J CLIN IMMUNOL, V19, P250, DOI 10.1023/A:1020531322556; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Sauty A, 1999, J IMMUNOL, V162, P3549; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Solari R, 1997, J BIOL CHEM, V272, P9617; Soto H, 1998, P NATL ACAD SCI USA, V95, P8205, DOI 10.1073/pnas.95.14.8205; Struyf S, 1999, J IMMUNOL, V162, P4903; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; Weng YM, 1998, J BIOL CHEM, V273, P18288, DOI 10.1074/jbc.273.29.18288; Willimann K, 1998, EUR J IMMUNOL, V28, P2025, DOI 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; Yoshida T, 1998, J BIOL CHEM, V273, P16551, DOI 10.1074/jbc.273.26.16551; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	68	247	263	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					2986	2991		10.1074/jbc.M005652200	http://dx.doi.org/10.1074/jbc.M005652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11110785	hybrid			2022-12-25	WOS:000166784900003
J	Carofano, A; Czernichow, P; Breant, B				Carofano, A; Czernichow, P; Breant, B			Impaired beta-cell regeneration in perinatally malnourished rats: a study with STZ	FASEB JOURNAL			English	Article						malnutrition; beta-cell mass; proliferation; morphometry	DEPENDENT DIABETES-MELLITUS; TREATED NEWBORN RATS; GROWTH-FACTOR-II; LOW-PROTEIN-DIET; ENDOCRINE PANCREAS; NEONATAL-RAT; GLUCOSE-TOLERANCE; FETAL-GROWTH; ADULT-RATS; STREPTOZOTOCIN	We investigated the mechanisms implicated in beta -cell mass reduction observed during late fetal and early postnatal malnutrition in the rat. Beta-cell regeneration, including proliferation and neogenesis, was studied after neonatal beta -cell destruction by streptozotocin (STZ). STZ was injected at birth and maternal food restriction was continued until weaning. Beta-cell mass, proliferation, and islet number were quantified by morphometrical measurements on pancreatic sections in STZ-injected normal (C-STZ) and malnourished (R-STZ) rats, with noninjected C and R rats as controls. At day 4, only 20% of the beta cell-mass remained in C-STZ rats. It regenerated to 50% that of noninjected controls, mainly through active neogenesis, as shown by the entire recovery of islet number/cm(2), and also through moderately increased beta -cell proliferation. In contrast, beta -cell mass from R-STZ animals poorly regenerated, despite a dramatic increase of beta -cell proliferation, because islet number/cm(2) recovered insufficiently. In conclusion, perinatal malnutrition impairs neogenesis and the capacity of beta -cell regeneration by neogenesis but preserves beta -cell proliferation, which remains the elective choice to increase beta -cell mass. These results provide an explanation for the impaired capacity of malnourished animals to adapt their beta -cell mass during aging or pregnancy, which aggravate glucose tolerance.	Hop Robert Debre, INSERM, U457, F-75019 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Breant, B (corresponding author), Hop Robert Debre, INSERM, U457, 48 Blvd Serurier, F-75019 Paris, France.	bbreant@infobiogen.fr						BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Blondeau B, 1999, ENDOCRINOLOGY, V140, P4208, DOI 10.1210/en.140.9.4208; BONNERWEIR S, 1993, DIABETES, V42, P1715, DOI 10.2337/diabetes.42.12.1715; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; BONNERWEIR S, 1981, DIABETES, V30, P64, DOI 10.2337/diabetes.30.1.64; BONNEVIENIELSEN V, 1981, DIABETES, V30, P424, DOI 10.2337/diabetes.30.5.424; CANTENYS D, 1981, VIRCHOWS ARCH B, V35, P109; DUTRILLAUX MC, 1982, VIRCHOWS ARCH B, V39, P173, DOI 10.1007/BF02892846; FERRAND N, 1995, AM J PHYSIOL-CELL PH, V269, pC1250, DOI 10.1152/ajpcell.1995.269.5.C1250; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Garofano A, 1998, DIABETOLOGIA, V41, P1114, DOI 10.1007/s001250051038; Garofano A, 1999, DIABETOLOGIA, V42, P711, DOI 10.1007/s001250051219; Garofano A, 1998, BIOL NEONATE, V73, P89, DOI 10.1159/000013964; Garofano A, 1997, DIABETOLOGIA, V40, P1231, DOI 10.1007/s001250050812; GU DL, 1993, DEVELOPMENT, V118, P33; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Movassat J, 1999, DIABETOLOGIA, V42, P1098, DOI 10.1007/s001250051277; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; Petrik J, 1999, ENDOCRINOLOGY, V140, P4861, DOI 10.1210/en.140.10.4861; Petrik J, 1998, ENDOCRINOLOGY, V139, P2994, DOI 10.1210/en.139.6.2994; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; PORTHA B, 1974, DIABETES, V23, P889, DOI 10.2337/diab.23.11.889; ROSENBERG L, 1983, J SURG RES, V35, P63, DOI 10.1016/0022-4804(83)90127-0; SCAGLIA L, 1995, ENDOCRINOLOGY, V136, P5461, DOI 10.1210/en.136.12.5461; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; SCHNEDL WJ, 1994, DIABETES, V43, P1326, DOI 10.2337/diabetes.43.11.1326; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; SWENNE I, 1982, DIABETES, V31, P745; VINIK A, 1996, DIABETES REV, V4, P235; WANG RN, 1995, DIABETOLOGIA, V38, P1405, DOI 10.1007/BF00400600; WANG RN, 1994, DIABETOLOGIA, V37, P1088; Wang RN, 1996, DIABETOLOGIA, V39, P548, DOI 10.1007/BF00403301	36	39	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2611	2617		10.1096/fj.00-0015com	http://dx.doi.org/10.1096/fj.00-0015com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099480				2022-12-25	WOS:000165723400032
J	Miao, HQ; Lee, P; Lin, H; Soker, S; Klagsbrun, M				Miao, HQ; Lee, P; Lin, H; Soker, S; Klagsbrun, M			Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression	FASEB JOURNAL			English	Article						VEGF; VEGF receptors; motility; prostate carcinoma	ENDOTHELIAL GROWTH-FACTOR; FACTOR VEGF; MEMBRANE-PROTEIN; TYROSINE KINASE; FACTOR RECEPTOR; IN-VIVO; IDENTIFICATION; INHIBITION; FACTOR-2; PROLIFERATION	Neuropilin-1 (NRP1) is a VEGF(165) and semaphorin receptor expressed by vascular endothelial cells (EC) and tumor cells. The function of NRP1 in tumor cells is unknown, NRP1 was overexpressed in Dunning rat prostate carcinoma AT2.1 cells using a tetracycline-inducible promoter. Concomitant with increased NRP1 expression in response to a tetracycline homologue, doxycycline (Dox), basal cell. motility, and VEGF(165) binding were increased three- to fourfold in vitro, However, induction of NRP1 did not affect tumor cell proliferation. When rats injected with AT2.1/NRP1 tumor cells were fed Dox, NRP1 synthesis was induced in vivo and AT2.1 cell tumor size was increased 2.5- to 7-fold in a 3-4 wk period compared to controls. The larger tumors with induced NRP1 expression were characterized by markedly increased microvessel density, increased proliferating EC, dilated blood vessels, and notably less tumor cell apoptosis compared to noninduced controls. It was concluded that NRP1 expression results in enlarged tumors associated with substantially enhanced tumor angiogenesis.	Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA; Childrens Hosp, Dept Urol, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Klagsbrun, M (corresponding author), Childrens Hosp, Dept Surg Res, Room 1061,300 Longwood Ave, Boston, MA 02115 USA.	klagsbrun@a1.tch.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA037392, R56CA037392, R37CA037392, P01CA045548] Funding Source: NIH RePORTER; NCI NIH HHS [CA45548, CA37392] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dor Y, 1997, TRENDS CARDIOVAS MED, V7, P289, DOI 10.1016/S1050-1738(97)00091-1; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fujisawa H, 1995, DEV NEUROSCI-BASEL, V17, P343, DOI 10.1159/000111304; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kolodkin AL, 1996, TRENDS NEUROSCI, V19, P507, DOI 10.1016/S0166-2236(96)10057-6; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Miao HQ, 1997, J CLIN INVEST, V99, P1565, DOI 10.1172/JCI119319; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Presta LG, 1997, CANCER RES, V57, P4593; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tordjman R, 1999, BLOOD, V94, P2301, DOI 10.1182/blood.V94.7.2301.419k24_2301_2309; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	48	248	264	1	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2532	2539		10.1096/fj.00-0250com	http://dx.doi.org/10.1096/fj.00-0250com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099472				2022-12-25	WOS:000165723400024
J	Rosati, B; Marchetti, P; Crociani, O; Lecchi, M; Lupi, R; Arcangeli, A; Olivotto, M; Wanke, E				Rosati, B; Marchetti, P; Crociani, O; Lecchi, M; Lupi, R; Arcangeli, A; Olivotto, M; Wanke, E			Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: the role of HERG K+ channels in firing and release	FASEB JOURNAL			English	Article						pancreas; eag gene family; erg gene; nesidioblastosis	PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; ISLET B-CELLS; POTASSIUM CHANNEL; ELECTRICAL-ACTIVITY; ACTION-POTENTIALS; VENTRICULAR MYOCYTES; I-KR; CURRENTS; CALCIUM; MOUSE	The human ether-a-go-go-related genes (herg) are expressed in tissues other than heart and brain where the HERG K+ channels are known to regulate the repolarization of the heart action potential and the neuronal spike-frequency accommodation. We provide evidence that herg1 transcripts are present in human pancreatic islets that were used to study both insulin secretion and electrical activity with radioimmunoassay and single cell perforated patch-clamp techniques, respectively. Glucose- and arginine-induced islets insulin secretion data suggested a net increase of release under perfusion with antiarrhythmic drug known to selectively block HERG channels. Indeed we could routinely isolate a K+ current that was recognized as biophysically and pharmacologically similar to the HERG current. An analysis of the glucose- and arginine-induced electrical activity (several applications during 30 min) in terms of firing frequency and putative insulin release was done in control and in the presence of selective blockers of HERG channels: the firing frequency and the release increased by 32% and 77%, respectively. It is concluded that HERG channels have a crucial role in regulating insulin secretion and firing of human beta -cells. This raises the possibility that some genetically characterized hyperinsulinemic diseases of unknown origin might involve mutations in the HERG channels.	Univ Milan, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Osped Cisanello, Dept Endocrinol & Metab, Metab Unit, I-56100 Pisa, Italy; Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy	University of Milan; University of Florence	Wanke, E (corresponding author), Univ Milan, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.		Marchetti, Piero/J-7439-2013	Marchetti, Piero/0000-0003-4907-0635; Crociani, Olivia/0000-0003-3485-2132	Telethon [1046] Funding Source: Medline	Telethon(Fondazione Telethon)		AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Barbosa RM, 1998, J PHYSIOL-LONDON, V510, P135, DOI 10.1111/j.1469-7793.1998.135bz.x; Barnett DW, 1995, PFLUG ARCH EUR J PHY, V431, P272, DOI 10.1007/BF00410201; Bolea S, 1997, PFLUG ARCH EUR J PHY, V433, P699, DOI 10.1007/s004240050334; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; Chouabe C, 1998, MOL PHARMACOL, V54, P695; Conget I, 1997, PANCREAS, V14, P71, DOI 10.1097/00006676-199701000-00011; DIXON JE, 1994, CIRC RES, V75, P252, DOI 10.1161/01.RES.75.2.252; DUNNE MJ, 1990, J MEMBRANE BIOL, V114, P53, DOI 10.1007/BF01869384; FALKE LC, 1989, FEBS LETT, V251, P167, DOI 10.1016/0014-5793(89)81448-6; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; GILLIS KD, 1992, PFLUG ARCH EUR J PHY, V420, P121, DOI 10.1007/BF00378654; Gopel SO, 1999, J GEN PHYSIOL, V114, P759, DOI 10.1085/jgp.114.6.759; Gurrola GB, 1999, FASEB J, V13, P953, DOI 10.1096/fasebj.13.8.953; KELLY RP, 1991, J PHYSIOL-LONDON, V443, P175, DOI 10.1113/jphysiol.1991.sp018829; KINDMARK H, 1991, FEBS LETT, V291, P310, DOI 10.1016/0014-5793(91)81309-V; Kukuvitis A, 1997, J CLIN ENDOCR METAB, V82, P1192, DOI 10.1210/jc.82.4.1192; LEFEBVRE PJ, 1997, DIABETES MELITUS, P1307; Macfarlane WM, 1997, FEBS LETT, V413, P304, DOI 10.1016/S0014-5793(97)00874-0; MAGISTRETTI J, 1996, TRENDS NEUROSCI, V19, P531; MARCHETTI P, 1995, DIABETES, V44, P375, DOI 10.2337/diabetes.44.4.375; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; Nadal A, 1999, J PHYSIOL-LONDON, V517, P85, DOI 10.1111/j.1469-7793.1999.0085z.x; Paquette T, 1998, BIOPHYS J, V74, P1278, DOI 10.1016/S0006-3495(98)77841-5; PRESSEL DM, 1990, J MEMBRANE BIOL, V116, P273, DOI 10.1007/BF01868466; Pupilli C, 1999, DIABETES, V48, P2309, DOI 10.2337/diabetes.48.12.2309; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; Schonherr R, 1999, EUR J NEUROSCI, V11, P753, DOI 10.1046/j.1460-9568.1999.00493.x; Service FJ, 1999, J CLIN ENDOCR METAB, V84, P1582, DOI 10.1210/jc.84.5.1582; Sherman A, 1996, AM J PHYSIOL-ENDOC M, V271, pE362, DOI 10.1152/ajpendo.1996.271.2.E362; Shi WM, 1997, J NEUROSCI, V17, P9423; SMITH PA, 1995, PFLUG ARCH EUR J PHY, V430, P808, DOI 10.1007/BF00386180; SPINELLI W, 1993, CARDIOVASC RES, V27, P1580, DOI 10.1093/cvr/27.9.1580; SUTTON RP, 1991, J PHYSL, V443, P175; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Titus SA, 1997, J NEUROSCI, V17, P875; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438	42	118	122	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2601	2610		10.1096/fj.00-0077com	http://dx.doi.org/10.1096/fj.00-0077com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099479				2022-12-25	WOS:000165723400031
J	Huang, LL; Sowa, Y; Sakai, T; Pardee, AB				Huang, LL; Sowa, Y; Sakai, T; Pardee, AB			Activation of the p21(WAF1/CIP1) promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites	ONCOGENE			English	Article						SAHA; p31 promoter; Sp1/Sp3	WAF1/CIP1 GENE PROMOTER; GROWTH-FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; N-COR; BINDING; REPRESSION; P300; INDUCTION; INDUCERS; HOMOLOG	Suberoylanilide hydroxamic acid (SAHA) is a novel histone deacetylase inhibitor with high potency in inducing differentiation of cultured murine erythroleukemia cells. We have recently demonstrated that SAHA induces cell cycle arrest and apoptosis in human breast cancer cells, accompanied by up-regulation of the cyclin-dependent kinase inhibitor, p21(WAF1/CIP1) via a p53-independent mechanism. In this study, we used p21 gene expression as a model system to elucidate the molecular mechanism(s) underlying SAHA-mediated gene activation. Treatment of human breast cancer cell line MICF7 cells with SAHA induced p21 mRNA as a consequence of an immediate-early gene activation. Moreover, SAHA activated the p21 promoter primarily through two Spl sites located at -82 and -69 relative to the transcription start site. Furthermore, Spl and Sp3 proteins were the major factors binding to the Spl site of the p21 promoter. However, SAHA did not alter their DNA binding activities, suggesting that SAHA mediates p21 promoter activity by a mechanism other than altering the DNA binding activities of Spl and Sp3, Further studies using the GAL4 luciferase assay system demonstrated that both GAL4-Sp1 and GAL4-Sp3 fusion proteins supported SAHA-mediated gene activation from a promoter driven by five GAL4 DNA binding sites, and that GAL4-Sp3 fusion protein,vas suppressive in the absence of SAHA treatment. Collectively, our results suggest that SAHA activates the p21 promoter through the Spl sites, and that both Spl and Sp3 proteins can mediate SAHA-induced gene activation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Kyoto Prefectural University of Medicine	Pardee, AB (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Biol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [R01CA61253] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061253] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cohen LA, 1999, ANTICANCER RES, V19, P4999; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DESAI D, 1999, P AM ASSOC CANC RES, V40, P2396; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	41	188	193	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5712	5719		10.1038/sj.onc.1203963	http://dx.doi.org/10.1038/sj.onc.1203963			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126357				2022-12-25	WOS:000165477700002
J	MacCarthy-Morrogh, L; Wood, L; Brimmell, M; Johnson, PWM; Packham, G				MacCarthy-Morrogh, L; Wood, L; Brimmell, M; Johnson, PWM; Packham, G			Identification of a novel human BCL-X promoter and exon	ONCOGENE			English	Article						apoptosis; BCL-X-L; splicing; promoter; transcription	INDUCED APOPTOSIS; BCL-X(L); EXPRESSION; GENE; CANCER; CELLS	BCL-X-L is a key anti-apoptotic BCL-2 family protein that is widely expressed in human cancer cells and is induced in response to diverse survival signals. The translation initiation codon for BCL-X-L is located in BCL-X exon II and previous analyses have indicated that BCL-X-L RNAs initiate close to the start of exon IT or additionally contain a non-coding first exon (exon IA) spliced to exon TI, Using 5' RACE we have now identified a novel BCL-X non-coding exon (exon IB) which is spliced directly to exon IJ[ in place of exon IA, Exon IB-containing RNAs encoded BCL-X-L and were detected in non-malignant lymphocytes and lymphoma cells from lymph node biopsies and mere expressed at significant levels in cell lines derived from ovarian, colon and breast cancers. We identified two TATA-hox sequences upstream of exon TB and demonstrated that surrounding genomic sequences contained strong promoter activity in lymphoma cells (approximately 300-fold active relative to controls). We have therefore identified a powerful new BCL-X promoter and a novel exon that contributes to BCL-X-L expression.	Univ Southampton, Southampton Gen Hosp, Sch Med, CRC Wessex Med Oncol Unit,Canc Sci Div, Southampton SO16 6YD, Hants, England; Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, Sch Med, London W12 1PG, England	University of Southampton; Imperial College London; Ludwig Institute for Cancer Research	Packham, G (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, CRC Wessex Med Oncol Unit,Canc Sci Div, Ctr Block,Level F, Southampton SO16 6YD, Hants, England.		Johnson, Peter/L-2403-2018; Johnson, Peter/O-3529-2019	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Packham, Graham/0000-0002-9232-5691				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; FANG W, 1994, J IMMUNOL, V153, P4388; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Harigai M, 1996, ONCOGENE, V12, P1369; Krajewska M, 1996, CANCER RES, V56, P2422; Lohmann CM, 2000, CYTOMETRY, V42, P61, DOI 10.1002/(SICI)1097-0320(20000215)42:1<61::AID-CYTO9>3.0.CO;2-5; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pena JC, 1998, CANCER RES, V58, P2111; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x	19	14	14	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5534	5538		10.1038/sj.onc.1203949	http://dx.doi.org/10.1038/sj.onc.1203949			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114731				2022-12-25	WOS:000165396100014
J	Fu, DX; Sarker, RI; Abe, K; Bolton, E; Maloney, PC				Fu, DX; Sarker, RI; Abe, K; Bolton, E; Maloney, PC			Structure/function relationships in OxlT, the oxalate-formate transporter of Oxalobacter formigenes - Assignment of transmembrane helix 11 to the translocation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE-PROTEINS; ANION-EXCHANGE; LACTOSE CARRIER; RECONSTITUTION; RESIDUES; IDENTIFICATION; SUPERFAMILY; ANTIPORT; FEATURES	OxlT, the oxalate:formate antiporter of Oxalobacter formigenes, has a lone charged residue, lysine 355 (Lys-355), at the center of transmembrane helix 11 (TM11). Because Lys-355 is the only charged residue in the hydrophobic sector, we tested the hypothesis that lysine 355 contributes to the binding site for the anionic substrate, oxalate. This idea was supported by mutational analysis, which showed that of five variants studied (Lys-355 --> Cys, Gly, Gin, Arg, or Thr), residual function was found for only the K355R derivative, in which catalytic efficiency had fallen 2,600-fold. Further insight came from a study of TM11 single-cysteine mutants, using the impermeant, thiol-specific reagents, carboxyethyl methanethiosulfonate and ethyltrimethyl-ammonium methanethiosulfonate. Of the five reactive positions identified in TM11, four were at the cytoplasmic or periplasmic ends of TM11 (S344C and A345C, and G366C and A370C, respectively), whereas the fifth was at the center of the helix (S359C). Added study with carboxyethyl methanethiosulfonate and ethylsulfonate methylthiosulfonate showed that the attack on S359C could be blocked by the presence of the substrate, oxalate, and that protection could be predicted quantitatively by a kinetic model in which S359C is accessible only in the unliganded form of OxlT. Parallel study showed that the proteoliposomes used in such work contained OxlT of right side-out and inside-out orientations in about equal amounts. Accordingly, full inhibition of S359C by the impermeable methanethiosulfonate-linked probes must reflect an approach from both the cytosolic and periplasmic surfaces of the protein. This, coupled with the finding of substrate protection, leads us to conclude that S359C lies on the translocation pathway through OxlT, Since position 359 and 355 lie on the same helical face, we suggest that Lys-355 also lies on the translocation pathway, consistent with the idea that the essential nature of Lys-355 reflects its role in binding the anionic substrate, oxalate.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Maloney, PC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.	pmaloney@jhmi.edu		Fu, Dax/0000-0002-2663-1316				Abe K, 1996, J BIOL CHEM, V271, P6789, DOI 10.1074/jbc.271.12.6789; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Fann MC, 1998, J BIOL CHEM, V273, P33735, DOI 10.1074/jbc.273.50.33735; Fu DX, 1998, J BIOL CHEM, V273, P17962, DOI 10.1074/jbc.273.28.17962; Fu DX, 1997, J BIOL CHEM, V272, P2129; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; Hall JA, 1999, J BIOL CHEM, V274, P6148, DOI 10.1074/jbc.274.10.6148; Harold F. M., 1996, ESCHERICHIA COLI SAL, P283; Kaback HR, 1998, ACTA PHYSIOL SCAND, V163, P21; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE JI, 1992, J BIOL CHEM, V267, P20758; MALONEY PC, 1990, PHILOS T ROY SOC B, V326, P437, DOI 10.1098/rstb.1990.0023; MALONEY PC, 1992, J BIOL CHEM, V267, P10531; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MALONEY PC, 1996, ESCHERICHIA COLI SAL, P1130; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; VARADHACHARY A, 1990, MOL MICROBIOL, V4, P1407, DOI 10.1111/j.1365-2958.1990.tb00720.x; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	28	26	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8753	8760		10.1074/jbc.M008417200	http://dx.doi.org/10.1074/jbc.M008417200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11113128	hybrid			2022-12-25	WOS:000167607700020
J	Misawa, H; Kawasaki, Y; Mellor, J; Sweeney, N; Jo, K; Nicoll, RA; Bredt, DS				Misawa, H; Kawasaki, Y; Mellor, J; Sweeney, N; Jo, K; Nicoll, RA; Bredt, DS			Contrasting localizations of MALS/LIN-7 PDZ proteins in brain and molecular compensation in knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; TUMOR-SUPPRESSOR GENE; BASOLATERAL MEMBRANE; EPITHELIAL-CELLS; NMDA RECEPTOR; COMPLEX; CASK/LIN-2; DOMAIN; PATHWAYS; SYNAPSES	Proteins containing PDZ (postsynaptic density-95, discs large, zonula occludens) domains play a-general role in recruiting receptors and enzymes to specific synaptic sites. In Caenorhabditis elegans, a complex of three PDZ proteins, LIN-2/7/10, mediates basolateral targeting of a receptor tyrosine kinase. Homologs of these LIN proteins have also been identified in higher organisms, and here we analyze the MALS/Veli (mammalian LIN-7/vertebrate homolog of LIN-7) proteins in brain. Immunohistochemical staining and in situ hybridization show that MALS occur differentially in discrete populations of neurons throughout the brain. Most neurons express only one MALS protein, although some cells contain two or even all three MALS isoforms, At the subcellular level, MALS proteins are found in both dendritic and axonal locations, suggesting that they may regulate processes at both pre- and postsynaptic sites. Targeted disruption of MALS-1 and MALS-2 does not yield a detectable phenotype, and hippocampal synaptic function and plasticity are intact in the MALS-1/2 double knockouts. Interestingly, MALS-3 protein is dramatically induced in the MALS-1/2 double knockouts, implying that dynamic changes in protein expression may play an important regulatory role for this family of synaptic PDZ proteins.	Univ Calif San Francisco, Sch Med, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bredt, DS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.		MELLOR, Jack/B-4548-2019	MELLOR, Jack/0000-0002-7706-8105				Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Hata Y, 1996, J NEUROSCI, V16, P2488; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hsueh YP, 1998, PROG BRAIN RES, V116, P123, DOI 10.1016/S0079-6123(08)60434-3; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; MCGEE AW, 2001, IN PRESS J NEUROSCI; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	25	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9264	9272		10.1074/jbc.M009334200	http://dx.doi.org/10.1074/jbc.M009334200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11104771	hybrid			2022-12-25	WOS:000167607700086
J	Timchenko, NA; Cai, ZJ; Welm, AL; Reddy, S; Ashizawa, T; Timchenko, LT				Timchenko, NA; Cai, ZJ; Welm, AL; Reddy, S; Ashizawa, T; Timchenko, LT			RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL INHIBITORY PROTEIN; CCAAT/ENHANCER-BINDING-PROTEIN; MYOTONIC-DYSTROPHY; TRIPLET REPEAT; MESSENGER-RNA; C/EBP-ALPHA; GENE; EXPRESSION; DEVELOP; CLONING	An RNA CUG triplet repeat binding protein, CUGBP1, regulates splicing and translation of various RNAs, Expansion of RNA CUG repeats in the 3'-untranslated repeat of the mutant myotonin protein kinase (DMPK) mRNA in myotonic dystrophy (DM) is associated with alterations in binding activity of CUGBP1. To investigate whether CUGBP1 is directly affected by expansion of CUG repeats in DM tissues, we examined the intracellular status of CUGBP1 in DM patients as well as in cultured cells over expressing RNA CUG repeats. The analysis of RNA.protein complexes showed that, in control tissues, the majority of CUGBP1 is free of RNA, whereas in DM patients the majority of CUGBP1 is associated with RNA containing CUG repeats. Similarly to DM patients, overexpression of RNA CUG repeats in cultured cells results in the re-allocation of CUGBP1 from a free state to the RNA.protein complexes containing CUG repeats, CUG repeat-dependent translocation of CUGBP1 into RNA protein complexes is associated with increased levels of CUGBP1 protein and its binding activity. Experiments with cyclohexamide-dependent block of protein synthesis showed that the half-life of CUGBP1 is increased in cells expressing CUG repeats. Alteration of CUGBP1 in DM is accompanied by alteration in translation of a transcription factor CCAAT/enhancer-binding protein beta (C/EBP beta), which has been previously described to be a target of CUGBP1. Analysis of C/EBP beta isoforms in DM patients with altered levels of CUGBP1 showed that translation of a dominant negative isoform, LIP, is induced by CUGBP1. Results of this paper demonstrate that the expansion of CUG repeats in DM affects RNA-binding proteins and leads to alteration in RNA processing.	Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Southern California	Timchenko, LT (corresponding author), Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, 1 Baylor Plaza, Houston, TX 77030 USA.	lubovt@bcm.tmc.edu			NIAMS NIH HHS [AR10D443887] Funding Source: Medline; NIA NIH HHS [AG00765-01, AG16392] Funding Source: Medline; NIGMS NIH HHS [GM55188-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG016392] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BOUCHER CA, 1995, HUM MOL GENET, V4, P1919, DOI 10.1093/hmg/4.10.1919; Calkhoven CF, 2000, GENE DEV, V14, P1920; Caskey CT, 1996, COLD SPRING HARB SYM, V61, P607; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; Good PJ, 2000, J BIOL CHEM, V275, P28583, DOI 10.1074/jbc.M003083200; Harper P.S., 1989, MYOTONIC DYSTROPHY; JANSEN G, 1995, HUM MOL GENET, V4, P843, DOI 10.1093/hmg/4.5.843; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; Klesert TR, 2000, NAT GENET, V25, P105, DOI 10.1038/75490; Lu XH, 1999, HUM MOL GENET, V8, P53, DOI 10.1093/hmg/8.1.53; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Michalowski S, 1999, NUCLEIC ACIDS RES, V27, P3534, DOI 10.1093/nar/27.17.3534; Miller JW, 2000, EMBO J, V19, P4439, DOI 10.1093/emboj/19.17.4439; Ordway JM, 1996, BIOTECHNIQUES, V21, P609; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Tian B, 2000, RNA, V6, P79, DOI 10.1017/S1355838200991544; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; Timchenko LT, 1999, AM J HUM GENET, V64, P360, DOI 10.1086/302268; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Welm AL, 2000, J BIOL CHEM, V275, P27406	30	232	239	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7820	7826		10.1074/jbc.M005960200	http://dx.doi.org/10.1074/jbc.M005960200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11124939	hybrid			2022-12-25	WOS:000167474900022
J	Walker, CS; Shetty, RP; Clark, K; Kazuko, SG; Letsou, A; Olivera, BM; Bandyopadhyay, PK				Walker, CS; Shetty, RP; Clark, K; Kazuko, SG; Letsou, A; Olivera, BM; Bandyopadhyay, PK			On a potential global role for vitamin K-dependent gamma-carboxylation in animal systems - Evidence for a gamma-glutamyl carboxylase in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-CONTAINING CONOTOXIN; CONANTOKIN-G; MEMBRANE-BINDING; CONUS VENOMS; GLA DOMAIN; PROTEINS; SNAIL; GENE; PROTHROMBIN; ION	The vitamin K-dependent gamma -carboxylation of glutamate to gamma -carboxyglutamate was originally well characterized in the mammalian blood clotting cascade. gamma -Carboxyglutamate has also been found in a number of other mammalian proteins and in neuropeptides from the venoms of marine snails belonging to the genus Conus, suggesting wider prevalence of gamma -carboxylation, We demonstrate that an open reading frame from a Drosophila melanogaster cDNA clone encodes a protein with vitamin K-dependent gamma -carboxylase activity. The open reading frame, 670 amino acids in length, is truncated at the C-terminal end compared with mammalian gamma -carboxylase, which is 758 amino acids. The mammalian gene has 14 introns; in Drosophila there are two much shorter introns but in positions precisely homologous to two of the mammalian introns. In addition, a deletion of 6 nucleotides is observed when cDNA and genomic sequences are compared. In situ hybridization to fixed embryos indicated ubiquitous presence of carboxylase mRNA throughout embryogenesis. Northern blot analysis revealed increased mRNA levels in 12-24-h embryos. The continued presence of carboxylase mRNA suggests that it plays an important role during embryogenesis. Although the model substrate FLEEL is carboxylated by the enzyme, a substrate containing the propeptide of a Conus carboxylase substrate, conantokin G, is poorly carboxylated. Its occurrence in vertebrates, molluscan systems (i.e. Conus), and Drosophila and the apparently strong homology between the three systems suggest that this is a highly conserved and widely distributed posttranslational modification in biological systems.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bandyopadhyay, PK (corresponding author), Univ Utah, Dept Biol, 257 S 1400 E,Rm 201, Salt Lake City, UT 84112 USA.				NIGMS NIH HHS [GM48677] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES AJ, 1992, DEVELOPMENT, V116, P865; Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; Begley GS, 2000, J BIOL CHEM, V275, P36245, DOI 10.1074/jbc.M003944200; Blandl T, 1997, BIOCHEM J, V328, P777, DOI 10.1042/bj3280777; Brenner B, 1998, BLOOD, V92, P4554, DOI 10.1182/blood.V92.12.4554.424k42_4554_4559; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Bush KA, 1999, BIOCHEMISTRY-US, V38, P14660, DOI 10.1021/bi991640l; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craig AG, 1999, EUR J BIOCHEM, V264, P271, DOI 10.1046/j.1432-1327.1999.00624.x; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; Deutsch M, 1999, NUCLEIC ACIDS RES, V27, P3219, DOI 10.1093/nar/27.15.3219; ESMON CT, 1975, J BIOL CHEM, V250, P4744; ESMON CT, 1995, CURR BIOL, V5, P743, DOI 10.1016/S0960-9822(95)00150-3; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; Frohman Michael A., 1994, P14; HAUSCHKA PV, 1988, CURRENT ADV VITAMIN, P237; KULIOPULOS A, 1992, BIOCHEMISTRY-US, V31, P9436, DOI 10.1021/bi00154a016; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MANN KG, 1990, BLOOD, V76, P1; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MYERS RA, 1990, J TOXICOL-TOXIN REV, V9, P179, DOI 10.3109/15569549009033113; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; PRICE PA, 1985, J BIOL CHEM, V260, P4971; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P6906, DOI 10.1021/bi970321w; Romero EE, 1998, EXP CELL RES, V243, P334, DOI 10.1006/excr.1998.4151; ROTH DA, 1995, J BIOL CHEM, V270, P5305, DOI 10.1074/jbc.270.10.5305; Sambrook J., 2002, MOL CLONING LAB MANU; Skjaerbaek N, 1997, J BIOL CHEM, V272, P2291; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; Stronach BE, 1996, J CELL BIOL, V134, P1179, DOI 10.1083/jcb.134.5.1179; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; Warder SE, 1997, FEBS LETT, V411, P19, DOI 10.1016/S0014-5793(97)00573-5; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; Wu SM, 1997, BLOOD, V89, P4058, DOI 10.1182/blood.V89.11.4058	40	41	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7769	7774		10.1074/jbc.M009576200	http://dx.doi.org/10.1074/jbc.M009576200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11110799	hybrid			2022-12-25	WOS:000167474900015
J	Khaled, AR; Reynolds, DA; Young, HA; Thompson, CB; Muegge, K; Durum, SK				Khaled, AR; Reynolds, DA; Young, HA; Thompson, CB; Muegge, K; Durum, SK			Interleukin-3 withdrawal induces an early increase in mitochondrial membrane potential unrelated to the Bcl-2 fammily - Roles of intracellular pH, ADP transport, and F0F1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; CYTOCHROME-C; INHIBITOR PROTEIN; CULTURED-CELLS; ATP SYNTHASE; APOPTOSIS; RELEASE; BAX; DEATH; BCECF	Cytokines such as interleukin-3 (IL-3) promote the survival of hematopoietic cells through mechanisms that are not well characterized. Withdrawal of IL-3 from an IL-3-dependent pro-B cell line induced early stress-related events that preceded cell death by more than 40 h. Intracellular pH rose above pH 7.8, peaking 2-3 h post-IL-3 withdrawal, and induced a transient increase in mitochondrial membrane potential (Delta psi (m)) detected using several different dyes. Similar events were observed following IL-7 withdrawal from a different dependent cell line. Bcl-2, Bax, and caspases were unrelated to these early events. Intracellular alkaline pH inhibited the mitochondrial import of ADP, which would limit ATP synthesis. Total cellular ATP sharply declined during this early period, presumably as a consequence of suppressed ADP import. This was followed by an increase in reduced pyridine nucleotides. The transient increase in Delta psi (m) was blocked by oligomycin, an inhibitor of F0F1. ATPase that may have undergone reversal caused by the abnormal ADP-ATP balance within mitochondria. These findings suggest a novel sequence of early events following trophic factor withdrawal in which alkaline pH inhibits ADP import into mitochondria, reversing the F0F1. ATPase, which in turn consumes ATP and pumps out protons, raising Delta psi (m).	NCI, Sect Cytokines & Immun, Mol Immunoregulat Lab, Div Basic Sci,NIH, Frederick, MD 21702 USA; NCI, Expt Immunol Lab, Div Basic Sci, NIH, Frederick, MD 21702 USA; Sci Applicat Int Corp, Frederick, MD 21702 USA; Univ Penn, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); University of Pennsylvania	Durum, SK (corresponding author), NCI, Sect Cytokines & Immun, Mol Immunoregulat Lab, Div Basic Sci,NIH, Bldg 560,Rm 31-71, Frederick, MD 21702 USA.	durums@mail.ncifcrf.gov	Young, Howard/A-6350-2008	Young, Howard/0000-0002-3118-5111; durum, scott/0000-0003-1307-9582				ALBERTS B, 1998, MOL BIOL CELL; Banki K, 1999, J IMMUNOL, V162, P1466; BENDER JG, 1985, J LEUKOCYTE BIOL, V38, P603, DOI 10.1002/jlb.38.5.603; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Carlson K, 1999, TOXICOL APPL PHARM, V160, P33, DOI 10.1006/taap.1999.8741; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; delPeso L, 1997, SCIENCE, V278, P687; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; Franck P, 1996, J BIOTECHNOL, V46, P187, DOI 10.1016/0168-1656(95)00189-1; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUERRIERI F, 1987, FEBS LETT, V213, P67, DOI 10.1016/0014-5793(87)81466-7; HARRIS DA, 1991, BIOCHEM J, V280, P561, DOI 10.1042/bj2800561; Johnson Daniel E., 1998, Frontiers in Bioscience, V3, pD313; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; Lebowitz MS, 1996, ARCH BIOCHEM BIOPHYS, V330, P342, DOI 10.1006/abbi.1996.0261; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; LICHTMAN AH, 1986, NATURE, V324, P489, DOI 10.1038/324489a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Minamikawa T, 1999, EXP CELL RES, V246, P26, DOI 10.1006/excr.1998.4290; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Oster G, 1999, STRUCTURE, V7, pR67, DOI 10.1016/S0969-2126(99)80046-X; Papa S, 1996, EUR J BIOCHEM, V240, P461, DOI 10.1111/j.1432-1033.1996.0461h.x; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; ROUSLIN W, 1989, J BIOL CHEM, V264, P15224; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; THORELL B, 1983, CYTOMETRY, V4, P61, DOI 10.1002/cyto.990040109; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Weinlich M, 1998, J EXP BIOL, V201, P57; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	45	77	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6453	6462		10.1074/jbc.M006391200	http://dx.doi.org/10.1074/jbc.M006391200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11102440	hybrid			2022-12-25	WOS:000167261000052
J	Einolf, HJ; Guengerich, FP				Einolf, HJ; Guengerich, FP			Fidelity of nucleotide insertion at 8-Oxo-7,8-dihydroguanine by mammalian DNA polymerase delta - Steady-state and pre-steady-state kinetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; HIV-1 REVERSE-TRANSCRIPTASE; TEMPLATE-PRIMER COMPLEX; SACCHAROMYCES-CEREVISIAE; MUTAGENIC SUBSTRATE; SECONDARY STRUCTURE; DNTPS OPPOSITE; II EXO(-); MISINCORPORATION; REPLICATION	Nucleotide insertion opposite 8-oxo-7,8-dihydroguanine (8-oxoG) by fetal calf thymus DNA polymerase delta (pol delta) was examined by steady-state and pre-steady-state rapid quench kinetic analyses. In steady-state reactions with the accessory protein proliferating cell nuclear antigen (PCNA), pol delta preferred to incorporate dCTP opposite 8- oxoG with an efficiency of incorporation an order of magnitude lower than incorporation into unmodified DNA (mainly due to an increased K-m). Pre-steady-state kinetic analysis of incorporation opposite 8-oxoG showed biphasic kinetics for incorporation of either dCTP or dATP, with rates similar to dCTP incorporation opposite G, large phosphorothioate effects (>100), and oligonucleotide dissociation apparently rate-limiting in the steady-state. Although pol delta preferred to incorporate dCTP (14% misincorporation of dATP) the extension past the A:8-oxoG mispair predominated. The presence of PCNA was found to be a more essential factor for nucleotide incorporation opposite 8-oxoG adducts than unmodified DNA, increased presteady-state rates of nucleotide incorporation by >2 orders of magnitude, and was essential for nucleotide extension beyond 8-oxoG. pol delta replication fidelity at 8-oxoG depends upon contributions from K-m,K-d(dNTP), and rates of phosphodiester bond formation, and PCNA is an important accessory protein for incorporation and extension at 8-oxoG adducts.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Einolf, HJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Med Res Bldg 1,23rd & Pierce Ave, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [F32CA075731, R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA44353, F32 CA75731] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; CADET J, 1998, PHYSL BIOCH PHARM, P1; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; FRIEDBERG E, 1995, DNA REPAIR MUTAGENIS; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Furge LL, 1998, BIOCHEMISTRY-US, V37, P3567, DOI 10.1021/bi9722094; Furge LL, 1997, BIOCHEMISTRY-US, V36, P6475, DOI 10.1021/bi9627267; Furge LL, 1999, BIOCHEMISTRY-US, V38, P4818, DOI 10.1021/bi982163u; Goodman MF, 1998, NATURE, V395, P221, DOI 10.1038/26111; Hindges R, 1997, BIOL CHEM, V378, P345; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kim MS, 1998, CHEM RES TOXICOL, V11, P311, DOI 10.1021/tx970206m; Kornberg A., 1992, DNA REPLICATION; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; Langouet S, 1998, BIOCHEMISTRY-US, V37, P5184, DOI 10.1021/bi972327r; Langouet S, 1997, BIOCHEMISTRY-US, V36, P6069, DOI 10.1021/bi962526v; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Lowe LG, 1996, BIOCHEMISTRY-US, V35, P9840, DOI 10.1021/bi960485x; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; McConnell M, 1996, BIOCHEMISTRY-US, V35, P8268, DOI 10.1021/bi9530649; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Morales JC, 2000, J AM CHEM SOC, V122, P1001, DOI 10.1021/ja993464+; Mozzherin DJ, 1999, J BIOL CHEM, V274, P19862, DOI 10.1074/jbc.274.28.19862; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; NG L, 1993, J BIOL CHEM, V268, P13571; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Schumacher SB, 2000, NUCLEIC ACIDS RES, V28, P620, DOI 10.1093/nar/28.2.620; SEARLE C, 1984, CHEM CARCINOGENS, V1; SEARLE CE, 1984, CHEM CARCINOGENS, V2; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1999, BIOCHEMISTRY-US, V38, P715, DOI 10.1021/bi981854n; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; XIAO W, 1991, EMBO J, V10, P2179, DOI 10.1002/j.1460-2075.1991.tb07753.x; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647	51	113	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3764	3771		10.1074/jbc.M006696200	http://dx.doi.org/10.1074/jbc.M006696200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11110788	hybrid			2022-12-25	WOS:000166921200007
J	Sekine, S; Shimada, A; Nureki, O; Cavarelli, J; Moras, D; Vassylyev, DG; Yokoyama, S				Sekine, S; Shimada, A; Nureki, O; Cavarelli, J; Moras, D; Vassylyev, DG; Yokoyama, S			Crucial hole of the HIGH-loop lysine for the catalytic activity of arginyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; RECOGNITION; ACTIVATION; SEQUENCE; PROGRAM	The presence of two short signature sequence motifs (His-Ile-Gly-His (HIGH) and Lys-Met-Ser-Lys (KMSK)) is a characteristic of the class I aminoacyl-tRNA synthetases. These motifs constitute a portion of the catalytic site in three dimensions and play an important role in catalysis. In particular, the second lysine of the KMSK motif (K2) is the crucial catalytic residue for stabilization of the transition state of the amino acid activation reaction (aminoacyl-adenylate formation). Arginyl-tRNA synthetase (ArgRS) is unique among all of the class I enyzmes, as the majority of ArgRS species lack canonical KMSK sequences. Thus, the mechanism by which this group of ArgRSs achieves the catalytic reaction is not well understood. Using three-dimensional modeling in combination with sequence analysis and site-directed mutagenesis, we found a conserved lysine in the KMSK-lacking ArgRSs upstream of the HIGH sequence motif, which is likely to be a functional counterpart of the canonical class I K2 lysine. The results suggest a plausible partition of the ArgRSs into two major groups, on the basis of the conservation of the HIGH lysine.	RIKEN, Cellular Signaling Lab, Harima Inst, Sayo, Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	RIKEN; University of Tokyo; Institut National de la Sante et de la Recherche Medicale (Inserm)	Yokoyama, S (corresponding author), RIKEN, Cellular Signaling Lab, Harima Inst, 1-1-1 Kouto,Mikazuki Cho, Sayo, Hyogo 6795148, Japan.		Cavarelli, Jean/P-3566-2016; Sekine, Shun-ichi/N-5450-2015; Vassylyev, Dmitry/A-9005-2008; Yokoyama, Shigeyuki/N-6911-2015	Cavarelli, Jean/0000-0001-8620-8723; Sekine, Shun-ichi/0000-0001-8174-8704; Yokoyama, Shigeyuki/0000-0003-3133-7338				CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; Cavarelli J, 1998, EMBO J, V17, P5438, DOI 10.1093/emboj/17.18.5438; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MECHULAM Y, 1991, J MOL BIOL, V217, P465, DOI 10.1016/0022-2836(91)90750-Z; MEHLER AH, 1967, J BIOL CHEM, V242, P5495; Meinnel Thierry, 1995, P251; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mitra K, 1966, J Biol Chem, V241, P5161; MITRA SK, 1967, J BIOL CHEM, V242, P5490; NUREKI O, 1994, J MOL BIOL, V236, P710, DOI 10.1006/jmbi.1994.1184; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; Rath VL, 1998, STRUCT FOLD DES, V6, P439, DOI 10.1016/S0969-2126(98)00046-X; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Schimmel P, 1998, FASEB J, V12, P1599, DOI 10.1096/fasebj.12.15.1599; SCHMITT E, 1994, J MOL BIOL, V242, P566, DOI 10.1006/jmbi.1994.1601; Sekine S, 1996, J MOL BIOL, V256, P685, DOI 10.1006/jmbi.1996.0118; ZAWADZKI V, 1991, NUCLEIC ACIDS RES, V19, P1948, DOI 10.1093/nar/19.8.1948	21	16	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3723	3726		10.1074/jbc.C000756200	http://dx.doi.org/10.1074/jbc.C000756200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11106639	hybrid			2022-12-25	WOS:000166921200002
J	Troussard, AA; Costello, P; Yoganathan, TN; Kumagai, S; Roskelley, CD; Dedhar, S				Troussard, AA; Costello, P; Yoganathan, TN; Kumagai, S; Roskelley, CD; Dedhar, S			The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9)	ONCOGENE			English	Article						tumor invasion; matrix metalloproteinases; integrins; signal transduction; AP-1 transcription factor	ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; IV COLLAGENASE; GROWTH-FACTOR; E-CADHERIN; IN-VITRO; CELL-ADHESION; EXPRESSION; GELATINASE; INHIBITORS	Overexpression of Integrin Linked Kinase (ILK) in intestinal and mammary epithelial cells results in a highly invasive phenotype, associated with increased levels of expression of the matrix metalloproteinase MMP-9. This increase was at the transcriptional level as determined by MMP-9 promoter-CAT reporter assays. Mutations in the two AP-1 binding sites within the MMP-9 promoter completely inhibited the reporter activity. We have previously shown that ILK inhibits glycogen synthase kinase-3 (GSK-3) activity, Transient transfection of wild-type GSK-3 beta in ILK-overexpressing cells decreased MMP-9 promoter activity and AP-I activity, indicating that ILK can stimulate MMP-9 expression via GSK-3 beta and AP-1 transcription factor, A small molecule inhibitor of the ILK kinase reduced the in vitro invasiveness of ILK-overexpressing cells as well as the invasiveness of several human brain tumor cell lines. Furthermore, both MMP-9 promoter and AP-1 activities mere inhibited by the ILK inhibitor. Invasiveness of ILK-overexpressing cells was also reduced by inhibition of MMP-9. These data demonstrate that ILK can induce an invasive phenotype via AP-1-dependent upregulation of MMP-9.	British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6P2, Canada; Kanazawa Univ, Sch Med, Kanazawa, Ishikawa 920, Japan; Univ British Columbia, Dept Anat, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; Kanazawa University; University of British Columbia; University of British Columbia	Dedhar, S (corresponding author), British Columbia Canc Agcy, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		Roskelley, Calvin D/F-4630-2011	Dedhar, Shoukat/0000-0003-4355-1657				Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Llorens A, 1998, LAB INVEST, V78, P1131; Luo J, 1999, CANCER RES, V59, P3552; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Ozes ON, 1999, NATURE, V401, P82; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; Sato F, 1999, BRIT J CANCER, V80, P1366, DOI 10.1038/sj.bjc.6690530; SATO H, 1993, ONCOGENE, V8, P395; Simon C, 1998, CANCER RES, V58, P1135; Tamaki M, 1997, J NEUROSURG, V87, P602, DOI 10.3171/jns.1997.87.4.0602; Tonn JC, 1999, INT J CANCER, V80, P764, DOI 10.1002/(SICI)1097-0215(19990301)80:5<764::AID-IJC22>3.0.CO;2-J; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	31	167	176	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5444	5452		10.1038/sj.onc.1203928	http://dx.doi.org/10.1038/sj.onc.1203928			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114721				2022-12-25	WOS:000165396100004
J	Brinson, AE; Harden, TK				Brinson, AE; Harden, TK			Differential regulation of the uridine nucleotide-activated P2Y4 and P2Y6 receptors - Ser-333 and Ser-334 in the carboxyl terminus are involved in agonist-dependent phosphorylation desensitization and internalization of the P2Y4 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA-ADRENERGIC-RECEPTOR; PHOSPHOLIPASE-C; KINASE-C; ASTROCYTOMA-CELLS; HETEROLOGOUS DESENSITIZATION; ADENYLYL-CYCLASE; UTP; ATP; EXPRESSION	Agonist-promoted regulation of the uridine nucleotide activated human P2Y4 receptor (P2Y4-R) and P2Y6 receptor (P2Y6-R) was studied. Incubation of P2Y4-R-expressing 1321N1 human astrocytoma cells with the cognate agonist UTP resulted in rapid desensitization of the inositol phosphate response and a 50% loss of cell surface receptors. In contrast, incubation of P2Y6-R-expressing cells with the cognate agonist UDP caused neither rapid desensitization nor rapid loss of cell surface receptors. Removal of UTP from the medium of UTP-pretreated cells resulted in rapid and complete recovery of surface P2Y4-R even after 12 h of agonist treatment. Although extended incubation with UDP also caused a loss of surface P2Y6-R, rapid recovery of surface P2Y6-R did not occur following removal of agonist. Pharmacological studies indicated that neither protein kinase C nor other Ca2+-activated kinases were involved in agonist-promoted desensitization or loss of surface P2Y4-R or P2Y6-R Mutational analyses were carried out to identify domains involved in agonist-dependent regulation of P2Y4-R Sequential truncation of the carboxyl-terminal domain revealed that sequence between amino acids 332 and 343 was necessary for UTP-promoted desensitization and internalization. Further mutational analyses of the three serines in this domain confirmed that Ser-333 and Ser-334 play a major role in these agonist promoted changes in P2Y4-R. Experiments were carried out with [P-32]P-i-labeled cells to ascertain the role of phosphorylation in regulation of P2Y4-R Incubation with UTP for 2 min caused a marked increase in phosphorylation of both the wild-type P2Y4-R and the P2Y4-343 truncation mutant. In contrast, no UTP-promoted phosphorylation of the P2Y4-332 truncation mutant was observed. Taken together, these results demonstrate differential regulation of uridine nucleotide-activated P2Y4-R and P2Y6-R and indicate that Ser-333 and Ser-334 in the carboxyl terminus of P2Y4-R are important for UTP-dependent phosphorylation, desensitization, and loss of surface receptors.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Harden, TK (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	tkh@med.unc.edu			NHLBI NIH HHS [HL34322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BROWN HA, 1991, MOL PHARMACOL, V40, P648; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; Comstock K E, 1997, Methods Mol Biol, V62, P207; COWEN DS, 1990, J BIOL CHEM, V265, P16181; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; DOSS RC, 1981, J BIOL CHEM, V256, P2281; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; FISHER SK, 1995, EUR J PHARM-MOLEC PH, V288, P231, DOI 10.1016/0922-4106(95)90035-7; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HARDEN TK, 1986, MOL PHARMACOL, V30, P200; HARDEN TK, 1998, IUPHAR COMPENDIUM RE, P209; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kennedy C, 2000, MOL PHARMACOL, V57, P926; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAZAROWSKI ER, 1994, J BIOL CHEM, V269, P11830; Lazarowski ER, 1999, BRIT J PHARMACOL, V127, P1272, DOI 10.1038/sj.bjp.0702654; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MENNITI FS, 1991, MOL PHARMACOL, V40, P727; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; RITTENHOUSE SE, 1985, J BIOL CHEM, V260, P8657; Robaye B, 1997, EUR J PHARMACOL, V329, P231, DOI 10.1016/S0014-2999(97)89184-4; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; SEIFERT R, 1989, EUR J BIOCHEM, V181, P277, DOI 10.1111/j.1432-1033.1989.tb14722.x; Spurney RF, 1998, J BIOL CHEM, V273, P28496, DOI 10.1074/jbc.273.43.28496; Sromek SM, 1998, MOL PHARMACOL, V54, P485, DOI 10.1124/mol.54.3.485; STUTCHFIELD J, 1990, FEBS LETT, V262, P256, DOI 10.1016/0014-5793(90)80204-V; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; VANDERMERWE PA, 1989, FEBS LETT, V243, P333, DOI 10.1016/0014-5793(89)80156-5; VONKUGELGEN I, 1987, N-S ARCH PHARMACOL, V336, P556, DOI 10.1007/BF00169313; WALDO GL, 1984, MOL PHARMACOL, V26, P424; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Willars GB, 1998, BIOCHEM J, V333, P301, DOI 10.1042/bj3330301; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; Zimmermann H, 1996, DRUG DEVELOP RES, V39, P337, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<337::AID-DDR15>3.0.CO;2-Z	60	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11939	11948		10.1074/jbc.M009909200	http://dx.doi.org/10.1074/jbc.M009909200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11114308	hybrid			2022-12-25	WOS:000168081800068
J	Kelley, SO; Steinberg, SV; Schimmel, P				Kelley, SO; Steinberg, SV; Schimmel, P			Fragile T-stem in disease-associated human mitochondrial tRNA sensitizes structure to local and distant mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POINT MUTATION; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; TRNA(ILE) GENE; CARDIOMYOPATHY; DETERMINANT; TRANSCRIPTS; SYNTHETASE	Mutations in human mitochondrial isoleucine tRNA (hs mt tRNA(Ile)) are associated with cardiomyopathy and opthalmoplegia. A recent study showed that opthalmoplegia-related mutations gave rise to severe decreases in aminoacylation efficiencies and that the defective mutant tRNAs were effective inhibitors of aminoacylation of the wild-type substrate. The results suggested that the effectiveness of the mutations was due in large part to an inherently fragile mitochondrial tRNA structure. Here, we investigate mutant tRNAs associated with cardiomyopathy, and a series of rationally designed second-site substitutions introduced into both opthalmoplegia- and cardiomyopathy-related mutant tRNAs. A source of structural fragility was uncovered. An inherently unstable T-stem appears susceptible to misalignments. This susceptibility sensitizes both domains of the L-shaped tRNA structure to base substitutions that are deleterious. Thus, the fragile T-stem makes the structure of this human mitochondrial tRNA particularly vulnerable to local and distant mutations.	Scripps Res Inst, Skaggs Inst Chem Biol, Beckman Ctr, La Jolla, CA 92037 USA; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Scripps Research Institute; Universite de Montreal	Kelley, SO (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, Beckman Ctr, La Jolla, CA 92037 USA.	shana.kelley@bc.edu; schimmel@scripps.edu	Kelley, Shana/ABA-7403-2021; Kelley, Shana/H-5856-2015	Kelley, Shana/0000-0003-3360-5359	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015539, R01GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cai YC, 2000, J BIOL CHEM, V275, P20308, DOI 10.1074/jbc.M001899200; CASALI C, 1995, BIOCHEM BIOPH RES CO, V213, P588, DOI 10.1006/bbrc.1995.2172; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166; Degoul F, 1998, HUM MOL GENET, V7, P347, DOI 10.1093/hmg/7.3.347; Enriquez JA, 2000, J BIOL CHEM, V275, P11207, DOI 10.1074/jbc.275.15.11207; Farrow MA, 1999, BIOCHEMISTRY-US, V38, P16898, DOI 10.1021/bi9920782; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Kelley SO, 2000, NAT STRUCT BIOL, V7, P862, DOI 10.1038/79612; Martin Nancy C., 1995, P127; Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.3.CO;2-Y; MITOMAP, 2000, HUM MIT GEN DAT; NUREKI O, 1994, J MOL BIOL, V236, P710, DOI 10.1006/jmbi.1994.1184; Pallanck Leo, 1995, P371; Ramesh V, 1997, RNA, V3, P1220; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORELLI FM, 1995, BIOCHEM BIOPH RES CO, V216, P835, DOI 10.1006/bbrc.1995.2697; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; Silvestri G, 1996, BIOCHEM BIOPH RES CO, V220, P623, DOI 10.1006/bbrc.1996.0453; Takai D, 1999, J BIOL CHEM, V274, P11199, DOI 10.1074/jbc.274.16.11199; TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I; TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9; Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	26	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10607	10611		10.1074/jbc.M008320200	http://dx.doi.org/10.1074/jbc.M008320200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11110797	hybrid			2022-12-25	WOS:000167980900007
J	Dominguez-Solis, JR; Gutierrez-Alcala, G; Romero, LC; Gotor, C				Dominguez-Solis, JR; Gutierrez-Alcala, G; Romero, LC; Gotor, C			The cytosolic O-acetylserine(thiol)lyase gene is regulated by heavy metals and can function in cadmium tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; BRASSICA-JUNCEA L; ARABIDOPSIS-THALIANA; PHYTOCHELATIN SYNTHASE; GLUTATHIONE SYNTHESIS; ATP SULFURYLASE; MAIZE SEEDLINGS; PLANTS; EXPRESSION; BIOSYNTHESIS	Regulation of the expression of the cytosolic O-acetyl-serine(thiol)lyase gene (Atcys-3A) from Arabidopsis thaliana under heavy metal stress conditions has been investigated. Northern blot analysis of Atcys-3A expression shows a 7-fold induction after 18 h of cadmium treatment. Addition of 50 muM CdCl2 to the irrigation medium of mature Arabidopsis plants induces a rapid accumulation of the mRNA throughout the leaf lamina, the root and stem cortex, and stem vascular tissues when compared with untreated plants, as observed by in situ hybridization. High pressure liquid chromatography analysis of GSH content shows a transient increase after 18 h of metal treatment. Our results are compatible with a high cysteine biosynthesis rate under heavy metal stress required for the synthesis of GSH and phytochelatins, which are involved in the plant detoxification mechanism. Arabidopsis-transformed plants overexpressing the Atcys-3A gene by up to g-fold show increased tolerance to cadmium when grown in medium containing 250 muM CdCl2, suggesting that increased cysteine availability is responsible for cadmium tolerance. In agreement with these results, exogenous addition of cystine can, to some extent, also favor the growth of wild type plants in cadmium-containing medium. Cadmium accumulates to higher levels in leaves of tolerant transformed lines than in wild-type plants.	CSIC, Ctr Invest Cientif Isla Cartuja, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; Univ Sevilla, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); University of Sevilla	Gotor, C (corresponding author), CSIC, Ctr Invest Cientif Isla Cartuja, Inst Bioquim Vegetal & Fotosintesis, Avda Americo Vespucio S-N, Seville 41092, Spain.		Romero, Luis C./B-7138-2012; Gotor, Cecilia/B-7173-2012	Romero, Luis C./0000-0002-2414-4813; Gotor, Cecilia/0000-0003-4272-7446				Barroso C, 1999, PLANT MOL BIOL, V40, P729, DOI 10.1023/A:1006285016296; BARROSO C, 1995, FEBS LETT, V363, P1, DOI 10.1016/0014-5793(95)00255-8; Barroso C., 1997, CURR TOP PHYTOCHEM, V1, P19; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Chen JJ, 1997, PHYSIOL PLANTARUM, V101, P165, DOI 10.1034/j.1399-3054.1997.1010122.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; FARAGO S, 1994, J PLANT PHYSIOL, V144, P433, DOI 10.1016/S0176-1617(11)82119-X; Gotor C, 1997, PLANT J, V11, P347, DOI 10.1046/j.1365-313X.1997.11020347.x; Gutierrez-Alcala G, 2000, P NATL ACAD SCI USA, V97, P11108, DOI 10.1073/pnas.190334497; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; Heiss S, 1999, PLANT MOL BIOL, V39, P847, DOI 10.1023/A:1006169717355; HOWDEN R, 1995, PLANT PHYSIOL, V107, P1059, DOI 10.1104/pp.107.4.1059; Leustek T, 1996, PHYSIOL PLANTARUM, V97, P411, DOI 10.1034/j.1399-3054.1996.970228.x; LUNN JE, 1990, PLANT PHYSIOL, V94, P1345, DOI 10.1104/pp.94.3.1345; NEWTON GL, 1981, ANAL BIOCHEM, V114, P383, DOI 10.1016/0003-2697(81)90498-X; Noctor G, 1998, J EXP BOT, V49, P623, DOI 10.1093/jexbot/49.321.623; RAUSER WE, 1991, PLANT PHYSIOL, V97, P128, DOI 10.1104/pp.97.1.128; RUEGSEGGER A, 1992, PLANT PHYSIOL, V99, P428, DOI 10.1104/pp.99.2.428; Schafer HJ, 1998, PLANT MOL BIOL, V37, P87, DOI 10.1023/A:1005929022061; SCHNEIDER S, 1995, BOT ACTA, V108, P34, DOI 10.1111/j.1438-8677.1995.tb00828.x; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Xiang CB, 1998, PLANT CELL, V10, P1539, DOI 10.1105/tpc.10.9.1539; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2; Zhu YL, 1999, PLANT PHYSIOL, V121, P1169, DOI 10.1104/pp.121.4.1169	24	130	155	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9297	9302		10.1074/jbc.M009574200	http://dx.doi.org/10.1074/jbc.M009574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121418	hybrid			2022-12-25	WOS:000167607700090
J	Harada, Y; Tanabe, E; Watanabe, R; Weiss, BD; Matsumoto, A; Ariga, H; Koiwai, O; Fukui, Y; Kubo, M; June, CH; Abe, R				Harada, Y; Tanabe, E; Watanabe, R; Weiss, BD; Matsumoto, A; Ariga, H; Koiwai, O; Fukui, Y; Kubo, M; June, CH; Abe, R			Novel role of phosphatidylinositol 3-kinase in CD28-mediated costimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL COSTIMULATION; PHOSPHOINOSITIDE 3-KINASE; CO-STIMULATION; SIGNAL-TRANSDUCTION; CD28 COSTIMULATION; IN-VIVO; KINASE; ASSOCIATION; CTLA-4; PHOSPHORYLATION	Ligation of the CD28 surface receptor provides a major costimulatory signal for full scale T cell activation. Despite extensive studies, the intracellular signaling pathways delivered by CD28 ligation are not fully understood. A particularly controversial matter is the role of phosphatidylinositol 3-kinase (PI3K) in CD28-mediated costimulation. It is known that the binding site for PI3K and Grb-2 lies nested within the YMNM motif of the CD28 cytoplasmic domain. To elucidate the role of PI3K during CD28-mediated interleukin-2 (IL-2) production, CD28 YMNM point and deletion mutants were expressed in Jurkat cells. We then measured IL-2 promoter activation after CD28 ligation. Our results showed that the Y189F mutant, which disrupts binding by PI3K, and the YMNM deletion mutant both demonstrated reduced but significant activity for IL-2 promoter activation. In contrast, the N191A mutant, which retains PI3K binding ability, resulted in a complete abrogation of activity, suggesting that PI3K mediates a negative effect upon transcriptional activation of the IL-2 gene. Consistent with this idea, we found that the addition of a PI3K pharmacological inhibitor augmented IL-2 promoter activity, whereas coexpression of a constitutively active form of PI3K reduced this activity. Taken together, these data indicate that PI3K, when associated with the YMNM motif, may act as a negative mediator in CD28-mediated IL-2 gene transcription.	Tokyo Univ Sci, Res Inst Biol Sci, Chiba 2780022, Japan; Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, Chiba 2780022, Japan; USN, Med Res Ctr, Bethesda, MD 20889 USA; Hokkaido Univ, Fac Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan; Univ Tokyo, Fac Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Tokyo University of Science; Tokyo University of Science; United States Department of Defense; United States Navy; Hokkaido University; University of Tokyo; University of Pennsylvania; Pennsylvania Medicine	Abe, R (corresponding author), Tokyo Univ Sci, Res Inst Biol Sci, 2669 Yamazaki, Chiba 2780022, Japan.	rabe@rs.noda.sut.ac.jp	Fukui, Yasuhisa/E-8806-2010; Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143; Harada, Yohsuke/0000-0002-8023-1030				ABE R, 1995, J IMMUNOL, V154, P985; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Boussiotis VA, 1996, IMMUNOL REV, V153, P5, DOI 10.1111/j.1600-065X.1996.tb00918.x; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CROOKS MEC, 1995, MOL CELL BIOL, V15, P6820; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; GhiottoRagueneau M, 1996, EUR J IMMUNOL, V26, P34, DOI 10.1002/eji.1830260106; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KEARNEY ER, 1995, J IMMUNOL, V155, P1032; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Kita Y, 1998, J CELL SCI, V111, P907; Krummel MF, 1996, INT IMMUNOL, V8, P519, DOI 10.1093/intimm/8.4.519; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LU YL, 1995, EUR J IMMUNOL, V25, P533, DOI 10.1002/eji.1830250234; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SCHNEIDER H, 1995, J EXP MED, V181, P351, DOI 10.1084/jem.181.1.351; Sperling AI, 1996, IMMUNOL REV, V153, P155, DOI 10.1111/j.1600-065X.1996.tb00924.x; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Tamatani T, 2000, INT IMMUNOL, V12, P51, DOI 10.1093/intimm/12.1.51; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; TRUITT KE, 1995, J IMMUNOL, V155, P4702; UEDA Y, 1995, INT IMMUNOL, V7, P957, DOI 10.1093/intimm/7.6.957; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; Zell T, 1996, J IMMUNOL, V156, P883; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	42	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9003	9008		10.1074/jbc.M005051200	http://dx.doi.org/10.1074/jbc.M005051200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11113113	hybrid			2022-12-25	WOS:000167607700053
J	Losey, FG; Engel, N				Losey, FG; Engel, N			Isolation and characterization of a urobilinogenoidic chlorophyll catabolite from Hordeum vulgare L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENESCENT LEAVES; CHLORELLA-PROTOTHECOIDES; STRUCTURE ELUCIDATION; HIGHER-PLANTS; A CATABOLITE; BREAKDOWN; DEGRADATION; MONOOXYGENASE; TETRAPYRROLES; CONSTITUTION	A new type of chlorophyll catabolite was isolated from extracts of de-greened primary leaves of barley (Hordeum vulgare cv, Lambic), Its constitution was elucidated by one-dimensional and two-dimensional (H-1,C-13)-homo- and heteronuclear NMR spectroscopic techniques and by high resolution mass spectroscopy. The isolated catabolite, a water-soluble, colorless, and nonfluorescent linear tetrapyrrole, resembles urobilinogen in which one of the propionic side chains forms a five membered isocylic ring system, indicating its origin from the chlorophylls.	Univ Fribourg, Inst Organ Chem, CH-1700 Fribourg, Switzerland	University of Fribourg	Engel, N (corresponding author), Univ Fribourg, Inst Organ Chem, Chemin Musee 9, CH-1700 Fribourg, Switzerland.							CAMPBELL NA, 1990, BIOLOGY, P566; CURTY C, 1995, FEBS LETT, V364, P41, DOI 10.1016/0014-5793(95)00348-D; Curty C, 1997, PLANT PHYSIOL BIOCH, V35, P707; Curty C, 1996, PHYTOCHEMISTRY, V42, P1531, DOI 10.1016/0031-9422(96)00155-0; CURTY C, 1996, THESIS U FRIBOURG SW; Engel N, 1996, PLANT PHYSIOL BIOCH, V34, P77; ENGEL N, 1991, FEBS LETT, V293, P131, DOI 10.1016/0014-5793(91)81168-8; Folly P, 1999, J BIOL CHEM, V274, P21811, DOI 10.1074/jbc.274.31.21811; Gossauer A, 1996, J PHOTOCH PHOTOBIO B, V32, P141, DOI 10.1016/1011-1344(95)07257-8; GOSSAUER A, 1979, PORPHYRINS, V6, P625; HENDRY GAF, 1987, NEW PHYTOL, V107, P255, DOI 10.1111/j.1469-8137.1987.tb00181.x; Hortensteiner S, 1998, J BIOL CHEM, V273, P15335, DOI 10.1074/jbc.273.25.15335; ITURRASPE J, 1995, J ORG CHEM, V60, P6664, DOI 10.1021/jo00126a007; Krautler B, 1999, ACCOUNTS CHEM RES, V32, P35, DOI 10.1021/ar970225n; KRAUTLER B, 1992, PLANT PHYSIOL BIOCH, V30, P333; KRAUTLER B, 1991, ANGEW CHEM INT EDIT, V30, P1315, DOI 10.1002/anie.199113151; MERRITT JE, 1979, PURE APPL CHEM, V51, P2251; MIYAKE K, 1995, PLANT CELL PHYSIOL, V36, P109; MOSS GP, 1987, PURE APPL CHEM, V59, P779, DOI 10.1351/pac198759060779; OKADA M, 1987, PLANT CELL PHYSIOL, V28, P1435; Peoples M.B., 1988, SENESCENCE AGING PLA, P181, DOI DOI 10.1016/B978-0-12-520920-5.50012-2; ROSYBEL D, 1999, PHYSIOL PLANTARUM, V107, P32; STAHL E, 1909, BIOL CHLOROPHYLLS; Suzuki Y, 1999, PLANT CELL PHYSIOL, V40, P909, DOI 10.1093/oxfordjournals.pcp.a029622; VANDENHOEK C, 1995, ALGAE INTRO PHYCOLOG, P483	25	62	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8643	8647		10.1074/jbc.M009288200	http://dx.doi.org/10.1074/jbc.M009288200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11115504	hybrid			2022-12-25	WOS:000167607700006
J	Manifava, M; Thuring, JWJF; Lim, ZY; Packman, L; Holmes, AB; Ktistakis, NT				Manifava, M; Thuring, JWJF; Lim, ZY; Packman, L; Holmes, AB; Ktistakis, NT			Differential binding of traffic-related proteins to phosphatidic acid- or phosphatidylinositol (4,5)-bisphosphate-coupled affinity reagents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; ADP-RIBOSYLATION FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHOLIPASE-D; MEMBRANE-FUSION; GOLGI MEMBRANES; ENDOPLASMIC-RETICULUM; LYSOPHOSPHATIDIC ACID; MASS-SPECTROMETRY; VESICLE FORMATION	Phosphatidic acid (PA) is an important bioactive lipid, but its molecular targets remain unknown. To identify such targets, we have synthesized and coupled PA to an agarose-based matrix, Affi-Gel 10. Using this matrix as an affinity reagent, we have identified a substantial number of potential PA-binding proteins from brain cytosol, One class of such proteins is known to be involved in intracellular traffic and it included coatomer, ADP-ribosylation factor (Arf), N-ethylmaleimide-sensitive factor (NSF), and kinesin, Binding of these proteins to PA beads was suppressed by soluble PA, and it occurred preferentially over binding to beads coupled to phosphatidylinositol (4,5)-bisphosphate. For coatomer, Arf, and NSF, we verified direct binding to PA beads using purified proteins. For recombinant Arf1 and Arf6, binding to PA required myristoylation. In addition, for NSF and Arf6, an ATPase and a GTPase, respectively, binding to PA beads was extremely sensitive to the nucleotide state of the protein. finding to PA may be a property linking together distinct participants in one complete round of membrane transport from a donor to an acceptor compartment.	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge; University of Cambridge	Ktistakis, NT (corresponding author), Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England.							Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Bloom GS, 1998, J CELL BIOL, V140, P1277, DOI 10.1083/jcb.140.6.1277; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONSTAM DB, 1995, J BIOL CHEM, V270, P26931, DOI 10.1074/jbc.270.45.26931; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Goldberg J, 2000, CELL, V100, P671, DOI 10.1016/S0092-8674(00)80703-5; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Ishizuka Y, 1999, BBA-MOL CELL RES, V1450, P92, DOI 10.1016/S0167-4889(99)00039-7; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lin JW, 1998, NEURON, V21, P267, DOI 10.1016/S0896-6273(00)80534-6; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Manifava M, 1999, J BIOL CHEM, V274, P1072, DOI 10.1074/jbc.274.2.1072; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Muller JMM, 1999, NAT CELL BIOL, V1, P335, DOI 10.1038/14025; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; ROTH MG, 1997, CURR OPIN CELL BIOL, V9, P619; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Shinozaki K, 1999, MOL BRAIN RES, V71, P364, DOI 10.1016/S0169-328X(99)00181-3; Siddhanta A, 2000, J BIOL CHEM, V275, P12023, DOI 10.1074/jbc.275.16.12023; SINGER WD, 1997, ANNU REV BIOCHEM, V66, P457; Song J, 1998, J CELL SCI, V111, P2257; SPRANG A, 1998, P NATL ACAD SCI USA, V95, P11199; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	57	106	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8987	8994		10.1074/jbc.M010308200	http://dx.doi.org/10.1074/jbc.M010308200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124268	hybrid			2022-12-25	WOS:000167607700051
J	Yoder, MD; Thomas, LM; Tremblay, JM; Oliver, RL; Yarbrough, LR; Helmkamp, GM				Yoder, MD; Thomas, LM; Tremblay, JM; Oliver, RL; Yarbrough, LR; Helmkamp, GM			Structure of a multifunctional protein - Mammalian phosphatidylinositol transfer protein complexed with phosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-DEGENERATION-B; PHOSPHOLIPID TRANSFER PROTEIN; C-TERMINUS; CRYSTAL-STRUCTURE; BINDING-SITES; IN-VITRO; YEAST; CLONING; PROGRAM; MUTANT	Eukaryotic phosphatidylinositol transfer protein is a ubiquitous multifunctional protein that transports phospholipids between membrane surfaces and participates in cellular phospholipid metabolism during signal transduction and vesicular trafficking. The three-dimensional structure of the alpha -isoform of rat phosphatidylinositol transfer protein complexed with one molecule of phosphatidylcholine, one of its physiological ligands, has been determined to 2.2 Angstrom resolution by x-ray diffraction techniques. A single beta -sheet and several long alpha -helices define an enclosed internal cavity in which a single molecule of the phospholipid is accommodated with its polar head group in the center of the protein and fatty acyl chains projected toward the surface. Other structural features suggest mechanisms by which cytosolic phosphatidylinositol transfer protein interacts with membranes for lipid exchange and associates with a variety of lipid and protein kinases.	Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Missouri System; University of Missouri Kansas City; University of Kansas; University of Kansas Medical Center	Yoder, MD (corresponding author), Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, 5100 Rockhill Rd, Kansas City, MO 64110 USA.	yoderm@umkc.edu			NCRR NIH HHS [1P41 RR12408-01A1] Funding Source: Medline; NIGMS NIH HHS [GM59162, GM24035] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024035, R01GM059162] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1996, ACTA CRYSTALLOGR D, V52, P32; Aikawa Y, 1997, BIOCHEM BIOPH RES CO, V236, P559, DOI 10.1006/bbrc.1997.7009; ALB JG, 1995, P NATL ACAD SCI USA, V92, P8826, DOI 10.1073/pnas.92.19.8826; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chang JHT, 1997, J NEUROSCI, V17, P5881; Cockcroft S, 1998, BIOESSAYS, V20, P423, DOI 10.1002/(SICI)1521-1878(199805)20:5<423::AID-BIES9>3.3.CO;2-U; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; DAUM G, 1984, BIOCHIM BIOPHYS ACTA, V794, P385, DOI 10.1016/0005-2760(84)90004-3; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; Garcia FL, 2000, J MOL BIOL, V295, P595, DOI 10.1006/jmbi.1999.3355; GAY GD, 1995, J MOL BIOL, V254, P968, DOI 10.1006/jmbi.1995.0669; Guo J, 1997, DEV GENET, V20, P235; Hara S, 1997, J BIOL CHEM, V272, P14908, DOI 10.1074/jbc.272.23.14908; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jouannic N, 1998, EUR J BIOCHEM, V258, P402, DOI 10.1046/j.1432-1327.1998.2580402.x; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KASURINEN J, 1990, BIOCHEMISTRY-US, V29, P8548, DOI 10.1021/bi00489a007; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; Kearns BG, 1998, TRENDS CELL BIOL, V8, P276, DOI 10.1016/S0962-8924(98)01281-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Lev S, 1999, MOL CELL BIOL, V19, P2278; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Oliver RL, 1999, ACTA CRYSTALLOGR D, V55, P522, DOI 10.1107/S0907444998009901; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Paul KS, 1998, FEBS LETT, V431, P91, DOI 10.1016/S0014-5793(98)00722-4; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; SCHERMOLY MJ, 1983, BRAIN RES, V268, P197, DOI 10.1016/0006-8993(83)90410-9; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Swigart P, 2000, BIOCHEM J, V347, P837, DOI 10.1042/0264-6021:3470837; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; Tremblay JM, 1996, J BIOL CHEM, V271, P21075, DOI 10.1074/jbc.271.35.21075; Tremblay JM, 1998, BBA-LIPID LIPID MET, V1389, P91; Trevino RJ, 1999, J BIOL CHEM, V274, P13938, DOI 10.1074/jbc.274.20.13938; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; van Tiel CM, 2000, J BIOL CHEM, V275, P21532, DOI 10.1074/jbc.M002203200; VANPARIDON PA, 1988, BIOCHEMISTRY-US, V27, P6208, DOI 10.1021/bi00417a003; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; Voziyan PA, 1996, BIOCHEMISTRY-US, V35, P12526, DOI 10.1021/bi960562o; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	56	106	110	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9246	9252		10.1074/jbc.M010131200	http://dx.doi.org/10.1074/jbc.M010131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11104777	Green Accepted, hybrid			2022-12-25	WOS:000167607700084
J	Zeitlmann, L; Sirim, P; Kremmer, E; Kolanus, W				Zeitlmann, L; Sirim, P; Kremmer, E; Kolanus, W			Cloning of ACP33 as a novel intracellular ligand of CD4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; RECEPTOR SIGNAL-TRANSDUCTION; ALPHA/BETA-HYDROLASE FOLD; PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; IL-2 PRODUCTION; MEMBRANE; BINDING; FAMILY; ASSOCIATION	CD4 recruitment to T cell receptor (TCR)-peptide-major histocompatibility class II complexes is required for stabilization of low affinity antigen recognition by T lymphocytes. The cytoplasmic portion of CD4 is thought to amplify TCR-initiated signal transduction via its association with the protein tyrosine kinase p56(lck). Here we describe a novel functional determinant in the cytosolic tail of CD4 that inhibits TCR-induced T cell activation. Deletion of two conserved hydrophobic amino acids from the CD4 carboxyl terminus resulted in a pronounced enhancement of CD4-mediated T cell costimulation. This effect was observed in the presence or absence of p56(lck), implying involvement of alternative cytosolic ligands of CD4. A two-hybrid screen with the intracellular portion of CD4 identified a previously unknown 33-kDa protein, ACP33 (acidic cluster protein 33), as a novel intracellular binding partner of CD4. Since interaction with ACP33 is abolished by deletion of the hydrophobic CD4 C-terminal amino acids mediating repression of T cell activation, we propose that ACP33 modulates the stimulatory activity of CD4. Furthermore, we demonstrate that interaction with CD4 is mediated by the noncatalytic alpha/beta hydrolase fold domain of ACP33. This suggests a previously unrecognized function for alpha/beta hydrolase fold domains as a peptide binding module mediating protein-protein interactions.	Univ Munich, Genzentrum, Mol Biol Lab, D-81377 Munich, Germany; GSF, Inst Mol Immunol, D-81377 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Kolanus, W (corresponding author), Univ Munich, Genzentrum, Mol Biol Lab, Feodor Lynen Str 25, D-81377 Munich, Germany.		Zeitlmann, Lutz/AAF-3586-2019					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Aravind L, 1998, CURR BIOL, V8, pR111, DOI 10.1016/S0960-9822(98)70982-0; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; Bonnard M, 1999, J IMMUNOL, V162, P1252; Bosselut R, 1999, J EXP MED, V190, P1517, DOI 10.1084/jem.190.10.1517; Bowers K, 1997, INT J BIOCHEM CELL B, V29, P871, DOI 10.1016/S1357-2725(96)00154-9; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; CINEK T, 1995, IMMUNOGENETICS, V41, P110, DOI 10.1007/BF00182321; Coudronniere N, 1998, EUR J IMMUNOL, V28, P1445, DOI 10.1002/(SICI)1521-4141(199805)28:05<1445::AID-IMMU1445>3.0.CO;2-P; Cousin X, 1998, NUCLEIC ACIDS RES, V26, P226, DOI 10.1093/nar/26.1.226; CRISE B, 1992, J BIOL CHEM, V267, P13593; Cruikshank W W, 1998, Int Rev Immunol, V16, P523, DOI 10.3109/08830189809043007; Cruikshank WW, 1996, J IMMUNOL, V157, P5240; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Gaubin M, 1999, J IMMUNOL, V162, P2631; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; Gratton S, 1998, J IMMUNOL, V161, P3551; Hampl J, 1997, IMMUNITY, V7, P379, DOI 10.1016/S1074-7613(00)80359-3; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JULIUS M, 1993, IMMUNOL TODAY, V14, P177; Killeen N, 1996, CURR TOP MICROBIOL, V205, P89; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Konig R, 1996, CURR TOP MICROBIOL, V205, P19; Korthauer U, 2000, J IMMUNOL, V164, P308, DOI 10.4049/jimmunol.164.1.308; Kremmer E, 1999, J GEN VIROL, V80, P1305, DOI 10.1099/0022-1317-80-5-1305; LAURENTWINTER C, 1995, RES MICROBIOL, V146, P5, DOI 10.1016/0923-2508(96)80266-X; Lemasson I, 1996, J IMMUNOL, V156, P859; Madrenas J, 1997, J EXP MED, V185, P219, DOI 10.1084/jem.185.2.219; MANGER B, 1985, J IMMUNOL, V135, P3669; Mesnard J. M., 1997, Journal of Allergy and Clinical Immunology, V99, pS210; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Moutouh L, 1998, J VIROL, V72, P8061, DOI 10.1128/JVI.72.10.8061-8072.1998; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Ogasawara H, 1999, IMMUNOLOGY, V96, P215; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Parolini I, 1999, J BIOL CHEM, V274, P14176, DOI 10.1074/jbc.274.20.14176; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Ravichandran KS, 1996, CURR TOP MICROBIOL, V205, P47; Rees S, 1996, BIOTECHNIQUES, V20, P102; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Vidal K, 1999, J IMMUNOL, V163, P4811; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; Zamoyska R, 1998, CURR OPIN IMMUNOL, V10, P82, DOI 10.1016/S0952-7915(98)80036-8; Zeitlmann L, 1998, J BIOL CHEM, V273, P15445, DOI 10.1074/jbc.273.25.15445	63	30	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9123	9132		10.1074/jbc.M009270200	http://dx.doi.org/10.1074/jbc.M009270200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11113139	hybrid			2022-12-25	WOS:000167607700069
J	Knotts, TA; Orkiszewski, RS; Cook, RG; Edwards, DP; Weigel, NL				Knotts, TA; Orkiszewski, RS; Cook, RG; Edwards, DP; Weigel, NL			Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; HORMONE-DEPENDENT PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; GLUCOCORTICOID RECEPTOR; SIGNALING PATHWAYS; B-ISOFORM; A-FORM; TARGET-CELLS; IN-VITRO	We have previously reported the identification of seven in vivo phosphorylation sites in the amino-terminal region of the human progesterone receptor (PR). From our previous in vivo studies, it was evident that several phosphopeptides remained unidentified. In particular, we wished to determine whether human PR contains a phosphorylation site in the hinge region, as do other steroid receptors including chicken PR, human androgen receptor, and mouse estrogen receptor. Previously, problematic trypsin cleavage sites hampered our ability to detect phosphorylation sites in large incomplete tryptic peptides. Using a combination of mass spectrometry and in vitro phosphorylation, we have identified six previously unidentified phosphorylation sites in human PR. Using nanoelectrospray ionization mass spectrometry, we have identified two new in vivo phosphorylation sites, Ser(20) and Ser(676), in baculovirus-expressed human PR. Ser(676) is analogous to the hinge site identified in other steroid receptors, Additionally, precursor ion scans identified another phosphopeptide that contains Ser(130)-Pro(131), a likely candidate for phosphorylation. In vitro phosphorylation of PR with Cdk2 has revealed five additional in vitro Cdk2 phosphorylation sites: Ser(25), Ser(213), Thr(430), Ser(554), and Ser(676). At least two of these, Ser(213) and Ser(676), are authentic in, vivo sites. We confirmed the presence of the Cdk2-phosphorylated peptide containing Ser(213) in PR from in vivo labeled T47D cells, indicating that this is an in vivo site. Our combined studies indicate that most, if not all, of the Ser-Pro motifs in human PR are sites for phosphorylation. Taken together, these data indicate that the phosphorylation of PR is highly complex, with at least 14 phosphorylation sites.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Prot Chem Core Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Weigel, NL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA057539, P30CA046934] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57539, P30 CA46934] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALLEN G, 1981, LABORATORY TECHNIQUE, P43; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; Beck CA, 1996, J BIOL CHEM, V271, P19546, DOI 10.1074/jbc.271.32.19546; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Clemm DL, 2000, MOL ENDOCRINOL, V14, P52, DOI 10.1210/me.14.1.52; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; Endoh H, 1999, MOL CELL BIOL, V19, P5363; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Giangrande PH, 2000, MOL CELL BIOL, V20, P3102, DOI 10.1128/MCB.20.9.3102-3115.2000; Giangrande PH, 1997, J BIOL CHEM, V272, P32889, DOI 10.1074/jbc.272.52.32889; HARPER JW, 1993, CELL, V75, P805; HU JM, 1994, MOL ENDOCRINOL, V8, P1709, DOI 10.1210/me.8.12.1709; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LESSEY BA, 1983, ENDOCRINOLOGY, V112, P1267, DOI 10.1210/endo-112-4-1267; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Neville DCA, 1997, PROTEIN SCI, V6, P2436; POLETTI A, 1993, MOL ENDOCRINOL, V7, P241, DOI 10.1210/me.7.2.241; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; SHERIDAN PL, 1988, MOL ENDOCRINOL, V2, P1329, DOI 10.1210/mend-2-12-1329; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SHERIDAN PL, 1989, J BIOL CHEM, V264, P7054; Shyamala G, 2000, P NATL ACAD SCI USA, V97, P3044, DOI 10.1073/pnas.97.7.3044; Shyamala G, 1998, P NATL ACAD SCI USA, V95, P696, DOI 10.1073/pnas.95.2.696; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; Takimoto GS, 1996, J BIOL CHEM, V271, P13308, DOI 10.1074/jbc.271.23.13308; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; Zhang YX, 1997, MOL ENDOCRINOL, V11, P823, DOI 10.1210/me.11.6.823; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605	48	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8475	8483		10.1074/jbc.M009805200	http://dx.doi.org/10.1074/jbc.M009805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11110801	hybrid			2022-12-25	WOS:000167474900108
J	Araujo, FD; Croteau, S; Slack, AD; Milutinovic, S; Bigey, P; Price, GB; Zannis-Hajopoulos, M; Szyf, M				Araujo, FD; Croteau, S; Slack, AD; Milutinovic, S; Bigey, P; Price, GB; Zannis-Hajopoulos, M; Szyf, M			The DNMT1 target recognition domain resides in the N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNA METHYLTRANSFERASE; MOUSE CELLS; CYTOSINE-5 METHYLTRANSFERASES; METHYLATION; GENE; REPLICATION; INHIBITION; BINDING; COMPLEX; TRANSFORMATION	DNA-cytosine-5-methyltransferase 1 (DNMT1) is the enzyme believed to be responsible for maintaining the epigenetic information encoded by DNA methylation patterns. The target recognition domain of DNMT1, the domain responsible for recognizing hemimethylated CGs, is unknown. However, based on homology with bacterial cytosine DNA methyltransferases it has been postulated that the entire catalytic domain, including the target recognition domain, is localized to 500 amino acids at the C terminus of the protein. The N-terminal domain has been postulated to have a regulatory role, and it has been suggested that the mammalian DNMT1 is a fusion of a prokaryotic methyltransferase and a mammalian DNA-binding protein. Using a combination of in vitro translation of different DNMT1 deletion mutant peptides and a solid-state hemimethylated substrate, we show that the target recognition domain of DNMT1 resides in the N terminus (amino acids 122-417) in proximity to the proliferating cell nuclear antigen binding site. Hemimethylated CGs were not recognized specifically by the postulated catalytic domain. We have previously shown that the hemimethylated substrates utilized here act as DNMT1 antagonists and inhibit DNA replication. Our results now indicate that the DNMT1-PCNA interaction can be disrupted by substrate binding to the DNMT1 N terminus. These results point toward new directions in our understanding of the structure-function of DNMT1.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.			bigey, pascal/0000-0002-6795-8569				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1988, GENE, V74, P9, DOI 10.1016/0378-1119(88)90238-7; Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Margot JB, 2000, J MOL BIOL, V297, P293, DOI 10.1006/jmbi.2000.3588; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pradhan S, 2000, EMBO J, V19, P2103, DOI 10.1093/emboj/19.9.2103; Ramchandani S, 1998, BIOL CHEM, V379, P535; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEGFRIED Z, 1997, CURR BIOL, V7, P305; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; Szyf M, 1998, CANCER METAST REV, V17, P219, DOI 10.1023/A:1006023023787; SZYF M, 1991, J BIOL CHEM, V266, P10027; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; Szyf M, 2000, ANN NY ACAD SCI, V910, P156; WYSZYNSKI MW, 1993, NUCLEIC ACIDS RES, V21, P295, DOI 10.1093/nar/21.2.295; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; YISRAELI J, 1984, METHYLATION BIOCH BI, P353; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092; Zimmermann C, 1997, BIOL CHEM, V378, P393, DOI 10.1515/bchm.1997.378.5.393	44	47	53	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6930	6936		10.1074/jbc.M009037200	http://dx.doi.org/10.1074/jbc.M009037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11104769	hybrid			2022-12-25	WOS:000167442900011
J	Deutsch, DG; Glaser, ST; Howell, JM; Kunz, JS; Puffenbarger, RA; Hillard, CJ; Anbumrad, N				Deutsch, DG; Glaser, ST; Howell, JM; Kunz, JS; Puffenbarger, RA; Hillard, CJ; Anbumrad, N			The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Meeting of the International-Cannabinoid-Research-Society	JUN 18-20, 1999	BURLINGTON, VERMONT	Int Cannabinoid Res Soc			N-ARACHIDONOYLETHANOLAMINE ANANDAMIDE; ENDOGENOUS CANNABINOID ANANDAMIDE; BRAIN; RECEPTORS; CELLS; AMIDOHYDROLASE; IDENTIFICATION; BIOCHEMISTRY; DEGRADATION; TRANSPORTER	Anandamide is an endogenous compound that acts as an agonist at cannabinoid receptors, It is inactivated via intracellular degradation after its uptake into cells by a carrier-mediated process that depends upon a concentration gradient. The fate of anandamide in those cells containing an amidase called fatty-acid amide hydrolase (FAAH) is hydrolysis to arachidonic acid and ethanolamine. The active site nucleophilic serine of FAAH is inactivated by a variety of inhibitors including methyl-arachidonylfluorophosphonate (MAFP) and palmityl-sulfonyl fluoride. In the current report, the net uptake of anandamide in cultured neuroblastoma (N18) and glioma (C6) cells, which contain FAAH, was decreased by nearly 50% after 6 min of incubation in the presence of MAFP, Uptake in laryngeal carcinoma (Hep2) cells, which lack FAAH, is not inhibited by MAFP. Free anandamide was found in all MAFP-treated cells and in control Hep2 cells, whereas phospholipid was the main product in N18 and C6 control cells when analyzed by TLC, The intracellular concentration of anandamide in N18, C6, and Hep2 cells was up to 18-fold greater than the extracellular concentration of 100 nM, which strongly suggests that it is sequestered within the cell by binding to membranes or proteins. The accumulation of anandamide and/or its breakdown products was found to vary among the different cell types, and this correlated approximately with the amount of FAAH activity, suggesting that the breakdown of anandamide is in part a driving force for uptake. This was shown most clearly in Hepa cells transfected with FAAH. The uptake in these cells was 2-fold greater than in vector-transfected or untransfected Hepa cells. Therefore, it appears that FAAH inhibitors reduce anandamide uptake by cells by shifting the anandamide concentration gradient in a direction that favors equilibrium. Because inhibition of FAAH increases the levels of extracellular anandamide, it may be a useful target for the design of therapeutic agents.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Medical College of Wisconsin	Deutsch, DG (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Hillard, Cecilia J/O-6693-2018		NIDA NIH HHS [DA09155, DA09374] Funding Source: Medline; NIDDK NIH HHS [DK33301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009155, R01DA009374] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abumrad N, 1998, J LIPID RES, V39, P2309; Arreaza G, 1999, FEBS LETT, V454, P57, DOI 10.1016/S0014-5793(99)00774-7; Arreaza G, 1997, NEUROSCI LETT, V234, P59, DOI 10.1016/S0304-3940(97)00673-3; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; CHAN PH, 1982, J NEUROSCI RES, V8, P67, DOI 10.1002/jnr.490080110; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; DePetrocellis L, 1997, BIOCHEM BIOPH RES CO, V231, P82, DOI 10.1006/bbrc.1997.6000; Deutsch DG, 1997, BIOCHEM BIOPH RES CO, V231, P217, DOI 10.1006/bbrc.1997.6072; Deutsch DG, 1997, BIOCHEM PHARMACOL, V53, P255, DOI 10.1016/S0006-2952(96)00830-1; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, FEBS LETT, V436, P449, DOI 10.1016/S0014-5793(98)01175-2; Di Marzo V, 1998, NEUROBIOL DIS, V5, P386, DOI 10.1006/nbdi.1998.0214; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Gifford AN, 1999, EUR J PHARMACOL, V383, P9, DOI 10.1016/S0014-2999(99)00609-3; Goparaju SK, 1999, BBA-MOL CELL BIOL L, V1441, P77, DOI 10.1016/S1388-1981(99)00143-2; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Hillard CJ, 1997, J LIPID RES, V38, P2383; Hillard CJ, 2000, CHEM PHYS LIPIDS, V108, P123, DOI 10.1016/S0009-3084(00)00191-2; Jarrahian A, 2000, J NEUROCHEM, V74, P2597, DOI 10.1046/j.1471-4159.2000.0742597.x; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; Maccarrone M, 1999, FEBS LETT, V447, P277, DOI 10.1016/S0014-5793(99)00308-7; Maccarrone M, 1998, J BIOL CHEM, V273, P32332, DOI 10.1074/jbc.273.48.32332; MADSHUS IH, 1987, J CELL PHYSIOL, V131, P6, DOI 10.1002/jcp.1041310103; Martin BR, 1999, LIFE SCI, V65, P573, DOI 10.1016/S0024-3205(99)00281-7; Martin BR, 2000, J PHARMACOL EXP THER, V294, P1209; McArthur MJ, 1999, J LIPID RES, V40, P1371; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Omeir RL, 1999, BIOCHEM BIOPH RES CO, V264, P316, DOI 10.1006/bbrc.1999.1524; OMEIR RL, 1995, LIFE SCI, V56, P199; Patricelli MP, 1999, BIOCHEMISTRY-US, V38, P9804, DOI 10.1021/bi990637z; Piomelli D, 1999, P NATL ACAD SCI USA, V96, P5802, DOI 10.1073/pnas.96.10.5802; Rakhshan F, 2000, J PHARMACOL EXP THER, V292, P960; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Ueda N, 1999, FEBS LETT, V454, P267, DOI 10.1016/S0014-5793(99)00820-0	38	176	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6967	6973		10.1074/jbc.M003161200	http://dx.doi.org/10.1074/jbc.M003161200			7	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11118429	hybrid			2022-12-25	WOS:000167442900016
J	Kirschenbaum, F; Hsu, SC; Cordell, B; McCarthy, JV				Kirschenbaum, F; Hsu, SC; Cordell, B; McCarthy, JV			Substitution of a glycogen synthase kinase-3 beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; MUTATIONS; COMPLEX; ENDOPROTEOLYSIS; AXIN; ACTIVATION; SUBSTRATE; COMPONENT; CANCER; BRAIN	The majority of cases with early onset familial Alzheimer's disease have been attributed to mutations in the presenilin 1 (PSI) gene. PS1 protein is a component of a high molecular weight membrane-bound complex that also contains beta -catenin, The physiological relevance of the association between PS1 and beta -catenin remains controversial. In this study, we report the identification and functional characterization of a highly conserved glycogen synthase binase-3 beta consensus phosphorylation site within the hydrophilic loop domain of PS1, Site-directed mutagenesis, together with in vitro and in vivo phosphorylation assays, indicates that PS1 residues Ser(353) and Ser(357)are glycogen synthase kinase-3 beta targets. Substitution:of one or both of these residues greatly reduces the ability of PS1 to associate with beta -catenin. By disrupting this interaction, we demonstrate that the association between PSI and beta -catenin has no effect on A beta peptide production, beta -catenin stability, or cellular susceptibility to apoptosis. Significantly, in the absence of PS1/beta -catenin association, we found no alteration in beta -catenin signaling using induction of this pathway by exogenous expression of Wnt-1 or beta -catenin and a Tcf/Lef transcriptional assay. These results argue against a pathologically relevant role for the association between PS1 and beta -catenin in familial Alzheimer's disease.	Scios Inc, Sunnyvale, CA 94086 USA	Scios	Cordell, B (corresponding author), Scios Inc, 820 W Maude Ave, Sunnyvale, CA 94086 USA.	cordell@sciosinc.com	mccarthy, justin/AAG-7550-2019	mccarthy, justin/0000-0002-2667-7365				Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Kang DE, 1999, J NEUROSCI, V19, P4229; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Mattson MP, 1998, J NEUROCHEM, V70, P1; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tesco G, 1998, J BIOL CHEM, V273, P33909, DOI 10.1074/jbc.273.51.33909; Thinakaran G, 1999, J CLIN INVEST, V104, P1321, DOI 10.1172/JCI8728; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Weihl CC, 1999, J NEUROSCI, V19, P5360; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	30	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7366	7375		10.1074/jbc.M004697200	http://dx.doi.org/10.1074/jbc.M004697200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11104755	hybrid			2022-12-25	WOS:000167442900070
J	Moral, Z; Dong, K; Wei, Y; Sterling, H; Deng, H; Ali, SR; Gu, RM; Huang, XY; Hebert, SC; Giebisch, G; Wang, WH				Moral, Z; Dong, K; Wei, Y; Sterling, H; Deng, H; Ali, SR; Gu, RM; Huang, XY; Hebert, SC; Giebisch, G; Wang, WH			Regulation of ROMK1 channels by protein-tyrosine kinase and -tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; POTASSIUM-CHANNEL; K+ CHANNEL; COUPLED RECEPTORS; BREFELDIN-A; PHOSPHORYLATION; SRC; MODULATION; ACTIVATION; SENSITIVITY	We have used the two-electrode voltage clamp technique and the patch clamp technique to investigate the regulation of ROMK1 channels by protein-tyrosine phosphatase (PTP) and protein-tyrosine kinase (PTK) in oocytes: coexpressing ROMK1 and cSrc. Western blot analysis detected the presence of the endogenous PTP-1D isoform in the oocytes. Addition of phenylarsine oxide (PAO), an inhibitor of PTP, reversibly reduced K+ current by 55% in oocytes coinjected with ROMK1 and cSrc. In contrast, PAO had no significant effect on K+ current: in oocytes injected with ROMK1 alone. Moreover, application of herbimycin A, an inhibitor of PTK, increased K+ current by 120% and completely abolished the effect of PAO in oocytes coexpressing ROMK1 and care. The effects of herbimycin A and PAO were absent in oocytes expressing the ROMK1 mutant R1Y337A in which the tyrosine residue at position 337 was mutated to alanine. However, addition of exogenous cSrc had no significant effect on the activity of ROMX1 channels in inside-out patches. Moreover, the effect of PAO was completely abolished by treatment of oocytes with 20% sucrose and 250 mug/ml concanavalin A, agents that inhibit the endocytosis of ROMK1 channels. Furthermore, the effect of herbimycin A is absent in the oocytes pretreated with either colchicine, an inhibitor of microtubules,or taxol, an agent that freezes microtubules. We conclude that PTP and PTK play an important role in regulating ROMK1 channels. Inhibiting PTP increases the internalization of ROMK1 channels, whereas blocking PTK stimulates the insertion of ROMK1 channels.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Cornell Univ, Coll Med, Dept Physiol, New York, NY 10021 USA	New York Medical College; Yale University; Cornell University	Wang, WH (corresponding author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	wenhui_wang@nymc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037605, R01DK054983, R01DK047402, P01DK017433, R29DK047402] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK054983, R01 DK047402, R01 DK054983-08, DK 54983, P01 DK017433, DK 37605, DK 47402, DK 17433] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEGUM N, 1994, AM J PHYSIOL, V267, pE14, DOI 10.1152/ajpendo.1994.267.1.E14; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; Bowlby MR, 1997, J GEN PHYSIOL, V110, P601, DOI 10.1085/jgp.110.5.601; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Hamm-Alvarez SF, 1998, PHYSIOL REV, V78, P1109, DOI 10.1152/physrev.1998.78.4.1109; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Izaguirre G, 1999, J BIOL CHEM, V274, P37012, DOI 10.1074/jbc.274.52.37012; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MacGregor GG, 1998, AM J PHYSIOL-RENAL, V275, pF415, DOI 10.1152/ajprenal.1998.275.3.F415; Macica CM, 1996, AM J PHYSIOL-RENAL, V271, pF588, DOI 10.1152/ajprenal.1996.271.3.F588; Macica CM, 1998, AM J PHYSIOL-RENAL, V274, pF175, DOI 10.1152/ajprenal.1998.274.1.F175; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; PALMER LG, 1994, J GEN PHYSIOL, V104, P693, DOI 10.1085/jgp.104.4.693; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PREVARSKAYA NB, 1995, J BIOL CHEM, V270, P24292, DOI 10.1074/jbc.270.41.24292; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; WANG T, 1995, RENAL PHYSIOL BIOCH, V18, P169; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wang WH, 2000, AM J PHYSIOL-RENAL, V278, pF165, DOI 10.1152/ajprenal.2000.278.1.F165; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; Wei Y, 2000, J BIOL CHEM, V275, P20502, DOI 10.1074/jbc.M000783200; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	37	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7156	7163		10.1074/jbc.M008671200	http://dx.doi.org/10.1074/jbc.M008671200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11114300	hybrid, Green Accepted			2022-12-25	WOS:000167442900043
J	Topping, TB; Woodbury, RL; Diamond, DL; Hardy, SJS; Randall, LL				Topping, TB; Woodbury, RL; Diamond, DL; Hardy, SJS; Randall, LL			Direct demonstration that homotetrameric chaperone SecB undergoes a dynamic dimer-tetramer equilibrium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI	We have shown here that the cytosolic bacterial chaperone SecB is a structural dimer of dimers that undergoes a dynamic equilibrium between dimer and tetramer in the native state. We demonstrated this equilibrium by mixing two tetrameric species of SecB that can be distinguished by size. We showed that the homotetrameric species exchanged dimers, because when the mixture was analyzed both by size exclusion chromatography and native polyacrylamide gel electrophoresis a third hybrid tetrameric species was detected. Furthermore, treatment of SecB with 5,5'-dithiobis-(2-nitrobenzoic acid), which modifies the sulfhydryl group on cysteines, caused irreversible dissociation to a dimer indicating that cysteine must be involved in the stabilizing interactions at the dimer interface. It is clear that the two dimer-dimer interfaces of the SecB tetramer are differentially stable. Dissociation at one interface allows for a dynamic dimer-tetramer equilibrium. Because only dimers were exchanged it is clear that the other interface between dimers is significantly more stable, otherwise oligomers should have formed with a random distribution of monomers.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Randall, LL (corresponding author), Univ Missouri, Dept Biochem, Schweitzer Hall,Rm 117, Columbia, MO 65211 USA.				NIGMS NIH HHS [GM29798, T32-GM08336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029798, T32GM008336, R01GM029798] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRANKSHAW MW, 1995, CURRENT PROTOCOLS PR; Diamond DL, 1997, J BIOL CHEM, V272, P28994, DOI 10.1074/jbc.272.46.28994; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; Miller J. H., 1972, EXPT MOL GENETICS, P431; Muren EM, 1999, J BIOL CHEM, V274, P19397, DOI 10.1074/jbc.274.27.19397; Panse VG, 2000, BIOCHEMISTRY-US, V39, P2362, DOI 10.1021/bi992484l; Randall LL, 1998, METHOD ENZYMOL, V290, P444, DOI 10.1016/S0076-6879(98)90037-4; RANDALL LL, 1977, EUR J BIOCHEM, V75, P43, DOI 10.1111/j.1432-1033.1977.tb11502.x; Smith VF, 1996, PROTEIN SCI, V5, P488; Volkert TL, 1999, BIOCHEM BIOPH RES CO, V264, P949, DOI 10.1006/bbrc.1999.1590	10	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7437	7441		10.1074/jbc.M009584200	http://dx.doi.org/10.1074/jbc.M009584200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11110800	hybrid			2022-12-25	WOS:000167442900080
J	Wan, LL; Kim, JK; Pollard, VW; Dreyfuss, G				Wan, LL; Kim, JK; Pollard, VW; Dreyfuss, G			Mutational definition of RNA-binding and protein-protein interaction domains of heterogeneous nuclear RNP C1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; A-PROTEIN; U1 RNA; RIBONUCLEOPROTEIN-PARTICLES; RANDOM MUTAGENESIS; CRYSTAL-STRUCTURE; HNRNP PROTEINS; DNA-POLYMERASE; HIGH-AFFINITY; SPECIFICITY	The heterogeneous nuclear ribonucleoprotein (hn-RNP) C proteins, among the most abundant pre-mRNA-binding proteins in the eukaryotic nucleus, have a single RNP motif RNA-binding domain. The RNA-binding domain (RBD) is comprised of similar to 80-100 amino acids, and its structure has been determined. However, relatively little is known about the role of specific amino acids of the RED in the binding to RNA. We have devised a phage display-based screening method for the rapid identification of amino acids in hnRNP C1 that are essential for its binding to RNA. The identified mutants were further tested for binding to poly(U)-Sepharose, a substrate to which wild type hnRNP C1 binds with high affinity. We found both previously predicted, highly conserved residues as well as additional residues in the RED to be essential for C1 RNA binding, We also identified three mutations in the leucine-rich C1-C1 interaction domain near the carboxyl terminus of the protein that both abolished C1 oligomerization and reduced RNA binding. These results demonstrate that although the RED is the primary determinant of C1 RNA binding, residues in the C1-C1 interaction domain also influence the RNA binding activity of the protein. The experimental approach we described should be generally applicable for the screening and identification of amino acids that play a role in the binding of proteins to nucleic acid substrates.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.	gdreyfuss@hhmi.upenn.edu	Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BARNETT SF, 1989, MOL CELL BIOL, V9, P492, DOI 10.1128/MCB.9.2.492; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; FORNE T, 1995, J BIOL CHEM, V270, P16476, DOI 10.1074/jbc.270.27.16476; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; Kataoka N, 2000, MOL CELL, V6, P673, DOI 10.1016/S1097-2765(00)00065-4; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1994, RNA PROTEIN INTERACT, P127; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Leung DW, 1989, TECHNIQUE, V1, P11; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; McAfee JG, 1996, RNA, V2, P1139; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P1212, DOI 10.1021/bi951974k; MCAFEE JG, 1997, EUKARYOTIC MRNA PROC, P68; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Petersen C, 2000, J BIOL CHEM, V275, P4081, DOI 10.1074/jbc.275.6.4081; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; Shahied-Milam L, 1998, J BIOL CHEM, V273, P21359, DOI 10.1074/jbc.273.33.21359; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; SWANSON MS, 1995, PREMRNA PROCESSING, P17; Temsamani J, 1996, J BIOL CHEM, V271, P24922, DOI 10.1074/jbc.271.40.24922; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WILUSZ J, 1988, MOL CELL BIOL, V8, P4477, DOI 10.1128/MCB.8.10.4477; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	45	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7681	7688		10.1074/jbc.M010207200	http://dx.doi.org/10.1074/jbc.M010207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113151	hybrid			2022-12-25	WOS:000167442900110
J	Wu, JV; Joo, NS; Krouse, ME; Wine, JJ				Wu, JV; Joo, NS; Krouse, ME; Wine, JJ			Cystic fibrosis transmembrane conductance regulator gating requires cytosolic electrolytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; PERIPLASMIC HISTIDINE PERMEASE; CL CONDUCTANCE; ATP HYDROLYSIS; IONIC-STRENGTH; FUNCTIONAL RECONSTITUTION; EPITHELIAL-CELLS; PHOSPHORYLATION; TRANSPORTER; ACTIVATION	Cystic fibrosis transmembrane conductance regulator (CFTR), which causes cystic fibrosis when nonfunctional, is an anion channel and a member of the ATP binding cassette superfamily. After phosphorylation, CFTR gates by binding and hydrolyzing ATP. We show that CFTR open probability (P-o) also depends on the electrolyte concentration of the cytosol. Inside-out patches from Calu-3 cells were transiently exposed to solutions of 160 mM salt or solutions in which up to 90% of the salt was replaced by nonionic osmolytes such as sucrose. In lowered salt solutions, CFTR P-o declined within 1 s to a stable lower value that depended on the electrolyte concentration, (K-1/2 approximate to 80 mM NaCl). P-o was rapidly restored in normal salt concentrations without regard to the electrolyte species. Reducing external electrolytes did not affect CFTR P-o. The same results were obtained when CFTR was stably phosphorylated with adenosine 5'-O-(thiotriphosphate). The decrease in P-o resulted entirely from an increase in mean closed time. Increasing ATP levels up to 20-fold did not counteract the effect of low electrolytes. The same effect was observed for CFTR expressed in C127 cells but not for a different species of anion channel. Cytosolic electrolytes are an unsuspected, essential cofactor for CFTR gating.	Stanford Univ, Cyst Fibrosis Res Lab, Stanford, CA 94305 USA	Stanford University	Wine, JJ (corresponding author), Stanford Univ, Cyst Fibrosis Res Lab, Bldg 420, Stanford, CA 94305 USA.	wine@stanford.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051817] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51817] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Blatt MR, 1997, J MEMBRANE BIOL, V158, P241, DOI 10.1007/s002329900261; Borisov OV, 1998, EUR PHYS J B, V4, P205, DOI 10.1007/s100510050371; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CHENG SH, 1995, AM J PHYSIOL-LUNG C, V268, pL615, DOI 10.1152/ajplung.1995.268.4.L615; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Cotten JF, 1997, J BIOL CHEM, V272, P25617, DOI 10.1074/jbc.272.41.25617; Cotten JF, 1999, J BIOL CHEM, V274, P5429, DOI 10.1074/jbc.274.9.5429; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Foskett JK, 1998, ANNU REV PHYSIOL, V60, P689, DOI 10.1146/annurev.physiol.60.1.689; Gadsby David C., 1999, Physiological Reviews, V79, pS77; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; Harrington MA, 1999, J BIOL CHEM, V274, P27536, DOI 10.1074/jbc.274.39.27536; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; Haws CM, 1996, AM J PHYSIOL-CELL PH, V270, pC1544, DOI 10.1152/ajpcell.1996.270.5.C1544; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kottgen M, 1996, PFLUG ARCH EUR J PHY, V431, P549, DOI 10.1007/s004240050034; Linsdell P, 1996, AM J PHYSIOL-CELL PH, V271, pC628, DOI 10.1152/ajpcell.1996.271.2.C628; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; MARSHALL J, 1994, J BIOL CHEM, V269, P2987; MARSHALL WS, 1991, INVEST OPHTH VIS SCI, V32, P1562; Nilius B, 1998, J PHYSIOL-LONDON, V506, P353, DOI 10.1111/j.1469-7793.1998.353bw.x; PENNEFATHER P, 1992, BIOPHYS J, V61, P448, DOI 10.1016/S0006-3495(92)81850-7; Pusch M, 1999, J PHYSIOL-LONDON, V515, P341, DOI 10.1111/j.1469-7793.1999.341ac.x; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; REDDY MM, 1994, AM J PHYSIOL-CELL PH, V267, pC1136, DOI 10.1152/ajpcell.1994.267.4.C1136; Reddy MM, 1998, AM J PHYSIOL-CELL PH, V275, pC1040, DOI 10.1152/ajpcell.1998.275.4.C1040; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; Schultz BD, 1996, J MEMBRANE BIOL, V151, P63, DOI 10.1007/s002329900058; Shapiro AB, 1997, EUR J BIOCHEM, V250, P115, DOI 10.1111/j.1432-1033.1997.00115.x; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; STUTTS MJ, 1994, J BIOL CHEM, V269, P8667; Tia S, 1996, NEUROPHARMACOLOGY, V35, P1375, DOI 10.1016/S0028-3908(96)00018-4; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; Xia YF, 1997, NAT MED, V3, P802, DOI 10.1038/nm0797-802; YANG AS, 1994, J MOL BIOL, V237, P602, DOI 10.1006/jmbi.1994.1258; Zeltwanger S, 1999, J GEN PHYSIOL, V113, P541, DOI 10.1085/jgp.113.4.541	47	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6473	6478		10.1074/jbc.M009305200	http://dx.doi.org/10.1074/jbc.M009305200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11112782	hybrid			2022-12-25	WOS:000167261000055
J	Di Popolo, A; Memoli, A; Apicella, A; Tuccillo, C; di Palma, A; Ricchi, P; Acquaviva, AM; Zarrilli, R				Di Popolo, A; Memoli, A; Apicella, A; Tuccillo, C; di Palma, A; Ricchi, P; Acquaviva, AM; Zarrilli, R			IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE(2) synthesis in Caco-2 human colon carcinoma cells	ONCOGENE			English	Article						IGF-II; IGF-Ir; COX-2; PGE(2); colon cancer	GROWTH-FACTOR-I; ENTEROCYTE-LIKE DIFFERENTIATION; ACTIVATED PROTEIN-KINASE; MESSENGER-RNA EXPRESSION; NF-KAPPA-B; CANCER-CELLS; CYCLOOXYGENASE-2 EXPRESSION; COLORECTAL-CANCER; PROSTAGLANDIN E-2; EPITHELIAL-CELLS	Nonsteroidal anti-inflammatory drugs reduce the risk of colon cancer and this effect is mediated in part through inhibition of type 2 prostaglandin endoperoxide synthase/cyclo-oxygenase (COX-2). In the present study, me demonstrate that COX-2 expression and PGE(2) synthesis are up-regulated by an IGF-II/IGF-I receptor autocrine pathway in Caco-2 colon carcinoma cells. COX-2 mRNA and PGE(2) levels are higher in proliferating cells compared with post-confluent differentiated cells and in cells that constitutively overexpress IGF-II, Up-regulation of COX-2 expression by IGF-II is mediated through activation of IGF-I receptor because: (i) treatment of Caco-2 cells with a blocking antibody to the IGF-I receptor inhibits COX-2 mRNA expression; (ii) transfection of Caco-2 cells with a dominant negative IGF-I receptor reduces COX-2 expression and activity, Also, the blockade of the PI3-kinase, that mediates the proliferative effect of IGF-I receptor in Caco-2 cells, inhibits IGF-II-dependent COX-2 up-regulation and PGE(2) synthesis. Moreover, COX-2 expression and activity inversely correlate with the increase of apoptosis in parental, IGF-II and dominant-negative IGF-I receptor transfected cells. This study suggests that induction of proliferation and tumor progression of colon cancer cells by the IGF-II/IGF-I receptor pathway may depend on the activation of COX-2-related events.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Ctr Endocrinol & Oncol Sperimentale G Salvatore, CNR, I-80131 Naples, Italy; II Ateneo Napoli, Dipartimento Internist Clin & Sperimentale, Div Gastroenterol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Acquaviva, AM (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, Ctr Endocrinol & Oncol Sperimentale G Salvatore, CNR, Via S Pansini 5, I-80131 Naples, Italy.		Ricchi, Paolo/J-5140-2019; Zarrilli, Raffaele/F-5067-2012	Ricchi, Paolo/0000-0001-7361-3308; Zarrilli, Raffaele/0000-0003-4191-9032; ACQUAVIVA, Angela Maria/0000-0001-9538-2766				Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074/jbc.274.11.7545; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; Garrouste FL, 1997, ENDOCRINOLOGY, V138, P2021, DOI 10.1210/en.138.5.2021; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; KATO H, 1993, J BIOL CHEM, V268, P2655; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Nardone G, 1996, HEPATOLOGY, V23, P1304, DOI 10.1053/jhep.1996.v23.pm0008675143; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PIGNATA S, 1994, CELL GROWTH DIFFER, V5, P967; PINTO M, 1983, BIOL CELL, V47, P323; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; PODOLSKY DK, 1993, AM J PHYSIOL, V264, P179; POMMIER GJ, 1992, CANCER RES, V52, P3182; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Ricchi P, 1997, INT J CANCER, V73, P880; Romano M, 1998, J BIOL CHEM, V273, P28560, DOI 10.1074/jbc.273.44.28560; RUBIN R, 1995, LAB INVEST, V73, P311; Sheng HM, 1998, CANCER RES, V58, P362; SIMON TC, 1995, CURR OPIN GENET DEV, V5, P577, DOI 10.1016/0959-437X(95)80026-3; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Zarrilli R, 1999, AM J GASTROENTEROL, V94, P3376, DOI 10.1111/j.1572-0241.1999.03376.x; ZARRILLI R, 1994, CELL GROWTH DIFFER, V5, P1085; Zarrilli R, 1996, J BIOL CHEM, V271, P8108, DOI 10.1074/jbc.271.14.8108; Zarrilli R, 1999, GASTROENTEROLOGY, V116, P1358, DOI 10.1016/S0016-5085(99)70500-7; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	40	92	96	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5517	5524		10.1038/sj.onc.1203952	http://dx.doi.org/10.1038/sj.onc.1203952			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114729				2022-12-25	WOS:000165396100012
J	Pierce, A; Spooncer, E; Wooley, S; Dive, C; Francis, JM; Miyan, J; Owen-Lynch, PJ; Dexter, TM; Whetton, AD				Pierce, A; Spooncer, E; Wooley, S; Dive, C; Francis, JM; Miyan, J; Owen-Lynch, PJ; Dexter, TM; Whetton, AD			Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation	ONCOGENE			English	Article						Bcr-Abl; p53; CML; differentiation; haemopoietic	CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC-CELL LINE; CHRONIC MYELOCYTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; WILD-TYPE P53; BLAST CRISIS; HOMOLOGOUS RECOMBINATION; RETROVIRAL TRANSDUCTION; CLONAL EVOLUTION; PROGENITOR CELLS	Chronic myeloid leukaemia is a haemopoietic stem cell disorder, the hallmark of which is the expression of the Bcr-Abl Protein Tyrosine Kinase (PTK), We have previously reported that activation of a temperature sensitive Bcr-Abl PTK in the multipotent haemopoietic cell line FDCP-Mix for short periods resulted in subtle changes including, a transient suppression of apoptosis and no inhibition of differentiation. In contrast, activation of the Bcr-Abl PTK for 12 weeks results in cells that display a delay in differentiation at the early granulocyte stage. Plow cytometric analysis also indicates that the expression of cell surface differentiation markers and nuclear morphology are uncoupled. Furthermore, a significant number of the mature neutrophils display abnormal morphological features. Prolonged exposure to Bcr-Abl PTK results in interleukin-3 independent growth and decreased p53 protein levels. FDCP-Mix cells expressing a dominant negative p53 and p53(null) FDCP-Mix cells demonstrate that the reduction in p53 is causally related to the delay in development. Returning the cells to the restrictive temperature restores the p53 protein levels, the growth factor dependence and largely relieves the effects on development. We conclude that prolonged Bcr-Abl PTK activity within multipotent cells results in a reduction of p53 that drives a delayed and abnormal differentiation.	Christie Hosp NHS Trust, Canc Res Campaign, Dept Expt Haematol, Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England; UMIST, Leukaemia Res Fund Cellular Dev Unit, Manchester M60 1QD, Lancs, England; UMIST, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Manchester, Sch Biol Sci, Mol & Cellular Pharmacol Grp, Manchester M13 9PT, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester; University of Manchester; University of Manchester	Spooncer, E (corresponding author), Christie Hosp NHS Trust, Canc Res Campaign, Dept Expt Haematol, Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England.		Miyan, Jaleel/AAB-1910-2021	Miyan, Jaleel/0000-0002-1835-0143; Owen-Lynch, Penelope Jane/0000-0002-5928-2327; WHETTON, ANTHONY D/0000-0002-1098-3878; Dive, Caroline/0000-0002-1726-8850; Pierce, Andrew/0000-0001-5995-2469				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; CARLESSO N, 1994, ONCOGENE, V9, P149; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Evans CA, 1999, BLOOD, V94, P1504, DOI 10.1182/blood.V94.5.1504.417a27_1504_1514; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FLEMING TJ, 1993, J IMMUNOL, V151, P2399; FOTI A, 1991, BLOOD, V77, P2441; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; Gotoh A, 1997, Curr Opin Hematol, V4, P3; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; LANEUVILLE P, 1992, BLOOD, V80, P1788; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lub M, 1996, J LEUKOCYTE BIOL, V59, P648, DOI 10.1002/jlb.59.5.648; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Maguer-Satta V, 1998, ONCOGENE, V16, P237, DOI 10.1038/sj.onc.1201533; MASHAL R, 1990, BLOOD, V75, P180; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; METCALF D, 1974, BLOOD, V43, P847, DOI 10.1182/blood.V43.6.847.847; NAKAI H, 1995, BRIT J HAEMATOL, V90, P147, DOI 10.1111/j.1365-2141.1995.tb03393.x; NAKAI H, 1995, LEUKEMIA LYMPHOMA, V19, P213, DOI 10.3109/10428199509107891; NAKAI H, 1992, CANCER RES, V52, P6588; PEDERSEN B, 1982, BRIT J HAEMATOL, V51, P339, DOI 10.1111/j.1365-2141.1982.tb02789.x; Pierce A, 1998, J CELL SCI, V111, P815; Pierce A, 1998, ONCOGENE, V17, P667, DOI 10.1038/sj.onc.1201969; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROVIRA A, 1995, ANN HEMATOL, V70, P129; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sambrook J., MOL CLONING LAB MANU; Seliger B, 1996, EUR J HAEMATOL, V57, P230; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shounan Y, 1996, LEUKEMIA, V10, P1619; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SPOONCER E, 1994, LEUKEMIA, V8, P620; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; STRIFE A, 1988, SEMIN HEMATOL, V25, P1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Verfaillie CM, 1998, HEMATOL ONCOL CLIN N, V12, P1, DOI 10.1016/S0889-8588(05)70495-0; WILLIAMS J, 1995, WILLIAMS HEMATOLOGY	59	29	29	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5487	5497		10.1038/sj.onc.1203940	http://dx.doi.org/10.1038/sj.onc.1203940			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114726				2022-12-25	WOS:000165396100009
J	Huber, AH; Stewart, DB; Laurents, DV; Nelson, WJ; Weis, WI				Huber, AH; Stewart, DB; Laurents, DV; Nelson, WJ; Weis, WI			The cadherin cytoplasmic domain is unstructured in the absence of beta-catenin - A possible-mechanism for regulating cadherin turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; PROTEIN-TYROSINE-PHOSPHATASE; TERMINAL PEST DOMAIN; CELL-CELL ADHESION; COMPLEX-FORMATION; KINASE SUBSTRATE; PTP-MU; PHOSPHORYLATION; REGION; DEGRADATION	Cadherins are single pass transmembrane proteins that mediate Ca2+-dependent homophilic cell-cell adhesion by linking the cytoskeletons of adjacent cells. In adherens junctions, the cytoplasmic domain of cadherins bind to beta -catenin, which in turn binds to the actin-associated protein alpha -catenin, The physical properties of the E-cadherin cytoplasmic domain and its interactions with beta -catenin have been investigated. Proteolytic sensitivity, tryptophan fluorescence, circular dichroism, and H-1 MMR measurements indicate that murine E-cadherin cytoplasmic domain is unstructured, Upon binding to beta -catenin, the domain becomes resistant to proteolysis, suggesting that it structures upon binding. Cadherin-beta -catenin complex stability is modestly dependent on ionic strength, indicating that, contrary to previous proposals, the interaction is not dominated by electrostatics, Comparison of 18 cadherin sequences indicates that their cytoplasmic domains are unlikely to be structured in isolation. This analysis also reveals the presence of PEST sequences, motifs associated with ubiquitin/proteosome degradation, that overlap the previously identified beta -catenin-binding site. It is proposed that binding of cadherins to beta -catenin prevents recognition of degradation-signals that are exposed in the unstructured cadherin cytoplasmic domain, favoring a cell surface population of catenin-bound cadherins capable of participating in cell adhesion.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, 299 Campus Dr W, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011; Laurents, Douglas V/E-7527-2015	Weis, William I/0000-0002-5583-6150; Laurents, Douglas V/0000-0002-4187-165X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056169] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35227, GM56169] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERLE H, 1994, J CELL SCI, V107, P3655; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CREIGHTON TE, 1989, PROTEIN STRUCTURE PR; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUGER KA, 1995, DEV BIOL, V172, P115, DOI 10.1006/dbio.1995.0009; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GURUPRASAD K, 1990, PROTEIN ENG, V4, P155, DOI 10.1093/protein/4.2.155; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Hericourt F, 2000, BIOCHEM J, V349, P417, DOI 10.1042/0264-6021:3490417; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Marchal C, 2000, J BIOL CHEM, V275, P23608, DOI 10.1074/jbc.M001735200; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Polakis P, 2000, GENE DEV, V14, P1837; PONTIUS BW, 1993, TRENDS BIOCHEM SCI, V18, P181, DOI 10.1016/0968-0004(93)90111-Y; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SHORE EM, 1991, J BIOL CHEM, V266, P19672; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	64	200	208	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12301	12309		10.1074/jbc.M010377200	http://dx.doi.org/10.1074/jbc.M010377200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11121423	hybrid			2022-12-25	WOS:000168081800115
J	Gordon, E; Flouret, B; Chantalat, L; van Heijenoort, J; Mengin-Lecreulx, D; Dideberg, O				Gordon, E; Flouret, B; Chantalat, L; van Heijenoort, J; Mengin-Lecreulx, D; Dideberg, O			Crystal structure of UDP-N-acetylmuramoyl-L-alanyl-D-glutamate: meso-diaminopimelate ligase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; L-ALANINE; PEPTIDOGLYCAN BIOSYNTHESIS; BACTERIAL PEPTIDOGLYCAN; DIFFRACTION DATA; PROTEIN; MURD; PEPTIDE; ACID; IDENTIFICATION	UDP-N-acetylmuramoyl-L-alanyl-D-glutamate aminopimelate ligase is a cytoplasmic enzyme that catalyzes the addition of meso-diaminopimelic acid to nucleotide precursor UDP-N-acetylmuramoyl-L-alanyl-D-glutamate in the biosynthesis of bacterial cell-wall peptidoglycan. The crystal structure of the Escherichia coli enzyme in the presence of the final product of the enzymatic reaction, UDP-MurNAc-L-Ala-gamma -D-Glu-meso-A(2)pm, has been solved to 2.0 Angstrom resolution. Phase information was obtained by multiwavelength anomalous dispersion using the K shell edge of selenium. The protein consists of three domains, two of which have a topology reminiscent of the equivalent domain found in the already established three-dimensional structure of the UDP-N-acetylmuramoyl-L-alanine: D-glutamate-ligase (MurD) ligase, which catalyzes the immediate previous step of incorporation of D-glutamic acid in the biosynthesis of the peptidoglycan precursor. The refined model reveals the binding site for UDP-MurNAc-L-Ala-gamma -D-Glu-meso-A(2)pm, and comparison with the six known MurD structures allowed the identification of residues involved in the enzymatic mechanism. Interestingly, during refinement, an excess of electron density was observed, leading to the conclusion that, as in MurD, a carbamylated lysine residue is present in the active site. In addition, the structural determinant responsible for the selection of the amino acid to be added to the nucleotide precursor was identified.	Inst Biol Struct Jean Pierre Ebel, CEA, CNRS, Lab Cristallog Macromol, F-38027 Grenoble 1, France; Univ Paris Sud, Inst Biochim & Biophys Mol & Cellulaire, CNRS,UMR 8619, Lab Enveloppes Bacteriennes & Antibiot, F-91405 Orsay, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Dideberg, O (corresponding author), Inst Biol Struct Jean Pierre Ebel, CEA, CNRS, Lab Cristallog Macromol, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	otto@ibs.fr		MENGIN-LECREULX, Dominique/0000-0003-3205-0275; Gordon, Elspeth Jane/0000-0002-9876-8020				ABOGHALIA M, 1985, EUR J BIOCHEM, V153, P81, DOI 10.1111/j.1432-1033.1985.tb09269.x; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Auger G, 1998, PROTEIN EXPRES PURIF, V13, P23, DOI 10.1006/prep.1997.0850; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertrand JA, 1999, J MOL BIOL, V289, P579, DOI 10.1006/jmbi.1999.2800; Bertrand JA, 2000, J MOL BIOL, V301, P1257, DOI 10.1006/jmbi.2000.3994; Bertrand JA, 1997, EMBO J, V16, P3416, DOI 10.1093/emboj/16.12.3416; Bouhss A, 1999, BIOCHEMISTRY-US, V38, P12240, DOI 10.1021/bi990517r; Bouhss A, 1997, BIOCHEMISTRY-US, V36, P11556, DOI 10.1021/bi970797f; Bouhss A, 1999, FEBS LETT, V453, P15, DOI 10.1016/S0014-5793(99)00684-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUGG TDH, 1992, NAT PROD REP, V9, P199, DOI 10.1039/np9920900199; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Eveland SS, 1997, BIOCHEMISTRY-US, V36, P6223, DOI 10.1021/bi9701078; Falk PJ, 1996, BIOCHEMISTRY-US, V35, P1417, DOI 10.1021/bi952078b; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; IKEDA M, 1990, J GEN APPL MICROBIOL, V36, P179, DOI 10.2323/jgam.36.179; ITO E, 1973, J BIOL CHEM, V248, P3131; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LABISCHINSKI H, 1994, N COMP BIOC, V27, P23; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Mengin-Lecreulx D, 1999, J BACTERIOL, V181, P5909, DOI 10.1128/JB.181.19.5909-5914.1999; Mengin-Lecreulx D, 1998, J BACTERIOL, V180, P4406, DOI 10.1128/JB.180.17.4406-4412.1998; MenginLecreulx D, 1996, J BACTERIOL, V178, P5347, DOI 10.1128/jb.178.18.5347-5352.1996; MENGINLECREULX D, 1994, J BACTERIOL, V176, P4321, DOI 10.1128/jb.176.14.4321-4327.1994; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Pompeo F, 1998, J BACTERIOL, V180, P4799, DOI 10.1128/JB.180.18.4799-4803.1998; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; Ravelli RBG, 1997, J APPL CRYSTALLOGR, V30, P551, DOI 10.1107/S0021889897003543; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sheng Y, 2000, J MOL BIOL, V302, P427, DOI 10.1006/jmbi.2000.3987; Sun XL, 1998, P NATL ACAD SCI USA, V95, P6647, DOI 10.1073/pnas.95.12.6647; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Vaganay S, 1996, MICROB DRUG RESIST, V2, P51, DOI 10.1089/mdr.1996.2.51; van Heijenoort J, 1998, CELL MOL LIFE SCI, V54, P300, DOI 10.1007/s000180050155; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	48	115	117	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10999	11006		10.1074/jbc.M009835200	http://dx.doi.org/10.1074/jbc.M009835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11124264	hybrid			2022-12-25	WOS:000167980900059
J	Wilson, HL; Dipp, M; Thomas, JM; Lad, C; Galione, A; Evans, AM				Wilson, HL; Dipp, M; Thomas, JM; Lad, C; Galione, A; Evans, AM			ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase act as a redox sensor - A primary role for cyclic ADP-ribose in hypoxic pulmonary vasoconstriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PULMONARY; CA2+ RELEASE; INTRAPULMONARY ARTERIES; INTRACELLULAR CA2+; INSULIN-SECRETION; ENDOGENOUS LEVELS; CALCIUM-RELEASE; K+ CHANNELS; CADP-RIBOSE; CELLS	Hypoxic pulmonary vasoconstriction is unique to pulmonary arteries and serves to match lung perfusion to ventilation. However, in disease states this process can promote hypoxic pulmonary hypertension. Hypoxic pulmonary vasoconstriction is associated with increased NADH levels in pulmonary artery smooth muscle and with intracellular Ca2+ release from ryanodine-sensitive stores. Because cyclic ADP-ribose (cADPR) regulates ryanodine receptors and is synthesized from beta -NAD(+), we investigated the regulation by beta -NADH of cADPR synthesis and metabolism and the role of cADPR in hypoxic pulmonary vasoconstriction. Significantly higher rates of cADPR synthesis occurred in smooth muscle homogenates of pulmonary arteries, compared with homogenates of systemic arteries. When the beta -NAD(+):beta -NADH ratio was reduced, the net amount of cADPR accumulated increased. This was due, at least in part, to the inhibition of cADPR hydrolase by beta -NADH. Furthermore, hypoxia induced a 10-fold increase in cADPR levels in pulmonary artery smooth muscle, and a membrane-permeant cADPR antagonist, 8-bromo. cADPR, abolished hypoxic pulmonary vasoconstriction in pulmonary artery rings. We propose that the cellular redox state may be coupled via an increase in beta -NADH levels to enhanced cADPR synthesis, activation of ryanodine receptors, and sarcoplasmic reticulum Ca2+ release. This redox-sensing pathway may offer new therapeutic targets for hypoxic pulmonary hypertension.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Oxford; University of Oxford	Evans, AM (corresponding author), Univ St Andrews, Sch Biol, Div Biomed Sci, Buke Bldg, St Andrews KY16 9TS, Fife, Scotland.	ame3@st-and.ac.uk	Wilson, Heather/O-5909-2019; Galione, Antony/E-5884-2011	Wilson, Heather/0000-0002-7892-3425; Galione, Antony/0000-0002-4132-7646				ARCHER SL, 1993, CIRC RES, V73, P1100, DOI 10.1161/01.RES.73.6.1100; Bae YM, 1999, J PHYSIOL-LONDON, V514, P747, DOI 10.1111/j.1469-7793.1999.747ad.x; BISCOE TJ, 1990, J PHYSIOL-LONDON, V428, P39, DOI 10.1113/jphysiol.1990.sp018199; CLAPP LH, 1991, EXP PHYSIOL, V76, P677, DOI 10.1113/expphysiol.1991.sp003535; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CORNFIELD D, 1993, AM J PHYSIOL, V265, pL1; Cui Y, 1999, BIOCHEM J, V342, P269, DOI 10.1042/0264-6021:3420269; DIPP M, 2000, J PHYSL, V526, pS26P; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Euler Us V, 1946, ACTA PHYSL SCAND, V12, P301, DOI [10.1111/j.1748-1716.1946.tb00389.x, DOI 10.1111/J.1748-1716.1946.TB00389.X]; Evans AM, 1996, J PHYSIOL-LONDON, V496, P407, DOI 10.1113/jphysiol.1996.sp021694; EVANS WH, 1986, BIOL MEMBR, P1; Galione A, 2000, CRC METH SIG TRANS, P249; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALIONE A, 1996, RYANODINE RECEPTORS, P52; Gelband CH, 1997, CIRCULATION, V96, P3647; Graeff RM, 1997, METHOD ENZYMOL, V280, P230; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HALPERN W, 1987, J PHYSL, V265, pP21; HARDER DR, 1985, J APPL PHYSIOL, V59, P1389, DOI 10.1152/jappl.1985.59.5.1389; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Jabr RI, 1997, BRIT J PHARMACOL, V122, P21, DOI 10.1038/sj.bjp.0701326; KOVITZ KL, 1993, AM J PHYSIOL, V260, pL516; LEACH RM, 1994, AM J PHYSIOL, V266, pL223, DOI 10.1152/ajplung.1994.266.3.L223; Leach RM, 2000, AM J PHYSIOL-LUNG C, V278, pL294, DOI 10.1152/ajplung.2000.278.2.L294; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1991, J BIOL CHEM, V266, P2276; MADDEN JA, 1992, AM J PHYSIOL, V263, pL384, DOI 10.1152/ajplung.1992.263.3.L384; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Okamoto H, 1997, DIABETOLOGIA, V40, P1485, DOI 10.1007/s001250050854; Osipenko ON, 1997, BRIT J PHARMACOL, V120, P1461, DOI 10.1038/sj.bjp.0701075; POST JM, 1992, AM J PHYSIOL, V262, pC882, DOI 10.1152/ajpcell.1992.262.4.C882; Robertson TP, 2000, J PHYSIOL-LONDON, V525, P669, DOI 10.1111/j.1469-7793.2000.t01-1-00669.x; Robertson TP, 2000, BRIT J PHARMACOL, V131, P5, DOI 10.1038/sj.bjp.0703537; ROBERTSON TP, 1995, AM J PHYSIOL-HEART C, V268, pH301, DOI 10.1152/ajpheart.1995.268.1.H301; Salgado AP, 1999, MOL CELL ENDOCRINOL, V154, P79, DOI 10.1016/S0303-7207(99)00085-4; SALVATERRA CG, 1993, AM J PHYSIOL, V264, pL323, DOI 10.1152/ajplung.1993.264.3.L323; Sethi JK, 1996, BIOCHEM J, V319, P613, DOI 10.1042/bj3190613; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358; Shigemori K, 1996, AM J PHYSIOL-LUNG C, V270, pL803, DOI 10.1152/ajplung.1996.270.5.L803; Sonnleitner A, 1998, EMBO J, V17, P2790, DOI 10.1093/emboj/17.10.2790; WADSWORTH RM, 1994, TRENDS PHARMACOL SCI, V15, P47, DOI 10.1016/0165-6147(94)90109-0; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Wilson HL, 1998, BIOCHEM J, V331, P837, DOI 10.1042/bj3310837; Yamaguchi N, 1997, BIOCHEM BIOPH RES CO, V240, P772, DOI 10.1006/bbrc.1997.7583; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	50	108	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11180	11188		10.1074/jbc.M004849200	http://dx.doi.org/10.1074/jbc.M004849200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11116136	hybrid			2022-12-25	WOS:000167980900081
J	Amir-Ahmady, B; Salati, LM				Amir-Ahmady, B; Salati, LM			Regulation of the processing of glucose-6-phosphate dehydrogenase mRNA by nutritional status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; RNA-POLYMERASE-II; NUCLEAR POSTTRANSCRIPTIONAL MECHANISM; MITOTIC APPARATUS PROTEIN; ACETYL-COA CARBOXYLASE; S14 GENE-TRANSCRIPTION; MESSENGER-RNA; RAT-LIVER; THYROID-HORMONE; SPLICING COMPLEXES	Expression of glucose-6-phosphate dehydrogenase (G6PD) gene during starvation and refeeding is regulated by a posttranscriptional mechanism occurring in the nucleus. The amount of G6PD mRNA at different stages of processing was measured in RNA isolated from the nuclear matrix fraction of mouse liver. This nuclear fraction contains nascent transcripts and RNA undergoing processing. Using a ribonuclease protection assay with probes that cross an exon-intron boundary in the G6PD transcript, the abundance of mRNAs that contain the intron (unspliced) and without the intron (spliced) was measured. Refeeding resulted in 6- and 8-fold increases in abundance of G6PD unspliced and spliced RNA respectively, in the nuclear matrix fraction. However, the amount of G6PD unspliced RNA was at most 15% of the amount of spliced RNA. During refeeding, G6PD spliced RNA accumulated at a rate significantly greater than unspliced RNA. Further, the amount of partially spliced RNA exceeded the amount of unspliced RNA indicating that the enhanced accumulation occurs early in processing, Starvation and refeeding did not regulate either the rate of polyadenylation or the length of the poly(A) tail. Thus, the G6PD gene is regulated during refeeding by enhanced efficiency of splicing of its RNA and this processing protects the mRNA from decay, a novel mechanism for nutritional regulation of gene expression.	W Virginia Univ, Hlth Sci Ctr, Dept Biochem, Morgantown, WV 26506 USA	West Virginia University	Salati, LM (corresponding author), W Virginia Univ, Hlth Sci Ctr, Dept Biochem, POB 9142, Morgantown, WV 26506 USA.				NIDDK NIH HHS [R01 DK046897, DK46897] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046897, R29DK046897, R56DK046897] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antoniou M, 1998, NUCLEIC ACIDS RES, V26, P721, DOI 10.1093/nar/26.3.721; BERDANIER CD, 1979, J NUTR, V109, P1766, DOI 10.1093/jn/109.10.1766; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; BURMEISTER LA, 1991, J BIOL CHEM, V266, P22905; CARRAZANA EJ, 1988, MOL CELL BIOL, V8, P2267, DOI 10.1128/MCB.8.6.2267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIEJEK EM, 1982, BIOCHEMISTRY-US, V21, P4945, DOI 10.1021/bi00263a018; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; Custodio N, 1999, EMBO J, V18, P2855, DOI 10.1093/emboj/18.10.2855; DOZIN B, 1986, P NATL ACAD SCI USA, V83, P4705, DOI 10.1073/pnas.83.13.4705; EHRETSMANN CP, 1995, MOL CELL ENDOCRINOL, V110, P185, DOI 10.1016/0303-7207(95)03531-B; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; Eldridge AG, 1999, P NATL ACAD SCI USA, V96, P6125, DOI 10.1073/pnas.96.11.6125; ELMeskini R, 1997, ENDOCRINOLOGY, V138, P379, DOI 10.1210/en.138.1.379; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; GEREZ L, 1995, J BIOL CHEM, V270, P19569, DOI 10.1074/jbc.270.33.19569; GLOCK GE, 1955, BIOCHEM J, V61, P390, DOI 10.1042/bj0610390; GLOCK GE, 1954, BIOCHEM J, V56, P171, DOI 10.1042/bj0560171; Goethe R, 1998, J IMMUNOL, V160, P4970; Gonzalez CI, 1996, J BIOL CHEM, V271, P25801, DOI 10.1074/jbc.271.42.25801; GOZUKARA EM, 1972, BIOCHIM BIOPHYS ACTA, V286, P155, DOI 10.1016/0304-4165(72)90101-8; Grillasca JP, 1997, FEBS LETT, V401, P38, DOI 10.1016/S0014-5793(96)01433-0; HAMBLIN PS, 1989, J BIOL CHEM, V264, P21646; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Hillgartner FB, 1996, BIOCHEM J, V319, P263, DOI 10.1042/bj3190263; Hirose Y, 2000, GENE DEV, V14, P1415; Hodge DL, 1997, ARCH BIOCHEM BIOPHYS, V348, P303, DOI 10.1006/abbi.1997.0373; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1994, J LIPID RES, V35, P1076; KALLAJOKI M, 1991, EMBO J, V10, P3351, DOI 10.1002/j.1460-2075.1991.tb04899.x; KATSURADA A, 1990, EUR J BIOCHEM, V190, P435, DOI 10.1111/j.1432-1033.1990.tb15593.x; KILEDJIAN M, 1991, J BIOL CHEM, V266, P4207; KIM KS, 1992, BIOCHEM BIOPH RES CO, V189, P264, DOI 10.1016/0006-291X(92)91553-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; Li SL, 1997, J EXP MED, V185, P985, DOI 10.1084/jem.185.6.985; LIAW CW, 1984, J BIOL CHEM, V259, P7253; MAEKAWA T, 1991, EUR J CELL BIOL, V54, P255; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; MURPHY D, 1992, MOL CELL BIOL, V12, P2624, DOI 10.1128/MCB.12.6.2624; NAKAYASU H, 1991, P NATL ACAD SCI USA, V88, P10312, DOI 10.1073/pnas.88.22.10312; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; Nickerson JA, 1995, INT REV CYTOL, V162A, P67; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; Osman F, 1999, GENE DEV, V13, P3280, DOI 10.1101/gad.13.24.3280; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Porter D, 1997, ANAL BIOCHEM, V247, P279, DOI 10.1006/abio.1997.2059; PROSTKO CR, 1989, BIOCHEM J, V258, P295, DOI 10.1042/bj2580295; ROGNSTAD R, 1979, J BIOL CHEM, V254, P1969; SCHRODER HC, 1987, J BIOL CHEM, V262, P8917; Sessler AM, 1996, J BIOL CHEM, V271, P29854, DOI 10.1074/jbc.271.47.29854; Stabile LP, 1998, J LIPID RES, V39, P1951; Stabile LP, 1996, ARCH BIOCHEM BIOPHYS, V332, P269, DOI 10.1006/abbi.1996.0342; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; SUN JM, 1994, J CELL BIOCHEM, V55, P252, DOI 10.1002/jcb.240550212; TANG TK, 1994, J CELL SCI, V107, P1389; TANG TK, 1993, J CELL SCI, V104, P249; TEPPERMAN HM, 1964, AM J PHYSIOL, V206, P357, DOI 10.1152/ajplegacy.1964.206.2.357; TOUSSON A, 1991, J CELL BIOL, V112, P427, DOI 10.1083/jcb.112.3.427; Walker JD, 1996, ENDOCRINOLOGY, V137, P2293, DOI 10.1210/en.137.6.2293; WAN KM, 1994, P NATL ACAD SCI USA, V91, P594, DOI 10.1073/pnas.91.2.594; WATANABE A, 1973, ARCH BIOCHEM BIOPHYS, V158, P43, DOI 10.1016/0003-9861(73)90595-X; WINBERRY L, 1977, J BIOL CHEM, V252, P7796; WOLFE RG, 1978, J NUTR, V108, P1708, DOI 10.1093/jn/108.10.1708; ZEITLIN S, 1987, MOL CELL BIOL, V7, P111, DOI 10.1128/MCB.7.1.111; ZENG CQ, 1994, P NATL ACAD SCI USA, V91, P1505, DOI 10.1073/pnas.91.4.1505; ZENG CQ, 1994, CELL MOTIL CYTOSKEL, V29, P167, DOI 10.1002/cm.970290208; Zhang J, 1996, RNA, V2, P235; ZHOU H, 1994, J BIOL CHEM, V269, P22433; Zollo M, 1993, DNA Seq, V3, P319, DOI 10.3109/10425179309020830	78	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10514	10523		10.1074/jbc.M010535200	http://dx.doi.org/10.1074/jbc.M010535200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124967	Green Published, hybrid			2022-12-25	WOS:000167996400120
J	Knollmann, BC; Blatt, SA; Horton, K; de Freitas, F; Miller, T; Bell, M; Housmans, PR; Weissman, NJ; Morad, M; Potter, JD				Knollmann, BC; Blatt, SA; Horton, K; de Freitas, F; Miller, T; Bell, M; Housmans, PR; Weissman, NJ; Morad, M; Potter, JD			Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIASTOLIC CHAMBER STIFFNESS; SUDDEN-DEATH; MOUSE MODEL; MYOSIN; TIME	The cardiac troponin T (TnT) 179N mutation has been linked to familial hypertrophic cardiomyopathy and a high incidence of sudden death, despite causing little or no cardiac hypertrophy. In skinned fibers, 179N increased myofilamental calcium sensitivity (Miller, T,, Szczesna, D,, Housmans, P, Il,, Zhao, J., deFreitas, F., Gomes, A V., Culbreath, L,, McCue, J,, Wang, Y,, Xu, Y.,Kerrick, W. G., and Potter, J. D, (2001) J, Biol. Chen. 276, 3743-3755), To further study the functional consequences of this mutation, we compared the cardiac performance of transgenic mice expressing either human TnT-179N or human wild-type TnT. In isolated hearts, cardiac function was different depending on the Ca2+ concentration of the perfusate; systolic function was significantly increased in Tg-179N hearts at 0.5 and 1 mmol/liter, At higher Ca2+ concentrations, systolic function was not different, but diastolic dysfunction became manifest as increased end-diastolic pressure and time to 90% relaxation, In vivo measurements by echocardiography and Doppler confirmed that base-line systolic function was significantly higher in Tg-179N mice without evidence for diastolic dysfunction. Inotropic stimulation with isoproterenol resulted only in a modest contractile response but caused significant mortality in Tg-179N mice. Doppler studies ruled out aortic outflow obstruction and were consistent with increased chamber stiffness. We conclude that in vivo, the increased myofilament Ca2+ sensitivity due to the 179N mutation enhances base-line contractility but leads to cardiac dysfunction during inotropic stimulation.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Pathol, Miami, FL 33136 USA; Georgetown Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA; Washington Hosp Ctr, Cardiovasc Res Inst, Washington, DC 20010 USA; Mayo Clin & Mayo Fdn, Dept Anesthesiol, Rochester, MN 55905 USA	University of Miami; University of Miami; Georgetown University; Georgetown University; MedStar Washington Hospital Center; Mayo Clinic	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	jdpotter@miami.edu		Knollmann, Bjorn/0000-0003-4956-9735	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042325, R01HL016152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036365] Funding Source: NIH RePORTER; NHLBI NIH HHS [2R01 HL42325, R01 HL16152] Funding Source: Medline; NIAMS NIH HHS [AR 45391] Funding Source: Medline; NIGMS NIH HHS [R01 GM36365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APSTEIN CS, 1978, AM J PHYSIOL, V235, pH636, DOI 10.1152/ajpheart.1978.235.6.H637; Berul CI, 1997, J CLIN INVEST, V99, P570, DOI 10.1172/JCI119197; Christensen G, 1997, AM J PHYSIOL-HEART C, V272, pH2513, DOI 10.1152/ajpheart.1997.272.6.H2513; DILSIZIAN V, 1993, J AM COLL CARDIOL, V22, P796, DOI 10.1016/0735-1097(93)90193-5; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Georgakopoulos D, 1999, NAT MED, V5, P327, DOI 10.1038/6549; Ho CY, 2000, CIRCULATION, V102, P1950, DOI 10.1161/01.CIR.102.16.1950; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; Landesberg A, 1999, AM J PHYSIOL-HEART C, V276, pH998, DOI 10.1152/ajpheart.1999.276.3.H998; Lim CC, 1999, AM J PHYSIOL-HEART C, V277, pH2083, DOI 10.1152/ajpheart.1999.277.5.H2083; Lim DS, 2000, J MOL CELL CARDIOL, V32, P365, DOI 10.1006/jmcc.1999.1081; LITTLE WC, 1995, CIRCULATION, V92, P1933, DOI 10.1161/01.CIR.92.7.1933; Maron BJ, 2000, NEW ENGL J MED, V342, P365, DOI 10.1056/NEJM200002103420601; MCKENNEY PA, 1994, J AM COLL CARDIOL, V24, P1189, DOI 10.1016/0735-1097(94)90097-3; McKenney PA, 1999, AM J CARDIOL, V84, P914, DOI 10.1016/S0002-9149(99)00465-8; Mikane T, 1997, AM J PHYSIOL-HEART C, V273, pH2891, DOI 10.1152/ajpheart.1997.273.6.H2891; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Mitchell GF, 1998, AM J PHYSIOL-HEART C, V274, pH747, DOI 10.1152/ajpheart.1998.274.3.H747; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; Prasad K, 1998, HEART, V79, P538, DOI 10.1136/hrt.79.6.538; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; Spindler M, 1998, J CLIN INVEST, V101, P1775, DOI 10.1172/JCI1940; STOMER H, 1997, AM J PHYSIOL, V272, pH501; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Tardiff JC, 1999, J CLIN INVEST, V104, P469, DOI 10.1172/JCI6067; Varnava A, 1999, HEART, V82, P621, DOI 10.1136/hrt.82.5.621; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680	31	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10039	10048		10.1074/jbc.M006745200	http://dx.doi.org/10.1074/jbc.M006745200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11113119	hybrid			2022-12-25	WOS:000167996400063
J	Mark, BL; Vocadlo, DJ; Knapp, S; Triggs-Raine, BL; Withers, SG; James, MNG				Mark, BL; Vocadlo, DJ; Knapp, S; Triggs-Raine, BL; Withers, SG; James, MNG			Crystallographic evidence for substrate-assisted catalysis in a bacterial beta-hexosaminidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS-DISEASE; ACID-SEQUENCE SIMILARITIES; ELECTRON-DENSITY MAPS; GLYCOSYL HYDROLASES; STREPTOMYCES-PLICATUS; ACTIVE-SITE; MECHANISMS; CLASSIFICATION; CHITOBIASE; HYDROLYSIS	beta -Hexosaminidase, a family 20 glycosyl hydrolase, catalyzes the removal of beta -1,4-linked N-acetylhexosamine residues from oligosaccharides and their conjugates, Heritable deficiency of this enzyme results in various forms of GalNAc-beta (1,4)-[N-acetylneuraminic acid (2,3)]-Gal-beta (1,4)-Glc-ceramide gangliosidosis, including Tay-Sachs disease. We have determined the x-ray crystal structure of a P-hexosaminidase from Streptomyces plicatus to 2.2 Angstrom resolution (Protein Data Bank code 1HP4), P-Hexosaminidases are believed to use a substrate-assisted catalytic mechanism that generates a cyclic oxazolinium ion intermediate. We have solved and refined a complex between the cyclic intermediate analogue N-acethlglucosamine-thiazoline and beta -hexosaminidase from S, plicatus to 2.1 Angstrom resolution (Protein Data Bank code 1HP5), Difference Fourier analysis revealed the pyranose ring of N-acetylglucosamine-thiazoline bound in the enzyme active site with a conformation close to that of a C-4(1) chair. A tryptophan-lined hydrophobic pocket envelops the thiazoline ring, protecting it from solvolysis at the iminium ion carbon. Within this pocket, Tyr(393) and Asp(313) appear important for positioning the 2-acetamido group of the substrate for nucleophilic attack at the anomeric center and for dispersing the positive charge distributed into the oxazolinium ring upon cyclization, This complex provides decisive structural evidence for substrate-assisted catalysis and the formation of a covalent, cyclic intermediate in family 20 beta -hexosaminidases.	Univ Alberta, Dept Biochem, MRC, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Rutgers State Univ, Dept Chem, New Brunswick, NJ 08903 USA; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W3, Canada	University of Alberta; University of British Columbia; Rutgers State University New Brunswick; University of Manitoba	James, MNG (corresponding author), Univ Alberta, Dept Biochem, MRC, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.		Withers, Stephen G/I-7229-2019; Triggs-Raine, Barbara/AAF-6209-2021; Vocadlo, David J/E-5508-2014	Withers, Stephen G/0000-0002-6722-5701; Triggs-Raine, Barbara/0000-0003-4719-6779; Vocadlo, David J/0000-0001-6897-5558; Mark, Brian/0000-0002-7344-1355				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BROWN CA, 1989, J BIOL CHEM, V264, P21705; BROWN CA, 1993, AM J HUM GENET, V53, P497; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cao ZM, 1997, J BIOL CHEM, V272, P14975, DOI 10.1074/jbc.272.23.14975; CHURCH WB, 1992, J MOL BIOL, V227, P577, DOI 10.1016/0022-2836(92)90911-3; Cowtan K, 1999, ACTA CRYSTALLOGR D, V55, P1555, DOI 10.1107/S0907444999007416; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; Drouillard S, 1997, BIOCHEM J, V328, P945, DOI 10.1042/bj3280945; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fernandes MJG, 1997, J BIOL CHEM, V272, P814, DOI 10.1074/jbc.272.2.814; Gravel R. A., 1995, METABOLIC BASIS INHE, P1807; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hou YM, 2000, BIOCHEMISTRY-US, V39, P6219, DOI 10.1021/bi992464j; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIRBY AJ, 1984, ACCOUNTS CHEM RES, V17, P305, DOI 10.1021/ar00105a002; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; Knapp S, 1996, J AM CHEM SOC, V118, P6804, DOI 10.1021/ja960826u; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI ECK, 1994, BIOCHEMISTRY-US, V33, P14743, DOI 10.1021/bi00253a012; LEGLER G, 1992, CARBOHYD RES, V233, P113, DOI 10.1016/S0008-6215(00)90924-8; Mark BL, 1998, J BIOL CHEM, V273, P19618, DOI 10.1074/jbc.273.31.19618; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pennybacker M, 1997, J BIOL CHEM, V272, P8002, DOI 10.1074/jbc.272.12.8002; Prag G, 2000, J MOL BIOL, V300, P611, DOI 10.1006/jmbi.2000.3906; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; Sambrook J., 2002, MOL CLONING LAB MANU; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; Sulzenbacher G, 1996, BIOCHEMISTRY-US, V35, P15280, DOI 10.1021/bi961946h; TANAKA A, 1990, AM J HUM GENET, V46, P329; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; THUNNISSEN AMWH, 1995, BIOCHEMISTRY-US, V34, P12729, DOI 10.1021/bi00039a032; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; WEAVER LH, 1995, J MOL BIOL, V245, P54, DOI 10.1016/S0022-2836(95)80038-7; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+	50	227	246	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10330	10337		10.1074/jbc.M011067200	http://dx.doi.org/10.1074/jbc.M011067200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124970	hybrid			2022-12-25	WOS:000167996400099
J	Thuresson, ED; Lakkides, KM; Rieke, CJ; Sun, Y; Wingerd, BA; Micielli, R; Mulichak, AM; Malkowski, MG; Garavito, RM; Smith, WL				Thuresson, ED; Lakkides, KM; Rieke, CJ; Sun, Y; Wingerd, BA; Micielli, R; Mulichak, AM; Malkowski, MG; Garavito, RM; Smith, WL			Prostaglandin endoperoxide H synthase-1 - The functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid01	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-DEPENDENT INHIBITION; CRYSTAL-STRUCTURE; TYROSYL RADICALS; STRUCTURAL BASIS; GENE-EXPRESSION; G/H SYNTHASE-1; ARGININE 120; ASPIRIN; OVINE; FIBROBLASTS	Prostaglandin endoperoxide H syntheses (PGHSs) catalyze the committed step in the biosynthesis of prostaglandins and thromboxane, the conversion of arachidonic acid, two molecules of O-2, and two electrons to prostaglandin endoperoxide H-2 (PGH(2)), Formation of PGH(2) involves an initial oxygenation of arachidonate to yield PGG(2) catalyzed by the cyclooxygenase activity of the enzyme and then a reduction of the 15-hydroperoxyl group of PGG(2) to form PGH(2) catalyzed by the peroxidase activity. The cyclooxygenase active site is a hydrophobic channel that protrudes from the membrane binding domain into the core of the globular domain of PGHS. In the crystal structure of Co3+-heme ovine PGHS-1 complexed with arachidonic acid, 19 cyclooxygenase active site residues are predicted to make a total of 50 contacts with the substrate (Malkowski, M, G, Ginell, S,, Smith, W, L., and Garavito, R, M, (2000) Science 289, 1933-1937); two of these are hydrophilic, and 48 involve hydrophobic interactions. We performed mutational analyses to determine the roles of 14 of these residues and 4 other closely neighboring residues in arachidonate binding and oxygenation. Mutants were analyzed for peroxidase and cyclooxygenase activity, and the products formed by various mutants were characterized, Overall, the results indicate that cyclooxygenase active site residues of PGHS-1 fall into five functional categories as follows: (a) residues directly involved in hydrogen abstraction from C-13 of arachidonate (Tyr-385); (b) residues essential for positioning C-13 of arachidonate for hydrogen abstraction (Gly-533 and Tyr-348); (c) residues critical for high affinity arachidonate binding (Arg-120); (d) residues critical for positioning arachidonate in a conformation so that when hydrogen abstraction does occur the molecule is optimally arranged to yield PGG, versus monohydroperoxy acid products (Val-349, Trp-387, and Leu-534); and (e) all other active site residues, which individually make less but measurable contributions to optimal catalytic efficiency.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Smith, WL (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, 513 Biochem Bldg, E Lansing, MI 48824 USA.	smithww@pilot.msu.edu	Malkowski, Michael G/G-4939-2011	Malkowski, Michael G/0000-0003-1025-0014; Malkowski, Michael/0000-0002-1203-7463	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [F31NR010170] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL56773] Funding Source: Medline; NIGMS NIH HHS [P01 GM57323] Funding Source: Medline; NINR NIH HHS [NRS HL10170] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callan OH, 1996, J BIOL CHEM, V271, P3548; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FOEGH ML, 1989, PROSTAGLANDINS CLIN, P131; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; GUND P, 1977, J MED CHEM, V20, P1146, DOI 10.1021/jm00219a007; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HSI LC, 1993, J LIPID MEDIATOR, V6, P131; HSI LC, 1995, BIOCHEM BIOPH RES CO, V207, P652, DOI 10.1006/bbrc.1995.1237; HULKOWER KI, 1994, ARTHRITIS RHEUM-US, V37, P653, DOI 10.1002/art.1780370508; JONES DA, 1993, J BIOL CHEM, V268, P9049; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAZ A, 1990, ADV PROSTAG THROMB L, V20, P22; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; So OY, 1998, J BIOL CHEM, V273, P5801, DOI 10.1074/jbc.273.10.5801; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; Thuresson ED, 2001, J BIOL CHEM, V276, P10358, DOI 10.1074/jbc.M009378200; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Wong E, 1997, J BIOL CHEM, V272, P9280; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742	50	116	122	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10347	10357		10.1074/jbc.M009377200	http://dx.doi.org/10.1074/jbc.M009377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11121412	hybrid			2022-12-25	WOS:000167996400101
J	Gu, XS; Shin, BH; Akbarali, Y; Weiss, A; Boltax, J; Oettgen, P; Libermann, TA				Gu, XS; Shin, BH; Akbarali, Y; Weiss, A; Boltax, J; Oettgen, P; Libermann, TA			Tel-2 is a novel transcriptional repressor related to the Ets factor Tel/ETV-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; BONE MORPHOGENETIC PROTEIN-6; LARGE T-ANTIGEN; RETINOIC ACID; SUBSTRATE-SPECIFICITY; GROWTH-FACTOR; CHROMOSOME-TRANSLOCATION; EWINGS-SARCOMA; RECEPTOR-BETA; GENE FUSION	We report here the isolation of Tel-2, a novel member of the Ets transcription factor family, with high homology to Tel/ETV-6. Tel-2 is the second mammalian member of the Tel Ets family subclass whose prototype Tel is involved in various chromosomal translocations in human cancers. Six differentially expressed alternative splice products of Tel-2 were characterized encoding different Tel-2 isoforms which either contain or lack the amino-terminal Pointed domain and also vary at the carboxyl terminus. In contrast to Tel, which is highly expressed in several different cell types and tissues, Tel-2 is only weakly expressed in a variety of tissues and cell types, including placenta, prostate, spleen, liver, and lung. Tel-2 binds to functionally relevant Ets-binding sites of several genes and only the Tel-2 isoform containing the Pointed domain and the DNA-binding domain acts as a strong repressor of transcription. The retinoic acid receptor alpha and bone morphogenetic protein-6B (BMP-6) genes are specifically repressed by Tel-2 indicating a function for Tel-2 as an inhibitor of differentiation. Due to the important involvement of Tel in human cancer and the location of Tel-2 within the MHC cluster region, Tel-2 might be involved in chromosomal translocations in human cancer as well.	Beth Israel Deaconess Med Ctr, Dept Med, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Harvard Medical School	Libermann, TA (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, New England Baptist Bone & Joint Inst, 4 Blackfan Circle, Boston, MA 02115 USA.	tliberma@caregroup.harvard.edu	Libermann, Towia/F-9866-2010; Oettgen, Peter/AAF-5026-2021	Libermann, Towia/0000-0002-4006-8179				Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUIJS A, 1995, ONCOGENE, V10, P1511; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cohen-Tanugi A, 1998, DIFFERENTIATION, V63, P115, DOI 10.1046/j.1432-0436.1998.6330115.x; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dhulipal Prasad D. K., 1997, Indian Journal of Experimental Biology, V35, P315; Ebisawa T, 1999, J CELL SCI, V112, P3519; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Gandrillon O, 1998, ONCOGENE, V16, P563, DOI 10.1038/sj.onc.1201550; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; GITELMAN SE, 1995, CELL GROWTH DIFFER, V6, P827; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Grimsrud CD, 1999, J BONE MINER RES, V14, P475, DOI 10.1359/jbmr.1999.14.4.475; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HEATH JK, 1989, ENDOCRINOLOGY, V124, P3060; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Honchel R, 1996, CANCER RES, V56, P145; HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671; Ino T, 1995, ONCOGENE, V11, P2705; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JEON IS, 1995, ONCOGENE, V10, P1229; JURKA J, 1989, J MOL EVOL, V29, P496, DOI 10.1007/BF02602921; Kameda T, 2000, DEV GROWTH DIFFER, V42, P229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kisseljov F, 1996, INT J CANCER, V69, P484, DOI 10.1002/(SICI)1097-0215(19961220)69:6<484::AID-IJC12>3.3.CO;2-G; Kodama Y, 1997, ENDOCR J, V44, P375, DOI 10.1507/endocrj.44.375; Koizumi Y, 1997, CLIN CANCER RES, V3, P1067; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; Kusafuka K, 1999, PATHOL INT, V49, P1023, DOI 10.1046/j.1440-1827.1999.00991.x; Lafage-Proust MH, 1999, J CELL PHYSIOL, V179, P267, DOI 10.1002/(SICI)1097-4652(199906)179:3<267::AID-JCP4>3.0.CO;2-0; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; Mazurenko N, 1999, ONCOL REP, V6, P859; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; McLean TW, 1996, BLOOD, V88, P4252; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Mo Y, 1998, MOL CELL, V2, P201, DOI 10.1016/S1097-2765(00)80130-6; Moore E, 1999, J PATHOL, V187, P403, DOI 10.1002/(SICI)1096-9896(199903)187:4<403::AID-PATH284>3.0.CO;2-J; Nuka S, 1997, CELL STRUCT FUNCT, V22, P27, DOI 10.1247/csf.22.27; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Poirel H, 2000, ONCOGENE, V19, P4802, DOI 10.1038/sj.onc.1203830; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; RUKSTALIS DB, 1989, CANCER RES, V49, P5087; Saitoh Y, 1998, GENE CHROMOSOME CANC, V22, P165, DOI 10.1002/(SICI)1098-2264(199807)22:3<165::AID-GCC1>3.0.CO;2-U; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Suto Y, 1997, GENE CHROMOSOME CANC, V18, P254, DOI 10.1002/(SICI)1098-2264(199704)18:4<254::AID-GCC3>3.0.CO;2-#; TOGARI A, 1991, GEN PHARMACOL, V22, P287, DOI 10.1016/0306-3623(91)90450-K; VAN DH, 1995, EMBO J, V14, P1798; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Yagasaki F, 1999, GENE CHROMOSOME CANC, V26, P192, DOI 10.1002/(SICI)1098-2264(199911)26:3<192::AID-GCC2>3.0.CO;2-E; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yeatman TJ, 1996, CLIN EXP METASTAS, V14, P246; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	94	41	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9421	9436		10.1074/jbc.M010070200	http://dx.doi.org/10.1074/jbc.M010070200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11108721	hybrid			2022-12-25	WOS:000167607700107
J	Joyce-Brady, M; Jean, JC; Hughey, RP				Joyce-Brady, M; Jean, JC; Hughey, RP			gamma-glutamyltransferase and its isoform mediate an endoplasmic reticulum stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-A; GLUTAMYL-TRANSPEPTIDASE; MESSENGER-RNA; EXPRESSION; GENES; MOUSE; GENERATION; MECHANISM; VARIANTS; INTRONS	Although use of multiple alternative first exons generates unique noncoding 5'-ends for gamma -glutamyltransferase (GGT) cDNAs in several species, we show here that alternative splicing events also alter coding exons in mouse GGT to produce at least four protein isoforms, GGT Delta1 introduces CAG four bases upstream of the primary ATG codon and encodes an active GGT heterodimeric ectoenzyme identical to constitutive GGT cDNA but translational efficiency is reduced 2-fold, GGT Delta2-5 deletes the last eight nucleotides of exon 2 through most of exon 5 in-frame, selectively eliminating residues 96-231 from the amphipathic N-terminal subunit, including four N-glycan consensus sites, while leaving the C-terminal hydrophilic subunit intact. GGT Delta7 introduces 22 bases from intron 7 causing a frameshift and a premature stop codon so a truncated polypeptide is encoded terminating with 14 novel residues but retaining the first 339 residues of the native GGT protein. GGT Delta8-9 deletes the terminal four nucleotides of exon 8 plus all of exon 9 and inserts 24 bases from intron 9 in-frame so the C-terminal subunit of the encoded polypeptide loses residues 401-444 but gains eight internal hydrophobic residues. In contrast to the product of GGT Delta1, those derived from GGT Delta2-5, Delta7, Delta8-9 all lack transferase activity and persist as single-chain glycoproteins retained largely in the endoplasmic reticulum as determined by immunofluorescence microscopy and constitutive endoglycosidase Il sensitivity in metabolically labeled cells. The developmental-stage plus tissue-specific regulation of the alternative splicing events at GGT Delta7 and GGT Delta8-9 implies unique roles for these GGT protein isoforms, The ability of the GGT Delta1 and GGT Delta7 to mediate the induction of C/EBP homologous protein-10, CHOP-10, and immunoglobulin heavy chain binding protein, BiP, implicates a specific role for these two GGT protein isoforms in the endoplasmic reticulum stress response.	Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div,Lab Epithelial Cell Biol, Pittsburgh, PA 15213 USA	Boston University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Joyce-Brady, M (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA.			Jean, Jyh-Chang/0000-0002-6569-5910; Joyce-Brady, Martin/0000-0002-1898-6002	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026012] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL47049] Funding Source: Medline; NIDDK NIH HHS [DK26012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; CAPRARO MA, 1983, FEBS LETT, V157, P139, DOI 10.1016/0014-5793(83)81132-6; COURTAY C, 1994, BIOCHEM J, V297, P503, DOI 10.1042/bj2970503; CURTHOYS NP, 1992, GLUTATHIONE METABOLI, P217; Dietrich RC, 1997, MOL CELL, V1, P151, DOI 10.1016/S1097-2765(00)80016-7; Drozdz R, 1998, FREE RADICAL BIO MED, V25, P786, DOI 10.1016/S0891-5849(98)00127-0; Gottardi C.J., 1992, J TISS CULT METHODS, V14, P173; HUGHEY RP, 1976, J BIOL CHEM, V251, P7863; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IKEDA Y, 1993, J BIOL CHEM, V268, P3980; IKEDA Y, 1995, J BIOL CHEM, V270, P12471, DOI 10.1074/jbc.270.21.12471; Jean JC, 1999, MUTAGENESIS, V14, P31, DOI 10.1093/mutage/14.1.31; KARINCH AM, 1995, AM J RESP CELL MOL, V12, P77, DOI 10.1165/ajrcmb.12.1.7811473; KARINCH AM, 1995, BIOCHEM J, V307, P327, DOI 10.1042/bj3070327; LAPERCHE Y, 1992, GLUTATHIONE METABOLI, P79; Leh H, 1996, FEBS LETT, V394, P258, DOI 10.1016/0014-5793(96)00965-9; PAWLAK A, 1990, J BIOL CHEM, V265, P3256; RAJAGOPALAN S, 1993, P NATL ACAD SCI USA, V90, P6179, DOI 10.1073/pnas.90.13.6179; RamseyEwing A, 1996, J BIOL CHEM, V271, P16962, DOI 10.1074/jbc.271.28.16962; SAKAMURO D, 1988, GENE, V73, P1; Shi ZZ, 1995, GENE, V167, P233, DOI 10.1016/0378-1119(95)00618-4; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; Tarn WY, 1997, TRENDS BIOCHEM SCI, V22, P132, DOI 10.1016/S0968-0004(97)01018-9; WEISZ OA, 1994, METHOD CELL BIOL, V43, P137; WETMORE LA, 1993, P NATL ACAD SCI USA, V90, P7461, DOI 10.1073/pnas.90.16.7461; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	29	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9468	9477		10.1074/jbc.M004352200	http://dx.doi.org/10.1074/jbc.M004352200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11116135	hybrid			2022-12-25	WOS:000167607700112
J	Wilson, GM; Sutphen, K; Chuang, KY; Brewer, G				Wilson, GM; Sutphen, K; Chuang, KY; Brewer, G			Folding of A+U-rich RNA elements modulates AUF1 binding - Potential roles in regulation of mRNA turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; RECEPTOR MESSENGER-RNA; IN-VITRO SYSTEM; FLUORESCENCE ANISOTROPY; HAIRPIN RIBOZYME; MAMMALIAN-CELLS; RIBOSOMAL-RNA; STABILITY; PROTEIN; DECAY	In mammals, A+U-rich elements (AREs) are potent cis-acting determinants of rapid cytoplasmic mRNA turnover. Recognition of these sequences by AUF1 is associated with acceleration of mRNA decay, likely involving recruitment or assembly of multi-subunit transacting complexes. Previously, we demonstrated that AUF1 deletion mutants formed tetramers on U-rich RNA substrates by sequential addition of protein dimers (Wilson, G. M., Sun, Y., Lu, H,, and Brewer, G, (1999) J, Biol. Chem. 274, 33374-33381). Here, we show that binding of the full-length p37 isoform of AUF1 to these RNAs proceeds via a similar mechanism, allowing delineation of equilibrium binding constants for both stages of tetramer assembly. However, association of AUF1 with the ARE from tumor necrosis factor (TNF alpha) mRNA was significantly inhibited by magnesium ions. Further fluorescence and hydrodynamic experiments indicated that Mg2+ induced or stabilized a conformational change in the TNF alpha ARE. Based on the solution of parameters describing both the protein-RNA and Mg2+-RNA equilibria, we present a dynamic, global equilibrium binding model describing the relationship between Mg2+ and AUF1 binding to the TNF alpha ARE. These studies provide the first evidence that some AREs may adopt higher order RNA structures that regulate their interaction with traits-acting factors and indicate that mRNA structural remodeling has the potential to modulate the turnover rates of some ARE-containing mRNAs.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Wilson, GM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA.	wilsongm@umdnj.edu; brewerga@umdnj.edu	Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507	NCI NIH HHS [R01 CA 52443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; Blyn LB, 2000, NUCLEIC ACIDS RES, V28, P1778, DOI 10.1093/nar/28.8.1778; Brewer G, 1999, J BIOL CHEM, V274, P16174, DOI 10.1074/jbc.274.23.16174; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; BRISTOW MR, 1993, J CLIN INVEST, V92, P2737, DOI 10.1172/JCI116891; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; FASMAN GD, 1976, CRC HDB BIOCH MOL BI, P589; Ford LP, 1999, METHODS, V17, P21, DOI 10.1006/meth.1998.0703; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Gluick TC, 1997, J MOL BIOL, V270, P451, DOI 10.1006/jmbi.1997.1119; Gonzalez RL, 1999, J MOL BIOL, V289, P1267, DOI 10.1006/jmbi.1999.2841; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Kieft JS, 1999, J MOL BIOL, V292, P513, DOI 10.1006/jmbi.1999.3095; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Misra VK, 2000, J MOL BIOL, V299, P813, DOI 10.1006/jmbi.2000.3769; Nair TM, 2000, NUCLEIC ACIDS RES, V28, P1935, DOI 10.1093/nar/28.9.1935; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Qin PZF, 1999, METHODS, V18, P60, DOI 10.1006/meth.1999.0757; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; ROSS HJ, 1991, BLOOD, V77, P1787; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; Sclavi B, 1998, SCIENCE, V279, P1940, DOI 10.1126/science.279.5358.1940; Serebrov V, 1998, NUCLEIC ACIDS RES, V26, P2723, DOI 10.1093/nar/26.11.2723; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Walter F, 1998, RNA, V4, P719, DOI 10.1017/S135583829898030X; Walter F, 1998, BIOCHEMISTRY-US, V37, P17629, DOI 10.1021/bi9821115; Walter NG, 1998, EMBO J, V17, P2378, DOI 10.1093/emboj/17.8.2378; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xiong Y, 2000, RNA, V6, P1316, DOI 10.1017/S135583820000090X; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yu YT, 1999, METHODS, V18, P13, DOI 10.1006/meth.1999.0752; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	56	61	63	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8695	8704		10.1074/jbc.M009848200	http://dx.doi.org/10.1074/jbc.M009848200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124962	hybrid			2022-12-25	WOS:000167607700012
J	Chamoy, L; Nicolai, M; Ravaux, J; Quennedey, B; Gaill, F; Delachambre, J				Chamoy, L; Nicolai, M; Ravaux, J; Quennedey, B; Gaill, F; Delachambre, J			A novel chitin-binding protein from the vestimentiferan Riftia pachyptila interacts specifically with beta-chitin - Cloning, expression, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROTHERMAL VENT WORMS; ALPHA-CHITIN; TUBE WORM; SYSTEM; CDNA; DOMAIN; GENE; SERRATIA-MARCESCENS-2170; INVERTEBRATES; SECRETION	A cDNA from Riftia pachyptila was cloned. It encodes a novel 21.3-kDa protein from the worm protective tube, named RCBP (for Riftia chitin-binding protein). On the basis of partial tube-peptide sequences previously obtained, experiments using reverse transcriptase-mediated polymerase chain reaction and rapid amplification of cDNA ends led to the complete cDNA sequence. Analysis of its deduced amino acid sequence shows the presence of two chitin-binding domains. These domains are closely related to type 2 chitin-binding domains that are restricted to the animal kingdom. We showed by affinity assay and immunogold labeling that RCBP is the first protein so far known that binds specifically beta -chitin and that is unable to bind the most common alpha -form found in chitin secreting animals. The RCBP mRNA was found to be present in specific epidermal cells from the worm body wall, but never in the chitin-secreting gland cells. This unexpected result clearly indicates that this tube protein is synthesized in specialized areas of the outer epithelium and that at least two different tissues are involved in this exoskeleton synthesis.	Univ Bourgogne, CNRS, Unite Mixte Rech 5548, F-21000 Dijon, France; Univ Paris 06, CNRS, Unite Mixte Rech 7622, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Delachambre, J (corresponding author), Univ Bourgogne, CNRS, Unite Mixte Rech 5548, 6 Blvd Gabriel, F-21000 Dijon, France.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON B, 1995, COMMUN ALGEBRA, V23, P177, DOI 10.1080/00927879508825214; BLAAK H, 1995, EUR J BIOCHEM, V229, P132, DOI 10.1111/j.1432-1033.1995.tb20447.x; BLACK MB, 1994, MAR BIOL, V120, P33; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; BOUHIN B, 1992, INSECT MOL BIOL, V1, P53; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELANO P, 1993, BIOTECHNIQUES, V15, P26; Chamoy L, 2000, BIOCHEM J, V350, P421, DOI 10.1042/0264-6021:3500421; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAILL F, 1992, J STRUCT BIOL, V109, P116, DOI 10.1016/1047-8477(92)90043-A; GAILL F, 1992, ADVANCES IN CHITIN AND CHITOSAN, P216; GAILL F, 1993, FASEB J, V7, P558, DOI 10.1096/fasebj.7.6.8472894; GAILL F, 1992, BIOL CELL, V76, P201, DOI 10.1016/0248-4900(92)90213-K; GAILL F, 1986, MAR ECOL PROG SER, V34, P267, DOI 10.3354/meps034267; Gardiner S.L., 1993, MICROSCOPIC ANATOMY, V12, P371; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Jones M., 1985, B BIOL SOC WASH, V6, P117; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Kolbe S, 1998, MICROBIOL-SGM, V144, P1291, DOI 10.1099/00221287-144-5-1291; Korchi A, 1999, FEBS LETT, V449, P125, DOI 10.1016/S0014-5793(99)00414-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martoja R, 1967, INITIATION TECHNIQUE; MULISCH M, 1993, EUR J PROTISTOL, V29, P1, DOI 10.1016/S0932-4739(11)80291-9; Muzzarelli R. A., 1977, CHITIN; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; RAIKHEL NV, 1993, ANNU REV PLANT PHYS, V44, P591, DOI 10.1146/annurev.pp.44.060193.003111; Ravaux J, 2000, MAR BIOL, V136, P505, DOI 10.1007/s002270050710; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shen ZC, 1999, J MOL EVOL, V48, P341, DOI 10.1007/PL00006478; Shen ZC, 1998, J BIOL CHEM, V273, P17665, DOI 10.1074/jbc.273.28.17665; SHILLITO B, 1995, J STRUCT BIOL, V114, P67, DOI 10.1006/jsbi.1995.1006; SHILLITO B, 1993, J STRUCT BIOL, V111, P59, DOI 10.1006/jsbi.1993.1036; SOUTHWARD EC, 1988, J MAR BIOL ASSOC UK, V74, P265; Southward Eve C., 1993, P327; Suetake T, 2000, J BIOL CHEM, V275, P17929, DOI 10.1074/jbc.C000184200; Suzuki K, 1998, BIOSCI BIOTECH BIOCH, V62, P128, DOI 10.1271/bbb.62.128; Tjoelker LW, 2000, J BIOL CHEM, V275, P514, DOI 10.1074/jbc.275.1.514; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Watanabe T, 1997, J BACTERIOL, V179, P7111, DOI 10.1128/jb.179.22.7111-7117.1997; WHITEHOUSE RL, 1984, BIOL CELL, V51, P389, DOI 10.1111/j.1768-322X.1984.tb00314.x; Yamagami T, 1996, BIOSCI BIOTECH BIOCH, V60, P1081, DOI 10.1271/bbb.60.1081; Zeltins A, 1997, EUR J BIOCHEM, V246, P557, DOI 10.1111/j.1432-1033.1997.t01-1-00557.x	44	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8051	8058		10.1074/jbc.M009244200	http://dx.doi.org/10.1074/jbc.M009244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113138	hybrid			2022-12-25	WOS:000167474900054
J	Eguchi, S; Dempsey, PJ; Frank, GD; Motley, ED; Inagami, T				Eguchi, S; Dempsey, PJ; Frank, GD; Motley, ED; Inagami, T			Activation of MAPKs by angiotensin II in vascular smooth muscle cells - Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-COUPLED RECEPTORS; NECROSIS-FACTOR-ALPHA; N-TERMINAL KINASE; TYROSINE KINASE; SIGNAL-TRANSDUCTION; CARDIOVASCULAR-DISEASE; TRANSACTIVATION; PATHWAYS; DISINTEGRIN	In cultured vascular smooth muscle cells (VSMC), the vasculotrophic factor, angiotensin II (AngII) activates three major MAPKs via the G(q)-coupled AT(1) receptor. Extracellular signal-regulated kinase (ERK) activation by AngII requires Ca2+-dependent "transactivation" of the EGF receptor that may involve a metalloprotease to stimulate processing of an EGF receptor ligand from its precursor. Whether EGF receptor transactivation also contributes to activation of other members of MAPKs such as p38MAPK and c-Jun N-terminal kinase (JNK) by AngII remains unclear. In the present study, we have examined the effects of a synthetic metalloprotease inhibitor BB2116, and the EGF receptor kinase inhibitor AG1478 on AngII-induced activation of MAPKs in cultured VSMC, BB2116 markedly inhibited ERK activation induced by AngII or the Ca2+ ionophore A23187 without affecting the activation by EGF or PDGF, BB2116 as well as HB-EGF neutralizing antibody inhibited the EGF receptor transactivation by AngII, suggesting a critical role of HB-EGF in the metalloprotease-dependent EGF receptor transactivation. In addition to the ERK activation, activation of p38MAPK and JNK by AngII was inhibited by an AT(1) receptor antagonist, RNH6270. A23187 and EGF markedly activate p38MAPK, whereas A23187 but not EGF markedly activates JNK, indicating the possible contribution of the EGF receptor transactivation to the p38MAPK activation, The findings that both BB2116 and AG1478 specifically inhibited activation of p38MAPK but not JNK by AngII support this hypothesis. From these data, we conclude that ERK and p38MAPK activation by AngII requires the metalloprotease-dependent EGF receptor transactivation, whereas the JNK activation is regulated without involvement of EGF receptor transactivation.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Meharry Med Coll, Dept Anat & Physiol, Nashville, TN 37208 USA; Pacific NW Res Inst, Seattle, WA 98122 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Meharry Medical College	Eguchi, S (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.				NHLBI NIH HHS [HL03220, HL58205] Funding Source: Medline; NIDDK NIH HHS [DK20593, DK59778] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003220, R01HL058205, R37HL058205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059778, P60DK020593] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Dostal DE, 1999, CIRC RES, V85, P643, DOI 10.1161/01.RES.85.7.643; Dzau VJ, 1998, EUR HEART J, V19, pJ2; EGUCHI S, 1994, ENDOCRINOLOGY, V134, P222, DOI 10.1210/en.134.1.222; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Eguchi S, 1999, EUR J PHARMACOL, V376, P203, DOI 10.1016/S0014-2999(99)00357-X; Eguchi S, 2000, REGUL PEPTIDES, V91, P13, DOI 10.1016/S0167-0115(00)00126-9; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Goodfriend TL, 1996, NEW ENGL J MED, V334, P1649, DOI 10.1056/NEJM199606203342507; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HANSEN HP, 1995, INT J CANCER, V63, P750, DOI 10.1002/ijc.2910630524; Inagami T, 1999, J AM SOC NEPHROL, V10, pS57; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ishida M, 1998, CIRC RES, V82, P7; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; Iwasaki H, 2000, AM J PHYSIOL-HEART C, V278, pH521, DOI 10.1152/ajpheart.2000.278.2.H521; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kim S, 1998, CIRCULATION, V97, P1731, DOI 10.1161/01.CIR.97.17.1731; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MIZUNO M, 1995, EUR J PHARMACOL, V285, P181, DOI 10.1016/0014-2999(95)00401-6; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; New LG, 1998, TRENDS CARDIOVAS MED, V8, P220, DOI 10.1016/S1050-1738(98)00012-7; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Schmitz U, 1998, CIRC RES, V82, P1272, DOI 10.1161/01.RES.82.12.1272; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yamakawa T, 1998, HYPERTENSION, V31, P248, DOI 10.1161/01.HYP.31.1.248; Zempo N, 1996, ARTERIOSCL THROM VAS, V16, P28, DOI 10.1161/01.ATV.16.1.28; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	61	240	249	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7957	7962		10.1074/jbc.M008570200	http://dx.doi.org/10.1074/jbc.M008570200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11116149	hybrid			2022-12-25	WOS:000167474900041
J	Hautbergue, G; Goguel, V				Hautbergue, G; Goguel, V			Activation of the cyclin-dependent kinase CTDK-I requires the heterodimerization of two unstable subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; RING FINGER PROTEIN; REPEAT DOMAIN; P-TEFB; HIV-1 TAT; PHOSPHORYLATION; TRANSCRIPTION; DEGRADATION; KIN28	RNA polymerase II CTD kinases are key elements in the control of mRNA synthesis, They constitute a family of cyclin-dependent kinases activated by C-type cyclins. Unlike most cyclin-dependent kinase complexes, which are composed of a catalytic and a regulatory subunit, the yeast CTD kinase I complex contains three specific subunits: a kinase subunit (Ctk1), a cyclin subunit (Ctk2), and a third subunit (Ctk3) of unknown function that does not exhibit any similarity to known proteins. Like the Ctk2 cyclin that is regulated at the level of protein turnover, Ctk3 is an unstable protein processed through a ubiquitin-proteasome pathway. Interestingly, Ctk2 and Ctk3 physical interaction is required to protect both subunits from degradation, pointing to a new mechanism for cyclin turnover regulation. We also show that Ctk2 and Ctk3 can each interact independently with the kinase. However, despite the formation of CDW cyclin complexes in vitro, the Ctk2 cyclin is unable to activate its CDK: both Ctk2 and Ctk3 are required for Ctk1 CTD kinase activation. The different specific features governing CTDK-I regulation probably reflect requirement for the transcriptional response to multiple growth conditions.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Goguel, V (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France.	goguel@jonas.saclay.cea.fr						Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cooper KF, 1999, MOL CELL BIOL, V19, P3338; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; CROSS FR, 1993, MOL CELL BIOL, V13, P3266, DOI 10.1128/MCB.13.6.3266; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Espinoza FH, 1998, MOL CELL BIOL, V18, P6365, DOI 10.1128/MCB.18.11.6365; Faye G, 1997, MOL GEN GENET, V255, P460, DOI 10.1007/s004380050518; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hautbergue G, 1999, MOL CELL BIOL, V19, P2527; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hirst M, 1999, MOL CELL, V3, P673, DOI 10.1016/S1097-2765(00)80360-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; Kimmelman J, 1999, MOL CELL BIOL, V19, P4774; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Lee JM, 1997, J BIOL CHEM, V272, P10990; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Marchal C, 1998, MOL CELL BIOL, V18, P314, DOI 10.1128/MCB.18.1.314; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Nishiyama A, 2000, GENE DEV, V14, P2344, DOI 10.1101/gad.823200; Patturajan M, 1999, J BIOL CHEM, V274, P27823, DOI 10.1074/jbc.274.39.27823; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; SUROSKY RT, 1994, MOL CELL BIOL, V14, P3446, DOI 10.1128/MCB.14.5.3446; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Valay JG, 1996, CR ACAD SCI III-VIE, V319, P183; WAHI M, 1995, GENETICS, V140, P79; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	72	20	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8005	8013		10.1074/jbc.M010162200	http://dx.doi.org/10.1074/jbc.M010162200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11118453	hybrid			2022-12-25	WOS:000167474900048
J	Paumi, CM; Ledford, DG; Smitherman, PK; Townsend, AJ; Morrow, CS				Paumi, CM; Ledford, DG; Smitherman, PK; Townsend, AJ; Morrow, CS			Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance - Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-RESISTANCE; ALPHA-CLASS; MEMBRANE-VESICLES; TUMOR-CELLS; TRANSPORT; DETOXIFICATION; BIOACTIVATION; BIOSYNTHESIS; MECHANISM; P1-1	We investigated the role of phase II (conjugation) and phase III (efflux) detoxification of the anticancer drugs melphalan (MLP) and chlorambucil (CHB). Although both drugs are substrates of Alpha-class glutathione S-transferases (GST) and the monoglutathionyl conjugates formed in these enzymatic reactions are transported by MRP1, we found that GSTA1-1 and MRP1 acted in synergy to confer resistance to CHB but not to MLP (Morrow, C. S., Smitherman, P. K., Dish, S. K., Schneider, E., and Townsend, A. J. (1998) J. Biol, Chem. 273, 20114-20120). To explain this selectivity of MRP1/GST-mediated resistance, we report results of side-by-side experiments comparing the kinetics of MLP- versus CHB-glutathione conjugate: formation, product inhibition of GSTA1-1 catalysis, and transport by MRP1. The monoglutathionyl conjugate of CHB, CHB-SG, is a very strong competitive inhibitor of GSTA1-1 (K-i 0.14 muM) that is >30-fold more potent than that of the corresponding conjugate of MLP, MLP-SG (K-i 4.7 muM). The efficiency of GSTA1-1-mediated monoglutathionyl conjugate formation is more than 4-fold higher for CHB than MLP. Lastly, both CHB-SG and MLP-SG are efficiently transported by MRP1 with similar V-max although the K-m for CHB-SG (0.37 muM) is significantly lower than for MLP-SG: (1.1 muM) These results indicate that MRP1 is required for GSTA1-1-mediated resistance to CHB in order to relieve potent product inhibition of the enzyme by intracellular CHB-SG formed, The kinetic properties of MRP1 are well suited to eliminate CHB-SG at pharmacologically relevant concentrations, For MLP detoxification, where product inhibition of GSTA1-1 is less important, GSTA1-1 does not confer resistance because of the relatively poorer catalytic efficiency of MLP-SG formation. Similar analyses can be useful for predicting the pharmacological and toxicological consequences of MRP and GST expression on cellular sensitivity to various other electrophilic xenobiotics.	Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Morrow, CS (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.		Townsend, Alan/AAE-9602-2019		NCI NIH HHS [CA70338, CA64579] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064579, R01CA070338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMQUIST KC, 1995, CANCER RES, V55, P102; Anders MW, 1998, ANNU REV PHARMACOL, V38, P501, DOI 10.1146/annurev.pharmtox.38.1.501; Awasthi S, 1996, DRUG METAB DISPOS, V24, P371; Barnouin K, 1998, BRIT J CANCER, V77, P201, DOI 10.1038/bjc.1998.34; CIACCIO PJ, 1990, CANCER COMMUN, V2, P279, DOI 10.3727/095535490820874263; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; DEKANT W, 1990, TOXICOL LETT, V53, P53, DOI 10.1016/0378-4274(90)90094-3; Dekant W, 1996, ADV EXP MED BIOL, V387, P297; Diah SK, 1999, TOXICOL APPL PHARM, V157, P85, DOI 10.1006/taap.1999.8672; DULIK DM, 1987, DRUG METAB DISPOS, V15, P195; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HALL AG, 1994, CANCER RES, V54, P3369; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Keppler D, 1998, METHOD ENZYMOL, V292, P607; KREBS EG, 1955, METHOD ENZYMOL, V1, P407, DOI 10.1016/0076-6879(55)01066-5; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; MEYER DJ, 1993, XENOBIOTICA, V23, P823, DOI 10.3109/00498259309059411; MEYER DJ, 1992, BRIT J CANCER, V66, P433, DOI 10.1038/bjc.1992.292; Morrow CS, 1998, CARCINOGENESIS, V19, P109, DOI 10.1093/carcin/19.1.109; MORROW CS, 1990, CANCER CELL-MON REV, V2, P15; Morrow CS, 1998, J BIOL CHEM, V273, P20114, DOI 10.1074/jbc.273.32.20114; Morrow CS, 2000, MOL CARCINOGEN, V29, P170, DOI 10.1002/1098-2744(200011)29:3<170::AID-MC6>3.0.CO;2-W; SCHLEMMER SR, 1995, ANAL BIOCHEM, V228, P226, DOI 10.1006/abio.1995.1343; SCHNEIDER E, 1994, CANCER RES, V54, P152; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; TEW KD, 1994, CANCER RES, V54, P4313	27	91	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7952	7956		10.1074/jbc.M009400200	http://dx.doi.org/10.1074/jbc.M009400200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11115505	hybrid			2022-12-25	WOS:000167474900040
J	Anderson, KL; Nelson, SL; Perkin, HB; Smith, KA; Klemsz, MJ; Torbett, BE				Anderson, KL; Nelson, SL; Perkin, HB; Smith, KA; Klemsz, MJ; Torbett, BE			PU.1 is a lineage-specific regulator of tyrosine phosphatase CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PU.1; B-LYMPHOCYTE DEVELOPMENT; SRC-FAMILY KINASES; SPI-B; MYELOID DEVELOPMENT; CELL MATURATION; ETS-PROTEIN; T-CELLS; GENE; MACROPHAGE	The hematopoietic cell-specific ets family transcription factor PU.1 regulates many lymphoid and myeloid genes. We have determined that PU.1 is critical for lineage-specific expression of the tyrosine phosphatase CD45, CD45 is expressed exclusively in hematopoietic cells at all stages of development, except for mature red cells and platelets, Although CD45 is normally expressed in all leukocyte lineages, it is critically regulated by PU.1 only in myeloid cells. Whereas myeloid cells from PU.1 null mice failed to express CD45, lymphoid cells were CD45(+) by flow cytometry, Additionally, mRNA for CD45 was absent from PU.1-deficient myeloid cells. To understand the molecular basis for these observations, we characterized a transcriptional regulatory region of the murine CD45 gene containing exons 1a, 1b, and 2, Distinct transcriptional initiation sites for CD45 were demonstrated in T and B cells versus myeloid cells. A transcriptional initiation site in exon 1b (P1b) was principally utilized by myeloid cells. A PU.1 binding site was identified upstream of exon Ib by sequence analysis and DNA binding assays. Using this region of the CD45 locus we demonstrated that PU.1 directly transactivated reporter gene expression, Finally, retrovirus-mediated restoration of PU.1 expression to PU.1-deficient myeloid cells resulted in expression of cell surface CD45 and restored phosphatase activity, confirming the role of PU.1 in the positive regulation of this well known signaling molecule, We conclude that CD45 is regulated differentially in myeloid and lymphoid cells and that sequences critical to direct myeloid expression include a PU.1 binding site upstream of the P1b transcriptional initiation site.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Scripps Research Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Torbett, BE (corresponding author), Scripps Res Inst, Dept Mol Med, MEM55,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA071384] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049886] Funding Source: NIH RePORTER; NCI NIH HHS [CA71384] Funding Source: Medline; NHLBI NIH HHS [T328HLO7195-22] Funding Source: Medline; NIDDK NIH HHS [DK49886] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Bemark M, 1999, J BIOL CHEM, V274, P10259, DOI 10.1074/jbc.274.15.10259; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; DIMARTINO JF, 1994, INT IMMUNOL, V6, P1279, DOI 10.1093/intimm/6.8.1279; Fialkow L, 1997, J IMMUNOL, V158, P5409; HALL LR, 1988, J IMMUNOL, V141, P2781; Hashimoto S, 1999, INT IMMUNOL, V11, P1423, DOI 10.1093/intimm/11.9.1423; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; Lauring J, 1999, MOL CELL BIOL, V19, P2601; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Monroe RJ, 1999, P NATL ACAD SCI USA, V96, P12713, DOI 10.1073/pnas.96.22.12713; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NG DHW, 1995, J IMMUNOL METHODS, V179, P177, DOI 10.1016/0022-1759(94)00281-Z; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; SAGA Y, 1987, P NATL ACAD SCI USA, V84, P5364, DOI 10.1073/pnas.84.15.5364; SAGA Y, 1988, MOL CELL BIOL, V8, P4889, DOI 10.1128/MCB.8.11.4889; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Stone JD, 1997, J IMMUNOL, V158, P5773; Su GH, 1996, J EXP MED, V184, P203, DOI 10.1084/jem.184.1.203; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	36	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7637	7642		10.1074/jbc.M009133200	http://dx.doi.org/10.1074/jbc.M009133200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11114304	hybrid			2022-12-25	WOS:000167442900105
J	Kipp, H; Pichetshote, N; Arias, IM				Kipp, H; Pichetshote, N; Arias, IM			Transporters on demand - Intrahepatic pools of canalicular ATP binding cassette transporters in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN-2; MEMBRANE-VESICLES; EXPORT PUMP; PHOSPHOINOSITIDE 3-KINASE; DEPENDENT TRANSPORT; ABC TRANSPORTERS; ACID-SECRETION; P-GLYCOPROTEIN; TRAFFICKING; TURNOVER	ABC transporter trafficking in rat liver induced by cAMP or taurocholate and [S-35]methionine metabolic labeling followed by subcellular fractionation were used to identify and characterize intrahepatic pools of ABC transporters. ABC transporter trafficking induced by cAMP or:taurocholate is a physiologic response to a temporal demand for increased bile secretion. Administration of cAMP or taurocholate to rats increased amounts of SPGP, MDR1, and MDR2 in the bile canalicular membrane by S-fold; these effects abated after 6 h and were insensitive to prior treatment of rats with cycloheximide. Half-lives of ABC transporters were 5 days, which suggests cycling of ABC transporters between canalicular membrane and intrahepatic sites before degradation. In vivo [35S]methionine labeling of rats followed by immunoprecipitation of (sister of P-glycoprotein) (SPGP) from subcellular liver fractions revealed a steady state distribution after 20 h of SPGP between canalicular membrane and a combined endosomal fraction. After mobilization of transporters from intrahepatic sites with cAMP or taurocholate, a significant increase in the amount of ABC transporters in canalicular membrane vesicles was observed, whereas the decrease in the combined endosomal fraction remained below detection limits in Western blots. This observation is in accordance with relatively large intracellular ABC transporter pools compared with the amount present in the bile canalicular membrane. Furthermore, trafficking of newly synthesized SPGP through intrahepatic sites was accelerated by additional administration of cAMP but not by taurocholate, indicating two distinct intrahepatic pools. Our data indicate that ABC transporters cycle between the bile canaliculus and at least two large intrahepatic ABC transporter pools, one of which is mobilized to the canalicular membrane by cAMP and the other, by taurocholate, In parallel to regulation of other membrane transporters, we propose that the "cAMP-pool" in hepatocytes corresponds to a recycling endosome, whereas recruitment from the "taurocholate-pool'' involves a hepatocyte-specific mechanism.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Arias, IM (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	irwin.arias@tufts.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035652, P30DK034928, R01DK035652] Funding Source: NIH RePORTER; NIDDK NIH HHS [30DK34928, DK35652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ameen NA, 1999, J CELL SCI, V112, P887; Buchler M, 1996, J BIOL CHEM, V271, P15091; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; Dombrowski F, 2000, BIOCHEM J, V348, P183, DOI 10.1042/0264-6021:3480183; ELOVSON J, 1980, J BIOL CHEM, V255, P5816; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; GATMAITAN ZC, 1995, PHYSIOL REV, V75, P261, DOI 10.1152/physrev.1995.75.2.261; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; INOUE M, 1982, HEPATOLOGY, V2, P572; INOUE M, 1983, J BIOL CHEM, V258, P5183; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KHAN MN, 1989, J BIOL CHEM, V264, P12931; Kipp H, 2000, SEMIN LIVER DIS, V20, P339, DOI 10.1055/s-2000-9388; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; Kullak-Ublick GA, 2000, J HEPATOL, V32, P3, DOI 10.1016/S0168-8278(00)80411-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma Q, 2000, J BIOL CHEM, V275, P12676, DOI 10.1074/jbc.275.17.12676; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; MORTIMORE GE, 1987, LYSOSOMES THEIR ROLE, P415; Mukhopadhayay S, 1997, AM J PHYSIOL-GASTR L, V273, pG842, DOI 10.1152/ajpgi.1997.273.4.G842; Nies AT, 1996, J LIPID RES, V37, P1125; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; Paulusma CC, 2000, HEPATOLOGY, V31, P684, DOI 10.1002/hep.510310319; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Rodman JS, 2000, J CELL SCI, V113, P183; Rost D, 1999, HEPATOLOGY, V29, P814, DOI 10.1002/hep.510290319; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Sai Y, 1999, J CELL SCI, V112, P4535; SCOTT LJ, 1992, J BIOL CHEM, V267, P6099; SHANKS MR, 1994, J CELL SCI, V107, P813; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; TANABE T, 1979, J BIOL CHEM, V254, P1038; TAUBER R, 1989, BIOL CHEM H-S, V370, P1221, DOI 10.1515/bchm3.1989.370.2.1221; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOLK BA, 1983, FEBS LETT, V163, P150, DOI 10.1016/0014-5793(83)81183-1; Wakabayashi Y, 2000, HEPATOLOGY, V32, p435A; Yao XB, 1996, AM J PHYSIOL-CELL PH, V271, pC61, DOI 10.1152/ajpcell.1996.271.1.C61	43	150	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7218	7224		10.1074/jbc.M007794200	http://dx.doi.org/10.1074/jbc.M007794200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113123	hybrid			2022-12-25	WOS:000167442900051
J	Yamamoto, Y; Inagaki, N; Satoh, K				Yamamoto, Y; Inagaki, N; Satoh, K			Overexpression and characterization of carboxyl-terminal processing protease for precursor D1 protein - Regulation of enzyme-substrate interaction by molecular environments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II REACTION-CENTER; CHLOROPLAST MEMBRANE POLYPEPTIDE; BACTERIAL SIGNAL PEPTIDASE; PHOTOSYSTEM-II; SCENEDESMUS-OBLIQUUS; CHLAMYDOMONAS-REINHARDTII; SPINACH-CHLOROPLASTS; TSP PROTEASE; COMPLEX; SITE	CtpA, which is classified as a novel type of serine protease with a Ser/Lys catalytic dyad, is responsible for the C-terminal processing of precursor D1 protein (pD1) of the photosystem II reaction center, a process that is indispensable for the integration of water-splitting machinery id photosynthesis. In this study, overexpression in Escherichia coli and one-step purification of spinach CtpA were carried out to analyze the characteristics of this new type of protease and to elucidate the molecular interactions in the C-terminal processing of pD1 on the thylakoid membrane. The successful accumulation of functional CtpA in E. coli may argue against the possibility, based on homology to E. coli Tsp, that the enzyme is involved in the degradation of incomplete proteins in chloroplasts,. e.g. by utilizing the ssrA-tagging system. Analysis' using a synthetic pD1 oligopeptide demonstrated that the enzymatic properties (including substrate recognition) of overexpressed CtpA with an extra sequence of GSHMLE at the N terminus were indistinguishable from those of the native enzyme. CtpA was insensitive to penem, which has been shown to inhibit some Ser/Lys-type proteases, suggesting that the catalytic center of CtpA is quite unique. By using the substrate in different molecular environments (i.e. synthetic pD1 oligopeptide in solution and pD1 in photosystem II enriched thylakoid membrane), we observed a dramatic difference in the pH profile and affinity for the: substrate, suggesting the presence of a specific interaction of CtpA with a factor(s) that modulates the pH dependence of proteolytic action in response to physiological conditions.	Okayama Univ, Fac Sci, Dept Biol, Okayama 7008530, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan	Okayama University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Satoh, K (corresponding author), Okayama Univ, Fac Sci, Dept Biol, Okayama 7008530, Japan.	kimiyuki@cc.okayama-u.ac.jp		Inagaki, Noritoshi/0000-0001-8738-6636				Adam Z, 1996, PLANT MOL BIOL, V32, P773, DOI 10.1007/BF00020476; ALLSOP AE, 1995, BIOORG MED CHEM LETT, V5, P443, DOI 10.1016/0960-894X(95)00052-U; Barbrook AC, 1996, FEBS LETT, V398, P198, DOI 10.1016/S0014-5793(96)01239-2; Bishop N.I., 1971, METHODS ENZYMOLOGY A, P53, DOI 10.1016/S0076-6879(71)23079-2; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; Chaal BK, 1998, J BIOL CHEM, V273, P689, DOI 10.1074/jbc.273.2.689; DINER BA, 1988, J BIOL CHEM, V263, P8972; FUJITA S, 1995, PLANT CELL PHYSIOL, V36, P1169; FUJITA S, 1989, FEBS LETT, V255, P1, DOI 10.1016/0014-5793(89)81049-X; Inagaki N, 1996, PLANT MOL BIOL, V30, P39, DOI 10.1007/BF00017801; Karnauchov I, 1997, EUR J BIOCHEM, V249, P497, DOI 10.1111/j.1432-1033.1997.t01-1-00497.x; Keiler KC, 1996, J BIOL CHEM, V271, P2589, DOI 10.1074/jbc.271.5.2589; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KUWABARA T, 1982, PLANT CELL PHYSIOL, V23, P533, DOI 10.1093/oxfordjournals.pcp.a076378; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1992, J BIOL CHEM, V267, P17494; Liao DI, 2000, NAT STRUCT BIOL, V7, P749, DOI 10.1038/78973; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; METZ J, 1980, BIOCHEM BIOPH RES CO, V94, P560, DOI 10.1016/0006-291X(80)91268-1; METZ JG, 1984, PLANT PHYSIOL, V76, P829, DOI 10.1104/pp.76.3.829; MINAMI E, 1985, PLANT CELL PHYSIOL, V26, P839; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; Oelmuller R, 1996, J BIOL CHEM, V271, P21848, DOI 10.1074/jbc.271.36.21848; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; RUTHERFORD AW, 1988, BIOCHIM BIOPHYS ACTA, V932, P171, DOI 10.1016/0005-2728(88)90152-1; SATOH K, 1996, OXYGENIC PHOTOSYNTHE, P193; SCHRADER S, 1992, PLANT MOL BIOL, V19, P251, DOI 10.1007/BF00027346; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; Taguchi F, 1998, PLANT CELL PHYSIOL, V39, P1324, DOI 10.1093/oxfordjournals.pcp.a029337; TAGUCHI F, 1995, J BIOL CHEM, V270, P10711, DOI 10.1074/jbc.270.18.10711; TAKAHASHI M, 1988, FEBS LETT, V240, P6, DOI 10.1016/0014-5793(88)80330-2; Takahashi Y, 1996, PLANT CELL PHYSIOL, V37, P161, DOI 10.1093/oxfordjournals.pcp.a028927; TAKAHASHI Y, 1990, PLANT CELL PHYSIOL, V31, P273; Trost JT, 1997, J BIOL CHEM, V272, P20348, DOI 10.1074/jbc.272.33.20348; Yamamoto Y, 1999, NATO ASI 3 HIGH TECH, V64, P271	41	34	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7518	7525		10.1074/jbc.M008877200	http://dx.doi.org/10.1074/jbc.M008877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11099501				2022-12-25	WOS:000167442900090
J	Huang, L; Wang, ZW; Li, C				Huang, L; Wang, ZW; Li, C			Modulation of circulating leptin levels by its soluble receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE; SIGNAL-TRANSDUCTION; DIABETIC MICE; PLASMA LEPTIN; DB/DB MICE; OB RNA; EXPRESSION; PROTEIN; SERUM; IDENTIFICATION	Leptin is an adipocyte-derived hormone with potent weight reducing effects. Genetically obese rodents with mutations of leptin or the leptin receptor are defective in leptin signaling and develop morbid obesity and diabetes. Interestingly, the levels of both leptin mRNA and protein are increased by up to 20-fold in these animals, suggesting the existence of a feedback mechanism controlling the amount of leptin in circulation. In this report, we attempted to determine whether the up-regulation of circulating leptin in Zucker Diabetic Fatty rats, which are nonresponsive to leptin due to a receptor point mutation, is entirely due to increased expression of leptin, We demonstrate that the high level of circulating leptin in these rats is attributable to at least two factors: increased leptin expression by the adipose tissue and delayed clearance of leptin from circulation due to binding to its soluble receptor. The latter conclusion was supported by three lines of evidence: 1) The soluble leptin receptor is up-regulated by about 20-fold in Zucker Diabetic Fatty rats; 2) Adenovirus-mediated overexpression of the soluble leptin receptor results in a similar -fold increase of circulating leptin; 3) In ob/ob mice, which have no endogenous leptin, exogenously administered leptin reaches a higher level when the soluble leptin receptor is overexpressed. The weight-reducing effect of leptin is enhanced in C57Bl/6 ob/ob mice with overexpression of the soluble leptin receptor. Soluble leptin receptor may be a significant factor determining the amount of total leptin in circulation.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, C (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, 5323 H Hines Blvd, Dallas, TX 75390 USA.	Cai.Li@UTSouthwestern.edu						CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cohen SL, 1996, NATURE, V382, P589, DOI 10.1038/382589a0; CONSIDINE RV, 1996, NEW ENGL J MED, V334, P324; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gavrilova O, 1997, J BIOL CHEM, V272, P30546, DOI 10.1074/jbc.272.48.30546; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; Huang L, 2000, Cell Res, V10, P81, DOI 10.1038/sj.cr.7290038; Kastin AJ, 1999, PEPTIDES, V20, P1449, DOI 10.1016/S0196-9781(99)00156-4; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Lahlou N, 2000, DIABETES, V49, P1347, DOI 10.2337/diabetes.49.8.1347; Landt M, 2000, CLIN CHEM, V46, P379; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lewandowski K, 1999, J CLIN ENDOCR METAB, V84, P300, DOI 10.1210/jc.84.1.300; Li C, 1998, J BIOL CHEM, V273, P10078, DOI 10.1074/jbc.273.16.10078; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Ranganathan S, 1998, J LIPID RES, V39, P724; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; WuPeng XS, 1997, DIABETES, V46, P513, DOI 10.2337/diabetes.46.3.513; Yamaguchi M, 1998, BIOCHEM BIOPH RES CO, V252, P363, DOI 10.1006/bbrc.1998.9636; Zhang YY, 1997, BIOCHEM BIOPH RES CO, V240, P492, DOI 10.1006/bbrc.1997.7622; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	34	209	222	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6343	6349		10.1074/jbc.M009795200	http://dx.doi.org/10.1074/jbc.M009795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11102451	hybrid			2022-12-25	WOS:000167261000039
J	Talukder, AH; Jorgensen, HF; Mandal, M; Mishra, SK; Vadlamudi, RK; Clark, BFC; Mendelsohn, J; Kumar, R				Talukder, AH; Jorgensen, HF; Mandal, M; Mishra, SK; Vadlamudi, RK; Clark, BFC; Mendelsohn, J; Kumar, R			Regulation of elongation factor-1 alpha expression by growth factors and anti-receptor blocking antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; BREAST-CANCER; MESSENGER-RNA; CELLS; GENE; PROTEIN; PHOSPHORYLATION; STIMULATION; TRANSLATION; TRANSFORMATION	The epidermal growth factor (EGF) family and its receptors regulate normal and cancerous epithelial cell proliferation, a process that could be suppressed by anti-receptor blocking antibodies. Polypeptide elongation factor-1 alpha (EF-1 alpha) is a multifunctional protein whose levels are positively correlated with the proliferative state of cells. To identify genes, whose expression may be modulated by anti-receptor blocking antibodies, we performed a differential display screening and isolated differentially expressed cDNAs. Isolates from one clone were 100% identical to human EF-1 alpha. Both EGF and heregulin-beta1 (HRG) induced EF-1 alpha promoter activity and mRNA and protein expression. Growth factor-mediated EF-1 alpha expression was effectively blocked by pretreatment with humanized anti-EGF receptor antibody C225 or anti-human epidermal growth factor receptor-2 (HER2) antibody herceptin. Mutants and pharmacological inhibitors of p38(MAPK),d MER, but not phosphatidylinositol 3-kinase, suppressed both constitutive and HRG-induced stimulation of EF-1 alpha promoter activity in MCF-7 cells. Deletion analysis of the promoter suggested the requirement of the -393 to -204 region for growth factor-mediated transcription of EF-1 alpha. Fine mapping and point mutation studies revealed a role of the SP1 site in the observed HRG-mediated regulation of the EF-1 alpha promoter. In addition, we also provide new evidence to suggest that HRG stimulation of the EF-1 alpha promoter involves increased physical interactions with acetylated histone H3 and histone H4. These results suggest that regulation of EF-1 alpha expression by extracellular signals that function through human EGF receptor family members that are widely deregulated in human cancers and that growth factor regulation of EF-1 alpha expression involve histone acetylation.	Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Aarhus Univ, Inst Mol & Struct Biol, DK-8000 Aarhus, Denmark	University of Texas System; UTMD Anderson Cancer Center; Aarhus University	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323; Mishra, Sandip/0000-0002-0776-6581; Jorgensen, Helle/0000-0002-7909-2977	NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746, R01CA080066] Funding Source: NIH RePORTER; NCI NIH HHS [CA65746, CA80066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Alroy I, 1999, MOL CELL BIOL, V19, P1961; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; BillautMulot O, 1996, GENE, V174, P19, DOI 10.1016/0378-1119(96)00254-5; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chang YWE, 1997, J BIOL CHEM, V272, P28252, DOI 10.1074/jbc.272.45.28252; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/pnas.97.1.377; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Condiotti R, 1996, LEUKEMIA RES, V20, P169, DOI 10.1016/0145-2126(95)00142-5; Das T, 1998, P NATL ACAD SCI USA, V95, P1449, DOI 10.1073/pnas.95.4.1449; DHARMAWARDHANE S, 1991, CELL MOTIL CYTOSKEL, V20, P279, DOI 10.1002/cm.970200404; EZEKIEL MP, 1998, P AM SOC CLIN ONCOL, V12; FAN Z, 1993, J BIOL CHEM, V268, P21073; Gangwani L, 1998, J CELL BIOL, V143, P1471, DOI 10.1083/jcb.143.6.1471; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KOCH I, 1990, ONCOGENE, V5, P839; Kolettas E, 1998, ANTICANCER RES, V18, P385; KREIG PA, 1989, DEV BIOL, V133, P93; Kumar R, 1996, CLIN CANCER RES, V2, P1215; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KUMAR R, 2001, IN PRESS SEMIN ONCOL; LORENI F, 1993, NUCLEIC ACIDS RES, V21, P4721, DOI 10.1093/nar/21.20.4721; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; OKAZAKI K, 1995, EUR J CELL BIOL, V66, P75; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; ROTH WW, 1987, MOL CELL BIOL, V7, P3929, DOI 10.1128/MCB.7.11.3929; SANDERS J, 1992, NUCLEIC ACIDS RES, V20, P5907, DOI 10.1093/nar/20.22.5907; Sanders J, 1996, J CELL SCI, V109, P1113; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WAKABAYASHIITO N, 1994, J BIOL CHEM, V269, P29831; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YANG WN, 1993, J BIOL CHEM, V268, P392; Zhang K, 1996, J BIOL CHEM, V271, P3884	50	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5636	5642		10.1074/jbc.M006824200	http://dx.doi.org/10.1074/jbc.M006824200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11104760	hybrid			2022-12-25	WOS:000167115100033
J	Elkin, M; Miao, HQ; Nagler, A; Aingorn, E; Reich, R; Hemo, I; Dou, HL; Pines, M; Vlodavsky, I				Elkin, M; Miao, HQ; Nagler, A; Aingorn, E; Reich, R; Hemo, I; Dou, HL; Pines, M; Vlodavsky, I			Halofuginone: a potent inhibitor of critical steps in angiogenesis progression	FASEB JOURNAL			English	Article						neovascularization; type I collagen; halofuginone; matrix metalloproteinase-2; extracellular matrix	SMALL-INTESTINAL SUBMUCOSA; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; TUMOR ANGIOGENESIS; COLLAGEN-SYNTHESIS; GROWTH; PROLIFERATION; EXPRESSION; METALLOPROTEINASES; DIFFERENTIATION	We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. These results together with the well-documented role of extracellular matrix (ECM) components and matrix degrading enzymes in formation of new blood vessels led us to investigate the effect of halofuginone on the angiogenic process. In a variety of experimental system, representing sequential events in the angiogenic cascade, halofuginone treatment resulted in profound inhibitory effect. Among these are the abrogation of endothelial cell MMP-2 expression and basement membrane invasion, capillary tube formation, and vascular sprouting, as well as deposition of subendothelial ECM. The most conclusive anti-angiogenic activity of halofuginone was demonstrated in vivo (mouse corneal micropocket assay) by showing a marked inhibition of basic fibroblast growth factor (bFGF) -induced neovascularization in response to systemic administration of halofuginone, either i.p. or in the diet. The ability of halofuginone to interfere with key events in neovascularization, together with its oral bioavailability and safe use as an anti-parasitic agent, make it a promising drug for further evaluation in the treatment of a wide range of diseases associated with pathological angiogenesis.	Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Bone Marrow Transplantat, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Ophthalmol, IL-91120 Jerusalem, Israel; Agr Res Org, Volcani Ctr, Inst Anim Sci, IL-50250 Bet Dagan, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Vlodavsky, I (corresponding author), Hadassah Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.	vlodavsk@cc.huji.ac.il						ABRAMOVITCH R, 1999, NEOPLASIA, V32, P321; ALBINI A, 1987, CANCER RES, V47, P3239; Badylak S, 1999, BIOMATERIALS, V20, P2257, DOI 10.1016/S0142-9612(99)00156-8; Badylak SF, 1998, J BIOMAT SCI-POLYM E, V9, P863, DOI 10.1163/156856298X00208; BENELLI R, 1994, ONCOL RES, V6, P251; BENEZRA M, 1994, ARTERIOSCLER THROMB, V14, P1992, DOI 10.1161/01.ATV.14.12.1992; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Elkin M, 1999, CANCER RES, V59, P4111; Elkin M, 1999, CLIN CANCER RES, V5, P1982; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; FOUSER L, 1991, J BIOL CHEM, V266, P18345; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; GOSPODAROWICZ D, 1980, J SUPRAMOL STR CELL, V13, P339, DOI 10.1002/jss.400130307; GRANOT I, 1991, POULTRY SCI, V70, P1559, DOI 10.3382/ps.0701559; GRANOT I, 1993, BIOCHIM BIOPHYS ACTA, V1156, P107, DOI 10.1016/0304-4165(93)90123-P; Grant D S, 1997, EXS, V79, P317; Halevy O, 1996, BIOCHEM PHARMACOL, V52, P1057, DOI 10.1016/0006-2952(96)00427-3; HERRON GS, 1986, J BIOL CHEM, V261, P2814; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; INGBER D, 1988, LAB INVEST, V59, P44; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; Itoh T, 1998, CANCER RES, V58, P1048; JACKSON CJ, 1991, EXP CELL RES, V192, P319, DOI 10.1016/0014-4827(91)90194-Y; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; LIOTTA LA, 1981, BIOCHEMISTRY-US, V20, P100, DOI 10.1021/bi00504a017; Maekawa R, 1999, CANCER RES, V59, P1231; Nagler A, 1997, KIDNEY INT, V52, P1561, DOI 10.1038/ki.1997.486; Nagler A, 1997, ARTERIOSCL THROM VAS, V17, P194, DOI 10.1161/01.ATV.17.1.194; NICOSIA RF, 1990, LAB INVEST, V63, P115; NICOSIA RF, 1991, IN VITRO CELL DEV B, V27, P961; Pines M, 1998, GEN PHARMACOL, V30, P445, DOI 10.1016/S0306-3623(97)00307-8; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROONEY P, 1993, J CELL SCI, V105, P213; Rooney R, 1997, TUMOUR ANGIOGENESIS, P141; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Voytik-Harbin SL, 1998, TISSUE ENG, V4, P157, DOI 10.1089/ten.1998.4.157; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	44	86	89	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2477	2485		10.1096/fj.00-0292com	http://dx.doi.org/10.1096/fj.00-0292com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099465				2022-12-25	WOS:000165723400017
J	Kang, TB; Yi, J; Yang, WR; Wang X; Jiang, AX; Pei, DQ				Kang, TB; Yi, J; Yang, WR; Wang, X; Jiang, AX; Pei, DQ			Functional characterization of MT3-MMP in transfected MDCK cells: progelatinase A activation and tubulogenesis in 3-D collagen lattice	FASEB JOURNAL			English	Article						ECM; zymogen; membrane-bound MMP; 3-D collagen; tubulogenesis	3 MATRIX METALLOPROTEINASES; MEMBRANE-TYPE 1; HEPATOCYTE GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; TISSUE LOCALIZATION; MT-MMPS; INTRACELLULAR ACTIVATION; HUMAN STROMELYSIN-3; BREAST-CARCINOMA; IV COLLAGENASE	MT3-MMP, a membrane-anchored matrix metalloproteinase, has been proposed to participate in the remodeling of extracellular matrix either by direct proteolysis or via activating other enzymes such as progelatinase A. To test this hypothesis, we analyzed the effect of exogenously transfected MT3-MMP in a tissue remodeling system: growth and tubulogenesis of Madin-Darby canine kidney (MDCK) cells in collagen gels. Although the parental cells require MMP activities for both growth and tubulogenesis, over-expression of wild-type MT3-MMP, but not its catalytically inactive mutant, leads to further enhancement of both processes, independent of its downstream substrate, progelatinase A, Mechanistically, MT3-MMP accomplishes such an effect by displaying on cell surfaces as active species, ready to activate progelatinase A or degrade ECM molecules. These data strongly suggest that MT3-MMP possesses the potential to directly enhance the growth and invasiveness of cells in vivo, two critical processes for development and carcinogenesis.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	peixx003@tc.umn.edu	Wang, Xing/G-2917-2015	Jiang, Aixiang/0000-0002-6153-7595	NCI NIH HHS [CA76308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076308, R29CA076308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Deryugina EI, 1998, CANCER RES, V58, P3743; Goss KJH, 1998, INT J CANCER, V78, P629; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kadono Y, 1998, BIOCHEM BIOPH RES CO, V251, P681, DOI 10.1006/bbrc.1998.9531; Kajita M, 1999, FEBS LETT, V457, P353, DOI 10.1016/S0014-5793(99)01065-0; KAWAHARA E, 1993, JPN J CANCER RES, V84, P409, DOI 10.1111/j.1349-7006.1993.tb00151.x; Kitagawa Y, 1999, J UROLOGY, V162, P905, DOI 10.1097/00005392-199909010-00088; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Konaka H, 1999, J UROLOGY, V161, P342, DOI 10.1016/S0022-5347(01)62143-8; KONO T, 1990, Journal of Dermatology (Tokyo), V17, P2; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; Llano E, 1999, CANCER RES, V59, P2570; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGASE H, 1986, J BIOL CHEM, V261, P1421; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Puente XS, 1996, CANCER RES, V56, P944; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shofuda K, 1998, LAB INVEST, V78, P915; Shofuda K, 1997, J BIOL CHEM, V272, P9749; STOKER M, 1985, J CELL SCI, V77, P209; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TURKSEN K, 1991, CELL REGUL, V2, P613, DOI 10.1091/mbc.2.8.613; Ueno H, 1997, CANCER RES, V57, P2055; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yoshiyama Y, 1998, ACTA NEUROPATHOL, V96, P347, DOI 10.1007/s004010050904	47	43	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2559	2568		10.1096/fj.00-0269com	http://dx.doi.org/10.1096/fj.00-0269com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099475				2022-12-25	WOS:000165723400027
J	Kim, DW; Gazourian, L; Quadri, SA; Romieu-Mourez, R; Sherr, DH; Sonenshein, GE				Kim, DW; Gazourian, L; Quadri, SA; Romieu-Mourez, R; Sherr, DH; Sonenshein, GE			The RelA NF-kappa B subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells	ONCOGENE			English	Article						NF-kappa B; RelA; AhR; c-myc oncogene; breast cancer	BREAST-CANCER; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; PROGNOSTIC FACTOR; PROTEIN; DIOXIN; TRANSCRIPTION; ACTIVATION; BINDING; LIGAND; GENE	NF-kappaB/Rel transcription factors regulate many genes involved in control of cellular proliferation, neoplastic transformation, and apoptosis, including the c-myc oncogene, Recently, we have observed that levels of NF-kappaB and aryl hydrocarbon receptor (AhR), which mediates malignant transformation by environmental carcinogens, are highly elevated and appear constitutively active in breast cancer cells. ReI factors have been found to functionally interact with other transcription factors. Here we demonstrate a physical and functional association between the RelA subunit of NF-kappaB and AhR resulting in the activation of c-myc gene transcription in breast cancer cells. RelA and AhR proteins were coimmunoprecipitated from cytoplasmic and nuclear extracts of non-malignant MCF-10F breast epithelial and malignant Hs578T breast cancer cells. In transient cotransfection, RelA and AhR gene products demonstrated cooperation in transactivation of the c-myc promoter, which was dependent on the NF-kappaB elements, and in induction of endogenous c-Myc protein levels. A novel AhR/RelA-containing NF-kappaB element binding complex was identified by electrophoretic mobility shift analysis of nuclear extracts from RelA and AhR co-transfected Hs578T cells. Thus, the RelA and AhR proteins functionally cooperate to bind to NF-kappaB elements and induce c-myc gene expression. These findings suggest a novel signaling mechanism whereby the Ah receptor can stimulate proliferation and tumorigenesis of mammary cells.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Program Res Womens Hlth, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Environm Hlth, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Program Res Womens Hlth, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University; Boston University	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.			Sherr, David/0000-0003-3353-0553	NCI NIH HHS [R01 CA 82742] Funding Source: Medline; NIEHS NIH HHS [1P42ES 07381, R01 ES06086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381, R01ES006086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott BD, 1999, TOXICOL APPL PHARM, V155, P62, DOI 10.1006/taap.1998.8601; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; Bellas RE, 1999, CELL GROWTH DIFFER, V10, P287; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Dickinson LA, 1999, J BIOL CHEM, V274, P12765, DOI 10.1074/jbc.274.18.12765; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Enan E, 1996, BIOCHEM PHARMACOL, V52, P1599, DOI 10.1016/S0006-2952(96)00566-7; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Ferrier R, 1999, ONCOGENE, V18, P995, DOI 10.1038/sj.onc.1202374; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; GRILLI M, 1991, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Hushka LJ, 1998, TOXICOL APPL PHARM, V152, P200, DOI 10.1006/taap.1998.8508; JAIN S, 1994, J BIOL CHEM, V269, P31518; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Lahvis GP, 1998, BIOCHEM PHARMACOL, V56, P781, DOI 10.1016/S0006-2952(98)00134-8; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; NEBERT DW, 1990, ENVIRON HEALTH PERSP, V88, P13, DOI 10.2307/3431045; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; PAVELIC ZP, 1991, ANTICANCER RES, V11, P1421; Perdew GH, 1996, BIOCHEM MOL BIOL INT, V39, P589; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; Robles R, 2000, ENDOCRINOLOGY, V141, P450, DOI 10.1210/en.141.1.450; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Trombino AF, 2000, BREAST CANCER RES TR, V63, P117, DOI 10.1023/A:1006443104670; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Yamaguchi K, 1997, TOXICOL APPL PHARM, V147, P190, DOI 10.1006/taap.1997.8263; Yamaguchi K, 1997, J IMMUNOL, V158, P2165	50	192	203	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5498	5506		10.1038/sj.onc.1203945	http://dx.doi.org/10.1038/sj.onc.1203945			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114727				2022-12-25	WOS:000165396100010
J	Cao, S; Yao, J; McCabe, TJ; Yao, Q; Katusic, ZS; Sessa, WC; Shah, V				Cao, S; Yao, J; McCabe, TJ; Yao, Q; Katusic, ZS; Sessa, WC; Shah, V			Direct interaction between endothelial nitric-oxide synthase and dynamin-2 - Implications for nitric-oxide synthase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT VESICLES; CAVEOLIN BINDING; CALMODULIN; RECEPTOR; DOMAIN; PALMITOYLATION; DISSOCIATION; ASSOCIATION; ENDOCYTOSIS; EXPRESSION	Endothelial nitric-oxide synthase (eNOS) is regulated in part through specific protein interactions. Dynamin-2 is a large GTPase residing within similar membrane compartments as eNOS, Here we show that dynamin-2 binds directly with eNOS thereby augmenting eNOS activity, Double label confocal immunofluorescence demonstrates colocalization of eNOS and dynamin in both Clone 9 cells cotransfected with green fluorescent protein-dynamin and eNOS, as well as in bovine aortic endothelial cells (BAEC) expressing both proteins endogenously, predominantly in a Gels membrane distribution. Immunoprecipitation of eNOS from BAEC lysate coprecipitates dynamin and, conversely, immunoprecipitation of dynamin coprecipitates eNOS. Additionally, the calcium ionophore, A23187, a reagent that promotes nitric oxide release, enhances coprecipitation of dynamin with eNOS in BAEC, suggesting the interaction between the proteins can be regulated by intracellular signals. In vitro studies demonstrate that glutathione S-transferase (GST)-dynamin-2 quantitatively precipitates both purified recombinant eNOS protein as well as in vitro transcribed S-35-labeled eNOS from solution indicating a direct interaction between the proteins in vitro, Scatchard analysis of binding studies demonstrates an equilibrium dissociation constant (K-d) of 27.6 nM. Incubation of purified recombinant eNOS protein with GST-dynamin-2 significantly increases eNOS activity as does overexpression of dynamin-2 in ECV 304 cells stably transfected with eNOS-green fluorescent protein. These studies demonstrate a direct protein-protein interaction between eNOS and dynamin-2, thereby identifying a new NOS-associated protein and providing a novel function for dynamin. These events may have relevance for eNOS regulation and trafficking within vascular endothelium.	Mayo Clin & Mayo Fdn, GI Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA	Mayo Clinic; Mayo Clinic; Yale University	Shah, V (corresponding author), Mayo Clin & Mayo Fdn, GI Res Unit, 200 1st St SW,Alfred 2-435, Rochester, MN 55905 USA.	shah.vijay@mayo.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002529] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-57665, HL-53524] Funding Source: Medline; NIDDK NIH HHS [DK-02529] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andries LJ, 1998, CIRC RES, V82, P195; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Dessy C, 2000, EMBO J, V19, P4272, DOI 10.1093/emboj/19.16.4272; Feron O, 1999, J CLIN INVEST, V103, P897, DOI 10.1172/JCI4829; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Lai MM, 1999, J BIOL CHEM, V274, P25963, DOI 10.1074/jbc.274.37.25963; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MIKI H, 1994, J BIOL CHEM, V269, P5489; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Peterson TE, 1999, CIRC RES, V85, P29; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shah V, 1999, GASTROENTEROLOGY, V117, P1222, DOI 10.1016/S0016-5085(99)70408-7; Shah V, 1997, J CLIN INVEST, V100, P2923, DOI 10.1172/JCI119842; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575	35	97	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14249	14256		10.1074/jbc.M006258200	http://dx.doi.org/10.1074/jbc.M006258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11120737	hybrid			2022-12-25	WOS:000168356600098
J	Misura, KMS; Scheller, RH; Weis, WI				Misura, KMS; Scheller, RH; Weis, WI			Self-association of the H3 region of syntaxin 1A - Implications for intermediates in snare complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; N-TERMINAL DOMAIN; 3-DIMENSIONAL STRUCTURE; FUSION COMPLEX; PROTEIN; BINDING; EXOCYTOSIS; SWITCH	Intracellular membrane fusion requires SNARE proteins found on the vesicle and target membranes. SNAREs associate by formation of a parallel four-helix bundle, and it has been suggested that formation of this complex promotes membrane fusion. The membrane proximal region of the cytoplasmic domain of the SNARE syntaxin 1A, designated H3, contributes one of the four helices to the SNARE complex. In the crystal structure of syntaxin 1A H3, four molecules associate as a homotetramer composed of two pairs of parallel helices that are anti-parallel to each other. The H3 oligomer observed in the crystals is also found in solution, as assessed by gel filtration and chemical cross-linking studies. The crystal structure reveals that the highly conserved Phe-216 packs against conserved Gln-226 residues present on the anti-parallel pair of helices. Modeling indicates that Phe-216 prevents parallel, tetramer formation. Mutation of Phe-216 to Leu appears to allow formation of parallel tetramers, whereas mutation to ALa destabilizes the protein, These results indicate that Phe-216 has a role in preventing formation of stable parallel helical bundles, thus favoring the interaction of the H3 region of syntaxin la with other proteins involved in membrane fusion.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol & Cellular Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, 299 Campus Dr W, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NIGMS NIH HHS [T32-GM08294] Funding Source: Medline; NIMH NIH HHS [MH38710, MH58570] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038710, R37MH038710] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hazzard J, 1999, J BIOMOL NMR, V14, P203, DOI 10.1023/A:1008382027065; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; Kee Y, 1996, J NEUROSCI, V16, P1975; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lerman JC, 2000, BIOCHEMISTRY-US, V39, P8470, DOI 10.1021/bi0003994; May Alice Starr, **NON-TRADITIONAL**; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Woodman PG, 1997, BBA-MOL CELL RES, V1357, P155, DOI 10.1016/S0167-4889(97)00039-6; Zhong PY, 1997, BIOCHEMISTRY-US, V36, P4317, DOI 10.1021/bi9625408; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250	38	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13273	13282		10.1074/jbc.M009636200	http://dx.doi.org/10.1074/jbc.M009636200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11118447	hybrid			2022-12-25	WOS:000168198600111
J	Halaban, R; Cheng, E; Svedine, S; Aron, R; Hebert, DN				Halaban, R; Cheng, E; Svedine, S; Aron, R; Hebert, DN			Proper folding and endoplasmic reticulum to Golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMELANOTIC MELANOMA-CELLS; HUMAN P-GLYCOPROTEIN; HUMAN MELANOCYTES; PROTEIN; IDENTIFICATION; GROWTH; MELANOGENESIS; AUTOACTIVATION; MICROPHTHALMIA; TRANSCRIPTION	Tyrosinase is essential for pigmentation and is a source of tumor-derived antigenic peptides and cellular immune response. Wild type tyrosinase in melanoma cells and certain albino mutants in untransformed melanocytes are targeted to proteolytic degradation by the 26 S proteasome due to retention of the misfolded protein in the endoplasmic reticulum and its subsequent retranslocation to the cytosol. Here, we demonstrate that the substrates DOPA and tyrosine induced in melanoma cells a transition of misfolded wild type tyrosinase to the native form that is resistant to proteolysis, competent to exit the endoplasmic reticulum, and able to produce melanin. Because the enzymatic activity of tyrosinase is induced by DOPA, we propose that proper folding of the wild type protein, just like mutant forms, is tightly linked to its catalytic state. Loss of pigmentation, therefore, in tyrosinase-positive melanoma cells is a consequence of tumor-induced metabolic changes that suppress tyrosinase activity and DOPA production within these cells.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Univ Massachusetts, Program Mol & Cellular Biol, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	Yale University; University of Massachusetts System; University of Massachusetts Amherst	Halaban, R (corresponding author), Yale Univ, Sch Med, Dept Dermatol, POB 208059,15 York St,HRT 610, New Haven, CT 06520 USA.	ruth.halaban@yale.edu			NATIONAL CANCER INSTITUTE [R29CA044542, R01CA044542, R01CA079864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942, R01AR039848] Funding Source: NIH RePORTER; NCI NIH HHS [CA44542, CA79864] Funding Source: Medline; NIAMS NIH HHS [AR41942, AR39848] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; BINGHAM MJ, 1995, J PHYSIOL-LONDON, V482, P583, DOI 10.1113/jphysiol.1995.sp020542; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CHEN YT, 1995, P NATL ACAD SCI USA, V92, P8125, DOI 10.1073/pnas.92.18.8125; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dierick HA, 1997, HUM MOL GENET, V6, P409, DOI 10.1093/hmg/6.3.409; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Halaban R, 1996, J INVEST DERMATOL, V106, P1266, DOI 10.1111/1523-1747.ep12348972; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; HALABAN R, 1988, P NATL ACAD SCI USA, V85, P7241, DOI 10.1073/pnas.85.19.7241; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HALABAN R, 1977, EXP CELL RES, V108, P119, DOI 10.1016/S0014-4827(77)80017-7; HALABAN R, 1977, EXP CELL RES, V108, P111, DOI 10.1016/S0014-4827(77)80016-5; Halaban R, 2000, J EXP MED, V191, P1005, DOI 10.1084/jem.191.6.1005; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; JIMBOW K, 1994, JOURNAL OF DERMATOLOGY, VOL 21, NO 11, NOVEMBER 1994, P894, DOI 10.1111/j.1346-8138.1994.tb03309.x; KANG XQ, 1995, J IMMUNOL, V155, P1343; LERNER AB, 1949, J BIOL CHEM, V178, P185; LERNER AB, 1987, J INVEST DERMATOL, V89, P219, DOI 10.1111/1523-1747.ep12470973; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Maeurer MJ, 1996, MELANOMA RES, V6, P11, DOI 10.1097/00008390-199602000-00003; Moffat M, 1997, EXP NEUROL, V144, P69, DOI 10.1006/exnr.1996.6390; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Mosse CA, 1998, J EXP MED, V187, P37, DOI 10.1084/jem.187.1.37; Naish-Byfield S, 1998, PIGM CELL RES, V11, P127, DOI 10.1111/j.1600-0749.1998.tb00722.x; Petrescu SM, 2000, BIOCHEMISTRY-US, V39, P5229, DOI 10.1021/bi000107z; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; POMERANTZ SH, 1976, ANAL BIOCHEM, V75, P86, DOI 10.1016/0003-2697(76)90058-0; RAPER HH, 1928, PHYSIOL REV, V8, P349; Riley PA, 1999, CELL MOL BIOL, V45, P951; RILEY PA, 1998, MECH INHIBITION MELA, P401; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SLOMINSKI A, 1990, J THEOR BIOL, V143, P123, DOI 10.1016/S0022-5193(05)80292-9; SLOMINSKI A, 1989, PIGM CELL RES, V2, P109, DOI 10.1111/j.1600-0749.1989.tb00170.x; SLOMINSKI A, 1989, LIFE SCI, V45, P1799, DOI 10.1016/0024-3205(89)90520-1; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Topalian SL, 1996, J EXP MED, V183, P1965, DOI 10.1084/jem.183.5.1965; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; YAVUZER U, 1995, ONCOGENE, V10, P123; ZAKUT R, 1993, ONCOGENE, V8, P2221	44	74	78	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11933	11938		10.1074/jbc.M008703200	http://dx.doi.org/10.1074/jbc.M008703200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11124258	hybrid			2022-12-25	WOS:000168081800067
J	Utsumi, T; Sato, M; Nakano, K; Takemura, D; Iwata, H; Ishisaka, R				Utsumi, T; Sato, M; Nakano, K; Takemura, D; Iwata, H; Ishisaka, R			Amino acid residue penultimate to the amino-terminal Gly residue strongly affects two cotranslational protein modifications, N-myristoylation and N-acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; METHIONINE AMINOPEPTIDASE; SUBSTRATE-SPECIFICITY; CANDIDA-ALBICANS; RAT-LIVER; MYRISTOYLTRANSFERASE; YEAST; COA; ACETYLTRANSFERASE; ACYLATION	To examine the amino-terminal sequence requirements for cotranslational protein N-myristoylation, a series of site-directed mutagenesis of N-terminal region were performed using tumor necrosis factor as a nonmyristoylated model protein. Subsequently, the susceptibility of these mutants to protein N-myristoylation was evaluated by metabolic labeling in an in vitro translation system or in transfected cells, It was found that the amino acid residue at position 3 in an N-myristoylation consensus motif, Met-Gly-X-X-X-Ser-X-X-X, strongly affected the susceptibility of the protein to two different cotranslational protein modifications, N-myristoylation and N-acetylation; 10 amino acids (Ala, Ser, Cys, Thr, Val, Asn, Leu, lie, Gin, and His) with a radius of gyration smaller than 1.80 Angstrom directed N-myristoylation, two negatively charged residues (Asp and Glu) directed N-acetylation, and two amino acids (Gly and Met) directed heterogeneous modification with both N-myristoylation and N-acetylation, The amino acid requirements at this position for the two modifications were dramatically changed when Ser at position 6 in the consensus motif was replaced with Ale. Thus, the amino acid residue penultimate to the N-terminal Gly residue strongly affected two cotranslational protein modifications, N-myristoylation and N-acetylation, and the amino acid requirements at this position for these two modifications were significantly affected by downstream residues.	Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan; Yamaguchi Univ, Fac Agr, Dept Vet Med, Yamaguchi 7538515, Japan	Yamaguchi University; Yamaguchi University	Utsumi, T (corresponding author), Yamaguchi Univ, Fac Agr, Dept Biol Chem, Yamaguchi 7538515, Japan.							Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; BROWN JL, 1970, BIOCHIM BIOPHYS ACTA, V221, P480, DOI 10.1016/0005-2795(70)90218-7; Dailey TA, 1996, PROTEIN SCI, V5, P98; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; Giang DG, 1998, J BIOL CHEM, V273, P6595, DOI 10.1074/jbc.273.12.6595; Glover CJ, 1997, J BIOL CHEM, V272, P28680, DOI 10.1074/jbc.272.45.28680; HEUCKEROTH RO, 1988, J BIOL CHEM, V263, P2127; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Lee T.W., 1988, J BUS PSYCHOL, V2, P263, DOI [10.1007/BF01014043, DOI 10.1007/BF01014043]; LODGE JK, 1994, J BIOL CHEM, V269, P2996; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; McWherter CA, 1997, J BIOL CHEM, V272, P11874, DOI 10.1074/jbc.272.18.11874; MOERSCHELL RP, 1990, J BIOL CELL, V265, P19637; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; UTSUMI T, 1993, J BIOL CHEM, V268, P9511; Utsumi T, 1996, ARCH BIOCHEM BIOPHYS, V326, P179, DOI 10.1006/abbi.1996.0063; Utsumi T, 1998, ARCH BIOCHEM BIOPHYS, V349, P216, DOI 10.1006/abbi.1997.0468; UTSUMI T, 1995, MOL CELL BIOL, V15, P6389; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; YAMADA R, 1991, BIOCHEMISTRY-US, V30, P1017, DOI 10.1021/bi00218a019	37	61	63	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10505	10513		10.1074/jbc.M006134200	http://dx.doi.org/10.1074/jbc.M006134200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124252	hybrid			2022-12-25	WOS:000167996400119
J	Sakai, K; Busby, WH; Clarke, JB; Clemmons, DR				Sakai, K; Busby, WH; Clarke, JB; Clemmons, DR			Tissue transglutaminase facilitates the polymerization of insulin-like growth factor-binding protein-1 (IGFBP-1) and leads to loss of IGFBP-1's ability to inhibit insulin-like growth factor-I-stimulated protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; FACTOR (IGF)-BINDING PROTEIN-1; CROSS-LINKING ENZYMES; HUMAN AMNIOTIC-FLUID; BIOLOGIC ACTIONS; MUSCLE-CELLS; SITES; PHOSPHORYLATION; IDENTIFICATION; FIBRONECTIN	Insulin-like growth factor-binding protein-1 (IG-FBP-1) binds to insulin-like growth factors (IGFs) and has been shown to inhibit or stimulate cellular responses to IGF-I in vitro. This capacity of IGFBP-1 to inhibit or stimulate IGF-I actions correlates with its ability to form stable high molecular weight multimers, Since the ability of some proteins to polymerize is dependent upon transglutamination, we determined if tissue transglutaminase could catalyze this reaction and the effect of polymerization of IGFBP-1 upon IGF-I action, Following incubation with pure tissue transglutaminase (Tg), IGFBP-1 formed covalently linked multimers that were stable during SDS-polyacrylamide gel electrophoresis using reducing conditions. Dephosphorylated IGFBP-1 polymerized more rapidly and to a greater extent compared with native (phosphorylated) IGFBP-1. Exposure to IGF-I stimulated transglutamination of IGFBP-1 in vitro. An IGFBP-1 mutant in which Gln(66)-Gln(67) had been altered to Ala(66)-Ala(67) (Q66A/Q67A) was relatively resistant to polymerization by Tg compared with native IGFBP-1. Tg localized in fibroblast membranes was also shown to catalyze the formation of native IGFBP-1 multimers, however, Q66A/Q67A IG-FBP-1 failed to polymerize. Although the mutant IG-FBP-1 potently inhibited IGF-I stimulated protein synthesis in pSMC cultures, the same concentration of native IGFBP-1 had no inhibitory effect. The addition of higher concentrations of native IGFBP-1 did inhibit the protein synthesis response, and this degree of inhibition correlated with the amount of monomeric IGFBP-1 that was present. In conclusion, IGFBP-1 is a substrate for tissue transglutaminase and Tg leads to the formation of high molecular weight covalently linked multimers. Polymerization is an important post-translational modification of IGFBP-1 that regulates cellular responses to IGF-I.	Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Clemmons, DR (corresponding author), Univ N Carolina, Sch Med, Dept Med, CB7170, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL-56580] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; BUSBY WH, 1989, ENDOCRINOLOGY, V125, P773, DOI 10.1210/endo-125-2-773; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CAMBELL PG, 1991, J CELL PHYSL, V149, P293; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRAUMAN AG, 1989, ENDOCRINOLOGY, V124, P2289, DOI 10.1210/endo-124-5-2289; Frost RA, 1999, ENDOCRINOLOGY, V140, P3962, DOI 10.1210/en.140.9.3962; FROST RA, 1991, J BIOL CHEM, V266, P18082; Galiano RD, 1996, J CLIN INVEST, V98, P2462, DOI 10.1172/JCI119064; Gaudry CA, 1999, EXP CELL RES, V252, P104, DOI 10.1006/excr.1999.4633; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HOCHENADL C, 1995, J BIOL CHEM, V270, P23415; HOECK WG, 1994, J CELL BIOCHEM, V56, P262, DOI 10.1002/jcb.240560220; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1993, J BIOL CHEM, V268, P1125; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KANZAKI S, 1994, ENDOCRINOLOGY, V134, P1254; MCCUSKER RH, 1988, J CELL PHYSIOL, V137, P505, DOI 10.1002/jcp.1041370316; MCCUSKER RH, 1990, J CELL PHYSIOL, V144, P244, DOI 10.1002/jcp.1041440210; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; RITVOS O, 1988, ENDOCRINOLOGY, V122, P2150, DOI 10.1210/endo-122-5-2150; Sakai K, 1997, ENDOCR J, V44, P409, DOI 10.1507/endocrj.44.409; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; TSUBOI R, 1995, J INVEST DERMATOL, V104, P199, DOI 10.1111/1523-1747.ep12612755; Westwood M, 1997, ENDOCRINOLOGY, V138, P1130, DOI 10.1210/en.138.3.1130	41	46	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8740	8745		10.1074/jbc.M008359200	http://dx.doi.org/10.1074/jbc.M008359200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121406	hybrid, Green Published			2022-12-25	WOS:000167607700018
J	Zhou, A; Faint, R; Charlton, P; Dafforn, TR; Carrell, RW; Lomas, DA				Zhou, A; Faint, R; Charlton, P; Dafforn, TR; Carrell, RW; Lomas, DA			Polymerization of plasminogen activator inhibitor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SHEET-A; ESCHERICHIA-COLI; ALPHA-1-PROTEINASE INHIBITOR; REACTIVE LOOP; IN-VIVO; CONFORMATIONAL DISEASE; ANGSTROM STRUCTURE; CRYSTAL-STRUCTURE; SERPIN; ANTITHROMBIN	The activity of the serine proteinase inhibitor (serpin) plasminogen activator inhibitor-1 (PAI-1) is controlled by the intramolecular incorporation of the reactive loop into beta -sheet A with the generation of an inactive latent species. Other members of the serpin superfamily can be pathologically inactivated by intermolecular linkage between the reactive loop of one molecule and beta -sheet A of a second to form chains of polymers associated with diverse diseases. It has long been believed that PAI-1 is unique among active serpins in that it does not form polymers. We show here that recombinant native and latent PAI-1 spontaneously form polymers in vitro at low pH although with distinctly different electrophoretic patterns of polymerization. The polymers of both the native and latent species differ from the typical loop-A-sheet polymers of other serpins in that they readily dissociate back to their original monomeric form. The findings with PAI-1 are compatible with different mechanisms of linkage, each involving beta -strand addition of the reactive loop to s7A in native PAI-1 and to s1C in latent PAI-1. Glycosylated native and latent PAI-1 can also form polymers under similar conditions, which may be of in vivo importance in the low pH environment of the platelet.	Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Dept Med,Resp Med Unit, Cambridge CB2 2XY, England; Xenova Ltd, Slough SL1 4EF, Berks, England	University of Cambridge; University of Cambridge	Zhou, A (corresponding author), Univ Cambridge, Wellcome Trust Ctr Mol Mech Dis, Cambridge Inst Med Res, Dept Haematol, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Zhou, Aiwu/G-4700-2010; Dafforn, Tim/A-9072-2015	Dafforn, Tim/0000-0003-2257-6679; ZHOU, Aiwu/0000-0002-2555-5091				AULAK KS, 1993, J BIOL CHEM, V268, P18088; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Bjorquist P, 1998, BIOCHEMISTRY-US, V37, P1227, DOI 10.1021/bi971554q; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1997, PROTEIN SCI, V6, P89; Chang WSW, 1998, J BIOL CHEM, V273, P3695, DOI 10.1074/jbc.273.6.3695; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Dunstone MA, 2000, PROTEIN SCI, V9, P417; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1996, NAT STRUCT BIOL, V3, P910, DOI 10.1038/nsb1196-910; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; JOVIN TM, 1973, ANN NY ACAD SCI, V209, P477, DOI 10.1111/j.1749-6632.1973.tb47551.x; KATAGIRI K, 1988, EUR J BIOCHEM, V176, P81, DOI 10.1111/j.1432-1033.1988.tb14253.x; Koloczek H, 1996, PROTEIN SCI, V5, P2226, DOI 10.1002/pro.5560051109; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; KVASSMAN JO, 1995, J BIOL CHEM, V270, P27942, DOI 10.1074/jbc.270.46.27942; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; LINDO VS, 1995, BRIT J HAEMATOL, V89, P589, DOI 10.1111/j.1365-2141.1995.tb08368.x; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, J BIOL CHEM, V268, P516; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; Mahadeva R, 1999, J CLIN INVEST, V103, P999, DOI 10.1172/JCI4874; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; PATSTON PA, 1995, FEBS LETT, V368, P401, DOI 10.1016/0014-5793(95)00694-5; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; Sreerama N, 1999, PROTEIN SCI, V8, P370; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Sui GC, 1998, BIOCHEM J, V331, P409, DOI 10.1042/bj3310409; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; WARDELL MR, 1993, J MOL BIOL, V234, P1253, DOI 10.1006/jmbi.1993.1676; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1; Zhou A, 1996, BIOCHEM MOL BIOL INT, V39, P235; Zhou AW, 1999, BLOOD, V94, P3388, DOI 10.1182/blood.V94.10.3388.422k20_3388_3396	57	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9115	9122		10.1074/jbc.M010631200	http://dx.doi.org/10.1074/jbc.M010631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11102455	hybrid			2022-12-25	WOS:000167607700068
J	Chu, C; Kohtz, DS				Chu, C; Kohtz, DS			Identification of the E2A gene products as regulatory targets of the G(1) cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; LOOP-HELIX PROTEINS; DNA-BINDING PROTEINS; HUMAN BREAST-CANCER; B-CELL DEVELOPMENT; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; ECTOPIC EXPRESSION; TRANSLOCATION BREAKPOINTS	The E2A gene products, E12 and E47, are multifunctional transcription factors that as homodimers regulate B cell development, growth, and survival. In this report, the E2A gene products are shown to be targets for regulation by the G(1) cyclin-dependent kinases. Two novel G(1) cyclin-dependent kinase sites are identified on the N-terminal domain of E12/E47, One site displays homology to a preferential D-type cyclin-dependent kinase site (serine 780) on the retinoblastoma susceptibility gene product (pRB) and, consistent with this homology, is more efficiently phosphorylated by cyclin D1-CDK4 than by the other cyclin-dependent kinases (CDK) that were tested. The second kinase site is phosphorylated by both cyclin D1-CDK4 and cyclin A/E-CDK2 complexes. Mutation studies indicated that phosphorylation of the cyclin D1-CDK4 site, or more potently, of both the cyclin D1-CDK4 and cyclin A/E-CDK2 sites, negatively regulates the growth suppressor function associated with the N-terminal domain of E12/E47, Transient expression studies showed that ectopic expression of cyclin D1 or E negatively regulates sequence-specific activation of gene transcription by E12/E47, Analysis of site mutants, however, indicated that inhibition of E12/E47 transcriptional activity did not require the N-terminal G(1) cyclin-dependent kinase sites. Together, the results suggest that the growth suppressor and transcriptional activator functions of E12/E47 are targets for regulation by G(1) cyclin-dependent kinases but that the mechanisms of regulation for each function are distinct.	Mt Sinai Sch Med, Dept Pathol 1194, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Kohtz, DS (corresponding author), Mt Sinai Sch Med, Dept Pathol 1194, 1 Gustave Levy Pl, New York, NY 10029 USA.	stave.kohtz@mssm.edu			NCI NIH HHS [CA-72775] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072775] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altura RA, 1998, BLOOD, V92, P1397, DOI 10.1182/blood.V92.4.1397.416k19_1397_1405; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CORBEIL HB, 1995, ONCOGENE, V11, P909; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DARBON JM, 1994, ONCOGENE, V9, P3127; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Dreyling MH, 1997, CANCER RES, V57, P4608; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARPER JW, 1993, CELL, V75, P805; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Honda H, 1999, BLOOD, V93, P2780; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inukai T, 1998, MOL CELL BIOL, V18, P6035, DOI 10.1128/MCB.18.10.6035; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; KIESS M, 1995, ONCOGENE, V10, P159; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Massari ME, 1996, MOL CELL BIOL, V16, P121; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEEKER TC, 1991, LEUKEMIA, V5, P733; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRABNU S, 1997, MOL CELL BIOL, V27, P5888; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Reya T, 1998, CURR OPIN IMMUNOL, V10, P158, DOI 10.1016/S0952-7915(98)80244-6; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; vanDiest PJ, 1997, AM J PATHOL, V150, P705; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WU LT, 1994, ONCOGENE, V9, P2089; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zukerberg LR, 1996, BLOOD, V88, P268, DOI 10.1182/blood.V88.1.268.bloodjournal881268; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	88	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8524	8534		10.1074/jbc.M008371200	http://dx.doi.org/10.1074/jbc.M008371200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11114297	hybrid			2022-12-25	WOS:000167474900114
J	Dass, B; McMahon, KW; Jenkins, NA; Gilbert, DJ; Copeland, NG; MacDonald, CC				Dass, B; McMahon, KW; Jenkins, NA; Gilbert, DJ; Copeland, NG; MacDonald, CC			The gene for a variant form of the polyadenylation protein CstF-64 is on chromosome 19 and is expressed in pachytene spermatocytes in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CLEAVAGE STIMULATION FACTOR; PRE-MESSENGER-RNA; 3' UNTRANSLATED REGION; B-CELL DIFFERENTIATION; POLY(A) ADDITION SITE; BINDING DOMAIN; POINT MUTATIONS; MOUSE GENOME; TERMINATION	Many mRNAs in male germ cells lack the canonical AAUAAA but are normally polyadenylated (Wallace, A. M., Dass, B., Ravnik, S. E., Tonk, V., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., and MacDonald, C. C. (1999) Proc. Natl. Acad Sci. U. S. A. 96, 6763-6768). Previously, we demonstrated the presence of two distinct forms of the M-r 64,000 protein of the cleavage stimulation factor (CstF-64) in mouse male germ cells and in brain, a somatic M-r 64,000 form and a variant M-r 70,000 form. The variant form was specific to meiotic and postmeiotic germ cells. We localized the gene for the somatic CstF-64 to the X chromosome, which would be inactivated during male meiosis. This suggested that the variant CstF-64 was an autosomal homolog activated during that time. We have named the variant form "tau CstF-64," and we describe here the cloning and characterization of the mouse tau CstF-64 cDNA, which maps to chromosome 19. The mouse tau CstF-64 protein fits the criteria of the variant CstF-64, including antibody reactivity, size, germ cell expression, and a common proteolytic digest pattern with tau CstF-64 from testis. Features of m tau CstF-64 that might allow it to promote the germ cell pattern of polyadenylation include a Pro --> Ser substitution in the RNA-binding domain and significant changes in the region that interacts with CstF-77.	Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Med Ctr, SW Canc Ctr, Lubbock, TX 79430 USA; NCI, Mouse Canc Genet Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MacDonald, CC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, 3601 4th St, Lubbock, TX 79430 USA.	cbbccm2@ttuhsc.edu		MacDonald, Clinton/0000-0003-3209-1982	NICHD NIH HHS [R01 HD037109, 1R01 HD37109-01A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD037109] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bagga PS, 1998, NUCLEIC ACIDS RES, V26, P5343, DOI 10.1093/nar/26.23.5343; Barbaux S, 1996, COMP BIOCHEM PHYS B, V114, P313, DOI 10.1016/0305-0491(96)00023-5; Beyer K, 1997, J BIOL CHEM, V272, P26769, DOI 10.1074/jbc.272.42.26769; Blake JA, 2000, NUCLEIC ACIDS RES, V28, P108, DOI 10.1093/nar/28.1.108; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DASS B, 2001, IN PRESS BIOL REPROD; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; EDWALDSGILBERT G, 1993, MOL CELL BIOL, V13, P3472, DOI 10.1128/MCB.13.6.3472; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; Gunderson SI, 1998, MOL CELL, V1, P255, DOI 10.1016/S1097-2765(00)80026-X; Hatton LS, 2000, NUCLEIC ACIDS RES, V28, P520, DOI 10.1093/nar/28.2.520; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Huang YQ, 1996, MOL CELL BIOL, V16, P1534; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; McCarrey JR, 1999, J ANDROL, V20, P635; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Nagata T, 1999, J MOL BIOL, V287, P221, DOI 10.1006/jmbi.1999.2616; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; OBRIEN DA, 1987, BIOL REPROD, V37, P147, DOI 10.1095/biolreprod37.1.147; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; Richardson JM, 1999, BIOCHEMISTRY-US, V38, P12869, DOI 10.1021/bi990724r; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; TALBOT CC, 1999, CURRENT PROTOCOLS HU; Vagner S, 2000, GENE DEV, V14, P403; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; Wallace AM, 1999, P NATL ACAD SCI USA, V96, P6763, DOI 10.1073/pnas.96.12.6763; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WILUSZ J, 1990, MOL CELL BIOL, V10, P1244, DOI 10.1128/MCB.10.3.1244; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	61	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8044	8050		10.1074/jbc.M009091200	http://dx.doi.org/10.1074/jbc.M009091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113135	hybrid			2022-12-25	WOS:000167474900053
J	Floyd, SR; Porro, EB; Slepnev, VI; Ochoa, GC; Tsai, LH; De Camilli, P				Floyd, SR; Porro, EB; Slepnev, VI; Ochoa, GC; Tsai, LH; De Camilli, P			Amphiphysin 1 binds the cyclin-dependent kinase (cdk) 5 regulatory subunit p35 and is phosphorylated by cdk5 and cdc2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIFF-MAN SYNDROME; BREAST-CANCER; NEURITE OUTGROWTH; MITOTIC PHOSPHORYLATION; FUNCTIONAL HOMOLOG; TYROSINE KINASE; PROTEIN; ACTIVATOR; CLATHRIN; BRAIN	Amphiphysin 1 is a phosphoprotein expressed at high levels in neurons, where it participates in synaptic vesicle endocytosis and neurite outgrowth. It is a substrate for cyclin-dependent kinase (cdk) 5, a member of the cyclin-dependent protein kinase family, which has been functionally linked to neuronal migration and neurite outgrowth via its action on the actin cytoskeleton. The yeast homologue of amphiphysin, Rvs167, functions in endocytosis and actin dynamics, is phosphorylated by the cdk5 homologue Pho85, and binds the Pho85 regulatory subunit Pcl2, We show here that amphiphysin 1 interacts with the cdk5-activating subunit p35 and that this interaction is mediated by the conserved NH2-terminal region of amphiphysin, Amphiphysin I colocalizes with p35 in the growth cones of neurons and at actin-rich peripheral lamellipodia in transfected fibroblasts. Amphiphysin is phosphorylated by cdk5 in a region including serines 272, 276, and 285, Amphiphysin I is also phosphorylated by the cdc2/cyclin B kinase complex in the same region and undergoes mitotic phosphorylation in dividing cells, These data indicate that phosphorylation by members of the cyclin-dependent kinase family is a conserved property of amphiphysin and suggest that this phosphorylation may play an important physioiogical role both in mitosis and in differentiated cells.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Howard Hughes Medical Institute; Yale University; Yale University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	De Camilli, P (corresponding author), Howard Hughes Med Inst, Dept Cell Biol, 295 Congress Ave, New Haven, CT 06510 USA.				NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS37007, NS36251] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R01NS036251, R01NS037007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banker G., 1991, CULTURING NERVE CELL; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; DECAMILLI P, 1993, J EXP MED, V178, P2219, DOI 10.1084/jem.178.6.2219; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; Floyd S, 1998, MOL MED, V4, P29, DOI 10.1007/BF03401727; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; Huang DQ, 1999, P NATL ACAD SCI USA, V96, P14445, DOI 10.1073/pnas.96.25.14445; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Mundigl O, 1998, J NEUROSCI, V18, P93; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Nishizawa M, 1999, J BIOL CHEM, V274, P33859, DOI 10.1074/jbc.274.48.33859; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rosales JL, 2000, J CELL BIOCHEM, V78, P151, DOI 10.1002/(SICI)1097-4644(20000701)78:1<151::AID-JCB14>3.0.CO;2-L; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Stone KL, 1998, ELECTROPHORESIS, V19, P1046, DOI 10.1002/elps.1150190620; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Williams Kenneth R., 1996, P541, DOI 10.1007/978-1-60327-259-9_91; WILLIAMS KR, 1997, MOL BIOTECHNOL, P155; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	42	108	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8104	8110		10.1074/jbc.M008932200	http://dx.doi.org/10.1074/jbc.M008932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113134	hybrid			2022-12-25	WOS:000167474900061
J	Qin, ZH; Wan, YM; Kikly, KK; Sapp, E; Kegel, KB; Aronin, N; DiFiglia, M				Qin, ZH; Wan, YM; Kikly, KK; Sapp, E; Kegel, KB; Aronin, N; DiFiglia, M			Pro-caspase-8 is predominantly localized in mitochondria and released into cytoplasm upon apoptotic stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; NECROSIS-FACTOR RECEPTOR; CYTOCHROME-C RELEASE; CELL-DEATH; NEURONAL APOPTOSIS; MEDIATED APOPTOSIS; OUTER-MEMBRANE; CASPASE-8; FAS; TRANSLOCATION	The recruitment and cleavage of pro-caspase-8 to produce the active form of caspase-8 is a critical biochemical event in death receptor-mediated apoptosis, However, the source of pro-caspase-8 available for activation by apoptotic triggers is unknown. In human fibroblasts and mouse clonal striatal cells, confocal microscopy revealed that pro-caspase-8 immunofluorescence was colocalized with cytochrome c in mitochondria and was also distributed diffusely in some nuclei. Biochemical analysis of subcellular fractions indicated that pro-caspase-8 was enriched in mitochondria and in nuclei. Pro-caspase-8 was found in the intermembrane space, inner membrane, and matrix of mitochondria after limited digestion of mitochondrial fractions, and this distribution was confirmed by immunogold electron microscopy. Pro-caspase-8 and cytochrome c were released from isolated mitochondria that were treated with an inhibitor of the ADP/ATP carrier atractyloside, which opens the mitochondria permeability transition pore. Release was blocked by the mitochondria permeability transition pore inhibitor cyclosporin A (CsA), After clonal striatal cells were exposed for 6 h to an apoptotic inducer tumor necrosis factor-alpha (TNF-alpha), mitochondria immunoreactive for cytochrome c and pro-caspase-8 became clustered at perinuclear sites. Pro-caspase-8 and cytochrome c levels decreased in mitochondrial fractions and increased, along with pro-caspase-8 cleavage products, in the cytoplasm of the TNF-alpha -treated striatal cells. CsA blocked the TNF-alpha -induced release of pro-caspase 8 but not cytochrome c, Internucleosomal DNA fragmentation started at 6 h and peaked 12 h after TNF-alpha treatment. These results suggest that pro-caspase 8 is predominantly localized in mitochondria and is released upon apoptotic stimulation through a CsA-sensitive mechanism.	Massachusetts Gen Hosp, Lab Cellular Neurobiol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA; Univ Massachusetts, Med Ctr, Dept Med & Cell Biol, Worcester, MA 01655 USA	Harvard University; Massachusetts General Hospital; Harvard University; GlaxoSmithKline; University of Massachusetts System; University of Massachusetts Worcester	Qin, ZH (corresponding author), Massachusetts Gen Hosp, Lab Cellular Neurobiol, Bldg 149,Rm 6604,13th St, Charlestown, MA 02129 USA.	difiglia@helix.mgh.harvard.edu			NINDS NIH HHS [NS 16367, NS 35711, NS 38194] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016367, R01NS038194, P01NS016367, R01NS035711] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Chen RW, 1999, J NEUROSCI, V19, P9654; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Depraetere V, 1998, SCAND J IMMUNOL, V47, P523; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Ellerby HM, 1997, J NEUROSCI, V17, P6165; EVANS VG, 1993, CELL BIOL INT, V17, P461, DOI 10.1006/cbir.1993.1087; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; GASNIER F, 1993, ANAL BIOCHEM, V212, P173, DOI 10.1006/abio.1993.1309; Green D R, 1992, Semin Immunol, V4, P379; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grub S, 2000, TOXICOL APPL PHARM, V163, P209, DOI 10.1006/taap.1999.8887; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLEIN KG, 1995, MOL BIOCHEM PARASIT, V70, P207, DOI 10.1016/0166-6851(95)00013-Q; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mooney B, 1996, BIOCHEM BIOPH RES CO, V218, P309, DOI 10.1006/bbrc.1996.0054; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Qin ZH, 1999, J NEUROSCI, V19, P4023; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; SHERARWINWHYATT LM, 2000, CELL DEATH DIFFER, V7, P155; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; SZABO I, 1991, J BIOL CHEM, V266, P3376; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; WAINWRIGHT MS, 1995, J NEUROSCI, V15, P676; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Waterhouse NJ, 1999, J CLIN IMMUNOL, V19, P378, DOI 10.1023/A:1020550716138; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	65	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8079	8086		10.1074/jbc.M007028200	http://dx.doi.org/10.1074/jbc.M007028200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11102441	hybrid			2022-12-25	WOS:000167474900058
J	Rodeheffer, MS; Boone, BE; Bryan, AC; Shadel, GS				Rodeheffer, MS; Boone, BE; Bryan, AC; Shadel, GS			Nam1p, a protein involved in RNA processing and translation, is coupled to transcription through an interaction with yeast mitochondrial RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; SIGMA-FACTORS; DNA; IDENTIFICATION; MAINTENANCE; INITIATION; STABILITY; PRODUCT; SYSTEM	Alignment of three fungal mtRNA polymerases revealed conserved amino acid sequences in an aminoterminal region of the Saccharomyces cerevisiae enzyme implicated previously as harboring an important functional domain. Phenotypic analysis of deletion and point mutations, in conjunction with a yeast two-hybrid assay, revealed that Nam1p, a protein involved in RNA processing and translation in mitochondria, binds specifically to this domain, The significance of this interaction in vivo was demonstrated by the fact that the temperature-sensitive phenotype of a deletion mutation (rpo41 Delta2), which impinges on this amino-terminal domain, is suppressed by overproducing Nam1p. In addition, mutations in the amino-terminal domain result specifically in decreased steady-state levels of mature mitochondrial CYTB and COXI transcripts, which is a primary defect observed in NAM1 null mutant yeast strains. Finally, one point mutation (R129D) did not abolish Nam1p binding, yet displayed an obvious COX1/CYTB transcript defect. This mutation exhibited the most severe mitochondrial phenotype, suggesting that mutations in the amino-terminal domain can perturb other critical interactions, in addition to Nam1p binding, that contribute to the observed phenotypes. These results implicate the amino-terminal domain of mtRNA polymerases in coupling additional factors and activities involved in mitochondrial gene expression directly to the transcription machinery.	Emory Univ, Sch Med, Rollins Res Ctr, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Shadel, GS (corresponding author), Emory Univ, Sch Med, Rollins Res Ctr, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	gshadel@emory.edu			NHLBI NIH HHS [HL-59655, R01 HL059655-03, R01 HL059655] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059655] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHER E B, 1989, Molecular and General Genetics, V215, P517, DOI 10.1007/BF00427051; Bai C, 1997, METHOD ENZYMOL, V283, P141; DIECKMANN CL, 1994, INT REV CYTOL, V152, P145, DOI 10.1016/S0074-7696(08)62556-5; Fisk DG, 1999, EMBO J, V18, P2621, DOI 10.1093/emboj/18.9.2621; GREENLEAF AL, 1986, P NATL ACAD SCI USA, V83, P3391, DOI 10.1073/pnas.83.10.3391; GROUDINSKY O, 1993, MOL GEN GENET, V240, P419, DOI 10.1007/BF00280396; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JAEHNING JA, 1993, MOL MICROBIOL, V8, P1, DOI 10.1111/j.1365-2958.1993.tb01197.x; JANG SH, 1991, J BIOL CHEM, V266, P22671; LEWIN AS, 1995, MOL CELL BIOL, V15, P6971; LISOWSKY T, 1989, MOL GEN GENET, V219, P125, DOI 10.1007/BF00261167; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sastry S, 1998, P NATL ACAD SCI USA, V95, P9111, DOI 10.1073/pnas.95.16.9111; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; SHADEL GS, 1995, MOL CELL BIOL, V15, P2101; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; Shadel GS, 1999, AM J HUM GENET, V65, P1230, DOI 10.1086/302630; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Small ID, 2000, TRENDS BIOCHEM SCI, V25, P46, DOI 10.1016/S0968-0004(99)01520-0; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615; WALLIS MG, 1994, EUR J BIOCHEM, V222, P27, DOI 10.1111/j.1432-1033.1994.tb18837.x; Wang YH, 1999, P NATL ACAD SCI USA, V96, P8046, DOI 10.1073/pnas.96.14.8046; XU BJ, 1992, NUCLEIC ACIDS RES, V20, P1053, DOI 10.1093/nar/20.5.1053	30	79	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8616	8622		10.1074/jbc.M009901200	http://dx.doi.org/10.1074/jbc.M009901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11118450	Green Accepted, hybrid			2022-12-25	WOS:000167474900126
J	Lapinski, PE; Neubig, RR; Raghavan, M				Lapinski, PE; Neubig, RR; Raghavan, M			Walker A lysine mutations of TAP1 and TAP2 interfere with peptide translocation but not peptide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; TRANSMEMBRANE CONDUCTANCE REGULATOR; ANTIGEN-PROCESSING TAP; HUMAN P-GLYCOPROTEIN; NUCLEOTIDE-BINDING; ABC TRANSPORTER; MULTIDRUG-RESISTANCE; HISTIDINE PERMEASE; ATP HYDROLYSIS; ENCODED TRANSPORTER	We generated mutants of the transporter associated with antigen-processing subunits TAP1 and TAPE that were altered at the conserved lysine residue in the Walker,A motifs of the nucleotide binding domains (NBD); In other ATP binding cassette transporters, mutations of the lysine have been shown to reduce or abrogate the ATP hydrolysis activity and in some cases impair nucleotide binding, Mutants TAP1(K544M) and TAP2(K509M) were expressed in insect cells, and the effects of the mutations on nucleotide binding, peptide binding, and peptide translocation were assessed. The mutant TAP1 subunit is significantly impaired for nucleotide binding relative to wild type TAP1. The identical mutation in TAP2 does not significantly impair nucleotide binding relative to wild type TAPE. Using fluorescence quenching assays to measure the binding of fluorescent peptides, we show that both mutants, in combination with their wild type partners, can bind peptides. Since the mutant TAP1 is significantly impaired for nucleotide binding, these results indicate that nucleotide binding to TAP1 is not a requirement for peptide binding to TAP complexes. Peptide translocation is undetectable for TAP1 TAP2(K509M) complexes, but low levels of translocation are detectable with TAP1(K544M) TAP2 complexes. These results suggest an impairment in nucleotide hydrolysis by TAP complexes containing either mutant TAP subunit and indicate that the presence of one intact TAP NBD is insufficient for efficient catalysis of peptide translocation. Taken together, these results also suggest the possibility of distinct functions for TAP1 and TAP2 NBD during a single translocation cycle.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Raghavan, M (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, 5641 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.			Neubig, Richard/0000-0003-0501-0008	NIAID NIH HHS [R01 AI44115-01, R01 AI044115] Funding Source: Medline; NIAMS NIH HHS [5P60AR20557] Funding Source: Medline; NIGMS NIH HHS [GM39561] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Crossen R., 1996, BACULOVIRUS EXPRESSI; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; ELLIOT T, 1997, ADV IMMUNOL, P47; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Knittler MR, 1999, CURR BIOL, V9, P999, DOI 10.1016/S0960-9822(99)80448-5; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; Koopmann JO, 2000, IMMUNITY, V13, P117, DOI 10.1016/S1074-7613(00)00013-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lapinski PE, 2000, J BIOL CHEM, V275, P6831, DOI 10.1074/jbc.275.10.6831; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Momburg F, 1998, ADV IMMUNOL, V68, P191, DOI 10.1016/S0065-2776(08)60560-X; MULLER KM, 1994, J BIOL CHEM, V269, P14032; Muller M, 1996, J BIOL CHEM, V271, P1877; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Neumann L, 1999, J MOL BIOL, V294, P1203, DOI 10.1006/jmbi.1999.3329; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG K, 1994, FEBS LETT, V350, P337, DOI 10.1016/0014-5793(94)00806-X	43	61	61	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7526	7533		10.1074/jbc.M009448200	http://dx.doi.org/10.1074/jbc.M009448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11099504	hybrid			2022-12-25	WOS:000167442900091
J	Kreitz, S; Ritzi, M; Baack, M; Knippers, R				Kreitz, S; Ritzi, M; Baack, M; Knippers, R			The human origin recognition complex protein 1 dissociates from chromatin during S phase in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME-MAINTENANCE PROTEINS; PRE-REPLICATIVE COMPLEXES; DNA-POLYMERASE-ALPHA; MCM PROTEINS; SACCHAROMYCES-CEREVISIAE; CDC6 PROTEIN; XENOPUS; YEAST; ORC; INITIATION	We investigated the association of human origin recognition complex (ORC) proteins hOrc1p and hOrc2p with chromatin in HeLa cells. Independent procedures including limited nuclease digestion and differential salt extraction of isolated nuclei showed that a complex containing hOrc1p and hOrc2p occurs in a nuclease-resistant compartment of chromatin and can be eluted with moderate high salt concentrations. A second fraction of hOrc2p that dissociates in vitro at low salt conditions was found to occur in a chromatin compartment characterized by its high accessibility to micrococcal nuclease. Functional differences between these two sites become apparent in HeLa cells that synchronously enter the S phase after a release from a double-thymidine block. The hOrc1p/hOrc2p-containing complexes dissociate from their chromatin sites during S phase and reassociate at the end of mitosis. In contrast, the fraction of hOrc2p in nuclease-accessible, more open chromatin remains bound during all phases of the cell cycle. We propose that the hOrc1p/hOrc2p-containing complexes are components of the human origin recognition complex. Thus, the observed cell cycle-dependent release of the hOrc1p/hOrc2p-containing complexes is in line with previous studies with Xenopus and Drosophila systems, which indicated that a change in ORC stability occurs after prereplication complex formation. This could be a powerful mechanism that prevents the rereplication of already replicated chromatin in the metazoan cell cycle.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; GSF Haematologikum, D-81377 Munich, Germany	University of Konstanz	Kreitz, S (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.							ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Asano M, 1999, EMBO J, V18, P2435, DOI 10.1093/emboj/18.9.2435; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Berezney Ronald, 1995, V162A, P1; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Dillin A, 1998, SCIENCE, V279, P1733, DOI 10.1126/science.279.5357.1733; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; HANCOCK R, 1974, J MOL BIOL, V86, P649, DOI 10.1016/0022-2836(74)90187-9; HARLOW E, 1988, ANTIBODIES LAB HDB; Herbig U, 1999, MOL BIOL CELL, V10, P2631, DOI 10.1091/mbc.10.8.2631; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KREK W, 1995, METHOD ENZYMOL, V254, P114; Krude T, 1996, J CELL SCI, V109, P309; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana David G., 1999, Frontiers in Bioscience, V4, pd805, DOI 10.2741/Quintana; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Richter A, 1997, EUR J BIOCHEM, V247, P136, DOI 10.1111/j.1432-1033.1997.00136.x; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; ROSE SM, 1984, J BIOL CHEM, V259, P8534; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Rowles A, 1999, J CELL SCI, V112, P2011; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Sun W, 2000, J CELL SCI, V113, P683; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; You ZY, 1999, MOL CELL BIOL, V19, P8003; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	54	89	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6337	6342		10.1074/jbc.M009473200	http://dx.doi.org/10.1074/jbc.M009473200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11102449	hybrid			2022-12-25	WOS:000167261000038
J	Nozaki, T; Shigeta, Y; Saito-Nakano, Y; Imada, M; Kruger, WD				Nozaki, T; Shigeta, Y; Saito-Nakano, Y; Imada, M; Kruger, WD			Characterization of transsulfuration and cysteine biosynthetic pathways in the protozoan hemoflagellate, Trypanosoma cruzi - Isolation and molecular characterization of cystathionine beta-synthase and serine acetyltransferase from Trypanosoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE ENTAMOEBA-HISTOLYTICA; SACCHAROMYCES-CEREVISIAE; TRYPANOTHIONE REDUCTASE; BACTERIAL EXPRESSION; FILAMENTOUS FUNGI; ESCHERICHIA-COLI; OXIDATIVE STRESS; BRUCEI-BRUCEI; HEME PROTEIN; GENE	Sulfur-containing amino acids play an important role in a variety of cellular functions such as protein synthesis, methylation, and polyamine and glutathione synthesis. We cloned and characterized cDNA encoding cystathionine beta -synthase (CBS), which is a key enzyme of transsulfuration pathway, from a hemoflagellate protozoan parasite Trypanosoma cruzi. T. cruzi CBS, unlike mammalian CBS, lacks the regulatory carboxyl terminus, does not contain heme, and is not activated by S-adenosylmethionine. T. cruzi CBS mRNA is expressed as at least six independent isotypes with sequence microheterogeneity from tandemly linked multicopy genes. The enzyme forms a homotetramer and, in addition to CBS activity, the enzyme has serine sulfhydrylase and cysteine synthase (CS) activities in vitro. Expression of the T. cruzi CBS in Saccharomyces cerevisiae and Escherichia coli demonstrates that the CBS and CS activities are functional in vivo. Enzymatic studies on T. cruzi extracts indicate that there is an additional CS enzyme and stage-specific control of CBS and CS expression. We also cloned and characterized cDNA encoding serine acetyltransferase (SAT), a key enzyme in the sulfate assimilatory cysteine biosynthetic pathway. Dissimilar to bacterial and plant SAT, a recombinant T. cruzi SAT showed allosteric inhibition by L-cysteine, L-cystine, and, to a lesser extent, glutathione. Together, these studies demonstrate the T. cruzi is a unique protist in possessing both transsulfuration and sulfur assimilatory pathways.	Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, Tokyo 1628640, Japan; Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA	National Institute of Infectious Diseases (NIID); Fox Chase Cancer Center	Nozaki, T (corresponding author), Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	nozaki@nih.go.jp	Kruger, Warren/Y-2541-2018; kruger, warren/A-6407-2008	kruger, warren/0000-0002-4990-3695				BAECKER PA, 1980, ANAL BIOCHEM, V102, P16, DOI 10.1016/0003-2697(80)90310-3; BENDER DA, 1985, AMINO ACID METABOLIS; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; BRAUNSTE.AE, 1971, BIOCHIM BIOPHYS ACTA, V242, P247, DOI 10.1016/0005-2744(71)90105-7; BRENER Z, 1982, B WORLD HEALTH ORGAN, V60, P463; CHUNG SH, 1990, NUCLEIC ACIDS RES, V18, P4561, DOI 10.1093/nar/18.15.4561; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; COOPER R, 1993, J CELL BIOL, V122, P149, DOI 10.1083/jcb.122.1.149; COOPER R, 1991, MOL BIOCHEM PARASIT, V49, P45, DOI 10.1016/0166-6851(91)90129-T; CRANE MSJ, 1982, EXP PARASITOL, V54, P87, DOI 10.1016/0014-4894(82)90114-X; DENK D, 1987, J GEN MICROBIOL, V133, P515; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; DUSZENKO M, 1985, J EXP MED, V162, P1256, DOI 10.1084/jem.162.4.1256; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; Goldberg B, 2000, ARCH BIOCHEM BIOPHYS, V377, P49, DOI 10.1006/abbi.2000.1740; GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P366; HARIHARAN S, 1993, MOL BIOCHEM PARASIT, V57, P15, DOI 10.1016/0166-6851(93)90240-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jhee KH, 2000, J BIOL CHEM, V275, P11541, DOI 10.1074/jbc.C000056200; KAHN S, 1990, J EXP MED, V172, P589, DOI 10.1084/jem.172.2.589; KASHIWAMATA S, 1970, BIOCHIM BIOPHYS ACTA, V212, P488, DOI 10.1016/0005-2744(70)90255-X; KERY V, 1995, ARCH BIOCHEM BIOPHYS, V316, P24, DOI 10.1006/abbi.1995.1005; Kredich N.M., 1987, ESCHERICHIA COLI SAL, P419; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; KRUGER WD, 1994, P NATL ACAD SCI USA, V91, P6614, DOI 10.1073/pnas.91.14.6614; LUMSDEN WHR, 1979, BIOL KENETOPLASTIDA; Marzluf GA, 1997, ANNU REV MICROBIOL, V51, P73, DOI 10.1146/annurev.micro.51.1.73; MARZLUF GA, 1993, ANNU REV MICROBIOL, V47, P31, DOI 10.1146/annurev.micro.47.1.31; MCCARTHYBURKE C, 1989, GENE, V82, P177, DOI 10.1016/0378-1119(89)90043-7; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; NICHOLSON ML, 1995, MOL GEN GENET, V247, P623, DOI 10.1007/BF00290354; Noji M, 1998, J BIOL CHEM, V273, P32739, DOI 10.1074/jbc.273.49.32739; Nozaki T, 1999, J BIOL CHEM, V274, P32445, DOI 10.1074/jbc.274.45.32445; NOZAKI T, 1991, J PROTOZOOL, V38, P234, DOI 10.1111/j.1550-7408.1991.tb04435.x; Nozaki T, 1999, MOL BIOCHEM PARASIT, V102, P283, DOI 10.1016/S0166-6851(99)00108-5; Nozaki T, 1998, MOL BIOCHEM PARASIT, V97, P33, DOI 10.1016/S0166-6851(98)00129-7; Nozaki T, 1998, BBA-PROTEIN STRUCT M, V1429, P284, DOI 10.1016/S0167-4838(98)00245-3; Nozaki T, 2000, MOL BIOCHEM PARASIT, V107, P129, DOI 10.1016/S0166-6851(00)00177-8; Ohmori S, 1999, BBA-GEN SUBJECTS, V1472, P587, DOI 10.1016/S0304-4165(99)00184-1; Ono B, 1999, YEAST, V15, P1365, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1365::AID-YEA468>3.0.CO;2-U; Ono B, 1996, YEAST, V12, P1153, DOI 10.1002/(SICI)1097-0061(19960915)12:11<1153::AID-YEA16>3.0.CO;2-2; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; SAITO K, 1992, P NATL ACAD SCI USA, V89, P8078, DOI 10.1073/pnas.89.17.8078; SAITO K, 1994, J BIOL CHEM, V269, P28187; SAITO K, 1993, FEBS LETT, V328, P111, DOI 10.1016/0014-5793(93)80976-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHOEMAKER JP, 1970, EXP PARASITOL, V27, P403, DOI 10.1016/0014-4894(70)90045-7; STURMAN JA, 1986, J NUTR, V116, P655, DOI 10.1093/jn/116.4.655; SWAROOP M, 1992, J BIOL CHEM, V267, P11455; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANVOORHIS WC, 1993, J EXP MED, V178, P681, DOI 10.1084/jem.178.2.681; World Health Organization, 1995, WORLD HLTH REP 1995; YAMAGATA S, 1981, J BACTERIOL, V147, P688, DOI 10.1128/JB.147.2.688-690.1981; YARLETT N, 1988, MOL BIOCHEM PARASIT, V27, P1, DOI 10.1016/0166-6851(88)90019-9	60	88	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6516	6523		10.1074/jbc.M009774200	http://dx.doi.org/10.1074/jbc.M009774200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11106665	hybrid			2022-12-25	WOS:000167261000060
J	Razani, B; Zhang, XL; Bitzer, M; von Gersdorff, G; Bottinger, EP; Lisanti, MP				Razani, B; Zhang, XL; Bitzer, M; von Gersdorff, G; Bottinger, EP; Lisanti, MP			Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RICH MEMBRANE DOMAINS; MAP KINASE CASCADE; SCAFFOLDING DOMAIN; TYROSINE KINASE; PLASMA-MEMBRANE; SMAD PROTEINS; OLIGOMERIC STRUCTURE; MUTATIONAL ANALYSIS; DOWN-REGULATION	Transforming growth factor-beta (TGF-beta) signaling proceeds from the cell membrane to the nucleus through the cooperation of the type I and II serine/threonine kinase receptors and their downstream SMAD effecters. Although various regulatory proteins affecting TGF-beta -mediated events have been described, relatively little is known about receptor interactions at the level of the plasma membrane. Caveolae are cholesterol-rich membrane microdomains that, along with their marker protein caveolin-1 (Cav-1), have been implicated in the compartmentalization and regulation of certain signaling events. Here, we demonstrate that specific components of the TGF-beta cascade are associated with caveolin-1 in caveolae and that Cav-1 interacts with the Type I TGF-beta receptor. Additionally, Cav-1 is able to suppress TGF-beta -mediated phosphorylation of Smad-2 and subsequent downstream events. We localize the Type I TGF-beta receptor interaction to the scaffolding domain of Cav-1 and show that it occurs in a physiologically relevant time frame, acting to rapidly dampen signaling initiated by the TGF-beta receptor complex.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1800 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Bitzer, Markus/0000-0002-3711-2984; Razani, Babak/0000-0002-7172-9240	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Bitzer M, 2000, GENE DEV, V14, P187; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Koskinen PJ, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000292; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lisanti MP, 1999, METH MOL B, V116, P51; Liu J, 1999, J BIOL CHEM, V274, P15781, DOI 10.1074/jbc.274.22.15781; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Razani B, 2000, J CELL SCI, V113, P2103; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1997, CELL MOL BIOL, V43, P293; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Weisberg E, 1998, MECH DEVELOP, V79, P17, DOI 10.1016/S0925-4773(98)00160-9; Wells RG, 1999, J BIOL CHEM, V274, P5716, DOI 10.1074/jbc.274.9.5716; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yu Q, 2000, GENE DEV, V14, P163; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	85	277	285	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6727	6738		10.1074/jbc.M008340200	http://dx.doi.org/10.1074/jbc.M008340200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11102446	hybrid			2022-12-25	WOS:000167261000085
J	Federici, M; Hribal, ML; Ranalli, M; Marselli, L; Porzio, O; Lauro, D; Borboni, P; Lauro, R; Marchetti, P; Melino, G; Sesti, G				Federici, M; Hribal, ML; Ranalli, M; Marselli, L; Porzio, O; Lauro, D; Borboni, P; Lauro, R; Marchetti, P; Melino, G; Sesti, G			The common Arg(972) polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets	FASEB JOURNAL			English	Article									Univ Roma Tor Vergata, Dept Internal Med, Mol Med Lab, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med, Biochem Lab, IDI,IRCCS, Rome, Italy; Univ Pisa, Dept Endocrinol & Metab, I-56100 Pisa, Italy	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Pisa	Sesti, G (corresponding author), Univ Roma Tor Vergata, Dept Internal Med, Mol Med Lab, Via Tor Vergata 135, I-00133 Rome, Italy.		Sesti, Giorgio/B-1509-2012; Marchetti, Piero/J-7439-2013; Federici, Massimo/G-9940-2012; Lauro, Davide/K-4683-2018	Marchetti, Piero/0000-0003-4907-0635; Federici, Massimo/0000-0003-4989-5194; PORZIO, OTTAVIA/0000-0001-5931-8679; Lauro, Davide/0000-0002-8597-4415; Sesti, Giorgio/0000-0002-1618-7688; Marselli, Lorella/0000-0002-6698-2962	Telethon [E.0695] Funding Source: Medline	Telethon(Fondazione Telethon)			0	81	81	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					22	24						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099486				2022-12-25	WOS:000166312400008
J	Siegert, JL; Rushton, JJ; Sellers, WR; Kaelin, WG; Robbins, PD				Siegert, JL; Rushton, JJ; Sellers, WR; Kaelin, WG; Robbins, PD			Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAF(II)250 kinase activity	ONCOGENE			English	Article						cyclin D1; Rb; TAF(II)250; kinase	RNA-POLYMERASE-II; SUSCEPTIBILITY GENE-PRODUCT; CELL-CYCLE; HISTONE DEACETYLASE; SP1-MEDIATED TRANSCRIPTION; REPRESSES TRANSCRIPTION; DIFFERENTIAL REGULATION; ESTROGEN-RECEPTOR; INITIATION-FACTOR; RB INTERACTS	The retinoblastoma tumor suppressor protein has been shown to bind directly and inhibit a transcriptionally-important amino-terminal kinase domain of TATA-binding protein-associated factor TAF(II)250. Cyclin D1 also is able to associate! with the amino terminus of TAF(II)250 in a region, cry similar to or overlapping the Rb-binding site. In this study, we ha,le examined whether cyclin D1 affects the functional interaction between Rb and TAF(II)250. We observed that when cyclin D1 is coincubated with Rb and TAF(II)250, the ability of Rb to inhibit TAF(II)250 kinase activity is effectively blocked, However, cyclin D1 by itself has no apparent effect on TAF(II)250 kinase activity. We further found that the Rb-related protein p107 can inhibit TAF(II)250 kinase activity, and this inhibition is likewise alleviated by cyclin D1, Cyclin D1 prevents the kinase-inhibitory effect of an Rb mutant unable to bind to D-type cyclins, indicating that it is acting through its association with TAF(II)250 and not with Rb, However, we found no evidence of TAF(II)250-binding competition between Rb and cyclin D1 in vitro. The adenovirus ELA protein, which also binds to both Rb and TAF(II)250, exhibited a suppressive effect on Rb-mediated kinase inhibition similar to that seen with cyclin D1, Our results suggest a novel means by which cyclin D1 may be able to independently regulate the activity of Rb.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Robbins, PD (corresponding author), Univ New Mexico, Dept Mol Genet & Microbiol, Canc Res Ctr 125, Sch Med, Albuquerque, NM 87131 USA.				PHS HHS [55227] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adnane J, 1999, ONCOGENE, V18, P239, DOI 10.1038/sj.onc.1202297; ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYASHIDA T, 1994, GENE, V141, P267; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; Lei L, 1998, MOL CELL BIOL, V18, P2130, DOI 10.1128/MCB.18.4.2130; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Rushton JJ, 1997, CELL GROWTH DIFFER, V8, P1099; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; Sekiguchi T, 1999, ONCOGENE, V18, P1797, DOI 10.1038/sj.onc.1202508; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SHAO ZH, 1995, ONCOGENE, V10, P221; Siegert JL, 1999, MOL CELL BIOL, V19, P846; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	51	17	17	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5703	5711		10.1038/sj.onc.1203966	http://dx.doi.org/10.1038/sj.onc.1203966			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126356				2022-12-25	WOS:000165477700001
J	Knight, EL; Warner, AJ; Maxwell, A; Prigent, SA				Knight, EL; Warner, AJ; Maxwell, A; Prigent, SA			Chimeric VEGFRs are activated by a small-molecule dimerizer and mediate downstream signalling cascades in endothelial cells	ONCOGENE			English	Article						VEGF; receptor; angiogenesis; signalling	RECEPTOR TYROSINE KINASE; GROWTH-FACTOR VEGF; PHOSPHATIDYLINOSITOL 3-KINASE; VASCULAR ENDOTHELIUM; FUNCTIONAL-ANALYSIS; BINDING-SITES; PLC-GAMMA; FLT-1; KDR; TRANSDUCTION	Despite much interest in vascular endothelial growth factor (VEGF) and its receptors (VEGFRs -1 and -2), VEGF-induced signalling cascades remain incompletely defined. Attempts to assign individual responses to a particular receptor have used either transfected cell lines, receptor-specific growth factors or antisense oligonucleotides. Such studies have attributed the majority of VEGF-induced responses to activation of VEGFR-2. As a consequence of poor growth factor-induced VEGFR-1 autophosphorylation however, observations from these studies may instead reflect the relative activation of the two receptors. We have generated novel chimeric VEGF receptors in which the dimerization domain of the B subunit of DNA gyrase is fused to the cytoplasmic domain of VEGFRs -1 and -2. When expressed in porcine aortic endothelial cells, both chimeric VEGFR-1 and -2 autophosphorylate in response to addition of the small-molecule dimerizing agent, coumermycin. Once activated, both receptors induce downstream signalling cascades, exemplified here by the activation of MAPK, PLC gamma and PKB/Akt. Furthermore, we demonstrate that the Y1175 residue of VEGFR-2 is essential for the activation of PLC gamma mediated by this chimeric receptor. In contrast to previous reports which show a limited ability of VEGFR-1 to mediate signalling cascades, we show that once sufficiently activated, VEGFR-1 signals in a similar manner to VEGFR-2 in endothelial cells.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Prigent, SA (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Maxwell, Anthony/0000-0002-5756-6430				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Esser S, 1998, J CELL SCI, V111, P1853; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Huang LW, 1999, J BIOL CHEM, V274, P38183, DOI 10.1074/jbc.274.53.38183; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V251, P77, DOI 10.1006/bbrc.1998.9442; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kume A, 1999, BIOCHEM BIOPH RES CO, V260, P9, DOI 10.1006/bbrc.1999.0859; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Warner AJ, 2000, BIOCHEM J, V347, P501, DOI 10.1042/0264-6021:3470501; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yang JX, 1998, CURR BIOL, V8, P11, DOI 10.1016/S0960-9822(98)70015-6; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	45	17	18	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5398	5405		10.1038/sj.onc.1203915	http://dx.doi.org/10.1038/sj.onc.1203915			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103941				2022-12-25	WOS:000165302300011
J	Fernandez, J; Yaman, I; Mishra, R; Merrick, WC; Snider, MD; Lamers, WH; Hatzoglou, M				Fernandez, J; Yaman, I; Mishra, R; Merrick, WC; Snider, MD; Lamers, WH; Hatzoglou, M			Internal ribosome entry site-mediated translation of a mammalian mRNA is regulated by amino acid availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE TRANSPORTER CAT-1; CULTURED ANIMAL-CELLS; MOLECULAR-BIOLOGY; NONCODING REGION; GENE-EXPRESSION; C-MYC; INITIATION; BINDING; IDENTIFICATION; SEGMENT	The cationic amino acid transporter, Cat-1, facilitates the uptake of the essential amino acids arginine and lysine, Amino acid starvation causes accumulation and increased translation of cat-1 mRNA, resulting in a 58-fold increase in protein levels and increased arginine uptake. A bicistronic mRNA expression system was used to demonstrate the presence of an internal ribosomal entry sequence (IRES) within the 5'-untranslated region of the cat-1 mRNA. This study shows that IRES-mediated translation of the cat-1 mRNA is regulated by amino acid availability. This IRES causes an increase in translation under conditions of amino acid starvation. In contrast, cap-dependent protein synthesis is inhibited during amino acid starvation, which is well correlated with decreased phosphorylation of the cap-binding protein, eIF4E. These findings reveal a new aspect of mammalian gene expression and regulation that provides a cellular stress response; when the nutrient supply is limited, the activation of IRES mediated translation of mammalian mRNAs results in the synthesis of proteins essential for cell survival.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	Case Western Reserve University; Case Western Reserve University; University of Amsterdam; Academic Medical Center Amsterdam	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	mxh8@po.cwru.edu	yaman, ibrahim/A-7192-2016; Lamers, Wouter H./D-2965-2012	yaman, ibrahim/0000-0002-3987-1984; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007319, R01DK053307] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32 DK07319, R01 DK53307-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115; Carter MS, 2000, COLD SPRING HARBOR M, V39, P615; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Deffaud C, 2000, J VIROL, V74, P846, DOI 10.1128/JVI.74.2.846-850.2000; Doering CB, 2000, AM J PHYSIOL-CELL PH, V279, pC1587, DOI 10.1152/ajpcell.2000.279.5.C1587; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Geballe AP, 2000, COLD SPRING HARBOR M, V39, P595; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hattori Y, 1999, AM J PHYSIOL-HEART C, V276, pH2020, DOI 10.1152/ajpheart.1999.276.6.H2020; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; Jackson RJ, 1995, RNA, V1, P985; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; Liu J, 1998, AMINO ACIDS, V15, P321, DOI 10.1007/BF01320897; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Pilipenko EV, 2000, GENE DEV, V14, P2028; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Sella O, 1999, MOL CELL BIOL, V19, P5429; SHENG SJ, 1992, PROTEIN EXPRES PURIF, V3, P337, DOI 10.1016/1046-5928(92)90010-T; SHNEIER R, 2000, TRANSLATIONAL CONTRO, P901; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; Zhang Y, 1997, Methods Mol Biol, V69, P61	42	130	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12285	12291		10.1074/jbc.M009714200	http://dx.doi.org/10.1074/jbc.M009714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11114306	hybrid			2022-12-25	WOS:000168081800113
J	Lundell, K; Hansson, R; Wikvall, K				Lundell, K; Hansson, R; Wikvall, K			Cloning and expression of a pig liver taurochenodeoxycholic acid 6 alpha-hydroxylase (CYP4A21) - A novel member of the CYP4A subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-HYDROXYLASE; LAURIC ACID; CDNA CLONING; MESSENGER-RNA; BILE-ACIDS; MICROSOMES; (OMEGA-1)-HYDROXYLATION; IDENTIFICATION; RABBIT; RAT	A cytochrome P450 expressed in pig liver was cloned by polymerase chain reaction using oligonucleotide primers based on amino acid sequences of the purified taurochenodeoxycholic acid 6 alpha -hydroxylase. This enzyme catalyzes a 6 alpha -hydroxylation of chenodeoxycholic acid, and the product hyocholic acid is considered to be a primary bile acid specific for the pig. The cDNA encodes a protein of 504 amino acids. The primary structure of the porcine taurochenodeoxycholic acid 6 alpha -hydroxylase, designated CYP4A21, shows about 75% identity with known members of the CYP4A subfamily in rabbit and man. Transfection of the cDNA for CYP4A21 into COS cells resulted in the synthesis of an enzyme that was recognized by antibodies raised against the purified pig liver enzyme and catalyzed 6 alpha -hydroxylation of taurochenodeoxycholic acid. The hitherto known CYP4A enzymes catalyze hydroxylation of fatty acids and prostaglandins and have frequently been referred to as fatty acid hydroxylases. A change in substrate specificity from fatty acids or prostaglandins to a steroid nucleus among CYP4A enzymes is notable. The results of mutagenesis experiments indicate that three amino acid substitutions in a region around position 315 which is highly conserved in all previously known CYP4A and CYP4B enzymes could be involved in the altered catalytic activity of CYP4A21.	Uppsala Univ, Dept Pharmaceut Biosci, Div Biochem, S-75123 Uppsala, Sweden	Uppsala University	Lundell, K (corresponding author), Uppsala Univ, Dept Pharmaceut Biosci, Div Biochem, Box 578, S-75123 Uppsala, Sweden.	Kerstin.Lundell@farmbio.uu.se						ALTERMAN MA, 1995, BIOCHEM BIOPH RES CO, V214, P1089, DOI 10.1006/bbrc.1995.2397; ALTERMAN MA, 1995, ARCH BIOCHEM BIOPHYS, V320, P289, DOI 10.1016/0003-9861(95)90012-8; AMET Y, 1994, BIOCHEM BIOPH RES CO, V203, P1168, DOI 10.1006/bbrc.1994.2305; Amet Y, 1995, BIOCHEM PHARMACOL, V50, P1775, DOI 10.1016/0006-2952(95)02040-3; Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; ARAYA Z, 1995, EUR J BIOCHEM, V231, P855, DOI 10.1111/j.1432-1033.1995.tb20771.x; BOSTROM H, 1986, J LIPID RES, V27, P807; Chang YT, 1999, PROTEINS, V34, P403, DOI 10.1002/(SICI)1097-0134(19990215)34:3<403::AID-PROT12>3.0.CO;2-D; Courillon F, 1998, BIOL NEONATE, V73, P76, DOI 10.1159/000013963; Dierks EA, 1998, J BIOL CHEM, V273, P23055, DOI 10.1074/jbc.273.36.23055; Dierks EA, 1998, BIOCHEMISTRY-US, V37, P1839, DOI 10.1021/bi972458s; ESSER V, 1988, J BIOL CHEM, V263, P13282; Fausto N., 1994, LIVER BIOL PATHOBIOL; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GASSER R, 1989, MOL PHARMACOL, V35, P617; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HASLEWOOD GA, 1967, J LIPID RES, V8, P535; Hoch U, 2000, ARCH BIOCHEM BIOPHYS, V373, P63, DOI 10.1006/abbi.1999.1504; Hoch U, 2000, J BIOL CHEM, V275, P26952; Ishida H, 1999, J BIOCHEM-TOKYO, V126, P19, DOI 10.1093/oxfordjournals.jbchem.a022422; JOHNSON EF, 1990, BIOCHEMISTRY-US, V29, P873, DOI 10.1021/bi00456a004; KAWASHIMA H, 1994, J BIOCHEM, V116, P74, DOI 10.1093/oxfordjournals.jbchem.a124506; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS DFV, 1995, XENOBIOTICA, V25, P333, DOI 10.3109/00498259509061857; MATSUBARA S, 1987, J BIOL CHEM, V262, P13366; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; NORMAN A, 1955, ARK KEMI, V8, P331; OKITA RT, 1991, METHOD ENZYMOL, V206, P432; PALMER CNA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P161, DOI 10.1016/0167-4781(93)90285-L; Powell PK, 1996, ARCH BIOCHEM BIOPHYS, V335, P219, DOI 10.1006/abbi.1996.0501; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P43; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; SUMMERFIELD JA, 1976, BIOCHEM J, V154, P507, DOI 10.1042/bj1540507; Waterman M.R, 1991, METHOD ENZYMOL, V206, P100, DOI 10.1016/0076-6879(91)06081-d; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; Wietholtz H, 1996, J HEPATOL, V24, P713, DOI 10.1016/S0168-8278(96)80268-6; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; YOKOTANI N, 1989, J BIOL CHEM, V264, P21665	41	20	23	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9606	9612		10.1074/jbc.M006584200	http://dx.doi.org/10.1074/jbc.M006584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11113117	hybrid			2022-12-25	WOS:000167996400005
J	Chen, CH; Pore, N; Behrooz, A; Ismail-Beigi, F; Maity, A				Chen, CH; Pore, N; Behrooz, A; Ismail-Beigi, F; Maity, A			Regulation of glut1 mRNA by hypoxia-inducible factor-1 - Interaction between H-ras and hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GENE; ENDOTHELIAL GROWTH-FACTOR; FACTOR 1-ALPHA; TUMOR ANGIOGENESIS; HUMAN CANCER; EXPRESSION; ONCOGENES; CELLS; TRANSCRIPTION; PATHWAY	Oncogenic transformation and hypoxia both induce glut1 mRNA, We studied the interaction between the ras oncogene and hypoxia in up-regulating glut1 mRNA levels using Rat1 fibroblasts transformed with H-ras (Rat1-ras), Transformation with H-ras led to a substantial increase in glut1 mRNA levels under normoxic conditions and additively increased glut1 mRNA levels in concert with hypoxia. Using a luciferase reporter construct containing 6 kilobase pairs of the glut1 promoter, we showed that this effect was mediated at the transcriptional level. Promoter activity was much higher in Rat1-ras cells than in Rat1 cells and could be down-regulated by cotransfection with a dominant negative Ras construct (RasN17). A 480-base pair (bp) cobalt/hypoxia-responsive fragment of the promoter containing a HIF-1 binding site showed significantly higher activity in Rat1-ras cells than in Rat1 cells, suggesting that Ras might mediate its effect through HIF-1 even under normoxic conditions. Consistent with this, Rat1-ras cells displayed higher levels of HIF1-alpha protein under normoxic conditions. In addition, a promoter construct containing a 4-bp mutation in the HIF1 binding site showed lower activity in Rat1 ras cells than a construct with an intact HIF1 binding site. The activity of the latter construct but not the former could be down-regulated by RasN17, supporting the importance of the HIF1 binding site in regulation by Ras, The phosphatidylinositol 3-kinase inhibitor LY29004 down-regulated glut1 promoter activity and mRNA levels under normoxia and also decreased HIF1 alpha protein levels in these cells. Collectively these results indicate that H-Ras up-regulates the glut1 promoter, at least in part, by increasing HIF-1 alpha protein levels leading to transactivation of promoter through the HIF-1 binding site.	Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Case Western Reserve Univ, Sch Med, Dept Med & Mol Biol & Microbiol, Cleveland, OH 44106 USA	University of Pennsylvania; Case Western Reserve University	Maity, A (corresponding author), Univ Penn, Sch Med, Dept Radiat Oncol, Rm 195,John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.			Maity, Amit/0000-0001-7151-2845	NIDDK NIH HHS [DK 49450] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049450] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Behrooz A, 1997, J BIOL CHEM, V272, P5555, DOI 10.1074/jbc.272.9.5555; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BOS JL, 1989, CANCER RES, V49, P4682; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Feldser D, 1999, CANCER RES, V59, P3915; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HIRAKI Y, 1989, MOL ENDOCRINOL, V3, P1470, DOI 10.1210/mend-3-9-1470; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; HOLM E, 1995, CANCER RES, V55, P1373; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kozlovsky N, 1997, J BIOL CHEM, V272, P33367, DOI 10.1074/jbc.272.52.33367; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; Mazure NM, 1996, CANCER RES, V56, P3436; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; MERRALL NW, 1993, CELL SIGNAL, V5, P667, DOI 10.1016/0898-6568(93)90028-K; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; Ouiddir A, 1999, AM J RESP CELL MOL, V21, P710, DOI 10.1165/ajrcmb.21.6.3751; RACKER E, 1985, P NATL ACAD SCI USA, V82, P3535, DOI 10.1073/pnas.82.11.3535; RAK J, 1995, CANCER RES, V55, P4575; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WARBURG O, 1930, METABOLISM TUMORS; YAMAMOTO T, 1990, BIOCHEM BIOPH RES CO, V170, P223, DOI 10.1016/0006-291X(90)91263-R; Younes M, 1996, CANCER RES, V56, P1164; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9; Zundel W, 2000, GENE DEV, V14, P391	37	544	573	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9519	9525		10.1074/jbc.M010144200	http://dx.doi.org/10.1074/jbc.M010144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11120745	hybrid			2022-12-25	WOS:000167607700118
J	Lundberg, R; Mavinakere, M; Campbell, C				Lundberg, R; Mavinakere, M; Campbell, C			Deficient DNA end joining activity in extracts from Fanconi anemia fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; GENE; PROTEIN; CELLS; BINDING; REPAIR; FIDELITY; CLONING	Fanconi anemia (FA) is a genetic disorder associated with genomic instability and cancer predisposition. Cultured cells from FA patients display a high level of spontaneous chromosome breaks and an increased frequency of intragenic deletions, suggesting that FA cells may have deficiencies in properly processing DNA double strand breaks. In this study, an in vitro plasmid DNA end joining assay was used to characterize the end joining capabilities of nuclear extracts from diploid FA fibroblasts from complementation groups A, C, and D, The Fanconi anemia extracts had 3-9-fold less DNA end joining activity and rejoined substrates with significantly less fidelity than normal extracts. Wild-type end joining activity could be reconstituted by mixing FA-D extracts with FA-A or FA-C extracts, while mixing FA-A and FA-C extracts had no effect on end joining activity. Protein expression levels of the DNA-dependent protein kinase (DNA-PK)/Ku-dependent nonhomologous DNA end-joining proteins Xrcc4, DNA ligase IV, Ku70, and Ku86 in FA and normal extracts were indistinguishable, as were DNA-dependent protein kinase and DNA end binding activities. The end joining activity as measured by the assay was not sensitive to the DNA-PK inhibitor wortmannin or dependent on the nonhomologous DNA end-joining factor Xrcc4, However, when DNA/protein ratios were lowered, the end joining activity became wortmannin-sensitive and no difference in end joining activity was observed between normal and FA extracts. Taken together, these results suggest that the FA fibroblast extracts have a deficiency in a DNA end joining process that is distinct from the DNA-PK/Ku-dependent nonhomologous DNA end joining pathway.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Campbell, C (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	campb034@maroon.tc.umn.edu			NCI NIH HHS [CA61906] Funding Source: Medline; NIA NIH HHS [AG16678] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA061906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016678] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUERBACH AD, 1991, CANCER GENET CYTOGEN, V51, P1, DOI 10.1016/0165-4608(91)90002-C; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDBERG A, 1995, CARCINOGENESIS, V16, P555, DOI 10.1093/carcin/16.3.555; Cheong N, 1999, INT J RADIAT BIOL, V75, P67, DOI 10.1080/095530099140825; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Coffey G, 1999, NUCLEIC ACIDS RES, V27, P3348, DOI 10.1093/nar/27.16.3348; DAndrea AD, 1997, BLOOD, V90, P1725, DOI 10.1182/blood.V90.5.1725; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; DUCKWORTHRYSIECKI G, 1985, CANCER RES, V45, P416; Escarceller M, 1997, SOMAT CELL MOLEC GEN, V23, P401, DOI 10.1007/BF02673750; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; Johnson AP, 1996, MUTAT RES-DNA REPAIR, V364, P103, DOI 10.1016/0921-8777(96)00028-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liang F, 1996, J BIOL CHEM, V271, P14405, DOI 10.1074/jbc.271.24.14405; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; NORTH P, 1990, NUCLEIC ACIDS RES, V18, P6205, DOI 10.1093/nar/18.21.6205; PAPADOPOULO D, 1990, P NATL ACAD SCI USA, V87, P8383, DOI 10.1073/pnas.87.21.8383; POWIS G, 1994, CANCER RES, V54, P2419; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Thyagarajan B, 1997, J BIOL CHEM, V272, P23328, DOI 10.1074/jbc.272.37.23328; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; ZDZIENICKA MZ, 1995, MUTAT RES-DNA REPAIR, V336, P203, DOI 10.1016/0921-8777(95)00003-3	36	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9543	9549		10.1074/jbc.M008634200	http://dx.doi.org/10.1074/jbc.M008634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124945	hybrid			2022-12-25	WOS:000167607700122
J	Triepels, RH; Hanson, BJ; van den Heuvel, LP; Sundell, L; Marusich, MF; Smeitink, JA; Capaldi, RA				Triepels, RH; Hanson, BJ; van den Heuvel, LP; Sundell, L; Marusich, MF; Smeitink, JA; Capaldi, RA			Human complex I defects can be resolved by monoclonal antibody analysis into distinct subunit assembly patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; NUCLEAR GENES; MUTATION; DEFICIENCY; PATIENT; ENZYME; MTDNA; CHAIN	Complex I defects are one of the most frequent causes of mitochondrial respiratory chain disorders. Therefore, it is important to find new approaches for detecting and characterizing Complex I deficiencies. In this paper, we introduce a new set of monoclonal antibodies that react with 39-, 30-, 20-, 18-,15-, and 8-kDa subunits of Complex I. These antibodies are shown to aid in diagnosis of Complex I deficiencies and add understanding to the genotype-phenotype relationships of different mutations, A total of II different patients were examined. Four patients had undefined Complex I defects, whereas the other patients had defects in NDUFV1, NDUFS2 (two patients), NDUFS4 (two patients), NDUFS7 and NDUFS8. We show here that Western blotting with these antibodies, particularly when used in conjunction with sucrose gradient studies and enzymatic activity measurements, helps distinguish catalytic versus assembly defects and further distinguishes between mutations in different subunits. Furthermore, different mutations in the same gene are shown to give very similar subunit profiles, and we show that one of the patients is a good candidate for having a defect in a Complex I assembly factor.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA; Univ Nijmegen St Radboud Hosp, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands	University of Oregon; University of Oregon; Radboud University Nijmegen	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	rcapaldi@oregon.uoregon.edu	Marusich, Michael/AAQ-3447-2020; Smeitink, Jan/C-1351-2013; van den Heuvel, L.P.W.J./H-8044-2014; van den Heuvel, Lambertus/AAM-1772-2021	van den Heuvel, L.P.W.J./0000-0003-3917-6727; van den Heuvel, Lambertus/0000-0003-3917-6727	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24526] Funding Source: Medline; NIGMS NIH HHS [GM07759] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; BOUGERON T, 1995, NAT GENET, V11, P144; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; FISCHER JC, 1986, CLIN CHIM ACTA, V155, P263, DOI 10.1016/0009-8981(86)90246-9; Galante Y M, 1978, Methods Enzymol, V53, P15; GALANTE YM, 1979, ARCH BIOCHEM BIOPHYS, V192, P559, DOI 10.1016/0003-9861(79)90126-7; Garcia JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; Harlow E., 1988, ANTIBODIES LAB MANUA; Hatefi Y, 1978, Methods Enzymol, V53, P11; LI YY, 1995, BIOCHEM BIOPH RES CO, V210, P211, DOI 10.1006/bbrc.1995.1648; Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154; Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G; MARUSICH MF, 1988, J IMMUNOL METHODS, V114, P155, DOI 10.1016/0022-1759(88)90167-6; Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6; Papadopoulou LC, 1999, NAT GENET, V23, P333; Poyau A, 2000, HUM GENET, V106, P194, DOI 10.1007/s004390051028; Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432; Smeitink JAM, 1998, HUM MOL GENET, V7, P1573, DOI 10.1093/hmg/7.10.1573; Teraoka M, 1999, HUM GENET, V105, P560, DOI 10.1007/s004390051145; Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150; Triepels R, 2000, HUM GENET, V106, P385, DOI 10.1007/s004390000278; Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6; van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716; von Kleist-Retzow JC, 1999, BBA-MOL BASIS DIS, V1455, P35, DOI 10.1016/S0925-4439(99)00050-2; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X	29	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8892	8897		10.1074/jbc.M009903200	http://dx.doi.org/10.1074/jbc.M009903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11112787	hybrid, Green Published			2022-12-25	WOS:000167607700039
J	Donnet, C; Arystarkhova, E; Sweadner, KJ				Donnet, C; Arystarkhova, E; Sweadner, KJ			Thermal denaturation of the Na,K-ATPase provides evidence for alpha-alpha oligomeric interaction and gamma subunit association with the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; TRANSFORM INFRARED-SPECTROSCOPY; MEMBRANE H+-ATPASE; P-TYPE ATPASES; NA+/K+-ATPASE; SARCOPLASMIC-RETICULUM; NA/K-ATPASE; RENAL NA,K-ATPASE; CROSS-LINKING; TRYPSINIZED NA,K-ATPASE	Thermal denaturation can help elucidate protein domain substructure. We previously showed that the Na,K-ATPase partially unfolded when heated to 55 degreesC (Arystarkhova, E,, Gibbons, D. L,, and Sweadner, K, J. (1995) J, Biol, Chem, 270, 8785-8796). The beta subunit unfolded without leaving the membrane, but three transmembrane spans (M8-M10) and the C terminus of the alpha subunit were extruded, while the rest of alpha retained its normal topology with respect to the lipid bilayer, Here we investigated thermal denaturation further, with several salient results. First, trypsin sensitivity at both surfaces of alpha was increased, but not sensitivity to V8 protease, suggesting that the cytoplasmic domains and extruded domain were less tightly packed but still retained secondary structure. Second, thermal denaturation was accompanied by SDS-resistant aggregation of a subunits as dimers, trimers, and tetramers without beta or gamma subunits, This implies specific alpha-alpha contact. Third, the gamma subunit, like the C-terminal spans of alpha, was selectively lost from the membrane. This suggests its association with M8-M10 rather than the more firmly anchored transmembrane spans. The picture that emerges is of a Na,K-ATPase complex of alpha, beta, and gamma subunits in which a can associate in assemblies as large as tetramers via its cytoplasmic domain, while beta and gamma subunits associate with alpha primarily in its C-terminal portion, which has a unique structure and thermal instability.	Massachusetts Gen Hosp, Ctr Neurosci, Lab Membrane Biol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Sweadner, KJ (corresponding author), Massachusetts Gen Hosp, Ctr Neurosci, Lab Membrane Biol, Charlestown, MA 02129 USA.	sweadner@helix.mgh.harvard.edu			NHLBI NIH HHS [R01 HL36271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMLER E, 1992, BIOPHYS J, V61, P553, DOI 10.1016/S0006-3495(92)81859-3; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; Arystarkhova E, 1996, J BIOL CHEM, V271, P23407, DOI 10.1074/jbc.271.38.23407; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2000, INT CONGR SER, V1207, P489; ASKARI A, 1980, BIOCHEM BIOPH RES CO, V93, P448, DOI 10.1016/0006-291X(80)91098-0; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CHOW DC, 1995, J EXP BIOL, V198, P1; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLINS JH, 1982, BIOCHIM BIOPHYS ACTA, V686, P7, DOI 10.1016/0005-2736(82)90145-6; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; Froehlich JP, 1997, ANN NY ACAD SCI, V834, P280, DOI 10.1111/j.1749-6632.1997.tb52259.x; GANJEIZADEH M, 1995, J BIOL CHEM, V270, P15707, DOI 10.1074/jbc.270.26.15707; Gasset M, 1997, J BIOL CHEM, V272, P1608, DOI 10.1074/jbc.272.3.1608; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; Haltia Tuomas, 1995, Biochimica et Biophysica Acta, V1241, P295, DOI 10.1016/0304-4157(94)00161-6; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; HEBERT H, 1990, FEBS LETT, V268, P83, DOI 10.1016/0014-5793(90)80978-R; Heimburg T, 1997, J BIOL CHEM, V272, P25685, DOI 10.1074/jbc.272.41.25685; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; Ivanov A, 2000, BIOCHEMISTRY-US, V39, P9778, DOI 10.1021/bi001004j; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; Linnertz H, 1998, J BIOL CHEM, V273, P28813, DOI 10.1074/jbc.273.44.28813; Liu LQ, 1997, J BIOL CHEM, V272, P14380, DOI 10.1074/jbc.272.22.14380; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MAHANEY JE, 1992, BIOCHEMISTRY-US, V31, P2025, DOI 10.1021/bi00122a019; Martin DW, 2000, P NATL ACAD SCI USA, V97, P3195, DOI 10.1073/pnas.050558397; MIMURA K, 1993, BIOCHIM BIOPHYS ACTA, V1145, P63, DOI 10.1016/0005-2736(93)90382-A; MOHRAZ M, 1987, J CELL BIOL, V105, P1, DOI 10.1083/jcb.105.1.1; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; Or E, 1999, J BIOL CHEM, V274, P2802, DOI 10.1074/jbc.274.5.2802; Or E, 1998, BIOCHEMISTRY-US, V37, P8197, DOI 10.1021/bi9730442; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; RABON EC, 1993, J BIOL CHEM, V268, P8012; Sagne C, 1996, BIOCHEM J, V316, P825, DOI 10.1042/bj3160825; Sarvazyan NA, 1997, J BIOL CHEM, V272, P7855, DOI 10.1074/jbc.272.12.7855; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Shainskaya A, 1998, J BIOL CHEM, V273, P7311, DOI 10.1074/jbc.273.13.7311; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; SWEADNER KJ, 1991, ANAL BIOCHEM, V194, P130, DOI 10.1016/0003-2697(91)90159-Q; SWEADNER KJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P13, DOI 10.1016/0005-2736(90)90431-M; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Weber K, 1972, Methods Enzymol, V26, P3; Yokoyama T, 1999, J BIOL CHEM, V274, P31792, DOI 10.1074/jbc.274.45.31792; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	65	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7357	7365		10.1074/jbc.M009131200	http://dx.doi.org/10.1074/jbc.M009131200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11099502	hybrid			2022-12-25	WOS:000167442900069
J	Wiradjaja, F; Ooms, LM; Whisstock, JC; McColl, B; Helfenbaum, L; Sambrook, JF; Gething, MJ; Mitchell, CA				Wiradjaja, F; Ooms, LM; Whisstock, JC; McColl, B; Helfenbaum, L; Sambrook, JF; Gething, MJ; Mitchell, CA			The yeast inositol polyphosphate 5-phosphatase Inp54p localizes to the endoplasmic reticulum via a C-terminal hydrophobic anchoring tail - Regulation of secretion from the endoplasmic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; CYTOCHROME B(5); MEMBRANE-PROTEIN; PLASMA-MEMBRANE; TRANSMEMBRANE DOMAIN; TARGETING SIGNAL; GOLGI-APPARATUS; FAMILY MEMBERS	budding yeast Saccharomyces cerevisiae has four inositol polyphosphate B-phosphatase (5-phosphatase) genes, INP51, INP52, INP53, and INP54, all of which hydrolyze phosphatidylinositol (4,5)-bisphosphate. INP54 encodes a protein of 44 kDa which consists of a 5-phosphatase domain and a C-terminal leucine-rich tail, but lacks the N-terminal SacI domain and proline-rich region found in the other three yeast 5-phosphatases. We report that Inp54p belongs to the family of tail-anchored proteins and is localized to the endoplasmic reticulum via a C-terminal hydrophobic tail. The hydrophobic tail comprises the last 13 amino acids of the protein and is sufficient to target green fluorescent protein to the endoplasmic reticulum. Protease protection assays demonstrated that the N terminus of Inp54p is oriented toward the cytoplasm of the cell, with the C terminus of the protein also exposed to the cytosol. Null mutation of INP54 resulted in a 2-fold increase in secretion of a reporter protein, compared with wild-type yeast or cells deleted for any of the SacI domain-containing Ei-phosphatases. We propose that Inp54p plays a role in regulating secretion, possibly by modulating the levels of phosphatidylinositol (4,5)-bisphosphate on the cytoplasmic surface of the endoplasmic reticulum membrane.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia	Monash University; Peter Maccallum Cancer Center; University of Melbourne	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3800, Australia.	Christina.Mitchell@med.monash.edu.au	Ooms, Lisa/AGZ-7420-2022	Whisstock, James/0000-0003-4200-5611; Mitchell, Christina A/0000-0001-9372-3192; Ooms, Lisa Michelle/0000-0002-8918-9932				Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bascom RA, 1999, J BIOL CHEM, V274, P2953, DOI 10.1074/jbc.274.5.2953; Becker F, 1999, J CELL BIOL, V146, P273, DOI 10.1083/jcb.146.2.273; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; da Fonseca FG, 2000, J VIROL, V74, P7508, DOI 10.1128/JVI.74.16.7508-7517.2000; DAILEY HA, 1978, J BIOL CHEM, V253, P8203; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DeCorte V, 1997, FEBS LETT, V401, P191, DOI 10.1016/S0014-5793(96)01471-8; Egan B, 1999, FEBS LETT, V451, P243, DOI 10.1016/S0014-5793(99)00581-5; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kim PK, 1999, J BIOL CHEM, V274, P36876, DOI 10.1074/jbc.274.52.36876; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; Kong AM, 2000, J BIOL CHEM, V275, P24052, DOI 10.1074/jbc.M000874200; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; Kuroda R, 1996, J BIOCHEM-TOKYO, V120, P828; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lan L, 2000, BIOCHEM J, V349, P611, DOI 10.1042/0264-6021:3490611; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; OLIVOSGLANDER IM, 1995, AM J HUM GENET, V57, P817; Ooms LM, 2000, MOL CELL BIOL, V20, P9376, DOI 10.1128/MCB.20.24.9376-9390.2000; Paddon C, 1996, MOL MICROBIOL, V19, P1007, DOI 10.1046/j.1365-2958.1996.444973.x; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PAREKH R, 1995, PROTEIN EXPRES PURIF, V6, P537, DOI 10.1006/prep.1995.1071; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; Pedrazzini E, 2000, J CELL BIOL, V148, P899, DOI 10.1083/jcb.148.5.899; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Singer-Kruger B, 1998, J CELL SCI, V111, P3347; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stolz LE, 1998, GENETICS, V148, P1715; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Wattenberg B, 2001, TRAFFIC, V2, P66, DOI 10.1034/j.1600-0854.2001.20108.x; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; WILSBACH K, 1993, EMBO J, V12, P3049, DOI 10.1002/j.1460-2075.1993.tb05974.x; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zhang XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/jbc.273.3.1574	69	22	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7643	7653		10.1074/jbc.M010471200	http://dx.doi.org/10.1074/jbc.M010471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11116155	hybrid			2022-12-25	WOS:000167442900106
J	Humphrey, GW; Wang, YH; Russanova, VR; Hirai, T; Qin, J; Nakatani, Y; Howard, BH				Humphrey, GW; Wang, YH; Russanova, VR; Hirai, T; Qin, J; Nakatani, Y; Howard, BH			Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; NUCLEAR MATRIX; POLYAMINE OXIDASE; BINDING-PROTEINS; DNA METHYLATION; N-COR; YEAST; GENE; RPD3; SUPERFAMILY	Human histone deacetylases I (HDAC1) and II (HDAC2) are homologous proteins (84% identity) that catalyze release of acetyl groups from modified N-terminal lysines of core histones, Histone deacetylation is correlated with both transient and persistent states of transcriptional inactivity (i.e. silencing) in many eukaryotes, In this study, we analyzed complexes containing HDAC1 and HDAC2 to identify the proteins most stably associated with these deacetylases. Complex cI (9.5 S) contained transcriptional corepressor CoREST/ kiaa0071 and a protein homologous to FAD-dependent oxidoreductases, kiaa0601, Complex cII (15 S) contained greater than or equal to 15 proteins, including CHD3/4 (Mi-2), Mta-L1, RbAp48/ 46, and MBD3, characteristic of vertebrate nucleosome-remodeling complexes. Under native conditions, cI and cII may contain HDAC1, HDAC2 or both; these can be dissociated to cI and cII core complexes containing only HDAC1 or HDAC2, The (m)CpG-binding protein MBD2 was associated only with the HDAC1 cII core complex, A model is proposed in which HDAC1 core complexes can be targeted to methylated DNA via MBD2 with recruitment of HDAC2 occurring through formation of HDAC1/2 cII dimers, We note that the cI component CoREST/kiaa0071 and the cII component Mta-L1 share a region of homology that includes a SANT domain; this domain may play a role in complex assembly.	NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Dana-Farber Cancer Institute; Baylor College of Medicine; Baylor College of Medicine	Howard, BH (corresponding author), NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008719] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008719] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; BUCKLERWHITE AJ, 1980, CELL, V22, P37, DOI 10.1016/0092-8674(80)90152-X; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Dailey TA, 1998, J BIOL CHEM, V273, P13658, DOI 10.1074/jbc.273.22.13658; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; DeRubertis F, 1996, NATURE, V384, P589; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; FujimotoNishiyama A, 1997, GENE, V195, P267, DOI 10.1016/S0378-1119(97)00172-8; Futamura M, 1999, J HUM GENET, V44, P52, DOI 10.1007/s100380050107; Grewal SIS, 1998, GENETICS, V150, P563; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guenther MG, 2000, GENE DEV, V14, P1048; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HENDZEL MJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P307, DOI 10.1016/0167-4781(92)90443-4; KAUFMANN SH, 1981, EXP CELL RES, V132, P105, DOI 10.1016/0014-4827(81)90088-4; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ohara O, 1997, DNA Res, V4, P53, DOI 10.1093/dnares/4.1.53; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tavladoraki P, 1998, FEBS LETT, V426, P62, DOI 10.1016/S0014-5793(98)00311-1; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	52	256	282	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6817	6824		10.1074/jbc.M007372200	http://dx.doi.org/10.1074/jbc.M007372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11102443	hybrid			2022-12-25	WOS:000167261000095
J	Zhang, JC; Claffey, K; Sakthivel, R; Darzynkiewicz, Z; Shaw, DE; Leal, J; Wang, YC; Lu, FM; McCrae, KR				Zhang, JC; Claffey, K; Sakthivel, R; Darzynkiewicz, Z; Shaw, DE; Leal, J; Wang, YC; Lu, FM; McCrae, KR			Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5	FASEB JOURNAL			English	Article						angiogenesis; coagulation; neovascularization; tumor; endothelium	TUMOR ANGIOGENESIS; BINDING-PROTEIN; HUMAN ANGIOSTATIN; CONTACT SYSTEM; IN-VITRO; RECEPTOR; MECHANISM; PLASMA; GROWTH; METASTASIS	We previously reported that the binding of two-chain high molecular weight kininogen (HKa) to endothelial cells may occur through interactions with endothelial urokinase receptors. Since the binding of urokinase to urokinase receptors activates signaling responses and may stimulate mitogenesis, we assessed the effect of HKa binding on endothelial cell proliferation. Unexpectedly, HKa inhibited proliferation in response to several growth factors, with 50% inhibition caused by similar to 10 nM HKa. This activity was Zn2+ dependent and not shared by either single-chain high molecular weight kininogen (HK) or low molecular weight kininogen. HKa selectively inhibited the proliferation of human umbilical vein and dermal microvascular endothelial cells, but did not affect that of umbilical vein or human aortic smooth muscle cells, trophoblasts, fibroblasts, or carcinoma cells. Inhibition of endothelial proliferation by HKa was associated with endothelial cell apoptosis and unaffected by antibodies that block the binding of HK or HKa to any of their known endothelial receptors. Recombinant HK domain 5 displayed activity similar to that of HKa. In vivo, HKa inhibited neovascularization of subcutaneously implanted Matrigel plugs, as well as rat corneal angiogenesis. These results demonstrate that HKa is a novel inhibitor of angiogenesis, whose activity is dependent on the unique conformation of the two-chain molecule.	Case Western Reserve Univ, Sch Med, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; Univ Connecticut, Sch Med, Ctr Vasc Biol, Dept Physiol, Farmington, CT USA; New York Med Coll, Valhalla, NY 10595 USA; DE Shaw & Co Inc, New York, NY USA; Attenuon LLC, San Diego, CA USA; Abbott Labs, Div Pharmaceut Prod, Dept Chemotherapeut, Abbott Pk, IL 60064 USA; Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA	Case Western Reserve University; Case Western Reserve University; University of Connecticut; New York Medical College; Abbott Laboratories; Drexel University	McCrae, KR (corresponding author), Case Western Reserve Univ, Sch Med, Div Hematol Oncol, BRB 3,10900 Euclid Ave, Cleveland, OH 44106 USA.	kxm71@po.cwru.edu		Darzynkiewicz, Zbigniew/0000-0002-2040-7081	NATIONAL CANCER INSTITUTE [R01CA083134, R01CA028704] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050827] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA028704, CA83134, R01 CA028704-23] Funding Source: Medline; NHLBI NIH HHS [HL50827] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; Asakura S, 1998, J BIOCHEM-TOKYO, V124, P473, DOI 10.1093/oxfordjournals.jbchem.a022138; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; BERRETTINI M, 1986, BLOOD, V68, P455; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; CONRAD TJ, 1994, LAB INVEST, V70, P426; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; DISS EM, 1992, AM J OBSTET GYNECOL, V167, P1046, DOI 10.1016/S0002-9378(12)80036-6; EWALD GA, 1995, CIRCULATION, V91, P28, DOI 10.1161/01.CIR.91.1.28; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOURNIER GA, 1981, INVEST OPHTH VIS SCI, V21, P351; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HOFFMEISTER HM, 1995, CIRCULATION, V91, P2520, DOI 10.1161/01.CIR.91.10.2520; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; KAPLAN AP, 1987, BLOOD, V70, P1; Karlsrud TS, 1996, INTENS CARE MED, V22, P760; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KLENIEWSKI J, 1992, J LAB CLIN MED, V120, P129; Kozik A, 1998, J BIOL CHEM, V273, P33224, DOI 10.1074/jbc.273.50.33224; Lee TH, 1998, J BIOL CHEM, V273, P28805, DOI 10.1074/jbc.273.44.28805; MERRIFIELD RB, 1969, ADV ENZYMOL RAMB, V32, P221; MORI K, 1981, J BIOCHEM-TOKYO, V89, P1465, DOI 10.1093/oxfordjournals.jbchem.a133339; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Obermair A, 1998, AM J OBSTET GYNECOL, V178, P314, DOI 10.1016/S0002-9378(98)80018-5; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Pavord S, 1997, BRIT J HAEMATOL, V97, P762, DOI 10.1046/j.1365-2141.1997.1282947.x; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; REDDIGARI SR, 1993, BLOOD, V81, P1306; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Sanders RJ, 1998, CANCER INVEST, V16, P329, DOI 10.3109/07357909809084653; Shariat-Madar Z, 1999, J BIOL CHEM, V274, P7137, DOI 10.1074/jbc.274.11.7137; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; Sim BKL, 1997, CANCER RES, V57, P1329; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; VOGEL R, 1988, J BIOL CHEM, V263, P12661; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; WEISEL JW, 1994, J BIOL CHEM, V269, P10100; Wu ZG, 1997, BIOCHEM BIOPH RES CO, V236, P651, DOI 10.1006/bbrc.1997.7032; Zhang JC, 1996, BLOOD, V88, P3880, DOI 10.1182/blood.V88.10.3880.bloodjournal88103880; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273	69	97	111	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2589	2600		10.1096/fj.99-1025com	http://dx.doi.org/10.1096/fj.99-1025com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099478				2022-12-25	WOS:000165723400030
J	Rodriguez, MS; Dargemont, C; Hay, RT				Rodriguez, MS; Dargemont, C; Hay, RT			SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NF-KAPPA-B; UBIQUITIN-RELATED MODIFIER; PORE COMPLEX; COVALENT MODIFICATION; ENZYME; PML; LOCALIZATION; DEGRADATION; RANGAP1	SUMO-1 is a small ubiquitin-related modifier that is covalently linked to many cellular protein targets. Proteins modified by SUMO-1 and the SUMO-l-activating and -conjugating enzymes are located predominantly in the nucleus. Here we define a transferable sequence containing the psi KXE motif, where psi represents a large hydrophobic amino acid, that confers the ability to be SUMO-l-modified on proteins to which it is linked. Whereas addition of short sequences from p53 and I kappaB alpha containing the psi KXE motif, to a carrier protein is sufficient for modification in vitro, modification in vivo requires the additional presence of a nuclear localization signal. Thus, protein substrates must be targeted to the nucleus to undergo SUMO-1 conjugation.	Univ St Andrews, Sch Biol, St Andrews KY16 9ST, Fife, Scotland; Inst Jacques Monod, Lab Transport Nucleocytoplasm, CNRS UMR 7592, F-75251 Paris 05, France	University of St Andrews; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Hay, RT (corresponding author), Univ St Andrews, Sch Biol, Biomol Sci Bldg, St Andrews KY16 9ST, Fife, Scotland.		Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024				ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; ERRICO A, UNPUB; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hodges M, 1998, CURR BIOL, V8, pR749, DOI 10.1016/S0960-9822(07)00477-0; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	43	601	626	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12654	12659		10.1074/jbc.M009476200	http://dx.doi.org/10.1074/jbc.M009476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11124955	hybrid			2022-12-25	WOS:000168198600026
J	El Kharroubi, A; Piras, G; Stewart, CL				El Kharroubi, A; Piras, G; Stewart, CL			DNA demethylation reactivates a subset of imprinted genes in uniparental mouse embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; ALLELE-SPECIFIC METHYLATION; DEPENDENT KINASE INHIBITOR; GERM-LINE; SNRPN GENE; H19 GENE; EXPRESSION; IDENTIFICATION; MECHANISMS; ESTABLISHMENT	Although most imprinted genes show allelic differences in DNA methylation, it is not clear whether methylation regulates the expression of some or all imprinted genes in somatic cells. To examine the mechanisms of silencing of imprinted alleles, we generated novel uniparental mouse embryonic fibroblasts exclusively containing either the paternal or the maternal genome. These fibroblasts retain parent-of-origin allele-specific expression of 12 imprinted genes,examined for more than 30 cell generations. We show that p57(Kip2) (cyclin-dependent kinase inhibitor protein 2) and Igf2 (insulinlike growth factor 2) are induced by inhibiting histone deacetylases; however, their activated state is reversed quickly by withdrawal of trichostatin A. In contrast, DNA demethylation results in the heritable expression of a subset of imprinted genes including H19 (H19 fetal liver mRNA), p57(Kip2), Peg3/Pw1 (paternally expressed gene 3), and Zac1 (zinc finger-binding protein regulating apoptosis and cell cycle arrest). Other imprinted genes such as Grb10 (growth factor receptor-bound protein 10), Peg1/Mest (paternally expressed gene 1/mesoderm-specific transcript), Sgce (epsilon-sarcoglycan), Snrpn (small nuclear ribonucleoprotein polypeptide N), and U2af1 (U2 small nuclear ribonucleoprotein auxiliary factor), remain inactive, despite their exposure to inhibitors of histone deacetylases and DNA methylation. These results demonstrate that changes in DNA methylation but not histone acetylation create a heritable epigenetic state at some imprinted loci in somatic cells.	NCI, Canc & Dev Biol Lab, Div Basic Sci, FCRDC,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	El Kharroubi, A (corresponding author), NCI, Canc & Dev Biol Lab, Div Basic Sci, FCRDC,NIH, Bldg 539,Rm 135,1050 Boyles St,POB B, Frederick, MD 21702 USA.							BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTON SC, 1984, NATURE, V311, P374, DOI 10.1038/311374a0; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Brannan CI, 1999, CURR OPIN GENET DEV, V9, P164, DOI 10.1016/S0959-437X(99)80025-2; Caspary T, 1998, MOL CELL BIOL, V18, P3466, DOI 10.1128/MCB.18.6.3466; Constancia M, 1998, GENOME RES, V8, P881, DOI 10.1101/gr.8.9.881; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; ElKharroubi A, 1996, MOL CELL BIOL, V16, P2958; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GUILLEMOT F, 1995, NAT GENET, V9, P235, DOI 10.1038/ng0395-235; HATADA I, 1995, NUCLEIC ACIDS RES, V23, P36, DOI 10.1093/nar/23.1.36; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; Hogan B, 1994, MANIPULATING MOUSE E; Hu JF, 1997, MOL ENDOCRINOL, V11, P1891, DOI 10.1210/me.11.13.1891; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; LESTER SC, 1982, SOMAT CELL GENET, V8, P265, DOI 10.1007/BF01538681; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MANN JR, 1990, CELL, V62, P251, DOI 10.1016/0092-8674(90)90363-J; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; Miyoshi N, 1998, P NATL ACAD SCI USA, V95, P1102, DOI 10.1073/pnas.95.3.1102; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Olek A, 1997, NAT GENET, V17, P275, DOI 10.1038/ng1197-275; Pedone PV, 1999, FEBS LETT, V458, P45, DOI 10.1016/S0014-5793(99)01124-2; Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; Shin JY, 2000, CANCER RES, V60, P262; STEWART CL, 1985, EMBO J, V4, P3701, DOI 10.1002/j.1460-2075.1985.tb04138.x; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; SURANI MAH, 1986, CELL, V45, P127, DOI 10.1016/0092-8674(86)90544-1; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	48	72	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8674	8680		10.1074/jbc.M009392200	http://dx.doi.org/10.1074/jbc.M009392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124954	hybrid			2022-12-25	WOS:000167607700010
J	Koo, SH; Dutcher, AK; Towle, HC				Koo, SH; Dutcher, AK; Towle, HC			Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY-ELEMENT; FATTY-ACID SYNTHASE; PYRUVATE-KINASE GENE; BINDING PROTEIN-1; CARBOHYDRATE REGULATION; S-14 GENE; RESPONSE ELEMENT; RAT HEPATOCYTES; CULTURED-CELLS; PROMOTER	Transcription of a number of genes involved in lipogenesis is stimulated by dietary carbohydrate in the mammalian liver. Both insulin and increased glucose metabolism have been proposed to be initiating signals for this process, but the pathways by which these effecters act to alter transcription have not been resolved. We have previously defined by electrophoretic mobility shift assay a factor in nuclear extracts from rat liver, designated the carbohydrate-responsive factor (ChoRF), that binds to liver-type pyruvate kinase and S-14 promoters at sites critical for regulation by carbohydrate, The sterol regulatory element binding protein-1c (SREBP-1c) has also emerged as a major transcription factor involved in this nutritional response. In this study, we examined the relationship between SREBP-1c and ChoRF in lipogenic gene induction. The two factors were found to possess distinct DNA binding specificities both in vitro and in hepatocytes. Reporter constructs containing binding sites for ChoRF were responsive to glucose but not directly to insulin. On the other hand, reporter constructs with an SREBP-1c site responded directly to insulin. The S-14 gene possesses binding sites for both ChoRF and SREBP, and both sites were found to be functionally important for the response of this promoter to glucose and insulin in hepatocytes. Consequently, we propose that SREBP-1c and ChoRF are independent transcription factors that mediate signals generated by insulin and glucose, respectively. For many lipogenic enzyme genes, these two factors may provide an integrated signaling system to support the overall nutritional response to dietary carbohydrate.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Towle, HC (corresponding author), 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.		Adiels, Martin/C-9278-2011; Koo, Seung-Hoi/E-2763-2015	Koo, Seung-Hoi/0000-0001-8769-2879; Stoeckman, Angela/0000-0002-2009-0424	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26919] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agius L, 1997, BIOCHEM SOC T, V25, P145, DOI 10.1042/bst0250145; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cunningham BA, 1998, THYROID, V8, P815, DOI 10.1089/thy.1998.8.815; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JUMP DB, 1990, MOL ENDOCRINOL, V4, P1655, DOI 10.1210/mend-4-11-1655; Kaytor EN, 2000, MOL CELL BIOCHEM, V210, P13, DOI 10.1023/A:1007006429041; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Miller SP, 1999, DIABETES, V48, P1645, DOI 10.2337/diabetes.48.8.1645; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Rufo C, 1999, BIOCHEM BIOPH RES CO, V261, P400, DOI 10.1006/bbrc.1999.1034; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1995, BIOTECHNIQUES, V18, P813; SHIH HM, 1994, J BIOL CHEM, V269, P9380; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840	48	116	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9437	9445		10.1074/jbc.M010029200	http://dx.doi.org/10.1074/jbc.M010029200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11112788	hybrid			2022-12-25	WOS:000167607700108
J	Korchak, HM; Kilpatrick, LE				Korchak, HM; Kilpatrick, LE			Roles for beta II-protein kinase C and RACK1 in positive and negative signaling for superoxide anion generation in differentiated HL60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE NADPH OXIDASE; RESPIRATORY BURST OXIDASE; HUMAN-NEUTROPHILS; INTRACELLULAR RECEPTORS; MEMBRANE ASSOCIATION; PHORBOL ESTER; PHOSPHORYLATION; LOCALIZATION; SUBUNIT; P47(PHOX)	beta -Protein kinase (PKC)is essential for ligand-initiate. assembly of the NADPH oxidase far generation of superoxide anion (O-2(radical anion). Neutrophils and neutrophilic HL60 cells contain both betaI and beta II-PKC, isotypes that are derived by alternate splicing. betaI-PKC-positive and betaI-PKC null HL60 cells generated equivalent amounts of O-2(radical anion) in response to fMet-Leu-Phe and phorbol myristate acetate. However, antisense depletion of beta II-PKC from betaI-PKC null cells inhibited ligand-initiated O-2(radical anion) generation, fMet-Leu-Phe triggered association of a cytosolic NADPH oxidase component, p47(phox), with beta II-PKC but not with RACK1, a binding protein for beta II-PKC. Thus, RACK1 was not a component of the signaling complex for NADPH oxidase assembly. Inhibition of beta -PKC/RACK1 association by an inhibitory peptide or by antisense depletion of RACK1 enhanced O-2(radical anion) generation. Therefore, beta II-PKC but not betaI-PKC is essential for activation of O-2(radical anion) generation and plays a positive role in signaling for NADPH oxidase activation in association with p47(phox). In contrast; RACK1 is involved in negative signaling for O-2(radical anion) generation. RACK1 binds to beta II-PKC but not with the p47(phox). beta II-PKC complex. RACK1 may divert beta II-PKC to other signaling pathways requiring beta -PKC for signal transduction. Alternatively, RACK1 may sequester beta II-PKC to down-regulate O-2(radical anion) generation.	Childrens Hosp Philadelphia, Immunol Sect, Joseph Stokes Jr Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Korchak, HM (corresponding author), Childrens Hosp Philadelphia, Immunol Sect, Joseph Stokes Jr Res Inst, Room 1208C Abramson Bldg,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.				NIAID NIH HHS [AI24840] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024840] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; Dekker LV, 2000, BIOCHEM J, V347, P285, DOI 10.1042/0264-6021:3470285; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; Faux MC, 1999, BIOCHEM J, V343, P443, DOI 10.1042/0264-6021:3430443; Fowler L, 1998, CELL GROWTH DIFFER, V9, P177; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; Gokmen-Polar Y, 1998, J BIOL CHEM, V273, P20261, DOI 10.1074/jbc.273.32.20261; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; KORCHAK HM, 1984, J BIOL CHEM, V259, P4076; Korchak HM, 1998, J BIOL CHEM, V273, P27292, DOI 10.1074/jbc.273.42.27292; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MAJUMDAR S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P276, DOI 10.1016/0167-4889(93)90056-U; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 2000, SEMIN IMMUNOL, V12, P55, DOI 10.1006/smim.2000.0207; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Newton AC, 1996, CURR BIOL, V6, P806, DOI 10.1016/S0960-9822(02)00600-0; Niggli V, 1999, EXP CELL RES, V250, P558, DOI 10.1006/excr.1999.4548; Park HS, 1999, BIOCHEM BIOPH RES CO, V259, P38, DOI 10.1006/bbrc.1999.0721; Park JW, 1997, J BIOL CHEM, V272, P11035; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Sergeant S, 1997, J IMMUNOL, V159, P2877; Sim ATR, 1999, CELL CALCIUM, V26, P209, DOI 10.1054/ceca.1999.0072; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Wooten Marie W., 1993, Cytobios, V76, P19; Yan XW, 2000, BIOCHEM J, V349, P709, DOI 10.1042/bj3490709	45	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8910	8917		10.1074/jbc.M008326200	http://dx.doi.org/10.1074/jbc.M008326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11120743	hybrid			2022-12-25	WOS:000167607700042
J	Nugent, C; Prins, JB; Whitehead, JP; Wentworth, JM; Chatterjee, VKK; O'Rahilly, S				Nugent, C; Prins, JB; Whitehead, JP; Wentworth, JM; Chatterjee, VKK; O'Rahilly, S			Arachidonic acid stimulates glucose uptake in 3T3-L1 adipocytes by increasing GLUT1 and GLUT4 levels at the plasma membrane - Evidence for involvement of lipoxygenase metabolites and peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; INSULIN-RESISTANCE; PPAR-GAMMA; GENE-EXPRESSION; DIFFERENTIAL INHIBITION; MUSCLE; TRANSPORT; LIGAND; EICOSANOIDS; ALPHA	Exposure of insulin-sensitive tissues to free fatty acids can impair glucose disposal through inhibition of carbohydrate oxidation and glucose transport. However, certain fatty acids and their derivatives can also act as endogenous ligands for peroxisome proliferator-activated receptor gamma (PPAR gamma), a nuclear receptor that positively modulates insulin sensitivity. To clarify the effects of externally delivered fatty acids on glucose uptake in an insulin-responsive cell type, we systematically examined the effects of a range of fatty acids on glucose uptake in 3T3-L1 adipocytes. Of the fatty acids examined, arachidonic acid (AA) had the greatest positive effects, significantly increasing basal and insulin-stimulated glucose uptake by 1.8- and 2-fold, respectively, with effects being maximal at 4 h at which time membrane phospholipid content of AA was markedly increased. The effects of AA were sensitive to the inhibition of protein synthesis but were unrelated to changes in membrane fluidity. AA had no effect on total cellular levels of glucose transporters, but significantly increased levels of GLUT1 and GLUT4 at the plasma membrane. While the effects of AA were insensitive to cyclooxygenase inhibition, the lipoxygenase inhibitor, nordihydroguaiaretic acid, substantially blocked the AA effect on basal glucose uptake. Furthermore, adenoviral expression of a dominant-negative PPAR gamma mutant attenuated the AA potentiation of basal glucose uptake. Thus, AA potentiates basal and insulin-stimulated glucose uptake in 3T3-L1 adipocytes by a cyclooxygenase-independent mechanism that increases the levels of both GLUT1 and GLUT4 at the plasma membrane. These effects are at least partly dependent on de novo protein synthesis, an intact lipoxygenase pathway and the activation of PPAR gamma with these pathways having a greater role in the absence than in the presence of insulin.	Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QR, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Box 157, Cambridge CB2 2QR, England.	sorahill@hgmp.mrc.ac.uk	Whitehead, Jonathan/F-5022-2014; O'Rahilly, Stephen/ABF-6509-2020; Prins, Johannes/I-3610-2019; Prins, Johannes B/M-5884-2013	O'Rahilly, Stephen/0000-0003-2199-4449; Prins, Johannes/0000-0001-9497-927X; Prins, Johannes B/0000-0001-9497-927X; Wentworth, John/0000-0002-5197-3529; Whitehead, Jonathan/0000-0003-3978-3148; Chatterjee, Vengalil Krishna/0000-0002-2654-8854				Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; BODEN G, 1995, J CLIN INVEST, V96, P1261, DOI 10.1172/JCI118160; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; BORKMAN M, 1993, NEW ENGL J MED, V328, P238, DOI 10.1056/NEJM199301283280404; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; Day C, 1999, DIABETIC MED, V16, P179, DOI 10.1046/j.1464-5491.1999.00023.x; ELKEBBI IM, 1994, METABOLISM, V43, P953, DOI 10.1016/0026-0495(94)90173-2; Fong JC, 1999, CELL SIGNAL, V11, P53, DOI 10.1016/S0898-6568(98)00031-X; Fong JC, 1996, CELL SIGNAL, V8, P179, DOI 10.1016/0898-6568(95)02052-7; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GRUNFELD C, 1981, BIOCHEM BIOPH RES CO, V103, P219, DOI 10.1016/0006-291X(81)91682-X; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hansen PA, 1998, J BIOL CHEM, V273, P26157, DOI 10.1074/jbc.273.40.26157; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KNODELL RG, 1990, GASTROENTEROLOGY, V98, P1320, DOI 10.1016/0016-5085(90)90351-Z; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; Ma HW, 1998, J BIOL CHEM, V273, P30131, DOI 10.1074/jbc.273.46.30131; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Pan DA, 1995, J CLIN INVEST, V96, P2802, DOI 10.1172/JCI118350; PAN DA, 1993, J NUTR, V123, P512, DOI 10.1093/jn/123.3.512; RANDLE PJ, 1963, LANCET, V1, P785; RICHELSEN B, 1987, BIOCHEM J, V247, P389, DOI 10.1042/bj2470389; Roden M, 1999, DIABETES, V48, P358, DOI 10.2337/diabetes.48.2.358; Shimaya A, 1998, HORM METAB RES, V30, P543, DOI 10.1055/s-2007-978929; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Storlien LH, 1996, DIABETOLOGIA, V39, P621, DOI 10.1007/BF00418533; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; Stouthard JML, 1996, BIOCHEM BIOPH RES CO, V220, P241, DOI 10.1006/bbrc.1996.0389; STUBBS CD, 1990, BIOCHEM SOC T, V18, P779, DOI 10.1042/bst0180779; Tafuri SR, 1996, ENDOCRINOLOGY, V137, P4706, DOI 10.1210/en.137.11.4706; TEBBEY PW, 1994, J BIOL CHEM, V269, P639; TOBIAS LD, 1979, LIPIDS, V14, P181, DOI 10.1007/BF02533870; Urso B, 1999, J BIOL CHEM, V274, P30864, DOI 10.1074/jbc.274.43.30864; Wang T, 1999, ANAL BIOCHEM, V269, P198, DOI 10.1006/abio.1999.4022; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	47	90	97	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9149	9157		10.1074/jbc.M009817200	http://dx.doi.org/10.1074/jbc.M009817200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124961	hybrid			2022-12-25	WOS:000167607700072
J	Sato, Y; Kiriazis, H; Yatani, A; Schmidt, AG; Hahn, H; Ferguson, DG; Sako, H; Mitarai, S; Honda, R; Mesnard-Rouiller, L; Frank, KF; Beyermann, B; Wu, GY; Fujimori, K; Dorn, GW; Kranias, EG				Sato, Y; Kiriazis, H; Yatani, A; Schmidt, AG; Hahn, H; Ferguson, DG; Sako, H; Mitarai, S; Honda, R; Mesnard-Rouiller, L; Frank, KF; Beyermann, B; Wu, GY; Fujimori, K; Dorn, GW; Kranias, EG			Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM FUNCTION; CARDIAC-SPECIFIC OVEREXPRESSION; LEFT-VENTRICULAR HYPERTROPHY; HEART-FAILURE; ENDOPLASMIC-RETICULUM; TRANSGENIC MICE; DILATED CARDIOMYOPATHY; SKELETAL ACTIN; IONIC CURRENTS; IN-VIVO	Cardiac-specific overexpression of murine cardiac calsequestrin results in depressed cardiac contractile parameters, low Ca2+-induced Ca2+ release from sarcoplasmic reticulum (SR) and cardiac hypertrophy in transgenic mice. To test the hypothesis that inhibition of phospholamban activity may rescue some of these phenotypic alterations, the calsequestrin overexpressing mice were cross-bred with phospholamban-knockout mice. Phospholamban ablation in calsequestrin overexpressing mice led to reversal of the depressed cardiac contractile parameters in Langendorff-perfused hearts or in vivo. This was associated with increases of SR Ca2+ storage, assessed by caffeine-induced Na+-Ca2+ exchanger currents. The inactivation time of the L-type Ca2+ current (I-Ca) which has an inverse correlation with Ca2+-induced SR Ca2+ release, and the relation between the peak current density and half-inactivation time were also normalized, indicating a restoration in the ability of I-Ca to trigger SR Ca2+ release. The prolonged action potentials in calsequestrin overexpressing cardiomyocytes also reversed to normal upon phospholamban ablation. Furthermore, ablation of phospholamban restored the expression levels of atrial natriuretic factor and alpha -skeletal actin mRNA as well as ventricular myocyte size. These results indicate that attenuation of phospholamban function may pr-event or overcome functional and remodeling defects in hypertrophied hearts.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Div Cardiol, Cincinnati, OH 45267 USA; Natl Inst Hlth Sci, Div Xenobiot Metab & Disposit, Tokyo 158, Japan; Case Western Reserve Univ, Dept Anat, Cleveland, OH 44106 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; National Institute of Health Sciences - Japan; Case Western Reserve University	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	kraniaeg@email.uc.edu			NCRR NIH HHS [P40RR12358] Funding Source: Medline; NHLBI NIH HHS [HL52318, HL26057] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012358] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026057, R37HL026057, P50HL052318] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALONSO S, 1990, J MOL BIOL, V211, P727, DOI 10.1016/0022-2836(90)90073-U; BENJAMIN EJ, 1995, CIRCULATION, V92, P835, DOI 10.1161/01.CIR.92.4.835; Bers DM, 1998, ANN NY ACAD SCI, V853, P157, DOI 10.1111/j.1749-6632.1998.tb08264.x; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Chien KR, 2000, NAT MED, V6, P942, DOI 10.1038/79595; Cho MC, 1999, J BIOL CHEM, V274, P22251, DOI 10.1074/jbc.274.32.22251; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; DORN GW, 1994, AM J PHYSIOL, V267, pH400, DOI 10.1152/ajpheart.1994.267.1.H400; EATON GJ, 1978, AM J PATHOL, V90, P173; Eisner DA, 1998, CARDIOVASC RES, V38, P589, DOI 10.1016/S0008-6363(98)00062-5; FAY WP, 1990, J AM COLL CARDIOL, V16, P821, DOI 10.1016/S0735-1097(10)80328-6; GWATHMEY JK, 1993, CARDIOVASC RES, V27, P199, DOI 10.1093/cvr/27.2.199; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; Kiriazis H, 2000, ANNU REV PHYSIOL, V62, P321, DOI 10.1146/annurev.physiol.62.1.321; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Li L, 1998, AM J PHYSIOL-HEART C, V274, pH1335, DOI 10.1152/ajpheart.1998.274.4.H1335; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Lim HW, 1999, NAT MED, V5, P246, DOI 10.1038/6430; LIU NG, 1994, J BIOL CHEM, V269, P28635; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Marian AJ, 2000, LANCET, V355, P58, DOI 10.1016/S0140-6736(99)06187-5; Masaki H, 1997, AM J PHYSIOL-HEART C, V272, pH606, DOI 10.1152/ajpheart.1997.272.2.H606; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Mitarai S, 2000, AM J PHYSIOL-HEART C, V279, pH139, DOI 10.1152/ajpheart.2000.279.1.H139; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NABORS CE, 1969, ANAT REC, V164, P153, DOI 10.1002/ar.1091640203; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Pan BS, 1999, J MOL CELL CARDIOL, V31, P159, DOI 10.1006/jmcc.1998.0854; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Rizzo V, 2000, AM HEART J, V139, P529; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Sako H, 1997, AM J PHYSIOL-CELL PH, V273, pC1666, DOI 10.1152/ajpcell.1997.273.5.C1666; Santana LF, 1997, J PHYSIOL-LONDON, V503, P21, DOI 10.1111/j.1469-7793.1997.021bi.x; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; Schmidt AG, 2000, J MOL CELL CARDIOL, V32, P1735, DOI 10.1006/jmcc.2000.1209; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SEILER C, 1995, BRIT HEART J, V74, P508; Szymanska G, 2000, PFLUG ARCH EUR J PHY, V439, P339, DOI 10.1007/s004240050948; Thamilarasan M, 1999, AM HEART J, V137, P381, DOI 10.1016/S0002-8703(99)70481-3; Tsutsui H, 1997, AM J PHYSIOL-HEART C, V272, pH168, DOI 10.1152/ajpheart.1997.272.1.H168; Vikstrom KL, 1998, CIRC RES, V82, P773, DOI 10.1161/01.RES.82.7.773; WANG JX, 1994, AM J PHYSIOL, V267, pH918, DOI 10.1152/ajpheart.1994.267.3.H918; Wang W, 2000, J PHYSIOL-LONDON, V524, P399, DOI 10.1111/j.1469-7793.2000.00399.x; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	52	88	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9392	9399		10.1074/jbc.M006889200	http://dx.doi.org/10.1074/jbc.M006889200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11115498	hybrid			2022-12-25	WOS:000167607700103
J	Wang, L; Gralla, JD				Wang, L; Gralla, JD			Roles for the C-terminal region of sigma 54 in transcriptional silencing and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE RNA-POLYMERASE; TURN-HELIX MOTIF; ESCHERICHIA-COLI; TYPHIMURIUM SIGMA(54); MUTANT FORMS; IN-VIVO; PROTEIN; SEQUENCES; DOMAIN; RECOGNITION	Twenty-one conserved positively charged and aromatic amino acids between residues 331 and 462 of sigma 54 were changed to alanine, and the mutant proteins were studied by transcription, band shift analysis, and footprinting in vitro. A small segment corresponding to the rpoN box was found to be most important for binding duplex DNA. Two amino acids, 52 residues apart, were found to be critical for maintaining transcriptional silencing in the absence of activator. These two activator bypass mutants and several other mutants failed to bind the type of fork junction DNA thought to be required to maintain silencing. The two bypass mutants showed a binding pattern to DNA probes that was unique, both in comparison to other C-terminal mutants and to previously known N-terminal bypass mutants. On this basis, a model is proposed for the role of the C terminus and the N terminus of sigma 54 in enhancer-dependent transcription.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	gralla@chem.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; CANNON W, 1993, MOL MICROBIOL, V8, P287, DOI 10.1111/j.1365-2958.1993.tb01573.x; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; CANNON W, 1994, MOL MICROBIOL, V11, P227, DOI 10.1111/j.1365-2958.1994.tb00303.x; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Casaz P, 1999, J MOL BIOL, V292, P229, DOI 10.1006/jmbi.1999.3076; Casaz P, 1999, J MOL BIOL, V285, P507, DOI 10.1006/jmbi.1998.2328; Chaney M, 1999, MOL MICROBIOL, V33, P1200, DOI 10.1046/j.1365-2958.1999.01566.x; COPPARD JR, 1991, MOL MICROBIOL, V5, P1309, DOI 10.1111/j.1365-2958.1991.tb00777.x; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gallegos MT, 2000, J MOL BIOL, V297, P849, DOI 10.1006/jmbi.2000.3608; Gralla JD, 2000, NAT STRUCT BIOL, V7, P530, DOI 10.1038/76732; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Guo YL, 1997, J BACTERIOL, V179, P1239, DOI 10.1128/jb.179.4.1239-1245.1997; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; HSIEH ML, 1994, J MOL BIOL, V239, P15, DOI 10.1006/jmbi.1994.1347; Kelly MT, 1999, J BACTERIOL, V181, P3351, DOI 10.1128/JB.181.11.3351-3357.1999; Kelly MT, 2000, J BACTERIOL, V182, P513, DOI 10.1128/JB.182.2.513-517.2000; MERRICK M, 1992, J BACTERIOL, V174, P7221, DOI 10.1128/jb.174.22.7221-7226.1992; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MORRIS L, 1994, J BIOL CHEM, V269, P11563; North AK, 1997, J MOL BIOL, V267, P17, DOI 10.1006/jmbi.1996.0838; Oguiza JA, 1999, MOL MICROBIOL, V33, P873, DOI 10.1046/j.1365-2958.1999.01542.x; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; Syed A, 1997, MOL MICROBIOL, V23, P987, DOI 10.1046/j.1365-2958.1997.2851651.x; Syed A, 1998, J BACTERIOL, V180, P5619, DOI 10.1128/JB.180.21.5619-5625.1998; Taylor M, 1996, MOL MICROBIOL, V22, P1045, DOI 10.1046/j.1365-2958.1996.01547.x; VANSLOOTEN JC, 1990, J BACTERIOL, V172, P5563, DOI 10.1128/jb.172.10.5563-5574.1990; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; Wang JT, 1997, P NATL ACAD SCI USA, V94, P9538, DOI 10.1073/pnas.94.18.9538; Wang L, 1999, J BACTERIOL, V181, P7558, DOI 10.1128/JB.181.24.7558-7565.1999; Wang L, 1998, J BACTERIOL, V180, P5626, DOI 10.1128/JB.180.21.5626-5631.1998; WONG CN, 1994, J MOL BIOL, V236, P81, DOI 10.1006/jmbi.1994.1120	40	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8979	8986		10.1074/jbc.M009587200	http://dx.doi.org/10.1074/jbc.M009587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124262	hybrid			2022-12-25	WOS:000167607700050
J	Ghosh, AK; Lacson, R; Liu, PX; Cichy, SB; Danilkovich, A; Guo, SD; Unterman, TG				Ghosh, AK; Lacson, R; Liu, PX; Cichy, SB; Danilkovich, A; Guo, SD; Unterman, TG			A nucleoprotein complex containing CCAAT/enhancer-binding protein beta interacts with an insulin response sequence in the insulin-like growth factor-binding protein-1 gene and contributes to insulin-regulated gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHOSPHOENOLPYRUVATE CARBOXYKINASE; C/EBP-ALPHA; PEPCK GENE; NUCLEAR FACTOR; TRANSCRIPTION; KINASE; PROMOTER; IDENTIFICATION; FAMILY	Highly related insulin response sequences (IRBs) mediate effects of insulin on the expression of multiple genes in the liver, including insulin-like growth factor binding protein-1 (IGFBP-1) and phosphoenolpyruvate carboxykinase (PEPCK). Gel shift studies reveal that oligonucleotide probes containing an IRS from the IGFBP-1 or PEPCK gene form a similar complex with hepatic nuclear proteins. Unlabeled competitors containing the IGFBP-1 or PEPCK IRS or a binding site for C/EBP proteins inhibit the formation of this complex. Antibody against C/EBP beta (but not other C/EBP proteins) supershifts this complex, and Western blotting of affinity purified proteins confirms that C/EBP beta is present in this complex, Studies with affinity purified and recombinant protein indicate that C/EBP beta does not interact directly with the IRS, but that other factors are required, Gel shift assays and reporter gene studies with constructs containing point mutations within the IRS reveal that the ability to interact with factors required for the formation of this complex correlates well with the ability of insulin to regulate promoter activity via this IRS (r = 0.849, p < 0.01), Replacing the IRS in reporter gene constructs with a C/EBP-binding site (but not an HNF-3/forkhead site or cAMP response element) maintains the effect of insulin on promoter activity. Together, these findings indicate that a nucleoprotein complex containing C/EBP<beta> interacts with IRSs from the IGFBP-1 and PEPCK genes in a sequence-specific fashion and may contribute to the ability of insulin to regulate gene expression.	VA Affairs Chicago Hlth Care Syst, W Side Div, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Unterman, TG (corresponding author), VA Affairs Chicago Hlth Care Syst, W Side Div, Rm 5A122A Res MP 151,820 S Damen Ave, Chicago, IL 60612 USA.	unterman@uic.edu	Danilkovich, Alexey/E-4014-2010; GHOSH, AYAN/GYV-5906-2022	Danilkovich, Alexey/0000-0002-4650-9860; 	NIDDK NIH HHS [DK41430] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041430, R29DK041430] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; Baer M, 1998, BLOOD, V92, P4353, DOI 10.1182/blood.V92.11.4353.423k21_4353_4365; Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; Bauknecht T, 1996, J VIROL, V70, P7695, DOI 10.1128/JVI.70.11.7695-7705.1996; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P771; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Unterman T., 1995, Progress in Growth Factor Research, V6, P119, DOI 10.1016/0955-2235(95)00020-8; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yeagley D, 2000, J BIOL CHEM, V275, P17814, DOI 10.1074/jbc.M909842199	50	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8507	8515		10.1074/jbc.M008541200	http://dx.doi.org/10.1074/jbc.M008541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11116147	hybrid			2022-12-25	WOS:000167474900112
J	Sun, YM; Flanagan, CA; Illing, N; Ott, TR; Sellar, R; Fromme, BJ; Hapgood, J; Sharp, P; Sealfon, SC; Millar, RP				Sun, YM; Flanagan, CA; Illing, N; Ott, TR; Sellar, R; Fromme, BJ; Hapgood, J; Sharp, P; Sealfon, SC; Millar, RP			A chicken gonadotropin-releasing hormone receptor that confers agonist activity to mammalian antagonists - Identification of D-Lys(6) in the ligand and extracellular loop two of the receptor as determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GNRH RECEPTOR; CLINICAL-APPLICATIONS; ACTIVATION; BINDING; MUTATION; CLONING; GENE; INTERNALIZATION; EXPRESSION	Mammalian receptors for gonadotropin-releasing hormone (GnRH) have over 85% sequence homology and similar ligand selectivity. Biological studies indicated that the chicken GnRH receptor has a distinct pharmacology, and certain antagonists of mammalian GnRH receptors function as agonists. To explore the structural determinants of this, we have cloned a chicken pituitary GnRH receptor and demonstrated that it has marked differences in primary amino acid sequence (59% homology) and in its interactions with GnRH analogs. The chicken GnRH receptor had high affinity for mammalian GnRH (K-i 4.1 +/- 1.2 nM), similar to the human receptor (K-i 4.8 +/- 1.2 nM). But, in contrast to the human receptor, it also had high affinity for chicken GnRH ([Gln(8)]GnRH) and GnRH II ([His(5),Trp(7),Tyr(8)]GnRH) (K-i 5.3 +/- 0.5 and 0.6 +/- 0.01 nM). Three mammalian receptor antagonists were also pure antagonists in the chicken GnRH receptor. Another three, characterized by D-Lys(6) or D-isopropyl-Lys(6) moieties, functioned as pure antagonists in the human receptor but were full or partial agonists in the chicken receptor. This suggests that the Lys side chain interacts with functional groups of the chicken GnRH receptor to stabilize it in the active conformation and that these groups are not available in the activated human GnRH receptor. Substitution of the human receptor extracellular loop two with the chicken extracellular loop two identified this domain as capable of conferring agonist activity to mammalian antagonists. Although functioning of antagonists as agonists has been shown to be species-dependent for several GPCRs, the dependence of this on an extracellular domain has not been described.	MRC, Human Reprod Sci Unit, Edinburgh EH3 9ET, Midlothian, Scotland; Univ Cape Town, MRC, UCT Res Unit Mol Reprod Endocrinol, ZA-7925 Cape Town, South Africa; Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa; Roslin Inst Edinburgh, Div Integrat Biol, Roslin EH25 9PS, Midlothian, Scotland; CUNY, Mt Sinai Med Ctr, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	University of Cape Town; University of Cape Town; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Millar, RP (corresponding author), MRC, Human Reprod Sci Unit, 37 Chalmers St, Edinburgh EH3 9ET, Midlothian, Scotland.		Flanagan, Colleen/ABG-2109-2020; Hapgood, Janet P/P-2549-2018; Millar, Robert P/A-4853-2012; Sun, Yuh-Man/N-1579-2014	Hapgood, Janet P/0000-0002-4414-4861; SEALFON, Stuart/0000-0001-5791-1217; Millar, Robert P/0000-0003-3606-2708; Flanagan, Colleen A./0000-0003-2803-8986	NIDDK NIH HHS [R01 DK46943] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046943] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARBIERI RL, 1992, TRENDS ENDOCRIN MET, V3, P30, DOI 10.1016/1043-2760(92)90089-J; Borda E, 1999, INT J CARDIOL, V70, P23, DOI 10.1016/S0167-5273(99)00041-8; CASPER RF, 1991, CAN MED ASSOC J, V144, P153; CHI L, 1993, MOL CELL ENDOCRINOL, V91, pR1, DOI 10.1016/0303-7207(93)90278-R; Claude PA, 1996, P NATL ACAD SCI USA, V93, P5715, DOI 10.1073/pnas.93.12.5715; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAVIDSON JS, 1995, MOL CELL ENDOCRINOL, V107, P241, DOI 10.1016/0303-7207(94)03449-4; Davidson JS, 1997, BIOCHEMISTRY-US, V36, P12881, DOI 10.1021/bi971377t; Davidson JS, 1996, J BIOL CHEM, V271, P15510, DOI 10.1074/jbc.271.26.15510; DAVIES HML, 1995, ADV NITROG HETERCYC, V1, P1, DOI DOI 10.1016/S1521-4478(06)80013-2; DODGSON JB, 1979, CELL, V17, P879, DOI 10.1016/0092-8674(79)90328-3; FAN NC, 1994, MOL CELL ENDOCRINOL, V103, pR1; Fianagan CA, 1999, J BIOL CHEM, V274, P28880, DOI 10.1074/jbc.274.41.28880; FLANAGAN CA, 1994, J BIOL CHEM, V269, P22636; Flanagan CA, 2000, BIOCHEMISTRY-US, V39, P8133, DOI 10.1021/bi000085g; Fu ML, 1998, RECEPTOR CHANNEL, V6, P99; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Guarnieri F, 1996, J AM CHEM SOC, V118, P5580, DOI 10.1021/ja952745o; Han M, 1997, J BIOL CHEM, V272, P23081, DOI 10.1074/jbc.272.37.23081; Hauser F, 1998, BIOCHEM BIOPH RES CO, V249, P822, DOI 10.1006/bbrc.1998.9230; Illing N, 1999, P NATL ACAD SCI USA, V96, P2526, DOI 10.1073/pnas.96.5.2526; ILLING N, 1993, BIOCHEM BIOPH RES CO, V196, P745, DOI 10.1006/bbrc.1993.2312; JACOBS GFM, 1995, MOL CELL ENDOCRINOL, V108, P107, DOI 10.1016/0303-7207(94)03463-4; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Lebesgue D, 1998, EUR J PHARMACOL, V348, P123, DOI 10.1016/S0014-2999(98)00136-8; Lin XW, 1998, MOL ENDOCRINOL, V12, P161, DOI 10.1210/me.12.2.161; Maliekal JC, 1997, S AFR J CHEM-S-AFR T, V50, P217; Masuda MO, 1998, FASEB J, V12, P1551, DOI 10.1096/fasebj.12.14.1551; MILLAR RP, 1986, ENDOCRINOLOGY, V119, P224, DOI 10.1210/endo-119-1-224; MILLAR RP, 1989, J BIOL CHEM, V264, P21007; MILLAR RP, 1987, S AFR MED J, V72, P748; Morin D, 1998, FEBS LETT, V441, P470, DOI 10.1016/S0014-5793(98)01585-3; Myburgh DB, 1998, BIOCHEM J, V331, P893, DOI 10.1042/bj3310893; Noda K, 1996, BIOCHEMISTRY-US, V35, P16435, DOI 10.1021/bi961593m; Pawson AJ, 1998, J ENDOCRINOL, V156, pR9, DOI 10.1677/joe.0.156R009; Reinhart J, 1997, MOL CELL ENDOCRINOL, V130, P1, DOI 10.1016/S0303-7207(97)00064-6; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Spivak CE, 1997, MOL PHARMACOL, V52, P983, DOI 10.1124/mol.52.6.983; STRADER CD, 1989, J BIOL CHEM, V264, P16470; Sun YM, 1998, ENDOCRINOLOGY, V139, P3390, DOI 10.1210/en.139.8.3390; Tensen C, 1997, EUR J BIOCHEM, V243, P134, DOI 10.1111/j.1432-1033.1997.0134a.x; Troskie B, 1998, GEN COMP ENDOCR, V112, P296, DOI 10.1006/gcen.1998.7156; Troskie BE, 2000, ENDOCRINOLOGY, V141, P1764, DOI 10.1210/en.141.5.1764; Wurch T, 1999, BRIT J PHARMACOL, V126, P939, DOI 10.1038/sj.bjp.0702379; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZHOU W, 1995, J BIOL CHEM, V270, P18853, DOI 10.1074/jbc.270.32.18853	53	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7754	7761		10.1074/jbc.M009020200	http://dx.doi.org/10.1074/jbc.M009020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11112780	hybrid			2022-12-25	WOS:000167474900013
J	Dai, BS; Wu, H; Holthuizen, E; Singh, P				Dai, BS; Wu, H; Holthuizen, E; Singh, P			Identification of a novel cis element required for cell density-dependent down-regulation of insulin-like growth factor-2 P3 promoter activity in CaCo2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-II OVEREXPRESSION; FACTOR (IGF)-II; FACTOR SYSTEM; EXPRESSION; GENE; DIFFERENTIATION; LINE; PROLIFERATION; ACTIVATION; MECHANISM	The activity of the exogenous, full-length insulin-like growth factor-2 (IGF-2) P3 promoter is significantly upregulated during the logarithmic growth phase but rapidly declines in confluent CaCo2 cells undergoing differentiation. Nuclear run-on assays confirmed cell density-dependent regulation of endogenous P3 promoter. To identify regulatory elements in the P3 promoter that may be required for regulating cell density-dependent transcriptional activity, we used the methods of promoter truncation, electrophoretic mobility shift assay, DNase footprintinp, and mutation analysis. The relative activity of the full-length (-1229/+140) and truncated (-1090/+140) promoter was identical, being similar to 19, 27, 7, and 3% of pSV-luc activity on days 3, 5, 7, and 9 of cell culture, respectively. However, truncation to -1048 resulted in complete loss of cell density-dependent downregulation of P3 promoter activity on days 7 and 9, suggesting the presence of regulatory elements between -1091 and -1048 sequence. Further stepwise truncation to -515 did not change promoter activity. Truncation to -138/+140 resulted in complete loss of promoter activity, suggesting that the core promoter was within the -515/-138 segment. A 14-basepair footprint (-1084/-1070) was identified by DNase footprinting within the distal -1091/-1048 segment. Electrophoretic mobility shift assay with wild type and mutant probes confirmed the presence of a novel 7-base pair (CGAGGGC) (-1084/-1078) cis element (P3-D); its mutation abolished binding. Functionality of P3-D cis element was confirmed by measuring the activity of core P3 promoter ligated to distal P3 segment containing either the mutant or wild type P3-D element. We have, therefore, identified a novel cis element, P3-D, that appears to play a critical role in regulating IGF-2 P3 promoter activity in a cell density/differentiation-dependent manner.	Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77555 USA; Univ Utrecht, Physiol Chem Lab, NL-3586 CG Utrecht, Netherlands	University of Texas System; University of Texas Medical Branch Galveston; Utrecht University	Singh, P (corresponding author), Univ Texas, Med Branch, Dept Anat & Neurosci, 10-138 Med Res Bldg,1043, Galveston, TX 77555 USA.	posingh@utmb.edu			NCI NIH HHS [CA60087, CA72992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABMAYR SM, 1988, CURRENT PROTOCOLS MO; Dai BS, 1997, ENDOCRINOLOGY, V138, P332, DOI 10.1210/en.138.1.332; Djelloul S, 1997, FEBS LETT, V406, P234, DOI 10.1016/S0014-5793(97)00208-1; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FREJER S, 1999, GUT, V44, P704; GREENBERG ME, 1994, CURRENT PROTOCOLS MO; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; Hodzic D, 1997, HORM METAB RES, V29, P549, DOI 10.1055/s-2007-979099; HOLTHUIZEN P, 1991, MODERN CONCEPTS INSU, P733; Holthuizen PE, 1999, CONT ENDOCRINOL, V17, P37; Kawamoto K, 1999, CANCER, V85, P18, DOI 10.1002/(SICI)1097-0142(19990101)85:1<18::AID-CNCR3>3.0.CO;2-4; Lahm H, 1996, BIOCHEM BIOPH RES CO, V220, P334, DOI 10.1006/bbrc.1996.0406; LAMONERIE T, 1995, EXP CELL RES, V216, P342, DOI 10.1006/excr.1995.1043; Li SL, 1998, CELL TISSUE RES, V291, P469, DOI 10.1007/s004410051016; MacDonald RG, 1999, J GASTROEN HEPATOL, V14, P72, DOI 10.1046/j.1440-1746.1999.01803.x; PERDUE JF, 1991, ENDOCRINOLOGY, V129, P3101, DOI 10.1210/endo-129-6-3101; PETERSON MD, 1992, J CELL SCI, V102, P581; Rietveld LEG, 1997, BIOCHEM J, V327, P689; Rietveld LEG, 1999, BIOCHEM J, V338, P799, DOI 10.1042/0264-6021:3380799; Simmons JG, 1999, AM J PHYSIOL-GASTR L, V276, pG817, DOI 10.1152/ajpgi.1999.276.4.G817; Singh P, 1998, GASTROENTEROLOGY, V114, P1221, DOI 10.1016/S0016-5085(98)70428-7; SINGH P, 1991, IN VITRO CELL DEV B, V27, P755; Singh P, 2000, J CLIN LIGAND ASSAY, V23, P214; Singh P, 1996, ENDOCRINOLOGY, V137, P1764, DOI 10.1210/en.137.5.1764; SINGH P, 1994, AM J PHYSIOL-GASTR L, V267, pG608, DOI 10.1152/ajpgi.1994.267.4.G608; SINGH P, 1994, CANCER RES, V266, pG459; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; TRICOLI JV, 1986, CANCER RES, V46, P6169; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; VANDIJK MA, 1992, MOL CELL ENDOCRINOL, V88, P175, DOI 10.1016/0303-7207(92)90022-X; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Winkler R, 1999, HORM METAB RES, V31, P148, DOI 10.1055/s-2007-978713; ZARRILLI R, 1994, CELL GROWTH DIFFER, V5, P1085; Zarrilli R, 1996, J BIOL CHEM, V271, P8108, DOI 10.1074/jbc.271.14.8108; Zhang LJ, 1998, ONCOGENE, V17, P1261, DOI 10.1038/sj.onc.1202050; Zhang LJ, 1996, CANCER RES, V56, P1367	37	8	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6937	6944		10.1074/jbc.M007789200	http://dx.doi.org/10.1074/jbc.M007789200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11112775	hybrid			2022-12-25	WOS:000167442900012
J	Sarkela, TM; Berthiaume, J; Elfering, S; Gybina, AA; Giulivi, C				Sarkela, TM; Berthiaume, J; Elfering, S; Gybina, AA; Giulivi, C			The modulation of oxygen radical production by nitric oxide in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-L-ARGININE; HYDROGEN-PEROXIDE; SYNTHASE; GLUTATHIONE; INACTIVATION; INHIBITION; METABOLISM; OXIDATION; MECHANISM; CHEMISTRY	Biological systems that produce or are exposed to nitric oxide (NO.) exhibit changes in the rate of oxygen free radical production. Considering that mitochondria are the main intracellular source of oxygen radicals, and based on the recently documented production of NO. by intact mitochondria, we investigated whether NO., produced by the mitochondrial nitric-oxide synthase, could affect the generation of oxygen radicals. Toward this end, changes in H2O2 production by rat liver mitochondria were monitored at different rates of endogenous NO. production. The observed changes in H2O2 production indicated that NO. affected the rate of oxygen radical production by modulating the rate of O-2 consumption at the cytochrome oxidase level. This mechanism was supported by these three experimental proofs: 1) the reciprocal correlation between H2O2 production and respiratory rates under different conditions of NO. production; 2) the pattern of oxidized/reduced carriers in the presence of NO., which pointed to cytochrome oxidase as the crossover point; and 3) the reversibility of these effects, evidenced in the presence of oxymyoglobin, which excluded a significant role for other NO.-derived species such as peroxynitrite. Other sources of H2O2 investigated, such as the aerobic formation of nitrosoglutathione and the GSH-mediated decay of nitrosoglutathione, were found quantitatively negligible compared with the total rate of H2O2 production.	Univ Minnesota, Dept Chem, Duluth, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth	Giulivi, C (corresponding author), Univ Minnesota, Dept Chem, 10 Univ Dr, Duluth, MN 55812 USA.		Giulivi, Cecilia/ABB-7809-2020; Giulivi, Cecilia/AAV-6774-2021	Giulivi, Cecilia/0000-0003-1033-7435; 				BECKMAN JS, 1996, NITRIC OXIDE PRINCIP, P1, DOI DOI 10.1016/B978-012435555-2/50002-4; BOVERIS A, 1977, ANAL BIOCHEM, V80, P145, DOI 10.1016/0003-2697(77)90634-0; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, BBA-BIOENERGETICS, V1366, P265, DOI 10.1016/S0005-2728(98)00125-X; GIULIVI C, 1994, FREE RADICAL BIO MED, V16, P123, DOI 10.1016/0891-5849(94)90249-6; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GIULIVI C, 1996, P 3 ANN M OX SOC, P25; Giulivi Cecilia, 1999, P77; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; MARTENS ME, 1988, ANN NEUROL, V24, P630, DOI 10.1002/ana.410240507; MEISTER A, 1983, SCIENCE, V220, P470; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; OLKEN NM, 1994, BIOCHEMISTRY-US, V33, P14784, DOI 10.1021/bi00253a017; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; SAUNDERS BC, 1964, PEROXIDASE, P169; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; YONETANI T, 1961, J BIOL CHEM, V236, P1680	33	103	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6945	6949		10.1074/jbc.M007625200	http://dx.doi.org/10.1074/jbc.M007625200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11106647	hybrid			2022-12-25	WOS:000167442900013
J	Vener, AV; Harms, A; Sussman, MR; Vierstra, RD				Vener, AV; Harms, A; Sussman, MR; Vierstra, RD			Mass spectrometric resolution of reversible protein phosphorylation in photosynthetic membranes of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; POSTTRANSLATIONAL MODIFICATIONS; CHLOROPLAST PHOSPHOPROTEINS; AFFINITY-CHROMATOGRAPHY; SIGNAL-TRANSDUCTION; PLANT CHLOROPLASTS; IN-VIVO; SITE; PHOSPHATASE; KINASES	The use of mass spectrometry to characterize the phosphorylome, i.e. the constituents of the proteome that become phosphorylated, was demonstrated using the reversible phosphorylation of chloroplast thylakoid proteins as an example. From the analysis of tryptic peptides released from the surface of drabidopsis thylakoids, the principal phosphoproteins were identified by matrix-assisted laser desorption/ionization and electrospray ionization mass spectrometry. These studies revealed that the D1, D2, and CP43 proteins of the photosystem II core are phosphorylated at their N-terminal threonines (Thr), the peripheral PsbH protein is phosphorylated at Thr-2, and the mature light harvesting polypeptides LCHII are phosphorylated at Thr-3, In addition, a doubly phosphorylated form of PsbH modified at both Thr-2 and Thr-4 was detected. By comparing the levels of phospho- and nonphosphopeptides, the in vivo phosphorylation states of these proteins were analyzed under different physiological conditions. None of these thylakoid proteins were completely phosphorylated in the steady state conditions of continuous light or completely dephosphorylated after a long dark adaptation. However, rapid reversible hyperphosphorylation of PsbH at Thr-4 in response to growth in light/dark transitions and a pronounced specific dephosphorylation of the D1, D2, and CP43 proteins during heat shock was detected. Collectively, our data indicate that changes in the phosphorylation of photosynthetic proteins are more rapid during heat stress than during normal light/dark transitions. These mass spectrometry methods offer a new approach to assess the stoichiometry of in vivo protein phosphorylation in complex samples.	Univ Wisconsin, Dept Hort, Madison, WI 53706 USA; Univ Wisconsin, Cell & Mol Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Ctr Biotechnol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Vener, AV (corresponding author), Univ Wisconsin, Dept Hort, 1575 Linden Dr, Madison, WI 53706 USA.			Harms, Amy/0000-0002-2931-4295				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; Andersson B, 1997, PHYSIOL PLANTARUM, V100, P780, DOI 10.1034/j.1399-3054.1997.1000405.x; ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; Annan RS, 1997, J PROTEIN CHEM, V16, P391, DOI 10.1023/A:1026384605285; Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; Barber J, 1997, PHYSIOL PLANTARUM, V100, P817, DOI 10.1034/j.1399-3054.1997.1000408.x; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNETT J, 1980, EUR J BIOCHEM, V104, P85, DOI 10.1111/j.1432-1033.1980.tb04403.x; BENNETT J, 1980, P NATL ACAD SCI-BIOL, V77, P5253, DOI 10.1073/pnas.77.9.5253; Carlberg I, 1999, BIOCHEMISTRY-US, V38, P3197, DOI 10.1021/bi982506o; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; EBBERT V, 2000, IN PRESS PHOTOSYNTH; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Kruse O, 1997, FEBS LETT, V408, P276, DOI 10.1016/S0014-5793(97)00439-0; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MICHEL H, 1991, J BIOL CHEM, V266, P17584; MICHEL HP, 1987, FEBS LETT, V212, P103, DOI 10.1016/0014-5793(87)81565-X; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; O'Connor HE, 1998, BBA-BIOENERGETICS, V1364, P63, DOI 10.1016/S0005-2728(98)00013-9; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Resing KA, 1997, METHOD ENZYMOL, V283, P29; Rintamaki E, 1997, J BIOL CHEM, V272, P30476, DOI 10.1074/jbc.272.48.30476; Rintamaki E, 1996, J BIOL CHEM, V271, P14870, DOI 10.1074/jbc.271.25.14870; Rokka A, 2000, PLANT PHYSIOL, V123, P1525, DOI 10.1104/pp.123.4.1525; Sato S, 1999, DNA Res, V6, P283, DOI 10.1093/dnares/6.5.283; SILVERSTEIN T, 1993, FEBS LETT, V334, P101, DOI 10.1016/0014-5793(93)81690-2; Snyders S, 1999, J BIOL CHEM, V274, P9137, DOI 10.1074/jbc.274.14.9137; Summer EJ, 1997, PLANT PHYSIOL, V113, P1359, DOI 10.1104/pp.113.4.1359; Vener AV, 1998, CURR OPIN PLANT BIOL, V1, P217, DOI 10.1016/S1369-5266(98)80107-6; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; Vener AV, 1999, BIOCHEMISTRY-US, V38, P14955, DOI 10.1021/bi990971v; VENER AV, 1990, BIOSYSTEMS, V24, P53, DOI 10.1016/0303-2647(90)90029-Z; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225	38	166	191	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6959	6966		10.1074/jbc.M009394200	http://dx.doi.org/10.1074/jbc.M009394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113141	hybrid			2022-12-25	WOS:000167442900015
J	Waite, KJ; Floyd, ZE; Arbour-Reily, P; Stephens, JM				Waite, KJ; Floyd, ZE; Arbour-Reily, P; Stephens, JM			Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-MEDIATED PHOSPHORYLATION; NECROSIS-FACTOR-ALPHA; PPAR-GAMMA; TRANSCRIPTIONAL REPRESSION; ADIPOSE CONVERSION; SIGNAL TRANSDUCERS; 3T3-L1 ADIPOCYTES; ADIPOGENESIS; DIFFERENTIATION; INHIBITION	Interferon-gamma (IFN-gamma) is known primarily for its roles in immunological responses but also has been shown to affect fat metabolism and adipocyte gene expression. To further investigate the effects of IFN-gamma on fat cells, we examined the effects of this cytokine on the expression of adipocyte transcription factors in 3T3-L1 adipocytes, Although IFN-gamma regulated the expression of several adipocyte transcription factors, IFN-gamma treatment resulted in a rapid reduction of both peroxisome proliferator-activated receptor (PPAR) protein and mRNA. A 48-h exposure to IFN-gamma also resulted in a decrease of both CCAAT/enhancer-binding alpha and sterol regulatory element binding protein (SREBP-1) expression. The short half-life of both the PPAR gamma mRNA and protein likely contributed to the rapid decline of both cytosolic and nuclear PPAR gamma in the presence of IFN-gamma. Our studies clearly demonstrated that the IFN-gamma -induced loss of PPAR gamma protein is partially inhibited in the presence of two distinct proteasome inhibitors. Moreover, IFN-gamma also inhibited the transcription of PPAR gamma, which was accompanied by a decrease in PPAR gamma mRNA accumulation. In addition, exposure to IFN-gamma resulted in a substantial increase in STAT I expression and a small increase in STAT 3 expression. IFN-gamma treatment of 3T3-L1 adipocytes (48-96 h) resulted in a substantial inhibition of insulin-sensitive glucose uptake. These data clearly demonstrate that IFN-gamma treatment results in the development of insulin resistance, which is accompanied by the regulation of various adipocyte transcription factors, in particular the synthesis and degradation of PPAR gamma.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Stephens, JM (corresponding author), Louisiana State Univ, Dept Biol Sci, 508 Life Sci Bldg, Baton Rouge, LA 70803 USA.	jsteph1@unix1.sncc.lsu.edu	Stephens, Jacqueline M/R-5217-2018; Floyd, Elizabeth/W-2758-2019; Floyd, Elizabeth/N-1962-2017	Floyd, Elizabeth/0000-0002-3002-6186; Floyd, Elizabeth/0000-0002-3002-6186	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052968] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK52968-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; CARAP HS, 1999, ENDOCRINOLOGY, V140, P392; CARAP HS, 1997, J BIOL CHEM, V272, P10811; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deng JB, 2000, ENDOCRINOLOGY, V141, P2370, DOI 10.1210/en.141.7.2370; DOERRLER W, 1994, CYTOKINE, V6, P478, DOI 10.1016/1043-4666(94)90074-4; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GREGOIRE F, 1992, J CELL PHYSIOL, V151, P300, DOI 10.1002/jcp.1041510211; Grossberg S E, 1980, Ann N Y Acad Sci, V350, P294, DOI 10.1111/j.1749-6632.1980.tb20629.x; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KEAY S, 1980, P NATL ACAD SCI-BIOL, V77, P4099, DOI 10.1073/pnas.77.7.4099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Morrison RF, 1999, J CELL BIOCHEM, P59; Rosen ED, 2000, GENE DEV, V14, P1293; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Stephens JM, 1999, BIOCHEM BIOPH RES CO, V262, P216, DOI 10.1006/bbrc.1999.0889; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; Stephens JM, 1996, J BIOL CHEM, V271, P10441, DOI 10.1074/jbc.271.18.10441; Stewart WC, 1999, BBA-MOL CELL RES, V1452, P188, DOI 10.1016/S0167-4889(99)00129-9; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; Zhou YC, 1999, J BIOL CHEM, V274, P2672, DOI 10.1074/jbc.274.5.2672; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	29	120	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7062	7068		10.1074/jbc.M007894200	http://dx.doi.org/10.1074/jbc.M007894200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11106650	Green Published, hybrid			2022-12-25	WOS:000167442900030
J	Feliciangeli, S; Kitabgi, P; Bidard, JN				Feliciangeli, S; Kitabgi, P; Bidard, JN			The role of dibasic residues in prohormone sorting to the regulated secretory pathway - A study with proneurotensin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROMEDIN-N-PRECURSOR; TRANS-GOLGI NETWORK; TRANSFECTED PC12 CELLS; PITUITARY ATT-20 CELLS; DISULFIDE-BONDED LOOP; PANCREATIC BETA-CELLS; CHROMOGRANIN-B; BIOCHEMICAL-CHARACTERIZATION; GRANULE BIOGENESIS; CARBOXYPEPTIDASE-E	The mechanisms by which prohormone precursors are sorted to the regulated secretory pathway in neuroendocrine cells remain poorly understood. Here, we investigated the presence of sorting signal(s) in proneurotensin/neuromedin N. The precursor sequence starts with a long N-terminal domain followed by a Lys-Arg-(neuromedin N)-Lys-Arg-(neurotensin)-Lys-Arg- sequence and a short C-terminal tail. An additional Arg-Arg dibasic is contained within the neurotensin sequence. Mutated precursors were expressed in endocrine insulinoma cells and analyzed for their regulated secretion. Deletion mutants revealed that the N-terminal domain and the Lys-Arg (C-terminal tail) sequence were not critical for precursor sorting to secretory granules. In contrast, the Lys-Arg-(neuromedin N)-Lys-Arg-(neurotensin) sequence contained essential sorting information. Point mutation of all three dibasic sites within this sequence abolished regulated secretion. However, keeping intact any one of the three dibasic sequences was sufficient to maintain regulated secretion. Finally, fusing the dibasic-containing C-terminal domain of the precursor to the C terminus of beta -lactamase, a bacterial enzyme that is constitutively secreted when expressed in neuroendocrine cells, resulted in efficient sorting of the fusion protein to secretory granules in insulinoma cells. We conclude that dibasic motifs within the neuropeptide domain of proneurotensin/neuromedin N constitute a necessary and sufficient signal for sorting proteins to the regulated secretory pathway.	CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Kitabgi, P (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, 660 Route Lucioles, F-06560 Valbonne, France.		Feliciangeli, Sylvain/Q-1292-2016	Feliciangeli, Sylvain/0000-0003-3358-3719				ARVAN P, 1991, J BIOL CHEM, V266, P14171; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BAILYES EM, 1991, ENZYME, V45, P301, DOI 10.1159/000468903; Barbero P, 1998, J BIOL CHEM, V273, P25339, DOI 10.1074/jbc.273.39.25339; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BIDARD JN, 1993, BIOCHEM J, V291, P225, DOI 10.1042/bj2910225; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRAKCH N, 1994, BIOCHEM BIOPH RES CO, V205, P221, DOI 10.1006/bbrc.1994.2653; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHEVRIER D, 1993, MOL CELL ENDOCRINOL, V94, P213, DOI 10.1016/0303-7207(93)90170-O; CHIDGEY MAJ, 1990, EUR J BIOCHEM, V190, P139, DOI 10.1111/j.1432-1033.1990.tb15556.x; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; DENADAI F, 1994, NEUROSCIENCE, V60, P159, DOI 10.1016/0306-4522(94)90211-9; DOBNER PR, 1987, P NATL ACAD SCI USA, V84, P3516, DOI 10.1073/pnas.84.10.3516; EFRAT S, 1993, DIABETES, V42, P901, DOI 10.2337/diabetes.42.6.901; EFRAT S, 1991, J BIOL CHEM, V266, P11141; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Glombik MM, 2000, BIOCHIMIE, V82, P315, DOI 10.1016/S0300-9084(00)00195-4; GORR SU, 1995, FEBS LETT, V361, P8, DOI 10.1016/0014-5793(95)00142-V; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HALBAN PA, 1994, BIOCHEM J, V299, P1; Harrison TM, 1996, CELL BIOL INT, V20, P293, DOI 10.1006/cbir.1996.0033; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; Kuliawat R, 2000, MOL BIOL CELL, V11, P1959, DOI 10.1091/mbc.11.6.1959; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; NAGAHAMA M, 1990, FEBS LETT, V264, P67, DOI 10.1016/0014-5793(90)80766-C; NAKAYAMA K, 1989, FEBS LETT, V257, P89, DOI 10.1016/0014-5793(89)81793-4; Natori S, 1996, P NATL ACAD SCI USA, V93, P4431, DOI 10.1073/pnas.93.9.4431; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; ROVERE C, 1993, PEPTIDES, V14, P983, DOI 10.1016/0196-9781(93)90075-R; ROY P, 1991, MOL CELL ENDOCRINOL, V82, P237, DOI 10.1016/0303-7207(91)90037-S; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SEVARINO KA, 1991, J BIOL CHEM, V266, P18507; STEINER DF, 1992, DIABETOLOGIA, V35, pS41, DOI 10.1007/BF00586278; Thiele C, 1997, CURR BIOL, V7, P496; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU Y, 1994, J BIOL CHEM, V269, P18408	49	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6140	6150		10.1074/jbc.M009613200	http://dx.doi.org/10.1074/jbc.M009613200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11104773	hybrid			2022-12-25	WOS:000167261000014
J	Zouki, C; Zhang, SL; Chan, JSD; Filep, JG				Zouki, C; Zhang, SL; Chan, JSD; Filep, JG			Peroxynitrite induces integrin-dependent adhesion of human neutrophils to endothelial cells via activation of the Raf-1/MEK/Erk pathway	FASEB JOURNAL			English	Article									Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Dept Med, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal	Filep, JG (corresponding author), Hop Maison Neuve Rosemont, Res Ctr, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.								0	79	84	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					25	27						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099490				2022-12-25	WOS:000166312400009
J	Kamalati, T; Jolin, HE; Fry, MJ; Crompton, MR				Kamalati, T; Jolin, HE; Fry, MJ; Crompton, MR			Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation	ONCOGENE			English	Article						BRK; breast cancer; epithelial cells; EGF; erbB3; PI 3-kinase	EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GASTROINTESTINAL-TRACT; RECEPTOR FAMILY; PROTEIN-KINASE; GENE; TUMORS	A high proportion of human breast cancers, in contrast with normal mammary tissue, express the intracellular tyrosine kinase BRK, BRK expression enhances the mitogenic response of mammary epithelial cells to epidermal growth factor, and conferment of a proliferative advantage through this mechanism may account for the frequent elevation of BRK expression in tumours, Here we report that BRK expression in mammary epithelial cells, at pathologically relevant levels, results in an enhanced phosphorylation of the epidermal growth factor receptor-related receptor erbB3 in response to epidermal growth factor. As a consequence, erbB3 recruits increased levels of phosphoinositide 3-kinase, and this is associated with a potentiated activation of Akt, This effect of BRK on the regulation of phosphoinositide 3-kinase and Akt activity may account for BRK's ability to enhance mammary cell mitogenesis, and raises the possibility that breast tumours expressing BRK may acquire a resistance to pro-apoptotic signals.	Univ London, Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Univ London Imperial Coll Sci Technol & Med, CRC Labs, Sch Med, London W12 0NN, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of London; Royal Holloway University London; Imperial College London; MRC Laboratory Molecular Biology; University of Reading	Crompton, MR (corresponding author), Univ London, Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England.			Fry, Michael/0000-0001-8518-1370				Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Lee HY, 1998, MOL CELLS, V8, P401; Llor X, 1999, CLIN CANCER RES, V5, P1767; Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	28	89	91	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5471	5476		10.1038/sj.onc.1203931	http://dx.doi.org/10.1038/sj.onc.1203931			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114724				2022-12-25	WOS:000165396100007
J	Lebars, I; Hu, RM; Lallemand, JY; Uzan, M; Bontems, F				Lebars, I; Hu, RM; Lallemand, JY; Uzan, M; Bontems, F			Role of the substrate conformation and of the S1 protein in the cleavage efficiency of the T4 endoribonuclease RegB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T7 RNA-POLYMERASE; MESSENGER-RNA; ESCHERICHIA-COLI; BIOLOGICAL MACROMOLECULES; BACTERIOPHAGE-T4; NMR; STABILITY; LOCALIZATION; RIBONUCLEASE; DEGRADATION	The T4 endoribonuclease RegB is involved in the inactivation of the phage early messengers. It cuts specifically in the middle of GGAG sequences found in early messenger intergenic regions but not GGAG sequences located in coding sequences or in late messengers. In vitro RegB activity is very low but is enhanced by a factor up to 100 by the ribosomal protein S1. In the absence of clear sequence motif distinguishing substrate and non-substrate GGAG-containing RNAs, we postulated the existence of a structural determinant. To test this hypothesis, we correlated the structure, probed by NMR spectroscopy, with the cleavage propensity of short RNA molecules derived from an artificial substrate. A kinetic analysis of the cleavage was performed in the presence and absence of SI. In the absence of S1, RegB efficiently hydrolyses substrates in which the last G of the GGAG motif is located in a short stem between two loops. Both strengthening and weakening of this structure strongly decrease the cleavage rate, indicating that this structure constitutes a positive cleavage determinant. Based on our results and those of others, we speculate that S1 favors the formation of the structure recognized by RegB and can thus be considered a "presentation protein".	Ecole Polytech, Lab Dept Chim Synthese Organ, Grp Resonance Magnet Nucl, F-91128 Palaiseau, France; Inst Jaques Monod, F-75005 Paris, France	Institut Polytechnique de Paris; UDICE-French Research Universities; Universite Paris Cite	Bontems, F (corresponding author), Ecole Polytech, Lab Dept Chim Synthese Organ, Grp Resonance Magnet Nucl, F-91128 Palaiseau, France.	francois.bontems@polytechnique.fr	Lebars, Isabelle/P-8651-2016	Lebars, Isabelle/0000-0003-0157-4033				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CAZENAVE C, 1994, P NATL ACAD SCI USA, V91, P6972, DOI 10.1073/pnas.91.15.6972; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; DELSUC MA, 1989, FUND THEOR, V36, P285; Derrigo M, 2000, INT J MOL MED, V5, P111; Jayasena VK, 1996, BIOCHEMISTRY-US, V35, P2349, DOI 10.1021/bi951879b; Kaberdin VR, 2000, J MOL BIOL, V301, P257, DOI 10.1006/jmbi.2000.3962; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LANE AN, 1994, METHOD ENZYMOL, V239, P596; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Petersen C, 1993, CONTROL MESSENGER RN, P117; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROUH A, 1993, J MAGN RESON SER A, V102, P357, DOI 10.1006/jmra.1993.1117; RUCKMAN J, 1994, J BIOL CHEM, V269, P26655; RUCKMAN J, 1993, THESIS U COLORADO; Sanson B, 2000, J MOL BIOL, V297, P1063, DOI 10.1006/jmbi.2000.3626; SANSON B, 1993, J MOL BIOL, V233, P429, DOI 10.1006/jmbi.1993.1522; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; SUBRAMANIAN AR, 1981, EUR J BIOCHEM, V119, P245, DOI 10.1111/j.1432-1033.1981.tb05600.x; UZAN M, 1988, P NATL ACAD SCI USA, V85, P8895, DOI 10.1073/pnas.85.23.8895; Vytvytska O, 1998, P NATL ACAD SCI USA, V95, P14118, DOI 10.1073/pnas.95.24.14118; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	28	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13264	13272		10.1074/jbc.M010680200	http://dx.doi.org/10.1074/jbc.M010680200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11118457	hybrid			2022-12-25	WOS:000168198600110
J	Blomgren, K; Zhu, CL; Wang, XY; Karlsson, JO; Leverin, AL; Bahr, BA; Mallard, C; Hagberg, H				Blomgren, K; Zhu, CL; Wang, XY; Karlsson, JO; Leverin, AL; Bahr, BA; Mallard, C; Hagberg, H			Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia - A mechanism of "pathological apoptosis"?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; DNA FRAGMENTATION; CELL-DEATH; RAT-BRAIN; HIPPOCAMPAL SLICES; PROTEASE FAMILIES; NEURONAL DAMAGE; FODRIN CLEAVAGE; CALPASTATIN; INHIBITOR	The relative contributions of apoptosis and necrosis in brain injury have been a matter of much debate. Caspase-3 has been identified as a key protease in the execution of apoptosis, whereas calpains have mainly been implicated in excitotoxic neuronal injury. In a model of unilateral hypoxia-ischemia in 7-day-old rats, caspase-3-like activity increased 16-fold 24 h postinsult, coinciding with cleavage of the caspase-3 proenzyme and endogenous caspase-3 substrates, This activation was significantly decreased by pharmacological calpain inhibition, using CX295, a calpain inhibitor that did not inhibit purified caspase-3 in vitro. Activation of caspase-3 by m-calpain, but not mu -calpain, was facilitated in a dose-dependent manner in vitro by incubating cytosolic fractions, containing caspase-3 preform, with calpains. This facilitation required the presence of some active caspase-3 and could be abolished by including the specific calpain inhibitor calpastatin. This indicates that initial cleavage of caspase-3 by m-calpain, producing a 29-kDa fragment, facilitates the subsequent cleavage into active forms. This is the first report to our knowledge suggesting a direct link between the early, excitotoxic, calcium-mediated activation of calpain after cerebral hypoxia-ischemia and the subsequent activation of caspase-3, thus representing a tentative pathway of "pathological apoptosis.".	Univ Gothenburg, Inst Physiol & Pharmacol, Perinatal Ctr, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Queen Silvia Childrens Hosp, Dept Pediat, Perinatal Ctr, SE-41685 Gothenburg, Sweden; Henan Med Univ, Affiliated Hosp 3, Dept Pediat, Zhengzhou 450052, Peoples R China; Univ Gothenburg, Inst Anat & Cell Biol, SE-40530 Gothenburg, Sweden; Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA; Univ Connecticut, Neurosci Program, Storrs, CT 06269 USA; Sahlgrens Univ Hosp, Dept Obstet & Gynecol, Perinatal Ctr, SE-41685 Gothenburg, Sweden	University of Gothenburg; Queen Silvia Children's Hospital; University of Gothenburg; Zhengzhou University; University of Gothenburg; University of Connecticut; University of Connecticut; Sahlgrenska University Hospital	Blomgren, K (corresponding author), Univ Gothenburg, Inst Physiol & Pharmacol, Perinatal Ctr, POB 432, SE-40530 Gothenburg, Sweden.	klas.blomgren@fysiologi.gu.se	Zhu, Changlian/AAN-6205-2020	Blomgren, Klas/0000-0002-0476-7271; Wang, Xiaoyang/0000-0001-9717-8160; Hagberg, Henrik/0000-0003-3962-1448; Mallard, Carina/0000-0001-8953-919X; Zhu, Changlian/0000-0002-5029-6730				BAHR BA, 1995, J PHARMACOL EXP THER, V273, P902; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BEDNARSKI E, 1995, BRAIN RES, V694, P147, DOI 10.1016/0006-8993(95)00851-G; BELLES B, 1988, PFLUG ARCH EUR J PHY, V412, P554, DOI 10.1007/BF00582548; Blomgren K, 1999, J BIOL CHEM, V274, P14046, DOI 10.1074/jbc.274.20.14046; BLOMGREN K, 1995, BRAIN RES, V684, P143, DOI 10.1016/0006-8993(95)00399-B; BLOMGREN K, 1989, NEUROCHEM RES, V14, P1149, DOI 10.1007/BF00965622; Canu N, 1998, J NEUROSCI, V18, P7061; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Chen J, 1998, J NEUROSCI, V18, P4914; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; HAGBERG H, 1994, BIOL NEONATE, V66, P205; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jin KL, 1999, J NEUROCHEM, V72, P1204, DOI 10.1046/j.1471-4159.1999.0721204.x; KARLSSON JO, 1994, ANAL BIOCHEM, V219, P144, DOI 10.1006/abio.1994.1243; KARLSSON JO, 1985, BIOCHEM J, V231, P201, DOI 10.1042/bj2310201; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Ma JY, 1998, BRIT J PHARMACOL, V124, P756, DOI 10.1038/sj.bjp.0701871; MacManus JP, 1999, J CEREBR BLOOD F MET, V19, P502, DOI 10.1097/00004647-199905000-00004; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Namura S, 1998, J NEUROSCI, V18, P3659; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Ni BH, 1998, J CEREBR BLOOD F MET, V18, P248, DOI 10.1097/00004647-199803000-00003; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Puka-Sundvall M, 2000, NEUROREPORT, V11, P2833, DOI 10.1097/00001756-200009110-00002; Pulera MR, 1998, STROKE, V29, P2622, DOI 10.1161/01.STR.29.12.2622; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; Squier MKT, 1997, J IMMUNOL, V158, P3690; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Villa PG, 1998, J CELL SCI, V111, P713; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yue X, 1997, NEUROPATH APPL NEURO, V23, P16; Zhu CL, 2000, J NEUROCHEM, V75, P819, DOI 10.1046/j.1471-4159.2000.0750819.x	60	361	373	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10191	10198		10.1074/jbc.M007807200	http://dx.doi.org/10.1074/jbc.M007807200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124942	hybrid			2022-12-25	WOS:000167996400081
J	Poon, KKH; Chen, CL; Wong, SL				Poon, KKH; Chen, CL; Wong, SL			Roles of glucitol in the GutR-mediated transcription activation process in Bacillus subtilis - Tight binding of GutR to its binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; COLI MALTOSE SYSTEM; ESCHERICHIA-COLI; RNA-POLYMERASE; KLEBSIELLA-PNEUMONIAE; GENE; EXPRESSION; PROTEIN; DEHYDROGENASE; MALTOTRIOSE	Glucitol induction in Bacillus subtilis requires a transcription activator, GutR, and a sequence located upstream of the gut promoter, To understand the initial steps involved in the GutR-mediated transcription activation process and the physiological roles of glucitol, GutR was overproduced and purified, In the absence of glucitol, GutR exists as a monomer and binds directly to its binding site in the gut regulatory region, This binding site was mapped to a 29-base pair imperfect inverted repeat located between -78 and -50, and there is only one GutR binding site within the regulatory region. The kinetic parameters of the interaction between GutR and its binding site were monitored in real time using surface plasmon resonance. The half-life of the GutR-DNA complex in the absence of glucitol was estimated to be 6.8 min. In contrast, in the presence of glucitol, the half-life of the complex was extended to longer than 19 h by affecting only the off-rate but not the on-rate. This effect is glucitol-specific, These data indicate that glucitol binds to GutR and induces GutR to have an extremely tight binding at its binding site. The physiological relevance of this process in transcription activation is discussed.	Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada	University of Calgary	Wong, SL (corresponding author), Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.		Chen, Chyi-Liang/GVT-1758-2022	Chen, Chyi-Liang/0000-0003-4591-0924				BLAZY B, 1980, MOL BIOL REP, V6, P39, DOI 10.1007/BF00775753; Boos W, 2000, TRENDS GENET, V16, P404, DOI 10.1016/S0168-9525(00)02086-2; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; CHALUMEAU H, 1978, J BACTERIOL, V134, P921; GARCIA GM, 1986, CELL, V45, P453, DOI 10.1016/0092-8674(86)90331-4; GAY P, 1983, J BACTERIOL, V153, P1133, DOI 10.1128/JB.153.3.1133-1137.1983; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HALLING SM, 1977, BIOCHEMISTRY-US, V16, P2880, DOI 10.1021/bi00632a012; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; MOSZER I, 1995, MICROBIOL-SGM, V141, P261, DOI 10.1099/13500872-141-2-261; Neri D, 1996, TRENDS BIOTECHNOL, V14, P465, DOI 10.1016/S0167-7799(96)10067-6; NG K, 1992, J BIOL CHEM, V267, P24989; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; Peng HL, 1997, J BACTERIOL, V179, P1497, DOI 10.1128/jb.179.5.1497-1504.1997; RAIBAUD O, 1987, J BACTERIOL, V169, P3059, DOI 10.1128/jb.169.7.3059-3061.1987; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; Schreiber V, 1999, J BIOL CHEM, V274, P33220, DOI 10.1074/jbc.274.47.33220; SHIMOTSU H, 1986, GENE, V43, P85; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; Stockley PG, 1998, BIOSENS BIOELECTRON, V13, P637, DOI 10.1016/S0956-5663(98)00019-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VIDALINGIGLIARDI D, 1993, J BIOL CHEM, V268, P24527; VIDALINGIGLIARDI D, 1991, J MOL BIOL, V218, P323, DOI 10.1016/0022-2836(91)90715-I; Wu SC, 1999, J BIOTECHNOL, V72, P185, DOI 10.1016/S0168-1656(99)00101-7; WU XC, 1990, J BIOL CHEM, V265, P6845; WU XC, 1991, J BACTERIOL, V173, P4952, DOI 10.1128/jb.173.16.4952-4958.1991; YE RQ, 1994, J BACTERIOL, V176, P3314, DOI 10.1128/jb.176.11.3314-3320.1994; YE RQ, 1994, J BACTERIOL, V176, P3321, DOI 10.1128/jb.176.11.3321-3327.1994	31	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9620	9625		10.1074/jbc.M009864200	http://dx.doi.org/10.1074/jbc.M009864200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11118449	hybrid			2022-12-25	WOS:000167996400007
J	Boren, J; Ekstrom, U; Agren, B; Nilsson-Ehle, P; Innerarity, TL				Boren, J; Ekstrom, U; Agren, B; Nilsson-Ehle, P; Innerarity, TL			The molecular mechanism for the genetic disorder familial defective apolipoprotein B100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; CATION-PI INTERACTIONS; MONOCLONAL-ANTIBODY; BINDING SITE; B-100; LDL; IDENTIFICATION; MUTATION; TRYPTOPHAN; OXIDATION	Familial defective apolipoprotein B100 (FDB) is a genetic disorder in which low density lipoproteins (LDL) bind defectively to the LDL receptor, resulting in hypercholesterolemia and premature atherosclerosis. FDB is caused by a mutation (R3500Q) that changes the conformation of apolipoprotein (apo) B100 near the receptor-binding site. Pie previously showed that arginine, not simply a positive charge, at residue 3500 is essential for normal receptor binding and that the carboxyl terminus of apoB100 is necessary for mutations affecting arginine 3500 to disrupt LDL receptor binding. Thus, normal receptor binding involves an interaction between arginine 3500 and tryptophan 4369 in the carboxyl tail of apoB100. W4369Y LDL and R3500Q LDL isolated from transgenic mice had identically defective LDL binding and a higher affinity for the monoclonal antibody MB47, which has an epitope flanking residue 3500. We conclude that arginine 3500 interacts with tryptophan 4369 and facilitates the conformation of apoB100 required for normal receptor binding of LDL. From our findings, we developed a model that explains how the carboxyl terminus of apoB100 interacts with the backbone of apoB100 that enwraps the LDL particle. Our model also explains how all known ligand-defective mutations in apoB100, including a newly discovered R3480W mutation in apoB100, cause defective receptor binding.	Gothenburg Univ, Wallenberg Lab, S-41345 Gothenburg, Sweden; Univ Lund Hosp, Dept Clin Chem, Inst Lab Med, S-22185 Lund, Sweden; Helsingborg Hosp, Dept Internal Med, S-25187 Helsingborg, Sweden; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA	University of Gothenburg; Lund University; Skane University Hospital; Helsingborgs Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Boren, J (corresponding author), Gothenburg Univ, Sahlgrens Univ Hosp, Wallenberg Lab, S-41345 Gothenburg, Sweden.	jan.boren@wlab.wall.gu.se			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD KS, 1992, LIPOPROTEIN ANAL PRA, P145; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; CHATTERTON JE, 1995, J LIPID RES, V36, P2027; Clark PL, 1996, PROTEIN SCI, V5, P1108; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Fisher E, 1999, CLIN CHEM, V45, P1026; GAFFNEY D, 1995, ARTERIOSCL THROM VAS, V15, P1025, DOI 10.1161/01.ATV.15.8.1025; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gantz DL, 2000, J LIPID RES, V41, P1464; Giessauf A, 1996, FEBS LETT, V389, P136; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Havel RJ, 1995, METABOLIC MOL BASES, V7th, P1841, DOI [10.1036/ommbid.142, DOI 10.1036/OMMBID.142]; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; KRUL ES, 1992, J LIPID RES, V33, P1037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LUNDKATZ S, 1991, J BIOL CHEM, V266, P2701; McCormick SPA, 1997, J BIOL CHEM, V272, P23616, DOI 10.1074/jbc.272.38.23616; MCCORMICK SPA, 1994, GENET ANAL-BIOMOL E, V11, P158, DOI 10.1016/1050-3862(94)90036-1; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; Myant NB, 1997, GENOMICS, V45, P78, DOI 10.1006/geno.1997.4898; PARHOFER KG, 1990, J LIPID RES, V31, P2001; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; PULLINGER CR, 1995, J CLIN INVEST, V95, P1225, DOI 10.1172/JCI117772; RAUH G, 1992, CLIN INVESTIGATOR, V70, P77, DOI 10.1007/BF00422946; REYFTMANN JP, 1990, BIOCHIM BIOPHYS ACTA, V1042, P159, DOI 10.1016/0005-2760(90)90002-F; Segrest JP, 1998, J LIPID RES, V39, P85; SORIA LF, 1989, P NATL ACAD SCI USA, V86, P587, DOI 10.1073/pnas.86.2.587; THOMAS CE, 1991, J PHARMACOL EXP THER, V256, P1182; TYBJAERGHANSEN A, 1990, ATHEROSCLEROSIS, V80, P235, DOI 10.1016/0021-9150(90)90031-D; Wang XY, 2000, ARTERIOSCL THROM VAS, V20, P1301, DOI 10.1161/01.ATV.20.5.1301; WEISGRABER KH, 1988, P NATL ACAD SCI USA, V85, P9758, DOI 10.1073/pnas.85.24.9758; Yang CY, 1999, BIOCHEMISTRY-US, V38, P15903, DOI 10.1021/bi991464g; YOUNG SG, 1994, J LIPID RES, V35, P399	38	104	107	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9214	9218		10.1074/jbc.M008890200	http://dx.doi.org/10.1074/jbc.M008890200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11115503	hybrid			2022-12-25	WOS:000167607700080
J	Obunike, JC; Lutz, EP; Li, ZH; Paka, L; Katopodis, T; Strickland, DK; Kozarsky, KF; Pillarisetti, S; Goldberg, IJ				Obunike, JC; Lutz, EP; Li, ZH; Paka, L; Katopodis, T; Strickland, DK; Kozarsky, KF; Pillarisetti, S; Goldberg, IJ			Transcytosis of lipoprotein lipase across cultured endothelial cells requires both heparan sulfate proteoglycans and the very low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMA-LIPOPROTEINS; IN-VITRO; PROTEIN; BINDING; CATABOLISM; METABOLISM; MICE; INHIBITION	Lipoprotein lipase (LPL), the major enzyme responsible for the hydrolysis of circulating lipoprotein triglyceride molecules, is synthesized in myocytes and adipocytes but functions while bound to heparan sulfate proteoglycans (HSPGs) on the luminal surface of vascular endothelial cells. This requires transfer of LPL from the abluminal side to the luminal side of endothelial cells. Studies were performed to investigate the mechanisms of LPL transcytosis using cultured monolayers of bovine aortic endothelial cells. We tested whether HSPGs and. members of the low density lipoprotein (LDL) receptor superfamily were involved in transfer of LPL from the basolateral to the apical side of cultured endothelial cells; Heparinase/heparinitase treatment of the basolateral cell surface or addition of heparin to the basolateral medium decreased the movement of LPL, This suggested a:requirement for HSPGs. To assess the role of receptors, we used either receptor-associated protein, the 39-kDa inhibitor of ligand binding to the LDL receptor-related protein and the very low density lipoprotein (VLDL) receptor,or specific receptor antibodies. Receptor-associated protein reduced I-125-LPL and LPL activity transfer across the monolayers, When the basolateral surface of the cells was treated with antibodies, only anti=VLDL receptor antibodies inhibited transcytosis, Moreover, overexpression of the VLDL receptor using adenoviral-mediated gene transfer increased LPL transcytosis, Thus, movement of active LPL across endothelial cells involves both HSPGs and VLDL receptor.	Columbia Univ, Coll Phys & Surg, Dept Med, Div Prevent Med & Nutr, New York, NY 10032 USA; Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	Columbia University; American Red Cross; GlaxoSmithKline	Goldberg, IJ (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Div Prevent Med & Nutr, 630 W 168th St, New York, NY 10032 USA.				NHLBI NIH HHS [HL-03323, HL-45095, HL-50784] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, R37HL045095, R01HL045095, K14HL003323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BENGTSSONOLIVECRONA G, 1985, BIOCHEM J, V226, P409, DOI 10.1042/bj2260409; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CORNICELLI JA, 1983, ARTERIOSCLEROSIS, V3, P560, DOI 10.1161/01.ATV.3.6.560; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; FRIEDMAN G, 1982, BIOCHIM BIOPHYS ACTA, V711, P114, DOI 10.1016/0005-2760(82)90016-9; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; Goldberg IJ, 1996, J LIPID RES, V37, P693; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hocquette JF, 1998, COMP BIOCHEM PHYS B, V121, P201, DOI 10.1016/S0305-0491(98)10090-1; Hussain MM, 2000, J BIOL CHEM, V275, P29324, DOI 10.1074/jbc.M005317200; Kako Y, 1999, J LIPID RES, V40, P2185; Kwok S, 1997, HORM METAB RES, V29, P524, DOI 10.1055/s-2007-979094; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; Magrane J, 1998, J LIPID RES, V39, P2172; Marino M, 2000, J BIOL CHEM, V275, P7125, DOI 10.1074/jbc.275.10.7125; McFadden G, 1997, BIOCHEM PHARMACOL, V54, P1271, DOI 10.1016/S0006-2952(97)00182-2; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Medh JD, 1996, J BIOL CHEM, V271, P17073, DOI 10.1074/jbc.271.29.17073; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Mostov K, 1991, Semin Cell Biol, V2, P411; Obunike JC, 1996, J LIPID RES, V37, P2439; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; Pillarisetti S, 1999, METH MOL B, V109, P267; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; Stins MF, 1999, INFECT IMMUN, V67, P5522, DOI 10.1128/IAI.67.10.5522-5525.1999; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Tacken PJ, 2000, J LIPID RES, V41, P2055; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; van Vlijmen BJM, 1999, J BIOL CHEM, V274, P35219, DOI 10.1074/jbc.274.49.35219; Veniant MM, 1998, J CLIN INVEST, V102, P1559, DOI 10.1172/JCI4164; Weinstock PH, 1997, P NATL ACAD SCI USA, V94, P10261, DOI 10.1073/pnas.94.19.10261; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLIAMS SE, 1994, ANN NY ACAD SCI, V737, P1, DOI 10.1111/j.1749-6632.1994.tb44297.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	45	75	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8934	8941		10.1074/jbc.M008813200	http://dx.doi.org/10.1074/jbc.M008813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121409	hybrid			2022-12-25	WOS:000167607700045
J	Chen, Y; Lai, MZ				Chen, Y; Lai, MZ			c-Jun NH2-terminal kinase activation leads to a FADD-dependent but Fas ligand-independent cell death in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; LUNG-CANCER CELLS; PROTEIN-KINASE; GAMMA-RADIATION; PATHWAY; EXPRESSION; DOMAIN; P38; JNK; INHIBITION	Persistent c-Jun NH2-terminal kinase (JNK) activation induces cell death. Different mechanisms are ascribed to JNK-induced cell death. Most of the JNK-apoptosis studies employ stress stimuli known to activate kinases other than JNK. Here we used overexpression of mitogen-activated protein kinase kinase 7 (MKK7) to activate selectively JNK in T lymphoma Jurkat cells. Similar to that reported previously, Fas ligand (FasL) expression was up-regulated by JNK activation. Dominant negative-FADD and caspase-8 inhibitor benzyloxycarbonyl-Ile-Glu-Thr-Asp effectively inhibited MKK7-induced cell death, supporting a major involvement of FADD cascade. However, MKK7-induced cell death was not prevented by antagonist antibody ZB4 and Fas-Fc, indicating that Fas-FasL interaction is minimally involved. Confocal microscopy revealed that persistent JNK activation led to clustering of Fas. Our results suggest that, in contrast to that reported previously, JNK alone-induced death in Jurkat cells is FADD-dependent but is not triggered by Fas-FasL interaction.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Taiwan Univ, Sch Med, Grad Inst Immunol, Taipei, Taiwan; Natl Yang Ming Univ, Grad Inst Microbiol & Immunol, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Yang Ming Chiao Tung University	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	mblai@ccvax.sinica.edu.tw	Chen, Yun/AAB-2132-2020; Lai, Ming-Zong/AAA-4408-2021	Chen, Yun/0000-0001-6917-7814; Lai, Ming-Zong/0000-0002-3237-4803				Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Matsui K, 1998, J IMMUNOL, V161, P3469; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Skov S, 1997, J CELL BIOL, V139, P1523, DOI 10.1083/jcb.139.6.1523; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	51	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8350	8357		10.1074/jbc.M008431200	http://dx.doi.org/10.1074/jbc.M008431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11106658	hybrid			2022-12-25	WOS:000167474900092
J	Steimle, PA; Naismith, T; Licate, L; Egelhoff, TT				Steimle, PA; Naismith, T; Licate, L; Egelhoff, TT			WD repeat domains target Dictyostelium myosin heavy chain kinases by binding directly to myosin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II KINASE; PROTEIN-KINASE; CATALYTIC DOMAIN; CRYSTAL-STRUCTURE; BETA-SUBUNIT; COILED-COIL; PHOSPHORYLATION; IDENTIFICATION; ACTIN; PURIFICATION	Myosin heavy chain kinase (MHCK) A phosphorylates mapped sites at the C-terminal tail of Dictyostelium myosin II heavy chain, driving disassembly of myosin filaments both in vitro and in vivo. MHCK A is organized into three functional domains that include an N-terminal coiled-coil region, a central kinase catalytic domain unrelated to conventional protein kinases, and a WD repeat domain at the C terminus. MHCK B is a homologue of MHCK A that possesses structurally related catalytic and WD repeat domains. In the current study, we explored the role of the WD repeat domains in defining the activities of both MHCK A and MHCK B using recombinant bacterially expressed truncations of these kinases either with or without their WD repeat domains. We demonstrate that substrate targeting is a conserved function of the WD repeat domains of both MHCK A and MHCK B and that this targeting is specific for Dictyostelium myosin II filaments. We also show that the mechanism of targeting involves direct binding of the WD repeat domains to the myosin substrate. To our knowledge, this is the first report of WD repeat domains physically targeting attached kinase domains to their substrates, The examples presented here may serve as a paradigm for enzyme targeting in other systems.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Egelhoff, TT (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	tte@po.cwru.edu			NIGMS NIH HHS [GM50009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050009, R01GM050009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUADOVELASCO M, 1993, PROTEIN EXPRES PURIF, V4, P328, DOI 10.1006/prep.1993.1042; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; COTE GP, 1987, J BIOL CHEM, V262, P1065; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; EGELHOFF TT, 1999, GUIDEBOOK CYTOSKELET, P460; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; Janda L, 1996, J BACTERIOL, V178, P1487, DOI 10.1128/jb.178.5.1487-1489.1996; Kolman MF, 1997, J BIOL CHEM, V272, P16904, DOI 10.1074/jbc.272.27.16904; KUCZMARSKI ER, 1987, J CELL BIOL, V105, P2989, DOI 10.1083/jcb.105.6.2989; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; LEE RJ, 1994, J CELL SCI, V107, P2875; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; MEDLEY QG, 1990, BIOCHEMISTRY-US, V29, P8992, DOI 10.1021/bi00490a016; MEDLEY QG, 1991, METHOD ENZYMOL, V196, P23; Murphy MB, 1999, EUR J BIOCHEM, V264, P582, DOI 10.1046/j.1432-1327.1999.00670.x; Newell PC, 1995, BIOSCIENCE REP, V15, P445, DOI 10.1007/BF01204348; Pavur KS, 2000, BIOCHEMISTRY-US, V39, P12216, DOI 10.1021/bi0007270; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Spudich JA, 1995, COLD SPRING HARB SYM, V60, P783, DOI 10.1101/SQB.1995.060.01.084; Steinbacher S, 1999, EMBO J, V18, P2923, DOI 10.1093/emboj/18.11.2923; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082; YUMURA S, 1993, CELL STRUCT FUNCT, V18, P379, DOI 10.1247/csf.18.379; YUMURA S, 1994, CELL STRUCT FUNCT, V19, P143, DOI 10.1247/csf.19.143	32	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6853	6860		10.1074/jbc.M008992200	http://dx.doi.org/10.1074/jbc.M008992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11106661	hybrid			2022-12-25	WOS:000167261000100
J	Wellmer, F; Schafer, E; Harter, K				Wellmer, F; Schafer, E; Harter, K			The DNA binding properties of the parsley bZIP transcription factor CPRF4a are regulated by light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; G-BOX; NUCLEAR IMPORT; HIGHER-PLANTS; FACTOR GBF1; ARABIDOPSIS; PROTEINS; PHOSPHORYLATION; HETERODIMERIZATION; PHOTORECEPTORS	The common plant regulatory factors (CPRFs) from parsley are transcription factors with a basic leucine zipper motif that bind to cis-regulatory elements frequently found in promoters of light-regulated genes. Recent studies have revealed that certain CPRF proteins are regulated in response to light by changes in their expression level and in their intracellular localization. Here, we describe an additional mechanism contributing to the light-dependent regulation of CPRF proteins. We show that the DNA binding activity of the factor CPRF4a is modulated in a phosphorylation-dependent manner and that cytosolic components are involved in the regulation of this process. Moreover, we have identified a cytosolic kinase responsible for CPRF4a phosphorylation. Modification of recombinant CPRF4a by this kinase, however, is insufficient to cause a full activation of the factor, suggesting that additional modifications are required. Furthermore, we demonstrate that the DNA binding activity of the factor is modified upon light treatment. The results of additional irradiation experiments suggest that this photoresponse is controlled by different photoreceptor systems. We discuss the possible role of CPRF4a in light signal transduction as well as the emerging regulatory network controlling CPRF activities in parsley.	Univ Freiburg, Inst Biol Bot 2, D-79104 Freiburg, Germany	University of Freiburg	Harter, K (corresponding author), Univ Freiburg, Inst Biol Bot 2, Schanzlestr 1, D-79104 Freiburg, Germany.			Wellmer, Frank/0000-0002-2095-0981				ARMSTRONG GA, 1992, PLANT CELL, V4, P525, DOI 10.1105/tpc.4.5.525; Batschauer A, 1998, PLANTA, V206, P479, DOI 10.1007/s004250050425; Chattopadhyay S, 1998, PLANT CELL, V10, P673, DOI 10.1105/tpc.10.5.673; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; FROHNMEYER H, 1994, PLANT J, V5, P437, DOI 10.1111/j.1365-313X.1994.00437.x; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; HARTER K, 1994, P NATL ACAD SCI USA, V91, P5038, DOI 10.1073/pnas.91.11.5038; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIDAKA H, 1993, PROTEIN PHOSPHORYLAT; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Kircher S, 1998, MOL GEN GENET, V257, P595, DOI 10.1007/s004380050687; Kircher S, 1999, J CELL BIOL, V144, P201, DOI 10.1083/jcb.144.2.201; KLIMCZAK LJ, 1992, PLANT CELL, V4, P87, DOI 10.1105/tpc.4.1.87; KLIMCZAK LJ, 1995, PLANT CELL, V7, P105, DOI 10.1105/tpc.7.1.105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin CT, 2000, TRENDS PLANT SCI, V5, P337, DOI 10.1016/S1360-1385(00)01687-3; Liu LS, 1999, EUR J BIOCHEM, V262, P247, DOI 10.1046/j.1432-1327.1999.00349.x; MARINZGARCIA JF, 2000, SCIENCE, V288, P859; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; MENKENS AE, 1994, P NATL ACAD SCI USA, V91, P2522, DOI 10.1073/pnas.91.7.2522; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Oyama T, 1997, GENE DEV, V11, P2983, DOI 10.1101/gad.11.22.2983; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Sprenger-Haussels M, 2000, PLANT J, V22, P1, DOI 10.1046/j.1365-313x.2000.00687.x; Terzaghi WB, 1997, PLANT J, V11, P967, DOI 10.1046/j.1365-313X.1997.11050967.x; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; Wellmer F, 1999, J BIOL CHEM, V274, P29476, DOI 10.1074/jbc.274.41.29476	30	18	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6274	6279		10.1074/jbc.M007971200	http://dx.doi.org/10.1074/jbc.M007971200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11106651	hybrid, Green Accepted			2022-12-25	WOS:000167261000030
J	Meyer, T; Wellner-Kienitz, MC; Biewald, A; Bender, K; Eickel, A; Pott, L				Meyer, T; Wellner-Kienitz, MC; Biewald, A; Bender, K; Eickel, A; Pott, L			Depletion of phosphatidylinositol 4,5-bisphosphate by activation of phospholipase C-coupled receptors causes slow inhibition but not desensitization of G protein-gated inward rectifier K+ current in atrial myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; RECTIFYING POTASSIUM CHANNELS; GTP-BINDING PROTEINS; NUCLEOTIDE SENSITIVITY; MUSCARINIC RECEPTORS; DOWN-REGULATION; M-2 RECEPTORS; ATP CHANNELS; RAT; ADENOSINE	G protein-gated inwardly rectifier K+ current in atrial myocytes (I-K(ACh)) upon stimulation with aeetylcholine (ACh) shows a fast desensitizing component (t(1/2) similar to 5 s), After washout of ACh, I-K(ACh) recovers from fast desensitization within < 30 s, A recent hypothesis suggests that fast desensitization is caused by depletion of phosphatidylinositol 4,5-bisphosphate (PtIns( 4,5)P-2), resulting from costimulation of phospholipase C (PLC)-coupled M-3 receptors (M(3)AChR). The effects of stimulating two established PLC-coupled receptors, cy-adrenergic and endothelin (ETA), on I-K(ACh) were studied in rat atrial myocytes. Stimulation of these receptors caused activation of I-K(ACh) and inhibition of the M(2)AChR-activated current. In myocytes loaded with GTP gammaS (guanosine 5 ' -3-O-(thio) triphosphate), causing stable activation of I-K(ACh), inhibition via alpha -agonists and ET-1 was studied in isolation. Stimulation of either type of receptor under this condition, via G(q/11), caused a slow inhibition (t(1/2) similar to 50 s) by about 10%. No comparable effect on GTP gammaS-activated I-K(ACh) was induced by ACh, suggesting that PLC-coupled M(3)AChRs are not functionally expressed in rat myocytes, which was supported by the finding that M(3)AChR transcripts were not detected by reverse transcriptase-polymerase chain reaction in identified atrial myocytes. Supplementing the pipette solution with PtIns(4,5)P-2 significantly reduced inhibition of I-K(ACh) but had no effect on fast desensitization. From these data it is concluded that stimulation of PLC-coupled receptors causes slow inhibition of I-K(ACh) by depletion of PtIns(4,5)P-2, whereas fast desensitization of I-K(ACh) is not related to PtIns(4,5)P-2 depletion. As muscarinic stimulation by ACh does not, exert inhibition of I-K(ACh) comparable to stimulation of alpha (1)- and ETA receptors, expression of functional. PLC-coupled muscarinic receptors in rat atrial myocytes is unlikely.	Ruhr Univ Bochum, Inst Physiol, D-44780 Bochum, Germany	Ruhr University Bochum	Pott, L (corresponding author), Ruhr Univ Bochum, Inst Physiol, D-44780 Bochum, Germany.		Pott, Lutz/E-5304-2011	Pott, Lutz/0000-0002-4000-4132				Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Bohm SK, 1997, BIOCHEM J, V322, P1; BRAUN AP, 1992, PFLUG ARCH EUR J PHY, V421, P431, DOI 10.1007/BF00370253; Brodde OE, 1999, PHARMACOL REV, V51, P651; Bunemann M, 2000, J BIOL CHEM, V275, P12537, DOI 10.1074/jbc.275.17.12537; Bunemann M, 1995, J PHYSIOL-LONDON, V489, P701; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Bunemann M, 1997, J PHYSIOL-LONDON, V501, P549, DOI 10.1111/j.1469-7793.1997.549bm.x; BUNEMANN M, 1995, J PHYSIOL-LONDON, V482, P81; BUNEMANN M, 1996, J PHYSIOL-LONDON, V492, P351; Cho H, 2001, J BIOL CHEM, V276, P159, DOI 10.1074/jbc.M004826200; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Himmel HM, 2000, MOL PHARMACOL, V58, P449, DOI 10.1124/mol.58.2.449; Hong SG, 1996, AM J PHYSIOL-HEART C, V270, pH526, DOI 10.1152/ajpheart.1996.270.2.H526; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Karschin A, 1999, NEWS PHYSIOL SCI, V14, P215; KIM DH, 1993, CIRC RES, V73, P89, DOI 10.1161/01.RES.73.1.89; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; KURACHI Y, 1987, PFLUG ARCH EUR J PHY, V410, P227, DOI 10.1007/BF00580270; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; Leung YM, 2000, J BIOL CHEM, V275, P10182, DOI 10.1074/jbc.275.14.10182; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Sharma VK, 1996, CIRC RES, V79, P86, DOI 10.1161/01.RES.79.1.86; Shui Z, 1997, J PHYSIOL-LONDON, V505, P77, DOI 10.1111/j.1469-7793.1997.077bc.x; Shyng SL, 2000, P NATL ACAD SCI USA, V97, P937, DOI 10.1073/pnas.97.2.937; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Sorota S, 1999, J PHYSIOL-LONDON, V514, P413, DOI 10.1111/j.1469-7793.1999.413ae.x; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Wellner-Kienitz MC, 1999, FEBS LETT, V451, P279, DOI 10.1016/S0014-5793(99)00594-3; Wellner-Kienitz MC, 2000, CIRC RES, V86, P643, DOI 10.1161/01.RES.86.6.643; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292; Yamada M, 1998, PHARMACOL REV, V50, P723; Yamaguchi H, 1997, AM J PHYSIOL-HEART C, V273, pH1745, DOI 10.1152/ajpheart.1997.273.4.H1745; ZHANG R, 1991, CELL GROWTH DIFFER, V2, P1	41	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5650	5658		10.1074/jbc.M009179200	http://dx.doi.org/10.1074/jbc.M009179200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11104770	hybrid			2022-12-25	WOS:000167115100035
J	Sallese, M; Salvatore, L; D'Urbano, E; Sala, G; Storto, M; Launey, T; Nicoletti, F; Knopfel, T; De Blasi, A				Sallese, M; Salvatore, L; D'Urbano, E; Sala, G; Storto, M; Launey, T; Nicoletti, F; Knopfel, T; De Blasi, A			The G-protein-coupled receptor kinase GRK4 mediates homologous desensitization of metabotropic glutamate receptor 1	FASEB JOURNAL			English	Article						Purkinje cells; mGlu(1) receptor; receptor internalization; GRK; antisense knock down	CEREBELLAR PURKINJE-CELLS; LONG-TERM DEPRESSION; SPLICE VARIANTS; RGS PROTEINS; IDENTIFICATION; EXPRESSION; MGLUR1; MICE; PHOSPHORYLATION; LOCALIZATION	G-protein-coupled receptor kinases (GRKs) are involved in the regulation of many G-protein-coupled receptors. As opposed to the other GRKs, such as rhodopsin kinase (GRK1) or beta -adrenergic receptor kinase (beta ARK, GRK2), no receptor substrate for GRK4 has been so far identified. Here we show that GRK4 is expressed in cerebellar Purkinje cells, where it regulates mGlu(1) metabotropic glutamate receptors, as indicated by the following: I) When coexpressed in heterologous cells (HEK293), mGlu(1) receptor signaling was desensitized by GRK4 in an agonist-dependent manner (homologous desensitization). 2) In transfected HEK293 and in cultured Purkinje cells, the exposure to glutamate agonists induced internalization of the receptor and redistribution of GRK4. There was a substantial colocalization of the receptor and kinase both under basal condition and after internalization. 3) Kinase activity was necessary for desensitizing mGlu(1a) receptor and agonist-dependent phosphorylation of this receptor was also documented. 4) Antisense treatment of cultured Purkinje cells, which significantly reduced the levels of GRK4 expression, induced a marked modification of the mGlu(1)-mediated functional response, consistent with an impaired receptor desensitization. The critical role for GRK4 in regulating mGlu(1) receptors implicates a major involvement of this kinase in the physiology of Purkinje cell, and in motor learning.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, Italy; RIKEN, Brain Sci Inst, Wako, Saitama 35101, Japan; INM Neuromed, Pozzilli, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; RIKEN; IRCCS Neuromed	De Blasi, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, Via Nazl, I-66030 Santa Maria Imbaro, Italy.		Storto, Marianna/G-8745-2012; Nicoletti, Ferdinando/K-4410-2016; Nicoletti, Ferdinando/T-4898-2019; Knöpfel, Thomas/B-1128-2008; Sallese, Michele/J-5347-2016; Sala, Gianluca/C-2056-2017; Launey, Thomas/A-2605-2010; Nicoletti, Ferdinando/A-2446-2010	Knöpfel, Thomas/0000-0002-5718-0765; Sallese, Michele/0000-0002-2555-3571; Sala, Gianluca/0000-0002-4494-915X; Launey, Thomas/0000-0001-9153-9260; NICOLETTI, Ferdinando/0000-0003-3366-7269; marianna, storto/0000-0002-0159-7449; Nicoletti, Ferdinando/0000-0003-0917-443X	Telethon [1238] Funding Source: Medline	Telethon(Fondazione Telethon)		AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Carruthers AM, 1997, MOL PHARMACOL, V52, P406, DOI 10.1124/mol.52.3.406; CATANIA MV, 1991, J NEUROCHEM, V56, P1329, DOI 10.1111/j.1471-4159.1991.tb11429.x; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; CONTRERA JG, 1993, J PHARMACOL EXP THER, V265, P433; Flor PJ, 1996, J NEUROCHEM, V67, P58; Furuya S, 1998, BRAIN RES PROTOC, V3, P192, DOI 10.1016/S1385-299X(98)00040-3; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Iacovelli L, 1999, MOL PHARMACOL, V56, P316, DOI 10.1124/mol.56.2.316; Iacovelli L, 1999, FASEB J, V13, P1; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; KANAI Y, 1994, J BIOL CHEM, V269, P20599; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; PANNESE M, 1995, DEVELOPMENT, V121, P707; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Sallese M, 1997, J BIOL CHEM, V272, P10188; SALLESE M, 1994, BIOCHEM BIOPH RES CO, V199, P848, DOI 10.1006/bbrc.1994.1306; Salvatore L, 1999, FEBS LETT, V449, P146, DOI 10.1016/S0014-5793(99)00420-2; Saugstad JA, 1998, J NEUROSCI, V18, P905; Smitt PS, 2000, NEW ENGL J MED, V342, P21, DOI 10.1056/NEJM200001063420104; STAUB C, 1992, EUR J NEUROSCI, V4, P832, DOI 10.1111/j.1460-9568.1992.tb00193.x; Virlon B, 1998, ENDOCRINOLOGY, V139, P2784, DOI 10.1210/en.139.6.2784; YUZAKI M, 1992, J NEUROSCI, V12, P4253	39	109	112	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2569	2580		10.1096/fj.00-0072com	http://dx.doi.org/10.1096/fj.00-0072com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099476				2022-12-25	WOS:000165723400028
J	Heck, M; Hofmann, KP				Heck, M; Hofmann, KP			Maximal rate and nucleotide dependence of rhodopsin-catalyzed transducin activation - Initial rate analysis based on a double displacement mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; BOVINE PHOTORECEPTOR-MEMBRANES; HETEROTRIMERIC G-PROTEIN; GTP-BINDING PROTEIN; LIGHT-SCATTERING; METARHODOPSIN-II; RETINAL RODS; DISK MEMBRANES; PHOTOEXCITED RHODOPSIN; MOLECULAR MECHANISM	Despite the growing structural information on receptors and G proteins, the information on affinities and kinetics of protein-protein and protein-nucleotide interactions is still not complete. In this study on photoactivated rhodopsin (R*) and the rod G protein, G(t), we have used kinetic light scattering, backed by direct biochemical assays, to follow G protein activation. Our protocol includes the following: (i) to measure initial rates on the background of rapid depletion of the G(t)GDP substrate; (ii) to titrate G(t)GDP, GTP, and GDP; and (iii) to apply a double displacement reaction scheme to describe the results. All data are simultaneously fitted by one and the same set of parameters. We obtain values of K-m = 2200 G(t)/mum(2) for G(t)GDP and K-m = 230 muM for GTP; dissociation constants are K-d = 530 G(t)/mum(2) for R*-G(t)GDP dissociation and K-d = 270 muM for GDP release from R*G(t)GDP, once formed. Maximal catalytic rates per photoexcited rhodopsin are 600 G(t)/s at 22 degreesC and 1300 G(t)/s at 34 degreesC, The analysis provides a tool to allocate and quantify better the effects of chemical or mutational protein modifications to individual steps in signal transduction.	Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Heck, M (corresponding author), Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, Schumannstr 20-21, D-10098 Berlin, Germany.							BAEHR W, 1982, J BIOL CHEM, V257, P6452; BAUER PJ, 1988, J PHYSIOL-LONDON, V401, P309, DOI 10.1113/jphysiol.1988.sp017164; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BENNETT N, 1985, J BIOL CHEM, V260, P4156; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKERT F, 1992, BIOPHYS J, V63, P616, DOI 10.1016/S0006-3495(92)81650-8; BRUCKERT F, 1988, EUR BIOPHYS J BIOPHY, V16, P207; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; GODCHAUX W, 1979, J BIOL CHEM, V254, P7874; GUTFREUND H, 1995, KINETICS LIFE SCI, P237; Heck M, 2000, METHOD ENZYMOL, V315, P329; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; Hofmann K. P., 1996, BIOMEMBR A&B, V2, P141; Hofmann K. P., 2000, HDB BIOL PHYSICS, P91, DOI 10.1016/s1383-8121(00)80006-8; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; HOFMANN KP, 1999, RHODOPSINS PHOTOTRAN, V224, P158; KAHLERT M, 1991, BIOPHYS J, V59, P375, DOI 10.1016/S0006-3495(91)82231-7; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KOHL B, 1987, BIOPHYS J, V52, P271, DOI 10.1016/S0006-3495(87)83214-9; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; LAMB TD, 1987, J OPT SOC AM A, V4, P2295, DOI 10.1364/JOSAA.4.002295; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Leskov IB, 2000, NEURON, V27, P525, DOI 10.1016/S0896-6273(00)00063-5; LIEBMAN PA, 1984, ADV CYCLIC NUCL PROT, V17, P215; LIEBMAN PA, 1979, VISION RES, V19, P375, DOI 10.1016/0042-6989(79)90097-X; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PANICO J, 1990, J BIOL CHEM, V265, P18922; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PARISH CA, 1994, BIOCHEMISTRY-US, V33, P9986, DOI 10.1021/bi00199a023; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; RENSLAND H, 1995, BIOCHEMISTRY-US, V34, P593, DOI 10.1021/bi00002a026; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; SCHLEICHER A, 1987, J MEMBRANE BIOL, V95, P271, DOI 10.1007/BF01869489; SEGEL IH, 1975, ENZYME KINETICS, P606; Seitz HR, 1999, BIOCHEMISTRY-US, V38, P7950, DOI 10.1021/bi990298+; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; Waelbroeck M, 1997, J THEOR BIOL, V187, P15, DOI 10.1006/jtbi.1997.0411; YEE R, 1978, J BIOL CHEM, V253, P8902; Zera EM, 1996, J BIOL CHEM, V271, P12925, DOI 10.1074/jbc.271.22.12925	56	137	139	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10000	10009		10.1074/jbc.M009475200	http://dx.doi.org/10.1074/jbc.M009475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11116153	hybrid			2022-12-25	WOS:000167996400058
J	Rimseliene, R; Janulaitis, A				Rimseliene, R; Janulaitis, A			Mutational analysis of two putative catalytic motifs of the type IV restriction endonuclease Eco57I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROPERTIES; AMINO-ACID SUBSTITUTIONS; MODIFICATION SYSTEM; SALMONELLA-TYPHIMURIUM; MODIFICATION ENZYMES; ALKALINE EXTRACTION; PLASMID DNA; SEQUENCE; GENES; RECOGNITION	The role of two sequence motifs (SM) as putative cleavage catalytic centers (77)PDX(13)EAK (SM I) and (811)PDX(20)DQK (SM II) of type TV restriction endonuclease Eco57I was studied by site-directed mutational analysis. Substitutions within SM I; D78N, D78A, D78K, and E92Q reduced cleavage activity of Eco57I to a level undetectable both in vivo and in vitro, Residual endonucleolytic activity of the E92Q mutant was detected only when the Mg2+ in the standard reaction mixture was replaced with Mn2+. The mutants D78N and E92Q retained the ability to interact with DNA specifically. The mutants also retained DNA methylation activity of Eco57I, The properties of the SM I mutants indicate that Asp(78) and Glu(92) residues are essential for cleavage activity of the Eco57I, suggesting that the sequence motif (77)PDX(13)EAK represents the cleavage active site of this endonuclease, Eco57I mutants containing single amino acid substitutions within SIM II (D812A, D833N, 833A) revealed only a small or moderate decrease of cleavage activity as compared with wild-type Eco57I, indicating that the SM II motif does not represent the catalytic center of Eco571, The results, taken together, allow us to conclude that the Eco571 restriction endonuclease has one catalytic center for cleavage of DNA.	Inst Biotechnol, Vilnius, Lithuania	Vilnius University	Janulaitis, A (corresponding author), Inst Biotechnol, Graiciuno 8, Vilnius, Lithuania.							AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; DARTOIS V, 1993, GENE, V127, P105, DOI 10.1016/0378-1119(93)90623-B; Davies GP, 1999, J MOL BIOL, V290, P565, DOI 10.1006/jmbi.1999.2908; Davies GP, 1998, NUCLEIC ACIDS RES, V26, P4828, DOI 10.1093/nar/26.21.4828; HUMBELIN M, 1988, J MOL BIOL, V200, P23, DOI 10.1016/0022-2836(88)90330-0; Janscak P, 1999, NUCLEIC ACIDS RES, V27, P2638, DOI 10.1093/nar/27.13.2638; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6043, DOI 10.1093/nar/20.22.6043; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6051, DOI 10.1093/nar/20.22.6051; JANULAITIS A, 1996, BIOLOGIJA, V2, P28; Jeltsch A, 1996, PROTEIN ENG, V9, P413, DOI 10.1093/protein/9.5.413; KIM YG, 1994, P NATL ACAD SCI USA, V91, P883, DOI 10.1073/pnas.91.3.883; KONG HM, 1993, NUCLEIC ACIDS RES, V21, P987, DOI 10.1093/nar/21.4.987; Kong HM, 1998, J MOL BIOL, V279, P823, DOI 10.1006/jmbi.1998.1821; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lagunavicius A, 1997, BIOCHEMISTRY-US, V36, P11086, DOI 10.1021/bi963125i; Lubys A, 1996, NUCLEIC ACIDS RES, V24, P2760, DOI 10.1093/nar/24.14.2760; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; MARKO MA, 1982, ANAL BIOCHEM, V121, P382, DOI 10.1016/0003-2697(82)90497-3; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Nastri HG, 1997, J BIOL CHEM, V272, P25761, DOI 10.1074/jbc.272.41.25761; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Piekarowicz A, 1999, J MOL BIOL, V293, P1055, DOI 10.1006/jmbi.1999.3198; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Roberts RJ, 2000, NUCLEIC ACIDS RES, V28, P306, DOI 10.1093/nar/28.1.306; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sapranauskas R, 2000, J BIOL CHEM, V275, P30878, DOI 10.1074/jbc.M003350200; Skirgaila R, 1998, J MOL BIOL, V279, P473, DOI 10.1006/jmbi.1998.1803; Skirgaila R, 1998, BIOL CHEM, V379, P595; SKOWRON P, 1993, GENE, V125, P1, DOI 10.1016/0378-1119(93)90738-O; Stankevicius K, 1998, NUCLEIC ACIDS RES, V26, P1084, DOI 10.1093/nar/26.4.1084; Su P, 1999, APPL ENVIRON MICROB, V65, P686; SUGISAKI H, 1991, J BIOL CHEM, V266, P13952; Szegedi SS, 2000, NUCLEIC ACIDS RES, V28, P3972, DOI 10.1093/nar/28.20.3972; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596; WHITEHEAD PR, 1985, ARCH MICROBIOL, V141, P70, DOI 10.1007/BF00446742; YUAN R, 1981, ANNU REV BIOCHEM, V50, P285, DOI 10.1146/annurev.bi.50.070181.001441	44	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10492	10497		10.1074/jbc.M008687200	http://dx.doi.org/10.1074/jbc.M008687200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124947	hybrid			2022-12-25	WOS:000167996400117
J	Kokame, K; Kato, H; Miyata, T				Kokame, K; Kato, H; Miyata, T			Identification of ERSE-II, a new cis-actin element responsible for the ATF6-dependent mammalian unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; VASCULAR ENDOTHELIAL-CELLS; CCAAT REGULATORY ELEMENT; TRANSCRIPTION FACTOR; TRANSMEMBRANE PROTEIN; GRP78/BIP PROMOTER; ACTIVATION; KINASE; GENE; INDUCTION	Herp is a 54-kDa membrane protein in the endoplasmic reticulum (ER). The mRNA expression level of Herp is increased by the accumulation of unfolded proteins in the ER. Transcriptional changes designed to deal with this type of ER stress is called the unfolded protein response (UPR). Most mammalian UPR-target genes encode ER resident molecular chaperones: GRP78, GRP94, and calreticulin. The promoter regions of these genes contain a cis-acting ER stress response element, ERSE, with the consensus sequence of CCAAT-N-9-CCACG. Under conditions of ER stress, p50ATF6 (the active form of the transcription factor, ATF6) binds to CCACG when CCAAT is bound by the general transcription factor, NF-Y/CBF. Here, we report the genomic structure of human Herp and the presence of a new ER stress response element, ERSE-II, in its promoter region. The gene for Herp consists of eight exons, localized to chromosome 16q12.2-13. The promoter region contains a single ERSE-like sequence. In reporter gene assays, disruption of this cis-element resulted in a partial reduction of the transcriptional response to ER stress, suggesting that the element is functional for the UPR. These results also suggest the involvement of additional elements in the UPR. Further analysis, using an optimized plasmid containing an mRNA-destabilizing sequence, revealed ERSE-II (ATTGG-N-CCACG) as the second ER stress response element. Interestingly, ERSE-II was also dependent on p50ATF6, in a manner similar to that of ERSE, despite the disparate structure. The strong induction of Herp mRNA by ER stress would be achieved by the cooperation of ERSE and ERSE-II.	Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Kokame, K (corresponding author), Natl Cardiovasc Ctr, Res Inst, 5-7-1 Fujishirodai, Osaka 5658565, Japan.			Kokame, Koichi/0000-0002-9654-6299				Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Kaneda S, 2000, J BIOCHEM-TOKYO, V128, P529, DOI 10.1093/oxfordjournals.jbchem.a022783; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; ROY B, 1995, MOL CELL BIOL, V15, P2263; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Laar T, 2000, FEBS LETT, V469, P123, DOI 10.1016/S0014-5793(00)01253-9; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	30	197	209	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9199	9205		10.1074/jbc.M010486200	http://dx.doi.org/10.1074/jbc.M010486200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11112790	hybrid			2022-12-25	WOS:000167607700078
J	Sigurdsson, S; Trujillo, K; Song, BW; Stratton, S; Sung, P				Sigurdsson, S; Trujillo, K; Song, BW; Stratton, S; Sung, P			Basis for avid homologous DNA strand exchange by human Rad51 and RPA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; BREAK REPAIR; HRP-A; RECOMBINATION; RECA; POLARITY; CLONING	Human Rad51 (hRad51), a member of a conserved family of general recombinases, is shown here to have an avid capability to make DNA joints between homologous DNA molecules and promote highly efficient DNA strand exchange of the paired molecules over at least 5.4 kilobase pairs. Furthermore, maximal efficiency of homologous DNA pairing and strand exchange is strongly dependent on the heterotrimeric single-stranded DNA binding factor hRPA and requires conditions that lessen interactions of the homologous duplex with the hRad51-single-stranded DNA nucleoprotein filament, The homologous DNA pairing and strand exchange system described should be valuable for dissecting the action mechanism of hRad51 and for deciphering its functional interactions with other recombination factors.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA.		Sigurdsson, Stefan/L-9820-2015	Sigurdsson, Stefan/0000-0002-5284-0058	NCI NIH HHS [P01 CA81020] Funding Source: Medline; NIEHS NIH HHS [R01 ES07061] Funding Source: Medline; NIGMS NIH HHS [R01GM57814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA081020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1999, J MOL BIOL, V291, P363, DOI 10.1006/jmbi.1999.2954; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; KAOHUANG Y, 1977, P NATL ACAD SCI USA, V74, P4228, DOI 10.1073/pnas.74.10.4228; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665	19	132	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8798	8806		10.1074/jbc.M010011200	http://dx.doi.org/10.1074/jbc.M010011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124265	hybrid			2022-12-25	WOS:000167607700026
J	Cheriyath, V; Roy, AL				Cheriyath, V; Roy, AL			Structure-function analysis of TFII-I - Roles of the N-teriminal end, basic region, and I-repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILLIAMS-BEUREN-SYNDROME; PUTATIVE TRANSCRIPTION FACTOR; BRUTONS TYROSINE KINASE; V-BETA PROMOTER; BINDING PROTEIN; INITIATOR ELEMENT; SYNDROME DELETION; GENE-EXPRESSION; B/HLH/Z DOMAIN; IDENTIFICATION	The transcription factor TFII-I can bind specifically to several DNA sequence elements and is implicated in both basal and activated transcription. There are four alternatively spliced isoforms of TFII-I, all characterized by the presence of six I-repeats, R1-R6, each containing a potential helix-loop-helix motif implicated in protein-protein interactions. These isoforms exhibit both homomeric and heteromeric interactions that lead to nuclear localization. In this study we mapped two distinct regions in TFII-I that affect its DNA binding. Deletion of either of these regions led to abrogation of DNA binding and transcriptional activation from both the Vp and c-fos promoters. The I-repeats, as expected, were capable of mediating homomeric interactions either individually or in combination. Unexpectedly, an additional homomeric interaction domain was found within the N-terminal end of TFII-I that includes a putative leucine zipper motif. These data suggest a model in which TFII-I undergoes regulated homomeric interaction mediated by both the N-terminal end and the I-repeats.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Program Immunol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University; Tufts University	Roy, AL (corresponding author), Tufts Univ, Sch Med, Dept Biochem, 136 Harrison Ave, Boston, MA 02111 USA.	ananda.roy@tufts.edu			NIAID NIH HHS [AI45150] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI045150, R01AI045150] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bayarsaihan D, 2000, P NATL ACAD SCI USA, V97, P7342, DOI 10.1073/pnas.97.13.7342; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; Franke Y, 1999, CYTOGENET CELL GENET, V86, P296, DOI 10.1159/000015322; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Mobley CM, 2000, J VIROL, V74, P6511, DOI 10.1128/JVI.74.14.6511-6519.2000; Novina CD, 1997, METHODS, V12, P254, DOI 10.1006/meth.1997.0477; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; Osborne LR, 1999, GENOMICS, V57, P279, DOI 10.1006/geno.1999.5784; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Tassabehji M, 1999, EUR J HUM GENET, V7, P737, DOI 10.1038/sj.ejhg.5200396; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; Wang YK, 1998, GENOMICS, V48, P163, DOI 10.1006/geno.1997.5182; Wu YX, 1999, J BIOL CHEM, V274, P3207, DOI 10.1074/jbc.274.5.3207; Yan XM, 2000, BIOCHEM J, V345, P749, DOI 10.1042/0264-6021:3450749; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Zandi E, 1999, MOL CELL BIOL, V19, P4547	27	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8377	8383		10.1074/jbc.M008411200	http://dx.doi.org/10.1074/jbc.M008411200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113127	hybrid			2022-12-25	WOS:000167474900096
J	Choosakoonkriang, S; Wiethoff, CM; Anchordoquy, TJ; Koe, GS; Smith, JG; Middaugh, CR				Choosakoonkriang, S; Wiethoff, CM; Anchordoquy, TJ; Koe, GS; Smith, JG; Middaugh, CR			Infrared spectroscopic characterization of the interaction of cationic lipids with plasmid DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF-THYMUS DNA; DIFFERENTIAL SCANNING CALORIMETRY; GENE DELIVERY; PHOSPHOLIPID-BILAYERS; PHYSICOCHEMICAL CHARACTERIZATION; CONFORMATIONAL DISORDER; IN-VITRO; COMPLEXES; TRANSFECTION; EFFICIENCY	Fourier transform infrared spectroscopy was used to characterize the interaction of the cationic lipids 1,2-dioleoyl-3-trimethylammonium-propane and dioctadecyldimethylammonium bromide with plasmid DNA. The effect of incorporating the neutral colipids cholesterol and dioleoylphosphatidylethanolamine on this interaction was also examined. Additionally, dynamic and phase analysis light scattering were used to monitor the size and zeta potential of the resulting complexes under conditions similar to the Fourier transform infrared measurements. Results suggest that upon interaction of cationic lipids with DNA, the DNA remains in the B form. Distinct changes in the frequency of several infrared bands arising from the DNA bases, however, suggest perturbation of their hydration upon interaction with cationic lipids. A direct interaction of the lipid ammonium headgroup with and dehydration of the DNA phosphate is observed when DNA is complexed with these lipids. Changes in the apolar regions of the lipid bilayer are minimal, whereas the interfacial regions of the membrane show changes in hydration or molecular packing. Incorporation of helper lipids into the cationic membranes results in increased conformational disorder of the apolar region and further dehydration of the interfacial region. Changes in the hydration of the DNA bases were also observed as the molar ratio of helper lipid in the membranes was increased.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA; Valentis Inc, Burlingame, CA 94010 USA	University of Kansas; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Middaugh, CR (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2095 Constant Ave, Lawrence, KS 66047 USA.							Ahmad R, 1996, J BIOMOL STRUCT DYN, V13, P795, DOI 10.1080/07391102.1996.10508892; Akao T, 1996, FEBS LETT, V391, P215, DOI 10.1016/0014-5793(96)00736-3; ALEX S, 1989, INORG CHIM ACTA, V157, P271, DOI 10.1016/S0020-1693(00)80552-6; Arakawa H, 2000, J BIOL CHEM, V275, P10150, DOI 10.1074/jbc.275.14.10150; Bhattacharya S, 1998, BIOCHEMISTRY-US, V37, P7764, DOI 10.1021/bi971772j; Binder H, 1998, BIOPHYS J, V74, P1908, DOI 10.1016/S0006-3495(98)77900-7; Birchall JC, 1999, INT J PHARM, V183, P195, DOI 10.1016/S0378-5173(99)00117-9; BLOOMFIELD V, 2000, NUCL ACIDS, P31; BRAUN CS, 2001, IN PRESS METHODS MOL; Crook K, 1998, GENE THER, V5, P137, DOI 10.1038/sj.gt.3300554; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; DAVIES MA, 1990, BIOCHEMISTRY-US, V29, P4368, DOI 10.1021/bi00470a016; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; Hirsch-Lemer D, 1998, BBA-BIOMEMBRANES, V1370, P17, DOI 10.1016/S0005-2736(97)00239-3; Hirsch-Lerner D, 1999, BBA-BIOMEMBRANES, V1461, P47, DOI 10.1016/S0005-2736(99)00145-5; Huebner S, 1999, BIOPHYS J, V76, P3158, DOI 10.1016/S0006-3495(99)77467-9; Hyde SC, 2000, GENE THER, V7, P1156, DOI 10.1038/sj.gt.3301212; Kennedy MT, 2000, BIOPHYS J, V78, P1620, DOI 10.1016/S0006-3495(00)76714-2; Koltover I, 1999, BIOPHYS J, V77, P915, DOI 10.1016/S0006-3495(99)76942-0; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; Lewis RNAH, 1996, BIOPHYS J, V70, P2736, DOI 10.1016/S0006-3495(96)79843-0; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; LOBO BA, 2001, IN PRESS METHODS MOL; MENDELSOHN R, 1989, BIOCHEMISTRY-US, V28, P8934, DOI 10.1021/bi00448a037; Mohammadi S, 1998, BIOCHEMISTRY-US, V37, P6165, DOI 10.1021/bi972964h; Neault JF, 1996, FEBS LETT, V382, P26, DOI 10.1016/0014-5793(96)00093-2; Neault JF, 1999, BIOPHYS J, V76, P2177, DOI 10.1016/S0006-3495(99)77372-8; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; Regelin AE, 2000, BBA-BIOMEMBRANES, V1464, P151, DOI 10.1016/S0005-2736(00)00126-7; Ross PC, 1999, GENE THER, V6, P651, DOI 10.1038/sj.gt.3300863; SMITH SO, 1992, BIOCHEMISTRY-US, V31, P11660, DOI 10.1021/bi00161a054; TAILLANDIER E, 1992, METHOD ENZYMOL, V211, P307; TAJMIRRIAHI HA, 1993, J BIOMOL STRUCT DYN, V11, P83, DOI 10.1080/07391102.1993.10508711; TILCOCK CPS, 1986, CHEM PHYS LIPIDS, V40, P109, DOI 10.1016/0009-3084(86)90066-6; Welsh MJ, 1999, HUM GENE THER, V10, P1559, DOI 10.1089/10430349950017897; Xu YH, 1999, BIOPHYS J, V77, P341, DOI 10.1016/S0006-3495(99)76894-3; Zuidam NJ, 1999, INT J PHARM, V183, P43, DOI 10.1016/S0378-5173(99)00041-1; Zuidam NJ, 1999, FEBS LETT, V457, P419, DOI 10.1016/S0014-5793(99)01053-4; Zuidam NJ, 1998, BBA-BIOMEMBRANES, V1368, P115, DOI 10.1016/S0005-2736(97)00187-9; Zuidam NJ, 1997, BBA-BIOMEMBRANES, V1329, P211, DOI 10.1016/S0005-2736(97)00110-7	41	64	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8037	8043		10.1074/jbc.M010592200	http://dx.doi.org/10.1074/jbc.M010592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11118456	hybrid			2022-12-25	WOS:000167474900052
J	Pigeon, C; Ilyin, G; Courselaud, B; Leroyer, P; Turlin, B; Brissot, P; Loreal, O				Pigeon, C; Ilyin, G; Courselaud, B; Leroyer, P; Turlin, B; Brissot, P; Loreal, O			A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACHEAL EPITHELIAL-CELLS; HEPATIC STELLATE CELLS; MESSENGER-RNA; TRANSFERRIN RECEPTOR; HEREDITARY HEMOCHROMATOSIS; SUBCELLULAR-LOCALIZATION; CHROMOSOMAL LOCATION; RAT HEPATOCYTES; DIETARY IRON; EXCESS IRON	Considering that the development of hepatic lesions related to iron overload diseases might be a result of abnormally expressed hepatic genes, we searched for new genes up-regulated under the condition of iron excess. By suppressive subtractive hybridization performed between livers from carbonyl iron-overloaded and control mice, we isolated a 225-base pair cDNA. By Northern blot analysis, the corresponding mRNA was confirmed to be overexpressed in livers of experimentally (carbonyl iron and iron-dextran-treated mice) and spontaneously (beta (2)-microglobulin knockout mice) iron-overloaded mice. In addition, beta (2)-microglobulin knockout mice fed with a low iron content diet exhibited a decrease of hepatic mRNA expression. The murine full-length cDNA was Isolated and was found to encode an 83-amino acid protein presenting a strong homology in its C-terminal region to the human antimicrobial peptide hepcidin, In addition, we cloned the corresponding rat and human orthologue cDNAs, Both mouse and human genes named HEPC are constituted of 3 exons and 2 introns and are located on chromosome 7 and 19, respectively, in close proximity to USF2 gene. In mouse and human, HEPC mRNA was predominantly expressed in the liver. During both in vivo and in vitro studies, HEPC mRNA expression was enhanced in mouse hepatocytes under the effect of lipopolysaccharide. Finally, to analyze the intracellular localization of the predicted protein, we used the green fluorescent protein chimera expression vectors. The murine green fluorescent protein-prohepcidin protein was exclusively localized in the nucleus. When the putative nuclear localization signal was deleted, the resulting protein was addressed to the cytoplasm. Taken together, our data strongly suggest that the product of the new liver-specific gene HEPC might play a specific role during iron overload and exhibit additional functions distinct from its antimicrobial activity.	CHRU Pontchaillou, INSERM, U522, F-35033 Rennes, France; CHRU Pontchaillou, Lab Anatomopathol B, Rennes, France; CHRU Pontchaillou, Serv Malad Foie, F-35033 Rennes, France	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Rennes; CHU Rennes	Pigeon, C (corresponding author), CHRU Pontchaillou, INSERM, U522, F-35033 Rennes, France.	christelle.pigeon@rennes.inserm.fr	Turlin, Bruno/AAL-7410-2020; Loreal, Olivier/G-3366-2013	Turlin, Bruno/0000-0002-9779-8041; Loreal, Olivier/0000-0002-7428-3766				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AZARI P, 1967, ARCH BIOCHEM BIOPHYS, V118, P138, DOI 10.1016/0003-9861(67)90289-5; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bals R, 1999, INFECT IMMUN, V67, P3542, DOI 10.1128/IAI.67.7.3542-3547.1999; BARRY M, 1971, LANCET, V1, P100; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Boelaert JR, 1996, ACTA CLIN BELG, V51, P213, DOI 10.1080/22953337.1996.11718513; BROCK JH, 1987, HAEMATOLOGIA, V20, P237; Brown KE, 1998, FREE RADICAL BIO MED, V24, P545, DOI 10.1016/S0891-5849(97)00284-0; Canonne-Hergaux F, 1999, BLOOD, V93, P4406, DOI 10.1182/blood.V93.12.4406.412k21_4406_4417; CARTHEW P, 1991, HEPATOLOGY, V13, P534, DOI 10.1016/0270-9139(91)90308-I; Choi JK, 2000, MOL VIS, V6, P222; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DESOUSA M, 1994, IMMUNOL LETT, V39, P105, DOI 10.1016/0165-2478(94)90094-9; DEUGNIER YM, 1992, GASTROENTEROLOGY, V102, P2050, DOI 10.1016/0016-5085(92)90331-R; DEUGNIER YM, 1993, GASTROENTEROLOGY, V104, P228, DOI 10.1016/0016-5085(93)90856-8; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; Diamond G, 2000, INFECT IMMUN, V68, P113, DOI 10.1128/IAI.68.1.113-119.2000; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DIETER P, 1988, EXP CELL RES, V139, P599; DOOLITTLE RL, 1981, LAB INVEST, V45, P558; Eisenstein RS, 1998, NUTR REV, V56, P356, DOI 10.1111/j.1753-4887.1998.tb01679.x; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fimmel CJ, 1996, J IMMUNOL, V157, P2601; Fletcher LM, 1999, J GASTROEN HEPATOL, V14, P202, DOI 10.1046/j.1440-1746.1999.01836.x; Fujimoto Y, 1998, Rinsho Byori, V46, P9; Graham RM, 1998, J HEPATOL, V29, P603, DOI 10.1016/S0168-8278(98)80156-6; Griffon B, 1998, HEPATOLOGY, V28, P1300, DOI 10.1002/hep.510280519; GROOTVELD M, 1989, J BIOL CHEM, V264, P4417; GUALDI R, 1994, GASTROENTEROLOGY, V107, P1118, DOI 10.1016/0016-5085(94)90237-2; GUGUEN C, 1975, BIOL GASTRO-ENTEROL, V8, P223; Guillouzo A, 1998, ENVIRON HEALTH PERSP, V106, P511, DOI 10.2307/3433803; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; HIRAYAMA M, 1993, HEPATOLOGY, V18, P874, DOI 10.1002/hep.1840180420; HOUGLUM K, 1994, AM J PHYSIOL-GASTR L, V267, pG908, DOI 10.1152/ajpgi.1994.267.5.G908; Houglum K, 1997, HEPATOLOGY, V26, P605, DOI 10.1002/hep.510260311; IKEDA H, 1992, HEPATOLOGY, V15, P282, DOI 10.1002/hep.1840150218; Ilyin G, 1998, ANIMAL CELL CULTURE TECHNIQUES, P371; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Ke YH, 1998, J BIOL CHEM, V273, P23637, DOI 10.1074/jbc.273.37.23637; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOBUNE M, 1994, HEPATOLOGY, V19, P1468, DOI 10.1002/hep.1840190623; KOCAREK TA, 1994, BIOCHEM PHARMACOL, V48, P1815, DOI 10.1016/0006-2952(94)90468-5; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Kuwata H, 1998, BBA-PROTEIN STRUCT M, V1429, P129, DOI 10.1016/S0167-4838(98)00224-6; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Le Seyec J, 1998, J VIROL, V72, P5573, DOI 10.1128/JVI.72.7.5573-5578.1998; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; LOREAL O, 1992, J HEPATOL, V16, P122, DOI 10.1016/S0168-8278(05)80104-7; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; Montosi G, 1998, HEPATOLOGY, V27, P1611, DOI 10.1002/hep.510270622; Mori K, 1999, J BIOCHEM-TOKYO, V125, P627, DOI 10.1093/oxfordjournals.jbchem.a022329; Moyo VM, 1998, BLOOD, V91, P1076; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; Niederau Claus, 1999, Journal of Hepatology, V30, P6; Ohtake T, 1999, BRIT J CANCER, V81, P393, DOI 10.1038/sj.bjc.6690707; Olivieri NF, 1999, NEW ENGL J MED, V341, P99, DOI 10.1056/NEJM199907083410207; OLYNYK JK, 1995, GASTROENTEROLOGY, V108, P1104, DOI 10.1016/0016-5085(95)90209-0; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; PIETRANGELO A, 1995, J CLIN INVEST, V95, P1824, DOI 10.1172/JCI117861; PIETRANGELO A, 1990, HEPATOLOGY, V11, P798, DOI 10.1002/hep.1840110513; Pigeon C, 1999, J HEPATOL, V30, P926, DOI 10.1016/S0168-8278(99)80149-4; Piperno A, 1998, HEPATOLOGY, V28, P1105, DOI 10.1002/hep.510280427; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; POTTER BJ, 1989, AM J PHYSIOL, V257, pG524, DOI 10.1152/ajpgi.1989.257.4.G524; PRICE PJ, 1982, IN VITRO CELL DEV B, V18, P576; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rakba N, 1998, BIOCHEM PHARMACOL, V55, P1797, DOI 10.1016/S0006-2952(98)00009-4; RISDON RA, 1975, J PATHOL, V116, P83, DOI 10.1002/path.1711160204; Rizzardini M, 1998, HEPATOLOGY, V27, P703, DOI 10.1002/hep.510270311; Santos M, 1998, BLOOD, V91, P3059, DOI 10.1182/blood.V91.8.3059.3059_3059_3065; SONDERGAARD L, 1993, TRENDS GENET, V9, P193, DOI 10.1016/0168-9525(93)90113-V; STEINGRIMSSON E, 1995, GENOMICS, V28, P179, DOI 10.1006/geno.1995.1129; TRINDER D, 1990, AM J PHYSIOL, V259, pG611, DOI 10.1152/ajpgi.1990.259.4.G611; Trinder D, 1998, AM J PHYSIOL-GASTR L, V275, pG279, DOI 10.1152/ajpgi.1998.275.2.G279; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; Wakabayashi H, 1999, BIOSCI BIOTECH BIOCH, V63, P955, DOI 10.1271/bbb.63.955; WIEBEL FJ, 1984, EUR J BIOCHEM, V145, P455, DOI 10.1111/j.1432-1033.1984.tb08577.x	86	1309	1431	6	80	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7811	7819		10.1074/jbc.M008923200	http://dx.doi.org/10.1074/jbc.M008923200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113132	hybrid			2022-12-25	WOS:000167474900021
J	Quraishi, O; Storer, AC				Quraishi, O; Storer, AC			Identification of internal autoproteolytic cleavage sites within the prosegments of recombinant procathepsin B and procathepsin S - Contribution of a plausible unimolecular autoproteolytic event for the processing of zymogens belonging to the papain family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-B; CRYSTAL-STRUCTURE; CYSTEINE PROTEASE; ANGSTROM RESOLUTION; SLOW-BINDING; ACTIVE-SITE; OCCLUDING LOOP; IN-VITRO; PROPEPTIDE; INHIBITION	The steps involved in the maturation of proenzymes belonging to the papain family of cysteine proteases have been difficult to characterize. Intermolecular processing at or near the pro/mature junction, due either to the catalytic activity of active enzyme or to exogeneous proteases, has been well documented for this family of proenzymes. In addition, kinetic studies are suggestive of a slow unimolecular mechanism of autoactivation which is independent of proenzyme concentration. However, inspection of the recently determined x-ray crystal structures does not support this evidence. This is due primarily to the extensive distances between the catalytic thiolate-imidazolium ion pair and the putative site of proteolysis near the pro/mature junction required to form mature protein. Furthermore, the pro-segments for this family of precursors have been shown to bind through the substrate binding clefts in a direction opposite to that expected for natural substrates. We report, using cystatin C- and N-terminal sequencing, the identification of autoproteolytic intermediates of processing in vitro for purified recombinant procathepsin B and procathepsin S. Inspection of the x-ray crystal structures reported to date indicates that these reactions occur within a segment of the proregion which binds through the substrate binding clefts of the enzymes, thus suggesting that these reactions are occurring as unimolecular processes.	Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Biotechnol Sector, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Prot Engn Network Centres Excellence, Montreal, PQ H3G 1Y6, Canada	National Research Council Canada; McGill University; McGill University	Storer, AC (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Biotechnol Sector, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.							ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ARAD D, 1990, J AM CHEM SOC, V112, P491, DOI 10.1021/ja00158a004; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; Carmona E, 1996, BIOCHEMISTRY-US, V35, P8149, DOI 10.1021/bi952736s; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; Chagas JR, 1996, FEBS LETT, V392, P233, DOI 10.1016/0014-5793(96)00822-8; Chen YM, 1996, FEBS LETT, V393, P24, DOI 10.1016/0014-5793(96)00847-2; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; Groves MR, 1996, STRUCTURE, V4, P1193, DOI 10.1016/S0969-2126(96)00127-X; Guncar G, 1998, STRUCTURE, V6, P51; HALL A, 1993, BIOCHEM J, V291, P123, DOI 10.1042/bj2910123; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; JAQUELINE, 1998, FOLDING DESIGN, V3, P271; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; LaLonde JM, 1999, BIOCHEMISTRY-US, V38, P862, DOI 10.1021/bi9822271; Li YY, 1996, J MOL BIOL, V262, P591, DOI 10.1006/jmbi.1996.0537; MACH L, 1994, J BIOL CHEM, V269, P13030; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Maubach G, 1997, EUR J BIOCHEM, V250, P745, DOI 10.1111/j.1432-1033.1997.00745.x; MENARD R, 1991, BIOCHEMISTRY-US, V30, P8924, DOI 10.1021/bi00101a002; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Quraishi O, 1999, BIOCHEMISTRY-US, V38, P5017, DOI 10.1021/bi981950o; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; ROWAN AD, 1993, BIOCHEM J, V294, P923, DOI 10.1042/bj2940923; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; Sivaraman J, 1999, PROTEIN SCI, V8, P283; Sivaraman J, 2000, J MOL BIOL, V295, P939, DOI 10.1006/jmbi.1999.3410; Sloane B F, 1990, Semin Cancer Biol, V1, P137; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; Volkov A, 1996, J MOL BIOL, V262, P595, DOI 10.1006/jmbi.1996.0538; WINKLER FK, 1971, J MOL BIOL, V59, P169, DOI 10.1016/0022-2836(71)90419-0	49	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8118	8124		10.1074/jbc.M005851200	http://dx.doi.org/10.1074/jbc.M005851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11115496	hybrid			2022-12-25	WOS:000167474900063
J	Flipphi, M; Mathieu, M; Cirpus, I; Panozzo, C; Felenbok, B				Flipphi, M; Mathieu, M; Cirpus, I; Panozzo, C; Felenbok, B			Regulation of the aldehyde dehydrogenase gene (aldA) and its role in the control of the coinducer level necessary for induction of the ethanol utilization pathway in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; ZINC BINUCLEAR CLUSTER; UTILIZATION REGULON; DNA-BINDING; TRANSLATION TERMINATION; ALCOHOL-DEHYDROGENASE; TRANSACTIVATOR ALCR; CREA REPRESSOR; ACTIVATOR ALCR; CLONING	Expression of the structural genes for alcohol and aldehyde dehydrogenase, alcA and aldA, respectively, enables the fungus Aspergillus nidulans to grow on ethanol. The :pathway-specific transcriptional activator AlcR mediates the induction of ethanol catabolism in the presence of a coinducing compound. Ethanol catabolism is further subject to negative control mediated by the general carbon catabolite repressor CreA. Here we show that, in contrast to alcA and alcR, the aldA gene is not directly subject to CreA repression. A single cis-acting element mediates AlcR activation of aldA. Furthermore, we show that the induction of the ale gene system is linked to in situ aldehyde dehydrogenase activity. In aldA loss-of-function mutants, the ale genes are induced under normally noninducing conditions. This pseudo-constitutive expression correlates with the nature of the mutations, suggesting that this feature is caused by an intracellular accumulation of a coinducing compound. Conversely, constitutive overexpression of abdA results in suppression of induction in the presence of: ethanol, This shows unambiguously that acetaldehyde is the sole physiological inducer of ethanol catabolism. We hypothesize that the intracellular acetaldehyde concentration is the critical factor governing the induction of the ale gene system.	Univ Paris 11, CNRS UMR 8621, Inst Genet & Microbiol, Ctr Univ Orsay, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Felenbok, B (corresponding author), Univ Paris 11, CNRS UMR 8621, Inst Genet & Microbiol, Ctr Univ Orsay, Batiment 409, F-91405 Orsay, France.							ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; ARMITT S, 1976, J GEN MICROBIOL, V92, P263, DOI 10.1099/00221287-92-2-263; BUXTON FP, 1989, GENE, V84, P329, DOI 10.1016/0378-1119(89)90507-6; CLUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; CREASER EH, 1985, BIOCHEM J, V225, P449, DOI 10.1042/bj2250449; CREASER EH, 1987, INT J BIOCHEM, V19, P1009, DOI 10.1016/0020-711X(87)90185-6; CREBELLI R, 1989, MUTAT RES, V215, P187, DOI 10.1016/0027-5107(89)90183-8; CUBERO B, 1994, EMBO J, V13, P407, DOI 10.1002/j.1460-2075.1994.tb06275.x; Czaplinski K, 1999, BIOESSAYS, V21, P685, DOI 10.1002/(SICI)1521-1878(199908)21:8<685::AID-BIES8>3.0.CO;2-4; DARLINGTON AJ, 1965, NATURE, V206, P599, DOI 10.1038/206599a0; DUNCAN RJS, 1971, EUR J BIOCHEM, V22, P538, DOI 10.1111/j.1432-1033.1971.tb01574.x; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; FELENBOK B, 1991, J BIOTECHNOL, V17, P11, DOI 10.1016/0168-1656(91)90023-O; Felenbok B, 1994, Prog Ind Microbiol, V29, P141; FELENBOK B, 1996, MYCOTA, V3, P369; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; FILLINGER S, 1995, FEBS LETT, V368, P547, DOI 10.1016/0014-5793(95)00736-S; Fillinger S, 1996, MOL MICROBIOL, V20, P475, DOI 10.1046/j.1365-2958.1996.5301061.x; GWYNNE DI, 1987, GENE, V51, P205, DOI 10.1016/0378-1119(87)90309-X; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; JONES RP, 1989, ENZYME MICROB TECH, V11, P130, DOI 10.1016/0141-0229(89)90073-2; KULMBURG P, 1992, MOL CELL BIOL, V12, P1932, DOI 10.1128/MCB.12.5.1932; KULMBURG P, 1993, MOL MICROBIOL, V7, P847, DOI 10.1111/j.1365-2958.1993.tb01175.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; LOCKINGTON R, 1987, MOL MICROBIOL, V1, P275, DOI 10.1111/j.1365-2958.1987.tb01933.x; LOCKINGTON RA, 1985, GENE, V33, P137, DOI 10.1016/0378-1119(85)90088-5; Lockington RA, 1997, GENE, V191, P61, DOI 10.1016/S0378-1119(97)00032-2; MARCH J, 1985, ADV ORG CHEM, P805; Mathieu M, 2000, MOL MICROBIOL, V36, P123, DOI 10.1046/j.1365-2958.2000.01833.x; MATHIEU M, 1994, EMBO J, V13, P4022, DOI 10.1002/j.1460-2075.1994.tb06718.x; Muro-Pastor MI, 1999, EMBO J, V18, P1584, DOI 10.1093/emboj/18.6.1584; Nikolaev I, 1999, MOL MICROBIOL, V31, P1115, DOI 10.1046/j.1365-2958.1999.01250.x; Nikolaev I, 1999, J BIOL CHEM, V274, P9795, DOI 10.1074/jbc.274.14.9795; OESTREICHER N, 1993, J BIOL CHEM, V268, P23382; PAGE MM, 1972, BIOCH J S, V127, P17; PAGE MM, 1971, THESIS U CAMBRIDGE C; Panozzo C, 1998, J BIOL CHEM, V273, P6367, DOI 10.1074/jbc.273.11.6367; Panozzo C, 1997, J BIOL CHEM, V272, P22859, DOI 10.1074/jbc.272.36.22859; PATEMAN JA, 1983, PROC R SOC SER B-BIO, V217, P243, DOI 10.1098/rspb.1983.0009; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; PICKETT M, 1987, GENE, V51, P217, DOI 10.1016/0378-1119(87)90310-6; PUNT PJ, 1991, J BIOTECHNOL, V17, P19, DOI 10.1016/0168-1656(91)90024-P; ROBERTS T, 1979, MOL GEN GENET, V177, P57, DOI 10.1007/BF00267253; Sambrook J., 2002, MOL CLONING LAB MANU; SEALYLEWIS HM, 1984, CURR GENET, V8, P253, DOI 10.1007/BF00419721; SPECHT CA, 1982, ANAL BIOCHEM, V119, P158, DOI 10.1016/0003-2697(82)90680-7; Strauss J, 1999, MOL MICROBIOL, V32, P169, DOI 10.1046/j.1365-2958.1999.01341.x; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9	52	49	57	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6950	6958		10.1074/jbc.M005769200	http://dx.doi.org/10.1074/jbc.M005769200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11102439	hybrid			2022-12-25	WOS:000167442900014
J	Jenkins, CM; Wolf, MJ; Mancuso, DJ; Gross, RW				Jenkins, CM; Wolf, MJ; Mancuso, DJ; Gross, RW			Identification of the calmodulin-binding domain of recombinant calcium-independent phospholipase A(2)beta - Implications for structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ARACHIDONIC-ACID; SMOOTH-MUSCLE; CATALYTIC DOMAIN; NUCLEAR-ENVELOPE; PEPTIDE COMPLEX; EXCHANGE FACTOR; RECOGNITION; SEQUENCE; CELLS	Calcium-independent phospholipase A(2) (iPLA(2)) is the major phospholipase A, activity in many cell types, and at least one isoform of this enzyme class is physically and functionally coupled to calmodulin (CaM) in a reversible calcium-dependent fashion. To identify the domain in recombinant iPLA(2)beta (riPLA(2)beta) underlying this interaction, multiple techniques were employed. First, we identified calcium-activated CaM induced alterations in the kinetics of proteolytic fragment generation during limited trypsinolysis (i.e. CaM footprinting), Tryptic digests of riPLA(2)beta (83 kDa) in the presence of EGTA alone, Ca+2 alone, or EGTA and CaM together resulted in the production of a major 68-kDa protein whose kinetic rate of formation was specifically attenuated in incubations containing CaM and Ca+2 together. Western blotting utilizing antibodies directed against either the N- or C-terminal regions of riPLA(2)beta indicated the specific protection of riPLA(2)beta by calcium-activated CaM at a cleavage site approximate to 15 kDa from the C terminus. Moreover, calcium-activated calmodulin increased the kinetic rate of tryptic cleavage near the active site of riPLA(2)beta. Second, functional characterization of products from these partial tryptic digests demonstrated that approximate to 90% of the 68-kDa riPLA(2)beta tryptic product (i.e. lacking the 18-kDa C-terminus) did not bind to a CaM affinity matrix in the presence of Ca2+, although >95% of the noncleaved riPLA(2)beta as well as a 40-kDa C-terminal peptide bound tightly under these conditions. Third, when purified riPLA(2)beta was subjected to exhaustive trypsinolysis followed by ternary complex CaM affinity chromatography, a unique tryptic peptide ((694)AWSEM-VGIQYFR(705)) within the 15-kDa C-terminal fragment was identified by RP-HPLC, which bound to CaM-agarose in the presence but not the absence of calcium ion. Fourth, fluorescence energy transfer experiments demonstrated that this peptide (694-705) bound to dansyl-calmodulin in a calcium-dependent fashion. Collectively, these results identify multiple contact points in the 15-kDa C terminus as being the major but not necessarily the only binding site responsible for the calcium-dependent regulation of iPLA(2)beta by CaM.	Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Chem, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gross, RW (corresponding author), Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Med, 660 S Euclid Ave,Campus Box 8020, St Louis, MO 63110 USA.		WOLF, MATTHEW/AHC-5201-2022; wolf, matthew/C-2315-2008	Wolf, Matthew/0000-0001-8004-4852	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041250, P01HL057278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 PO1 HL 57278-02, 2 R02 HL 41250-06A1] Funding Source: Medline; NIDDK NIH HHS [P60DK20579-22] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; ANAGLI J, 1995, EUR J BIOCHEM, V233, P701, DOI 10.1111/j.1432-1033.1995.701_3.x; ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Delidow B C, 1993, Methods Mol Biol, V15, P217, DOI 10.1385/0-89603-244-2:217; EDELMAN AM, 1985, J BIOL CHEM, V260, P1275; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; *INF INC, 2000, VECT NTI SUIT VERS 6; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KINCAID RL, 1982, J BIOL CHEM, V257, P638; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LOWE PN, 1996, BIOCHEM J, V376, P524; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; McHowat J, 1998, AM J PHYSIOL-CELL PH, V274, pC447, DOI 10.1152/ajpcell.1998.274.2.C447; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MIYAKE R, 1992, BIOCHIM BIOPHYS ACTA, V1165, P167, DOI 10.1016/0005-2760(92)90183-V; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Wolf MJ, 1995, FEBS LETT, V377, P358, DOI 10.1016/0014-5793(95)01371-7; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; WOLF RA, 1985, J BIOL CHEM, V260, P7295; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313	47	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7129	7135		10.1074/jbc.M010439200	http://dx.doi.org/10.1074/jbc.M010439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11118454	hybrid			2022-12-25	WOS:000167442900039
J	Goodman, MD; Hargrove, MS				Goodman, MD; Hargrove, MS			Quaternary structure of rice nonsymbiotic hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME-BASED SENSORS; GENE; BINDING; PROTEIN; PLANT; LEGHEMOGLOBIN; PARASPONIA; KINETICS; OXYGEN	Plant nonsymbiotic hemoglobins are hexacoordinate heme proteins found in all plants. Although expression is linked with hypoxic environmental conditions (Taylor, E. R., Nie, X. Z., Alexander, W. M., and Hill, R. D. (1994) Plant Mel. Biol. 24, 853-862), no discrete physio logical function has yet been attributed to this family of proteins. The crystal structure of a nonsymbiotic hemo globin from rice has recently been determined. The crystalline protein is homodimeric and hexacoordinate with two histidine side chains coordinating the heme iron atom. Despite the fact that the amino acids responsible for the subunit interface are relatively conserved among the nonsymbiotic hemoglobins, previous work suggests that this group of proteins might display variability in quaternary structure (Duff, S. M. G., Wittenberg, J. B., and Hill, R. D. (1997) J. Biol. Chem. 272, 16746-16752; Arredondo-Peter, R., Hargrove, M. S., Sarath, G., Moran, J. F., Lohrman, J., Olson, J. S., and Klucas, R. V. (1997) Plant Physiol. 115, 1259-1266). Analytical ultracentrifugation and size exclusion high pressure liquid chromatography were used to investigate the quaternary structure of rice nonsymbiotic hemoglobin at various states of ligation and oxidation. Additionally, site-directed mutagenesis was used to test the role of several interface amino acids in dimer formation and ligand binding. Results were analyzed in light of possible physiological functions and indicate that the plant nonsymbiotic hemoglobins are not oxygen transport proteins but more closely resemble known oxygen sensors.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Hargrove, MS (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	msh@iastate.edu						Andersson CR, 1996, P NATL ACAD SCI USA, V93, P5682, DOI 10.1073/pnas.93.12.5682; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; APPLEBY CA, 1983, SCIENCE, V220, P951, DOI 10.1126/science.220.4600.951; APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; Arredondo-Peter R, 1998, PLANT PHYSIOL, V118, P1121, DOI 10.1104/pp.118.4.1121; Arredondo-Peter R., 2000, Plant Physiology, V122, P1458; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; DURSHLAG H, 1986, THERMODYNAMIC DATA B; GALICK RL, 1979, ARCH BIOCHEM BIOPHYS, V194, P13; GIANGIACOMA L, 2000, INT C INV DIOX BIND, P51; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hendriks T, 1998, BBA-GENE STRUCT EXPR, V1443, P193, DOI 10.1016/S0167-4781(98)00206-1; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; MITCHELL DT, 1995, J MOL BIOL, V251, P421, DOI 10.1006/jmbi.1995.0445; Olson J S, 1981, Methods Enzymol, V76, P631; Riggs A., 1981, Methods in Enzymology, V76, P5; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; Scott NL, 2000, PROTEIN SCI, V9, P587; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Sowa AW, 1998, P NATL ACAD SCI USA, V95, P10317, DOI 10.1073/pnas.95.17.10317; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; TAYLOR ER, 1994, PLANT MOL BIOL, V24, P853, DOI 10.1007/BF00014440; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; WITTENBERG JB, 1986, J BIOL CHEM, V261, P3624	32	46	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6834	6839		10.1074/jbc.M009254200	http://dx.doi.org/10.1074/jbc.M009254200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11106662	hybrid, Green Submitted			2022-12-25	WOS:000167261000097
J	Feng, ZP; Hamid, J; Doering, C; Jarvis, SE; Bosey, GM; Bourinet, E; Snutch, TP; Zamponi, GW				Feng, ZP; Hamid, J; Doering, C; Jarvis, SE; Bosey, GM; Bourinet, E; Snutch, TP; Zamponi, GW			Amino acid residues outside of the pore region contribute to N-type calcium channel permeation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CA2+ CHANNEL; ION PERMEATION; VOLTAGE; SELECTIVITY; CONDUCTION; CLONING; MEMBER; FAMILY; LOCUS; HEART	It is widely believed that the selectivity of voltage-dependent calcium channels is mainly controlled by amino acid residues contained within four p-loop motifs forming the pore of the channel. An examination of the amino acid sequences of high voltage-activated calcium channels reveals that their domain Ill S5-H5 regions contain a highly conserved motif with homology to known EF hand calcium binding proteins, hinting that this region may contribute to channel permeation. To test this hypothesis, we used site-directed mutagenesis to replace three conserved negatively charged residues in the N-type calcium channel alpha (1B) subunit (Glu-1321, Asp-1323, and Glu-1332) with positively charged amino acids (lysine and arginine) and studied their effect on ion selectivity using whole cell and single channel patch clamp recordings. Whereas the wild type channels conducted barium much more effectively than calcium, the mutant displayed nearly equal permeabilities for these two ions, Individual. replacement of residue 1332 or a double substitution of residues 1321 and 1323 with lysine and arginine, respectively, were equally effective. Disruption of the putative EF hand motif through replacement of the central glycine residue (1326) with proline resulted in a similar effect, indicating that the responses observed with the triple mutant, were not due to changes in the net charge of the channel. Overall, our data indicate that residues outside of the narrow region of the pore have the propensity to contribute to calcium channel permeation. They also raise the possibility that interactions of calcium ions with a putative calcium binding domain at the extracellular side of the channel may underlie the differential permeabilities of the channel for barium and calcium ions.	Univ Calgary, Dept Physiol & Biophys, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; NeuroMed Technol Inc, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; CNRS, Inst Human Genet, F-34094 Montpellier, France	University of Calgary; University of Calgary; University of British Columbia; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Neurosci Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Zamponi, Gerald W./0000-0002-0644-9066; bourinet, emmanuel/0000-0001-8021-0419				Bourinet E, 1996, J NEUROSCI, V16, P4983; CARBONE E, 1987, J PHYSIOL-LONDON, V386, P571, DOI 10.1113/jphysiol.1987.sp016552; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Cibulsky SM, 2000, J GEN PHYSIOL, V116, P349, DOI 10.1085/jgp.116.3.349; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; Hille B., 1992, IONIC CHANNELS EXCIT; Lee JH, 1999, J NEUROSCI, V19, P1912; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Sather William A., 1994, Current Opinion in Neurobiology, V4, P313, DOI 10.1016/0959-4388(94)90091-4; STEA A, 1995, HDB RECEPTORS CHANNE, P113; TANG SQ, 1993, J BIOL CHEM, V268, P13026; Williamson AV, 1999, BIOPHYS J, V77, P2575, DOI 10.1016/S0006-3495(99)77092-X; Wu XS, 2000, J BIOL CHEM, V275, P31778, DOI 10.1074/jbc.M004829200; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zamponi GW, 1996, PFLUG ARCH EUR J PHY, V431, P470	21	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5726	5730		10.1074/jbc.C000791200	http://dx.doi.org/10.1074/jbc.C000791200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11120735	hybrid			2022-12-25	WOS:000167115100045
J	Tegeder, I; Niederberger, E; Israr, E; Guhring, H; Brune, K; Euchenhofer, C; Grosch, S; Geisslinger, G				Tegeder, I; Niederberger, E; Israr, E; Guhring, H; Brune, K; Euchenhofer, C; Grosch, S; Geisslinger, G			Inhibition of NF-kappa B and AP-1 activation by R- and S-flurbiprofen	FASEB JOURNAL			English	Article									Goethe Univ Frankfurt, Ctr Pharmacol, D-60590 Frankfurt, Germany; Univ Erlangen Nurnberg, Inst Expt Pharmakol & Toxikol, D-91054 Erlangen, Germany	Goethe University Frankfurt; University of Erlangen Nuremberg	Geisslinger, G (corresponding author), Goethe Univ Frankfurt, Ctr Pharmacol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	geisslinger@em.uni-frankfurt.de	Tegeder, Irmgard/AAM-2266-2020; Groesch, Sabine/H-4251-2018; Tegeder, Irmgard/AAM-2246-2020	Tegeder, Irmgard/0000-0001-7524-8025; Groesch, Sabine/0000-0002-7262-6307; Tegeder, Irmgard/0000-0001-7524-8025					0	75	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					2	4		10.1096/fasebj.15.1.2	http://dx.doi.org/10.1096/fasebj.15.1.2			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099482	Bronze			2022-12-25	WOS:000166312400001
J	Berns, H; Humar, R; Hengerer, B; Kiefer, FN; Battegay, EJ				Berns, H; Humar, R; Hengerer, B; Kiefer, FN; Battegay, EJ			RACK1 is up-regulated in angiogenesis and human carcinomas	FASEB JOURNAL			English	Article						receptor for activated PKC beta; signaling; angiogenic process; endothelium; cancer	PROTEIN-KINASE-C; ENDOTHELIAL-CELLS; IN-VITRO; GROWTH-FACTOR; INTRACELLULAR RECEPTOR; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; ESTROUS-CYCLE; MESSENGER-RNA; CORPORA-LUTEA	Angiogenesis is crucial for many biological and pathological processes including the ovarian cycle and tumor growth, To identify molecules relevant for angiogenesis, we performed mRNA fingerprinting and subsequent Northern blot analysis using bovine cord-forming vs, monolayer-forming endothelial cells (EC) in vitro and staged bovine corpora lutea in vivo. We detected the receptor for activated C kinase 1 (RACK1), the specific receptor for activated protein kinase C beta (PKC beta), to be up-regulated in bovine cord-forming EC in vitro and in angiogenically active stages of bovine corpora lutea in vivo, Thereafter we established and determined the complete bovine RACK1 cDNA sequence. RACK1 was massively induced in subconfluent vs. contact-inhibited bovine EC, during angiogenesis in vitro, active phases of the murine ovarian cycle, human tumor angiogenesis, and in cancer cells in vivo as assessed by quantitative PCR and in situ hybridization, RACK1 transcripts were localized to proliferating EC in vitro and the endothelium of tumor neovascularizations in vivo by in situ hybridization, PKC beta plays an important role in angiogenesis and cancer growth. Our data suggest that downstream signaling of PKC beta in angiogenically active vs. inactive tissues and endothelium is affected by the availability of RACK1.	Univ Basel Hosp, Dept Res, Head Lab Vasc Biol, Cardiovasc Res Grp, CH-4031 Basel, Switzerland; Univ Basel Hosp, Med Outpatient Div, CH-4031 Basel, Switzerland; Novartis, Nervous Syst Therapeut Area, CH-4002 Basel, Switzerland	University of Basel; University of Basel; Novartis	Battegay, EJ (corresponding author), Univ Basel Hosp, Dept Res, Head Lab Vasc Biol, Cardiovasc Res Grp, Petersgraben 3, CH-4031 Basel, Switzerland.							Battegay EJ, 1996, TRENDS GLYCOSCI GLYC, V8, P231, DOI 10.4052/tigg.8.231; BATTEGAY EJ, 1995, J MOL MED, V73, P333; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; CHAMPLIN AK, 1973, BIOL REPROD, V8, P491, DOI 10.1093/biolreprod/8.4.491; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTTAPEREIRA G, 1980, J CELL PHYSIOL, V102, P183, DOI 10.1002/jcp.1041020209; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; Doanes AM, 1999, BIOCHEM BIOPH RES CO, V255, P545, DOI 10.1006/bbrc.1999.0227; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Frueh FW, 1997, MOL PHARMACOL, V51, P363; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; HENGERER B, 1993, BIOTECHNIQUES, V14, P522; HU DE, 1995, INFLAMMATION, V19, P39, DOI 10.1007/BF01534379; IMAI Y, 1994, MOL BRAIN RES, V24, P313, DOI 10.1016/0169-328X(94)90144-9; IRELAND JJ, 1980, J DAIRY SCI, V63, P155, DOI 10.3168/jds.S0022-0302(80)82901-8; IRUELAARISPE ML, 1991, ARTERIOSCLER THROMB, V11, P805, DOI 10.1161/01.ATV.11.4.805; IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406; Jones MK, 1998, BIOCHEM BIOPH RES CO, V249, P118, DOI 10.1006/bbrc.1998.9095; Kanashiro CA, 1998, CLIN EXP PHARMACOL P, V25, P974, DOI 10.1111/j.1440-1681.1998.tb02170.x; Kolarova H, 1996, BIOTECHNIQUES, V20, P196; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIAW L, 1993, ARTERIOSCLER THROMB, V13, P985, DOI 10.1161/01.ATV.13.7.985; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; MIETTINEN M, 1983, AM J CLIN PATHOL, V79, P32, DOI 10.1093/ajcp/79.1.32; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; REYNOLDS LP, 1992, FASEB J, V6, P886, DOI 10.1096/fasebj.6.3.1371260; RICKEN AM, 1995, HISTOCHEM CELL BIOL, V103, P345, DOI 10.1007/BF01457809; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rosales OR, 1998, CELL SIGNAL, V10, P589, DOI 10.1016/S0898-6568(98)00002-3; Schenk S, 1999, MOL BIOL CELL, V10, P2933, DOI 10.1091/mbc.10.9.2933; SPANELBOROWSKI K, 1987, ACTA ANAT, V128, P227; Thommen R, 1997, J CELL BIOCHEM, V64, P403; TSOPANOGLOU NE, 1993, J VASC RES, V30, P202, DOI 10.1159/000158995; VERNON RB, 1995, AM J PATHOL, V147, P873; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Yoshiji H, 1999, CANCER RES, V59, P4413; Zhou LY, 1996, J INVEST DERMATOL, V107, P248, DOI 10.1111/1523-1747.ep12329733	44	100	106	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2549	2558		10.1096/fj.99-1038com	http://dx.doi.org/10.1096/fj.99-1038com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099474				2022-12-25	WOS:000165723400026
J	Klein, MA; Ruedi, D; Nozaki, M; Dell, EW; Diserens, AC; Seelentag, W; Janzer, RC; Aguzzi, A; Hegi, ME				Klein, MA; Ruedi, D; Nozaki, M; Dell, EW; Diserens, AC; Seelentag, W; Janzer, RC; Aguzzi, A; Hegi, ME			Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant	ONCOGENE			English	Article						p53 germline mutation; transdominance; gain-of-function; turner penetrance; mouse brain tumor model	EPIDERMAL GROWTH-FACTOR; LI-FRAUMENI-SYNDROME; SRC TRANSGENIC MICE; MALIGNANT PROGRESSION; GERMLINE MUTATIONS; SUPPRESSOR GENE; FACTOR RECEPTOR; EGF RECEPTOR; FACTOR-ALPHA; V-SRC	p53-germline mutations located in the core DNA-binding domain have been associated with a more dominant tumor penetrance especially for breast cancer and brain tumors. We previously reported an unusual accumulation of CNS turners associated with a unique p53 germline mutation, Y236 Delta (deletion of codon 236). To test whether this tissue-specific tumor predisposition reflects a gain-of-function activity of Y236 Delta, we generated transgenic mice expressing Y236 Delta in astrocytes using the regulatory elements of the glial fibrillary acidic protein (G-FAP) gene. After transplacental exposure to N-ethyl-N-nitrosourea (25mg/kg BW) brain tumors developed in 18% (7/39) of GFAP-Y236 Delta transgenic p53(+/-) mice, while in p53(+/-) mice the incidence was 28% (11/40) (P > 0.3). However, the mean tumor latency for GFAP-Y236 Delta /p53(+/-) mice was significantly shorter than for p53(+/-) mice, with 19.9 weeks vs 31.6 weeks (P = 0.039), respectively. Taken together, cell specific expression of Y236 Delta results in an acceleration of tumor progression but does not confer a higher tumor penetrance. Conceivably, the transdominant effect of Y236 Delta provided a growth advantage early in the progression of neoplastic cells, since the endogenous p53 wild-type allele was lost in all brain tumors independent of the genotype. This reflects well observations from human astrocytic neoplasms with p53 mutations.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Univ Hosp, Inst Pathol, CH-1011 Lausanne, Switzerland; Univ Hosp, Div Neuropathol, CH-1011 Lausanne, Switzerland	University of Zurich; University Zurich Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Hegi, ME (corresponding author), CHU Vaudois, Dept Neurosurg, Lab Tumor Biol & Genet, BH19-110, CH-1011 Lausanne, Switzerland.		Hegi, Monika/O-4796-2015; Aguzzi, Adriano/A-3351-2008	Hegi, Monika/0000-0003-0855-6495; Aguzzi, Adriano/0000-0002-0344-6708				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Chene P, 1999, INT J CANCER, V82, P17, DOI 10.1002/(SICI)1097-0215(19990702)82:1<17::AID-IJC4>3.0.CO;2-6; Chene P, 1997, J MOL BIOL, V273, P873, DOI 10.1006/jmbi.1997.1360; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DENLINGER RH, 1974, INT J CANCER, V13, P559, DOI 10.1002/ijc.2910130416; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FORRESTER K, 1995, ONCOGENE, V10, P2103; FRASER H, 1971, J PATHOL, V103, P266, DOI 10.1002/path.1711030410; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hegi ME, 2000, CANCER RES, V60, P3019; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Hermanson M, 1996, CANCER RES, V56, P164; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Ichimura K, 1996, ONCOGENE, V13, P1065; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; Kleihues P, 1997, AM J PATHOL, V150, P1; Kleihues P, 2000, PATHOLOGY GENETICS T; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1988, CANCER RES, V48, P5358; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LUBBE J, 1995, BRAIN PATHOL, V5, P15, DOI 10.1111/j.1750-3639.1995.tb00572.x; LUONGO C, 1994, CANCER RES, V54, P5947; Maddalena AS, 1999, BRAIN PATHOL, V9, P627; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marino S, 2000, GENE DEV, V14, P994; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MUCKE L, 1991, NEW BIOL, V3, P465; Oda H, 1997, CANCER RES, V57, P646; Patel AC, 2000, CARCINOGENESIS, V21, P1691, DOI 10.1093/carcin/21.9.1691; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; Rosenberg JE, 1996, ONCOGENE, V13, P2483; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TIMME TL, 1994, BIOTECHNIQUES, V17, P461; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Vital A, 1998, J NEUROPATH EXP NEUR, V57, P1061, DOI 10.1097/00005072-199811000-00009; VONDEIMLING A, 1992, CANCER RES, V52, P2897; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	55	9	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5329	5337		10.1038/sj.onc.1203941	http://dx.doi.org/10.1038/sj.onc.1203941			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103934				2022-12-25	WOS:000165302300004
J	Ciesielski-Treska, J; Ulrich, G; Chasserot-Golaz, S; Zwiller, J; Revel, MO; Aunis, D; Bader, MF				Ciesielski-Treska, J; Ulrich, G; Chasserot-Golaz, S; Zwiller, J; Revel, MO; Aunis, D; Bader, MF			Mechanisms underlying neuronal death induced by chromogranin A-activated microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ALZHEIMERS-DISEASE; CYTOCHROME-C; FAS LIGAND; CELL-DEATH; NEUROLOGICAL DISEASES; CEREBROSPINAL-FLUID; DYSTROPHIC NEURITES; INDUCED APOPTOSIS; SECRETOGRANIN-II	The neurotoxic effects of activated microglia in neurodegenerative diseases are well established. We recently provided evidence that chromogranin A (CGA), a multifunctional protein localized in dystrophic neurites and in senile plaques, induces an activated phenotype and secretion of neurotoxins by rat microglia in culture. In the present study, we focused on the mechanisms underlying neuronal degeneration triggered by CGA-activated microglia, We found that neuronal death exhibits apoptotic features, characterized by the externalization of phosphatidylserine and the fragmentation of DNA. Microglial neurotoxins markedly stimulate the phosphorylation and activity of neuronal p38 mitogen-activated protein kinase and provoke the release of mitochondrial cytochrome c, which precedes apoptosis. Inhibition of p38 kinase with SE 203580 partially protects neurons from death induced by CGA-activated microglia. Furthermore, neurons are also protected by Fas-Fc, which antagonizes the interactions between the death receptor Fas and its ligand Fast and by cell-permeable peptides that inhibit caspases 8 and 3. Thus, CGA triggers the release of microglial neurotoxins that mobilize several death-signaling pathways in neurons. Our results further support the idea that CGA, which is upregulated in many neuropathologies, represents a potent endogeneous inflammatory factor possibly responsible for neuronal degeneration.	Unite INSERM U338 Biol Commun Cellulaire, Ctr Neurochim, F-67084 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Ciesielski-Treska, J (corresponding author), CNRS UPR 2356, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.		Dominique, Aunis/W-1419-2019; Bader, Marie-France/O-2098-2016; Chasserot-Golaz, Sylvette/K-7625-2017	Chasserot-Golaz, Sylvette/0000-0002-7437-2558				BADER MF, 1994, GLIA, V11, P336, DOI 10.1002/glia.440110406; BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; Becher B, 1998, TRENDS NEUROSCI, V21, P114, DOI 10.1016/S0166-2236(97)01180-6; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; CETIN Y, 1993, P NATL ACAD SCI USA, V90, P2360, DOI 10.1073/pnas.90.6.2360; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; CIESIELSKITRESKA J, 1991, J NEUROSCI RES, V29, P362, DOI 10.1002/jnr.490290312; Cotman CW, 1996, BRAIN PATHOL, V6, P493, DOI 10.1111/j.1750-3639.1996.tb00878.x; Crain BJ, 1996, AM J PATHOL, V149, P1087; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; DICKSON DW, 1997, J NEUROPATHOL EXP NE, V56, P521; Du YS, 1997, J NEUROCHEM, V69, P1382; Eder U, 1998, J NEURAL TRANSM, V105, P39, DOI 10.1007/s007020050036; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; Ferrer I, 1998, J NEUROPATH EXP NEUR, V57, P218, DOI 10.1097/00005072-199803000-00002; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769; Gottfries CG, 1998, J NEURAL TRANSM, V105, P773, DOI 10.1007/s007020050094; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Joashi UC, 1999, EUR J NEUROSCI, V11, P91, DOI 10.1046/j.1460-9568.1999.00409.x; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kingham PJ, 1999, J NEUROCHEM, V73, P538, DOI 10.1046/j.1471-4159.1999.0730538.x; Kingham PJ, 2000, J NEUROCHEM, V74, P1452, DOI 10.1046/j.1471-4159.2000.0741452.x; KIRCHMAIR R, 1994, NEUROSCIENCE, V63, P1179, DOI 10.1016/0306-4522(94)90582-7; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lannuzel A, 1997, ANN NEUROL, V42, P847, DOI 10.1002/ana.410420605; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MUNOZ DG, 1991, LAB INVEST, V64, P826; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; NISHIMURA T, 1995, BRAIN RES, V695, P137, DOI 10.1016/0006-8993(95)00699-Q; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; RAUL C, 1999, J CELL BIOL K, V29, P1049; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V262, P1; Spanaus KS, 1998, EUR J IMMUNOL, V28, P4398, DOI 10.1002/(SICI)1521-4141(199812)28:12<4398::AID-IMMU4398>3.0.CO;2-Y; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Taupenot L, 1996, NEUROSCIENCE, V72, P377, DOI 10.1016/0306-4522(96)83172-1; Thal DR, 1998, J BRAIN RES, V39, P175; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Virdee K, 1997, J NEUROCHEM, V69, P550; Walton M, 1999, BRAIN RES REV, V29, P137, DOI 10.1016/S0165-0173(98)00053-8; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YASUHARA O, 1994, NEUROSCI LETT, V170, P13, DOI 10.1016/0304-3940(94)90227-5	56	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13113	13120		10.1074/jbc.M009711200	http://dx.doi.org/10.1074/jbc.M009711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11124958	hybrid			2022-12-25	WOS:000168198600091
J	Gil, D; Gutierrez, D; Alarcon, B				Gil, D; Gutierrez, D; Alarcon, B			Intracellular redistribution of nucleolin upon interaction with the CD3 epsilon chain of the T cell receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ZETA-CHAIN; ACTIVATION; PROTEIN; IDENTIFICATION; SUFFICIENT; RETENTION; DOMAIN; TAIL	T cell activation through the antigen receptor (TCR) involves the cytoplasmic tails of the CD3 subunits CD3 gamma, CD3 delta, CD3 epsilon, and CD3 zeta. Whereas the biological significance of the cytoplasmic tails of these molecules is suggested, in part, by their evolutionarily conserved sequences, their interactions with signal transduction molecules are not completely understood. We used affinity chromatography columns of glutathione S-transferase fused to the CD3 epsilon cytoplasmic tail to isolate proteins that specifically interact with this subunit. In this way, we identified the shuttling protein nucleolin as a specific CD3 epsilon -interacting molecule. Using competition studies and affinity chromatography on peptide columns, we were able to identify a central proline-rich sequence as the nucleolin-interacting sequence in CD3 epsilon. Transfection in COS cells of wild type CD3 epsilon, but not of nonbinding mutants of CD3 epsilon, resulted in redistribution of nucleolin from the nucleus and nucleoli to the cytoplasm. This property was transferred to a CD8 protein chimera by appending the cytoplasmic tail of CD3 epsilon. We also found that nucleolin associated with the TCR complex. This association was increased upon TCR engagement, suggesting that the CD3 epsilon /nucleolin interaction may have a role in T cell activation.	Univ Autonoma Madrid, Ctr Biol Mol, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Alarcon, B (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		MD, Gutierrez-Lopez/P-2965-2014; Alarcon, Balbino/N-9648-2016	Alarcon, Balbino/0000-0001-7820-1070; Gutierrez Lopez, Maria Dolores/0000-0002-9979-5573				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Borroto A, 1998, J BIOL CHEM, V273, P12807, DOI 10.1074/jbc.273.21.12807; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chen CY, 2000, GENE DEV, V14, P1236; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; deAos I, 1997, J BIOL CHEM, V272, P25310, DOI 10.1074/jbc.272.40.25310; Deng JS, 1996, MOL BIOL REP, V23, P191, DOI 10.1007/BF00351168; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; Geiger TL, 1999, J IMMUNOL, V162, P5931; Ginisty H, 1999, J CELL SCI, V112, P761; Gobel TWF, 1997, EUR J IMMUNOL, V27, P194, DOI 10.1002/eji.1830270129; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; Larrucea S, 1998, J BIOL CHEM, V273, P31718, DOI 10.1074/jbc.273.48.31718; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; Meyer GA, 2000, J BIOL CHEM, V275, P3857, DOI 10.1074/jbc.275.6.3857; Nakano H, 1996, J BIOL CHEM, V271, P6483, DOI 10.1074/jbc.271.11.6483; PESSANO S, 1985, EMBO J, V4, P337, DOI 10.1002/j.1460-2075.1985.tb03634.x; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SHINKAI Y, 1995, IMMUNITY, V2, P401; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; SunderPlassmann R, 1997, EUR J IMMUNOL, V27, P2001, DOI 10.1002/eji.1830270826; Waggoner S, 1998, J VIROL, V72, P6699, DOI 10.1128/JVI.72.8.6699-6709.1998; Yamazaki T, 1999, J BIOL CHEM, V274, P18173, DOI 10.1074/jbc.274.26.18173	27	15	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11174	11179		10.1074/jbc.M010114200	http://dx.doi.org/10.1074/jbc.M010114200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11115514	hybrid			2022-12-25	WOS:000167980900080
J	Chen, CC; Chen, NY; Lau, LF				Chen, CC; Chen, NY; Lau, LF			The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; ACTIVATED PROTEIN-KINASE; CELL-ADHESION; EXTRACELLULAR-MATRIX; HEPARAN-SULFATE; ENDOTHELIAL-CELLS; FIBRONECTIN RECEPTOR; RHO GTPASES; MAP KINASE; INTEGRIN	The angiogenic inducers cysteine-rich angiogenic protein 61 (Cyr61) and connective tissue growth factor (CTGF) are structurally related, extracellular matrix-associated heparin-binding proteins. Both can stimulate chemotaxis and promote proliferation in endothelial cells and fibroblasts in culture and induce neovascularization in vivo. Encoded by inducible immediate early genes, Cyr61 and CTGF are synthesized upon growth factor stimulation in cultured fibroblasts and during cutaneous wound healing in dermal fibroblasts, Recently, we have shown that adhesion of primary human fibroblasts to immobilized Cyr61 is mediated through integrin cr,P, and cell surface heparan sulfate proteoglycans (HSPGs) (Chen, N,, Chen, C,-C,, and Lau, L,F, (2000) J, Biol, Chem, 275, 24953-24961), providing the first demonstration of an absolute requirement for HSPGs in integrin-mediated cell attachment. We show in this study that CTGF also mediates fibroblast adhesion through the same mechanism and demonstrate that fibroblasts adhesion to immobilized Cyr61 or CTGF induces distinct adhesive signaling responses consistent with their biological activities. Compared with fibroblast adhesion to fibronectin, laminin, or type I collagen, cell adhesion to Cyr61 or CTGF induces 1) more extensive and prolonged formation of filopodia and lamellipodia, concomitant with formation of integrin alpha (6)beta (1)-containing focal complexes localized at leading edges of pseudopods; 2) activation of intracellular signaling molecules including focal adhesion kinase, paxillin, and Rac with similar rapid kinetics; 3) sustained activation of p42/p44 MAPKs lasting for at least 9 h; and 4) prolonged gene expression changes including up-regulation of MMP-1 (collagenase-l) and MMP-3 (stromelysin-l) mRNAs and proteins sustained for at least 24 h, Together, these results establish Cyr61 and CTGF as bona fide adhesive substrates with specific signaling capabilities, provide a molecular basis for their activities in fibroblasts through integrin alpha (6)beta (1) and HSPG-mediated signaling during attachment and indicate that these proteins may function in matrix remodeling through the activation of metalloproteinases during angiogenesis and wound healing.	Univ Illinois, Coll Med, Dept Mol Genet MC 669, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet MC 669, 900 S Ashland Ave, Chicago, IL 60607 USA.	lflau@uic.edu		Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER; NCI NIH HHS [CA46565, CA80080] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHEN WT, 1985, J CELL BIOL, V100, P1103, DOI 10.1083/jcb.100.4.1103; Couchman JR, 1999, J CELL SCI, V112, P3415; DAMSKY CH, 1985, J CELL BIOL, V100, P1528, DOI 10.1083/jcb.100.5.1528; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Dogic D, 1998, J CELL SCI, V111, P793; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Feitsma K, 2000, J BIOL CHEM, V275, P9396, DOI 10.1074/jbc.275.13.9396; Fini ME, 1998, BIOL EXTRAC, P299; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARLOW E, 1988, ANTIBODIES LABORATOR, P488; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Lamme EN, 1996, J HISTOCHEM CYTOCHEM, V44, P1311, DOI 10.1177/44.11.8918906; LANGE TS, 1994, EXP CELL RES, V214, P381, DOI 10.1006/excr.1994.1271; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; LATINKIC BV, 1994, THESIS U ILLINOIS CH; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OLIVER MH, 1989, J CELL SCI, V92, P513; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SHAW LM, 1993, J BIOL CHEM, V268, P11401; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; Sydor AM, 1996, J CELL BIOL, V134, P1197, DOI 10.1083/jcb.134.5.1197; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Wilson KE, 1999, J IMMUNOL, V163, P3621; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	90	250	277	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10443	10452		10.1074/jbc.M008087200	http://dx.doi.org/10.1074/jbc.M008087200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11120741	hybrid			2022-12-25	WOS:000167996400112
J	Degtyareva, N; Subramanian, D; Griffith, JD				Degtyareva, N; Subramanian, D; Griffith, JD			Analysis of the binding of p53 to DNAs containing mismatched and bulged bases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE MSH2; HOMOLOGOUS RECOMBINATION; MOLECULAR SWITCH; HOLLIDAY JUNCTIONS; CELLULAR-RESPONSE; STRAND TRANSFER; PROTEIN; DAMAGE; REPAIR	The tumor suppressor protein p53 modulates cellular response to DNA damage by a variety of mechanisms that may include direct recognition of some forms of primacy DNA damage. Linear 49-base pair duplex DNAs were constructed containing all possible single-base mismatches as well as a S-cytosine bulge. Filter binding and gel retardation assays revealed that the affinity of p53 for a number of these lesions was equal to or greater than that of the human mismatch repair complex, hMSH2-hMSH6, under the same binding conditions. However, other mismatches including G/T, which is bound strongly by hMSH2-hMSH6, were poorly recognized by p53. The general order of affinity of p53 was greatest for a 3-cytosine bulge followed by A/G and C/C mismatches, then C/T and G/T mismatches, and finally all the other mismatches.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu	Degtyareva, Natalya/AAI-5500-2021	Degtyareva, Natalya/0000-0002-7141-6308	NATIONAL CANCER INSTITUTE [R01CA070343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NCI NIH HHS [CA70343] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; GAMPER H, 1985, DNA-J MOLEC CELL BIO, V4, P157, DOI 10.1089/dna.1985.4.157; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hupp TR, 1999, CELL MOL LIFE SCI, V55, P88, DOI 10.1007/s000180050272; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; STEINMEYER K, 1988, ONCOGENE, V3, P501; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Wang XW, 1996, CANCER SURV, V28, P169; WANG YH, 1993, J BIOL CHEM, V268, P17571; Wiesmuller L, 1996, J VIROL, V70, P737; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497	47	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8778	8784		10.1074/jbc.M006795200	http://dx.doi.org/10.1074/jbc.M006795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124254	hybrid			2022-12-25	WOS:000167607700023
J	Niehof, M; Streetz, K; Rakemann, T; Bischoff, SC; Manns, MP; Horn, F; Trautwein, C				Niehof, M; Streetz, K; Rakemann, T; Bischoff, SC; Manns, MP; Horn, F; Trautwein, C			Interleukin-6-induced tethering of STAT3 to the LAP/C/EBP beta promoter suggests a new mechanism of transcriptional regulation by STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; SIGNAL TRANSDUCER GP130; CCAAT/ENHANCER-BINDING PROTEINS; GENE-TRANSCRIPTION; C/EBP-BETA; DIFFERENTIAL ACTIVATION; GLUCOCORTICOID RECEPTOR; CYTOPLASMIC DOMAIN; RAT HEPATOCYTES; NUCLEAR FACTOR	LAP/C/EBP beta is a member of the C/EBP family of transcription factors and contributes to the regulation of the acute phase response in hepatocytes. Here we show that IL-6 controls LAP/C/EBP beta gene transcription and identify an IL-6 responsive element in the LAP/C/EBP beta promoter, which contains no STAT3 DNA binding motif. However, luciferase reporter gene assays showed that STAT3 activation through the gp130 signal transducer molecule is involved in mediating IL-6-dependent LAP/C/EBP beta transcription. Southwestern analysis indicated that IL-6 induces binding of a 68-kDa protein to the recently characterized CRE-like elements in the LAP/C/EBP beta promoter. Transfection experiments using promoter constructs with mutated CRE-like elements revealed that these sites confer IL-6 responsiveness. Further analysis using STAT1/STAT3 chimeras identified specific domains of the protein that are required for the IL-6-dependent increase in LAP/C/EBP beta gene transcription; Overexpression of the amino-terminal domain of STAT3 blocked the IL-6-mediated response, suggesting that the STAT3 amino terminus has an important function in IL-8-mediated transcription of the LAP/C/EBP beta gene. These data lead to a model of how tethering STAT3 to a DNA-bound complex contributes to IL-6-dependent LAP/C/EBP beta gene transcription. Our analysis describes a new mechanism by which STAT3 controls gene transcription and which has direct implication for the acute phase response in liver cells.	Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany; Univ Leipzig, Inst Clin Immunol, D-04129 Leipzig, Germany	Hannover Medical School; Leipzig University	Trautwein, C (corresponding author), Hannover Med Sch, Dept Gastroenterol & Hepatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	trautwein.christian@mh-hannover.de						Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Berrier A, 1998, J IMMUNOL, V161, P2267; Bock CT, 1999, HEPATOLOGY, V29, P1236, DOI 10.1002/hep.510290426; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CHANG CJ, 1995, DNA CELL BIOL, V14, P529, DOI 10.1089/dna.1995.14.529; Chen JP, 1999, FEBS LETT, V457, P162, DOI 10.1016/S0014-5793(99)01031-5; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Gronning LM, 1999, ENDOCRINOLOGY, V140, P835, DOI 10.1210/en.140.2.835; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Hirano T, 1998, Int Rev Immunol, V16, P249; Hoey T, 1997, SCIENCE, V278, P1578, DOI 10.1126/science.278.5343.1578; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Kojima H, 1996, ONCOGENE, V12, P547; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mackiewicz A, 1997, Int Rev Cytol, V170, P225, DOI 10.1016/S0074-7696(08)61623-X; Matsuno F, 1996, J BIOCHEM-TOKYO, V119, P524; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Pohnke Y, 1999, J BIOL CHEM, V274, P24808, DOI 10.1074/jbc.274.35.24808; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Rakemann T, 1999, J BIOL CHEM, V274, P1257, DOI 10.1074/jbc.274.3.1257; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Shen BJ, 1997, DNA CELL BIOL, V16, P703, DOI 10.1089/dna.1997.16.703; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; TRAUTWEIN C, 1995, J BIOL CHEM, V270, P15130, DOI 10.1074/jbc.270.25.15130; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yukawa K, 1998, J BIOL CHEM, V273, P31345, DOI 10.1074/jbc.273.47.31345; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	65	89	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9016	9027		10.1074/jbc.M009284200	http://dx.doi.org/10.1074/jbc.M009284200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11114305	hybrid			2022-12-25	WOS:000167607700055
J	Nirodi, C; NagDas, S; Gygi, SP; Olson, G; Aebersold, R; Richmond, A				Nirodi, C; NagDas, S; Gygi, SP; Olson, G; Aebersold, R; Richmond, A			A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DEPENDENT TRANSCRIPTION; ALPHA GENE; IN-VITRO; CELLS; COACTIVATOR; ACTIVATION; PROTEIN; BINDING	The melanoma growth stimulatory activity/growth-regulated protein, CXCL1, is constitutively expressed at high levels during inflammation and progression of melanocytes into malignant melanoma. It has been shown previously that CXCL1 overexpression in melanoma cells is due to increased transcription as well as stability of the CXCL1 message. The transcription of CXCL1 is regulated through several cis-acting elements including Sp1, NF-kappaB, HMGI(Y), and the immediate upstream region(IUR) element (nucleotides -94 to -78), which lies immediately upstream to the nuclear factor kappaB (NF-kappaB) element. Previously, it has been shown that the IUR is necessary for basal and cytokine-induced transcription of the CXCL1 gene. UV cross-linking and Southwestern blot analyses indicate that the IUR oligonucleotide probe selectively binds a 115-kDa protein. In this study, the IUR element has been further characterized. We show here that proximity of the IUR element to the adjacent NF-kappaB element is critical to its function as a positive regulatory element. Using binding site oligonucleotide affinity chromatography, we have selectively purified the 115-kDa IUR-F. Mass spectrometry/mass spectrometry/matrix-assisted laser desorption ionization/time of flight spectroscopy and amino acid analysis as well as microcapillary reverse phase chromatography electrospray ionization tandem mass spectrometry identified this protein as the 114-kDa poly(ADP-ribose) polymerase (PARP1). Furthermore, 3-aminobenzamide, an inhibitor of PARP-specific ADP-ribosylation, inhibits CXCL1 promoter activity and reduces levels of CXCL1 mRNA. The data point to the possibility that PARP may be a coactivator of CXCL1 transcription.	Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Dept Vet Affairs, Nashville, TN 37232 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Inst Syst Biol, Seattle, WA 98105 USA	Vanderbilt University; Harvard University; Harvard Medical School; Institute for Systems Biology (ISB)	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, MCN T-2212, Nashville, TN 37232 USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NATIONAL CANCER INSTITUTE [R01CA056704, P30CA068485, R01CA116021] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA056704-09, R01 CA056704-08, R01 CA116021, CA56704, R01 CA116021-01, P30 CA068485] Funding Source: Medline; NIAMS NIH HHS [5P30AR4194] Funding Source: Medline; BLRD VA [IK6 BX005225] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); BLRD VA		Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Devalaraja MN, 1999, CANCER RES, V59, P1372; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lindahl T, 1995, J CELL SCI, P73; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Plaza S, 1999, ONCOGENE, V18, P1041, DOI 10.1038/sj.onc.1202406; RICHMOND A, 1996, CHEMOATTRACTANT LIGA, P87; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang XC, 1999, INVEST OPHTH VIS SCI, V40, P477; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210	23	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9366	9374		10.1074/jbc.M009897200	http://dx.doi.org/10.1074/jbc.M009897200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11112786	Green Accepted, hybrid			2022-12-25	WOS:000167607700100
J	Luo, CW; Lin, HJ; Chen, YH				Luo, CW; Lin, HJ; Chen, YH			A novel heat-labile phospholipid-binding protein, SVSVII, in mouse seminal vesicle as a sperm motility enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER PROTEINS; AMINO-ACID SEQUENCE; HUMAN FACTOR-VIII; CIRCULAR-DICHROISM; MAJOR PROTEINS; PHASE SEPARATIONS; GENOMIC STRUCTURE; HOUSE MOUSE; PLASMA; PURIFICATION	SVS VII, one of seven major proteins in mouse seminal vesicle secretion, was purified to homogeneity. Neither glycoconjugate nor free thiol group was detected in the protein. The primary structure deduced from the corresponding cDNA was confirmed using amino acid sequence determination, which supported the finding that SVS VII consists of 76 amino acid residues with five disulfide bridges. Accordingly, it has a theoretical molecular mass of 8538, which was proven using the mass spectrum of SVS VII, The CD spectrum of SVS VII in 50 nM phosphate buffer at pH 7.4 appeared as one negative band arising from the beta form at 217 nm and several fine structures due to nonpeptide chromophores including a prominent band for the disulfide bond at 250 nm, This, together with the predicted secondary structures, indicated no helices but a mixture of beta form, beta turn, and unordered form in SVS VII. A cytochemical study illustrated the presence of the SVS VII-binding region on the entire surface of mouse sperm. The SVS VII-sperm binding was inhibited by the dispersed sperm lipids. The results of TLC overlay assay for the binding of I-125-SVS VII to phospholipids and the interaction between SVS VII and phospholipid liposomes demonstrated a specific binding of this protein to both phosphatidylethanolamine and phosphatidylserine. The SVS VII-sperm binding greatly enhanced sperm motility but did not induce sperm capacitation. Heating the protein solution for 10 min at 90 degreesC unfolded the protein molecule, and the unfolded SVS VII immobilized the sperm.	Natl Taiwan Univ, Coll Sci, Inst Biochem Sci, Taipei 106, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 106, Taiwan	National Taiwan University; Academia Sinica - Taiwan	Chen, YH (corresponding author), Natl Taiwan Univ, Coll Sci, Inst Biochem Sci, POB 23-106, Taipei 106, Taiwan.	mrlab@ccms.ntu.edu.tw		Lin, Han-Jia/0000-0002-4929-6573				ALSOMAI N, 1994, REPROD FERT DEVELOP, V6, P165, DOI 10.1071/RD9940165; BARROS C, 1977, REV MICROSC ELECT, V4, P107; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; BEYCHOK S, 1968, J BIOL CHEM, V243, P151; BLOOM JW, 1989, THROMB RES, V54, P261, DOI 10.1016/0049-3848(89)90084-4; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; BUTLER WJ, 1975, J REPROD FERTIL, V43, P183, DOI 10.1530/jrf.0.0430183; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chen LL, 1998, BIOL REPROD, V59, P1498, DOI 10.1095/biolreprod59.6.1498; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHEN YH, 1987, MOL ENDOCRINOL, V1, P707, DOI 10.1210/mend-1-10-707; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHEN YH, 1982, BIOCHEMISTRY-US, V21, P2592, DOI 10.1021/bi00540a003; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLEGG ED, 1973, J REPROD FERTIL, V34, P379, DOI 10.1530/jrf.0.0340379; CORONEL CE, 1992, J BIOL CHEM, V267, P20909; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; DESNOYERS L, 1992, J BIOL CHEM, V267, P10149; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FOLCH J, 1957, J BIOL CHEM, V226, P497; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENGE BR, 1989, J BIOL CHEM, V264, P10917; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; HANSPAL JS, 1983, ANAL BIOCHEM, V132, P288, DOI 10.1016/0003-2697(83)90010-6; HAWGOOD S, 1989, AM J PHYSIOL, V257, pL13, DOI 10.1152/ajplung.1989.257.2.L13; HOEKSTRA D, 1982, BIOCHEMISTRY-US, V21, P2833, DOI 10.1021/bi00541a004; Huang YH, 1999, BIOCHEM J, V343, P241, DOI 10.1042/0264-6021:3430241; Huang YH, 2000, BIOL REPROD, V63, P1562, DOI 10.1095/biolreprod63.5.1562; IWAMOTO T, 1992, MOL REPROD DEV, V31, P55, DOI 10.1002/mrd.1080310110; JENG H, 1993, BIOCHEM BIOPH RES CO, V191, P435, DOI 10.1006/bbrc.1993.1236; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI ML, 1991, ARCH BIOCHEM BIOPHYS, V290, P265, DOI 10.1016/0003-9861(91)90540-Y; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; LIU TY, 1987, J PROTEIN CHEM, V6, P263; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MANJUNATH P, 1994, BIOL REPROD, V50, P27, DOI 10.1095/biolreprod50.1.27; MANJUNATH P, 1987, BIOCHEM J, V241, P685, DOI 10.1042/bj2410685; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MIYAKE M, 1989, GAMETE RES, V24, P49, DOI 10.1002/mrd.1120240108; NAGPURKAR A, 1983, J BIOL CHEM, V258, P518; Nichol R, 1997, J REPROD FERTIL, V110, P79, DOI 10.1530/jrf.0.1100079; OHNISHI S, 1974, BIOCHEMISTRY-US, V13, P881, DOI 10.1021/bi00702a008; PANG SF, 1979, J REPROD FERTIL, V56, P129, DOI 10.1530/jrf.0.0560129; PEITZ B, 1988, J REPROD FERTIL, V83, P169, DOI 10.1530/jrf.0.0830169; PEITZ B, 1986, BIOL REPROD, V35, P608, DOI 10.1095/biolreprod35.3.608; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Robert M, 1996, BIOL REPROD, V55, P813, DOI 10.1095/biolreprod55.4.813; RUIZROMERO J, 1995, ANDROLOGIA, V27, P149; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Thaler CD, 1996, J BIOL CHEM, V271, P23289, DOI 10.1074/jbc.271.38.23289; Therien I, 1999, BIOL REPROD, V61, P590, DOI 10.1095/biolreprod61.3.590; Therien I, 1997, BIOL REPROD, V57, P1080, DOI 10.1095/biolreprod57.5.1080; THERIEN I, 1995, BIOL REPROD, V52, P1372, DOI 10.1095/biolreprod52.6.1372; USUI T, 1963, J BIOCHEM-TOKYO, V54, P283, DOI 10.1093/oxfordjournals.jbchem.a127785; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WARD CR, 1984, DEV BIOL, V104, P287, DOI 10.1016/0012-1606(84)90084-8; Wilhelm KM, 1996, CRYOBIOLOGY, V33, P320, DOI 10.1006/cryo.1996.0032; WIRTZ KWA, 1982, LIPID PROTEIN INTERA, P151; ZILVERSMIT DB, 1983, METHOD ENZYMOL, V98, P565	67	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6913	6921		10.1074/jbc.M006954200	http://dx.doi.org/10.1074/jbc.M006954200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11118436	Green Published, hybrid			2022-12-25	WOS:000167442900009
J	Harmer, TL; Schleif, R				Harmer, TL; Schleif, R			The C-terminal end of AraC tightly binds to the rest of its domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE ALIGNMENT; DATABASE; DNA	Genes were synthesized to express two DNA binding domains of AraC connected by short linkers. The abilities of the resulting proteins to bind to DNA containing AraC half-sites separated by the usual four bases as well as an additional two or three helical turns of the DNA were measured. The inability of some of the protein constructs to bind to widely separated half-sites indicates that the C-terminal 14 amino acids of AraC are firmly bound to the rest of the DNA binding domain.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Schleif, R (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.		Luke, Tara Harmer/S-5923-2019; Harmer Luke, Tara/R-6816-2018	Luke, Tara Harmer/0000-0003-2529-1708; Harmer Luke, Tara/0000-0003-2529-1708; Schleif, Robert/0000-0002-4430-7085	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018277, R01GM018277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTELL CR, 1981, CELL, V27, P15, DOI 10.1016/0092-8674(81)90356-1; HAHN S, 1984, J MOL BIOL, V180, P61, DOI 10.1016/0022-2836(84)90430-3; HENDRICKSON W, 1984, J MOL BIOL, V178, P611, DOI 10.1016/0022-2836(84)90241-9; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; Kwon HJ, 2000, NAT STRUCT BIOL, V7, P424; Prytulla S, 1996, FEBS LETT, V399, P283, DOI 10.1016/S0014-5793(96)01278-1; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; Saviola B, 1998, J MOL BIOL, V278, P539, DOI 10.1006/jmbi.1998.1712; Schleif R, 1999, PROTEINS, V34, P1, DOI 10.1002/(SICI)1097-0134(19990101)34:1<1::AID-PROT1>3.0.CO;2-C; Schleif R. F., 1981, PRACTICAL METHODS MO; Soisson SM, 1997, SCIENCE, V276, P421, DOI 10.1126/science.276.5311.421; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	14	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4886	4888		10.1074/jbc.M007956200	http://dx.doi.org/10.1074/jbc.M007956200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11104764	hybrid			2022-12-25	WOS:000168484300049
J	Genini, D; Sheeter, D; Rought, S; Zaunders, JJ; Susin, SA; Kroemer, G; Richman, DD; Carson, DA; Corbeil, J; Leoni, LM				Genini, D; Sheeter, D; Rought, S; Zaunders, JJ; Susin, SA; Kroemer, G; Richman, DD; Carson, DA; Corbeil, J; Leoni, LM			HIV induces lymphocyte apoptosis by a p53-initiated, mitochondrial-mediated mechanism	FASEB JOURNAL			English	Article									Univ Calif San Diego, Dept Med 0663, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; San Diego Hlth Care Syst & Vet Med Res Fdn, La Jolla, CA 92161 USA; Inst Gustave Roussy, CNRS, UMR1599, F-94805 Villejuif, France	University of California System; University of California San Diego; University of California System; University of California San Diego; Veterans Medical Research Foundation; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Leoni, LM (corresponding author), Univ Calif San Diego, Dept Med 0663, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Zaunders, John/J-6553-2012; Corbeil, Jacques/AAW-9739-2020; Susin, Santos A/Q-6754-2017; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	Zaunders, John/0000-0002-5912-5989; Corbeil, Jacques/0000-0002-9973-2740; Susin, Santos A/0000-0002-3366-1628; KROEMER, Guido/0000-0002-9334-4405; 					0	95	98	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					5	6						2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099484				2022-12-25	WOS:000166312400002
J	Gallucci, RM; Simeonova, PP; Matheson, JM; Kommineni, C; Guriel, JL; Sugawara, T; Luster, MI				Gallucci, RM; Simeonova, PP; Matheson, JM; Kommineni, C; Guriel, JL; Sugawara, T; Luster, MI			Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice	FASEB JOURNAL			English	Article						inflammation; cytokines; gene therapy	TRANSCRIPTION FACTORS C/EBP; GROWTH-FACTOR EXPRESSION; IN-VIVO INTRODUCTION; CULTURED FIBROBLASTS; GENE-EXPRESSION; KERATINOCYTE DIFFERENTIATION; INFLAMMATORY CYTOKINES; STAT3 ACTIVATION; BINDING-PROTEINS; IL-6 GENE	It has been postulated that an inflammatory response after cutaneous wounding is a prerequisite for healing, and inflammatory cytokines, such as interleukin-6 (IL-6), might be intimately involved in this process. IL-6-deficient transgenic mice (IL-6 KO) displayed significantly delayed cutaneous wound healing compared with wild-type control animals, requiring up to threefold longer to heal. This was characterized by minimal epithelial bridge formation, decreased inflammation, and granulation tissue formation. Using electrophoretic mobility shift assays of wound tissue from IL-6 KO mice, decreased AP-1 transcription factor activation was shown compared with wild-type mice 16 h after wounding. lit situ hybridization of wound tissue from wild-type mice revealed IL-6 mRNA expression primarily in the epidermis at the leading edge of the wound. Delayed wound healing in IL-6 KO mice was reversed with a single dose of recombinant murine IL-6 or intradermal injection of an expression plasmid containing the full-length murine IL-6 cDNA. Treatment with rmIL-6 also reconstituted wound healing in dexamethasone-treated immunosuppressed mice. The results of this study may indicate a potential use for IL-6 therapeutically where cutaneous wound healing is impaired.	NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo, Japan	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Daiichi Sankyo Company Limited	Luster, MI (corresponding author), NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, MS 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	myl6@cdc.gov						Adcock I M, 1997, Monaldi Arch Chest Dis, V52, P178; Aragane Y, 1996, J INVEST DERMATOL, V106, P1192, DOI 10.1111/1523-1747.ep12347985; BAXTER JD, 1972, AM J MED, V53, P573, DOI 10.1016/0002-9343(72)90154-4; Bello YM, 2000, JAMA-J AM MED ASSOC, V283, P716, DOI 10.1001/jama.283.6.716; BLUETHMANN H, 1994, J LEUKOCYTE BIOL, V56, P565, DOI 10.1002/jlb.56.5.565; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; Bruccoleri A, 1997, HEPATOLOGY, V25, P133, DOI 10.1002/hep.510250125; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHEDID M, 1994, J BIOL CHEM, V269, P10753; CHENKIANG S, 1993, CURR OPIN IMMUNOL, V5, P124, DOI 10.1016/0952-7915(93)90091-6; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; FAHEY TJ, 1991, J SURG RES, V50, P308, DOI 10.1016/0022-4804(91)90196-S; FORD HR, 1989, ARCH SURG-CHICAGO, V124, P1422; FUGGER L, 1989, J IMMUNOGENET, V16, P461; GIULIANI AL, 1993, CELL IMMUNOL, V149, P208, DOI 10.1006/cimm.1993.1148; GOODMAN L, 1994, J BIOL CHEM, V269, P19250; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Howie S E, 1992, Exp Dermatol, V1, P230, DOI 10.1111/j.1600-0625.1992.tb00081.x; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Hubner G, 1996, EXP CELL RES, V228, P106, DOI 10.1006/excr.1996.0305; KOCH AE, 1993, PATHOBIOLOGY, V61, P239, DOI 10.1159/000163802; Kondo T, 1996, INT J LEGAL MED, V108, P231, DOI 10.1007/BF01369816; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; MATEO RB, 1994, AM J PHYSIOL, V266, pR1840, DOI 10.1152/ajpregu.1994.266.6.R1840; Maytin EV, 1999, DEV BIOL, V216, P164, DOI 10.1006/dbio.1999.9460; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; MORAIN WD, 1990, CLIN PLAST SURG, V17, P493; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Oyama N, 1998, J DERMATOL SCI, V16, P120, DOI 10.1016/S0923-1811(97)00040-6; Paquet P, 1996, INT ARCH ALLERGY IMM, V109, P308, DOI 10.1159/000237257; Rincon M, 1996, MOL CELL BIOL, V16, P1074; Sato M, 1999, ARCH DERMATOL RES, V291, P400, DOI 10.1007/s004030050429; Sawamura D, 1998, J IMMUNOL, V161, P5633; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEHGAL PB, 1990, J INVEST DERMATOL, V94, pS2, DOI 10.1111/1523-1747.ep12874963; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Solis-Herruzo JA, 1999, J BIOL CHEM, V274, P30919, DOI 10.1074/jbc.274.43.30919; Takeda K, 1998, J IMMUNOL, V161, P4652; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; Vogel JC, 1999, P ASSOC AM PHYSICIAN, V111, P190, DOI 10.1046/j.1525-1381.1999.99223.x; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	46	315	333	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2525	2531		10.1096/fj.00-0073com	http://dx.doi.org/10.1096/fj.00-0073com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099471				2022-12-25	WOS:000165723400023
J	England, K; Watson, J; Beale, G; Warner, M; Cross, J; Rumsby, M				England, K; Watson, J; Beale, G; Warner, M; Cross, J; Rumsby, M			Signalling pathways regulating the dephosphorylation of Ser(729) in the hydrophobic domain of protein kinase C epsilon upon cell passage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PHOSPHORYLATION; ACTIVATION; ALPHA; DELTA; INHIBITOR; MEMBRANE; GROWTH; ACTIN; SITE	We have recently demonstrated that in quiescent fibroblasts protein kinase C (PKC) epsilon (95) is phosphorylated at Ser(729), Ser(703), and Thr(566) and that upon passage of quiescent cells phosphorylation at Ser(729) is lost, giving rise to PKC epsilon (87). Ser(729) may be rephosphorylated later, suggesting cycling between pKC epsilon (87) and PKC epsilon (95). Here we show that the dephosphorylation at Ser(729) is insensitive to okadaic acid, calyculin, ascomycin C, and cyclosporin A, suggesting that dephosphorylation at this site is not mediated through protein phosphatases 1, 2A or 2B, We demonstrate that this dephosphorylation at Ser(729) requires serum and cell readhesion and is sensitive to rapamycin, PD98059, chelerythrine, and Ro-31-8220, These results suggest that the phosphorylation status of Ser(729) in the hydrophobic domain at Ser(729) is regulated independently of the phosphorylation status of other sites in PKC epsilon, by a mTOR-sensitive phosphatase, The mitogen-activated protein kinase pathway and PKC are also implicated in regulating the dephosphorylation at Ser(729).	Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK	England, K (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Biochem, Tumour Biol Lab, Lee Maltings Complex,Prospect Row, Cork, Ireland.							Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Chun J, 1997, J CELL PHYSIOL, V173, P361, DOI 10.1002/(SICI)1097-4652(199712)173:3<361::AID-JCP8>3.0.CO;2-L; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; DUMONT FJ, 1990, J IMMUNOL, V144, P251; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; ENGLAND K, 2000, BIOCHEM J, V35, P219; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; Gysin S, 1997, EUR J BIOCHEM, V249, P156, DOI 10.1111/j.1432-1033.1997.t01-2-00156.x; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; HARDIE DG, 1995, PROTEIN PHOSPHORYLAT, P109; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Kim JY, 1997, MOL CELLS, V7, P594; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lehel C, 1996, BIOCHEM BIOPH RES CO, V223, P98, DOI 10.1006/bbrc.1996.0852; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ORR JW, 1994, J BIOL CHEM, V269, P27715; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; POWIS G, 1994, CANCER RES, V54, P2419; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; ZHANG J, 1994, J BIOL CHEM, V269, P19578; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	48	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10437	10442		10.1074/jbc.M009421200	http://dx.doi.org/10.1074/jbc.M009421200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11121415	hybrid			2022-12-25	WOS:000167996400111
J	Clain, J; Fritsch, J; Lehmann-Che, J; Bali, M; Arous, N; Goossens, M; Edelman, A; Fanen, P				Clain, J; Fritsch, J; Lehmann-Che, J; Bali, M; Arous, N; Goossens, M; Edelman, A; Fanen, P			Two mild cystic fibrosis-associated mutations result in severe cystic fibrosis when combined in cis and reveal a residue important for cystic fibrosis transmembrane conductance regulator processing and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED MUTATIONS; CHLORIDE CHANNEL ACTIVITY; INTRACELLULAR LOOP; CYTOPLASMIC LOOP; CFTR; IDENTIFICATION; GENE; PROTEINS; DOMAINS; BINDING	The number of complex cystic fibrosis transmembrane conductance regulator (CFTR) genotypes identified as having double-mutant alleles with two mutations inherited in cis has been growing. We investigated the structure-function relationships of a severe cystic fibrosis (CF)-associated double mutant (R347H-D979A) to evaluate the contribution of each mild mutation to the phenotype, CFTR mutants expressed in HeLa cells were analyzed for protein biosynthesis and Cl- channel activity. Our data show that R347H is associated with mild defective Cl- channel activity and that the D979A defect leads to misprocessing. The mutant R347H-D979A combines both defects for a dramatic decrease in Cl- current. To decipher the molecular mechanism of this phenotype, single and double mutants with different charge combinations at residues 347 and 979 were constructed as charged residues were involved in this complex genotype. These studies revealed that residue 979, located in the third cytoplasmic loop, is critical for CFTR processing and Cl- channel activity highlighting the role of charged residues. These results have also important implications for CF, as they show that two mutations in cis can act in concert to alter dramatically CFTR function contributing to the wide phenotypic variability of CF disease.	Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France; Fac Med Necker, INSERM, U467, F-75015 Paris, France; Hop St Vincent de Paul, CNRS, UPR 1524, F-75674 Paris, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Fanen, P (corresponding author), Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France.			Fanen, Pascale/0000-0002-3273-5349; Clain, Jerome/0000-0002-0232-5058; Lehmann-Che, jacqueline/0000-0001-6685-3354				CASALS T, 1995, HUM GENET, V95, P205; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Cotten JF, 1996, J BIOL CHEM, V271, P21279, DOI 10.1074/jbc.271.35.21279; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; DORK T, 1991, HUM GENET, V87, P441; DORK T, 1996, CYSTIC FIBROSIS MUTA; Duarte A, 1996, HUM MUTAT, V8, P134, DOI 10.1002/(SICI)1098-1004(1996)8:2<134::AID-HUMU5>3.0.CO;2-B; Fanen P, 1997, J BIOL CHEM, V272, P30563, DOI 10.1074/jbc.272.48.30563; Fanen P, 1999, FEBS LETT, V452, P371, DOI 10.1016/S0014-5793(99)00647-X; Fritsch J, 1996, J PHYSIOL-LONDON, V490, P115, DOI 10.1113/jphysiol.1996.sp021130; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Hojo S, 1998, CLIN GENET, V53, P50, DOI 10.1034/j.1399-0004.1998.531530110.x; Honig B., 1992, CURR OPIN STRUC BIOL, V2, P40; Kalin N, 1992, Hum Mutat, V1, P204, DOI 10.1002/humu.1380010305; Linsdell P, 1996, AM J PHYSIOL-CELL PH, V271, pC628, DOI 10.1152/ajpcell.1996.271.2.C628; MANAVALAN P, 1993, J PROTEIN CHEM, V12, P279, DOI 10.1007/BF01028190; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; RIORDAN JR, 1989, SCIENCE, V245, P1066; Seibert FS, 1996, J BIOL CHEM, V271, P27493, DOI 10.1074/jbc.271.44.27493; Seibert FS, 1997, BIOCHEMISTRY-US, V36, P11966, DOI 10.1021/bi9712652; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Tucker Stephen J., 1992, Human Molecular Genetics, V1, P77, DOI 10.1093/hmg/1.2.77; VERLINGUE C, 1993, PRENATAL DIAG, V13, P1143, DOI 10.1002/pd.1970131210; XIE JX, 1995, J BIOL CHEM, V270, P28084; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618	28	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9045	9049		10.1074/jbc.M008979200	http://dx.doi.org/10.1074/jbc.M008979200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11118444	hybrid			2022-12-25	WOS:000167607700058
J	Vihinen, H; Ahola, T; Tuittila, M; Merits, A; Kaariainen, L				Vihinen, H; Ahola, T; Tuittila, M; Merits, A; Kaariainen, L			Elimination of phosphorylation sites of semliki forest virus replicase protein nsP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; CASEIN KINASE-II; TEMPERATURE-SENSITIVE MUTANTS; STRAND RNA-SYNTHESIS; SINDBIS VIRUS; MINUS-STRAND; P PROTEIN; PHOSPHOPROTEIN-P; GENE-EXPRESSION; C-ZETA	nsP3 is one of the four RNA replicase subunits encoded by alphaviruses. The specific essential functions of nsP3 remain unknown, but it is known to be phosphorylated on serine and threonine residues. Here we have completed mapping of the individual phosphorylation sites on Semliki Forest virus nsP3 (482 amino acids) by point mutational analysis of threonine residues. This showed that threonines 344 and 345 represented the major threonine phosphorylation sites in nsP3. Experiments with deletion variants suggested that nsP3 itself had no kinase activity; instead, it was likely to be phosphorylated by multiple cellular kinases. Phosphorylation was not necessary for the peripheral membrane association of nsP3, which was mediated by the N-terminal region preceding the phosphorylation sites. Two deletion variants of nsP3 with either reduced or undetectable phosphorylation were studied in the context of virus infection. Cells infected with mutant viruses produced close to wild type levels of infectious virions; however, the rate of viral RNA synthesis was significantly reduced in the mutants. A virus totally defective in nsP3 phosphorylation and exhibiting a decreased rate of RNA synthesis also exhibited greatly reduced pathogenicity in mice.	Univ Helsinki, Inst Biotechnol, Program Cellular Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20520 Turku, Finland	University of Helsinki; Abo Akademi University	Vihinen, H (corresponding author), Univ Helsinki, Inst Biotechnol, Program Cellular Biotechnol, Viikki Bioctr, POB 56,Viikinkaari 9, FIN-00014 Helsinki, Finland.	helena.vihinen@helsinki.fi	Merits, Andres/H-3125-2015	Merits, Andres/0000-0001-8193-0071				Ahola T, 1999, EMBO J, V18, P3164, DOI 10.1093/emboj/18.11.3164; Ahola T, 1997, J VIROL, V71, P392, DOI 10.1128/JVI.71.1.392-397.1997; AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; Atkins GJ, 1999, J GEN VIROL, V80, P2287, DOI 10.1099/0022-1317-80-9-2287; BARIK S, 1992, J VIROL, V66, P1109, DOI 10.1128/JVI.66.2.1109-1118.1992; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BARTON DJ, 1988, J VIROL, V62, P3597, DOI 10.1128/JVI.62.10.3597-3602.1988; Byrappa S, 1996, VIROLOGY, V216, P228, DOI 10.1006/viro.1996.0052; DAS T, 1995, VIROLOGY, V211, P218, DOI 10.1006/viro.1995.1394; de Cedron MG, 1999, FEBS LETT, V448, P19, DOI 10.1016/S0014-5793(99)00321-X; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; Gupta AK, 2000, J VIROL, V74, P91, DOI 10.1128/JVI.74.1.91-98.2000; HAHN YS, 1989, J VIROL, V63, P3142, DOI 10.1128/JVI.63.7.3142-3150.1989; Huntley CC, 1997, J BIOL CHEM, V272, P16578, DOI 10.1074/jbc.272.26.16578; Hwang LN, 1999, J VIROL, V73, P5613, DOI 10.1128/JVI.73.7.5613-5620.1999; KAARIAINEN L, 1987, J CELL SCI, P231; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KERANEN S, 1974, ACTA PATH MICRO IM B, VB 82, P810; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; LAAKKONEN P, 1994, J VIROL, V68, P7418, DOI 10.1128/JVI.68.11.7418-7425.1994; LASTARZA MW, 1994, J VIROL, V68, P5781, DOI 10.1128/JVI.68.9.5781-5791.1994; LASTARZA MW, 1994, VIROLOGY, V202, P224, DOI 10.1006/viro.1994.1338; LEMM JA, 1994, EMBO J, V13, P2925, DOI 10.1002/j.1460-2075.1994.tb06587.x; LI GP, 1990, VIROLOGY, V179, P416, DOI 10.1016/0042-6822(90)90310-N; LILJESTROM P, 1991, J VIROL, V65, P4107; Liu Z, 1997, VIROLOGY, V232, P198, DOI 10.1006/viro.1997.8548; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837; PERANEN J, 1995, VIROLOGY, V208, P610, DOI 10.1006/viro.1995.1192; PERANEN J, 1991, J VIROL, V65, P1623; PERANEN J, 1988, J GEN VIROL, V69, P2165, DOI 10.1099/0022-1317-69-9-2165; PERANEN J, 1991, J GEN VIROL, V72, P195, DOI 10.1099/0022-1317-72-1-195; SHIRAKO Y, 1994, J VIROL, V68, P1874, DOI 10.1128/JVI.68.3.1874-1885.1994; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Tuittila MT, 2000, J VIROL, V74, P4579, DOI 10.1128/JVI.74.10.4579-4589.2000; Vasiljeva L, 2000, J BIOL CHEM, V275, P17281, DOI 10.1074/jbc.M910340199; Vihinen H, 2000, J BIOL CHEM, V275, P27775; WANG YF, 1994, J VIROL, V68, P6466, DOI 10.1128/JVI.68.10.6466-6475.1994; WYATT LS, 1995, VIROLOGY, V210, P202, DOI 10.1006/viro.1995.1332	40	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5745	5752		10.1074/jbc.M006077200	http://dx.doi.org/10.1074/jbc.M006077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11104756	hybrid			2022-12-25	WOS:000167115100048
J	Cheng, XD; Phelps, C; Taylor, SS				Cheng, XD; Phelps, C; Taylor, SS			Differential binding of cAMP-dependent protein kinase regulatory subunit isoforms I alpha and II beta to the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC-MUSCLE; A ANCHORING PROTEIN; AUTOPHOSPHORYLATION SITE; MOLECULAR-CLONING; ESCHERICHIA-COLI; SKELETAL-MUSCLE; LOCALIZATION; EXPRESSION; INHIBITOR; TISSUES	Limited trypsin digestion of type I cAMP-dependent protein kinase holoenzyme results in a proteolytic-resistant Delta (1-72) regulatory subunit core, indicating that interaction between the regulatory and catalytic subunits extends beyond the autoinhibitory site in the R subunit at the NR, terminus. Sequence alignment of the two R subunit isoforms, Rf and RII, reveals a significantly sequence diversity at this specific region. To determine whether this sequence diversity is functionally important for interaction with the catalytic subunit, specific mutations, R133A and D328A, are introduced into sites adjacent to the active site cleft in the catalytic subunit. While replacing Arg(133) with Ala decreases binding affinity for RII, interaction between the catalytic subunit and RI is not affected. In contrast, mutant C(D328A) showed a decrease in affinity for binding RI while maintaining similar affinities for Rn as compared with the wild-type catalytic subunit. These results suggest that sequence immediately NH2-terminal to the consensus inhibition site in RI and RII interacts with different sites at the proximal region of the active site cleft in the catalytic subunit. These isoform-specific differences would dictate a significantly different domain organization in the type I and type II holoenzymes.	Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, Sch Med, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, La Jolla, CA 92093 USA.	staylor@ucsd.edu			NIGMS NIH HHS [GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angelo R, 1998, J BIOL CHEM, V273, P14633, DOI 10.1074/jbc.273.23.14633; Banky P, 1998, J BIOL CHEM, V273, P35048, DOI 10.1074/jbc.273.52.35048; BEEBE SJ, 1986, ENZYMES, V17, P43; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; BUECHLER YJ, 1993, J BIOL CHEM, V268, P16495; CHENG HC, 1986, J BIOL CHEM, V261, P989; Cheng XD, 1998, BIOCHEMISTRY-US, V37, P14005, DOI 10.1021/bi981057p; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CORBIN JD, 1975, J BIOL CHEM, V250, P218; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; DURGERIAN S, 1989, J BIOL CHEM, V264, P9807; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ERLICHMAN J, 1974, J BIOL CHEM, V249, P5000; Gangal M, 1999, P NATL ACAD SCI USA, V96, P12394, DOI 10.1073/pnas.96.22.12394; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; Gibson RM, 1997, J BIOL CHEM, V272, P31998, DOI 10.1074/jbc.272.51.31998; Hemmer W, 1997, ANAL BIOCHEM, V245, P115, DOI 10.1006/abio.1996.9952; Herberg FW, 1997, PROTEIN SCI, V6, P569; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; Huang LJS, 1998, J BIOL CHEM, V273, P26739, DOI 10.1074/jbc.273.41.26739; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JOACHIM S, 1990, EUR J CELL BIOL, V51, P76; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; PARISET C, 1989, J CELL BIOL, V109, P1195, DOI 10.1083/jcb.109.3.1195; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; ROSEN OM, 1975, J BIOL CHEM, V250, P7788; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; SLICE LW, 1989, J BIOL CHEM, V264, P20940; SUGDEN PH, 1976, BIOCHEM J, V159, P423, DOI 10.1042/bj1590423; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEN W, 1994, J BIOL CHEM, V269, P8423; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	51	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4102	4108		10.1074/jbc.M006447200	http://dx.doi.org/10.1074/jbc.M006447200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11110787	hybrid			2022-12-25	WOS:000166921200051
J	Adnane, J; Bizouarn, FA; Chen, Z; Ohkanda, J; Hamilton, AD; Munoz-Antonia, T; Sebti, SM				Adnane, J; Bizouarn, FA; Chen, Z; Ohkanda, J; Hamilton, AD; Munoz-Antonia, T; Sebti, SM			Inhibition of farnesyltransferase increases TGF beta type II receptor expression and enhances the responsiveness of human cancer cells to TGF beta	ONCOGENE			English	Article						farnesyltransferase inhibitors; Ras; transforming growth factor beta; tumor growth and transformation	GROWTH-FACTOR-BETA; TRANSFORMED THYROID-CELLS; FAMILY MEDIATOR SMAD1; GTP-BINDING PROTEIN; K-RAS; SIGNALING PATHWAYS; TRANSGENIC MICE; H-RAS; N-RAS; EPITHELIAL-CELLS	Several small GTPases of the Ras superfamily have been shown to antagonize TGF beta signaling in human tumor cell lines. Some of these GTPases are post-translationally modified by farnesylation, a lipid modification catalyzed by farnesyltransferase and required for the proteins to attach to membranes and to function. In this study, we investigated the effect of the farnesyltransferase inhibitor FTI-277 on TGF beta -regulated cell growth and transcription. Treatment of the human pancreatic tumor cell line, Panc-1, with FTI-277 enhanced the ability of TGF beta to inhibit both anchorage-dependent and -independent tumor cell growth. FTI-277 also enhanced the ability of TGF beta to induce transcription, as measured by p3TP-lux reporter activity and collagen synthesis. The enhancement of TGF beta responses by FTI-277 correlated with the stimulation of transcription and protein expression of type II TGF beta receptor (T beta RII). Consequently, FTI-277-treated cells exhibited a higher level of TGF beta binding to its receptor. Thus, inhibition of protein farnesylation stimulates T beta RII expression, which leads to increased TGF beta receptor binding and signaling as well as inhibition of tumor cell growth and transformation.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Ohkanda, Junko/I-6102-2019	Ohkanda, Junko/0000-0001-9663-5104	NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; CARMICHAEL J, 1987, CANCER RES, V47, P936; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; Choi SE, 1999, CELL SIGNAL, V11, P71, DOI 10.1016/S0898-6568(98)00033-3; Coppa A, 1997, J CELL PHYSIOL, V172, P200, DOI 10.1002/(SICI)1097-4652(199708)172:2<200::AID-JCP7>3.0.CO;2-S; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; FILMUS J, 1992, ONCOGENE, V7, P521; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; HOWE PH, 1993, J BIOL CHEM, V268, P21448; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Jennings MT, 1998, J NEURO-ONCOL, V36, P123, DOI 10.1023/A:1005863419880; Kim YS, 1999, ARCH PHARM RES, V22, P1, DOI 10.1007/BF02976427; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kohl NE, 1999, ANN NY ACAD SCI, V886, P91, DOI 10.1111/j.1749-6632.1999.tb09404.x; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lobell RB, 1998, CANCER METAST REV, V17, P203, DOI 10.1023/A:1006018922878; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Mangues R, 1998, CANCER RES, V58, P1253; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; MunozAntonia T, 1996, CANCER RES, V56, P4831; Norgaard P, 1999, ANN NY ACAD SCI, V886, P265, DOI 10.1111/j.1749-6632.1999.tb09432.x; Oliff A, 1999, BBA-REV CANCER, V1423, pC19, DOI 10.1016/S0304-419X(99)00007-4; Omer CA, 2000, CANCER RES, V60, P2680; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; SERRA R, 1992, CELL GROWTH DIFFER, V3, P693; SIPES NJ, 1990, MOL CARCINOGEN, V3, P12, DOI 10.1002/mc.2940030106; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; SUN JZ, 1995, CANCER RES, V55, P4243; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Turco A, 1999, INT J CANCER, V80, P85, DOI 10.1002/(SICI)1097-0215(19990105)80:1<85::AID-IJC17>3.0.CO;2-P; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZHAO J, 1995, CANCER RES, V55, P6181; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	70	19	24	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5525	5533		10.1038/sj.onc.1203920	http://dx.doi.org/10.1038/sj.onc.1203920			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114730				2022-12-25	WOS:000165396100013
J	Ahomadegbe, JC; Tourpin, S; Kaghad, M; Zelek, L; Vayssade, M; Mathieu, MC; Rochard, F; Spielmann, M; Tursz, T; Caput, D; Riou, G; Benard, J				Ahomadegbe, JC; Tourpin, S; Kaghad, M; Zelek, L; Vayssade, M; Mathieu, MC; Rochard, F; Spielmann, M; Tursz, T; Caput, D; Riou, G; Benard, J			Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: Prevalence of alterations in inflammatory breast cancers	ONCOGENE			English	Article						p73; monoallelic expression; inflammatory breast carcinoma	TUMOR-SUPPRESSOR GENE; P53; MUTATION; OVEREXPRESSION; PROTEIN; NEUROBLASTOMA; CARCINOMA; DELETION	The p73 gene is a p53 homologue located at 1p36-33, a region submitted to deletions in breast cancer (BC) and putatively imprinted. To study whether p73 was associated with breast carcinogenesis, loss of heterozygosity (LOH), allele expression and transcript levels were assessed in 59 BC, including 39 BC presenting no inflammatory symptoms (NBC) and 20 inflammatory BC (IBC). IBC is a rare but aggressive form of cancer with a very Door prognosis. Normal breast epithelium (BE) and lymphocytes from patients were used as controls. StyI polymorphism generating GC and/or AT alleles was used to select 22 heterozygous patients, p73 LOH was significantly higher in IBC than in NBC [five of eight cases (62%) versus two of 14 cases (14%); Fisher's exact test, P = 0.05]. p73 was biallelically expressed in all BE. In contrast, 12 of 16 (75%) BC were monoallelically expressed, showing that allele silencing was significantly associated with breast carcinogenesis (P = 0.012), AT being the preferential silent allele (10 out of 12 tumours). p73 mRNA levels in NBC and IBC were two- and threefold lower than in BE, respectively, suggesting that decreased expression could be related to tumour aggressiveness. In conclusion, LOH, allele silencing and decreased expression of the p73 gene may play a role in breast carcinogenesis.	Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, F-94800 Villejuif, France; Inst Gustave Roussy, Dept Med, F-94800 Villejuif, France; Inst Gustave Roussy, Dept Anatomopathol, F-94800 Villejuif, France; Inst Gustave Roussy, Dept Chirurg, F-94800 Villejuif, France; Sanofi Rech, F-31676 Labege, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Sanofi-Aventis; Sanofi France	Benard, J (corresponding author), Inst Gustave Roussy, Dept Biol Clin, Unite Marqueurs Genet Canc, Rue Camille Desmoulins, F-94800 Villejuif, France.		Laurent, Zelek/F-2906-2017	Laurent, Zelek/0000-0001-7455-2009				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; BEAHRS OH, 1992, AM JOINT COMMITTEE C, P149; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BIECHE I, 1994, CANCER RES, V54, P4274; Cordon-Cardo C, 1999, J EXP MED, V190, P1367, DOI 10.1084/jem.190.10.1367; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; PETER M, 1992, INT J CANCER, V52, P544, DOI 10.1002/ijc.2910520408; RIOU G, 1993, J NATL CANCER I, V85, P1765, DOI 10.1093/jnci/85.21.1765; Shishikura T, 1999, INT J CANCER, V84, P321, DOI 10.1002/(SICI)1097-0215(19990621)84:3<321::AID-IJC21>3.0.CO;2-S; SHITTOOR SR, 1998, BREAST COMPREHENSIVE, V2, P1260; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 1999, CANCER RES, V59, P3257	22	45	46	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5413	5418		10.1038/sj.onc.1203914	http://dx.doi.org/10.1038/sj.onc.1203914			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103943				2022-12-25	WOS:000165302300013
J	Gouble, A; Morello, D				Gouble, A; Morello, D			Synchronous and regulated expression of two AU-binding proteins, AUF1 and HuR, throughout murine development	ONCOGENE			English	Article						AU-rich element; c-myc mRNA; murine development; hnRNP proteins; mRNA turnover	MESSENGER-RNA STABILITY; RICH ELEMENT; NEUROGENIC CELLS; TRANSGENIC MICE; ELAV PROTEINS; GENE; IDENTIFICATION; DEGRADATION; GROWTH; PURIFICATION	The AUF1 (hnRNPD) and HuR (ELAV-like) proteins, potential trans-acting factors for regulated mRNA decay, bind in vitro to A+U-rich elements (AREs) found in the 3' untranslated region (3' UTR) of many labile transcripts. In an effort to determine whether these trans-acting factors are likely to play a role in embryogenesis, we have analysed their expression during mouse development both at the mRNA and protein levels. We show that AUF1 and HuR are expressed at all the developmental stages analysed from day 8.5 of embryonic development to adulthood. Expression levels are dynamic, varying between tissues and developmental stages. However, a strong positive correlation between AUF1 and HuR protein levels was observed in all examined tissues. Finally, we compared AUF1 and HuR expression with accumulation of one common target mRNA, c-myc. The similar spatio-temporal distribution of these proteins and of c-myc mRNA is in agreement with a potential concerted role in ARE-mediated control of mRNA stability.	Univ Toulouse 3, CNRS, UMR 5547, Ctr Dev Biol, F-31062 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Morello, D (corresponding author), Univ Toulouse 3, CNRS, UMR 5547, Ctr Dev Biol, Batiment 4R3,118 Route Narbonne, F-31062 Toulouse 4, France.							Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Antic D, 1998, J CELL SCI, V111, P183; Atasoy U, 1998, J CELL SCI, V111, P3145; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bhattacharya S, 1999, NUCLEIC ACIDS RES, V27, P1464, DOI 10.1093/nar/27.6.1464; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DREZEN JM, 1993, J IMMUNOL, V150, P2805; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HENICS T, 1994, J BIOL CHEM, V269, P5377; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; Lafon I, 1998, ONCOGENE, V16, P3413, DOI 10.1038/sj.onc.1201895; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MARUSICH MF, 1992, DEV BIOL, V149, P295, DOI 10.1016/0012-1606(92)90285-O; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; Nabors LB, 1998, J NEUROIMMUNOL, V92, P152, DOI 10.1016/S0165-5728(98)00196-9; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Perron M, 1999, MECH DEVELOP, V84, P139, DOI 10.1016/S0925-4773(99)00056-8; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	51	39	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5377	5384		10.1038/sj.onc.1203910	http://dx.doi.org/10.1038/sj.onc.1203910			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103939				2022-12-25	WOS:000165302300009
J	Xu, J; Teran-Garcia, M; Park, JHY; Nakamura, MT; Clarke, SD				Xu, J; Teran-Garcia, M; Park, JHY; Nakamura, MT; Clarke, SD			Polyunsaturated fatty acids suppress hepatic sterol regulatory element-binding protein-1 expression by accelerating transcript decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOGENIC GENE-EXPRESSION; RNA POLYMERASE-II; INSULIN-RESISTANCE; MESSENGER-RNA; SKELETAL-MUSCLE; CULTURED-CELLS; DIETARY-FAT; FISH-OIL; INDUCTION; MECHANISM	The reduction in hepatic abundance of sterol regulatory element binding protein-1 (SREBP-1) mRNA and protein associated with the ingestion of polyunsaturated fatty acids (PUFA) appears to be largely responsible for the PUFA-dependent inhibition of lipogenic gene transcription. Our initial studies indicated that the induction of SREBP-1 expression by insulin and glucose was blocked by PUFA, Nuclear run-on assays suggested PUFA reduced SREBP-1 mRNA by post-transcriptional mechanisms. In this report we demonstrate that PUFA enhance the decay of both SREBP-1a and -1c, When rat hepatocytes in monolayer culture were treated with albumin-bound 20:4(n-6) or 20:5(n-3) the half-life of total SREBP-1 mRNA was reduced by 50%. Ribonuclease protection assays revealed that the decay of SREBP-1c mRNA was more sensitive to PUFA than was SREBP-1a, i.e. the half-life of SREBP-1c and -1a was reduced from 10.0 to 4.6 h and 11.6 to 1.6 h, respectively. Interestingly, treating the hepatocytes with the translational inhibitor, cycloheximide, prevented the PUFA-dependent decay of SREBP-1, This suggests that SREBP-1 mRNA may need to undergo translation to enter the decay process, or that the decay process requires the synthesis of a rapidly turning over protein. Although the mechanism by which PUFA accelerate SREBP-1 mRNA decay remains to be determined, cloning and sequencing of the 3 ' -untranslated region for the rat SREBP-1 transcript revealed the presence of an A-U-rich region that is characteristic of a destablizing element.	Univ Texas, Div Nutr Sci, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Hallym Univ, Div Life Sci, Chunchon 200702, South Korea	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Hallym University	Clarke, SD (corresponding author), Univ Texas, Div Nutr Sci, 115 Gearing, Austin, TX 78712 USA.		Teran-Garcia, Margarita/B-5344-2009	Teran-Garcia, Margarita/0000-0002-8196-7605	NIDDK NIH HHS [DK 53872, DK 09723] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053872, F32DK009723] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Baillie RA, 1999, PROSTAG LEUKOTR ESS, V60, P351, DOI 10.1016/S0952-3278(99)80011-8; Baur LA, 1998, METABOLISM, V47, P106, DOI 10.1016/S0026-0495(98)90202-5; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CHEN Y, 1993, MOL CELL BIOL, V13, P4214, DOI 10.1128/MCB.13.7.4214; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1990, J NUTR, V120, P625, DOI 10.1093/jn/120.6.625; Clarke SD, 2000, BRIT J NUTR, V83, pS59; CLARKE SD, 1993, NUTR GENE EXPRESSION, P227; Day DA, 1998, J ENDOCRINOL, V157, P361, DOI 10.1677/joe.0.1570361; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Nakamura MT, 2000, J NUTR, V130, P1561, DOI 10.1093/jn/130.6.1561; NESTEL PJ, 1990, ANNU REV NUTR, V10, P149, DOI 10.1146/annurev.nu.10.070190.001053; Ntambi JM, 1999, J LIPID RES, V40, P1549; Perseghin G, 1999, DIABETES, V48, P1600, DOI 10.2337/diabetes.48.8.1600; Podolin DA, 1998, AM J PHYSIOL-REG I, V274, pR840, DOI 10.1152/ajpregu.1998.274.3.R840; Power GW, 1997, J NUTR, V127, P2142, DOI 10.1093/jn/127.11.2142; SALATI LM, 1986, ARCH BIOCHEM BIOPHYS, V246, P82, DOI 10.1016/0003-9861(86)90451-0; Sessler AM, 1996, J BIOL CHEM, V271, P29854, DOI 10.1074/jbc.271.47.29854; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Stabile LP, 1998, J LIPID RES, V39, P1951; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840	38	205	209	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9800	9807		10.1074/jbc.M008973200	http://dx.doi.org/10.1074/jbc.M008973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124951	hybrid			2022-12-25	WOS:000167996400031
J	Grivennikova, VG; Kapustin, AN; Vinogradov, AD				Grivennikova, VG; Kapustin, AN; Vinogradov, AD			Catalytic activity of NADH-ubiquinone oxidoreductase (Complex I) in intact mitochondria - Evidence for the slow active/inactive transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOLEMMAL VESICLES; IRON-SULFUR CLUSTERS; RESPIRATORY-CHAIN; HEART-MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; INACTIVE TRANSITION; ADENYLATE-CYCLASE; ALAMETHICIN; REDUCTASE; DEHYDROGENASE	The mammalian purified dispersed NADH-ubiquinone oxidoreductase (Complex I) and the enzyme in inside-out submitochondrial particles are known to be the slowly equilibrating mixture of the active and de-activated forms (Vinogradov, A. D. (1998) Biochim. Biophys. Acta 1364, 169-185). We report here the phenomenon of slow active/de-active transition in intact mitochondria where the enzyme is located within its natural environment being exposed to numerous mitochondrial matrix proteins. A simple procedure for permeabilization of intact mitochondria by channel-forming antibiotic alamethicin was worked out for the "in situ" assay of Complex I activity. Alamethicin-treated mitochondria catalyzed the rotenone-sensitive NADH-quinone reductase reaction with exogenousely added NADH and quinone-acceptor at the rates expected if the enzyme active sites would be freely accessible for the substrates. The matrix proteins were retained in alamethicin-treated mitochondria as judged by their high rotenone-sensitive malate-cytochrome c reductase activity in the presence of added NAD(+). The sensitivity of Complex I to N-ethylmaleimide and to the presence of Mg2+ was used as the diagnostic tools to detect the presence of the de-activated enzyme. The NADH-quinone reductase activity of alamethicin-treated mitochondria was sensitive to neither N-ethylmaleimide nor Mg2+. After exposure to elevated temperature (37 degreesC, the conditions known to induce de-activation of Complex 1) the enzyme activity became sensitive to the sulfhydryl reagent and/or Mg2+. The sensitivity to both inhibitors disappeared after brief exposure of the thermally de-activated mitochondria with malate/glutamate, NAD(+), and cytochrome c (the conditions known for the turnover-induced reactivation of the enzyme). We conclude that the slow active/de-active Complex I transition is a characteristic feature of the enzyme in intact mitochondria and discuss its possible physiological significance.	Moscow MV Lomonosov State Univ, Sch Biol, Dept Biochem, Moscow 119899, Russia	Lomonosov Moscow State University	Vinogradov, AD (corresponding author), Moscow MV Lomonosov State Univ, Sch Biol, Dept Biochem, Moscow 119899, Russia.		Grivennikova, Vera/AAM-3319-2021	Grivennikova, Vera/0000-0002-9132-7169				BATAYNEH N, 1986, ARCH BIOCHEM BIOPHYS, V250, P476, DOI 10.1016/0003-9861(86)90752-6; BESCH HR, 1977, J BIOL CHEM, V252, P7905; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; BURBAEV DS, 1989, FEBS LETT, V254, P47, DOI 10.1016/0014-5793(89)81007-5; BURNELL JN, 1975, BIOCHEM J, V150, P527, DOI 10.1042/bj1500527; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; DAS MK, 1985, BIOCHEM INT, V11, P357; Dutton PL, 1998, BBA-BIOENERGETICS, V1364, P245, DOI 10.1016/S0005-2728(98)00031-0; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; FOX RO, 1982, NATURE, V300, P325, DOI 10.1038/300325a0; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Gavrikova EV, 1999, FEBS LETT, V455, P36, DOI 10.1016/S0014-5793(99)00850-9; Gomall A. G, 1949, J BIOL CHEM, V177, P751; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; HALL C, 1966, BIOCHEM BIOPH RES CO, V25, P373, DOI 10.1016/0006-291X(66)90214-2; HANKE W, 1980, BIOCHIM BIOPHYS ACTA, V596, P456, DOI 10.1016/0005-2736(80)90134-0; Hatefi Y, 1978, Methods Enzymol, V53, P11; HORGAN DJ, 1968, J BIOL CHEM, V243, P5967; JACOBUS WE, 1982, ARCH BIOCHEM BIOPHYS, V219, P167, DOI 10.1016/0003-9861(82)90146-1; JONES LR, 1980, J BIOL CHEM, V255, P9971; Jung DW, 1997, BBA-BIOENERGETICS, V1320, P310, DOI 10.1016/S0005-2728(97)00036-4; KOTLYAR AB, 1990, BIOCHIM BIOPHYS ACTA, V1019, P151, DOI 10.1016/0005-2728(90)90137-S; KOTLYAR AB, 1992, BIOCHIM BIOPHYS ACTA, V1098, P144, DOI 10.1016/S0005-2728(05)80329-9; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; MAKLASHINA EO, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1221; Marsh D, 1996, BIOCHEM J, V315, P345, DOI 10.1042/bj3150345; MINAKAMI S, 1964, J BIOL CHEM, V239, P2049; Ohnishi T, 1998, BBA-BIOENERGETICS, V1365, P301, DOI 10.1016/S0005-2728(98)00082-6; Okun JG, 1999, BIOCHEM SOC T, V27, P596, DOI 10.1042/bst0270596; RAMSAY RR, 1992, BIOCHEM BIOPH RES CO, V189, P47, DOI 10.1016/0006-291X(92)91523-S; RITOV VB, 1992, GEN PHYSIOL BIOPHYS, V11, P49; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; SLED VD, 1993, J BIOENERG BIOMEMBR, V25, P347, DOI 10.1007/BF00762460; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Ushakova AV, 1999, BBA-BIOENERGETICS, V1409, P143, DOI 10.1016/S0005-2728(98)00156-X; Vinogradov AD, 1998, BBA-BIOENERGETICS, V1364, P169, DOI 10.1016/S0005-2728(98)00026-7; VINOGRADOV AD, 1993, J BIOENERG BIOMEMBR, V25, P367, DOI 10.1007/BF00762462; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1	42	94	95	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9038	9044		10.1074/jbc.M009661200	http://dx.doi.org/10.1074/jbc.M009661200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124957	hybrid			2022-12-25	WOS:000167607700057
J	Profit, AA; Lee, TR; Niu, J; Lawrence, DS				Profit, AA; Lee, TR; Niu, J; Lawrence, DS			Molecular rulers: An assessment of distance and spatial relationships of Src tyrosine kinase SH2 and active site regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; CRYSTAL-STRUCTURE; REGULATORY INTERACTIONS; CONSOLIDATED LIGANDS; FAMILY; PROTEIN; HCK; ACTIVATION; INHIBITOR; DOMAINS	The three-dimensional structures of the inactive conformations of Hck and Src, members of the Src protein-tyrosine kinase family, have recently been described. In both cases, the catalytic domain lies on the opposite face of the enzyme from the SH2 and SH3 domains. The active conformation of these enzymes has not yet been described. Given the known role of the SH2 and SH3 domains in promoting substrate binding, enzyme activation likely reorients the relative spatial arrangement between the SH2/SH3 domains and the active site region. We describe herein a series of "molecular rulers" and their use in assessing the topological and spatial relationships of the SH2 and active site regions of the Src protein-tyrosine kinase. These synthetic compounds contain sequences that are active site-directed (-Glu-Glu-Ile-Ile-(F-5)Phe-, where (F-5)Phe is pentafluorophenylalanine) and SH2-directed (-Tyr(P)-Glu-Glu-Ile-Glu-), separated by a sequence of variable length. The most potent bivalent compound, acetyl-Glu-Glu-Leu-Leu-(F-5)Phe-(GABA)(3)-Tyr(P)-Glu-Glu-Ile-Glu-amide (where GABA is gamma -aminobutyric acid), displays a >120-fold enhancement in inhibitory potency relative to the simple monovalent active site-directed species, acetyl-Glu-Glu-Leu-Leu-(F-5)Phe-amide. The short linker length (3 GABA residues) between the active site- and SH2-directed peptide fragments suggests that the corresponding domains on the Src kinase can assume a nearly contiguous spatial arrangement in the active form of the enzyme.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Lawrence, DS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	dlawrenc@aecom.yu.edu		Lee, Tae Ryong/0000-0002-6914-1237				BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; COWBURN D, 1995, J BIOL CHEM, V270, P26738, DOI 10.1074/jbc.270.45.26738; GARCIA P, 1994, J BIOL CHEM, V269, P30574; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Lawrence DS, 1998, PHARMACOL THERAPEUT, V77, P81, DOI 10.1016/S0163-7258(97)00052-1; Lee TR, 1999, J MED CHEM, V42, P784, DOI 10.1021/jm980663f; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; Niu JK, 1997, J BIOL CHEM, V272, P1493, DOI 10.1074/jbc.272.3.1493; Niu JK, 1997, J AM CHEM SOC, V119, P3844, DOI 10.1021/ja970037s; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Profit AA, 1999, J AM CHEM SOC, V121, P280, DOI 10.1021/ja983515n; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SHOKAT KM, 1995, CHEM BIOL, V2, P509, DOI 10.1016/1074-5521(95)90183-3; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SupertiFurga G, 1997, BIOESSAYS, V19, P447, DOI 10.1002/bies.950190602; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu QH, 1999, BIOCHEMISTRY-US, V38, P3491, DOI 10.1021/bi982744j; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9446	9451		10.1074/jbc.M009262200	http://dx.doi.org/10.1074/jbc.M009262200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11118446	hybrid			2022-12-25	WOS:000167607700109
J	Genevaux, P; Wawrzynow, A; Zylicz, M; Georgopoulos, C; Kelley, WL				Genevaux, P; Wawrzynow, A; Zylicz, M; Georgopoulos, C; Kelley, WL			DjlA is a third DnaK co-chaperone of Escherichia coli, and DjlA-mediated induction of colanic acid capsule requires DjlA-DnaK interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; J-DOMAIN; ATPASE ACTIVITY; POLYSACCHARIDE SYNTHESIS; BIOCHEMICAL-PROPERTIES; HSP70; GRPE; PURIFICATION; REPLICATION	DjlA is a 30-kDa type III membrane protein of Escherichia coli with the majority, including an extreme C-terminal putative J-domain, oriented toward the cytoplasm. No other regions of sequence similarity aside from the J-domain exist between DjlA and the known DnaK (Hsp70) co-chaperones DnaJ (Hsp40) and CbpA. In this study, we explored whether and to what extent DjlA possesses DnaK co-chaperone activity and under what conditions a DjlA-DnaK interaction could be important to the cell. We found that the DjlA J-domain can substitute fully for the J-domain of DnaJ using various in vivo functional complementation assays. In addition, the purified cytoplasmic fragment of DjlA was shown to be capable of stimulating DnaK ATPase in a manner indistinguishable from DnaJ, and, furthermore, DjlA could act as a DnaK co-chaperone in the reactivation of chemically denatured luciferase in vitro. DjlA expression in the cell is tightly controlled, and even its mild overexpression leads to induction of mucoid capsule. Previous analysis showed that DjlA-mediated induction of the wca capsule operon required the RcsC/RcsB two-component signaling system and that wca induction by DjlA was lost when cells contained mutations in either the dnaK or grpE gene. We now show using allele-specific genetic suppression analysis that DjlA must interact with DnaK for DjlA-mediated stimulation of capsule synthesis. Collectively, these results demonstrate that DjlA. is a co-chaperone for DnaK and that this chaperone-co-chaperone pair is implicated directly, or indirectly, in the regulation of colanic acid capsule.	Univ Geneva, Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva 4, Switzerland; Polish Acad Sci, UN Educ Sci & Cultural Org, Int Inst Mol & Cell Biol, Dept Mol Biol, PL-02109 Warsaw, Poland	University of Geneva; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Polish Academy of Sciences	Kelley, WL (corresponding author), Hop Univ Geneva, Div Malad Infect, 24 Rue Micheli du Crest, CH-1211 Geneva 4, Switzerland.	William.Kelley@medecine.unige.ch	Genevaux, Pierre/A-4851-2015	GENEVAUX, Pierre/0000-0001-7539-3126; Zylicz, Alicja/0000-0003-4174-3073				ALLEN PM, 1987, J MED MICROBIOL, V24, P363, DOI 10.1099/00222615-24-4-363; Auger I, 1996, NAT MED, V2, P306, DOI 10.1038/nm0396-306; BRILL JA, 1988, J BACTERIOL, V170, P2599, DOI 10.1128/jb.170.6.2599-2611.1988; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chamberlain LH, 1997, J BIOL CHEM, V272, P31420, DOI 10.1074/jbc.272.50.31420; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Clarke DJ, 1996, MOL MICROBIOL, V20, P1273, DOI 10.1111/j.1365-2958.1996.tb02646.x; Clarke DJ, 1997, MOL MICROBIOL, V25, P933, DOI 10.1111/j.1365-2958.1997.mmi528.x; Danese PN, 2000, J BACTERIOL, V182, P3593, DOI 10.1128/JB.182.12.3593-3596.2000; Deloche O, 1997, J BIOL CHEM, V272, P28539, DOI 10.1074/jbc.272.45.28539; Deloche O, 1996, J BIOL CHEM, V271, P23960, DOI 10.1074/jbc.271.39.23960; GEORGOPOULOS C, 1972, P NATL ACAD SCI USA, V68, P2977; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goffin L, 1998, MOL MICROBIOL, V30, P329, DOI 10.1046/j.1365-2958.1998.01067.x; GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Kelley WL, 1997, MOL MICROBIOL, V25, P913, DOI 10.1111/j.1365-2958.1997.mmi527.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Matsumoto K, 1999, J BIOCHEM, V126, P578, DOI 10.1093/oxfordjournals.jbchem.a022489; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; OPHIR T, 1994, APPL ENVIRON MICROB, V60, P740, DOI 10.1128/AEM.60.2.740-745.1994; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Rahn A, 1999, J BACTERIOL, V181, P2307, DOI 10.1128/JB.181.7.2307-2313.1999; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; RUSSO TA, 1995, MICROB PATHOGENESIS, V18, P269, DOI 10.1016/S0882-4010(05)80003-8; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Sledjeski DD, 1996, J BACTERIOL, V178, P1204, DOI 10.1128/jb.178.4.1204-1206.1996; SPENCE J, 1990, J BACTERIOL, V172, P7157, DOI 10.1128/jb.172.12.7157-7166.1990; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; STOUT V, 1994, RES MICROBIOL, V145, P389, DOI 10.1016/0923-2508(94)90086-8; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; UEGUCHI C, 1994, P NATL ACAD SCI USA, V91, P1054, DOI 10.1073/pnas.91.3.1054; UEGUCHI C, 1995, J BACTERIOL, V177, P3894, DOI 10.1128/jb.177.13.3894-3896.1995; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; WALL D, 1994, J BIOL CHEM, V269, P5446; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; YAMASHINO T, 1994, MOL MICROBIOL, V13, P475, DOI 10.1111/j.1365-2958.1994.tb00442.x; ZUBER M, 1995, J BACTERIOL, V177, P4238, DOI 10.1128/jb.177.15.4238-4244.1995; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	62	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7906	7912		10.1074/jbc.M003855200	http://dx.doi.org/10.1074/jbc.M003855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11106641	hybrid			2022-12-25	WOS:000167474900033
J	Hoare, SRJ; Gardella, TJ; Usdin, TB				Hoare, SRJ; Gardella, TJ; Usdin, TB			Evaluating the signal transduction mechanism of the parathyroid hormone 1 receptor - Effect of receptor-G-protein interaction on the ligand binding mechanism and receptor conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PEPTIDE RECEPTOR; FIRST EXTRACELLULAR LOOP; RADIOLIGAND BINDING; PTH/PTHRP RECEPTOR; CHIMERIC RECEPTORS; GUANINE-NUCLEOTIDE; TERMINAL REGION; KIDNEY-CELLS; AFFINITY; AGONIST	Ligand binding to the PTH1 receptor is described by a "two-site" model, in which the C-terminal portion of the ligand interacts with the N-terminal domain of the receptor (N interaction), and the N-terminal region of the ligand binds the juxtamembrane domain of the receptor (J interaction). Previous studies have not considered the dynamic nature of receptor conformation in ligand binding and receptor activation. In this study the ligand binding mechanism was compared for the G-protein-coupled (RG) and uncoupled (R) PTH1 receptor conformations. The two site model was confirmed by demonstration of spatially distinct binding sites for PTH(3-34) and PTH(1-14): PTH(1-11), which binds predominantly to the J domain, only partially inhibited binding of I-125-PTH(3-34); and PTH(3-34), shown to bind predominantly to the N domain, only partially inhibited PTH(1-14)-stimulated cAMP accumulation. To assess the effect of R-G coupling, ligand binding to R was measured by displacement of I-125-PTH(3-34) with 30 muM guanosine 5'-3-O-(thio)triphosphate (GTP gammaS) present, and binding to RG was measured by displacement of I-125-[MAP]PTHrP(1-36) (where MAP is model amphipathic peptide), a new radioligand that binds selectively to RG. Agonists bound with higher affinity to RG than R, whereas antagonists bound similarly to these states. The J interaction was responsible for enhanced agonist binding to RG: residues 1 and 2 were required for increased PTB(1-34) affinity for RG; residue 5 of MAP-PTHrP(1-36) was a determinant of R/RG binding selectivity, and PTH(1-14) bound selectively to RG. The N interaction was insensitive to R-G coupling; PTH(3-34) binding was GTP gammaS-insensitive. Finally, several observations suggest the receptor conformation is more "closed" at RG than R. At the R state, an open conformation is suggested by the simultaneous binding of PTH(1-14) and PTH(3-34). At RG PTH(1-14) better occluded binding of I-125-PTH(3-34) and agonist ligands bound pseudo-irreversibly, suggesting a more closed conformation of this receptor state. The results extend the two-site model to take into account R and RG conformations and suggest a model for differences of receptor conformation between these states.	NIMH, Cell Biol Unit, Genet Lab, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Usdin, TB (corresponding author), NIMH, Cell Biol Unit, Genet Lab, Rm 3D06,Bldg 36,36 Convent Dr, Bethesda, MD 20892 USA.		Hoare, Sam/J-9018-2019		NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002685, Z01MH002685] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; Behar V, 1996, ENDOCRINOLOGY, V137, P4217, DOI 10.1210/en.137.10.4217; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Beyermann M, 2000, J BIOL CHEM, V275, P5702, DOI 10.1074/jbc.275.8.5702; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clark JA, 1998, MOL ENDOCRINOL, V12, P193, DOI 10.1210/me.12.2.193; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Condon SM, 2000, J AM CHEM SOC, V122, P3007, DOI 10.1021/ja994033u; DELEAN A, 1980, J BIOL CHEM, V255, P7108; EHLERT FJ, 1988, MOL PHARMACOL, V33, P187; Figler RA, 1996, MOL PHARMACOL, V50, P1587; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; Friedman PA, 1999, ENDOCRINOLOGY, V140, P301, DOI 10.1210/en.140.1.301; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; GARDELLA TJ, 1995, J BIOL CHEM, V270, P6584, DOI 10.1074/jbc.270.12.6584; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Greenberg Z, 2000, BIOCHEMISTRY-US, V39, P8142, DOI 10.1021/bi000195n; Grill V, 1998, EUR J CANCER, V34, P222, DOI 10.1016/S0959-8049(97)10130-7; Grishina G, 2000, MOL PHARMACOL, V57, P1081; Hoare SRJ, 2000, J BIOL CHEM, V275, P27274; Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323; Hoare SRJ, 1999, J PHARMACOL TOXICOL, V41, P83, DOI 10.1016/S1056-8719(99)00024-6; Hoare SRJ, 2000, J BONE MINER RES, V15, P605, DOI 10.1359/jbmr.2000.15.3.605; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Jin L, 2000, J BIOL CHEM, V275, P27238; Juarranz MG, 1999, MOL PHARMACOL, V56, P1280, DOI 10.1124/mol.56.6.1280; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; MARTIN TJ, 1995, WILLIAMS TXB ENDOCRI, P967; Mierke DF, 1997, BIOCHEMISTRY-US, V36, P10372, DOI 10.1021/bi970771o; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; Piserchio A, 2000, BIOCHEMISTRY-US, V39, P8153, DOI 10.1021/bi000196f; POTTS JT, 1971, P NATL ACAD SCI USA, V68, P63, DOI 10.1073/pnas.68.1.63; POTTS JT, 1995, WILLIAMS TXB ENDOCRI, P920; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; ROSENBLATT M, 1980, ENDOCRINOLOGY, V107, P545, DOI 10.1210/endo-107-2-545; ROSENBLATT M, 1977, J BIOL CHEM, V252, P5847; Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199; Singh ATK, 1999, ENDOCRINOLOGY, V140, P131, DOI 10.1210/en.140.1.131; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; TEITELBAUM AP, 1982, ENDOCRINOLOGY, V111, P1524, DOI 10.1210/endo-111-5-1524; Turner PR, 1996, MOL ENDOCRINOL, V10, P132, DOI 10.1210/me.10.2.132; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; Vickery BH, 1996, J BONE MINER RES, V11, P1943; Wysolmerski JJ, 1998, ANNU REV PHYSIOL, V60, P431, DOI 10.1146/annurev.physiol.60.1.431	57	66	69	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7741	7753		10.1074/jbc.M009395200	http://dx.doi.org/10.1074/jbc.M009395200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11108715	hybrid			2022-12-25	WOS:000167474900012
J	Park, CH; Valore, EV; Waring, AJ; Ganz, T				Park, CH; Valore, EV; Waring, AJ; Ganz, T			Hepcidin, a urinary antimicrobial peptide synthesized in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE HOMOLOGY; INSECT IMMUNITY; HOST-DEFENSE; GENERATION; PRECURSOR; PROTEIN; INNATE	Cysteine-rich antimicrobial peptides are abundant in animal and plant tissues involved in host defense. In insects, most are synthesized in the fat body, an organ analogous to the liver of vertebrates. From human urine, we characterized a cysteine-rich peptide with three forms differing by amino-terminal truncation, and we named it hepcidin (Hepc) because of its origin in the liver and its antimicrobial properties. Two predominant forms, Hepc20 and Hepc25, contained 20 and 25 amino acid residues with all 8 cysteines connected by intramolecular disulfide bonds. Reverse translation and search of the data bases found homologous liver cDNAs in species from fish to human and a corresponding human genomic sequence on human chromosome 19. The full cDNA by 5' rapid amplification of cDNA ends was 0.4 kilobase pair, in agreement with hepcidin mRNA size on Northern blots. The liver was the predominant site of mRNA expression. The encoded prepropeptide contains 84 amino acids, but only the 20-25-amino acid processed forms were found in urine. Hepcidins exhibited antifungal activity against Candida albicans, Aspergillus fumigatus, and Aspergillus niger and antibacterial activity against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and group B Streptococcus. Hepcidin may be a vertebrate counterpart of cysteine-rich antimicrobial peptides produced in the fat body of insects.	Harbor UCLA Med Ctr, Dept Pediat, Los Angeles, CA 90059 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90059 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90059 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Ganz, T (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, CHS 37-055, Los Angeles, CA 90095 USA.		Ganz, Tomas/AAN-3308-2020; Ganz, Tomas/D-4567-2009	Ganz, Tomas/0000-0002-2830-5469	NHLBI NIH HHS [HL 46809] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046809] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FIELDS C G, 1991, Peptide Research, V4, P95; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Maniatis T., 1989, MOL CLONING LAB MANU; Mitta G, 2000, J CELL SCI, V113, P2759; Porter EM, 1997, INFECT IMMUN, V65, P2396, DOI 10.1128/IAI.65.6.2396-2401.1997; Tailor RH, 1997, J BIOL CHEM, V272, P24480, DOI 10.1074/jbc.272.39.24480; Tam JP, 2000, BIOCHEMISTRY-US, V39, P7159, DOI 10.1021/bi0003487; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zhang Y, 1997, FEMS MICROBIOL LETT, V149, P59, DOI 10.1111/j.1574-6968.1997.tb10308.x	23	1573	1789	3	141	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7806	7810		10.1074/jbc.M008922200	http://dx.doi.org/10.1074/jbc.M008922200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113131	hybrid			2022-12-25	WOS:000167474900020
J	Santini, CL; Bernadac, A; Zhang, M; Chanal, A; Ize, B; Blanco, C; Wu, LF				Santini, CL; Bernadac, A; Zhang, M; Chanal, A; Ize, B; Blanco, C; Wu, LF			Translocation of jellyfish green fluorescent protein via the Tat system of Escherichia coli and change of its periplasmic localization in response to osmotic up-shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; CELL-DIVISION; PERISEPTAL ANNULUS; PATHWAY; SITES; COMPARTMENTALIZATION; PROMOTER; MUTANTS; VECTORS; SPACE	The bacterial twin arginine translocation (Tat) pathway is capable of exporting cofactor-containing enzymes into the periplasm. To assess the capacity of the Tat pathway to export heterologous proteins and to gain information about the property of the periplasm, we fused the twin arginine signal peptide of the trimethyl-amine N-oxide reductase to the jellyfish green fluorescent protein (GFP), Unlike the Sec pathway, the Tat system successfully exported correctly folded GFP into the periplasm of Escherichia coli. Interestingly, GFP appeared as a halo in most cells and occasionally showed a polar localization in wild type strains. When subjected to a mild osmotic up-shock, GFP relocalized very quickly at the two poles of the cells. The conversion from the halo structure to a periplasmic gathering at particular locations was also observed with spherical cells of the Delta rodA-pbpA mutant or of the wild type strain treated with lysozyme. Therefore, the periplasm is not a uniform compartment and the polarization of GFP is unlikely to be caused by simple invagination of the cytoplasmic membrane at the poles. Moreover, the polar gathering of GFP is reversible; the reversion was accelerated by glucose and inhibited by azide and carbonyl cyanide m-chlorophenylhydrazone, indicating an active adaptation of the bacteria to the osmolarity in the medium. These results strongly suggest a relocalization of periplasmic substances in response to environmental changes. The polar area might be the preferential zone where bacteria sense the change in the environment.	CNRS, Chim Bacterienne Lab, UPR9043, F-13402 Marseille 20, France; CNRS, Inst Biol Struct & Microbiol, Serv Microscopie Elect, F-13402 Marseille, France; Univ Rennes 1, CNRS, UMR 6026, Equipe Osmoadaptat Chez Bacteries, F-35042 Rennes, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Wu, LF (corresponding author), CNRS, Chim Bacterienne Lab, UPR9043, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.		IZE, Bérengère/GLQ-7207-2022	IZE, Bérengère/0000-0001-9106-9254				ANBA J, 1984, BIOL CELL, V50, P273, DOI 10.1111/j.1768-322X.1984.tb00274.x; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; BAYER ME, 1968, J GEN MICROBIOL, V53, P395, DOI 10.1099/00221287-53-3-395; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; BOOS W, 1981, ARCH MICROBIOL, V129, P240, DOI 10.1007/BF00425258; BRASS JM, 1986, J BACTERIOL, V165, P787, DOI 10.1128/jb.165.3.787-795.1986; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; COOK WR, 1986, J BACTERIOL, V168, P1430, DOI 10.1128/jb.168.3.1430-1438.1986; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DIETZEL I, 1978, ARCH MICROBIOL, V118, P207, DOI 10.1007/BF00415731; Feilmeier BJ, 2000, J BACTERIOL, V182, P4068, DOI 10.1128/JB.182.14.4068-4076.2000; FOLEY M, 1989, MOL MICROBIOL, V3, P1329, DOI 10.1111/j.1365-2958.1989.tb00114.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hashemzadeh-Bonehi L, 1998, MOL MICROBIOL, V30, P676, DOI 10.1046/j.1365-2958.1998.01116.x; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Jacobs C, 1999, CELL, V97, P111, DOI 10.1016/S0092-8674(00)80719-9; Koch AL, 1998, CRIT REV MICROBIOL, V24, P23, DOI 10.1080/10408419891294172; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACALISTER TJ, 1983, P NATL ACAD SCI-BIOL, V80, P1372, DOI 10.1073/pnas.80.5.1372; MADDOCK JR, 1993, J BACTERIOL, V175, P7125, DOI 10.1128/JB.175.22.7125-7129.1993; MADDOCK JR, 1993, SCIENCE, V259, P1717; Miller J.H., 1972, EXPT MOL GENETICS; OLIVER DB, 1996, ESCHERICHIA COLI SAL, V1, P88; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Raskin DM, 1999, P NATL ACAD SCI USA, V96, P4971, DOI 10.1073/pnas.96.9.4971; Rodrigue A, 1996, FEBS LETT, V392, P81, DOI 10.1016/0014-5793(96)00788-0; ROTHFIELD LI, 1988, MICROBIOL SCI, V5, P182; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; STANLEY NR, 2001, IN PRESS J BACTERIOL; VINELLA D, 1993, J BACTERIOL, V175, P6704, DOI 10.1128/jb.175.20.6704-6710.1993; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; WOLDRINGH CL, 1994, MOL MICROBIOL, V14, P597, DOI 10.1111/j.1365-2958.1994.tb01299.x; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; XIA TH, 1993, J BACTERIOL, V175, P4729, DOI 10.1128/JB.175.15.4729-4737.1993; ZHAO GS, 1993, J GEN MICROBIOL, V139, P807, DOI 10.1099/00221287-139-4-807	38	166	174	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8159	8164		10.1074/jbc.C000833200	http://dx.doi.org/10.1074/jbc.C000833200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11099493	hybrid			2022-12-25	WOS:000167474900068
J	Tabata, M; Tabata, R; Grabowski, DR; Bukowski, RM; Ganapathi, MK; Ganapathi, R				Tabata, M; Tabata, R; Grabowski, DR; Bukowski, RM; Ganapathi, MK; Ganapathi, R			Roles of NF-kappa B and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITION; SENSITIVITY; CHEMOTHERAPY; RESISTANCE; ACTIVATION; MECHANISMS; EXPRESSION	Activation of signaling pathways after DNA damage induced by topoisomerase (topo) poisons can lead to cell death by apoptosis, Treatment of human nonsmall cell lung carcinoma (NSCLC-3 or NSCLC-5) cells with the topo I poison SN-38 or the topo II poison etoposide (VP-16) leads to activation of NF-kappaB before induction of apoptosis, Inhibiting the degradation of I kappaB alpha by pretreatment with the proteasome inhibitor MG-132 significantly inhibited NF-kappaB activation and apoptosis but not DNA damage induced by SN-38 or VP-16. Transfection of NSCLC-5 or NSCLC-5 cells with dominant negative mutant I kappaB alpha (mI kappaB alpha) inhibited SN-38 or VP-16 induced transcription and DNA binding activity of NF-kappaB without altering drug-induced apoptosis. Regulation of apoptosis by mitochondrial release of cytochrome c and activation of pro-caspase 9 followed by cleavage of poly(ADP-ribose) polymerase by effector caspases 3 and 7 was similar in neo and mI kappaB alpha cells treated with SN-38 or VP-16. In contrast to pretreatment with MG-132, exposure to MG-132 after SN-38 or VP-16 treatment of neo or mI kappaB alpha cells decreased cell cycle arrest in the S/G(2) + M fraction and enhanced apoptosis compared with drug alone. In summary, apoptosis induced by topoisomerase poisons in NSCLC cells is not mediated by NF-kappaB but can be manipulated by proteasome inhibitors.	Cleveland Clin Fdn, Taussig Canc Ctr, Expt Therapeut Program, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ganapathi, R (corresponding author), Cleveland Clin Fdn, Taussig Canc Ctr, Expt Therapeut Program, R40,9500 Euclid Ave, Cleveland, OH 44195 USA.	ganapar@cc.ccf.org			NATIONAL CANCER INSTITUTE [R01CA074939, R01CA035531] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA35531, R01 CA74939] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHIN KV, 1993, ADV CANCER RES, V60, P157; Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ganapathi MK, 1996, CELL GROWTH DIFFER, V7, P923; GANAPATHI R, 1991, MOL PHARMACOL, V39, P1; Grabowski DR, 1999, MOL PHARMACOL, V56, P1340, DOI 10.1124/mol.56.6.1340; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Kawamura KI, 1996, BIOCHEM PHARMACOL, V52, P1903, DOI 10.1016/S0006-2952(96)00692-2; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Muscarella DE, 1998, EXP CELL RES, V238, P155, DOI 10.1006/excr.1997.3832; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Schmitt E, 1999, DRUG RESIST UPDATE, V2, P21, DOI 10.1054/drup.1999.0065; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053	23	52	55	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8029	8036		10.1074/jbc.M009831200	http://dx.doi.org/10.1074/jbc.M009831200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11115510	hybrid			2022-12-25	WOS:000167474900051
J	Day, PJ; Owens, SR; Wesche, J; Olsnes, S; Roberts, LM; Lord, JM				Day, PJ; Owens, SR; Wesche, J; Olsnes, S; Roberts, LM; Lord, JM			An interaction between ricin and calreticulin that may have implications for toxin trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; GALACTOSE-BINDING; GOLGI-COMPLEX; CELL-SURFACE; RAT-LIVER; B-CHAIN; A-CHAIN; NUCLEOTIDE-SEQUENCE; COMMUNIS AGGLUTININ	Here we demonstrate that ricin is able to interact with the molecular chaperone calreticulin both in vitro and in vivo. The interaction occurred with ricin holotoxin, but not with free:ricin A chain; and it was prevented in the presence of lactose, suggesting that it was mediated by the lectin activity of the ricin B chain. This lectin is galactose-specific, and metabolic labeling with [H-3]galactose or treating galactose oxidase-modified calreticulin with sodium [H-3]borohydride indicated that Vero cell calreticulin possesses a terminally galactosylated oligosaccharide. Brefeldin A treatment indicated that the intracellular interaction occurred initially in a post-Golgi stack compartment,:possibly the trans-Golgi network, whereas the reductive separation of ricin subunits occurred in an earlier part of the secretory pathway, most probably the endoplasmic reticulum (ER), Intoxicating Vero cells with ricin whose A chain had been modified to include either a tyrosine sulfation site or the sulfation site plus available N-glycosylation sites, in the presence of (Na2OSO4)-S-35, confirmed that calreticulin interacted with endocytosed ricin that had already undergone retrograde transport to both the Golgi and the ER, Although we cannot exclude the possibility that the interaction between ricin and calreticulin is an indirect one, the data presented are consistent with the idea that calreticulin may function as a recycling carrier for retrograde transport of ricin from the Golgi to the ER.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway	University of Warwick; University of Oslo	Lord, JM (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	Mike.Lord@warwick.ac.uk		Wesche, Jorgen/0000-0002-9200-9162				Denning GM, 1997, BLOOD, V90, P372; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; ENDO Y, 1987, J BIOL CHEM, V262, P5908; GAHMBERG CG, 1973, J BIOL CHEM, V248, P4311; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HINO Y, 1978, J BIOCHEM, V83, P909, DOI 10.1093/oxfordjournals.jbchem.a132018; Jackson ME, 1999, J CELL SCI, V112, P467; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Lord J M, 1991, Semin Cell Biol, V2, P15; Lord JM, 1998, J CELL BIOL, V140, P733; LORD JM, 1985, FEBS LETT, V189, P72, DOI 10.1016/0014-5793(85)80844-9; LORD JM, 1985, EUR J BIOCHEM, V146, P411, DOI 10.1111/j.1432-1033.1985.tb08667.x; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; NEWTON DL, 1992, J BIOL CHEM, V267, P11917; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; Olsnes S, 1991, Semin Cell Biol, V2, P7; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PETER F, 1992, J BIOL CHEM, V267, P10631; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; ROSA P, 1992, J BIOL CHEM, V267, P12227; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; Simpson JC, 1999, FEBS LETT, V459, P80, DOI 10.1016/S0014-5793(99)01222-3; SPICER EK, 1982, J BIOL CHEM, V257, P5716; VAN PN, 1989, J BIOL CHEM, V264, P17494; VANDEURS B, 1985, EXP CELL RES, V159, P287, DOI 10.1016/S0014-4827(85)80003-3; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VILLAFRANCA JE, 1981, J BIOL CHEM, V256, P554; WAISMAN DM, 1985, J BIOL CHEM, V260, P1652; WALES R, 1991, J BIOL CHEM, V266, P19172; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; Wesche J, 1999, J BIOL CHEM, V274, P34443, DOI 10.1074/jbc.274.48.34443; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOULE RJ, 1981, CELL, V23, P551, DOI 10.1016/0092-8674(81)90151-3	42	50	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7202	7208		10.1074/jbc.M009499200	http://dx.doi.org/10.1074/jbc.M009499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113144	hybrid			2022-12-25	WOS:000167442900049
J	Rebres, RA; Green, JM; Reinhold, MI; Ticchioni, M; Brown, EJ				Rebres, RA; Green, JM; Reinhold, MI; Ticchioni, M; Brown, EJ			Membrane raft association of CD47 is necessary for actin polymerization and protein kinase C theta translocation in its synergistic activation of T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; SIGNAL-REGULATORY PROTEIN; CYTOSKELETAL REORGANIZATION; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; DEFICIENT MICE; LIPID RAFTS; RECEPTOR; COSTIMULATION; ADHESION	CD47 is-a ubiquitously expressed membrane protein with an extracellular Ig domain and a multiple membrane-spanning domain that can synergize with antigen to induce interleukin (IL)-2 secretion by T lymphocytes. Ligation of CD47 induced actin polymerization and increased Protein kinase C theta (PKC theta) association with the cytoskeleton independent of antigen receptor ligation, but ligation of mutant forms of the molecule missing either the Ig:domain or the multiple membrane-spanning domain did not. Simultaneous ligation of CD47 and CD3 led to additive effects on F-actin and synergistic effects on PKC theta cytoskeletal association. Disruption of membrane rafts by removal of cholesterol with cyclodextrin blocked CD47 induced actin polymerization, and mutant forms of CD47 that localized poorly to rafts failed to effect cytoskeletal rearrangement. However, raft association alone was not sufficient, because a raft-localized CD47 Ig domain bound to the membrane by a glycan phosphoinositol anchor was unable to induce actin polymerization. A mutant form of CD47 without its Ig domain that did not induce actin polymerization or localize to rafts still enhanced T cell receptor (TCR)-dependent tyrosine phosphorylation of PLC gamma and associated Ca2+ signaling but did not augment IL-2 secretion. Thus, CD47 synergy with TCR to increase [Ca2+](i) is indepedent of actin and rafts but is insufficient to explain CD47 cooperation with TCR in IL-2 synthesis. Full synergy with TCR requires CD47 localization to membrane rafts where ligation leads to TCR-independent signals causing actin polymerization and PKC theta translocation.	Univ Calif San Francisco, Program Host Pathogen Interact, Ctr Host Pathogen Interact, San Francisco, CA 94143 USA; Ctr Hosp Univ Nice, Lab Cent Immunol, F-06202 Nice, France	University of California System; University of California San Francisco; CHU Nice	Brown, EJ (corresponding author), Univ Calif San Francisco, Program Host Pathogen Interact, Ctr Host Pathogen Interact, Box 0654,513 Parnassus Ave, San Francisco, CA 94143 USA.		Ticchioni, Michel/P-8095-2016					Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Adams S, 1998, J IMMUNOL, V161, P1853; Aman MJ, 2000, CURR BIOL, V10, P393, DOI 10.1016/S0960-9822(00)00415-2; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bachmann MF, 1997, IMMUNITY, V7, P549, DOI 10.1016/S1074-7613(00)80376-3; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Caplan S, 2000, IMMUNOL TODAY, V21, P223, DOI 10.1016/S0167-5699(00)01604-2; CEROTTINI JC, 1972, NATURE-NEW BIOL, V237, P272, DOI 10.1038/newbio237272a0; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; GEPPERT TD, 1990, CELL IMMUNOL, V131, P205, DOI 10.1016/0008-8749(90)90247-O; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; Kaga S, 1998, J IMMUNOL, V160, P24; Kaga S, 1998, J IMMUNOL, V160, P4182; KUNZ D, 1992, J BIOL CHEM, V267, P9101; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; O'SHEA JJ, 1985, J IMMUNOL, V134, P2580; Penninger JM, 1999, EUR J IMMUNOL, V29, P1709, DOI 10.1002/(SICI)1521-4141(199905)29:05<1709::AID-IMMU1709>3.3.CO;2-F; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; Reinhold MI, 1999, INT IMMUNOL, V11, P707, DOI 10.1093/intimm/11.5.707; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sedwick CE, 1999, J IMMUNOL, V162, P1367; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Ticchioni M, 1997, J IMMUNOL, V158, P677; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Vallejo AN, 2000, J IMMUNOL, V164, P2947, DOI 10.4049/jimmunol.164.6.2947; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Waclavicek M, 1997, J IMMUNOL, V159, P5345; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251	47	43	45	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7672	7680		10.1074/jbc.M008858200	http://dx.doi.org/10.1074/jbc.M008858200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11114301	hybrid			2022-12-25	WOS:000167442900109
J	Krieg, M; Haas, R; Brauch, H; Acker, T; Flamme, I; Plate, KH				Krieg, M; Haas, R; Brauch, H; Acker, T; Flamme, I; Plate, KH			Up-regulation of hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function	ONCOGENE			English	Article						von Hippel-Lindau (VHL) tumor suppressor; gene; hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha; protein stability; renal clear cell carcinoma cell lines	ENDOTHELIAL GROWTH-FACTOR; PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; MESSENGER-RNA; FACTOR-I; FACTOR 1-ALPHA; ALPHA-SUBUNIT; FACTOR-1-ALPHA; ACTIVATION; EXPRESSION	Hypoxia induces transcription of a range of physiologically important genes including erythropoietin and vascular endothelial growth factor. The transcriptional activation is mediated by the hypoxia-inducible factor-1 (HIF-1), a heterodimeric member of the basic helix-loop-helix PAS family, composed of alpha and beta subunits, HLF-1 alpha shares 48 per cent identity with the recently identified HIF-2 alpha protein that is also stimulated by hypoxia, In a previous study of hemangioblastomas, the most frequent manifestation of hereditary von Hippel-Lindau disease (VHL), we found elevated levels of vascular endothelial growth factor and HIF-2 alpha. mRNA in stromal cells of the tumors. Mutations of the VHL tumor suppressor gene are associated with a variety of tumors such as renal clear cell carcinomas (RCC), In this study, we analysed the expression of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in a range of VHL wildtype and VHL deficient RCC cell lines. In the presence of functional VHL protein, HIF-1 alpha mRNA levels are elevated, whereas HIF-2 alpha mRNA expression is increased only in cells lacking a functional VHL gene product. On the protein levels, however, in VHL deficient cell lines, both HIF-alpha subunits are constitutively expressed, whereas re-introduction of a functional VHL gene restores the instability of HIF-1 alpha and HIF-2 alpha proteins under normoxic conditions. Moreover, immunohistochemical analyses of RCCs and hemangioblastomas demonstrate up-regulation of HIF-1 alpha and HIF-2 alpha in the tumor cells. The data presented here provide evidence for a role of the VHL protein in regulation of angiogenesis and erythropoiesis mediated by the HIF-1 alpha and HIF-2 alpha proteins.	Univ Erlangen Nurnberg, Dept Neuropathol, D-91054 Erlangen, Germany; Univ Freiburg, Sch Med, Neuroctr, D-79106 Freiburg, Germany; Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany; Univ Cologne, Ctr Mol Biol & Med, D-50931 Cologne, Germany	University of Erlangen Nuremberg; University of Freiburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Cologne	Plate, KH (corresponding author), Univ Erlangen Nurnberg, Dept Neuropathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany.			Brauch, Hiltrud/0000-0001-7531-2736; Acker, Till/0000-0001-6357-7227				Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; Glavac D, 1996, HUM GENET, V98, P271, DOI 10.1007/s004390050206; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; NEUMANN HPH, 1995, BRAIN PATHOL, V5, P181, DOI 10.1111/j.1750-3639.1995.tb00592.x; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; PLATE KH, 1993, CANCER RES, V53, P5822; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1998, J LAB CLIN MED, V131, P207, DOI 10.1016/S0022-2143(98)90091-9; Siemeister G, 1996, CANCER RES, V56, P2299; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wenger RH, 1997, BIOL CHEM, V378, P609; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	38	304	319	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5435	5443		10.1038/sj.onc.1203938	http://dx.doi.org/10.1038/sj.onc.1203938			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114720				2022-12-25	WOS:000165396100003
J	Yao, JL; Kops, O; Lu, PJ; Lu, KP				Yao, JL; Kops, O; Lu, PJ; Lu, KP			Functional conservation of phosphorylation-specific prolyl isomerases in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS/TRANS ISOMERASES; PROTEIN; PIN1; GENE; ESS1; ISOMERIZATION; SEQUENCE; IDENTIFICATION; ENCODES; FAMILY	The phosphorylation-specific peptidyl prolyl cis/trans isomerase (PPIase) Pin1 in humans and its homologues in yeast and animal species play an important role in cell cycle regulation. These PPIases consist of an NH2-terminal WW domain that binds to specific phosphoserine or phosphothreonine-proline motifs present in a subset of phosphoproteins and a COOH-terminal PPIase domain that specifically isomerizes the phosphorylated serine/threonine-proline peptide bonds. Here, we describe the isolation of MdPin1, a Pin1 homologue from the plant species apple (Malus domestica) and show that it has the same phosphorylation-specific substrate specificity and can be inhibited by juglone in vitro, as is the case for Pin1. A search in the plant expressed sequence tag data bases reveals that the Pin1-type PPIases are present in various plants, and there are multiple genes in one organism, such as soybean (Glycine max) and tomato (Lycopersicon esculentum). Furthermore, all these plant Pin1-type PPIases, including AtPin1 in Arabidopsis thaliana, do not have a WW domain, but all contain a four-amino acid insertion next to the phospho-specific recognition site of the active site. Interestingly, like Pin1, both MdPin1 and AtPin1 are able to rescue the lethal mitotic phenotype of a temperature-sensitive mutation in the Pin1 homologue ESS1/PTF1 gene in Saccharomyces cerevisiae, However, deleting the extra four amino acid residues abolished the ability of AtPin1 to rescue the yeast mutation under non overexpression conditions, indicating that these extra amino acids may be important for mediating the substrate interaction of plant enzymes. Finally, expression of MdPin1 is tightly associated with cell division both during apple fruit development in vivo and during cell cultures in vitro. These results have demonstrated that phosphorylation-specific PPIases are highly conserved functionally in yeast, animal, and plant species. Furthermore, the experiments suggest that although plant Pin1-type enzymes do not have a WW domain, they may fulfill the same functions as Pin1 and its homologues do in other organisms.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol Oncol,Canc Biol Program, Boston, MA 02215 USA; Hort & Food Res Inst New Zealand Ltd, Auckland, New Zealand	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; New Zealand Institute for Plant & Food Research Ltd	Lu, KP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol Oncol,Canc Biol Program, HIM 1047,330 Brookline Ave, Boston, MA 02215 USA.	klu@caregroup.harvard.edu	Yao, Jia-Long/N-8929-2017	Yao, Jia-Long/0000-0003-2570-8139	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058556, R01GM056230] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM56230, GM58556] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker LDP, 1998, PLANTA, V205, P197, DOI 10.1007/s004250050312; Chang S. J., 1993, Plant Molecular Biology Reporter, V11, P113, DOI 10.1007/BF02670468; CODRON H, 1979, PLANT SCI LETT, V17, P29, DOI 10.1016/0304-4211(79)90105-6; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dong YH, 1998, SEX PLANT REPROD, V11, P277, DOI 10.1007/s004970050154; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HENNIG L, 1988, BIOCHEMISTRY-US, V37, P5953; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; JACKSON D, 1986, TEMPERATE SUBTROPICA; Kops O, 1998, J BIOL CHEM, V273, P31971, DOI 10.1074/jbc.273.48.31971; Landrieu I, 2000, J BIOL CHEM, V275, P10577, DOI 10.1074/jbc.275.14.10577; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; Metzner M, 2001, J BIOL CHEM, V276, P13524, DOI 10.1074/jbc.M007005200; Percy AE, 1996, PHYSIOL PLANTARUM, V96, P43, DOI [10.1111/j.1399-3054.1996.tb00181.x, 10.1034/j.1399-3054.1996.960107.x]; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; SCHMID FX, 1995, CURR BIOL, V5, P993, DOI 10.1016/S0960-9822(95)00197-7; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TRAAS JA, 1992, PLANT J, V2, P723, DOI 10.1111/j.1365-313X.1992.tb00141.x; Uchida T, 1999, FEBS LETT, V446, P278, DOI 10.1016/S0014-5793(99)00239-2; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	41	51	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13517	13523		10.1074/jbc.M007006200	http://dx.doi.org/10.1074/jbc.M007006200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11118438	hybrid			2022-12-25	WOS:000168356600004
J	Parpal, S; Karlsson, M; Thorn, H; Stralfors, P				Parpal, S; Karlsson, M; Thorn, H; Stralfors, P			Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; 3T3-L1 ADIPOCYTES; MAP KINASE; MEDIATED TRANSPORT; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; RAT ADIPOCYTES; ADIPOSE-CELLS; RICH VESICLES	Insulin exerts its cellular control through receptor binding in caveolae in plasmalemma of target cells (Gustavsson, J,, Parpal, S,, Karlsson, M,, Ramsing, C,, Thorn, H,, Borg, M,, Lindroth, M,, Peterson, K, H,, Magnusson, K.-E., and Stralfors, P, (1999) FASEB, J, 13, 1961-1971), We now report that a progressive cholesterol depletion of 3T3-L1 adipocytes with beta -cyclodextrin gradually destroyed caveolae structures and concomitantly attenuated insulin stimulation of glucose transport, in effect making cells insulin-resistant. Insulin access to or affinity for the insulin receptor on rat adipocytes was not affected as determined by I-125-insulin binding. By immunoblotting of plasma membranes, total amount of insulin receptor and of caveolin remained unchanged. Receptor autophosphorylation in response to insulin was not affected by cholesterol depletion. Insulin treatment of isolated caveolae preparations increased autophosphorylation of receptor before and following cholesterol depletion. Insulin-increased tyrosine phosphorylation of an immediate downstream signal transducer, insulin receptor substrate-1, and activation of the further downstream protein kinase B were inhibited. In contrast, insulin signaling to mitogenic control as determined by control of the extracellular signal-related kinases 1/2, mitogen-activated protein kinase pathway was not affected. Insulin did not control She phosphorylation, and She did not control extracellular signal-related kinases 1/2, whereas cholesterol depletion constitutively phosphorylated She. In conclusion, caveolae are critical for propagating the insulin receptor signal to downstream targets and have the potential for sorting signal transduction for metabolic and mitogenic effects.	Linkoping Univ, Fac Hlth Sci, Dept Cell Biol, S-58185 Linkoping, Sweden	Linkoping University	Stralfors, P (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Cell Biol, S-58185 Linkoping, Sweden.	peter.stralfors@mcb.liu.se		Stralfors, Peter/0000-0002-1196-1806; Parpal, Santiago/0000-0003-2861-0516				ALEMANY S, 1987, NATURE, V330, P77, DOI 10.1038/330077a0; AMATRUDA JM, 1979, J BIOL CHEM, V254, P2619; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNEAU C, 1987, BIOCHIM BIOPHYS ACTA, V928, P297, DOI 10.1016/0167-4889(87)90189-3; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Christian AE, 1997, J LIPID RES, V38, P2264; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Dardevet D, 1999, J ENDOCRINOL, V162, P77, DOI 10.1677/joe.0.1620077; Dib K, 1998, J CLIN INVEST, V101, P1111, DOI 10.1172/JCI119884; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; FAN JY, 1983, J CELL SCI, V61, P219; FROST SC, 1987, J BIOL CHEM, V262, P9872; Fujimoto T, 1997, J HISTOCHEM CYTOCHEM, V45, P595, DOI 10.1177/002215549704500411; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gustavsson J, 1996, MOL MED, V2, P367, DOI 10.1007/BF03401634; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Hailstones D, 1998, J LIPID RES, V39, P369; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; HEIDER JG, 1978, J LIPID RES, V19, P514; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; KASUGA M, 1982, NATURE, V298, P667, DOI 10.1038/298667a0; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu HZ, 2000, BIOCHEM BIOPH RES CO, V274, P845, DOI 10.1006/bbrc.2000.3208; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MCCALLUM CD, 1995, BIOCHEMISTRY-US, V34, P1815, DOI 10.1021/bi00006a001; Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013; OKA Y, 1984, J BIOL CHEM, V259, P8125; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Pang L, 1999, BIOCHEMISTRY-US, V38, P12003, DOI 10.1021/bi990227a; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Qiao LY, 1999, J BIOL CHEM, V274, P10625, DOI 10.1074/jbc.274.15.10625; Rankin SE, 1997, BIOPHYS J, V73, P2446, DOI 10.1016/S0006-3495(97)78273-0; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STRALFORS P, 1988, EUR J BIOCHEM, V171, P199, DOI 10.1111/j.1432-1033.1988.tb13776.x; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Westermann M, 1999, HISTOCHEM CELL BIOL, V111, P71, DOI 10.1007/s004180050335; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	74	273	280	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9670	9678		10.1074/jbc.M007454200	http://dx.doi.org/10.1074/jbc.M007454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11121405	hybrid			2022-12-25	WOS:000167996400014
J	Kilav, R; Silver, J; Naveh-Many, T				Kilav, R; Silver, J; Naveh-Many, T			A conserved cis-acting element in the parathyroid hormone 3 '-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GENE-EXPRESSION; PTH SECRETION; BINDING; PROTEIN; DESTABILIZATION; IDENTIFICATION; PHOSPHORUS; SEQUENCE; RECEPTOR	Calcium and phosphate regulate parathyroid hormone (PTH) gene expression post-transcriptionally by changes in protein-PTH mRNA 3'-untranslated region (UTR) interactions, which determine PTH mRNA stability. We have identified the protein binding sequence in the PTH mRNA 3'-UTR and determined its functionality. The protein-binding element was identified by binding, competition, and antisense oligonucleotide interference. The sequence was preserved among species suggesting its importance. To study its functionality in the context of another RNA, a 63-base pair cDNA PTH sequence was fused to the growth hormone (GN) gene, There is no parathyroid (PT) cell line and therefore an in vitro degradation assay was used to determine the stability of transcripts for PTH, GH, and a chimeric GH-PTH 63 nucleotides with PT cytosolic proteins. The full-length PTH transcript was stabilized by PT proteins from rats fed a low calcium diet and destabilized by proteins from rats fed a low phosphate diet, correlating with PTH mRNA levels in vivo, These PT proteins did not affect the native GH transcript. However, the chimeric GH transcript was stabilized by low calcium PT proteins and destabilized by low phosphate PT proteins, similar to the PTH full-length transcript. Therefore, we have identified a PTH RNA-protein binding region and shown that it is sufficient to confer responsiveness to calcium and phosphate in a reporter gene. This defined element in the PTH mRNA 3'-UTR is necessary and sufficient for the regulation of PTH mRNA stability by calcium and phosphate.	Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Naveh-Many, T (corresponding author), Hadassah Univ Hosp, Serv Nephrol, Minerva Ctr Calcium & Bone Metab, POB 12000, IL-91120 Jerusalem, Israel.	tally@cc.huji.ac.il						Almaden Y, 1996, J BONE MINER RES, V11, P970; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Epstein E, 2000, J CLIN INVEST, V105, P505, DOI 10.1172/JCI8557; HENDY GN, 1981, P NATL ACAD SCI-BIOL, V78, P7365, DOI 10.1073/pnas.78.12.7365; KEMPER B, 1986, CRIT REV BIOCHEM MOL, V19, P353, DOI 10.3109/10409238609082545; KILAV R, 1995, J CLIN INVEST, V96, P327, DOI 10.1172/JCI118038; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; NAVEHMANY T, 1990, J CLIN INVEST, V86, P1313, DOI 10.1172/JCI114840; NAVEHMANY T, 1995, J CLIN INVEST, V96, P1786, DOI 10.1172/JCI118224; Nielsen PK, 1996, NEPHROL DIAL TRANSPL, V11, P1762; Rajagopalan LE, 1997, PROG NUCLEIC ACID RE, V56, P257, DOI 10.1016/S0079-6603(08)61007-7; ROSOL TJ, 1995, GENE, V160, P241, DOI 10.1016/0378-1119(94)00912-C; Schlegl J, 1997, RNA, V3, P1159; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; Silver Justin, 1996, P325; Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257	25	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8727	8733		10.1074/jbc.M005471200	http://dx.doi.org/10.1074/jbc.M005471200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11118432	hybrid			2022-12-25	WOS:000167607700016
J	Srivastava, S; Toraldo, G; Weitzmann, MN; Cenci, S; Ross, FP; Pacifici, R				Srivastava, S; Toraldo, G; Weitzmann, MN; Cenci, S; Ross, FP; Pacifici, R			Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING-FACTOR; HUMAN OSTEOBLASTIC CELLS; GENE-EXPRESSION; C-JUN; BONE-MARROW; PROTEIN-KINASE; POSTTRANSCRIPTIONAL REGULATION; OSTEOPROTEGERIN LIGAND; INTERLEUKIN-1 RECEPTOR	The differentiation of cells of the monocytic lineage into mature osteoclasts (OC) is specifically induced by the tumor necrosis factor-related factor, RANKL (receptor activator of NF-kappaB ligand; also known as OPGL, ODF, or TRANCE). Because inhibition of osteoclastogenesis is one of the main mechanisms by which estrogen (E2) prevents bone loss, it is likely that E2 may regulate either the production of, or the target cell responsiveness to RANKL. We found that E2 decreases the differentiation into OC of both murine bone marrow monocytes and RAW 264.7 cells, a monocytic line, by downregulating the activation of Jun N-terminal kinase 1 (JNK1). Diminished JNK1 activity results in decreased nuclear levels of the key osteoclastogenic transcription factors, c-Fos and c-Jun, and lower binding of these transcriptional inducers to DNK Thus, one novel mechanism by which E2 down-regulates osteoclastogenesis is by decreasing the responsiveness of OC precursors to RANKL.	Barnes Jewish Hosp, Div Bone & Mineral Dis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Pacifici, R (corresponding author), Barnes Jewish Hosp, Div Bone & Mineral Dis, 216 S Kings Highway, St Louis, MO 63110 USA.		Cenci, Simone/J-7700-2016	Cenci, Simone/0000-0003-1215-7518	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042404, R01AR041412] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 42404, AR 41412] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; Cenci S, 2000, J CLIN INVEST, V105, P1279, DOI 10.1172/JCI8672; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; David JP, 1999, J BONE MINER RES, V14, pS149; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FALKENBURG JHF, 1991, BLOOD, V78, P658; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Harlow E., 1988, ANTIBODIES LAB MANUA; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P539, DOI 10.1172/JCI118066; Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lea CK, 1999, ENDOCRINOLOGY, V140, P273, DOI 10.1210/en.140.1.273; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613; Pacifici R, 1996, J BONE MINER RES, V11, P1043; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Sarma U, 1998, J CELL PHYSIOL, V175, P99, DOI 10.1002/(SICI)1097-4652(199804)175:1<99::AID-JCP11>3.3.CO;2-L; SHERMAN ML, 1990, J CLIN INVEST, V85, P442, DOI 10.1172/JCI114457; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Taguchi Y, 1998, P ASSOC AM PHYSICIAN, V110, P559; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; WAKELING AE, 1987, J ENDOCRINOL, V112, pR7, DOI 10.1677/joe.0.112R007; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	51	258	284	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8836	8840		10.1074/jbc.M010764200	http://dx.doi.org/10.1074/jbc.M010764200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121427	hybrid			2022-12-25	WOS:000167607700032
J	Zhao, T; Heyduk, T; Eissenberg, JC				Zhao, T; Heyduk, T; Eissenberg, JC			Phosphorylation site mutations in heterochromatin protein 1 (HP1) reduce or eliminate silencing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHISTONE CHROMOSOMAL-PROTEIN; POSITION-EFFECT VARIEGATION; ORIGIN RECOGNITION COMPLEX; DNA-BINDING PROTEIN; CASEIN KINASE-II; PIM-1 KINASE; DROSOPHILA-MELANOGASTER; CHROMODOMAIN PROTEINS; CELL-CYCLE; CHROMATIN	HP1 is an essential heterochromatin-associated protein in Drosophila, HP1 has dosage-dependent effects on the silencing of euchromatic genes that are mislocalized to heterochromatin and is required for the normal expression of at least two heterochromatic genes. HP1 is multiply phosphorylated in vitro, and HP1 hyperphosphorylation is correlated with heterochromatin assembly during development. The purpose of this study was to test whether HP1 phosphorylation modifies biological activity and biochemical properties of HP1. To determine sites of HP1 phosphorylation in vivo and whether phosphorylation affects any biochemical properties of HP1, we expressed Drosophila HP1 in lepidopteran cultured cells using a recombinant baculovirus vector. Phosphopeptides were identified by matrix-assisted laser desorption ionization/time of flight mass spectroscopy; these peptides contain target sites for casein kinase II, protein tyrosine kinase, and PIM-1 kinase. Purified HP1 from bacterial (unphosphorylated) and lepidopteran (phosphorylated) cells has similar secondary structure. Phosphorylation has no effect on HP1 self-association but alters the DNA binding properties of HP1, suggesting that phosphorylation could differentially regulate HP1-dependent interactions. Serine-to-alanine and serine-to-glutamate substitutions at consensus protein kinase motifs resulted in reduction or loss of silencing activity of mutant HP1 in transgenic flies. These results suggest that dynamic phosphorylation/dephosphorylation regulates HP1 activity in heterochromatic silencing.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Eissenberg, JC (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	eissenjc@slu.edu			NIGMS NIH HHS [R55 GM57005] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM057005] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Ball LJ, 1997, EMBO J, V16, P2473, DOI 10.1093/emboj/16.9.2473; Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; BECKSTEAD R, 1999, ANN DROS RES C, V40, pA149; Brasher SV, 2000, EMBO J, V19, P1587, DOI 10.1093/emboj/19.7.1587; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; Cleard F, 1997, EMBO J, V16, P5280, DOI 10.1093/emboj/16.17.5280; Cowley DO, 2000, GENE DEV, V14, P366; EDMONDSON SP, 1995, BIOCHEMISTRY-US, V34, P13289, DOI 10.1021/bi00041a004; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1994, J BIOL CHEM, V269, P21315; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EISSENBERG JC, 1993, MOL GEN GENET, V240, P333, DOI 10.1007/BF00280383; Ephrussi B, 1944, GENETICS, V29, P148; Fanti L, 1998, MOL CELL, V2, P527, DOI 10.1016/S1097-2765(00)80152-5; Festenstein R, 1999, NAT GENET, V23, P457, DOI 10.1038/70579; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Huang DW, 1998, J CELL BIOL, V142, P307, DOI 10.1083/jcb.142.2.307; Huang H, 1999, MOL CELL BIOL, V19, P3624; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; LIAO PC, 1994, ANAL BIOCHEM, V219, P9, DOI 10.1006/abio.1994.1224; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; Lu BY, 2000, GENETICS, V155, P699; MEEK DW, 1992, BIOCHEM J, V287, P1; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Salzberg A, 1997, GENETICS, V147, P1723; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Sugimoto K, 1996, J BIOCHEM, V120, P153; WUSTMANN G, 1989, MOL GEN GENET, V217, P520, DOI 10.1007/BF02464926; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983; Zhao T, 2000, J BIOL CHEM, V275, P28332; Zhao T, 1999, J BIOL CHEM, V274, P15095, DOI 10.1074/jbc.274.21.15095	49	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9512	9518		10.1074/jbc.M010098200	http://dx.doi.org/10.1074/jbc.M010098200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121421	hybrid			2022-12-25	WOS:000167607700117
J	Buhr, A; Wagner, C; Fuchs, K; Sieghart, W; Sigel, E				Buhr, A; Wagner, C; Fuchs, K; Sieghart, W; Sigel, E			Two novel residues in M2 of the gamma-aminobutyric acid type A receptor affecting gating by GABA and picrotoxin affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL-LINING RESIDUES; ION CHANNELS; BINDING-SITE; A RECEPTOR; AMINO-ACID; SUBUNIT; ALPHA(1); IDENTIFICATION; PHARMACOLOGY; EXPRESSION	An amino acid residue was found in M2 of gamma -aminobutyric acid (GABA) type A receptors that has profound effects on the binding of picrotoxin to the receptor and therefore may form part of its binding pocket. In addition, it strongly affects channel gating. The residue is located N-terminally to residues suggested so far to be important for channel gating. Point mutated alpha (1)beta (3) receptors were expressed in Xenopus oocytes and analyzed using the electrophysiological techniques. Coexpression of the alpha (1) subunit with the mutated beta (3) subunit beta (3)L253F led to spontaneous picrotoxin-sensitive currents in the absence of GABA. Nanomolar concentrations of GABA further promoted channel opening. Upon washout of picrotoxin, a huge transient inward current was observed. The reversal potential of the inward current was indicative of a chloride ion selectivity. The amplitude of the inward current was strongly dependent on the picrotoxin concentration and on the duration of its application. There was more than a 100-fold decrease in picrotoxin affinity. A kinetic model is presented that mimics the gating behavior of the mutant receptor. The point mutation in the neighboring residue beta (3)A252V resulted in receptors that displayed an about 6-fold increased apparent affinity to GABA and an about 10-fold reduced sensitivity to picrotoxin.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Vienna, Brain Res Inst, Sect Biochem & Mol Biol, A-1090 Vienna, Austria	University of Bern; University of Vienna	Sigel, E (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.		Sieghart, Werner/A-4877-2013; Sigel, Erwin/F-7736-2015	Sieghart, Werner/0000-0002-0443-0302; 				Barnard EA, 1998, PHARMACOL REV, V50, P291; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Chang YC, 1996, J NEUROSCI, V16, P5415; Chang YC, 1998, MOL PHARMACOL, V53, P511, DOI 10.1124/mol.53.3.511; Dalziel JE, 2000, MOL PHARMACOL, V57, P875; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; HILL TL, 1977, FREE ENERGY TRANSDUC, P193; Jursky F, 2000, J NEUROCHEM, V74, P1310; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; Krishek BJ, 1996, MOL PHARMACOL, V49, P494; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Pan ZH, 1997, P NATL ACAD SCI USA, V94, P6490, DOI 10.1073/pnas.94.12.6490; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SIGEL E, 1989, FEBS LETT, V257, P377, DOI 10.1016/0014-5793(89)81576-5; SIGEL E, 1983, J BIOL CHEM, V258, P6965; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Tierney ML, 1996, J MEMBRANE BIOL, V154, P11, DOI 10.1007/s002329900128; WINGROVE PB, 1994, P NATL ACAD SCI USA, V91, P4569, DOI 10.1073/pnas.91.10.4569; Wooltorton JRA, 1997, EUR J NEUROSCI, V9, P2225, DOI 10.1111/j.1460-9568.1997.tb01641.x; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195	31	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7775	7781		10.1074/jbc.M008907200	http://dx.doi.org/10.1074/jbc.M008907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11114302	hybrid			2022-12-25	WOS:000167474900016
J	Duewel, HS; Radaev, S; Wang, J; Woodard, RW; Gatti, DL				Duewel, HS; Radaev, S; Wang, J; Woodard, RW; Gatti, DL			Substrate and metal complexes of 3-deoxy-D-manno-octulosonate-8-phosphate synthase from Aquifer aeolicus at 1.9-angstrom resolution - Implications for the condensation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE REACTION INTERMEDIATE; ACID 8-PHOSPHATE SYNTHASE; ESCHERICHIA-COLI; 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE; KDO8P SYNTHASE; 3-DEOXY-D-MANNO-2-OCTULOSONATE-8-PHOSPHATE SYNTHASE; CATALYTIC MECHANISM; PROTEIN STRUCTURES; PHOSPHOENOLPYRUVATE; STEREOCHEMISTRY	3-Deoxy-D-manno-octulosonate-8-phosphate synthase (KDO8PS) from the hyperthermophilic bacterium Aquifex aeolicus differs from its Escherichia coli counterpart in the requirement of a divalent metal for activity (Duewel, H. S., and Woodard, R. W. (2000) J. Biol. Chem. 275, 22824-22831), Here we report the crystal structure of the A. aeolicus enzyme, which was determined by molecular replacement using E. coli KDO8PS as a model. The structures of the metal-free and Cd2+ forms of the enzyme were determined in the uncomplexed state and in complex with various combinations of phosphoenolpyruvate (PEP), arabinose 5-phosphate (A5P), and erythrose 4-phosphate (E4P). Like the E. coli enzyme, A. aeolicus KDO8PS is a homotetramer containing four distinct active sites at the interface between subunits. The active site cavity is open in the substrate-free enzyme or when either A5P alone or PEP alone binds, and becomes isolated from the aqueous phase when both PEP and A5P (or E4P) bind together. In the presence of metal, the enzyme is asymmetric and appears to alternate catalysis between the active sites located on one face of the tetramer and those located on the other face. In the absence of metal, the asymmetry is lost. Details of the active site that may be important for catalysis are visible at the high resolution achieved in these structures. Most notably, the shape of the PEP-binding pocket forces PEP to assume a distorted geometry at C-2, which might anticipate the conversion from sp(2) to sp(3) hybridization occurring during intermediate formation and which may modulate PEP reactivity toward A5P. Two water molecules are located in van der Waals contact with the si and re sides of C-2(PEP), respectively. Abstraction of a proton from either of these water molecules by a protein group is expected to elicit a nucleophilic attack of the resulting hydroxide ion on the nearby C-2(PEP), thus triggering the beginning of the catalytic cycle.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Michigan, Coll Pharm, Interdepartmental Program Med Chem, Ann Arbor, MI 48109 USA	Wayne State University; University of Michigan System; University of Michigan	Gatti, DL (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.			Woodard, Ronald/0000-0002-7472-3653	NIAID NIH HHS [AI42868] Funding Source: Medline; NIGMS NIH HHS [GM53069] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI042868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BAASOV T, 1993, EUR J BIOCHEM, V217, P991, DOI 10.1111/j.1432-1033.1993.tb18330.x; BIRCK A, 2001, IN PRESS J MOL EVOL; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DELEO AB, 1968, BIOCHEM BIOPH RES CO, V32, P873, DOI 10.1016/0006-291X(68)90322-7; DOTSON GD, 1995, J BIOL CHEM, V270, P13698, DOI 10.1074/jbc.270.23.13698; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; Duewel HS, 2000, J BIOL CHEM, V275, P22824, DOI 10.1074/jbc.M000133200; Duewel HS, 1999, BIOCHEM BIOPH RES CO, V263, P346, DOI 10.1006/bbrc.1999.1361; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FLOSS HG, 1972, J BIOL CHEM, V247, P736; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; KOHEN A, 1992, EUR J BIOCHEM, V208, P443, DOI 10.1111/j.1432-1033.1992.tb17206.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVIN DH, 1959, J BIOL CHEM, V234, P2532; Li Y, 1996, P NATL ACAD SCI USA, V93, P4612, DOI 10.1073/pnas.93.10.4612; Liang PH, 1998, BIOCHEMISTRY-US, V37, P16390, DOI 10.1021/bi981374w; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Radaev S, 2000, ACTA CRYSTALLOGR D, V56, P516, DOI 10.1107/S0907444900002389; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Shumilin IA, 1999, STRUCTURE, V7, P865, DOI 10.1016/S0969-2126(99)80109-9; Souhassou M, 1996, ACTA CRYSTALLOGR B, V52, P865, DOI 10.1107/S0108768196005241; STEPHENS CM, 1992, J BIOL CHEM, V267, P5762; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; Taylor WP, 2000, J BIOL CHEM, V275, P32141, DOI 10.1074/jbc.M001900200; Wagner T, 2000, J MOL BIOL, V301, P389, DOI 10.1006/jmbi.2000.3957; Wagner T, 2000, J MOL BIOL, V301, P233, DOI 10.1006/jmbi.2000.3956	32	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8393	8402		10.1074/jbc.M007884200	http://dx.doi.org/10.1074/jbc.M007884200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11115499	hybrid			2022-12-25	WOS:000167474900098
J	Lang, M; Kroth, PG				Lang, M; Kroth, PG			Diatom fucoxanthin chlorophyll a/c-binding protein (FCP) and land plant light-harvesting proteins use a similar pathway for thylakoid membrane insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; CHLOROPLASTS; EVOLUTION; COMPLEX; INTEGRATION; PRECURSOR; PLASTIDS; REQUIREMENT; POLYPEPTIDE; MECHANISMS	The light-harvesting proteins in plastids of different lineages including algae and land plants represent a superfamily of chlorophyll-binding proteins that seem to be phylogenetically related, although some of the light-harvesting complex (LHC) proteins bind different carotenoids. LHCs can be divided into chlorophyll a/b-binding proteins found in green algae, euglenoids, and higher plants and into chlorophyll a/c-binding proteins of various algal tare. LHC proteins from diatoms are named fucoxanthin-chlorophyll a/c-binding proteins (FCP). In contrast to chlorophyll a/b-binding proteins, there is no information so far about the way FCPs integrate into thylakoid membranes. The diatom FCP preproteins have a bipartite presequence that is necessary to enable transport into the four membrane-bound diatom plastids, but similar to chlorophyll a/b-binding proteins there is apparently no presequence present for targeting to the thylakoid membrane. By establishing an in vitro import assay for diatom thylakoids, we demonstrated that thylakoid integration of diatom FCP depends on the presence of stromal factors and GTP. This indicates that a pathway involving signal recognition particles (SRP) is involved in membrane integration just as shown for LHCs in higher plants. We also demonstrate integration of diatom FCP into thylakoids of higher plants and vice versa SRP-dependent targeting of LHCs from pea and Arabidopsis into diatom thylakoids, The similar SRP-dependent modes of thylakoid integration of land plant LHCs and FCPs support recent analyses indicating a common origin of chlorophyll a/b- and a/c-binding proteins.	Univ Dusseldorf, Inst Biochem Pflanzen, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Kroth, PG (corresponding author), Univ Dusseldorf, Inst Biochem Pflanzen, Univ Str 1, D-40225 Dusseldorf, Germany.	Peter.Kroth@uni-duesseldorf.de	Kroth, Peter G/A-9728-2008	Kroth, Peter G/0000-0003-4734-8955				AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; BHAYA D, 1993, NUCLEIC ACIDS RES, V46, P71; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; Caron L, 1996, J MOL EVOL, V43, P270, DOI 10.1007/PL00006086; Cavalier-Smith T, 2000, TRENDS PLANT SCI, V5, P174, DOI 10.1016/S1360-1385(00)01598-3; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CLINE K, 1989, J BIOL CHEM, V264, P14225; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; Deane JA, 2000, PROTIST, V151, P239, DOI 10.1078/1434-4610-00022; Delwiche CF, 1997, PLANT SYST EVOL, P53; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; Durnford DG, 1999, J MOL EVOL, V48, P59, DOI 10.1007/PL00006445; Eppard M, 2000, PLANT BIOLOGY, V2, P283, DOI 10.1055/s-2000-3702; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Grossman AR, 1995, ANNU REV GENET, V29, P231, DOI 10.1146/annurev.ge.29.120195.001311; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; Kim SJ, 1999, J BIOL CHEM, V274, P4715, DOI 10.1074/jbc.274.8.4715; KOHORN BD, 1991, J BIOL CHEM, V266, P12048; KOTHEN G, 1995, BBA-BIOENERGETICS, V1229, P208, DOI 10.1016/0005-2728(95)00005-4; Kroth P, 1999, PHYSIOL PLANTARUM, V107, P136, DOI 10.1034/j.1399-3054.1999.100118.x; KROTHPANCIC PG, 1995, PLANT MOL BIOL, V27, P825, DOI 10.1007/BF00020236; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LAMPPA GK, 1987, J CELL BIOL, V105, P2641, DOI 10.1083/jcb.105.6.2641; Lang M, 1998, J BIOL CHEM, V273, P30973, DOI 10.1074/jbc.273.47.30973; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; Martinson TA, 1998, BBA-BIOENERGETICS, V1409, P72, DOI 10.1016/S0005-2728(98)00153-4; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; Robinson C, 1998, PLANT MOL BIOL, V38, P209, DOI 10.1023/A:1006041917853; Robinson C, 2000, BIOL CHEM, V381, P89, DOI 10.1515/BC.2000.013; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; SCHULDINER S, 1972, EUR J BIOCHEM, V25, P64, DOI 10.1111/j.1432-1033.1972.tb01667.x; Tan S, 1997, PHOTOSYNTH RES, V53, P129, DOI 10.1023/A:1005815321295; Tu CJ, 1999, J BIOL CHEM, V274, P27219, DOI 10.1074/jbc.274.38.27219; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wittpoth C, 1998, PLANTA, V206, P79, DOI 10.1007/s004250050376; WOLFE GR, 1994, NATURE, V367, P566, DOI 10.1038/367566a0; YALOVSKY S, 1992, J BIOL CHEM, V267, P20689	39	22	25	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7985	7991		10.1074/jbc.M006417200	http://dx.doi.org/10.1074/jbc.M006417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11120738	hybrid			2022-12-25	WOS:000167474900045
J	Clem, RJ; Sheu, TT; Richter, BWM; He, WW; Thornberry, NA; Duckett, CS; Hardwick, JM				Clem, RJ; Sheu, TT; Richter, BWM; He, WW; Thornberry, NA; Duckett, CS; Hardwick, JM			c-IAP1 is cleaved by caspases to produce a proapoptotic C-terminal fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; PROGRAMMED CELL-DEATH; APOPTOSIS PROTEINS; MAMMALIAN-CELLS; CYTOCHROME-C; BACULOVIRUS INHIBITOR; NMR STRUCTURE; BIR DOMAIN; IAP GENES; BCL-X(L)	Although:human c-IAP1 and c-IAP2 have been reported to-possess antiapoptotic activity against a variety of stimuli in several mammalian cell types, we observed that full-length c-IAP1 and c-IAP2 failed to protect cells from apoptosis induced by Bax overexpression, tumor necrosis factor alpha treatment or Sindbis virus infection. However, deletion of the C-terminal RING domains:of c-IAP1 and c-IAP2 restored antiapoptotic activity, indicating that this region negatively regulates the antiapoptotic function of the N-terminal BIR domain. This finding is consistent with the observation by others that the spacer region and RING domain of c-IAP1 functions as an E3 ligase, promoting autoubiquitination and degradation of c-IAP1. In addition, we found that c-IAP1 is cleaved during apoptosis to 52- and 35-kDa fragments. Both fragments contain the C-terminal end of c-IAP1 including the-RING finger. In vitro cleavage of c-IAP1 with apoptotic cell extracts or with purified recombinant caspase-3 produced similar fragments. Furthermore, transfection of cells with the spacer-RING domain alone Suppressed the antiapoptotic function of the N-terminal BIR domain of c-IAP1 and induced apoptosis, Optimal death-inducing activity of the spacer-RING required both the spacer region and the zinc-binding RING domain of c-IAP1 but did not require the caspase recruitment domain located within the spacer region, To the contrary, deletion of the caspase recruitment domain increased proapoptotic activity, apparently by stabilizing the C-terminal fragment.	Johns Hopkins Univ, Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Neurol & Pharmacol & Mol Sci, Baltimore, MD 21205 USA; NCI, Metab Branch, NIH, Bethesda, MD 20892 USA; Human Genome Sci Inc, Rockville, MD 20850 USA; Merck Res Labs, Dept Biochem, Rahway, NJ 07065 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); GlaxoSmithKline; Human Genome Sciences Inc; Merck & Company	Hardwick, JM (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Mol Microbiol & Immunol, E5140,615 N Wolfe St, Baltimore, MD 21205 USA.	hardwick@jhu.edu		Clem, Rollie/0000-0002-2368-720X; Sheu, Ting-Ting/0000-0001-5183-357X; Duckett, Colin/0000-0001-9413-2263				Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clem RJ, 1997, TRENDS CELL BIOL, V7, P337, DOI 10.1016/S0962-8924(97)01088-X; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Hardwick JM, 2000, METHOD ENZYMOL, V322, P492; Harvey AJ, 1997, CELL DEATH DIFFER, V4, P733, DOI 10.1038/sj.cdd.4400294; Hawkins CJ, 1998, CELL DEATH DIFFER, V5, P569, DOI 10.1038/sj.cdd.4400389; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang QH, 2000, P NATL ACAD SCI USA, V97, P1427, DOI 10.1073/pnas.97.4.1427; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Levine B, 1996, P NATL ACAD SCI USA, V93, P4810, DOI 10.1073/pnas.93.10.4810; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Orth R, 1997, J BIOL CHEM, V272, P8841; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vucic D, 1998, J BIOL CHEM, V273, P33915, DOI 10.1074/jbc.273.51.33915; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	45	95	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7602	7608		10.1074/jbc.M010259200	http://dx.doi.org/10.1074/jbc.M010259200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11106668	hybrid			2022-12-25	WOS:000167442900100
J	Parent, JL; Labrecque, P; Rochdi, MD; Benovic, JL				Parent, JL; Labrecque, P; Rochdi, MD; Benovic, JL			Role of the differentially spliced carboxyl terminus in thromboxane A(2) receptor trafficking - Identifcation of a distinct motif for tonic internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID INTERNALIZATION; CYTOPLASMIC TAIL; SORTING SIGNALS; ENDOCYTOSIS; ISOFORMS; DETERMINANTS; RECOGNITION; MODULATION	The thromboxane A(2) receptor (TP) is a G protein-coupled receptor that is expressed as two alternatively spliced isoforms, alpha (343 residues) and beta (407 residues) that share the first 328 residues. We have previously shown that TP beta, but not TP alpha, undergoes agonist-induced internalization in a dynamin-, GRK-, and arrestin-dependent manner. In the present report, we demonstrate that TP beta, but not TP alpha, also undergoes tonic internalization. Tonic internalization of TP beta was temperature- and dynamin-dependent and was inhibited by sucrose and NH4Cl treatment but unaffected by wildtype or dominant-negative GRKs or arrestins. Truncation and site-directed mutagenesis revealed that a YX(3)phi moth (where X is any residue and phi is a bulky hydro phobic residue) found in the proximal portion of the carboxyl-terminal tail of TP beta was critical for tonic internalization but had no role in agonist-induced internalization. Interestingly, introduction of either a YX(2)phi or YX(3)phi motif in the carboxyl-terminal tail of TP alpha induced tonic internalization of this receptor. Additional analysis revealed that tonically internalized TP beta undergoes recycling back to the cell surface suggesting that tonic internalization may play a role in maintaining an intracellular pool of TP beta, Our data demonstrate the presence of distinct signals for tonic and agonist-induced internalization of TP beta and represent the first report of a YX(3)phi motif involved in tonic internalization of a cell surface receptor.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Immunol & Microbiol, Philadelphia, PA 19107 USA; Univ Sherbrooke, Ctr Rech Clin, Serv Rhumatol, Sherbrooke, PQ J1K 2R1, Canada	Jefferson University; University of Sherbrooke	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Immunol & Microbiol, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@lac.jci.tju.edu			NIGMS NIH HHS [GM44944, GM47417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047417, R01GM044944, R37GM047417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HALUSHKA PV, 1995, J LIPID MEDIAT CELL, V12, P361, DOI 10.1016/0929-7855(95)00023-J; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; JADOT M, 1992, J BIOL CHEM, V267, P11069; KONG GH, 1994, J BIOL CHEM, V269, P13084; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MORINELLI TA, 1991, TRENDS CARDIOVAS MED, V1, P157, DOI 10.1016/1050-1738(91)90021-6; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NAIM HY, 1994, J BIOL CHEM, V269, P3928; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Shapiro MJ, 1998, J BIOL CHEM, V273, P29009, DOI 10.1074/jbc.273.44.29009; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SPURNEY RF, 1994, AM J PHYSIOL, V267, pF467, DOI 10.1152/ajprenal.1994.267.3.F467; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021	36	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7079	7085		10.1074/jbc.M009375200	http://dx.doi.org/10.1074/jbc.M009375200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11112783	hybrid			2022-12-25	WOS:000167442900032
J	Krueger, JK; Gallagher, SC; Zhi, G; Geguchadze, R; Persechini, A; Stull, JT; Trewhella, J				Krueger, JK; Gallagher, SC; Zhi, G; Geguchadze, R; Persechini, A; Stull, JT; Trewhella, J			Activation of myosin light chain kinase requires translocation of bound calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SMALL-ANGLE-SCATTERING; INTRASTERIC REGULATION; NEUTRON-SCATTERING; CATALYTIC SUBUNIT; PEPTIDE COMPLEX; RECOGNITION; SEQUENCE; BINDING; CRYSTAL	A novel translocation step is inferred from structural studies of the interactions between the intracellular calcium receptor protein calmodulin (CaM) and one of its regulatory targets. A mutant of CaM missing residues 2-8 (Delta NCaM) binds skeletal muscle myosin light chain kinase with high affinity but fails to activate catalysis. Small angle x-ray scattering data reveal that Delta NCaM occupies a position near the catalytic cleft in its complex with the kinase, whereas the native protein translocates to a position near the C-terminal end of the catalytic core. Thus, CaM residues 2-8 appear to facilitate movement of bound CaM away from the vicinity of the catalytic cleft.	Los Alamos Natl Lab, Div Biosci, Los Alamos, NM 87545 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Missouri, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Missouri System; University of Missouri Kansas City	Trewhella, J (corresponding author), Los Alamos Natl Lab, Div Biosci, Mail Stop M-888, Los Alamos, NM 87545 USA.	jtrewhella@lanl.gov	Krueger, Joanna/A-3110-2011	Trewhella, Jill/0000-0002-8555-6766	NHLBI NIH HHS [HL26043] Funding Source: Medline; NIDDK NIH HHS [DK44322] Funding Source: Medline; NIGMS NIH HHS [GM40528] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026043, R37HL026043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040528] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; Gallagher SC, 1999, BIOCHEMISTRY-US, V38, P6752, DOI 10.1021/bi982991n; GAO ZH, 1995, J BIOL CHEM, V270, P10125, DOI 10.1074/jbc.270.17.10125; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRUEGER JK, 1995, J BIOL CHEM, V270, P16848, DOI 10.1074/jbc.270.28.16848; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P13997, DOI 10.1021/bi981311d; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P17810, DOI 10.1021/bi981656w; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Persechini A, 1996, J BIOL CHEM, V271, P19279, DOI 10.1074/jbc.271.32.19279; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; Sanchez R, 1997, CURR OPIN STRUC BIOL, V7, P206, DOI 10.1016/S0959-440X(97)80027-9; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; Zhao JK, 1998, J BIOL CHEM, V273, P30448, DOI 10.1074/jbc.273.46.30448	24	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4535	4538		10.1074/jbc.C000857200	http://dx.doi.org/10.1074/jbc.C000857200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11124250	hybrid			2022-12-25	WOS:000168484300003
J	Poyet, JL; Srinivasula, SM; Alnemri, ES				Poyet, JL; Srinivasula, SM; Alnemri, ES			vCLAP, a caspase-recruitment domain-containing protein of equine herpesvirus-2, persistently activates the I kappa B kinases through oligomerization of IKK gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-VIRUS TYPE-1; TAX PROTEIN; TRANSCRIPTION FACTOR; ALPHA; COMPLEX; BETA; PHOSPHORYLATION; PATHWAY; SUBUNIT; IDENTIFICATION	vCLAP, the E10 gene product of equine herpesvirus-2, is a caspase-recruitment domain (CARD)-containing protein that has been shown to induce both apoptosis and NF-kappaB activation in mammalian cells. vCLAP has a cellular counterpart, Bcl10/cCLAP, which is also an activator of apoptosis and NF-kappaB, Recent studies demonstrated that vCLAP activates NF-kappaB through an I kappaB kinase (IKK)-dependent pathway, but the underlying mechanism remains unknown. In this report, we demonstrate that vCLAP associates stably with the IKK complex through direct binding to the C-terminal region of IKK gamma, Consistent with this finding, IKK gamma was found to be essential for vCLAP-induced NF-kappaB activation, and the association between vCLAP and the IKK complex induced persistent activation of the IKKs, Moreover, enforced oligomerization of the isolated C-terminal region of vCLAP, which interacts with IKK gamma, can trigger NF-KB activation. Finally, substitution of the C-terminal region of IKK gamma, which interacts with vCLAP, with the CARD of vCLAP or Bcl10 produced a molecule that was able to activate NF-kappaB when ectopically expressed in IKK gamma -deficient cells. These data suggest that vCLAP-induced oligomerization of IKK gamma, which is mediated by the CARD of vCLAP, could be the mechanism by which vCLAP induces activation of NF-kappaB.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Srinivasula, SM (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.		Poyet, Jean-Luc/G-7114-2017	Poyet, Jean-Luc/0000-0002-3747-255X	NCI NIH HHS [CA85421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad M, 1997, CANCER RES, V57, P615; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Inohara N, 2000, J BIOL CHEM, V275, P27823; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Meinl E, 1998, IMMUNOL TODAY, V19, P474, DOI 10.1016/S0167-5699(98)01309-7; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	35	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3183	3187		10.1074/jbc.C000792200	http://dx.doi.org/10.1074/jbc.C000792200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11113112	hybrid			2022-12-25	WOS:000166784900028
J	Bebenek, K; Matsuda, T; Masutani, C; Hanaoka, F; Kunkel, TA				Bebenek, K; Matsuda, T; Masutani, C; Hanaoka, F; Kunkel, TA			Proofreading of DNA polymerase eta-dependent replication errors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM VARIANT CELLS; THYMINE DIMER; FIDELITY; MUTAGENESIS; MUTATIONS; HYPERMUTABILITY; PHOTOPRODUCTS; EFFICIENT; PROTEIN; BYPASS	Human DNA polymerase eta, the product of the skin cancer susceptibility gene XPV, bypasses UV photoproducts in template DNA that block synthesis by other DNA polymerases. Pol eta lacks an intrinsic proofreading exonuclease and copies DNA with low fidelity, such that pol eta errors could contribute to mutagenesis unless they are corrected. Here we provide evidence that pol eta can compete with other human polymerases during replication of duplex DNA, and in so doing it lowers replication fidelity. However, we show that pol eta has low processivity and extends mismatched primer termini less efficiently than matched termini, These properties could provide an opportunity for extrinsic exonuclease(s) to proofread pol eta -induced replication errors. When we tested this hypothesis during replication in human cell extracts, pol eta -induced replication infidelity was found to be modulated by changing the dNTP concentration and to be enhanced by adding dGMP to a replication reaction. Both effects are classical hallmarks of exonucleolytic proofreading. Thus, pol eta is ideally suited for its role in reducing W-induced mutagenesis and skin cancer risk, in that its relaxed base selectivity may facilitate efficient bypass of UV photoproducts, while subsequent proofreading by extrinsic exonuclease(s) may reduce its mutagenic potential.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; CREST, Japan Sci & Technol Corp, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Osaka University; Japan Science & Technology Agency (JST); RIKEN	Kunkel, TA (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Masutani, Chikahide/I-6160-2014; Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788; Masutani, Chikahide/0000-0002-8600-8227	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065070, Z01ES065046, Z01ES065070] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; IZUTA S, 1995, J BIOL CHEM, V270, P2595, DOI 10.1074/jbc.270.6.2595; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Kokoska RJ, 2000, MOL CELL BIOL, V20, P7490, DOI 10.1128/MCB.20.20.7490-7504.2000; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Liu HB, 2000, GENETICS, V154, P503; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MYHR BC, 1979, MUTAT RES, V62, P341, DOI 10.1016/0027-5107(79)90089-7; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191	32	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2317	2320		10.1074/jbc.C000690200	http://dx.doi.org/10.1074/jbc.C000690200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11113111	hybrid			2022-12-25	WOS:000166784800003
J	Nguyen, KT; Wang, WJ; Chan, JLK; Wang, LH				Nguyen, KT; Wang, WJ; Chan, JLK; Wang, LH			Differential requirements of the MAP kinase and PI3 kinase signaling pathways in Src- versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epithelial cells	ONCOGENE			English	Article						Src; IR; IGFR; MAPK; PI3K; transformation	FACTOR-I RECEPTOR; ACTIVATED PROTEIN-KINASE; AVIAN-SARCOMA VIRUS; C-SRC; TYROSINE KINASES; STAT3 ACTIVATION; ONCOGENIC ROS; V-SRC; GENE; TUMOR	There have been few studies on the specific signaling pathways involved in the transformation of epithelial cells by oncogenic protein tyrosine kinases. Here we investigate the requirement of MAP (MAPK) and phosphatidylinositol 3-(PI3K) kinases in the transformation of rat intestinal epithelial (RIE) cells by oncogenic forms of insulin receptor (gag-IR), insulin-like growth factor-1 receptor (gag-ICFR), and v-Src. MAPK is not significantly activated in cells transformed by gag-IR and gag-IGFR but is activated in v-Src transformed cells. Treatment with PD98059, a MEK inhibitor, at concentrations where MAPK activity was reduced below the basal level showed that MAPK is partially required for the monolayer growth of parental and transformed RIE cells. However, MAPK is not essential for the focus forming ability of the three oncogene-transformed cells. It is also not necessary for the colony forming ability of gag-IR- and gag-IGFR-, but is partially required for v-Src-transformed cells. PI3K is significantly activated in all three oncogene transformed RIE cells. LY294002, a PI3K inhibitor, potently inhibited monolayer growth of all three oncogene-transformed cells. However, at concentrations of LY294002 where activated forms of Akt, a downstream component of the PI3K pathway, were undetectable, colony and focus forming abilities of the v-Src-RIE cells were only slightly affected whereas those of gag-IR/IGFR-RIE cells were greatly inhibited. These results were confirmed using a different pharmacological inhibitor, wortmannin, and a dominant negative form of PI3K, Delta p85. Similarly, rapamycin, known to inhibit p70S6 kinase, a downstream component of the PI3K-Akt pathway, also inhibited gag-IR/IGFR-induced, but not v-Src-induced, focus and colony formation. We conclude that the MAPK and PI3K signaling pathways are differentially required for transformation of RIE cells by oncogenic IR and IGFR versus Src and the pattern of requirements is different from that of fibroblast transformation.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA055054] Funding Source: NIH RePORTER; NCI NIH HHS [CA55054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; AMFO K, 1995, ONCOGENE, V11, P351; BASERGA R, 1995, CANCER RES, V55, P249; BECK EP, 1994, GYNECOL ONCOL, V53, P196, DOI 10.1006/gyno.1994.1115; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chan JLK, 1997, J BIOL CHEM, V272, P146; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Frittitta L, 1999, CANCER-AM CANCER SOC, V85, P492, DOI 10.1002/(SICI)1097-0142(19990115)85:2<492::AID-CNCR30>3.0.CO;2-I; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GARCIA R, 1991, ONCOGENE, V6, P1983; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; Greulich H, 1996, ONCOGENE, V12, P1689; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; Jiang YX, 1996, J BIOL CHEM, V271, P160, DOI 10.1074/jbc.271.1.160; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Ligon AH, 1998, J NEUROVIROL, V4, P217, DOI 10.3109/13550289809114521; LIN X, 1997, CANCER RES, V57, P2402; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAPA V, 1993, CANCER RES, V53, P3736; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; POON B, 1991, P NATL ACAD SCI USA, V88, P877, DOI 10.1073/pnas.88.3.877; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P894, DOI 10.1016/S0006-291X(05)80870-8; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; TAKEYA T, 1982, J VIROL, V44, P1; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WANG LH, 1987, P NATL ACAD SCI USA, V84, P5725, DOI 10.1073/pnas.84.16.5725; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058; YASHIRO T, 1989, ACTA ENDOCRINOL-COP, V121, P112, DOI 10.1530/acta.0.1210112; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	55	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5385	5397		10.1038/sj.onc.1203911	http://dx.doi.org/10.1038/sj.onc.1203911			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103940				2022-12-25	WOS:000165302300010
J	Gama-Carvalho, M; Carvalho, MP; Kehlenbach, A; Valcarcel, J; Carmo-Fonseca, M				Gama-Carvalho, M; Carvalho, MP; Kehlenbach, A; Valcarcel, J; Carmo-Fonseca, M			Nucleocytoplasmic shuttling of heterodimeric splicing factor U2AF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; RIBONUCLEOPROTEIN AUXILIARY FACTOR; PROTEIN-PROTEIN INTERACTIONS; SR PROTEINS; IN-VIVO; SEX-LETHAL; POLYPYRIMIDINE-TRACT; NUCLEAR EXPORT; HNRNP A1; SUBNUCLEAR LOCALIZATION	The U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) is a heterodimeric splicing factor composed of 65-kDa (U2AF(65)) and 35-kDa (U2AF(35)) subunits. The large subunit of USAF recognizes the intronic polypyrimidine tract, a sequence located adjacent to the 3 ' splice site that serves as an important signal for both constitutive and regulated pre-mRNA splicing. The small subunit U2AF35 interacts with the 3 ' splice site dinucleotide AG and is essential for regulated splicing, Like several other proteins involved in constitutive and regulated splicing, both U2AF65 and U2AF35 contain an arginine/ serine-rich (RS) domain. In the present study we determined the role of RS domains in the subcellular localization of U2AF. Both U2AF65 and U2AF35 are shown to shuttle continuously between the nucleus and the cytoplasm by a mechanism that involves carrier receptors and is independent from binding to mRNA. The RS domain on either U2AF65 or U2AF35 acts as a nuclear localization signal and is sufficient to target a heterologous protein to the nuclear speckles. Furthermore, the results suggest that the presence of an RS domain in either U2AF subunit is sufficient to trigger the nucleocytoplasmic import of the heterodimeric complex. Shuttling of U2AF between nucleus and cytoplasm possibly represents a means to control the availability of this factor to initiate spliceosome assembly and therefore contribute to regulate splicing.	Univ Lisbon, Fac Med, Inst Histol & Embryol, P-1649028 Lisbon, Portugal; European Mol Biol Lab, Gene Express Program, D-69117 Heidelberg, Germany	Universidade de Lisboa; European Molecular Biology Laboratory (EMBL)	Gama-Carvalho, M (corresponding author), Univ Lisbon, Fac Med, Inst Histol & Embryol, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal.	mgamacarvalho@fm.ul.pt	Gama-Carvalho, Margarida/E-6180-2012; Carvalho, Margarida/GZA-4406-2022; Valcarcel, Juan/O-9814-2014	Gama-Carvalho, Margarida/0000-0002-0365-6916; Valcarcel, Juan/0000-0001-5398-3571; Carmo-Fonseca, Maria/0000-0002-3402-7143				Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Burge C. B., 1999, RNA WORLD; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Calado A, 2000, RNA, V6, P245, DOI 10.1017/S1355838200991908; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Chiara MD, 1997, EMBO J, V16, P4746, DOI 10.1093/emboj/16.15.4746; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; FU XD, 1995, RNA, V1, P663; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; Gebauer F, 1998, RNA, V4, P142; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Guth S, 1999, MOL CELL BIOL, V19, P8263; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Ito T, 1999, EMBO J, V18, P4523, DOI 10.1093/emboj/18.16.4523; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Labourier E, 1999, NUCLEIC ACIDS RES, V27, P2377, DOI 10.1093/nar/27.11.2377; Lai MC, 2000, J BIOL CHEM, V275, P7950, DOI 10.1074/jbc.275.11.7950; Le Hir H, 2000, GENE DEV, V14, P1098; LEE CG, 1993, J BIOL CHEM, V268, P13472; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; MacMorris MA, 1999, P NATL ACAD SCI USA, V96, P3813, DOI 10.1073/pnas.96.7.3813; Maeda T, 1999, CARCINOGENESIS, V20, P2341, DOI 10.1093/carcin/20.12.2341; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V3, P151; Rudner DZ, 1998, MOL CELL BIOL, V18, P1765, DOI 10.1128/MCB.18.4.1765; Rudner DZ, 1998, GENE DEV, V12, P1010, DOI 10.1101/gad.12.7.1010; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; Shinozaki A, 1999, INT J BIOCHEM CELL B, V31, P1279, DOI 10.1016/S1357-2725(99)00101-6; Singh R, 2000, RNA, V6, P901, DOI 10.1017/S1355838200000376; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	72	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13104	13112		10.1074/jbc.M008759200	http://dx.doi.org/10.1074/jbc.M008759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11118443	hybrid			2022-12-25	WOS:000168198600090
J	Trentin, GA; Yin, XH; Tahir, S; Lhotak, S; Farhang-Fallah, J; Li, Y; Rozakis-Adcock, M				Trentin, GA; Yin, XH; Tahir, S; Lhotak, S; Farhang-Fallah, J; Li, Y; Rozakis-Adcock, M			A mouse homologue of the Drosophila tumor suppressor l(2)tid gene defines a novel pas GTPase-activating protein (RasGAP)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-ASSOCIATED PROTEIN; N-TERMINAL REGION; LARGE T-ANTIGEN; MOLECULAR-CLONING; DOCKING PROTEIN; CHAPERONE DNAJ; BINDING; RAS; PHOSPHORYLATION; HSP70	p120 GTPase-activating protein (GAP) down-regulates Pas by stimulating GTP hydrolysis of active Pas, In addition to its association with Pas, GAP has been shown to bind to several tyrosine-phosphorylated proteins in cells stimulated by growth factors or expressing transforming tyrosine kinase variants. Here we report the cloning and characterization of a novel GAP-binding protein, mTid-1, a DnaJ chaperone protein that represents the murine homolog of the Drosophila tumor suppressor l(2)tid gene. Three alternatively spliced variants of mTid-1 were isolated, two of which correspond to the recently identified hTid-1(L) and hTid-1(S) forms of the human TID1 gene that exhibit opposing effects on apo ptosis, We demonstrate that both cytoplasmic precursor and mitochondrial mature forms of mTid-1 associate with GAP in vivo. Interestingly, although mTid-1 is found tyrosine-phosphorylated in v-src-transformed fibroblast cells, GAP selectively binds to the unphosphorylated form of mTid-1. In immunofluorescence experiments, GAP and Tid-1 were shown to colocalize at perinuclear mitochondrial membranes in response to epidermal growth factor stimulation. These findings raise the possibility that Tid chaperone proteins may play a role in governing the conformation, activity, and/or subcellular distribution of GAP, thereby influencing its biochemical and biological activity within cells.	Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Fac Hlth Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; Baylor Coll Med, Dept Urol, Houston, TX 77035 USA; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University; Baylor College of Medicine; McMaster University	Rozakis-Adcock, M (corresponding author), Hamilton Reg Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada.	maria.rozakis@hrcc.on.ca						BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CYR DM, 1992, J BIOL CHEM, V267, P20927; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; INOUE A, 1995, J BIOL CHEM, V270, P22571, DOI 10.1074/jbc.270.38.22571; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kashige N, 2000, P NATL ACAD SCI USA, V97, P2093, DOI 10.1073/pnas.040547997; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Kurzik-Dumke U, 1998, CELL STRESS CHAPERON, V3, P12, DOI 10.1379/1466-1268(1998)003<0012:MLATEO>2.3.CO;2; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Yaglom JA, 1996, MOL CELL BIOL, V16, P3679; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	54	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13087	13095		10.1074/jbc.M009267200	http://dx.doi.org/10.1074/jbc.M009267200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11116152	hybrid			2022-12-25	WOS:000168198600088
J	Chu, SY; Tordova, M; Gilliland, GL; Gorshkova, I; Shi, Y; Wang, SL; Schwarz, FP				Chu, SY; Tordova, M; Gilliland, GL; Gorshkova, I; Shi, Y; Wang, SL; Schwarz, FP			The structure of the T127L/S128A mutant of cAMP receptor protein facilitates promoter site binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-DNA COMPLEX; CYCLIC-NUCLEOTIDE BINDING; GENE ACTIVATOR PROTEIN; ESCHERICHIA-COLI; REGULATORY PROTEIN; RESOLUTION; CONFORMATIONS; MUTAGENESIS; TRANSITION; MUTATIONS	The x-ray crystal structure of the cAMP-ligated T127L/ S128A double mutant of cAMP receptor protein (CRP) was determined to a resolution of 2.2 Angstrom Although this structure is close to that of the x-ray crystal structure of cAMP-ligated CRP with one subunit in the open form and one subunit in the closed form, a bound syn-cAMP is clearly observed in the closed subunit in a third binding site in the C-terminal domain. In addition, water-mediated interactions replace the hydrogen bonding interactions between the N-6 of anti-cAMP bound in the N-terminal domains of each subunit and the OH groups of the Thr(127) and Ser(128) residues in the C alpha -helix of wild type CRP, This replacement induces flexibility in the C alpha -helix at Ala(128), which swings the C-terminal domain of the open subunit more toward the N-terminal domain in the T127L/S128A double mutant of CRP (CRP*) than is observed in the open subunit of cAMP-ligated CRP, Isothermal titration calorimetry measurements on the binding of cAMP to CRP* show that the binding mechanism changes from an exothermic independent two-site binding mechanism at pH 7.0 to an endothermic interacting two-site mechanism at pH 5.2, similar to that observed for CRP at both pH levels. Differential scanning calorimetry measurements exhibit a broadening of the thermal denaturation transition of CRP*; relative to that of CRP at pH 7.0 but similar to the multipeak transitions observed for cAMP-ligated CRP. These properties and the bound syn-cAMP ligand, which has only been previously observed in the DNA bound x-ray crystal structure of cAMP-ligated CRP by Passner and Steitz (Passner, J. M., and Steitz, T. A. (1997) Proc. Nafl. Acad. Sci. U.S. A. 94, 2843-2847), imply that the cAMP-ligated CRP* structure is closer to the conformation of the allosterically activated structure than cAMP-ligated CRP. This may be induced by the unique flexibility at Ala128 and/or by the bound syn-cAMP in the hinge region of CRP*.	NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Maryland, Inst Biotechnol, Rockville, MD 20850 USA	National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland Baltimore	Gilliland, GL (corresponding author), NIST, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	gary.gilliland@nist.gov; frederick.schwarz@nist.gov						AIBA H, 1985, EMBO J, V4, P3329, DOI 10.1002/j.1460-2075.1985.tb04084.x; ANDERSON WB, 1971, J BIOL CHEM, V246, P5929; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BROWN AM, 1989, P NATL ACAD SCI USA, V86, P7387, DOI 10.1073/pnas.86.19.7387; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG X, 1998, BIOCHEMISTRY-US, V37, P50; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; Garcia AE, 1996, PROTEIN SCI, V5, P62; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; GORSHKOVA I, 1995, J BIOL CHEM, V270, P21679, DOI 10.1074/jbc.270.37.21679; GRONENBORN AM, 1982, BIOCHEMISTRY-US, V21, P4040, DOI 10.1021/bi00260a020; KIM J, 1992, P NATL ACAD SCI USA, V89, P9700, DOI 10.1073/pnas.89.20.9700; Kirchhoff W. H., 1993, 1401 NIST, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krueger S, 1998, J BIOL CHEM, V273, P20001, DOI 10.1074/jbc.273.32.20001; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE FJ, 1994, NUCLEIC ACIDS RES, V22, P2894; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOORE JL, 1993, THESIS G WASHINGTON; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; ROUSSEL A, 1996, TURBOFRODO SOFTWARE; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHWARZ FP, 1988, THERMOCHIM ACTA, V128, P267, DOI 10.1016/0040-6031(88)85371-1; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shi Y, 2000, BIOCHEMISTRY-US, V39, P7300, DOI 10.1021/bi000225m; Shi Y, 1999, J BIOL CHEM, V274, P6946, DOI 10.1074/jbc.274.11.6946; TAKAHASHI M, 1989, J MOL BIOL, V207, P783, DOI 10.1016/0022-2836(89)90244-1; Wang SL, 2000, J BIOL CHEM, V275, P33457, DOI 10.1074/jbc.M004877200; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG CP, 1990, OMEGA DATA ORIGIN, P66; YSERN X, 1994, J MOL BIOL, V238, P496; ZHANG XP, 1992, J BIOL CHEM, V267, P8136	38	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11230	11236		10.1074/jbc.M010428200	http://dx.doi.org/10.1074/jbc.M010428200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11124966	hybrid			2022-12-25	WOS:000167980900088
J	Schurmann, M; Sprenger, GA				Schurmann, M; Sprenger, GA			Fructose-6-phosphate aldolase is a novel class I aldolase from Escherichia coli and is related to a novel group of bacterial transaldolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; CRYSTAL-STRUCTURE; MUSCLE ALDOLASE; GENE; CLONING; MECHANISM; CLEAVAGE; SYSTEM; PLASMIDS; PROTEINS	We have cloned an open reading frame from the Escherichia coli K-12 chromosome that had been assumed earlier to be a transaldolase or a transaldolase-related protein, termed MipB, Here we show that instead a novel enzyme activity, fructose-6-phosphate aldolase, is encoded by this open reading frame, which is the first report of an enzyme that catalyzes an aldol cleavage of fructose 6-phosphate from any organism. We propose the name FSA (for fructose-six phosphate aldolase; gene name fsa). The recombinant protein was purified to apparent homogeneity by anion exchange and gel permeation chromatography with a yield of 40 mg of protein from 1 liter of culture. By using electrospray tandem mass spectroscopy, a molecular weight of 22,998 per subunit was determined. From gel filtration a size of 257,000 (+/- 20,000) was calculated. The enzyme most likely forms either a decamer or dodecamer of identical subunits, The purified enzyme displayed a V(max) of 7 units mg(-1) of protein for fructose B-phosphate cleavage (at 30 degreesC, pH 8.5 in 50 mM glycylglycine buffer). For the aldolization reaction a V(max) of 45 units mg(-1) of protein was found; K(m) values for the substrates were 9 mM for fructose 6-phosphate, 35 mM for dihydroxyacetone, and 0.8 mM for glyceraldehyde 3-phosphate. FSA did not utilize fructose, fructose l-phosphate, fructose 1,6-bisphosphate, or dihydroxyacetone phosphate. FSA is not inhibited by EDTA which points to a metal-independent mode of action. The lysine 85 residue is essential for its action as its exchange to arginine (K85R) resulted in complete loss of activity in line with the assumption that the reaction mechanism involves a Schiff base formation through this lysine residue (class I aldolase). Another fsa-related gene, talC of Escherichia coli, was shown to also encode fructose-6-phosphate aldolase activity and not a transaldolase as proposed earlier.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Sprenger, GA (corresponding author), Forschungszentrum Julich, Inst Biotechnol 1, Postfach 1913, D-52425 Julich, Germany.	g.sprenger@fz-juelich.de	Sprenger, Georg A./E-2384-2011	Sprenger, Georg A./0000-0002-7879-8978				ALEFOUNDER PR, 1989, BIOCHEM J, V257, P529, DOI 10.1042/bj2570529; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BONSIGNORE A, 1959, BIOCHEM BIOPH RES CO, V1, P79, DOI 10.1016/0006-291X(59)90066-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CRANS DC, 1992, BIOCHEMISTRY-US, V31, P6812, DOI 10.1021/bi00144a023; Flechner A, 1999, FEBS LETT, V447, P200, DOI 10.1016/S0014-5793(99)00285-9; Gefflaut T, 1995, PROG BIOPHYS MOL BIO, V63, P301, DOI 10.1016/0079-6107(95)00008-9; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; HORECKER BL, 1955, J BIOL CHEM, V212, P827; Jia J, 1996, STRUCTURE, V4, P715, DOI 10.1016/S0969-2126(96)00077-9; Jia J, 1997, PROTEIN SCI, V6, P119; Kohler U, 1996, PLANT MOL BIOL, V30, P213, DOI 10.1007/BF00017817; KRISHNAN G, 1991, EUR J BIOCHEM, V195, P343, DOI 10.1111/j.1432-1033.1991.tb15712.x; KROGER A, 1999, BIOL PROKARYOTES, P48; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Machajewski TD, 2000, ANGEW CHEM INT EDIT, V39, P1352, DOI 10.1002/(SICI)1521-3773(20000417)39:8<1352::AID-ANIE1352>3.0.CO;2-J; MARSH JJ, 1992, TRENDS BIOCHEM SCI, V17, P110, DOI 10.1016/0968-0004(92)90247-7; MILDVAN AS, 1971, BIOCHEMISTRY-US, V10, P1191, DOI 10.1021/bi00783a016; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Rai DK, 2000, RAPID COMMUN MASS SP, V14, P1184, DOI 10.1002/1097-0231(20000730)14:14<1184::AID-RCM7>3.0.CO;2-S; REIZER J, 1995, MICROBIOL-UK, V141, P961, DOI 10.1099/13500872-141-4-961; RICHARDS OC, 1961, J BIOL CHEM, V236, P3185; ROSE IA, 1965, J BIOL CHEM, V240, P1758; RUTTER WJ, 1964, FED PROC, V23, P1248; Sambrook J., 2002, MOL CLONING LAB MANU; Schorken U, 1998, FEBS LETT, V441, P247, DOI 10.1016/S0014-5793(98)01521-X; SPRENGER GA, 1989, J GEN MICROBIOL, V135, P1255; SPRENGER GA, 1995, J BACTERIOL, V177, P5930, DOI 10.1128/jb.177.20.5930-5936.1995; Tangney M, 1998, APPL ENVIRON MICROB, V64, P1612; Thomson GJ, 1998, BIOCHEM J, V331, P437, DOI 10.1042/bj3310437; Thorell S, 2000, FEBS LETT, V475, P205, DOI 10.1016/S0014-5793(00)01658-6; TRUNIGER V, 1994, J BACTERIOL, V176, P1796, DOI 10.1128/jb.176.6.1796-1800.1994; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WITKE C, 1993, J BACTERIOL, V175, P7495, DOI 10.1128/JB.175.22.7495-7499.1993; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	143	177	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11055	11061		10.1074/jbc.M008061200	http://dx.doi.org/10.1074/jbc.M008061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11120740	hybrid, Green Published			2022-12-25	WOS:000167980900066
J	Roberson, MS; Meermann, S; Morasso, MI; Mulvaney-Musa, JM; Zhang, T				Roberson, MS; Meermann, S; Morasso, MI; Mulvaney-Musa, JM; Zhang, T			A role for the homeobox protein distal-less 3 in the activation of the glycoprotein hormone alpha subunit gene in choriocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATE TRANSCRIPTIONAL RESPONSES; GONADOTROPIN-RELEASING-HORMONE; PITUITARY-SPECIFIC EXPRESSION; HUMAN CHORIONIC-GONADOTROPIN; IN-SITU HYBRIDIZATION; CHROMOSOME 17Q21.3-Q22; REGULATORY ELEMENTS; DLX HOMEOPROTEINS; HUMAN PLACENTA; PIT-1	Synthesis and secretion of chorionic gonadotropin in trophoblast cells of the placenta is required for establishment of early pregnancy in primates. Chorionic gonadotropin is a heterodimeric glycoprotein hormone consisting of alpha and beta subunits, Regulation of the a subunit gene within the placenta requires an array of cia elements within the 5'-flanking region of the promoter. Within this array of elements, the junctional regulatory element (JRE) putatively binds a placental-specific transcription factor. The aim of our studies was to determine the identity and role of the transcriptional regulator that binds to the JRE in choriocarcinoma cells (JEG3 cells). Mutations within the JRE resulted in reduction in basal expression of an a subunit reporter gene, suggesting that the JRE binding factor was necessary for full basal activity. Using electrophoretic mobility shift assays, we determined that the JRE was capable of serving as a homeobox factor-binding site. The homeobox factor, Distal-less 3 (Dlx 3) was found to be expressed in JEG3 cells and in the trophoblast layer of human chorionic villus but not in a gonadotrope cell line that also expresses the a subunit gene. Electrophoretic mobility shift assays revealed that recombinant Dlx 3 could bind specifically to the JRE and endogenous Dlx 3 was present in JRE/JEG3 nuclear protein complexes. Overexpression of Dlx 3 resulted in activation of an alpha subunit reporter gene. A JRE mutation resulted in attenuated activation of the a subunit reporter via an adjacent cis element, suggesting that JRE/ Dlx 3 interactions may facilitate regulation of the a subunit gene at sites immediately upstream of the JRE. Our studies support the conclusion that Dlx 3 is a placental-specific transcriptional regulator that binds to the JRE and contributes to expression of the alpha subunit gene in cells of trophoblast origin.	Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Roberson, MS (corresponding author), Cornell Univ, Dept Biomed Sci, T6-008A VRT, Ithaca, NY 14853 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD034722] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD034722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041124, Z01AR041124] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 34722] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; Andersen B, 1995, DEV BIOL, V172, P495, DOI 10.1006/dbio.1995.8040; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; ANDERSEN B, 1988, J BIOL CHEM, V263, P15578; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Baird DD, 1997, HUM REPROD, V12, P2607, DOI 10.1093/humrep/12.12.2607; Baird DD, 1999, FERTIL STERIL, V71, P40, DOI 10.1016/S0015-0282(98)00419-1; BAIRD DD, 1991, J CLIN ENDOCR METAB, V72, P793, DOI 10.1210/jcem-72-4-793; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; Bendall AJ, 2000, GENE, V247, P17, DOI 10.1016/S0378-1119(00)00081-0; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; Budworth PR, 1997, MOL ENDOCRINOL, V11, P1669, DOI 10.1210/me.11.11.1669; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Fazleabas AT, 1999, P NATL ACAD SCI USA, V96, P2543, DOI 10.1073/pnas.96.5.2543; Feledy JA, 1999, NUCLEIC ACIDS RES, V27, P764, DOI 10.1093/nar/27.3.764; France JT, 1996, AUST NZ J OBSTET GYN, V36, P325, DOI 10.1111/j.1479-828X.1996.tb02722.x; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; HAN VKM, 1993, MOL ASPECTS PLACENTA, P395; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KRATZER PG, 1990, AM J OBSTET GYNECOL, V163, P1497, DOI 10.1016/0002-9378(90)90613-C; Li RH, 1997, HUM REPROD, V12, P830, DOI 10.1093/humrep/12.4.830; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; Li YH, 1997, DEV BIOL, V188, P85, DOI 10.1006/dbio.1997.8640; Liu H C, 1995, Early Pregnancy, V1, P281; Maurer RA, 1999, RECENT PROG HORM RES, V54, P455; Morasso MI, 1997, MAMM GENOME, V8, P302, DOI 10.1007/s003359900427; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; Morasso MI, 1999, P NATL ACAD SCI USA, V96, P162, DOI 10.1073/pnas.96.1.162; NILSON JH, 1991, BIOL REPROD, V44, P231, DOI 10.1095/biolreprod44.2.231; Offield MF, 1996, DEVELOPMENT, V122, P983; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; Park GT, 1999, J BIOL CHEM, V274, P26599, DOI 10.1074/jbc.274.37.26599; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; Price JA, 1998, HUM MOL GENET, V7, P563, DOI 10.1093/hmg/7.3.563; Quinn LM, 1997, GENE, V187, P55, DOI 10.1016/S0378-1119(96)00706-8; Quinn LM, 1998, PLACENTA, V19, P87, DOI 10.1016/S0143-4004(98)90103-5; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; Roberson MS, 2000, MOL CELL BIOL, V20, P3331, DOI 10.1128/MCB.20.10.3331-3344.2000; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; SCHERER SW, 1995, MAMM GENOME, V6, P310, DOI 10.1007/BF00352432; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SCHODERBEK WE, 1993, J BIOL CHEM, V268, P3903; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; Watkins-Chow DE, 1998, TRENDS GENET, V14, P284, DOI 10.1016/S0168-9525(98)01476-0; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387	56	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10016	10024		10.1074/jbc.M007481200	http://dx.doi.org/10.1074/jbc.M007481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11113121	hybrid			2022-12-25	WOS:000167996400060
J	Sharma, M; Benharouga, M; Hu, W; Lukacs, GL				Sharma, M; Benharouga, M; Hu, W; Lukacs, GL			Conformational and temperature-sensitive stability defects of the Delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; SODIUM 4-PHENYLBUTYRATE; MUTATION; PROTEIN; DEGRADATION; TRANSPORT; CELLS; IDENTIFICATION; EXPRESSION; PATHWAY	Deletion of phenylalanine at position 508 (Delta F508) is the most common cystic fibrosis (CF)-associated mutation in the CF transmembrane conductance regulator (CFTR), a cAMP-regulated chloride channel. The consensus notion is that Delta F508 imposes a temperature-sensitive folding defect and targets newly synthesized CFTR for degradation at endoplasmic reticulum (ER). A limited amount of CFTR activity, however, appears at the cell surface in the epithelia of homozygous Delta F508 CFTR mice and patients, suggesting that the ER retention is not absolute in native tissues. To further elucidate the reasons behind the inability of Delta F508 CFTR to accumulate at the plasma membrane, its stability was determined subsequent to escape from the ER, induced by reduced temperature and glycerol. Biochemical and functional measurements show that rescued Delta F508 CFTR has a temperature-sensitive stability defect in post-ER compartments, including the cell surface. The more than 4-20-fold accelerated degradation rate between 37 and 40 degreesC is, most likely, due to decreased conformational stability of the rescued Delta F508 CFTR, demonstrated by in situ protease susceptibility and SDS-resistant thermoaggregation assays. We propose that the decreased stability of the spontaneously or pharmacologically rescued mutant may contribute to its inability to accumulate at the cell surface. Thus, therapeutic efforts to correct; the folding defect should be combined with stabilization of the native Delta F508 CFTR.	Hosp Sick Children, Program Lung & Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Lukacs, GL (corresponding author), Hosp Sick Children, Program Lung & Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Lukacs, Gergely/0000-0003-0900-0675				Bebok Z, 1998, AM J PHYSIOL-CELL PH, V275, pC599, DOI 10.1152/ajpcell.1998.275.2.C599; Bronsveld I, 2000, GASTROENTEROLOGY, V119, P32, DOI 10.1053/gast.2000.8524; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; Dray-Charier N, 1999, HEPATOLOGY, V29, P1624, DOI 10.1002/hep.510290634; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN ME, 1995, AM J PHYSIOL-CELL PH, V268, pC243, DOI 10.1152/ajpcell.1995.268.1.C243; French PJ, 1996, J CLIN INVEST, V98, P1304, DOI 10.1172/JCI118917; Gardner RG, 1999, EMBO J, V18, P5994, DOI 10.1093/emboj/18.21.5994; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Jiang CW, 1998, AM J PHYSIOL-CELL PH, V275, pC171, DOI 10.1152/ajpcell.1998.275.1.C171; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; King J, 1986, Methods Enzymol, V131, P250; Kinnman N, 2000, HEPATOLOGY, V32, P334, DOI 10.1053/jhep.2000.9111; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; Penque D, 2000, LAB INVEST, V80, P857, DOI 10.1038/labinvest.3780090; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Sagne C, 1996, BIOCHEM J, V316, P825, DOI 10.1042/bj3160825; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Steagall WK, 1999, GASTROENTEROLOGY, V116, P1379, DOI 10.1016/S0016-5085(99)70502-0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wolins N, 1997, J CELL BIOL, V139, P1735, DOI 10.1083/jcb.139.7.1735; ZEITLIN PL, 1998, PEDIATR PULM, V17, P277; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	47	174	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8942	8950		10.1074/jbc.M009172200	http://dx.doi.org/10.1074/jbc.M009172200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124952	hybrid			2022-12-25	WOS:000167607700046
J	Souttou, B; Brunet-De Carvalho, N; Raulais, D; Vigny, M				Souttou, B; Brunet-De Carvalho, N; Raulais, D; Vigny, M			Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NON-HODGKINS-LYMPHOMA; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; GENE; NUCLEOPHOSMIN; INSULIN; LINE; ALK	Anaplastic lymphoma kinase (ALK) is a novel neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems, suggesting a role in its normal development and function. To determine whether ALK could play a role in neuronal differentiation, we established a model system that allowed us to mimic the normal activation of this receptor. We expressed, in PC12 cells, a chimeric protein in which the extracellular domain of the receptor was replaced by the mouse IgG 2b Fc domain. The Fc domain induced the dimerization and oligomerization of the chimeric protein leading to receptor phosphorylation and activation, thus mimicking the effect of ligand binding, whereas the wild type ALK remained as a monomeric nonphosphorylated protein. Expression of the chimera, but not that of the wild type ALK or of a kinase inactive form of the chimera, induced the differentiation of PC12 cells. Analysis of the signaling pathways involved in this process pointed to an essential role of the mitogen-activated protein kinase cascade. These results are consistent with a role for ALK in neuronal differentiation.	Univ Paris 06, INSERM, U440, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Vigny, M (corresponding author), Univ Paris 06, INSERM, U440, 17 Rue Fer Moulin, F-75005 Paris, France.	vigny@ifm.inserm.fr						Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; DAHMER MK, 1988, ENDOCRINOLOGY, V122, P2109, DOI 10.1210/endo-122-5-2109; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Henderson CE, 1996, CURR OPIN NEUROBIOL, V6, P64, DOI 10.1016/S0959-4388(96)80010-9; Hwang JJ, 1997, MOL CELLS, V7, P438; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; Mark MD, 1997, J BIOL CHEM, V272, P17238, DOI 10.1074/jbc.272.27.17238; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Powers JF, 1999, CELL TISSUE RES, V295, P21, DOI 10.1007/s004410051209; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TENG KK, 1994, J NEUROSCI, V14, P2624; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETTER ML, 1995, CURR BIOL, V5, P168, DOI 10.1016/S0960-9822(95)00038-8; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	30	98	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9526	9531		10.1074/jbc.M007333200	http://dx.doi.org/10.1074/jbc.M007333200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121404	hybrid			2022-12-25	WOS:000167607700119
J	Gardner, LB; Li, Q; Park, MS; Flanagan, WM; Semenza, GL; Dang, CV				Gardner, LB; Li, Q; Park, MS; Flanagan, WM; Semenza, GL; Dang, CV			Hypoxia inhibits G(1)/S transition through regulation of p27 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; INDUCIBLE FACTOR 1-ALPHA; EMBRYONIC STEM-CELLS; RESTRICTION POINT; TUMOR-CELLS; CYCLIN-A; IN-VIVO; POTENTIAL MEDIATOR; UP-REGULATION; HUMAN CANCERS	Mammalian cellular responses to hypoxia include adaptive metabolic changes and a G(1) cell cycle arrest. Although transcriptional regulation of metabolic genes by the hypoxia-induced transcription factor (HIF-1) has been established, the mechanism for the hypoxia-induced G(1) arrest is not known. By using genetically defined primary wild-type murine embryo fibroblasts and those nullizygous for regulators of the G(1)/S checkpoint, we observed that the retinoblastoma protein is essential for the G(1)/S hypoxia-induced checkpoint, whereas p53 and p21 are not required. In addition, we found that the cyclin-dependent kinase inhibitor p27 is induced by hypoxia, thereby inhibiting CDK2 activity and forestalling S phase entry through retinoblastoma protein hypophosphorylation, Reduction or absence of p27 abrogated the hypoxia-induced G(1) checkpoint, suggesting that it is a key regulator of G(1)/S transition in hypoxic cells. Intriguingly, hypoxic induction of p27 appears to be transcriptional and through an HIF-1-independent region of its proximal promoter, This demonstration of the molecular mechanism of hypoxia-induced G(1)/S regulation provides insight into a fundamental response of mammalian cells to low oxygen tension.	Johns Hopkins Oncol Ctr, Dept Med, Baltimore, MD 21205 USA; Cornell Univ, Grad Sch Med Sci, Mol & Cellular Biol Program, New York, NY 10021 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA; Gilead Sci Inc, Foster City, CA 94404 USA	Johns Hopkins University; Johns Hopkins Medicine; Cornell University; Johns Hopkins University; Gilead Sciences	Dang, CV (corresponding author), Ross Res Bldg,Rm 1025,720 Rutland Ave, Baltimore, MD 21205 USA.		Dang, Chi/Y-3375-2019	Gardner, Lawrence/0000-0003-0191-0172; Dang, Chi/0000-0002-4031-2522	NCI NIH HHS [CA 51497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA051497, R29CA051497, R01CA051497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Amellem O, 1998, BRIT J CANCER, V77, P862, DOI 10.1038/bjc.1998.143; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arap W, 1997, ONCOGENE, V15, P2013, DOI 10.1038/sj.onc.1201389; ARTEEL GE, 1995, BRIT J CANCER, V72, P889, DOI 10.1038/bjc.1995.429; Barnhill RL, 1998, ARCH DERMATOL, V134, P991, DOI 10.1001/archderm.134.8.991; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dunn JF, 1997, ADV EXP MED BIOL, V428, P645; Durand RE, 1998, CANCER RES, V58, P3547; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Green SL, 1998, CANCER J SCI AM, V4, P218; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HOLLEY RW, 1968, P NATL ACAD SCI USA, V60, P300, DOI 10.1073/pnas.60.1.300; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JIANG B, 1997, J BIOL CHEM, V272, P19523; Kennedy AS, 1997, INT J RADIAT ONCOL, V37, P897, DOI 10.1016/S0360-3016(96)00539-1; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159; Krtolica A, 1999, BRIT J CANCER, V80, P1875, DOI 10.1038/sj.bjc.6690615; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Li Q, 1999, MOL CELL BIOL, V19, P5339; Lin KY, 1998, J AM CHEM SOC, V120, P8531, DOI 10.1021/ja981286z; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; LUDLOW JW, 1993, ONCOGENE, V8, P331; Luo Y, 1996, MOL CELL BIOL, V16, P6744; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RALEIGH JA, 1995, ACTA ONCOL, V34, P345, DOI 10.3109/02841869509093987; Raleigh JA, 1998, CANCER RES, V58, P3765; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P809; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; StCroix B, 1996, NAT MED, V2, P1204; TEICHER BA, 1995, HEMATOL ONCOL CLIN N, V9, P475; TIAN H, 1997, GENE DEV, V11, P78; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; Webster L, 1998, BRIT J CANCER, V77, P227, DOI 10.1038/bjc.1998.38; Wenger RH, 1998, CANCER RES, V58, P5678; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Zhang Y, 1997, BBA-GENE STRUCT EXPR, V1353, P307, DOI 10.1016/S0167-4781(97)00063-8; Zhong H, 1999, CANCER RES, V59, P5830	64	298	317	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7919	7926		10.1074/jbc.M010189200	http://dx.doi.org/10.1074/jbc.M010189200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11112789	hybrid			2022-12-25	WOS:000167474900035
J	Mosimann, SC; Gilbert, M; Dombrowski, D; To, R; Wakarchuk, W; Strynadka, NCJ				Mosimann, SC; Gilbert, M; Dombrowski, D; To, R; Wakarchuk, W; Strynadka, NCJ			Structure of a sialic acid-activating synthetase, CMP-acylneuraminate synthetase in the presence and absence of CDP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAEMOPHILUS-DUCREYI; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PROTEIN; CLASSIFICATION; IDENTIFICATION; BIOSYNTHESIS; INSIGHTS; ENZYME; DOMAIN	The x-ray crystallographic structure of selenomethionyl cytosine 5'-monophosphate-acylneuraminate synthetase (CMP-NeuAc synthetase) from Neisseria meningitidis has been determined at 2.0-Angstrom resolution using multiple-wavelength anomalous dispersion phasing, and a second structure, in the presence of the substrate analogue CDP, has been determined at 2.2-Angstrom resolution by molecular replacement. This work identifies the active site residues for this class of enzyme for the first time. The detailed interactions between the enzyme and CDP within the mononucleotide-binding pocket are directly observed, and the acylneuraminate-binding pocket has also been identified. A model of acylneuraminate bound to CMP-NeuAc synthetase has been constructed and provides a structural basis for understanding the mechanism of production of "activated" sialic acids. Sialic acids are key saccharide components on the surface of mammalian cells and can be virulence factors in a variety of bacterial species (e.g. Neisseria, Haemophilus, group B streptococci, etc.). As such, the identification of the bacterial CMP-NeuAc synthetase active site can serve as a starting point for rational drug design strategies.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	University of British Columbia; National Research Council Canada	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca	Wakarchuk, Warren/Q-9514-2017; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Gilbert, Michel/0000-0002-0204-4408				AMBROSE MG, 1992, BIOCHEMISTRY-US, V31, P775, DOI 10.1021/bi00118a019; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BITTERSUERMANN D, 1993, POLYSIALIC ACID MICR; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAN AWE, 1993, PROTEIN SCI, V2, P1574, DOI 10.1002/pro.5560021004; Gilbert M, 1998, NAT BIOTECHNOL, V16, P769, DOI 10.1038/nbt0898-769; Gilbert M, 1997, BIOTECHNOL LETT, V19, P417, DOI 10.1023/A:1018379607492; Haft RF, 1996, MOL MICROBIOL, V19, P555, DOI 10.1046/j.1365-2958.1996.395931.x; Hart TN, 1997, PROTEINS, P205; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JANN B, 1990, CURR TOP MICROBIOL, V150, P19; JANN K, 1985, VIRULENCE ESCHERICHI; Jelakovic S, 1996, FEBS LETT, V391, P157, DOI 10.1016/0014-5793(96)00724-7; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KEAN EL, 1991, GLYCOBIOLOGY, V5, P441; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KERN WF, 1993, LEUKEMIA LYMPHOMA, V12, P1, DOI 10.3109/10428199309059565; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAGERGARD T, 1992, MICROB PATHOGENESIS, V13, P203, DOI 10.1016/0882-4010(92)90021-F; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANDRELL RE, 1993, IMMUNOBIOLOGY, V187, P382, DOI 10.1016/S0171-2985(11)80352-9; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; PETSKO GA, 1993, TRENDS BIOCHEM SCI, V18, P372, DOI 10.1016/0968-0004(93)90091-Z; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REST RF, 1992, INFECT IMMUN, V60, P989, DOI 10.1128/IAI.60.3.989-997.1992; RICHARDSON JS, 1989, PRINCIPLES PATTERNS; ROSEMAN S, 1962, P NATL ACAD SCI USA, V48, P437, DOI 10.1073/pnas.48.3.437; Rosenberg A, 1995, BIOL SIALIC ACIDS; Samuels NM, 1999, BIOCHEMISTRY-US, V38, P6195, DOI 10.1021/bi990282j; SCHULZ GE, 1992, FARADAY DISCUSS, V93, P85, DOI 10.1039/fd9929300085; Schwabe C, 1996, FASEB J, V10, P184, DOI 10.1096/fasebj.10.1.8566541; Stoughton DM, 1999, BIOCHEM J, V343, P397, DOI 10.1042/0264-6021:3430397; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TIMMIS KN, 1985, CURR TOP MICROBIOL, V118, P197; Tullius MV, 1999, PROTEIN SCI, V8, P666; WARREN L, 1962, J BIOL CHEM, V237, P3527	41	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8190	8196		10.1074/jbc.M007235200	http://dx.doi.org/10.1074/jbc.M007235200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113120	hybrid			2022-12-25	WOS:000167474900072
J	Petkova, V; Romanowski, MJ; Sulijoadikusumo, I; Rohne, D; Kang, P; Shenk, T; Usheva, A				Petkova, V; Romanowski, MJ; Sulijoadikusumo, I; Rohne, D; Kang, P; Shenk, T; Usheva, A			Interaction between YY1 and the retinoblastoma protein - Regulation of cell cycle progression in differentiated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F TRANSCRIPTION FACTOR; SERUM RESPONSE FACTOR; TATA-BINDING PROTEIN; RNA POLYMERASE-II; ALPHA-ACTIN GENE; SMOOTH-MUSCLE; RB PROTEIN; ADENOVIRUS E1A; GROWTH-FACTOR; EXPRESSION	Overexpression of the transcription factor YY1 activates DNA synthesis in differentiated primary human coronary artery smooth muscle cells. Overexpression of the retinoblastoma protein together with YY1 blocked this effect. In growth-arrested cells, YY1 resides in a complex with the retinoblastoma protein, but the complex is not detected in serum-stimulated S phase cultures, indicating that the interaction of the retinoblastoma protein and YY1 is cell cycle-regulated. Recombinant retinoblastoma protein directly interacts with YY1, destabilizing the interaction of YY1 with DNA and inhibiting its transcription initiator function in vitro. We conclude that in differentiated cells elevation of the nuclear level of YY1 protein favors progression into the S phase, and we propose that this activity is regulated by its interaction with the retinoblastoma protein.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrinol, Boston, MA 02215 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Princeton University	Usheva, A (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrinol, 99 Brookline Ave,R313, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R37CA038965, R01CA038965] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062458] Funding Source: NIH RePORTER; NCI NIH HHS [CA38965] Funding Source: Medline; NHLBI NIH HHS [HL62458] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; CATALA F, 1995, MOL CELL BIOL, V15, P4585; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, COLD SPRING HARB SYM, V56, P187; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eliassen KA, 1998, MOL CELL BIOL, V18, P7106, DOI 10.1128/MCB.18.12.7106; FLANAGAN JR, 1995, CELL GROWTH DIFFER, V6, P185; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; IP JH, 1990, BIOMED PHARMACOTHER, V44, P343, DOI 10.1016/0753-3322(90)90087-P; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; NEVINS JR, 1991, COLD SPRING HARB SYM, V56, P157; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; SCHWARTZ SM, 1987, HUM PATHOL, V18, P240, DOI 10.1016/S0046-8177(87)80006-0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SIMONSON MS, 1995, AM J PHYSIOL-RENAL, V268, pF760, DOI 10.1152/ajprenal.1995.268.4.F760; Stephenson LA, 1998, KIDNEY INT, V54, P1175, DOI 10.1046/j.1523-1755.1998.00101.x; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995	40	72	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7932	7936		10.1074/jbc.M007411200	http://dx.doi.org/10.1074/jbc.M007411200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11118439	hybrid			2022-12-25	WOS:000167474900037
J	Alimonti, JB; Shi, LF; Baijal, PK; Greenberg, AH				Alimonti, JB; Shi, LF; Baijal, PK; Greenberg, AH			Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; CELL-DEATH; INITIATES APOPTOSIS; CASPASE ACTIVATION; SURVIVAL SIGNALS; BH3 DOMAIN; X-L; BAX; PROTEIN; PORE	Many cell death pathways converge at the mitochondria to induce release of apoptogenic proteins and permeability transition, resulting in the activation of effector caspases responsible for the biochemical and morphological alterations of apoptosis. The death receptor pathway has been described as a triphasic process initiated by the activation of apical caspases, a mitochondrial phase, and then the final phase of effector caspase activation. Granzyme B (GrB) activates apical and effector caspases as well as promotes cytochrome c (cyt C) release and loss of mitochondrial membrane potential. We investigated how GrB affects mitochondria utilizing an in vitro cell-free system and determined that cyt c release and permeability transition are initiated by distinct mechanisms. The cleavage of cytosolic BID by GrB results in truncated BID, initiating mitochondrial cyt c release. BID is the sole cytosolic protein responsible for this phenomenon in vitro, yet caspases were found to participate in cyt c release in some cells. On the other hand, GrB acts directly on mitochondria in the absence of cytosolic S100 proteins to open the permeability transition pore and to disrupt the proton electrochemical gradient. We suggest that GrB acts by two distinct mechanisms on mitochondria that ultimately lead to mitochondrial dysfunction and cellular demise.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	University of Manitoba	Greenberg, AH (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	agreenb@cc.umanitoba.ca						Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; Heibein JA, 1999, J IMMUNOL, V163, P4683; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacDonald G, 1999, J EXP MED, V189, P131, DOI 10.1084/jem.189.1.131; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Nagata S, 1999, NAT CELL BIOL, V1, pE143, DOI 10.1038/14094; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Pham CTN, 1998, J BIOL CHEM, V273, P1629, DOI 10.1074/jbc.273.3.1629; Pinkoski MJ, 1998, BLOOD, V92, P1044; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	68	126	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6974	6982		10.1074/jbc.M008444200	http://dx.doi.org/10.1074/jbc.M008444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11114298	hybrid, Green Submitted, Green Published			2022-12-25	WOS:000167442900017
J	Chen, RL; Lander, AD				Chen, RL; Lander, AD			Mechanisms underlying preferential assembly of heparan sulfate on glypican-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE; NERVOUS-SYSTEM; EPITHELIAL-CELLS; EXPRESSION; PROTEOGLYCAN; IDENTIFICATION; BIOSYNTHESIS; BINDING; GLYCOSAMINOGLYCANS; FIBROBLASTS	Glypicans are major cell surface heparan sulfate proteoglycans, the structures of which are characterized by the presence of a cysteine-rich globular domain, a short glycosaminoglycan (GAG) attachment region, and a glycosylphosphatidylinositol membrane anchor. Despite strong evolutionary conservation of the globular domains of glypicans, no function has yet been attributed to them. By using a novel quantitative approach for assessing proteoglycan glycosylation, we show here that removal of the globular domain from rat glypican-1 converts the proteoglycan from one that bears similar to 90% hepa ran sulfate (HS) to one that bears similar to 90% chondroitin sulfate. Mutational analysis shows that sequences at least 70 amino acids away from the glypican-1 GAG attachment site are required for preferential HS assembly, although more nearby sequences also play a role. The effects of the glypican-1 globular domain on HS assembly could also be demonstrated by fusing this domain to sequences representing the GAG attachment sites of other proteoglycans or, surprisingly, simply by expressing the isolated globular domain in cells and analyzing effects either on an exogenously expressed glypican l GAG; attachment domain or on endogenous proteoglycans. Quantitative analysis of the effect of the globular domain on GAG addition to proteoglycan core proteins suggested that preferential HS assembly is achieved, at least in part, through the inhibition of chondroitin sulfate assembly. These data identify the glypican-1 globular domain as a structural motif that potently influences GAG class determination and suggest that an important role of glypican globular domains is to ensure a high level of HS substitution of these proteoglycans.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Chen, RL (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 5207 Biol Sci II, Irvine, CA 92697 USA.				NINDS NIH HHS [NS26862] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026862] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BRAHIMIHORN MC, 1994, EUR J CELL BIOL, V64, P271; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; INKI P, 1992, LAB INVEST, V67, P225; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; Lander AD, 1996, PERSPECT DEV NEUROBI, V3, P347; LINKER A, 1972, BIOCHEMISTRY-US, V11, P563, DOI 10.1021/bi00754a013; LITWACK ED, 1994, J NEUROSCI, V14, P3713; Litwack ED, 1998, DEV DYNAM, V211, P72, DOI 10.1002/(SICI)1097-0177(199801)211:1<72::AID-AJA7>3.3.CO;2-8; LORIES V, 1992, J BIOL CHEM, V267, P1116; MANN DM, 1990, J BIOL CHEM, V265, P5317; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Prydz K, 2000, J CELL SCI, V113, P193; RAPRAEGER A, 1989, ANAL BIOCHEM, V179, P361, DOI 10.1016/0003-2697(89)90145-0; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; Saunders S, 1997, DEV BIOL, V190, P78, DOI 10.1006/dbio.1997.8690; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TURNBULL JE, 1988, BIOCHEM J, V251, P597, DOI 10.1042/bj2510597; UhlinHansen L, 1997, J BIOL CHEM, V272, P3200, DOI 10.1074/jbc.272.6.3200; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	37	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7507	7517		10.1074/jbc.M008283200	http://dx.doi.org/10.1074/jbc.M008283200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11106655	Green Published, hybrid			2022-12-25	WOS:000167442900089
J	Kim, J; Min, G; Kemper, B				Kim, J; Min, G; Kemper, B			Chromatin assembly enhances binding to the CYP2B1 phenobarbital-responsive unit (PBRU) of nuclear factor-1, which binds simultaneously with constitutive androstane receptor (CAR)/retinoid X receptor (RXR) and enhances CAR/RXR-mediated activation of the PBRU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-FLANKING REGION; ESTROGEN-RECEPTOR; DRUG-METABOLISM; MMTV PROMOTER; FACTOR-I; GENE; INDUCTION; CAR; TRANSCRIPTION; ELEMENT	Phenobarbital induction of CYP2B genes is mediated by a complex phenobarbital-responsive enhancer (PBRU), which contains a binding site for nuclear factor-1 (NF-1) flanked by two DR-4 nuclear receptor (NR) binding sites for a heterodimer of constitutive androstane receptor (CAR) and retinoid X receptor (RXR), To examine potential interactions between NF-1 and CAW RXR, binding of purified recombinant proteins to DNA, or to chromatin assembled using Drosophila embryo extract, was examined. NF-1 and CARRXR bound simultaneously and independently to the overlapping NF-1 and NR-1 sites; binding of CAR/RXR to the NR-2 site was modestly increased by NF-1 binding; and CAR/RXR bound to a new site in the PBRU region, designated NR-3, Assembly of plasmid DNA into chromatin using Drosophila extract resulted in linearly phased nucleosomes in the PBRU region. The apparent binding affinity of NF-1 was increased by about 10-fold in assembled chromatin compared with DNA, whereas CAR/RXR binding was decreased. As observed for DNA, however, simultaneous, largely independent, binding to the NF-1 and NR sites was observed. CAR-mediated transactivation of the PBRU in cultured cells of hepatic origin was inhibited by mutations in the NF-1 site, and overexpression of NF-1 increased CAR transactivation in HepG2 cells. These studies demonstrate that NF-1 and CAR/ RXR can both bind to the PBRU at the same time and that chromatin assembly increases NF-1 binding, which is consistent with previous in vivo footprinting studies in which the NF-1 site was occupied in untreated animals and the NF-1 and flanking NR sites were occupied after phenobarbital treatment. CAR-mediated trans-activation of the PBRU was increased by NF-1, analogous to NF-1 effects on phenobarbital induction in previous transient transfection studies and consistent with mediation of phenobarbital induction by CAR.	Univ Illinois, Dept Mol & Integrat Physiol, Coll Med, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Coll Med, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.				NIGMS NIH HHS [GM39360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Candau R, 1996, J STEROID BIOCHEM, V57, P19, DOI 10.1016/0960-0760(96)00262-2; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kim J, 1997, MOL CELL BIOL, V17, P3173, DOI 10.1128/MCB.17.6.3173; Kim J, 1997, J BIOL CHEM, V272, P29423, DOI 10.1074/jbc.272.47.29423; Kim J, 2000, NUCLEIC ACIDS RES, V28, P1126, DOI 10.1093/nar/28.5.1126; Ko HSP, 1996, MOL CELL BIOL, V16, P430; LIU S, 2001, IN PRESS BIOCH PHARM; Liu SQ, 1998, DNA CELL BIOL, V17, P461, DOI 10.1089/dna.1998.17.461; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; Ramsden R, 1999, GENE, V228, P169, DOI 10.1016/S0378-1119(98)00612-X; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Stoltz C, 1998, J BIOL CHEM, V273, P8528, DOI 10.1074/jbc.273.14.8528; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Venditti P, 1998, NUCLEIC ACIDS RES, V26, P3657, DOI 10.1093/nar/26.16.3657; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Wu SY, 1999, J BIOL CHEM, V274, P23480, DOI 10.1074/jbc.274.33.23480	27	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7559	7567		10.1074/jbc.M008090200	http://dx.doi.org/10.1074/jbc.M008090200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113125	hybrid			2022-12-25	WOS:000167442900095
J	Makise, M; Mima, S; Tsuchiya, T; Mizushima, T				Makise, M; Mima, S; Tsuchiya, T; Mizushima, T			Molecular mechanism for functional interaction between DnaA protein and acidic phospholipids - Identification of important amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTATIONAL ANALYSIS; ESCHERICHIA-COLI CHROMOSOME; UNSATURATED FATTY-ACIDS; INITIATOR PROTEIN; BINDING DOMAIN; ATP-BINDING; IN-VITRO; REPLICATION; MUTANTS; CARDIOLIPIN	DnaA protein, the initiator of chromosomal DNA replication in Escherichia coli, seems to be reactivated hom the ADP-bound form to its ATP-bound form through stimulation of ADP release by acidic phospholipids such as cardiolipin; We previously reported that two potential amphipathic helixes (Lys-327 to Ile-344 and Asp-357 to Val-374) of DnaA protein are involved in the functional interaction between DnaA and cardiolipin, In relation to one of these helixes (Asp-357 to Val-374), we demonstrated that basic amino acids in the helix, especially Lys-372, are vital for this interaction. In this study, we have identified an amino acid in the second potential amphipathic helix (Lys-327 to Ile-344), which would also appear to be involved in the interaction. We constructed three mutant dnaA genes with a single mutation (dnaAR328E, dnaAR334E, and dnaAR342E) and examined the function of the mutant proteins. DnaAR328E, but not DnaAR334E and DnaAR342E, was found to be more resistant to inhibition of its ATP binding activity by cardiolipin than the wild-type protein, The stimulation of ADP release from DnaAR328E by cardiolipin was also weaker than that observed with the other mutants and the wild-type protein, These results suggest that Arg-328 of DnaA protein is involved in the functional interaction of this protein with acidic phospholipids. We propose that acidic phospholipids bind to two basic amino acid residues (Arg-328 and Lys-372) of DnaA protein and change the higher order structure of its ATP-binding pocket, which in turn stimulates the release of ADP from the protein.	Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan; Japan Sci & Technol Corp, PRESTO, Okayama 7008530, Japan	Okayama University; Japan Science & Technology Agency (JST)	Mizushima, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.							Blaesing F, 2000, MOL MICROBIOL, V36, P557, DOI 10.1046/j.1365-2958.2000.01881.x; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hase M, 1998, J BIOL CHEM, V273, P28651, DOI 10.1074/jbc.273.44.28651; Hase M, 1998, J BIOCHEM-TOKYO, V123, P680; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kurokawa K, 1998, BIOCHEM BIOPH RES CO, V243, P90, DOI 10.1006/bbrc.1997.8069; Makise M, 2000, J BIOL CHEM, V275, P4513, DOI 10.1074/jbc.275.6.4513; Makise M, 1999, BIOL PHARM BULL, V22, P904; Mima S, 1999, FEMS MICROBIOL LETT, V176, P163; Mizushima T, 1997, EMBO J, V16, P3724, DOI 10.1093/emboj/16.12.3724; Mizushima T, 1998, J BIOL CHEM, V273, P20847, DOI 10.1074/jbc.273.33.20847; Mizushima T, 2000, J BIOCHEM-TOKYO, V127, P1; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Mizushima T, 1996, J BIOL CHEM, V271, P25178, DOI 10.1074/jbc.271.41.25178; Mizushima T, 1997, J BIOL CHEM, V272, P21195, DOI 10.1074/jbc.272.34.21195; Mizushima T, 1996, MOL GEN GENET, V252, P212, DOI 10.1007/BF02173222; Neuwald AF, 1999, GENOME RES, V9, P27; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHINPUKU T, 1995, BIOCHEM BIOPH RES CO, V212, P84, DOI 10.1006/bbrc.1995.1939; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; Suzuki E, 1998, BIOL PHARM BULL, V21, P657; Suzuki E, 1998, MOL MICROBIOL, V28, P95, DOI 10.1046/j.1365-2958.1998.00777.x; Weigel C, 1999, MOL MICROBIOL, V34, P53, DOI 10.1046/j.1365-2958.1999.01568.x; WEIMING X, 1995, P NATL ACAD SCI USA, P783; Yamaguchi Y, 1999, BIOCHEM J, V340, P433, DOI 10.1042/0264-6021:3400433; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	37	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7450	7456		10.1074/jbc.M009643200	http://dx.doi.org/10.1074/jbc.M009643200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11102450	hybrid			2022-12-25	WOS:000167442900082
J	Ramon, R; Vincent, F; Grolli, S; Conti, V; Malosse, C; Boyer, FD; Meillour, PNL; Spinelli, S; Cambillau, C; Tegoni, N				Ramon, R; Vincent, F; Grolli, S; Conti, V; Malosse, C; Boyer, FD; Meillour, PNL; Spinelli, S; Cambillau, C; Tegoni, N			The insect attractant 1-octen-3-ol is the natural ligand of bovine odorant-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITIES; PHEROMONE; RECEPTOR	Bovine odorant-binding protein (bOBP) is a dimeric lipocalin present in large amounts in the respiratory and olfactory nasal mucosa, The structure of bOBP refined at 2.0-Angstrom resolution revealed an elongated volume of electron density inside each buried cavity, indicating the presence of one (or several) naturally occurring copurified ligand(s) (Tegoni et al. (1996) Nat, Struct. Biol, 3, 863-867; Bianchet ct al, (1996) Nat, Struct, Biol. 3, 934-939), In the present work, by combining mass spectrometry, x-ray crystallography (1.8-Angstrom resolution), and fluorescence, it has been unambiguously established that natural bOBP contains the racemic form of 1-octen-3-ol. This volatile substance is a typical component of bovine breath and in general of odorous body emanations of humans and animals. The compound 1-octen-3-ol is also an extremely potent olfactory attractant for many insect species, including some parasite vectors like Anopheles, (Plasmodium) or Glossina (Trypanosoma), For the first time, a function can be assigned to an OBP, with a possible role of bOBP in the ecological relationships between bovine and insect species.	Univ Parma, Fac Vet Med, Ist Biochim Vet, I-43100 Parma, Italy; CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; INRA, Unite Phytopharm & Mediateurs Chim, F-78026 Versailles, France	University of Parma; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Ramon, R (corresponding author), Univ Parma, Fac Vet Med, Ist Biochim Vet, Via Taglio 8, I-43100 Parma, Italy.	vetbioc@unipr.it; tegoni@afmb.cnrs-mrs.fr	Vincent, Florence/F-7137-2016	vincent, Florence/0000-0002-8564-4184; NAGNAN-LE MEILLOUR, Patricia/0000-0003-4527-1827; Grolli, Stefano/0000-0003-4380-5725				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BIGNETTI E, 1987, CHEM SENSES, V12, P601, DOI 10.1093/chemse/12.4.601; BIGNETTI E, 1985, EUR J BIOCHEM, V149, P227, DOI 10.1111/j.1432-1033.1985.tb08916.x; Blanchet MA, 1996, NAT STRUCT BIOL, V3, P934, DOI 10.1038/nsb1196-934; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Boudjelal M, 1996, BIOCHEM J, V317, P23, DOI 10.1042/bj3170023; Briand L, 2000, EUR J BIOCHEM, V267, P3079, DOI 10.1046/j.1432-1033.2000.01340.x; BRUNGER AT, 1997, CRYSTALLOGRAPHIC NMR; CAVAGGIONI A, 1987, FEBS LETT, V212, P225, DOI 10.1016/0014-5793(87)81349-2; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; Dal Monte M, 1993, CHEM SENSES, V18, P713; ECKL P, 1995, MUTAT RES, V290, P183; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Flower DR, 1996, BIOCHEM J, V318, P1; Herent MF, 1995, CHEM SENSES, V20, P601, DOI 10.1093/chemse/20.6.601; Husson F, 1998, J MOL CATAL B-ENZYM, V5, P159, DOI 10.1016/S1381-1177(98)00026-5; Krieger J, 1999, SCIENCE, V286, P720, DOI 10.1126/science.286.5440.720; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Loebel D, 2000, BIOCHEM J, V350, P369, DOI 10.1042/0264-6021:3500369; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Patel RC, 1997, PROTEIN ENG, V10, P621, DOI 10.1093/protein/10.6.621; PELOSI P, 1982, BIOCHEM J, V201, P245, DOI 10.1042/bj2010245; Pelosi P, 1996, J NEUROBIOL, V30, P3; PELOSI P, 1990, CHEM SENSES, V15, P205, DOI 10.1093/chemse/15.2.205; PELOSI P, 1994, CRIT REV BIOCHEM MOL, V29, P199, DOI 10.3109/10409239409086801; PEVSNER J, 1989, CHEM SENSES, V1, P227; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Roussel A, 1991, SILICON GRAPHICS GEO, P81; SLESSOR KN, 1985, J CHEM ECOL, V11, P1659, DOI 10.1007/BF01012119; Spinelli S, 1998, BIOCHEMISTRY-US, V37, P7913, DOI 10.1021/bi980179e; Takken W, 1999, ANNU REV ENTOMOL, V44, P131, DOI 10.1146/annurev.ento.44.1.131; Tegoni M, 2000, BBA-PROTEIN STRUCT M, V1482, P229, DOI 10.1016/S0167-4838(00)00167-9; Tegoni M, 1996, NAT STRUCT BIOL, V3, P863, DOI 10.1038/nsb1096-863; van den Broek IVF, 1999, J INSECT PHYSIOL, V45, P1001, DOI 10.1016/S0022-1910(99)00081-5; Vincent F, 2001, J MOL BIOL, V305, P459, DOI 10.1006/jmbi.2000.4241; Vincent F, 2000, J MOL BIOL, V300, P127, DOI 10.1006/jmbi.2000.3820	39	67	67	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7150	7155		10.1074/jbc.M010368200	http://dx.doi.org/10.1074/jbc.M010368200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11114310	Green Published, hybrid			2022-12-25	WOS:000167442900042
J	Orlandini, M; Oliviero, S				Orlandini, M; Oliviero, S			In fibroblasts Vegf-D expression is induced by cell-cell contact mediated by cadherin-11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; FACTOR-B; TUMOR ANGIOGENESIS; ADHESION MOLECULES; TYROSINE KINASES; GENE-EXPRESSION; FACTOR FAMILY; IN-VITRO; FACTOR-A	Vascular endothelial growth factors (VEGFs) are a highly conserved family of growth factors all angiogenic in vivo with mitogenic and chemotactic activity on endothelial cells. VEGFs are expressed in fibroblasts either in hypoxia or in response to growth factors. Here we report that, differently from the other members of the family, Vegf-D is induced by cell-cell contact. By in situ hybridization we demonstrated that noninteracting fibroblasts express low levels of Vegf-D mRNA, whereas contacting cells express high levels of Vegf-D transcripts. By immunostaining we observed that the surface protein cadherin-11 is localized at the opposite sites of interacting cell surfaces. Ca2+ deprivation from the culture medium determined the loss of cadherin-11 from the cell surfaces and down-regulation of Vegf-D mRNA. Moreover, a cadherin-11 antisense RNA construct inhibited Vegf-D expression in confluent BALB/c fibroblasts, whereas in NIH 3T3 cells, which express low levels of cadherin-11, Vegf-D induction could be obtained by overexpression of cadherin-11. This suggests that cell interaction mediated by cadherin-11 induces the expression of the angiogenic factor Vegf-D in fibroblasts.	Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy	University of Siena	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.		oliviero, salvatore/R-6657-2019; Orlandini, Maurizio/AAF-8247-2020	oliviero, salvatore/0000-0002-3405-765X; Orlandini, Maurizio/0000-0002-6112-4889				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Avantaggiato V, 1998, MECH DEVELOP, V73, P221, DOI 10.1016/S0925-4773(98)00049-5; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOOM R, 1986, J VIROL, V58, P851, DOI 10.1128/JVI.58.3.851-859.1986; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHOEN T, 1996, J BIOL CHEM, V271, P736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DORUDI S, 1993, AM J PATHOL, V142, P981; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Grimmond S, 1996, GENOME RES, V6, P124, DOI 10.1101/gr.6.2.124; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; HOFFMANN I, 1995, DEV BIOL, V169, P337, DOI 10.1006/dbio.1995.1148; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Joukov V, 1996, EMBO J, V15, P290; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIMURA Y, 1995, DEV BIOL, V169, P347, DOI 10.1006/dbio.1995.1149; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; MAYER B, 1993, CANCER RES, V53, P1690; MINCHENKO A, 1994, LAB INVEST, V71, P374; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; Nicosia RF, 1998, AM J PATHOL, V153, P11, DOI 10.1016/S0002-9440(10)65539-3; Niki T, 2000, CLIN CANCER RES, V6, P2431; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; OKA H, 1993, CANCER RES, V53, P1696; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SIMONNEAU L, 1995, CELL ADHES COMMUN, V3, P115, DOI 10.3109/15419069509081281; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; UMBAS R, 1994, CANCER RES, V54, P3929; Yagi T, 2000, GENE DEV, V14, P1169	50	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6576	6581		10.1074/jbc.M009573200	http://dx.doi.org/10.1074/jbc.M009573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11108717	Green Published, hybrid			2022-12-25	WOS:000167261000068
J	Patel, VB; Cunningham, CC; Hantgan, RR				Patel, VB; Cunningham, CC; Hantgan, RR			Physiochemical properties of rat liver mitochondrial ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORRESPONDING GENE-SEQUENCES; CHRONIC ETHANOL-CONSUMPTION; ESCHERICHIA-COLI RIBOSOME; HEPATIC MITOCHONDRIAL; ANGSTROM RESOLUTION; CRYOELECTRON MICROSCOPY; BOUNDARY ANALYSIS; 70S RIBOSOME; TRANSFER-RNA; PROTEINS	In the present study, the physiochemical properties of rat liver mitochondrial ribosomes were examined and compared with Escherichia coli ribosomes, The sedimentation and translational diffusion coefficients as well as the molecular weight and buoyant density of rat mitochondrial ribosomes were determined. Sedimentation coefficients were established using the time-derivative algorithm (Philo, J, S, (2000) Anal, Biochem, 279, 151-163), The sedimentation coefficients of the intact monosome, large subunit, and small subunit were 55, 39, and 28 S, respectively. Mitochondrial ribosomes had a particle composition of 75% protein and 25% RNA. The partial specific volume was 0.688 ml/g, as determined from the protein and RNA composition. The buoyant density of formaldehyde-fixed ribosomes in cesium chloride was 1.41 g/cm(3). The molecular masses of mitochondrial and E, coli ribosomes determined by static lightscattering experiments were 3.57 +/- 0.14 MDa and 2.49 +/- 0.06 MDa, respectively. The diffusion coefficient obtained from dynamic light scattering measurements was 1.10 +/- 0.01 x 10(-7) cm(2) s(-1) for mitochondrial ribosomes and 1.72 +/- 0.03 x 10(-7) cm(2) s(-1) for the 70 S E, coli monosome, The hydration factor determined from these hydrodynamic parameters were 4.6 g of water/g of ribosome and 1.3 g/g for mitochondrial and E, coli ribosomes, respectively. A calculated hydration factor of 3.3 g/g for mitochondrial ribosomes was also obtained utilizing a calculated molecular mass and the Svedberg equation. These measurements of solvation suggest that ribosomes are highly hydrated structures. They are also in agreement with current models depicting ribosomes as porous structures containing numerous gaps and tunnels.	Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Cunningham, CC (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.	cunn@wfubmc.edu			PHS HHS [00279, 02887, 11272] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agrawal RK, 1999, INT J BIOCHEM CELL B, V31, P243, DOI 10.1016/S1357-2725(98)00149-6; Agrawal RK, 1999, CURR OPIN STRUC BIOL, V9, P215, DOI 10.1016/S0959-440X(99)80031-1; ALLEN SH, 1979, ARCH BIOCHEM BIOPHYS, V195, P112, DOI 10.1016/0003-9861(79)90332-1; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; Berne B, 1990, DYNAMIC LIGHT SCATTE; CAHILL A, 1995, ANAL BIOCHEM, V232, P47, DOI 10.1006/abio.1995.9962; Cahill A, 1996, ALCOHOL CLIN EXP RES, V20, P1362, DOI 10.1111/j.1530-0277.1996.tb01135.x; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Chinnery PF, 1999, LANCET, V354, pSI17; COLEMAN WB, 1990, BIOCHIM BIOPHYS ACTA, V1019, P142, DOI 10.1016/0005-2728(90)90136-R; COLEMAN WB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P178, DOI 10.1016/S0005-2728(05)80235-X; Dube P, 1998, J MOL BIOL, V279, P403, DOI 10.1006/jmbi.1998.1804; FAHIEN LA, 1992, J BIOL CHEM, V267, P10411; Frank J, 1998, BIOPHYS J, V74, P589, DOI 10.1016/S0006-3495(98)77817-8; FROMENTY B, 1995, GASTROENTEROLOGY, V108, P193, DOI 10.1016/0016-5085(95)90024-1; GABLER R, 1974, BIOPHYS J, V14, P528, DOI 10.1016/S0006-3495(74)85933-3; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; HAGA JY, 1970, J CELL BIOL, V47, P211, DOI 10.1083/jcb.47.1.211; HAMILTON MG, 1974, BIOCHEMISTRY-US, V13, P5400, DOI 10.1021/bi00723a024; HAMILTON MG, 1962, J BIOL CHEM, V237, P1155; HAMILTON MG, 1969, BIOCHEMISTRY-US, V8, P851, DOI 10.1021/bi00831a013; HAMILTON MG, 1971, METHOD ENZYMOL, V20, P512; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; HANTGAN RR, 1993, BIOCHEMISTRY-US, V32, P3935, DOI 10.1021/bi00066a013; HASCHMEYER RH, 1981, PRINCIPLES TECHNIQUE, V2, P110; HILL WE, 1969, J MOL BIOL, V44, P263, DOI 10.1016/0022-2836(69)90174-0; HOLLADAY LA, 1977, BIOCHEMISTRY-US, V16, P4895, DOI 10.1021/bi00641a024; IFFT JB, 1961, J PHYS CHEM-US, V65, P1138, DOI 10.1021/j100825a011; IGARASHI Y, 1973, J BIOCHEM-TOKYO, V73, P683, DOI 10.1093/oxfordjournals.jbchem.a130131; JOHNSON CS, 1981, SPECTROSCOPY BIOCH, V2, P177; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; KOPPEL DE, 1974, BIOCHEMISTRY-US, V13, P2712, DOI 10.1021/bi00710a009; LEISTER DE, 1974, J BIOL CHEM, V249, P5108; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; NIEUWENHUYSEN P, 1981, J BIOL CHEM, V256, P9626; O'Brien TW, 1999, J BIOL CHEM, V274, P36043, DOI 10.1074/jbc.274.51.36043; O'Brien TW, 2000, J BIOL CHEM, V275, P18153, DOI 10.1074/jbc.M909762199; OBRIEN TW, 1971, J BIOL CHEM, V246, P3409; PETERMANN ML, 1966, BIOCHIM BIOPHYS ACTA, V114, P264, DOI 10.1016/0005-2787(66)90308-X; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; PIETROMONACO SF, 1986, J MOL EVOL, V24, P110, DOI 10.1007/BF02099958; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; SACCHI A, 1973, BIOCHIM BIOPHYS ACTA, V308, P390, DOI 10.1016/0005-2787(73)90332-8; SACCHI A, 1977, BIOCHEM J, V168, P245, DOI 10.1042/bj1680245; SCAFATI AR, 1971, BIOPHYS J, V11, P370, DOI 10.1016/S0006-3495(71)86221-5; Sober H. A., 1968, CRC HDB BIOCH; SPIRIN AS, 1965, J MOL BIOL, V14, P611, DOI 10.1016/S0022-2836(65)80213-3; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; Svedberg T, 1940, THE ULTRACENTRIFUGE; Svergun DI, 1997, J MOL BIOL, V271, P588, DOI 10.1006/jmbi.1997.1190; Tanford C., 1961, PHYS CHEM MACROMOLEC, P356; TISSIERES A, 1959, J MOL BIOL, V1, P221, DOI 10.1016/S0022-2836(59)80029-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Heel M, 2000, CURR OPIN STRUC BIOL, V10, P259, DOI 10.1016/S0959-440X(00)00077-4; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602	60	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6739	6746		10.1074/jbc.M005781200	http://dx.doi.org/10.1074/jbc.M005781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11106644	Green Accepted, hybrid			2022-12-25	WOS:000167261000086
J	Hanada, M; Ninomiya-Tsuji, J; Komaki, K; Ohnishi, M; Katsura, K; Kanamaru, R; Matsumoto, K; Tamura, S				Hanada, M; Ninomiya-Tsuji, J; Komaki, K; Ohnishi, M; Katsura, K; Kanamaru, R; Matsumoto, K; Tamura, S			Regulation of the TAK1 signaling pathway by protein phosphatase 2C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE PHOSPHATASE; N-TERMINAL KINASE; MOLECULAR-CLONING; MAP KINASE; FISSION YEAST; HEAT-SHOCK; STRESS; CASCADE; TRANSDUCTION; ACTIVATION	Protein phosphatase 2C (PP2C) is implicated in the negative regulation of stress-activated protein kinase cascades in yeast and mammalian cells. In this study, we determined the role of PP2C beta -1, a major isoform of mammalian PP2C, in the TAK1 signaling pathway, a stress-activated protein kinase cascade that is activated by interleukin-l, transforming growth factor-beta, or stress. Ectopic expression of PP2C beta -1 inhibited the TAK1-mediated mitogen-activated protein kinase kinase 4-c-Jun amino-terminal kinase and mitogen activated protein kinase kinase 6-p38 signaling pathways. In vitro, PP2C beta -1 dephosphorylated and inactivated TAK1. Coimmunoprecipitation experiments indicated that PP2C beta -1 associates with the central region of TAK1. A phosphatase-negative mutant of PP2C beta -1, PP2C beta -1 (R/G), acted as a dominant negative mutant, inhibiting dephosphorylation of TAK1 by wild type PP2C beta -1 in vitro. In addition, ectopic expression of PP2C beta -1(R/G) enhanced interleukin-l-induced activation of an AP-1 reporter gene. Collectively, these results indicate that PP2C beta negatively regulates the TAK1 signaling pathway by direct dephosphorylation of TAK1.	Tohoku Univ, Inst Dev Aging & Canc, Dept Biochem, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Tohoku Univ, Sch Dent, Dept Geriatr Dent, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University; Nagoya University; Tohoku University	Tamura, S (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Biochem, Aoba Ku, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.			Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Beltman J, 1999, J BIOL CHEM, V274, P3772, DOI 10.1074/jbc.274.6.3772; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Gaits F, 1997, J BIOL CHEM, V272, P17873, DOI 10.1074/jbc.272.28.17873; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; KATO S, 1995, ARCH BIOCHEM BIOPHYS, V318, P387, DOI 10.1006/abbi.1995.1244; KATO S, 1994, GENE, V145, P311, DOI 10.1016/0378-1119(94)90026-4; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Kitani T, 1999, J BIOCHEM-TOKYO, V125, P1022, DOI 10.1093/oxfordjournals.jbchem.a022381; Kusuda K, 1998, BIOCHEM J, V332, P243, DOI 10.1042/bj3320243; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; TERASAWA T, 1993, ARCH BIOCHEM BIOPHYS, V307, P342, DOI 10.1006/abbi.1993.1598; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Travis SM, 1997, FEBS LETT, V412, P415, DOI 10.1016/S0014-5793(97)00837-5; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	32	118	123	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5753	5759		10.1074/jbc.M007773200	http://dx.doi.org/10.1074/jbc.M007773200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11104763	hybrid			2022-12-25	WOS:000167115100049
J	Huang, ZZ; Chen, CJ; Zeng, ZH; Yang, HP; Oh, J; Chen, LX; Lu, SC				Huang, ZZ; Chen, CJ; Zeng, ZH; Yang, HP; Oh, J; Chen, LX; Lu, SC			Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration	FASEB JOURNAL			English	Article									Univ So Calif, Sch Med, Dept Med,USC Liver Dis Res Ctr, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA	University of Southern California	Lu, SC (corresponding author), Univ So Calif, Sch Med, Dept Med,USC Liver Dis Res Ctr, Div Gastrointestinal & Liver Dis, HMR Bldg,415,2011 Zonal Ave, Los Angeles, CA 90033 USA.	shellylu@hsc.usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045334, R56DK045334, R29DK045334, P30DK048522] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48522, DK-45334] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Marinho HS, 1997, BBA-MOL BASIS DIS, V1360, P157, DOI 10.1016/S0925-4439(96)00075-0	1	154	166	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					19	21		10.1096/fj.00-0445fje	http://dx.doi.org/10.1096/fj.00-0445fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099488				2022-12-25	WOS:000166312400007
J	Muller, M; Fleischmann, BK; Selbert, S; Ji, GJ; Endl, E; Middeler, G; Muller, OJ; Schlenke, P; Frese, S; Wobus, AM; Hescheler, J; Katus, HA; Franz, WM				Muller, M; Fleischmann, BK; Selbert, S; Ji, GJ; Endl, E; Middeler, G; Muller, OJ; Schlenke, P; Frese, S; Wobus, AM; Hescheler, J; Katus, HA; Franz, WM			Selection of ventricular-like cardiomyocytes from ES cells in vitro	FASEB JOURNAL			English	Article						embryoid body; cardiac; green fluorescent protein; in vitro differentiation	EMBRYONIC STEM-CELLS; IN-VITRO; TRANSCRIPTION FACTOR; MYOCARDIAL TISSUE; TRANSGENIC MICE; GENE-EXPRESSION; IONIC CURRENTS; RETINOIC ACID; MUSCLE-CELLS; CA2+ CHANNEL	Ischemic disorders of the heart can cause an irreversible loss of cardiomyocytes resulting cause an irreversible loss of cardiomyocytes resulting in a substantial decrease of cardiac output. The therapy of choice is heart transplantation, a technique that is hampered by the low number of donor organs. in the present study, we describe the specific labeling, rapid but gentle purification and characterization of cardiomyocytes derived from mouse pluripotent embryonic stem (ES) cells. To isolate the subpopulation of ventricular-like cardiomyocytes, ES cells were stable transfected with the enhanced green fluorescent protein (EGFP) under transcriptional control of the ventricular-specific 2.1 kb myosin light chain-2v (MLC-2v) promoter and the 0.5 kb enhancer element of the cytomegalovirus (CMVenh.). First fluorescent cells were detected at day 6 + 8 of differentiation within EBs. Four weeks after initiation of differentiation 25% of the cardiomyocyte population displayed fluorescence. Immunohistochemistry revealed the exclusive cardiomyogenic nature of EGFP-positive cells. This was further corroborated by electrophysiological studies where preferentially ventricular phenotypes, but no pacemaker-like cardiomyocytes, were detected among the EGFP-positive population. The enzymatic digestion of EBs, followed by Percoll gradient centrifugation and fluorescence-activated cell sorting, resulted in a 97% pure population of cardiomyocytes. Based on this study, ventricular-like cardiomyocytes can be generated in vitro from EBs and labeled using CMVenh./MLC-2V-driven marker genes facilitating an efficient purification. This method may become an important tool for future cell replacement therapy of ischemic cardiomyopathy especially after the proof of somatic differentiation of human ES cells in vitro.	Med Univ Lubeck, Med Klin 2, D-23538 Lubeck, Germany; Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; Res Ctr, Div Mol Immunol, D-23845 Borstel, Germany; Inst Plant Genet & Crop Plant Res, D-06466 Gatersleben, Germany; Med Univ Lubeck, Dept Immunol, D-23538 Lubeck, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University of Cologne; Forschungszentrum Borstel; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; University of Lubeck	Franz, WM (corresponding author), Med Univ Lubeck, Med Klin 2, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	franz@medinf.mu-luebeck.de	Müller, Oliver J./H-4739-2016; Müller, Oliver/AAA-4399-2021	Müller, Oliver/0000-0001-8223-2638; Muller, Mathias/0000-0002-7879-3552				ANVERSA P, 1991, CIRC RES, V69, P1159, DOI 10.1161/01.RES.69.4.1159; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOUVAGNET P, 1984, CIRC RES, V55, P794, DOI 10.1161/01.RES.55.6.794; BUGAISKY LB, 1989, CIRC RES, V64, P493, DOI 10.1161/01.RES.64.3.493; DANGOOR M, 1990, J MUSCLE RES CELL M, V11, P216, DOI 10.1007/BF01843575; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Drab M, 1997, FASEB J, V11, P905, DOI 10.1096/fasebj.11.11.9285489; FRANZ WM, 1993, CIRC RES, V73, P629, DOI 10.1161/01.RES.73.4.629; Grepin C, 1997, DEVELOPMENT, V124, P2387; HAMILL OP, 1981, NATURE, V294, P462, DOI 10.1038/294462a0; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Ji GJ, 1999, FASEB J, V13, P313, DOI 10.1096/fasebj.13.2.313; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; KOH GY, 1995, J CLIN INVEST, V96, P2034, DOI 10.1172/JCI118251; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; LEE KJ, 1992, J BIOL CHEM, V267, P15875; Leor J, 1996, CIRCULATION, V94, P332; Li RK, 1996, CARDIOVASC RES, V32, P362, DOI 10.1016/0008-6363(96)00079-X; Li RK, 1997, CIRCULATION, V96, P179; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; Maltsev VA, 1999, CIRC RES, V84, P136, DOI 10.1161/01.RES.84.2.136; METZGER JM, 1994, J CELL BIOL, V126, P701, DOI 10.1083/jcb.126.3.701; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; Rothmann T, 1996, GENE THER, V3, P919; Schwarz ER, 1998, Z KARDIOL, V87, P1, DOI 10.1007/s003920050147; SEN A, 1988, J BIOL CHEM, V263, P19132; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wartenberg M, 1998, LAB INVEST, V78, P1301; Watanabe E, 1998, CELL TRANSPLANT, V7, P239, DOI 10.1016/S0963-6897(98)00011-6; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; ZEHELEIN J, 1993, Z KARDIOL S1, V82, P155	43	227	267	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2540	2548		10.1096/fj.00-0002com	http://dx.doi.org/10.1096/fj.00-0002com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099473				2022-12-25	WOS:000165723400025
J	Sein, TT; Thant, AA; Hiraiwa, Y; Amin, ARMR; Sohara, Y; Liu, YZ; Matsuda, S; Yamamoto, T; Hamaguchi, M				Sein, TT; Thant, AA; Hiraiwa, Y; Amin, ARMR; Sohara, Y; Liu, YZ; Matsuda, S; Yamamoto, T; Hamaguchi, M			A role for FAK in the concanavalin A-dependent secretion of matrix metalloproteinase-2 and-9	ONCOGENE			English	Article						matrix metalloproteinase; MMP-2; MMP-9; FAK; concanavalin A; signal transduction	FOCAL ADHESION KINASE; CELL-ADHESION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; C-RAS; COLLAGENASE; ACTIVATION; CANCER; INVASION; FIBROBLASTS	To study the signaling pathway critical for the secretion of matrix metalloproteinases (MMPs), we examined the role of focal adhesion kinase (FAK) in Concanavalin A (Con A)-stimulated cells, We established a cell line in which FAK gene was conditionally inducible by use of EAR-nub fibroblasts and the tetracycline repression system. In this cell line, FAK expression was undetectable in the presence of tetracycline but induced within 1 day by the removal of the drug. We found that FAK expression augmented the Con A-dependent secretion of MMP-9 and MMP-2, In contrast, proteolytic activation of MMP-2 by Con A-treatment did not require FAK expression. In addition, activation of MMP-secretion and tyrosine phosphorylation of FAK by Con A, but not the proteolytic activation of MMP-2, required attachment of the cells to the extracellular matrix. Taken together, our results suggest that the FAK signaling pathway play a pivotal role in the secretion of MMPs.	Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan	Nagoya University; University of Tokyo	Hamaguchi, M (corresponding author), Nagoya Univ, Sch Med, Lab Mol Pathogenesis, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.			AMIN, ARM/0000-0001-9144-2960				BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3053; HURUM S, 1982, BIOCHEM BIOPH RES CO, V107, P357, DOI 10.1016/0006-291X(82)91712-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kataoka M, 1996, INT J ONCOL, V8, P773; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIOTTA LA, 1986, CANCER RES, V46, P1; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Shibata K, 1997, CANCER RES, V57, P5416; Shibata K, 1998, CANCER RES, V58, P900; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S	17	75	81	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5539	5542		10.1038/sj.onc.1203932	http://dx.doi.org/10.1038/sj.onc.1203932			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114732				2022-12-25	WOS:000165396100015
J	Kogan, I; Ramjeesingh, M; Huan, LJ; Wang, YC; Bear, CE				Kogan, I; Ramjeesingh, M; Huan, LJ; Wang, YC; Bear, CE			Perturbation of the pore of the cystic fibrosis transmembrane conductance regulator (CFTR) inhibits its ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; NUCLEOTIDE-BINDING DOMAINS; CHLORIDE CHANNEL; CL CHANNEL; CELL-LINE; HYDROLYSIS; PERMEATION; MUTATIONS; ANION; GENE	Mutations in the cystic fibrosis gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) lead to altered chloride (Cl-) flux in affected epithelial tissues. CFTR is a Cl- channel that is regulated by phosphorylation, nucleotide binding, and hydrolysis, However, the molecular basis for the functional regulation of wild type and mutant CFTR remains poorly understood. CFTR possesses two nucleotide binding domains, a phosphorylation-dependent regulatory domain, and two transmembrane domains that comprise the pore through which Cl- permeates. Mutations of residues lining the channel pore (e.g. R347D) are typically thought to cause disease by altering the interaction of Cl- with the pore. However, in the present study we show that the R347D mutation and diphenylamine-2-carboxylate (an open pore inhibitor) also inhibit CFTR ATPase activity, revealing a novel mechanism for cross-talk from the pore to the catalytic domains. In both cases, the reduction in ATPase correlates with a decrease in nucleotide turnover rather than affinity. Finally, we demonstrate that glutathione (GSH) inhibits CFTR ATPase and that this inhibition is altered in the CFTR-R347D variant. These findings suggest that cross-talk between the pore and nucleotide binding domains of CFTR may be important in the in vivo regulation of CFTR in health and disease.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1XB, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1XB, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Bear, CE (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1XB, Canada.							AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; Arsalane K, 1997, AM J RESP CELL MOL, V17, P599, DOI 10.1165/ajrcmb.17.5.2833; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Chen TY, 1996, J GEN PHYSIOL, V108, P237, DOI 10.1085/jgp.108.4.237; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cotten JF, 1999, J BIOL CHEM, V274, P5429, DOI 10.1074/jbc.274.9.5429; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; Harrington MA, 1999, J BIOL CHEM, V274, P27536, DOI 10.1074/jbc.274.39.27536; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Linsdell P, 1998, J GEN PHYSIOL, V111, P601, DOI 10.1085/jgp.111.4.601; Linsdell P, 1998, AM J PHYSIOL-CELL PH, V275, pC323, DOI 10.1152/ajpcell.1998.275.1.C323; Linsdell P, 1996, J PHYSIOL-LONDON, V496, P687, DOI 10.1113/jphysiol.1996.sp021719; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; MCCARTY NA, 1993, J GEN PHYSIOL, V102, P1, DOI 10.1085/jgp.102.1.1; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; Pilewski JM, 1999, PHYSIOL REV, V79, P215; POOT M, 1995, J CELL PHYSIOL, V163, P555, DOI 10.1002/jcp.1041630316; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Pusch M, 1999, J PHYSIOL-LONDON, V515, P341, DOI 10.1111/j.1469-7793.1999.341ac.x; RAHMAN I, 1995, AM J PHYSIOL-LUNG C, V269, pL285, DOI 10.1152/ajplung.1995.269.3.L285; Ramjeesingh M, 1999, BIOCHEM J, V342, P119, DOI 10.1042/0264-6021:3420119; Ramjeesingh M, 1997, BIOCHEM J, V327, P17, DOI 10.1042/bj3270017; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; Ramjeesingh M, 1999, Methods Enzymol, V294, P227; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schultz BD, 1996, J MEMBRANE BIOL, V151, P63, DOI 10.1007/s002329900058; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SUN JD, 1988, EXP MOL PATHOL, V49, P254, DOI 10.1016/0014-4800(88)90038-X; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; Tabcharani JA, 1997, J GEN PHYSIOL, V110, P341, DOI 10.1085/jgp.110.4.341; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; WANGEMANN P, 1986, PFLUG ARCH        S2, V407, P128; Zeltwanger S, 1999, J GEN PHYSIOL, V113, P541, DOI 10.1085/jgp.113.4.541; Zhang ZR, 2000, J MEMBRANE BIOL, V175, P35, DOI 10.1007/s002320001053; Zhang ZR, 2000, BIOPHYS J, V79, P298, DOI 10.1016/S0006-3495(00)76292-8	57	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11575	11581		10.1074/jbc.M010403200	http://dx.doi.org/10.1074/jbc.M010403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11124965	hybrid			2022-12-25	WOS:000168081800023
J	Yung, TMC; Satoh, MS				Yung, TMC; Satoh, MS			Functional competition between poly(ADP-ribose) polymerase and its 24-kDa apoptotic fragment in DNA repair and transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE PRODUCT; EXCISION-REPAIR; CELLS; BINDING; ASSOCIATION; PARP; COACTIVATOR; INHIBITION; ELONGATION; INDUCTION	Poly(ADP-ribose) polymerase is a 113-kDa nuclear enzyme that binds to both damaged DNA and to RNA associated with actively transcribed regions of chromatin. Binding of poly(ADP-ribose) polymerase to DNA lesions activates it, catalyzing the covalent addition of multiple ADP-ribose polymers to the enzyme (automodification). During apoptosis, poly(ADP-ribose) polymerase is cleaved by caspase-3, resulting in the formation of an N-terminal 24-kDa fragment, containing the DNA binding domain, and a C-terminal 89-kDa catalytic fragment. The functional relevance of this cleavage is not well understood. We therefore prepared a recombinant 24-kDa poly(ADP-ribose) polymerase fragment and investigated the role of this fragment in DNA repair and transcription. The 24-kDa fragment retained its binding affinity for both DNA breaks and RNA. In an in vitro cell-free DNA repair assay, this fragment inhibited rejoining of DNA breaks and suppressed ADP-ribose polymer formation by competing with poly(ADP-ribose) polymerase in binding to DNA breaks. With regard to transcription, it has recently been demonstrated that binding of poly(ADP-ribose) polymerase to transcribed RNA reduces the rate of transcript elongation and that automodification of poly(ADP-ribose) polymerase bound to DNA breaks results in up-regulation of transcription. We tested the 24-kDa fragment for its ability to suppress transcript elongation, and we found that it competed against the up-regulation of transcription mediated by full-length poly(ADP-ribose) polymerase. The ability of the 24-kDa fragment to inhibit DNA repair, ADP-ribose polymer formation, and damage-dependent up-regulation of transcription may contribute to the apoptotic shift from cell survival to cell death mode.	Univ Laval, DNA Repair Grp, Hlth & Environm Unit, Med Ctr,CHUQ,Fac Med, Ste Foy, PQ G1V 4G2, Canada	Laval University	Satoh, MS (corresponding author), Univ Laval, DNA Repair Grp, Hlth & Environm Unit, Med Ctr,CHUQ,Fac Med, 2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	Masahiko.sato@crchul.ulaval.ca						ALTHAUS FR, 1987, ADP RIBOSYLATION PRO, P3; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; D'Silva I, 1999, BBA-PROTEIN STRUCT M, V1430, P119, DOI 10.1016/S0167-4838(98)00278-7; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Desnoyers S, 1996, EXP CELL RES, V227, P146, DOI 10.1006/excr.1996.0259; Duriez PJ, 1997, BBA-GEN SUBJECTS, V1334, P65, DOI 10.1016/S0304-4165(96)00077-3; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; FAKAN S, 1988, EXP CELL RES, V179, P517, DOI 10.1016/0014-4827(88)90289-3; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Halappanavar SS, 1999, J BIOL CHEM, V274, P37097, DOI 10.1074/jbc.274.52.37097; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1991, EXP CELL RES, V192, P524, DOI 10.1016/0014-4827(91)90072-3; Kim JW, 2000, J BIOL CHEM, V275, P8121, DOI 10.1074/jbc.275.11.8121; Kim JW, 2000, J CELL SCI, V113, P955; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; OHGUSHI H, 1980, J BIOL CHEM, V255, P6205; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Satoh MS, 1996, NUCLEIC ACIDS RES, V24, P3576, DOI 10.1093/nar/24.18.3576; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Smulson ME, 1998, CANCER RES, V58, P3495; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579	44	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11279	11286		10.1074/jbc.M008044200	http://dx.doi.org/10.1074/jbc.M008044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11124257	hybrid			2022-12-25	WOS:000167980900095
J	Mandal, M; Vadlamudi, R; Nguyen, D; Wang, RA; Costa, L; Bagheri-Yarmand, R; Mendelsohn, J; Kumar, R				Mandal, M; Vadlamudi, R; Nguyen, D; Wang, RA; Costa, L; Bagheri-Yarmand, R; Mendelsohn, J; Kumar, R			Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEINS; MONOCLONAL-ANTIBODY; HNRNP-K; FACTOR RECEPTOR; BREAST-CANCER; MESSENGER-RNA; CELLS; IDENTIFICATION; PRODUCT; TRANSFORMATION	Epidermal growth factor (EGF) family of growth factors and their receptors regulate normal and cancerous epithelial cell proliferation, a process that can be suppressed by antireceptor blocking antibodies. To identify genes whose expression may be modulated by antireceptor blocking antibodies, we performed a differential display screen with cells grown in the presence or absence of antireceptor blocking antibodies; isolates from one cDNA clone were 100% identical to human heterogeneous nuclear ribonucleoprotein K (hnRNP K), a protein with a conserved KH motif and RGG boxes, has been implicated in such functions as sequence-specific DNA binding, transcription, RNA binding, and nucleocytoplasmic shuttling. Both EGF and heregulin-beta1 induced expression of hnRNP K mRNA and protein in human breast cancer cells. This growth factor-mediated hnRNP K expression was effectively blocked by pretreatment of cultures with humanized anti-EGF receptor (EGFR) antibody C225, or anti-human epidermal growth factor receptor-2 (HERS) antibody. Anti-EGFR monoclonal antibody also caused regression of human tumor xenografts and reduction in hnRNP K levels in athymic mice, Samples from grade III human breast cancer contained more hnRNP K protein than samples from grade II cancer. Finally, overexpression of hnRNP K in breast cancer cells significantly increased target c-myc promoter activity and c-Myc protein, hnRNP K protein levels, and enhanced breast cancer cell proliferation and growth in an anchorage-independent manner. These results suggested that the activity of human EGF receptor family members regulates hnRNP K expression by extracellular growth promoting signals and that therapeutic humanized antibodies against EGFR and HER2 can effectively block this function.	Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022; Wang, Brian/HGA-9535-2022	Mandal, Mahitosh/0000-0003-3861-3323; Costa, Luis/0000-0002-4782-7318; Bagheri-Yarmand, Rozita/0000-0001-5139-6381	NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746] Funding Source: NIH RePORTER; NCI NIH HHS [CA65746, CA80066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; Charroux B, 1999, MOL CELL BIOL, V19, P7846, DOI 10.1128/mcb.19.11.7846; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; FAN Z, 1993, J BIOL CHEM, V268, P21073; GAILLARD C, 1994, NUCLEIC ACIDS RES, V22, P4183, DOI 10.1093/nar/22.20.4183; GILL GN, 1984, J BIOL CHEM, V259, P755; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; Lee MH, 1996, J BIOL CHEM, V271, P3420; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; MENDELSOHN J, 1999, P AN M AM SOC CLIN, V18, pA389; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Norton L, 1999, P AN M AM SOC CLIN, V18, p127a; PEREZSOLER R, 1998, P AN M AM SOC CLIN, V17, pA393; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Sueoka E, 1999, CANCER RES, V59, P1404; SWANSON MS, 1995, PREMRNA PROCESSING, P17; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Vadlamudi R, 1999, CANCER RES, V59, P2843; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Zhang K, 1996, J BIOL CHEM, V271, P3884	44	109	115	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9699	9704		10.1074/jbc.M008514200	http://dx.doi.org/10.1074/jbc.M008514200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11121407	hybrid			2022-12-25	WOS:000167996400017
J	Murakami, M; Koduri, RS; Enomoto, A; Shimbara, S; Seki, M; Yoshihara, K; Singer, A; Valentin, E; Ghomashchi, F; Lambeau, G; Gelb, MH; Kudo, I				Murakami, M; Koduri, RS; Enomoto, A; Shimbara, S; Seki, M; Yoshihara, K; Singer, A; Valentin, E; Ghomashchi, F; Lambeau, G; Gelb, MH; Kudo, I			Distinct arachidonate-releasing functions of mammalian secreted phospholipase A(2)s in human embryonic kidney 293 and rat mastocytoma RBL-2H3 cells through heparan sulfate shuttling and external plasma membrane mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; ACTIVATED MAST-CELLS; SMOOTH-MUSCLE CELLS; FATTY-ACID RELEASE; ESCHERICHIA-COLI; PROSTAGLANDIN GENERATION; RECOMBINANT EXPRESSION; EICOSANOID GENERATION; MESANGIAL CELLS; MOUSE	We analyzed the ability of a diverse set of mammalian secreted phospholipase A, (sPLA(2)) to release arachidonate for lipid mediator generation in two transfected cell lines. In human embryonic kidney 293 cells, the heparin-binding enzymes sPLA(2)-IIA, -IID, and -V promote stimulus-dependent arachidonic acid release and prostaglandin E, production in a manner dependent on the heparan sulfate proteoglycan glypican, In contrast, sPLA(2)-IB, -IIC, and -IIE, which bind weakly or not at all to heparanoids, fail to elicit arachidonate release, and addition of a heparin binding site to sPLA(2)-IIC allows it to release arachidonate, Heparin nonbinding sPLA(2)-X liberates arachidonic acid most likely from the phosphatidylcholine-rich outer plasma membrane in a glypican-independent manner. In rat mastocytoma RBL-2H3 cells that lack glypican, sPLA(2)-V and -X, which are unique among sPLA(2)s in being able to hydrolyze phosphatidylcholine-rich membranes, act most likely on the extracellular face of the plasma membrane to markedly augment IgE-dependent immediate production of leukotriene C, and platelet-activating factor. sPLA(2)-IB, -IIA, -IIC, -IID, and -IIE exert minimal effects in RBL-2H3 cells. These results are also supported by studies with sPLA(2), mutants and immunocytostaining and reveal that sPLA(2)-dependent lipid mediator generation occur by distinct (heparanoid-dependent and -independent) mechanisms in HEK293 and RBL-2H3 cells.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Showa University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.		Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL36235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R01HL036235, R37HL036235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; CUPILLARD L, 1997, J BIOL CHEM, V272, P15145; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DOLE VP, 1960, J BIOL CHEM, V235, P2595; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; Enomoto A, 2000, BIOCHEM BIOPH RES CO, V276, P667, DOI 10.1006/bbrc.2000.3468; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Ivandic B, 1999, ARTERIOSCL THROM VAS, V19, P1284, DOI 10.1161/01.ATV.19.5.1284; KIM KP, 2000, J BIOL CHEM; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1107, P217; KURIHARA H, 1991, BIOCHIM BIOPHYS ACTA, V1082, P285, DOI 10.1016/0005-2760(91)90204-U; Kuwata H, 2000, J IMMUNOL, V165, P4024, DOI 10.4049/jimmunol.165.7.4024; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Laine VJO, 1999, J IMMUNOL, V162, P7402; Laine VJO, 2000, INFECT IMMUN, V68, P87, DOI 10.1128/IAI.68.1.87-92.2000; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; Morioka Y, 2000, FEBS LETT, V487, P262, DOI 10.1016/S0014-5793(00)02350-4; Mounier C, 1996, EUR J BIOCHEM, V237, P778, DOI 10.1111/j.1432-1033.1996.0778p.x; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nakajima K, 1997, J BIOL CHEM, V272, P19708, DOI 10.1074/jbc.272.32.19708; NAKANO T, 1990, J BIOL CHEM, V265, P12745; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Sartipy P, 2000, CIRC RES, V86, P707, DOI 10.1161/01.RES.86.6.707; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; Tada K, 1998, J IMMUNOL, V161, P5008; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WRIGHT GC, 1990, J CLIN INVEST, V85, P1925, DOI 10.1172/JCI114655; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675	74	150	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10083	10096		10.1074/jbc.M007877200	http://dx.doi.org/10.1074/jbc.M007877200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11106649	hybrid			2022-12-25	WOS:000167996400068
J	Jiang, CJ; Shoji, K; Matsuki, R; Baba, A; Inagaki, N; Ban, H; Iwasaki, T; Imamoto, N; Yoneda, Y; Deng, XW; Yamamoto, N				Jiang, CJ; Shoji, K; Matsuki, R; Baba, A; Inagaki, N; Ban, H; Iwasaki, T; Imamoto, N; Yoneda, Y; Deng, XW; Yamamoto, N			Molecular cloning of a novel importin alpha homologue from rice, by which constitutive photomorphogenic 1 (COP1) nuclear localization signal (NLS)-protein is preferentially nuclear imported	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; AMINO-ACID MOTIF; PROTEIN IMPORT; ARABIDOPSIS-THALIANA; TRANSPORT FACTOR; BINDING-PROTEIN; HIGHER-PLANTS; BETA-CATENIN; IN-VITRO; INTERACTS	Nuclear import of proteins that contain classical nuclear localization signals (NLS) is initiated by importin alpha, a protein that recognizes and binds to the NLS in the cytoplasm. In this paper, we have cloned a cDNA for a novel importin ct homologue from rice which is in addition to our previously isolated rice importin alpha 1a and alpha2, and we have named it rice importin alpha 1b. In vitro binding and nuclear import assays using recombinant importin alpha 1b protein demonstrate that rice importin alpha 1b functions as a component of the NLS-receptor in plant cells. Analysis of the transcript levels for till three rice importin alpha genes revealed that the genes were not only differentially expressed but that they also responded to dark adaptation in green leaves. Furthermore, we also show that the COP1 protein bears a bipartite-type NLS and its nuclear import is mediated preferentially by the rice importin alb. These data suggest that each of the different; rice importin alpha proteins carry distinct groups of nuclear proteins, such that multiple isoforms of importin alpha contribute to the regulation of plant nuclear protein transport.	Natl Inst Agrobiol Resources, Dept Plant Physiol, Tsukuba, Ibaraki 3058602, Japan; Cent Res Inst Elect Power Ind, Chiba 2701194, Japan; Niigata Univ, Fac Sci, Dept Biol, Niigata 9502181, Japan; Natl Inst Genet, Struct Biol Ctr, Shizuoka 4118540, Japan; Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Osaka 5650871, Japan; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Ochanomizu Univ, Fac Sci, Dept Biol, Tokyo 1128610, Japan	National Institute of Agrobiological Sciences - Japan; Central Research Institute of Electric Power Industry - Japan; Niigata University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Osaka University; Yale University; Ochanomizu University	Jiang, CJ (corresponding author), Natl Inst Agrobiol Resources, Dept Plant Physiol, Tsukuba, Ibaraki 3058602, Japan.	cjjiang@abr.affrc.go.jp	Deng, Xing Wang/ABF-4107-2020; Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022; Inagaki, Noritoshi/0000-0001-8738-6636; Jiang, Chang-Jie/0000-0003-1845-541X				AKAMA K, 1992, PLANT CELL REP, V12, P7, DOI 10.1007/BF00232413; Ballas N, 1997, P NATL ACAD SCI USA, V94, P10723, DOI 10.1073/pnas.94.20.10723; BISCHOFF FR, 1995, METHOD ENZYMOL, V257, P135; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hicks GR, 1996, PLANT CELL, V8, P1337, DOI 10.1105/tpc.8.8.1337; Imamoto N, 1998, EUR J HISTOCHEM, V42, P9; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Iwasaki T, 1998, FEBS LETT, V428, P259, DOI 10.1016/S0014-5793(98)00540-7; Jiang CJ, 1998, FEBS LETT, V437, P127, DOI 10.1016/S0014-5793(98)01207-1; Jiang CJ, 1998, J BIOL CHEM, V273, P24083, DOI 10.1074/jbc.273.37.24083; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Matsuki R, 1998, PLANT CELL PHYSIOL, V39, P879, DOI 10.1093/oxfordjournals.pcp.a029448; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; NADLER SG, 1997, J BIOL CHEM, V272, P420; Nagy F, 2000, EMBO J, V19, P157, DOI 10.1093/emboj/19.2.157; Nemeth K, 1998, GENE DEV, V12, P3059, DOI 10.1101/gad.12.19.3059; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; SCHLEDZ M, 1998, PLANT PHYSIOL, V116, P868; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shoji K, 1998, GENE, V212, P279, DOI 10.1016/S0378-1119(98)00175-9; Smith HMS, 1997, PLANT PHYSIOL, V114, P411, DOI 10.1104/pp.114.2.411; Stacey MG, 1999, PLANT CELL, V11, P349, DOI 10.1105/tpc.11.3.349; Tsuji L, 1997, FEBS LETT, V416, P30, DOI 10.1016/S0014-5793(97)01092-2; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Welch K, 1999, MOL CELL BIOL, V19, P8400; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119	54	40	45	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9322	9329		10.1074/jbc.M006430200	http://dx.doi.org/10.1074/jbc.M006430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124253	hybrid			2022-12-25	WOS:000167607700094
J	Wilde, C; Chhatwal, GS; Schmalzing, G; Aktories, K; Just, I				Wilde, C; Chhatwal, GS; Schmalzing, G; Aktories, K; Just, I			A novel C3-like ADP-ribosyltransferase from Staphylococcus aureus modifying RhoE and Rnd3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ESCHERICHIA-COLI; GENE-PRODUCT; IDENTIFICATION; PROTEINS; PURIFICATION; TOXIN; EXOENZYME; FAMILY; ENZYME	Clostridium botulinum C3 is the prototype of the family of the C3-like transferases that ADP-ribosylate exclusively RhoA, -B and -C, The ADP-ribose at Asn-41 results in functional inactivation of Rho reflected by disaggregation of the actin cytoskeleton. We report on a new C3-like transferase produced by a pathogenic Staphylococcus aureus strain, The transferase designated C3(Stau) was cloned from the genomic DNA, At the amino acid level, C3(Stau) revealed an identity of 35% to C3 from C. botulinum and Clostridium limosum exoenzyme, respectively, and of 78% to EDIN from S, aureus, In addition to RhoA, which is the target of the other C3-like transferases, C3(Stau) modified RhoE and Rnd3. RhoE was ADP-ribosylated at Asn-44, which is equivalent to Asn-41 of RhoA, RhoE and Rnd3 are members of the Rho subfamily, which are deficient in intrinsic GTPase activity and possess a RhoA antagonistic cell function, The protein substrate specificity found with recombinant Rho proteins was corroborated by expression of RhoE in Xenopus laevis oocytes showing that RhoE was also modified in vivo by C3(Stau) but not by C3 from C. botulinum. The poor cell accessibility of C3(Stau) was overcome by generation of a chimeric toxin recruiting the cell entry machinery of C, botulinum C2 toxin, The chimeric C3(Stau) caused the same morphological and cytoskeletal changes as the chimeric C. botulinum C3. C3(Stau) is a new member of the family of the C3-like transferases but is also the prototype of a subfamily of RhoE/Rnd modifying transferases.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; German Res Ctr Biotechnol, D-38124 Braunschweig, Germany; Hannover Med Sch, Inst Toxikol, D-30625 Hannover, Germany	University of Freiburg; Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School	Just, I (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.	just.ingo@mh-hannover.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				Aktories K, 2000, HANDB EXP PHARM, V145, P207; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; AULLO P, 1993, EMBO J, V12, P921, DOI 10.1002/j.1460-2075.1993.tb05733.x; Barth H, 1999, J BIOL CHEM, V274, P27407, DOI 10.1074/jbc.274.39.27407; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Bayles KW, 1998, INFECT IMMUN, V66, P336, DOI 10.1128/IAI.66.1.336-342.1998; Boquet P, 1998, CURR OPIN MICROBIOL, V1, P66, DOI 10.1016/S1369-5274(98)80144-6; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Foster R, 1996, MOL CELL BIOL, V16, P2689; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; INOUE S, 1991, BIOCHEM BIOPH RES CO, V174, P459, DOI 10.1016/0006-291X(91)91438-I; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; JUST I, 1995, BIOCHEMISTRY-US, V34, P334, DOI 10.1021/bi00001a041; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1994, J CELL SCI, V107, P1653; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Menzies BE, 1998, INFECT IMMUN, V66, P5994, DOI 10.1128/IAI.66.12.5994-5998.1998; MORII N, 1995, METHOD ENZYMOL, V256, P196; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SUGAI M, 1992, J BIOL CHEM, V267, P2600; VAN AL, 1997, GENE DEV, V11, P2295; Wilde C, 2000, J BIOL CHEM, V275, P16478, DOI 10.1074/jbc.M910362199; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	27	82	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9537	9542		10.1074/jbc.M011035200	http://dx.doi.org/10.1074/jbc.M011035200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124969	hybrid			2022-12-25	WOS:000167607700121
J	Birukov, KG; Csortos, C; Marzilli, L; Dudek, S; Ma, SF; Bresnick, AR; Verin, AD; Cotter, RJ; Garcia, JGN				Birukov, KG; Csortos, C; Marzilli, L; Dudek, S; Ma, SF; Bresnick, AR; Verin, AD; Cotter, RJ; Garcia, JGN			Differential regulation of alternatively spliced endothelial cell myosin light chain kinase isoforms by p60(Src)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PROTEIN-KINASE; TISSUE DISTRIBUTION; SKELETAL-MUSCLE; PHOSPHORYLATION; EXPRESSION; CONTRACTION; ACTIVATION; CALMODULIN; SITES	The Ca2+/calmodulin-dependent endothelial cell myosin light chain kinase (MLCK) triggers actomyosin contraction essential for vascular barrier regulation and leukocyte diapedesis. Two high molecular weight MLCK splice variants, EC MLCK-1 and EC MLCK-2 (210-214 kDa), in human endothelium are identical except for a deleted single exon in MLCK-2 encoding a 69-amino acid stretch (amino acids 436-505) that contains potentially important consensus sites for phosphorylation by p60(Src) kinase (Lazar, V., and Garcia, J. G. (1999) Genomics 57, 256-267). We have now found that both recombinant EC MLCK splice variants exhibit comparable enzymatic activities but a 2-fold reduction of V-max, and a 2-fold increase in K-0.5 CaM when compared with the SM MLCK isoform, whereas K-m was similar in the three isoforms. However, only EC MLCK-1 is readily phosphorylated by purified p60(Src) in vitro, resulting in a 2- to 3-fold increase in EC MLCK-1 enzymatic activity (compared with EC MLCK-2 and SM MLCK). This increased activity of phospho-MLCK-1 was observed over a broad range of submaximal [Ca2+] levels with comparable EC50 [Ca2+] for both phosphorylated and unphosphorylated EC MLCK-1. The sites of tyrosine phosphorylation catalyzed by p60(Src) are Tyr(464) and Tyr(471) within the 69-residue stretch deleted in the MLCK-2 splice variant. These results demonstrate for the first time that p60(Src)-mediated tyrosine phosphorylation represents an important mechanism for splice variant-specific regulation of nonmuscle MLCK and vascular cell function.	Johns Hopkins Univ, Sch Med, JHAAC, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Johns Hopkins University; Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine	Garcia, JGN (corresponding author), Johns Hopkins Univ, Sch Med, JHAAC, Div Pulm & Crit Care Med, 4B-77A,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	drgarcia@welch.jhu.edu	Birukov, Konstantin/FJB-5755-2022; Garcia, Joe GN/E-8862-2010		NHLBI NIH HHS [HL58064, HL50533] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050533, P01HL058064] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe M, 1996, CELL STRUCT FUNCT, V21, P183, DOI 10.1247/csf.21.183; ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; Birukov KG, 1998, J CELL BIOCHEM, V70, P402, DOI 10.1002/(SICI)1097-4644(19980901)70:3<402::AID-JCB13>3.0.CO;2-M; BRESNICK AR, 1995, BIOCHEMISTRY-US, V34, P12576, DOI 10.1021/bi00039a012; COLLINGE M, 1992, MOL CELL BIOL, V12, P2359, DOI 10.1128/MCB.12.5.2359; Fisher SA, 1995, BIOCHEM BIOPH RES CO, V217, P696, DOI 10.1006/bbrc.1995.2829; GALLAGHER PJ, 1995, J BIOL CHEM, V270, P29090, DOI 10.1074/jbc.270.49.29090; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; Garcia JGN, 1997, AM J PHYSIOL-LUNG C, V273, pL172, DOI 10.1152/ajplung.1997.273.1.L172; Garcia JGN, 1998, J APPL PHYSIOL, V84, P1817, DOI 10.1152/jappl.1998.84.5.1817; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; Gilbert-McClain LI, 1998, J CELL BIOCHEM, V70, P141, DOI 10.1002/(SICI)1097-4644(19980701)70:1<141::AID-JCB14>3.0.CO;2-S; HASHIMOTO Y, 1990, ARCH BIOCHEM BIOPHYS, V278, P41, DOI 10.1016/0003-9861(90)90228-Q; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1985, J BIOL CHEM, V260, P27; IMAI S, 1967, NATURE, V213, P1044, DOI 10.1038/2131044a0; KAMM KE, 1986, SCIENCE, V232, P80, DOI 10.1126/science.3754063; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KASTURI R, 1993, J BIOL CHEM, V268, P7958; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOBAYASHI H, 1992, J BIOCHEM-TOKYO, V112, P786, DOI 10.1093/oxfordjournals.jbchem.a123976; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; MILLER JR, 1983, MOL PHARMACOL, V24, P235; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; POTIER MC, 1995, GENOMICS, V29, P562, DOI 10.1006/geno.1995.9965; ROUSH CL, 1988, J BIOL CHEM, V263, P10510; Saito H, 1998, J IMMUNOL, V161, P1533; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Shi S, 1998, ENDOTHELIUM-J ENDOTH, V6, P153, DOI 10.3109/10623329809072202; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Verin AD, 1998, AM J RESP CELL MOL, V19, P758, DOI 10.1165/ajrcmb.19.5.3125; Verin AD, 1998, AM J RESP CELL MOL, V19, P767, DOI 10.1165/ajrcmb.19.5.3126; WATTERSON DM, 1995, FEBS LETT, V373, P217; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16	51	115	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8567	8573		10.1074/jbc.M005270200	http://dx.doi.org/10.1074/jbc.M005270200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113114	hybrid			2022-12-25	WOS:000167474900119
J	Claas, C; Stipp, CS; Hemler, ME				Claas, C; Stipp, CS; Hemler, ME			Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; GPI-ANCHORED PROTEINS; HUMAN-MELANOMA CELLS; LOW-BUOYANT DENSITY; PLASMA-MEMBRANE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 4-KINASE; TM4SF PROTEINS; T-CELLS; INTEGRIN ALPHA-3-BETA-1	Recent literature suggests that tetraspanin proteins (transmembrane 4 superfamily; TM4SF proteins) may associate with each other and with many other transmembrane proteins to form large complexes that sometimes may be found in lipid rafts. Here we show that prototype complexes of CD9 or CD81 (TM4SF proteins) with alpha (3)beta (1) (an integrin) and complexes of CD63 (a TM4SF protein) with phosphatidylinositol 4-kinase (PtdIns 4-K) may indeed localize within lipid raft-like microdomains, as seen by three different criteria, First, these complexes localize to low density light membrane fractions in sucrose gradients. Second, CD9 and alpha (3) integrin colocalized with ganglioside GM1 as seen by double staining of Bred cells. Third, CD9-alpha3 beta1 and CD81-alpha3 beta1 complexes were shifted to a higher density upon cholesterol depletion from intact cells or cell lysate. However, CD9-alpha3 beta1, CD81-alpha3 beta1, and CD63-PtdIns 4-K complex formation itself was not dependent on localization into raftlike lipid microdomains, These complexes did not require cholesterol for stabilization, were maintained within well solubilized dense fractions from sucrose gradients, were stable at 37 degreesC, and were small enough to be included within CL6B gel filtration columns. In summary, prototype TM4SF protein complexes (CD9-alpha3 beta1, CD81-alpha3 beta1, and CD63-PtdIns 4-K) can be solubilized as discrete units, independent of lipid microdomains, although they do associate with microdomains resembling lipid rafts.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Hemler, ME (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Rm D-1430,44 Binney St, Boston, MA 02115 USA.	Martin_Hemler@DFCI.Harvard.edu			NCI NIH HHS [CA42368] Funding Source: Medline; NIGMS NIH HHS [GM38903] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abitorabi MA, 1997, J CELL BIOL, V139, P563, DOI 10.1083/jcb.139.2.563; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; BELL GM, 1992, J EXP MED, V175, P527, DOI 10.1084/jem.175.2.527; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BISHOP LA, 1995, CELL ADHES COMMUN, V3, P243, DOI 10.3109/15419069509081290; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; Horvath G, 1998, J BIOL CHEM, V273, P30537, DOI 10.1074/jbc.273.46.30537; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; IMAI T, 1995, J IMMUNOL, V155, P1229; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lozahic S, 2000, EUR J IMMUNOL, V30, P900, DOI 10.1002/1521-4141(200003)30:3<900::AID-IMMU900>3.0.CO;2-X; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; Martin TFJ, 2000, NAT CELL BIOL, V2, pE9, DOI 10.1038/71392; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Nichols TC, 1998, EUR J IMMUNOL, V28, P4123, DOI 10.1002/(SICI)1521-4141(199812)28:12<4123::AID-IMMU4123>3.0.CO;2-G; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Parolini I, 1999, J BIOL CHEM, V274, P14176, DOI 10.1074/jbc.274.20.14176; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Petty HR, 1997, J PHARMACEUT BIOMED, V15, P1405, DOI 10.1016/S0731-7085(96)02030-4; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Schmeiser K, 1999, CELL DEATH DIFFER, V6, P377, DOI 10.1038/sj.cdd.4400504; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Shevchenko A, 1997, ELECTROPHORESIS, V18, P2591, DOI 10.1002/elps.1150181415; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sincock PM, 1999, J CELL SCI, V112, P833; Skubitz KM, 1996, J IMMUNOL, V157, P3617; Skubitz KM, 2000, FEBS LETT, V469, P52, DOI 10.1016/S0014-5793(00)01240-0; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stipp CS, 2000, J CELL SCI, V113, P1871; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Tai XG, 1997, J IMMUNOL, V159, P3799; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; WU XR, 1994, J BIOL CHEM, V269, P13716; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629	90	262	271	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7974	7984		10.1074/jbc.M008650200	http://dx.doi.org/10.1074/jbc.M008650200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113129	hybrid			2022-12-25	WOS:000167474900044
J	Diamond, P; Shannon, MF; Vadas, MA; Coles, LS				Diamond, P; Shannon, MF; Vadas, MA; Coles, LS			Cold shock domain factors activate the granulocyte-macrophage colony-stimulating factor promoter in stimulated Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; Y-BOX PROTEINS; GM-CSF PROMOTER; SARCOMA VIRUS ENHANCER; LONG TERMINAL REPEAT; COMPLEX CLASS-I; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; GLIAL-CELLS; MUTATIONAL ANALYSIS	Cold shock domain (CSD) family members have been shown to play roles in either transcriptional activation or repression of many genes in various cell types. We have previously shown that CSD proteins dbpAv and dbpB (also known as YB-1) act to repress granulocyte-macrophage colony-stimulating factor transcription in human embryonic lung (HEL) fibroblasts via binding to single-stranded DNA regions across the promoter. Here we show that the same CSD factors are involved in granulocyte-macrophage colony-stimulating factor transcriptional activation in Jurkat T cells. Unlike the mechanisms of CSD repression in HEL fibroblasts, CSD-mediated activation in Jurkat T cells is not mediated through DNA binding but presumably through protein-protein interactions via the C terminus of the CSD protein with transcription factors such as RelA/NF-kappaB p65. We demonstrate that Jurkat T cells lack truncated CSD factor subtypes present in HEL fibroblasts, which raises the possibility that the cellular content of CSD proteins may determine their final role as activators or repressors of transcription.	Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia	Institute Medical & Veterinary Science Australia; Australian National University; John Curtin School of Medical Research	Diamond, P (corresponding author), Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, Frome Rd, Adelaide, SA 5000, Australia.	peter.diamond@imvs.sa.gov.au	Vadas, Mathew/R-1378-2019					Ansari SA, 1999, J GEN VIROL, V80, P2629, DOI 10.1099/0022-1317-80-10-2629; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BOUVET P, 1995, J BIOL CHEM, V270, P28297; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; Cleavinger PJ, 1996, VIROLOGY, V222, P133, DOI 10.1006/viro.1996.0404; Coles LS, 1996, NUCLEIC ACIDS RES, V24, P2311, DOI 10.1093/nar/24.12.2311; Coles LS, 2000, J BIOL CHEM, V275, P14482, DOI 10.1074/jbc.275.19.14482; COLES LS, 1994, NUCLEIC ACIDS RES, V22, P4276, DOI 10.1093/nar/22.20.4276; Dhalla AK, 1998, BIOCHEM J, V336, P373, DOI 10.1042/bj3360373; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; Graumann P, 1996, BIOESSAYS, V18, P309, DOI 10.1002/bies.950180409; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; ILOBERAS L, 1995, MOL CELL BIOL, V15, P5092; Ise T, 1999, CANCER RES, V59, P342; JENKINS F, 1995, J IMMUNOL, V155, P1240; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; KERR D, 1994, J VIROL, V68, P7637, DOI 10.1128/JVI.68.11.7637-7643.1994; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KUDO S, 1995, EUR J BIOCHEM, V231, P72; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Maniatis T., 1982, MOL CLONING LAB MANU; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Moorthamer M, 1999, FEBS LETT, V446, P343, DOI 10.1016/S0014-5793(99)00248-3; NAGATA S, 1986, EMBO J, V5, P575, DOI 10.1002/j.1460-2075.1986.tb04249.x; Nambiar A, 1998, J VIROL, V72, P900, DOI 10.1128/JVI.72.2.900-909.1998; Napolitano G, 2000, MOL ENDOCRINOL, V14, P486, DOI 10.1210/me.14.4.486; Ohmori M, 1996, MOL ENDOCRINOL, V10, P76, DOI 10.1210/me.10.1.76; OSBORNE CS, 1995, J IMMUNOL, V155, P226; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; Safak R, 1999, MOL CELL BIOL, V19, P2712; Saji M, 1997, J BIOL CHEM, V272, P20096, DOI 10.1074/jbc.272.32.20096; Sapru MK, 1996, J BIOL CHEM, V271, P7203, DOI 10.1074/jbc.271.12.7203; Sawaya BE, 1998, J GEN VIROL, V79, P239, DOI 10.1099/0022-1317-79-2-239; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; Schwartzbauer G, 1998, J BIOL CHEM, V273, P24760, DOI 10.1074/jbc.273.38.24760; Shang C, 1999, INT IMMUNOL, V11, P1945, DOI 10.1093/intimm/11.12.1945; SHANNON MF, 1995, J LEUKOCYTE BIOL, V57, P767, DOI 10.1002/jlb.57.5.767; Shannon MF, 1997, CRIT REV IMMUNOL, V17, P301, DOI 10.1615/CritRevImmunol.v17.i3-4.30; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHANNON MF, 1989, LYMPHOKINE RECEPTOR, V179, P73; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Swamynathan SK, 1997, J VIROL, V71, P2873, DOI 10.1128/JVI.71.4.2873-2880.1997; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YANG Y, 1988, LYMPHOKINES INTELRUK, V3, P375; Ye JP, 1996, MOL CELL BIOL, V16, P157; YE JP, 1994, NUCLEIC ACIDS RES, V22, P5672, DOI 10.1093/nar/22.25.5672	66	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7943	7951		10.1074/jbc.M009836200	http://dx.doi.org/10.1074/jbc.M009836200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11116154	hybrid			2022-12-25	WOS:000167474900039
J	Gilbert, PM; Burd, CG				Gilbert, PM; Burd, CG			GDP dissociation inhibitor domain II required for Rab GTPase recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; MEMBRANE-PROTEIN; GDP/GTP EXCHANGE; ACTIVATING PROTEINS; NUCLEOTIDE EXCHANGE; TRANSPORT GTPASES; VACUOLAR PROTEINS; PRENYLATED RAB; SMG P25A; YEAST	Rab GTPases are localized to distinct subsets of organelles within the cell, where they regulate SNARE-mediated membrane trafficking between organelles. One factor required for Rab localization and function is Rab GDP dissociation inhibitor (GDI), which is proposed to recycle Rab after vesicle fusion by extracting Rab from the membrane and loading Rab onto newly formed transport intermediates. GDI is composed of two domains; Rab binding is mediated by Domain I, and the function of Domain II is not known, In this study, Domain II of yeast GDI, encoded by the essential GDI1/SEC19 gene, was targeted in a genetic screen to obtain mutants that might lend insight into the function of this domain. In one gdi1 mutant, the cytosolic pools of all Rabs tested were depleted, and Rab accumulated on membranes, suggesting that this mutant Gdi1 protein has a general defect in extraction of Rab from membranes, In a second gdi1 mutant, the endosomal/vacuolar Rabs Vps21/Ypt51p and Ypt7p accumulated in the cytosol bound to Gdi1p, but localization of Ypt1p and Sec4p were not significantly affected. Using an in vitro assay which reconstitutes Gdi1p-mediated membrane loading of Rab, this mutant Gdi1p was found to be defective in loading of Vps21p but not Ypt1p, Loading of Vps21p by loading-defective Gdi1p was restored when acceptor membranes prepared from a deletion strain lacking Vps21p were used. These results suggest that membrane-associated Rab may regulate recruitment of GDI-Rab from the cytosol, possibly by regulating a GDI-Rab receptor. We conclude that Domain II of Gdi1p is essential for Rab loading and Rab extraction, and confirm that each of these activities is required for Gdi1p function in vivo.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Burd, CG (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.	cburd@mail.med.upenn.edu		Gilbert, Penney/0000-0001-5509-9616; Burd, Christopher/0000-0003-1831-8706				Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; Albert S, 1999, J BIOL CHEM, V274, P33186, DOI 10.1074/jbc.274.47.33186; ARAKI S, 1990, J BIOL CHEM, V265, P13007; Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; Chou JH, 2000, J BIOL CHEM, V275, P9433, DOI 10.1074/jbc.275.13.9433; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; Gerrard SR, 2000, MOL BIOL CELL, V11, P613, DOI 10.1091/mbc.11.2.613; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; Luan P, 2000, TRAFFIC, V1, P270, DOI 10.1034/j.1600-0854.2000.010309.x; Luan P, 1999, J BIOL CHEM, V274, P14806, DOI 10.1074/jbc.274.21.14806; Maniatis T., 1982, MOL CLONING LAB MANU; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Miller J.H., 1972, EXPT MOL GENETICS; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHIMMOLLER F, 1993, J CELL SCI, V106, P823; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SOLDATI T, 1995, J BIOL CHEM, V270, P25541, DOI 10.1074/jbc.270.43.25541; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5; Wu SK, 1998, J BIOL CHEM, V273, P26931, DOI 10.1074/jbc.273.41.26931; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954	44	13	13	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8014	8020		10.1074/jbc.M008845200	http://dx.doi.org/10.1074/jbc.M008845200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11116150	hybrid			2022-12-25	WOS:000167474900049
J	Hennig, L; Schafer, E				Hennig, L; Schafer, E			Both subunits of the dimeric plant photoreceptor phytochrome require chromophore for stability of the far-red light-absorbing form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO CHARACTERIZATION; PROTEIN; YEAST; PHYCOCYANOBILIN; PURIFICATION	The dimeric plant photoreceptor phytochrome is converted from its inactive red light-absorbing form (Pr) into the active far-red light-absorbing form (Pfr) upon light absorption. Dynamics of Pfr generation and of thermal Pfr-to-Pr conversion are of fundamental importance for inducing adequate responses to light signals. Here, we analyzed the role of subunit interactions on spectroscopic properties of dimeric phytochrome A. Using a coexpression system and affinity chromatography, we prepared mixed phytochrome dimers that can incorporate the essential chromophore only in one subunit. We demonstrate that such mixed dimers have unaltered difference spectra. In contrast, dark reversion differed greatly between Pfr-Pfr homodimers and Pfr-Pr heterodimers, the former being about 100-fold more stable. Temperature dependence of reaction rates revealed an additional stabilization of about 4 kcal/mol in homodimers. Consequences of these findings are discussed in relation to the biological function of, and functional diversification between, phytochrome family members.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	University of Freiburg	Schafer, E (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.		Hennig, Lars/G-2081-2011	Hennig, Lars/0000-0002-6645-1862				ABE A, 1988, AGR BIOL CHEM TOKYO, V52, P2035; Braslavsky SE, 1997, PLANT CELL ENVIRON, V20, P700, DOI 10.1046/j.1365-3040.1997.d01-101.x; BROCKMANN J, 1987, PLANT CELL ENVIRON, V10, P105, DOI 10.1111/1365-3040.ep11602037; Clough RC, 1997, PLANT CELL ENVIRON, V20, P713, DOI 10.1046/j.1365-3040.1997.d01-107.x; Eichenberg K, 2000, FEBS LETT, V470, P107, DOI 10.1016/S0014-5793(00)01301-6; Eichenberg K, 1999, J BIOL CHEM, V274, P354, DOI 10.1074/jbc.274.1.354; Elich TD, 1997, PLANT CELL, V9, P2271, DOI 10.1105/tpc.9.12.2271; Furuya M, 1996, TRENDS PLANT SCI, V1, P301; Gutfreund H, 1995, KINETICS LIFE SCI; Hennig L, 1998, PROTEIN EXPRES PURIF, V14, P367, DOI 10.1006/prep.1998.0969; KENDRICK RE, 1971, AM J BOT, V58, P424, DOI 10.2307/2441134; KUNKEL T, 1995, J BIOL CHEM, V270, P20193, DOI 10.1074/jbc.270.34.20193; KUNKEL T, 1993, EUR J BIOCHEM, V215, P587, DOI 10.1111/j.1432-1033.1993.tb18069.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI LM, 1992, J BIOL CHEM, V267, P19204; LIEBMAN PA, 1974, NATURE, V251, P31, DOI 10.1038/251031a0; Mancinelli Alberto L., 1994, P211; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; MORISHIMA N, 1990, J BIOL CHEM, V265, P15189; Murphy JT, 1997, PHOTOCHEM PHOTOBIOL, V65, P750, DOI 10.1111/j.1751-1097.1997.tb01920.x; Neff MM, 2000, GENE DEV, V14, P257; POPOV N, 1975, ACTA BIOL MED GER, V34, P1441; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Remberg A, 1998, BIOCHEMISTRY-US, V37, P9983, DOI 10.1021/bi980575x; Ruddat A, 1997, BIOCHEMISTRY-US, V36, P103, DOI 10.1021/bi962012w; Song PS, 1999, J BIOCHEM MOL BIOL, V32, P215; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	28	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7913	7918		10.1074/jbc.M009793200	http://dx.doi.org/10.1074/jbc.M009793200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11106666	hybrid			2022-12-25	WOS:000167474900034
J	Moritz, RL; Hall, NE; Connolly, LM; Simpson, RJ				Moritz, RL; Hall, NE; Connolly, LM; Simpson, RJ			Determination of the disulfide structure and N-glycosylation sites of the extracellular domain of the human signal transducer gp130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; STIMULATING FACTOR-RECEPTOR; AFFINITY INTERLEUKIN-6 RECEPTOR; IMMUNOGLOBULIN-LIKE DOMAIN; HUMAN GROWTH-HORMONE; CRYSTAL-STRUCTURE; ALPHA-CHAIN; FLAVOBACTERIUM-MENINGOSEPTICUM; MOLECULAR-CLONING; 2 DISTINCT	gp130 is the common signal transducing receptor subunit for the interleukin-6-type family of cytokines, Its extracellular region (sgp130) is predicted to consist of five fibronectin type III-like domains and an NH2-terminal Ig-like domain. Domains 2 and 3 constitute the cytokine-binding region defined by a set of four conserved cysteines and a WSXWS motif, respectively. Here we determine the disulfide structure of human sgp130 by peptide mapping, in the absence and presence of reducing agent, in combination with Edman degradation and mass spectrometry. Of the 13 cysteines present, 10 form disulfide bonds, two are present as free cysteines (Cys(279) and Cys(469)), and one (Cys(397)) is modified by S-cysteinylation. Of the 11 potential N-glycosylation sites, Asn(21), Asn(61), Asn(109), Asn(135), Asn(205), Asn(357), Asn(361), Asn(531), and Asn(542) are glycosylated but not Asn and Asn(368). The disulfide bonds, Cys(112)-Cys(122) and Cys(150)-Cys(160), are consistent with known cytokine-binding region motifs. Unlike granulocyte colony-stimulating factor receptor, the connectivities of the four cysteines in the NH2-terminal domain of gp130 (Cys(6)-Cys(32) and Cys(26)-Cys(81)) are consistent with known superfamily of Ig-like domains. An eight-residue loop in domain 5 is tethered by Cys(436)- Cys(444). We have created a model predicting that this loop maintains Cys(469) in a reduced form, available for ligand-induced intramolecular disulfide bond formation. Furthermore, we postulate that domain 5 may play a role in the disulfide-linked homodimerization and activation process of gp130.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Joint Prot Struct Lab, Melbourne Tumor Biol Branch, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Simpson, RJ (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Joint Prot Struct Lab, Melbourne Tumor Biol Branch, POB 2008, Parkville, Vic 3050, Australia.		Moritz, Robert L/B-9222-2011	Simpson, Richard/0000-0002-9834-0796; Hall, Nathan/0000-0001-8942-0498				Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; Barton VA, 2000, J BIOL CHEM, V275, P36197, DOI 10.1074/jbc.M004648200; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cole AR, 1999, J BIOL CHEM, V274, P7207, DOI 10.1074/jbc.274.11.7207; Dahmen H, 1998, BIOCHEM J, V331, P695, DOI 10.1042/bj3310695; de Pereda JM, 1999, EMBO J, V18, P4087, DOI 10.1093/emboj/18.15.4087; Desikan K R, 1999, Curr Opin Hematol, V6, P216, DOI 10.1097/00062752-199907000-00004; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Diamant M, 1997, FEBS LETT, V412, P379, DOI 10.1016/S0014-5793(97)00750-3; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; FUH G, 1990, J BIOL CHEM, V265, P3111; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Geissen M, 1998, DEVELOPMENT, V125, P4791; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; Hammacher A, 2000, BIOCHEM J, V345, P25, DOI 10.1042/0264-6021:3450025; Haniu M, 1998, J BIOL CHEM, V273, P28691, DOI 10.1074/jbc.273.44.28691; Haniu M, 1996, BIOCHEMISTRY-US, V35, P13040, DOI 10.1021/bi960213u; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Horsten U, 1997, J BIOL CHEM, V272, P23748, DOI 10.1074/jbc.272.38.23748; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JI H, 1994, ELECTROPHORESIS, V15, P391, DOI 10.1002/elps.1150150158; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Kernebeck T, 1999, PROTEIN SCI, V8, P5; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurth I, 1999, J IMMUNOL, V162, P1480; LIU JW, 1992, J BIOL CHEM, V267, P16763; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Moritz RL, 1999, GROWTH FACTORS, V16, P265, DOI 10.3109/08977199909069145; MORITZ RL, 1992, J CHROMATOGR, V599, P119; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; Moritz Robert L., 1994, Methods (Orlando), V6, P213, DOI 10.1006/meth.1994.1024; Muller-Newen G, 2000, J BIOL CHEM, V275, P4579, DOI 10.1074/jbc.275.7.4579; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; NICOLA NA, 1994, GUIDEBOOK CYTOKINES, P1; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PATTERSON SD, 1994, ANAL CHEM, V66, P3727, DOI 10.1021/ac00093a030; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; RICHARDSON JS, 1977, NATURE, V268, P495, DOI 10.1038/268495a0; SAITO M, 1992, J IMMUNOL, V148, P4066; SAITO T, 1993, J IMMUNOL METHODS, V163, P217, DOI 10.1016/0022-1759(93)90125-Q; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smith DK, 1998, PROTEIN SCI, V7, P886; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; WANG Y, 1992, GENOMICS, V14, P666, DOI 10.1016/S0888-7543(05)80166-1; WARD LD, 1994, J BIOL CHEM, V269, P23286; YASUKAWA K, 1992, IMMUNOL LETT, V31, P123, DOI 10.1016/0165-2478(92)90138-E; Yoon C, 2000, EMBO J, V19, P3530, DOI 10.1093/emboj/19.14.3530; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zhang JG, 1998, J BIOL CHEM, V273, P10798, DOI 10.1074/jbc.273.17.10798	78	28	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8244	8253		10.1074/jbc.M009979200	http://dx.doi.org/10.1074/jbc.M009979200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11098061	hybrid			2022-12-25	WOS:000167474900080
J	Guo, L; Lynch, J; Nakamura, K; Fliegel, L; Kasahara, H; Izumo, S; Komuro, I; Agellon, LB; Michalak, M				Guo, L; Lynch, J; Nakamura, K; Fliegel, L; Kasahara, H; Izumo, S; Komuro, I; Agellon, LB; Michalak, M			COUP-TF1 antagonizes Nkx2.5-mediated activation of the calreticulin gene during cardiac development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; EXPRESSION; HEART; HORMONE; DEFECTS; TINMAN; NKX2-5; GATA-4; TF	Calreticulin, a Ca2+ binding chaperone of the endoplasmic reticulum, is also highly expressed in the embryonic heart, and knockout of the calreticulin gene is lethal during embryogenesis because of impaired cardiac development. The protein is down-regulated after birth, and elevated expression of calreticulin in newborn hearts is associated with severe cardiac pathology and death. Here we show that the transcription factor Nkx2.5 activates expression of the calreticulin gene in the heart. Binding of chicken ovalbumin upstream promoter-transcription factor 1 to the Nkx2.5 binding site suppresses transcription from the calreticulin promoter. Nkx2.5 and chicken ovalbumin upstream promoter-transcription factor 1 play antagonistic roles in regulating the expression of calreticulin during cardiac development. These studies indicate that cardiac-specific transcription factor Nku2,5 plays a central role in activating calreticulin expression and that there is a cooperation between chicken ovalbumin upstream promoter-transcription factor 1 and Nkx2.5 at the calreticulin promoter.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Canadian Inst Hlth, Res Grp Mol Biol Membrane Prot, Edmonton, AB T6G 2H7, Canada; Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2H7, Canada; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Cardiovasc Div,Dept Med, Boston, MA 02215 USA; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan	University of Alberta; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Tokyo	Michalak, M (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.		Guo, Lei/E-9232-2011					AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Evans SM, 1999, SEMIN CELL DEV BIOL, V10, P73, DOI 10.1006/scdb.1999.0282; Fishman MC, 1997, DEVELOPMENT, V124, P2099; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Leng X, 1996, MOL CELL BIOL, V16, P2332; Lin HB, 1999, J BIOL CHEM, V274, P36796, DOI 10.1074/jbc.274.51.36796; Lou DQ, 1999, J BIOL CHEM, V274, P28385, DOI 10.1074/jbc.274.40.28385; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; Rauch F, 2000, EXP CELL RES, V256, P105, DOI 10.1006/excr.2000.4818; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547	22	48	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2797	2801		10.1074/jbc.C000822200	http://dx.doi.org/10.1074/jbc.C000822200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11106640	hybrid			2022-12-25	WOS:000166784800069
J	Sitte, N; Merker, K; Von Zglinicki, T; Grune, T; Davies, KJA				Sitte, N; Merker, K; Von Zglinicki, T; Grune, T; Davies, KJA			Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I - effects of proliferative senescence	FASEB JOURNAL			English	Article						aging; cross-linked proteins; lysosomes; protein oxidation; protein turnover; proteolysis; proteasome; senescence	CROSS-LINKED PROTEIN; OXIDIZED PROTEINS; MULTICATALYTIC PROTEASE; GLUTAMINE-SYNTHETASE; GENE-EXPRESSION; CELLS; PROTEOLYSIS; STRESS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; HYDROPHOBICITY	Oxidized and cross-linked proteins tend to accumulate in aging cells. Declining activity of proteolytic enzymes, particularly the proteasome, has been proposed as a possible explanation for this phenomenon, and direct inhibition of the proteasome by oxidized and cross-linked proteins has been demonstrated in vitro. We have further examined this hypothesis during both proliferative senescence (this paper) and postmitotic senescence (see the accompanying paper, ref 1) of human BJ fibroblasts. During proliferative senescence, we found a marked decline in all proteasome activities (trypsin-like activity, chymotrypsin-like activity, and peptidyl-glutamyl-hydrolyzing activity) and in lysosomal cathepsin activity. Despite the loss of proteasome activity, there was no concomitant change in cellular levels of actual proteasome protein (immunoassays) or in the steady-state levels of mRNAs for essential proteasome subunits. The decline in proteasome activities and lysosomal cathepsin activities was accompanied by dramatic increases in the accumulation of oxidized and cross-linked proteins. Furthermore, as proliferation stage increased, cells exhibited a decreasing ability to degrade the oxidatively damaged proteins generated by an acute, experimentally applied oxidative stress. Thus, oxidized and cross-linked proteins accumulated rapidly in cells of higher proliferation stages. Our data are consistent with the hypothesis that proteasome is progressively inhibited by small accumulations of oxidized and cross-linked proteins during proliferative senescence until late proliferation stages, when so much proteasome activity has been lost that oxidized proteins accumulate at ever-increasing rates. Lysosomes attempt to deal with the accumulating oxidized and cross-linked proteins, but declining lysosomal cathepsin activity apparently limits their effectiveness. This hypothesis, which may explain the progressive intracellular accumulation of oxidized and cross-linked proteins in aging, is further explored during postmitotic senescence in the accompanying paper (1).	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol Biol, Los Angeles, CA 90089 USA; Humboldt Univ, Fac Med Charite, Clin Phys Med, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Clin Rehabil, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Inst Pathol, D-10098 Berlin, Germany	University of Southern California; University of Southern California; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Room 306, Los Angeles, CA 90089 USA.			Davies, Kelvin/0000-0001-7790-3003; von Zglinicki, Thomas/0000-0002-5939-0248; Grune, Tilman/0000-0003-4775-9973	NIEHS NIH HHS [ES03598] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598, R23ES003598, R56ES003598] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGARWAL S, 1994, MECH AGEING DEV, V75, P11, DOI 10.1016/0047-6374(94)90024-8; AGARWAL S, 1994, ARCH BIOCHEM BIOPHYS, V309, P24, DOI 10.1006/abbi.1994.1078; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRADLEY MO, 1976, J BIOL CHEM, V251, P3521; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; GUILIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; INUBUSHI T, 1994, J BIOCHEM-TOKYO, V116, P282, DOI 10.1093/oxfordjournals.jbchem.a124520; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LIU AYC, 1989, J BIOL CHEM, V264, P12037; MELLMAN WJ, 1972, EXP CELL RES, V73, P399, DOI 10.1016/0014-4827(72)90064-X; Nakamura T, 1998, BBA-GENE STRUCT EXPR, V1399, P93, DOI 10.1016/S0167-4781(98)00105-5; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; Saretzki G, 1998, J GERONTOL A-BIOL, V53, pB438, DOI 10.1093/gerona/53A.6.B438; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; SOMMERBURG O, 1993, MEDIAT INFLAMM, V2, P27, DOI 10.1155/S0962935193000031; Stadtman E R, 1988, Basic Life Sci, V49, P331; Stadtman E R, 1992, EXS, V62, P64; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; Von Zglinicki T, 1998, ANN NY ACAD SCI, V854, P318; vonZglinicki T, 1995, GERONTOLOGY, V41, P95; WONG SHY, 1987, CLIN CHEM, V33, P214; Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X	43	179	183	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2495	2502		10.1096/fj.00-0209com	http://dx.doi.org/10.1096/fj.00-0209com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099467				2022-12-25	WOS:000165723400019
J	Sitte, N; Merker, K; Von Zglinicki, T; Davies, KJA; Grune, T				Sitte, N; Merker, K; Von Zglinicki, T; Davies, KJA; Grune, T			Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part II - aging of nondividing cells	FASEB JOURNAL			English	Article						aging; cross-linked proteins; lysosomes; proteasome; protein oxidation; proteolysis; protein turnover; senescence	CROSS-LINKED PROTEIN; RED BLOOD-CELLS; OXYGEN RADICALS; OXIDIZED PROTEINS; MULTICATALYTIC PROTEASE; LIPOFUSCIN PIGMENTS; ALZHEIMER-DISEASE; EPITHELIAL-CELLS; AGE; DAMAGE	Oxidized/cross-linked intracellular protein materials, known as ceroid pigment, age pigment, or lipofuscin, accumulate in postmitotic tissues. It is unclear, however, whether diminishing proteolytic capacities play a role in the accumulation of such oxidized intracellular proteins. Previous studies revealed that the proteasome is responsible for the degradation of most oxidized soluble cytoplasmic and nuclear proteins and, we propose, for the prevention of such damage accumulations. The present investigation was undertaken to test the changes in protein turnover, proteasome activity, lysosome activity, and protein oxidation status during the aging of nondividing cells. Since the companion paper shows that both proteasome activity and the overall protein turnover decline during proliferative senescence whereas the accumulation of oxidized proteins increases significantly, we decided to use the same human BJ fibroblasts, this time at confluency, at different PD levels (including those that are essentially postmitotic) to investigate the same parameters under conditions where cells do not divide. We find that the activity of the cytosolic proteasome declines dramatically during senescence of nondividing BJ fibroblasts. The peptidyl-glutamyl-hydrolyzing activity was particularly affected. This decline in proteasome activity was accompanied by a decrease in the overall turnover of short-lived (radiolabeled) proteins in the nondividing BJ fibroblasts. On the other hand, no decrease in the actual cellular proteasome content, as judged by immunoblots, was found. The decline in the activity of the proteasome was also accompanied by an increased accumulation of oxidized proteins, especially of oxidized and cross-linked material. Unlike the loss of lysosomal function seen in our accompanying studies of proliferative senescence (1), however, the present study of hyperoxic senescence in nondividing cells actually revealed marked increases in lysosomal cathepsin activity in all but the very 'oldest' postmitotic cells. Our comparative studies of proliferating (1)and nonproliferating (this paper) human BJ fibroblasts reveal a good correlation between the accumulation of oxidized/cross-linked proteins and the decline in proteasome activity and overall cellular protein turnover during in vitro senescence, which may predict a causal relationship during actual cellular aging.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol Biol, Los Angeles, CA 90089 USA; Humboldt Univ, Fac Med Charite, Clin Phys Med, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Clin Rehabil, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Inst Pathol, D-10098 Berlin, Germany	University of Southern California; University of Southern California; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Room 306, Los Angeles, CA 90089 USA.			Grune, Tilman/0000-0003-4775-9973; Davies, Kelvin/0000-0001-7790-3003; von Zglinicki, Thomas/0000-0002-5939-0248	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R23ES003598, R56ES003598, R01ES003598] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGARWAL S, 1994, MECH AGEING DEV, V75, P11, DOI 10.1016/0047-6374(94)90024-8; Andersen JK, 1996, J NEUROCHEM, V67, P2164; Anselmi B, 1998, J GERONTOL A-BIOL, V53, pB173, DOI 10.1093/gerona/53A.3.B173; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; CAO C, 1995, ARCH BIOCHEM BIOPHYS, V320, P106; CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P195, DOI 10.1006/abbi.1995.1359; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; Conconi M, 1997, MOL BIOL REP, V24, P45, DOI 10.1023/A:1006852506884; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; GUILIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Horie K, 1997, BIOCHEM BIOPH RES CO, V236, P327, DOI 10.1006/bbrc.1997.6944; INUBUSHI T, 1994, J BIOCHEM-TOKYO, V116, P282, DOI 10.1093/oxfordjournals.jbchem.a124520; JAHNGENHODGE J, 1997, J BIOL CHEM, V272, P28211; Kato Y, 1998, FEBS LETT, V439, P231, DOI 10.1016/S0014-5793(98)01372-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PORTA EA, 1991, ARCH GERONTOL GERIAT, V12, P303, DOI 10.1016/0167-4943(91)90036-P; PORTAL J, 1995, ORIENTAL ART, V41, P2; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROMERO MT, 1994, NEUROSCIENCE, V58, P217, DOI 10.1016/0306-4522(94)90169-4; SAHAKIAN JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P411, DOI 10.1006/abbi.1995.1248; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Stadtman E R, 1992, EXS, V62, P64; Terman A, 1995, GERONTOLOGY, V41, P319; Terman A, 1998, APMIS, V106, P265, DOI 10.1111/j.1699-0463.1998.tb01346.x; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; vonZglinicki T, 1995, GERONTOLOGY, V41, P95; Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X	53	129	133	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2503	2510		10.1096/fj.00-0210com	http://dx.doi.org/10.1096/fj.00-0210com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099468				2022-12-25	WOS:000165723400020
J	Johnston, IMP; Spence, HJ; Winnie, JN; McGarry, L; Vass, JK; Meagher, L; Stapleton, G; Ozanne, BW				Johnston, IMP; Spence, HJ; Winnie, JN; McGarry, L; Vass, JK; Meagher, L; Stapleton, G; Ozanne, BW			Regulation of a multigenic invasion programme by the transcription factor, AP-1: re-expression of a down-regulated gene, TSC-36, inhibits invasion	ONCOGENE			English	Article						transcription; AP-1; invasion	ONCOGENE-INDUCED TRANSFORMATION; DOMINANT-NEGATIVE MUTANT; C-JUN; CELL-TRANSFORMATION; PROTO-ONCOGENE; TUMOR INVASION; DNA-BINDING; IN-VITRO; MORPHOLOGICAL TRANSFORMATION; NEOPLASTIC TRANSFORMATION	The transcription factor AP-1 (activator protein-1) is required for transformation by many oncogenes, which function upstream of it in the growth factor-ras signal transduction pathway. Previously, we proposed that one role of AP-1 in transformation is to regulate the expression of a multigenic invasion programme. As a test of this proposal we sought to identify AP-1 regulated genes based upon their differential expression in 208F rat fibroblasts transformed by FBR-v-fos (FBR), and to determine if they functioned in the invasion programme. Subtracted cDNA libraries specific for up- or down-regulated genes in FBRs compared to 208Fs were constructed and analysed. Northern analysis revealed that the cDNAs in both libraries represented differentially expressed genes. Nucleic acid sequence analysis of randomly selected cDNA clones from each library coupled with searches of nucleic acid and amino acid sequence databases determined that many of the cDNAs represented proteins that function in various aspects of the invasion process. Functional analysis of one the down-regulated genes, TSC-36/follistatin-related protein (TSC-36/Frp), which has not previously been associated with invasion, demonstrated that its expression in FBRs inhibited in vitro invasion. These results support the proposal that AP-1 in transformed cells regulates a multigenic invasion programme.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Ozanne, BW (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.			Stapleton, Genevieve/0000-0002-7493-5277				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bardelli A, 1997, CIBA F SYMP, V212, P133; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRASELMANN S, 1992, J CELL SCI, P97; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Cook SJ, 1999, MOL CELL BIOL, V19, P330; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; Denhardt DT, 1996, CRIT REV ONCOGENESIS, V7, P261, DOI 10.1615/CritRevOncog.v7.i3-4.70; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Guang RJ, 2000, CANCER RES, V60, P749; HAJNAL A, 1993, CANCER RES, V53, P4670; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Janatpour MJ, 2000, DEVELOPMENT, V127, P549; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOOSS KU, 1995, ONCOGENE, V10, P603; KAPLAN PL, 1982, VIROLOGY, V123, P372, DOI 10.1016/0042-6822(82)90270-7; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim S, 1996, ONCOGENE, V12, P1043; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Liang P, 1997, Methods Mol Biol, V85, P3; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; Lutfiyya LL, 1998, GENETICS, V150, P1377; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Mashimo J, 1997, CANCER LETT, V113, P213, DOI 10.1016/S0304-3835(97)04700-9; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RIGBY PWJ, 1984, PHILOS T ROY SOC B, V307, P347, DOI 10.1098/rstb.1984.0138; SAEZ E, 1995, CANCER RES, V55, P6196; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TOH Y, 1994, J BIOL CHEM, V269, P22958; Treinies I, 1999, MOL CELL BIOL, V19, P321; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WERNERT N, 1994, CANCER RES, V54, P5683; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WICK M, 1992, ONCOGENE, V7, P859; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799; ZWIJSEN A, 1994, EUR J BIOCHEM, V225, P937, DOI 10.1111/j.1432-1033.1994.0937b.x	95	61	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5348	5358		10.1038/sj.onc.1203927	http://dx.doi.org/10.1038/sj.onc.1203927			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103936				2022-12-25	WOS:000165302300006
J	Sulzenbacher, G; Gal, L; Peneff, C; Fassy, F; Bourne, Y				Sulzenbacher, G; Gal, L; Peneff, C; Fassy, F; Bourne, Y			Crystal structure of Streptococcus pneumoniae N-acetyl-glucosamine-1-phosphate uridyltransferase bound to acetyl-coenzyme A reveals a novel active site architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIFUNCTIONAL GLMU PROTEIN; N-ACETYLGLUCOSAMINE; ESCHERICHIA-COLI; ACETYLTRANSFERASE; PYROPHOSPHORYLASE; 1-PHOSPHATE; MODEL	The bifunctional bacterial enzyme N-acetyl-glucosamine-1-phosphate uridyltransferase (GLmU) catalyzes the two-step formation of UDP-GlcNAc, a fundamental precursor in bacterial cell wall biosynthesis. With the emergence of new resistance mechanisms against beta -lactam and glycopeptide antibiotics, the biosynthetic pathway of UDP-GlcNAc represents an attractive target for drug design of new antibacterial agents. The crystal structures of Streptococcus pneumoniae GlmU in unbound form, in complex with acetyl-coenzyme A (AcCoA) and in complex with both AcCoA and the end product UDP-GlcNAc, have been determined and refined to 2.3, 2.5, and 1.75 Angstrom, respectively. The S. pneumoniae GlmU molecule is organized in two separate domains connected via a long cu-helical linker and associates as a trimer, with the 50-Angstrom -long left-handed beta -helix (LPH) C-terminal domains packed against each other in a parallel fashion and the C-terminal region extended far away from the LPH core and exchanged with the beta -helix from a neighboring subunit in the trimer, AcCoA binding induces the formation of a long and narrow tunnel, enclosed between two adjacent LPH domains and the interchanged C-terminal region of the third subunit, giving rise to an original active site architecture at the junction of three subunits.	AFMB, UMR6098, F-13402 Marseille 20, France; Aventis Pharma Hoechst Marion Roussel, Infect Dis Grp, F-93235 Romainville, France	UDICE-French Research Universities; Aix-Marseille Universite; Sanofi-Aventis; Sanofi France	Bourne, Y (corresponding author), AFMB, UMR6098, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	yves@afmb.cnrs-mrs.fr	gal, laurent/A-2824-2011; Bourne, Yves/AAC-4635-2022; Sulzenbacher, Gerlind/A-6801-2018	gal, laurent/0000-0001-6598-7262; Bourne, Yves/0000-0003-3850-0548; Sulzenbacher, Gerlind/0000-0003-4844-2820; Fassy, Florence/0000-0001-8337-9674				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P6689, DOI 10.1021/bi980106v; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P10363, DOI 10.1021/bi980759b; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEON HG, 1992, BIOCHEM PHARMACOL, V43, P2255; CHRISTOPHER JA, 1998, SPOCK; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Gehring AM, 1996, BIOCHEMISTRY-US, V35, P579, DOI 10.1021/bi952275a; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; MENGINLECREULX D, 1993, J BACTERIOL, V175, P6150, DOI 10.1128/JB.175.19.6150-6157.1993; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pompeo F, 1998, J BACTERIOL, V180, P4799, DOI 10.1128/JB.180.18.4799-4803.1998; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, V10, P1035; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Roussel A, 1991, SILICON GRAPHICS GEO, P81; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; SHEU KFR, 1978, J BIOL CHEM, V253, P3378; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; VUORIO R, 1991, FEBS LETT, V292, P90, DOI 10.1016/0014-5793(91)80841-P	28	83	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11844	11851		10.1074/jbc.M011225200	http://dx.doi.org/10.1074/jbc.M011225200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11118459	hybrid			2022-12-25	WOS:000168081800057
J	Garban, HJ; Bonavida, B				Garban, HJ; Bonavida, B			Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B - Role in sensitization of human tumor cells to tumor necrosis factor-alpha-induced cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; INDUCED APOPTOSIS; SUPEROXIDE ANION; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; GENE-EXPRESSION; DRUG-RESISTANCE; NADPH OXIDASE; COMBINATION	Tumor necrosis factor alpha (TNF-alpha) exerts its effect by two distinct-signaling pathways. It can trigger cytotoxicity in sensitive target cells. TNF-alpha can also promote nuclear factor kappaB (NF-kappaB) activity and regulate the expression of genes that interfere with apoptosis and thus conferring resistance to several apoptotic stimuli. We have observed that interferon-gamma (IFN-gamma) sensitizes human ovarian carcinoma cell lines to TNF-alpha -mediated apoptosis and further, IFN-gamma induces the expression of the inducible nitric-oxide synthase (iNOS) and the generation of nitric oxide (NO). This study, examines the role of NO in the sensitization of the ovarian carcinoma cell line AD10 to TNF-alpha -mediated cytotoxicity. Treatment of AD10 cells with the NOS inhibitor L-NMA. blocked the IFN-gamma -dependent sensitization whereas NO donors (S-nitroso-N-acetylpenicillamine) sensitized these cells to TNF-alpha cytotoxicity, Analysis of the activation status of NF-kappaB upon treatment with NO donors confirmed the inhibitory role of NO on both the NF-kappaB DNA-binding property and its activation. Moreover, the inhibition of NF-kappaB nuclear translocation by NO donors directly correlated with the intracellular concentration of H2O2 and was reversed by the addition of exogenous H2O2. These findings show that NO might interfere with TNF-alpha -dependent NF-kappaB activation by interacting with O-2(radical anion) and reducing the generation of H2O2, a potent NF-kappaB activator. Therefore, NO-mediated disruption of NF-kappaB activation results in the removal of anti-apoptotic/resistance signals and sensitizes tumor cells to cytotoxic cytokines like TNF-alpha.	Univ Calif Los Angeles, Sch Med, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol Mol Genet & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.			Garban, Hermes/0000-0001-7754-5357				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; Frost PJ, 1999, PROSTATE, V41, P20, DOI 10.1002/(SICI)1097-0045(19990915)41:1<20::AID-PROS4>3.0.CO;2-W; Fujii H, 1997, J BIOL CHEM, V272, P32773, DOI 10.1074/jbc.272.52.32773; Fukuto J M, 1995, Adv Pharmacol, V34, P1; Garban HJ, 1999, GYNECOL ONCOL, V73, P257, DOI 10.1006/gyno.1999.5374; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Han SY, 2000, BIOL PHARM BULL, V23, P420; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Hong YH, 1997, J IMMUNOL, V159, P2418; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li JR, 2000, SEMIN PERINATOL, V24, P46, DOI 10.1016/S0146-0005(00)80055-5; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; MIZUTANI Y, 1994, J UROLOGY, V151, P1697, DOI 10.1016/S0022-5347(17)35347-8; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; MORIMOTO H, 1993, CANCER RES, V53, P2591; Nemeth ZH, 1998, SHOCK, V10, P49, DOI 10.1097/00024382-199807000-00009; Park SK, 1997, BIOCHEM J, V322, P609, DOI 10.1042/bj3220609; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; SAFRIT JT, 1993, J UROLOGY, V149, P1202, DOI 10.1016/S0022-5347(17)36348-6; SAFRIT JT, 1993, GYNECOL ONCOL, V48, P214, DOI 10.1006/gyno.1993.1036; Sawyer ST, 2000, J HEMATOTH STEM CELL, V9, P21, DOI 10.1089/152581600319586; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Selinsky CL, 2000, CELL IMMUNOL, V200, P81, DOI 10.1006/cimm.2000.1622; Shi Q, 2000, CANCER RES, V60, P2579; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Taylor BS, 1998, BIOCHEMISTRY-MOSCOW+, V63, P766; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	50	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8918	8923		10.1074/jbc.M008471200	http://dx.doi.org/10.1074/jbc.M008471200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11118442	hybrid			2022-12-25	WOS:000167607700043
J	Goldberg, R; Pierron, M; Bordenave, M; Breton, C; Morvan, C; du Penhoat, CH				Goldberg, R; Pierron, M; Bordenave, M; Breton, C; Morvan, C; du Penhoat, CH			Control of mung bean pectinmethylesterase isoform activities - Influence of pH and carboxyl group distribution along the pectic chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT VIRULENCE FACTOR; HYPOCOTYL CELL-WALLS; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; PECTATE LYASE; ERWINIA-CHRYSANTHEMI; ASPERGILLUS-NIGER; NMR-SPECTROSCOPY; ACTIVE-SITE; PECTINESTERASE	Well-characterized pectin samples with a wide range of degrees of esterification (39-74%) were incubated with the solubilized pure alpha and gamma isoforms of pectinmethylesterase, from mung bean hypocotyl (Vigna radiata), Enzyme activity was determined at regular intervals along the deesterification pathway at pH 5.6 and pH 7,6, It has been demonstrated that the distribution of the carboxyl units along the pectin backbone controls the activity of the cell wall pectinmethylesterases to a much greater extent than the methylation degree, with a random distribution leading to the strongest activity. Polygalacturonic acid was shown to be a competitive inhibitor of the alpha isoform activity at pH 5.6 and to inhibit the gamma isoform activity at both pH 5.6 and pH 7,6, Under these conditions, the drop in enzyme activity was shown to be correlated to the formation of deesterified blocks of 19 +/- 1 galacturonic acid residues through simulations of the enzymatic digestion according to the mechanisms established previously (Catoire, L,, Pierron, M,, Morvan, C,, Herve du Penhoat, C,, and Goldberg, R, (1998) J, Biol, Chem. 273, 33150-33156), However, even in the absence of inhibition by the reaction product, activity dropped to negligible levels long before the substrate had been totally deesterified, Comparison of alpha and gamma isoform cDNAs suggests that the N-terminal region of catalytic domains might explain their subtle differences in activity revealed in this study. The role of pectinmethylesterase in the cell wall stiffening process along the growth gradient is discussed.	Univ Paris 06, CNRS, Unite Mixte Rech 7632, F-75252 Paris 05, France; Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble 9, France; Univ Rouen, Fac Sci, Serv Cooperat Univ Entreprises Organismes Reg, CNRS,Unite Propre Rech Enseignement Super Associe, F-76821 Mont St Aignan, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Universite de Rouen Normandie	Goldberg, R (corresponding author), Univ Paris 06, CNRS, Unite Mixte Rech 7632, Case 154,4 Pl Jussieu, F-75252 Paris 05, France.	goldberg@ccr.jussieu.fr						ALBANI D, 1991, PLANT MOL BIOL, V16, P501, DOI 10.1007/BF00023417; ANDERSEN AK, 1995, CARBOHYD RES, V273, P93, DOI 10.1016/0008-6215(95)00100-8; Axelos MAV, 1996, PROGR BIOTECHNOL, V14, P35, DOI 10.1016/S0921-0423(96)80244-9; BORDENAVE M, 1994, PLANT PHYSIOL, V106, P1151, DOI 10.1104/pp.106.3.1151; Bordenave M, 1996, PLANT MOL BIOL, V31, P1039, DOI 10.1007/BF00040722; BORDENAVE M, 1993, PHYTOCHEMISTRY, V33, P999, DOI 10.1016/0031-9422(93)85011-F; BORDENAVE M, 1996, MOD METHOD PLANT, V17, P165; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Catoire L, 1998, J BIOL CHEM, V273, P33150, DOI 10.1074/jbc.273.50.33150; Catoire L, 1998, EUR BIOPHYS J BIOPHY, V27, P127, DOI 10.1007/s002490050118; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVRIES JA, 1983, CARBOHYD POLYM, V3, P245; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Goldberg R, 1996, PROGR BIOTECHNOL, V14, P151, DOI 10.1016/S0921-0423(96)80253-X; GOLDSMID HJ, 1968, PHYS LETT A, VA 27, P523, DOI 10.1016/0375-9601(68)90898-0; Grasdalen H, 1996, CARBOHYD RES, V289, P105, DOI 10.1016/0008-6215(96)00079-1; JARVIS MC, 1984, PLANT CELL ENVIRON, V7, P153, DOI 10.1111/1365-3040.ep11614586; Jenkins J, 2001, J MOL BIOL, V305, P951, DOI 10.1006/jmbi.2000.4324; KOHN R, 1977, COLLECT CZECH CHEM C, V42, P731, DOI 10.1135/cccc19770731; Liberman M, 1999, ANN BOT-LONDON, V84, P225, DOI 10.1006/anbo.1999.0914; LIETZKE SE, 1994, PLANT PHYSIOL, V106, P849, DOI 10.1104/pp.106.3.849; MARKOVIC O, 1984, EXPERIENTIA, V40, P842; Mayans O, 1997, STRUCTURE, V5, P677, DOI 10.1016/S0969-2126(97)00222-0; MCCANN MC, 1994, J EXP BOT, V45, P1683, DOI 10.1093/jxb/45.Special_Issue.1683; MCQUEENMASON S, 1992, PLANT CELL, V4, P1425, DOI 10.1105/tpc.4.11.1425; MU H, 1994, PLANT MOL BIOL, V25, P539; Penel C, 1999, PHYTOCHEMISTRY, V51, P193, DOI 10.1016/S0031-9422(98)00741-9; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; REXOVABENKOVA L, 1972, BIOCHIM BIOPHYS ACTA, V276, P215, DOI 10.1016/0005-2744(72)90022-8; Richard L, 1996, GENE, V170, P207, DOI 10.1016/0378-1119(95)00766-0; van Santen Y, 1999, J BIOL CHEM, V274, P30474, DOI 10.1074/jbc.274.43.30474; VANCUTSEM P, 1996, PECTINS PECTINASES, V17, P135; Versteeg C., 1979, THESIS AGR U WAGENIN; Vitali J, 1998, PLANT PHYSIOL, V116, P69, DOI 10.1104/pp.116.1.69; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	37	38	40	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8841	8847		10.1074/jbc.M001791200	http://dx.doi.org/10.1074/jbc.M001791200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11120736	hybrid			2022-12-25	WOS:000167607700033
J	Habib, AA; Chatterjee, S; Park, SK; Ratan, RR; Lefebvre, S; Vartanian, T				Habib, AA; Chatterjee, S; Park, SK; Ratan, RR; Lefebvre, S; Vartanian, T			The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B - Identification of a novel receptor-tyrosine kinase signalosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BREAST-CANCER CELLS; DEATH DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-TRANSFORMATION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; TNF RECEPTOR; APOPTOSIS; ALPHA	The transcription factor nuclear factor-kappaB (NF-kappaB) is activated by a diverse number of stimuli including tumor necrosis factor-alpha, interleukin-1, UV irradiation, viruses, as well as receptor tyrosine kinases such as the epidermal growth factor receptor (EGFR), NF-kappaB activation by the tumor necrosis factor receptor (TNFR) involves the formation of a multiprotein complex termed a signalosome, Although previous studies have shown that the activated EGFR can induce NF-kappaB, the mechanism of this activation remains unknown. In this study, we identify components of the signalosome formed by the activated EGFR required to activate NF-kappaB and show that, although the activated EGFR uses mechanisms similar to the TNFR, it recruits a distinct signalosome, We show the EGFR forms a complex with a TNFR-interacting protein (RIP), which plays a key role in TNFR-induced NF-kappaB activation, but not with TRADD, an adaptor protein which serves to recruit RIP to the TNFR, Furthermore, we show that the EGFR associates with NF-kappaB-inducing kinase (NIK) and provide evidence suggesting multiprotein complex formation between the EGFR, RIP, and NIK, Using a dominant negative NIK mutant, we show that NIK activation is required for EGFR-mediated NF-kappaB induction. We also show that a S32/36 I kappaB alpha mutant blocks EGFR-induced NF-kappaB activation. Our studies also suggest that a high level of EGFR expression, a frequent occurrence in human tumors, is optimal for epidermal growth factor-induced NF-kappaB activation. Finally, although protein kinase B/Akt has been implicated in tumor necrosis factor and PDGF-induced NF-kappaB activation, our studies do not support a role for this protein in EGFR-induced NF-kappaB activation.	Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Habib, AA (corresponding author), Harvard Inst Med, Rm 836,77 Ave Louis Pasteur, Boston, MA 02115 USA.				NCI NIH HHS [K08 CA78741] Funding Source: Medline; NINDS NIH HHS [NS02028] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA078741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG DK, 1994, CANCER RES, V54, P5280; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Foo SY, 1999, TRENDS GENET, V15, P229; GALANG CK, 1994, ONCOGENE, V9, P2913; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MURPHY S, 1995, GLIA, V15, P77, DOI 10.1002/glia.440150109; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Ozes ON, 1999, NATURE, V401, P82; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VAN AD, 1996, SCIENCE, V274, P787; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	58	104	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8865	8874		10.1074/jbc.M008458200	http://dx.doi.org/10.1074/jbc.M008458200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11116146	hybrid			2022-12-25	WOS:000167607700036
J	Sun, H; El Yazal, J; Lockridge, O; Schopfer, LM; Brimijoin, S; Pang, YP				Sun, H; El Yazal, J; Lockridge, O; Schopfer, LM; Brimijoin, S; Pang, YP			Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase - Engineering effective butyrylcholinesterase mutants for cocaine detoxication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DATA-BANK; MOLECULAR-DYNAMICS; ACETYLCHOLINESTERASE; INTOXICATION; CONSTRAINTS; METABOLISM; HYDROLYSIS; BINDING; PLASMA	Butyrylcholinesterase (BChE) is important in cocaine metabolism, but it hydrolyzes (-)-cocaine only one-two thousandth as fast as the unnatural (+)-stereoisomer, A starting point in engineering BChE mutants that rapidly clear cocaine from the bloodstream, for overdose treatment, is to elucidate structural factors underlying the stereochemical difference in catalysis, Here, we report two three-dimensional Michaelis-Menten complexes of BChE liganded with natural and unnatural cocaine molecules, respectively, that were derived from molecular modeling and supported by experimental studies. Such complexes revealed that the benzoic ester group of both cocaine stereoisomers must rotate toward the catalytic Ser(198) for hydrolysis, Rotation of (-)-cocaine appears to be hindered by interactions of its phenyl ring with Phe(329) and Trp(430). These interactions do not occur with (+)-cocaine, Because the rate of (-)-cocaine hydrolysis is predicted to be determined mainly by the re-orientation step, it should not be greatly influenced by pH. In fact, measured rates of this reaction were nearly constant over the pH range from 5.5 to 8.5, despite large rate changes in hydrolysis of (+)-cocaine, Our models can explain why BChE hydrolyzes (+)-cocaine faster than (-)-cocaine, and they suggest that mutations of certain residues in the catalytic site could greatly improve catalytic efficiency and the potential for detoxication.	Mayo Clin, Ctr Canc, Mol Neurosci Program, Rochester, MN 55905 USA; Mayo Clin, Ctr Canc, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Fdn Med Educ & Res, Tumor Biol Program, Rochester, MN 55905 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst, Omaha, NE 68198 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Pang, YP (corresponding author), Mayo Clin, Ctr Canc, Mol Neurosci Program, Rochester, MN 55905 USA.			Pang, Yuan-Ping/0000-0003-0838-2560	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011707] Funding Source: NIH RePORTER; NIDA NIH HHS [DA011707] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berkman CE, 1997, BIOCHEM PHARMACOL, V54, P1261, DOI 10.1016/S0006-2952(97)00403-6; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CARROLL FI, 1991, J MED CHEM, V34, P883, DOI 10.1021/jm00107a003; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Felder CE, 1997, J MOL GRAPH MODEL, V15, P318, DOI 10.1016/S1093-3263(98)00005-9; FRISCH MJ, 1999, GAUSSIAN 98; GATLEY SJ, 1991, BIOCHEM PHARMACOL, V41, P1249, DOI 10.1016/0006-2952(91)90665-R; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; INABA T, 1978, CLIN PHARMACOL THER, V23, P547; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; MARZUK PM, 1995, NEW ENGL J MED, V332, P1753, DOI 10.1056/NEJM199506293322606; Mattes C, 1996, LIFE SCI, V58, pPL257, DOI 10.1016/0024-3205(96)00065-3; Mattes CE, 1997, TOXICOL APPL PHARM, V145, P372, DOI 10.1006/taap.1997.8188; MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0; MILLARD CB, 1992, BIOCHEM BIOPH RES CO, V189, P1280, DOI 10.1016/0006-291X(92)90212-4; PANG YP, 1994, J COMPUT AID MOL DES, V8, P669, DOI 10.1007/BF00124014; Pang YP, 1999, J AM CHEM SOC, V121, P1717, DOI 10.1021/ja9828410; PATI R, 1977, J PHYS CHEM A, V101, P6101; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Perola E, 2000, J MED CHEM, V43, P401, DOI 10.1021/jm990408a; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SCHRANK KS, 1992, NIDA RES MONOGR, V123, P110; Sherer EC, 1997, J PHYS CHEM A, V101, P8526, DOI 10.1021/jp971320g; Singh S, 2000, CHEM REV, V100, P925, DOI 10.1021/cr9700538; STEWART DJ, 1977, LIFE SCI, V20, P1557, DOI 10.1016/0024-3205(77)90448-9; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; WETLI CV, 1987, AM J FOREN MED PATH, V8, P1, DOI 10.1097/00000433-198703000-00001; Xie WH, 1999, MOL PHARMACOL, V55, P83, DOI 10.1124/mol.55.1.83	33	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9330	9336		10.1074/jbc.M006676200	http://dx.doi.org/10.1074/jbc.M006676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11104759	hybrid			2022-12-25	WOS:000167607700095
J	Arredondo, JJ; Ferreres, RM; Maroto, M; Cripps, RM; Marco, R; Bernstein, SI; Cervera, M				Arredondo, JJ; Ferreres, RM; Maroto, M; Cripps, RM; Marco, R; Bernstein, SI; Cervera, M			Control of Drosophila paramyosin/miniparamyosin gene expression - Differential regulatory mechanisms for muscle-specific transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMYOSIN MINIPARAMYOSIN GENE; TROPOMYOSIN-II GENE; DEVELOPMENTAL REGULATION; ENHANCER ELEMENTS; MULTIPLE PROTEINS; MEF2; MYOGENESIS; MESODERM; D-MEF2; TWIST	To define the transcriptional mechanisms contributing to stage- and tissue-specific expression of muscle genes, we performed transgenic analysis of Drosophila paramyosin gene regulation. This gene has two promoters, one for paramyosin and one for miniparamyosin, which are active in partially overlapping domains. Regions between -0.9 and -1.7 kilobases upstream of each initiation site contribute to the temporal and spatial expression patterns. By comparing the Drosophila melanogaster and Drosophila virilis promoters, conserved binding sites were found for known myogenic factors, including one MEF2 site and three E boxes. In contrast with previous data, our experiments with the paramyosin promoter indicate that the MEF2 site is essential but not sufficient for proper paramyosin gene transcription. Mutations in the three E boxes, on the other hand, do not produce any effect in embryonic/larval muscles. Thus MEF2 site- and E box-binding proteins can play different roles in the regulation of different muscle-specific genes, For the miniparamyosin promoters, several conserved sequences were shown to correspond to functionally important regions. Our data further show that the two promoters work independently. Even when both promoters are active in the same muscle fiber, the transcription driven by one of the promoters is not affected by transcription driven by the other.	Univ Autonoma Madrid, Fac Med, CSIC, Dept Bioquim, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); California State University System; San Diego State University; California State University System; San Diego State University	Cervera, M (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Dept Bioquim, Arzobispo Morcillo 4, E-28029 Madrid, Spain.		Marco-Ferreres, Raquel/J-7122-2012; Arredondo, Juan/L-2404-2013	Arredondo, Juan/0000-0002-6784-0990; Marco-Ferreres, Raquel/0000-0002-6109-3840; Bernstein, Sanford/0000-0001-7094-5390				Abmayr SM, 1998, CURR TOP DEV BIOL, V38, P35; Ashburner M., 1989, DROSOPHILA LAB HDB M; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BANDMAN E, 1992, DEV BIOL, V154, P273, DOI 10.1016/0012-1606(92)90067-Q; BATE M, 1991, DEVELOPMENT, V113, P79; BATE M, 1990, DEVELOPMENT, V110, P791; Baylies MK, 1998, CELL, V93, P921, DOI 10.1016/S0092-8674(00)81198-8; BECKER KD, 1992, J CELL BIOL, V116, P669, DOI 10.1083/jcb.116.3.669; Benoist P, 1998, J BIOL CHEM, V273, P7538, DOI 10.1074/jbc.273.13.7538; BERNSTEIN SI, 1993, INT REV CYTOL, V143, P63; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BODMER R, 1993, DEVELOPMENT, V118, P719; Borkowski OMD, 1995, DEVELOPMENT, V121, P4183; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; Cripps RM, 1998, GENE DEV, V12, P422, DOI 10.1101/gad.12.3.422; CURRIE DA, 1991, DEVELOPMENT, V113, P91; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FERNANDES J, 1991, DEVELOPMENT, V113, P67; GEYER PK, 1986, MOL CELL BIOL, V6, P3388, DOI 10.1128/MCB.6.10.3388; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; GREMKE L, 1993, DEV BIOL, V159, P513, DOI 10.1006/dbio.1993.1260; HANKE PD, 1988, MOL CELL BIOL, V8, P3591, DOI 10.1128/MCB.8.9.3591; HESS N, 1989, CELLULAR MOL BIOL MU, P621; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; KARLIK CC, 1986, MOL CELL BIOL, V6, P1965, DOI 10.1128/MCB.6.6.1965; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lin MH, 1997, DEV BIOL, V182, P240, DOI 10.1006/dbio.1996.8484; Lin MH, 1996, P NATL ACAD SCI USA, V93, P4623, DOI 10.1073/pnas.93.10.4623; Lin SC, 1997, DEVELOPMENT, V124, P4685; Lin SC, 1997, DEV GENET, V20, P297, DOI 10.1002/(SICI)1520-6408(1997)20:4<297::AID-DVG1>3.0.CO;2-2; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; Maroto M, 1996, J CELL BIOL, V134, P81, DOI 10.1083/jcb.134.1.81; MAROTO M, 1995, J BIOL CHEM, V270, P4375, DOI 10.1074/jbc.270.9.4375; MEREDITH J, 1993, DEV BIOL, V159, P500, DOI 10.1006/dbio.1993.1259; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Newlands S, 1998, GENE DEV, V12, P2748, DOI 10.1101/gad.12.17.2748; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; Reddy KL, 2000, DEV BIOL, V224, P401, DOI 10.1006/dbio.2000.9797; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Standiford DM, 1997, J MOL BIOL, V265, P40, DOI 10.1006/jmbi.1996.0710; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1	52	27	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8278	8287		10.1074/jbc.M009302200	http://dx.doi.org/10.1074/jbc.M009302200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11110792	hybrid			2022-12-25	WOS:000167474900084
J	Cote, J; Dupuis, S; Wu, JY				Cote, J; Dupuis, S; Wu, JY			Polypyrimidine track-binding protein binding downstream of caspase-2 alternative exon 9 represses its inclusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; IMMUNODEFICIENCY-VIRUS TYPE-1; GROWTH-FACTOR RECEPTOR-2; SPLICING ENHANCER; PREMESSENGER RNA; SEX-LETHAL; IN-VIVO; 5'-SPLICE-SITE SELECTION; 3'-SPLICE-SITE SELECTION; MYOTONIC-DYSTROPHY	We have been using the caspase-2 pre-mRNA as a model system to study the importance of alternative splicing in the regulation of programmed cell death. Inclusion or skipping of a cassette-type exon in the 3' portion of this pre-mRNA leads to the production of isoforms with antagonistic activity in apoptosis, We previously identified a negative regulatory element (In100) located in the intron downstream of alternative exon 9. The upstream portion of this element harbors a decoy 3' acceptor site that engages in nonproductive commitment complex interactions with the 5' splice site of exon 9, This in turn confers a competitive advantage to the exon-skipping splicing pattern. Further characterization of the In100 element reveals a second, functionally distinct, domain located downstream from the decoy 3' acceptor site. This downstream domain harbors several polypyrimidine track-binding protein (PTB)-binding sites. We show that PTB binding to these sites correlates with the negative effect on exon 9 inclusion. Finally, we show that both domains of the In100 element can function independently to repress exon 9 inclusion, although PTB binding in the vicinity of the decoy 3' splice site can modulate its activity. Our results thus reveal a complex composite element that regulates caspase-2 exon 9 alternative splicing through a novel mechanism.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Wu, JY (corresponding author), Washington Univ, Sch Med, Dept Pediat, 4938 Parkview Pl,MPRB Rm 3107, St Louis, MO 63110 USA.		Cote, Jocelyn/O-2351-2018	Cote, Jocelyn/0000-0001-9551-2284	NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576, R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967, R01 GM070967-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; Ashiya M, 1997, RNA, V3, P996; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BLACK DL, 1995, RNA, V1, P763; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Blanchette M, 1997, RNA, V3, P405; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; CHABOT B, 1992, NUCLEIC ACIDS RES, V20, P5197, DOI 10.1093/nar/20.19.5197; Chabot B., 1994, RNA PROCESSING PRACT, VI, P1; CHAN RC, 1995, MOL CELL BIOL, V15, P6377; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Chou MY, 1999, MOL CELL BIOL, V19, P69; Cote J, 1999, NUCLEIC ACIDS RES, V27, P2529, DOI 10.1093/nar/27.12.2529; Cote J, 2001, P NATL ACAD SCI USA, V98, P938, DOI 10.1073/pnas.031564098; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; Gersappe A, 1999, MOL CELL BIOL, V19, P364; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; Gooding C, 1998, RNA, V4, P85; Granadino B, 1997, P NATL ACAD SCI USA, V94, P7343, DOI 10.1073/pnas.94.14.7343; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; KUMAR S, 1995, FEBS LETT, V368, P69, DOI 10.1016/0014-5793(95)00602-6; LIN CH, 1995, RNA, V1, P234; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; McNally LM, 1999, J VIROL, V73, P2385, DOI 10.1128/JVI.73.3.2385-2393.1999; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; NORTON PA, 1993, BIOCHEM BIOPH RES CO, V195, P215, DOI 10.1006/bbrc.1993.2032; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; Perez I, 1997, RNA, V3, P764; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Polydorides AD, 2000, P NATL ACAD SCI USA, V97, P6350, DOI 10.1073/pnas.110128397; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Southby J, 1999, MOL CELL BIOL, V19, P2699; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; Sun HZ, 2000, MOL CELL BIOL, V20, P6414, DOI 10.1128/MCB.20.17.6414-6425.2000; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Troy CM, 1997, J NEUROSCI, V17, P1911; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VALCARCEL J, 1997, CURR BIOL, V7, P705; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; ZHANG L, 1999, BIOCHEM BIOPH RES CO, V254, P522	69	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8535	8543		10.1074/jbc.M008924200	http://dx.doi.org/10.1074/jbc.M008924200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11116151	Green Accepted, hybrid			2022-12-25	WOS:000167474900115
J	Feng, X; Gaeta, ML; Madge, LA; Yang, JH; Bradley, JR; Pober, JS				Feng, X; Gaeta, ML; Madge, LA; Yang, JH; Bradley, JR; Pober, JS			Caveolin-1 associates with TRAF2 to form a complex that is recruited to tumor necrosis factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN-ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; TNF RECEPTOR-1; STRUCTURAL BASIS; PLASMA-MEMBRANE; ACTIVATION; APOPTOSIS; PROTEINS; FAMILY	Tumor necrosis factor (TNF) receptor-associated factor (TRAF) 2 is an intracellular adapter protein, which, upon TNF stimulation, is directly recruited to the intracellular region of TNF receptor 2 (TNFR2) or indirectly, via TRADD, to the intracellular region of TNF receptor 1 (TNFR1). In cultured human umbilical vein endothelial cells, endogenous TRAF2 colocalizes with the membrane-organizing protein caveolin-1 at regions of enrichment subjacent to the plasma membrane as detected by confocal fluorescence microscopy. Both endogenous and transfected TRAF2 protein coimmunoprecipitate with caveolin-1 in the absence of ligand. Upon TNF treatment, the TRAF2-caveolin-1 complex transiently associates with TRADD, and upon overexpression of TNFR2, the TRAF2-caveolin-1 complex stably associates with and causes redistribution of this receptor as detected by confocal fluorescence microscopy, In human embryonic kidney 293 cells, which have minimal endogenous expression of caveolin-1, cotransfection of TRAF2 and caveolin-1 results in spontaneous association of these proteins which can further associate with and redistribute transfected TNFR2 molecules. The association of caveolin-1 with TNFR2 depends upon TRAF2. Cotransfection of caveolin-1 protein increases TRAF2 protein expression levels in HEK 293 cells, which correlates with enhancement of TNF and TRAF2 signaling, measured as transcription of a NF-kappaB promoter-reporter gene, although the caveolin-enhanced response to TNF is attenuated at higher caveolin levels. These findings suggest that intracellular distribution of activated TNF receptors may be regulated by caveolin-1 via its interaction with TRAF2.	Yale Univ, Sch Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06536 USA; Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England	Yale University; University of Cambridge	Pober, JS (corresponding author), Yale Univ, Sch Med, Interdepartmental Program Vasc Biol & Transplanta, 333 Cedar St, New Haven, CT 06536 USA.			Bradley, John/0000-0002-7774-8805				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BEUTLER B, 1995, J INVEST MED, V43, P227; BRADLEY JR, 1995, AM J PATHOL, V146, P27; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GAETA ML, 2001, IN PRESS LAB INVEST; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Goeddel DV, 1999, CHEST, V116, p69S, DOI 10.1378/chest.116.suppl_1.69S; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jones SJ, 1999, J IMMUNOL, V162, P1042; Ko YG, 1999, J IMMUNOL, V162, P7217; Ledgerwood EC, 1999, LAB INVEST, V79, P1041; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; Madge LA, 1999, J BIOL CHEM, V274, P13643, DOI 10.1074/jbc.274.19.13643; Min W, 1997, J IMMUNOL, V159, P3508; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wajant H, 1999, CYTOKINE GROWTH F R, V10, P15, DOI 10.1016/S1359-6101(98)00023-9; Weiss T, 1998, J IMMUNOL, V161, P3136; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2	42	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8341	8349		10.1074/jbc.M007116200	http://dx.doi.org/10.1074/jbc.M007116200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11112773	hybrid			2022-12-25	WOS:000167474900091
J	Martin, KA; Schalm, SS; Richardson, C; Romanelli, A; Keon, KL; Blenis, J				Martin, KA; Schalm, SS; Richardson, C; Romanelli, A; Keon, KL; Blenis, J			Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; C-ZETA; ACTIVATION; PHOSPHORYLATION; INHIBITION; TRANSLOCATION; TRANSLATION; PP70(S6K); P70(S6K); ISOTYPES	Ribosomal S6 kinase (S6K1), through phosphorylation of the 40 S ribosomal protein S6 and regulation of 5'-terminal oligopyrimidine tract mRNAs, is an important regulator of cellular translational capacity. S6K1 has also been implicated in regulation of cell size. We have recently identified S6K2, a homolog of S6K1, which phosphorylates S6 in vitro and is regulated by the phosphatidylinositide 3-kinase (PI3-K) and mammalian target of rapamycin pathways in vivo. Here, we characterize S6K2 regulation by PI3-K signaling intermediates and compare its regulation to that of S6K1, We report that S6K2 is activated similarly to S6K1 by the PI3-K effecters phosphoinositide-dependent kinase 1, Cdc42, Rac, and protein kinase C zeta but that S6K2 is more sensitive to basal activation by myristoylated protein kinase C zeta than is S6K1. The C-terminal sequence of S6K2 is divergent from that of S6K1, We find that the S6K2 C terminus plays a greater role in S6K2 regulation than does the S6K1 C terminus by functioning as a potent inhibitor of activation by various agonists, Removal of the S6K2 C terminus results in an enzyme that is hypersensitive to agonist-dependent activation. These data suggest that S6K1 and S6K2 are similarly activated by PI3-K effecters but that sequences unique to S6K2 contribute to stronger inhibition of its kinase activity. Understanding the regulation of the two S6K homologs may provide insight into the physiological roles of these kinases.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany	Harvard University; Harvard Medical School; Free University of Berlin	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.			Martin, Kathleen/0000-0002-1748-0034	NIGMS NIH HHS [GM51405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; Martin KA, 2001, J BIOL CHEM, V276, P7892, DOI 10.1074/jbc.M009972200; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; WENG QP, 1995, MOL CELL BIOL, V15, P2333	33	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7884	7891		10.1074/jbc.M006969200	http://dx.doi.org/10.1074/jbc.M006969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11108711	hybrid			2022-12-25	WOS:000167474900030
J	Pahan, K; Sheikh, FG; Liu, XJ; Hilger, S; McKinney, M; Petro, TM				Pahan, K; Sheikh, FG; Liu, XJ; Hilger, S; McKinney, M; Petro, TM			Induction of nitric-oxide synthase and activation of NF-kappa B by interleukin-12 p40 in microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PRIMARY ASTROCYTES; C-6 GLIAL-CELLS; MULTIPLE-SCLEROSIS; MESSENGER-RNA; MURINE MACROPHAGES; INHIBITS INDUCTION; RECEPTOR SUBUNITS; IFN-GAMMA; T-CELLS; EXPRESSION	Interleukin-12 (IL-12) is composed of two different subunits, p40 and p35. Expression of p40 mRNA but not that of p35 mRNA in excessive amount in the central nervous system of patients with multiple sclerosis (MS) suggests that IL-12 p40 may have a role in the pathogenesis of the disease. However, the mode of action of p40 is completely unknown. Because nitric oxide produced from the induction of nitric-oxide synthase (iNOS) also plays a vital role in the pathophysiology of MS, the present study was undertaken to explore the role of p40 in the induction of NO production and the expression of iNOS in microglia, Both IL-12 and p40(2), the p40 homodimer, dose-dependently induced the production of NO in BV-2 microglial cells. This induction of NO production was accompanied by an induction of iNOS protein and mRNA. Induction of NO production by the expression of mouse p40 cDNA but not that of the mouse p35 cDNA suggests that the p40 but not the p35 subunit of IL-12 is involved in the expression of iNOS, In addition to BV-2 glial cells, p40, also Induced the production of NO in mouse primary microglia and peritoneal macrophages. However, both IL-12 and p40, were unable to induce the production of NO in mouse primary astrocytes. Because activation of NF-kappaB is important for the expression of iNOS, we investigated the effect of p40, on the activation of NF-kappaB, Induction of the DNA binding as well as the transcriptional activity of NF-kappaB by p40, and inhibition of p40(2)-induced expression of iNOS by SN50, a cell-permeable peptide carrying the nuclear localization sequence of p50 NF-kappaB, but not by SN50M, a nonfunctional peptide mutant, suggests that p40, induces the expression of iNOS through the activation of NF-kappaB. This study delineates a novel role of IL-12 p40 in inducing the expression of iNOS in microglial cells, which may participate in the pathogenesis of neuroinflammatory diseases.	Univ Nebraska, Med Ctr, Dept Oral Biol, Lincoln, NE 68583 USA; Mayo Clin Jacksonville, Dept Pharmacol, Jacksonville, FL 32224 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; Mayo Clinic	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 40th & Holdrege, Lincoln, NE 68583 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39940, R01 NS039940, R01 NS039940-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aloisi F, 1997, J IMMUNOL, V159, P1604; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner T, 1997, J IMMUNOL, V158, P2940; Bright JJ, 1998, J NEUROIMMUNOL, V82, P22, DOI 10.1016/S0165-5728(97)00184-7; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Constantinescu CS, 2000, NEUROSCI LETT, V287, P171, DOI 10.1016/S0304-3940(00)01184-8; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; Fassbender K, 1998, NEUROLOGY, V51, P753, DOI 10.1212/WNL.51.3.753; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; GERMANN T, 1995, IMMUNOL TODAY, V16, P500, DOI 10.1016/0167-5699(95)80035-2; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Hu SX, 1995, GLIA, V15, P491, DOI 10.1002/glia.440150412; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JOHNSON AW, 1995, J NEUROL NEUROSUR PS, V58, P107, DOI 10.1136/jnnp.58.1.107; KOLB H, 1992, IMMUNOL TODAY, V13, P157, DOI 10.1016/0167-5699(92)90118-Q; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; RADI R, 1991, J BIOL CHEM, V266, P4244; Salkowski CA, 1997, J IMMUNOL, V158, P905; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suzumura A, 1998, BRAIN RES, V787, P139, DOI 10.1016/S0006-8993(97)01166-9; van Boxel-Dezaire AHH, 1999, ANN NEUROL, V45, P695, DOI 10.1002/1531-8249(199906)45:6<695::AID-ANA3>3.0.CO;2-R; Wang X, 1999, EUR J IMMUNOL, V29, P2007, DOI 10.1002/(SICI)1521-4141(199906)29:06<2007::AID-IMMU2007>3.0.CO;2-0; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WOLF SF, 1991, J IMMUNOL, V146, P3074; XIE QW, 1994, J BIOL CHEM, V269, P4705; Zipris D, 1996, J IMMUNOL, V156, P1315	56	130	135	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7899	7905		10.1074/jbc.M008262200	http://dx.doi.org/10.1074/jbc.M008262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11110796	Green Accepted, hybrid			2022-12-25	WOS:000167474900032
J	Song, KY; Jung, YS; Jung, DH; Lee, I				Song, KY; Jung, YS; Jung, DH; Lee, I			Human Ku70 interacts with heterochromatin protein 1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITION-EFFECT VARIEGATION; DOUBLE-STRAND BREAKS; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; DROSOPHILA-MELANOGASTER; CHROMOSOMAL PROTEIN; MOLECULAR-CLONING; TELOMERE LENGTH; MAMMALIAN-CELLS	Ku is involved in the metabolism of DNA ends, DNA repair, and the maintenance of telomeres. It consists of a heterodimer of 70- and 80-kDa subunits. Recently we have demonstrated that Ku70 interacted with TRFS, a mammalian telomere-binding protein. Using the same yeast two-hybrid screening system, we now show that Ku70 also interacts with heterochromatin protein la (HP1 alpha), a protein known to be associated with telomeres as well as heterochromatin. HP1 is a suppressor of the position effect variegation in Drosophila and acts as a transcriptional suppressor in mammalian cells. The interaction with Ku70 in the two-hybrid system was confirmed by a glutathione S-transferase pull-down study using bacterial recombinant proteins in vitro. The interaction was also reproduced in vivo in HeLa cells, where endogenous Ku70 coimmunoprecipitated with HP1 alpha. This interaction was more effective in acidic pH and weakened considerably as the pH of the reaction buffer was elevated up to 7.5. Ku80 did not interact with HP1 alpha directly. The interaction domains of Ku70 and HP1 alpha included the Leu-Ser repeat (amino acids 200-385) and the chrome shadow domain, respectively. Ku70 was largely colocalized with transfected HP1 alpha but not with a C-terminal deletion mutant, HP1 alpha (DeltaC). In contrast to HP1 alpha, Ku70 did not repress transcriptional activity of the reporter gene when tethered to DNA after transfection to mammalian cells. The implication of this interaction is discussed.	Univ Ulsan, Coll Med, Dept Pathol, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Biochem, Seoul 138736, South Korea	University of Ulsan; University of Ulsan	Lee, I (corresponding author), Univ Ulsan, Coll Med, Dept Pathol, 388-1 Poongnap-Dong, Seoul 138736, South Korea.							Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; Ainsztein AM, 1998, J CELL BIOL, V143, P1763, DOI 10.1083/jcb.143.7.1763; ANDERSON CW, 1996, MOL ANAL DNA REARRAN, P91; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Camara-Clayette V, 1999, NUCLEIC ACIDS RES, V27, P1656, DOI 10.1093/nar/27.7.1656; Cleard F, 1997, EMBO J, V16, P5280, DOI 10.1093/emboj/16.17.5280; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Fanti L, 1998, MOL CELL, V2, P527, DOI 10.1016/S1097-2765(00)80152-5; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; McDowell TL, 1999, P NATL ACAD SCI USA, V96, P13983, DOI 10.1073/pnas.96.24.13983; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; NIELSON AL, 1996, EMBO J, V18, P6385; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Osipovich O, 1997, J BIOL CHEM, V272, P27259, DOI 10.1074/jbc.272.43.27259; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Park SH, 1998, CYTOGENET CELL GENET, V81, P178, DOI 10.1159/000015022; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; REEVES WH, 1989, J BIOL CHEM, V264, P5047; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Romero F, 1996, MOL CELL BIOL, V16, P37; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SAUNDERS WS, 1993, J CELL SCI, V104, P573; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1989, J BIOL CHEM, V264, P13407; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Ye Q, 1996, J BIOL CHEM, V271, P14653, DOI 10.1074/jbc.271.25.14653; Yu E, 1998, HYBRIDOMA, V17, P413, DOI 10.1089/hyb.1998.17.413	64	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8321	8327		10.1074/jbc.M008779200	http://dx.doi.org/10.1074/jbc.M008779200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11112778	hybrid			2022-12-25	WOS:000167474900089
J	Watson, F; Kiernan, RS; Deavall, DG; Varro, A; Dimaline, R				Watson, F; Kiernan, RS; Deavall, DG; Varro, A; Dimaline, R			Transcriptional activation of the rat vesicular monoamine transporter 2 promoter in gastric epithelial cells - Regulation by gastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-DECARBOXYLASE PROMOTER; PHORBOL 12-MYRISTATE 13-ACETATE; MESSENGER-RNA ABUNDANCE; CHROMOGRANIN-A; DEPENDENT TRANSCRIPTION; HISTAMINE-SECRETION; CREB; EXPRESSION; PANCREASTATIN; BINDING	Vesicular monoamine transporter 2 is important for the accumulation of monoamine neurotransmitters into synaptic vesicles and histamine transport into secretory vesicles of the enterochromaffin like cell of the gastric corpus. In this study we have investigated the mechanisms regulating the transcriptional activation of the rat vesicular monoamine transporter 2 (VMAT2) promoter in gastric epithelial cells. Maintenance of basal levels of transcription was dependent on the presence of SP1, cAMP-response element (CRE), and overlapping AP2/SP1 consensus sequences within the region of promoter from -86 to +1 base pairs (bp), Gastrin stimulation increased transcriptional activity, and responsiveness was shown to be dependent on the CRE (-33 to -26 bp) and AP2/SP1 (-61 to -48 bp) consensus sites but independent of the SP1 site at -86 to -81 bp. Gastrin-induced transcription was dependent on the cooperative interaction of an uncharacterized nuclear factor of similar to 23.3 kDa that bound to the putative AP2/SP1 site, CRE-binding protein (CREB), and CREE-binding protein/ p300, Gastrin stimulation resulted in the increased binding of phosphorylated CREB to the promoter, but it did not result in the increased binding of the AP2/SP1-binding protein. The gastrin responsiveness of the promoter was shown to be dependent on both the protein kinase C and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-signaling pathways, which may converge on the AP2/SP1-binding protein.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Watson, F (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	watso@liv.ac.uk	Varro, Andras/M-2647-2016					Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAUERFEIND R, 1994, ANN NY ACAD SCI, V733, P385; BEAVEN MA, 1982, PHARM HISTAMINE RECE, P101; BLACK JW, 1987, TRENDS PHARMACOL SCI, V8, P486, DOI 10.1016/0165-6147(87)90044-7; CETIN Y, 1991, CELL TISSUE RES, V264, P231, DOI 10.1007/BF00313960; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DIMALINE R, 1993, J PHYSIOL-LONDON, V465, P449, DOI 10.1113/jphysiol.1993.sp019686; DIMALINE R, 1991, FEBS LETT, V281, P20, DOI 10.1016/0014-5793(91)80348-7; Dimaline R, 1996, J PHYSIOL-LONDON, V490, P249, DOI 10.1113/jphysiol.1996.sp021140; DIMALINE R, 1993, AM J PHYSIOL, V264, pG583, DOI 10.1152/ajpgi.1993.264.3.G583; Gainetdinov RR, 1998, J NEUROCHEM, V70, P1973; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; HAKANSON R, 1995, GASTROENTEROLOGY, V108, P1445, DOI 10.1016/0016-5085(95)90693-2; HAKANSON R, 1970, ACTA PHYSIOL SCAND, P1; Hocker M, 1997, AM J PHYSIOL-GASTR L, V272, pG822, DOI 10.1152/ajpgi.1997.272.4.G822; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; Hocker M, 1998, J BIOL CHEM, V273, P34000, DOI 10.1074/jbc.273.51.34000; Hu PPC, 1999, MOL ENDOCRINOL, V13, P2039, DOI 10.1210/me.13.12.2039; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MERICKEL A, 1995, NEUROPHARMACOLOGY, V34, P1543, DOI 10.1016/0028-3908(95)00148-Y; MONTMINY MR, 1993, GENE EXPRESSION GEN, P72; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OCONNOR DT, 1993, ANN NY ACAD SCI, V729, P36; PETER D, 1995, J NEUROSCI, V15, P6179; Prinz C, 1999, AM J PHYSIOL-CELL PH, V277, pC845, DOI 10.1152/ajpcell.1999.277.5.C845; PRINZ C, 1993, GASTROENTEROLOGY, V105, P449, DOI 10.1016/0016-5085(93)90719-S; Raychowdhury R, 1999, J BIOL CHEM, V274, P20961, DOI 10.1074/jbc.274.30.20961; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STABILE BE, 1990, ARCH SURG-CHICAGO, V125, P451; SYVERSEN U, 1993, ACTA ONCOL, V32, P161, DOI 10.3109/02841869309083906; Takahashi N, 1997, MOL BRAIN RES, V49, P7, DOI 10.1016/S0169-328X(97)00116-2; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; Varro A, 2000, GUT, V46, pA56; WATKINSON A, 1992, REGUL PEPTIDES, V40, P51, DOI 10.1016/0167-0115(92)90083-7; Watson F, 1999, BIOCHEM J, V337, P193, DOI 10.1042/0264-6021:3370193; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	44	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7661	7671		10.1074/jbc.M006697200	http://dx.doi.org/10.1074/jbc.M006697200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113118	hybrid			2022-12-25	WOS:000167442900108
J	Green-Willms, NS; Butler, CA; Dunstan, HM; Fox, TD				Green-Willms, NS; Butler, CA; Dunstan, HM; Fox, TD			Pet111p, an inner membrane-bound translational activator that limits expression of the Saccharomyces cerevisiae mitochondrial gene COX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED LEADER; MESSENGER-RNA; YEAST MITOCHONDRIA; NUCLEAR GENES; PROTEINS; BIOGENESIS; PREDICTION; PET309; SITES; DNA	The protein specified by the Saccharomyces cerevisiae nuclear gene PET111 specifically activates translation of the mitochondrially coded mRNA for cytochrome c oxidase subunit II (Cox2p). We found Pet111p specifically in mitochondria of both wild-type cells and cells expressing a chromosomal gene for a functional epitope-tagged form of Pet111p. Pet111p was associated with mitochondrial membranes and was highly resistant to extraction with alkaline carbonate. Pet111p was protected from proteolytic digestion by the mitochondrial inner membrane. Thus, it is exposed only on the matrix side, where it could participate directly in organellar translation and localize Cox2p synthesis by virtue of its functional interaction with the COX2 mRNA 5'-untranslated leader. We also found that Pet111p is present at levels limiting the synthesis of Cox2p by examining the effect of altered PET111 gene dosage in the nucleus on expression of a reporter gene, cox2::ARG8(m), that was inserted into mitochondrial DNA. The level of the reporter protein, Arg8p, was one-half that of wild type in a diploid strain heterozygous for a pet111 deletion mutation, whereas it was increased 2.8-fold in a strain bearing extra copies of PET111 on a high copy plasmid. Thus, Pet111p could play dual roles in both membrane localization and regulation of Cox2p synthesis within mitochondria.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Fox, TD (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Biotechnol Bldg, Ithaca, NY 14853 USA.	tdf1@cornell.edu		Fox, Thomas/0000-0001-7629-3661	NIGMS NIH HHS [GM29362, R01 GM029362, R01 GM029362-20, GM07617] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029362] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DK, 1997, J BACTERIOL, V179, P2281, DOI 10.1128/jb.179.7.2281-2288.1997; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BONNEFOY N, 2001, IN PRESS METHODS CEL, V65; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; Choquet Y, 1998, P NATL ACAD SCI USA, V95, P4380, DOI 10.1073/pnas.95.8.4380; CONSTANZO MC, 1990, ANNU REV GENET, V24, P91; COSTANZO MC, 1993, MOL CELL BIOL, V13, P4806, DOI 10.1128/MCB.13.8.4806; COSTANZO MC, 1988, P NATL ACAD SCI USA, V85, P2677, DOI 10.1073/pnas.85.8.2677; Costanzo MC, 2000, GENETICS, V154, P999; DAKE E, 1988, J BIOL CHEM, V263, P7691; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; FOX TD, 1996, TRANSLATIONAL CONTRO, P733; FOX TD, 1991, METHOD ENZYMOL, V194, P149; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Green-Willms NS, 1998, MOL CELL BIOL, V18, P1826, DOI 10.1128/MCB.18.4.1826; Grivell LA, 1999, FEBS LETT, V452, P57, DOI 10.1016/S0014-5793(99)00532-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, V1, P627; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x; Manthey GM, 1998, EUR J BIOCHEM, V255, P156, DOI 10.1046/j.1432-1327.1998.2550156.x; MCMULLIN TW, 1993, J BIOL CHEM, V268, P11737; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; MULERO JJ, 1994, MOL GEN GENET, V242, P383, DOI 10.1007/BF00281787; MULERO JJ, 1993, MOL BIOL CELL, V4, P1327, DOI 10.1091/mbc.4.12.1327; MULERO JJ, 1993, GENETICS, V133, P509; MULERO JJ, 1993, THESIS CORNELL U; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Persson B, 1996, PROTEIN SCI, V5, P363; PINKHAM JL, 1994, MOL CELL BIOL, V14, P4643, DOI 10.1128/MCB.14.7.4643; POUTRE CG, 1987, GENETICS, V115, P637; RODEL G, 1986, CURR GENET, V11, P41, DOI 10.1007/BF00389424; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; Sherman F., 1986, METHODS YEAST GENETI; Siep M, 2000, CURR GENET, V37, P213, DOI 10.1007/s002940050522; Steele DF, 1996, P NATL ACAD SCI USA, V93, P5253, DOI 10.1073/pnas.93.11.5253; STRICK CA, 1987, MOL CELL BIOL, V7, P2728, DOI 10.1128/MCB.7.8.2728; STRICK CA, 1988, THESIS CORNELL U; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; WIESENBERGER G, 1995, MOL CELL BIOL, V15, P3291; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	51	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6392	6397		10.1074/jbc.M009856200	http://dx.doi.org/10.1074/jbc.M009856200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11106667	hybrid			2022-12-25	WOS:000167261000044
J	Melman, YF; Domenech, A; de la Luna, S; McDonald, TV				Melman, YF; Domenech, A; de la Luna, S; McDonald, TV			Structural determinants of KvLQT1 control by the KCNE family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC POTASSIUM CURRENT; LONG-QT SYNDROME; LANGE-NIELSEN; CHANNEL GENE; K+ CHANNEL; ISK; MUTATION; SUBUNITS; JERVELL; FORM	KvLQT1 is a Shaker like voltage-gated potassium channel that when complexed with minK (KCNE1) pro duces the slowly activating delayed rectifier I-ks. The emerging family of KCNE1-related peptides includes KCNE1 and KCNE3, both of which complex with KvLQT1 to produce functionally distinct currents. Namely I-ks, the slowly activating delayed rectifier current, is produced by KvLQT1/KCNE1, whereas KvLQT1/KCNE3 yields a more rapidly activating current with a distinct constitutively active component. We exploited these functional differences and the general structural similarities of KCNE1 and KCNE3 to study which physical regions are critical for control of KvLQT1 by making chimerical constructs of KCNE1 and KCNE3. By using this approach, we have found that a three-amino acid stretch within the transmembrane domain is necessary and sufficient to confer specificity of control of activation kinetics by KCNE1 and KCNE3. Moreover, chimera analysis showed that different regions within the transmembrane domain control deactivation rates. Our results help to provide a basis for understanding the mechanism by which KCNE proteins control K+ channel activity.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Sect Mol Cardiol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Sect Mol Cardiol, Bronx, NY 10461 USA; Hosp Duran & Reynals Gran, Down Syndrome Res Grp, Med & Mol Genet Ctr IRO, Barcelona, Spain	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals	McDonald, TV (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Sect Mol Cardiol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		de la Luna, Susana/E-9553-2015	de la Luna, Susana/0000-0001-7765-916X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057388] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 57388] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chouabe C, 2000, CARDIOVASC RES, V45, P971, DOI 10.1016/S0008-6363(99)00411-3; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Duggal P, 1998, CIRCULATION, V97, P142, DOI 10.1161/01.CIR.97.2.142; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; HAMMILL OP, 1981, PFLUGERS ARCH, V391, P85; Kagan A, 2000, J BIOL CHEM, V275, P11241, DOI 10.1074/jbc.275.15.11241; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1989, FASEB J, V5, P331; Tapper AR, 2000, J GEN PHYSIOL, V116, P379, DOI 10.1085/jgp.116.3.379; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017	26	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6439	6444		10.1074/jbc.M010713200	http://dx.doi.org/10.1074/jbc.M010713200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11104781	hybrid			2022-12-25	WOS:000167261000050
J	Misumi, Y; Sohda, M; Tashiro, A; Sato, H; Ikehara, Y				Misumi, Y; Sohda, M; Tashiro, A; Sato, H; Ikehara, Y			An essential cytoplasmic domain for the Golgi localization of coiled-coil proteins with a COOH-terminal membrane anchor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MOLECULAR CHARACTERIZATION; VESICULAR TRANSPORT; SECRETORY PATHWAY; COMPLEX; APPARATUS; NETWORK; SYNTAXIN; IDENTIFICATION; REDISTRIBUTION	Giantin is a resident Golgi protein that has an extremely long cytoplasmic domain (about 370 kDa) and is anchored to the Golgi membrane by the COOH-terminal membrane anchoring domain (CMD) with no luminal extension. We examined the essential domain of giantin required for Golgi localization by mutational analysis. The Golgis localization of giantin was not affected by the deletion of its CMD or by substitution with the GRID of syntaxin-2, a plasma membrane protein. The giantin CMD fused to the cytoplasmic domain of syntaxin-2 could not retain the chimera in the Golgi apparatus. Sequential deletion analysis showed that the COOH-terminal sequence (positions 3059-3161) adjacent to the CMD was the essential domain required for the Golgi localization of giantin. We also examined two other Golgis-resident proteins, golgin-84 and syntaxin-5, with a similar membrane topology as giantin. It was confirmed that the cytoplasmic domain of about 100 residues adjacent to the CMD was required for their Golgi localization. Taken together, these results suggest that the COOH-terminally anchored Golgi proteins with long cytoplasmic extensions have the Golgi localization signal(s) in the cytoplasmic sequence adjacent to the CMD. This is in contrast to previous observations that a transmembrane domain is required for Golgi localization by other Golgi proteins transported from the endoplasmic reticulum.	Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 8140180, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan	Fukuoka University; Kanazawa University	Ikehara, Y (corresponding author), Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 8140180, Japan.							BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bascom RA, 1999, J BIOL CHEM, V274, P2953, DOI 10.1074/jbc.274.5.2953; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BOSSHART H, 1994, J CELL BIOL, V111, P2851; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; EMMELOT P, 1964, BIOCHIM BIOPHYS ACTA, V90, P126, DOI 10.1016/0304-4165(64)90125-4; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; Fujiwara T, 1998, J BIOL CHEM, V273, P3068, DOI 10.1074/jbc.273.5.3068; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HIROSE S, 1988, J BIOL CHEM, V263, P7426; IKEHARA Y, 1977, J BIOCHEM-TOKYO, V81, P619; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; ODA K, 1983, EUR J BIOCHEM, V135, P209, DOI 10.1111/j.1432-1033.1983.tb07639.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; SHIBKO S, 1965, J CELL BIOL, V25, P479, DOI 10.1083/jcb.25.3.479; Sohda M, 1998, J BIOL CHEM, V273, P5385, DOI 10.1074/jbc.273.9.5385; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Toki C, 1997, CELL STRUCT FUNCT, V22, P565, DOI 10.1247/csf.22.565; Vogel K, 2000, J BIOL CHEM, V275, P2959, DOI 10.1074/jbc.275.4.2959; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185	46	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6867	6873		10.1074/jbc.M010121200	http://dx.doi.org/10.1074/jbc.M010121200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11113150	hybrid			2022-12-25	WOS:000167261000102
J	Schwake, M; Friedrich, T; Jentsch, TJ				Schwake, M; Friedrich, T; Jentsch, TJ			An internalization signal in ClC-5, an endosomal Cl- channel mutated in Dent's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; MUSCLE CHLORIDE CHANNEL; LIDDLES-SYNDROME; BREFELDIN-A; XENOPUS-LAEVIS; SODIUM-CHANNEL; WW DOMAIN; ENDOCYTOSIS; EXPRESSION; ACTIVATION	The C1C-5 chloride channel resides mainly in vesicles of the endocytotic pathway and contributes to their acidification, Its disruption in mice entails a broad defect in renal endocytosis and causes secondary changes in calciotropic hormone levels. Inactivating mutations in Dent's disease lead to proteinuria and kidney stones. Possibly by recycling, a small fraction of C1C-5 also reaches the plasma membrane. Here we identify a carboxyl-terminal internalization motif in C1C-5, It resembles the PY motif, which is crucial for the endocytosis and degradation of epithelial Na+ channels. Mutating this motif increases surface expression and currents about a-fold. This is probably because of interactions with WW domains, because dominant negative mutants of the ubiquitin-protein ligase WWP2 increased surface expression and currents of C1C-5 only when its PY motif was intact. Stimulating endocytosis by expressing rab5 or its GTPase-deficient Q79L mutant decreased WT C1C-5 currents but did not affect channels with mutated motifs, Similarly, decreasing endocytosis by expressing the inactive S34N mutant of rab5 increased C1C-5 currents only if its PY-like motif was intact. Thus, the endocytosis of C1C-5, which itself is crucial for the endocytosis of other proteins, depends on the interaction of a carboxyl-terminal internalization signal with ubiquitin-protein ligases containing WW domains.	Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Falkenried 94, D-20246 Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de	Friedrich, Thomas/AAA-3418-2022; Schwake, Michael/F-5381-2010	Schwake, Michael/0000-0002-4173-2166; Jentsch, Thomas/0000-0002-3509-2553				Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Matsumura Y, 1999, NAT GENET, V21, P95, DOI 10.1038/5036; Mukhopadhyay A, 1997, J CELL BIOL, V136, P1227, DOI 10.1083/jcb.136.6.1227; MULNERLORILLON O, 1995, DEV BIOL, V170, P223, DOI 10.1006/dbio.1995.1209; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Rebhun JF, 1998, DNA SEQUENCE, V9, P295, DOI 10.3109/10425179809008468; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; Strous GJ, 1999, J CELL SCI, V112, P1417; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	34	111	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12049	12054		10.1074/jbc.M010642200	http://dx.doi.org/10.1074/jbc.M010642200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11116157	Green Published, hybrid			2022-12-25	WOS:000168081800083
J	Li, HZ; Macdonald, DM; Hronowski, XP; Costello, CE; Leeman, SE; Boyd, ND				Li, HZ; Macdonald, DM; Hronowski, XP; Costello, CE; Leeman, SE; Boyd, ND			Further definition of the substance P (SP)/neurokinin-1 receptor complex - MET-174 is the site of photoinsertion of p-benzoylhenylalanine SP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NK-1 RECEPTOR; ANALOG; CELLS	The covalent attachment site of a substance P (SP) analogue containing the photoreactive amino acid p-benzoyl-L-phenylalanine (Bpa) in position 8 of the C-terminal portion of the peptide was identified previously as Met-181 on the neurokinin-1 (NK-1) receptor. In this study, a second photoreactive SP analogue, Bpa(4)- SP, in which the Bpa residue is located in the N-terminal portion of the peptide, was used to define further the peptide-receptor interface. The NK-1 receptor expressed in Chinese hamster ovary cells was specifically and efficiently photolabeled with a radioiodinated derivative of Bpa(4)-SP, Fragmentation analysis of the photolabeled receptor restricted the site of photoincorporation of Bpa4-SP to an amino acid within the sequence Thr-173 to Arg-177 located on the N-terminal side of the E2 loop. To identify the specific amino acid in this sequence that serves as the covalent attachment site for Bpa(4)-SP, a small photolabeled receptor fragment was generated by chemical cleavage with cyanogen bromide. Matrix-assisted laser desorption/ionization time of flight mass spectrometric analysis of the purified fragment identified a single protonated molecular ion with a molecular mass of 1801.3 +/- 1.8, indicating that upon irradiation, the bound photoligand covalently attaches to the terminal methyl group of a methionine residue. This result, taken together with the results of the peptide mapping studies, establishes that the site of Bpa(4)-SP covalent attachment to the NK-1 receptor is Met-174.	Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA	Boston University; Boston University	Boyd, ND (corresponding author), Boston Univ, Sch Med, Dept Pharmacol, L611,80 E Concord St, Boston, MA 02118 USA.			Costello, Catherine/0000-0003-1594-5122; Leeman, Susan/0000-0002-0951-5364	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR10888] Funding Source: Medline; NINDS NIH HHS [NS 3134] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; BOYD ND, 1996, P NATL ACAD SCI USA, V94, P9475; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KAGE R, 1993, J NEUROCHEM, V60, P347, DOI 10.1111/j.1471-4159.1993.tb05857.x; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; KAGE R, 1995, J NEUROCHEM, V64, P316; Macdonald D, 2001, BIOCHEMISTRY-US, V40, P2530, DOI 10.1021/bi001880x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAKEDA Y, 1992, J NEUROCHEM, V59, P740, DOI 10.1111/j.1471-4159.1992.tb09430.x	10	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10589	10593		10.1074/jbc.M007397200	http://dx.doi.org/10.1074/jbc.M007397200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11116140	hybrid			2022-12-25	WOS:000167980900004
J	Thyagarajan, T; Sreenath, T; Cho, A; Wright, JT; Kulkarni, AB				Thyagarajan, T; Sreenath, T; Cho, A; Wright, JT; Kulkarni, AB			Reduced expression of dentin sialophosphoprotein is associated with dysplastic dentin in mice overexpressing transforming growth factor-beta 1 in teeth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENESIS IMPERFECTA; TGF-BETA; ODONTOBLAST DIFFERENTIATION; DENTINOGENESIS IMPERFECTA; PULP COMPLEX; IN-VITRO; GENE; MUTATION; COLLAGEN; GROWTH-FACTOR-BETA-1	Transforming growth factor (TGF)-beta1 is expressed in developing tooth from the initiation stage through adulthood. Odontoblast-specific expression of TGF-beta1 in the tooth continues throughout life; however, the precise biological functions of this growth factor in the odontoblasts are not clearly understood. Herein, we describe the generation of transgenic mice that overexpress active TGF-beta1 predominantly in the odontoblasts, Teeth of these mice show a significant reduction in the tooth mineralization, defective dentin formation, and a relatively high branching of dentinal tubules, Dentin extracellular matrix components such as type I and III collagens are increased and deposited abnormally in the dental pulp, similar to the hereditary human tooth disorders such as dentin dysplasia and dentinogenesis imperfecta, Calcium, one of the crucial inorganic components of mineralization, is also apparently increased in the transgenic mouse teeth. Most importantly, the expression of dentin sialophosphoprotein (dspp), a candidate gene implicated in dentinogenesis imperfecta II (MIM 125420), is significantly down-regulated in the transgenic teeth. Our results provide in vivo evidence suggesting that TGF-beta1 mediated expression of dspp is crucial for dentin mineralization, These findings also provide for the first time a direct experimental evidence indicating that decreased dspp gene expression along with the other cellular changes in odontoblasts may result in human hereditary dental disorders like dentinogenesis imperfecta II (MIM 125420) and dentin dysplasia (MIM 125400 and 125420).	NIDCR, Funct Genom Unit, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Sch Dent, Dept Pediat Dent, Chapel Hill, NC 27599 USA; NIDCR, Gene Targeting Facil, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Kulkarni, AB (corresponding author), NIDCR, Funct Genom Unit, NIH, Bldg 30,Rm 529,30 Convent Dr, Bethesda, MD 20892 USA.		Wright, John Timothy/AAX-5755-2020		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000698, ZIADE000698] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BONADIO J, 1990, J BIOL CHEM, V265, P2262; D'Souza RN, 1998, EUR J ORAL SCI, V106, P185, DOI 10.1111/j.1600-0722.1998.tb02174.x; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Fan M W, 1998, Chin J Dent Res, V1, P17; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679; Losco PE, 1995, TOXICOL PATHOL, V23, P677, DOI 10.1177/019262339502300605; MacDougall M, 1992, Proc Finn Dent Soc, V88 Suppl 1, P195; Martin A, 1998, EUR J ORAL SCI, V106, P117, DOI 10.1111/j.1600-0722.1998.tb02162.x; Massague J, 2000, GENE DEV, V14, P627; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; Nicholls AC, 1996, HUM MUTAT, V7, P219, DOI 10.1002/(SICI)1098-1004(1996)7:3<219::AID-HUMU6>3.0.CO;2-5; PEREIRA R, 1993, J CLIN INVEST, V91, P709, DOI 10.1172/JCI116252; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; RUCH JV, 1995, INT J DEV BIOL, V39, P51; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SAUK JJ, 1980, J ORAL PATHOL MED, V9, P210, DOI 10.1111/j.1600-0714.1980.tb00379.x; Sloan AJ, 1999, ARCH ORAL BIOL, V44, P149, DOI 10.1016/S0003-9969(98)00106-X; SMITH AJ, 1995, INT J DEV BIOL, V39, P273; Sreenath TL, 1999, INT J DEV BIOL, V43, P509; Thesleff I, 1997, MECH DEVELOP, V67, P111, DOI 10.1016/S0925-4773(97)00115-9; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; Tziafas D, 1998, EUR J ORAL SCI, V106, P192, DOI 10.1111/j.1600-0722.1998.tb02175.x; VAAHTOKARI A, 1991, DEVELOPMENT, V113, P985; Waltimo J, 1996, J ORAL PATHOL MED, V25, P256, DOI 10.1111/j.1600-0714.1996.tb01381.x; ZEICHNERDAVID M, 1995, INT J DEV BIOL, V39, P69	29	75	80	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11016	11020		10.1074/jbc.M010502200	http://dx.doi.org/10.1074/jbc.M010502200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11116156	hybrid, Green Published			2022-12-25	WOS:000167980900061
J	Taniguchi, T; Kawamata, T; Mukai, H; Hasegawa, H; Isagawa, T; Yasuda, M; Hashimoto, T; Terashima, A; Nakai, M; Ono, Y; Tanaka, C				Taniguchi, T; Kawamata, T; Mukai, H; Hasegawa, H; Isagawa, T; Yasuda, M; Hashimoto, T; Terashima, A; Nakai, M; Ono, Y; Tanaka, C			Phosphorylation of tau is regulated by PKN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLYCOGEN-SYNTHASE KINASE-3-BETA; MICROTUBULE-ASSOCIATED PROTEINS; ZIPPER-LIKE SEQUENCES; PHOSPHATASE-ACTIVITY; DYNAMIC INSTABILITY; ALZHEIMERS-DISEASE; ADDITIONAL MEMBERS; FATTY-ACIDS; RAT-BRAIN	For the phosphorylation state of microtubule-associated protein, tau plays a pivotal role in regulating microtubule networks in neurons. Tau promotes the assembly and stabilization of microtubules, The potential for tau to bind to microtubules is down-regulated after local phosphorylation, When we investigated the effects of PKN activation on tau phosphorylation, we found that PKN triggers disruption of the microtubule array both in vitro and in vivo and predominantly phosphorylates tau in microtubule binding domains (MBDs). PKN has a catalytic domain highly homologous to protein kinase C (PI(C), a kinase that phosphorylates Ser-313 (= Ser-324, the number used in this study) in MBDs, Thus, we identified the phosphorylation sites of PKN and PKC subtypes (PKC-alpha, -betaI, -beta II, -gamma, -delta, -epsilon, -xi, and -lambda) in MBDs, PKN phosphorylates Ser-258, Ser-320, and Ser-352, although all PKC subtypes phosphorylate Ser-258, Ser-293, Ser-324, and Ser-352, There is a PKN-specific phosphorylation site, Ser-320, in MBDs. HIA3, a novel phosphorylation-dependent antibody recognizing phosphorylated tau at Ser-320, showed immunoreactivity in Chinese hamster ovary cells expressing tau and the active form of PKN, but not in Chinese hamster ovary cells expressing tan and the inactive form of PKN, The immunoreactivity for phosphorylated tau at Ser-320 increased in the presence of a phosphatase inhibitor, FK506 treatment, which means that calcineurin (protein phosphatase 2B) may be involved in dephosphorylating tau at Ser-320 site. We also noted that PKN reduces the phosphorylation recognized by the phosphorylation-dependent antibodies AT8, AT180, and AT270 in vivo. Thus PKN serves as a regulator of microtubules by specific phosphorylation of tau, which leads to disruption of tubulin assembly.	Hyogo Inst Aging Brain & Cognit Disorders, Himeji, Hyogo 6700981, Japan; Kobe Univ, Grad Sch Sci, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan	Kobe University	Taniguchi, T (corresponding author), Hyogo Inst Aging Brain & Cognit Disorders, 520 Saisho Ko, Himeji, Hyogo 6700981, Japan.			Mukai, Hideyuki/0000-0002-0167-8695				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; CORREAS I, 1992, J BIOL CHEM, V267, P15721; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; Isagawa T, 2000, BIOCHEM BIOPH RES CO, V273, P209, DOI 10.1006/bbrc.2000.2926; Kawamata T, 1998, J NEUROSCI, V18, P7402; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; Matsuzawa K, 1997, BIOCHEM BIOPH RES CO, V234, P621, DOI 10.1006/bbrc.1997.6669; Mercken M, 1995, J NEUROSCI, V15, P8259; Morioka M, 1998, BIOCHEM BIOPH RES CO, V253, P342, DOI 10.1006/bbrc.1998.9783; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; MUKAI H, 1993, J BIOCHEM, V113, P292, DOI 10.1093/oxfordjournals.jbchem.a124041; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PREUSS U, 1995, MOL BIOL CELL, V6, P1397, DOI 10.1091/mbc.6.10.1397; PRYER NK, 1992, J CELL SCI, V103, P965; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; TANIGUCHI T, 1994, ONCOGENE, V9, P861; Wang JZ, 1998, FEBS LETT, V436, P28, DOI 10.1016/S0014-5793(98)01090-4; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Wilson DM, 1997, AM J PATHOL, V150, P2181; Yoshinaga C, 1999, J BIOCHEM, V126, P475, DOI 10.1093/oxfordjournals.jbchem.a022476	37	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10025	10031		10.1074/jbc.M007427200	http://dx.doi.org/10.1074/jbc.M007427200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11104762	hybrid			2022-12-25	WOS:000167996400061
J	Bubien, JK; Watson, B; Khan, MA; Langloh, ALB; Fuller, CM; Berdiev, B; Tousson, A; Benos, DJ				Bubien, JK; Watson, B; Khan, MA; Langloh, ALB; Fuller, CM; Berdiev, B; Tousson, A; Benos, DJ			Expression and regulation of normal and polymorphic epithelial sodium channel by human lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE; PRINCIPAL CELLS; GAMMA-SUBUNIT; BETA-SUBUNIT; CONDUCTANCE; ORGANIZATION; PROTEINS	Gene expression, protein expression, and function of amiloride-sensitive sodium channels were examined in human lymphocytes from normal individuals and individuals with Liddle's disease. Using reverse transcriptase polymerase chain reactions, expression of all three cloned epithelial sodium channel (ENaC) subunits was detected in lymphocytes. Polyclonal antibodies to bovine alpha -ENaC bound to the plasma membrane of normal and Liddle's lymphocytes. A quantitative analysis of fluorescence-tagged ENaC antibodies indicated a 2.5-fold greater surface binding of the antibodies to Liddle's lymphocytes compared with normal lymphocytes. The relative binding intensity increased significantly (25%; p < 0.001) for both normal and Liddle's cells after treatment with 40 <mu>M 8-CPT-cAMP. Amiloride-sensitive whole cell currents were recorded under basal and cAMP-treated conditions for both cell types. Liddle's cells had a 4.5-fold larger inward sodium conductance compared with normal cells. A specific 25% increase in the inward sodium current was observed in normal cells in response to cAMP treatment. Outside-out patches from both cell types under both treatment conditions revealed no obvious differences in the single channel conductance. The P-open was 4.2 +/- 3.9% for patches from non-Liddle's cells, and 27.7 +/- 5.4% in patches from Liddie's lymphocytes. Biochemical purification of a protein complex, using the same antibodies used for the immunohistochemistry, yielded a functional sodium channel complex that was inhibited by amiloride when reconstituted into lipid vesicles and incorporated into planar lipid bilayers, These four independent methodologies yielded findings consistent with the hypotheses that human lymphocytes express functional, regulatable ENaC and that the mutation responsible for Liddle's disease induces excessive channel expression.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Gerentol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Geriatr Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bubien, JK (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, UAb Stn, Birmingham, AL 35294 USA.	bubien@uab.edu	Fuller, Cathy/B-4046-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R43DK037207, R01DK052789, R44DK037207] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVENET P, 1988, J MEMBRANE BIOL, V105, P245, DOI 10.1007/BF01871001; BUBIEN JK, 1993, AM J PHYSIOL, V265, pC1175, DOI 10.1152/ajpcell.1993.265.4.C1175; Bubien JK, 1996, AM J PHYSIOL-CELL PH, V270, pC208, DOI 10.1152/ajpcell.1996.270.1.C208; BUBIEN JK, 1995, AM J PHYSIOL-CELL PH, V269, pC791, DOI 10.1152/ajpcell.1995.269.3.C791; BUBIEN JK, 1994, J BIOL CHEM, V269, P17780; BUBIEN JK, 1998, AM J PHYSIOL, V276, pC1405; Eaton D C, 1988, Ion Channels, V1, P251; FRINGS S, 1988, J MEMBRANE BIOL, V106, P157, DOI 10.1007/BF01871398; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; GARTY H, 1987, J MEMBRANE BIOL, V95, P91, DOI 10.1007/BF01869154; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; Ismailov II, 1996, J MEMBRANE BIOL, V149, P123, DOI 10.1007/s002329900013; Lindemann B, 1999, CURR TOP MEMBR, V47, P315; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; Matalon S, 1999, ANNU REV PHYSIOL, V61, P627, DOI 10.1146/annurev.physiol.61.1.627; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; Rossier B C, 1994, Curr Opin Nephrol Hypertens, V3, P487, DOI 10.1097/00041552-199409000-00003; SCHAFER JA, 1986, AM J PHYSIOL, V250, P1063; SCHLATTER E, 1987, PFLUG ARCH EUR J PHY, V409, P81, DOI 10.1007/BF00584753; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SMITH PR, 1991, ANNU REV PHYSIOL, V53, P509, DOI 10.1146/annurev.ph.53.030191.002453; Thomas CP, 1996, J BIOL CHEM, V271, P26062, DOI 10.1074/jbc.271.42.26062; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Zhang P, 1999, BIOPHYS J, V77, P3043, DOI 10.1016/S0006-3495(99)77135-3; Zuckerman JB, 1999, J BIOL CHEM, V274, P23286, DOI 10.1074/jbc.274.33.23286	26	31	33	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8557	8566		10.1074/jbc.M008886200	http://dx.doi.org/10.1074/jbc.M008886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113130	hybrid			2022-12-25	WOS:000167474900118
J	Pei, L				Pei, L			Identification of c-myc as a down-stream target for pituitary tumor-transforming gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION FUNCTION; BINDING PROTEIN; HUMAN HOMOLOG; EXPRESSION; MAX; PHOSPHORYLATION; SEQUENCE; GROWTH; TRANSACTIVATION; REQUIRES	Pituitary tumor-transforming gene (PTTG) encodes a protein implicated in cellular transformation and transcriptional regulation. To identify downstream target genes, I established cell lines with tightly regulated inducible expression of PTTG. DNA arrays were used to analyze gene expression profiles after PTTG induction. I identified c-myc oncogene as a major PTTG target. Induction of PTTG resulted in increased cell proliferation through activation of c-myc. I showed that PTTG activates c-myc transcription in transfected cells. PTTG binds to c-myc promoter near the transcription initiation site in a protein complex containing the upstream stimulatory factor (USF1). I have defined the PTTG DNA-binding site and mapped PTTG DNA binding domain to a region between amino acids 61 and 118. Furthermore, I demonstrated that PTTG DNA binding is required for its transcriptional activation function. These results definitively established the role of PTTG as a transcription activator and indicate that PTTG is involved in cellular transformation and tumorigenesis through activation of c-myc oncogene.	Univ Calif Los Angeles, Cedars Sinai Res Inst, Div Endocrinol & Metab, Sch Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Cedars Sinai Med Ctr, Div Endocrinol & Metab, 8700 Beverly Blvd,D3088, Los Angeles, CA 90048 USA.	pei@cshs.org			NIDDK NIH HHS [DK-02346, DK-56608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002346, R03DK056608] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blau HM, 1999, P NATL ACAD SCI USA, V96, P797, DOI 10.1073/pnas.96.3.797; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LUISI B, 1995, DNA PROTEIN STRUCTUR, V7; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Pei L, 1998, J BIOL CHEM, V273, P5219, DOI 10.1074/jbc.273.9.5219; Pei L, 1999, J BIOL CHEM, V274, P3151, DOI 10.1074/jbc.274.5.3151; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Ramos-Morales F, 2000, ONCOGENE, V19, P403, DOI 10.1038/sj.onc.1203320; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	44	123	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8484	8491		10.1074/jbc.M009654200	http://dx.doi.org/10.1074/jbc.M009654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11115508	hybrid			2022-12-25	WOS:000167474900109
J	Trantirek, L; Hynkova, K; Nagata, Y; Murzin, A; Ansorgova, A; Sklenar, V; Damborsky, J				Trantirek, L; Hynkova, K; Nagata, Y; Murzin, A; Ansorgova, A; Sklenar, V; Damborsky, J			Reaction mechanism and stereochemistry of gamma-hexachlorocyclohexane dehydrochlorinase LinA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PAUCIMOBILIS; CRYSTAL-STRUCTURE; SPECTROSCOPY; PURIFICATION; EXCHANGE; PROTEINS	gamma -Hexachlorocyclohexane dehydrochlorinase (LinA) catalyzes the initial steps in the biotransformation of the important insecticide gamma -hexachlorocyclohexane (gamma -HCH) by the soil bacterium Sphingomonas paucimobilis UT26, Stereochemical analysis of the reaction products formed during conversion of gamma -HCH by LinA was investigated by GC-MS, NMR, CD, and molecular modeling. The NMR spectra of 1,3,4,5,6-pentachlorocyclohexene (PCCH) produced from gamma -HCH using either enzymatic dehydrochlorination or alkaline dehydrochlorination were compared and found to be identical. Both enantiomers present in the racemate of synthetic gamma -PCCH were converted by LinA, each at a different rate. 1,2,4-trichlorobenzene (1,2,4-TCB) was detected as the only product of the biotransformation of biosynthetic gamma -PCCH, 1,2,4-TCB and 1,2,3-TCB were identified as the dehydrochlorination products of racemic gamma -PCCH, delta -PCCH was detected as the only product of dehydrochlorination of delta -HCH, LinA requires the presence of a 1,2-biaxial HCl pair on a substrate molecule. LinA enantiotopologically differentiates two 1,2-biaxial HCl pairs present on gamma -HCH and gives rise to a single PCCH enantiomer 1,3(R),4(S),5(S),6(R)-PCCH. Furthermore, LinA enantiomerically differentiates 1,3(S),4(R),5(R),6(S)PCCH and 1,3(R),4(S),5(S), 6(R)-PCCH. The proposed mechanism of enzymatic biotransformation of gamma -HCH to 1,2,4-TCB by LinA consists of two 1,2-anti conformationally dependent dehydrochlorinations followed by 1,4-anti dehydrochlorination.	Masaryk Univ, Lab Biomol Struct & Dynam, CS-61137 Brno, Czech Republic; Tohoku Univ, Inst Genet Ecol, Sendai, Miyagi 9808577, Japan; Univ Cambridge, Ctr Mrc, Ctr Prot Engn, Cambridge CB2 2QH, England	Masaryk University Brno; Tohoku University; University of Cambridge	Damborsky, J (corresponding author), Masaryk Univ, Lab Biomol Struct & Dynam, Kotlarska 2, CS-61137 Brno, Czech Republic.		Trantirek, Lukas/F-9923-2014; Sklenar, Vladimir/F-9118-2011; Damborsky, Jiri/H-3799-2012; Sklenar, Vladimir/R-4602-2019	Sklenar, Vladimir/0000-0001-9988-4093; Damborsky, Jiri/0000-0002-7848-8216; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTSCH R, 1980, CHEM REV, V6, P453; Bour P, 1999, J PHYS CHEM A, V103, P5099, DOI 10.1021/jp982550d; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Bullock TL, 1996, J MOL BIOL, V260, P422, DOI 10.1006/jmbi.1996.0411; CHIANG JF, 1969, J AM CHEM SOC, V91, P1898, DOI 10.1021/ja01036a004; CRISTOL SJ, 1950, J AM CHEM SOC, V73, P674; CRISTOL SJ, 1946, J AM CHEM SOC, V69, P338; IMAI R, 1991, J BACTERIOL, V173, P6811, DOI 10.1128/jb.173.21.6811-6819.1991; IZUMI Y, 1977, STEREODIFFERENTIATIN; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; LIPKE H, 1959, J BIOL CHEM, V234, P2123; LUNDQVIST T, 1994, STRUCTURE, V2, P937, DOI 10.1016/S0969-2126(94)00095-6; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Murzin AG, 1998, CURR OPIN STRUC BIOL, V8, P380, DOI 10.1016/S0959-440X(98)80073-0; NAGASAWA S, 1993, CHEMOSPHERE, V26, P1187, DOI 10.1016/0045-6535(93)90205-J; NAGASAWA T, 1982, J BIOL CHEM, V257, P13749; NAGATA Y, 1993, BIOSCI BIOTECH BIOCH, V57, P1582, DOI 10.1271/bbb.57.1582; Nakajima M., 1949, BOTYU KAGAKU, V14, P10; ORLOFF HD, 1954, J AM CHEM SOC, V76, P5484, DOI 10.1021/ja01650a068; SCHARPEN LH, 1968, J CHEM PHYS, V49, P2368, DOI 10.1063/1.1670409; TANAKA K, 1976, PESTIC BIOCHEM PHYS, V6, P392, DOI 10.1016/0048-3575(76)90050-X; Thomas JC, 1996, J BACTERIOL, V178, P6049, DOI 10.1128/jb.178.20.6049-6055.1996; Wiberg KB, 1998, CHEM PHYS LETT, V297, P60, DOI 10.1016/S0009-2614(98)01119-1; Wu ZR, 1997, SCIENCE, V276, P415, DOI 10.1126/science.276.5311.415; [No title captured]	28	51	57	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7734	7740		10.1074/jbc.M007452200	http://dx.doi.org/10.1074/jbc.M007452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11099497	hybrid			2022-12-25	WOS:000167474900011
J	May, JJ; Wendrich, TM; Marahiel, MA				May, JJ; Wendrich, TM; Marahiel, MA			The dhb operon of Bacillus subtilis encodes the biosynthetic template for the catecholic siderophore 2,3-dihydroxybenzoate-glycine-threonine trimeric ester bacillibactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONRIBOSOMAL PEPTIDE BIOSYNTHESIS; PHOSPHOPANTETHEINYL TRANSFERASE; ENTEROBACTIN; IRON; SYNTHETASES; EXPRESSION; ENZYME; PURIFICATION; BACTERIAL; DOMAINS	Bacillus subtilis was reported to produce the catecholic siderophore itoic acid (2,3-dihydroxybenzoate (DHB)-glycine) in response to iron deprivation, However, by inspecting the DNA sequences of the genes dhbE, dhbB, and dhbF as annotated by the B, subtilis genome project to encode the synthetase complex for the siderophore assembly, various sequence errors within the dhbF gene were predicted and confirmed by re-sequencing. According to the corrected sequence, dhbF encodes a dimodular instead of a monomodular nonribosomal peptide synthetase, We have heterologously expressed, purified, and assayed the substrate selectivity of the recombinant proteins DhbB, DhbE, and DhbF, DhbE, a stand-alone adenylation domain of 59.9 kDa, activates, in an ATP-dependent reaction, I)HB, which is subsequently transferred to the free thiol group of the cofactor phosphopantetheine of the bifunctional isochorismate lyase/aryl carrier protein DhbB, The third synthetase, DhbF, is a dimodular nonribosomal peptide synthetase of 264 kDa that specifically adenylates threonine and, to a lesser extent, glycine and that covalently loads both amino acids onto their corresponding peptidyl carrier domains. To functionally link the dhb gene cluster to siderophore synthesis, we have disrupted the dhbF gene. Comparative mass spectrometric analysis of culture extracts from both the wild type and the dhbF mutant led to the identification of a mass peak at mit 881 ([M-H](1-)) that corresponds to a cyclic trimeric ester of DHB-glycine-threonine.	Univ Marburg, Dept Chem, D-35032 Marburg, Germany	Philipps University Marburg	Marahiel, MA (corresponding author), Univ Marburg, Dept Chem, D-35032 Marburg, Germany.	marahiel@chemie.uni-marburg.de						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budzikiewicz H, 1997, Z NATURFORSCH C, V52, P551; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURKHOLDER PAUL R., 1952, AMER SCI, V40, P601; Butterton JR, 2000, J BACTERIOL, V182, P1731, DOI 10.1128/JB.182.6.1731-1738.2000; COOPER DG, 1981, APPL ENVIRON MICROB, V42, P408, DOI 10.1128/AEM.42.3.408-412.1981; Drechsel H, 1997, TRANSITION METALS IN MICROBIAL METABOLISM, P1; Gehring AM, 1997, BIOCHEMISTRY-US, V36, P8495, DOI 10.1021/bi970453p; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P2648, DOI 10.1021/bi9726584; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P11637, DOI 10.1021/bi9812571; GEHRING AM, 1998, THESIS HARVARD U; GRIFFITHS E, 1991, BIOL MET, V4, P7, DOI 10.1007/BF01135551; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; Harwood C.R., 1990, MOL BIOL METHODS BAC; HOCH JA, 1973, GENETICS, V73, P215; ITO T, 1993, APPL ENVIRON MICROB, V59, P2343, DOI 10.1128/AEM.59.7.2343-2345.1993; ITO T, 1958, J AM CHEM SOC, V80, P4645, DOI 10.1021/ja01550a058; KLEIN C, 1992, APPL ENVIRON MICROB, V58, P132, DOI 10.1128/AEM.58.1.132-142.1992; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Laland S G, 1973, Essays Biochem, V9, P31; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; Marahiel MA, 1997, CHEM BIOL, V4, P561, DOI 10.1016/S1074-5521(97)90242-8; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Mofid MR, 1999, ACTA CRYSTALLOGR D, V55, P1098, DOI 10.1107/S0907444999003674; NEILANDS JB, 1983, ADV INORG BIOCHEM, V5, P137; Payne Shelley M., 1993, Trends in Microbiology, V1, P66, DOI 10.1016/0966-842X(93)90036-Q; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Quadri LEN, 2000, MOL MICROBIOL, V37, P1, DOI 10.1046/j.1365-2958.2000.01941.x; Reuter K, 1999, EMBO J, V18, P6823, DOI 10.1093/emboj/18.23.6823; Rowland BM, 1996, J BACTERIOL, V178, P854, DOI 10.1128/jb.178.3.854-861.1996; RUSNAK F, 1991, BIOCHEMISTRY-US, V30, P2916, DOI 10.1021/bi00225a027; RUSNAK F, 1989, BIOCHEMISTRY-US, V28, P6827, DOI 10.1021/bi00443a008; RUSNAK F, 1990, BIOCHEMISTRY-US, V29, P1425, DOI 10.1021/bi00458a013; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; Shaw-Reid CA, 1999, CHEM BIOL, V6, P385, DOI 10.1016/S1074-5521(99)80050-7; SMITH NR, 1964, J GEN MICROBIOL, V34, P269, DOI 10.1099/00221287-34-2-269; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Trucksis M, 1998, P NATL ACAD SCI USA, V95, P14464, DOI 10.1073/pnas.95.24.14464; vonDohren H, 1997, CHEM REV, V97, P2675, DOI 10.1021/cr9600262; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9; Wyckoff EE, 1997, J BACTERIOL, V179, P7055, DOI 10.1128/jb.179.22.7055-7062.1997; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972	54	230	245	2	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7209	7217		10.1074/jbc.M009140200	http://dx.doi.org/10.1074/jbc.M009140200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11112781	hybrid			2022-12-25	WOS:000167442900050
J	Song, DK; Ashcroft, FM				Song, DK; Ashcroft, FM			ATP modulation of ATP-sensitive potassium channel ATP sensitivity varies with the type of SUR subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SULFONYLUREA RECEPTOR; K+ CHANNELS; RAT CRI-G1; PHOSPHOINOSITIDE 3-KINASE; NUCLEOTIDE SENSITIVITY; ACTIN CYTOSKELETON; INSULIN-SECRETION; LEPTIN ACTIVATION; SKELETAL-MUSCLE	ATP-sensitive potassium (K-ATP) channels comprise Kir and SUR subunits, Using recombinant K-ATP channels expressed in Xenopus oocytes, we observed that MgATP (100 mum) block of Kir6.2/SUR2A currents gradually declined with time, whereas inhibition of Kir6.2/SUR1 or Kir6.2 Delta C36 currents did not change. The decline in Kir6.2/SUR2A ATP sensitivity was not observed in Mg2+ free solution and was blocked by the phosphatidylinositol (PI) 3-kinase inhibitors LY 294002 (10 muM) and wortmannin (100 muM), and by neomycin (100 muM). These results suggest that a MgATP-dependent synthesis of membrane phospholipids produces a secondary decrease in the ATP sensitivity of Kir6.2/SUR2A, Direct application of the phospholipids PI 4,5-bisphosphate and PI 3,4,5-trisphosphate in the presence of 100 muM MgATP activated all three types of channel, but the response was faster for Kir6.2/SUR2A, Chimeric studies indicate that the different responses of Kir6,2/SUR2A and Kir6.2/SUR1 are mediated by the first six transmembrane domains of SUR, The MgATP-dependent loss of ATP sensitivity of Kir6.2/SUR2A was enhanced by the actin filament disrupter cytochalasin and blocked by phalloidin (which stabilizes the cytoskeleton). Phalloidin did not block the effect of PI 3,4,5 -trisphosphate. This suggests that MgATP may cause disruption of the cytoskeleton, leading to enhanced membrane phospholipid levels (or better targeting to the K-ATP channel) and thus to decreased channel ATP sensitivity.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Keimyung Univ, Sch Med, Dept Physiol, Choong Gu, Taegu 700712, South Korea	University of Oxford; Keimyung University	Ashcroft, FM (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.							Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 1998, CIRC RES, V83, P1132, DOI 10.1161/01.RES.83.11.1132; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Chutkow WA, 1999, J BIOL CHEM, V274, P13656, DOI 10.1074/jbc.274.19.13656; Chutkow WA, 1996, DIABETES, V45, P1439, DOI 10.2337/diabetes.45.10.1439; Enkvetchakul D, 2000, BIOPHYS J, V78, P2334, DOI 10.1016/S0006-3495(00)76779-8; Fan Z, 1999, J GEN PHYSIOL, V114, P251, DOI 10.1085/jgp.114.2.251; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FINDLAY I, 1986, PFLUG ARCH EUR J PHY, V407, P238, DOI 10.1007/BF00580683; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; Gribble FM, 2000, MOL PHARMACOL, V57, P1256; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; Gribble FM, 1998, DIABETES, V47, P1412, DOI 10.2337/diabetes.47.9.1412; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; Harvey J, 1998, J PHYSIOL-LONDON, V511, P695, DOI 10.1111/j.1469-7793.1998.695bg.x; Harvey J, 2000, J PHYSIOL-LONDON, V527, P95, DOI 10.1111/j.1469-7793.2000.00095.x; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; ISORROTO S, 1996, J BIOL CHEM, V271, P24321; JAMMEY PA, 1995, CHEM BIOL, V2, P61; Liss B, 1999, EMBO J, V18, P833, DOI 10.1093/emboj/18.4.833; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; POWIS G, 1994, CANCER RES, V54, P2419; Proks P, 1999, J BIOL CHEM, V274, P25393, DOI 10.1074/jbc.274.36.25393; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Settleman J, 2000, NAT CELL BIOL, V2, pE7, DOI 10.1038/71390; Shyng SL, 2000, P NATL ACAD SCI USA, V97, P937, DOI 10.1073/pnas.97.2.937; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Xie LH, 1999, J PHYSIOL-LONDON, V514, P655, DOI 10.1111/j.1469-7793.1999.655ad.x; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292	48	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7143	7149		10.1074/jbc.M009959200	http://dx.doi.org/10.1074/jbc.M009959200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11115512	Green Published, hybrid			2022-12-25	WOS:000167442900041
J	Wu, WI; Voelker, DR				Wu, WI; Voelker, DR			Characterization of phosphatidylserine transport to the locus of phosphatidylserine decarboxylase 2 in permeabilized yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSFER PROTEIN; PHOSPHOLIPASE-D; ANIMAL-CELLS; NULL ALLELE; IDENTIFICATION; TRANSLOCATION; CLONING; GENE; AMINOGLYCEROPHOSPHOLIPIDS	In yeast, nascent phosphatidylserine (PtdSer) can be transported to the mitochondria and Golgi/vacuole for decarboxylation to synthesize phosphatidylethanolamine (PtdEtn). In strains with a psd1 Delta allele for the mitochondrial PtdSer decarboxylase, the conversion of nascent PtdSer to PtdEtn can serve as an indicator of lipid transport to the locus of PtdSer decarboxylase 2 (Psd2p) in the Golgi/vacuole. We have followed the metabolism of [H-3]serine into PtdSer and PtdEtn to study lipid transport in permeabilized psd1 Delta yeast. The permeabilized cells synthesize H-3-PtdSer and, after a 20-min lag, decarboxylate it to form [H-3]PtdEtn, Formation of [H-3]PtdEtn is linear between 20 and 100 min of incubation and does not require ongoing PtdSer synthesis. PtdSer transport can be resolved into a two-component system using washed, permeabilized psd1 Delta cells as donors and membranes isolated by ultracentrifugation as accepters, With this system, the transport-dependent decarboxylation of nascent PtdSer is dependent upon the concentration of acceptor membranes, requires Mn2+ but not nucleotides, and is inhibited by EDTA High speed membranes isolated from a previously identified PtdSer transport mutant, pstB2, contain normal Psd2p activity but fail to reconstitute PtdSer transport and decarboxylation, Reconstitution with permutations of wild type and pstB2 Delta donors and accepters identifies the site of the mutant defect as the acceptor side of the transport reaction.	Natl Jewish Med & Res Ctr, Dept Med, Program Cell Biol, Denver, CO 80206 USA	National Jewish Health	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Program Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, F32GM019162, R01GM032453] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19162, GM32453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHLEITNER G, 1995, J BIOL CHEM, V270, P29836; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; DAUM G, 1982, J BIOL CHEM, V257, P3028; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Mayr JA, 1996, FEBS LETT, V393, P236, DOI 10.1016/0014-5793(96)00893-9; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; OHTA A, 1981, J BIOL CHEM, V256, P2219; Rothman JE, 1996, PROTEIN SCI, V5, P185; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; Voelker DR, 2000, BBA-MOL CELL BIOL L, V1486, P97, DOI 10.1016/S1388-1981(00)00051-2; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; Voelker DR, 1996, BIOCH LIPIDS LIPOPRO, P391; Waksman M, 1997, J BIOL CHEM, V272, P36; Wu WI, 2000, J BIOL CHEM, V275, P14446, DOI 10.1074/jbc.275.19.14446	23	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7114	7121		10.1074/jbc.M010278200	http://dx.doi.org/10.1074/jbc.M010278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11104779	hybrid			2022-12-25	WOS:000167442900037
J	Harding, TC; Xue, LZ; Bienemann, A; Haywood, D; Dickens, M; Tolkovsky, AM; Uney, JB				Harding, TC; Xue, LZ; Bienemann, A; Haywood, D; Dickens, M; Tolkovsky, AM; Uney, JB			Inhibition of JNK by overexpression of the JNK binding domain of JIP-1 prevents apoptosis in sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; N-TERMINAL KINASE; C-JUN; PROTEIN-KINASE; NERVOUS-SYSTEM; EXPRESSION; ACTIVATION; STRESS; PHOSPHORYLATION; PATHWAY	Studies in non-neuronal cells show that c-Jun N-terminal kinases (JNK) play a key role in apoptotic cell death. In some neurons JNK is also thought to initiate cell death by the activation of c-Jun, JNK inhibition has been achieved pharmacologically by inhibiting upstream kinases, but there has been no direct demonstration that inhibition of JNK can prevent neuronal death. We have therefore examined whether the JNK binding domain (JBD) of JNK-interacting protein-1 (JIP-1, a scaffold protein and specific inhibitor of JNK) can inhibit c-Jun phosphorylation and support the survival of sympathetic neurons deprived of NGF. We show that expression of the JBD in >80% of neurons was sufficient to prevent the phosphorylation of c-Jun and its nuclear accumulation as well as abrogate neuronal cell death induced by NGF deprivation. JBD expression also preserved the capacity of mitochondria to reduce MTT. Interestingly, although the PTB domain of JIP was reported to interact with rhoGEF, expression of the JBD domain was sufficient to localize the protein to the membrane cortex and growth cones. Hence, JNK activation is a key event in apoptotic death induced by NGF withdrawal, where its point of action lies upstream of mitochondrial dysfunction.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Bristol, Univ Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England; Univ Bristol, MRC, Ctr Synapt Plast, Bristol BS2 8HW, Avon, England; Univ Leicester, Dept Med, Leicester LE1 7RH, Leics, England	University of Cambridge; University of Bristol; University of Bristol; University of Leicester	Tolkovsky, AM (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.		Dickens, Martin/B-2001-2012		Biotechnology and Biological Sciences Research Council [GTH12528] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Coffey ET, 2000, J NEUROSCI, V20, P7602; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Eilers A, 1998, J NEUROSCI, V18, P1713; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fletcher GC, 2000, J CELL BIOL, V150, P741, DOI 10.1083/jcb.150.4.741; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harding TC, 1998, NAT BIOTECHNOL, V16, P553, DOI 10.1038/nbt0698-553; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; NEAME SJ, 1998, J CELL BIOL, V139, P205; Roberts ML, 2000, MOL CELL NEUROSCI, V16, P97, DOI 10.1006/mcne.2000.0867; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Virdee K, 1997, J NEUROCHEM, V69, P550; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	30	107	110	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4531	4534		10.1074/jbc.C000815200	http://dx.doi.org/10.1074/jbc.C000815200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11121395	hybrid			2022-12-25	WOS:000168484300002
J	Rang, A; Heise, T; Will, H				Rang, A; Heise, T; Will, H			Lack of a role of the interferon-stimulated response element-like region in interferon alpha-induced suppression of hepatitis B virus in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTION FACTOR; ENHANCER ACTIVITY; REGULATORY FACTOR; CELL-LINE; REPLICATION; DNA; INHIBITION; PROTEINS; GAMMA	The antiviral effect of interferon-alpha (IFN alpha) on hepatitis B virus (HBV) is well documented in vitro and in vivo, but the mechanisms involved are elusive. Recently, an interferon-stimulated response like element (ISRE) competent for binding of interferon-stimulated gene Factor-3 gamma (p48) has been identified in the HBV enhancer I region. Mutation of this element was shown to abrogate IFN alpha -mediated reduction of HBV X-gene promoter-driven reporter gene expression. This suggested a role of the ISRE and of p48 in IFN alpha -induced antiviral activity against productive HBV infection. Here, we analyzed the antiviral effect of both IFNa and enhanced p48 expression on complete HBV genomes containing the wildtype or mutated ISRE. In human hepatoma cells transfected with both genomes, viral RNA and replicative intermediates were reduced by IFNa treatment to a similar degree. Enhanced p48 expression increased IFN alpha -induced suppression of HBV RNA significantly from 75 +/- 22.5% to 46 +/- 9.8%, but this was independent of the integrity of the ISRE-like region. These data imply that p48 neither mediates the antiviral activity of IFNa against HBV nor down-regulates enhancer I activity by binding directly to the HBV ISRE-like region, but rather argue for an indirect role of p48,	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Will, H (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	will@hpi.uni-hamburg.de						Berthillon P, 1996, J HEPATOL, V25, P15, DOI 10.1016/S0168-8278(96)80322-9; Bock CT, 2000, J VIROL, V74, P2193, DOI 10.1128/JVI.74.5.2193-2202.2000; CASELMANN WH, 1992, J INFECT DIS, V166, P966, DOI 10.1093/infdis/166.5.966; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVIS MG, 1994, ANTIMICROB AGENTS CH, V38, P2921, DOI 10.1128/AAC.38.12.2921; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Grotzinger T, 1996, J BIOL CHEM, V271, P25253, DOI 10.1074/jbc.271.41.25253; HAMASAKI K, 1992, BIOCHEM BIOPH RES CO, V183, P904, DOI 10.1016/0006-291X(92)90569-7; HAYASHI Y, 1989, J VIROL, V63, P2936, DOI 10.1128/JVI.63.7.2936-2940.1989; KAKUMU S, 1992, J MED VIROL, V38, P62, DOI 10.1002/jmv.1890380113; KORBA BE, 1990, J MED VIROL, V31, P272, DOI 10.1002/jmv.1890310406; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; Nakao K, 1999, J BIOL CHEM, V274, P28075, DOI 10.1074/jbc.274.40.28075; Rang A, 1999, J HEPATOL, V31, P791, DOI 10.1016/S0168-8278(99)80279-7; Rang A, 2000, NUCLEIC ACIDS RES, V28, P1120, DOI 10.1093/nar/28.5.1120; Romero R, 1996, HEPATOLOGY, V23, P17, DOI 10.1053/jhep.1996.v23.pm0008550037; SCHALLER H, 1991, CURR TOP MICROBIOL, V168, P21; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TURKASPA R, 1990, J VIROL, V64, P1821, DOI 10.1128/JVI.64.4.1821-1824.1990; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315	24	16	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3531	3535		10.1074/jbc.C000584200	http://dx.doi.org/10.1074/jbc.C000584200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11106638	hybrid			2022-12-25	WOS:000166784900071
J	Bruzzone, S; Guida, L; Zocchi, E; Franco, L; De Flora, A				Bruzzone, S; Guida, L; Zocchi, E; Franco, L; De Flora, A			Connexin 43 hemi channels mediate Ca2+-regulated transmembrane NAD(+) fluxes in intact cells	FASEB JOURNAL			English	Article									Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; Univ Naples Federico II, CNR, Biocrystallog Ctr, I-80134 Naples, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	De Flora, A (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV 1, I-16132 Genoa, Italy.		Bruzzone, Santina/A-4264-2015	Bruzzone, Santina/0000-0003-2034-3716					0	390	396	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					10	12						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099492				2022-12-25	WOS:000166312400004
J	Wu, R; Connolly, D; Ngelangel, C; Bosch, FX; Munoz, N; Cho, KR				Wu, R; Connolly, D; Ngelangel, C; Bosch, FX; Munoz, N; Cho, KR			Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix	ONCOGENE			English	Article						cervical cancer; FGFR; oncogene	MULTIPLE-MYELOMA; CHROMOSOMAL TRANSLOCATION; ACTIVATING MUTATIONS; HUMAN-PAPILLOMAVIRUS; RAS GENE; ACHONDROPLASIA; ONCOGENE; CANCER; T(4/14)(P16.3,Q32); OVEREXPRESSION	Germline mutations of the gene encoding human fibroblast growth factor receptor 3 (FGFR3) have been shown to be responsible for several related autosomal dominant forms of syndromic craniosynostosis and short limb dwarfism. Somatic activating mutations of FGFR3 were recently reported to occur in three of 12 (25%) uterine cervical carcinomas and nine of 26 (35%) bladder carcinomas, suggesting that constitutive activation of FGFR3 may be an important mechanism underlying the development and/or progression of these common epithelial malignancies. In order to investigate further a possible role for FGFR3 mutations in cervical carcinogenesis, we performed sequence-based mutational analysis of FGFR3 in 51 primary cervical carcinomas and seven cervical carcinoma-derived cell lines. The regions analysed (exons 7, 10, 13, 15, and 19) encompassed all previously described FGFR3 mutations. A single nucleotide substitution at codon 249, predicting a serine to cysteine amino acid substitution (S249C) in the FGFR3 extracellular domain, was identified in one primary tumor. Only wild type FGFR3 alleles were identified in the remaining tumors and cell lines. The S249C mutation is the only FGFR3 mutation described to date in cervical carcinomas. These findings suggest that while activating mutations of FGFR3 occur in cervical cancer, they may not be as common as initially reported.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Philippines, Philippine Gen Hosp, Dept Med, Clin Epidemiol Unit, Manila, Philippines; Hosp Llobregat, Inst Catala Oncol, Serv Epidemiol & Registre Canc, E-08907 Barcelona, Spain; Int Agcy Res Canc, F-69372 Lyon 08, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of the Philippines System; University of the Philippines Manila; Catalan Institute of Oncology; University of Barcelona; World Health Organization; International Agency for Research on Cancer (IARC)	Cho, KR (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 4301 MSRBIII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		; BOSCH JOSE, FRANCESC XAVIER/J-6339-2012	Cho, Kathleen/0000-0003-0500-9998; BOSCH JOSE, FRANCESC XAVIER/0000-0002-7172-3412	NATIONAL CANCER INSTITUTE [R29CA064466] Funding Source: NIH RePORTER; NCI NIH HHS [CA64466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER VV, 1988, J SURG ONCOL, V39, P225, DOI 10.1002/jso.2930390403; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Finelli P, 1999, BLOOD, V94, P724, DOI 10.1182/blood.V94.2.724.414k05_724_732; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; Grendys EC, 1997, GYNECOL ONCOL, V65, P343, DOI 10.1006/gyno.1997.4649; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; IKEGAWA S, 1995, HUM GENET, V96, P309; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Katsumata N, 1998, ENDOCR J, V45, pS171, DOI 10.1507/endocrj.45.Suppl_S171; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; MITRA AB, 1994, CANCER RES, V54, P637; MUNOZ N, 1992, INT J CANCER, V52, P743, DOI 10.1002/ijc.2910520513; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Ngelangel C, 1998, JNCI-J NATL CANCER I, V90, P43, DOI 10.1093/jnci/90.1.43; Passos-Bueno MR, 1999, HUM MUTAT, V14, P115; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; RIOU G, 1988, ONCOGENE, V3, P329; RIOU GF, 1990, ANTICANCER RES, V10, P1225; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WONG YF, 1995, CANCER LETT, V95, P29, DOI 10.1016/0304-3835(95)03857-S; Wuchner C, 1997, HUM GENET, V100, P215, DOI 10.1007/s004390050493	31	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5543	5546		10.1038/sj.onc.1203934	http://dx.doi.org/10.1038/sj.onc.1203934			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114733				2022-12-25	WOS:000165396100016
J	Metzner, M; Stoller, G; Rucknagel, KP; Lu, KP; Fischer, G; Luckner, M; Kullertz, G				Metzner, M; Stoller, G; Rucknagel, KP; Lu, KP; Fischer, G; Luckner, M; Kullertz, G			Functional replacement of the essential ESS1 in yeast by the plant parvulin DlPar13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL CIS/TRANS ISOMERASE; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; DIGITALIS-LANATA; SUBSTRATE RECOGNITION; ARABIDOPSIS-THALIANA; REGULATORY MECHANISM; NEUROSPORA-CRASSA; PROTEIN; GENE	A functionally Pin1-like peptidyl-prolyl cis/trans isomerase (PPIase(1)) was isolated from proembryogenic masses (PEMs) of Digitalis lanata according to its enzymatic activity. Partial sequence analysis of the purified enzyme (DlPar13) revealed sequence homology to members of the parvulin family of PPIases. Similar to human Pin1 and yeast Ess1, it exhibits catalytic activity toward substrates containing (Thr(P)/Ser(P))-Pro peptide bonds and comparable inhibition kinetics with juglone. Unlike Pin1-type enzymes it lacks the phosphoserine or phosphothreonine binding WW domain. Western blotting with anti-DlPar13 serum recognized the endogenous form in nucleic and cytosolic fractions of the plant cells. Since the PIN1 homologue ESS1 is an essential gene, complementation experiments in yeast were performed. When overexpressed in Saccharomyces cerevisiae DlPar13 is almost as effective as hPin1 in rescuing the temperature-sensitive phenotype caused by a mutation in ESS1. In contrast, the human parvulin hPar14 is not able to rescue the lethal phenotype of this yeast strain at nonpermissive temperatures. These results suggest a function for DlPar13 rather similar to parvulins of the Pin1-type.	Max Planck Forschungstelle Enzymol Prot Faltung, D-06120 Halle, Germany; Univ Halle Wittenberg, Inst Pharmazeut Biol, D-06120 Halle, Germany; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Canc Biol Program, Boston, MA 02215 USA	Max Planck Society; Martin Luther University Halle Wittenberg; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kullertz, G (corresponding author), Max Planck Forschungstelle Enzymol Prot Faltung, Weinbergweg 22, D-06120 Halle, Germany.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Fischer G, 2000, CHEM SOC REV, V29, P119, DOI 10.1039/a803742f; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; Hennig L, 1998, BIOCHEMISTRY-US, V37, P5953, DOI 10.1021/bi973162p; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kops O, 1998, J BIOL CHEM, V273, P31971, DOI 10.1074/jbc.273.48.31971; Kullertz G, 1999, PLANTA, V208, P599, DOI 10.1007/s004250050598; Kullertz G, 1998, CLIN CHEM, V44, P502; Landrieu I, 2000, J BIOL CHEM, V275, P10577, DOI 10.1074/jbc.275.14.10577; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maleszka R, 1997, GENE, V203, P89, DOI 10.1016/S0378-1119(97)00522-2; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pfeifer T, 1999, RAPID COMMUN MASS SP, V13, P362, DOI 10.1002/(SICI)1097-0231(19990315)13:5<362::AID-RCM492>3.3.CO;2-9; Qi QG, 2000, J BIOL CHEM, V275, P9673, DOI 10.1074/jbc.275.13.9673; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Rulten S, 1999, BIOCHEM BIOPH RES CO, V259, P557, DOI 10.1006/bbrc.1999.0828; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scholze C, 1999, J PLANT PHYSIOL, V155, P212, DOI 10.1016/S0176-1617(99)80009-1; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Thomar S, 1998, BOT ACTA, V111, P22, DOI 10.1111/j.1438-8677.1998.tb00672.x; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; Uchida T, 1999, FEBS LETT, V446, P278, DOI 10.1016/S0014-5793(99)00239-2; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yao JL, 2001, J BIOL CHEM, V276, P13517, DOI 10.1074/jbc.M007006200; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	43	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13524	13529		10.1074/jbc.M007005200	http://dx.doi.org/10.1074/jbc.M007005200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11118437	hybrid			2022-12-25	WOS:000168356600005
J	Heitmeier, MR; Arnush, M; Scarim, AL; Corbett, JA				Heitmeier, MR; Arnush, M; Scarim, AL; Corbett, JA			Pancreatic beta-cell damage mediated by beta-cell production of interleukin-1 - A novel mechanism for virus-induced diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; DOUBLE-STRANDED-RNA; PROTEIN-KINASE PKR; HUMAN ISLETS; AUTOIMMUNE-DISEASE; MURINE MACROPHAGES; INSULIN-SECRETION; MOLECULAR MIMICRY; COXSACKIE-VIRUS; BB RAT	Viral infection is one environmental factor that may initiate beta -cell damage during the development of autoimmune diabetes. Formed during viral replication, double-stranded RNA (dsRNA) activates the antiviral response in infected cells. In combination, synthetic dsRNA (polyinosinic-polycytidylic acid, poly(I-C)) and interferon (IFN)-gamma stimulate inducible nitric-oxide synthase (iNOS) expression, inhibit insulin secretion, and induce islet degeneration. Interleukin-1 (IL-1) appears to mediate dsRNA + IFN-gamma -induced islet damage in a nitric oxide-dependent manner, as the interleukin-l receptor antagonist protein prevents dsRNA + IFN-gamma -induced iNOS expression, inhibition of insulin secretion, and islet degeneration. IL-1 beta is synthesized as an inactive precursor protein that requires cleavage by the IL-1 beta -converting enzyme (ICE) for activation. dsRNA and IFN-gamma stimulate IL-1 beta expression and ICE activation in primary beta -cells, respectively. Selective ICE inhibition attenuates dsRNA + IFN-gamma -induced iNOS expression by primary beta -cells. In addition, poly(I-C) + IFN-gamma -induced iNOS expression and nitric oxide production by human islets are prevented by interleukin-1 receptor antagonist protein, indicating that human islets respond to dsRNA and IFN-gamma in a manner similar to rat islets, These studies provide biochemical evidence for a novel mechanism by which viral infection may initiate beta -cell damage during the development of autoimmune diabetes. The viral replicative intermediate dsRNA stimulates beta -cell production of pro-IL-1 beta, and following cleavage to its mature form by IFN-beta -activated ICE, IL-1 then initiates beta -cell damage in a nitric oxide-dependent fashion.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NIAID NIH HHS [AI44458] Funding Source: Medline; NIDDK NIH HHS [DK-52194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; Arnush M, 1998, J IMMUNOL, V160, P2684; Arnush M, 1998, J CLIN INVEST, V102, P516, DOI 10.1172/JCI844; ATKINSON MA, 1994, J CLIN INVEST, V94, P2125, DOI 10.1172/JCI117567; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; BROWN R, 1997, CURRENT PROTOCOLS MO, V2; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; CORBETT JA, 1994, BIOCHEM J, V299, P719, DOI 10.1042/bj2990719; CORBETT JA, 1996, NITRIC OXIDE PRINCIP, P177; CORBETT JA, 1996, AM J PHYSIOL, V39, pC1581; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; EWEL CH, 1992, DIABETES, V41, P1016, DOI 10.2337/diabetes.41.8.1016; GEPTS W, 1965, DIABETES, V14, P619, DOI 10.2337/diab.14.10.619; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Heitmeier MR, 1999, J BIOL CHEM, V274, P12531, DOI 10.1074/jbc.274.18.12531; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; Hill JR, 1996, J BIOL CHEM, V271, P22672, DOI 10.1074/jbc.271.37.22672; Hirasawa K, 1997, J VIROL, V71, P4024, DOI 10.1128/JVI.71.5.4024-4031.1997; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; HUGHES JH, 1990, J CLIN INVEST, V86, P856, DOI 10.1172/JCI114785; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KERR IM, 1992, J INTERFERON RES, V12, P237, DOI 10.1089/jir.1992.12.237; Kreil TR, 1996, VIROLOGY, V219, P304, DOI 10.1006/viro.1996.0252; LACY PE, 1991, AM J PATHOL, V138, P1183; LENGYEL P, 1987, EMBO J, V19, P3630; Maclaren NK, 1997, MOL MED TODAY, V3, P76, DOI 10.1016/S1357-4310(96)10056-3; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MELKOVA Z, 1995, J IMMUNOL, V155, P5711; NOTKINS AL, 1984, CONCEPTS VIRAL PATHO; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; SOBEL DO, 1992, DIABETES, V41, P515, DOI 10.2337/diabetes.41.4.515; Stephens LA, 1999, ENDOCRINOLOGY, V140, P3219, DOI 10.1210/en.140.7.3219; vonHerrath MG, 1996, CURR OPIN IMMUNOL, V8, P878, DOI 10.1016/S0952-7915(96)80019-7; vonHerrath MG, 1996, IMMUNOL REV, V152, P111; vonHerrath MG, 1997, BIOCHEM SOC T, V25, P630, DOI 10.1042/bst0250630; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WRIGHT PH, 1971, DIABETES, V20, P33, DOI 10.2337/diab.20.1.33; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; YOON JW, 1995, DIABETES METAB REV, V11, P83, DOI 10.1002/dmr.5610110202; YOON JW, 1978, J EXP MED, V148, P1068, DOI 10.1084/jem.148.4.1068	46	58	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11151	11158		10.1074/jbc.M009159200	http://dx.doi.org/10.1074/jbc.M009159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11108714	hybrid			2022-12-25	WOS:000167980900077
J	Klekotka, PA; Santoro, SA; Zutter, MM				Klekotka, PA; Santoro, SA; Zutter, MM			alpha 2 integrin subunit cytoplasmic domain-dependent cellular migration requires p38 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; EPIDERMAL GROWTH-FACTOR; CYCLE PROGRESSION; GENE-EXPRESSION; ALPHA-1-BETA-1 INTEGRIN; RHO-FAMILY; IN-VIVO; COLLAGEN; ADHESION	The alpha (2) integrin subunit cytoplasmic domain uniquely supported epidermal growth factor (EGF)-stimulated migration on type I collagen. p38 MAP kinase- and phosphatidylinositol 3-kinase-specific inhibitors, but not a MEK-specific inhibitor, eliminated EGF-stimulated and unstimulated alpha (2)-cytoplasmic domain-dependent migration. Following adhesion to collagenous matrices, cells expressing the full-length alpha (2) integrin subunit, but not cells expressing a chimeric alpha (2) integrin subunit in which the alpha (2)-cytoplasmic domain was replaced by the cytoplasmic domain of the alpha (1)-subunit, exhibited sustained and robust phosphorylation of p38 MAP kinase, Expression of dominant negative p38 MAP kinase inhibited alpha (2)-cytoplasmic domain-dependent, EGF stimulated migration as well as unstimulated migration on collagen, Expression of constitutively active Rac1(Val-12) augmented p38 MAP kinase activation and alpha (2)-cytoplasmic domain-dependent migration. It also rescued the ability of cells expressing the alpha (1)-cytoplasmic domain to activate p38 MAPK and to migrate. These results suggest that the alpha (2) integrin cytoplasmic domain uniquely stimulates the p38 MAP kinase pathway that is required for unstimulated and EGF-stimulated migration on type I collagen.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Zutter, MM (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Box 8118,660 S Euclid St, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R01CA083690, R01CA070275] Funding Source: NIH RePORTER; NCI NIH HHS [CA70275, CA83690] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERDICHEVSKY F, 1992, J CELL SCI, V102, P437; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEFRANCISCHI JN, 1993, BRIT J PHARMACOL, V110, P1381; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FRANCISCHI JN, 1993, AGENTS ACTIONS, V39, pC139, DOI 10.1007/BF01972746; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gardner H, 1999, J CELL SCI, V112, P263; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KEELY PJ, 1995, J CELL SCI, V108, P595; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; Pozzi M, 1998, J CELL BIOL, V142, P587; Racine-Samson L, 1997, J BIOL CHEM, V272, P30911, DOI 10.1074/jbc.272.49.30911; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; Sakai T, 1999, J BIOL CHEM, V274, P15480, DOI 10.1074/jbc.274.22.15480; SANTORO SA, 1994, METHOD ENZYMOL, V245, P147; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181; Zutter MM, 1999, AM J PATHOL, V155, P927, DOI 10.1016/S0002-9440(10)65192-9; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	51	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9503	9511		10.1074/jbc.M006286200	http://dx.doi.org/10.1074/jbc.M006286200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121402	hybrid			2022-12-25	WOS:000167607700116
J	Li, NX; Banin, S; Quyang, HH; Li, GC; Courtois, G; Shiloh, Y; Karin, M; Rotman, G				Li, NX; Banin, S; Quyang, HH; Li, GC; Courtois, G; Shiloh, Y; Karin, M; Rotman, G			ATM is required for I kappa B kinase (IKK) activation in response to DNA double strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; C-ABL; CATALYTIC SUBUNIT; CELL-DEATH; DAMAGE; PHOSPHORYLATION; RADIOSENSITIVITY; INHIBITION	Following challenge with proinflammatory stimuli or generation of DNA double strand breaks (DSBs), transcription factor NF-kappaB translocates from the cytoplasm to the nucleus to activate expression of target genes. In addition, NF-kappaB plays a key role in protecting cells from proapoptotic stimuli, including DSBs. Patients suffering from the genetic disorder ataxia-telangiectasia, caused by mutations in the ATM gene, are highly sensitive to inducers of DSBs, such as ionizing radiation. Similar hypersensitivity is displayed by cell lines derived from ataxia-telangiectasia patients or Atm knockout mice. The ATM protein, a member of the phosphatidylinositol 3-kinase (PI3K)-like family, is a multifunctional protein kinase whose activity is stimulated by DSBs. As both ATM and NF-kappaB deficiencies result in increased sensitivity to DSBs, we examined the role of ATM in NF-kappaB activation. We report that ATM is essential for NF-kappaB activation in response to DSBs but not proinflammatory stimuli, and this activity is mediated via the I kappaB kinase complex. DNA-dependent protein kinase, another member of the PI3K-like family, PI3K itself, and c-Abl, a nuclear tyrosine kinase,are not required for this response.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA; Inst Pasteur, Unite Biol Mol Express Gen, F-75724 Paris, France	University of California System; University of California San Diego; Tel Aviv University; Sackler Faculty of Medicine; Memorial Sloan Kettering Cancer Center; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gillman Dr, La Jolla, CA 92093 USA.			COURTOIS, Gilles/0000-0003-3117-9595				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CAPOROSSI D, 1993, MUTAT RES, V290, P265, DOI 10.1016/0027-5107(93)90167-E; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Johnson RT, 1999, BIOCHEM BIOPH RES CO, V261, P317, DOI 10.1006/bbrc.1999.1024; Jung M, 1997, CANCER RES, V57, P24; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Lavin MF, 1998, RADIOTHER ONCOL, V47, P113, DOI 10.1016/S0167-8140(98)00027-9; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Westphal CH, 1998, CANCER RES, V58, P5637; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	44	148	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8898	8903		10.1074/jbc.M009809200	http://dx.doi.org/10.1074/jbc.M009809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11114307	hybrid			2022-12-25	WOS:000167607700040
J	Mantey, SA; Coy, DH; Pradhan, TK; Igarashi, H; Rizo, IM; Shen, L; Hou, W; Hocart, SJ; Jensen, RT				Mantey, SA; Coy, DH; Pradhan, TK; Igarashi, H; Rizo, IM; Shen, L; Hou, W; Hocart, SJ; Jensen, RT			Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING PEPTIDE; GUINEA-PIG PANCREAS; HIGH-AFFINITY; DISPERSED ACINI; ENZYME-SECRETION; SIDE-CHAINS; CELLS; PHARMACOLOGY; CHOLECYSTOKININ; IDENTIFICATION	The orphan receptor, bombesin (Bn) receptor subtype 3 (BRS-3), shares high homology with bombesin receptors (neuromedin B receptor (NMB-R) and gastrin-releasing peptide receptor (GRP-R)). This receptor is widely distributed in the central nervous system and gastrointestinal tract; target disruption leads to obesity, diabetes, and hypertension, however, its role in physiological and pathological processes remain unknown due to lack of selective ligands or identification of its natural ligand. We have recently discovered (Mantey, S. A., Weber, H. C., Saint, E., Akeson, M., Ryan, R. R. Pradhan, T. K., Searles, R. P., Spindel, E. R., Battey, J. F., Coy, D. H., and Jensen, R. T. (1997) J. Biol. Chem. 272, 26062-26071) that [D-Tyr(6),beta -Ala(11),Phe(13),Nle(14)]Bn-(6-14) has high affinity for BRS-3 and using this ligand showed BRS-3 has a unique pharmacology with high affinity for no known natural Bn peptides. However, use of this ligand is limited because it has high affinity for all known Bn receptors. In the present study we have attempted to identify BRS-3 selective ligands using a strategy of rational peptide design with the substitution of conformationally restricted amino acids into the prototype ligand [D-Tyr(6),beta -Ala(11),Phe(13),Nle(14)]Bn-(6-14) or its D-Phe(6) analogue. Each of the 22 peptides synthesized had binding affinities determined for hBRS-3, hGRPR, and hNMBR, and hBRS-3 selective ligands were tested for their ability to activate phospholipase C and increase inositol phosphates ([H-3]inositol phosphate). Using this approach we have identified a number of BRS-3 selective ligands. These ligands functioned as receptor agonists and their binding affinities were reflected in their potencies for altering [H-3]inositol phosphate. Two peptides with an (R)- or (S)-amino-3-phenylpropionic acid substitution for beta -Ala(11) in the prototype ligand had the highest selectivity for the hBRS-3 over the mammalian Bn receptors and did not interact with receptors for other gastrointestinal hormone s/neurotransmitters. Molecular modeling demonstrated these two selective BRS-3 ligands had a unique conformation of the position 11 beta -amino acid. This selectivity was of sufficient magnitude that these should be useful in explaining the role of hBRS-3 activation in obesity, glucose homeostasis, hypertension, and other physiological or pathological processes.	NIDDKD, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; Tulane Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Tulane University	Jensen, RT (corresponding author), NIDDKD, Digest Dis Branch, NIH, Bldg 10,Room 9C-103,10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.	robertj@bdg10.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK053100, ZIADK053100] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akeson M, 1997, J BIOL CHEM, V272, P17405, DOI 10.1074/jbc.272.28.17405; BATTEY J, 1991, TRENDS NEUROSCI, V14, P524, DOI 10.1016/0166-2236(91)90005-F; BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BENYA RV, 1994, MOL PHARMACOL, V46, P235; BENYA RV, 1995, MOL PHARMACOL, V47, P10; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COY DH, 1991, J BIOL CHEM, V266, P16441; FATHI Z, 1993, J BIOL CHEM, V268, P5979; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; Ito T, 2000, AM J PHYSIOL-GASTR L, V278, pG64, DOI 10.1152/ajpgi.2000.278.1.G64; Jensen Robert T., 1994, P1377; JENSEN RT, 1983, AM J PHYSIOL, V245, pG186, DOI 10.1152/ajpgi.1983.245.2.G186; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; JENSEN RT, 1984, BIOCHIM BIOPHYS ACTA, V804, P181, DOI 10.1016/0167-4889(84)90148-4; Katsuno T, 1999, BIOCHEMISTRY-US, V38, P7307, DOI 10.1021/bi990204w; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; Lin JT, 1995, EUR J PHARMACOL, V294, P55, DOI 10.1016/0014-2999(95)00510-2; MANTEY S, 1993, MOL PHARMACOL, V43, P762; Mantey SA, 1997, J BIOL CHEM, V272, P26062, DOI 10.1074/jbc.272.41.26062; MCCAMMON JA, 1979, BIOCHEMISTRY-US, V18, P927, DOI 10.1021/bi00573a001; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; PEIKIN SR, 1978, AM J PHYSIOL, V235, pE743, DOI 10.1152/ajpendo.1978.235.6.E743; PEIKIN SR, 1979, J BIOL CHEM, V254, P5321; Pradhan TK, 1998, EUR J PHARMACOL, V343, P275, DOI 10.1016/S0014-2999(97)01527-6; ROZENGURT E, 1988, ANN NY ACAD SCI, V547, P277, DOI 10.1111/j.1749-6632.1988.tb23896.x; Ryan FR, 1999, J PHARMACOL EXP THER, V290, P1202; Ryan RR, 1998, J PHARMACOL EXP THER, V287, P366; Ryan RR, 1998, J BIOL CHEM, V273, P13613, DOI 10.1074/jbc.273.22.13613; SASAKI Y, 1987, PEPTIDES, V8, P119, DOI 10.1016/0196-9781(87)90174-4; Seebach D, 1999, ANGEW CHEM INT EDIT, V38, P1595, DOI 10.1002/(SICI)1521-3773(19990601)38:11<1595::AID-ANIE1595>3.0.CO;2-0; TACHE Y, 1988, ANN NY ACAD SCI, V547, P183, DOI 10.1111/j.1749-6632.1988.tb23886.x; Taylor JE, 1996, PEPTIDES, V17, P1257, DOI 10.1016/S0196-9781(96)00189-1; *TRIP INC, 2000, SYBYL MOL MOD SOFTW; VIGNA SR, 1988, ANN NY ACAD SCI, V547, P131, DOI 10.1111/j.1749-6632.1988.tb23881.x; VIGUE P, 1997, EUR J BIOCHEM, V272, pR433; WANG LH, 1992, BIOCHEM J, V286, P641, DOI 10.1042/bj2860641; WANG LH, 1990, J BIOL CHEM, V265, P15695; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wu JM, 1996, MOL PHARMACOL, V50, P1355; YU DH, 1987, AM J PHYSIOL, V253, pG793, DOI 10.1152/ajpgi.1987.253.6.G793; YU DH, 1990, AM J PHYSIOL, V258, pG86, DOI 10.1152/ajpgi.1990.258.1.G86; ZHOU ZC, 1986, AM J PHYSIOL, V251, pG391, DOI 10.1152/ajpgi.1986.251.3.G391	44	62	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9219	9229		10.1074/jbc.M008737200	http://dx.doi.org/10.1074/jbc.M008737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11112777	hybrid			2022-12-25	WOS:000167607700081
J	Pircher, TJ; Geiger, JN; Zhang, DY; Miller, CP; Gaines, P; Wojchowski, DM				Pircher, TJ; Geiger, JN; Zhang, DY; Miller, CP; Gaines, P; Wojchowski, DM			Integrative signaling by minimal erythropoietin receptor forms and c-kit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL-FACTOR; BCL-X-L; DIPEPTIDYL-PEPTIDASE-I; MOLECULAR-CLONING; ERYTHROID PROGENITORS; HEMATOPOIETIC-CELLS; STAT5 ACTIVATION; GENE-EXPRESSION; CYCLE ARREST; SH2 DOMAIN	Erythroid homeostasis depends critically upon erythropoietin (Epo) and stem cell factor cosignaling in late progenitor cells. Epo bioresponses are relayed efficiently by minimal receptor forms that retain a single Tyr-343 site for STATE binding, while forms that lack all cytoplasmic Tyr(P) sites activate JAK2 and the transcription of c-Myc plus presumed additional target genes. In FDCER cell lines, which express endogenous c-Kit, the signaling capacities of such minimal Epo receptor forms (ER-HY343 and ER-HY343F) have been dissected to reveal: 1) that Epo-dependent mitogenesis, survival, and bcl-x gene expression via ER-HY343 depend upon the intactness of the Tyr-343 STATE binding site; 2) that ER-HY343-dependent bcl-x(L) gene transcription is enhanced markedly via c-Kit; 3) that socs-3, plfap, dpp-l, and cacy-bp gene transcription is induced via ER-HY343, whereas dpp-1 and cacy-bp gene expression is also supported by ER-HY343F; 4) that ectopically expressed SOCS-3 suppresses proliferative signaling by not only ER-HY343 but also c-Kit; and 5) that in FDCER and primary erythroid cells, c-Kit appears to provide the primary route to MAPK activation. Thus, integration circuits exist in only select downstream pathways within Epo and stem call factor receptor signaling.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Grad Program Genet, University Pk, PA 16802 USA; Penn State Univ, Grad Program Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, DM (corresponding author), Penn State Univ, Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	dmw1@psu.edu			NIDDK NIH HHS [R01 DK44491] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brizzi MF, 1996, ONCOGENE, V13, P2067; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Chida D, 1999, BLOOD, V93, P1567, DOI 10.1182/blood.V93.5.1567.405k29_1567_1578; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; De Sepulveda P, 1999, EMBO J, V18, P904; DEHAAN G, 1995, STEM CELLS, V13, P65, DOI 10.1002/stem.5530130109; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Filipek A, 1998, J NEUROCHEM, V70, P1793, DOI 10.1046/j.1471-4159.1998.70051793.x; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Gregory RC, 2000, CYTOKINE, V12, P845, DOI 10.1006/cyto.2000.0686; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Joneja B, 1997, J BIOL CHEM, V272, P11176, DOI 10.1074/jbc.272.17.11176; Joneja B, 1997, BLOOD, V90, P3533, DOI 10.1182/blood.V90.9.3533; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kobayashi M, 1996, BIOTECHNIQUES, V21, P398; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LEE JC, 1982, J IMMUNOL, V128, P2393; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Miller CP, 1999, BLOOD, V94, P3381, DOI 10.1182/blood.V94.10.3381.422k25_3381_3387; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pham CTN, 1997, J BIOL CHEM, V272, P10695, DOI 10.1074/jbc.272.16.10695; Pircher TJ, 1999, MOL ENDOCRINOL, V13, P555, DOI 10.1210/mend.13.4.0263; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Rao NV, 1997, J BIOL CHEM, V272, P10260; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Won S, 1999, J NEUROCHEM, V73, P2358, DOI 10.1046/j.1471-4159.1999.0732358.x; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yoo JY, 2000, BRIT J CANCER, V82, P683	57	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8995	9002		10.1074/jbc.M007473200	http://dx.doi.org/10.1074/jbc.M007473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124255	hybrid			2022-12-25	WOS:000167607700052
J	Xie, Z; Ho, WT; Exton, JH				Xie, Z; Ho, WT; Exton, JH			Requirements and effects of palmitoylation of rat PLD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHOLIPASE-D DEFINES; C-TERMINAL DOMAINS; PROTEIN-KINASE-C; D1; PHOSPHORYLATION; SUPERFAMILY; EXPRESSION; D2; ASSOCIATION	Rat brain phospholipase D1 (rPLD1) has two highly conserved motifs (HXKX4D), denoted HKD, located in the N- and C-terminal halves, which are required for phospholipase D activity. The two halves of rPLD1 can associate in vivo, and the association is essential for catalytic activity and Ser/Thr phosphorylation of the enzyme. In this study, we found that this association is also required for palmitoylation of rPLD1, which occurs on cysteines 240 and 241, In addition, palmitoylation of rPLD1 requires the N-terminal sequence but not the conserved C-terminal sequence, since rPLD1 that lacks the first 168 amino acids is not palmitoylated in vivo, while the inactive C-terminal deletion mutant is. Palmitoylation of rPLD1 is not necessary for catalytic activity, since N-terminal truncation mutants lacking the first 168 or 319 amino acids exhibit high basal activity although they cannot be stimulated by protein kinase C (PKC), The lack of response to PKC is not due to the lack of palmitoylation, since mutation of both Cys(240) and Cys(241) to alanine in full-length rPLD1 abolishes palmitoylation, but the mutant still retains basal activity and responds to PKC, Palmitoylation-deficient rPLD1 can associate with crude membranes; however, the association is weakened. Wild type rPLD1 remains membrane-associated when extracted with 1 M NaCl or Na2CO3 (pH 11), while rPLD1 mutants that lack palmitoylation are partially released. In addition, we found that palmitoylation-deficient mutants are much less modified by Ser/ Thr phosphorylation compared with wild type rPLD1, Characterization of the other cysteine mutations of rPLD1 showed that mutation of cysteine 310 or 612 to alanine increased basal phospholipase D activity 2- and 4-fold, respectively, In summary, palmitoylation of rPLD1 requires interdomain association and the presence of the N- terminal 168 amino acids. Mutations of cysteines 240 and 241 to alanine abolish the extensive Ser/Thr phosphorylation of the enzyme and weaken its association with membranes.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.	john.exton@mcmail.vanderbilt.edu						Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Houle MG, 1999, BBA-MOL CELL BIOL L, V1439, P135, DOI 10.1016/S1388-1981(99)00090-6; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Manifava M, 1999, J BIOL CHEM, V274, P1072, DOI 10.1074/jbc.274.2.1072; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Park SK, 1998, BIOCHEM BIOPH RES CO, V244, P364, DOI 10.1006/bbrc.1998.8275; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Ponting CP, 1996, PROTEIN SCI, V5, P914; Rudge SA, 1999, BBA-MOL CELL BIOL L, V1439, P167, DOI 10.1016/S1388-1981(99)00092-X; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; Siddiqi AR, 2000, BBA-MOL CELL RES, V1497, P103, DOI 10.1016/S0167-4889(00)00049-5; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Soskic V, 1999, J BIOL CHEM, V274, P8539, DOI 10.1074/jbc.274.13.8539; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Sugars JM, 1999, J BIOL CHEM, V274, P30023, DOI 10.1074/jbc.274.42.30023; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Watanabe H, 2000, BBA-MOL CELL RES, V1495, P121, DOI 10.1016/S0167-4889(99)00165-2; Xie Z, 2000, EUR J BIOCHEM, V267, P7138, DOI 10.1046/j.1432-1327.2000.01816.x; Xie Z, 2000, J BIOL CHEM, V275, P24962, DOI 10.1074/jbc.M909745199; Xie Z, 1998, J BIOL CHEM, V273, P34679, DOI 10.1074/jbc.273.52.34679; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035; Zhang Y, 2000, J BIOL CHEM, V275, P35224, DOI 10.1074/jbc.M003329200	41	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9383	9391		10.1074/jbc.M009425200	http://dx.doi.org/10.1074/jbc.M009425200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121416	hybrid			2022-12-25	WOS:000167607700102
J	Yang, IY; Hossain, M; Miller, H; Khullar, S; Johnson, F; Grollman, A; Moriya, M				Yang, IY; Hossain, M; Miller, H; Khullar, S; Johnson, F; Grollman, A; Moriya, M			Responses to the major acrolein-derived deoxyguanosine adduct in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOCYCLIC DNA-ADDUCTS; 1,N-2-PROPANODEOXYGUANOSINE ADDUCTS; IN-VITRO; MUTAGENESIS; PROPANODEOXYGUANOSINE; MALONDIALDEHYDE; MECHANISMS; MISMATCH; LESIONS; CELLS	Acrolein, a reactive alpha,beta -unsaturated aldehyde found ubiquitously in the environment and formed endogenously in mammalian cells, reacts with DNA to form an exocyclic DNA adduct, 3H-8-hydroxy-3-(beta -D-2'-deoxyribofuranosyl)-5,6,7,8-tetrahydropyrido[3,2-a]pu rine-9-one (gamma -OH-PdG). The cellular processing and mutagenic potential of gamma -OH-PdG have been examined, using a site-specific approach in which a single adduct is embedded in double-strand plasmid DNA. Analysis of progeny plasmid reveals that this adduct is excised by nucleotide excision repair. The apparent level of inhibition of DNA synthesis is similar to 70% in Escherichia coli Delta recA, uvrA. The block to DNA synthesis can be overcome partially by recA-dependent recombination repair. Targeted G --> T transversions were observed at a frequency of 7 x 10(-4)/translesion synthesis. Inactivation of polB, dinB, and umuD,C genes coding for "SOS" DNA polymerases did not affect significantly the efficiency or fidelity of translesion synthesis. In vitro primer extension experiments revealed that the Klenow fragment of polymerase I catalyzes error-prone synthesis, preferentially incorporating dAMP and dGMP opposite gamma -OH-PdG, We conclude from this study that DNA polymerase III catalyzes translesion synthesis across gamma -OH-PdG in an error-free manner. Nucleotide excision repair, recombination repair, and highly accurate translesion synthesis combine to protect E. coli from the potential genotoxicity of this DNA adduct.	SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Moriya, M (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA.		Miller, Holly/I-6942-2015	Miller, Holly/0000-0002-9076-5335	NATIONAL CANCER INSTITUTE [R01CA076163, P01CA047995, R56CA076163] Funding Source: NIH RePORTER; NCI NIH HHS [CA76163, P01CA47995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; BASU AK, 1993, BIOCHEMISTRY-US, V32, P12793, DOI 10.1021/bi00210a031; BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; CHENG KC, 1991, P NATL ACAD SCI USA, V88, P9974, DOI 10.1073/pnas.88.22.9974; Chung FL, 1999, MUTAT RES-FUND MOL M, V424, P71, DOI 10.1016/S0027-5107(99)00009-3; COHEN SM, 1992, CANCER RES, V52, P3577; de los Santos C, 2001, J BIOL CHEM, V276, P9077, DOI 10.1074/jbc.M009028200; ESCARCELLAR M, 1994, J BACTERIOL, V10, P6221; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; Hashim MF, 1996, J BIOL CHEM, V271, P9160, DOI 10.1074/jbc.271.15.9160; HOLLSTEIN M, 1994, CARCINOGENESIS, V15, P1, DOI 10.1093/carcin/15.1.1; Johnson KA, 1997, J BIOL CHEM, V272, P11434; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; Khullar S, 1999, J MED CHEM, V42, P947, DOI 10.1021/jm980605u; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; Kornberg A., 1992, DNA REPLICATION; Levine RL, 2000, CANCER RES, V60, P4098; Mao H, 1999, P NATL ACAD SCI USA, V96, P6615, DOI 10.1073/pnas.96.12.6615; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; Marnett LJ, 1999, MUTAT RES-FUND MOL M, V424, P83, DOI 10.1016/S0027-5107(99)00010-X; Miller J. H., 1992, SHORT COURSE BACTERI, P263; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; Nair J, 1999, MUTAT RES-FUND MOL M, V424, P59, DOI 10.1016/S0027-5107(99)00008-1; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nath RG, 1996, CANCER RES, V56, P452; PALEJWALA VA, 1991, BIOCHEMISTRY-US, V30, P8736, DOI 10.1021/bi00100a004; Pandya GA, 1996, BIOCHEMISTRY-US, V35, P11487, DOI 10.1021/bi960170h; Pandya GA, 2000, J BACTERIOL, V182, P6598, DOI 10.1128/JB.182.23.6598-6604.2000; SANTERRE A, 1994, P NATL ACAD SCI USA, V91, P2240, DOI 10.1073/pnas.91.6.2240; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SIEGEL EC, 1982, MUTAT RES, V93, P25, DOI 10.1016/0027-5107(82)90122-1; SIMHA D, 1991, BIOCHEMISTRY-US, V30, P8727, DOI 10.1021/bi00100a003; SINGER B, 1991, CARCINOGENESIS, V12, P745, DOI 10.1093/carcin/12.4.745; SINGER B, 1999, IARC SCI PUBLICATION, V150; SMITH RA, 1990, CANCER RES, V50, P3005; VanderVeen LA, 2001, J BIOL CHEM, V276, P9066, DOI 10.1074/jbc.M008900200; WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543; ZHANG WF, 1995, CHEM RES TOXICOL, V8, P157, DOI 10.1021/tx00043a021	40	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9071	9076		10.1074/jbc.M008918200	http://dx.doi.org/10.1074/jbc.M008918200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124950	hybrid			2022-12-25	WOS:000167607700062
J	Adamska, I; Kruse, E; Kloppstech, K				Adamska, I; Kruse, E; Kloppstech, K			Stable insertion of the early light-induced proteins into etioplast membranes requires chlorophyll-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTENOID-BINDING-SITES; INDUCIBLE PROTEINS; HIGHER-PLANTS; ARABIDOPSIS-THALIANA; HARVESTING COMPLEX; CHLAMYDOMONAS-REINHARDTII; POLYACRYLAMIDE GELS; ESCHERICHIA-COLI; PHOTOSYSTEM-II; BOUND PROTEASE	Etiolated plant seedlings exposed to light respond by transient accumulation of the nucleus-encoded, plastid-located early light-inducible proteins (Elips), These proteins are distant relatives of the light-harvesting chlorophyll a/b-binding gene family and bind pigments with unusual characteristics. To investigate whether accumulation of flips in plastid membranes is post-translationally regulated by pigments, reconstitution studies were performed, where in vitro transcribed and translated low molecular mass Elip precursors of barley were combined with lysed barley etioplasts complemented with various compositions of isolated pigments. We showed that the membrane insertion of Elips, as proven by protease protection assays and washes with a chao-tropic salt or alkali, depended strictly on chlorophyll a but not on chlorophyll b or xanthophyll zeaxanthin. The amount of inserted Elips increased almost linearly with the chlorophyll a concentration, and the insertion efficiency was not significantly influenced by a light intensity between 1 and 1,000 mu mol.m(-2).s(-1). In contrast, in vitro import of Elip precursors into greening plastids was enhanced by high intensity light. Thus, we conclude that although chlorophylls bound to flips seem to not be involved in light harvesting, they are crucial for a stable insertion of these proteins into the plastid membrane.	Univ Stockholm, Arrhenius Labs Nat Sci, Dept Biochem, S-10691 Stockholm, Sweden; Inst Pflanzengenet & Kulturpflanzenforsch, D-06466 Gatersleben, Germany; Leibniz Univ Hannover, Inst Bot, D-30419 Hannover, Germany	Stockholm University; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Leibniz University Hannover	Adamska, I (corresponding author), Univ Stockholm, Arrhenius Labs Nat Sci, Dept Biochem, S-10691 Stockholm, Sweden.	Iwona@biokemi.su.se						ADAMSKA I, 1993, J BIOL CHEM, V268, P5438; Adamska I, 1999, EUR J BIOCHEM, V260, P453, DOI 10.1046/j.1432-1327.1999.00178.x; ADAMSKA I, 1992, P NATL ACAD SCI USA, V89, P2610, DOI 10.1073/pnas.89.7.2610; ADAMSKA I, 2001, ADV PHOTOSYNTHESIS R, V8; APEL K, 1978, EUR J BIOCHEM, V85, P581, DOI 10.1111/j.1432-1033.1978.tb12273.x; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BAUMGARTNER BJ, 1993, PLANT PHYSIOL, V101, P781, DOI 10.1104/pp.101.3.781; BELLEMARE G, 1982, J BIOL CHEM, V257, P7762; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; Boudreau E, 1997, EMBO J, V16, P6095, DOI 10.1093/emboj/16.20.6095; Braun P, 1996, PLANT PHYSIOL, V110, P1405, DOI 10.1104/pp.110.4.1405; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; DemmigAdams B, 1996, FASEB J, V10, P403, DOI 10.1096/fasebj.10.4.8647339; Eichacker LA, 1996, J BIOL CHEM, V271, P32174, DOI 10.1074/jbc.271.50.32174; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; FUNK C, 1995, J BIOL CHEM, V270, P30141; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; GREEN BR, 1995, PHOTOSYNTH RES, V44, P139, DOI 10.1007/BF00018304; GRIMM B, 1989, PLANT MOL BIOL, V13, P583, DOI 10.1007/BF00027318; GRIMM B, 1987, EUR J BIOCHEM, V167, P493, DOI 10.1111/j.1432-1033.1987.tb13364.x; Heddad M, 2000, P NATL ACAD SCI USA, V97, P3741, DOI 10.1073/pnas.050391397; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; HOOBER JK, 1992, PLANT PHYSIOL, V99, P932, DOI 10.1104/pp.99.3.932; Jansson S, 2000, PLANT MOL BIOL, V42, P345, DOI 10.1023/A:1006365213954; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Kim SJ, 1999, J BIOL CHEM, V274, P4715, DOI 10.1074/jbc.274.8.4715; KOHORN BD, 1991, J BIOL CHEM, V266, P12048; KROL M, 1995, PLANT PHYSIOL, V107, P873, DOI 10.1104/pp.107.3.873; KRUSE E, 1992, EUR J BIOCHEM, V208, P195, DOI 10.1111/j.1432-1033.1992.tb17174.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Kuttkat A, 1997, J BIOL CHEM, V272, P20451, DOI 10.1074/jbc.272.33.20451; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY H, 1993, J BIOL CHEM, V268, P20892; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; MEYER G, 1984, EUR J BIOCHEM, V138, P201, DOI 10.1111/j.1432-1033.1984.tb07900.x; Montane MH, 2000, GENE, V258, P1, DOI 10.1016/S0378-1119(00)00413-3; PAULSEN H, 1995, PHOTOCHEM PHOTOBIOL, V62, P367, DOI 10.1111/j.1751-1097.1995.tb02357.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; POTTER E, 1993, EUR J BIOCHEM, V214, P779, DOI 10.1111/j.1432-1033.1993.tb17980.x; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tziveleka LA, 1998, PLANT PHYSIOL, V117, P961, DOI 10.1104/pp.117.3.961	48	39	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8582	8587		10.1074/jbc.M010447200	http://dx.doi.org/10.1074/jbc.M010447200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11114311	hybrid			2022-12-25	WOS:000167474900121
J	Guo, SD; Cichy, SB; He, XW; Yang, QY; Ragland, M; Ghosh, AK; Johnson, PF; Unterman, TG				Guo, SD; Cichy, SB; He, XW; Yang, QY; Ragland, M; Ghosh, AK; Johnson, PF; Unterman, TG			Insulin suppresses transactivation by CAAT/enhancer-binding proteins beta (C/EBP beta) - Signaling to p300/CREB-binding protein by protein kinase B disrupts interaction with the major activation domain of C/EBP beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION; GENE-TRANSCRIPTION; GLUCOCORTICOID RESPONSE; COACTIVATOR CBP; NUCLEAR-PROTEIN; LEUCINE-ZIPPER; FACTOR FKHR; PHOSPHORYLATION; P300; CREB	CAAT/enhancer-binding proteins (C/EBPs) play an important role in the regulation of gene expression in insulin-responsive tissues. We have found that a complex containing C/EBP beta interacts with an insulin response sequence in the insulin-like growth factor-binding protein-1 (IGFBP-1) gene and that a C/EBP-binding site can mediate effects of insulin on promoter activity. Here, we examined mechanisms mediating this effect of insulin. The ability of insulin to suppress promoter activity via a C/EBP-binding site is blocked by LY294002, a phosphatidylinositol 3-kinase inhibitor, but not by rapamycin, which blocks activation of p70(S6 kinase). Dominant negative phosphatidylinositol 3-kinase and protein kinase B (PKB) block the effect of insulin, while activated PKB suppresses promoter function via a C/EBP-binding site, mimicking the effect of insulin, Coexpression studies indicate that insulin and PKB suppress transactivation by C/EBP beta, but not C/EBP alpha, and that N-terminal transactivation domains in C/EBP beta are required. Studies with Gal4 fusion proteins reveal that insulin and PKB suppress transactivation by the major activation domain in C/EBP beta (AD II), located between amino acids 31 and 83, Studies with E1A protein indicate that interaction with p300/CBP is required for transactivation by AD II and the effect of insulin and PKB, Based on a consensus sequence, we identified a PKB phosphorylation site (Ser(1834)) within the region of p300/CBP known to bind C/EBP beta, Mammalian two-hybrid studies indicate that insulin and PKB disrupt interactions between this region of p300 and AD II and that Ser(1834) is critical for this effect. Signaling by PKB and phosphorylation of Ser(1834) may play an important role in modulating interactions between p300/CBP and transcription factors and mediate effects of insulin and related growth factors on gene expression.	Univ Illinois, Coll Med, Chicago, IL 60612 USA; Res Genet Inc, Huntsville, AL 35801 USA; NCI, Eukaryot Transcript Regulat Sect, Regulat Cell Growth Lab, Frederick Canc Res & Dev Ctr, Bethesda, MD 20892 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Unterman, TG (corresponding author), Vet Affairs Chicago Hlth Care Syst W Side, Rm 5A122A Res MP 151,820 S Damen Ave, Chicago, IL 60612 USA.	unterman@uic.edu	GHOSH, AYAN/GYV-5906-2022; Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725	NIDDK NIH HHS [DK41430] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041430, R29DK041430] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; Ghosh AK, 2001, J BIOL CHEM, V276, P8507, DOI 10.1074/jbc.M008541200; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yeagley D, 2000, J BIOL CHEM, V275, P17814, DOI 10.1074/jbc.M909842199	65	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8516	8523		10.1074/jbc.M008542200	http://dx.doi.org/10.1074/jbc.M008542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11116148	hybrid			2022-12-25	WOS:000167474900113
J	Pearson, G; English, JM; White, MA; Cobb, MH				Pearson, G; English, JM; White, MA; Cobb, MH			ERK5 and ERK2 cooperate to regulate NF-kappa B and cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; RIBOSOMAL S6 KINASE; MAP KINASE; PROTEIN-KINASE-1 BMK1; SIGNAL-TRANSDUCTION; TYROSINE KINASES; GENE-EXPRESSION; IN-VITRO; RAF	We have previously demonstrated an involvement of MEK5 and ERK5 in RafBXB-stimulated focus formation in NIH3T3 cells. We find here that MEK5 and ERK5 cooperate with the RafBXB effecters MEK1/2 and ERK1/2 to induce foci. To further understand MEK5-ERK5-dependent signaling, we examined potential MEK5-ERK5 effecters that might influence focus-forming activity. Consistent with results from our focus-formation assays, constitutively active variants of MEK5 and MEK1 synergize to activate NF-kappaB, and MEK5 and ERK5 are required for activation of NP-kappaB by RafBXB. The MEK5-ERK5 pathway is also sufficient to activate both NF-kappaB and p90 ribosomal S6 kinase, Our results support the hypothesis that NF-kappaB and p90 ribosomal S6 kinase are involved in MEK5-ERK5-dependent focus formation and may serve as integration points for ERK5 and ERK1/2 signaling.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75390 USA; Schering Plough Corp, Res Inst, Dept Biol Res Oncol, Kenilworth, NJ 07033 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Merck & Company; Schering Plough Corporation	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NCI NIH HHS [CA71443, R01 CA071443, R01 CA071443-14] Funding Source: Medline; NIDDK NIH HHS [R37 DK034128, DK34128, R01 DK034128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mineo C, 1997, J BIOL CHEM, V272, P10345; Monia BP, 1997, ANTI-CANCER DRUG DES, V12, P327; Naumann U, 1997, Recent Results Cancer Res, V143, P237; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; Pearson G, 2000, J BIOL CHEM, V275, P37303, DOI 10.1074/jbc.C000570200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Troppmair J, 1998, ONCOGENE, V17, P685, DOI 10.1038/sj.onc.1201981; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	44	111	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7927	7931		10.1074/jbc.M009764200	http://dx.doi.org/10.1074/jbc.M009764200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11118448	Green Accepted, hybrid			2022-12-25	WOS:000167474900036
J	Bose, I; Irazoqui, JE; Moskow, JJ; Bardes, ESG; Zyla, TR; Lew, DJ				Bose, I; Irazoqui, JE; Moskow, JJ; Bardes, ESG; Zyla, TR; Lew, DJ			Assembly of scaffold-mediated complexes containing Cdc42p, the exchange factor Cdc24p and the effector Cla4p required for cell cycle-regulated phosphorylation of Cdc24p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; GTP-BINDING PROTEIN; BUD-SITE SELECTION; GUANINE-NUCLEOTIDE-EXCHANGE; RHO-TYPE GTPASES; ACTIN CYTOSKELETON; PHEROMONE-RESPONSE; ACTIVATING PROTEIN; MOLECULAR-CLONING; POLARIZED GROWTH	In budding yeast cells, the cytoskeletal polarization and depolarization events that shape the bud are triggered at specific times during the cell cycle by the cyclin-dependent kinase Cdc28p, Polarity establishment also requires the small GTPase Cdc42p and its exchange factor, Cdc24p, but the mechanism whereby Cdc28p induces Cdc42p-dependent polarization is unknown. Here we show that Cdc24p becomes phosphorylated in a cell cycle-dependent manner, triggered by Cdc28p, However, the role of Cdc28p is indirect, and the phosphorylation appears to be catalyzed by the pal-activated kinase family member Cla4p and also depends on Cdc42p and the scaffold protein Bem1p, Expression of GTP-Cdc42p, the product of Cdc24p-mediated GDP/GTP exchange; stimulated Cdc24p phosphorylation independent of cell cycle cues, raising the possibility that the phosphorylation is part of a feedback regulatory pathway. Bem1p binds directly to Cdc24p, to Cla4p, and to GTP-bound Cdc42p and can mediate complex formation between these proteins in vitro. We suggest that Bem1p acts to concentrate polarity establishment proteins at a discrete site, facilitating polarization and promoting Cdc24p phosphorylation at specific times during the cell cycle.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Lew, DJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3686, Durham, NC 27710 USA.		Irazoqui, Javier E/A-8028-2013	Irazoqui, Javier/0000-0001-6553-1329	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053050] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; Bender L, 1996, J CELL BIOL, V133, P879, DOI 10.1083/jcb.133.4.879; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; Chung CY, 2000, P NATL ACAD SCI USA, V97, P5225, DOI 10.1073/pnas.97.10.5225; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gulli MP, 2000, MOL CELL, V6, P1155, DOI 10.1016/S1097-2765(00)00113-1; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Guthrie C, 1991, METHODS ENZYMOL, V194; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Hudson JR, 1997, GENOME RES, V7, P1169, DOI 10.1101/gr.7.12.1169; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Lew DJ, 1997, MOL CELLULAR BIOL YE, P607; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; Matsui Y, 1996, J CELL BIOL, V133, P865, DOI 10.1083/jcb.133.4.865; McMillan JN, 1998, J CELL BIOL, V142, P1487, DOI 10.1083/jcb.142.6.1487; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; Moore DD, 1995, GLOB MOB SURV; Moskow JJ, 2000, MOL CELL BIOL, V20, P7559, DOI 10.1128/MCB.20.20.7559-7571.2000; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; Nern A, 2000, J CELL BIOL, V148, P1115, DOI 10.1083/jcb.148.6.1115; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Oehlen LJWM, 1998, J BIOL CHEM, V273, P25089, DOI 10.1074/jbc.273.39.25089; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; Pruyne D, 2000, J CELL SCI, V113, P365; Pruyne D, 2000, J CELL SCI, V113, P571; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Sambrook J., 2002, MOL CLONING LAB MANU; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENSON BJ, 1995, GENE DEV, V9, P2949, DOI 10.1101/gad.9.23.2949; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Toenjes KA, 1999, CURR BIOL, V9, P1183, DOI 10.1016/S0960-9822(00)80022-6; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Yang PR, 1999, J BIOL CHEM, V274, P36052, DOI 10.1074/jbc.274.51.36052; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Zahner JE, 1996, MOL CELL BIOL, V16, P1857; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1993, J BIOL CHEM, V268, P24629; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	72	153	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7176	7186		10.1074/jbc.M010546200	http://dx.doi.org/10.1074/jbc.M010546200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113154	hybrid			2022-12-25	WOS:000167442900046
J	Liu, HY; Chiang, YC; Pan, J; Chen, JJ; Salvadore, C; Audino, DC; Badarinarayana, V; Palaniswamy, V; Anderson, B; Denis, CL				Liu, HY; Chiang, YC; Pan, J; Chen, JJ; Salvadore, C; Audino, DC; Badarinarayana, V; Palaniswamy, V; Anderson, B; Denis, CL			Characterization of CAF4 and CAF16 reveals a functional connection between the CCR4-NOT complex and a subset of SRB proteins of the RNA polymerase II holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NEGATIVE REGULATOR; GENE-EXPRESSION; YEAST; TRANSCRIPTION; KINASE; ACTIVATION; COMPONENTS; BINDING; DOMAINS	The CCR4-NOT transcriptional regulatory complex affects transcription both positively and negatively and consists of the following two complexes: a core 1 x 10(6) dalton (1 MDa) complex consisting of CCR4, CAF1, and the five NOT proteins and a larger, less defined 1.9-MDa complex. We report here the identification of two new factors that associate with the CCR4-NOT proteins as follows: CAF4, a WD40-containing protein, and CAF16, a putative ABC ATPase, Whereas neither CAF4 nor CAF16 was part of the core CCR4-NOT complex, both CAF16 and CAF4 appeared to be present in the 1.9-MDa complex. CAF4 also displayed physical interactions with multiple CCR4-NOT components and with DBF2, a likely component of the 1.9-MDa complex. In addition, both CAF4 and CAF16 were found to interact in a CCR4-dependent manner with SRB9, a component of the SRB complex that is part of the yeast RNA polymerase II holoenzyme. The three related SRB proteins, SRB9, SRB10, and SRB11, were found to interact with and to coimmunoprecipitate DBF2, CAF4, CCR4, NOT2, and NOT1, Defects in SRB9 and SRB10 also affected processes at the ADH2 locus known to be controlled by components of the CCR4 NOT complex; an srb9 mutation was shown to reduce ADH2 derepression and either an srb9 or srb10 allele suppressed spt10-enhanced expression of ADH2. In addition, srb9 and srb10 alleles increased ADR1(c)-dependent ADH2 expression; not4 and not5 deletions are the only other known defects that elicit this phenotype. These results suggest a close physical and functional. association between components of the CCR4-NOT complexes and the SRB9, -10, and -11 components of the holoenzyme.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Denis, CL (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA.				NIGMS NIH HHS [GM41512] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Badarinarayana V, 2000, GENETICS, V155, P1045; Bai YL, 1999, MOL CELL BIOL, V19, P6642; BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; Benson JD, 1998, EMBO J, V17, P6714, DOI 10.1093/emboj/17.22.6714; Berk AJ, 1995, P NATL ACAD SCI USA, V92, P11952, DOI 10.1073/pnas.92.26.11952; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; Collart MA, 1996, MOL CELL BIOL, V16, P6668; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; COOK WJ, 1994, MOL CELL BIOL, V14, P629, DOI 10.1128/MCB.14.1.629; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; DEAN M, 1994, YEAST, V10, P377, DOI 10.1002/yea.320100310; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DENIS CL, 1994, GENETICS, V138, P1005; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hata H, 1998, GENETICS, V148, P571; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Hirst M, 1999, MOL CELL, V3, P673, DOI 10.1016/S1097-2765(00)80360-3; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Komarnitsky SI, 1998, MOL CELL BIOL, V18, P2100, DOI 10.1128/MCB.18.4.2100; Kuchin S, 2000, P NATL ACAD SCI USA, V97, P7916, DOI 10.1073/pnas.140109897; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lemaire M, 2000, J BIOL CHEM, V275, P26925; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Oberholzer U, 1998, GENE, V207, P61, DOI 10.1016/S0378-1119(97)00605-7; POOLE RK, 1993, MOL MICROBIOL, V10, P421, DOI 10.1111/j.1365-2958.1993.tb02673.x; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; QIN SL, 1990, J BIOL CHEM, V265, P1903; SAKAI A, 1992, NUCLEIC ACIDS RES, V20, P6227, DOI 10.1093/nar/20.23.6227; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Song WJ, 1996, MOL CELL BIOL, V16, P115; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Tabtiang RK, 1998, MOL CELL BIOL, V18, P4707, DOI 10.1128/MCB.18.8.4707; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Verdone L, 1997, J BIOL CHEM, V272, P30828, DOI 10.1074/jbc.272.49.30828; WAHI M, 1995, GENETICS, V140, P79; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	50	94	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7541	7548		10.1074/jbc.M009112200	http://dx.doi.org/10.1074/jbc.M009112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113136	hybrid			2022-12-25	WOS:000167442900093
J	Nakanishi, Y; Saijo, T; Wada, Y; Maeshima, M				Nakanishi, Y; Saijo, T; Wada, Y; Maeshima, M			Mutagenic analysis of functional residues in putative substrate-binding site and acidic domains of vacuolar H+-pyrophosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING INORGANIC PYROPHOSPHATASE; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; SARCOPLASMIC-RETICULUM; INHIBITION; MEMBRANE; PLANT; EXPRESSION; TRANSPORT; CALCIUM	Vacuolar H+-translocating inorganic pyrophosphatase(V-PPase) uses PP, as an energy donor and requires, free Mg2+ for enzyme activity and stability. To determine the catalytic domain, we analyzed charged residues (ASp(253), Lys(261), GlU(263), ASp(279), Asp(283), Asp(287), Asp(723), Asp(727), and Asp(731)) in the putative PPi-binding site and two conserved acidic regions of mung bean V-PPase by site-directed mutagenesis and heterologous expression in yeast. Amino acid substitution of the residues with alanine and conservative residues resulted in a marked decrease in PPi hydrolysis activity and a complete loss of H+ transport activity. The conformational change of V-PPase induced by the binding of the substrate was reflected in the susceptibility to trypsin, Wild-type V-PPase was completely digested by trypsin but not in the presence of Mg-PPi, while two V-PPase mutants, K261A and E263A, became sensitive to trypsin even in the presence of the substrate. These results suggest that the second acidic region is also implicated in the substrate hydrolysis and that at least two residues, Lys(261) and GLU(263), are essential for the substrate-binding function. From the observation that the conservative mutants K261R and E263D showed partial activity of PPi hydrolysis but no proton pump activity, we estimated that two residues, Lys(261) and GlU(263), might be related to the energy conversion from PP, hydrolysis to H+ transport. The importance of two residues, Asp(253) and GlU(263), in the Mg2+-binding function was also suggested from the trypsin susceptibility in the presence of Mg2+. Furthermore, it was found that the two acidic regions include essential common motifs shared among the P-type ATPases.	Nagoya Univ, Grad Sch Bioagr Sci, Biochem Lab, Nagoya, Aichi 4648601, Japan; Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Osaka 5670047, Japan	Nagoya University; Osaka University	Maeshima, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Biochem Lab, Nagoya, Aichi 4648601, Japan.	maeshima@agr.nagoya-u.ac.jp	Maeshima, Masayoshi/D-3073-2013	Maeshima, Masayoshi/0000-0002-1611-5481				Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Baltscheffsky M, 1999, FEBS LETT, V457, P525, DOI 10.1016/S0014-5793(99)00914-X; Baltscheffsky M, 1998, BBA-BIOENERGETICS, V1364, P301, DOI 10.1016/S0005-2728(98)00062-0; BAYKOV AA, 1993, FEBS LETT, V327, P199, DOI 10.1016/0014-5793(93)80169-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; Drozdowicz YM, 1999, FEBS LETT, V460, P505, DOI 10.1016/S0014-5793(99)01404-0; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gordon-Weeks R, 1999, BIOCHEM J, V337, P373, DOI 10.1042/0264-6021:3370373; GordonWeeks R, 1996, PLANT PHYSIOL, V111, P195, DOI 10.1104/pp.111.1.195; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Ikeda M, 1999, J EXP BOT, V50, P139, DOI 10.1093/jexbot/50.330.139; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KIM EJ, 1995, J BIOL CHEM, V270, P2630, DOI 10.1074/jbc.270.6.2630; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; MAESHIMA M, 1991, EUR J BIOCHEM, V196, P11, DOI 10.1111/j.1432-1033.1991.tb15779.x; Nakanishi Y, 1998, PLANT PHYSIOL, V116, P589, DOI 10.1104/pp.116.2.589; Nakanishi Y, 1999, BBA-BIOMEMBRANES, V1418, P245, DOI 10.1016/S0005-2736(99)00037-1; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; REA PA, 1992, PLANT PHYSIOL, V100, P1706, DOI 10.1104/pp.100.4.1706; ROSENBERG S, 1990, METHOD ENZYMOL, V185, P341; Sherman F, 1979, METHODS YEAST GENETI; Stokes DL, 2000, EUR J BIOCHEM, V267, P5274, DOI 10.1046/j.1432-1327.2000.01569.x; Takasu A, 1997, J BIOCHEM-TOKYO, V122, P883, DOI 10.1093/oxfordjournals.jbchem.a021837; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Ueoka-Nakanishi H, 2000, EUR J BIOCHEM, V267, P3090, DOI 10.1046/j.1432-1033.2000.01343.x; Vartanian JP, 1996, NUCLEIC ACIDS RES, V24, P2627, DOI 10.1093/nar/24.14.2627; Williams LE, 2000, BBA-BIOMEMBRANES, V1465, P104, DOI 10.1016/S0005-2736(00)00133-4; ZHEN RG, 1994, PLANT PHYSIOL, V104, P153, DOI 10.1104/pp.104.1.153; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340; Zhen RG, 1997, ADV BOT RES, V25, P297, DOI 10.1016/S0065-2296(08)60156-1	36	90	92	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7654	7660		10.1074/jbc.M009743200	http://dx.doi.org/10.1074/jbc.M009743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113147	hybrid			2022-12-25	WOS:000167442900107
J	Quinlivan, EP; McPartlin, J; Weir, DG; Scott, J				Quinlivan, EP; McPartlin, J; Weir, DG; Scott, J			Mechanism of the antimicrobial drug trimethoprim revisited	FASEB JOURNAL			English	Article						folate catabolism; folic acid; antifolate; dihydrofolate reductase	METABOLISM	We tested the hypothesis that the mechanism of action of the antifolate drug trimethoprim is through accumulation of bacterial dihydrofolate resulting in depletion of tetrahydrofolate coenzymes required for purine and pyrimidine biosynthesis. The folate pool of a strain of Escherichia coli (NCIMB 8879) was prelabeled with the folate biosynthetic precursor [H-3]-p-aminobenzoic acid before treatment with trimethoprim. Folates in untreated E. coli were present as tetrahydrofolate coenzymes. In trimethoprim-treated cells, however, a rapid transient accumulation of dihydrofolate occurred, followed by complete conversion of all forms of folate to cleaved catabolites (pteridines and para-aminobenzoylglutamate) and the stable nonreduced form of the vitamin, folic acid. Both para-aminobenzoylglutamate and folic acid were present in the cell in the form of polyglutamates. Removal of trimethoprim resulted in the reconversion of the accumulated folic acid to tetrahydrofolate cofactors for subsequent participation in the one-carbon cycle. Whereas irreversible catabolism is probably bactericidal, conversion to folic acid may constitute a bacteriostatic mechanism since, as we show, folic acid can be used by the bacteria and proliferation is resumed once trimethoprim is removed. Thus, the clinical effectiveness of this important drug may depend on the extent to which the processes of either catabolism or folic acid production occur in different bacteria or during different therapeutic regimes.	Univ Dublin Trinity Coll, Dept Clin Med, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	McPartlin, J (corresponding author), St James Hosp, Sir Patrick Duns Trinity Coll Lab, Vitamin Res Lab, Dublin 8, Ireland.	jmcprtln@tcd.ie	Quinlivan, Eoin/AAJ-1979-2021; Quinlivan, Eoin P/B-8454-2008	Quinlivan, Eoin/0000-0002-0908-1762; Quinlivan, Eoin P/0000-0002-0908-1762				BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P477; BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P489; BROWN JP, 1974, J GEN MICROBIOL, V84, P163, DOI 10.1099/00221287-84-1-163; BRUMFITT W, 1980, BRIT J HOSP MED, V23, P281; BUSHBY SRM, 1968, BRIT J PHARMACOL, V33, P72, DOI 10.1111/j.1476-5381.1968.tb00475.x; HITCHINGS GH, 1989, IN VITRO CELL DEV B, V25, P303; LUKIENKO PI, 1985, FARMAKOL TOKSIKOL, V48, P53; MCNULTY H, 1995, J NUTR, V125, P99; MCPARTLIN J, 1993, LANCET, V341, P148, DOI 10.1016/0140-6736(93)90007-4; MINI E, 1990, J CHEMOTHERAPY, V2, P17; Mitchell HK, 1941, J AM CHEM SOC, V63, P2284, DOI 10.1021/ja01853a512; Molloy AM, 1997, METHOD ENZYMOL, V281, P43; MURPHY M, 1976, BRIT J HAEMATOL, V84, P211; OLIVEIRA MBM, 1989, CELL BIOCHEM FUNCT, V7, P135, DOI 10.1002/cbf.290070209; Richards RME, 1996, J PHARM PHARMACOL, V48, P981, DOI 10.1111/j.2042-7158.1996.tb06017.x; SHANE B, 1989, VITAM HORM, V45, P263; THEN RL, 1993, J CHEMOTHERAPY, V5, P361, DOI 10.1080/1120009X.1993.11741082	17	45	47	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2519	2524		10.1096/fj.99-1037com	http://dx.doi.org/10.1096/fj.99-1037com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099470				2022-12-25	WOS:000165723400022
J	Sandhu, C; Donovan, J; Bhattacharya, N; Stampfer, M; Worland, P; Slingerland, J				Sandhu, C; Donovan, J; Bhattacharya, N; Stampfer, M; Worland, P; Slingerland, J			Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells	ONCOGENE			English	Article						senescence; cell cycle; Cdc25A; p15(INK4B); cyclin E-cdk2; HMEC	GROWTH-FACTOR-BETA; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE; CDK INHIBITORS; DNA-SYNTHESIS; G(1)/S TRANSITION; DEPENDENT KINASES; PROTEIN-KINASE; GENE STATUS	Replicative senescence may be an important tumor suppressive mechanism for human cells. We investigated the mechanism of cell cycle arrest at senescence in human mammary epithelial cells (HMECs) that have undergone a period of 'self-selection', and as a consequence exhibit diminished p16(INK4A) levels. As HMECs approached senescence, the proportion of cells with a 2N DNA content increased and that in S phase decreased progressively. Cyclin D1-cdk4, cyclin E-cdk2 and cyclin A-cdk2 activities were not abruptly inhibited, but rather diminished steadily with increasing population age. In contrast to observations in fibroblast, p21(Cip1) was not increased at senescence in HMECs. There was no increase in p27(Kip1) levels nor in KIP association with targets cdks. While p15(INK4B) and its binding to both cdk4 and cdk6 increased with increasing passage, some cyclin D1-bound cdk4 and cdk6 persisted in senescent cells, whose inhibition could not be attributed to p15(INK4B). The inhibition of cyclin E-cdk2 in senescent HMECs was accompanied by increased inhibitory phosphorylation of cdk2, in association with a progressive loss of Cdc25A. Recombinant Cdc25A strongly reactivated cyclin E-cdk2 from senescent HMECs suggesting that reduction of Cdc25A contributes to cyclin E-cdk2 inhibition and G1 arrest at senescence. Although ectopic expression of Cdc25A failed to extend the lifespan of HMECs, the exogenous Cdc25A appeared to lack activity in these cells, since it neither shortened the G1-to-S phase interval nor activated cyclin E-cdk2. In contrast, in the breast cancer-derived MCF-7 line, Cdc25A overexpression increased both cyclin E-cdk2 activity and the S phase fraction. Thus, mechanisms leading to HMEC immortalization may involve not only the re-induction of Cdc25A expression, but also activation of this phosphatase.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Res, Toronto, ON M4N 3M5, Canada; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Mitotix Inc, Cambridge, MA 02139 USA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Slingerland, J (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Canc Res, S-238,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.				NCI NIH HHS [CA-24844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024844, R37CA024844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRENNER AJ, 1995, CANCER RES, V55, P2892; BRENNER AJ, 1998, IN PRESS ONCOGENE; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Enders GH, 1996, ONCOGENE, V12, P1239; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Foster SA, 1996, ONCOGENE, V12, P1773; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gasparotto D, 1997, CANCER RES, V57, P2366; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HERMAN JG, 1995, CANCER RES, V55, P4525; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAMB A, 1994, SCIENCE, V264, P440; Kim IY, 1996, ENDOCRINOLOGY, V137, P991, DOI 10.1210/en.137.3.991; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nijjar T, 1999, CANCER RES, V59, P5112; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKINSON K, 1990, CARCINOGENESIS, V11, P195, DOI 10.1093/carcin/11.2.195; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Reznikoff CA, 1996, CANCER RES, V56, P2886; Roberts L, 1998, FORSCH KOMPLEMENTMED, V5, P82, DOI 10.1159/000057115; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; Sandhu C, 2000, CANCER RES, V60, P2616; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1992, TRANSFORMATION HUMAN, P117; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2392; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wong DJ, 1997, CANCER RES, V57, P2619; YAMASHITA M, 1992, DEV BIOL, V1, P8; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	71	41	46	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5314	5323		10.1038/sj.onc.1203908	http://dx.doi.org/10.1038/sj.onc.1203908			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103932	Green Published			2022-12-25	WOS:000165302300002
J	Campeau, E; Gravel, RA				Campeau, E; Gravel, RA			Expression in Escherichia coli of N- and C-terminally deleted human holocarboxylase synthetase - Influence of the N-terminus on biotinyilation and identification of a minimum functional protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE CARBOXYLASE DEFICIENCY; ACETYL-COA CARBOXYLASE; BIOTIN HOLOENZYME SYNTHETASE; COENZYME-A CARBOXYLASE; CARRIER PROTEIN; DNA-BINDING; POSTTRANSLATIONAL MODIFICATION; TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA	Biotin functions as a covalently bound cofactor of biotindependent carboxylases. Biotin attachment is catalyzed by biotin protein ligases, called holocarboxylase synthetase in mammals and BirA in prokaryotes. These enzymes show a high degree of sequence similarity in their biotinylation domains but differ markedly in the length and sequence of their N terminus. BirA is also the repressor of the biotin operon, and its DNA attachment site is located in its N terminus. The function of the eukaryotic N terminus is unknown. Holocarboxylase synthetase with N- and C-terminal deletions were evaluated for the ability to catalyze biotinylation after expression in Escherichia coli using bacterial and human acceptor substrates. We showed that the minimum functional protein is comprised of the last 349 of the 726-residue protein, which includes the biotinylation domain. Significantly, enzyme containing intermediate length, N-terminal deletions interfered with biotin transfer and interaction with different peptide acceptor substrates. We propose that the N terminus of holocarboxylase synthetase contributes to biotinylation through N- and C-terminal interactions and may affect acceptor substrate recognition. Our findings provide a rationale for the biotin responsiveness of patients with point mutations in the N-terminal sequence of holocarboxylase synthetase, Such mutant enzyme may respond to biotin-mediated stabilization of the substrate-bound complex.	McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Res Inst,Dept Biol, Montreal, PQ H3Z 2Z3, Canada; McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Res Inst,Dept Human Genet, Montreal, PQ H3Z 2Z3, Canada; McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Res Inst,Dept Pediat, Montreal, PQ H3Z 2Z3, Canada	McGill University; McGill University; McGill University	Gravel, RA (corresponding author), Univ Calgary, Dept Cell Biol & Anat, Room 250 Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.							Aoki Y, 1999, HUM GENET, V104, P143, DOI 10.1007/s004390050927; Aoki Y, 1995, BBA-MOL BASIS DIS, V1272, P168, DOI 10.1016/0925-4439(95)00082-8; Aoki Y, 1997, PEDIATR RES, V42, P849, DOI 10.1203/00006450-199712000-00021; Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; BARKER DF, 1981, J MOL BIOL, V146, P469, DOI 10.1016/0022-2836(81)90043-7; Baumgartner ER, 1997, INT J VITAM NUTR RES, V67, P377; BOWER S, 1995, J BACTERIOL, V177, P2572, DOI 10.1128/jb.177.9.2572-2575.1995; BUONCRISTIANI MR, 1986, GENE, V44, P255, DOI 10.1016/0378-1119(86)90189-7; BURRI BJ, 1981, J CLIN INVEST, V68, P1491, DOI 10.1172/JCI110402; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CHAPMANSMITH A, 1999, J NUTR, V477, pS484; CHAUHAN J, 1991, J BIOL CHEM, V266, P10035; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DAKSHINAMURTI K, 1994, MOL CELL BIOCHEM, V132, P127, DOI 10.1007/BF00926921; Dupuis L, 1996, HUM MOL GENET, V5, P1011, DOI 10.1093/hmg/5.7.1011; Dupuis L, 1999, MOL GENET METAB, V66, P80, DOI 10.1006/mgme.1998.2785; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Kwon K, 2000, PROTEIN SCI, V9, P1530, DOI 10.1110/ps.9.8.1530; LEONDELRIO A, 1995, P NATL ACAD SCI USA, V92, P4626, DOI 10.1073/pnas.92.10.4626; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LI SJ, 1992, J BIOL CHEM, V267, P855; Lindqvist Y, 1996, CURR OPIN STRUC BIOL, V6, P798, DOI 10.1016/S0959-440X(96)80010-8; MCALLISTER HC, 1966, J BIOL CHEM, V241, P2855; MURTIF VL, 1987, J BIOL CHEM, V262, P11813; Nenortas E, 1996, J BIOL CHEM, V271, P7559, DOI 10.1074/jbc.271.13.7559; Polyak SW, 1999, J BIOL CHEM, V274, P32847, DOI 10.1074/jbc.274.46.32847; Reche P, 1998, BIOCHEM J, V329, P589, DOI 10.1042/bj3290589; Reddy DV, 2000, BIOCHEMISTRY-US, V39, P2509, DOI 10.1021/bi9925367; REED KE, 1991, J BIOL CHEM, V266, P11425; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; Sakamoto O, 1999, PEDIATR RES, V46, P671, DOI 10.1203/00006450-199912000-00006; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SAUNDERS M, 1979, J CLIN INVEST, V64, P1695, DOI 10.1172/JCI109632; SAUNDERS ME, 1982, AM J HUM GENET, V34, P590; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINGH IN, 1988, MOL CELL BIOCHEM, V79, P47, DOI 10.1007/BF00229397; SPENCE JT, 1984, J BIOL CHEM, V259, P6393; Stockert RJ, 1997, J BIOL CHEM, V272, P9161; Streaker ED, 1998, BIOCHEMISTRY-US, V37, P3210, DOI 10.1021/bi9715019; Suormala T, 1997, PEDIATR RES, V41, P666, DOI 10.1203/00006450-199705000-00011; Suzuki Y, 1996, CLIN CHIM ACTA, V251, P41, DOI 10.1016/0009-8981(96)06291-2; SUZUKI Y, 1994, NAT GENET, V8, P122, DOI 10.1038/ng1094-122; Tissot G, 1998, EUR J BIOCHEM, V258, P586, DOI 10.1046/j.1432-1327.1998.2580586.x; Tissot G, 1997, BIOCHEM J, V323, P179, DOI 10.1042/bj3230179; Val DL, 1995, BIOCHEM J, V312, P817, DOI 10.1042/bj3120817; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; Wolfe BE, 1995, IN SESSION-PSYCHOTH, V1, P1; Xu Y, 1995, BIOCHEMISTRY-US, V34, P16624, DOI 10.1021/bi00051a010; Xu Y, 1996, BIOCHEMISTRY-US, V35, P1783, DOI 10.1021/bi952269e; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f	52	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12310	12316		10.1074/jbc.M009717200	http://dx.doi.org/10.1074/jbc.M009717200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11124959	hybrid			2022-12-25	WOS:000168081800116
J	Hong, DH; Yue, GH; Adamian, M; Li, TS				Hong, DH; Yue, GH; Adamian, M; Li, TS			Retinitis pigmentosa GTPase regulator (RPGR)-interacting protein is stably associated with the photoreceptor ciliary axoneme and anchors RPGR to the connecting cilium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; RETINAL RODS; BASAL BODIES; MYOSIN VIIA; TRANSPORT; MEMBRANE; GENE; MICROTUBULES; LOCALIZATION; HOMOLOGY	Retinitis pigmentosa (RP) is a blinding retinal disease in which the photoreceptor cells degenerate. Mutations in the gene for retinitis pigmentosa GTPase regulator (RPGR) are a frequent cause of RP. The function of RPGR is not well understood, but it is thought to be a putative guanine nucleotide exchange factor for an unknown G protein. Ablation of the RPGR gene in mice suggested a role in maintaining the polarized distribution of opsin across the cilia. To investigate its function, we used a protein interaction screen to identify candidate proteins that may interact physiologically with RPGR. One such protein, designated RPGR-interacting protein (RPGRIP), is expressed specifically in rod and cone photoreceptors. It consists of an N-terminal region predicted to form coiled coil structures linked to a C-terminal tail that binds RPGR. In vivo, both proteins co-localize in the photoreceptor connecting cilia. RPGRIP is stably associated with the ciliary axoneme independent of RPGR and is resistant to extraction under conditions that partially solubilized other cytoskeletal components. When over-expressed in heterologous cell lines, RPGRIP appears in insoluble punctate and filamentous structures. These data suggest that RPGRIP is a structural component of the ciliary axoneme, and one of its functions is to anchor RPGR within the cilium. RPGRIP is the only protein known to localize specifically in the photoreceptor connecting cilium, As such, it is a candidate gene for human photoreceptor disease. The tissue-specific expression of RPGRIP explains why mutations in the ubiquitously expressed RPGR confer a photoreceptor-specific phenotype.	Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Li, TS (corresponding author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Berman Gund Lab Study Retinal Degenerat, 243 Charles St, Boston, MA 02114 USA.				NATIONAL EYE INSTITUTE [R01EY010309] Funding Source: NIH RePORTER; NEI NIH HHS [EY10309] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARIKAWA K, 1993, INVEST OPHTH VIS SCI, V34, P2145; Besharse JC., 1990, CILIARY FLAGELLAR ME, P389; Boylan JP, 2000, HUM MOL GENET, V9, P2085, DOI 10.1093/hmg/9.14.2085; GILULA NB, 1972, J CELL BIOL, V53, P494, DOI 10.1083/jcb.53.2.494; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hong DH, 2000, P NATL ACAD SCI USA, V97, P3649, DOI 10.1073/pnas.060037497; HORST CJ, 1987, J CELL BIOL, V105, P2973, DOI 10.1083/jcb.105.6.2973; HORST CJ, 1990, CELL MOTIL CYTOSKEL, V17, P329, DOI 10.1002/cm.970170408; Iguchi N, 1999, FEBS LETT, V456, P315, DOI 10.1016/S0014-5793(99)00967-9; IVELL R, 1992, INT J ANDROL, V15, P85, DOI 10.1111/j.1365-2605.1992.tb01117.x; Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315; LINCK RW, 1990, ADV CELL BIOL, V3, P35; Liu XR, 1999, J NEUROSCI, V19, P6267; Liu XR, 1997, CELL MOTIL CYTOSKEL, V37, P240, DOI 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.3.CO;2-2; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MURESAN V, 1993, J CELL SCI, V104, P1229; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Roepman R, 2000, HUM MOL GENET, V9, P2095, DOI 10.1093/hmg/9.14.2095; ROHLICH P, 1975, CELL TISSUE RES, V161, P421; ROOF D, 1991, J COMP NEUROL, V305, P289, DOI 10.1002/cne.903050210; Rosenbaum JL, 1999, J CELL BIOL, V144, P385, DOI 10.1083/jcb.144.3.385; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SPENCER M, 1988, INVEST OPHTH VIS SCI, V29, P1012; Stephens RE, 1998, CELL MOTIL CYTOSKEL, V40, P379, DOI 10.1002/(SICI)1097-0169(1998)40:4<379::AID-CM6>3.0.CO;2-6; STEPHENS RE, 1989, J CELL SCI, V92, P391; Sung CH, 2000, INT REV CYTOL, V195, P215; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Vervoort R, 2000, NAT GENET, V25, P462, DOI 10.1038/78182; VONSCHANTZ M, 1994, INVEST OPHTH VIS SCI, V35, P2558; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; Wolfrum U, 2000, CELL MOTIL CYTOSKEL, V46, P95, DOI 10.1002/1097-0169(200006)46:2<95::AID-CM2>3.0.CO;2-Q; Yan D, 1998, J BIOL CHEM, V273, P19656, DOI 10.1074/jbc.273.31.19656	35	153	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12091	12099		10.1074/jbc.M009351200	http://dx.doi.org/10.1074/jbc.M009351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11104772	hybrid			2022-12-25	WOS:000168081800089
J	Proudfoot, AEI; Fritchley, S; Borlat, F; Shaw, JP; Vilbois, F; Zwahlen, C; Trkola, A; Marchant, D; Clapham, PR; Wells, TNC				Proudfoot, AEI; Fritchley, S; Borlat, F; Shaw, JP; Vilbois, F; Zwahlen, C; Trkola, A; Marchant, D; Clapham, PR; Wells, TNC			The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CC-CHEMOKINE RANTES; PLATELET FACTOR-IV; IDENTIFICATION; RESIDUES; GLYCOSAMINOGLYCANS; MUTAGENESIS; MIP-1-BETA; PROTEIN-1; MECHANISM	The chemokine RANTES (regulated on activation normal T cell expressed and secreted; CCL5) binds selectively to glycosaminoglycans (GAGs) such as heparin, chondroitin sulfate, and dermatan sulfate. The primary sequence of RANTES contains two clusters of basic residues, (RKNR47)-R-44 and (KKWVR59)-K-55. The first is a BBXB motif common in heparin-binding proteins, and the second is located in the loop directly preceding the C-terminal helix. We have mutated these residues to alanine, both as point mutations as well as triple mutations of the 40s and 50s clusters. Using a binding assay to heparin beads with radiolabeled proteins, the (44)AANA(47) mutant demonstrated an 80% reduction in its capacity to bind heparin, whereas the (55)AAWVA(59) mutant retained full binding capacity. Mutation of the (RKNR47)-R-44 Site reduced the selectivity of RANTES binding to different GAGs. The mutants were tested for their integrity by receptor binding assays on CCR1 and CCR5 as well as their ability to induce chemotaxis in vitro. In all assays the single point mutations and the triple 50s cluster mutation caused no significant difference in activity compared with the wild type sequence. However, the triple 40s mutant showed a 80-fold reduction in affinity for CCR1, despite normal binding to CCR5. It was only able to induce monocyte chemotaxis at micromolar concentrations. The triple 40s mutant was also able to inhibit HIV-1 infectivity, but consistent with its abrogated GAG binding capacity, it no longer induced enhanced infectivity at high concentrations.	Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Newcastle Univ, Sch Med, Dept Surg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Lausanne, Inst Chim Organ, BCH, CH-1015 Lausanne, Switzerland; Univ Zurich Hosp, Dept Med, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland; UCL, Sch Med, Windeyer Inst Med Sci, Dept Mol Pathol,Wohl Vir Ctr, London W1T 4JF, England	Newcastle University - UK; University of Lausanne; University of Zurich; University Zurich Hospital; University of London; University College London; UCL Medical School	Proudfoot, AEI (corresponding author), Serono Pharmaceut Res Inst, 14 Chemin Aulx, CH-1228 Geneva, Switzerland.	amanda.proudfoot@serono.com	Trkola, Alexandra/K-2115-2012	Trkola, Alexandra/0000-0003-1013-876X; Zwahlen, Catherine/0000-0002-4909-6416; Wells, Timothy/0000-0001-9796-847X				Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chakravarty L, 1998, J BIOL CHEM, V273, P29641, DOI 10.1074/jbc.273.45.29641; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Coulin F, 1997, EUR J BIOCHEM, V248, P507, DOI 10.1111/j.1432-1033.1997.00507.x; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Gordon CJ, 1999, J VIROL, V73, P684, DOI 10.1128/JVI.73.1.684-694.1999; Graham GJ, 1996, EMBO J, V15, P6506, DOI 10.1002/j.1460-2075.1996.tb01041.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Jackson DG, 1997, BIOCHEM SOC T, V25, P220, DOI 10.1042/bst0250220; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Koopmann W, 1999, J IMMUNOL, V163, P2120; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Kuschert GSV, 1997, METHOD ENZYMOL, V287, P369; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; MARQUEZINI MV, 1995, CARDIOLOGY, V86, P143, DOI 10.1159/000176860; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Proudfoot AEI, 2000, METH MOL B, V138, P75; Reeves JD, 2000, METH MOL B, V138, P209; ROBERTS CR, 2000, LUNG; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STUCKEY JA, 1992, PROTEINS, V14, P277, DOI 10.1002/prot.340140213; Trkola A, 1999, J VIROL, V73, P6370, DOI 10.1128/JVI.73.8.6370-6379.1999; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; WASTY F, 1993, DIABETOLOGIA, V36, P316, DOI 10.1007/BF00400234; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Wells TNC, 1999, INFLAMM RES, V48, P353, DOI 10.1007/s000110050472; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	43	207	214	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10620	10626		10.1074/jbc.M010867200	http://dx.doi.org/10.1074/jbc.M010867200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11116158	hybrid			2022-12-25	WOS:000167980900009
J	Zaika, A; Irwin, M; Sansome, C; Moll, UM				Zaika, A; Irwin, M; Sansome, C; Moll, UM			Oncogenes induce and activate endogenous p73 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P73; P53 HOMOLOG P73; KINASE C-ABL; P53-RELATED PROTEIN; CELL-LINES; APOPTOTIC RESPONSE; P53-HOMOLOG P73; ADENOVIRUS E1A; DNA-DAMAGE; GENE	The identification of upstream pathways that signal to TP73 is crucial for understanding the biological role of this gene. Since some evidence suggests that TP73 might play a role in tumorigenesis, we asked whether oncogenes can induce and activate endogenous TP73. Here, we show that endogenous p73 alpha and beta proteins are up-regulated in p53-deficient tumor cells in response to overexpressed E2F1, c-Myc, and Elk E2F1, c-Myc, and E1A-mediated p73 up-regulation leads to activation of the p73 transcription function, as shown by p73-responsive reporter activity and by induction of known endogenous p73 target gene products such as p21 and HDM2. Importantly, E2F1-, c-Myc-, and E1A-mediated activation of endogenous p73 induces apoptosis in SaOs-2 cells. Conversely, inactivation of p73 by a dominant negative p73 inhibitor (p73DD), but not by a mutant p73DD, inhibits oncogene-induced apoptosis. These data show that oncogenes can signal to TP73 in vivo. Moreover, in the absence of p53, oncogenes may enlist p73 to induce apoptosis in tumor cells.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Moll, UM (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.							Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Agami R, 1999, NATURE, V399, P809; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Cai YYC, 2000, CARCINOGENESIS, V21, P683, DOI 10.1093/carcin/21.4.683; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Ding Y, 1999, DNA Res, V6, P347, DOI 10.1093/dnares/6.5.347; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gong JG, 1999, NATURE, V399, P806; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Herath NI, 2000, HEPATOLOGY, V31, P601, DOI 10.1002/hep.510310309; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Imyanitov EN, 1999, ONCOGENE, V18, P4640, DOI 10.1038/sj.onc.1202863; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; KOSKINEN PJ, 1993, SEMIN CANCER BIOL, V4, P3; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Loiseau H, 1999, NEUROSCI LETT, V263, P173, DOI 10.1016/S0304-3940(99)00130-5; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Nomoto S, 1998, CANCER RES, V58, P1380; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Peters UR, 1999, CANCER RES, V59, P4233; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Sunahara M, 1998, INT J ONCOL, V13, P319; Tsao H, 1999, CANCER RES, V59, P172; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	59	124	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11310	11316		10.1074/jbc.M005737200	http://dx.doi.org/10.1074/jbc.M005737200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11115495	hybrid			2022-12-25	WOS:000167980900099
J	Arai, A; Nosaka, Y; Kanda, E; Yamamoto, K; Miyasaka, N; Miura, O				Arai, A; Nosaka, Y; Kanda, E; Yamamoto, K; Miyasaka, N; Miura, O			Rap1 is activated by erythropoietin or interleukin-3 and is involved in regulation of beta(1) integrin-mediated hematopoietic cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAP1; ADAPTER PROTEIN CRKL; EXCHANGE FACTOR C3G; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; DEPENDENT ACTIVATION; SUPPRESSOR ACTIVITY; POINT MUTATIONS; HUMAN PLATELETS; GROWTH-FACTOR	The CrkL adaptor protein is involved in signaling from the receptor for erythropoietin (Epo) as well as interleukin (IL)-3 and activates P, integrin-mediated hematopoietic cell adhesion through its interaction with C3G, a guanine nucleotide exchange factor for Rap1, We demonstrate here that Epo as well as IL-3 activates Rap1 in an IL-3-dependent hematopoietic cell line, 32D, expressing the Epo receptor. The cytokine-induced activation of Rap1 was augmented in cells that inducibly overexpress CrkL or C3G. The CrkL-mediated enhancement of cell adhesion was inhibited by expression of a dominant negative mutant of Rap1, Rap1A-17N, whereas an activated mutant of Rap1, Rap1A-63E, activated beta (1) integrin-dependent adhesion of hematopoietic cells. In 32D cells, Rap1 was also activated by phorbol 12-myristate 13-acetate and ionomycin, which also enhanced cell adhesion to fibronectin, whereas U73122, an inhibitor of phospholipase C, inhibited both cytokine-induced activation of Rap1 and cell adhesion. It was also demonstrated that Rap1 as well as CrkL is involved in signaling from the EpoR endogenously expressed in a human leukemic cell line, UT-7, These results suggest that Epo and IL-3 activate Rap1 at least partly through the CrkL-C3G complex as well as through additional pathways most likely involving phospholipase C gamma and strongly implicate Rap1 in regulation of beta (1) integrin-mediated hematopoietic cell adhesion.	Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 113, Japan; Tokyo Med & Dent Univ, Dept Bioregulatory Med & Rheumatol, Bunkyo Ku, Tokyo 113, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.			Miura, Osamu/0000-0002-0981-3054				Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; FELLER SM, 1995, ONCOGENE, V10, P1465; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gotoh A, 1997, ANN HEMATOL, V75, P207, DOI 10.1007/s002770050344; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOMATSU N, 1991, CANCER RES, V51, P341; KOVACH NL, 1995, BLOOD, V85, P159, DOI 10.1182/blood.V85.1.159.bloodjournal851159; LEVESQUE JP, 1995, J EXP MED, V181, P1805, DOI 10.1084/jem.181.5.1805; Levesque JP, 1996, BLOOD, V88, P1168, DOI 10.1182/blood.V88.4.1168.bloodjournal8841168; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; PIZON V, 1988, ONCOGENE, V3, P201; RAO P, 1994, CANCER RES, V54, P777; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; REN HY, 1994, J BIOL CHEM, V269, P19633; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Shibayama H, 1998, CELL IMMUNOL, V187, P27, DOI 10.1006/cimm.1998.1318; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, CANCER RES, V54, P2563; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Uemura N, 1999, ONCOGENE, V18, P3343, DOI 10.1038/sj.onc.1202689; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	50	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10453	10462		10.1074/jbc.M004627200	http://dx.doi.org/10.1074/jbc.M004627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124936	hybrid			2022-12-25	WOS:000167996400113
J	Buckley, KA; Wagstaff, SC; McKay, G; Gaw, A; Hipskind, RA; Bilbe, G; Gallagher, JA; Bowler, WB				Buckley, KA; Wagstaff, SC; McKay, G; Gaw, A; Hipskind, RA; Bilbe, G; Gallagher, JA; Bowler, WB			Parathyroid hormone potentiates nucleotide-induced [Ca2+](i) release in rat osteoblasts independently of G(q) activation or cyclic monophosphate accumulation - A mechanism for localizing systemic responses in bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS EXPRESSION; EXTRACELLULAR NUCLEOTIDES; PROTEIN-KINASE; INTRACELLULAR CA2+; CYTOSOLIC CALCIUM; RECEPTOR; CELLS; PHOSPHORYLATION; CAMP; PATHWAY	The regulation of tissue turnover requires the coordinated activity of both local and systemic factors. Nucleotides exist transiently in the extracellular environment, where they serve as ligands to P2 receptors, Here we report that the localized release of these nucleotides can sensitize osteoblasts to the activity of systemic factors. We have investigated the ability of parathyroid hormone (PTH), a principal regulator of bone resorption and formation, to potentiate signals arising from nucleotide stimulation of UMR-106 clonal rat osteoblasts, PTH receptor activation alone did not lead to [Ca2+](i) elevation in these cells, indicating no G(q) coupling, however, activation of G(q)-coupled P2Y(1) receptors resulted in characteristic [Ca2+](i) release. PTH potentiated this nucleotide-induced Ca2+ release, independently of Ca2+ influx, PTH-(1-31), which activates only G(s), mimicked the actions of PTH-(1-34), whereas PTH-(3-34), which only activates G(q), was unable to potentiate nucleotide-induced [Ca2+](i) release. Despite this coupling of the PTHR to G(s), cAMP accumulation or protein kinase A activation did not contribute to the potentiation, 3-Isobutyl-1-methylxanthine, but not forskolin effectively potentiated nucleotide-induced [Ca2+](i) release, however, further experiments proved that cyclic monophosphates were not involved in the potentiation mechanism. Costimulation of UMR-106 cells with P2Y(1) agonists and PTH led to increased levels of cAMP response element-binding protein phosphorylation and a synergistic effect was observed on endogenous c-fos gene expression following costimulation, In fact the calcium responsive Ca/cAMP response element of the c-fos promoter alone was effective at driving this synergistic gene expression. These findings demonstrate that nucleotides can provide a targeted response to systemic factors, such as PTH, and have important implications for PTH-induced signaling in bone.	Univ Liverpool, Dept Human Anat & Cell Biol, Human Bone Cell Res Grp, Liverpool L69 3GE, Merseyside, England; AstraZeneca Charnwood Biosci, Loughborough LE11 5RH, Leics, England; Inst Genet Mol Montpellier, CNRS, UMR 5535, Montpellier, France; Novartis Pharma AG, CH-4002 Basel, Switzerland	University of Liverpool; AstraZeneca; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Novartis	Buckley, KA (corresponding author), Univ Liverpool, Dept Human Anat & Cell Biol, Human Bone Cell Res Grp, Liverpool L69 3GE, Merseyside, England.			Buckley, Katherine/0000-0002-6585-8943; Wagstaff, Simon/0000-0003-0577-5537				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ArmamentoVillareal R, 1997, J BONE MINER RES, V12, P384, DOI 10.1359/jbmr.1997.12.3.384; BOLAND CJ, 1986, ENDOCRINOLOGY, V118, P980, DOI 10.1210/endo-118-3-980; Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315; Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756-3282(97)00280-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVITELLI R, 1992, ENDOCRINOLOGY, V130, P2392, DOI 10.1210/en.130.4.2392; DASARATHY Y, 1988, J CELL PHYSIOL, V137, P179, DOI 10.1002/jcp.1041370122; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; Dixon CJ, 1997, BRIT J PHARMACOL, V120, P777; Dixon CJ, 1999, BRIT J PHARMACOL, V127, P1680, DOI 10.1038/sj.bjp.0702653; DONAHUE HJ, 1988, J BIOL CHEM, V263, P13522; Du PF, 2000, ENDOCRINE, V12, P25, DOI 10.1385/ENDO:12:1:25; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Jimenez AI, 1999, GLIA, V26, P119, DOI 10.1002/(SICI)1098-1136(199904)26:2<119::AID-GLIA3>3.0.CO;2-D; Jones SJ, 1997, BONE, V21, P393, DOI 10.1016/S8756-3282(97)00174-9; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; KAPLAN AD, 1995, ENDOCRINOLOGY, V136, P1674, DOI 10.1210/en.136.4.1674; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Koshiba M, 1997, P NATL ACAD SCI USA, V94, P831, DOI 10.1073/pnas.94.3.831; Kuntzweiler TA, 1998, DRUG DEVELOP RES, V44, P14, DOI 10.1002/(SICI)1098-2299(199805)44:1<14::AID-DDR3>3.0.CO;2-S; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; PANNABECKER T, 1987, BRAIN RES, V423, P13, DOI 10.1016/0006-8993(87)90819-5; RAISZ LG, 1963, NATURE, V197, P1015, DOI 10.1038/1971015a0; REIMER WJ, 1992, AM J PHYSIOL, V263, pC1040, DOI 10.1152/ajpcell.1992.263.5.C1040; SCHOFL C, 1991, BIOCHEM J, V274, P15, DOI 10.1042/bj2740015; Short AD, 2000, J BIOL CHEM, V275, P1807, DOI 10.1074/jbc.275.3.1807; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Tong YH, 1996, J BIOL CHEM, V271, P8183, DOI 10.1074/jbc.271.14.8183; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; YAMAGUCHI DT, 1987, J BIOL CHEM, V262, P7711	35	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9565	9571		10.1074/jbc.M005672200	http://dx.doi.org/10.1074/jbc.M005672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124938	Green Published, hybrid			2022-12-25	WOS:000167607700125
J	Chen, CC; Fang, M; Majumder, A; Wu, HY				Chen, CC; Fang, M; Majumder, A; Wu, HY			A 72-base pair AT-rich DNA sequence element functions as a bacterial gene silencer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-CHROMOSOME INACTIVATION; COLI BGL PROMOTER; ESCHERICHIA-COLI; LEU-500 PROMOTER; SALMONELLA-TYPHIMURIUM; H-NS; LINE-1 ELEMENTS; CURVED DNA; TRANSCRIPTION; ACTIVATION	We have previously demonstrated that sequential activation of the bacterial ilvIH-leuO-leuABCD gene cluster involves a promoter-relay mechanism. In the current study, we show that the final activation of the leuABCD operon is through a transcriptional derepression mechanism. The leuABCD operon is transcriptionally repressed by the presence of a 318-base pair AT-rich upstream element. LeuO is required for derepressing the repressed leuABCD operon, Deletion analysis of the repressive effect of the 318-bp element has led to the identification of a 72-bp AT-rich (78% A+T) DNA sequence element, AT4, which is capable of silencing a number of unrelated promoters in addition to the leuABCD promoter. AT4-mediated gene silencing is orientation-independent and occurs within a distance of 300 base pairs. Furthermore, an increased gene-silencing effect was observed with:a tandemly repeated AT4 dimer. The possible mechanism of AT4-mediated gene silencing in bacteria is discussed.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Wu, HY (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053617, R01GM053617] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53617] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey JA, 2000, P NATL ACAD SCI USA, V97, P6634, DOI 10.1073/pnas.97.12.6634; CAO LQ, 1994, GENE, V139, P163, DOI 10.1016/0378-1119(94)90750-1; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHEN DR, 1992, P NATL ACAD SCI USA, V89, P8784, DOI 10.1073/pnas.89.18.8784; CHEN DR, 1993, BIOCHEMISTRY-US, V32, P13162, DOI 10.1021/bi00211a027; CHEN DR, 1994, J BACTERIOL, V176, P3757, DOI 10.1128/JB.176.12.3757-3764.1994; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; El Hanafi D, 2000, MOL MICROBIOL, V37, P583; Fang M, 1998, J BIOL CHEM, V273, P29929, DOI 10.1074/jbc.273.45.29929; Fang M, 2000, BIOCHEM BIOPH RES CO, V276, P64, DOI 10.1006/bbrc.2000.3440; Fang M, 1998, J BACTERIOL, V180, P626, DOI 10.1128/JB.180.3.626-633.1998; GIAEVER GN, 1988, BIOPHYS CHEM, V29, P7, DOI 10.1016/0301-4622(88)87020-0; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; HAUGHN GW, 1986, J BACTERIOL, V166, P1113, DOI 10.1128/jb.166.3.1113-1117.1986; Kim SK, 1999, P NATL ACAD SCI USA, V96, P8557, DOI 10.1073/pnas.96.15.8557; Klauck E, 1997, MOL MICROBIOL, V25, P559, DOI 10.1046/j.1365-2958.1997.4911852.x; LILLEY DMJ, 1991, MOL MICROBIOL, V5, P779, DOI 10.1111/j.1365-2958.1991.tb00749.x; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; Lyon MF, 2000, P NATL ACAD SCI USA, V97, P6248, DOI 10.1073/pnas.97.12.6248; MERRICK MJ, 1995, MICROBIOL REV, V59, P604, DOI 10.1128/MMBR.59.4.604-622.1995; MILLER JH, 1980, OPERON, P31; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; MUKAI FH, 1963, P NATL ACAD SCI USA, V50, P140, DOI 10.1073/pnas.50.1.140; Mukerji M, 1997, MOL MICROBIOL, V24, P617, DOI 10.1046/j.1365-2958.1997.3621725.x; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PETTIJOHN DE, 1996, ESCHERICHIA COLI SAL, V1, P158; RICHARDSON SMH, 1988, EMBO J, V7, P1863, DOI 10.1002/j.1460-2075.1988.tb03019.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; Rodionov O, 1999, SCIENCE, V283, P546, DOI 10.1126/science.283.5401.546; Schnetz K, 1996, NUCLEIC ACIDS RES, V24, P2422, DOI 10.1093/nar/24.12.2422; SCHNETZ K, 1995, EMBO J, V14, P2545, DOI 10.1002/j.1460-2075.1995.tb07252.x; SEKIGUCHI M, 1967, P NATL ACAD SCI USA, V58, P2315, DOI 10.1073/pnas.58.6.2315; SHEI GJ, 1995, MOL CELL BIOL, V15, P3496; SHI XL, 1995, J BACTERIOL, V177, P810, DOI 10.1128/jb.177.3.810-814.1995; STUBER D, 1981, P NATL ACAD SCI-BIOL, V78, P167, DOI 10.1073/pnas.78.1.167; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; TRUCKSIS M, 1981, J BACTERIOL, V147, P679, DOI 10.1128/JB.147.2.679-681.1981; Ueguchi C, 1998, J BACTERIOL, V180, P190, DOI 10.1128/JB.180.1.190-193.1998; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; WU HY, 1995, CELL, V82, P445, DOI 10.1016/0092-8674(95)90433-6; WU HY, 1991, J MOL BIOL, V219, P615, DOI 10.1016/0022-2836(91)90658-S; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YAMADA H, 1991, MOL GEN GENET, V230, P332, DOI 10.1007/BF00290685	46	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9478	9485		10.1074/jbc.M010501200	http://dx.doi.org/10.1074/jbc.M010501200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121424	hybrid			2022-12-25	WOS:000167607700113
J	McLoughlin, DM; Standen, CL; Lau, KF; Ackerley, S; Bartnikas, TP; Gitlin, JD; Miller, CCJ				McLoughlin, DM; Standen, CL; Lau, KF; Ackerley, S; Bartnikas, TP; Gitlin, JD; Miller, CCJ			The neuronal adaptor protein X11 alpha interacts with the copper chaperone for SOD1 and regulates SOD1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; AMYOTROPHIC-LATERAL-SCLEROSIS; BINDING DOMAIN PROTEINS; SUPEROXIDE-DISMUTASE; ALZHEIMERS-DISEASE; PDZ DOMAINS; CRYSTAL-STRUCTURE; OXIDATIVE STRESS; GENE; LOCALIZATION	The neuronal adaptor protein X11 alpha: participates in the formation of multiprotein complexes and intracellular trafficking. It contains a series of discrete protein-protein interaction domains including two contiguous C-terminal PDZ domains. We used the yeast two-hybrid system to screen for proteins that interact with the PDZ domains of human X11 alpha, and we isolated a clone encoding domains II and III of the copper chaperone for Cu,Zn-superoxide dismutase-1 (CCS). The X11 alpha /CCS interaction was confirmed in coimmunoprecipitation studies plus glutathione S-transferase fusion protein pull-down assays and was shown to be mediated via PDZ2 of X11 alpha and a sequence within the carboxyl terminus of domain III of CCS. CCS delivers the copper cofactor to the antioxidant superoxide dismutase-1 (SOD1) enzyme and is required for its activity. Overexpression of X11 alpha inhibited SOD1 activity in transfected Chinese hamster ovary cells which suggests that X11 alpha binding to CCS is inhibitory to SOD1 activation. X11 alpha also interacts with another copper-binding protein found in neurons, the Alzheimer's disease amyloid precursor protein. Thus, X11 alpha may participate in copper homeostasis within neurons.	Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Inst Psychiat, Dept Neurol, London SE5 8AF, England; Inst Psychiat, Sect Old Age Psychiat, London SE5 8AF, England; Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	University of London; King's College London; University of London; King's College London; University of London; King's College London; Washington University (WUSTL)	Miller, CCJ (corresponding author), Inst Psychiat, Dept Neurosci, De Crespigny Pk,Denmark Hill, London SE5 8AF, England.	chris.miller@iop.kcl.ac.uk	Miller, Christopher/H-5733-2012	Lau, Kwok-Fai/0000-0002-0193-1152; McLoughlin, Declan/0000-0003-4574-2799; Miller, Christopher/0000-0002-5130-1845	NIDDK NIH HHS [DK44464] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044464, R01DK044464] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; Blanco G, 1998, MAMM GENOME, V9, P473, DOI 10.1007/s003359900800; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Brownlees J, 2000, J CELL SCI, V113, P401; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gamonet F, 1998, EUR J BIOCHEM, V251, P716, DOI 10.1046/j.1432-1327.1998.2510716.x; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hata Y, 1996, J NEUROSCI, V16, P2488; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P1589, DOI 10.1021/bi992822i; Lau KF, 2000, NEUROREPORT, V11, P3607, DOI 10.1097/00001756-200011090-00041; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; McLoughlin DM, 1996, FEBS LETT, V397, P197; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Multhaup G, 1998, BIOCHEMISTRY-US, V37, P7224, DOI 10.1021/bi980022m; Okamoto M, 2000, EUR J NEUROSCI, V12, P3067, DOI 10.1046/j.1460-9568.2000.00200.x; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Okamoto M, 1998, EUR J CELL BIOL, V77, P161, DOI 10.1016/S0171-9335(98)80103-9; Oschkinat H, 1999, NAT STRUCT BIOL, V6, P408, DOI 10.1038/8203; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; White AR, 1999, J NEUROSCI, V19, P9170; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	54	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9303	9307		10.1074/jbc.M010023200	http://dx.doi.org/10.1074/jbc.M010023200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11115513	hybrid			2022-12-25	WOS:000167607700091
J	Shogomori, H; Futerman, AH				Shogomori, H; Futerman, AH			Cholera toxin is found in detergent-insoluble rafts/domains at the cell surface of hippocampal neurons but is internalized via a raft-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; RECEPTOR-MEDIATED ENDOCYTOSIS; CAVEOLAE-LIKE DOMAINS; COATED PIT FORMATION; INTRACELLULAR TRAFFICKING; MEMBRANE DOMAINS; PLASMA-MEMBRANE; LIPID COMPLEXES; GOLGI-APPARATUS; UP-REGULATION	A number of studies have demonstrated that cholera toxin (CT) is found in detergent-insoluble, cholesterol-enriched domains (rafts) in various cells, including neurons. We now demonstrate that even though CT is associated with these domains at the cell surface of cultured hippocampal neurons, it is internalized via a raft-independent mechanism, at both early and late stages of neuronal development. CT transport to the Golgi apparatus, and its subsequent degradation, is inhibited by hypertonic medium (sucrose), and by chlorpromazine; the former blocks clathrin recruitment, and the latter causes aberrant endosomal accumulation of clathrin. Moreover, both internalization of the transferrin receptor (Tf-R), which occurs via a clathrin-dependent mechanism, and CT internalization, are inhibited to a similar extent by sucrose. In contrast, the cholesterol-binding agents filipin and methyl-beta -cyclodextrin have no effect on the rate of CT or Tf-R internalization. Finally, once internalized, CT becomes more detergent-soluble, and chlorpromazine treatment renders internalized CT completely detergent-soluble. We propose two models to explain how, despite being detergent-insoluble at the cell surface, CT is nevertheless internalized via a raft-independent mechanism in hippocampal neurons.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Eckhardt, Erik/G-1567-2010	Futerman, Anthony/0000-0003-0013-0115				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Boldin SA, 2000, J BIOL CHEM, V275, P9905, DOI 10.1074/jbc.275.14.9905; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Burack MA, 2000, NEURON, V26, P465, DOI 10.1016/S0896-6273(00)81178-2; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; FRA AM, 1994, J BIOL CHEM, V269, P30745; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Goslin K., 1998, CULTURING NERVE CELL, P339; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; JOHNSON LS, 1994, J CELL PHYSIOL, V158, P29, DOI 10.1002/jcp.1041580105; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; Ledesma MD, 1999, EMBO J, V18, P1761, DOI 10.1093/emboj/18.7.1761; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; McGraw T. E., 1999, CURRENT PROTOCOLS CE; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PARTON RG, 1992, J CELL BIOL, V119, P123, DOI 10.1083/jcb.119.1.123; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; Prinetti A, 2000, J BIOL CHEM, V275, P11658, DOI 10.1074/jbc.275.16.11658; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; Schapiro FB, 1998, AM J PHYSIOL-CELL PH, V274, pC319, DOI 10.1152/ajpcell.1998.274.2.C319; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Schwarz A, 1996, BBA-REV BIOMEMBRANES, V1286, P247, DOI 10.1016/S0304-4157(96)00011-1; Shogomori H, 1999, FEBS LETT, V458, P107, DOI 10.1016/S0014-5793(99)01146-1; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sofer A, 1996, J CELL SCI, V109, P2111; SOFER A, 1995, J BIOL CHEM, V270, P12117, DOI 10.1074/jbc.270.20.12117; Sofer A, 1996, J NEUROCHEM, V67, P2134; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Winckler B, 1999, NEURON, V23, P637, DOI 10.1016/S0896-6273(01)80021-0	50	133	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9182	9188		10.1074/jbc.M009414200	http://dx.doi.org/10.1074/jbc.M009414200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11113142	hybrid			2022-12-25	WOS:000167607700076
J	Sun, HZ; Li, HY; Mason, AB; Woodworth, RC; Sadler, PJ				Sun, HZ; Li, HY; Mason, AB; Woodworth, RC; Sadler, PJ			Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SERUM TRANSFERRIN; N-LOBE; H-1-NMR SPECTROSCOPY; CRYSTAL-STRUCTURE; METAL-BINDING; IRON; NMR; COMPLEXES; CELLS; PHARMACOKINETICS	Several bismuth compounds are currently used as antiulcer drugs, but their mechanism of action is not well established. Proteins are thought to be target sites. In this work we establish that the competitive binding of Bi3+ to the blood serum proteins albumin and transferrin, as isolated proteins and in blood plasma, can be monitored via observation of H-1 and C-13 NMR resonances of isotopically labeled [epsilon-C-13]Met transferrin. We show that Met(132) in the I132M recombinant N-lobe transferrin mutant is a sensitive indicator of N-lobe metal binding. Bi3+ binds to the specific Fe3+ sites of transferrin and the observed shifts of Met resonances suggest that Bi3+ induces similar conformational changes in the N-lobe of transferrin in aqueous solution and plasma. Bi3+ binding to albumin is nonspecific and Cys(34) is not a major binding site, which is surprising because Bi3+ has a high affinity for thiolate sulfur. This illustrates that the potential target sites for metals (in this case Bi3+) in proteins depend not only on their presence but also on their accessibility. Bi3+ binds to transferrin in preference to albumin both in aqueous solution and in blood plasma.	Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China	University of Edinburgh; University of Vermont; University of Hong Kong	Sadler, PJ (corresponding author), Univ Edinburgh, Dept Chem, Kings Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.		Mason, Anne B/A-6754-2008; /D-3123-2009	/0000-0001-6697-6899				ABRAMS MJ, 1993, SCIENCE, V261, P725, DOI 10.1126/science.8102010; Aisen P, 1998, MET IONS BIOL SYST, V35, P585; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; BALDWIN GS, 1993, COMP BIOCHEM PHYS B, V106, P203, DOI 10.1016/0305-0491(93)90028-4; BAXTER GF, 1989, PHARM J, V243, P805; Beatty EJ, 1996, BIOCHEMISTRY-US, V35, P7635, DOI 10.1021/bi960684g; Beatty EJ, 1997, PROTEIN ENG, V10, P583, DOI 10.1093/protein/10.5.583; Bierer DW, 1990, REV INFECT DIS, V12, P3; Brock J. H., 1985, Topics in Molecular and Structural Biology, V7, P183; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CHASTEEN ND, 1977, COORDIN CHEM REV, V22, P1; CHASTEEN ND, 1990, IRON TRANSPORT STORA, P69; CHRISTODOULOU J, 1994, EUR J BIOCHEM, V225, P363, DOI 10.1111/j.1432-1033.1994.00363.x; CHRISTODOULOU J, 1995, FEBS LETT, V376, P1, DOI 10.1016/0014-5793(95)01231-2; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; Guo ML, 2000, BIOCHEMISTRY-US, V39, P10023, DOI 10.1021/bi000798z; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Harris D., 1989, IRON CARRIERS IRON P, P239; He QY, 1999, BIOCHEM J, V344, P881, DOI 10.1042/0264-6021:3440881; JANATOVA J, 1968, J BIOL CHEM, V243, P3612; KOZAK RW, 1986, TRENDS BIOTECHNOL, V4, P259, DOI 10.1016/0167-7799(86)90189-7; KRATZ F, 1994, J BIOL CHEM, V269, P2581; KUBAL G, 1992, BIOCHEM J, V285, P711, DOI 10.1042/bj2850711; KUBAL G, 1992, J AM CHEM SOC, V114, P1117, DOI 10.1021/ja00029a066; Kurokawa H, 1999, J BIOL CHEM, V274, P28445, DOI 10.1074/jbc.274.40.28445; LAMBERT JR, 1991, REV INFECT DIS    S8, V13, P691; LAMBERT JR, 1997, ALIMENT PHARM THERAP, V11, pS27; LEIBMAN A, 1979, BLOOD, V53, P1058; LEWIS SD, 1980, BIOCHEMISTRY-US, V19, P6129, DOI 10.1021/bi00567a028; Li HY, 1997, J ANAL ATOM SPECTROM, V12, P1111, DOI 10.1039/a700269f; Li HY, 1996, J BIOL CHEM, V271, P9483, DOI 10.1074/jbc.271.16.9483; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; MARTIN RB, 1992, ALUMINUM BIOL MED, P18; Mason A B, 1991, Protein Expr Purif, V2, P214, DOI 10.1016/1046-5928(91)90074-S; MASON AB, 1993, BIOCHEMISTRY-US, V32, P5472, DOI 10.1021/bi00071a025; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Peters T., 1996, ALL ALBUMIN BIOCH GE; RAO N, 1990, PHARMACEUT RES, V7, P237, DOI 10.1023/A:1015813826597; RAO N, 1990, PHARMACEUT RES, V7, P188, DOI 10.1023/A:1015841105215; ROSKAMS AJ, 1990, P NATL ACAD SCI USA, V87, P9024, DOI 10.1073/pnas.87.22.9024; SADLER PJ, 1992, EUR J BIOCHEM, V205, P631, DOI 10.1111/j.1432-1033.1992.tb16821.x; Sadler PJ, 1996, CHEM-EUR J, V2, P701, DOI 10.1002/chem.19960020615; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; SLIKKERVEER A, 1989, MED TOXICOL ADV DRUG, V4, P303, DOI 10.1007/BF03259915; SUMMERS SP, 1994, INORG CHEM, V33, P88, DOI 10.1021/ic00079a017; Sun HZ, 1999, CHEM REV, V99, P2817, DOI 10.1021/cr980430w; Sun HZ, 1998, FEBS LETT, V422, P315, DOI 10.1016/S0014-5793(98)00034-9; Sun HZ, 1999, BIOCHEM J, V337, P105, DOI 10.1042/0264-6021:3370105; WELCH MJ, 1980, INORGANIC CHEM BIOL, P121; ZUCCOLA HJ, 1993, THESIS GEORGIA I TEC	52	51	57	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8829	8835		10.1074/jbc.M004779200	http://dx.doi.org/10.1074/jbc.M004779200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11110794	Green Published, hybrid			2022-12-25	WOS:000167607700031
J	Trent, MS; Pabich, W; Raetz, CRH; Miller, SI				Trent, MS; Pabich, W; Raetz, CRH; Miller, SI			A PhoP/PhoQ-induced lipase (PagL) that catalyzes 3-O-deacylation of lipid a precursors in membranes of Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION MASS-SPECTROMETRY; RESISTANT PMRA-MUTANTS; ESCHERICHIA-COLI; PHOP-PHOQ; RHIZOBIUM-LEGUMINOSARUM; NMR-SPECTROSCOPY; GENE-EXPRESSION; REGULATED GENES; OUTER-MEMBRANE; BOUND ENZYME	Pathogenic bacteria modify the structure of the lipid A portion of their lipopolysaccharide in response to environmental changes. Some lipid A modifications are important for virulence and resistance to cationic antimicrobial peptides. The two-component system PhoP/PhoQ plays a central role in regulating lipid A modification. We now report the discovery of a PhoP/PhoQ-activated gene (pagL) in Salmonella typhimurium, encoding a deacylase that removes the R-3-hydroxymyristate moiety attached at position 3 of certain lipid A precursors. The deacylase gene (pagL) was identified by assaying for loss of deacylase activity in extracts of 14 random TnphoA::pag insertion mutants. The pagL gene encodes a protein of 185 amino acid residues unique to S. typhimurium and closely related organisms such as Salmonella typhi. Heterologous expression of pagL in Escherichia coli on plasmid pWLP21 results in loss of the R-3-hydroxymyristate moiety at position 3 in similar to 90% of the lipid A molecules but does not inhibit cell growth. PagL is synthesized with a 20-amino acid N-terminal signal peptide and is localized mainly in the outer membrane, as judged by assays of separated S. typhimurium membranes and by SDS-polyacrylamide gel analysis of membranes from E. coli cells that overexpress PagL. The function of PagL is unknown, given that S. typhimurium mutants lacking pagL display no obvious phenotypes, but PagL might nevertheless play a role in pathogenesis if it serves to modulate the cytokine response of an infected animal host.	Univ Washington, Dept Microbiol & Med, Seattle, WA 98195 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	University of Washington; University of Washington Seattle; Duke University	Miller, SI (corresponding author), Univ Washington, Dept Microbiol & Med, K-140 Hlth Sci Bldg,Box 357710, Seattle, WA 98195 USA.	millersi@u.washington.edu			NIAID NIH HHS [AI-30479, 1 F32 AI1056-01] Funding Source: Medline; NIGMS NIH HHS [GM-51310] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Ernst RK, 1999, J INFECT DIS, V179, pS326, DOI 10.1086/513850; Ernst RK, 1999, SCIENCE, V286, P1561, DOI 10.1126/science.286.5444.1561; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Groisman EA, 1998, BIOESSAYS, V20, P96, DOI 10.1002/(SICI)1521-1878(199801)20:1<96::AID-BIES13>3.0.CO;2-3; Gunn JS, 1998, MICROB PATHOGENESIS, V25, P77, DOI 10.1006/mpat.1998.0217; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KARIBIAN D, 1991, INT J MASS SPECTROM, V111, P273, DOI 10.1016/0168-1176(91)85060-Y; KUMADA H, 1995, J BACTERIOL, V177, P2098, DOI 10.1128/jb.177.8.2098-2106.1995; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Rakeman JL, 1999, J BACTERIOL, V181, P3096, DOI 10.1128/JB.181.10.3096-3104.1999; RAY BL, 1984, J BIOL CHEM, V259, P4852; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Skorupski K, 1996, GENE, V169, P47, DOI 10.1016/0378-1119(95)00793-8; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; van Deuren M, 2000, CLIN MICROBIOL REV, V13, P144, DOI 10.1128/CMR.13.1.144-166.2000; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Vescovi EG, 1997, J BIOL CHEM, V272, P1440, DOI 10.1074/jbc.272.3.1440; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	70	162	171	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9083	9092		10.1074/jbc.M010730200	http://dx.doi.org/10.1074/jbc.M010730200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11108722	hybrid			2022-12-25	WOS:000167607700064
J	Baldwin, GS; Hollande, F; Yang, ZY; Karelina, Y; Paterson, A; Strang, R; Fourmy, D; Neumann, G; Shulkes, A				Baldwin, GS; Hollande, F; Yang, ZY; Karelina, Y; Paterson, A; Strang, R; Fourmy, D; Neumann, G; Shulkes, A			Biologically active recombinant human Progastrin(6-80) contains a tightly bound calcium ion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; MOLECULAR-CLONING; COLORECTAL-CARCINOMA; CHROMOSOMAL LOCALIZATION; FUNCTIONAL EXPRESSION; GENE-EXPRESSION; TRANSGENIC MICE; HUMAN GASTRIN; CELL-LINES; RECEPTOR	Evidence is accumulating that gastrin precursors may act as growth factors for the colonic mucosa in vivo. The aims of this study were to prepare recombinant human progastrin(6-80) and to investigate its structure and biological activities in vitro. Human progastrin(6-80) was expressed in Escherichia coli as a glutathione S-transferase fusion protein. After thrombin cleavage progastrine(6-80) was purified by reverse phase high pressure liquid chromatography and characterized by radioimmunoassay, amino acid sequencing, and mass spectrometry, Assays for metal ions by atomic emission spectroscopy revealed the presence of a single tightly bound calcium ion. Progastrin(6-80) at concentrations in the pM to nM range stimulated proliferation of the conditionally transformed mouse colon cell line YAMC. The observations that progastrin(6-80) did not bind to either the cholecystokinin (CCK)-A or the gastrin/CCK-B receptor expressed in COS cells and that antagonists selective for either receptor did not reverse the proliferative effects of progastrin(6-80) suggested that progastrin(6-80) stimulated proliferation independently of either the CCK-A or the gastrin/CCK-B receptor. We conclude that recombinant human progastrin(6-80) is biologically active and contains a single calcium ion. With the exception of the well known zinc-dependent polymerization of insulin and proinsulin, this is the first report of selective, high affinity binding of metal ions to a prohormone.	Austin Hosp, Univ Dept Surg, Heidelberg, Vic 3084, Australia; Univ Melbourne, Russell Grimwade Sch Biochem, Parkville, Vic 3052, Australia; La Trobe Univ, Dept Biochem, Bundoora, Vic 3083, Australia; Univ Montpellier, Fac Pharm, F-34059 Montpellier, France; CHU Rangueil, INSERM, U151, F-31054 Toulouse, France	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; La Trobe University; Universite de Montpellier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Baldwin, GS (corresponding author), A&RMC, Dept Surg, AUstin Campus,Studley Rd, Heidelberg, Vic 3084, Australia.		Fourmy, Daniel/AAE-3703-2019; Hollande, Frederic/GLS-4120-2022; Hollande, Frederic/E-3133-2013	Fourmy, Daniel/0000-0001-9910-4827; Hollande, Frederic/0000-0002-7046-8392; Baldwin, Graham/0000-0002-0944-8747				Baldwin GS, 1998, GUT, V42, P581, DOI 10.1136/gut.42.4.581; Bishop L, 1998, GASTROENTEROLOGY, V115, P1154, DOI 10.1016/S0016-5085(98)70086-1; Blundell T L, 1971, Recent Prog Horm Res, V27, P1; BOEL E, 1983, P NATL ACAD SCI-BIOL, V80, P2866, DOI 10.1073/pnas.80.10.2866; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CICCOTOSTO GD, 1995, GASTROENTEROLOGY, V109, P1142, DOI 10.1016/0016-5085(95)90572-3; DEREWENDA U, 1989, BRIT MED BULL, V45, P4, DOI 10.1093/oxfordjournals.bmb.a072320; DEWEERTH A, 1993, BIOCHEM BIOPH RES CO, V194, P811, DOI 10.1006/bbrc.1993.1894; Dockray GJ, 1996, PHYSIOL REV, V76, P767, DOI 10.1152/physrev.1996.76.3.767; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GALLAGHER SR, 1988, CURRENT PROTOCOLS PR; GARDNER JD, 1987, PHYSL GASTROINTESTIN, V2, P1109; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; HUEBNER VD, 1991, J BIOL CHEM, V266, P12223; HUTTON JC, 1982, BIOCHEM J, V204, P171, DOI 10.1042/bj2040171; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; MANTAMADIOTIS T, 1994, BIOCHEM BIOPH RES CO, V201, P1382, DOI 10.1006/bbrc.1994.1856; Moore C, 1997, DNA SEQUENCE, V8, P39, DOI 10.3109/10425179709020883; MORLEY JS, 1965, NATURE, V207, P1356, DOI 10.1038/2071356a0; PEGGION E, 1983, BIOPOLYMERS, V22, P2443, DOI 10.1002/bip.360221110; PEGGION E, 1984, BIOPOLYMERS, V23, P1225, DOI 10.1002/bip.360230707; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; REHFELD JF, 1994, EUR J BIOCHEM, V223, P765, DOI 10.1111/j.1432-1033.1994.tb19051.x; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 1996, CANCER RES, V56, P4111; SINGH P, 2000, AM J PHYSIOL, V278, pC390; SIPOS T, 1970, BIOCHEMISTRY-US, V9, P2766, DOI 10.1021/bi00816a003; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TORDA AE, 1985, BIOCHEMISTRY-US, V24, P1720, DOI 10.1021/bi00328a023; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang W, 1997, PEPTIDES, V18, P1295, DOI 10.1016/S0196-9781(97)00206-4; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Yang ZY, 1998, CANCER LETT, V124, P187, DOI 10.1016/S0304-3835(97)00476-X	36	65	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7791	7796		10.1074/jbc.M009985200	http://dx.doi.org/10.1074/jbc.M009985200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113148	hybrid			2022-12-25	WOS:000167474900018
J	Hotze, EM; Wilson-Kubalek, EM; Rossjohn, J; Parker, MW; Johnson, AE; Tweten, RK				Hotze, EM; Wilson-Kubalek, EM; Rossjohn, J; Parker, MW; Johnson, AE; Tweten, RK			Arresting pore formation of a cholesterol-dependent cytolysin by disulfide trapping synchronizes the insertion of the transmembrane ss-sheet from a prepore intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL ALPHA-HEMOLYSIN; PERFRINGOLYSIN-O; MEMBRANE INSERTION; FORMING TOXINS; MECHANISM; AEROLYSIN; PROTEIN; COMPLEX; CHANNELS; AUREUS	Perfringolysin O (PFO), a member of the cholesterol-dependent cytolysin family of pore-forming toxins, forms large oligomeric complexes comprising up to 50 monomers. In the present study, a disulfide bridge was introduced between cysteine-substituted serine 190 of transmembrane hairpin 1 (TMH1) and cysteine-substituted glycine 57 of domain 2 of PFO. The resulting disulfide-trapped mutant (pFO(C190-C57)) was devoid of hemolytic activity and could not insert either of its transmembrane beta -hairpins (TMHs) into the membrane unless the disulfide was reduced. Both the size of the oligomer formed on the membrane and its rate of formation were unaffected by the oxidation state of the Cys(190)- Cys(57) disulfide bond; thus, the disulfide-trapped PFO was assembled into a prepore complex on the membrane. The conversion of this prepore to the pore complex was achieved by reducing the C190-C57 disulfide bond, PFOC190-C57 that was allowed to form the prepore prior to the reduction of the disulfide exhibited a dramatic increase in the rate of PFO-dependent hemolysis and the membrane insertion of its TMHs when compared with toxin that had the disulfide reduced prior mixing the toxin with membranes. Therefore, the rate-limiting step in pore formation is prepore assembly, not TMH insertion. These data demonstrate that the prepore is a legitimate intermediate during the insertion of the large transmembrane beta -sheet of the PFO oligomer. Finally, the PFO TMHs do not appear to insert independently, but instead their insertion is coupled.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; St Vincents Inst Med Res, Prot Crystallog Lab, Fitzroy, Vic 3065, Australia	University of Oklahoma System; University of Oklahoma Health Sciences Center; Scripps Research Institute; St. Vincent's Institute of Medical Research; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; St. Vincent's Institute of Medical Research	Tweten, RK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, BMSB,Rm 1053,940 Stanton L Young Blvd, Oklahoma City, OK 73190 USA.	rod-tweten@ouhsc.edu	Parker, Michael W/F-9069-2013; Johnson, Arthur E/G-3457-2012; Rossjohn, Jamie/F-9032-2013	Parker, Michael W/0000-0002-3101-1138; Rossjohn, Jamie/0000-0002-2020-7522	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI037657, R01AI037657] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37657, R01 AI037657] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alouf JE, 1999, BACTERIAL TOXINS COM, P443; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BHAKDI S, 1984, BACTERIAL PROTEIN TO, V24, P173; CHAKRABORTY T, 1990, INFECT IMMUN, V58, P2127, DOI 10.1128/IAI.58.7.2127-2132.1990; DARST SA, 1988, J MOL BIOL, V203, P269, DOI 10.1016/0022-2836(88)90107-6; GOTTSCHALK S, 1995, GENE THER, V2, P498; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; Heuck AP, 2000, MOL CELL, V6, P1233, DOI 10.1016/S1097-2765(00)00119-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; Moniatte M, 1996, FEBS LETT, V384, P269, DOI 10.1016/0014-5793(96)00328-6; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Prigent D., 1976, BIOCHIM BIOPHYS ACTA, V433, P422; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; ROSSJOHN J, 1999, BACTERIAL TOXINS COM, P406; Sellman BR, 1997, MOL MICROBIOL, V23, P551, DOI 10.1046/j.1365-2958.1997.d01-1876.x; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WATSON KC, 1974, BIOCHEM J, V140, P95, DOI 10.1042/bj1400095; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x	29	112	113	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8261	8268		10.1074/jbc.M009865200	http://dx.doi.org/10.1074/jbc.M009865200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11102453	hybrid			2022-12-25	WOS:000167474900082
J	LeHoux, JG; Dupuis, G; Lefebvre, A				LeHoux, JG; Dupuis, G; Lefebvre, A			Control of CYP11B2 gene expression through differential regulation of its promoter by atypical and conventional protein kinase C isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADRENOCORTICAL-CELLS; ADRENAL GLOMERULOSA CELLS; ANGIOTENSIN-II; CA2+-REGULATED EXPRESSION; ALDOSTERONE SYNTHASE; PHOSPHORYLATION; STEROIDOGENESIS; MUTAGENESIS; ACTIVATION; POTASSIUM	We reported previously that the protein kinase C (PKC) inhibitor GF109203X stimulated the hamster CYP11B2 promoter activity in transfected NCI-H295 cells, PKC alpha, -epsilon, and -zeta were detected in hamster adrenal tons glomerulosa and NCI-H295 cells, and PKC theta in NCI-H295 cells, 12-O-Tetradecanoylphorbol-13-acetate (TPA) inhibited basal and stimulated cytochrome P450 aldosterone synthase mRNA expression by angiotensin (AII), dibutyryl cyclic adenosine 3':5'-monophosphate (Bt(2)cAMP), or KCl in NCI-H295 cells. Basal CYP11B2 promoter activity was inhibited in cells cotransfected with constitutively active (CA) PKC alpha, -epsilon, and -theta mutants, whereas it was increased with CA-PKC zeta. Dominant negative (DN) PKC alpha, -theta, -epsilon, and -zeta mutants stimulated the promoter activity, AII-, KCl-, and Bt(2)cAMP-stimulatory effects were abolished in cells cotransfected with CA-PKC alpha, -epsilon or -theta. The effect of Bt(2)cAMP was abolished by CA-PKC zeta but AII and KCl were still able to enhance the promoter activity, DN-PKC alpha, -epsilon, -theta, or -zeta did not inhibit these effects, Go6976 enhanced promoter activity, providing further evidence that PKC alpha was involved. Various CYP11B2 promoter constructs were used to identify the area associated with TPA and PKC inhibition. TPA and CA-PKC alpha, -epsilon, or -theta abolished the effects of AII, KCl, and Bt(2)cAMP on the activity of -102 and longer constructs. In summary, our findings suggest that the hamster CYP11B2 gene is under differential control by conventional (alpha) and atypical (zeta) PKC.	Univ Sherbrooke, Fac Med, Dept Biochem, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	LeHoux, JG (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochem, Sherbrooke, PQ J1H 5N4, Canada.							Bird IM, 1998, ENDOCR RES, V24, P345, DOI 10.3109/07435809809032614; Bird IM, 1998, J CLIN ENDOCR METAB, V83, P1592, DOI 10.1210/jc.83.5.1592; BIRD IM, 1995, ENDOCRINOLOGY, V136, P5677, DOI 10.1210/en.136.12.5677; CALVERT R, 1994, ANAT RECORD, V240, P358, DOI 10.1002/ar.1092400308; Clyne CD, 1997, MOL ENDOCRINOL, V11, P638, DOI 10.1210/me.11.5.638; Coulombe N, 1996, ENDOCR RES, V22, P653, DOI 10.1080/07435809609043759; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; GIROUD CJP, 1956, P SOC EXP BIOL MED, V92, P154; GUILLON G, 1995, ENDOCRINOLOGY, V136, P1285, DOI 10.1210/en.136.3.1285; HANJNOCZKY H, 1992, ENDOCRINOLOGY, V130, P2230; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeHoux JG, 1998, J MOL ENDOCRINOL, V20, P183, DOI 10.1677/jme.0.0200183; LEHOUX JG, 1992, ENDOCRINOLOGY, V131, P1874, DOI 10.1210/en.131.4.1874; LeHoux JG, 1996, J ENDOCRINOL, V149, P341, DOI 10.1677/joe.0.1490341; LEHOUX JG, 1996, ADV MOL CEL, V14, P149; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NAKANO S, 1990, ENDOCRINOLOGY, V126, P125, DOI 10.1210/endo-126-1-125; NATARAJAN R, 1994, MOL CELL ENDOCRINOL, V101, P59, DOI 10.1016/0303-7207(94)90219-4; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; Reyland ME, 1998, AM J PHYSIOL-CELL PH, V275, pC780, DOI 10.1152/ajpcell.1998.275.3.C780; REYLAND ME, 1993, MOL ENDOCRINOL, V7, P1021, DOI 10.1210/me.7.8.1021; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Smith RD, 1999, ENDOCRINOLOGY, V140, P1385, DOI 10.1210/en.140.3.1385; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; Veronneau S, 1996, J STEROID BIOCHEM, V57, P125, DOI 10.1016/0960-0760(95)00249-9; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725	31	37	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8021	8028		10.1074/jbc.M009495200	http://dx.doi.org/10.1074/jbc.M009495200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11115506	hybrid			2022-12-25	WOS:000167474900050
J	McGee, MP; Chou, T				McGee, MP; Chou, T			Surface-dependent coagulation enzymes - Flow kinetics of factor Xa generation on live cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; BLOOD-COAGULATION; EXTRAVASCULAR COAGULATION; FACTOR-VII; ACTIVATION; PROTEINS; MONOLAYERS; REACTOR; COMPLEX; TRANSITIONS	The initial surface reactions of the extrinsic coagulation pathway on live cell membranes were examined under flow conditions. Generation of activated coagulation factor X (fXa) was measured on spherical monolayers of epithelial cells with a total surface area of 41-47 cma expressing tissue factor (TF) at 225 fmol/cm(2). Concentrations of reactants and product were monitored as a function of time with radiolabeled proteins and a chromogenic substrate at resolutions of 2-8 s. At physiological concentrations of fVIIa and fX, the reaction rate was 3.05 +/- 0.75 fmol fXa/s/cm(2), independent of flux, and 10 times slower than that expected for collision-limited reactions. Rates were also independent of surface fVIIa concentrations within the range 0.6-25 fmol/cm(2). The transit time of fX activated on the reaction chamber was prolonged relative to transit times of nonreacting tracers or preformed fXa. Membrane reactions were modeled using a set of nonlinear kinetic equations and a lagged normal density curve to track the expected surface concentration of reactants for various hypothetical reaction mechanisms. The experimental results were theoretically predicted only when the models used a slow intermediate reaction step, consistent with surface diffusion. These results provide evidence that the transfer of substrate within the membrane is rate-limiting in the kinetic mechanisms leading to initiation of blood coagulation by the TF pathway.	Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC 27157 USA; Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90095 USA	Wake Forest University; Wake Forest Baptist Medical Center; University of California System; University of California Los Angeles	McGee, MP (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Med, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	mmcgee@wfubmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057936] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57936] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDELMAN D, 1987, J CHEM PHYS, V86, P3673, DOI 10.1063/1.451970; BACH R, 1986, BIOCHEMISTRY-US, V25, P2134; Bagatolli LA, 2000, BIOPHYS J, V78, P290, DOI 10.1016/S0006-3495(00)76592-1; BASSINGT.JB, 1966, CIRC RES, V18, P398, DOI 10.1161/01.RES.18.4.398; Bassingthwaighte J. B., 1984, HDB PHYSL 2, VIV, P549; BERG CH, 1983, RANDOM WALKS BIOL; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BILLY D, 1995, J BIOL CHEM, V270, P1029, DOI 10.1074/jbc.270.3.1029; Brinkhous KM, 1941, AM J PHYSIOL, V132, P0666, DOI 10.1152/ajplegacy.1941.132.3.666; CARSON SD, 1987, THROMB RES, V47, P379, DOI 10.1016/0049-3848(87)90453-1; CHANG P, 1995, AM J HEMATOL, V50, P79, DOI 10.1002/ajh.2830500202; CHERRY RJ, 1979, BIOCHIM BIOPHYS ACTA, V559, P289, DOI 10.1016/0304-4157(79)90009-1; COLMAN RW, 1994, HEMOSTASIS THROMBOSI; CRONE C, 1963, ACTA PHYSL SCAND, V181, P103; CURRY FE, 1984, HDB PHYSL, V4, P314; Discher DE, 1996, BIOPHYS J, V71, P1680, DOI 10.1016/S0006-3495(96)79424-9; DOBROSKI DR, 1998, THROMBOSIS HEMORRHAG, P837; DRAKE TA, 1989, AM J PATHOL, V134, P1087; DVORAK HF, 1985, SCIENCE, V227, P1059, DOI 10.1126/science.3975602; DZUNG TL, 1992, J BIOL CHEM, V267, P15447; DZUNG TL, 1998, AM J PHYSIOL, V274, pH769; EATON BM, 1981, AM J PHYSIOL, V241, pC106, DOI 10.1152/ajpcell.1981.241.3.C106; Ellison EH, 1998, BIOCHEMISTRY-US, V37, P7997, DOI 10.1021/bi973118+; FAIR DS, 1987, J BIOL CHEM, V262, P11692; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gir S, 1996, ANN BIOMED ENG, V24, P394, DOI 10.1007/BF02660888; GRABOWSKI EF, 1993, BLOOD, V81, P3265; KARINO T, 1987, ANN NY ACAD SCI, V516, P422, DOI 10.1111/j.1749-6632.1987.tb33063.x; Kim KS, 1998, BIOPHYS J, V75, P2274, DOI 10.1016/S0006-3495(98)77672-6; KOP JMM, 1984, J BIOL CHEM, V259, P3993; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; LEE AG, 1998, BIOCHIM BIOPHYS ACTA, V1376, P297; London F, 1996, BIOCHEMISTRY-US, V35, P12146, DOI 10.1021/bi960097v; LUAN P, 1995, BIOCHEMISTRY-US, V34, P9874, DOI 10.1021/bi00031a008; MACFARLANE RG, 1964, NATURE, V202, P498, DOI 10.1038/202498a0; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.physchem.42.1.171; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; MCGEE MP, 1989, BLOOD, V74, P1583; MCGEE MP, 1994, J EXP MED, V179, P1847, DOI 10.1084/jem.179.6.1847; MCGEE MP, 1992, J BIOL CHEM, V267, P24333; McGee MP, 1999, THROMB HAEMOSTASIS, V82, P93; McGee MP, 1998, BIOCHEM J, V330, P533; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; PERAN S, 1986, BIOCHIM BIOPHYS ACTA, V856, P231, DOI 10.1016/0005-2736(86)90032-5; PLOPLIS VA, 1987, J BIOL CHEM, V262, P9503; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; REPKE D, 1990, P NATL ACAD SCI USA, V87, P7623, DOI 10.1073/pnas.87.19.7623; ROTHBERGER H, 1984, J CLIN INVEST, V73, P1524, DOI 10.1172/JCI111358; SANDERS NL, 1985, BLOOD, V66, P204; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; SCHMIDSCHOENBEIN GW, 1975, MICROVASC RES, V10, P153, DOI 10.1016/0026-2862(75)90003-5; Seaton Barbara A., 1996, P355; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; ZWEIFACH BW, 1979, CARDIOVASCULAR PHYSL, V3, P216	57	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7827	7835		10.1074/jbc.M003275200	http://dx.doi.org/10.1074/jbc.M003275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11108710	hybrid, Green Submitted			2022-12-25	WOS:000167474900023
J	Yan, SZ; Beeler, JA; Chen, YB; Shelton, RK; Tang, WJ				Yan, SZ; Beeler, JA; Chen, YB; Shelton, RK; Tang, WJ			The regulation of type 7 adenylyl cyclase by its C1b region and Escherichia coli peptidylprolyl isomerase, SlyD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; CYTOSOLIC DOMAINS; CATALYTIC MECHANISM; DISCRETE REGIONS; PROTEIN-KINASE; IDENTIFICATION; FORSKOLIN; FAMILY; SITE; G(S-ALPHA)	Mammalian membrane-bound adenylyl cyclase consists of two highly conserved cytoplasmic domains (C1a and C2a) separated by a less conserved connecting region, C1b, and one of two transmembrane domains, M2, The C1a and C2a domains form a catalytic core that can be stimulated by forskolin and the stimulatory G protein subunit alpha (G alpha (s)), In this study, we analyzed the regulation of type 7 adenylyl cyclase (AC7) by C1b. The C1a, G1b, and C2a domains of AC7 were purified separately. Escherichia coli SlyD protein, a cis-trans peptidylprolyl isomerase (PPIase), copurifies with AC7 C1b (7C1b), SlyD protein can inhibit the G alpha (s)- and/or forskolin-activated activity of both soluble and membrane-bound AC7, Mutant forms of SlyD with reduced PPIase activity are less potent in the inhibition of AC7 activity. Interestingly, different isoforms of mammalian membrane-bound adenylyl cyclase can be either inhibited or stimulated by SlyD protein, raising the possibility that mammalian PPIase may regulate enzymatic activity of mammalian adenylyl cyclase. Purified 7C1b-SlyD complex has a greater inhibitory effect on AC7 activity than SlyD alone. This inhibition by 7C1b is abolished in a 7C1b mutant in which a conserved glutamic acid (amino acid residue 582) is changed to alanine, Inhibition of adenylyl cyclase activity by 7C1b is further confirmed by using 7C1b purified from an E. coli slyD-deficient strain. This inhibitory activity of AC7 is also observed with the 28-mer peptides derived from a region of C1b conserved in AC7 and AC2 but is not observed with a peptide derived from the corresponding region of AC6. This inhibitory activity exhibited by the C1b domain may result from the interaction of 7C1b with 7C1a and 7C2a and may serve to hold AC7 in the basal nonstimulated state.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA	University of Chicago; Icahn School of Medicine at Mount Sinai	Tang, WJ (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St,MC0926, Chicago, IL 60637 USA.			Tang, Wei-Jen/0000-0002-8267-8995; Beeler, Jeff/0000-0002-1344-1337	NIDDK NIH HHS [DK38761] Funding Source: Medline; NIGMS NIH HHS [GM53459] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053459] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONI FA, 1995, J BIOL CHEM, V270, P28055; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Chang M, 2000, J BIOL CHEM, V275, P7021, DOI 10.1074/jbc.275.10.7021; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; Doronin S, 1998, J BIOL CHEM, V273, P32416, DOI 10.1074/jbc.273.49.32416; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hottenrott S, 1997, J BIOL CHEM, V272, P15697, DOI 10.1074/jbc.272.25.15697; HOTTENROTT S, 1999, THESIS PHILIPPS U MA; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; Lee JP, 1999, P NATL ACAD SCI USA, V96, P3251, DOI 10.1073/pnas.96.6.3251; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; Lu PJ, 1999, NATURE, V399, P784; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Mitterauer T, 1998, BIOCHEMISTRY-US, V37, P16183, DOI 10.1021/bi981441m; Roof WD, 1997, MOL MICROBIOL, V25, P1031, DOI 10.1046/j.1365-2958.1997.5201884.x; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Scholich K, 1999, SCIENCE, V283, P1328, DOI 10.1126/science.283.5406.1328; Scholich K, 1997, P NATL ACAD SCI USA, V94, P2915, DOI 10.1073/pnas.94.7.2915; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; YAN SZ, 2001, IN PRESS METHODS ENZ; Yoshimura M, 1996, MOL PHARMACOL, V50, P43; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	46	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8500	8506		10.1074/jbc.M010361200	http://dx.doi.org/10.1074/jbc.M010361200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113152	hybrid			2022-12-25	WOS:000167474900111
J	Chimploy, K; Mathews, CK				Chimploy, K; Mathews, CK			Mouse ribonucleotide reductase control - Influence of substrate binding upon interactions with allosteric effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS; LARGE SUBUNIT; RECOMBINANT MOUSE; DEOXYRIBONUCLEOTIDE; PURIFICATION; ASSAY; GENE	Using ribonucleotide reductase encoded by vaccinia virus as a model for the mammalian enzyme, our laboratory developed an assay that allows simultaneous monitoring of the reduction of ADP, CDP, GDP, and UDP. That study found ADP reduction to be specifically inhibited by ADP itself. To learn whether this effect is significant for cellular regulation, we have analyzed recombinant mouse ribonucleotide reductase, We report that allosteric control properties originally described in single-substrate assays operate also under our four-substrate assay conditions. Three distinctions from the vaccinia enzyme were seen: 1) higher sensitivity to allosteric modifiers; 2) higher activity with UDP as substrate; and 3) significant inhibition by ADP of GDP reduction as well as that of ADP itself. Studies of the effects of ADP and other substrates upon binding of effecters indicate that binding of ribonucleoside diphosphates at the catalytic site influences dNTP binding at the specificity site. We also examined the activities of hybrid ribonucleotide reductases, composed of a mouse subunit combined with a vaccinia subunit. As previously reported, a vaccinia R1/mouse R2 hybrid has low but significant activity. Surprisingly, a mouse R1/vaccinia R2 hybrid was more active than either mouse R1/R2 or vaccinia R1/R2, possibly explaining why mutations affecting vaccinia ribonucleotide reductase have only small effects upon viral DNA replication.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 55134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson J, 2000, J BIOL CHEM, V275, P19443, DOI 10.1074/jbc.M001490200; BJORKLUND S, 1993, P NATL ACAD SCI USA, V90, P11322, DOI 10.1073/pnas.90.23.11322; CHILD SJ, 1990, VIROLOGY, V174, P625, DOI 10.1016/0042-6822(90)90119-C; DAVIS R, 1994, J BIOL CHEM, V269, P23171; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; Hendricks SP, 1998, J BIOL CHEM, V273, P29512, DOI 10.1074/jbc.273.45.29512; Hendricks SP, 1997, J BIOL CHEM, V272, P2861, DOI 10.1074/jbc.272.5.2861; HOWELL ML, 1992, J BIOL CHEM, V267, P1705; HOWELL ML, 1993, J BIOL CHEM, V268, P7155; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; RAJAGOPAL I, 1995, J BIOL CHEM, V270, P27415, DOI 10.1074/jbc.270.46.27415; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SHAPIRO HS, 1968, HDB BIOCH, pH46; SLABAUGH MB, 1993, J BIOL CHEM, V268, P17803; SLABAUGH MB, 1984, J VIROL, V52, P501, DOI 10.1128/JVI.52.2.501-506.1984; TENGELSEN LA, 1988, VIROLOGY, V164, P121, DOI 10.1016/0042-6822(88)90627-7; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361	21	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7093	7100		10.1074/jbc.M006232200	http://dx.doi.org/10.1074/jbc.M006232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11099495	hybrid			2022-12-25	WOS:000167442900034
J	Gardoni, F; Bellone, C; Cattabeni, F; Di Luca, M				Gardoni, F; Bellone, C; Cattabeni, F; Di Luca, M			Protein kinase c activation modulates alpha-calmodulin kinase II bindiag to NR2A subunit of N-methyl-D-aspaatttt receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTORS; NMDA RECEPTOR; POSTSYNAPTIC DENSITY; PHOSPHORYLATION; CAMKII; BRAIN; EXPRESSION; CALCIUM; NEURONS	The N-methyl-D-aspartate (NMDA) receptor subunits NR2 possess extended intracellular C-terminal domains by which they can directly interact with a large number of postsynaptic density (PSD) proteins involved in synaptic clustering and signaling. We have previously shown that PSD-associated alpha -calmodulin kinase II (alpha CaMKII) binds with high affinity to the C-terminal domain of the NR2A subunit, Here, we show that residues 1412-1419 of the cytosolic tail of NR2A are critical for alpha CaMKII binding, and we identify, by site directed mutagenesis, PKC-dependent phosphorylation of NR2A(Ser(1416)) as a key mechanism in inhibiting alpha CaMKII-binding and promoting dissociation of alpha CaMKII(.)NR2A complex. In addition, we show that stimulation of PKC activity in hippocampal slices either with phorbol esters or with the mGluRs specific agonist trans-1-amino-1,3-cyclopentanedicarboxylic acid (t-ACPD) decreases alpha CaMKII binding to NMDA receptor complex. Thus, our data provide clues on understanding the molecular basis of a direct cross-talk between alpha CaMKII and PKC pathways in the postsynaptic compartment.	Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy	University of Milan	Gardoni, F (corresponding author), Univ Milan, Inst Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	fabrizio.gardoni@unimi.it	Gardoni, Fabrizio/A-3135-2009; DiLuca, Monica/A-7632-2012	Gardoni, Fabrizio/0000-0003-4598-5563; DiLuca, Monica/0000-0003-2298-615X; bellone, camilla/0000-0002-6774-6275	Telethon [946] Funding Source: Medline	Telethon(Fondazione Telethon)		Caputi A, 1997, J NEUROCHEM, V68, P2523; Caputi A, 1999, EUR J NEUROSCI, V11, P141, DOI 10.1046/j.1460-9568.1999.00414.x; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; Ehlers MD, 1996, CURR OPIN CELL BIOL, V8, P484, DOI 10.1016/S0955-0674(96)80024-X; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Hall RA, 1997, J BIOL CHEM, V272, P4135, DOI 10.1074/jbc.272.7.4135; Hisatsune C, 1997, J BIOL CHEM, V272, P20805, DOI 10.1074/jbc.272.33.20805; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; Lu WY, 2000, J NEUROSCI, V20, P4452, DOI 10.1523/JNEUROSCI.20-12-04452.2000; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; Meyer T, 2000, TRENDS CELL BIOL, V10, P238, DOI 10.1016/S0962-8924(00)01764-5; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Strack S, 2000, J BIOL CHEM, V275, P25061, DOI 10.1074/jbc.C000319200; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Suen P, 1998, MOL BRAIN RES, V59, P215, DOI 10.1016/S0169-328X(98)00157-0; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; WANG JH, 1992, P NATL ACAD SCI USA, V17, P4600; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Zheng X, 1999, P NATL ACAD SCI USA, V96, P15262, DOI 10.1073/pnas.96.26.15262	32	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7609	7613		10.1074/jbc.M009922200	http://dx.doi.org/10.1074/jbc.M009922200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11104776	hybrid			2022-12-25	WOS:000167442900101
J	Kern, B; Shen, JH; Starbuck, M; Karsenty, G				Kern, B; Shen, JH; Starbuck, M; Karsenty, G			Cbfa1 contributes to the osteoblast-specific expression of type I collagen genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; CLEIDOCRANIAL DYSPLASIA; ALPHA-2(I) COLLAGEN; REGULATORY FACTORS; COL1A1 PROMOTER; BONE-FORMATION; TRANSCRIPTION; MOUSE; ALPHA-1(I); ELEMENTS	Type I collagen is composed of two chains, alpha1(I) and alpha2(I), encoded by two distinct genes, the alpha1(I) and alpha2(I) collagen genes, that are highly expressed in osteoblasts. In most physiological situations, alpha1(I) and alpha2(I) collagen expression is coregulated, suggesting that identical transcription factors control their expression. Here, we studied the role of Cbfa1, an osteoblast-specific transcription factor, in the control of alpha1(I) and alpha2(I) collagen expression in osteoblasts. A consensus Cbfa1-binding site, termed OSE2, is present at the same location in the alpha1(I) collagen promoter at approximately -1347 base pairs (bp) of the rat, mouse, and human genes Cbfa1 can bind to this site, as demonstrated by electrophoretic mobility shift assay (EMSA) and supershift experiments using an anti-Cbfa1 antibody, Mutagenesis of the alpha1(I) collagen OSE2 at - 1347 bp reduced the activity of a alpha1(I) collagen promoter fragment 2- to 3-fold. Moreover, multimers of this OSE2 at -1347bp confer osteoblast-specific activity to a minimum alpha1(I) collagen promoter fragment in DNA transfection experiments as well as in transgenic mice, An additional Cbfa1-binding element is present in the alpha1(I) collagen promoter of mouse, rat, and human at approximately position -372, This site binds Cbfa1 only weakly and does not act as a cis-acting activator of transcription when tested in DNA transfection experiments. Similar to alpha1(I) collagen, the mouse alpha2(I) collagen gene contains multiple OSE2 sites, of which one is conserved across multiple species. In EMSA, Cbfa1 binds to this site and multimers of this alpha2(I) OSE2 element confer osteoblast-specific activity to the minimum alpha1(I) collagen promoter in DNA transfection experiments. Thus, our results suggest that Cbfa1 is one of the positive regulators of the osteoblast-specific expression of both type I collagen genes.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01AR45548] Funding Source: Medline; NIDCR NIH HHS [R01DE11290] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; GEHRONROBEY P, 1996, PRINCIPLES BONE BIOL, P155; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KURIKAWA M, 1996, J BIOL CHEM, V271, P16870; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Moore DD, 1995, GLOB MOB SURV; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PEPLING ME, 1995, P NATL ACAD SCI USA, V92, P9087, DOI 10.1073/pnas.92.20.9087; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; SANDBERG M, 1988, DEV BIOL, V130, P324, DOI 10.1016/0012-1606(88)90438-1; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; TADIC T, 1998, BONE, V23, pS539; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	25	260	279	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7101	7107		10.1074/jbc.M006215200	http://dx.doi.org/10.1074/jbc.M006215200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11106645	hybrid			2022-12-25	WOS:000167442900035
J	Linke, T; Wilkening, G; Sadeghlar, F; Mozcall, H; Bernardo, K; Schuchman, E; Sandhoff, K				Linke, T; Wilkening, G; Sadeghlar, F; Mozcall, H; Bernardo, K; Schuchman, E; Sandhoff, K			Interfacial regulation of acid ceramidase activity - Stimulation of ceramide degradation by lysosomal lipids and sphingolipid activator proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAPOSIN-D; SAP-B; PHOSPHOLIPIDS; BINDING; PEPTIDE; DISEASE; LIVER	The lysosomal degradation of ceramide is catalyzed by acid ceramidase and requires sphingolipid activator proteins (SAP) as cofactors in vivo. The aim of this study was to investigate how ceramide is hydrolyzed by acid ceramidase at the water-membrane interface in the presence of sphingolipid activator proteins in a liposomal assay system. The degradation of membrane-bound ceramide was significantly increased both in the absence and presence of SAP-D when anionic lysosomal phospholipids such as bis(monoacylglycero)phosphate, phosphatidylinositol, and dolichol phosphate were incorporated into substrate-bearing liposomes. Higher ceramide degradation rates were observed in vesicles with increased membrane curvature. Dilution assays indicated that acid ceramidase remained bound to the liposomal surface during catalysis. Not only SAP-D, but also SAP-C and SAP-A, were found to be stimulators of ceramide hydrolysis in the presence of anionic phospholipids. This finding was confirmed by cell culture studies, in which SAP-A, -C, and -D reduced the amount of ceramide storage observed in fibroblasts of a patient suffering from prosaposin deficiency. Strong protein-lipid interactions were observed for both SAP-D and acid ceramidase in surface plasmon resonance experiments. Maximum binding of SAP-D and acid ceramidase to lipid bilayers occurred at pH 4.0. Our results demonstrate that anionic, lysosomal lipids are required for efficient hydrolysis of ceramide by acid ceramidase.	Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Inst Med Mikrobiol & Hyg, D-50935 Cologne, Germany	University of Bonn; Icahn School of Medicine at Mount Sinai	Sandhoff, K (corresponding author), Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.	sandhoff@uni-bonn.de						AL BJM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P245, DOI 10.1016/0005-2760(89)90274-9; ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; AZUMA N, 1994, ARCH BIOCHEM BIOPHYS, V311, P354, DOI 10.1006/abbi.1994.1248; BECKER E, 1999, THESIS U BONN GERMAN; BLEISTEIN J, 1980, H-S Z PHYSIOL CHEM, V361, P595; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1483, P199, DOI 10.1016/S1388-1981(99)00188-2; Burkhardt JK, 1997, EUR J CELL BIOL, V73, P10; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CRISTOMANOU H, 1996, BIOL CHEM HOPPESEYLE, V367, P879; DANG QQ, 1982, LIPIDS, V17, P798, DOI 10.1007/BF02535356; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hauser H., 1993, PHOSPHOLIPIDS HDB, P603; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; LEIPPE M, 1992, EMBO J, V11, P3501, DOI 10.1002/j.1460-2075.1992.tb05432.x; Linke T, 2000, METHOD ENZYMOL, V311, P201; LINKE T, 2000, IN PRESS BIOL CHEM; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; MOSER HW, 1995, METABOLIC MOL BASES, P2589; Nag K, 1999, AM J PHYSIOL-LUNG C, V277, pL1179, DOI 10.1152/ajplung.1999.277.6.L1179; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PONTING CP, 1994, PROTEIN SCI, V3, P359; Qi XY, 1998, BIOCHEMISTRY-US, V37, P11544, DOI 10.1021/bi980785+; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SLATER JL, 1992, STRUCTURE BIOL MEMBR, P175; STREMMEL W, 1976, H-S Z PHYSIOL CHEM, V357, P803, DOI 10.1515/bchm2.1976.357.1.803; Tatti M, 1999, EUR J BIOCHEM, V263, P486, DOI 10.1046/j.1432-1327.1999.00521.x; Tatulian S. A., 1993, PHOSPHOLIPIDS HDB, P511; VACCARO AM, 1990, BIOCHIM BIOPHYS ACTA, V1033, P73, DOI 10.1016/0304-4165(90)90196-4; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114; Wilkening G, 2000, J BIOL CHEM, V275, P35814, DOI 10.1074/jbc.M006568200; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271; Wrobe D, 2000, J INHERIT METAB DIS, V23, P63, DOI 10.1023/A:1005603014401; WU YY, 1994, J BIOL CHEM, V269, P16276; ZSCHOCHE A, 1994, EUR J BIOCHEM, V222, P83, DOI 10.1111/j.1432-1033.1994.tb18844.x	41	99	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5760	5768		10.1074/jbc.M006846200	http://dx.doi.org/10.1074/jbc.M006846200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11104761	hybrid			2022-12-25	WOS:000167115100050
J	Boerner, JL; Danielsen, A; McManus, MJ; Maihle, NJ				Boerner, JL; Danielsen, A; McManus, MJ; Maihle, NJ			Activation of Rho is required for ligand-independent oncogenic signaling by a mutant epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASE; SWISS 3T3 FIBROBLASTS; ACTIN STRESS FIBERS; PHOSPHORYLATION; BINDING; TRANSFORMATION; SRC; PP125(FAK); PAXILLIN	Mutations in the epidermal growth factor receptor have been identified in several human tumor types, including gliomas, These receptor mutants have deletions in their extracellular ligand-binding domains and are, therefore, no longer regulated by ligand, resulting in constitutive activation of the receptor kinase, These mutants have been proposed to transduce oncogenic signals via ligand-independent signaling pathways. Avian viral homologues of these oncogenic epidermal growth factor receptors exhibit structurally homologous deletions and form tumors in chickens. One such mutant, S3v-ErbB, transforms fibroblasts in vitro, and transformation has been correlated with the formation of a novel tyrosine phosphoprotein complex, V-ErbB-mediated complex formation and transformation have been shown to occur independently of Ras activation. The major aims of this study are to further characterize this ligand-independent v-ErbB oncogenic signaling pathway. Here we show that both vErbB-mediated phosphoprotein complex formation and transformation are inhibited by a dominant negative mutant of Rho. This inhibition is specific for dominant negative Rho; dominant negative mutants of Rac and Cdc42 have no effect on transformation or on tyrosine phosphorylation of the phosphoprotein complex. Based on these observations, we propose that S3v-ErbB stimulates a Rho-dependent tyrosine kinase, resulting in complex formation and ultimately oncogenic transformation.	Mayo Clin & Mayo Fdn, Dept Biochem, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Maihle, NJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem, Tumor Biol Program, 200 1st St SW, Rochester, MN 55905 USA.				NCI NIH HHS [CA75238, CA75926, CA79808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA075926, R01CA079808, R29CA075238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; Boerner JL, 2000, J CELL SCI, V113, P935; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CONNOLLY DC, 1994, J VIROL, V68, P6804, DOI 10.1128/JVI.68.10.6804-6810.1994; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; Flinn HM, 1996, J CELL SCI, V109, P1133; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Gaston I, 2000, EXP HEMATOL, V28, P77, DOI 10.1016/S0301-472X(99)00130-7; Harden N, 1996, MOL CELL BIOL, V16, P1896; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; Johnson JL, 1996, J BIOL CHEM, V271, P21574, DOI 10.1074/jbc.271.35.20981; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P4868, DOI 10.1128/MCB.8.11.4868; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; McManus MJ, 2000, J BIOL CHEM, V275, P35328, DOI 10.1074/jbc.M005399200; Movilla N, 1999, MOL CELL BIOL, V19, P7870; PERONA R, 1993, ONCOGENE, V8, P1285; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Wang Z, 1999, J BIOL CHEM, V274, P33807, DOI 10.1074/jbc.274.47.33807	38	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3691	3695		10.1074/jbc.M003801200	http://dx.doi.org/10.1074/jbc.M003801200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11110781	hybrid			2022-12-25	WOS:000166784900092
J	Ferrari, D; La Sala, A; Chiozzi, P; Morelli, A; Falzoni, S; Girolomoni, G; Idzko, M; Dichmann, S; Norgauer, J; Di Virgilio, F				Ferrari, D; La Sala, A; Chiozzi, P; Morelli, A; Falzoni, S; Girolomoni, G; Idzko, M; Dichmann, S; Norgauer, J; Di Virgilio, F			The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release	FASEB JOURNAL			English	Article						extracellular nucleotides; nucleotide receptors; IL-1 beta; TNF-alpha; inflammation	EPIDERMAL LANGERHANS CELLS; EXTRACELLULAR ATP; MICROGLIAL CELLS; PLASMA-MEMBRANE; GATED CHANNELS; MACROPHAGES; LYMPHOCYTES; MODULATION; ADENOSINE; MECHANISM	We investigated the expression of purinoceptors in human dendritic cells, providing functional, pharmacological, and biochemical evidence that immature and mature cells express P2Y and P2X subtypes, coupled to increase in the intracellular Ca2+ membrane depolarization, and secretion of inflammatory cytokines. The ATP-activated Ca2+ change was biphasic, with a fast release from intracellular stores and a delayed influx across the plasma membrane. A prolonged exposure to ATP was toxic to dendritic cells that swelled, lost typical dendrites, became phase lucent, detached from the substrate, and eventually died. These changes were highly suggestive of expression of the cytotoxic receptor P2X(7), as confirmed by ability of dendritic cells to become permeant to membrane impermeant dyes such as Lucifer yellow or ethidium bromide. The P2X(7) receptor ligand 2',3'-(4benzoyl-benzoyl)-ATP was a better agonist then ATP for Ca2+ increase and plasma membrane depolarization. Oxidized ATP, a covalent blocker of P2X receptors, and the selective P2X(7) antagonist KN-62 inhibited both permeabilization and Ca2+ changes induced by ATP. The following purinoceptors were expressed by immature and mature dendritic cells: P2Y(1), P2Y(2), P2Y(5), P2Y(11) and P2X(1), P2X(4), P2X(7). Finally, stimulation of LPS-matured cells with ATP triggered release of IL-1 beta and TNF-alpha. Purinoceptors may provide a new avenue to modulation of dendritic cells function.	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy; IRCCS, Immunol Lab, Ist Dermopat Immacolata, Rome, Italy; Univ Freiburg, Dept Pneumol, Freiburg, Germany; Univ Freiburg, Dept Dermatol, Freiburg, Germany	University of Ferrara; University of Ferrara; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Freiburg; University of Freiburg	Ferrari, D (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via L Borsari 46, I-44100 Ferrara, Italy.		GIROLOMONI, Giampiero/AAC-3405-2022; la Sala, Andrea/A-3228-2009; Di Virgilio, Francesco/J-3754-2018; DI VIRGILIO, Francesco/O-4634-2019; Ferrari, Davide/F-5644-2015	la Sala, Andrea/0000-0003-1268-6516; Di Virgilio, Francesco/0000-0003-3566-1362; DI VIRGILIO, Francesco/0000-0003-3566-1362; Ferrari, Davide/0000-0002-5727-9204; Chiozzi, Paola/0000-0003-4952-334X; Falzoni, Simonetta/0000-0002-6594-0357	Telethon [961] Funding Source: Medline	Telethon(Fondazione Telethon)		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; APASOV S, 1995, IMMUNOL REV, V146, P5, DOI 10.1111/j.1600-065X.1995.tb00680.x; Apasov SG, 1997, J IMMUNOL, V158, P5095; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V3, P118; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; CHAKER MB, 1984, J INVEST DERMATOL, V82, P496, DOI 10.1111/1523-1747.ep12261031; Chvatchko Y, 1996, IMMUNITY, V5, P275, DOI 10.1016/S1074-7613(00)80322-2; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Dichmann S, 2000, BLOOD, V95, P973, DOI 10.1182/blood.V95.3.973.003k47_973_978; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; DIVIRGILIO F, 2000, IN PRESS BLOOD; DIVIRGILIO F, 2000, IN PRESS HDB EXPT PH; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1996, J IMMUNOL, V156, P1531; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 1997, J IMMUNOL, V159, P1451; FERRARI D, 1994, AM J PHYSIOL-CELL PH, V267, pC886, DOI 10.1152/ajpcell.1994.267.4.C886; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gargett CE, 1997, BRIT J PHARMACOL, V120, P1483, DOI 10.1038/sj.bjp.0701081; GIROLOMONI G, 1993, J INVEST DERMATOL, V100, P282, DOI 10.1111/1523-1747.ep12469769; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; HICKMAN SE, 1994, BLOOD, V84, P2452; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Jiang QS, 1998, J CELL BIOL, V143, P645, DOI 10.1083/jcb.143.3.645; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Liu QH, 1999, FEBS LETT, V445, P402, DOI 10.1016/S0014-5793(99)00161-1; Ma WY, 1999, NATURE, V400, P894, DOI 10.1038/23743; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Mutini C, 1999, J IMMUNOL, V163, P1958; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Perregaux DG, 1998, J IMMUNOL, V160, P2469; Ralevic V, 1998, PHARMACOL REV, V50, P413; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sikora A, 1999, J IMMUNOL, V163, P558; Solini A, 1999, J CELL SCI, V112, P297; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; SUPRENANT A, 1996, SCIENCE, V272, P735; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225	54	124	131	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2466	2476		10.1096/fj.00-0031com	http://dx.doi.org/10.1096/fj.00-0031com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099464				2022-12-25	WOS:000165723400016
J	Krucher, NA; Zygmunt, A; Mazloum, N; Tamrakar, S; Ludlow, JW; Lee, MYWT				Krucher, NA; Zygmunt, A; Mazloum, N; Tamrakar, S; Ludlow, JW; Lee, MYWT			Interaction of the retinoblastoma protein (pRb) with the catalytic subunit of DNA polymerase delta (p125)	ONCOGENE			English	Article						DNA polymerase delta; retinoblastoma; cyclin dependent kinase; cell cycle	LARGE-T-ANTIGEN; TRANSCRIPTION FACTOR; REPRESS TRANSCRIPTION; HISTONE DEACETYLASE; BINDING PROTEIN; E1A PROTEINS; RB; PRODUCT; CYCLINS; GENE	The retinoblastoma gene product (pRb) interacts with many cellular proteins to function in the control of cell division, differentiation, and apoptosis, Several pRb binding proteins complex with pRb through an amino acid sequence called the LXCXE motif, The catalytic subunit of DNA polymerase delta (p125) contains a LXCXE motif, To further study the biochemical function of this polymerase, we sought to determine if p125 interacts with pRb, Experiments using GST-pRb fusion proteins showed that p125 from breast epithelial (MCF10A) cell extracts associates with pRb. In addition, GST-p125 fusion proteins bound pRb from the same cell extracts. The pRb that associated with GST-p125 was largely unphosphorylated, Coimmunoprecipitation experiments using cell cycle synchronized cells revealed that p125 and pRb form a complex predominantly during G(1) phase, the phase during which pRb is mostly unphosphorylated. In vitro phosphorylation of GST-pRb by the cyclin dependent kinases reduced the ability of p125 to associate with GST-pRb, Addition of the LXCXE containing protein SV40 large T antigen to GST-pRb blocks the ability of p125 to associate with pRb, suggesting that it may be through a LXCXE sequence by which p125 interacts with pRb, Finally, in vitro polymerase assays demonstrate that GST-pRb fusion protein stimulates DNA polymerase delta activity.	Pace Univ Pleasantville, Dept Biol Sci, Pleasantville, NY 10570 USA; New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA; Univ Rochester, Dept Biochem & Biophys, Rochester, NY USA	Pace University; New York Medical College; University of Rochester	Krucher, NA (corresponding author), Pace Univ Pleasantville, Dept Biol Sci, 861 Bedford Rd, Pleasantville, NY 10570 USA.				NHGRI NIH HHS [NIHGM31973] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; JONES RE, 1990, J BIOL CHEM, V265, P12782; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MO J, 2000, BIOCHEMISTRY-US, V39, P2745; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH DH, 1988, MOL CELL BIOL, V8, P3883; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Takemura M, 1997, ONCOGENE, V15, P2483, DOI 10.1038/sj.onc.1201431; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Woitach JT, 1998, NAT GENET, V19, P371, DOI 10.1038/1258; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561	36	8	8	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5464	5470		10.1038/sj.onc.1203930	http://dx.doi.org/10.1038/sj.onc.1203930			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114723				2022-12-25	WOS:000165396100006
J	Shisheva, A; Rusin, B; Ikonomov, OC; DeMarco, C; Sbrissa, D				Shisheva, A; Rusin, B; Ikonomov, OC; DeMarco, C; Sbrissa, D			Localization and insulin-regulated relocation of phosphoinositide 5-kinase PIKfyve in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; FAB1P; KINASE; DOMAIN; DISSOCIATION; 3-KINASE; CYTOSKELETON; MECHANISM; SUBSTRATE; TRANSPORT	The mammalian phosphoinositide kinase PIKfyve catalyzes the synthesis of phosphatidylinositol 5-P and phosphatidylinositol 3,5-P-2, thought essential in cellular functions, including membrane trafficking. To discern the intracellular loci of PIKfyve products' formation, we have examined the localization of PIKfyve protein versus enzymatic activity and a possible acutely regulated redistribution in 3T3-L1 adipocytes. Subcellular fractions of resting cells that were positive for immunoreactive PIKfyve, such as cytosol (similar to 76%), internal structures (low density microsomal fraction (LDM), composed of recycling endosomes, GLUT4 storage compartment, Golgi, and cytoskeletal elements) (similar to 20%), and plasma membrane ((similar to)4%), expressed enzymatically active PIKfyve. While the presence of a FYVE finger in PIKfyve predicts early endosome targeting, density gradient sedimentation, immunoadsorption, and fluorescence microscopy analyses segregated the LDM-associated PIKfyve from the membranes of the recycling endosomes and GLUT4. PIKfyve fluorescence staining largely coincided with trans-Golgis network/multivesicular body markers, indicating PIKfyve's role in the late endocytic/biosynthetic pathways. A subfraction of particulate PIKfyve resisted nonionic detergent treatment, implying association with cytoskeletal structures, previously found positive for key members of the insulin signaling cascade. Upon acute stimulation of 3T3-L1 adipocytes with insulin or pervanadate, a portion of the cytosolic PIKfyve was recruited onto LDM, which was coupled with a commensurate increase of PIKfyve lipid kinase activity and an electrophoretic mobility shift. We suggest the recruited PIKfyve specifies the site and timing of phosphoinositide signals that are relevant to the acute insulin action.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	Wayne State University	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.	ashishev@moose.med.wayne.edu						Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; FEY EG, 1984, P NATL ACAD SCI-BIOL, V81, P4409, DOI 10.1073/pnas.81.14.4409; FORD T, 1994, ANAL BIOCHEM, V220, P360, DOI 10.1006/abio.1994.1350; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; GRIFFITHS G, 1990, J CELL SCI, V95, P441; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; IKONOMOV OC, 1999, EXPRESSION GENETICS; Ito K, 1999, BIOCHEM BIOPH RES CO, V257, P206, DOI 10.1006/bbrc.1999.0430; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Sbrissa D, 2000, DIABETES, V49, pA338; Sbrissa D, 2000, DIABETES, V49, pA15; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHISHEVA A, 1993, ENDOCRINOLOGY, V133, P1562, DOI 10.1210/en.133.4.1562; Shisheva A, 1999, MOL CELL BIOL, V19, P623; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SHISHEVA A, 1995, EUR J CELL BIOL, V68, P143; SHISHEVA A, 2001, INSULIN SIGNALING CU, P189; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; White MF, 1998, RECENT PROG HORM RES, V53, P119; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597	44	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11859	11869		10.1074/jbc.M008437200	http://dx.doi.org/10.1074/jbc.M008437200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11112776	hybrid			2022-12-25	WOS:000168081800059
J	Kim, KP; Rafter, JD; Bittova, L; Han, SK; Snitko, Y; Munoz, NM; Leff, AR; Cho, WH				Kim, KP; Rafter, JD; Bittova, L; Han, SK; Snitko, Y; Munoz, NM; Leff, AR; Cho, WH			Mechanism of human group V phospholipase A(2) (PLA(2))-induced leukotriene biosynthesis in human neutrophils - A potential role of heparan sulfate binding in PLA(2) internalization and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIZED MIXED LIPOSOMES; ARACHIDONIC-ACID; P388D(1) MACROPHAGES; MAST-CELLS; GROUP-IIA; PROSTAGLANDIN PRODUCTION; MEMBRANE-BINDING; RELEASE; BOVINE; ENZYMES	Human group V phospholipase A(2) (hVPLA(2)) has been shown to have high activity to elicit leukotriene production in human neutrophils (Han, S. K., Kim, K. P., Koduri, R., Bittdva, L., Munoz, N. M., Leff, A. R., Wilton, D. C., Gelb, M. H., and Cho, W. (1999) J. Biol. Chem. 274, 11881-11888). To determine the mechanism by which hVPLA(2) interacts with cell membranes to induce leukotriene formation, we mutated surface cationic residues and a catalytic residue of hVPLA(2) and measured the interactions Of mutants with model membranes, immobilized heparin, and human neutrophils. These studies showed that cationic residues, Lys(7), Lys(11), and Arg(34), constitute:a part of the interfacial binding surface of hVPLA(2), which accounts for its moderate preference for anionic membranes. Additionally, hVPLA(2) binds heparin with high affinity and has a well defined heparin-binding site. The site is composed of Arg(100), Lys(101), Lys(107), Arg(108), and Arg(111), and is spatially distinct from its interfacial binding surface. Importantly, the activities of the mutants to hydrolyze cell membrane phospholipids and induce leukotriene biosynthesis, when enzymes were added exogenously to neutrophils, correlated with their activities on phosphatidylcholine membranes but not with their affinities for anionic membranes and heparin. These results indicate that hVPLA(2) acts directly on the outer plasma membranes of neutrophils to release fatty acids and lysophospholipids. Further studies suggest that products of hVPLA(2) hydrolysis trigger the cellular leukotriene production by activating cellular enzymes involved in leukotriene formation. Finally, the temporal and spatial resolution of exogenously added hVPLA(2) and mutants suggests that binding to cell surface heparan sulfate proteoglycans is important for the internalization and clearance of cell surface-bound hVPLA(2).	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Cho, WH (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.		Bittova, Lenka/K-4375-2015	Bittova, Lenka/0000-0002-3556-5234; Kim, Kwang Pyo/0000-0003-0095-3787	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399, R01HL046368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56399, HL46368] Funding Source: Medline; NIGMS NIH HHS [GM52598] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 2000, J BIOL CHEM, V275, P4783, DOI 10.1074/jbc.275.7.4783; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DUA R, 1995, J BIOL CHEM, V270, P263, DOI 10.1074/jbc.270.1.263; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; Enomoto A, 2000, BIOCHEM BIOPH RES CO, V276, P667, DOI 10.1006/bbrc.2000.3468; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kim KP, 2000, BIOCHEM J, V348, P643, DOI 10.1042/0264-6021:3480643; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Lee BI, 1999, BIOCHEMISTRY-US, V38, P7811, DOI 10.1021/bi9906017; Munoz NM, 2000, HYBRIDOMA, V19, P171, DOI 10.1089/02724570050031220; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; ROGERS J, 1992, BIOCHEMISTRY-US, V31, P6056, DOI 10.1021/bi00141a014; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Snitko Y, 1999, BIOCHEMISTRY-US, V38, P7803, DOI 10.1021/bi990600e; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WU SK, 1994, ANAL BIOCHEM, V221, P152, DOI 10.1006/abio.1994.1391; WU SK, 1993, BIOCHEMISTRY-US, V32, P13902, DOI 10.1021/bi00213a020; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P12400, DOI 10.1021/bi962972i; YUAN W, 1990, BIOCHEMISTRY-US, V29, P6082, DOI 10.1021/bi00477a028	40	80	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11126	11134		10.1074/jbc.M004604200	http://dx.doi.org/10.1074/jbc.M004604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11118430	hybrid			2022-12-25	WOS:000167980900074
J	Lasch, P; Petras, T; Ullrich, O; Backmann, J; Naumann, D; Grune, T				Lasch, P; Petras, T; Ullrich, O; Backmann, J; Naumann, D; Grune, T			Hydrogen peroxide-induced structural alterations of RNase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; NUCLEAR-MAGNETIC-RESONANCE; RIBONUCLEASE-A; GLUTAMINE-SYNTHETASE; OXIDIZED PROTEINS; SURFACE HYDROPHOBICITY; OXIDATIVE MODIFICATION; SELECTIVE DEGRADATION; METHIONINE OXIDATION; MODIFIED HEMOGLOBIN	Proteins exposed to oxidative stress are degraded via proteolytic pathways. In the present study, we undertook a series of in vitro experiments to establish a correlation between the structural changes induced by mild oxidation of the model protein RNase A and the proteolytic rate found upon exposure of the modified protein toward the isolated 20 S proteasome. Fourier transform infrared spectroscopy was used as a structure-sensitive probe. We report here strong experimental evidence for oxidation-induced conformational rearrangements of the model protein RNase A and, at the same time, for covalent modifications of amino acid side chains. Oxidation-related conformational changes, induced by H2O2. exposure of the protein may be monitored in the amide I region, which is sensitive to changes in protein secondary structure. A comparison of the time- and H2O2 concentration-dependent changes in the amide I region demonstrates a high degree of similarity to spectral alterations typical for temperature-induced unfolding of RNase A. In addition, spectral parameters of amino acid side chain marker bands (Tyr, Asp) revealed evidence for covalent modifications. Proteasome digestion measurements on oxidized RNase A revealed a specific time and H2O2 concentration dependence; at low initial concentration of the oxidant, the RNase A turnover rate increases with incubation time and concentration. Based on these experimental findings, a col-relation between structural alterations detected upon RNase A oxidation and proteolytic rates of RNase A is established, and possible mechanisms of the proteasome recognition process of oxidatively damaged proteins are discussed.	Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, D-10098 Berlin, Germany; Robert Koch Inst, D-13353 Berlin, Germany; Free Univ Brussels, Dept Struct Biol ULTR, B-1640 Rhode St Genese, Belgium; CUNY Hunter Coll, Dept Chem & Biochem, New York, NY 10021 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Robert Koch Institute; City University of New York (CUNY) System; Hunter College (CUNY)	Lasch, P (corresponding author), Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, Schumannstr 20-21, D-10098 Berlin, Germany.			Backmann, Jan/0000-0002-3323-8838; Lasch, Peter/0000-0001-6193-3144; Grune, Tilman/0000-0003-4775-9973				BACKMANN J, 1995, FEBS LETT, V364, P175, DOI 10.1016/0014-5793(95)00387-O; Backmann J, 1996, PROTEINS, V24, P379; Berlett BS, 1996, J BIOL CHEM, V271, P4177, DOI 10.1074/jbc.271.8.4177; Bohley P, 1996, BIOL CHEM, V377, P425; Bonisch H, 1996, ARCH BIOCHEM BIOPHYS, V333, P75, DOI 10.1006/abbi.1996.0366; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; Chen B, 1999, J PHARM SCI-US, V88, P477, DOI 10.1021/js980273g; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P215, DOI 10.1016/0891-5849(88)90015-9; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; FABIAN H, 1994, BIOCHEMISTRY-US, V33, P10725, DOI 10.1021/bi00201a021; FABIAN H, 1995, BIOCHEMISTRY-US, V34, P13651, DOI 10.1021/bi00041a046; FABIAN H, 1993, J MOL BIOL, V232, P967, DOI 10.1006/jmbi.1993.1442; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; Gao J, 1998, BIOPHYS J, V74, P1115, DOI 10.1016/S0006-3495(98)77830-0; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; GUNZLER H, 1996, IR SPEKTROSKOPIE EIN; HARIS PI, 1986, BIOCHIM BIOPHYS ACTA, V874, P255, DOI 10.1016/0167-4838(86)90024-5; HEYN MP, 1981, BIOCHEMISTRY-US, V20, P7109, DOI 10.1021/bi00528a009; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Hsu YR, 1996, PROTEIN SCI, V5, P1165; Hubbard S. J., 1993, NACCESS; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; Liu CW, 1998, BBA-PROTEIN STRUCT M, V1385, P53, DOI 10.1016/S0167-4838(98)00044-2; OLINGER JM, 1986, BIOCHIM BIOPHYS ACTA, V869, P89, DOI 10.1016/0167-4838(86)90314-6; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Pace CN, 1999, PROTEIN SCI, V8, P1500, DOI 10.1110/ps.8.7.1500; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; Panick G, 1999, BIOCHEMISTRY-US, V38, P6512, DOI 10.1021/bi982825f; Reinstadler D, 1999, PROTEINS, V34, P303, DOI 10.1002/(SICI)1097-0134(19990215)34:3<303::AID-PROT4>3.0.CO;2-H; Reinstadler D, 1996, BIOCHEMISTRY-US, V35, P15822, DOI 10.1021/bi961810j; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; SALO DC, 1988, FREE RADICAL BIO MED, V5, P335, DOI 10.1016/0891-5849(88)90105-0; SANTORO J, 1993, J MOL BIOL, V229, P722, DOI 10.1006/jmbi.1993.1075; Schultz CP, 1998, BIOSPECTROSCOPY, V4, pS19, DOI 10.1002/(SICI)1520-6343(1998)4:5+<S19::AID-BSPY3>3.0.CO;2-N; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Sommerburg O, 1998, FREE RADICAL BIO MED, V24, P1369, DOI 10.1016/S0891-5849(98)00012-4; Stadtman ER, 1995, LIFE SCI R, V56, P129; Troullier A, 2000, NAT STRUCT BIOL, V7, P78, DOI 10.1038/71286; Tsai AM, 1998, BIOTECHNOL BIOENG, V59, P273, DOI 10.1002/(SICI)1097-0290(19980805)59:3<273::AID-BIT2>3.3.CO;2-0; Ullrich O, 1999, ARCH BIOCHEM BIOPHYS, V362, P211, DOI 10.1006/abbi.1998.1031; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; Watson AA, 1998, BIOCHEMISTRY-US, V37, P12700, DOI 10.1021/bi9810757; WLODAWER A, 1982, J BIOL CHEM, V257, P1325; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399	61	94	95	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9492	9502		10.1074/jbc.M008528200	http://dx.doi.org/10.1074/jbc.M008528200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11115501	hybrid			2022-12-25	WOS:000167607700115
J	Qiao, S; Iwashita, T; Furukawa, T; Yamamoto, M; Sobue, G; Takahashi, M				Qiao, S; Iwashita, T; Furukawa, T; Yamamoto, M; Sobue, G; Takahashi, M			Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE LAR; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; INSULIN-RECEPTOR; INDUCED TRANSFORMATION; SIGNAL-TRANSDUCTION; DOCKING SITE; EXPRESSION; GENE; ACTIVATION	Protein-tyrosine-phosphatases (PTPs), in conjunction with protein-tyrosine kinases, play essential regulatory roles in diverse cellular activities by modulating the phosphorylation state of target proteins. Leukocyte common antigen-related (LAR) protein is a widely expressed receptor-type protein-tyrosine-phosphatase that is implicated in the regulation of intracellular signaling triggered by both cell adhesion and peptide growth factors, The gene for LAR is localized to human chromosome 1p32, a region frequently deleted in tumors of neuroectodermal origin, including neuroblastoma, pheochromocytoma, and medullary thyroid carcinoma. On the other hand, the RET gene codes for a transmembrane tyrosine kinase and is responsible for the development of multiple endocrine neoplasia (MEN) 2A and 2B, To explore the potential role of LAR in RET tyrosine kinase activity and RET-induced signal transduction, we cotransfected LAR and RET with a MEN2A or MEN2B mutation (designated RET-MEN2A or RET-MEN2B) into the MH 3T3 cell line. Here we show that LAR reduces the constitutive tyrosine autophosphorylation and kinase activity of RET-MENSA but not RET-MEN2B, accompanying a significant decrease of phosphorylation of phospholipase C gamma, AKT, and ERK1/2. Interestingly, LAR expression significantly decreased the levels of disulfide-linked RET-MEN2A dimerization, Moreover, reduced oncogenic activity of RET-MEN2A by overexpression of EAR was observed both by an in vitro colony formation assay and by in vivo tumorigenicity in scid mice. These results thus suggest that LAR may contribute to deactivation of the RET-MEN2A mutant protein and reduction of its oncogenic activity in vivo.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan; Kagoshima Univ, Fac Med, Inst Canc Res, Kakoshima 8908520, Japan	Nagoya University; Nagoya University; Kagoshima University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683; Furukawa, Tatsuhiko/0000-0003-1655-4123				Ahmad F, 1997, J BIOL CHEM, V272, P448; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BROWNSHIMER S, 1992, CANCER RES, V52, P478; Cao LG, 1998, J BIOL CHEM, V273, P21077, DOI 10.1074/jbc.273.33.21077; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Chernoff J, 1999, J CELL PHYSIOL, V180, P173; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Honkaniemi J, 1998, MOL BRAIN RES, V60, P1, DOI 10.1016/S0169-328X(98)00151-X; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Iwashita T, 1996, ONCOGENE, V12, P481; JIRIK FR, 1992, CYTOGENET CELL GENET, V61, P266, DOI 10.1159/000133418; Kawai K, 2000, CANCER RES, V60, P5254; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; LONGO FM, 1993, J BIOL CHEM, V268, P26503; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; SAHIN M, 1995, P NATL ACAD SCI USA, V92, P7859, DOI 10.1073/pnas.92.17.7859; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUZUKI T, 1995, ONCOGENE, V10, P191; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909; Yang T, 1999, MOL CARCINOGEN, V25, P139, DOI 10.1002/(SICI)1098-2744(199906)25:2<139::AID-MC9>3.3.CO;2-K; Yeo TT, 1997, J NEUROSCI RES, V47, P348, DOI 10.1002/(SICI)1097-4547(19970201)47:3<348::AID-JNR13>3.0.CO;2-Y; ZANDER NF, 1993, ONCOGENE, V8, P1175; Zhang JS, 1998, MOL CELL NEUROSCI, V10, P271, DOI 10.1006/mcne.1998.0663; Zhang WR, 1996, MOL ENDOCRINOL, V10, P575, DOI 10.1210/me.10.5.575	62	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9460	9467		10.1074/jbc.M008744200	http://dx.doi.org/10.1074/jbc.M008744200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121408	hybrid			2022-12-25	WOS:000167607700111
J	Sorsa, T; Heikkinen, S; Abbott, MB; Abusamhadneh, E; Laakso, T; Tilgmann, C; Serimaa, R; Annila, A; Rosevear, PR; Drakenberg, T; Pollesello, P; Kilpelainen, I				Sorsa, T; Heikkinen, S; Abbott, MB; Abusamhadneh, E; Laakso, T; Tilgmann, C; Serimaa, R; Annila, A; Rosevear, PR; Drakenberg, T; Pollesello, P; Kilpelainen, I			Binding of levosimendan, a calcium sensitizer, to cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HIGH-AFFINITY LIGANDS; REGULATORY DOMAIN; NMR; DRUG; PHOSPHORYLATION; SCATTERING; PROTEINS; BEPRIDIL; COMPLEX	Levosimendan is an inodilatory drug that mediates its cardiac effect by the calcium sensitization of contractile proteins. The target protein of levosimendan is cardiac troponin C (cTnC). In the current work, we have studied the interaction of levosimendan with Ca2+-saturated cTnC by heteronuclear NMR and small angle x-ray scattering. A specific interaction between levosimendan and the Ca2+-loaded regulatory domain of recombinant cTnC(C35C) was observed. The changes in the NMR spectra of the N-domain of full-length cTnC(C35S), due to the binding of levosimendan to the primary site, were indicative of a slow conformational exchange. In contrast, no binding of levosimendan to the regulatory domain of cTnC(A-Cys) where all the cysteine residues are mutated to serine, was detected. Moreover, it was shown that levosimendan was in fast exchange on the NMR time scale with a secondary binding site in the C-domain of both cTnC(C35S) and cTnC(A-Cys). The small angle x-ray scattering experiments confirm the binding of levosimendan to Ca2+-saturated cTnC but show no domain-domain closure. The experiments were run in the absence of the reducing agent dithiothreitol and the preservative sodium azide (NaN3), since we found that levosimendan reacts with these chemicals, commonly used for preparation of NMR protein samples.	Univ Helsinki, Inst Biotechnol, NMR Lab, FIN-00014 Helsinki, Finland; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Helsinki, Dept Phys, Xray Lab, FIN-00014 Helsinki, Finland; Orion Pharm, Res & Dev, FIN-02101 Espoo, Finland; Univ Lund, Ctr Chem, Dept Phys Chem 2, S-22100 Lund, Sweden; VTT Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki; University System of Ohio; University of Cincinnati; University of Helsinki; Lund University; VTT Technical Research Center Finland	Kilpelainen, I (corresponding author), Univ Helsinki, Inst Biotechnol, NMR Lab, POB 56, FIN-00014 Helsinki, Finland.		Pollesello, Piero/I-6884-2019	Pollesello, Piero/0000-0001-6994-768X; Tilgmann, Carola/0000-0001-6241-2359	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044324] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44324] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; ENDOH M, 1995, GEN PHARMACOL, V26, P1, DOI 10.1016/0306-3623(94)00144-C; Finley N, 1999, FEBS LETT, V453, P107, DOI 10.1016/S0014-5793(99)00693-6; FUJISAWA T, 1987, J APPL CRYSTALLOGR, V20, P349, DOI 10.1107/S0021889887086497; Gagne SM, 1998, BIOCHEM CELL BIOL, V76, P302, DOI 10.1139/bcb-76-2-3-302; Gaponenko V, 1999, J BIOL CHEM, V274, P16681, DOI 10.1074/jbc.274.24.16681; Guinier A., 1955, SMALL ANGLE SCATTERI; HAIKALA H, 1995, J MOL CELL CARDIOL, V27, P1859, DOI 10.1016/0022-2828(95)90009-8; Hajduk PJ, 1999, J MED CHEM, V42, P2315, DOI 10.1021/jm9901475; Hajduk PJ, 1997, SCIENCE, V278, P497, DOI 10.1126/science.278.5337.497; Hasenfuss G, 1998, CIRCULATION, V98, P2141, DOI 10.1161/01.CIR.98.20.2141; HORTON RM, 1995, MOL BIOTECHNOL, V3, P93, DOI 10.1007/BF02789105; HOWARTH JW, 1995, PROTEIN SCI, V4, P671; Kleerekoper Q, 1999, J BIOL CHEM, V274, P23932, DOI 10.1074/jbc.274.34.23932; Kleerekoper Q, 1998, J BIOL CHEM, V273, P8153, DOI 10.1074/jbc.273.14.8153; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; Levijoki J, 2000, J MOL CELL CARDIOL, V32, P479, DOI 10.1006/jmcc.1999.1093; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Li Y, 2000, P NATL ACAD SCI USA, V97, P5140, DOI 10.1073/pnas.090098997; LIN X, 1994, BIOCHEMISTRY-US, V33, P14434, DOI 10.1021/bi00252a009; MARCH J, 1985, ADV ORGANIC CHEM REA, P743; OVASKA M, 1991, PROTEINS, V11, P79, DOI 10.1002/prot.340110202; Paakkonen K, 1998, J BIOL CHEM, V273, P15633, DOI 10.1074/jbc.273.25.15633; Pan BS, 1996, J BIOL CHEM, V271, P817, DOI 10.1074/jbc.271.2.817; POLLESELLO P, 1994, J BIOL CHEM, V269, P28584; PUTKEY JA, 1993, J BIOL CHEM, V268, P6827; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777	33	111	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9337	9343		10.1074/jbc.M007484200	http://dx.doi.org/10.1074/jbc.M007484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11113122	hybrid			2022-12-25	WOS:000167607700096
J	Chan, D; Ho, MSP; Cheah, KSE				Chan, D; Ho, MSP; Cheah, KSE			Aberrant signal peptide cleavage of collagen X in Schmid metaphyseal chondrodysplasia - Implications for the molecular basis of the disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; IN-VITRO; DIABETES-INSIPIDUS; ALPHA-1(X) NC1; MUTATIONS; MUTANT; DOMAIN; EXPRESSION; GENE; TRANSLOCATION	Schmid metaphyseal chondrodysplasia results from mutations in the collagen X (COL10A1) gene. With the exception of two cases, the known mutations are clustered in the C-terminal nonhelical (NC1) domain of the collagen X. In vitro and cell culture studies have shown that the NC1 mutations result in impaired collagen X trimer assembly and secretion. In the two other cases, missense mutations that alter Gly(18) at the -1 position of the putative signal peptide cleavage site were identified (Ikegawa, S., Nakamura, K,, Nagano, A., Haga, N,, and Nakamura, Y. (1997) Hum, Mutat. 9, 131-135). To study their impact on collagen X biosynthesis using in vitro cell-free translation in the presence of microsomes, and cell transfection assays, these two mutations were created in COL10A1 by site-directed mutagenesis. The data suggest that translocation of the mutant pre-alpha1(X) chains into the microsomes is not affected, but cleavage of the signal peptide is inhibited, and the mutant chains remain anchored to the membrane of microsomes, Cell-free translation and transfection studies in cells showed that the mutant chains associate into trimers but cannot form a triple helix, The combined effect of both the lack of signal peptide cleavage and helical configuration is impaired secretion. Thus, despite the different nature of the NC1 and signal peptide mutations in collagen X, both result in impaired collagen X secretion, probably followed by intracellular retention and degradation of mutant chains, and causing the Schmid metaphyseal chandrodysplasia phenotype.	Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Chan, D (corresponding author), Univ Hong Kong, Dept Biochem, Li Shu Fan Bldg,5 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.		Cheah, Kathryn/C-4222-2009; Ho, Matthew/ACZ-8423-2022; Chan, Danny/C-4203-2009	Chan, Danny/0000-0003-3824-5778				BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; Beuret N, 1999, J BIOL CHEM, V274, P18965, DOI 10.1074/jbc.274.27.18965; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Chan D, 1998, MATRIX BIOL, V17, P169, DOI 10.1016/S0945-053X(98)90056-7; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1999, J BIOL CHEM, V274, P13091, DOI 10.1074/jbc.274.19.13091; Chan D, 1998, J CLIN INVEST, V101, P1490, DOI 10.1172/JCI1976; Fitzgerald J, 1999, J BIOL CHEM, V274, P27392, DOI 10.1074/jbc.274.39.27392; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ikegawa S, 1997, HUM MUTAT, V9, P131, DOI 10.1002/(SICI)1098-1004(1997)9:2<131::AID-HUMU5>3.3.CO;2-U; ITO M, 1993, J CLIN INVEST, V91, P2565, DOI 10.1172/JCI116494; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; McLaughlin SH, 1999, J BIOL CHEM, V274, P7570, DOI 10.1074/jbc.274.11.7570; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P21797; RACCHI M, 1993, J BIOL CHEM, V268, P5735; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79	24	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7992	7997		10.1074/jbc.M003361200	http://dx.doi.org/10.1074/jbc.M003361200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11115494	hybrid			2022-12-25	WOS:000167474900046
J	Labrecque, J; Deschenes, J; McNicoll, N; De Lean, A				Labrecque, J; Deschenes, J; McNicoll, N; De Lean, A			Agonistic induction of a covalent dimer in a mutant of natriuretic peptide receptor-A documents a juxtamembrane interaction that accompanies receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GUANYLYL-CYCLASE; ERYTHROPOIETIN RECEPTOR; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; BINDING DOMAIN; DISULFIDE BOND; ANP RECEPTOR; DIMERIZATION; IDENTIFICATION	The natriuretic peptide receptor-A (NPR-A) is composed of an extracellular domain with a ligand binding site, a transmembrane-spanning domain, a kinase homology domain, and a guanylyl cyclase domain. In response to agonists (atrial natriuretic peptide (ANP) and brain natriuretic peptide), the kinase homology domain-mediated guanylate cyclase repression is removed, which allows the production of cyclic GMP, Previous work from our laboratory strongly indicated that agonists are exerting their effects through the induction of a juxtamembrane dimeric contact. However, a direct demonstration of this mechanism remains to be provided. As a tool, we are now using the properties of a new mutation, D435C, It introduces a cysteine at a position in NPR-A corresponding to a supplementary cysteine found in NPR-C6, another receptor of this family (a disulfide-linked dimer), Although this D435C mutation only leads to trace levels of NPR-A disulfide-linked dimer at basal state, covalent dimerization can be induced by a treatment with rat ANP or with other agonists, The NPR-A(D435C) mutant has not been subjected to significant structural alterations, since it shares with the wild type receptor a similar dose response pattern of cellular guanylyl cyclase activation. However, a persistent activation accompanies NPR-A(D435C) dimer formation after the removal of the inducer agonist, On the other hand, a construction where the intracellular domain of NPR-A(D435C) has been truncated (Delta KCD435C) displays a spontaneous and complete covalent dimerization, In addition, the elimination of the intracellular domain in wild type Delta KC and Delta KCD435C is associated with an increase of agonist binding affinity, this effect being more pronounced with the weak agonist pBNP, Also, a D435C secreted extracellular domain remains unlinked even after incubation with rat ANP, In summary, these results demonstrate, in a dynamic fashion, the agonistic induction of a dimeric contact in the juxtamembrane domain of NPR-A, In addition, this process seems to require membrane attachment of the receptor. Finally, the intracellular domain represses this contact at the basal state, showing its potent influence on the outer juxtamembrane domain.	Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	De Lean, A (corresponding author), Univ Montreal, Fac Med, Dept Pharmacol, CP 6128,Ctr Ville, Montreal, PQ H3C 3J7, Canada.							AnandSrivastava MB, 1996, J BIOL CHEM, V271, P19324, DOI 10.1074/jbc.271.32.19324; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; Cohen D, 1996, J BIOL CHEM, V271, P9863, DOI 10.1074/jbc.271.16.9863; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DELEAN A, 1978, AM J PHYSIOL, V235, pF97; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FETHIERE J, 1989, MOL PHARMACOL, V35, P584; Garbers DL, 1999, METHODS, V19, P477, DOI 10.1006/meth.1999.0890; Huo XW, 1999, BIOCHEMISTRY-US, V38, P16941, DOI 10.1021/bi9919448; ITAKURA M, 1994, J BIOL CHEM, V269, P8314; JEWETT JRS, 1993, EMBO J, V12, P769, DOI 10.1002/j.1460-2075.1993.tb05711.x; KATZ BA, 1986, J BIOL CHEM, V261, P5480; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; Labrecque J, 1999, J BIOL CHEM, V274, P9752, DOI 10.1074/jbc.274.14.9752; LAROSE L, 1991, BIOCHEMISTRY-US, V30, P8991; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Marquis M, 1999, MOL CELL BIOCHEM, V194, P23, DOI 10.1023/A:1006835808554; Misono KS, 1999, BIOCHEMISTRY-US, V38, P516, DOI 10.1021/bi982127v; Miyagi M, 2000, BBA-PROTEIN STRUCT M, V1478, P30, DOI 10.1016/S0167-4838(00)00002-9; MIZUNO T, 1993, J BIOL CHEM, V268, P5162; NAKAO K, 1992, J HYPERTENS, V10, P907; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Potter LR, 1999, METHODS, V19, P506, DOI 10.1006/meth.1999.0893; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; Tanner KG, 1997, BIOCHEMISTRY-US, V36, P14889, DOI 10.1021/bi9706834; THOMPSON DK, 1995, J BIOL CHEM, V270, P425, DOI 10.1074/jbc.270.1.425; van den Akker F, 2000, NATURE, V406, P101, DOI 10.1038/35017602; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025; Wilson IA, 1999, CURR OPIN STRUC BIOL, V9, P696, DOI 10.1016/S0959-440X(99)00032-9	38	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8064	8072		10.1074/jbc.M005550200	http://dx.doi.org/10.1074/jbc.M005550200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11124937	hybrid			2022-12-25	WOS:000167474900056
J	Martens, JR; Sakamoto, N; Sullivan, SA; Grobaski, TD; Tamkun, MM				Martens, JR; Sakamoto, N; Sullivan, SA; Grobaski, TD; Tamkun, MM			Isoform-specific localization of voltage-gated K+ channels to distinct lipid raft populations - Targeting of Kv1.5 to 3 caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC POTASSIUM CHANNEL; GPI-ANCHORED PROTEINS; ION CHANNELS; CELL-SURFACE; TYROSINE KINASE; PLASMA-MEMBRANE; MOLECULAR-BASIS; EXPRESSION; MICRODOMAINS; DOMAINS	The precise subcellular localization of ion channels is often necessary to ensure rapid and efficient integration of both intracellular and extracellular signaling events. Recently, we have identified lipid raft association as a novel mechanism for the subcellular sorting of specific voltage gated K+ channels to regions of the membrane rich in signaling complexes. Here, we demonstrate isoform-specific targeting of voltage-gated KC (Kv) channels to distinct lipid raft populations with the finding that Kv1.5 specifically targets to caveolae. Multiple lines of evidence indicate that Kv1.5 and Kv2.1 exist in distinct raft domains: 1) channel/raft association shows differential sensitivity to increasing concentrations of Triton X-100; 2) unlike Kv2.1, Kv1.5 colocalizes with caveolin on the cell surface and redistributes with caveolin following microtubule disruption; and 3) immunoisolation of caveolae copurifies Kv1.5 channel. Both depletion of cellular cholesterol and inhibition of sphingolipid synthesis alter Kv1.5 channel function by inducing a hyperpolarizing shift in the voltage dependence of activation and inactivation. The differential targeting of Kv channel subtypes to caveolar and noncaveolar rafts within a single membrane represents a unique mechanism of compartmentalization, which may permit isoform-specific modulation of K+ channel function.	Colorado State Univ, Dept Physiol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University	Tamkun, MM (corresponding author), Colorado State Univ, Dept Physiol, Ft Collins, CO 80523 USA.	tamkunmm@lamar.colostate.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008496] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049330] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49330] Funding Source: Medline; NICHD NIH HHS [1F32HD08496-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		An RH, 1999, J PHYSIOL-LONDON, V516, P19, DOI 10.1111/j.1469-7793.1999.019aa.x; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Badizadegan K, 2000, AM J PHYSIOL-GASTR L, V278, pG895, DOI 10.1152/ajpgi.2000.278.6.G895; Bentley GN, 1999, BBA-BIOMEMBRANES, V1418, P176, DOI 10.1016/S0005-2736(99)00021-8; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; El-Husseini AE, 2000, J BIOL CHEM, V275, P23904, DOI 10.1074/jbc.M909919199; Elinder F, 1996, J GEN PHYSIOL, V108, P325, DOI 10.1085/jgp.108.4.325; Elinder F, 1998, J MEMBRANE BIOL, V165, P183, DOI 10.1007/s002329900432; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; Hulme JT, 1999, CIRC RES, V85, P489, DOI 10.1161/01.RES.85.6.489; Johnson BD, 1999, ADV SEC MESS PHOSPH, V33, P203; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; MAYS DJ, 1995, J CLIN INVEST, V96, P282, DOI 10.1172/JCI118032; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Parkin ET, 1997, J NEUROCHEM, V69, P2179; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; Rich TC, 2000, J GEN PHYSIOL, V116, P147, DOI 10.1085/jgp.116.2.147; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SNYDERS DJ, 1992, MOL PHARMACOL, V41, P322; SNYDERS DJ, 1993, J GEN PHYSIOL, V101, P513, DOI 10.1085/jgp.101.4.513; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; UEBELE VN, 1994, FEBS LETT, V340, P104, DOI 10.1016/0014-5793(94)80181-9	44	192	196	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8409	8414		10.1074/jbc.M009948200	http://dx.doi.org/10.1074/jbc.M009948200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11115511	hybrid			2022-12-25	WOS:000167474900100
J	Mulligan-Kehoe, MJ; Wagner, R; Wieland, C; Powell, R				Mulligan-Kehoe, MJ; Wagner, R; Wieland, C; Powell, R			A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATOMEDIN-B DOMAIN; LEWIS-LUNG-CARCINOMA; UROKINASE RECEPTOR; ENDOTHELIAL-CELLS; ANGIOGENESIS INHIBITOR; REACTIVE-CENTER; TISSUE-TYPE; EXTRACELLULAR-MATRIX; BINDING MOTIF; VITRONECTIN	Plasminogen activator inhibitor-1 (PAI-1) is a serpin protease inhibitor that binds plasminogen activators (uPA and tPA) at a reactive center loop located at the carboxyl-terminal amino acid residues 320-351. The loop is stretched across the top of the active PAI-1 protein maintaining the molecule in a rigid conformation, In the latent PAI-1 conformation, the reactive center loop is inserted into one of the beta sheets, thus making the reactive center loop unavailable for interaction with the plasminogen activators. We truncated porcine PAI-1 at the amino and carboxyl termini to eliminate the reactive center loop, part of a heparin binding site, and a vitronectin binding site. The region we maintained corresponds to amino acids 80-265 of mature human PAI-1 containing binding sites for vitronectin, heparin (partial), up, tPA, fibrin, thrombin, and the helix F region. The interaction of "inactive" PAI-1, rPAI-1(23), with plasminogen and uPA induces the formation of a proteolytic protein with angiostatin properties, Increasing amounts of rPAI-1(23) inhibit the proteolytic angiostatin fragment. Endothelial cells exposed to exogenous rPAI-1(23) exhibit reduced proliferation, reduced tube formation, and 47% apoptotic cells within 48 h, Transfected endothelial cells secreting rPAI-1(23) have a 30% reduction in proliferation, vastly reduced tube formation, and a 50% reduction in cell migration in the presence of VEGF. These two studies show that rPAI-1(23) interactions with uPA and plasminogen can inhibit plasmin by two mechanisms. In one mechanism, rPAI-1(23) cleaves plasmin to form a proteolytic ansostatin-like protein. In a second mechanism, rPAI-1(23) can bind uPA and/or plasminogen to reduce the number of uPA and plasminogen interactions, hence reducing the amount of plasmin that is produced.	Dartmouth Med Sch, Dartmouth Coll, Dept Surg, Div Vasc Surg, Lebanon, NH 03756 USA	Dartmouth College	Mulligan-Kehoe, MJ (corresponding author), Dartmouth Med Sch, Dartmouth Coll, Dept Surg, Div Vasc Surg, Borwell 530 E,1 Med Ctr Dr, Lebanon, NH 03756 USA.			Jarrahian, Courtney/0000-0003-3046-6891	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059590] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL59590] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allaire E, 1998, CIRCULATION, V98, P249, DOI 10.1161/01.CIR.98.3.249; ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Bijnens AP, 1997, THROMB HAEMOSTASIS, V77, P350; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; Cornelius LA, 1998, J IMMUNOL, V161, P6845; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CUBELLIS MV, 1989, P NATL ACAD SCI USA, V86, P4828, DOI 10.1073/pnas.86.13.4828; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Egelund R, 1997, EUR J BIOCHEM, V248, P775, DOI 10.1111/j.1432-1033.1997.t01-1-00775.x; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EHRLICH HJ, 1992, J BIOL CHEM, V267, P13029; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Falcone DJ, 1998, J BIOL CHEM, V273, P31480, DOI 10.1074/jbc.273.47.31480; Fitton HL, 1997, BIOL CHEM, V378, P1059; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; HESS S, 1995, THROMB HAEMOSTASIS, V74, P258; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JALLAT S, 1986, PROTEIN ENG, V1, P29, DOI 10.1093/protein/1.1.29; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KEIJER J, 1991, BLOOD, V78, P401; KIRKEGAARD T, 1998, EUR J BIOL CHEM, V12, P7; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KOST C, 1992, J BIOL CHEM, V267, P12098; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LORIDONROSA B, 1988, AM J CLIN PATHOL, V90, P7, DOI 10.1093/ajcp/90.1.7; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIMURO J, 1987, BLOOD, V70, P721; Mulligan-Kehoe MJ, 1999, J MOL BIOL, V289, P41, DOI 10.1006/jmbi.1999.2749; O'Mahony CA, 1998, SURGERY, V124, P388, DOI 10.1016/S0039-6060(98)70145-X; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; OLSON D, 1992, J BIOL CHEM, V267, P9129; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; PROIA R, 2000, P 68 ANN SESS OH WAN, V51, P371; REICH E, 1978, MOL BASIS BIOL DEGRA, P155; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEPHENS AW, 1987, J BIOL CHEM, V262, P1044; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; Vleugels N, 2000, BBA-PROTEIN STRUCT M, V1476, P20, DOI 10.1016/S0167-4838(99)00224-1; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WEI Y, 1994, J BIOL CHEM, V269, P32390	71	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8588	8596		10.1074/jbc.M006434200	http://dx.doi.org/10.1074/jbc.M006434200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113116	hybrid			2022-12-25	WOS:000167474900122
J	Sellman, BR; Nassi, S; Collier, RJ				Sellman, BR; Nassi, S; Collier, RJ			Point mutations in anthrax protective antigen that block translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM C2 TOXIN; LETHAL FACTOR; MEMBRANE TRANSLOCATION; BILAYER-MEMBRANES; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; EDEMA FACTOR; LOW-PH; CHANNELS; FRAGMENT	The protective antigen (PA) moiety of anthrax toxin delivers the toxin's enzymatic moieties to the cytosol of mammalian cells by a mechanism associated with its ability to heptamerize and form a transmembrane pore. Here we report that mutations in Lys-397, Asp-425, or Phe-427 ablate killing of CHO-K1 cells by a cytotoxic PA ligand. These mutations blocked PA's ability to mediate pore formation and translocation in cells but had no effect on its receptor binding, proteolytic activation, or ability to oligomerize and bind the toxin's enzymatic moieties. The mutation-sensitive residues lie in the 2 beta (7)-2 beta (8) and 2 beta (10)-2 beta (11) loops of domain 2 and are distant both in primary structure and topography from the 2 beta (2)-2 beta (3) loop, which is believed to participate in formation of a transmembrane beta -barrel. These results suggest that Lys-397, Asp-425, and Phe-427 participate in conformational rearrangements of a heptameric pore precursor that are necessary for pore formation and translocation. Identification of these residues will aid in elucidating the mechanism of translocation and may be useful in developing therapeutic and prophylactic agents against anthrax.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine	Collier, RJ (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA.			Collier, R John/0000-0002-2427-4239	NIAID NIH HHS [R37-AI22021] Funding Source: Medline; NIGMS NIH HHS [T-32-GM-07228, GM-29210] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029210, R01GM029210, T32GM007228] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614; DONOVAN JJ, 1986, BIOCHEMISTRY-US, V25, P2872, DOI 10.1021/bi00358a020; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; ESCUYER V, 1991, INFECT IMMUN, V59, P3381, DOI 10.1128/IAI.59.10.3381-3386.1991; FALNES PO, 1992, J BIOL CHEM, V267, P12284; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Fujii N, 1996, BIOCHEM BIOPH RES CO, V220, P353, DOI 10.1006/bbrc.1996.0409; Gibert M, 1997, SYST APPL MICROBIOL, V20, P337, DOI 10.1016/S0723-2020(97)80001-X; Gill D., 1978, BACTERIAL TOXINS CEL, P291; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Little SF, 1996, MICROBIOL-SGM, V142, P707, DOI 10.1099/13500872-142-3-707; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Perelle S, 1997, INFECT IMMUN, V65, P1402, DOI 10.1128/IAI.65.4.1402-1407.1997; PERELLE S, 1993, INFECT IMMUN, V61, P5147, DOI 10.1128/IAI.61.12.5147-5156.1993; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID A, 1994, J BIOL CHEM, V269, P16706; SINGH Y, 1994, J BIOL CHEM, V269, P29039; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	34	84	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8371	8376		10.1074/jbc.M008309200	http://dx.doi.org/10.1074/jbc.M008309200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113126	hybrid			2022-12-25	WOS:000167474900095
J	Pescarolo, MP; Bagnasco, L; Malacarne, D; Melchiori, A; Valente, P; Millo, E; Bruno, S; Basso, S; Parodi, S				Pescarolo, MP; Bagnasco, L; Malacarne, D; Melchiori, A; Valente, P; Millo, E; Bruno, S; Basso, S; Parodi, S			A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems	FASEB JOURNAL			English	Article									Natl Inst Canc Res, Expt Oncol Lab, I-16132 Genoa, Italy; Univ Genoa, Dept Expt Med, Biochem Sect, Genoa, Italy; Univ Genoa, Dept Expt Med, Sect Human Anat, Genoa, Italy; Adv Biotechnol Ctr, Immunopharmacol Sect, Genoa, Italy; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; University of Genoa; University of Genoa	Parodi, S (corresponding author), Natl Inst Canc Res, Expt Oncol Lab, Largo R Benzi 10, I-16132 Genoa, Italy.		Millo, Enrico/K-3218-2018; Bruno, Silvia/B-8980-2013	Millo, Enrico/0000-0002-4019-0051; bruno, silvia/0000-0001-8799-8325					0	39	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					31	33						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099487				2022-12-25	WOS:000166312400011
J	Vilkaitis, G; Dong, AP; Weinhold, E; Cheng, XD; Klimasauskas, S				Vilkaitis, G; Dong, AP; Weinhold, E; Cheng, XD; Klimasauskas, S			Functional roles of the conserved threonine 250 in the target recognition domain of HhaI DNA methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BASE; METHYLATION; CYTOSINE; MISMATCHES; 2-AMINOPURINE; FLUORESCENCE; REPAIR	DNA cytosine-5-methyltransferase HhaI recognizes the GCGC sequence and flips the inner cytosine out of DNA helix and into the catalytic site for methylation. The 5'-phosphate of the flipped out cytosine is in contact with the conserved Thr-250 from the target recognition domain. We have produced 12 mutants of Thr-250 and examined their methylation potential in vivo. Six active mutants were subjected to detailed biochemical and structural studies. Mutants with similar or smaller side chains (Ser, Cys, and Gly) are very similar to wild-type enzyme in terms of steady-state kinetic parameters k(cat), K-M(DNA), R-m(AdoMet). In contrast, the mutants with builder side chains (Asn, Asp, and His) show increased K-m values for both substrates. Fluorescence titrations and stopped flow kinetic analysis of interactions with duplex oligonucleotides containing 2-aminopurine at the target base position indicate that the T250G mutation leads to a more polar but less solvent-accessible position of the flipped out target base. The x-ray structure of the ternary M.HhaI(T250G).DNA.AdoHcy complex shows that the target cytosine is locked in the catalytic center of enzyme. The space created by the mutation is filled by water molecules and the adjacent DNA backbone atoms dislocate slightly toward the missing side chain. In aggregate, our results suggest that the side chain of Thr-250 is involved in constraining the conformation the DNA backbone and the target base during its rotation into the catalytic site of enzyme.	Inst Biotechnol, Lab Biol DNA Modificat, LT-2028 Vilnius, Lithuania; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Max Planck Inst Mol Physiol, Abt Phys Biochem, D-44227 Dortmund, Germany	Vilnius University; Emory University; Max Planck Society	Klimasauskas, S (corresponding author), Inst Biotechnol, Lab Biol DNA Modificat, LT-2028 Vilnius, Lithuania.		Klimasauskas, Saulius/M-3053-2016; Vilkaitis, Giedrius/AAI-9157-2021	Klimasauskas, Saulius/0000-0002-1395-2030; Vilkaitis, Giedrius/0000-0003-2427-3997	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049245] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49245] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CHENG X, 1993, COLD SPRING HARB SYM, V58, P331, DOI 10.1101/SQB.1993.058.01.039; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Cousins J., 1997, KINETASYST VERSION 2; Dryden D. S, 1999, BACTERIAL DNA METHYL, P283; ERDMANN D, 1992, GENE, V117, P15, DOI 10.1016/0378-1119(92)90484-7; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; Klimasauskas S, 1998, EMBO J, V17, P317, DOI 10.1093/emboj/17.1.317; KLIMASAUSKAS S, 1991, NUCLEIC ACIDS RES, V19, P6183, DOI 10.1093/nar/19.22.6183; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Kumar S, 1997, NUCLEIC ACIDS RES, V25, P2773, DOI 10.1093/nar/25.14.2773; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LEATHERBARROW RJ, 1992, GRAPHIT VERSION 3 0; McCullough AK, 1997, J BIOL CHEM, V272, P27210, DOI 10.1074/jbc.272.43.27210; MI S, 1995, NUCLEIC ACIDS RES, V23, P620, DOI 10.1093/nar/23.4.620; O'Gara M, 1998, NAT STRUCT BIOL, V5, P872, DOI 10.1038/2312; OGara M, 1996, J MOL BIOL, V263, P597, DOI 10.1006/jmbi.1996.0601; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Roberts RJ, 2000, NUCLEIC ACIDS RES, V28, P306, DOI 10.1093/nar/28.1.306; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Serva S, 1998, NUCLEIC ACIDS RES, V26, P3473, DOI 10.1093/nar/26.15.3473; Stivers JT, 1998, NUCLEIC ACIDS RES, V26, P3837, DOI 10.1093/nar/26.16.3837; TRAUTNER TA, 1988, NUCLEIC ACIDS RES, V16, P6649, DOI 10.1093/nar/16.14.6649; Vassylyev DG, 1997, CURR OPIN STRUC BIOL, V7, P103, DOI 10.1016/S0959-440X(97)80013-9; Vertino PM, 1999, S ADENOSYLMETHIONINE, P341; WARD DC, 1969, J BIOL CHEM, V244, P1228; WU JC, 1987, J BIOL CHEM, V262, P4778; XU D, 1994, BIOCHEMISTRY-US, V33, P9792; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	44	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 8	2000	275	49					38722	38730		10.1074/jbc.M005278200	http://dx.doi.org/10.1074/jbc.M005278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	381AH	11102456	hybrid			2022-12-25	WOS:000165739800081
J	Russell, JP; Powell, DJ; Cunnane, M; Greco, A; Portella, G; Santoro, M; Fusco, A; Rothstein, JL				Russell, JP; Powell, DJ; Cunnane, M; Greco, A; Portella, G; Santoro, M; Fusco, A; Rothstein, JL			The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium	ONCOGENE			English	Article						neoplasia; nerve growth factor receptor; papillary thyroid carcinoma; RET/PTC; transgenic mice; TRK-T1	CHERNOBYL REACTOR ACCIDENT; COILED-COIL DOMAIN; PAPILLARY CARCINOMAS; RET/PTC1 ONCOGENE; RET REARRANGEMENT; TRANSGENIC MICE; TARGETED EXPRESSION; MOLECULAR-GENETICS; HIGH PREVALENCE; ACTIVATION	Genetic analysis of human papillary thyroid carcinomas (PTC) has revealed unique chromosomal translocations that form oncogenic fusion proteins and promote thyroid tumorigenesis in up to 60% of tumors examined, Although, the majority of thyroid specific translocations involve the growth factor receptor c-RET, variant rearrangements of the receptor for nerve growth factor, NTRK1 have also been described, One such translocation, TRK=T1, forms a fusion protein composed of the carboxyl terminal tyrosine kinase domain of NTRK1 and the amino terminal portion of TPR (Translocated Promoter Region), To determine if TRK-TI expression can cause thyroid cancer in vivo, we developed transgenic mice that express the human TRK-T1 fusion protein in the thyroid. Immunohistochemical analysis of TRK=T1 transgenic mouse thyroids revealed TRK-T1 staining within the thyroid follicular epithelium. In contrast to nontransgenic littermates, 54% of transgenic mice developed thyroid abnormalities that included follicular hyperplasia and papillary carcinoma. Furthermore, all transgenic mice examined greater than 7 months of age developed thyroid hyperplasia and/or carcinoma. These data support the conclusion that TRK-T1 is oncogenic iii vivo and contributes to the neoplastic transformation of the thyroid.	Thomas Jefferson Univ, Dept Microbiol Immunol & Otolaryngol HNS, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Inst Nazl Tumori, Div Expt Oncol A, Milan, Italy; Univ Naples, Ctr Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Cantanzaro, Italy	Jefferson University; Jefferson University; Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Dept Microbiol Immunol & Otolaryngol HNS, Kimmel Canc Inst, Philadelphia, PA 19107 USA.		Greco, Angela/C-1953-2017; Portella, Giuseppe/AFU-6826-2022	Greco, Angela/0000-0003-2994-0349; Fusco, Alfredo/0000-0003-3332-5197; PORTELLA, Giuseppe/0000-0001-8276-9769	NATIONAL CANCER INSTITUTE [P01CA021124, P01CA076259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007492] Funding Source: NIH RePORTER; NCI NIH HHS [CA21124, CA76259] Funding Source: Medline; NIAID NIH HHS [T32-AI07492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Beimfohr C, 1999, INT J CANCER, V80, P842, DOI 10.1002/(SICI)1097-0215(19990315)80:6<842::AID-IJC7>3.0.CO;2-Z; Bongarzone I, 1998, CLIN CANCER RES, V4, P223; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Delvincourt C, 1996, CLIN BIOCHEM, V29, P267, DOI 10.1016/0009-9120(96)00006-9; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRECO A, 1995, MOL CELL BIOL, V15, P6118; GRECO A, 1992, ONCOGENE, V7, P237; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; HOGAN B, 1986, MANIPULATING MOUSE E; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1995, ONCOGENE, V11, P2459; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Portella G, 1999, ONCOL RES, V11, P421; Powell DJ, 1998, CANCER RES, V58, P5523; Rabes HM, 1998, RECENT RES CANCER, V154, P248; Rochefort P, 1996, ONCOGENE, V12, P111; ROSAI J, 1990, TUMORS THYROID GLAND; Sagartz JE, 1997, LAB INVEST, V76, P307; Santoro M, 1996, ONCOGENE, V12, P1821; SOZZI G, 1992, GENE CHROMOSOME CANC, V5, P212, DOI 10.1002/gcc.2870050307; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458	28	82	83	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5729	5735		10.1038/sj.onc.1203922	http://dx.doi.org/10.1038/sj.onc.1203922			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126359				2022-12-25	WOS:000165477700004
J	Thuresson, ED; Malkowski, MG; Lakkides, KM; Rieke, CJ; Mulichak, AM; Ginell, SL; Garavito, RM; Smith, WL				Thuresson, ED; Malkowski, MG; Lakkides, KM; Rieke, CJ; Mulichak, AM; Ginell, SL; Garavito, RM; Smith, WL			Mutational and X-ray crystallographic analysis of the interaction of dihomo-gamma-linolenic acid with prostaglandin endoperoxide H syntheses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE ACTIVE-SITE; ARACHIDONIC-ACID; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; ARGININE 120; SYNTHASE-1; BINDING; INHIBITORS; BIOSYNTHESIS; OXYGENATION	Prostaglandin endoperoxide H synthases-1 and -2 (PGHSs) catalyze the committed step in prostaglandin biosynthesis, Both isozymes can oxygenate a variety of related polyunsaturated fatty acids. We report here the x-ray crystal structure of dihomo-gamma -linolenic acid (DHLA) in the cyclooxygenase site of PGHS-1 and the effects of active site substitutions on the oxygenation of DHLA, and we compare these results to those obtained previously with arachidonic acid (AA), DHLA is bound within the cyclooxygenase site in the same overall L-shaped conformation as Ak C-1 and C-11 through C-20 are in the same positions for both substrates, but the positions of C-2 through C-10 differ by up to 1.74 Angstrom In general, substitutions of active site residues caused parallel changes in the oxygenation of both AA and DHLA. Two significant exceptions were Val-349 and Ser-530, A V349A substitution caused an 800-fold decrease in the V-max/K-m for DHLA but less than a a-fold change with AA; kinetic evidence indicates that C-13 of DHLA is improperly positioned with respect to Tyr-385 in the V349A mutant thereby preventing efficient hydrogen abstraction. Val-349 contacts C-5 of DHLA and appears to serve as a structural bumper positioning the carboxyl half of DHLA, which, in turn, positions properly the omega -half of this substrate, A V349A substitution in PGHS-2 has similar, minor effects on the rates of oxygenation of AA and DHLA. Thus, Val-349 is a major determinant of substrate specificity for PGHS-1 but not for PGHS-2. Ser-530 also influences the substrate specificity of PGHS-1; an S530T substitution causes 40- and 760-fold decreases in oxygenation efficiencies for AA and DHLA respectively.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	Michigan State University; United States Department of Energy (DOE); Argonne National Laboratory	Smith, WL (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, 513 Biochem Bldg, E Lansing, MI 48824 USA.	smithww@pilot.msu.edu	Malkowski, Michael G/G-4939-2011	Malkowski, Michael G/0000-0003-1025-0014; Malkowski, Michael/0000-0002-1203-7463	NHLBI NIH HHS [R01 HL56773, F32 HL10170-01] Funding Source: Medline; NIGMS NIH HHS [P01 GM57323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056773, F32HL010170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYWARDENA MY, 1989, BIOCHIM BIOPHYS ACTA, V1003, P161, DOI 10.1016/0005-2760(89)90250-6; BAER AN, 1991, BIOCHIM BIOPHYS ACTA, V1085, P45, DOI 10.1016/0005-2760(91)90230-F; BAER AN, 1991, J LIPID RES, V32, P341; BALAZY M, 1991, J BIOL CHEM, V266, P23561; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DeWitt DL, 1999, MOL PHARMACOL, V55, P625; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; ELLIOTT WJ, 1985, J BIOL CHEM, V260, P987; ENGELS F, 1986, FEBS LETT, V209, P249, DOI 10.1016/0014-5793(86)81121-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HSI LC, 1993, J LIPID MEDIATOR, V6, P131; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KNAPP HR, 1990, PROSTAGLANDINS, V39, P407, DOI 10.1016/0090-6980(90)90122-C; Koshkin V, 1999, BBA-PROTEIN STRUCT M, V1430, P341, DOI 10.1016/S0167-4838(99)00016-3; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAGARDE M, 1984, BIOMED BIOCHIM ACTA, V43, pS319; LANDS WEM, 1973, ADV BIOSCI, V9, P15; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; Larsen LN, 1996, BBA-LIPID LIPID MET, V1299, P47, DOI 10.1016/0005-2760(95)00188-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAVER HA, 1991, PROSTAG LEUKOTR ESS, V42, P217, DOI 10.1016/0952-3278(91)90086-K; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Malkowski MG, 2000, ARCH BIOCHEM BIOPHYS, V380, P39, DOI 10.1006/abbi.2000.1906; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; Marnett LJ, 1999, TRENDS PHARMACOL SCI, V20, P465, DOI 10.1016/S0165-6147(99)01385-1; NEEDLEMAN P, 1980, PROSTAG OTH LIPID M, V19, P165, DOI 10.1016/0090-6980(80)90163-X; NUGTEREN DH, 1987, PROSTAGLANDINS, V33, P403, DOI 10.1016/0090-6980(87)90022-0; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; OLIW EH, 1984, J BIOL CHEM, V259, P2716; OTTO JC, 1993, J BIOL CHEM, V268, P18234; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Smith WL, 2000, E SCHERING RES FDN W, V31, P53; SPECTOR AA, 1983, J LIPID RES, V24, P1595; Spencer AG, 1999, J BIOL CHEM, V274, P32936, DOI 10.1074/jbc.274.46.32936; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; Thuresson ED, 2001, J BIOL CHEM, V276, P10347, DOI 10.1074/jbc.M009377200; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695	57	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10358	10365		10.1074/jbc.M009378200	http://dx.doi.org/10.1074/jbc.M009378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11121413	hybrid			2022-12-25	WOS:000167996400102
J	Fabisiewicz, A; Worth, L				Fabisiewicz, A; Worth, L			Escherichia coli MutS,L modulate RuvAB-dependent branch migration between diverged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MISMATCH REPAIR; HOMEOLOGOUS RECOMBINATION; SALMONELLA-TYPHIMURIUM; RECA-PROTEIN; SACCHAROMYCES-CEREVISIAE; HOLLIDAY JUNCTIONS; STRAND EXCHANGE; GENETIC-RECOMBINATION; INTERSPECIES RECOMBINATION; MEIOTIC RECOMBINATION	This study examines the interaction between Escherichia coli MutS,L and E. coli RuvAB during E. coli Reck-promoted strand exchange. RuvAB is a branch migration complex that stimulates heterologous strand exchange, Previous studies indicate that RuvAB increases the rate at which heteroduplex products are formed by RecA, that RuvA and RuvB are required for this stimulation, and that RuvAB does not stimulate homologous strand exchange. This study indicates that MutS,L inhibit the formation of full-length heteroduplex DNA between M13-fd DNA in the presence of RuvAB, such that less than 2% of the linear substrate is converted to product. Inhibition depends on the time at which MutS,L are added to the reaction and is strongest when MutS,L are added during initiation. The kinetics of the strand exchange reaction suggest that MutS,L directly inhibit RuvAB-dependent branch migration in the absence of Reck The inhibition requires the formation of base-base mismatches and ATP utilization; no effect on RuvAB-promoted strand exchange is seen if an ATP-deficient mutant of MutS (MutS501) is included in the reaction instead of wild-type MutS. These results are consistent with a role for MutS,L in maintaining genomic stability and replication fidelity.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Worth, L (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	worth@niehs.nih.gov		Fabisiewicz, Anna/0000-0002-9334-1773	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065083] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams DE, 1996, J MOL BIOL, V263, P582, DOI 10.1006/jmbi.1996.0600; ADAMS DE, 1994, P NATL ACAD SCI USA, V91, P9901, DOI 10.1073/pnas.91.21.9901; ALANI E, 1994, GENETICS, V137, P19; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; BORTS RH, 1990, GENETICS, V124, P573; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; Chambers SR, 1996, MOL CELL BIOL, V16, P6110; Chen WL, 1999, GENETICS, V151, P1299; Chen WL, 1998, MOL CELL BIOL, V18, P6525, DOI 10.1128/MCB.18.11.6525; COOPER DL, 1993, J BIOL CHEM, V268, P11823; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; Datta A, 1996, MOL CELL BIOL, V16, P1085; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Evans E, 2000, MOL CELL BIOL, V20, P7839, DOI 10.1128/MCB.20.21.7839-7844.2000; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Hunter N, 1996, EMBO J, V15, P1726, DOI 10.1002/j.1460-2075.1996.tb00518.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; IYPE LE, 1995, J BIOL CHEM, V270, P19473, DOI 10.1074/jbc.270.33.19473; IYPE LE, 1994, J BIOL CHEM, V269, P24967; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; MacFarland KJ, 1997, J BIOL CHEM, V272, P17675, DOI 10.1074/jbc.272.28.17675; Matic I, 2000, METH MOL B, V152, P149; MATIC I, 1994, GENETICS, V136, P17; Matic I, 2000, J BACTERIOL, V182, P5922, DOI 10.1128/JB.182.20.5922-5924.2000; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Nicholson A, 2000, GENETICS, V154, P133; PARSONS CA, 1995, EMBO J, V14, P5736, DOI 10.1002/j.1460-2075.1995.tb00260.x; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RAYSSIGUIER C, 1991, BIOCHIMIE, V73, P371, DOI 10.1016/0300-9084(91)90103-8; Selva EM, 1997, MOL GEN GENET, V257, P71; SELVA EM, 1995, GENETICS, V139, P1175; SHEN P, 1989, MOL GEN GENET, V218, P358, DOI 10.1007/BF00331291; Stambuk S, 1998, GENETICS, V150, P533; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; WALDMAN AS, 1987, P NATL ACAD SCI USA, V84, P5340, DOI 10.1073/pnas.84.15.5340; Worth L, 1998, J BIOL CHEM, V273, P23176, DOI 10.1074/jbc.273.36.23176; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197; Yang D, 1997, MOL CELL BIOL, V17, P3614, DOI 10.1128/MCB.17.7.3614; ZAHRT TC, 1994, J BACTERIOL, V176, P1527, DOI 10.1128/jb.176.5.1527-1529.1994; Zahrt TC, 1997, P NATL ACAD SCI USA, V94, P9786, DOI 10.1073/pnas.94.18.9786	49	19	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9413	9420		10.1074/jbc.M005176200	http://dx.doi.org/10.1074/jbc.M005176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11106642	hybrid			2022-12-25	WOS:000167607700106
J	Kerr, KM; Sauna, ZE; Ambudkar, SV				Kerr, KM; Sauna, ZE; Ambudkar, SV			Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in human P-glycoprotein - Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MULTIDRUG TRANSPORTER; NUCLEOTIDE-BINDING DOMAINS; CYCLOSPORINE-A; TRANSITION-STATE; MAMMALIAN-CELLS; RESISTANCE CDNA; INSECT CELLS; SITE; PURIFICATION; EXPRESSION	P-glycoprotein (Pgp) is a transmembrane protein conferring multidrug resistance to cells by extruding a variety of amphipathic cytotoxic agents using energy from ATP hydrolysis. The objective of this study was to understand how substrates affect the catalytic cycle of ATP hydrolysis by Pgp, The ATPase activity of purified and reconstituted recombinant human Pgp was measured using a continuous cycling assay. Pgp hydrolyzes ATP in the absence of drug at a basal rate of 0.5 mu mol.min.mg(-1) with a K-m for ATP of 0.33 mM. This basal rate can be either increased or decreased depending on the Pgp substrate used, without an effect on the K-m for ATP or 8-azidoATP and K-i for ADP, suggesting that substrates do not affect nucleotide binding to Pgp, Although inhibitors of Pgp activity, cyclosporin A, its analog PSC833, and rapamycin decrease the rate of ATP hydrolysis with respect to the basal rate, they do not completely inhibit the activity. Therefore, these drugs can be classified as substrates. Vanadate (Vi)-induced trapping of [alpha-P-32]8-azidoADP was used to probe the effect of substrates on the transition state of the ATP hydrolysis reaction. The K-m for [alpha-P-32]8-azidoATP (20 muM) is decreased in the presence of Vi; however, it is not changed by drugs such as verapamil or cyclosporin A. Strikingly, the extent of Vi-induced [alpha-P-32]8-azidoADP trapping correlates directly with the fold stimulation of ATPase activity at steady state, Furthermore, P-i exhibits very low affinity for Pgp (K(i)similar to 30 mM for Vi-induced 8-azidoADP trapping). In aggregate, these data demonstrate that the release of Vi trapped [alpha-P-32]8-azidoADP from Pgp is the rate-limiting step in the steady-state reaction. We suggest that substrates modulate the rate of ATPase activity of Pgp by controlling the rate of dissociation of ADP following ATP hydrolysis and that ADP release is the rate-limiting step in the normal catalytic cycle of Pgp.	NCI, Cell Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambudkar, SV (corresponding author), NCI, Cell Biol Lab, Div Basic Sci, NIH, Bldg 37,Rm 1B-22,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	ambudkar@helix.nih.gov	Ambudkar, Suresh V/L-1317-2016; Sauna, Zuben E./AAA-7149-2019; Ambudkar, Suresh V/B-5964-2008					ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Ambudkar SV, 1998, METHOD ENZYMOL, V292, P504; Ambudkar SV, 1998, METHOD ENZYMOL, V292, P492; Croop JM, 1998, METHOD ENZYMOL, V292, P101; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Dey S, 1999, BIOCHEMISTRY-US, V38, P6630, DOI 10.1021/bi983038l; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DIDIER A, 1995, ANTI-CANCER DRUG, V6, P669, DOI 10.1097/00001813-199510000-00006; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; Garrigos M, 1997, EUR J BIOCHEM, V244, P664, DOI 10.1111/j.1432-1033.1997.00664.x; Germann UA, 1998, METHOD ENZYMOL, V292, P427; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Litman T, 1997, BBA-MOL BASIS DIS, V1361, P147, DOI 10.1016/S0925-4439(97)00025-2; Litman T, 1997, BBA-MOL BASIS DIS, V1361, P169, DOI 10.1016/S0925-4439(97)00027-6; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Pascaud C, 1998, BIOCHEM J, V333, P351, DOI 10.1042/bj3330351; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Ramachandra M, 1996, MOL BIOL CELL, V7, P1485, DOI 10.1091/mbc.7.10.1485; RAO US, 1995, J BIOL CHEM, V270, P6686; RAO US, 1994, MOL PHARMACOL, V45, P773; Rebbeor JF, 1998, BBA-BIOMEMBRANES, V1369, P85, DOI 10.1016/S0005-2736(97)00185-5; Romsicki Y, 1999, BIOCHEMISTRY-US, V38, P6887, DOI 10.1021/bi990064q; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; SAUNA ZE, 2001, IN PRESS J BIOL CHEM; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; SCHRAMM U, 1995, AM J PHYSIOL-RENAL, V268, pF46, DOI 10.1152/ajprenal.1995.268.1.F46; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Senior AE, 1998, METHOD ENZYMOL, V292, P514; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Sharom FJ, 1997, BIOCHEM SOC T, V25, P1088, DOI 10.1042/bst0251088; Shepard RL, 1998, BIOCHEM PHARMACOL, V56, P719, DOI 10.1016/S0006-2952(98)00212-3; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956	55	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8657	8664		10.1074/jbc.M010044200	http://dx.doi.org/10.1074/jbc.M010044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121420	hybrid			2022-12-25	WOS:000167607700008
J	Pukrop, T; Gradl, D; Henningfeld, KA; Knochel, W; Wedlich, D; Kuhl, M				Pukrop, T; Gradl, D; Henningfeld, KA; Knochel, W; Wedlich, D; Kuhl, M			Identification of two regulatory elements within the high mobility group box transcription factor XTCF-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA ENHANCER FUNCTION; BETA-CATENIN; BINDING-PROTEIN; HMG-DOMAIN; DIFFERENTIAL EXPRESSION; NUCLEAR-LOCALIZATION; XENOPUS DEVELOPMENT; GENE-EXPRESSION; FACTOR LEF-1; WNT	Some members of the Wnt family of extracellular glycoproteins regulate target gene expression by inducing stabilization and nuclear accumulation of beta -catenin, which functions as a transcriptional activator after binding to transcription factors of the T-cell factor! lymphoid enhancer factor (TCF/LEF) family. Three different members of this family have been identified in Xenopus laevis thus far that differ in their ability to influence mesodermal differentiation and to activate expression of the Wnt target gene fibronectin, Here we report on the isolation and characterization of additional variants of XTCF-4. We:show that the differential ability of these proteins and other members of the TCF family to activate target genes is neither due to preferential interaction with transcriptional cofactors of the groucho family or SMAD4 nor to different DNA binding affinities, Expression of these proteins in an epithelial cell line reveals differences in their ability to form a ternary complex with DNA and beta -catenin. Interestingly, formation of this ternary complex was not sufficient to activate target gene expression as previously thought. Our experiments identify two amino acid sequence motifs, LVPQ and SFLSS, in the central domain of XTCF-4 that regulate the formation of the DNA-TCF-beta -catenin complex or activation of target genes, respectively Biochemical studies reveal that the phosphorylation state of these XTCF-4 variants correlates with their ability to form a ternary complex with beta -catenin and DNA but not to activate target gene expression, The described variants of XTFC-4 with their different properties in complex formation provide strong evidence that in addition to the regulation of beta -catenin stability the isoforms of TCF/LEF transcription factors and their posttranslational modifications define the cellular response of a Wnt/wingless signal.	Univ Ulm, Biochem Abt, D-89081 Ulm, Germany	Ulm University	Kuhl, M (corresponding author), Univ Gottingen, Abt Entwicklungbiochem, Jr Grp SFB 271, Humboldtallee 23, D-37073 Gottingen, Germany.							Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Choudhury BK, 1997, GENE, V195, P41, DOI 10.1016/S0378-1119(97)00150-9; Dahlquist F W, 1978, Methods Enzymol, V48, P270; Etard C, 2000, MECH DEVELOP, V94, P219, DOI 10.1016/S0925-4773(00)00305-1; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Hadeball B, 1998, MECH DEVELOP, V72, P101, DOI 10.1016/S0925-4773(98)00022-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Konig A, 2000, MECH DEVELOP, V93, P211, DOI 10.1016/S0925-4773(00)00266-5; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; LABBE E, 2000, GENE DEV, V97, P8358; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 2000, MECH DEVELOP, V91, P311, DOI 10.1016/S0925-4773(99)00259-2; Molenaar M, 1998, MECH DEVELOP, V75, P151, DOI 10.1016/S0925-4773(98)00085-9; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Wisniewski JR, 1999, J BIOL CHEM, V274, P20116; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	37	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8968	8978		10.1074/jbc.M007533200	http://dx.doi.org/10.1074/jbc.M007533200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124256	hybrid			2022-12-25	WOS:000167607700049
J	Diao, JY; Khine, AA; Sarangi, F; Hsu, E; Iorio, C; Tibbles, LA; Woodgett, JR; Penninger, J; Richardson, CD				Diao, JY; Khine, AA; Sarangi, F; Hsu, E; Iorio, C; Tibbles, LA; Woodgett, JR; Penninger, J; Richardson, CD			X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; NECROSIS-FACTOR-ALPHA; SV40 T-ANTIGEN; HBX PROTEIN; C-JUN; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; KAPPA-B; CELL-DEATH; TRANSCRIPTION FACTOR	The X protein from a chronic strain of hepatitis B virus (HBx) was determined to inhibit Fas-mediated apoptosis and promote cell survival. Fas-mediated apoptosis is the major cause of hepatocyte damage during liver disease. Experiments demonstrated that cell death caused by anti-Fas antibodies was blocked by the expression of HBx in human primary hepatocytes and mouse embryo fibroblasts. This effect was also observed in mouse erythroleukemia cells that lacked p53, indicating that protection against Fas-mediated apoptosis was independent of p53. Components of the signal transduction pathways involved in this protection were studied. The SAPK/JNK pathway has previously been suggested to be a survival pathway for some cells undergoing Fas-mediated apoptosis, and kinase assays showed that SAPK activity was highly up-regulated in cells expressing the HBx protein. Normal mouse fibroblasts expressing HBx were protected from death, whereas identical fibroblasts lacking the SEK1 component from the SAPK pathway succumbed to Fas-mediated apoptosis, whether HBx was present or not. Assays showed that caspase 3 and 8 activities and the release of cytochrome c from mitochondria were inhibited, in the presence of HBx, following stimulation with anti-Fas antibodies. Coprecipitation and confocal immunofluorescence microscopy experiments demonstrated that HBx localizes with a cytoplasmic complex containing MEKK1, SER1, SAPK, and 14-3-3 proteins. Finally, mutational analysis of HBx demonstrated that a potential binding region for 14-3-3 proteins was essential for induction of SAPK/JNK activity and protection from Fas-mediated apoptosis.	Amgen Res Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Richardson, CD (corresponding author), Amgen Res Inst, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.		Woodgett, Jim/F-1087-2010; Penninger, Josef M/I-6860-2013	Woodgett, Jim/0000-0003-3731-5797; Penninger, Josef M/0000-0002-8194-3777				Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Barry M, 1998, CURR OPIN IMMUNOL, V10, P422, DOI 10.1016/S0952-7915(98)80116-7; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Cong YS, 1997, J BIOL CHEM, V272, P16482, DOI 10.1074/jbc.272.26.16482; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Feitelson MA, 1997, AM J PATHOL, V150, P1141; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GANEM D, 1996, FIELDS VIROLOGY, V2, P6881; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Han JH, 1998, ONCOGENE, V17, P2993, DOI 10.1038/sj.onc.1202215; Hardwick JM, 1998, SEMIN CELL DEV BIOL, V9, P339, DOI 10.1006/scdb.1998.0243; Henkler F, 1998, J GEN VIROL, V79, P2737, DOI 10.1099/0022-1317-79-11-2737; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hildt E, 1996, SEMIN VIROL, V7, P333, DOI 10.1006/smvy.1996.0041; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; Koike K, 1995, INTERVIROLOGY, V38, P134, DOI 10.1159/000150424; Koshy R., 1998, HEPATITIS B VIRUS MO; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Kumar A, 1998, J IMMUNOL, V161, P776; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; Lee Y, 1998, GENE, V207, P111, DOI 10.1016/S0378-1119(97)00603-3; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Miller LK, 1998, SEMIN VIROL, V8, P445, DOI 10.1006/smvy.1998.0149; Mitsui H, 1998, HEPATOLOGY, V27, P1362, DOI 10.1002/hep.510270524; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1999, DEVELOPMENT, V126, P505; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Pear Warren S., 1997, P41; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; ROUQUET N, 1995, ONCOGENE, V11, P1061; Rouquet N, 1996, CELL DEATH DIFFER, V3, P91; Schaefer S, 1998, J GEN VIROL, V79, P767, DOI 10.1099/0022-1317-79-4-767; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; See RH, 1998, MOL CELL BIOL, V18, P4012, DOI 10.1128/MCB.18.7.4012; SEIFER M, 1991, J HEPATOL, V13, P61, DOI DOI 10.1016/0168-8278(91)90026-8; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Shintani Y, 1999, J GEN VIROL, V80, P3257, DOI 10.1099/0022-1317-80-12-3257; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; TAKADA S, 1994, ONCOGENE, V9, P341; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; VAN AD, 1996, SCIENCE, V274, P787; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1995, CANCER RES, V55, P6012; Weil R, 1999, MOL CELL BIOL, V19, P6345; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Xu X, 1996, ONCOGENE, V13, P135; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	100	135	156	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8328	8340		10.1074/jbc.M006026200	http://dx.doi.org/10.1074/jbc.M006026200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11099494	hybrid			2022-12-25	WOS:000167474900090
J	Schulein, R; Zuhlke, K; Krause, G; Rosenthal, W				Schulein, R; Zuhlke, K; Krause, G; Rosenthal, W			Functional rescue of the nephrogenic diabetes insipidus-causing vasopressin V-2 receptor mutants G185C and R202C by a second site suppressor mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V2 VASOPRESSIN; TYPE-2 RECEPTOR; MOLECULAR-BASIS; BINDING; GENE; TRANSPORT; RESIDUES	Mutations in the gene of the G protein-coupled vasopressin V-2 receptor (V-2 receptor) cause X-linked nephrogenic diabetes insipidus (NDI). Most of the missense mutations on the extracellular face of the receptor introduce additional cysteine residues. Several groups have proposed that these residues might disrupt the conserved disulfide bond of the V-2 receptor. To test this hypothesis, we first calculated a structure model of the extracellular receptor domains. The model suggests that the additional cysteine residues may form a second disulfide bond with the free, nonconserved extracellular cysteine residue Cys-195 rather than impairing the conserved bond. To address this question experimentally, we used the NDI-causing mutant receptors G185C and R202C. Their Cys-195 residues were replaced by alanine to eliminate the hypothetical second disulfide bonds. This second site mutation led to functional rescue of both NDI-causing mutant receptors, strongly suggesting that the second disulfide bonds are indeed formed. Furthermore we show that residue Cys-195, which is sensitive to "additional cysteine" mutations, is not conserved among the V-2 receptors of other species and that the presence of an uneven number of extracellular cysteine residues, as in the human V-2 receptor, is rare among class I G protein-coupled receptors.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Schulein, R (corresponding author), Forschungsinst Mol Pharmakol, Robert-Rossle-Str 10, D-13125 Berlin, Germany.	schuelein@fmp-berlin.de						Ala Y, 1998, J AM SOC NEPHROL, V9, P1861; BICHET DG, 1994, AM J HUM GENET, V55, P278; CHINI B, 2000, EXP PHYSIOL, V85, P59; Cotte N, 1998, J BIOL CHEM, V273, P29462, DOI 10.1074/jbc.273.45.29462; Elling CE, 2000, BIOCHEMISTRY-US, V39, P667, DOI 10.1021/bi991777b; Goodman M, 1996, MOL PHYLOGENET EVOL, V5, P269, DOI 10.1006/mpev.1996.0021; Hausmann H, 1996, P NATL ACAD SCI USA, V93, P6907, DOI 10.1073/pnas.93.14.6907; Klussmann E, 2000, REV PHYSIOL BIOCH P, V141, P33, DOI 10.1007/BFb0119577; Krause G, 2000, MOL PHARMACOL, V57, P232; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; PAN Y, 1994, J BIOL CHEM, V269, P31933; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; Sadeghi HM, 1997, MOL ENDOCRINOL, V11, P706, DOI 10.1210/me.11.6.706; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulein R, 1996, J BIOL CHEM, V271, P28844, DOI 10.1074/jbc.271.46.28844; Schulein R, 2000, FEBS LETT, V466, P101, DOI 10.1016/S0014-5793(99)01764-0; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; ter Laak AM, 1999, RECEPTOR CHANNEL, V6, P295; TSUKAGUCHI H, 1995, J CLIN INVEST, V96, P2043, DOI 10.1172/JCI118252; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99; WILDIN RS, 1994, AM J HUM GENET, V55, P266; Yokoyama K, 1996, J AM SOC NEPHROL, V7, P410	26	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8384	8392		10.1074/jbc.M007045200	http://dx.doi.org/10.1074/jbc.M007045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11116139	hybrid			2022-12-25	WOS:000167474900097
J	Chin, LS; Raynor, MC; Wei, XL; Chen, HQ; Li, L				Chin, LS; Raynor, MC; Wei, XL; Chen, HQ; Li, L			Hrs interacts with sorting nexin 1 and regulates degradation of epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER DOMAIN; EARLY ENDOSOMES; SIGNAL-TRANSDUCTION; SACCHAROMYCES-CEREVISIAE; PREVACUOLAR COMPARTMENT; MEMBRANE-PROTEINS; FYVE FINGER; LATE-GOLGI; BINDING; IDENTIFICATION	Hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) is a mammalian homologue of yeast vacuolar protein sorting (Vps) protein Vps27p; however, the role of Hrs in lysosomal trafficking is unclear. Here, we report that Hrs interacts with sorting nexin 1 (SNX1), a recently identified mammalian homologue of yeast Vps5p that recognizes the lysosomal targeting code of epidermal growth factor receptor (EGFR) and participates in lysosomal trafficking of the receptor, Biochemical analyses demonstrate that Hrs and SNX1 are ubiquitous proteins that exist in both cytosolic and membrane-associated pools, and that the association of Hrs and SNX occurs on cellular membranes but not in the cytosol. Furthermore, endogenous SNX1 and Hrs form a similar to 550-kDa complex that excludes EGFR. Immunofluorescence and subcellular fractionation studies show that Hrs and SNX1 colocalize on early endosomes, By using deletion analysis, we have mapped the binding domains of Hrs and SNX1 that mediate their association. Overexpression of Hrs or its SNX1-binding domain inhibits ligand-induced degradation of EGFR, but does not affect either constitutive or ligand-induced receptor-mediated endocytosis. These results suggest that Hrs may regulate lysosomal trafficking through its interaction with SNX1.	Univ N Carolina, Dept Pharmacol, Sch Med, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Mol Physiol, Sch Med, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Li, L (corresponding author), Univ N Carolina, Dept Pharmacol, Sch Med, Bowles Ctr Alcohol Studies, Rm 1025A Thurston Bowles, Chapel Hill, NC 27599 USA.			Chin, Lih-Shen/0000-0002-0817-0368; Li, Lian/0000-0003-4700-1134	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037939] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37939] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hayakawa A, 2000, J BIOL CHEM, V275, P29636, DOI 10.1074/jbc.M002696200; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kwong J, 2000, J CELL SCI, V113, P2273; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mellman I, 1996, CURR OPIN CELL BIOL, V8, P497, DOI 10.1016/S0955-0674(96)80026-3; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nothwehr SF, 1997, J CELL SCI, V110, P1063; Oksvold MP, 2000, J HISTOCHEM CYTOCHEM, V48, P21, DOI 10.1177/002215540004800103; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PIIPER A, 1995, BIOCHEM J, V309, P621, DOI 10.1042/bj3090621; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Sambrook J., 2002, MOL CLONING LAB MANU; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Voos W, 1998, J CELL BIOL, V140, P577, DOI 10.1083/jcb.140.3.577	44	163	169	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7069	7078		10.1074/jbc.M004129200	http://dx.doi.org/10.1074/jbc.M004129200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11110793	hybrid, Green Published			2022-12-25	WOS:000167442900031
J	Keummerle, JF; Murthy, KS				Keummerle, JF; Murthy, KS			Coupling of the insulin-like growth factor-I receptor tyrosine kinase to G(12) in human intestinal smooth muscle - G(beta gamma)-Dependent mitogen-activated protein kinase activation and growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3'-KINASE; PHOSPHOLIPASE C-BETA-3; ADENYLYL-CYCLASE; BINDING PROTEINS; CELLS; INHIBITION; 3-KINASE; SUBUNITS	Endogenous insulin-like growth factor-1 (IGF-I) stimulates growth of cultured human intestinal smooth muscle by activating distinct mitogen-activated protein (MAP) kinase-dependent and phosphatidylinositol 3-kinase-dependent signaling pathways. In Rat1 and Balb/ c3T3 fibroblasts and in neurons the IGF-I receptor is coupled to an inhibitory G protein, G, which mediates G(beta gamma)-dependent MAP kinase activation. The present study determined whether in normal human intestinal smooth muscle cells the IGF-I receptor activates a heterotrimeric G protein and the role of G protein activation in mediating IGF-I-induced growth. IGF-I elicited IGF-I receptor tyrosine phosphorylation, resulting in the specific activation of G(i2). Gp, subunits selectively mediated IGF-I-dependent MAP kinase activation; G(alpha i2) subunits selectively mediated IGF-I dependent inhibition of adenylyl cyclase actvity. IGF-I-stimulated MAP kinase activation and growth were inhibited by pertussis toxin, an inhibitor of G(i)/G(o) activation. Cyclic AMP inhibits growth of human intestinal muscle cells. ICE-I inhibited both basal and forskolin-stimulated cAMP levels. This inhibition was attenuated in the presence of pertussis toxin. IGF-I stimulated phosphatidylinositol 3-kinase activation, in contrast to MAP kinase activation, occurred independently of G(i2) activation. These data suggest that IGF-I specifically activates G(i2), resulting in concurrent G(beta gamma)-dependent stimulation of MAP kinase activity and growth, and G(alpha i2)-dependent inhibition of cAMP levels resulting in disinhibition of cAMP-mediated growth suppression.	Virginia Commonwealth Univ, Div Gastroenterol, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Physiol, Med Coll Virginia, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Keummerle, JF (corresponding author), Virginia Commonwealth Univ, Div Gastroenterol, Med Coll Virginia, Dept Med, Med Coll Virginia Campus,POB 980711, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK049691, R01DK049691, R29DK049691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASERGA R, 1994, CELL PROLIFERAT, V27, P62; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Bonisch D, 1998, MOL PHARMACOL, V54, P241, DOI 10.1124/mol.54.2.241; Bushman TL, 1998, AM J PHYSIOL-GASTR L, V275, pG1282, DOI 10.1152/ajpgi.1998.275.6.G1282; CAMBREY AD, 1995, CLIN SCI, V89, P611, DOI 10.1042/cs0890611; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cospedal R, 1999, BIOCHEM J, V342, P407, DOI 10.1042/0264-6021:3420407; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; FRANCIS GL, 1993, BIOCHEM J, V293, P719; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; Kuemmerle JF, 2000, AM J PHYSIOL-GASTR L, V278, pG710, DOI 10.1152/ajpgi.2000.278.5.G710; Kuemmerle JF, 1998, AM J PHYSIOL-GASTR L, V275, pG151, DOI 10.1152/ajpgi.1998.275.1.G151; Kuemmerle JF, 1997, GASTROENTEROLOGY, V113, P817, DOI 10.1016/S0016-5085(97)70176-8; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LI CH, 1993, P NATL ACAD SCI USA, V90, P11713; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Murthy KS, 1997, J BIOL CHEM, V272, P21317, DOI 10.1074/jbc.272.34.21317; Murthy KS, 1996, MOL PHARMACOL, V50, P870; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; OKAMOTO T, 1992, FEBS LETT, V305, P125, DOI 10.1016/0014-5793(92)80878-K; OKAMOTO T, 1990, BIOCHEM BIOPH RES CO, V168, P1201, DOI 10.1016/0006-291X(90)91156-M; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Parrizas M, 1997, J BIOL CHEM, V272, P154; Reape TJ, 1996, AM J PHYSIOL-HEART C, V270, pH1141, DOI 10.1152/ajpheart.1996.270.4.H1141; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YAMAMOTO M, 1994, EXP CELL RES, V212, P62, DOI 10.1006/excr.1994.1118	46	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7187	7194		10.1074/jbc.M011145200	http://dx.doi.org/10.1074/jbc.M011145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11120746	hybrid			2022-12-25	WOS:000167442900047
J	Kim, I; Moon, SO; Kim, SH; Kim, HJ; Koh, YS; Koh, GY				Kim, I; Moon, SO; Kim, SH; Kim, HJ; Koh, YS; Koh, GY			Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NITRIC-OXIDE SYNTHASE; IN-VITRO; PHOSPHORYLATION; RECEPTOR; PATHWAY; INHIBITOR; BINDING; FLT-1	Vascular endothelial growth factor (VEGF) induces adhesion molecules on endothelial cells during inflammation. Here we examined the mechanisms underlying VEGF-stimulated expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1)1 and E-selectin in human umbilical vein endothelial cells. VEGF (20 ng/ml) increased expression of ICAM-1, VCAM-1, and E-selectin mRNAs in a time-dependent manner. These effects were significantly suppressed by Flk-1/kinase-insert domain containing receptor (KDR) antagonist and by inhibitors of phospholipase C, nuclear factor (NF)-B-K, sphingosine kinase, and protein kinase C, but they were not affected by inhibitors of mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) 1/2 or nitric-oxide synthase, Unexpectedly, the phosphatidylinositol (PI) 3'-kinase inhibitor wortmannin enhanced both basal and VEGF-stimulated adhesion molecule expression, whereas insulin, a PI 3'-kinase activator, suppressed both basal and VEGF-stimulated expression, Gel shift analysis revealed that VEGF stimulated NF-B-K activity, This effect was inhibited by phospholipase C, NF-B-K, or protein kinase C inhibitor, VEGF increased VCAM-1 and ICAM-1 protein levels and increased leukocyte adhesiveness in a NF-KB-dependent manner. These results suggest that VEGF-stimulated expression of ICAM-1, VCARI-1, and E-selectin mRNAs was mainly through NF-KB activation with PI 3'-kinase-mediated suppression, but was independent of nitric oxide and MEK, Thus, VEGF simultaneously activates two signal transduction pathways that have opposite functions in the induction of adhesion molecule expression. The existence of parallel inverse signaling implies that the induction of adhesion molecule expression by VEGF is very finely regulated.	Chonbuk Natl Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, Chonju 560180, South Korea; Chonbuk Natl Univ, Sch Med, Dept Urol, Chonju 560180, South Korea	Jeonbuk National University; Jeonbuk National University	Koh, GY (corresponding author), Chonbuk Natl Univ, Sch Med, Natl Creat Res Initiat Ctr Cardiac Regenerat, San 2-20, Chonju 560180, South Korea.	gykoh@moak.chonbuk.ac.kr	Kim, Injune/C-1710-2011; Koh, Gou Young/C-1615-2011	Kim, Injune/0000-0001-9244-815X; 				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; AKESON AL, 1993, J IMMUNOL METHODS, V163, P181, DOI 10.1016/0022-1759(93)90121-M; Bischoff J, 1997, J CLIN INVEST, V100, pS37; Boyle EM, 1998, CIRCULATION, V98, pII282; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gimbrone MA, 1997, J CLIN INVEST, V100, pS61; GIMBRONE MA, 1995, MOL CARDIOVASCULAR M, P49; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lu M, 1999, INVEST OPHTH VIS SCI, V40, P1808; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Olivera A, 1999, FASEB J, V13, P1593, DOI 10.1096/fasebj.13.12.1593; PARK JE, 1994, J BIOL CHEM, V269, P25646; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thurston G, 2000, MICROCIRCULATION, V7, P67, DOI 10.1038/sj.mn.7300155; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006	36	604	649	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7614	7620		10.1074/jbc.M009705200	http://dx.doi.org/10.1074/jbc.M009705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11108718	hybrid			2022-12-25	WOS:000167442900102
J	Werthen, M; Lundgren, T				Werthen, M; Lundgren, T			Intracellular Ca2+ mobilization and kinase activity during acylated homoserine lactone-dependent quorum sensing in Serratia liquefaciens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIBRIO-FISCHERI; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATOR; AUTOINDUCER-BINDING; TERMINAL REGION; LUX REGULON; CALCIUM; LUMINESCENCE; SEQUENCE; DOMAIN	Quorum sensing in Gram-negative bacteria involves acylated homoserine lactones (AHLs) and a transcription factor, activated by the AHLs. In this study, a possible involvement of intracellular Ca2+ as second messenger and/or protein kinase activity during signal transduction is analyzed. When N-hexanoyl-L-homoserine lactone was added to a suspension of Fura-2-loaded Serratia liquefaciens, there was a decline in [Ca2+](i), measured as a decrease in the Fura-2 fluorescence ratio. As controls, the addition of the signal molecule N-3-oxohexanoyl-L-homoserine lactone, which is not produced by S. liquefaciens, did not induce changes in [Ca2+](i). Using a protein kinase activity assay on AHL- stimulated cells, an increase in kinase activity after N-butanoyl-L-homoserine lactone stimulation of S. liquefaciens cells was detected, whereas the kinase activity induced by N-3-oxohexanoyl-L-homoserine lactone was not statistically significant. The conclusion from this study is that changes in [Ca2+](i) are involved in quorum sensing signal transduction in the Gram-negative bacteria S. liquefaciens. We also conclude that kinase activity is induced in S. liquefaciens upon AHL stimulation. We suggest that the transient intracellular [Ca2+] changes and kinase activity, activated by the AHL signal, are critical for the quorum-sensing signal transduction.	Univ Gothenburg, Dept Cell & Mol Biol Microbiol, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Fac Odontol, Dept Oral Biochem, SE-40530 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Werthen, M (corresponding author), Univ Gothenburg, Dept Cell & Mol Biol Microbiol, POB 462, SE-40530 Gothenburg, Sweden.			Lundgren, Ted/0000-0002-1985-2524				Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BASSLER BL, 1993, MOL MICROBIOL, V9, P773, DOI 10.1111/j.1365-2958.1993.tb01737.x; BASSLER BL, 1994, MOL MICROBIOL, V12, P403, DOI 10.1111/j.1365-2958.1994.tb01029.x; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; CHOI SH, 1991, P NATL ACAD SCI USA, V88, P11115, DOI 10.1073/pnas.88.24.11115; DEVINE JH, 1988, BIOCHEMISTRY-US, V27, P837, DOI 10.1021/bi00402a052; DEVINE JH, 1989, P NATL ACAD SCI USA, V86, P5688, DOI 10.1073/pnas.86.15.5688; Eberl L, 1996, MOL MICROBIOL, V20, P127, DOI 10.1111/j.1365-2958.1996.tb02495.x; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; Givskov M, 1997, FEMS MICROBIOL LETT, V148, P115, DOI 10.1016/S0378-1097(96)00530-7; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANZELKA BL, 1995, J BACTERIOL, V177, P815, DOI 10.1128/jb.177.3.815-817.1995; Jones HE, 1999, CELL CALCIUM, V25, P265, DOI 10.1054/ceca.1999.0028; KAPLAN HB, 1987, P NATL ACAD SCI USA, V84, P6639, DOI 10.1073/pnas.84.19.6639; Kennelly PJ, 1996, J BACTERIOL, V178, P4759, DOI 10.1128/jb.178.16.4759-4764.1996; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; KOLIBACHUK D, 1993, J BACTERIOL, V175, P7307, DOI 10.1128/JB.175.22.7307-7312.1993; Kuo A, 1996, J BACTERIOL, V178, P971, DOI 10.1128/jb.178.4.971-976.1996; Motley ST, 1999, INFECT IMMUN, V67, P5386, DOI 10.1128/IAI.67.10.5386-5394.1999; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Norris V, 1996, J BACTERIOL, V178, P3677, DOI 10.1128/jb.178.13.3677-3682.1996; ONEK LA, 1992, J GEN MICROBIOL, V138, P1039, DOI 10.1099/00221287-138-6-1039; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; SALMOND GPC, 1995, MOL MICROBIOL, V16, P615, DOI 10.1111/j.1365-2958.1995.tb02424.x; SITNIKOV DM, 1995, MOL MICROBIOL, V17, P801, DOI 10.1111/j.1365-2958.1995.mmi_17050801.x; Smith R J, 1995, Adv Microb Physiol, V37, P83, DOI 10.1016/S0065-2911(08)60144-7; STEVENS AM, 1994, P NATL ACAD SCI USA, V91, P12619, DOI 10.1073/pnas.91.26.12619; TISA LS, 1995, P NATL ACAD SCI USA, V92, P10777, DOI 10.1073/pnas.92.23.10777; WATKINS NJ, 1995, BIOCHEM J, V306, P865, DOI 10.1042/bj3060865; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832	31	19	22	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6468	6472		10.1074/jbc.M009223200	http://dx.doi.org/10.1074/jbc.M009223200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11102448	hybrid			2022-12-25	WOS:000167261000054
J	Feigelson, S; Grabovsky, V; Winter, E; Chen, LL; Pepinsky, RB; Yednock, T; Yablonski, D; Lobb, R; Alon, R				Feigelson, S; Grabovsky, V; Winter, E; Chen, LL; Pepinsky, RB; Yednock, T; Yablonski, D; Lobb, R; Alon, R			The Src kinase p56(lck) up regulates VLA-4 integrin affinity - Implications for rapid spontaneous and chemokine-triggered T cell adhesion to VCAM-1 and fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; MULTIPLE ACTIVATION STATES; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CROSS-LINKING; P-SELECTIN; PHOSPHATIDYLINOSITOL 3-KINASE; VASCULAR ENDOTHELIUM; PHYSIOLOGICAL FLOW	In circulating lymphocytes, the VLA-4 integrin preexists in multiple affinity states that mediate spontaneous tethering, rolling, and arrest on its endothelial ligand, vascular cell adhesion molecule-1 (VCAM-1), The regulation and function of VLA-4 affinity in lymphocytes has never been elucidated. We show here that p56(lck), the major Src kinase in T cells, is a key regulator of high affinity VLA-4, This high affinity is essential for the rapid development of firm adhesion of resting T cells to VCAM-1 and to their extracellular matrix ligand, fibronectin, Lck-regulated VLA-4 function does not require intact TCR nor several key components of the TCR signaling pathway, including ZAP-70 and SLP-76, Furthermore, stimulation of p56(lck) by the phosphatase inhibitor, pervanadate, triggers firm VLA-4-dependent adhesion to VCAM-1, Although Lck is not required for chemokine receptor signaling to mitogen-activated protein kinase, the presence of Lck-regulated high affinity VLA-4 also facilitates firm adhesion triggered by the chemokine, SDF-1, at short-lived contacts. Surprisingly, bond formation rates, ability to tether cells to VLA-4 ligand, and VLA-4 tether bond stability under shear flow are not affected by VLA-4 affinity or Lck activity. Thus, the ability of high affinity VLA-4 to arrest cells on VCAM-1 under flow arises from instantaneous post-ligand strengthening rather than from increased kinetic stability of individual VLA-4 bonds. These results suggest that p56(lck) maintains high affinity VLA-4 on circulating lymphocytes, which determines their ability to strengthen VLA-4 adhesion and rapidly respond to proadhesive chemokine signals at endothelial sites.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Elan Pharmaceut Inc, San Francisco, CA 94080 USA; Biogen Inc, Cambridge, MA 02142 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel	Weizmann Institute of Science; Biogen; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Alon, R (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	ronalon@wicc.weizmann.ac.il	ALON, RONEN/GRX-6987-2022	Yablonski, Deborah/0000-0003-2979-0440; Alon, Ronen/0000-0001-9161-6369				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; ARROYO AG, 1995, EUR J IMMUNOL, V25, P1720, DOI 10.1002/eji.1830250635; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CARMO AM, 1993, EUR J IMMUNOL, V23, P2196, DOI 10.1002/eji.1830230922; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; Chan JR, 2000, J IMMUNOL, V164, P746, DOI 10.4049/jimmunol.164.2.746; Chen C, 1999, J IMMUNOL, V162, P1084; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Ilangumaran S, 1999, LEUKEMIA LYMPHOMA, V35, P455, DOI 10.1080/10428199909169610; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Jin YJ, 1998, J IMMUNOL, V161, P1743; Johnston B, 1996, J EXP MED, V183, P1995, DOI 10.1084/jem.183.5.1995; Konstantopoulos K, 1997, J LEUKOCYTE BIOL, V61, P179, DOI 10.1002/jlb.61.2.179; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Lim YC, 2000, MICROCIRCULATION, V7, P201, DOI 10.1038/sj.mn.7300103; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; LUSCINSKAS FW, 1995, J EXP MED, V181, P1179, DOI 10.1084/jem.181.3.1179; Mannion BA, 1996, J IMMUNOL, V157, P2039; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PAGE TH, 1995, EUR J IMMUNOL, V25, P2956, DOI 10.1002/eji.1830251036; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Rose DM, 2000, BLOOD, V95, P602, DOI 10.1182/blood.V95.2.602; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Sethi T, 1999, MOL BIOL CELL, V10, P1799, DOI 10.1091/mbc.10.6.1799; SHIMIZU Y, 1992, J EXP MED, V175, P577, DOI 10.1084/jem.175.2.577; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stewart MP, 1996, J IMMUNOL, V156, P1810; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; Warnock RA, 1998, J EXP MED, V187, P205, DOI 10.1084/jem.187.2.205; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740; Zell T, 1996, J IMMUNOL, V156, P883; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	77	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13891	13901		10.1074/jbc.M004939200	http://dx.doi.org/10.1074/jbc.M004939200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11102438	hybrid			2022-12-25	WOS:000168356600055
J	Eble, JA; Beermann, B; Hinz, HJ; Schmidt-Hederich, A				Eble, JA; Beermann, B; Hinz, HJ; Schmidt-Hederich, A			alpha(2)beta(1) integrin is not recognized by rhodocytin but is the specific, high affinity target of rhodocetin, an RGD-independent disintegrin and potent inhibitor of cell adhesion to collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-AGGREGATION INHIBITOR; MALAYAN PIT VIPER; CALLOSELASMA-RHODOSTOMA; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; 3-DIMENSIONAL COLLAGEN; GLYCOPROTEIN IA/IIA; GENE-EXPRESSION; IV COLLAGEN; VENOM	We have recombinantly expressed a soluble form of human alpha (2)beta (1) integrin that lacks the membrane-anchoring transmembrane domains as well as the cytoplasmic tails of both integrin subunits. This soluble alpha (2)beta (1) integrin binds to its collagen ligands the same way as the wildtype alpha (2)beta (1) integrin. Furthermore, like the wild-type form, it can be activated by manganese ions and an integrin-activating antibody. However, it does not bind to rhodocytin, a postulated agonist of alpha (2)beta (1) integrin from the snake venom of Calloselasma rhodostoma, which elicits platelet aggregation, Tacking advantage of the recombinantly expressed, soluble alpha (2)beta (1) integrin, an inhibition assay was established in which samples can be tested for their capability to inhibit binding of soluble alpha (2)beta (1) integrin to immobilized collagen. Thus, by scrutinizing the C. rhodostoma snake venom in this protein-protein interaction assay, we found a component of the snake venom that inhibits the interaction of soluble alpha (2)beta (1) integrin to type I collagen efficiently. N-terminal sequences identified this inhibitor as rhodocetin, a recently published antagonist of collagen-induced platelet aggregation. We could demonstrate that its inhibitory effect bases on its strong and specific binding to alpha (2)beta (1) integrin, proving that rhodocetin is a disintegrin. Standing apart from the growing group of RGD-dependent snake venom disintegrins, rhodocetin interacts with alpha (2)beta (1) integrin in an RGD-independent manner. Furthermore, its native conformation, which is stabilized by disulfide bridges, is indispensibly required for its inhibitory activity. Rhodocetin does not contain any major collagenous structure despite its high affinity to alpha (2)beta (1) integrin, which binds to collagenous molecules much more avidly than to noncollagenous Ligands, such as laminin. Blocking alpha (2)beta (1) integrin as the major collagen receptor on platelets, rhodocetin is responsible for hampering collagen-induced, alpha (2)beta (1) integrin-mediated platelet activation, leading to hemorrhages and bleeding disorders of the snakebite victim. Moreover, having a widespread tissue distribution, alpha (2)beta (1) integrin also mediates cell adhesion, spreading, and migration. We showed that rhodocetin is able to inhibit alpha (2)beta (1) integrin-mediated adhesion of fibrosarcoma cells to type I collagen completely.	Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Munster, Inst Phys Chem, D-48149 Munster, Germany	University of Munster; University of Munster	Eble, JA (corresponding author), Univ Munster, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.							AU LC, 1993, BIOCHEM J, V294, P387, DOI 10.1042/bj2940387; AU LC, 1991, BIOCHEM BIOPH RES CO, V181, P585, DOI 10.1016/0006-291X(91)91230-A; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CALVETE JJ, 1997, INTEGRIN LIGAND INTE, P157; Chung CH, 1999, BIOCHEM BIOPH RES CO, V263, P723, DOI 10.1006/bbrc.1999.1457; Chung MCM, 1996, ARCH BIOCHEM BIOPHYS, V325, P199, DOI 10.1006/abbi.1996.0025; DECKMYN H, 1990, THROMB HAEMOSTASIS, V64, P74; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; EBLE JA, 1997, INTEGRIN LIGAND INTE, P1; Eckes B, 2000, MATRIX BIOL, V19, P325, DOI 10.1016/S0945-053X(00)00077-9; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Heemskerk JWM, 1999, THROMB HAEMOSTASIS, V81, P782; Heino J, 2000, MATRIX BIOL, V19, P319, DOI 10.1016/S0945-053X(00)00076-7; HEYN MP, 1975, BIOCHEMISTRY-US, V14, P2962, DOI 10.1021/bi00684a026; HUANG TF, 1995, BIOCHEM J, V309, P1021, DOI 10.1042/bj3091021; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Inoue K, 1999, BIOCHEM BIOPH RES CO, V256, P114, DOI 10.1006/bbrc.1999.0295; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Lochter A, 1999, MOL BIOL CELL, V10, P271, DOI 10.1091/mbc.10.2.271; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; Nakamura T, 1999, J BIOL CHEM, V274, P11897, DOI 10.1074/jbc.274.17.11897; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; Shin Y, 1998, BIOCHEM BIOPH RES CO, V245, P741, DOI 10.1006/bbrc.1998.8516; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Tuckwell DS, 2000, BIOCHEM J, V350, P485, DOI 10.1042/0264-6021:3500485; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; Wang RH, 1999, BIOCHEMISTRY-US, V38, P7584, DOI 10.1021/bi982132z; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5	44	98	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12274	12284		10.1074/jbc.M009338200	http://dx.doi.org/10.1074/jbc.M009338200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11121411	hybrid			2022-12-25	WOS:000168081800112
J	Miller, GJ; Dunn, SD; Ball, EH				Miller, GJ; Dunn, SD; Ball, EH			Interaction of the N- and C-terminal domains of vinculin - Characterization and mapping studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL PROTEIN VINCULIN; TALIN-BINDING; TAIL DOMAIN; INTRAMOLECULAR ASSOCIATION; ACIDIC PHOSPHOLIPIDS; ESCHERICHIA-COLI; ACTIN-BINDING; SITE; ADHESION; PURIFICATION	The vinculin head to tail intramolecular self-association controls its binding sites for other components of focal adhesions. To study this interaction, the head and tail domains were expressed, purified, and assayed for various characteristics of complex formation. Analytical centrifugation demonstrated a strong interaction in solution and formation of a complex more asymmetric than either of the individual domains. A survey of binding conditions using a solid-phase binding assay revealed characteristics of both electrostatic and hydrophobic forces involved in the binding. In addition, circular dichroism of the individual domains and the complex demonstrated that conformational changes likely occur in both domains during association, The interaction sites were more closely mapped on the protein sequence by deletion mutagenesis. Amino acids 181-226, a basic region within the acidic head domain, were identified as a binding site for the vinculin tail, and residues 1009-1066 were identified as sufficient for binding the head. Moreover, mutation of an acidic patch in the tail (residues 1013-1015) almost completely eliminated its ability to interact with the head domain further supporting the significance of ionic interactions in the binding. Our data indicate that the interaction between the head and tail domains of vinculin occurs through oppositely charged contact sites and results in conformational changes in both domains.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Ball, EH (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	ehball@julian.uwo.ca	Dunn, Stanley/D-3418-2013	Ball, Eric/0000-0003-2542-9156				Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; BALL EH, 1995, PROTEIN EXPRES PURIF, V6, P33, DOI 10.1006/prep.1995.1005; BALL EH, 1986, J CELL BIOL, V103, P641, DOI 10.1083/jcb.103.2.641; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; GILMORE AP, 1992, J CELL SCI, V103, P719; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; JUDD RC, 1990, METHOD ENZYMOL, V182, P613; Kawabe H, 1999, J BIOL CHEM, V274, P30914, DOI 10.1074/jbc.274.43.30914; KILIC F, 1991, J BIOL CHEM, V266, P8734; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; VOLBERG T, 1995, J CELL SCI, V108, P2253; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; WOOD CK, 1994, J CELL SCI, V107, P709; Xu WM, 1998, DEVELOPMENT, V125, P327	33	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11729	11734		10.1074/jbc.M008646200	http://dx.doi.org/10.1074/jbc.M008646200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11124946	hybrid			2022-12-25	WOS:000168081800042
J	Pujol, N; Bonnerot, C; Ewbank, JJ; Kohara, Y; Thierry-Mieg, D				Pujol, N; Bonnerot, C; Ewbank, JJ; Kohara, Y; Thierry-Mieg, D			The Caenorhabditis elegans unc-32 gene encodes alternative forms of a vacuolar ATPase a subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; C-ELEGANS; MESSENGER-RNA; MOLECULAR-CLONING; LEADER SEQUENCE; V-ATPASES; EXPRESSION; OSTEOPETROSIS; ACIDIFICATION; ORGANIZATION	Eukaryotes possess multiple isoforms of the a subunit of the V-0 complex of vacuolar-type Ht-ATPases (V-ATPases). Mutations in the V-ATPase a3 isoform have recently been shown to result in osteopetrosis, a fatal disease in humans, but no function has yet been ascribed to other isoforms. In Caenorhabditis elegans, the unc-32 mutant was originally isolated on the basis of its movement defect. We have isolated four new mutant alleles, the strongest of which is embryonic lethal. We show here that unc-32 corresponds to one of the four genes encoding a V-ATPase a subunit in the nematode, and we present their expression patterns and a molecular analysis of the gene family, unc-32 gives rise via alternative splicing to at least six transcripts. In the uncoordinated alleles, the transcript unc-32 B is affected, suggesting that it encodes an isoform that is targeted to synaptic vesicles of cholinergic neurons, where it would control neurotransmitter uptake or release. Other isoforms expressed widely during embryogenesis are mutated in the lethal alleles and would be involved in other acidic organelles. Our results indicate that V-ATPase a subunit genes are highly regulated and have tissue-specific function.	Univ Mediterranee, INSERM, Lab Genet & Physiol Dev, CNRS, F-13288 Marseille 9, France; CNRS, Ctr Rech Biochim Macromol, F-34293 Montpellier, France; Univ Mediterranee, INSERM, Ctr Immunol Marseille Luminy, CNRS, F-13288 Marseille 9, France; Natl Inst Genet, Shizuoka 4118540, Japan	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Pujol, N (corresponding author), Univ Mediterranee, INSERM, Lab Genet & Physiol Dev, CNRS, Luminy Case 907, F-13288 Marseille 9, France.		Pujol, Nathalie/K-3880-2012; Ewbank, Jonathan J/G-4948-2010	Pujol, Nathalie/0000-0001-8889-3197; Ewbank, Jonathan J/0000-0002-1257-6862; Thierry-Mieg, Danielle/0000-0001-9568-4211				BRENNER S, 1974, GENETICS, V77, P71; Chalfie M., 1988, NEMATODE CAENORHABDI, P337; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERGUSON EL, 1989, GENETICS, V123, P109; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 2000, J EXP BIOL, V203, P71; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Futai M, 2000, J EXP BIOL, V203, P107; Gasnier B, 2000, BIOCHIMIE, V82, P327, DOI 10.1016/S0300-9084(00)00221-2; Heinemann T, 1999, GENOMICS, V57, P398, DOI 10.1006/geno.1999.5751; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; LYNCH AS, 1995, NAT GENET, V11, P309, DOI 10.1038/ng1195-309; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Morrison M, 1997, P NATL ACAD SCI USA, V94, P9782, DOI 10.1073/pnas.94.18.9782; Nelson N, 2000, J EXP BIOL, V203, P89; NELSON N, 1992, J EXP BIOL, V172, P149; NGUYEN M, 1995, GENETICS, V140, P527; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nosaka K, 1999, J BIOL CHEM, V274, P34129, DOI 10.1074/jbc.274.48.34129; Oka T, 2000, J BIOL CHEM, V275, P29556, DOI 10.1074/jbc.M002756200; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; PENG SB, 1994, J BIOL CHEM, V269, P17262; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Tabara H, 1996, NUCLEIC ACIDS RES, V24, P2119, DOI 10.1093/nar/24.11.2119; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; WILLS N, 1983, CELL, V33, P575, DOI 10.1016/0092-8674(83)90438-5; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	35	59	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11913	11921		10.1074/jbc.M009451200	http://dx.doi.org/10.1074/jbc.M009451200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11110798	Green Published, hybrid			2022-12-25	WOS:000168081800065
J	Lightning, LK; Huang, H; Moenne-Loccoz, P; Loehr, TM; Schuller, DJ; Poulos, TL; de Montellano, PRO				Lightning, LK; Huang, H; Moenne-Loccoz, P; Loehr, TM; Schuller, DJ; Poulos, TL; de Montellano, PRO			Disruption of an active site hydrogen bond converts human heme oxygenase-1 into a peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRONIC CONTROL; COUPLED OXIDATION; CRYSTAL-STRUCTURE; RESONANCE RAMAN; CATALYTIC SITE; COMPLEX; REPLACEMENT; EXPRESSION; PROTEIN; EPR	The crystal structure of heme oxygenase-l suggests that Asp-140 may participate in a hydrogen bonding network involving ligands coordinated to the heme iron atom. To examine this possibility, Asp-140 was mutated to an alanine, phenylalanine, histidine, leucine, or asparagine, and the properties of the purified proteins were investigated, UV-visible and resonance Raman spectroscopy indicate that the distal water ligand is lost from the iron in all the mutants except, to some extent, the D140N mutant. In the D140H mutant, the distal water ligand is replaced by the new His-140 as the sixth iron ligand, giving a bis-histidine complex, The D140A, D140H, and D140N mutants retain a trace (<3%) of biliverdin forming activity, but the D140F and D140L mutants are inactive in this respect. However, the two latter mutants retain a low ability to form verdoheme, an intermediate in the reaction sequence. All the Asp-140 mutants exhibit a new peroxidase activity. The results indicate that disruption of the distal hydrogen bonding environment by mutation of Asp-140 destabilizes the ferrous dioxygen complex and promotes conversion of the ferrous hydroperoxy intermediate obtained by reduction of the ferrous dioxygen complex to a ferryl species at the expense of its normal reaction with the porphyrin ring.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA	University of California System; University of California San Francisco; University of California System; University of California Irvine; University of California System; University of California Irvine	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, Rm S-926, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu		MOENNE-LOCCOZ, PIERRE/0000-0002-7684-7617	NIDDK NIH HHS [DK30297] Funding Source: Medline; NIGMS NIH HHS [GM34468] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034468] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Crusats J, 1998, J ORG CHEM, V63, P602, DOI 10.1021/jo9714728; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; De Montellano PRO, 2001, ADV INORG CHEM, V51, P359; de Montellano PRO, 2000, CURR OPIN CHEM BIOL, V4, P221; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Liu Y, 2000, J BIOL CHEM, V275, P34501, DOI 10.1074/jbc.M004245200; LLOYD E, 1995, J AM CHEM SOC, V117, P6434, DOI 10.1021/ja00129a003; Maines M.D., 1992, HEME OXYGENASE CLIN; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; PEMBER SO, 1984, J BIOL CHEM, V259, P590; RAPHAEL AL, 1991, J AM CHEM SOC, V113, P1038, DOI 10.1021/ja00003a045; RAPHAEL AL, 1989, PROTEINS, V6, P338, DOI 10.1002/prot.340060316; Rodriguez JC, 1998, BIOCHEMISTRY-US, V37, P13082, DOI 10.1021/bi9809324; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAEFER WH, 1985, BIOCHEMISTRY-US, V24, P3254, DOI 10.1021/bi00334a027; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; SHEN AL, 1991, J BIOL CHEM, V266, P19976; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Torpey J, 1997, J BIOL CHEM, V272, P22008, DOI 10.1074/jbc.272.35.22008; Torpey J, 1996, J BIOL CHEM, V271, P26067, DOI 10.1074/jbc.271.42.26067; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; Youngs HL, 2000, BIOCHEMISTRY-US, V39, P9994, DOI 10.1021/bi000679j	28	81	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10612	10619		10.1074/jbc.M010349200	http://dx.doi.org/10.1074/jbc.M010349200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11121422	hybrid			2022-12-25	WOS:000167980900008
J	Biemesderfer, D; DeGray, B; Aronson, PS				Biemesderfer, D; DeGray, B; Aronson, PS			Active (9.6 S) and inactive (21 S) oligomers of NHE3 in microdomains of the renal brush border	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+ EXCHANGER ISOFORM; THICK ASCENDING LIMB; NA-K-ATPASE; PARATHYROID-HORMONE; PROXIMAL TUBULE; RAT-KIDNEY; TRANSPORT; MEMBRANE; PHOSPHORYLATION; IDENTIFICATION	We have previously shown that Na+-H+ exchanger isoform NHE3 exists as both 9.6 and 21 S (megalin-associated) oligomers in the renal brush border (1), To characterize the oligomeric forms of the renal brush border Na+-H+ exchanger in more detail, we performed membrane fractionation studies. We found that similar amounts of NHE3 were present in microvilli and a non-microvillar membrane domain of high density (dense vesicles), Horseradish peroxidase-labeled endosomes were not prevalent in the dense membrane fraction, However, megalin, which localizes primarily to the intermicrovillar microdomain of the brush border, was enriched in the dense vesicles, implicating this microdomain as the likely source of these membranes. Immunolocalization of NHE3 confirmed that a major fraction of the transporter colocalized with megalin in the intermicrovillar region of the brush border. Immunoprecipitation studies demonstrated that in microvilli the majority of NHE3 was not bound to megalin, while in the dense vesicles most of the NHE3 coprecipitated with megalin, Moreover, sucrose velocity gradient centrifugation experiments revealed that most NHE3 in microvilli sedimented with an S value of 9,6, while the S value of NHE3 in dense vesicles was 21, Finally, we examined the functional state of NHE3 in both membrane fractions. As assayed by changes in acridine orange fluorescence, imposing an outwardly directed Na+ gradient caused generation of an inside acid pH gradient in the microvilli, indicating Na+-H+ exchange activity, but not in the dense vesicles. Taken together, these data demonstrate that renal brush border NHE3 exists in two oligomeric states: a 9.6 S active form present in microvilli and a 21 S, megalin-associated, inactive form in the intermicrovillar microdomain of the apical plasma membrane, Thus, regulation of renal brush border Na+-H+ exchange activity may be mediated by shifting the distribution between these forms of NHE3.	Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Biemesderfer, D (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, 333 Cedar St,LMP 2073,POB 208029, New Haven, CT 06520 USA.	daniel.biemesderfer@yale.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033793, R37DK033793] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33793] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ambuhl PM, 1996, AM J PHYSIOL-RENAL, V271, pF917, DOI 10.1152/ajprenal.1996.271.4.F917; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; Aronson PS, 1997, AM J PHYSIOL-RENAL, V273, pF179, DOI 10.1152/ajprenal.1997.273.2.F179; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; Biemesderfer D, 1999, J BIOL CHEM, V274, P17518, DOI 10.1074/jbc.274.25.17518; BIEMESDERFER D, 1998, J AM SOC NEPHROL, V9, P62; BLOCH RD, 1993, CONTRIB NEPHROL, V101, P19; BURNHAM C, 1982, BIOCHIM BIOPHYS ACTA, V685, P260, DOI 10.1016/0005-2736(82)90066-9; Cabado AG, 1996, J BIOL CHEM, V271, P3590; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; Collazo R, 2000, J BIOL CHEM, V275, P31601, DOI 10.1074/jbc.M000600200; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; DUDOUET B, 1987, J CELL BIOL, V105, P359, DOI 10.1083/jcb.105.1.359; Fan LZ, 1999, J BIOL CHEM, V274, P11289, DOI 10.1074/jbc.274.16.11289; Griffith O. M., 1983, TECHNIQUES PREPARATI; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; IINO Y, 1979, AM J PHYSIOL, V236, pF387, DOI 10.1152/ajprenal.1979.236.4.F387; Kim GH, 1999, J AM SOC NEPHROL, V10, P935; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kwon TH, 1999, AM J PHYSIOL-RENAL, V277, pF257, DOI 10.1152/ajprenal.1999.277.2.F257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLEAN W, 1973, J HISTOCHEM CYTOCHEM, V22, P1077; Orlando RA, 1997, P NATL ACAD SCI USA, V94, P2368, DOI 10.1073/pnas.94.6.2368; PENG Y, 1998, J AM SOC NEPHROL, V9, P10; RODMAN JS, 1986, J CELL BIOL, V102, P77, DOI 10.1083/jcb.102.1.77; SABOLIC I, 1990, METHOD ENZYMOL, V191, P505; SAHOLIC I, 1990, AM J PHYSIOL, V258, pF1245; TSE CM, 1992, J BIOL CHEM, V267, P9340; WANG T, 1990, J PHARMACOL EXP THER, V252, P689; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; Zhang YB, 1999, AM J PHYSIOL-RENAL, V276, pF711, DOI 10.1152/ajprenal.1999.276.5.F711; [No title captured]	39	78	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10161	10167		10.1074/jbc.M008098200	http://dx.doi.org/10.1074/jbc.M008098200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11120742	hybrid			2022-12-25	WOS:000167996400077
J	Chang, JY; Li, L				Chang, JY; Li, L			The structure of denatured alpha-lactalbumin elucidated by the technique of disulfide scrambling - Fractionation of conformational isomers of alpha-lactalbumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; RESIDUAL STRUCTURE; PROTEIN; COOPERATIVITY; INTERMEDIATE; TRANSITION; PEPTIDE; BINDING; CORE; BOND	The structure of denatured alpha -lactalbumin (alpha -LA) has been characterized using the method of disulfide scrambling. Under denaturing conditions (urea, guanidine hydrochloride, guanidine thiocyanate, organic solvent or elevated temperature) and in the presence of thiol initiator, alpha -LA denatures by shuffling its four native disulfide bonds and converts to a mixture of fully oxidized scrambled structures. Analysis by reversed-phase HPLC reveals that the denatured alpha -LA comprises a minimum of 45 fractions of scrambled isomers. Among them, six well populated isomers have been isolated and structurally characterized. Their relative concentrations, which represent the fingerprinting of the denatured alpha -LA, vary substantially under different denaturing conditions. These results permit independent plotting of the denaturation and unfolding curves of alpha -LA Most importantly, unique isomers of partially unfolded alpha -LA were shown to populate at mild and selected denaturing conditions. Organic solvent disrupts preferentially the hydrophobic alpha -helical domain, generating a predominant isomer containing two native disulfide bonds at the beta -sheet domain and two scrambled disulfide bonds at the alpha -helical region. Thermal denaturation selectively unfolds the beta -sheet domain of alpha -LA, producing a prevalent isomer that exhibits structural characteristics of the molten globule state of alpha -LA.	Inst Mol Med, Res Ctr Prot Chem, Houston, TX 77030 USA; Univ Texas, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System	Chang, JY (corresponding author), Inst Mol Med, Res Ctr Prot Chem, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	Rowen.Chang@uth.tmc.edu						Arai M, 1996, FOLD DES, V1, P275, DOI 10.1016/S1359-0278(96)00041-7; Bai P, 2000, BIOCHEMISTRY-US, V39, P372, DOI 10.1021/bi992056f; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; Bulychev A, 1999, J PROTEIN CHEM, V18, P771, DOI 10.1023/A:1020681518265; Chandra N, 1998, BIOCHEMISTRY-US, V37, P4767, DOI 10.1021/bi973000t; Chang JY, 1999, ANAL BIOCHEM, V268, P147, DOI 10.1006/abio.1998.3047; Chang JY, 2000, FEBS LETT, V473, P183, DOI 10.1016/S0014-5793(00)01515-5; Chang JY, 1999, PROTEIN SCI, V8, P1463, DOI 10.1110/ps.8.7.1463; Chang JY, 1999, J BIOL CHEM, V274, P123, DOI 10.1074/jbc.274.1.123; Chang JY, 2000, J BIOL CHEM, V275, P14205, DOI 10.1074/jbc.275.19.14205; Creighton TE, 1997, TRENDS BIOCHEM SCI, V22, P6, DOI 10.1016/S0968-0004(96)20030-1; De Laureto PP, 1999, PROTEIN SCI, V8, P2290; DELAURETO PP, 1995, BIOCHEMISTRY-US, V34, P12596, DOI 10.1021/bi00039a015; Demarest SJ, 1999, J MOL BIOL, V294, P213, DOI 10.1006/jmbi.1999.3228; Demarest SJ, 1998, J MOL BIOL, V283, P279, DOI 10.1006/jmbi.1998.2099; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; EWBANK JJ, 1995, NAT STRUCT BIOL, V2, P10, DOI 10.1038/nsb0195-10a; Forge V, 1999, J MOL BIOL, V288, P673, DOI 10.1006/jmbi.1999.2687; Gast K, 1998, PROTEIN SCI, V7, P2004, DOI 10.1002/pro.5560070917; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; Griko YV, 1999, J PROTEIN CHEM, V18, P361, DOI 10.1023/A:1021099714901; GUSSAKOVSKY EE, 1995, PROTEIN SCI, V4, P2319, DOI 10.1002/pro.5560041109; Ikeguchi M, 1998, PROTEIN SCI, V7, P1564, DOI 10.1002/pro.5560070710; IKEGUCHI M, 1992, BIOCHEMISTRY-US, V31, P12695, DOI 10.1021/bi00165a021; Kataoka M, 1997, PROTEIN SCI, V6, P422; Kim S, 1998, PROTEIN SCI, V7, P1930, DOI 10.1002/pro.5560070908; KLEFHABER T, 1995, NATURE, V375, P513; KUWAJIMA K, 1993, FEBS LETT, V334, P265, DOI 10.1016/0014-5793(93)80691-M; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1979, BIOCHEMISTRY-US, V18, P878, DOI 10.1021/bi00572a022; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; KUWAJIMA K, 1977, J MOL BIOL, V114, P241, DOI 10.1016/0022-2836(77)90208-X; Luo YZ, 1999, P NATL ACAD SCI USA, V96, P11283, DOI 10.1073/pnas.96.20.11283; Pace C N, 1986, Methods Enzymol, V131, P266; Pande VS, 1998, P NATL ACAD SCI USA, V95, P1490, DOI 10.1073/pnas.95.4.1490; Permyakov EA, 2000, FEBS LETT, V473, P269, DOI 10.1016/S0014-5793(00)01546-5; Pfeil W, 1998, PROTEINS, V30, P43, DOI 10.1002/(SICI)1097-0134(19980101)30:1<43::AID-PROT4>3.0.CO;2-L; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PTITSYN OB, 1995, TRENDS BIOCHEM SCI, V20, P376, DOI 10.1016/S0968-0004(00)89081-7; PTITSYN OB, 1994, FEBS LETT, V341, P15, DOI 10.1016/0014-5793(94)80231-9; Redfield C, 1999, NAT STRUCT BIOL, V6, P948, DOI 10.1038/13318; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; Song JX, 1998, J MOL BIOL, V280, P167, DOI 10.1006/jmbi.1998.1826; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; TANFORD C, 1967, J AM CHEM SOC, V89, P5023, DOI 10.1021/ja00995a034; Uversky VN, 1996, BIOPHYS CHEM, V60, P79, DOI 10.1016/0301-4622(96)00009-9; VANDERHEEREN G, 1994, J BIOL CHEM, V269, P7090; Vanderheeren G, 1996, BIOCHEMISTRY-US, V35, P16753, DOI 10.1021/bi9608830; Wu LC, 1996, BIOCHEMISTRY-US, V35, P859, DOI 10.1021/bi951408p; Wu LC, 1998, J MOL BIOL, V280, P175, DOI 10.1006/jmbi.1998.1825; WU LC, 1995, NAT STRUCT BIOL, V2, P281, DOI 10.1038/nsb0495-281	55	55	56	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9705	9712		10.1074/jbc.M010700200	http://dx.doi.org/10.1074/jbc.M010700200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11118458	hybrid			2022-12-25	WOS:000167996400018
J	Dorus, S; Mimura, H; Epstein, W				Dorus, S; Mimura, H; Epstein, W			Substrate-binding clusters of the K+-transporting kdp ATPase of Escherichia coli investigated by amber suppression scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM-TRANSPORT; SARCOPLASMIC-RETICULUM; CATION-TRANSPORT; LAC REPRESSOR; OCCLUSION; PYROPHOSPHATASE; CA2+-ATPASE; MUTATION; SUBUNIT; MUTANTS	The Kdp-ATPase of Escherichia coli is a four-subunit P-type ATPase that accumulates K+ with high affinity and specificity, Residues clustered in four regions of the KdpA subunit of Kdp were implicated as critical for K+ binding from the analysis of mutants with reduced affinity for K+ (Buurman, E,, Rim, K,-T,, and Epstein, W, (1995) J, Biol Chem, 270, 6678-66851) K+ binding by this pump has been analyzed in detail by site-directed mutagenesis, We have examined 83 of the 557 residues in KdpA, from 11 to 34 residues in each of four binding clusters known to affect K+ binding. Amber mutations were constructed in a plasmid carrying the kdpFABC structural genes. Transferring these plasmids to 12 suppressor strains, each inserting a different amino acid at amber codons, created 12 different substitutions at the mutated sites. This study delineates the four clusters and confirms that they are important for K+ affinity but have little effect on the rate of transport. At only 21 of the residues studied did at least three substitutions alter affinity for K+, an indication that a residue is in or very near a K+ binding site. At many residues lysine was the only substitution that altered its affinity, The effect of lysine is most likely a repulsive effect of this cationic residue on K+ and thus reflects the effective distance between a residue and the site of binding or passage of K+ in Kdpk Once a crystallographic structure of Kdp is available, this measure of effective distance will help identify the path of K+ as it moves through the KdpA subunit to cross the membrane.	Univ Chicago, MGCB, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Epstein, W (corresponding author), Univ Chicago, MGCB, Dept Mol Genet & Cell Biol, 920 E 58th St, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM053018] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53018] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altendorf K, 1998, ACTA PHYSIOL SCAND, V163, P137; ALTENDORF K, 1996, BIOMEMBR, V5, P403; Andersen JP, 1998, ACTA PHYSIOL SCAND, V163, P45; BEAUGE LA, 1979, NATURE, V280, P510, DOI 10.1038/280510a0; BUURMAN ET, 1995, J BIOL CHEM, V270, P6678, DOI 10.1074/jbc.270.12.6678; DAVIES JM, 1992, P NATL ACAD SCI USA, V89, P11701, DOI 10.1073/pnas.89.24.11701; DOSCH DC, 1984, J BACTERIOL, V160, P1188, DOI 10.1128/JB.160.3.1188-1190.1984; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; Durell SR, 2000, BIOPHYS J, V78, P188, DOI 10.1016/S0006-3495(00)76584-2; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; Maruyama C, 1998, PLANT CELL PHYSIOL, V39, P1045, DOI 10.1093/oxfordjournals.pcp.a029301; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; POLAREK JW, 1988, METHOD ENZYMOL, V157, P705; RABON EC, 1993, J BIOL CHEM, V268, P8012; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; RHOADS DB, 1976, J GEN PHYSIOL, V67, P325, DOI 10.1085/jgp.67.3.325; RHOADS DB, 1978, J GEN PHYSIOL, V72, P283, DOI 10.1085/jgp.72.3.283; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Sambrook J., 1989, MOL CLONING LAB MANU, P74; Schrader M, 2000, BIOPHYS J, V79, P802, DOI 10.1016/S0006-3495(00)76337-5; STRIGINI P, 1970, Journal of Molecular Biology, V47, P517, DOI 10.1016/0022-2836(70)90319-0; Strock C, 1998, J BIOL CHEM, V273, P15104, DOI 10.1074/jbc.273.24.15104; TOGOSHIMA C, 2000, NATURE, V405, P647; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	30	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9590	9598		10.1074/jbc.M009365200	http://dx.doi.org/10.1074/jbc.M009365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11106663	hybrid			2022-12-25	WOS:000167996400003
J	Korner, K; Jerome, V; Schmidt, T; Muller, R				Korner, K; Jerome, V; Schmidt, T; Muller, R			Cell cycle regulation of the murine cdc25B promoter - Essential role for nuclear factor-Y and a proximal repressor element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-MYB TRANSCRIPTION; CCAAT-BINDING FACTOR; NF-Y; FISSION YEAST; TYROSINE PHOSPHATASE; DEPENDENT EXPRESSION; PROTEIN PHOSPHATASE; COREPRESSOR ELEMENT; ACTIVATES P34CDC2; PHASE-TRANSITION	Expression of the cdc25B gene is up-regulated late during cell cycle progression (S/G(2)). We have cloned the murine cdc25B promoter to identify elements involved in transcriptional regulation. A detailed structure-function analysis led to the identification of several elements that are located upstream of a canonical Inr motif at the site of transcription initiation and are involved in transcriptional activation and regulation. Activation of the promoter is largely mediated by NF-Y and Sp1/3 interacting with one and four proximal binding sites, respectively. In addition, NF-Y plays an essential role in cell cycle regulation in conjunction with a repressor element (cell cycle-regulated repressor) located similar to 30 nucleotides upstream of the putative Inr element and overlapping a consensus TATA motif. The cell cycle-regulated repressor is unrelated to the previously described cell cycle-regulated repressor elements. Taken together, our observations suggest that expression of the cdc25B gene is controlled through a novel mechanism of cell cycle-regulated transcription.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35033 Marburg, Germany.	mueller@imt.uni-marburg.de	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Adachi N, 2000, GENE, V245, P49, DOI 10.1016/S0378-1119(00)00040-8; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; Bennett JD, 1996, ONCOGENE, V13, P1073; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Brehm A, 1999, BRIT J CANCER, V80, P38; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Facchinetti V, 2000, ONCOGENE, V19, P3931, DOI 10.1038/sj.onc.1203730; Forrest ARR, 1999, BIOCHEM BIOPH RES CO, V260, P510, DOI 10.1006/bbrc.1999.0870; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gasparotto D, 1997, CANCER RES, V57, P2366; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HERBER, 1994, ONCOGENE, V9, P2105; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Huet X, 1996, MOL CELL BIOL, V16, P3789; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; Korner K, 1997, NUCLEIC ACIDS RES, V25, P4933, DOI 10.1093/nar/25.24.4933; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lammer C, 1998, J CELL SCI, V111, P2445; Lavia P, 1999, BIOESSAYS, V21, P221; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Li FZ, 1999, CANCER RES, V59, P3143; Linhoff MW, 1997, MOL CELL BIOL, V17, P4589, DOI 10.1128/MCB.17.8.4589; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NAGATA A, 1991, NEW BIOL, V3, P959; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; Philips A, 1999, ONCOGENE, V18, P6222, DOI 10.1038/sj.onc.1203017; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; Sorensen P, 1999, J BIOL CHEM, V274, P30943, DOI 10.1074/jbc.274.43.30943; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wu WG, 1998, CANCER RES, V58, P4082; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yao Y, 1999, ONCOGENE, V18, P5159, DOI 10.1038/sj.onc.1202908; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1997, NUCLEIC ACIDS RES, V25, P4926, DOI 10.1093/nar/25.24.4926; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	67	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9662	9669		10.1074/jbc.M008696200	http://dx.doi.org/10.1074/jbc.M008696200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11104768	Green Published, hybrid			2022-12-25	WOS:000167996400013
J	Yun, CW; Bauler, M; Moore, RE; Klebba, PE; Philpott, CC				Yun, CW; Bauler, M; Moore, RE; Klebba, PE; Philpott, CC			The role of the FRE family of plasma membrane reductases in the uptake of siderophore-iron in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR FACILITATOR SUPERFAMILY; MOLECULAR CHARACTERIZATION; TRANSPORT PROTEIN; FERRIC REDUCTASE; COPPER UPTAKE; GENE ENCODES; FET3 GENE; YEAST; OXIDASE; IDENTIFICATION	Saccharomyces cerevisiae takes up siderophore-bound iron through two distinct systems, one that requires siderophore transporters of the ARN family and one that requires the high affinity ferrous iron transporter on the plasma membrane. Uptake through the plasma membrane ferrous iron transporter requires that the iron first must dissociate from the siderophore and undergo reduction to the ferrous form. FRE1 and FRE2 encode cell surface metalloreductases that are required for reduction and uptake of free ferric iron. The yeast genome contains five additional FRE1 and FRE2 homologues, four of which are regulated by iron and the major iron-dependent transcription factor, Aft1p, but whose function remains unknown. Fre3p was required for the reduction and uptake of ferrioxamine B-iron and for growth on ferrioxamine B, ferrichrome, triacetyl-fusarinine C, and rhodotorulic acid in the absence of Fre1p and Fre2p, By indirect immunofluorescence, Fre3p was expressed on the plasma membrane in a pattern similar to that of Fet3p, a component of the high affinity ferrous transporter. Enterobactin, a catecholate siderophore, was not a substrate for Fre3p, and reductive uptake required either Fre1p or Fre2p, Fre4p could facilitate utilization of rhodotorulic acid-iron when the siderophore was present in higher concentrations. We propose that Fre3p and Fre4p are siderophore-iron reductases and that the apparent redundancy of the PRE genes confers the capacity to utilize iron from a variety of siderophore sources.	NIDDK, Liver Dis Sect, NIH, Bethesda, MD 20892 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Univ Wisconsin, Dept Chem, Oshkosh, WI 54901 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Oklahoma System; University of Oklahoma - Norman; University of Wisconsin System	Philpott, CC (corresponding author), NIDDK, Liver Dis Sect, NIH, Bldg 10,Rm 9B16,10 Ctr Dr, Bethesda, MD 20892 USA.	carolinep@intra.niddk.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054507, Z01DK054507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053836] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albrecht-Gary AM, 1998, MET IONS BIOL SYST, V35, P239; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1998, J BIOL CHEM, V273, P22415, DOI 10.1074/jbc.273.35.22415; Byers BR, 1998, MET IONS BIOL SYST, V35, P37; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; Finegold AA, 1996, J BIOL CHEM, V271, P31021, DOI 10.1074/jbc.271.49.31021; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; Heymann P, 1999, BIOMETALS, V12, P301, DOI 10.1023/A:1009252118050; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; LESUISSE E, 1994, MYCOLOGY S, V11, P149; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; RUTZ JM, 1991, J BACTERIOL, V173, P5964, DOI 10.1128/jb.173.19.5964-5974.1991; Schneider BL, 1996, YEAST, V12, P129, DOI 10.1002/(SICI)1097-0061(199602)12:2<129::AID-YEA891>3.0.CO;2-O; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Van der Helm D., 1994, METAL IONS FUNGI, V11, P39; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	34	120	129	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10218	10223		10.1074/jbc.M010065200	http://dx.doi.org/10.1074/jbc.M010065200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11120744	hybrid			2022-12-25	WOS:000167996400085
J	Fricke, WM; Kaliraman, V; Brill, SJ				Fricke, WM; Kaliraman, V; Brill, SJ			Mapping the DNA topoisomerase III binding domain of the Sgs1 DNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; WERNERS-SYNDROME GENES; ROTHMUND-THOMSON-SYNDROME; ESCHERICHIA-COLI RECQ; BLOOMS-SYNDROME; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; SYNDROME PROTEIN; HYPER-RECOMBINATION; YEAST	Several members of the RecQ family of DNA helicases are known to interact with DNA topoisomerase III (Top3). Here we show that the Saccharomyces cerevisiae Sgs1 and Top3 proteins physically interact in cell extracts and bind directly in vitro. Sgs1 and Top3 proteins coimmunoprecipitate from cell extracts under stringent conditions, indicating that Sgs1 and Top3 are present in a stable complex, The domain of Sgs1 which interacts with Top3 was identified by expressing Sgs1 truncations in yeast. The results indicate that the NH2-terminal 158 amino acids of Sgs1 are sufficient for the high affinity interaction between Sgs1 and Top3. lit vitro assays using purified Top3 and NH2-terminal Sgs1 fragments demonstrate that at feast part of the interaction is through direct protein-protein interactions with these 158 amino acids. Consistent with these physical data, we find that mutant phenotypes caused by a point mutation or small deletions in the Sgs1 NH2 terminus can be suppressed by Top3 overexpression. We conclude that Sgs1 and Top3 form a tight complex in vivo and that the first 158 amino acids of Sgs1 are necessary and sufficient for this interaction. Thus, a primary role of the Sgs1. amino terminus is to mediate the Top3 interaction.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Brill, SJ (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Dept Mol Biol & Biochem, 679 Hoes Lane, Piscataway, NJ 08854 USA.	brill@mbcl.rutgers.edu		Kaliraman, Vivek/0000-0002-6803-4341	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016637] Funding Source: NIH RePORTER; NIA NIH HHS [AG16637, R01 AG016637-02] Funding Source: Medline; NIGMS NIH HHS [GM55583, R01 GM055583, R01 GM055583-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett RJ, 2000, J BIOL CHEM, V275, P26898; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; Duno M, 2000, MOL GEN GENET, V264, P89, DOI 10.1007/s004380000286; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, GENE DEV, V14, P81; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; Goodwin A, 1999, NUCLEIC ACIDS RES, V27, P4050, DOI 10.1093/nar/27.20.4050; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; Heo SJ, 1999, GENES CELLS, V4, P619, DOI 10.1046/j.1365-2443.1999.00288.x; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson FB, 2000, CANCER RES, V60, P1162; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KIM RA, 1992, J BIOL CHEM, V267, P17178; Kim YC, 2000, NUCLEIC ACIDS RES, V28, P2012, DOI 10.1093/nar/28.9.2012; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; Maftahi M, 1999, NUCLEIC ACIDS RES, V27, P4715, DOI 10.1093/nar/27.24.4715; Miozzo M, 1998, INT J CANCER, V77, P504; Mullen JR, 2001, GENETICS, V157, P103; Mullen JR, 2000, GENETICS, V154, P1101; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Ng SW, 1999, NUCLEIC ACIDS RES, V27, P993, DOI 10.1093/nar/27.4.993; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; ROSE MD, 1990, METHODS YEAST GENETI, P119; Rothstein R, 1995, GENOME RES, V5, P421, DOI 10.1101/gr.5.5.421; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; SIKORSKI RS, 1989, GENETICS, V122, P19; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1991, J BIOL CHEM, V266, P6659; Wang Y, 2000, GENE DEV, V14, P927; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	58	84	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8848	8855		10.1074/jbc.M009719200	http://dx.doi.org/10.1074/jbc.M009719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11124263	Green Accepted, hybrid			2022-12-25	WOS:000167607700034
J	Jankowski, J; Hagemann, J; Tepel, M; van der Giet, M; Stephan, N; Henning, L; Gouni-Berthold, H; Sachinidis, A; Zidek, W; Schluter, H				Jankowski, J; Hagemann, J; Tepel, M; van der Giet, M; Stephan, N; Henning, L; Gouni-Berthold, H; Sachinidis, A; Zidek, W; Schluter, H			Dinucleotides as growth-promoting extracellular mediators - Presence of dinucleoside diphosphates Ap(2)A, Ap(2)G, and Gp(2)G in releasable granules of platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIADENOSINE PHOSPHATES; WHOLE-BLOOD; CHROMATOGRAPHY; IDENTIFICATION; SEROTONIN; MUSCLE	Dinucleoside diphosphates, Ap(2)A, Ap(2)G, and Gp(2)G represent a new class of growth-promoting extracellular mediators, which are released from granules after activation of platelets. The presence of theses substances was shown after purification from a platelet concentrate. The substances were identified by UV spectrometry, retention time comparison with authentic substances, matrix-assisted laser desorption/ionization mass spectrometry, post-source-decay matrix-assisted laser desorption/ionization mass spectrometry, and enzymatic analysis. Ap(2)A, Ap(2)G, and Gp(2)G have growth-stimulating effects on vascular smooth muscle cells in nanomolar concentrations as shown by [H-3]thymidine incorporation measurements, The calculated EC50 (log M; mean +/- S.E.) values were -6.07 +/- 0.14 for Ap(2)A, -6.27 +/- 0.25 for Ap(2)G, and -6.91 +/- 0.44 for Gp(2)G. At least 61.5 +/- 4.3% of the dinucleoside polyphosphates are released by platelet activation. The intraplatelet concentrations suggest that, in the close environment of a platelet thrombus, similar dinucleoside polyphosphate concentrations can be found as in platelets, Intraplatelet concentration can be estimated:in the range of 1/20 to 1/100 of the concentration of ATP, In conclusion, Ap(2)A, Ap(2)G, and Gp(2)G derived from releasable granules of human platelets may play a regulatory role in vascular smooth muscle growth as growth-promoting mediators.	Free Univ Berlin, Klinikum Benjamin Franklin, Med Klin 4, D-12200 Berlin, Germany; Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; Univ Bonn, Med Poliklin, D-53111 Bonn, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cologne; University of Bonn	Schluter, H (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Med Klin 4, Hindenburgdamm 30, D-12200 Berlin, Germany.		Sachinidis, Agapios/AAD-4178-2020; Sachinidis, Agapios/AAM-7988-2020; Tepel, Martin/GRS-9581-2022; Schluter, Hartmut/D-1371-2015	Schluter, Hartmut/0000-0002-9358-7036; Tepel, Martin/0000-0002-0086-0997				ANDERSON GM, 1987, LIFE SCI, V40, P1063, DOI 10.1016/0024-3205(87)90568-6; BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; Beaven G.H., 1955, NUCL ACIDS, V1, P493, DOI DOI 10.1002/JPS.3030440720; Bo XN, 2000, J BIOL CHEM, V275, P14401, DOI 10.1074/jbc.275.19.14401; CORASH L, 1977, BLOOD, V49, P71; ERLINGE D, 1995, EUR J PHARM-MOLEC PH, V289, P135, DOI 10.1016/0922-4106(95)90178-7; FLODGAARD H, 1982, BIOCHEM J, V208, P737, DOI 10.1042/bj2080737; GARRISON PN, 1992, DETERMINATION DINUCL, P29; HEIDENREICH S, 1995, J CLIN INVEST, V95, P2862, DOI 10.1172/JCI117992; HERVIG T, 1990, CLIN CHEM, V36, P28; HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P; HOLMSEN H, 1965, SCAND J CLIN LAB INV, V17, P230, DOI 10.3109/00365516509075340; Jankowski J, 1999, J BIOL CHEM, V274, P23926, DOI 10.1074/jbc.274.34.23926; Jankowski J, 1998, J CHROMATOGR B, V719, P63, DOI 10.1016/S0378-4347(98)00408-3; KITZLER JW, 1992, INTRACELLULAR FUNCTI, P135; Luo J, 1999, FASEB J, V13, P695, DOI 10.1096/fasebj.13.6.695; LUTHJE J, 1983, BIOCHEM BIOPH RES CO, V115, P253, DOI 10.1016/0006-291X(83)90997-X; McLennan AG., 1992, AP4A OTHER DINUCLEOS; Nofer JR, 1998, ARTERIOSCL THROM VAS, V18, P861, DOI 10.1161/01.ATV.18.6.861; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; PLATEAU P, 1992, SYNTHESIS NPNN N EQU, P63; PUCK TT, 1957, J EXP MED, V106, P145, DOI 10.1084/jem.106.1.145; Ralevic V, 1998, PHARMACOL REV, V50, P413; REMY P, 1992, INTRACELLULAR FUNCTI, P151; Schluter H, 1996, J AUTON PHARMACOL, V16, P357, DOI 10.1111/j.1474-8673.1996.tb00053.x; Schluter H, 1998, J CLIN INVEST, V101, P682, DOI 10.1172/JCI119882; SCHLUTER H, 1994, NATURE, V367, P186, DOI 10.1038/367186a0; SULKOWSKI E, 1974, BIOCHEM BIOPH RES CO, V57, P463, DOI 10.1016/0006-291X(74)90954-1; vanderGiet M, 1997, BRIT J PHARMACOL, V120, P1453, DOI 10.1038/sj.bjp.0701074; WHITE JG, 1987, HEMOSTASIS THROMBOSI, P537	30	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8904	8909		10.1074/jbc.M009527200	http://dx.doi.org/10.1074/jbc.M009527200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11115507	hybrid			2022-12-25	WOS:000167607700041
J	Kassam, G; Kwon, M; Yoon, YS; Graham, KS; Young, MK; Gluck, S; Waisman, DM				Kassam, G; Kwon, M; Yoon, YS; Graham, KS; Young, MK; Gluck, S; Waisman, DM			Purification and characterization of A(61) - An angiostatin-like plasminogen fragment produced by plasmin autodigestion in the absence of sulfhydryl donors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNEXIN-II TETRAMER; LINKED OLIGOSACCHARIDE UNIT; LEWIS-LUNG-CARCINOMA; ANGIOGENESIS INHIBITOR; DIFFERENTIAL AUTOLYSIS; CIRCULAR-DICHROISM; ENDOTHELIAL-CELLS; GENERATION; ACTIVATION; CANCER	Plasmin, a broad spectrum proteinase, is inactivated by an autoproteolytic reaction that results in the destruction of the heavy and light chains of the protein. Recently we demonstrated that a 61-kDa plasmin fragment was one of the major products of this autoproteolytic reaction (Fitzpatrick, S, L,, Kassam, G,, Choi, K, S,, Kang, H, Ri,, Fogg, D, K,, and Waisman, D, M, (2000)Bio chemistry 39, 1921-1028), In the present communication we have identified the 61-kDa plasmin fragment as a novel four kringle-containing protein consisting of the amino acid sequence Lys(78)-Lys(468). To avoid Confusion with the plasmin(ogen) fragment, angiostatin(R) (Lys(78)- Ala(440)), we have named this protein A(61) Unlike angiostatin A(61) was produced in vitro from plasmin autodigestion: in the absence of sulfhydryl donors, A(61) bound to lysine-Sepharose and also underwent a large increase in fluorescence yield upon binding of the lysine analogue, trans-4-aminomethylcyclohexanecarboxylic acid. Circular dichroism suggested that A(61), was composed of 21% beta -strand, 14% beta -turn, 18% 3(1)-helix and 8% 3(10)-heIix. A(61) was an anti-angiogenic protein as indicated by the inhibition of bovine capillary endothelial cell proliferation. Plasminogen was converted to A(61) by HT1080 cells and bovine capillary endothelial cells. Furthermore, a plasminogen fragment similar to A(61) was present in the serum of humans as well as normal and tumor-bearing mice. These results establish that plasmin turnover can generate anti-angiogenic plasmin fragments in a nonpathological setting.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	University of Calgary; University of Calgary; City of Hope; Beckman Research Institute of City of Hope	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Waisman, David/0000-0002-5097-9662				BAILEY JM, 1992, PROTEIN SCI, V1, P1622, DOI 10.1002/pro.5560011210; BOYD VL, 1992, ANAL BIOCHEM, V206, P344, DOI 10.1016/0003-2697(92)90376-I; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CASTELLINO FJ, 1986, ARCH BIOCHEM BIOPHYS, V247, P312, DOI 10.1016/0003-9861(86)90589-8; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Falcone DJ, 1998, J BIOL CHEM, V273, P31480, DOI 10.1074/jbc.273.47.31480; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; GAFFNEY PJ, 1977, HAEMOSTASIS, V6, P72; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; GRAHAM KS, 1999, Patent No. 5986071; GRIMARD M, 1976, BIOCHIMIE, V58, P1409; HAYES ML, 1979, J BIOL CHEM, V254, P8772; HAYES ML, 1979, J BIOL CHEM, V254, P8777; Hoffman R, 1998, J INVEST DERMATOL, V111, P1140, DOI 10.1046/j.1523-1747.1998.00429.x; JESPERSEN J, 1986, THROMB RES, V41, P395, DOI 10.1016/0049-3848(86)90250-1; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Komorowicz E, 1998, BIOCHEMISTRY-US, V37, P9112, DOI 10.1021/bi980180d; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; Lucas R, 1998, BLOOD, V92, P4730; MacDonald NJ, 1999, BIOCHEM BIOPH RES CO, V264, P469, DOI 10.1006/bbrc.1999.1486; Machovich R, 1990, Blood Coagul Fibrinolysis, V1, P273, DOI 10.1097/00001721-199008000-00004; Marti DN, 1999, BIOCHEMISTRY-US, V38, P15741, DOI 10.1021/bi9917378; MISSELWITZ R, 1994, INT J BIOL MACROMOL, V16, P187, DOI 10.1016/0141-8130(94)90050-7; O'Mahony CA, 1998, J SURG RES, V77, P55, DOI 10.1006/jsre.1998.5334; O'Reilly MS, 1999, J BIOL CHEM, V274, P29568, DOI 10.1074/jbc.274.41.29568; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Pirie-Shepherd SR, 1999, J LAB CLIN MED, V134, P553, DOI 10.1016/S0022-2143(99)90093-8; REDDY KNN, 1980, BIOCHEM BIOPH RES CO, V92, P1016, DOI 10.1016/0006-291X(80)90803-7; Sack RA, 1999, CURR EYE RES, V18, P186, DOI 10.1076/ceyr.18.3.186.5367; SHI GY, 1988, THROMB RES, V51, P355, DOI 10.1016/0049-3848(88)90371-4; Sim BKL, 1997, CANCER RES, V57, P1329; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; TAKADA A, 1988, THROMB RES, V50, P285, DOI 10.1016/0049-3848(88)90229-0; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; WALTHER PJ, 1974, J BIOL CHEM, V249, P1173; Westphal JR, 2000, INT J CANCER, V86, P760, DOI 10.1002/(SICI)1097-0215(20000615)86:6<760::AID-IJC2>3.0.CO;2-4; WU HL, 1987, P NATL ACAD SCI USA, V84, P8793, DOI 10.1073/pnas.84.24.8793	48	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8924	8933		10.1074/jbc.M009071200	http://dx.doi.org/10.1074/jbc.M009071200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11114303	hybrid			2022-12-25	WOS:000167607700044
J	Fernandez-Belda, F; Fortea, MI; Soler, F				Fernandez-Belda, F; Fortea, MI; Soler, F			Testing the versatility of the sarcoplasmic reticulum Ca2+-ATPase reaction cycle when p-nitrophenyl phosphate is the substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-TRANSPORT; ACETYL PHOSPHATE; CATALYTIC CYCLE; CA2+ TRANSPORT; ION-TRANSPORT; ATPASE; HYDROLYSIS; INHIBITION; THAPSIGARGIN; MECHANISM	A detailed characterization of p-nitrophenyl phosphate as energy-donor Substrate for the sarcoplasmic reticulum Ca2+-ATPase was undertaken in this study. The fact that p-nitrophenyl phosphate can be hydrolyzed in the presence or absence of Ca2+ by the purified enzyme is consistent with the observed phenomenon of intramolecular uncoupling. Under the most favorable conditions, which include neutral pH, intact microsomal vesicles, and low free Ca2+ in the lumen, the Ca2+/P-i coupling ratio was 0.6. A rise or decrease in pH, high free Ca2+ in the lumenal space, or the addition of dimethyl sulfoxide increase the intramolecular uncoupling. Alkaline pH and/or high free Ca2+ in the lumen potentiate the accumulation of enzyme conformations with high Ca2+ affinity, Acidic pH and/or dimethyl sulfoxide favor the accumulation of enzyme conformations with low Ca2+ affinity. Under standard assay conditions, two uncoupled routes, together with a coupled route, are operative during the hydrolysis of p-nitrophenyl phosphate in the presence of Ca2+. The prevalence of any one of the uncoupled catalytic cycles is dependent on the working conditions. The proposed reaction scheme constitutes a general model for understanding the mechanism of intramolecular energy uncoupling.	Univ Murcia, Dept Bioquim & Biol Mol A, Edificio Vet, E-30071 Murcia, Spain	University of Murcia	Fernandez-Belda, F (corresponding author), Univ Murcia, Dept Bioquim & Biol Mol A, Edificio Vet, Campus Espinardo, E-30071 Murcia, Spain.	fbelda@um.es	Soler, Fernando/S-1441-2019					ASANO S, 1992, J BIOL CHEM, V267, P6590; BEAUGE L, 1984, BIOCHIM BIOPHYS ACTA, V772, P411, DOI 10.1016/0005-2736(84)90159-7; BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CARIDE AJ, 1983, BIOCHIM BIOPHYS ACTA, V734, P363, DOI 10.1016/0005-2736(83)90136-0; CARVALHOALVES PC, 1987, J BIOL CHEM, V262, P6610; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FERREIRAPEREIRA A, 1994, J BIOL CHEM, V269, P12074; FORGE V, 1993, J BIOL CHEM, V268, P10953; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; Hua SM, 1999, BIOPHYS J, V77, P2217, DOI 10.1016/S0006-3495(99)77062-1; INESI G, 1980, J BIOL CHEM, V255, P6040; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; INESI G, 1971, SCIENCE, V171, P901, DOI 10.1126/science.171.3974.901; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; MEDDA P, 1983, EUR J BIOCHEM, V137, P7, DOI 10.1111/j.1432-1033.1983.tb07788.x; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MELTZER S, 1984, J BIOL CHEM, V259, P4244; NAKAMURA Y, 1986, J BIOL CHEM, V261, P3090; NAKAMURA Y, 1978, J BIOCHEM-TOKYO, V83, P571, DOI 10.1093/oxfordjournals.jbchem.a131945; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PICK U, 1982, J BIOL CHEM, V257, P6111; PUCELL A, 1971, J BIOL CHEM, V246, P3389; ROBINSON JD, 1983, BIOCHIM BIOPHYS ACTA, V731, P406, DOI 10.1016/0005-2736(83)90035-4; ROSSI B, 1979, J BIOL CHEM, V254, P2302; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SARKADI B, 1980, BIOCHIM BIOPHYS ACTA, V598, P326, DOI 10.1016/0005-2736(80)90010-3; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; Suzuki H, 1996, J BIOL CHEM, V271, P5481, DOI 10.1074/jbc.271.10.5481; TANIGUCHI K, 1988, J BIOL CHEM, V263, P12943; THE R, 1977, EUR J BIOCHEM, V74, P611, DOI 10.1111/j.1432-1033.1977.tb11430.x; WEBER A, 1971, J GEN PHYSIOL, V57, P50, DOI 10.1085/jgp.57.1.50; Wells KM, 1998, J BIOL CHEM, V273, P5020, DOI 10.1074/jbc.273.9.5020; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	41	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7998	8004		10.1074/jbc.M008648200	http://dx.doi.org/10.1074/jbc.M008648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11115502	hybrid			2022-12-25	WOS:000167474900047
J	Leo, E; Deveraux, QL; Buchholtz, C; Welsh, K; Matsuzawa, S; Stennicke, HR; Salvesen, GS; Reed, JC				Leo, E; Deveraux, QL; Buchholtz, C; Welsh, K; Matsuzawa, S; Stennicke, HR; Salvesen, GS; Reed, JC			TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor-alpha-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DRUG-INDUCED APOPTOSIS; ZINC-FINGER PROTEIN; INDUCED CELL-DEATH; FACTOR FAMILY; INTERACTING PROTEIN; CYTOPLASMIC DOMAIN; TRANSCRIPTIONAL ACTIVATION; LYMPHOCYTE-TRANSFORMATION; SIGNAL TRANSDUCER	TRAF family proteins are signal-transducing adapter proteins that interact with the cytosolic domains of tumor necrosis factor (TNF) family receptors, Here we show that TRAF1 (but not TRAF2-6) is cleaved by certain caspases in vitro and during TNF-alpha- and Fas-induced apoptosis in vivo. (LEVD163)-L-160 was identified as the caspase cleavage site within TRAF1, generating two distinct fragments. Significant enhancement of TNF receptor-1 (CD120a)- and, to a lesser extent, Fas (CD95)-mediated apoptosis was observed when overexpressing the C-terminal TRAF1 fragment in HEK293T and HT1080 cells. The same fragment was capable of potently suppressing TNF receptor-1- and TRAF2-mediated nuclear factor-kappaB activation in reporter gene assays, providing a potential mechanism for the enhancement of TNF-mediated apoptosis. Cell death induced by other death receptor-independent stimuli such as cisplatin, staurosporine, and UV irradiation did not result in cleavage of TRAF1, and overexpression of the C-terminal TRAF1 fragment did not enhance cell death in these cases. TRAF1 cleavage was markedly reduced in cells that contain little procaspase-8 protein, suggesting that this apical protease in the TNF/Fas death receptor pathway is largely responsible. These data identify TRAF1 as a specific target of caspases activated during TNF- and Fas-induced apoptosis and illustrate differences in the repertoire of protease substrates cleaved during activation of different apoptotic pathways.	Burnham Inst, La Jolla, CA 92037 USA; Heidelberg Univ, Dept Hematol Oncol, D-69115 Heidelberg, Germany	Sanford Burnham Prebys Medical Discovery Institute; Ruprecht Karls University Heidelberg	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-inst.org			NCI NIH HHS [CA72994, CA69381] Funding Source: Medline; NIA NIH HHS [AG15402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381, R01CA072994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dunn IF, 1999, MOL IMMUNOL, V36, P611, DOI 10.1016/S0161-5890(99)00075-9; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Friesen C, 1999, CELL DEATH DIFFER, V6, P471, DOI 10.1038/sj.cdd.4400512; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; GALANG CK, 1994, ONCOGENE, V9, P2913; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HU HM, 1994, J BIOL CHEM, V269, P30069; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	83	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8087	8093		10.1074/jbc.M009450200	http://dx.doi.org/10.1074/jbc.M009450200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11098060	hybrid			2022-12-25	WOS:000167474900059
J	Nakai, Y; Nakai, M; Hayashi, H; Kagamiyama, H				Nakai, Y; Nakai, M; Hayashi, H; Kagamiyama, H			Nuclear localization of yeast Nfs1p is required for cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; IN-VITRO BIOSYNTHESIS; COLI TRANSFER-RNA; FE-S CLUSTER; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CYSTEINE DESULFURASE; BIOTIN SYNTHASE; NIFS GENE; PROTEINS	Saccharomyces cerevisiae Nfs1p is mainly found in the mitochondrial matrix and has been shown to participate in iron-sulfur cluster assembly. We show here that Nfs1p contains a potential nuclear localization signal, RRRPR, in its mature part. When this sequence was mutated to RRGSR, the mutant protein could not restore cell growth under chromosomal NFS1-depleted conditions. However, this mutation did not affect the function of Nfs1p in biogenesis of mitochondrial iron-sulfur proteins. The growth defect of the mutant was complemented by simultaneous expression of the mature Nfs1p, which contains the intact nuclear localization signal but lacks its mitochondrial-targeting presequence, These results suggest that a fraction of Nfs1p is localized in the nucleus and is essential for cell viability.	Osaka Med Coll, Dept Biochem, Takatsuki, Osaka 5698686, Japan; Osaka Univ, Inst Prot Res, Div Enzymol, Suita, Osaka 5650871, Japan	Osaka Medical College; Osaka University	Kagamiyama, H (corresponding author), Osaka Med Coll, Dept Biochem, 2-7 Daigaku-machi, Takatsuki, Osaka 5698686, Japan.							Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Bui BTS, 2000, EUR J BIOCHEM, V267, P2688; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; Culver GM, 1997, J BIOL CHEM, V272, P13203, DOI 10.1074/jbc.272.20.13203; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fansler B., 1969, METHODS ENZYMOL, V13, P26; Flint DH, 1996, J BIOL CHEM, V271, P16068; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kispal G, 1996, J BIOL CHEM, V271, P24458, DOI 10.1074/jbc.271.40.24458; Kiyasu T, 2000, J BACTERIOL, V182, P2879, DOI 10.1128/JB.182.10.2879-2885.2000; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; NAKAI M, 1993, J BIOCHEM-TOKYO, V114, P919, DOI 10.1093/oxfordjournals.jbchem.a124277; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; Paz I, 1999, J BIOL CHEM, V274, P21741, DOI 10.1074/jbc.274.31.21741; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; Sambrook J., 2002, MOL CLONING LAB MANU; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; SHERMAN F, 1986, LABORATORY COURSE MA, P117; Shulga N, 1999, J BIOL CHEM, V274, P16501, DOI 10.1074/jbc.274.23.16501; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Ueki N, 1998, NAT BIOTECHNOL, V16, P1338, DOI 10.1038/4315; Ye X, 1997, MOL CELL BIOL, V17, P1714, DOI 10.1128/MCB.17.3.1714; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	48	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8314	8320		10.1074/jbc.M007878200	http://dx.doi.org/10.1074/jbc.M007878200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11110795	hybrid			2022-12-25	WOS:000167474900088
J	Wang, XQ; Sun, P; Al-Qamari, A; Tai, T; Kawashima, I; Paller, AS				Wang, XQ; Sun, P; Al-Qamari, A; Tai, T; Kawashima, I; Paller, AS			Carboohydrate-carbohydrate binding of ganglioside to integrin alpha(5) modulates alpha(5)beta(1) function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; KERATINOCYTE ADHESION; SIGNAL-TRANSDUCTION; MELANOMA-CELLS; FIBRONECTIN; LECTIN; RECOGNITION; SURFACE	Gangliosides GT1b and GD3, components of keratinocyte membranes, inhibit keratinocyte adhesion to fibronectin. Although ganglioside sialylation is known to be important, the mechanism of inhibition is unknown. Using purified insect recombinant alpha (5) and beta (1) proteins and alpha (5)beta (1) integrin from lysed keratinocyte-derived SCC12 cells, we have shown that GT1b and GD3 inhibit the binding of alpha (5)beta (1) to fibronectin. Co-immunoprecipitation of GT1b and alpha (5)beta (1) from SCC12 cells and direct binding of GT1b and GD3 to affinity-purified alpha (5)beta (1) from SCC12 cells and insect recombinant alpha (5)beta (1), particularly the alpha (5) subunit, further suggest interaction between ganglioside and alpha (5)beta (1). The carbohydrate moieties of integrin appear to be critical since gangliosides are unable to bind deglycosylated forms of alpha (5)beta (1) from SCC12 and insect cells or poorly glycosylated recombinant alpha (5)beta (1) from Escherichia coli cells. The GT1b-alpha (5)beta (1) interaction is inhibited by concanavalin A, suggesting that GT1b binds to mannose structures in alpha (5)beta (1). The preferential binding of GT1b to high mannose rather than reduced mannose ovalbumin further implicates the binding of GT1b to mannose structures. These data provide evidence that highly sialylated gangliosides regulate alpha (5)beta (1)-mediated adhesion of epithelial cells to fibronectin through carbohydrate-carbohydrate interactions between GT1b and the alpha (5) subunit of alpha (5)beta (1) integrin.	Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Dermatol, Chicago, IL 60614 USA; Tokyo Metropolitan Inst Med Sci, Dept Tumor Immunol, Bunkyo Ku, Tokyo 1138613, Japan	Northwestern University; Northwestern University; Tokyo Metropolitan Institute of Medical Science	Paller, AS (corresponding author), Childrens Mem Hosp, Div Dermatol 107, 2300 Childrens Plaza, Chicago, IL 60614 USA.			Paller, Amy/0000-0001-6187-6549	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044619] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR44619] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ARNSMEIER SL, 1995, J LIPID RES, V36, P911; CHAMMAS R, 1991, J BIOL CHEM, V266, P3349; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Disatnik MH, 1999, J BIOL CHEM, V274, P32486, DOI 10.1074/jbc.274.45.32486; EGGENS I, 1989, J BIOL CHEM, V264, P9476; GATES RE, 1993, BIOCHEM J, V289, P221, DOI 10.1042/bj2890221; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HANAI N, 1988, J BIOL CHEM, V263, P6296; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; KLEINMAN HK, 1979, P NATL ACAD SCI USA, V76, P3367, DOI 10.1073/pnas.76.7.3367; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; KOYAMA T, 1992, J BIOL CHEM, V267, P25939; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez M, 1998, J BIOL CHEM, V273, P33644, DOI 10.1074/jbc.273.50.33644; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Nakagawa H, 1996, EUR J BIOCHEM, V237, P76, DOI 10.1111/j.1432-1033.1996.0076n.x; ODA Y, 1986, EUR J BIOCHEM, V159, P239, DOI 10.1111/j.1432-1033.1986.tb09859.x; Oda Y, 2000, J BIOL CHEM, V275, P26772; PALLER AS, 1995, J INVEST DERMATOL, V105, P237, DOI 10.1111/1523-1747.ep12317572; PALLER AS, 1995, EXP CELL RES, V217, P118, DOI 10.1006/excr.1995.1070; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; PALLER AS, 1992, J INVEST DERMATOL, V98, P226, DOI 10.1111/1523-1747.ep12555896; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; PERKINS RM, 1982, EXP CELL RES, V141, P31; POMIES P, 1995, BIOCHEMISTRY-US, V34, P5104, DOI 10.1021/bi00015a022; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; Song Y, 1998, J BIOL CHEM, V273, P2517, DOI 10.1074/jbc.273.5.2517; Sung CC, 1998, EXP CELL RES, V239, P311, DOI 10.1006/excr.1997.3897; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; WEILAND F, 1988, BIOCHIMIE PARIS, V70, P1493; YAMADA KM, 1981, J CELL PHYSIOL, V109, P343, DOI 10.1002/jcp.1041090218; YEDNAK MA, 1994, MOL CHEM NEUROPATHOL, V21, P369, DOI 10.1007/BF02815362; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217; Zheng MZ, 2000, ARCH BIOCHEM BIOPHYS, V374, P93, DOI 10.1006/abbi.1999.1613	44	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8436	8444		10.1074/jbc.M006097200	http://dx.doi.org/10.1074/jbc.M006097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11118433	hybrid			2022-12-25	WOS:000167474900103
J	Zhang, FL; Luo, L; Gustafson, E; Lachowicz, J; Smith, M; Qiao, XD; Liu, YH; Chen, GD; Pramanik, B; Laz, TM; Palmer, K; Bayne, M; Monsma, FJ				Zhang, FL; Luo, L; Gustafson, E; Lachowicz, J; Smith, M; Qiao, XD; Liu, YH; Chen, GD; Pramanik, B; Laz, TM; Palmer, K; Bayne, M; Monsma, FJ			ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P2Y(1) RECEPTOR; AMINO-ACIDS	P2Y receptors are a class of G protein-coupled receptors activated primarily by ATP, UTP, and UDP. Five mammalian P2Y receptors have been cloned so far including P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11. P2Y1, P2Y2, and P2Y6 couple to the activation of phospholipase C, whereas P2Y4 and P2Y11 couple to the activation of both phospholipase C and the adenylyl cyclase pathways. Additional ADP receptors linked to G alpha (i) have been described but have not yet been cloned, SP1999 is an orphan G protein-coupled receptor, which is highly expressed in brain, spinal cord, and blood platelets. In the present study, we demonstrate that SP1999 is a G alpha (i)-coupled receptor that is potently activated by ADP. In an effort to identify ligands for SP1999, fractionated rat spinal cord extracts were assayed for Ca2+ mobilization activity against Chinese hamster ovary cells transiently transfected with SP1999 and chimeric G alpha subunits (G alpha (q/i)), A substance that selectively activated SP1999-transfected cells was identified and purified through a series of chromatographic steps. Mass spectral analysis of the purified material definitively identified it as ADP. ADP was subsequently shown to inhibit forskolin-stimulated adenylyl cyclase activity through selective activation of SP1999 with an EC50 of 60 nM. Other nucleotides were able to activate SP1999 with a rank order of potency 2-MeS-ATP = 2-MeS-ADP > ADP = adenosine 5'-O-2-(thio)diphosphate > 2-Cl-ATP > adenosine 5'-O-(thiotriphosphate). Thus, SP1999 is a novel, G alpha (i)-linked receptor for ADP.	Schering Plough Corp, Res Inst, Human Genome Res, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Cent Nervous Syst Cardiovasc Res, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Struct Chem, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Immunol Res, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Zhang, FL (corresponding author), Schering Plough Corp, Res Inst, Human Genome Res, K-15-1-1945, Kenilworth, NJ 07033 USA.							BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BOYER JL, 1993, J PHARMACOL EXP THER, V267, P1140; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HARDEN TK, 1982, MOL PHARMACOL, V21, P570; Hechler B, 1998, BRIT J HAEMATOL, V103, P858, DOI 10.1046/j.1365-2141.1998.01056.x; Hoffmann C, 1999, J BIOL CHEM, V274, P14639, DOI 10.1074/jbc.274.21.14639; Jiang QL, 1997, MOL PHARMACOL, V52, P499, DOI 10.1124/mol.52.3.499; Ralevic V, 1998, PHARMACOL REV, V50, P413; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238	17	171	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8608	8615		10.1074/jbc.M009718200	http://dx.doi.org/10.1074/jbc.M009718200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11104774	hybrid			2022-12-25	WOS:000167474900125
J	Briede, JJ; Tans, G; Willems, GM; Hemker, HC; Lindhout, T				Briede, JJ; Tans, G; Willems, GM; Hemker, HC; Lindhout, T			Regulation of platelet factor Va-dependent thrombin generation by activated protein C at the surface of collagen-adherent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BOND CLEAVAGES; FACTOR-XA; PROTHROMBINASE COMPLEX; PROCOAGULANT ACTIVITY; COFACTOR ACTIVITIES; FACTOR VA(R506Q); ROTATING-DISC; INACTIVATION; INHIBITION; ANTICOAGULANT	Recent studies have indicated that factor Va bound to activated platelets is partially protected from inactivation by activated protein C (APC), To explore whether this sustained factor Va activity could maintain ongoing thrombin generation, the kinetics of platelet factor Va-dependent prothrombinase activity and its inhibition by APC were studied. In an attempt to mimic physiologically relevant conditions, platelets were adhered to collagen: type I-coated discs. These discs were then spun in solutions containing prothrombin and factor Xa either in the absence or presence of APC. The experiments were performed in the absence of platelet-derived microparticles, with thrombin generation and inhibition confined to the surface of the adherent platelets. APC completely inactivated platelet-associated prothrombinase activity with an overall second order rate constant of 3.3 x 10(6) M-1 s(-1), which was independent of the prothrombin concentration over a wide range around the apparent K-m for prothrombin. Kinetic studies on prothrombinase assembled at a planar phospholipid membrane composed of 25 mol % phosphatidylserine and 75 mol % phosphatidylcholine revealed a similar second order rate constant of inhibition (2.5 x 106 M-1 s(-1)). Collectively, these data demonstrate that ongoing platelet factor Va-dependent thrombin generation at the surface of collagen-adherent platelets is effectively inhibited by APC, No differences were observed between the kinetics of APC inactivation of plasma-derived factor Va or platelet factor Va as part of the prothrombinase associated with, respectively, a planar membrane of synthetic phospholipids or collagen-adherent platelets.	Univ Limburg, Dept Biochem, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands	Hasselt University; Maastricht University	Lindhout, T (corresponding author), Univ Limburg, Dept Biochem, Cardiovasc Res Inst Maastricht, POB 616, NL-6200 MD Maastricht, Netherlands.			Hemker, Coen/0000-0003-1669-2358; Briede, Jacco/0000-0003-1405-5232				Alberio L, 2000, BLOOD, V95, P1694, DOI 10.1182/blood.V95.5.1694.005k24_1694_1702; ANDREE HAM, 1994, BIOCHEMISTRY-US, V33, P4368, DOI 10.1021/bi00180a034; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BILLY D, 1995, BIOCHEMISTRY-US, V34, P13699, DOI 10.1021/bi00041a052; BILLY D, 1995, J BIOL CHEM, V270, P1029, DOI 10.1074/jbc.270.3.1029; Camire RM, 1998, BLOOD, V91, P2818, DOI 10.1182/blood.V91.8.2818.2818_2818_2829; CASTNER JF, 1984, BIOCHEMISTRY-US, V23, P2203, DOI 10.1021/bi00305a016; COMP PC, 1979, BLOOD, V54, P1272; Dormann D, 2000, BLOOD, V96, P2469, DOI 10.1182/blood.V96.7.2469.h8002469_2469_2478; GIESEN PLA, 1991, J BIOL CHEM, V266, P18720; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Heemskerk JWM, 1999, THROMB HAEMOSTASIS, V81, P782; Hoekema L, 1997, BIOCHEMISTRY-US, V36, P3331, DOI 10.1021/bi9623284; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Larson PJ, 1998, BIOCHEMISTRY-US, V37, P5029, DOI 10.1021/bi972428p; MONKOVIC DD, 1990, J BIOL CHEM, V265, P17132; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1993, J BIOL CHEM, V268, P21130; ROSING J, 1980, J BIOL CHEM, V255, P274; Salemink I, 1999, J BIOL CHEM, V274, P28225, DOI 10.1074/jbc.274.40.28225; SCHOEN P, 1991, THROMB HAEMOSTASIS, V66, P435; SHIZUKA R, 1995, THROMB RES, V78, P189, DOI 10.1016/0049-3848(95)00046-1; SHU FR, 1976, ANAL CHEM, V48, P1679, DOI 10.1021/ac50006a014; SIDELMANN J, 1995, THROMB HAEMOSTASIS, V74, P993; Smirnov MD, 1999, BLOOD, V94, P3839, DOI 10.1182/blood.V94.11.3839.423k07_3839_3846; SPEIJER H, 1995, THROMB HAEMOSTASIS, V73, P648; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; SWORDS NA, 1993, ARTERIOSCLER THROMB, V13, P1602, DOI 10.1161/01.ATV.13.11.1602; Tans G, 1997, SEMIN HEMATOL, V34, P244; TANS G, 1991, BLOOD, V77, P2641; Taube J, 1999, BLOOD, V93, P3792, DOI 10.1182/blood.V93.11.3792.411k06_3792_3797; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WILLEMS GM, 1993, BLOOD, V82, P497, DOI 10.1182/blood.V82.2.497.bloodjournal822497	35	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7164	7168		10.1074/jbc.M009230200	http://dx.doi.org/10.1074/jbc.M009230200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11113137	hybrid, Green Published			2022-12-25	WOS:000167442900044
J	Ueda, H; Morishita, R; Yamauchi, J; Itoh, H; Kato, K; Asano, T				Ueda, H; Morishita, R; Yamauchi, J; Itoh, H; Kato, K; Asano, T			Regulation of Rac and Cdc42 pathways by G(i) during lysophosphatidic acid-induced cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GTP-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; N-TERMINAL KINASE; STRESS FIBER FORMATION; KIDNEY 293 CELLS; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; SIGNALING PATHWAYS; P115 RHOGEF	The pertussis toxin-sensitive G protein, G(i), has been implicated in lysophosphatidic acid-induced cell mito genesis and migration, but the mechanisms remain to be detailed. In the present study, we found that pertussis toxin blocks lysophosphatidic acid induced cell spreading of NIH 3T3 fibroblasts on fibronectin. This prevention of cell spreading was eliminated by the expression of constitutively active mutants of Rho family small GTP-binding proteins, Rac and Cdc42, but not by Rho. In addition, activation of the endogenous forms was suppressed by pertussis toxin, indicating that G, induced cell spreading is mediated through the Rac and Cdc42 pathway. Transfection of constitutively active mutants of G alpha (i) and G alpha (11) and G beta gamma subunits enhanced spreading of pertussis toxin-treated cells. G beta (1) with G gamma (12), a major G gamma form in fibroblasts, was more effective for increasing cell spreading than G beta (1)gamma (2) or G beta (1) plus G gamma (12)S2A, a mutant in which Ser-2, a phosphorylation site for protein kinase C, is replaced with alanine. In addition, a protein kinase C inhibitor diminished G beta (1)gamma (12)-induced cell spreading, suggesting a role for phosphorylation of the protein. These findings indicate that both G alpha (i) and G beta gamma stimulate Rac and Cdc42 pathways with lysophosphatidic acid-induced cell spreading on fibronectin.	Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Aichi 4800392, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Asano, T (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Aichi 4800392, Japan.							AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; ASANO T, 1995, J NEUROCHEM, V64, P1267; Asano T, 1998, EUR J BIOCHEM, V251, P314, DOI 10.1046/j.1432-1327.1998.2510314.x; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORISHITA R, 1988, EUR J BIOCHEM, V174, P87, DOI 10.1111/j.1432-1033.1988.tb14066.x; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Neptune ER, 1999, J BIOL CHEM, V274, P2824, DOI 10.1074/jbc.274.5.2824; Nishida K, 1999, FEBS LETT, V459, P186, DOI 10.1016/S0014-5793(99)01244-2; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sakai T, 1999, J BIOL CHEM, V274, P15480, DOI 10.1074/jbc.274.22.15480; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; SCHGGER H, 1987, ANAL BIOCHEM, V166, P368; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Ueda H, 1999, J BIOL CHEM, V274, P12124, DOI 10.1074/jbc.274.17.12124; Ueda H, 2000, J BIOL CHEM, V275, P2098, DOI 10.1074/jbc.275.3.2098; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	42	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6846	6852		10.1074/jbc.M007541200	http://dx.doi.org/10.1074/jbc.M007541200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11099498	hybrid			2022-12-25	WOS:000167261000099
J	Zhou, B; Wu, L; Shen, K; Zhang, JL; Lawrence, DS; Zhang, ZY				Zhou, B; Wu, L; Shen, K; Zhang, JL; Lawrence, DS; Zhang, ZY			Multiple regions of MAP kinase phosphatase 3 are involved in its recognition and activation by ERK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL-REGULATED KINASE; DUAL-SPECIFICITY PHOSPHATASES; OF-FUNCTION MUTATION; CATALYTIC ACTIVATION; IN-VIVO; INTERACTION MOTIF; DOCKING SITE; PTP-SL; BINDING	Mitogen-activated protein kinase phosphatase 3 (MKP3) is a specific regulator of extracellular signal-regulated protein kinase 2 (ERK2). Association of ERK2 with MKP3 results in a powerful increase in MKP3 phosphatase activity. To determine the molecular basis of the specific ERK2 recognition by MKP3 and the ERK2-induced MKP3 activation, we have carried out a systematic mutational and deletion analysis of MKP3. Using activation-based and competition-based assays, we are able to quantitatively evaluate the contributions that residues/regions within MKP3 make to ERK2 binding and ERK2-induced MKP3 activation. Our results show that recognition and activation of MKP3 by ERK2 involves multiple regions of MKP3. Thus, the kinase inter action motif (KIM; residues 61-75) in MKP3 plays a major role (135-fold) for high affinity ERK2 binding. The most important residue in the KIM sequence of MKP3 is Arg(65), which probably interacts with Asp(319) in ERK2. In addition to KIM, a unique sequence conserved in cytosolic MKPs (residues 161-177 in MKP3) also contributes to ERK2 binding (15-fold). However, these two regions are not essential for ERK2-induced MKP3 activation. A third ERK2 binding site is localized in the C terminus of MKP3 (residues 348-381). Although deletion of this region or mutation of the putative ERK specific docking sequence (364)FTAP(367) in this region reduces MKP3's affinity for ERK2 by less than 10-fold, this region is absolutely required for ERK2-induced MKP3 activation.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [CA69202] Funding Source: Medline; NIGMS NIH HHS [GM55242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Karim FD, 1999, MOL CELL, V3, P741, DOI 10.1016/S1097-2765(01)80006-X; Keng YF, 1999, EUR J BIOCHEM, V259, P809, DOI 10.1046/j.1432-1327.1999.00090.x; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Mason C, 1996, MECH DEVELOP, V55, P133, DOI 10.1016/0925-4773(96)00495-9; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zhan XL, 1999, GENE DEV, V13, P2811, DOI 10.1101/gad.13.21.2811; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	37	105	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6506	6515		10.1074/jbc.M009753200	http://dx.doi.org/10.1074/jbc.M009753200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11104775	hybrid			2022-12-25	WOS:000167261000059
J	Xiong, Y; Kern, P; Chang, HC; Reinherz, EL				Xiong, Y; Kern, P; Chang, HC; Reinherz, EL			T cell receptor binding to a pMHCII ligand is kinetically distinct from and independent of CD4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; IMMUNODEFICIENCY-VIRUS GP120; TCR FAB FRAGMENT; ALPHA-BETA; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; TYROSINE KINASE; LYMPHOCYTES-T; ANTIGEN RECEPTOR; ATOMIC-STRUCTURE	Immune recognition of pMHCII ligands by a helper T lymphocyte involves its antigen-specific T cell receptor (TCR) and CD4 coreceptor. We have characterized the binding of both molecules to the same pMHCII. The D10 ap TCR heterodimer binds to conalbumin/I-A(k) with virtually identical kinetics and affinity as the single chain V alphaV beta domain module (scD10) (Kd = 6-8 muM). The CD4 ectodomain does not alter either interaction. Moreover, CD4 alone demonstrates weak pMHCII binding (K-d = 200 muM), with no discernable affinity for the cup TCR heterodimer. Hence, rather than providing a major contribution to binding energy, the critical role for the coreceptor in antigen-specific activation likely results from transient inducible recruitment of the CD4 cytoplasmic tail-associated lck tyrosine kinase to the pMHCII-ligated TCR complex.	Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Reinherz, EL (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI043649, R01AI019807, R37AI019807, R56AI019807, R01AI143649] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19807, AI43649] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; CRISE B, 1992, J BIOL CHEM, V267, P13593; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, J IMMUNOL, V157, P5403; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Ghendler Y, 1998, P NATL ACAD SCI USA, V95, P10061, DOI 10.1073/pnas.95.17.10061; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; Hampl J, 1997, IMMUNITY, V7, P379, DOI 10.1016/S1074-7613(00)80359-3; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, IMMUNOL TODAY, V10, P234, DOI 10.1016/0167-5699(89)90260-0; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Kern P, 1999, J BIOL CHEM, V274, P27237, DOI 10.1074/jbc.274.38.27237; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Kersh EN, 1999, J EXP MED, V190, P1627, DOI 10.1084/jem.190.11.1627; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Khandekar SS, 1997, J BIOL CHEM, V272, P32190, DOI 10.1074/jbc.272.51.32190; Khandekar SS, 1997, MOL IMMUNOL, V34, P493, DOI 10.1016/S0161-5890(97)00044-8; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANGE G, 1994, STRUCTURE, V2, P469, DOI 10.1016/S0969-2126(00)00048-4; LAW YM, 1994, J EXP MED, V179, P1233, DOI 10.1084/jem.179.4.1233; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; Liu J, 1996, J BIOL CHEM, V271, P33639, DOI 10.1074/jbc.271.52.33639; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SAKIHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444, DOI 10.1073/pnas.92.14.6444; Sakihama T, 2000, EUR J IMMUNOL, V30, P279; SAKIHAMA T, 1995, IMMUNOL TODAY, V16, P581, DOI 10.1016/0167-5699(95)80081-6; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Vignali DAA, 1996, J EXP MED, V183, P2097, DOI 10.1084/jem.183.5.2097; Vignali DAA, 1999, J IMMUNOL, V162, P1431; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; WEBER S, 1993, INT IMMUNOL, V5, P695, DOI 10.1093/intimm/5.6.695; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	69	82	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5659	5667		10.1074/jbc.M009580200	http://dx.doi.org/10.1074/jbc.M009580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11106664	hybrid			2022-12-25	WOS:000167115100036
J	Shaked-Mishan, P; Ulrich, N; Ephros, M; Zilberstein, D				Shaked-Mishan, P; Ulrich, N; Ephros, M; Zilberstein, D			Novel intracellular Sb-V reducing activity correlates with antimony susceptibility in Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTILEISHMANIAL ACTIVITY; SODIUM STIBOGLUCONATE; PENTAVALENT ANTIMONY; AXENIC AMASTIGOTES; GROWN AMASTIGOTES; RESISTANCE; PROMASTIGOTES; TARENTOLAE; MECHANISMS; SPECIATION	The standard treatment of human visceral leishmaniasis involves the use of pentavalent antimony (Sb-V). Its mechanism of action is unknown because of the limited information available about intracellular antimony metabolism and about the genes that regulate these processes. Herein, flow injection-inductively coupled plasma mass spectrometry (ICP-MS), flow injection hydride generation ICP-MS, and ion chromatography ICP-RIS were used to measure antimony accumulation and intracellular metabolism in the human protozoan parasite Leishmania donovani. Amastigotes (the intracellular form) and promastigotes (the extracellular form) accumulate Sb-V and Sb-III via separate transport systems. Stage-specific intracellular Sb-V reducing activity was apparent in amastigotes, which reduced the negligibly toxic Sb-V to highly toxic Sb-III. This amastigote-specific reducing activity was deficient in the Pentostam-resistant mutant L. donovani Ld1S.20. These data indicate that parasite susceptibility to Sb-V correlates with its level of Sb-V reducing activity. Also, in promastigotes of both wild-type L. donovani and the Pentostam-resistant mutant L. donovani Ld1S.20, Sb-V inhibited the toxicity of Sb-III but not of Asm. Both Sb-V and Sb-III were toxic to wild-type amastigotes. However, as observed in promastigotes, in mutant amastigotes Sb-V inhibits Sb-III but not As-III activity, Anion exchange chromatography showed that intracellular antimony metabolism occurred in both promastigotes and amastigotes. These data demonstrate that the interaction between the two antimony oxidation states occurs intracellularly, within the parasite. The results also indicate that Sb-V anti-leishmanial activity is dependent on its reduction to Sb-III. The mechanism of this novel intracellular Sb-V reduction has yet to be identified, and it may or may not be enzymatic, This is the first description of intracellular Sb-V reducing activity in Leishmania as well as in any prokaryotic or eukaryotic cell.	Technion Israel Inst Technol, Dept Biol, Carmel Med Ctr, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Pediat, Carmel Med Ctr, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Fac Med, IL-32000 Haifa, Israel; Leibniz Univ Hannover, Dept Inorgan Chem, D-30167 Hannover, Germany	Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Leibniz University Hannover	Zilberstein, D (corresponding author), Technion Israel Inst Technol, Dept Biol, Carmel Med Ctr, IL-32000 Haifa, Israel.	danz@tx.technion.ac.il						AMINSPECTOR S, 2001, IN PRESS PARASITOL T; Basselin M, 1996, BIOCHEM J, V315, P631, DOI 10.1042/bj3150631; BERMAN JD, 1985, ANTIMICROB AGENTS CH, V27, P916, DOI 10.1128/AAC.27.6.916; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; Callahan HL, 1997, ANTIMICROB AGENTS CH, V41, P818, DOI 10.1128/AAC.41.4.818; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; Chattopadhayay R, 1996, INDIAN J MED RES, V104, P349; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; DEY S, 1994, MOL BIOCHEM PARASIT, V67, P49, DOI 10.1016/0166-6851(94)90095-7; DEYARBUH AL, 1994, ANN TROP MED PARASIT, V88, P37; DWYER DM, 1977, EXP PARASITOL, V41, P341, DOI 10.1016/0014-4894(77)90107-2; Ephros M, 1997, ANTIMICROB AGENTS CH, V41, P1064, DOI 10.1128/AAC.41.5.1064; Ephros M, 1999, ANTIMICROB AGENTS CH, V43, P278, DOI 10.1128/AAC.43.2.278; GOODWIN LG, 1995, T ROY SOC TROP MED H, V89, P339, DOI 10.1016/0035-9203(95)90572-3; GOODWIN LG, 1943, BIOCHEM J, V22, P236; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; Haimeur A, 1998, ANTIMICROB AGENTS CH, V42, P1689, DOI 10.1128/AAC.42.7.1689; Handman E, 2000, ADV PARASIT, V44, P1; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; Liu JY, 1997, J BIOL CHEM, V272, P21084, DOI 10.1074/jbc.272.34.21084; Mazareb S, 1999, EXP PARASITOL, V91, P341, DOI 10.1006/expr.1998.4391; Mengeling BJ, 1997, GLYCOBIOLOGY, V7, P847, DOI 10.1093/glycob/7.6.847; Mukhopadhyay R, 1998, FEMS MICROBIOL LETT, V168, P127, DOI 10.1016/S0378-1097(98)00430-3; Ouellette M, 1998, DRUG RESIST UPDATE, V1, P43, DOI 10.1016/S1368-7646(98)80213-6; Roberts WL, 1998, ANTIMICROB AGENTS CH, V42, P1076, DOI 10.1128/AAC.42.5.1076; ROBERTS WL, 1995, ANTIMICROB AGENTS CH, V39, P1234, DOI 10.1128/AAC.39.6.1234; ROBERTS WL, 1993, ANTIMICROB AGENTS CH, V37, P1842, DOI 10.1128/AAC.37.9.1842; Rosen B P, 1995, J Basic Clin Physiol Pharmacol, V6, P251; Rosen BP, 1999, TRENDS MICROBIOL, V7, P207, DOI 10.1016/S0966-842X(99)01494-8; Saar Y, 1998, MOL BIOCHEM PARASIT, V95, P9, DOI 10.1016/S0166-6851(98)00062-0; Sereno D, 1998, ANTIMICROB AGENTS CH, V42, P3097, DOI 10.1128/AAC.42.12.3097; Ulrich N, 2000, ANAL CHIM ACTA, V417, P201, DOI 10.1016/S0003-2670(00)00939-9; Ulrich N, 1998, ANAL CHIM ACTA, V359, P245, DOI 10.1016/S0003-2670(97)00656-9; Ulrich N, 1998, FRESEN J ANAL CHEM, V360, P797, DOI 10.1007/s002160050810; Ulrich N, 2000, FRESEN J ANAL CHEM, V368, P62, DOI 10.1007/s002160000441	36	173	179	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3971	3976		10.1074/jbc.M005423200	http://dx.doi.org/10.1074/jbc.M005423200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11110784	hybrid			2022-12-25	WOS:000166921200035
J	Achison, M; Elton, CM; Hargreaves, PG; Knight, CG; Barnes, MJ; Farndale, RW				Achison, M; Elton, CM; Hargreaves, PG; Knight, CG; Barnes, MJ; Farndale, RW			Integrin-independent tyrosine phosphorylation of p125(fak) in human platelets stimulated by collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; RECEPTOR GAMMA-CHAIN; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-VI; PROTEIN-KINASE; ALPHA(2)BETA(1) INTEGRIN; PHOSPHOLIPASE C-GAMMA-2; FLOW CONDITIONS; ACTIVATION; PP125(FAK)	Collagen fibers or a glycoprotein VI-specific collagen-related peptide (CRP-XL) stimulated tyrosine phosphorylation of the focal adhesion kinase, p125(fak) (FAK), in human platelets. An integrin alpha (2)beta (2)-specific triple-helical peptide ligand, containing the sequence GFOGER (single-letter nomenclature, O = Hyp) was without effect. Antibodies to the alpha (2) and beta (1) integrin subunits did not inhibit platelet FAK tyrosine phosphorylation caused by either collagen fibers or CRP-XL, Tyrosine phoslphorylation of FAK caused by CRP-XL or thrombin, but not that caused by collagen fibers, was partially inhibited by GR144053F, an antagonist of integrin alpha (IIb)beta (3). The intracellular Ca2+ chelator, BAPTA, and the protein kinase C inhibitor, Ro31-8220, were each highly effective inhibitors of the FAK tyrosine phosphorylation caused by collagen or CRP-XL. These data suggest that, in human platelets, 1) occupation or clustering of the integrin alpha (2)beta (1) is neither sufficient nor necessary for activation of FAK, 2) the fibrinogen receptor alpha (IIb)beta (3) is not required for activation of FAK by collagen fibers, and 3) both intracellular Ca2+ and protein kinase C activity are essential intermediaries of FAK activation.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Farndale, RW (corresponding author), Univ Cambridge, Dept Biochem, Bldg O,Downing Site,Tennis Court Rd, Cambridge CB2 1QW, England.							Achison M, 1996, BLOOD COAGUL FIBRIN, V7, P149, DOI 10.1097/00001721-199603000-00009; Alberio L, 1999, EUR J CLIN INVEST, V29, P1066; Alessandro R, 1998, BIOCHEM BIOPH RES CO, V248, P635, DOI 10.1006/bbrc.1998.8705; Asazuma N, 1996, THROMB HAEMOSTASIS, V75, P648; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Barnes M J, 1998, Curr Opin Hematol, V5, P314, DOI 10.1097/00062752-199809000-00002; BLOCKMANS D, 1995, BLOOD REV, V9, P143, DOI 10.1016/0268-960X(95)90020-9; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; Carlsson LE, 1999, BLOOD, V93, P3583, DOI 10.1182/blood.V93.11.3583.410k34_3583_3586; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 1999, HAEMOSTASIS, V29, P16; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; Haimovich B, 1996, J BIOL CHEM, V271, P16332, DOI 10.1074/jbc.271.27.16332; HARGREAVES PG, 1994, THROMB HAEMOSTASIS, V72, P634; Hargreaves PG, 1996, THROMB HAEMOSTASIS, V76, P248; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Heemskerk JWM, 1999, THROMB HAEMOSTASIS, V81, P782; Ichinohe T, 1997, J BIOL CHEM, V272, P63; Inoue K, 1999, BIOCHEM BIOPH RES CO, V256, P114, DOI 10.1006/bbrc.1999.0295; KAMIGUTI AS, 1997, J BIOL CHEM, V272, P32559; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Kehrel B, 1998, BLOOD, V91, P491; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lyman S, 1997, J BIOL CHEM, V272, P22538, DOI 10.1074/jbc.272.36.22538; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; Morton LF, 1997, J BIOL CHEM, V272, P11044; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Moshfegh K, 1999, LANCET, V353, P351, DOI 10.1016/S0140-6736(98)06448-4; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; Onley DJ, 2000, J BIOL CHEM, V275, P24560, DOI 10.1074/jbc.M004111200; PLOW EF, 1980, J BIOL CHEM, V255, P971; POLANOWSKAGRABOWSKA R, 1993, BIOCHEM J, V296, P543, DOI 10.1042/bj2960543; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Raja S, 1997, J BIOL CHEM, V272, P10941; Rodriguez-Fernandez JL, 1999, BIOESSAYS, V21, P1069, DOI 10.1002/(SICI)1521-1878(199912)22:1<1069::AID-BIES13>3.0.CO;2-C; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Sage S.O., 1996, PRACT APPROACH SER, P67; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; TANDON NN, 1995, THROMB HAEMOSTASIS, V73, P1357; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; Verkleij MW, 1998, BLOOD, V91, P3808; VUORI K, 1993, J BIOL CHEM, V268, P21459	63	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3167	3174		10.1074/jbc.M007186200	http://dx.doi.org/10.1074/jbc.M007186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11110790	hybrid			2022-12-25	WOS:000166784900026
J	Tao, YX; Williams-Skipp, C; Scheinman, RI				Tao, YX; Williams-Skipp, C; Scheinman, RI			Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; C-JUN; ANTIINFLAMMATORY ACTION; FUNCTIONAL ANTAGONISM; MOLECULAR MECHANISMS; AP-1; INHIBITION; ACTIVATION; PROTEIN; IMMUNOSUPPRESSION	Glucocorticoids (GCs) function, in part, through the ability of the glucocorticoid receptor (GR) to activate gene expression and in part through the transrepression of AP-1 and NF-kappaB, Here we characterize the effect of GR DNA binding domain (DBD) mutations, previously analyzed for changes in the ability to activate gene expression or transrepress AP-1. We have identified a GR mutant capable of distinguishing between transrepression of NF-kappaB and AP-1. Using circular dichroism spectroscopy, we show that this mutation does not appreciably alter GR DBD conformation, suggesting that functional differences between the mutant and wild type protein are the result of an alteration of a specific interaction surface. These data suggest that transrepression of NF-kappaB and AP-1 occurs through distinct protein-protein interactions and argue against the hypothesis that transrepression occurs through competition for a single coactivator protein. Introduction of these mutations into GC-resistant CEM lymphoblastic T cells restored dexamethasone (DEX)-mediated apoptosis as did wild type GR regardless of whether these mutants were transrepression or activation defective. Thus, HEX-mediated apoptosis in transformed T cells is more complex than originally appreciated.	Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Scheinman, RI (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, 4200 E 9th Ave, Denver, CO 80262 USA.							AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P13463, DOI 10.1021/bi00212a011; Brack A, 1997, J CLIN INVEST, V99, P2842, DOI 10.1172/JCI119477; Brostjan C, 1997, J IMMUNOL, V158, P3836; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DUKE RC, 1991, CURRENT PROTOCOLS IM; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; NORMAN MR, 1977, CANCER RES, V37, P3785; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Unlap MT, 1997, MOL BRAIN RES, V45, P83, DOI 10.1016/S0169-328X(96)00240-9; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; WRANGE O, 1989, J BIOL CHEM, V264, P5253; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	35	71	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2329	2332		10.1074/jbc.C000526200	http://dx.doi.org/10.1074/jbc.C000526200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11106637	hybrid			2022-12-25	WOS:000166784800006
J	Tanaka, M; Koul, D; Davies, MA; Liebert, M; Steck, PA; Grossman, HB				Tanaka, M; Koul, D; Davies, MA; Liebert, M; Steck, PA; Grossman, HB			MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells	ONCOGENE			English	Article						MMAC1/PTEN; bladder cancer; growth suppression; doxorubicin; chemosensitization	TUMOR-SUPPRESSOR GENE; PROSTATE-CANCER; GERMLINE MUTATIONS; COWDEN-DISEASE; P53 GENE; GLIOBLASTOMA-MULTIFORME; MULTIDRUG-RESISTANCE; NATURAL-HISTORY; PTEN/MMAC1 GENE; PTEN	The development and progression of bladder cancer is associated with multiple alterations in the genome, including loss of chromosome 10. Recently, MMAC1/ PTEN, a phosphatidylinositol phosphatase, has been mapped to chromosome 10q23. We previously demonstrated that MMAC1/PTEN has tumor suppressive properties in glioblastoma and prostate cancer. To investigate the efficacy of gene therapy with MMAC1/ PTEN, we examined whether the exogenous introduction of MMAC1/PTEN via an adenoviral vector (Ad-MMAC) can inhibit tumor growth and reverse drug resistance to doxorubicin in human bladder cancer cells. Human bladder cancer cell lines UM-UC-3 and T24 were infected with Ad-MMAC to induce exogenous expression of MMAC1/PTEN. The cells were then analysed for cell growth and expression of phosphorylated protein kinase B (Akt/PKB) and MMAC1/PTEN. UM-UC-6dox, a doxorubicin resistant subline, was infected with Ad-MMAC to evaluate its role in reversing drug resistance to doxorubicin. We found that MMAC1/ PTEN suppressed tumor growth in UM-UC-3 and T24 cells with arrest in the G1 phase of the cell cycle. We also showed that gene therapy with MMAC1/PTEN abrogated phosphorylated Akt/PKB expression in UM-UC-3, T24 and UMUC-6dox cells, and restored doxorubicin sensitivity in UM-UC-6dox. These data demonstrate that MMAC1/PTEN can induce growth suppression and increase sensitivity to doxorubicin in bladder cancer cells and suggest that the MMAC1/ PTEN gene and its pathways can be therapeutic targets for bladder cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Grossman, HB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Davies, Michael/GWV-2527-2022		NATIONAL CANCER INSTITUTE [U01CA056973, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA56973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN HJ, 1994, J UROLOGY, V151, P263, DOI 10.1016/S0022-5347(17)34929-7; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Cairns P, 1997, CANCER RES, V57, P4997; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Cookson MS, 1997, J UROLOGY, V158, P62, DOI 10.1097/00005392-199707000-00017; Corral DA, 1997, WORLD J UROL, V15, P139, DOI 10.1007/BF02201986; Dahia PLM, 1997, CANCER RES, V57, P4710; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; FUJIWARA T, 1994, CANCER RES, V54, P2287; Guldberg P, 1997, CANCER RES, V57, P3660; Gurnani M, 1999, CANCER CHEMOTH PHARM, V44, P143, DOI 10.1007/s002800050959; Herr HW, 1997, WORLD J UROL, V15, P84, DOI 10.1007/BF02201977; KANAMARU H, 1989, UROL RES, V17, P259; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; KIM WJ, 1995, JPN J CANCER RES, V86, P969, DOI 10.1111/j.1349-7006.1995.tb03009.x; Kozlowski J, 1999, J UROLOGY, V162, P1581, DOI 10.1016/S0022-5347(05)68170-0; KROFT SH, 1994, LAB INVEST, V71, P158; Levine RL, 1998, CANCER RES, V58, P3254; LI DM, 1997, CANCER RES, V57, P2130; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIU J, 2000, IN PRESS MOL CARCINO; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Maxwell GL, 1998, CANCER RES, V58, P2500; NAITO S, 1995, JPN J CANCER RES, V86, P1112, DOI 10.1111/j.1349-7006.1995.tb03028.x; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Ogawa N, 1997, INT J CANCER, V73, P367, DOI 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A; Pu YS, 1996, J UROLOGY, V156, P271, DOI 10.1016/S0022-5347(01)66015-4; Rhei E, 1997, CANCER RES, V57, P3657; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Sano T, 1999, CANCER RES, V59, P1820; SHINOHARA N, 1993, J UROLOGY, V150, P505, DOI 10.1016/S0022-5347(17)35536-2; STARINK TM, 1986, CLIN GENET, V29, P222; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; TANAKA M, 1995, CANCER RES, V55, P3228; Tashiro H, 1997, CANCER RES, V57, P3935; Thakar M., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P633; USANSKY JI, 1991, SELECT CANCER THER, V7, P139, DOI 10.1089/sct.1991.7.139; Wang SI, 1997, CANCER RES, V57, P4183; Warde P, 1997, WORLD J UROL, V15, P125, DOI 10.1007/BF02201984; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246	46	97	107	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5406	5412		10.1038/sj.onc.1203918	http://dx.doi.org/10.1038/sj.onc.1203918			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103942				2022-12-25	WOS:000165302300012
J	Asano, T; Ashida, M				Asano, T; Ashida, M			Cuticular pro-phenoloxidase of the silkworm, Bombyx mori - Purification and demonstration of its transport from hemolymph	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL OXIDASE; MANDUCA-SEXTA; LARVAL CUTICLE; MICROBIAL ACTIVATION; MOLECULAR-CLONING; TOBACCO HORNWORM; PROPHENOLOXIDASE; PROTEIN; INTEGUMENT; ENZYME	Pro-phenoloxidase (proPO) in insects is implicated in the defense against microbes and wounding. The presence of proPO in the cuticle was suggested more than 30 years ago, but it has not been purified. The extract of cuticles of the silkworm, Bombyx mori, was shown to contain two proPO isoforms (F-type and S-type proPOs, which have slightly different mobilities in polyacrylamide gel electrophoresis under nondenaturing conditions). The two isoforms were purified to homogeneity. From hemolymph of the same insect, two types of proPO with the same electrophoretic mobilities as those of cuticular isoforms were separated and were shown to be different at five amino acid residues in one of their subunits, The isoforms in the hemolymph and cuticle were activated by a specific activating enzyme. The resulting active phenoloxidases exhibited almost the same substrate specificities and specific activities toward o-diphenols, The substrate specificities and the susceptibilities to inhibitors, including carbon monoxide, indicated that the purified proPO isoforms were not zymogens of laccase-type phenoloxidase, The proPO in hemolymph was shown to be transported to the cuticle. This demonstration was corroborated by the failure to detect proPO transcripts by Northern analysis of total RNA from epidermal cells. In reversed-phase column chromatography, cuticular and hemolymph proPOs gave distinct elution profiles, indicating that some yet to be identified modification occurs in hemolymph proPO and results in the formation of cuticular proPO. There was little transportation of cuticular proPO to the cuticle when it was injected into the hemocoel, The nature of the modification is described in the accompanying paper (Asano, T., and Ashida, M. (2001) J. Biol. Chem. 276, 11.113-11125).	Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600819, Japan	Hokkaido University	Ashida, M (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600819, Japan.	ashida@pop.lowtem.hokudai.ac.jp						Ahmed A, 1999, P NATL ACAD SCI USA, V96, P14795, DOI 10.1073/pnas.96.26.14795; ANDERSEN SO, 1978, INSECT BIOCHEM, V8, P143, DOI 10.1016/0020-1790(78)90065-3; ASADA N, 1993, JPN J GENET, V68, P219, DOI 10.1266/jjg.68.219; Asano T, 2001, J BIOL CHEM, V276, P11113, DOI 10.1074/jbc.M008425200; ASHIDA M, 1980, INSECT BIOCHEM, V10, P37, DOI 10.1016/0020-1790(80)90036-0; ASHIDA M, 1971, ARCH BIOCHEM BIOPHYS, V144, P749, DOI 10.1016/0003-9861(71)90383-3; Ashida M., 1990, P239; ASHIDA M, 1995, P NATL ACAD SCI USA, V92, P10698, DOI 10.1073/pnas.92.23.10698; Ashida M., 1997, MOL MECH IMMUNE RESP, P135; ASO Y, 1985, INSECT BIOCHEM, V15, P9, DOI 10.1016/0020-1790(85)90038-1; ASO Y, 1984, INSECT BIOCHEM, V14, P463, DOI 10.1016/0020-1790(84)90103-3; Barrett F. Michael, 1991, P195; BARRETT FM, 1987, CAN J ZOOL, V65, P1158, DOI 10.1139/z87-181; BARRETT FM, 1987, ARCH INSECT BIOCHEM, V5, P99, DOI 10.1002/arch.940050205; BARRETT FM, 1984, CAN J ZOOL, V62, P834, DOI 10.1139/z84-122; BARRETT FM, 1981, INSECT BIOCHEM, V11, P17, DOI 10.1016/0020-1790(81)90036-6; BINNINGTON KC, 1988, TISSUE CELL, V20, P405, DOI 10.1016/0040-8166(88)90073-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREY PT, 1993, P NATL ACAD SCI USA, V90, P6275, DOI 10.1073/pnas.90.13.6275; Csikos G, 1999, J CELL SCI, V112, P2113; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FUJIMOTO K, 1995, P NATL ACAD SCI USA, V92, P7769, DOI 10.1073/pnas.92.17.7769; Gotz P., 1986, P153; HALL M, 1995, P NATL ACAD SCI USA, V92, P7764, DOI 10.1073/pnas.92.17.7764; HIRUMA K, 1988, DEV BIOL, V130, P87, DOI 10.1016/0012-1606(88)90416-2; Hyuk T, 1997, MOL CELLS, V7, P90; IWAMA R, 1986, INSECT BIOCHEM, V16, P547, DOI 10.1016/0020-1790(86)90032-6; Jiang HB, 1997, INSECT BIOCHEM MOLEC, V27, P835, DOI 10.1016/S0965-1748(97)00066-0; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; Keilin D, 1939, NATURE, V143, P23, DOI 10.1038/143023b0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIFOOK J, 1966, J INSECT PHYSIOL, V12, P195, DOI 10.1016/0022-1910(66)90136-3; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOCKE M, 1971, TISSUE CELL, V3, P103, DOI 10.1016/S0040-8166(71)80034-4; Locke Michael, 1991, P1; MASON HS, 1965, ANNU REV BIOCHEM, V34, P595, DOI 10.1146/annurev.bi.34.070165.003115; MORGAN TD, 1990, INSECT BIOCHEM, V20, P251, DOI 10.1016/0020-1790(90)90042-S; Muller HM, 1999, J BIOL CHEM, V274, P11727, DOI 10.1074/jbc.274.17.11727; PYE AE, 1974, NATURE, V251, P610, DOI 10.1038/251610a0; Sanchez D, 1998, MOL BIOL EVOL, V15, P415, DOI 10.1093/oxfordjournals.molbev.a025938; SASS M, 1994, J INSECT PHYSIOL, V40, P407, DOI 10.1016/0022-1910(94)90159-7; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; WIGGLESWORTH V B, 1972, P827; Woods D F, 1993, J Cell Sci Suppl, V17, P171; YAMAZAKI IH, 1989, RES J, V5, P1; YASUHARA Y, 1995, ARCH BIOCHEM BIOPHYS, V320, P14, DOI 10.1006/abbi.1995.1337; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4	48	95	103	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11100	11112		10.1074/jbc.M008426200	http://dx.doi.org/10.1074/jbc.M008426200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11118441	hybrid			2022-12-25	WOS:000167980900072
J	Dalziel, M; Whitehouse, C; McFarlane, I; Brockhausen, I; Gschmeissner, S; Schwientek, T; Clausen, H; Burchell, JM; Taylor-Papadimitriou, J				Dalziel, M; Whitehouse, C; McFarlane, I; Brockhausen, I; Gschmeissner, S; Schwientek, T; Clausen, H; Burchell, JM; Taylor-Papadimitriou, J			The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; BETA-GALACTOSIDE ALPHA-2,3-SIALYLTRANSFERASES; GOLGI-APPARATUS; CORE-PROTEIN; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; TANDEM REPEAT; HELA-CELLS; SIALYLTRANSFERASE; GLYCOSYLATION	In breast cancer, the O-glycans added to the MUC1 mucin are core 1- rather than core a-based. We have analyzed whether competition by the glycosyltransferase, ST3Gal-I, which transfers sialic acid to galactose in the core 1 substrate, is key to this switch in MUC1 glycosylation that results in the expression of the cancer-associated SM3 epitope. Of the three enzymes known to convert core 1 to core 2, by the addition of GlcNAc to GalNAc in core1 C2GnT1 is the dominant enzyme expressed in normal breast tissue. Expression of C2GnT1 is low or absent in around 50% of breast cancers, whereas expression of ST3Gal-I is consistently increased. Mapping of ST3Gal-I and C2GnT1 within the Golgi pathway showed some overlap. To examine functional competition, the enzymes were overexpressed in T47D cells, which normally make core 1-based structures, have no detectable C2GnT1 activity and express the SM3 epitope. Overexpression of C2GnT1 resulted in loss of binding of SM3 to MUC1, accompanied by a decrease in the GalNAc/GlcNAc ratio, indicative of a switch to core 2 structures. Transfection of a C2GnT1 expressing line with ST3Gal-I restored SM3 binding and reduced GlcNAc incorporation into MUC1 O-glycans. Thus, even when C2GnT1 is expressed, the O-glycans added to MUC1 become core 1-dominated structures, provided expression of ST3Gal-I is increased as it is in breast cancer.	Guys Hosp, Imperial Canc Res Fund, Breast Canc Biol Grp, London SE1 9RT, England; Queens Univ, Dept Med, Div Rheumatol, Kingston, ON K7L 3N6, Canada; Imperial Canc Res Fund, Electron Microscopy Unit, London WC2A 3PX, England; Univ Copenhagen, Fac Hlth Sci, Sch Dent, DK-2200 Copenhagen N, Denmark	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Queens University - Canada; Cancer Research UK; University of Copenhagen	Taylor-Papadimitriou, J (corresponding author), Guys Hosp, Imperial Canc Res Fund, Breast Canc Biol Grp, 3rd Floor,Thomas Guy House, London SE1 9RT, England.		clausen, henrik/AAD-8016-2021; Burchell, Joy/G-4560-2012	Dalziel, Martin/0000-0002-8967-6378; Burchell, Joy/0000-0003-0413-3823				BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Beum PV, 1999, J BIOL CHEM, V274, P24641, DOI 10.1074/jbc.274.35.24641; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Brockhausen I, 1998, ACTA ANAT, V161, P36; BURCHELL J, 1989, INT J CANCER, V44, P691, DOI 10.1002/ijc.2910440423; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; Burchell J, 1999, GLYCOBIOLOGY, V9, P1307, DOI 10.1093/glycob/9.12.1307; BURCHELL J, 1987, CANCER RES, V47, P5476; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; GENDLER SJ, 1990, J BIOL CHEM, V268, P3801; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; HANISCH FG, 1989, J BIOL CHEM, V264, P872; Hanisch FG, 1996, EUR J BIOCHEM, V236, P318, DOI 10.1111/j.1432-1033.1996.00318.x; Hull S R, 1989, Cancer Commun, V1, P261; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; KUHNS W, 1993, GLYCOCONJUGATE J, V10, P381, DOI 10.1007/BF00731043; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Muller S, 1999, J BIOL CHEM, V274, P18165, DOI 10.1074/jbc.274.26.18165; Nath D, 1999, IMMUNOLOGY, V98, P213; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; PEMBERTON L, 1992, BIOCHEM BIOPH RES CO, V185, P167, DOI 10.1016/S0006-291X(05)80971-4; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; Recchi MA, 1998, CANCER RES, V58, P4066; Rottger S, 1998, J CELL SCI, V111, P45; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; SKIRONCOSKY D, 1997, J BIOL CHEM, V272, P22695; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; TAYLORPAPADIMITRIOU J, 1981, INT J CANCER, V28, P17, DOI 10.1002/ijc.2910280104; TSUJI S, 1996, GLYCOBIOLOGY, V6, P5; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; WHITEHOUSE C, 1998, THESIS U LONDON; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215	39	146	153	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11007	11015		10.1074/jbc.M006523200	http://dx.doi.org/10.1074/jbc.M006523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11118434	hybrid			2022-12-25	WOS:000167980900060
J	Yamagata, Y; Ogasahara, K; Hioki, Y; Lee, SJ; Nakagawa, A; Nakamura, H; Ishida, M; Kuramitsu, S; Yutani, K				Yamagata, Y; Ogasahara, K; Hioki, Y; Lee, SJ; Nakagawa, A; Nakamura, H; Ishida, M; Kuramitsu, S; Yutani, K			Entropic stabilization of the tryptophan synthase alpha-subunit from a hyperthermophile, Pyrococcus furiosus - X-ray analysis and calorimetry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE SALT BRIDGES; AMINO-ACID SUBSTITUTION; CRYSTAL-STRUCTURE; CONFORMATIONAL STABILITY; ELECTROSTATIC INTERACTIONS; GLUTAMATE-DEHYDROGENASE; THERMOTOGA-MARITIMA; CITRATE SYNTHASE; STRUCTURAL BASIS; BETA-SUBUNITS	The structure of the tryptophan synthase alpha -subunit from Pyrococcus furiosus was determined by x-ray analysis at 2.0-Angstrom resolution, and its stability was examined by differential scanning calorimetry. Although the structure of the tryptophan synthase alpha (2)beta (2) complex from Salmonella typhimurium has been already determined, this is the first report of the structure of the alpha -subunit alone, The alpha -subunit from P, furiosus (Pf-alpha -subunit) lacked 12 and 6 residues at the N and C termini, respectively, and one residue each in two loop regions as compared with that from S, typhimurium (St-alpha -subunit), resulting in the absence of an N-terminal helix and the shortening of a C-terminal helix, The structure of the Pf-alpha -subunit was essentially similar to that of the St-alpha -subunit in the alpha (2)beta (2) complex, The differences between both structures were discussed in connection with the higher stability of the Pf-alpha -subunit and the complex formation of the alpha- and beta -subunits. Calorimetric results indicated that the Pf-alpha -subunit has extremely high thermostability and that its higher stability is caused by an entropic effect. On the basis of structural information of both proteins, we analyzed the contributions of each stabilization factor and could conclude that hydrophobic interactions in the protein interior do not contribute to the higher stability of the Pf-alpha -subunit. Rather, the increase in ion pairs, decrease in cavity volume, and entropic effects due to shortening of the polypeptide chain play important roles in extremely high stability in Pf-alpha -subunit.	Osaka Univ, Inst Prot Res, Osaka 5650871, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Osaka 5650871, Japan; Tokyo Univ Fisheries, Minato Ku, Tokyo 1088477, Japan; Osaka Univ, Grad Sch Sci, Toyonaka, Osaka 5600043, Japan	Osaka University; Osaka University; Tokyo University of Marine Science & Technology; Osaka University	Yutani, K (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Osaka 5650871, Japan.	yutani@protein.osaka-u.ac.jp	Nakagawa, Atsushi/M-5731-2019; ISHIDA, Masami/O-1909-2014; Nakagawa, Atsushi/D-4329-2009; Yamagata, Yoshiki/T-6489-2019	Nakagawa, Atsushi/0000-0002-1700-7861; Nakagawa, Atsushi/0000-0002-1700-7861; 				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1976, BIOCHEM BIOPH RES CO, V72, P146, DOI 10.1016/0006-291X(76)90972-4; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1993, XPLOR VERSION 3 8 5; CAVAGNERO S, 1995, BIOCHEMISTRY-US, V34, P9865, DOI 10.1021/bi00031a007; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DAY MW, 1992, PROTEIN SCI, V1, P1494, DOI 10.1002/pro.5560011111; DeDecker BS, 1996, J MOL BIOL, V264, P1072, DOI 10.1006/jmbi.1996.0697; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; EDMONDSON SP, 1995, BIOCHEMISTRY-US, V34, P13289, DOI 10.1021/bi00041a004; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; ERWIN CR, 1990, PROTEIN ENG, V4, P87, DOI 10.1093/protein/4.1.87; Funahashi J, 1999, PROTEIN ENG, V12, P841, DOI 10.1093/protein/12.10.841; HECHT M H, 1986, Proteins Structure Function and Genetics, V1, P43, DOI 10.1002/prot.340010108; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; HERNING T, 1992, BIOCHEMISTRY-US, V31, P7077, DOI 10.1021/bi00146a008; Hiraga K, 1997, J BIOL CHEM, V272, P4935, DOI 10.1074/jbc.272.8.4935; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Isupov MN, 1999, J MOL BIOL, V291, P651, DOI 10.1006/jmbi.1999.3003; Jaenicke R, 1996, ADV PROTEIN CHEM, V48, P181; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; Knapp S, 1997, J MOL BIOL, V267, P916, DOI 10.1006/jmbi.1996.0900; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar S, 2000, PROTEINS, V38, P368, DOI 10.1002/(SICI)1097-0134(20000301)38:4<368::AID-PROT3>3.0.CO;2-R; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVITT M, 1976, J MOL BIOL, V104, P59, DOI 10.1016/0022-2836(76)90004-8; LYU PCC, 1992, J MOL BIOL, V223, P343, DOI 10.1016/0022-2836(92)90735-3; MacedoRibeiro S, 1996, STRUCTURE, V4, P1291, DOI 10.1016/S0969-2126(96)00137-2; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miles E W, 1995, Subcell Biochem, V24, P207; Nakamura H, 1996, Q REV BIOPHYS, V29, P1, DOI 10.1017/S0033583500005746; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLSON H, 1992, BIOPOLYMERS, V32, P1431, DOI 10.1002/bip.360321103; OOBATAKE M, 1993, PROG BIOPHYS MOL BIO, V59, P237, DOI 10.1016/0079-6107(93)90002-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; RUSSELL RJM, 1994, STRUCTURE, V2, P1157, DOI 10.1016/S0969-2126(94)00118-9; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SANDBERG WS, 1991, P NATL ACAD SCI USA, V88, P1706, DOI 10.1073/pnas.88.5.1706; Sanz-Aparicio J, 1998, PROTEINS, V33, P567, DOI 10.1002/(SICI)1097-0134(19981201)33:4<567::AID-PROT9>3.0.CO;2-U; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; SCHULZ GE, 1969, EUR J BIOCHEM, V10, P195, DOI 10.1111/j.1432-1033.1969.tb00673.x; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; SHORTLE D, 1990, BIOCHEMISTRY-US, V30, P9686; Spek EJ, 1998, PROTEIN SCI, V7, P2431, DOI 10.1002/pro.5560071121; Starich MR, 1996, J MOL BIOL, V255, P187, DOI 10.1006/jmbi.1996.0016; SUGISAKI Y, 1990, THERMOCHIM ACTA, V163, P117, DOI 10.1016/0040-6031(90)80386-D; Szilagyi A, 2000, STRUCTURE, V8, P493, DOI 10.1016/S0969-2126(00)00133-7; Tahirov TH, 1998, J MOL BIOL, V284, P101, DOI 10.1006/jmbi.1998.2146; Takano K, 2000, BIOCHEMISTRY-US, V39, P12375, DOI 10.1021/bi000849s; Takano K, 1998, J MOL BIOL, V280, P749, DOI 10.1006/jmbi.1998.1906; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; Usher KC, 1998, PROTEIN SCI, V7, P403; Vetriani C, 1998, P NATL ACAD SCI USA, V95, P12300, DOI 10.1073/pnas.95.21.12300; Weyand M, 1999, BIOCHEMISTRY-US, V38, P16469, DOI 10.1021/bi9920533; Xiao L, 1999, J MOL BIOL, V289, P1435, DOI 10.1006/jmbi.1999.2810; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441; YUTANI K, 1977, NATURE, V267, P274, DOI 10.1038/267274a0	76	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11062	11071		10.1074/jbc.M009987200	http://dx.doi.org/10.1074/jbc.M009987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11118452	hybrid, Green Published			2022-12-25	WOS:000167980900067
J	Balbin, M; Fueyo, A; Knauper, V; Lopez, JM; Alvarez, J; Sanchez, LM; Quesada, V; Bordallo, J; Murphy, G; Lopez-Otin, C				Balbin, M; Fueyo, A; Knauper, V; Lopez, JM; Alvarez, J; Sanchez, LM; Quesada, V; Bordallo, J; Murphy, G; Lopez-Otin, C			Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; MATRIX METALLOPROTEINASES; MAMMALIAN COLLAGENASES; SUBSTRATE-SPECIFICITY; TISSUE INHIBITOR; MOUSE; CLONING; GENE; MATRILYSIN; DOMAIN	Remodeling of fibrillar collagen in mouse tissues has been widely attributed to the activity of collagenase-3 (matrix metalloproteinase-13 (MMP-13)), the main collagenase identified in this species. This proposal has been largely based on the repeatedly unproductive attempts to detect the presence in murine tissues of interstitial collagenase (MMP-1), a major collagenase in many species, including humans. In this work, we have performed an extensive screening of murine genomic and cDNA libraries using as probe the full-length cDNA for human MMP-1, We report the identification of two novel members of the MMP gene family which are contained within the cluster of MMP genes located at murine chromosome 9. The isolated cDNAs contain open reading frames of 464 and 463 amino acids and are 82% identical, displaying all structural features characteristic of archetypal MMPs, Comparison for sequence similarities revealed that the highest percentage of identities was found with human interstitial collagenase (MMP-1), The new proteins were tentatively called Mcol-A and Mcol-B (Murine collagenase-like e and B), Analysis of the enzymatic activity of the recombinant proteins revealed that both are catalytically autoactivable but only Mcol-A is able to degrade synthetic peptides and type I and II fibrillar collagen. Both Mcol-A and Mcol-B genes are located in the A1-A2 region of mouse chromosome 9, Mcol-A occupying a position syntenic to the human MMP-1 locus at 11q22. Analysis of the expression of these novel MMPs in murine tissues revealed their predominant presence during mouse embryogenesis, particularly in mouse trophoblast giant cells. According to their structural and functional characteristics, we propose that at least one of these novel members of the MMP family, Mcol-A, may play roles as interstitial collagenase in murine tissues and could represent a true orthologue of human MMP-1.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Oncol, E-33006 Oviedo, Spain; Univ Oviedo, Fac Med, Dept Biol Func, Inst Oncol, E-33006 Oviedo, Spain; Univ Oviedo, Fac Med, Dept Morfol & Biol Celular, Inst Oncol, E-33006 Oviedo, Spain; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of Oviedo; University of Oviedo; University of Oviedo; University of East Anglia	Balbin, M (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Oncol, E-33006 Oviedo, Spain.	mbf@sauron.quimica.uniovi.es	Balbín, Milagros/I-4206-2015; Quesada, Víctor/B-6557-2014; Fueyo, Antonio/ABH-3243-2020; bordallo, javier/X-5360-2019; Lopez-Otin, Carlos/AAB-2106-2020	Balbín, Milagros/0000-0001-5325-0407; Quesada, Víctor/0000-0002-8398-3457; Fueyo, Antonio/0000-0002-7121-9398; bordallo, javier/0000-0002-5786-3929; Lopez-Otin, Carlos/0000-0001-6964-1904; Knauper, Vera/0000-0002-3965-9924				Alexander CM, 1996, DEVELOPMENT, V122, P1723; Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bode W, 1999, ANN NY ACAD SCI, V878, P73, DOI 10.1111/j.1749-6632.1999.tb07675.x; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Caterina J, 1999, GENOMICS, V62, P308, DOI 10.1006/geno.1999.5990; CAWSTON TE, 1981, METHOD ENZYMOL, V80, P711; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GROSS J, 1965, P NATL ACAD SCI USA, V54, P1197, DOI 10.1073/pnas.54.4.1197; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; Huebner JL, 1998, ARTHRITIS RHEUM-US, V41, P877, DOI 10.1002/1529-0131(199805)41:5<877::AID-ART16>3.0.CO;2-#; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korenberg JR, 1999, GENOME RES, V9, P514; Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OOFUSA K, 1994, INT J DEV BIOL, V38, P345; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pendas AM, 2000, CLIN CHIM ACTA, V291, P137, DOI 10.1016/S0009-8981(99)00225-9; Pendas AM, 1996, GENOMICS, V37, P266, DOI 10.1006/geno.1996.0557; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Qin XJ, 1997, BIOL REPROD, V56, P800, DOI 10.1095/biolreprod56.4.800; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Rinkenberger JL, 1997, DEV GENET, V21, P6, DOI 10.1002/(SICI)1520-6408(1997)21:1&lt;6::AID-DVG2&gt;3.0.CO;2-B; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; TAMURA M, 1994, DNA SEQUENCE, V5, P63, DOI 10.3109/10425179409039706; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Uria JA, 2000, CANCER RES, V60, P4745; Vettraino IM, 1996, PLACENTA, V17, P557, DOI 10.1016/S0143-4004(96)80072-5; Welch AR, 1996, BIOCHEMISTRY-US, V35, P10103, DOI 10.1021/bi9601969; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402	46	193	201	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10253	10262		10.1074/jbc.M009586200	http://dx.doi.org/10.1074/jbc.M009586200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11113146	hybrid			2022-12-25	WOS:000167996400090
J	Baird, JW; Ryan, KM; Hayes, I; Hampson, L; Heyworth, CM; Clark, A; Wootton, M; Ansell, JD; Menzel, U; Hole, N; Graham, GJ				Baird, JW; Ryan, KM; Hayes, I; Hampson, L; Heyworth, CM; Clark, A; Wootton, M; Ansell, JD; Menzel, U; Hole, N; Graham, GJ			Differentiating embryonal stem cells are a rich source of haemopoietic gene products and suggest erythroid preconditioning of primitive haemopoietic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO GENERATION; HEMATOPOIETIC LINEAGES; TRANSCRIPTION FACTOR; EXPRESSION SCREEN; CDNA CLONING; YOLK-SAC; PROTEIN; IDENTIFICATION; CULTURE; MOUSE	The difficulties associated with studying molecular mechanisms important in hemopoietic stem cell (HSC) function such as the problems of purifying homogeneous stem cell populations, have prompted us to adapt the murine ES cell system as an in vitro model of HSC generation and function. We now report that careful analysis of the time course of HSC generation in differentiating ES cells allows them to be used as a source of known and novel hemopoietic gene products. We have generated a subtracted library using cDNA from ES cells collected just prior to and just following the emergence of HSCs. Analysis of this library shows it to be a rich source of known hemopoietic and hemopoietic related gene products with 44% of identifiable cDNAs falling into these camps. We have demonstrated the value of this system as a source of novel genes of relevance to HSC function by characterizing a novel membrane protein encoding cDNA that is preferentially expressed in primitive hemopoietic cells. Intriguingly, further analysis of the known components of the subtracted library is suggestive of erythroid preconditioning of the ES cell-derived HSC. We have used dot-blot and in situ analysis to indicate that this erythroid preconditioning is probably restricted to primitive but not definitive HSC.	Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Graham, GJ (corresponding author), Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Hampson, Lynne/E-1583-2011; Graham, Gerard/D-1240-2009	Ryan, Kevin M./0000-0002-1059-9681; Hampson, Lynne/0000-0002-0656-0127; Graham, Gerard/0000-0002-7801-204X				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Bagutti C, 1996, DEV BIOL, V179, P184, DOI 10.1006/dbio.1996.0250; BALZER HJ, 1994, NUCLEIC ACIDS RES, V22, P2853, DOI 10.1093/nar/22.14.2853; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BURKERT U, 1991, NEW BIOL, V3, P698; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Choi K, 1998, DEVELOPMENT, V125, P725; CHOI KH, 1994, ONCOGENE, V9, P1261; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FRAICHARD A, 1995, J CELL SCI, V108, P3181; Gascard P, 2000, CURR OPIN HEMATOL, V7, P123, DOI 10.1097/00062752-200003000-00009; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Graham GJ, 1997, INT J EXP PATHOL, V78, P197, DOI 10.1046/j.1365-2613.1997.270361.x; GUIMARAES MJ, 1995, DEVELOPMENT, V121, P3335; GUTIERREZRAMOS JC, 1992, P NATL ACAD SCI USA, V89, P9171, DOI 10.1073/pnas.89.19.9171; Hole N, 1996, BLOOD, V88, P1266, DOI 10.1182/blood.V88.4.1266.bloodjournal8841266; Hole Nicholas, 1994, P235; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Huang YQ, 2000, BLOOD, V95, P1993, DOI 10.1182/blood.V95.6.1993; ITOH M, 1995, DEV BIOL, V167, P317; KAGEYAMA T, 1995, METHOD ENZYMOL, V248, P120; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOPTIO RR, 1985, J BIOL CHEM, V262, P8035; KORSGREN C, 1994, GENOMICS, V21, P478, DOI 10.1006/geno.1994.1304; KRAUSE DS, 1994, BLOOD, V85, P159; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LEWIN AR, 1991, EUR J BIOCHEM, V199, P417, DOI 10.1111/j.1432-1033.1991.tb16139.x; Ling V, 1997, EUR J IMMUNOL, V27, P509, DOI 10.1002/eji.1830270223; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; Mao M, 1998, P NATL ACAD SCI USA, V95, P8175, DOI 10.1073/pnas.95.14.8175; Medvinsky A, 1999, BLOOD, V94, P3613; MOREL N, 1991, J CELL SCI, V98, P351; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Nichols J, 1996, MECH DEVELOP, V57, P123, DOI 10.1016/0925-4773(96)00531-X; PALACIOS R, 1995, P NATL ACAD SCI USA, V92, P7530, DOI 10.1073/pnas.92.16.7530; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; POTOCNIK AJ, 1994, EMBO J, V13, P5274, DOI 10.1002/j.1460-2075.1994.tb06861.x; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; Robb L, 1998, BIOESSAYS, V20, P611, DOI 10.1002/(SICI)1521-1878(199808)20:8<611::AID-BIES3>3.0.CO;2-L; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; SCHOENHAUT DS, 1986, GENE, V48, P55, DOI 10.1016/0378-1119(86)90351-3; Simmons PJ, 1997, BAILLIERE CLIN HAEM, V10, P485, DOI 10.1016/S0950-3536(97)80022-4; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; TESTA NG, 1993, HAEMOPOIESIS PRACTIC; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; Whetton AD, 1999, TRENDS CELL BIOL, V9, P233, DOI 10.1016/S0962-8924(99)01559-7; WILES MV, 1991, DEVELOPMENT, V111, P259; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155	62	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9189	9198		10.1074/jbc.M008354200	http://dx.doi.org/10.1074/jbc.M008354200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11106657	hybrid			2022-12-25	WOS:000167607700077
J	Stoss, O; Olbrich, M; Hartmann, AM; Konig, H; Memmott, J; Andreadis, A; Stamm, S				Stoss, O; Olbrich, M; Hartmann, AM; Konig, H; Memmott, J; Andreadis, A; Stamm, S			The STAR/GSG family protein rSLM-2 regulates the selection of alternative splice sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL NERVOUS-SYSTEM; SRC SUBSTRATE SAM68; LIGHT-CHAIN-B; MESSENGER-RNA; BINDING-PROTEIN; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ENHANCER COMPLEX; PREMESSENGER RNA; NUCLEAR-PROTEIN	We identified the rat Sam68-like mammalian protein (rSLM-2), a member of the STAR (signal transduction and activation of RNA) protein family as a novel splicing regulatory protein. Using the yeast two-hybrid system, coimmunoprecipitations, and pull-down assays, we demonstrate that rSLM-2 interacts with various proteins involved in the regulation of alternative splicing, among them the serine/arginine-rich protein SRp30c, the splicing-associated factor YT521-B and the scaffold attachment factor B, rSLM-2 can influence the splicing pattern of the CD44v5, human transformer-2 beta and tau minigenes in cotransfection experiments. This effect can be reversed by rSLM-2-interacting proteins, Employing rSLM-2 deletion variants, gel mobility shift assays, and linker scan mutations of the CD44 minigene, we show that the rSLM-2-dependent inclusion of exon v5 of the CD44 pre-mRNA is dependent on a short purine-rich sequence. Because the related protein of rSLM-2, Sam68, is believed to play a role as an adapter protein during signal transduction, we postulate that rSLM-2 is a link between signal transduction pathways and pre-mRNA processing.	Max Planck Inst Neurobiol, D-82152 Martinsried, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Eunice Kennedy Shriver Ctr Mental Retardat Inc, Waltham, MA 02254 USA	Max Planck Society; Helmholtz Association; Karlsruhe Institute of Technology	Stamm, S (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.	stefan@stamms-lab.net	Hartmann, Annette/AAS-6331-2021	Konig, Harald/0000-0002-0117-0939	NINDS NIH HHS [R01 NS38051] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038051] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREADIS A, 1995, NUCLEIC ACIDS RES, V23, P3585, DOI 10.1093/nar/23.17.3585; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BREDFORD MT, 2000, J BIOL CHEM, V275, P16030; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Chou MY, 1999, MOL CELL BIOL, V19, P69; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; COUCHIE D, 1992, P NATL ACAD SCI USA, V89, P4378, DOI 10.1073/pnas.89.10.4378; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Daoud R, 1999, EUR J NEUROSCI, V11, P788, DOI 10.1046/j.1460-9568.1999.00486.x; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Elliott DJ, 2000, HISTOL HISTOPATHOL, V15, P239, DOI 10.14670/HH-15.239; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FU XD, 1995, RNA, V1, P663; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; GOEDERT M, 1992, P NATL ACAD SCI USA, V89, P1983, DOI 10.1073/pnas.89.5.1983; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; Hahm B, 1998, FEBS LETT, V425, P401, DOI 10.1016/S0014-5793(98)00269-5; Hanamura A, 1998, RNA, V4, P430; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Ishizuka T, 1996, DIABETES RES CLIN PR, V33, P159, DOI 10.1016/0168-8227(96)01324-1; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KING PH, 1994, J NEUROSCI, V14, P1943; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; Lang V, 1997, EUR J IMMUNOL, V27, P3360, DOI 10.1002/eji.1830271235; LEE HJ, 1990, J NEUROSCI, V10, P1779; Lee JS, 1999, GENE, V240, P133, DOI 10.1016/S0378-1119(99)00421-7; LUI HX, 1998, GENE DEV, V12, P1998; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MCKAY NG, 1994, BIOCHEM BIOPH RES CO, V199, P1005, DOI 10.1006/bbrc.1994.1329; Misteli T, 2000, J CELL SCI, V113, P1841; Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292; Nayler O, 2000, J CELL BIOL, V150, P949, DOI 10.1083/jcb.150.5.949; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Nayler O, 1998, GENOMICS, V53, P191, DOI 10.1006/geno.1998.5471; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Rain JC, 1998, RNA, V4, P551, DOI 10.1017/S1355838298980335; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; Sanchez-Margalet V, 1999, FEBS LETT, V455, P307, DOI 10.1016/S0014-5793(99)00887-X; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; Smith MA, 1997, J BIOL CHEM, V272, P15675, DOI 10.1074/jbc.272.25.15675; Stamm S, 1999, MOL BRAIN RES, V64, P108, DOI 10.1016/S0169-328X(98)00313-1; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; Stoss O, 1999, J BIOL CHEM, V274, P10951, DOI 10.1074/jbc.274.16.10951; Stoss O, 1999, BRAIN RES PROTOC, V4, P383, DOI 10.1016/S1385-299X(99)00043-4; STOSS O, 2000, IN PRESS GENE THER M, V5; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; Venables JP, 2000, HUM MOL GENET, V9, P685, DOI 10.1093/hmg/9.5.685; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Wei ML, 1998, J NEUROCHEM, V70, P1346; Weighardt F, 1999, J CELL SCI, V112, P1465; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	79	80	89	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8665	8673		10.1074/jbc.M006851200	http://dx.doi.org/10.1074/jbc.M006851200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11118435	hybrid			2022-12-25	WOS:000167607700009
J	Dagsgaard, C; Taylor, LE; O'Brien, KM; Poyton, RO				Dagsgaard, C; Taylor, LE; O'Brien, KM; Poyton, RO			Effects of anoxia and the mitochondrion on expression of aerobic nuclear COX genes in yeast - Evidence for a signaling pathway from the mitochondrial genome to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; SUBUNIT-V; HYPOXIA-TOLERANCE; MEMBRANE SYSTEM; CAROTID-BODY; O-2 SENSOR; OXYGEN; PROTEIN; TRANSCRIPTION	Eucaryotic cells contain at least two general classes of oxygen-regulated nuclear genes: aerobic genes and hypoxic genes. Hypoxic genes are induced upon exposure to anoxia while aerobic genes are down-regulated. Recently, it has been reported that induction of some hypoxic nuclear genes in mammals and yeast requires mitochondrial respiration and that cytochrome-e oxidase functions as an oxygen sensor during this process, In this study, we have examined the role of the mitochondrion and cytochrome-e oxidase in the expression of yeast aerobic nuclear COX genes. We have found that the down-regulation of these genes in anoxic cells is reflected in reduced levels of their subunit polypeptides and that cytochrome-e oxidase subunits I, II, III, Vb, VI, VII, and VIIa are present in promitochondria from anoxic cells. By using nuclear cor mutants and mitochondrial rho(o) and mit(-) mutants, we have found that neither respiration nor cytochrome-e oxidase is required for the down-regulation of these genes in cells exposed to anoxia but that a mitochondrial genome is required for their full expression under both normoxic and anoxic conditions. This requirement for a mitochondrial genome is unrelated to the presence or absence of a functional holocytochrome-c oxidase, We have also found that the down-regulation of these genes in cells exposed to anoxia and the down-regulation that results from the absence of a mitochondrial genome are independent of one another. These findings indicate that the mitochondrial genome, acting independently of respiration and oxidative phosphorylation, affects the expression of the aerobic nuclear COX genes and suggest the existence of a signaling pathway from the mitochondrial genome to the nucleus,	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Poyton, RO (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030228] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63324] Funding Source: Medline; NIGMS NIH HHS [GM30228] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKER H, 1995, NEWS PHYSIOL SCI, V10, P211; ACKER H, 1994, ANN NY ACAD SCI, V718, P3; ALEXANDER NJ, 1979, J BIOL CHEM, V254, P2471; ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; BONITZ SG, 1980, J BIOL CHEM, V255, P1922; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Burke PV, 1997, J BIOL CHEM, V272, P14705, DOI 10.1074/jbc.272.23.14705; Burke PV, 1998, J EXP BIOL, V201, P1163; Burke PV, 1998, APPL ENVIRON MICROB, V64, P1040; BUTOW RA, 1988, PHILOS T ROY SOC B, V319, P127; CAMERON VL, 1989, J BIOL CHEM, V264, P13391; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 2000, J APPL PHYSIOL, V88, P1880, DOI 10.1152/jappl.2000.88.5.1880; Conlan RS, 1999, J BIOL CHEM, V274, P205, DOI 10.1074/jbc.274.1.205; Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000; CUMSKY MG, 1985, P NATL ACAD SCI USA, V82, P2235, DOI 10.1073/pnas.82.8.2235; DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Hochachka PW, 1998, J EXP BIOL, V201, P1243; Huang LE, 1997, KIDNEY INT, V51, P548, DOI 10.1038/ki.1997.76; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; LI M, 1982, J BIOL CHEM, V257, P5921; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAARSE AC, 1984, EMBO J, V3, P2831, DOI 10.1002/j.1460-2075.1984.tb02216.x; MATTICK JS, 1977, MOL GEN GENET, V152, P267, DOI 10.1007/BF00693080; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MORIMOTO R, 1979, MOL GEN GENET, V170, P1; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; PETERSEN PL, 1993, J BIOL CHEM, V268, P9937; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Poyton RO, 1999, RESP PHYSIOL, V115, P119, DOI 10.1016/S0034-5687(99)00028-6; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Ratcliffe PJ, 1997, NEPHROL DIAL TRANSPL, V12, P1842, DOI 10.1093/ndt/12.9.1842; ROGERS PJ, 1973, J BACTERIOL, V115, P88, DOI 10.1128/JB.115.1.88-97.1973; ROTHERMEL BA, 1995, J BIOL CHEM, V270, P29476, DOI 10.1074/jbc.270.49.29476; Sambrook J., 2002, MOL CLONING LAB MANU; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 2000, ADV EXP MED BIOL, V475, P303; SERRANO R, 1980, EUR J BIOCHEM, V105, P419, DOI 10.1111/j.1432-1033.1980.tb04516.x; SLONIMSKI PP, 1976, EUR J BIOCHEM, V61, P27, DOI 10.1111/j.1432-1033.1976.tb09994.x; SULKOWSKI E, 1964, NATURE, V202, P36, DOI 10.1038/202036a0; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520; TSANG SS, 1993, BIOTECHNIQUES, V14, P380; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; Williamson D H, 1975, Methods Cell Biol, V12, P335; Wilson DF, 2000, ADV EXP MED BIOL, V475, P259; WOODROW G, 1979, J BIOL CHEM, V254, P6088; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; WRIGHT RM, 1989, NUCLEIC ACIDS RES, V17, P1103, DOI 10.1093/nar/17.3.1103	64	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7593	7601		10.1074/jbc.M009180200	http://dx.doi.org/10.1074/jbc.M009180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11099503	hybrid			2022-12-25	WOS:000167442900099
J	Imamura, T; Izumi, H; Nagatani, G; Ise, T; Nomoto, M; Iwamoto, Y; Kohno, K				Imamura, T; Izumi, H; Nagatani, G; Ise, T; Nomoto, M; Iwamoto, Y; Kohno, K			Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY JUNCTION DNA; HMG-1; RECOGNITION; GENE	A nonhistone chromosomal protein, high mobility group (HMG) I, is ubiquitous in higher eukaryotic cells and binds preferentially to cisplatin-modified DNA. HMG1 also functions as a coactivator of p53, a tumor suppressor protein. We investigated physical interactions between HMG1 and p53 and the influence of p53 on the:ability of HMG1 to recognize damaged DNA. Using immunochemical coprecipitation, we observed binding of HMG1 and p53, Interaction between HMG1 and p53 required the HMG A box of HMG1 and amino acids 363-376 of p53. Cisplatin-modified DNA binding by HMG1 was significantly enhanced by p53. An HMG1-specific antibody that recognized the A box of this protein also stimulated cisplatin-modified DNA binding. These data suggest that an interaction with either p53 or antibody may induce conformational change in the HMG1 A box that optimizes DNA binding by HMG1. Interaction of p53 with HMG1 after DNA damage may promote activation of specific HMG1 binding to damaged DNA in vivo and provide a molecular link, between DNA damage and p53-mediated DNA repair.	Univ Occupat & Environm Hlth, Dept Biol Mol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Kyushu Univ, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan	University of Occupational & Environmental Health - Japan; Kyushu University	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Dept Biol Mol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp						BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; Chao JC, 1996, BBA-GENE STRUCT EXPR, V1307, P213, DOI 10.1016/0167-4781(96)00052-8; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARLOW E, 1999, USING ANTIBODIES LAB, P74; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ise T, 1999, CANCER RES, V59, P342; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; Webb M, 1999, J MOL BIOL, V294, P373, DOI 10.1006/jmbi.1999.3150; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	28	81	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7534	7540		10.1074/jbc.M008143200	http://dx.doi.org/10.1074/jbc.M008143200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11106654	hybrid			2022-12-25	WOS:000167442900092
J	Travis, AJ; Jorgez, CJ; Merdiushev, T; Jones, BH; Dess, DM; Diaz-Cueto, L; Storey, BT; Kopf, GS; Moss, SB				Travis, AJ; Jorgez, CJ; Merdiushev, T; Jones, BH; Dess, DM; Diaz-Cueto, L; Storey, BT; Kopf, GS; Moss, SB			Functional relationships between capacitation-dependent cell signaling and compartmentalized metabolic pathways in murine spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; PENTOSE-PHOSPHATE PATHWAY; SPERM ACROSOME REACTION; MOUSE SPERM; FIBROUS SHEATH; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; BOVINE SPERM; GLUCOSE; MOTILITY; HEXOKINASE	Spermatozoa are highly polarized cells with specific metabolic pathways compartmentalized in different regions. Previously, we hypothesized that glycolysis is organized in the fibrous sheath of the flagellum to provide ATP to dynein ATPases that generate motility and to protein kinases that regulate motility. Although a recent report suggested that glucose is not essential for murine sperm capacitation, we demonstrated that glucose (but not lactate or pyruvate) was necessary and sufficient to support the protein tyrosine phosphorylation events associated with capacitation. The effect of glucose on this signaling pathway was downstream of cAMP, and appeared to arise indirectly as a consequence of metabolism as opposed to a direct signaling effect Moreover, the phosphorylation events were not affected by uncouplers of oxidative respiration, inhibitors of electron transfer, or by a lack of substrates for oxidative respiration in the medium. Further experiments aimed,at identifying potential regulators of sperm,glycolysis focused on a germ cell-specific isoform of hexokinase, HK1-SC, which localizes to the fibrous sheath. HK1-SC: activity and biochemical localization did not change during sperm capacitation, suggesting that glycolysis in sperm is regulated either at the level of substrate availability or by downstream enzymes. These data Support the hypothesis that ATP specifically produced by a compartmentalized glycolytic pathway in the principal piece of the flagellum, as opposed to ATP generated by mitochondria in the mid-piece, is strictly required for protein tyrosine phosphorylation events that take place during sperm capacitation. The relationship between these pathways suggests that spermatozoa offer a model system for the study of integration of compartmentalized metabolic and signaling pathways.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Moss, SB (corresponding author), Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Biomed Res Bldg II-III, Philadelphia, PA 19104 USA.			Jones, Brian/0000-0002-4575-5613	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006274, T32HD007305, R01HD033052] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-07065, 1RO1-RR00188-01] Funding Source: Medline; NICHD NIH HHS [P01-HD-06274, T32-HD-07305-15, HD-33052] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALVAREZ JG, 1993, HUM REPROD, V8, P1087, DOI 10.1093/oxfordjournals.humrep.a138198; Bajpai M, 1998, EUR J ENDOCRINOL, V138, P322, DOI 10.1530/eje.0.1380322; BELL GI, 1993, J BIOL CHEM, V268, P19161; Bunch DO, 1998, BIOL REPROD, V58, P834, DOI 10.1095/biolreprod58.3.834; Carrera A, 1996, DEV BIOL, V180, P284, DOI 10.1006/dbio.1996.0301; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; COOPER TG, 1984, GAMETE RES, V9, P55, DOI 10.1002/mrd.1120090106; FRASER LR, 1981, J REPROD FERTIL, V61, P25, DOI 10.1530/jrf.0.0610025; GANDHI KK, 1982, J REPROD FERTIL, V64, P145, DOI 10.1530/jrf.0.0640145; GONSE PH, 1962, SPERMATOZOAN MOTILIT, P99; Han P, 1999, J BIOL CHEM, V274, P22337, DOI 10.1074/jbc.274.32.22337; HARRISON RA, 1971, BIOCHEM J, V124, P741, DOI 10.1042/bj1240741; Heytler P G, 1979, Methods Enzymol, V55, P462; HOPPE PC, 1976, BIOL REPROD, V15, P39, DOI 10.1095/biolreprod15.1.39; HOSKINS DD, 1975, BIOL REPROD, V12, P566, DOI 10.1095/biolreprod12.5.566; Johnson LR, 1999, BIOL REPROD, V60, P683, DOI 10.1095/biolreprod60.3.683; KALAB P, 1994, J BIOL CHEM, V269, P3810; Kaldis Philipp, 1997, Advances in Developmental Biology, V5, P275, DOI 10.1016/S1566-3116(08)60040-7; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; Kopf GS, 1999, ADV D BIOCH, V5, P83, DOI 10.1016/S1064-2722(08)60017-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mori C, 1998, MOL REPROD DEV, V49, P374, DOI 10.1002/(SICI)1098-2795(199804)49:4&lt;374::AID-MRD4&gt;3.0.CO;2-K; MOUNIB MS, 1964, NATURE, V201, P943, DOI 10.1038/201943a0; Noiles EE, 1997, CRYOBIOLOGY, V35, P79, DOI 10.1006/cryo.1997.2033; PARRISH JJ, 1989, BIOL REPROD, V41, P683, DOI 10.1095/biolreprod41.4.683; Redkar AA, 1999, J ANDROL, V20, P500; ROGERS BJ, 1975, BIOL REPROD, V13, P568, DOI 10.1095/biolreprod13.5.568; ROGERS BJ, 1990, BIOL REPROD, V43, P1064, DOI 10.1095/biolreprod43.6.1064; Si YM, 1999, BIOL REPROD, V61, P240, DOI 10.1095/biolreprod61.1.240; Storey BT, 1998, MOL REPROD DEV, V49, P400, DOI 10.1002/(SICI)1098-2795(199804)49:4<400::AID-MRD7>3.0.CO;2-R; STOREY BT, 1977, BIOL REPROD, V16, P549; STOREY BT, 1978, ARCH ANDROLOGY, V1, P169, DOI 10.3109/01485017808988334; STOREY BT, 1980, J EXP ZOOL, V211, P361, DOI 10.1002/jez.1402110313; STOREY BT, 1980, J EXP ZOOL, V212, P61, DOI 10.1002/jez.1402120109; STOREY BT, 1975, FERTIL STERIL, V26, P1257; TASH JS, 1989, CELL MOTIL CYTOSKEL, V14, P332, DOI 10.1002/cm.970140303; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; Travis AJ, 1998, MOL BIOL CELL, V9, P263, DOI 10.1091/mbc.9.2.263; Urner F, 1999, BIOL REPROD, V60, P733, DOI 10.1095/biolreprod60.3.733; Urner F, 1996, BIOL REPROD, V55, P917, DOI 10.1095/biolreprod55.4.917; Urner F, 1999, BIOL REPROD, V60, P973, DOI 10.1095/biolreprod60.4.973; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Westhoff D, 1997, J CELL SCI, V110, P1821	45	143	148	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7630	7636		10.1074/jbc.M006217200	http://dx.doi.org/10.1074/jbc.M006217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11115497	hybrid			2022-12-25	WOS:000167442900104
J	Foos, G; Hauser, CA				Foos, G; Hauser, CA			Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness	ONCOGENE			English	Article						prostate cancer; Ets2 overexpression; dominant negative Ets2; transformation	MEDIATED CELLULAR-TRANSFORMATION; COLON-CANCER CELLS; ANDROGEN RECEPTOR; INDUCED APOPTOSIS; GENE-EXPRESSION; CARCINOMA CELLS; RAS; ACTIVATION; PROTEIN; LINES	The Ets family of transcription factors are important downstream targets in cellular transformation, as altering Ets activity has been found to reverse the transformed phenotype of Ras transformed mouse fibroblasts and of several human tumor cell lines. To determine whether Ets factors are important targets in the largely uncharacterized aberrant signaling in prostate cancer, we have altered Ets activity in the prostate tumor cell line PPC-1, by stable expression of either full-length Ets2, or a dominant inhibitor of Ets activity, the Ets2 DNA binding domain (Ets2DBD). Analysis of multiple independent clonal cell lines revealed that expression of either Ets2 or the Ets2DBD inhibited the anchorage-independent growth of PPC-1 cells up to 20-fold. In contrast to our previous findings with Ras-transformed NIH3T3 cells, PPC-1 cell lines expressing either Ets2 or the EtsDBD exhibited slower attached cell growth, increased Ets-dependent gene expression, and up to a 10-fold increase in apoptotic cell death. The p21(cip) gene was identified as a potential target of altered Ets signaling. Interestingly, the two distinct Ets2 constructs had strikingly different effects on in vitro invasiveness. Expression of the Ets2DBD almost completely blocked PPC-1 cell invasion through Matrigel, whereas overexpression of full-length Ets2 did not inhibit invasion. Overall, these results demonstrate that the balance of Ets factor activity can regulate multiple aspects of the transformed phenotype of PPC-1 prostate tumor cells, including anchorage-independent growth, survival, and invasiveness.	La Jolla Canc Res Ctr, Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Hauser, CA (corresponding author), La Jolla Canc Res Ctr, Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA063130, R01CA074547] Funding Source: NIH RePORTER; NCI NIH HHS [CA63130, CA74547] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; BORNER MM, 1995, CANCER RES, V55, P2122; BROTHMAN AR, 1989, INT J CANCER, V44, P898, DOI 10.1002/ijc.2910440525; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; CHEN TR, 1993, CYTOGENET CELL GENET, V62, P183, DOI 10.1159/000133468; Chen ZQ, 1997, CANCER RES, V57, P2013; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; HUNCHAREK M, 1995, CANCER EPIDEM BIOMAR, V4, P681; Konishi N, 1997, PROSTATE, V30, P53; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Rees S, 1996, BIOTECHNIQUES, V20, P102; Royai R, 1996, SEMIN ONCOL, V23, P35; Sapi E, 1998, CANCER RES, V58, P1027; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Shao NS, 1998, ONCOGENE, V17, P527, DOI 10.1038/sj.onc.1201931; Shi XB, 1996, WORLD J UROL, V14, P318, DOI 10.1007/BF00184605; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Wasilenko WJ, 1996, INT J CANCER, V68, P259, DOI 10.1002/(SICI)1097-0215(19961009)68:2<259::AID-IJC20>3.0.CO;2-4; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; Webber MM, 1997, PROSTATE, V30, P58; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673	47	32	33	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5507	5516		10.1038/sj.onc.1203946	http://dx.doi.org/10.1038/sj.onc.1203946			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114728				2022-12-25	WOS:000165396100011
J	Horstmann, S; Ferrari, S; Klempnauer, KH				Horstmann, S; Ferrari, S; Klempnauer, KH			An alternatively spliced isoform of B-Myb is a transcriptional inhibitor	ONCOGENE			English	Article						B-myb; cyclin; transactivation; cycle	CELL-CYCLE REGULATION; C-MYB; V-MYB; A-MYB; MESSENGER-RNA; PROTEIN TRUNCATION; MIM-1 GENE; S-PHASE; ACTIVATION; EXPRESSION	B-Myb is a highly conserved member of the Myb transcription factor family. The primary transcript of the B-myb gene is spliced alternatively in two mRNAs which either contain or lack a sequence corresponding to the so-called exon 9A of c-myb, Recent studies showed that full-length B-Myb containing the exon 9A encoded amino acids is a cell cycle regulated transcription factor whose activity is stimulated by cyclin A/Cdk 2-dependent phosphorylation at the carboxyl-terminus of B-Myb. We have now investigated in more detail the transactivation potential of the shorter isoform of B-Myb lacking exon 9A, Here, we show that B-Myb lacking exon 9A has no transactivation activity even in the presence of cyclin A. This inactivity of the shorter isoform of B-Myb is not due an improper subcelluar localization, Our work suggests that B-Myb lacking exon 9A may act as an inhibitor for full-length B-Myb mediated transactivation, Furthermore, by analysing the transactivation potential of Gal4/B-Myb fusion proteins we have identified the amino-terminal part of the exon 9A as the principal transactivation domain of full-length B-Myb, The results presented here demonstrate that B-myb encodes both an activator and an inhibitor of transcription and, thus, reveal an additional level of regulation of B-Myb activity beside the known cyclin dependent mechanisms.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland	University of Munster; Novartis	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.		Ferrari, Stefano/I-7357-2016; Buchinger, Sebastian/M-3003-2013	Ferrari, Stefano/0000-0002-6607-215X; Buchinger, Sebastian/0000-0003-4859-8972				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU YL, 1991, ONCOGENE, V6, P1549; Kamano H, 1995, ONCOGENE, V11, P2575; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Latchman DS, 1996, PHILOS T R SOC B, V351, P511, DOI 10.1098/rstb.1996.0049; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; METTUS RV, 1994, ONCOGENE, V9, P3077; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Robinson C, 1996, ONCOGENE, V12, P1855; ROSSON D, 1987, ANN NY ACAD SCI, V511, P219, DOI 10.1111/j.1749-6632.1987.tb36250.x; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; Sitzmann J, 1996, ONCOGENE, V12, P1889; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Woo CH, 1998, J VIROL, V72, P6813, DOI 10.1128/JVI.72.8.6813-6821.1998; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	50	9	9	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5428	5434		10.1038/sj.onc.1203937	http://dx.doi.org/10.1038/sj.onc.1203937			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114719				2022-12-25	WOS:000165396100002
J	Sinibaldi, D; Wharton, W; Turkson, J; Bowman, T; Pledger, WJ; Jove, R				Sinibaldi, D; Wharton, W; Turkson, J; Bowman, T; Pledger, WJ; Jove, R			Induction of p21(WAF1/CIP1) and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: Role of activated STAT3 signaling	ONCOGENE			English	Article						cell cycle control; Src oncoprotein; STAT3; cyclin D1; p21; WAF1/CIP1	DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH-FACTOR; PERIPHERAL-BLOOD CELLS; DNA-BINDING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE ACTIVATION; V-SRC; CDK INHIBITORS; CELLULAR-TRANSFORMATION; POTENTIAL MEDIATOR	While the activated viral Src oncoprotein, v-Src, induces uncontrolled cell growth, the mechanisms underlying cell cycle deregulation by v-Src have not been fully defined. Previous studies demonstrated that v-Src induces constitutively active STAT3 signaling that is required for cell transformation and recent data have implicated STAT3 in the transcriptional control of critical cell cycle regulators. Here we show in mouse fibroblasts stably transformed by v-Src that mRNA and protein levels of p21 (WAF1/CIP1), cyclin D1, and cyclin E are elevated. Using reporter constructs in transient-transfection assays, the cyclin D1 and p21 promoters were both found to be transcriptionaly induced by v-Src in a STAT3-dependent manner. The kinase activities of cyclin D/CDK4, 6 and cyclin E/CDK2 complexes were only slightly elevated, consistent with the findings that coordinate increases in p21, cyclin D1 and cyclin E resulted in an increase in cyclin/CDK/p21 complexes. Similar results were obtained in NTH3T3 and BALB/c 3T3 cells stably transformed by v-Src, indicating that these regulatory events associated with STAT3 signaling represent common mechanisms independent of cell line or clonal variation. These findings suggest that STAT3 has an essential role in the regulation of critical cell cycle components in v-Src transformed mouse fibroblasts.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA067360, R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652, CA67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Barboule N, 1998, INT J CANCER, V76, P891, DOI 10.1002/(SICI)1097-0215(19980610)76:6<891::AID-IJC20>3.0.CO;2-4; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Besser D, 1999, MOL CELL BIOL, V19, P1401; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; Frank DA, 1999, MOL MED, V5, P432; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Geng Y, 1996, ONCOGENE, V12, P1173; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Hibberts NA, 1999, CLIN CANCER RES, V5, P2133; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lonardo F, 1999, CANCER RES, V59, P2470; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu M, 1999, CANCER, V85, P669, DOI 10.1002/(SICI)1097-0142(19990201)85:3<669::AID-CNCR17>3.0.CO;2-F; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WeberNordt RM, 1996, BLOOD, V88, P809; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	72	255	276	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5419	5427		10.1038/sj.onc.1203947	http://dx.doi.org/10.1038/sj.onc.1203947			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114718				2022-12-25	WOS:000165396100001
J	Cahill, CM; Tzivion, G; Nasrin, N; Ogg, S; Dore, J; Ruvkun, G; Alexander-Bridges, M				Cahill, CM; Tzivion, G; Nasrin, N; Ogg, S; Dore, J; Ruvkun, G; Alexander-Bridges, M			Phosphatidylinositol 3-kinase signaling inhibits DAF-16 DNA binding and function via 14-3-3-dependent and 14-3-3-independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-1 GENE-EXPRESSION; TRANSCRIPTION FACTOR FKHR; AGE-1 PI3 KINASE; FORKHEAD TRANSCRIPTION; FAMILY-MEMBER; PHOSPHOENOLPYRUVATE CARBOXYKINASE; INSULIN; PHOSPHORYLATION; ACTIVATION; LONGEVITY	In Caenorhabditis elegans, an insulin-like signaling pathway to phosphatidylinositol S-kinase (PI 3-kinase) and AKT negatively regulates the activity of DAF-16, a Forkhead transcription factor. We show that in mammalian cells, C, elegans DAF-16 is a direct target of AKT and that AKT phosphorylation generates 14-3-3 binding sites and regulates the nuclear/cytoplasmic distribution of DAF-16 as previously shown for its mammalian homologs FKHR and FKHRL1. In vitro, interaction of AKT-phosphorylated DAF-16 with 14-3-3 prevents DAF-16 binding to its target site in the insulin-like growth factor binding protein-1 gene, the insulin response element. In HepG2 cells, insulin signaling to PI 3-kinase/AKT inhibits the ability of a GAL4 DNA binding domain/DAF-16 fusion protein to activate transcription via the insulinlike growth factor binding protein-1-insulin response element, but not the GAL4 DNA binding site, which suggests that insulin inhibits the interaction of DAF-16 with its cognate DNA site. Elimination of the DAF-16/1433 association by mutation of the AKT/14-3-3 sites in DAF-16, prevents 14-3-3 inhibition of DAF-16 DNA binding and insulin inhibition of DAF-16 function. Similarly, inhibition of the DAF-16/14-3-3 association by exposure of cells to the PI 3-kinase inhibitor LY294002, enhances DAF-16 DNA binding and transcription activity. Surprisingly constitutively nuclear DAF-16 mutants that lack AKT/14-3-3 binding sites also show enhanced DNA binding and transcription activity in response to LY294002, pointing to a 14-3-3-independent mode of regulation. Thus, our results demonstrate at least two mechanisms, one 14-3-3-dependent and the other 14-3-3-independent, whereby PI S-kinase signaling regulates DAF-16 DNA binding and transcription function.	Massachusetts Gen Hosp, Dept Med, Diabet Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Alexander-Bridges, M (corresponding author), Massachusetts Gen Hosp, Dept Med, Diabet Unit, 306 Wellman,50 Blossom St, Boston, MA 02114 USA.	alex-bri@helix.mgh.harvard.edu	Tzivion, Guri/D-8954-2011		NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK057200, T32DK007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014161, R37AG014161] Funding Source: NIH RePORTER; NCI NIH HHS [CA73818-1] Funding Source: Medline; NIA NIH HHS [AG05790, AG14161] Funding Source: Medline; NIDDK NIH HHS [T32 DK07028-24, DK57200A01] Funding Source: Medline; NIGMS NIH HHS [GM58012] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; GOTTLIEB S, 1994, GENETICS, V137, P107; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; KOPS G, 1989, NATURE, V398, P630; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MattoYelin M, 1997, MOL BIOL CELL, V8, P1889, DOI 10.1091/mbc.8.10.1889; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	38	165	169	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13402	13410		10.1074/jbc.M010042200	http://dx.doi.org/10.1074/jbc.M010042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11124266	hybrid			2022-12-25	WOS:000168198600128
J	Gourves, AS; Defais, M; Johnson, NP				Gourves, AS; Defais, M; Johnson, NP			Equilibrium binding of single-stranded DNA to the secondary DNA binding site of the bacterial recombinase RecA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-RECOMBINATION; CROSS-LINKING; PROTEIN; EXCHANGE; REPAIR; LOOP; COMPLEXES; MECHANISM; PEPTIDE; DOMAIN	The bacterial recombinase RecA forms a nucleoprotein filament in vitro with single-stranded DNA (ssDNA) at its primary DNA binding site, site I, This filament has a second site, site II, which binds ssDNA and double-stranded DNA. We have investigated the binding of ssDNA to the RecA protein in the presence of adenosine 5'-O-(thiotriphosphate) cofactor using fluorescence anisotropy, The RecA protein carried out DNA strand exchange with a 5'-fluorescein-labeled 32-mer oligonucleotide. The anisotropy signal was shown to measure oligonucleotide binding to RecA, and the relationship between signal and binding density was determined. Binding of ssDNA to site I of RecA was stable at high NaCl concentrations. Binding to site II could be described by a simple two-state equilibrium, K = 4.5 +/- 1.5 x 10(5) M-1 (37 degreesC, 150 mM NaCl, pH 7,4). The reaction was enthalpy-driven and entropy-opposed. It depended on salt concentration and was sensitive to the type of monovalent anion, suggesting that anion-dependent protein conformations contribute to ssDNA binding at site II.	Inst Pharmacol & Biol Struct, CNRS, UMR 5089, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Johnson, NP (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.							Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bazemore LR, 1997, J BIOL CHEM, V272, P14672, DOI 10.1074/jbc.272.23.14672; Bazemore LR, 1997, P NATL ACAD SCI USA, V94, P11863, DOI 10.1073/pnas.94.22.11863; BLANCO M, 1975, MOL MECHANISMS REPAI, P379; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; CAZAUX C, 1992, J MOL BIOL, V223, P823, DOI 10.1016/0022-2836(92)90243-D; Cazaux C, 1998, J BIOL CHEM, V273, P28799, DOI 10.1074/jbc.273.44.28799; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; Gourves AS, 2000, J BIOL CHEM, V275, P10864, DOI 10.1074/jbc.275.15.10864; Hortnagel K, 1999, J MOL BIOL, V286, P1097, DOI 10.1006/jmbi.1998.2515; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; Johnson NP, 1996, J BIOL CHEM, V271, P19675, DOI 10.1074/jbc.271.33.19675; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P112; LARMINAT F, 1992, J BACTERIOL, V174, P6264, DOI 10.1128/JB.174.19.6264-6269.1992; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P58; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; Mazin AV, 1998, EMBO J, V17, P1161, DOI 10.1093/emboj/17.4.1161; MAZIN AV, 1996, P NATL ACAD SCI USA, V93, P10674; MENETSKI JP, 1992, J BIOL CHEM, V267, P10400; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MORIMATSU K, 1995, EUR J BIOCHEM, V228, P772, DOI 10.1111/j.1432-1033.1995.0772m.x; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; Rehrauer WM, 1996, J BIOL CHEM, V271, P11996, DOI 10.1074/jbc.271.20.11996; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Selmane T, 1999, FEBS LETT, V446, P30, DOI 10.1016/S0014-5793(99)00181-7; STASIAK A, 1994, EXPERIENTIA, V50, P192, DOI 10.1007/BF01924002; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAKAHASHI M, 1994, ADV BIOPHYS, V30, P1, DOI 10.1016/0065-227X(94)90009-4; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; ZLOTNICK A, 1993, J BIOL CHEM, V268, P22525	34	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9613	9619		10.1074/jbc.M004855200	http://dx.doi.org/10.1074/jbc.M004855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11121401	hybrid			2022-12-25	WOS:000167996400006
J	Le Chatelier, E; Janniere, L; Ehrlich, SD; Canceill, D				Le Chatelier, E; Janniere, L; Ehrlich, SD; Canceill, D			The RepE initiator is a double-stranded and single-stranded DNA-binding protein that forms an atypical open complex at the onset of replication of plasmid pAM beta 1 from gram-positive bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; T-ANTIGEN; IN-VIVO; CONFORMATIONAL-CHANGES; SV40 ORIGIN; HELICASE; SEQUENCES; INVITRO; RNA	The RepE protein of the broad host range pAM beta1 plasmid from Gram-positive bacteria is absolutely required for replication. To elucidate its role, we purified the protein to near homogeneity and analyzed its interactions with different nucleic acids using gel retardation assays and footprinting experiments. We show that RepE is monomeric in solution and binds specifically, rapidly, and durably to the origin at a unique double-stranded binding site immediately upstream from the initiation site of DNA replication. The binding induces only a weak bend (31 degrees), Unexpectedly, RepE also binds nonspecifically to single-stranded DNA with a 2-4-fold greater affinity than for double-stranded origin. On a supercoiled plasmid, RepE binding to the double-stranded origin leads to the denaturation of the AT-rich sequence immediately downstream from the binding site to form an open complex. This open complex is atypical since (i) its formation requires neither multiple RepE binding sites on the double-stranded origin nor strong bending of the origin, (ii) it occurs in the absence of any cofactors (only RepE and supercoiling are required), and (iii) its melted region serves as a substrate for RepE binding. These original properties together with the fact that pAM beta1 replication depends on a transcription step through the origin on DNA polymerase I to initiate replication and on a primosome to load the replisome suggest that the main function of RepE is to assist primer generation at the origin.	INRA, Lab Genet Microbienne, F-78350 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay	Canceill, D (corresponding author), INRA, Lab Genet Microbienne, Domaine Vilvert, F-78350 Jouy En Josas, France.	canceill@biotec.jouy.inra.fr	LE CHATELIER, Emmanuelle/O-1243-2017; Ehrlich, S./Y-2423-2019	LE CHATELIER, Emmanuelle/0000-0002-2724-0536; Ehrlich, S./0000-0002-7563-4046; Janniere, Laurent/0000-0003-2353-3160				AUBORN KJ, 1988, J VIROL, V62, P2204, DOI 10.1128/JVI.62.6.2204-2208.1988; Bidnenko V, 1998, MOL MICROBIOL, V28, P1005, DOI 10.1046/j.1365-2958.1998.00862.x; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; Boulikas T, 1996, J CELL BIOCHEM, V60, P297, DOI 10.1002/(SICI)1097-4644(19960301)60:3<297::AID-JCB2>3.0.CO;2-R; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Brantl S, 1996, J MOL BIOL, V255, P275, DOI 10.1006/jmbi.1996.0023; BRUAND C, 1993, P NATL ACAD SCI USA, V90, P11668, DOI 10.1073/pnas.90.24.11668; BRUAND C, 1995, EMBO J, V14, P2642, DOI 10.1002/j.1460-2075.1995.tb07262.x; BRUAND C, 1991, EMBO J, V10, P2171, DOI 10.1002/j.1460-2075.1991.tb07752.x; Bruand C, 1998, MOL MICROBIOL, V30, P135, DOI 10.1046/j.1365-2958.1998.01044.x; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CEGLOWSKI P, 1993, FEMS MICROBIOL LETT, V109, P145, DOI 10.1016/0378-1097(93)90011-P; Challberg M., 1996, DNA REPLICATION EUKA, P721; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; DICKERSON RE, 1999, OXFORD HDB NUCL ACID, P145; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; ECKDAHL TT, 1990, NUCLEIC ACIDS RES, V18, P1609, DOI 10.1093/nar/18.6.1609; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; Espinosa M, 2000, HORIZONTAL GENE POOL, P1; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; Giraldo R, 1998, EMBO J, V17, P4511, DOI 10.1093/emboj/17.15.4511; GIRALDO R, 1992, J MOL BIOL, V228, P787, DOI 10.1016/0022-2836(92)90864-G; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; Hiasa H, 1999, J BIOL CHEM, V274, P27244, DOI 10.1074/jbc.274.38.27244; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Janniere L, 1997, MOL MICROBIOL, V23, P525, DOI 10.1046/j.1365-2958.1997.d01-1874.x; Kaguni JM, 1997, MOL CELLS, V7, P145; Khan Saleem A., 1998, Plasmid, V40, P1, DOI 10.1006/plas.1998.1358; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Konieczny I, 1997, J BIOL CHEM, V272, P33312, DOI 10.1074/jbc.272.52.33312; Konopa G, 1999, FEMS MICROBIOL LETT, V174, P25, DOI 10.1016/S0378-1097(99)00116-0; Kornberg A., 1992, DNA REPLICATION; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELNIKOVA AF, 1978, EUR J BIOCHEM, V84, P301, DOI 10.1111/j.1432-1033.1978.tb12169.x; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MENSAWILMOT K, 1989, EMBO J, V8, P2393, DOI 10.1002/j.1460-2075.1989.tb08369.x; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; Mizushima T, 2000, J BIOCHEM-TOKYO, V127, P1; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; Mouw M, 1998, VIROLOGY, V251, P123, DOI 10.1006/viro.1998.9375; MUKHERJEE S, 1985, CELL, V43, P189, DOI 10.1016/0092-8674(85)90023-6; MUKHOPADHYAY G, 1993, J MOL BIOL, V231, P19, DOI 10.1006/jmbi.1993.1253; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; Rice PA, 1997, CURR OPIN STRUC BIOL, V7, P86, DOI 10.1016/S0959-440X(97)80011-5; RIELE HT, 1986, EMBO J, V5, P631, DOI 10.1002/j.1460-2075.1986.tb04257.x; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SIMON D, 1988, BIOCHIMIE, V70, P559, DOI 10.1016/0300-9084(88)90093-4; SNYDER M, 1986, NATURE, V324, P87, DOI 10.1038/324087a0; TAKECHI S, 1995, EMBO J, V14, P5141, DOI 10.1002/j.1460-2075.1995.tb00196.x; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; THORNER LK, 1993, J VIROL, V67, P6000, DOI 10.1128/JVI.67.10.6000-6014.1993; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Yang J, 1995, METHOD ENZYMOL, V259, P452; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZANNISHADJOPOUL.M, 1999, J CELL BIOCHEM, V75, P32	73	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10234	10246		10.1074/jbc.M010118200	http://dx.doi.org/10.1074/jbc.M010118200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124267	hybrid, Green Published			2022-12-25	WOS:000167996400088
J	Brouillard, F; Bouthier, M; Leclerc, T; Clement, A; Baudouin-Legros, M; Edelman, A				Brouillard, F; Bouthier, M; Leclerc, T; Clement, A; Baudouin-Legros, M; Edelman, A			NF-kappa B mediates up-regulation of CFTR gene expression in Calu-3 cells by interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS GENE; TRANSCRIPTION FACTORS; PROMOTER REGION; ACTIVATION; IDENTIFICATION; C/EBP; COOPERATIVITY	Inflammation of the airways is a major feature of the inherited disease cystic fibrosis. Previous studies have shown that the pro-inflammatory cytokines tumor necrosis factor alpha and interferon gamma reduce the expression of the cystic fibrosis transmembrane conductance regulator (CFTR) gene (CFTR) in HT-29 and T84 cells by acting post-transcriptionally. We have investigated the effect of the pro-inflammatory peptide interleukin 1 beta (IL-1 beta) on the expression of the CFTR in Calu-3 cells, IL-1 beta increased the production of CFTR mRNA in a dose- and time-dependent manner. Its action was inhibited by inhibitors of the NF-kappaB pathway, including N-acetyl-L-cysteine, pyrrolidine dithiocarbamate, and a synthetic cell-permeable peptide containing the NF-kappaB nuclear localization signal sequence. Gel shift analysis showed that IL-1 beta activated NF-kappaB in Calu-3 cells, and transfection experiments using p50 and RelA expressing vectors showed that exogenous transfected NF-kappaB subunits increased the concentration of CFTR mRNA. Gel shift analysis with antibody supershifting also showed that IL-1 beta caused the binding of NF-kappaB to a kappaB-like response element at position -1103 to -1093 in the CFTR 5'-flanking region. Transfection experiments using -2150 to +52 CFTR reporter gene constructs showed that the activity of the CFTR promoter is enhanced by exogenous transfected NF-kappaB and IL-1 beta and that this enhancement is due, at least in part, to the -1103 to -1093 kappaB site. We conclude that the intracellular signaling that; leads to increased CFTR mRNA in response to IL-1 beta in Calu-3 cells includes the binding of NF-kappaB to the -1103 kappaB element and a subsequent increase in CFTR promoter activity.	CHU Necker, INSERM, U467, F-75015 Paris, France; CHU St Antoine, Hop Trousseau, INSERM, U412, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Edelman, A (corresponding author), CHU Necker, INSERM, U467, 156 Rue Vaugirard, F-75015 Paris, France.							BESANCON F, 1994, AM J PHYSIOL-CELL PH, V267, pC1398, DOI 10.1152/ajpcell.1994.267.5.C1398; Cafferata EG, 2000, BBA-MOL BASIS DIS, V1500, P241, DOI 10.1016/S0925-4439(99)00105-2; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; KOH J, 1993, J BIOL CHEM, V268, P15912; Lacorte JM, 1997, J BIOL CHEM, V272, P23578, DOI 10.1074/jbc.272.38.23578; LEUNG KY, 1994, J BIOL CHEM, V269, P1579; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Matthews RP, 1996, J BIOL CHEM, V271, P31869, DOI 10.1074/jbc.271.50.31869; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; MCKEAN DJ, 1994, J EXP MED, V180, P1321, DOI 10.1084/jem.180.4.1321; NAKAMURA H, 1992, FEBS LETT, V314, P366, DOI 10.1016/0014-5793(92)81507-I; Pyatt DW, 1999, BLOOD, V93, P3302, DOI 10.1182/blood.V93.10.3302.410a38_3302_3308; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCHMITZ ML, 1995, IMMUNOBIOLOGY, V193, P116, DOI 10.1016/S0171-2985(11)80534-6; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417	27	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9486	9491		10.1074/jbc.M006636200	http://dx.doi.org/10.1074/jbc.M006636200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11114294	hybrid			2022-12-25	WOS:000167607700114
J	Ding, BC; Whetstine, JR; Witt, TL; Schuetz, JD; Matherly, LH				Ding, BC; Whetstine, JR; Witt, TL; Schuetz, JD; Matherly, LH			Repression of human reduced folate carrier gene expression by wild type p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; METHOTREXATE RESISTANCE; DIHYDROFOLATE-REDUCTASE; MEMBRANE-TRANSPORT; MULTIPLE PROMOTERS; LEUKEMIA-CELLS; MDR1 GENE; PROTEIN; DNA; GROWTH	The relationship between loss of functional p53 and human reduced folate carrier (hRFC) levels and function was examined in REH lymphoblastic leukemia cells, which express wild type p53, and in p53-null K562 cells (K562(pTet-on/p53)) engineered to express wild type p53 under control of a tetracycline-inducible promoter. Activation of p53 in REH cells by treatment with daunorubicin was accompanied by decreased (similar to5-fold) levels of hRFC transcripts and methotrexate transport. Treatment of K562(pTet-on/p53) cells with doxycycline resulted in a dose-dependent expression of p53 protein and transcripts, increased p21 protein, decreased dihydrofolate reductase, and G(1) arrest with decreased numbers of cells in S-phase. p53 induction was accompanied by up to 3-fold decreases in hRFC transcripts transcribed from the upstream hRFC-B promoter and similar losses of hRFC protein and methotrexate uptake capacity. Expression of p15 in an analogous inducible system in K562 cells resulted in a nearly identical decrease of S-phase cells and dihydrofolate reductase without effects on hRFC levels or activity. When the hRFC-B promoter was expressed as full-length and basal promoter-luciferase reporter constructs in K562(pTet-on/p53) cells, induction of p53 with doxycycline resulted in a 3-fold loss of promoter activity, which was reversed by cotransfection with a trans-dominant-negative p53. These studies show that wild type p53 acts as a repressor of hRFC gene expression, via a mechanism that is independent of its effects on cell cycle progression.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38101 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Matherly, LH (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.	matherly@kci.wayne.edu	Schuetz, John D/N-2692-2018		NCI NIH HHS [CA53535, CA77641] Funding Source: Medline; NIEHS NIH HHS [ES05851] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005851, R01ES005851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHELLO PL, 1980, MOL PHARMACOL, V18, P274; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CRISSMAN HA, 1973, J CELL BIOL, V59, P766, DOI 10.1083/jcb.59.3.766; DING BC, 2001, IN PRESS BIOCH PHARM; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FRY DW, 1982, J BIOL CHEM, V257, P1890; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Jansen G, 1999, CANC DRUG DISC DEV, P293; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee Y, 1997, EXP CELL RES, V234, P270, DOI 10.1006/excr.1997.3605; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MATHERLY LH, 1991, CANCER RES, V51, P3420; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Perego P, 1996, CANCER RES, V56, P556; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; Tolner B, 1998, GENE, V211, P331, DOI 10.1016/S0378-1119(98)00123-1; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang QJ, 1998, CANCER RES, V58, P5762; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WHETSTINE JR, 2000, J BIOL CHEM     1114; WHITE JC, 1981, J BIOL CHEM, V256, P5722; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; Wong SC, 1997, BIOCHEM PHARMACOL, V53, P199, DOI 10.1016/S0006-2952(96)00710-1; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; Zhang CC, 1998, CANCER CHEMOTH PHARM, V41, P223; Zhang L, 1998, BIOCHEM J, V332, P773, DOI 10.1042/bj3320773; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608	55	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8713	8719		10.1074/jbc.M005248200	http://dx.doi.org/10.1074/jbc.M005248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11106643	hybrid			2022-12-25	WOS:000167607700014
J	Fenczik, CA; Zent, R; Dellos, M; Calderwood, DA; Satriano, J; Kelly, C; Ginsberg, MH				Fenczik, CA; Zent, R; Dellos, M; Calderwood, DA; Satriano, J; Kelly, C; Ginsberg, MH			Distinct domains of CD98hc regulate integrins and amino acid transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CYTOPLASMIC DOMAINS; OUT SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES; HEAVY-CHAIN; PROTEINS; SYSTEM; 4F2; TRANSMEMBRANE; SPECIFICITY; ACTIVATION	CD98 is a cell surface heterodimer formed by the covalent linkage of CD98 heavy chain (CD98hc) with several different light chains to form amino acid transporters. CD98hc also binds specifically to the integrin beta (1A) cytoplasmic domain and regulates integrin function. In this study, we examined the relationship between the ability of CD98hc to stimulate amino acid transport and to affect integrin function. By constructing chimeras with CD98hc and a type II transmembrane protein (CD69),we found that the cytoplasmic and transmembrane domains of GD98hc are required for its effects on integrin function, while the extracellular domain is required for stimulation of isoleucine transport. Consequently, the capacity to promote amino acid transport is not required for CD98hc's effect on integrin function. Furthermore, a mutant of CD98hc that lacks its integrin binding site can still promote increased isoleucine transport. Thus, these two functions of CD98hc are separable and require distinct domains of the protein.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA; Vet Affairs Healthcare Syst VASDHS, San Diego, CA 92161 USA	Scripps Research Institute; University of California System; University of California San Diego	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA.		Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142	NHLBI NIH HHS [HL48728, HL59007] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; Armulik A, 1999, J BIOL CHEM, V274, P37030, DOI 10.1074/jbc.274.52.37030; Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; HAYNES BF, 1981, J IMMUNOL, V126, P1409; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Liu SC, 2000, J CELL SCI, V113, P3563; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; OHTA H, 1994, EMBO J, V13, P2044, DOI 10.1002/j.1460-2075.1994.tb06479.x; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Palacin M, 2000, CURR OPIN NEPHROL HY, V9, P547, DOI 10.1097/00041552-200009000-00015; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; Warren AP, 1996, BLOOD, V87, P3676, DOI 10.1182/blood.V87.9.3676.bloodjournal8793676; Warren AP, 2000, IMMUNOLOGY, V99, P62, DOI 10.1046/j.1365-2567.2000.00953.x; YAGITA H, 1986, CANCER RES, V46, P1478; Zent R, 2000, J BIOL CHEM, V275, P5059, DOI 10.1074/jbc.275.7.5059	30	106	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8746	8752		10.1074/jbc.M011239200	http://dx.doi.org/10.1074/jbc.M011239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11121428	hybrid			2022-12-25	WOS:000167607700019
J	Gisler, SM; Stagljar, I; Traebert, M; Bacic, D; Biber, J; Murer, H				Gisler, SM; Stagljar, I; Traebert, M; Bacic, D; Biber, J; Murer, H			Interaction of the type IIa Na/P-i cotransporter with PDZ proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; RAT-KIDNEY; PARATHYROID-HORMONE; NA+/H+-EXCHANGER; ESCHERICHIA-COLI; PLASMA-MEMBRANE; CHROMOSOME 1Q21; YEAST; IDENTIFICATION; EXPRESSION	The type IIa Na+-dependent inorganic phosphate (Na/P-i) cotransporter is localized in the apical membrane of proximal tubular cells and is regulated by an endocytotic pathway. Because molecular processes such as apical sorting, internalization, or subsequent degradation might be assisted by associated proteins, a yeast two-hybrid screen against the C-terminal, cytosolic tail of type IIa cotransporter was designed. Most of the potential proteins found belonged to proteins with multiple PDZ modules and were either identical/related to PDZK1 or identical to NHERF-1. Yeast trap truncation assays confined the peptide-protein association to the C-terminal amino acid residues TRL of type IIa cotransporter and to single PDZ domains of each identified protein, respectively. The specificity of these interactions were confirmed in yeast by testing other apical localized transmembraneous proteins. Moreover, the type IIa protein was recovered in vitro by glutathione S-transferase-fused PDZ proteins from isolated renal brush border membranes or from type IIa-expressing oocytes. Further, these PDZ proteins are immunohistochemically detected either in the microvilli or in the subapical compartment of proximal tubular cells. Our results suggest that the type IIa Na/P-i cotransporter interacts with various PDZ proteins that might be responsible for the apical sorting, parathyroid hormone controlled endocytosis or the lysosomal sorting of internalized type IIa cotransporter.	Univ Zurich Irchel, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich Irchel, Inst Vet Biochem, CH-8057 Zurich, Switzerland; Univ Zurich Irchel, Inst Anat, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich; University of Zurich	Biber, J (corresponding author), Univ Zurich Irchel, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; Beranger F, 1997, NUCLEIC ACIDS RES, V25, P2035, DOI 10.1093/nar/25.10.2035; BIBER J, 1993, PFLUG ARCH EUR J PHY, V424, P210, DOI 10.1007/BF00384344; BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; CHONG SS, 1995, AM J PHYSIOL-RENAL, V268, pF1038, DOI 10.1152/ajprenal.1995.268.6.F1038; CUSTER M, 1994, AM J PHYSIOL, V266, pF767, DOI 10.1152/ajprenal.1994.266.5.F767; Custer M, 1997, AM J PHYSIOL-RENAL, V273, pF801, DOI 10.1152/ajprenal.1997.273.5.F801; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Fan LZ, 1999, J BIOL CHEM, V274, P11289, DOI 10.1074/jbc.274.16.11289; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOFFMANN T, 1988, GENE, V74, P491, DOI 10.1016/0378-1119(88)90182-5; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Keusch I, 1998, KIDNEY INT, V54, P1224, DOI 10.1046/j.1523-1755.1998.00115.x; Knox FG., 1985, KIDNEY PHYSL PATHOPH, VNew York, P1351; Kocher O, 1998, LAB INVEST, V78, P117; Kocher O, 1996, AM J PATHOL, V149, P493; Kocher O, 1999, LAB INVEST, V79, P1161; Lambert G, 1999, PFLUG ARCH EUR J PHY, V437, P972, DOI 10.1007/s004240050869; Lotscher M, 1997, J CLIN INVEST, V99, P1302, DOI 10.1172/JCI119289; Miller J.H., 1972, EXPT MOL GENETICS; MOORE SK, 1990, DNA CELL BIOL, V9, P387, DOI 10.1089/dna.1990.9.387; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; PRINTEN JA, 1994, GENETICS, V138, P609; Rose MD., 1990, METHODS YEAST GENETI; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Staub O, 1997, CURR OPIN NEPHROL HY, V6, P447, DOI 10.1097/00041552-199709000-00007; Tasara T, 1999, BIOCHEMISTRY-US, V38, P1633, DOI 10.1021/bi9821162; Tenenhouse HS, 1999, NEPHROL DIAL TRANSPL, V14, P333, DOI 10.1093/ndt/14.2.333; Traebert M, 2000, AM J PHYSIOL-RENAL, V278, pF148, DOI 10.1152/ajprenal.2000.278.1.F148; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALDEN PD, 1993, MOL CELL BIOL, V13, P7625, DOI 10.1128/MCB.13.12.7625; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Weinman EJ, 2000, AM J PHYSIOL-RENAL, V279, pF393, DOI 10.1152/ajprenal.2000.279.3.F393; Werner A, 1998, J EXP BIOL, V201, P3135; White KE, 1998, ANN HUM GENET, V62, P287, DOI 10.1046/j.1469-1809.1998.6240287.x; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	55	194	200	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9206	9213		10.1074/jbc.M008745200	http://dx.doi.org/10.1074/jbc.M008745200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11099500	hybrid, Green Accepted			2022-12-25	WOS:000167607700079
J	Jensen, AD; Guarnieri, F; Rasmussen, SGF; Asmar, F; Ballesteros, JA; Gether, U				Jensen, AD; Guarnieri, F; Rasmussen, SGF; Asmar, F; Ballesteros, JA; Gether, U			Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta(2) adrenergic receptor mapped by site-selective fluorescent labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GONADOTROPIN-RELEASING-HORMONE; MEMBRANE-SPANNING SEGMENT; CONSTITUTIVE ACTIVATION; STRUCTURAL INSTABILITY; RHODOPSIN; MECHANISMS; BINDING; MUTATION; HELICES	The environmentally sensitive, sulfhydryl-reactive, fluorescent probe N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) ethylene-diamine (IANBD) was used as a molecular reporter of agonist-induced conformational changes in the beta (2) adrenergic receptor, a prototype hormone-activated G protein-coupled receptor. In the background of a mutant beta (2) adrenergic receptor, with a minimal number of endogenous cysteine residues, new cysteines were introduced in positions 269(6.31), 270(6.32), 271(6.33), and 272(6.34) at the cytoplasmic side of transmembrane segment (TM) 6, The resulting mutant receptors were fully functional and bound both agonists and antagonist with high affinities also upon IANBD labeling. Fluorescence spectroscopy analysis of the purified and site-selectively IANBD-labeled mutants suggested that the covalently attached fluorophore was exposed to a less polar environment at all four positions upon agonist binding. Whereas evidence for only a minor change in the molecular environment was obtained for positions 269(6.31) and 270(6.32), the full agonist isoproterenol caused clear dose-dependent and reversible increases in fluorescence emission at positions 271(6.33) and 272(6.34). The data suggest that activation of G protein-coupled receptors, which are activated by "diffusible" ligands, involves a structural rearrangement corresponding to the cytoplasmic part of TM 6, The preferred conformations of the IANBD moiety attached to the inserted cysteines were predicted by employing a computational method that incorporated the complex hydrophobic/hydrophilic environment in which the cysteines reside. Based on these preferred conformations, it is suggested that the spectral changes reflect an agonist-promoted movement of the cytoplasmic part of TM 6 away from the receptor core and upwards toward the membrane bilayer.	Univ Copenhagen, Panum Inst, Dept Med Physiol 12 5 22, Div Cellular & Mol Physiol, DK-2200 Copenhagen N, Denmark; Novasite Pharmaceut Inc, San Diego, CA 92121 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	University of Copenhagen; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Physiol 12 5 22, Div Cellular & Mol Physiol, DK-2200 Copenhagen N, Denmark.	gether@mfi.ku.dk		Rasmussen, Soren/0000-0002-1853-1841; Gether, Ulrik/0000-0002-0020-3807				Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BALLESTEROS JA, 1992, BIOPHYS J, V62, P107, DOI 10.1016/S0006-3495(92)81794-0; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; GUAN XM, 1992, MOL PHARMACOL, V41, P695; GUARNIERI F, 1995, J COMPUT CHEM, V16, P648, DOI 10.1002/jcc.540160512; Guarnieri F, 1996, J AM CHEM SOC, V118, P5580, DOI 10.1021/ja952745o; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Javitch JA, 1998, BIOCHEMISTRY-US, V37, P998, DOI 10.1021/bi972241y; Jensen AD, 2000, METH MOL B, V136, P345; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, DOI [10.1007/978-1-4757-3061-6, 10.1007/978-1-4757-3061-6_6, DOI 10.1007/978-1-4757-3061-6_6]; Liu J, 1996, J BIOL CHEM, V271, P6172, DOI 10.1074/jbc.271.11.6172; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; STRADER CD, 1994, ANNU REV BIOCHEM, V132, P63101; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	40	140	145	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9279	9290		10.1074/jbc.M004871200	http://dx.doi.org/10.1074/jbc.M004871200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11118431	hybrid			2022-12-25	WOS:000167607700088
J	Hellwage, J; Meri, T; Heikkila, T; Alitalo, A; Panelius, J; Lahdenne, P; Seppala, IJT; Meri, S				Hellwage, J; Meri, T; Heikkila, T; Alitalo, A; Panelius, J; Lahdenne, P; Seppala, IJT; Meri, S			The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYME-DISEASE SPIROCHETE; STREPTOCOCCAL-M-PROTEINS; DIFFERENTIAL EXPRESSION; NEISSERIA-GONORRHOEAE; ALTERNATIVE PATHWAY; ANTIBODY-RESPONSE; ERYTHEMA MIGRANS; SERUM RESISTANCE; C3B; IDENTIFICATION	Spirochete bacteria of the Borrelia burgdorferi sensu late complex cause Lyme borreliosis, The three pathogenic subspecies Borrelia garinii, Borrelia afzelii, and Borrelia burgdorferi sensu stricto differ in their disease profiles and susceptibility to complement lysis. We investigated whether complement resistance of Borreliae could be due to acquisition of the main soluble inhibitors of the alternative complement pathway, factor H and the factor H-like protein 1. When exposed to nonimmune EDTA-plasma, the serum-resistant B. afzelii and B. burgdorferi sensu stricto strains bound factor H/factor H-like protein 1 to their surfaces. Assays with radiolabeled proteins showed that factor a bound strongly to the B. burgdorferi sensu stricto strain, To identify factor H ligands on the borrelial surface, we analyzed a panel of outer surface proteins of B. burgdorferi sensu stricto with the surface plasmon resonance technique. The outer surface lipoprotein OspE was identified as a specific ligand for factor H. Using recombinant constructs of factor H, the binding site for OspE was localized to the C-terminal short consensus repeat domains 15-20. Specific binding of factor H to B, burgdorferi sensu stricto OspE may help the pathogen to evade complement attack and phagocytosis.	Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, HUCH Lab Diagnost, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00290 Helsinki, Finland; Hans Knoell Inst Nat Prod Res, Mol Immunobiol Grp, D-07745 Jena, Germany	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Hans Knoll Institute (HKI)	Meri, S (corresponding author), Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, Haartmaninkatu 3, FIN-00014 Helsinki, Finland.			Meri, Seppo/0000-0001-9142-501X				Akin E, 1999, INFECT IMMUN, V67, P173, DOI 10.1128/IAI.67.1.173-181.1999; Batsford S, 1998, J INFECT DIS, V178, P1676, DOI 10.1086/314477; BreitnerRuddock S, 1997, MED MICROBIOL IMMUN, V185, P253, DOI 10.1007/s004300050038; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Casjens S, 2000, MOL MICROBIOL, V35, P490, DOI 10.1046/j.1365-2958.2000.01698.x; Fernandez JG, 1997, MICROBIOS, V91, P165; Fikrig E, 1998, J INFECT DIS, V178, P1198, DOI 10.1086/515684; Fikrig E, 2000, J IMMUNOL, V164, P5344, DOI 10.4049/jimmunol.164.10.5344; Fikrig E, 1997, IMMUNITY, V6, P531, DOI 10.1016/S1074-7613(00)80341-6; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; GORDON DL, 1995, J IMMUNOL, V155, P348; GUO BP, 1995, INFECT IMMUN, V63, P3467, DOI 10.1128/IAI.63.9.3467-3472.1995; HEIMER GV, 1974, J CLIN PATHOL, V27, P254, DOI 10.1136/jcp.27.3.254; Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; Johnsson E, 1998, J IMMUNOL, V161, P4894; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Jokiranta TS, 1996, FEBS LETT, V393, P297; Junttila T, 1999, J CLIN MICROBIOL, V37, P1361, DOI 10.1128/JCM.37.5.1361-1365.1999; KOISTINEN V, 1989, COMPLEMENT INFLAMMAT, V6, P270, DOI 10.1159/000463102; Kotarsky H, 1998, J IMMUNOL, V160, P3349; Kraiczy Peter, 2000, Immunopharmacology, V49, P57, DOI 10.1016/S0162-3109(00)80163-0; KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; LAM TT, 1994, INFECT IMMUN, V62, P290, DOI 10.1128/IAI.62.1.290-298.1994; Lindahl G, 2000, CURR OPIN IMMUNOL, V12, P44, DOI 10.1016/S0952-7915(99)00049-7; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; Nadelman RB, 1998, LANCET, V352, P557, DOI 10.1016/S0140-6736(98)01146-5; Neeleman C, 1999, INFECT IMMUN, V67, P4517, DOI 10.1128/IAI.67.9.4517-4524.1999; NGUYEN TPK, 1994, INFECT IMMUN, V62, P2079, DOI 10.1128/IAI.62.5.2079-2084.1994; Oschmann P, 1998, J NEUROL, V245, P262, DOI 10.1007/s004150050216; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; PANGBURN MK, 1988, METHOD ENZYMOL, V162, P639; Probert WS, 1998, MOL MICROBIOL, V30, P1003, DOI 10.1046/j.1365-2958.1998.01127.x; Prodinger WM, 1998, BIOCHEM J, V331, P41, DOI 10.1042/bj3310041; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671; Ramamoorthy R, 1998, INFECT IMMUN, V66, P5119, DOI 10.1128/IAI.66.11.5119-5124.1998; Rautemaa R, 1999, MICROBES INFECT, V1, P785, DOI 10.1016/S1286-4579(99)80081-1; Schmidt B, 1996, J CLIN MICROBIOL, V34, P1359, DOI 10.1128/JCM.34.6.1359-1363.1996; Schwan TG, 2000, J CLIN MICROBIOL, V38, P382; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SOINI H, 1994, J CLIN MICROBIOL, V32, P2944, DOI 10.1128/JCM.32.12.2944-2947.1994; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEVENSON B, 1995, INFECT IMMUN, V63, P4535, DOI 10.1128/IAI.63.11.4535-4539.1995; Suhonen J, 2000, J INFECT DIS, V181, P195, DOI 10.1086/315195; Thanassi WT, 2000, ANN INTERN MED, V132, P661, DOI 10.7326/0003-4819-132-8-200004180-00009; Valenzuela JG, 2000, J BIOL CHEM, V275, P18717, DOI 10.1074/jbc.M001486200; VanDam AP, 1997, INFECT IMMUN, V65, P1228, DOI 10.1128/IAI.65.4.1228-1236.1997; WAHLBERG P, 1993, ANN MED, V25, P349, DOI 10.3109/07853899309147296; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147; Zhong WM, 1997, P NATL ACAD SCI USA, V94, P12533, DOI 10.1073/pnas.94.23.12533; Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7; Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6	57	282	291	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8427	8435		10.1074/jbc.M007994200	http://dx.doi.org/10.1074/jbc.M007994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113124	hybrid			2022-12-25	WOS:000167474900102
J	Tsuganezawa, H; Kobayashi, K; Iyori, M; Araki, T; Koizumi, A; Watanabe, SI; Kaneko, A; Fukao, T; Monkawa, T; Yoshida, T; Kim, DK; Kanai, Y; Endou, H; Hayashi, M; Saruta, T				Tsuganezawa, H; Kobayashi, K; Iyori, M; Araki, T; Koizumi, A; Watanabe, SI; Kaneko, A; Fukao, T; Monkawa, T; Yoshida, T; Kim, DK; Kanai, Y; Endou, H; Hayashi, M; Saruta, T			A new member of the HCO3- transporter superfamily is an apical anion exchanger of beta-intercalated cells in the kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL COLLECTING DUCT; FUNCTIONAL-CHARACTERIZATION; INTRACELLULAR PH; RABBIT KIDNEY; H+-ATPASE; CLONING; COTRANSPORTER; PROTEIN; ISOPROTERENOL; EXPRESSION	The kidneys play pivotal roles in acid-base homeostasis, and the acid-secreting (alpha -type) and bicarbonate-secreting (beta -type) intercalated cells in the collecting ducts are major sites for the final modulation of urinary acid secretion. Since the H+-ATPase and anion exchanger activities in these two types of intercalated cells exhibit opposite polarities, it has been suggested that the alpha- and beta -intercalated cells are interchangeable via a cell polarity change. Immunohistological studies, however, have failed to confirm that the apical anion exchanger of beta -intercalated cells is the band 3 protein localized to the basolateral membrane of alpha -inhercalated cells. In the present study, we show the evidence that a novel member of the anion exchanger and sodium bicarbonate cotransporter superfamily is an apical anion exchanger of beta -intercalated cells. Cloned cDNA from the beta -intercalated cells shows about 30% homology with anion exchanger types 1-3, and functional expression of this protein in COS-7 cells and Xenopus oocytes showed sodium-independent and 4,4' -diisothiocyanostilbene-2,2'-disulfonic acid-insensitive anion exchanger activity. Furthermore, immunohistological studies revealed that this novel anion exchanger is present on the apical membrane of beta -intercalated cells, although some beta -intercalated cells were negative for AE4 staining. We conclude that our newly cloned transporter is an apical anion exchanger of the beta -intercalated cells, whereas our data do not exclude the possibility that there may be another form of anion exchanger in these cells.	Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 1818611, Japan	Keio University; Keio University; Kyorin University	Hayashi, M (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.		Fukao, Taro/I-3246-2014; Hayashi, Matsuhiko/J-4748-2013; Monkawa, Toshiaki/F-2361-2010; Koizumi, Amane/E-7771-2011	Monkawa, Toshiaki/0000-0002-7876-7661; Koizumi, Amane/0000-0003-1177-0185				BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; Choi I, 2000, NATURE, V405, P571, DOI 10.1038/35014615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Emmons C, 1999, AM J PHYSIOL-RENAL, V276, pF635, DOI 10.1152/ajprenal.1999.276.4.F635; EMMONS C, 1994, J CLIN INVEST, V93, P417, DOI 10.1172/JCI116976; FEJESTOTH G, 1994, J BIOL CHEM, V269, P26717; FURUYA H, 1991, AM J PHYSIOL, V261, pF377, DOI 10.1152/ajprenal.1991.261.3.F377; HAYASHI M, 1991, J CLIN INVEST, V87, P1153, DOI 10.1172/JCI115112; HUMPHREYS BD, 1994, AM J PHYSIOL-CELL PH, V267, pC1295, DOI 10.1152/ajpcell.1994.267.5.C1295; IKEDA M, 1993, J MEMBRANE BIOL, V136, P231; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADSEN KM, 1992, AM J PHYSIOL, V262, pF1015, DOI 10.1152/ajprenal.1992.262.6.F1015; MILTON AE, 1998, AM J PHYSIOL-RENAL, V274, pF1086; MUTO S, 1990, J CLIN INVEST, V86, P1829, DOI 10.1172/JCI114913; NADER M, 1994, J PHYSIOL-LONDON, V481, P605, DOI 10.1113/jphysiol.1994.sp020467; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; RAJENDRAN VM, 1993, AM J PHYSIOL, V264, pG874, DOI 10.1152/ajpgi.1993.264.5.G874; Romero MF, 2000, J BIOL CHEM, V275, P24552, DOI 10.1074/jbc.M003476200; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SCHUSTER VL, 1986, AM J PHYSIOL, V251, pC347, DOI 10.1152/ajpcell.1986.251.3.C347; SCHUSTER VL, 1991, AM J PHYSIOL, V260, pF506, DOI 10.1152/ajprenal.1991.260.4.F506; SCHUSTER VL, 1993, ANNU REV PHYSIOL, V55, P267, DOI 10.1146/annurev.ph.55.030193.001411; SCHWARTZ GJ, 1985, NATURE, V318, P368, DOI 10.1038/318368a0; SEIDLER U, 1994, AM J PHYSIOL, V266, pG759, DOI 10.1152/ajpgi.1994.266.5.G759; Tanner MJA, 1997, MOL MEMBR BIOL, V14, P155, DOI 10.3109/09687689709048178; VANADELSBERG J, 1994, CELL, V76, P1953; VANADELSBERG JS, 1993, J BIOL CHEM, V268, P11283; WEINER ID, 1994, AM J PHYSIOL-RENAL, V267, pF952, DOI 10.1152/ajprenal.1994.267.6.F952	32	105	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8180	8189		10.1074/jbc.M004513200	http://dx.doi.org/10.1074/jbc.M004513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11102437	hybrid			2022-12-25	WOS:000167474900071
J	Duong, LT; Nakamura, I; Lakkakorpi, PT; Lipfert, L; Bett, AJ; Rodan, GA				Duong, LT; Nakamura, I; Lakkakorpi, PT; Lipfert, L; Bett, AJ; Rodan, GA			Inhibition of osteoclast function by adenovirus expressing antisense protein-tyrosine kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; BONE-RESORPTION; ALPHA(V)BETA(3) INTEGRIN; SEALING ZONE; IN-VIVO; PYK2; ACTIVATION; SRC; PHOSPHORYLATION; ECHISTATIN	Osteoclast activation is initiated by adhesion to bone, cytoskeletal rearrangement, formation of the sealing zone, and formation of the polarized ruffled membrane. Previous findings suggest that protein-tyrosine kinase 2 (PYK2), a cytoplasmic kinase related to focal adhesion kinase, participates in these events. This study examines the role of PYK2 in adhesion-mediated signaling and osteoclast function, using PYK2 antisense. We produced a recombinant adenovirus containing a 300-base pair reversed 5'-coding region of PYK2 and used full-length PYK2 as a control. Murine osteoclast-like cells or their mononuclear precursors were generated in a coculture of bone marrow and osteoblasts. Infection with antisense- adenovirus significantly reduced the expression of endogenous PYK2 protein relative to uninfected cells or to cells infected with sense PYK2 and caused: 1) a reduction in osteoclast formation in vitro; 2) inhibition of cell spreading and of actin ring formation in osteoclasts plated on glass or bone and of attachment and spreading of osteoclast precursors plated on vitronectin; 3) inhibition of bone resorption in vitro; 4) marked reduction in p130(Cas) tyrosine phosphorylation; and 5) no change in alpha (v)beta (3) integrin expression or c-Src tyrosine phosphorylation. Taken together, these findings support the hypothesis that PYK2 plays a central role in the adhesion-dependent cytoskeletal organization and sealing zone formation required for osteoclastic bone resorption.	Merck Sharp & Dohme Ltd, Res Labs, Dept Bone Biol & Osteoporosis Res, West Point, PA 19486 USA; Merck Sharp & Dohme Ltd, Res Labs, Dept Virus & Cell Biol, West Point, PA 19486 USA; Univ Turku, Dept Anat, Inst Biomed, FIN-20520 Turku, Finland	Merck & Company; Merck & Company; University of Turku	Duong, LT (corresponding author), Merck Sharp & Dohme Ltd, Res Labs, Dept Bone Biol & Osteoporosis Res, West Point, PA 19486 USA.							Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Benbernou N, 2000, J BIOL CHEM, V275, P7060, DOI 10.1074/jbc.275.10.7060; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Crippes BA, 1996, ENDOCRINOLOGY, V137, P918, DOI 10.1210/en.137.3.918; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945-053X(00)00051-2; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gismondi A, 2000, J IMMUNOL, V164, P2272, DOI 10.4049/jimmunol.164.5.2272; Hitt M M, 1997, Adv Pharmacol, V40, P137, DOI 10.1016/S1054-3589(08)60140-4; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Hunter AJ, 1997, J IMMUNOL, V159, P4806; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Lakkakorpi PT, 2001, J CELL SCI, V114, P149; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; Manie SN, 1997, J BIOL CHEM, V272, P15636, DOI 10.1074/jbc.272.25.15636; Masarachia P, 1998, ENDOCRINOLOGY, V139, P1401, DOI 10.1210/en.139.3.1401; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyazaki T, 2000, J BONE MINER RES, V15, P41, DOI 10.1359/jbmr.2000.15.1.41; Nakamura I, 1999, J CELL SCI, V112, P3985; Nakamura I, 1998, ENDOCRINOLOGY, V139, P5182, DOI 10.1210/en.139.12.5182; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869; Tanaka S, 1998, J BONE MINER RES, V13, P1714, DOI 10.1359/jbmr.1998.13.11.1714; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wang DM, 2000, J BIOL CHEM, V275, P12223, DOI 10.1074/jbc.275.16.12223; WESOLOWSKI G, 1995, EXP CELL RES, V219, P679, DOI 10.1006/excr.1995.1279; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Xiong WC, 1998, J CELL SCI, V111, P1981; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	50	57	73	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7484	7492		10.1074/jbc.M008368200	http://dx.doi.org/10.1074/jbc.M008368200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11102447	hybrid			2022-12-25	WOS:000167442900086
J	Szczesna, D; Ghosh, D; Gomes, AV; Guzman, G; Arana, C; Zhi, G; Stull, JT; Potter, JD				Szczesna, D; Ghosh, D; Gomes, AV; Guzman, G; Arana, C; Zhi, G; Stull, JT; Potter, JD			Familial hypertrophic cardiomyopathy mutations in the regulatory light chains of myosin affect their structure, Ca2+ binding, and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; FAILING HUMAN HEART; CARDIAC TROPONIN-T; SKELETAL-MUSCLE; ALPHA-TROPOMYOSIN; MOLECULAR-BASIS; MOTOR DOMAIN; DISEASE GENE; CONTRACTION; PROTEIN	The effect of the familial hypertrophic cardiomyopathy mutations, A13T, F18L, E22K, R58Q, and P95A, found in the regulatory light chains of human cardiac myosin has been investigated. The results demonstrate that E22K and R58Q, located in the immediate extension of the helices flanking the regulatory light chain Ca2+ binding site, had dramatically altered Ca2+ binding properties. The K-Ca value for E22K was decreased by similar to 17-fold compared with the wild-type light chain, and the R58Q mutant did not bind Ca2+. Interestingly, Ca2+ binding to the R58Q mutant was restored upon phosphorylation, whereas the E22K mutant could not be phosphorylated, In addition, the alpha -helical content of phosphorylated R58Q greatly increased with Ca2+ binding. The A13T mutation, located near the phosphorylation site (Ser-15) of the human cardiac regulatory light chain, had 3-fold lower K-Ca than wild-type light chain, whereas phosphorylation of this mutant increased the Ca2+ affinity 6-fold. Whereas phosphorylation of wildtype light chain decreased its Ca2+ affinity, the opposite was true for A13T. The alpha -helical content of the A13T mutant returned to the level of wild-type light chain upon phosphorylation, The phosphorylation and Ca2+ binding properties of the regulatory light chain of human cardiac myosin are important for physiological function, and alteration any of these could contribute to the development of hypertrophic cardiomyopathy.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Miami; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Szczesna, D (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.		Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026043, R37HL026043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045183] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296, HL26043] Funding Source: Medline; NIAMS NIH HHS [AR45183] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; ELDIN P, 1994, BIOCHEMISTRY-US, V33, P12558, DOI 10.1021/bi00208a005; Epstein ND, 1998, ADV EXP MED BIOL, V453, P105; Flavigny J, 1998, J MOL MED-JMM, V76, P208, DOI 10.1007/s001090050210; FREARSON N, 1976, NATURE, V264, P801, DOI 10.1038/264801a0; GAO ZH, 1995, J BIOL CHEM, V270, P10125, DOI 10.1074/jbc.270.17.10125; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HERRING BP, 1990, J BIOL CHEM, V265, P1724; HOLT JC, 1975, BIOCHEMISTRY-US, V14, P4600, DOI 10.1021/bi00692a007; Huang W, 1998, EUR J BIOCHEM, V257, P457, DOI 10.1046/j.1432-1327.1998.2570457.x; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Levine RJC, 1999, MOL CELL BIOCHEM, V195, P1, DOI 10.1023/A:1006940513097; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Moore DD, 1995, GLOB MOB SURV; MOORE R L, 1991, Medicine and Science in Sports and Exercise, V23, P1163; Morano I, 1999, J MOL MED-JMM, V77, P544, DOI 10.1007/s001099900031; Morano I, 1997, J MOL CELL CARDIOL, V29, P1177, DOI 10.1006/jmcc.1996.0353; MORANO I, 1994, J MOL CELL CARDIOL, V26, P361, DOI 10.1006/jmcc.1994.1045; MORANO I, 1985, FEBS LETT, V189, P221, DOI 10.1016/0014-5793(85)81027-9; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; POTTER JD, 1983, METHOD ENZYMOL, V102, P135; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221; SAYERS ST, 1983, FEBS LETT, V154, P305, DOI 10.1016/0014-5793(83)80172-0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOBIESZEK A, 1977, EUR J BIOCHEM, V73, P477, DOI 10.1111/j.1432-1033.1977.tb11340.x; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STAFFORD WF, 1978, BIOCHEMISTRY-US, V17, P607, DOI 10.1021/bi00597a008; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Szczesna D, 1996, J BIOL CHEM, V271, P5246; Szczesna Danuta, 1997, Biophysical Journal, V72, pA175; Szczesna Danuta, 1996, Biophysical Journal, V70, pA380; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TUAZON PT, 1982, EUR J BIOCHEM, V129, P205, DOI 10.1111/j.1432-1033.1982.tb07041.x; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WU CSC, 1976, BIOCHEMISTRY-US, V15, P3007, DOI 10.1021/bi00659a011	45	85	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7086	7092		10.1074/jbc.M009823200	http://dx.doi.org/10.1074/jbc.M009823200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11102452	hybrid			2022-12-25	WOS:000167442900033
J	Fraser, PE; Darabie, AA; McLaurin, J				Fraser, PE; Darabie, AA; McLaurin, J			Amyloid-beta interactions with chondroitin sulfate-derived monosaccharides and disaccharides - Implications for drug development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE FIBRIL FORMATION; ALZHEIMERS-DISEASE; A-BETA; HEPARAN-SULFATE; DERMATAN SULFATE; HIGH-AFFINITY; NEURITIC PLAQUES; CONGO RED; BINDING; GROWTH	In Alzheimer's disease, the major pathological features are diffuse and senile plaques that are primarily composed of the amyloid-beta (A beta) peptide. It has been proposed that proteoglycans and glycosaminoglycans (GAG) facilitate amyloid fibril formation and/or stabilize the plaque aggregates. To develop effective therapeutics based on A beta -GAG interactions, understanding the A beta binding motif on the GAG chain is imperative. Using electron microscopy, fluorescence spectroscopy, and competitive inhibition ELISAs, we have evaluated the ability of chondroitin sulfate-derived monosaccharides and disaccharides to induce the structural changes in A beta that are associated with GAG interactions. Our results demonstrate that the disaccharides GalNAc-4-sulfate(4S), Delta UA-GalNAc-6-sulfate(6S), and Delta UA-GalNAc-4,6-sulfate(4S,6S), the iduronic acid-2-sulfate analogues, and the monosaccharides D-GalNAc-4S, D-GalNAc-6S, and D-GalNAc-4S,6S, but not D-GalNAc, D-GlcNAc, or Delta UA-GalNAc, induce the fibrillar features of A beta -GAG interactions. The binding affinities of all chondroitin sulfate derived saccharides mimic those of the intact GAG chains. The sulfated monosaccharides and disaccharides compete with the intact chondroitin sulfate and heparin GAGs for A beta binding, as illustrated by competitive inhibition ELISAs. Therefore, the development of therapeutics based on the model of A beta -chondroitin sulfate binding may lead to effective inhibitors of the GAG-induced amyloid formation that is observed in vitro.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto	McLaurin, J (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg ,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.							Bohrmann B, 1999, J BIOL CHEM, V274, P15990, DOI 10.1074/jbc.274.23.15990; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; Castillo GM, 1997, J NEUROCHEM, V69, P2452; CELLA G, 1992, ANGIOLOGY, V43, P59, DOI 10.1177/000331979204300107; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; ERIKSSON S, 1995, P NATL ACAD SCI USA, V92, P2313, DOI 10.1073/pnas.92.6.2313; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; Gupta-Bansal R, 1998, J NEUROCHEM, V70, P292; Huang THJ, 1997, J MOL BIOL, V269, P214; Jao SC, 1997, AMYLOID, V4, P240, DOI 10.3109/13506129709003835; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Kisilevsky R, 1997, CRIT REV BIOCHEM MOL, V32, P361, DOI 10.3109/10409239709082674; LEVEUGLE B, 1994, NEUROREPORT, V5, P1389, DOI 10.1097/00001756-199406000-00025; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; McLaurin J, 1999, AMYLOID, V6, P233, DOI 10.3109/13506129909007334; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; McLaurin J, 1998, J MOL BIOL, V278, P183, DOI 10.1006/jmbi.1998.1677; McLaurin J, 2000, J BIOL CHEM, V275, P18495, DOI 10.1074/jbc.M906994199; MCLAURIN J, 2000, EUR J BIOCHEM, V267, P1; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Snow AD, 1996, EXP NEUROL, V138, P305, DOI 10.1006/exnr.1996.0069; SNOW AD, 1992, J HISTOCHEM CYTOCHEM, V40, P105, DOI 10.1177/40.1.1370306; SNOW AD, 1988, AM J PATHOL, V133, P456; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; VANGOOL D, 1993, DEMENTIA, V4, P308, DOI 10.1159/000107338; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; Webster S, 1996, J NEUROSCI RES, V46, P58, DOI 10.1002/(SICI)1097-4547(19961001)46:1<58::AID-JNR8>3.0.CO;2-E; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030	41	61	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6412	6419		10.1074/jbc.M008128200	http://dx.doi.org/10.1074/jbc.M008128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11106653	hybrid, Green Submitted			2022-12-25	WOS:000167261000047
J	Rhee, J; Lilien, J; Balsamo, J				Rhee, J; Lilien, J; Balsamo, J			Essential tyrosine residues for interaction of the non-receptor protein-tyrosine phosphatase PTP1B with N-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; CELL-CELL-ADHESION; BETA-CATENIN; CYTOPLASMIC DOMAIN; MEDIATED ADHESION; INSULIN-RECEPTOR; HUMAN PLATELETS; 1B INTERACTS; PHOSPHORYLATION; COMPLEX	Expression of a dominant-negative, catalytically inactive form of the nonreceptor protein-tyrosine phosphatase PTP1B in L-cells constitutively expressing N-cadherin results in loss of N-cadherin-mediated cell-cell adhesion. PTP1B interacts directly with the cytoplasmic domain of N-cadherin, and this association is regulated by phosphorylation of tyrosine residues in PTP1B. The following three tyrosine residues in PTP1B are potential substrates for tyrosine kinases: Tyr-66, Tyr-152, and Tyr- 153. To determine the tyrosine residue(s) that are crucial for the cadherin-PTP1B interaction we used site-directed mutagenesis to create catalytically inactive PTP1B constructs bearing additional single, double, or triple mutations in which tyrosine was substituted by phenylalanine. Mutation Y152F eliminates binding to N-cadherin in vitro, whereas mutations Y66F and Y153F do not. Overexpression of the catalytically inactive PTP1B with the Y152F mutation in L-cells constitutively expressing N-cadherin has no effect on N-cadherin-mediated adhesion, and immunoprecipitation reveals that the mutant Y152F PTP1B does not associate with N-cadherin in situ. Furthermore, among cells overexpressing the Y152F mutant endogenous PTP1B associates with N-cadherin and is tyro sine-phosphorylated.	Univ Iowa, Dept Biol Sci, Iowa City, IA 52242 USA	University of Iowa	Balsamo, J (corresponding author), Univ Iowa, Dept Biol Sci, 138 Biol Bldg, Iowa City, IA 52242 USA.	janne-balsamo@uiowa.edu			NATIONAL EYE INSTITUTE [R01EY012132] Funding Source: NIH RePORTER; NEI NIH HHS [EY12132] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GUMBINER BM, 1993, J CELL SCI, P155; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Lilien J, 1997, CURR TOP DEV BIOL, V35, P161, DOI 10.1016/S0070-2153(08)60259-8; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; PATHRE P, 2001, IN PRESS J NEUROSCI; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Wheelock MJ, 1996, CURR TOP MEMBR, V43, P169	30	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6640	6644		10.1074/jbc.M007656200	http://dx.doi.org/10.1074/jbc.M007656200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11106648	hybrid			2022-12-25	WOS:000167261000075
J	Spagnoli, A; Hwa, V; Horton, WA; Lunstrum, GP; Roberts, CT; Chiarelli, F; Torello, M; Rosenfeld, RG				Spagnoli, A; Hwa, V; Horton, WA; Lunstrum, GP; Roberts, CT; Chiarelli, F; Torello, M; Rosenfeld, RG			Antiproliferative effects of insulin-like growth factor-binding protein-3 in mesenchymal chondrogenic cell line RCJ3.1C5.18 - Relationship to differentiation stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	81st Annual Meeting of the Endocrine-Society	JUN 12-16, 1999	SAN DIEGO, CALIFORNIA	Endocrine Soc			I IGF-I; MESSENGER-RIBONUCLEIC-ACID; RECEPTOR GENE-EXPRESSION; HUMAN BIOLOGICAL-FLUIDS; THYMIDINE INCORPORATION; EXTRACELLULAR-MATRIX; HORMONE RECEPTORS; FACTOR (IGF)-I; CHONDROCYTES; IDENTIFICATION	Chondrogenesis results from a complex equilibrium between chondrocyte proliferation and differentiation. Insulin-like growth factors (IGFs) have a crucial role in chondrogenesis, but their mechanisms of action are not well defined. IG;F-binding protein-3 (IGFBP-3) is the major carrier for circulating IGFs in postnatal life, and has been shown to have IGF-independent effects on proliferation of several cancer cell lines. In this study, we have evaluated the IGF-independent and -dependent effects of IGFBP-3 on chondrocyte proliferation and the relationship of these effects with chondrocyte differentiation stage. We used the RCJ3.1C5.18 nontransformed mesenchymal chondrogenic cell line, which, over 2 weeks of culture, progresses through the differentiation pathway exhibited by chondrocytes in the growth plate. We demonstrated that IGFBP-3 inhibited, in a dose-dependent manner (1-30 nM), the proliferation of chondroprogenitors and early differentiated chondrocytes, stimulated by des-(1-3)-IGF-I and longR(3)-IGF-I (IGF-I analogs with reduced affinity for IGFBP-3), and by insulin and IGF-I. In terminally differentiated chondrocytes, IGFBP-3 retained the ability to inhibit cell proliferation stimulated by IGF-I, but had no effect on cell growth stimulated by insulin, or des-(l-3)-IGF-I or longR(3)IGF-I. By monolayer affinity cross-linking, we demonstrated a specific IGFBP-3-associated cell-membrane protein of similar to 20 kDa. We determined that IGFBP-3 has an antiproliferative effect on chondrocytes and, that this effect is related to the differentiation process. In chondroprogenitors and early differentiated chondrocytes, antiproliferative effect of IGFBP-3 is mainly IGF-independent, whereas, following terminal differentiation this effect is IGF-dependent.	Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97201 USA; Shriners Hosp Children, Dept Res, Portland, OR 97201 USA; Univ Chieti, Dept Pediat, I-66013 Chieti, Italy	Oregon Health & Science University; G d'Annunzio University of Chieti-Pescara	Spagnoli, A (corresponding author), Oregon Hlth Sci Univ, Dept Pediat, NRC-5,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772	NCI NIH HHS [CA58110] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNARD R, 1988, ENDOCRINOLOGY, V122, P2562, DOI 10.1210/endo-122-6-2562; BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DOMENE H, 1993, ENDOCRINOLOGY, V133, P675, DOI 10.1210/en.133.2.675; Durham SK, 1997, PEDIATR RES, V42, P335, DOI 10.1203/00006450-199709000-00014; ERICKSON GF, 1992, ENDOCRINOLOGY, V130, P1867, DOI 10.1210/en.130.4.1867; FIELDER PJ, 1993, GROWTH REGULAT, V3, P226; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GARGOSKY SE, 1992, ENDOCRINOLOGY, V131, P3051, DOI 10.1210/en.131.6.3051; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; Grigoriadis AE, 1996, DIFFERENTIATION, V60, P299, DOI 10.1046/j.1432-0436.1996.6050299.x; Horton WA, 1996, ENDOCRIN METAB CLIN, V25, P683, DOI 10.1016/S0889-8529(05)70347-9; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; JANSEN J, 1989, J ENDOCRINOL, V120, P245, DOI 10.1677/joe.0.1200245; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; Labarta JI, 1997, CLIN ENDOCRINOL, V47, P657, DOI 10.1046/j.1365-2265.1997.2581078.x; LAMSON G, 1989, J CLIN ENDOCR METAB, V69, P852, DOI 10.1210/jcem-69-4-852; LAMSON G, 1991, J CLIN ENDOCR METAB, V72, P1391, DOI 10.1210/jcem-72-6-1391; LOWE WL, 1988, MOL ENDOCRINOL, V2, P528, DOI 10.1210/mend-2-6-528; Lunstrum GP, 1999, J HISTOCHEM CYTOCHEM, V47, P1, DOI 10.1177/002215549904700101; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Matsumoto T, 1996, J ENDOCRINOL, V148, P355, DOI 10.1677/joe.0.1480355; Matsumoto T, 1996, J CLIN ENDOCR METAB, V81, P150, DOI 10.1210/jc.81.1.150; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; OH YM, 1993, J BIOL CHEM, V268, P14964; OHLSSON C, 1992, J ENDOCRINOL, V135, P115, DOI 10.1677/joe.0.1350115; OLNEY RC, 1993, ENDOCRINOLOGY, V133, P563, DOI 10.1210/en.133.2.563; Rees C, 1998, J CELL BIOCHEM, V71, P375, DOI 10.1002/(SICI)1097-4644(19981201)71:3<375::AID-JCB6>3.0.CO;2-M; Rosenfeld RG, 1999, PEDIATRICS, V104, P1018; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Spagnoli A, 1996, ENDOCRIN METAB CLIN, V25, P615, DOI 10.1016/S0889-8529(05)70343-1; SPAGNOLI A, 1997, CURR OPIN ENDOCRINOL, V4, P1; SUNIC D, 1995, BBA-GEN SUBJECTS, V1245, P43, DOI 10.1016/0304-4165(95)00076-N; TAKIGAWA M, 1987, BONE MINER, V2, P449; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WANG EM, 1995, ENDOCRINOLOGY, V136, P2741, DOI 10.1210/en.136.6.2741; WERTHER GA, 1990, J CLIN ENDOCR METAB, V70, P1725, DOI 10.1210/jcem-70-6-1725; WERTHER GA, 1993, J CLIN ENDOCR METAB, V76, P1638, DOI 10.1210/jc.76.6.1638; Wilson EM, 1997, J CLIN ENDOCR METAB, V82, P1301, DOI 10.1210/jc.82.4.1301	42	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5533	5540		10.1074/jbc.M005088200	http://dx.doi.org/10.1074/jbc.M005088200			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11110782	hybrid			2022-12-25	WOS:000167115100019
J	Adnane, J; Jackson, RJ; Nicosia, SV; Cantor, AB; Pledger, WJ; Sebti, SM				Adnane, J; Jackson, RJ; Nicosia, SV; Cantor, AB; Pledger, WJ; Sebti, SM			Loss of p21(WAF1/CIP1) accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model	ONCOGENE			English	Article						p21(WAF1/CIP1); mammary tumor model; ras oncogene	CELL-CYCLE ARREST; NIH 3T3 CELLS; HA-RAS; SKIN CARCINOGENESIS; GROWTH ARREST; C-MYC; MALIGNANT CONVERSION; INDUCED APOPTOSIS; ACTIVATED RAS; G(1) ARREST	Upregulation of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and subsequent cell growth arrest or senescence is one mechanism by which normal cells are believed to respond to stress induced by the constitutively activated GTPase Ras. We hypothesize that in the absence of p21, the onset of Ras-dependent oncogenesis is accelerated. To test this hypothesis, we crossed MMTV/v-Ha-ras transgenic mice into a p21-deficient background. By 63 days of age, all 8 ras/p21(-/-) mice developed either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors. In contrast, by the same age, only one out of nine of the ras/p21(+/+) mice developed a tumor. Furthermore, by 94 days of age, half of the ras/p21(-/-) mice, but none of the ras/p21(+/+) mice, developed mammary tumors. p21-deficiency also accelerated the development of salivary (T-50 = 66 days for ras/21(-/-) vs T-50 = 136 days for ras/p21(+/+)) and Harderian (T-50 = 52 days for ras/p21(-/-) vs T-50>221 days for ras/p21(+/+)) tumors. Furthermore, two out of the eight ras/p21(-/-) mice had metastatic lesions, one in its lungs, the other in its abdomen. None of the nine ras/p21(+/+) mice had metastatic lesions. By 4 months of age, the mammary tumor multiplicity was 10-fold greater in ras/p21(-/-) (average 3.40 tumors/mouse) than in ras/p21(+/+) (average 0.33 tumor/mouse) mice. However, once the tumors appeared, their growth rate, apoptosis level, and mitotic index were not affected by the loss of p21, suggesting that loss of p21 is critical in early but not late events of Ras oncogenesis. Altogether, the results show that tumor onset in MMTV/v-Ha-ras mice is p21-dependent with loss of p21 associated with earlier tumor appearance and increased tumor multiplicity and aggressiveness.	Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Pathol & Lab Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia, Tampa, FL 33612 USA.				NCI NIH HHS [CA67771, CA72694, CA78038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072694, P01CA078038, U19CA067771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Arber N, 1996, ONCOGENE, V12, P1903; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; Balbin M, 1996, J BIOL CHEM, V271, P15782, DOI 10.1074/jbc.271.26.15782; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BOS JL, 1989, CANCER RES, V49, P4682; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; CHOOI KF, 1994, CANCER RES, V54, P6434; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Davis R W, 1980, Methods Enzymol, V65, P404; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EFRAT S, 1990, MOL CELL BIOL, V10, P1779, DOI 10.1128/MCB.10.4.1779; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; FILMUS J, 1994, ONCOGENE, V9, P3627; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GAO X, 1995, ONCOGENE, V11, P1395; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; HEATH LA, 1992, INT J CANCER, V51, P310, DOI 10.1002/ijc.2910510222; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; IWAMOTO T, 1990, ONCOGENE, V5, P535; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MILLER BE, 1988, CANCER RES, V48, P5747; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; NAMBA H, 1995, CANCER RES, V55, P2075; NOOTER K, 1995, BRIT J CANCER, V71, P556, DOI 10.1038/bjc.1995.109; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; Ritland SR, 1997, CANCER RES, V57, P3520; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; SANDGREN EP, 1989, ONCOGENE, V4, P715; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAYLOR CR, 1994, HUM PATHOL, V25, P263, DOI 10.1016/0046-8177(94)90198-8; Terry LA, 1996, MOL CARCINOGEN, V16, P221, DOI 10.1002/(SICI)1098-2744(199608)16:4<221::AID-MC6>3.0.CO;2-I; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; Weinberg WC, 1999, CANCER RES, V59, P2050; Winston JT, 1996, ONCOGENE, V12, P127; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia K, 1999, MOL CELL BIOL, V19, P4819; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; Yao Y, 1999, ONCOGENE, V18, P5159, DOI 10.1038/sj.onc.1202908	75	83	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5338	5347		10.1038/sj.onc.1203956	http://dx.doi.org/10.1038/sj.onc.1203956			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103935				2022-12-25	WOS:000165302300005
J	Behrend, L; Milne, DM; Stoter, M; Deppert, W; Campbell, LE; Meek, DW; Knippschild, U				Behrend, L; Milne, DM; Stoter, M; Deppert, W; Campbell, LE; Meek, DW; Knippschild, U			IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects	ONCOGENE			English	Article						casein kinase 1; mitotic checkpoint; chromosome segregation; centrosome amplification; micronucleation	CELL-CYCLE PROGRESSION; SPINDLE CHECKPOINT; MOLECULAR-CLONING; P53 PROTEIN; DNA-DAMAGE; I ISOFORM; PHOSPHORYLATION; EXPRESSION; MOUSE; FIBROBLASTS	The p53-targeted kinases casein kinase 1 delta (CK1 delta) and casein kinase 1 epsilon (CK1 epsilon) have been proposed to be involved in regulating DNA repair and chromosomal segregation. Recently, we showed that CK1 delta localizes to the spindle apparatus and the centrosomes in cells with mitotic failure caused by DNA-damage prior to mitotic entry. We provide here evidence that 3-[(2,4,6-trimethoxyphenyl)methylidenyl]-indolin-2-one (IC261), a novel inhibitor of CK1 delta and CK1 epsilon, triggers the mitotic checkpoint control. At low micromolar concentrations IC261 inhibits cytokinesis causing a transient mitotic arrest. Cells containing active p53 arrest in the postmitotic G1 phase by blockage of entry into the S phase. Cells with non-functional p53 undergo postmitotic replication developing an 8N DNA content. The increase of DNA content is accompanied by a high amount of micronucleated and apoptotic cells. Immunfluorescence images show that at low concentrations IC261 leads to centrosome amplification causing multipolar mitosis. Our data are consistent with a role for CK1 delta and CK1 epsilon isoforms in regulating key aspects of cell division, possibly through the regulation of centrosome or spindle function during mitosis.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	Heinrich Pette Institute; University of Hamburg; University of Dundee	Knippschild, U (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Behrend L, 2000, EUR J CELL BIOL, V79, P240, DOI 10.1078/S0171-9335(04)70027-8; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Christenson E, 1997, Recent Results Cancer Res, V143, P263; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAHMUS ME, 1981, J BIOL CHEM, V256, P1239; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; ENDOW SA, 1994, J CELL SCI, V107, P859; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FujikawaYamamoto K, 1997, CELL STRUCT FUNCT, V22, P399, DOI 10.1247/csf.22.399; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan SH, 1998, CANCER RES, V58, P396; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kuret J, 1997, J NEUROCHEM, V69, P2506; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Longenecker KL, 1998, ACTA CRYSTALLOGR D, V54, P473, DOI 10.1107/S0907444997011724; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; MILNE DM, 1992, ONCOGENE, V7, P1361; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mountain V, 2000, ANAT REC, V261, P14, DOI 10.1002/(SICI)1097-0185(20000215)261:1<14::AID-AR5>3.0.CO;2-E; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; OTTO A, 1993, ONCOGENE, V8, P2591; Palazzo RE, 1999, J CELL SCI, V112, P1291; ROBERTS JR, 1990, CANCER RES, V50, P710; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sablina AA, 1998, J CELL SCI, V111, P977; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Santos JA, 1996, J CELL SCI, V109, P1847; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; SIMKOWSKI KW, 1980, J BIOL CHEM, V255, P6456; SINGH TJ, 1983, ARCH BIOCHEM BIOPHYS, V220, P615, DOI 10.1016/0003-9861(83)90454-X; SINGH TJ, 1995, J NEUROCHEM, V64, P1420; THOMAS NSB, 1991, ONCOGENE, V6, P317; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANDRE DD, 1989, J CELL SCI, V94, P245; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Yang PF, 2000, J BIOL CHEM, V275, P18905, DOI 10.1074/jbc.M002134200; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	66	103	108	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5303	5313		10.1038/sj.onc.1203939	http://dx.doi.org/10.1038/sj.onc.1203939			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103931				2022-12-25	WOS:000165302300001
J	Deszo, EL; Brake, DK; Cengel, KA; Kelley, KW; Freund, GG				Deszo, EL; Brake, DK; Cengel, KA; Kelley, KW; Freund, GG			CD45 negatively regulates monocytic cell differentiation by inhibiting phorbol 12-myristate 13-acetate-dependent activation and tyrosine phosphorylation of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE B-CELLS; MAP KINASE; SIGNAL TRANSDUCTION; ESTER; IDENTIFICATION; DIACYLGLYCEROL; PHOSPHATASE; SERINE; LYN; SRC	The protein-tyrosine phosphatase CD45 is expressed on all monocytic cells, but its function in these cells is not well defined. Here we report that CD45 negatively regulates monocyte differentiation by inhibiting phorbol 12-myristate 13-acetate (PMA)-dependent activation of protein kinase C (PKC) delta. We found that antisense reduction of CD45 in U937 monocytic cells (CD45as cells) increased by 100% the ability of PMA to enlarge cell size, increase cell cytoplasmic process width and length, and induce surface expression of CD11b. In addition, reduction in CD45 expression caused the duration of peak PMA-induced MEK and extracellular signal-regulated kinase (ERK) 1/2 activity to increase from 5 min to 30 min while leading to a 4-fold increase in PMA-dependent PKC delta activation. Importantly, PMA-dependent tyrosine phosphorylation of PKC delta was also increased 4-fold in CD45as cells. Finally, inhibitors of MEK (PD98059) and PKC delta (rottlerin) completely blocked PMA-induced monocytic cell differentiation. Taken together, these data indicate that CD45 inhibits PMA-dependent PKC delta activation by impeding PMA-dependent PKC delta tyrosine phosphorylation, Furthermore, this blunting of PKC delta activation leads to an inhibition of PKC delta -dependent activation of ERK1/2 and ERK1/2-dependent monocyte differentiation. These findings suggest that CD45 is a critical regulator of monocytic cell development.	Univ Illinois, Coll Med, Dept Pathol, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Freund, GG (corresponding author), Univ Illinois, Coll Med, Dept Pathol, 506 S Mathews Ave, Urbana, IL 61801 USA.	freun@ux1.cso.uiuc.edu			NCI NIH HHS [CA-61931] Funding Source: Medline; NIA NIH HHS [AG06246] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA061931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006246] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BARENDSEN N, 1990, LEUKEMIA RES, V14, P467, DOI 10.1016/0145-2126(90)90034-7; Bhatia M, 1996, EXP CELL RES, V222, P61, DOI 10.1006/excr.1996.0008; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Cengel KA, 1998, BIOCHEM J, V335, P397, DOI 10.1042/bj3350397; D'Oro U, 1999, J IMMUNOL, V162, P1879; DONOVAN JA, 1993, J AM SOC NEPHROL, V4, P976; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hayes AL, 1999, J BIOL CHEM, V274, P33455, DOI 10.1074/jbc.274.47.33455; He HC, 1999, CELL GROWTH DIFFER, V10, P307; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KATAGIRI T, 1995, J BIOL CHEM, V270, P27987; Katagiri T, 1999, J IMMUNOL, V163, P1321; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kontny E, 2000, J LEUKOCYTE BIOL, V67, P249, DOI 10.1002/jlb.67.2.249; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Kulas DT, 1996, J BIOL CHEM, V271, P755, DOI 10.1074/jbc.271.2.755; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LILES WC, 1995, J IMMUNOL, V155, P2175; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; ORR JW, 1992, J BIOL CHEM, V267, P15263; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEDRINACI S, 1990, INT J CANCER, V45, P294, DOI 10.1002/ijc.2910450215; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Schacher DH, 2000, J IMMUNOL, V164, P113, DOI 10.4049/jimmunol.164.1.113; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; SOZERI O, 1992, ONCOGENE, V7, P2259; TAOKA T, 1992, BLOOD, V80, P46; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Wang WJ, 1997, J BIOL CHEM, V272, P76; Woodford-Thomas T, 1993, Semin Cell Biol, V4, P409, DOI 10.1006/scel.1993.1049; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	49	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10212	10217		10.1074/jbc.M010589200	http://dx.doi.org/10.1074/jbc.M010589200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124968	hybrid			2022-12-25	WOS:000167996400084
J	Halim, AB; LeGros, L; Chamberlin, ME; Geller, A; Kotb, M				Halim, AB; LeGros, L; Chamberlin, ME; Geller, A; Kotb, M			Regulation of the human MAT2A gene encoding the catalytic alpha 2 subunit of methionine adenosyltransferase, MAT II - Gene organization, promoter characterization, and identification of a site in the proximal promoter that is essential for its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; ADENOSYL-L-METHIONINE; TRANSCRIPTION FACTORS; MOLECULAR MECHANISMS; PARTIAL-PURIFICATION; RAT-LIVER; 2A GENE; METABOLISM; EXPRESSION; CELLS	Mammalian methionine adenosyltransferase II (MAT II) consists of a catalytic alpha2/alpha2 ' and a regulatory beta subunit. Up-regulation of alpha2 subunit expression is associated with increased intracellular levels of S-adenosylmethionine, the major methyl group donor and a key compound in cell metabolism and polyamine synthesis. Previous studies have shown that expression of the alpha2 subunit is differentially regulated in normal and malignant cells, To delineate the molecular basis for the differential regulation of alpha2 subunit expression, we cloned and characterized the human MAT2A gene and its promoter and defined regions that contain enhancer and repressor elements, Detailed functional characterization of the proximal promoter of the MAT2A gene revealed the formation of three major protein-DNA complexes with probes containing three Spl sites (Spl-l at -14, Sp1-2 at -47, and Sp1-3 at -69), Competition with a probe copying sequence between -76 and -54, which contains the Sp1-3 site only, or mutation of this site, abolished complex formation. Furthermore, mutation of the Sp1-3 site, but not the Spl-l or Sp1-2 sites, inhibited the in vivo promoter activity by similar to 85%, Supershift assays showed that the transcription factors Sp2 and Sp3 are part of the complexes formed at the Sp1-3 site, and that Spl does not appear to be directly involved. The data indicate that complex formation is initiated at site Sp1-3, which appears to be essential for promoter activity. However, other regions of the proximal promoter may also contribute to the regulation of MAT2A gene expression. These studies may lead to the delineation of the molecular basis for the differential regulation of MAT2A expression in normal and leukemic T cells.	Univ Tennessee, Dept Surg, Memphis, TN 38163 USA; Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; Univ Tennessee, Vet Affairs Med Ctr, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Kotb, M (corresponding author), Univ Tennessee, Dept Surg, 956 Court Ave,Suite A-202, Memphis, TN 38163 USA.	Mkotb@utmem1.utmem.edu			NIGMS NIH HHS [GM-54892-09] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054892] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE T, 1981, J BIOCHEM-TOKYO, V90, P571, DOI 10.1093/oxfordjournals.jbchem.a133509; BELL KM, 1994, ACTA NEUROL SCAND, V89, P15, DOI 10.1111/j.1600-0404.1994.tb05404.x; BOTTIGLIERI T, 1994, ACTA NEUROL SCAND, V89, P19, DOI 10.1111/j.1600-0404.1994.tb05405.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; CANTONI GL, 1953, J BIOL CHEM, V204, P403; CHAWLA RK, 1994, BBA-GEN SUBJECTS, V1199, P45, DOI 10.1016/0304-4165(94)90094-9; DELAROSA J, 1992, J BIOL CHEM, V267, P10699; DELAROSA J, 1995, J BIOL CHEM, V270, P21860; DELAROSA J, 1992, CANCER RES, V52, P3361; ELORANTA TO, 1977, BIOCHEM J, V166, P521, DOI 10.1042/bj1660521; FINKELSTEIN JD, 1982, J NUTR, V112, P1011, DOI 10.1093/jn/112.5.1011; GELLER AM, 1986, EXP EYE RES, V43, P997, DOI 10.1016/0014-4835(86)90077-1; GELLER AM, 1988, EXP EYE RES, V47, P197, DOI 10.1016/0014-4835(88)90003-6; GERMAN DC, 1983, J BIOL CHEM, V258, P997; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Halim AB, 1999, J BIOL CHEM, V274, P29720, DOI 10.1074/jbc.274.42.29720; Hiroki T, 1997, EUR J BIOCHEM, V250, P653, DOI 10.1111/j.1432-1033.1997.00653.x; HOFFMAN DR, 1981, INT J BIOCHEM, V13, P745; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Keller H, 1999, GENE THER, V6, P931, DOI 10.1038/sj.gt.3300896; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KOTB M, 1985, J BIOL CHEM, V260, P3923; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; Kredich N M, 1980, Adv Enzyme Regul, V18, P181, DOI 10.1016/0065-2571(80)90015-1; LeGros HL, 1997, J BIOL CHEM, V272, P16040, DOI 10.1074/jbc.272.25.16040; LIAU MC, 1977, CANCER RES, V37, P427; LIAU MC, 1979, CANCER RES, V39, P2113; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Mao ZB, 1998, BIOCHEM BIOPH RES CO, V248, P479, DOI 10.1006/bbrc.1998.8965; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MATO JM, 1994, ADV EXP MED BIOL, V368, P113; MUDD SH, 1963, J BIOL CHEM, V238, P2164; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; Tobena R, 1996, BIOCHEM J, V319, P929, DOI 10.1042/bj3190929; Torres L, 2000, FASEB J, V14, P95, DOI 10.1096/fasebj.14.1.95; UBAGAI T, 1995, J CLIN INVEST, V96, P1943, DOI 10.1172/JCI118240	46	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9784	9791		10.1074/jbc.M002347200	http://dx.doi.org/10.1074/jbc.M002347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11124935	hybrid			2022-12-25	WOS:000167996400029
J	Martinez-Estrada, OM; Villa, A; Breviario, F; Orsenigo, F; Dejana, E; Bazzoni, G				Martinez-Estrada, OM; Villa, A; Breviario, F; Orsenigo, F; Dejana, E; Bazzoni, G			Association of junctional adhesion molecule with calcium/calmodulin-dependent serine protein kinase (CASK/LIN-2) in human epithelial Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION; BASOLATERAL MEMBRANE; ZO-1; RECOGNITION; OCCLUDIN; COMPLEX	We report here that junctional adhesion molecule (JAM) interacts with calcium/calmodulin-dependent serine protein kinase (CASK), a protein related to membrane-associated guanylate kinases. In Caco-2 cells, JAM and CASK were coprecipitated and found to colocalize at intercellular contacts along the lateral surface of the plasma membrane. Association of JAM with CASK requires the PSD95/dlg/ZO-1 (PDZ) domain of CASK and the putative PDZ-binding motif Phe-Leu-Val(COOH) in the cytoplasmic tail of JAM. Temporal dissociation in the junctional localization of the two proteins suggests that the association with CASK is not required for recruiting JAM to intercellular junctions. Compared with mature intercellular contacts, junction assembly was characterized by both enhanced solubility of CASK in Triton X-100 and reduced amounts of Triton-insoluble JAM-CASK complexes. We propose that JAM association with CASK is modulated during junction assembly, when CASK is partially released from its cytoskeletal associations.	Ist Ric Farmacol Mario Negri, Lab Vasc Biol, I-20157 Milan, Italy; San Raffaele Sci Inst, I-20132 Milan, Italy; Univ Milan, Milan, Italy; Univ Insubria, I-21100 Varese, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; University of Insubria	Bazzoni, G (corresponding author), Ist Ric Farmacol Mario Negri, Lab Vasc Biol, Via Eritrea 62, I-20157 Milan, Italy.		Martinez-Estrada, Ofelia M/V-4733-2017; Villa, Antonello/B-4781-2012	Martinez-Estrada, Ofelia M/0000-0002-1814-1974; Villa, Antonello/0000-0002-3820-8072; Orsenigo, Fabrizio/0000-0001-9135-8478; DEJANA, ELISABETTA/0000-0002-0007-0426				ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; Bazzoni G, 2000, J BIOL CHEM, V275, P30970, DOI 10.1074/jbc.M003946200; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Grignani F, 1998, CANCER RES, V58, P14; Hata Y, 1996, J NEUROSCI, V16, P2488; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Liu Y, 2000, J CELL SCI, V113, P2363; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Ozaki H, 1999, J IMMUNOL, V163, P553; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	22	101	102	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9291	9296		10.1074/jbc.M006991200	http://dx.doi.org/10.1074/jbc.M006991200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11120739	hybrid			2022-12-25	WOS:000167607700089
J	Arimura, Y; Ogimoto, M; Mitomo, K; Katagiri, T; Yamamoto, K; Volarevic, S; Mizuno, K; Yakura, H				Arimura, Y; Ogimoto, M; Mitomo, K; Katagiri, T; Yamamoto, K; Volarevic, S; Mizuno, K; Yakura, H			CD45 is required for CD40-induced inhibition of DNA synthesis and regulation of c-Jun NH2-terminal kinase and p38 in BAL-17 B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASES; CROSS-LINKING CD40; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; GROWTH-INHIBITION; GENE-EXPRESSION; TERMINAL KINASE; T-CELLS; PROLIFERATION	Stimulation of B cell antigen receptor (BCR) may induce proliferation, differentiation, or apoptosis, depending upon the maturational stage of the cell and the presence or absence of signals transmitted via coreceptors. One such signal is delivered via CD40; for instance, ligation of CD40 rescues B cells from BCR-induced apoptosis. Here we show that, in contrast to WEHI-231 cells, CD40 ligation did not reverse BCR-induced growth inhibition in the BAL-17 mature B cell line and CD40 ligation itself inhibited proliferation. This inhibitory signaling was not observed in CD45-deficient cells. Further analyses demonstrate that transfection of dominant-negative form of SEK1 or treatment with SB203580 strongly reduced CD40-induced inhibition of BAL-17 proliferation, suggesting a requirement for c-Jun NH2-terminal kinase and p38 in CD40-induced inhibition of proliferation. Interestingly, CD40-initiated activation of c-Jun NH2-terminal kinase and p38 was enhanced and sustained in CD45-deficient cells, and these phenotypes were reversed by transfecting CD45 gene. However, CD40-mediated induction of cell surface molecules was not affected in CD45-deficient cells. Taken collectively, these results suggest that CD45 exerts a decisive effect on selective sets of CD40-mediated signaling pathways, dictating B cell fate.	Tokyo Metropolitan Org Med Res, Dept Immunol & Signal Transduct, Tokyo Metropolitan Inst Neurosci, Tokyo 1838526, Japan; Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa 9200934, Japan; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Kanazawa University; Friedrich Miescher Institute for Biomedical Research	Yakura, H (corresponding author), Tokyo Metropolitan Org Med Res, Dept Immunol & Signal Transduct, Tokyo Metropolitan Inst Neurosci, 2-6 Musashidai, Tokyo 1838526, Japan.		Volarevic, Sinisa/O-4349-2018	Volarevic, Sinisa/0000-0003-4893-389X				BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BARRETT TB, 1991, J IMMUNOL, V146, P1722; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Clark LB, 1996, ADV IMMUNOL, V63, P43; Craxton A, 1998, J IMMUNOL, V161, P3225; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; GRUBER MF, 1989, J IMMUNOL, V142, P4144; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; HEATH AW, 1993, CELL IMMUNOL, V152, P468, DOI 10.1006/cimm.1993.1305; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ISHIDA T, 1995, J IMMUNOL, V155, P5527; Kashiwada M, 1996, EUR J IMMUNOL, V26, P1451, DOI 10.1002/eji.1830260708; Klaus S J, 1994, Semin Immunol, V6, P279, DOI 10.1006/smim.1994.1036; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1995, IMMUNITY, V2, P239, DOI 10.1016/1074-7613(95)90048-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; OGIMOTO M, 1995, EUR J IMMUNOL, V25, P2265, DOI 10.1002/eji.1830250823; OGIMOTO M, 1994, INT IMMUNOL, V6, P647, DOI 10.1093/intimm/6.4.647; PeguetNavarro J, 1997, J IMMUNOL, V158, P144; Purkerson JM, 1998, J IMMUNOL, V160, P2121; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHATTNER EJ, 1995, J EXP MED, V182, P1557, DOI 10.1084/jem.182.5.1557; Schauer SL, 1996, J IMMUNOL, V157, P81; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Sutherland CL, 1996, J IMMUNOL, V157, P3381; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VanKooten C, 1996, ADV IMMUNOL, V61, P1; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; YAKURA H, 1983, J EXP MED, V157, P1077, DOI 10.1084/jem.157.4.1077; YAN MH, 1994, NATURE, V372, P798	48	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8550	8556		10.1074/jbc.M009242200	http://dx.doi.org/10.1074/jbc.M009242200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11118445	hybrid			2022-12-25	WOS:000167474900117
J	Foury, F; Talibi, D				Foury, F; Talibi, D			Mitochondrial control of iron homeostasis - A genome wide analysis of gene expression in a yeast frataxin-deficient strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FRIEDREICHS-ATAXIA; SUPEROXIDE-DISMUTASE; TRANSCRIPTIONAL CONTROL; CRYSTAL-STRUCTURE; PLASMA-MEMBRANE; PROTEIN; IDENTIFICATION; HOMOLOG; ENCODES	Deletion of YFH1, the yeast frataxin homologue gene, elicits mitochondrial iron accumulation and alters cellular iron homeostasis. Here, we report a genome wide analysis of gene expression in a yfh1(Delta YFH1) deleted strain. Frataxin deficiency results in enhanced expression of some 70 genes including a set of genes, called the iron regulon, that are under the control of the iron-sensing transcription factor AFT1. Five new ALF1-dependent genes, YOR382w, YOR383c, YDR534c, YLR136c, and YLR205c were found. The first three genes presumably encode cell-wall glycosylphosphatidylinositol anchor proteins and exhibit a 30-100-fold increased expression. The triple deletion of these genes decreases efficiency in utilization of the iron of ferrioxamine B by the yeast cell. YLR136c bears homology to tristetraproline proteins, which are post-transcriptional regulators in mammalian cells. Deletion of YLR136c increases the mRNA levels of iron regulon members. YLR205c bears homology to heme oxygenases. Our data show that frataxin deficiency elicits iron mobilization from all iron sources in an AFT1-dependent manner. Wild-type and Delta YFH1 glycerol-grown cells exhibit similar high respiration rates, no mitochondrial iron accumulation, and high expression of the iron regulon, suggesting that under these conditions little iron is extruded from mitochondria. These data suggest that the activity of Yfh1p is not essential in cells grown on glycerol. This study has also revealed unexpected links between mitochondria and remote metabolic pathways since frataxin deficiency also enhances the expression of genes such as HSP30, that escape to AFT1 control. Finally, no oxidative stress gene is induced.	Unite Biochim Physiol, B-1348 Louvain, Belgium; Eurogentech, Parc Sci Sart Tilman, B-4102 Seraing, Belgium		Foury, F (corresponding author), Unite Biochim Physiol, Pl Croix Sud 2-20, B-1348 Louvain, Belgium.	foury@fysa.ucl.ac.be						Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; Bieszke JA, 1999, P NATL ACAD SCI USA, V96, P8034, DOI 10.1073/pnas.96.14.8034; Braley R, 1997, FEBS LETT, V418, P123, DOI 10.1016/S0014-5793(97)01359-8; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; Cho SJ, 2000, P NATL ACAD SCI USA, V97, P8932, DOI 10.1073/pnas.160270897; Craig EA, 1999, BIOL CHEM, V380, P1167, DOI 10.1515/BC.1999.148; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Gibson TJ, 1996, TRENDS NEUROSCI, V19, P465, DOI 10.1016/S0166-2236(96)20054-2; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Musco G, 2000, STRUCTURE, V8, P695, DOI 10.1016/S0969-2126(00)00158-1; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Puccio H, 2000, HUM MOL GENET, V9, P887, DOI 10.1093/hmg/9.6.887; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; RAVINDRANATH SD, 1975, J BIOL CHEM, V250, P6107; Richaud C, 1997, P NATL ACAD SCI USA, V94, P11736, DOI 10.1073/pnas.94.21.11736; Robertson LS, 2000, P NATL ACAD SCI USA, V97, P5984, DOI 10.1073/pnas.100113397; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; Wilson RB, 2000, ANN NEUROL, V47, P659, DOI 10.1002/1531-8249(200005)47:5<659::AID-ANA17>3.3.CO;2-K; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	52	155	159	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7762	7768		10.1074/jbc.M005804200	http://dx.doi.org/10.1074/jbc.M005804200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11112771	hybrid			2022-12-25	WOS:000167474900014
J	Giepmans, BNG; Hengeveld, T; Postma, FR; Moolenaar, WH				Giepmans, BNG; Hengeveld, T; Postma, FR; Moolenaar, WH			Interaction of c-Src with gap junction protein connexin-43 - Role in the regulation of cell-cell communication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; GENE-PRODUCT; INHIBITION; KINASE; FIBROBLASTS; DOMAIN	Cell-cell communication via connexin-43 (Cx43)-based gap junctions is transiently inhibited by certain mitogens, but the underlying regulatory mechanisms are incompletely understood. Our previous studies have implicated the c-Src tyrosine kinase in mediating transient closure of Cx43-based gap junctions in normal fibroblasts. Here we show that activated c-Src (c-SrcK(+)) phosphorylates the COOH-terminal tail of Cx43, both in vitro and in intact cells. Coimmunoprecipitation experiments reveal that Cx43 associates with c-SrcK(+) and, to a lesser extent, with wild-type c-Src, but not with kinase-dead c-Src, Mutation of residue Cx43 Tyr(265) (Cx43-Y265F mutant) abolishes both tyrosine phosphorylation of Cx43 and its coprecipitation with c-Src, Expression of c-SrcK(+) in Rat-1 cells disrupts gap junctional communication. Strikingly, the communication-defective phenotype is bypassed after coexpression of the Cx43-Y265F mutant or a COOH-terminally truncated version of Cx43 (Cx43 Delta 263) that lacks residue Tyr(265). Our results support a model in which activated c-Src phosphorylates the COOH-terminal tail of Cx43 on residue Tyr(265), resulting in a stable interaction between both proteins leading to inhibition of gap junctional communication.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Giepmans, Ben N.G./R-4564-2016	Giepmans, Ben N.G./0000-0001-5105-5915				AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HII CST, 1994, BIOCHEM J, V303, P475, DOI 10.1042/bj3030475; Hossain MZ, 1999, J BIOL CHEM, V274, P10489, DOI 10.1074/jbc.274.15.10489; HOTZWAGENBLATT A, 1993, CRIT REV ONCOGENESIS, V4, P541; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Toyofuku T, 1999, CIRC RES, V85, P672, DOI 10.1161/01.RES.85.8.672; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	20	156	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8544	8549		10.1074/jbc.M005847200	http://dx.doi.org/10.1074/jbc.M005847200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11124251	hybrid			2022-12-25	WOS:000167474900116
J	Hen, BG; Liu, NL; Yang, XM; Sun, HB; Yang, YC				Hen, BG; Liu, NL; Yang, XM; Sun, HB; Yang, YC			MRG1 expression in fibroblasts is regulated by Sp1/Sp3 and an Ets transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-SPECIFIC GENE; DNA-BINDING; SP1; ACTIVATION; PROMOTER; FAMILY; DOMAIN; PROTEIN; MSG1; TRANSACTIVATOR	MRG1 (melanocyte-specific gene 1 (MSG1)-related gene), a ubiquitously expressed transcription factor that interacts with p300/CBP, TATA-binding protein and Lhx2, is the founding member of a new family of transcription factors. Initial characterization of this newly discovered transcription factor has underscored its potential involvement in many important cellular processes through transcriptional modulation We previously demonstrated that MRG1 can be induced by various biological stimuli (Sun, H. B., Zhu, Y. X., Yin, T., Sledge, G., and Yang, Y. C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13555-13560). As a first step in understanding its role in different biological processes, we investigated mechanisms that regulate transcription of the mouse MRG1 gene in fibroblasts. Transient transfection of Rat1 fibroblast cells with sequential 5'-deletions of mouse MRG1 promoter luciferase fusion constructs indicated that the -104 to +121 region contains the full promoter activity. Deletion and site-directed mutations within this region revealed that the Ets-1 site at -97 to -94 and the Sp1 site at -51 to -46 are critical for MRG1 expression in fibroblasts. Gel mobility shift and supershift assays performed with Rat1 nuclear extracts identified nucleoprotein complexes binding to the Ets-1 site and the Sp1 site. In Drosophila SL2 cells, which lack the Sp and Ets family of transcription factors, expression of Sp1, Sp3, and Ets-1 or Elf-1 functionally stimulated MRG1 promoter activity in a synergistic manner. These results suggest that multiple transcription factors acting in synergy are responsible for MRG1 expression and the responsiveness of cells to different biological stimuli.	Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Med Hematol Oncol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Yang, YC (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.				NATIONAL CANCER INSTITUTE [R01CA078443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050570] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA78443] Funding Source: Medline; NIDDK NIH HHS [R01DK50570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; REESE MG, 1996, P 1996 PAC S JAN 2 7; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 2002, MOL CLONING LAB MANU; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825	40	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7937	7942		10.1074/jbc.M007470200	http://dx.doi.org/10.1074/jbc.M007470200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11114295	hybrid			2022-12-25	WOS:000167474900038
J	Hiraiwa, H; Pan, CJ; Lin, BC; Akiyama, TE; Gonzalez, FJ; Chou, JY				Hiraiwa, H; Pan, CJ; Lin, BC; Akiyama, TE; Gonzalez, FJ; Chou, JY			A molecular link between the common phenotypes of type 1 glycogen storage disease and HNF1 alpha-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-6-PHOSPHATASE GENE-TRANSCRIPTION; NUCLEAR FACTOR; MICROSOMAL GLUCOSE-6-PHOSPHATASE; INSULIN-SECRETION; CATALYTIC SUBUNIT; YOUNG MODY3; LIVER; MOUSE; EXPRESSION; PROTEINS	The clinical manifestations of type 1 glycogen storage disease (GSD-1) in patients deficient in the glucose-6-phosphatase (G6Pase) system (e.g. growth retardation, hepatomegaly, hyperlipidemia, and renal dysfunction) are shared by Hnf1 alpha (-/-) mice deficient of a transcriptional activator, hepatocyte nuclear factor 1 alpha (HNF1 alpha). However, the molecular mechanism is unknown. The G6Pase system, essential for the maintenance of glucose homeostasis, is comprised of glucose 6-phosphate transporter (G6PT) and G6Pase. G6PT translocates G6P from the cytoplasm to the lumen of the endoplasmic reticulum where it is metabolized by G6Pase to glucose and phosphate, Deficiencies in G6Pase and G6PT cause GSD-1a and GSD-1b, respectively. Hnf1 alpha (-/-) mice also develop noninsulin-dependent diabetes mellitus caused by defective insulin secretion. In this study, we sought to determine whether there is a molecular link between HNF1 alpha deficiency and function of the G6Pase system. Transactivation studies revealed that HNF1 alpha is required for transcription of the G6PT gene. Hepatic G6PT mRNA levels and microsomal G6P transport activity are also markedly reduced in Hnf1 alpha (-/-) mice as compared with Hnf1 alpha (+/+) and Hnf1 alpha (+/-) littermates. On the other hand, hepatic G6Pase mRNA expression and activity are up-regulated in Hnf1 alpha (-/-) mice, consistent with observations that: G6Pase expression is increased in diabetic animals. Taken together, the results strongly suggest that metabolic abnormalities in HNF1 alpha -null mice are caused in part by G6PT deficiency and by perturbations of the G6Pase system.	NICHD, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chou, JY (corresponding author), NICHD, Heritable Disorders Branch, NIH, Bldg 10,Rm 9S241, Bethesda, MD 20892 USA.		Lin, Baochuan/A-8390-2009	Lin, Baochuan/0000-0002-9484-0785	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000912] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000912] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Akiyama TE, 2000, J BIOL CHEM, V275, P27117; Annabi B, 1998, AM J HUM GENET, V62, P400, DOI 10.1086/301727; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; ARION WJ, 1980, J BIOL CHEM, V255, P396; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BEAUDET AL, 1980, J PEDIATR-US, V97, P906, DOI 10.1016/S0022-3476(80)80418-5; BLUMENFELD M, 1991, DEVELOPMENT, V113, P589; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen LY, 2000, J BIOL CHEM, V275, P34280, DOI 10.1074/jbc.M006439200; Chen Y-T, 1995, METABOLIC MOL BASES, P935; Chou JY, 1999, TRENDS ENDOCRIN MET, V10, P104; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; Froguel P, 1999, TRENDS ENDOCRIN MET, V10, P142, DOI 10.1016/S1043-2760(98)00134-9; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kure S, 2000, J PEDIATR-US, V137, P253, DOI 10.1067/mpd.2000.107472; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Lehto M, 1997, J CLIN INVEST, V99, P582, DOI 10.1172/JCI119199; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIN B, 1997, BIOCHEMISTRY-US, V46, P14096; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, P349; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; Vaxillaire M, 1997, HUM MOL GENET, V6, P583, DOI 10.1093/hmg/6.4.583; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	41	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7963	7967		10.1074/jbc.M010523200	http://dx.doi.org/10.1074/jbc.M010523200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11121425	hybrid			2022-12-25	WOS:000167474900042
J	Hunt, AN; Clark, GT; Attard, GS; Postle, AD				Hunt, AN; Clark, GT; Attard, GS; Postle, AD			Highly saturated endonuclear phosphatidylcholine is synthesized in situ and colocated with CDP-choline pathway enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN-KINASE-C; CHROMATIN PHOSPHOLIPIDS; NUCLEAR PHOSPHOLIPIDS; MASS-SPECTROMETRY; FRIEND-CELLS; RAT; DIACYLGLYCEROL; ASSOCIATION; CONTAIN	Chromatin-associated phospholipids are well recognized, A report that catalytically active endonuclear CTP:choline-phosphate cytidylyltransferase cu is necessary for cell survival questions whether endonuclear, CDP-choline pathway phosphatidylcholine synthesis may occur in situ. We report that chromatin from human IMR-32 neuroblastoma cells possesses such a biosynthetic pathway. First, membrane-free nuclei retain all three CDP-choline pathway enzymes in proportions comparable with the content of chromatin-associated phosphatidylcholine. Second, following supplementation of cells with deuterated choline and using electrospray ionization mass spectrometry, both the time course and molecular species labeling pattern of newly synthesized endonuclear and whole cell phosphatidylcholine revealed the operation of spatially separate, compositionally distinct biosynthetic routes. Specifically, endogenous and newly synthesized endonuclear phosphatidylcholine species are both characterized by a high degree of diacyl/alkylacyl chain saturation. This unusual species content and synthetic pattern (evident within 10 min of supplementation) are maintained through cell growth arrest by serum depletion and when proliferation is restored, suggesting that endonuclear disaturated phosphatidylcholine enrichment is essential and closely regulated. We propose that endonuclear phosphatidylcholine synthesis may regulate periodic nuclear accumulations of phosphatidylcholine-derived lipid second messengers. Furthermore, our estimates of saturated phosphatidylcholine nuclear volume occupancy of around 10% may imply a significant additional role in regulating chromatin structure.	Univ Southampton, Southampton Gen Hosp, Dept Child Hlth 803, Allergy & Inflammat Sci Div, Southampton SO16 6YD, Hants, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England	University of Southampton; University of Southampton	Hunt, AN (corresponding author), Univ Southampton, Southampton Gen Hosp, Dept Child Hlth 803, Allergy & Inflammat Sci Div, Level G,Ctr Block,Tremona Rd, Southampton SO16 6YD, Hants, England.		Hunt, Alan N/A-7432-2008; Attard, George S/C-3087-2009	Hunt, Alan N/0000-0001-5938-2152; Attard, George S/0000-0001-8304-0742; Postle, Anthony/0000-0001-7361-0756				ALBI E, 1994, LIPIDS, V29, P715, DOI 10.1007/BF02538916; Attard GS, 2000, P NATL ACAD SCI USA, V97, P9032, DOI 10.1073/pnas.160260697; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; BUNCE CM, 1988, ANAL BIOCHEM, V175, P67, DOI 10.1016/0003-2697(88)90362-4; BURDGE GC, 1994, BIOCHEM J, V303, P941, DOI 10.1042/bj3030941; CAESAR PA, 1988, BIOCHEM J, V253, P451, DOI 10.1042/bj2530451; Clark JM, 1997, BIOCHEM SOC T, V25, pS590, DOI 10.1042/bst025s590; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; D'Santos CS, 1999, CURR BIOL, V9, P437, DOI 10.1016/S0960-9822(99)80193-6; DeLong CJ, 2000, J BIOL CHEM, V275, P32325, DOI 10.1074/jbc.M004644200; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Elholm M, 2000, J LIPID RES, V41, P538; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; Fraschini A, 1999, EUR J CELL BIOL, V78, P416, DOI 10.1016/S0171-9335(99)80084-3; Han XL, 1995, J AM SOC MASS SPECTR, V6, P1202, DOI 10.1016/1044-0305(95)00568-4; HIRAI H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P191, DOI 10.1016/0167-4781(91)90054-P; HUNT AN, 1990, BIOCHIM BIOPHYS ACTA, V1043, P19, DOI 10.1016/0005-2760(90)90105-7; ISHIDATE K, 1992, METHOD ENZYMOL, V209, P121; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MANZOLI FA, 1982, ADV ENZYME REGUL, V20, P247, DOI 10.1016/0065-2571(82)90019-X; MANZOLI L, 1995, CANCER RES, V55, P2978; MARALDI NM, 1993, J CELL SCI, V104, P853; Marsh D., 1990, CRC HDB LIPID BILAYE; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; RICKWOOD D, 1997, SUBCELLULAR FRACTION, P72; ROSE HG, 1965, BIOCHIM BIOPHYS ACTA, V106, P577, DOI 10.1016/0005-2760(65)90073-1; Rubbini S, 1997, BIOCHEM BIOPH RES CO, V230, P302, DOI 10.1006/bbrc.1996.5950; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; VANCE DE, 1977, NATURE, V270, P268, DOI 10.1038/270268a0; Vann LR, 1997, BIOCHEM J, V327, P569; VENKATRAMAN JT, 1992, LIPIDS, V27, P94, DOI 10.1007/BF02535806; VesLosada A, 1996, MOL CELL BIOCHEM, V159, P1; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; Williams SD, 2000, J LIPID RES, V41, P1585	40	105	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8492	8499		10.1074/jbc.M009878200	http://dx.doi.org/10.1074/jbc.M009878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11121419	hybrid			2022-12-25	WOS:000167474900110
J	Kainou, T; Okada, K; Suzuki, K; Nakagawa, T; Matsuda, H; Kawamukai, M				Kainou, T; Okada, K; Suzuki, K; Nakagawa, T; Matsuda, H; Kawamukai, M			Dimer formation of octaprenyl-diphosphate synthase (IspB) is essential for chain length determination of ubiquinone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; ELECTRON-TRANSPORT; OXIDATIVE STRESS; SIDE-CHAIN; GENE; EXPRESSION; SEQUENCE	Ubiquinone (Q), composed of a quinone core and an isoprenoid side chain, is a key component of the respiratory chain and is an important antioxidant. In Escherichia coli, the side chain of Q-8 is synthesized by octaprenyl-diphosphate synthase, which is encoded by an essential gene, ispB. To determine how IspB regulates the length of the isoprenoid, we constructed 15 ispB mutants and expressed them in E. coli and Saccharomyces cerevisiae. The Y38A and R321V mutants produced Q-6 and Q-7, and the Y38A/R321V double mutant produced Q-5 and Q-6, indicating that these residues are involved in the determination of chain length. E. coli cells (ispB::cat) harboring an Arg-321 mutant were temperature-sensitive for growth, which indicates that Arg-321 is important for thermostability of IspB. Intriguingly, E. coli cells harboring wild-type ispB and the A79Y mutant produced mainly Q-6, although the activity of the enzyme with the A79Y mutation was completely abolished. When a heterodimer of His-tagged wild-type IspB and glutathione S-transferase-tagged IspB(A79Y) was formed, the enzyme produced a shorter length isoprenoid. These results indicate that although the A79Y mutant is functionally inactive, it can regulate activity upon forming a heterodimer with wild-type IspB, and this dimer formation is important for the determination of the isoprenoid chain length.	Shimane Univ, Fac Life & Environm Sci, Dept Appl Biosci & Biotechnol, Matsue, Shimane 6908504, Japan; Shimane Univ, Res Inst Mol Genet, Matsue, Shimane 6908504, Japan	Shimane University; Shimane University	Kawamukai, M (corresponding author), Shimane Univ, Fac Life & Environm Sci, Dept Appl Biosci & Biotechnol, 1060 Nishikawatsu, Matsue, Shimane 6908504, Japan.	kawamuka@life.shimane-u.ac.jp	Kawamukai, Makoto/AET-1038-2022	Kawamukai, Makoto/0000-0003-2929-8798				ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BLANCHARD L, 1993, GENE, V125, P185, DOI 10.1016/0378-1119(93)90326-X; Burke CC, 1999, P NATL ACAD SCI USA, V96, P13062, DOI 10.1073/pnas.96.23.13062; CHEN AJ, 1994, PROTEIN SCI, V3, P600; COLLINS MD, 1981, MICROBIOL REV, V45, P316, DOI 10.1128/MMBR.45.2.316-354.1981; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Kainou T, 1999, BBA-MOL CELL BIOL L, V1437, P333, DOI 10.1016/S1388-1981(99)00028-1; KOYAMA T, 1994, CAN J CHEM, V72, P75, DOI 10.1139/v94-012; Koyama T, 2000, BIOCHEMISTRY-US, V39, P463, DOI 10.1021/bi991621b; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; OHNUMA S, 1992, J BIOCHEM-TOKYO, V112, P743, DOI 10.1093/oxfordjournals.jbchem.a123969; OHNUMA S, 1993, BIOCHEM BIOPH RES CO, V192, P407, DOI 10.1006/bbrc.1993.1430; Ohnuma S, 1998, J BIOL CHEM, V273, P26705, DOI 10.1074/jbc.273.41.26705; Okada K, 1996, BBA-LIPID LIPID MET, V1302, P217, DOI 10.1016/0005-2760(96)00064-1; Okada K, 1998, FEBS LETT, V431, P241, DOI 10.1016/S0014-5793(98)00753-4; Okada K, 1997, J BACTERIOL, V179, P3058, DOI 10.1128/jb.179.9.3058-3060.1997; Okada K, 1998, EUR J BIOCHEM, V255, P52, DOI 10.1046/j.1432-1327.1998.2550052.x; Okada K, 1997, J BACTERIOL, V179, P5992, DOI 10.1128/jb.179.19.5992-5998.1997; ROSENBLATT DH, 1991, HDB ENV CHEM G, V3, P195; SAGAMI H, 1994, J BIOL CHEM, V269, P20561; Sambrook J., 2002, MOL CLONING LAB MANU; Scolnik P. A., 1995, PLANT PHYSIOL, V108, P1343; Shimizu N, 1998, J BACTERIOL, V180, P1578, DOI 10.1128/JB.180.6.1578-1581.1998; Soballe B, 1999, MICROBIOL-SGM, V145, P1817, DOI 10.1099/13500872-145-8-1817; Soballe B, 2000, MICROBIOL-SGM, V146, P787, DOI 10.1099/00221287-146-4-787; Suzuki K, 1997, J BIOCHEM, V121, P496; SUZUKI K, 1994, BIOSCI BIOTECH BIOCH, V58, P1814, DOI 10.1271/bbb.58.1814; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Uchida N, 2000, J BACTERIOL, V182, P6933, DOI 10.1128/JB.182.24.6933-6939.2000; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; Zhang YW, 1999, BIOCHEMISTRY-US, V38, P14638, DOI 10.1021/bi9913653; Zhang YW, 1997, J BACTERIOL, V179, P1417, DOI 10.1128/jb.179.4.1417-1419.1997	38	47	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7876	7883		10.1074/jbc.M007472200	http://dx.doi.org/10.1074/jbc.M007472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11108713	hybrid			2022-12-25	WOS:000167474900029
J	Trepakova, ES; Gericke, M; Hirakawa, Y; Weisbrod, RM; Cohen, RA; Bolotina, VM				Trepakova, ES; Gericke, M; Hirakawa, Y; Weisbrod, RM; Cohen, RA; Bolotina, VM			Properties of a native cation channel activated by Ca2+ store depletion in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT EAR ARTERY; CAPACITATIVE CALCIUM-ENTRY; CYCLOPIAZONIC ACID; INTRACELLULAR CA2+; SARCOPLASMIC-RETICULUM; MOUSE ANOCOCCYGEUS; HYPERTENSIVE RATS; PORTAL-VEIN; MAST-CELLS; INFLUX	Depletion of intracellular Ca2+ stores activates capacitative Ca2+ influx in smooth muscle cells, but the native store-operated channels that mediate such influx remain unidentified. Recently we demonstrated that calcium influx factor produced by yeast and human platelets with depleted Ca2+ stores activates small conductance cation channels in excised membrane patches from vascular smooth muscle cells (SMC). Here we characterize these channels in intact cells and present evidence that they belong to the class of store-operated channels, which are activated upon passive depletion of Ca2+ stores. Application of thapsigargin (TG), an inhibitor of sarco-endoplasmic reticulum Ca2+ ATPase, to individual SMC activated single 3-pS cation channels in cell-attached membrane patches. Channels remained active when inside-out membrane patches were excised from the cells. Excision of membrane patches from resting SMC did not by itself activate the channels. Load-ing SMC with BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), which slowly depletes Ca2+ stores without a rise in intracellular Ca2+, activated the same 3-pS channels in cell-attached membrane patches as well as whole cell nonselective cation currents in SMC, TG- and BAPTA-activated 3-pS channels were cation-selective but poorly discriminated among Ca2+, Sr2+, Ba2+, Na+, K+, and Cs+. Open channel probability did not change at negative membrane potentials but increased significantly at high positive potentials. Activation of 3-pS channels did not depend on intracellular Ca2+ concentration. Neither TG nor a variety of second messengers (including Ca2+, InsP3, InsP4, GTP gammaS, cyclic AMP, cyclic GIMP, ATP, and ADP) activated 3-pS channels in inside-out membrane patches. Thus, 3-pS nonselective cation channels are present and activated by TG or BAPTA-induced depletion of intracellular Ca2+ stores in intact SMC. These native store-operated cation channels can account for capacitative Ca2+ influx in SMC and can play an important role in regulation of vascular tone.	Boston Univ, Sch Med, Dept Med, Vasc Biol Unit, Boston, MA 02118 USA	Boston University	Bolotina, VM (corresponding author), Boston Univ, Sch Med, Dept Med, Vasc Biol Unit, 650 Albany St,X-704, Boston, MA 02118 USA.	vbolotina@med-med1.bu.edu		/0000-0002-1070-6408; Bolotina, Victoria/0000-0001-5862-181X	NHLBI NIH HHS [HL54150, HL07224, HL55993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055993, R01HL054150] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe F, 1996, BRIT J PHARMACOL, V118, P1711, DOI 10.1111/j.1476-5381.1996.tb15596.x; Arnon A, 2000, AM J PHYSIOL-CELL PH, V278, pC163, DOI 10.1152/ajpcell.2000.278.1.C163; BENHAM CD, 1985, NATURE, V316, P345, DOI 10.1038/316345a0; BENHAM CD, 1987, CIRC RES, V61, P10; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bolotina VM, 1997, BIOPHYS J, V72, pTHAM6; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CHEN C, 1991, CIRC RES, V69, P447, DOI 10.1161/01.RES.69.2.447; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Friel DD, 1996, CELL, V85, P617, DOI 10.1016/S0092-8674(00)81021-1; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; GUERRERO A, 1994, J GEN PHYSIOL, V104, P375, DOI 10.1085/jgp.104.2.375; Hirakawa Y, 1999, AM J PHYSIOL-HEART C, V277, pH1732, DOI 10.1152/ajpheart.1999.277.5.H1732; HOTH M, 1993, ANN NY ACAD SCI, V707, P198, DOI 10.1111/j.1749-6632.1993.tb38053.x; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUGHES AD, 1995, BRIT J PHARMACOL, V116, P2148, DOI 10.1111/j.1476-5381.1995.tb16424.x; INOUE R, 1987, PFLUG ARCH EUR J PHY, V410, P69, DOI 10.1007/BF00581898; INOUE R, 1993, J PHYSIOL-LONDON, V465, P427, DOI 10.1113/jphysiol.1993.sp019685; INOUE R, 1990, AM J PHYSIOL, V258, pC1173, DOI 10.1152/ajpcell.1990.258.6.C1173; Isenberg G, 1993, EXS, V66, P247; Iwamuro Y, 1999, BRIT J PHARMACOL, V126, P1107, DOI 10.1038/sj.bjp.0702416; Iwasawa K, 1997, J PHYSIOL-LONDON, V503, P237, DOI 10.1111/j.1469-7793.1997.237bh.x; KOMORI S, 1992, J PHYSIOL-LONDON, V450, P105, DOI 10.1113/jphysiol.1992.sp019118; KWAN CY, 1994, HYPERTENSION, V23, pI156, DOI 10.1161/01.HYP.23.1_Suppl.I156; LOIRAND G, 1986, PFLUG ARCH EUR J PHY, V407, P566, DOI 10.1007/BF00657519; LOIRAND G, 1991, J PHYSIOL-LONDON, V437, P461, DOI 10.1113/jphysiol.1991.sp018606; MAGGI CA, 1995, BRIT J PHARMACOL, V114, P127, DOI 10.1111/j.1476-5381.1995.tb14916.x; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; Nakajima T, 1996, J MOL CELL CARDIOL, V28, P707, DOI 10.1006/jmcc.1996.0066; *NAT AC SCI, 1996, GUID CAR US LAB AN; Nomura Y, 1997, BRIT J PHARMACOL, V120, P65, DOI 10.1038/sj.bjp.0700857; PACAUD P, 1991, J PHYSIOL-LONDON, V441, P477, DOI 10.1113/jphysiol.1991.sp018763; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Sekiguchi F, 1996, BRIT J PHARMACOL, V118, P857, DOI 10.1111/j.1476-5381.1996.tb15478.x; SIMS SM, 1992, J PHYSIOL-LONDON, V449, P377, DOI 10.1113/jphysiol.1992.sp019091; Skutella M, 1996, BIOCHEM BIOPH RES CO, V218, P837, DOI 10.1006/bbrc.1996.0149; Smaili SS, 1998, EUR J PHARMACOL, V342, P119, DOI 10.1016/S0014-2999(97)01537-9; Takemoto M, 1998, BRIT J PHARMACOL, V124, P1449, DOI 10.1038/sj.bjp.0701993; Tosun M, 1998, J PHARMACOL EXP THER, V285, P759; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Trepakova ES, 1999, CIRC RES, V84, P201, DOI 10.1161/01.RES.84.2.201; TREPAKOVA ES, 2000, BIOPHYS J, V78, P193; UYAMA Y, 1993, BRIT J PHARMACOL, V110, P565, DOI 10.1111/j.1476-5381.1993.tb13848.x; WANG Q, 1993, PFLUG ARCH EUR J PHY, V423, P28, DOI 10.1007/BF00374957; Wayman CP, 1996, BRIT J PHARMACOL, V117, P566, DOI 10.1111/j.1476-5381.1996.tb15228.x; Wayman CP, 1999, EUR J PHARMACOL, V376, P325, DOI 10.1016/S0014-2999(99)00400-8; XUAN YT, 1992, AM J PHYSIOL, V262, pC1258, DOI 10.1152/ajpcell.1992.262.5.C1258; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	56	124	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7782	7790		10.1074/jbc.M010104200	http://dx.doi.org/10.1074/jbc.M010104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11113149	hybrid			2022-12-25	WOS:000167474900017
J	Mulder, H; Lu, DH; Finley, J; An, J; Cohen, J; Antinozzi, PA; McGarry, JD; Newgard, CB				Mulder, H; Lu, DH; Finley, J; An, J; Cohen, J; Antinozzi, PA; McGarry, JD; Newgard, CB			Overexpression of a modified human malonyl-CoA decarboxylase blocks the glucose-induced increase in malonyl-CoA level but has no impact on insulin secretion in INS-1-derived (832/13) beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; ADENOVIRUS-MEDIATED TRANSFER; METABOLIC COUPLING FACTORS; CIRCULATING FATTY-ACIDS; SIGNAL-TRANSDUCTION; RELEASE; STIMULATION; GENE; EXOCYTOSIS; ESTERS	The long-chain acyl-CoA (LC-CoA) model of glucose stimulated insulin secretion (GSIS) holds that secretion is linked to a glucose induced increase in malonyl-CoA level and accumulation of LC-CoA in the cytosol. We have previously tested the validity of this proposal by overexpressing goose malonyl-CoA decarboxylase (MCD) in INS-1 cells, but these studies have been criticized due to: 1) the small insulin secretion response (2-4-fold) of the INS-1 cells used; 2) unknown contribution of the ATP-sensitive K+ (K-ATP) channel-independent pathway of GSIS in INS-1 cells, which has been implicated as the site at which lipids regulate insulin granule exocytosis; and 3) deletion of the N-terminal mitochondrial targeting sequence, but not the C-terminal peroxisomal targeting sequence in the goose MCD construct, raising the possibility that a significant fraction of the overexpressed enzyme was localized to peroxisomes. To address these outstanding concerns, INS-1 derived 832/13 cells, which exhibit robust K-ATP channel-dependent and -independent pathways of GSIS, were treated with a new adenovirus encoding human MCD lacking both its mitochondrial and peroxisomal targeting sequences (AdCMV-MCD Delta5), resulting in large increases in cytosolic MCD activity. Treatment of 832/13 cells with AdCMV-MCD Delta5 completely blocked the glucose-induced rise in malonyl-CoA and attenuated the inhibitory effect of glucose on fatty acid oxidation. However, MCD overexpression had no effect on K-ATP channel-dependent or -independent GSIS in 832/13 cells. Furthermore, combined treatment of 832/13 cells with AdCMV-MCD Delta5 and triacsin C, an inhibitor of long chain acyl CoA synthetase that reduces LC-CoA levels, did not impair GSIS. These findings extend our previous observations and are not consistent with the LC-CoA hypothesis as originally set forth.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Human Nutr, Dallas, TX 75390 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem & Med, Hanover, NH 03755 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Dartmouth College	Newgard, CB (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Rm Y8-212,5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Mulder, Hindrik/E-1045-2012	Mulder, Hindrik/0000-0002-6593-8417	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018573, R37DK018573, P01DK042582] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-42582, DK-18573] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; Dobbins RL, 1998, DIABETES, V47, P1613, DOI 10.2337/diabetes.47.10.1613; Gao JM, 1999, J LIPID RES, V40, P178; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Komatsu M, 1999, DIABETES, V48, P1543, DOI 10.2337/diabetes.48.8.1543; KOMATSU M, 1995, P NATL ACAD SCI USA, V92, P10728, DOI 10.1073/pnas.92.23.10728; Koyama K, 1997, DIABETES, V46, P1276, DOI 10.2337/diabetes.46.8.1276; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MCGARRY JD, 1978, J BIOL CHEM, V253, P8291; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; SENER A, 1991, BIOCHIMIE, V73, P1287, DOI 10.1016/0300-9084(91)90090-N; Stein DT, 1996, J CLIN INVEST, V97, P2728, DOI 10.1172/JCI118727; Yajima H, 2000, DIABETES, V49, P712, DOI 10.2337/diabetes.49.5.712; Zhang SY, 1998, CELL SIGNAL, V10, P35, DOI 10.1016/S0898-6568(97)00070-3; ZHOU YP, 1995, J CLIN ENDOCR METAB, V80, P1584, DOI 10.1210/jc.80.5.1584	26	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6479	6484		10.1074/jbc.M010364200	http://dx.doi.org/10.1074/jbc.M010364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11113153	hybrid			2022-12-25	WOS:000167261000056
J	Huwiler, A; Johansen, B; Skarstad, A; Pfeilschifter, J				Huwiler, A; Johansen, B; Skarstad, A; Pfeilschifter, J			Ceramide binds to the CaLB domain of cytosolic phospholipase A(2) and facilitates its membrane docking and arachidonic acid release	FASEB JOURNAL			English	Article									Univ Frankfurt Klinikum, Inst Pharmacol & Toxicol, Zentrum Pharmakol, D-60590 Frankfurt, Germany; Norwegian Univ Sci & Technol, Dept Bot, UNIGEN Ctr Mol Biol, N-7491 Trondheim, Norway	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Norwegian University of Science & Technology (NTNU)	Pfeilschifter, J (corresponding author), Univ Frankfurt Klinikum, Inst Pharmacol & Toxicol, Zentrum Pharmakol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.								0	108	109	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					7	9						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099485				2022-12-25	WOS:000166312400003
J	Kovala, AT; Harvey, KA; McGlynn, P; Boguslawski, G; Garcia, JGN; English, D				Kovala, AT; Harvey, KA; McGlynn, P; Boguslawski, G; Garcia, JGN; English, D			High-efficiency transient transfection of endothelial cells for functional analysis	FASEB JOURNAL			English	Article						FACS sorting; chemotaxis; heterotrimeric G-protein beta gamma subunits	GREEN FLUORESCENT PROTEIN; GENE-TRANSFER; SPHINGOSINE 1-PHOSPHATE; SIGNALING PATHWAY; RECEPTOR KINASE; ANGIOGENESIS; MIGRATION; CHEMOTAXIS; ACTIVATION; MECHANISMS	The definition of signaling pathways in endothelial cells has been hampered by the difficulty of transiently transfecting these cells with high efficiency. This investigation was undertaken to develop an efficient technique for the transfection of endothelial cells for functional analyses. Cells cotransfected with plasmid expressing green fluorescent protein (GFP) and the plasmid of interest were isolated by fluorescence-activated cell sorting (FACS) based on GFP expression. In the sorted cell population, a 2.5-fold enhancement in the number of cells expressing the gene of interest was observed, as confirmed by FAGS analysis and Western blotting. Sorted cells retained functional properties, as demonstrated by chemotaxis to the agonist sphingosine l-phosphate (SPP). To demonstrate the usefulness of this method for defining cellular signaling pathways, cells were cotransfected with plasmids encoding GFP and the carboxyl-terminal domain of the beta -adrenergic receptor kinase (beta ARKct), which inhibits signaling through the beta gamma dimer of heterotrimeric G-proteins. SPP-induced chemotaxis in sorted cells coexpressing beta ARKct was inhibited by 80%, demonstrating that chemotaxis was driven by a beta gamma -dependent pathway. However, no significant inhibition was observed in cells transfected with beta ARKct but not enriched by sorting. Thus, we have developed a method for enriching transfected cells that allows the elucidation of crucial mechanisms of endothelial cell activation and function. This method should find wide applicability in studies designed to define pathways responsible for regulation of motility and other functions in these dynamic cells.	Clarian Hlth Partners Inc, Methodist Res Inst, Expt Cell Res Program, Indianapolis, IN 46202 USA; Johns Hopkins Univ, Sch Med, Dept Pulm & Crit Care Med, Baltimore, MD 21224 USA; Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA	Indiana University System; Johns Hopkins University; Indiana University System; Indiana University-Purdue University Indianapolis	English, D (corresponding author), Methodist Res Inst, Expt Cell Res Program, 1701 N Senate Ave, Indianapolis, IN 46219 USA.		Garcia, Joe GN/E-8862-2010	Kovala, A. Thomas/0000-0002-2908-5613	NHLBI NIH HHS [P01 HL 50864] Funding Source: Medline; PHS HHS [R01 61751] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; CLAPMAN DE, 1995, NATURE, V365, P403; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Edgell CJS, 1998, BIOTECHNIQUES, V25, P264, DOI 10.2144/98252gt01; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Harvey KA, 1996, BRIT J HAEMATOL, V93, P515, DOI 10.1046/j.1365-2141.1996.d01-1706.x; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Keith MBA, 2000, BIOTECHNIQUES, V28, P148, DOI 10.2144/00281rr03; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lascombe I, 1996, BIOTECHNIQUES, V20, P88; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Lundell A, 1999, CIRCULATION, V100, P2018, DOI 10.1161/01.CIR.100.19.2018; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Merrick AF, 1996, TRANSPLANTATION, V62, P1085, DOI 10.1097/00007890-199610270-00011; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Niebauer J, 1999, J AM COLL CARDIOL, V34, P1201, DOI 10.1016/S0735-1097(99)00304-6; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Tanner FC, 1997, CARDIOVASC RES, V35, P522, DOI 10.1016/S0008-6363(97)00151-X; Teifel M, 1997, ENDOTHELIUM-J ENDOTH, V5, P21, DOI 10.3109/10623329709044156; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	33	31	32	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2486	2494		10.1096/fj.00-0147com	http://dx.doi.org/10.1096/fj.00-0147com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099466				2022-12-25	WOS:000165723400018
